Section,SetId,EffectiveTime,Version,Abbreviation,Long Form,,,
adverseReaction,fcabfaee-df20-4e7c-b951-8a454f0d355e,4/8/2011,2,ED,erectile dysfunction,,,
adverseReaction,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,WHO,World Health Organization,,,
adverseReaction,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,GI,gastrointestinal,,,
adverseReaction,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,i.e.,into a limited,,,
adverseReaction,966d728e-87ca-4491-9411-2ec253eca632,8/12/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,7d271f3b-e4f9-4d80-8dcf-28d49123f80e,1/24/2012,10,AEs,adverse events,,,
adverseReaction,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,WHO,World Health Organization,,,
adverseReaction,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,ALT,at baseline <3 times ULN,,,
adverseReaction,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,cUTI,complicated urinary tract infections,,,
adverseReaction,f5b905ec-5b95-bf90-60ba-3355df50acf0,8/26/2010,1,WHO,World Health Organization,,,
adverseReaction,f5b905ec-5b95-bf90-60ba-3355df50acf0,8/26/2010,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,9d73278f-c9c0-4e02-9879-8952a024421c,5/24/2011,4,SLE,Systemic lupus erythematosus,,,
adverseReaction,a90897e7-4352-44db-891b-763ac4c3bebe,12/8/2010,134,SGOT,significant  increase was observed in median AST,,,
adverseReaction,1522f0b9-2bbc-4785-bada-fa6ae7986bb4,7/25/2011,4,EPS,extrapyramidal symptoms,,,
adverseReaction,77523882-3a1e-48ea-9bbb-9fffdd7aa415,6/28/2011,1,TSH,thyrotropin stimulating  hormone,,,
adverseReaction,50ee3815-7675-4bc0-a88a-ab3886aea795,10/1/2009,1,TSS,toxic shock syndrome,,,
adverseReaction,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,b8cfe18e-7328-4832-aff8-0b4b9e715172,6/1/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,RLS,restless legs syndrome,,,
adverseReaction,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,NPN,non-protein nitrogen,,,
adverseReaction,171c535c-1ed3-47bc-a0d5-c6f0e6986292,8/18/2011,1,EEG,electroencephalogram,,,
adverseReaction,f719162f-cb78-487c-b172-ac10d009e6f5,3/1/2012,1,i.e.,into a limited,,,
adverseReaction,6281ca7c-2aec-4f14-b7e4-82401a701c96,9/19/2006,3,NMS,neuroleptic malignant syndrome,,,
adverseReaction,140e953d-d180-4097-80da-b3ecb50465d5,5/25/2010,10,ALL,acute lymphoid leukemia,,,
adverseReaction,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,EEG,electroencephalogram,,,
adverseReaction,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,CPK,creatine phosphokinase levels,,,
adverseReaction,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,PROactive,Prospective Pioglitazone Clinical Trial In Macrovascular Events,,,
adverseReaction,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,ALT,alanine aminotransferase,,,
adverseReaction,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,AST,aspartate aminotransferase,,,
adverseReaction,3fe3b576-567d-4589-9d4c-620b834b8746,2/4/2011,2126,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,80996f05-e322-40c5-b3b4-c12c747a88a6,12/28/2011,3424,WHO,World Health Organization,,,
adverseReaction,80996f05-e322-40c5-b3b4-c12c747a88a6,12/28/2011,3424,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,2f5f06de-ee98-44c0-be7e-9a998d1e5c16,8/6/2010,3,high,higher rates of total bilirubin,,,
adverseReaction,89b11e03-4921-4c59-ac5d-082bf755eab7,12/2/2010,116,ADH,antidiuretic hormone,,,
adverseReaction,89b11e03-4921-4c59-ac5d-082bf755eab7,12/2/2010,116,SJS,Stevens-Johnson syndrome,,,
adverseReaction,9ffdb1e8-fdc8-44d4-b558-210954138b2f,8/9/2011,10,BUN,blood urea increased,,,
adverseReaction,b8953ff7-3bba-4a0b-a486-f26fb81f05d9,4/20/2012,6,SOC,System Organ Class,,,
adverseReaction,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,PSA,prostate-specific antigen,,,
adverseReaction,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,GI,gastrointestinal,,,
adverseReaction,51e4144a-489e-436c-609a-39305f8f56ba,11/9/2011,20,TEN,toxic epidermal necrolysis,,,
adverseReaction,fcfc9676-4edc-460e-6199-8161b824908f,4/14/2008,10,ANA,antinuclear antibodies,,,
adverseReaction,9621AFB9-BC1E-41A0-91AC-59266491FE5F,10/2/2008,1,ADH,antidiuretic hormone,,,
adverseReaction,e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606,7/6/2011,4,ie,infrequently,,,
adverseReaction,6ebf24fd-41cd-4b3c-8176-a1436253ba2d,2/9/2012,6,SGOT,significant increase was observed in median AST,,,
adverseReaction,147ac314-1b2a-4c17-8c51-57cfe361b7fb,12/22/2011,5,ISMN,Isosorbide Mononitrate,,,
adverseReaction,7d9d8a97-66ec-40fc-a160-d282c8205e7a,3/27/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,7d9d8a97-66ec-40fc-a160-d282c8205e7a,3/27/2012,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,7d9d8a97-66ec-40fc-a160-d282c8205e7a,3/27/2012,1,CBC,complete blood count,,,
adverseReaction,7d9d8a97-66ec-40fc-a160-d282c8205e7a,3/27/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,000dde4b-1d94-442f-94c0-26e283e04d88,2/3/2010,8,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,9a2b64bb-011a-4b23-b097-7dce576c57f8,10/12/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,b073b082-7b57-4423-8c06-4fd4263d6f84,9/10/2010,4,SARs,serious adverse reactions,,,
adverseReaction,b073b082-7b57-4423-8c06-4fd4263d6f84,9/10/2010,4,CTC,Common Toxicity Criteria,,,
adverseReaction,54de10ef-fe5f-4930-b91d-6bbb04c664bd,1/28/2011,6,LDL,low density lipoprotein,,,
adverseReaction,54de10ef-fe5f-4930-b91d-6bbb04c664bd,1/28/2011,6,CPK,creatine phosphokinase,,,
adverseReaction,54de10ef-fe5f-4930-b91d-6bbb04c664bd,1/28/2011,6,APTC,Anti-Platelet Trialists' Collaborations,,,
adverseReaction,0ebcca1e-ca16-4483-429a-aec5dcacd1dc,4/24/2008,7,ANA,antinuclear antibodies,,,
adverseReaction,D7FA1D79-4CD3-4A55-B74B-B31E82E616A3,1/1/2007,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,b4c5fede-6eb9-4984-ad79-3f33acf0c15f,11/22/2010,100,SGOT,significant  increase was observed in median AST,,,
adverseReaction,c4877476-24ca-31d3-9392-ea14e2f929b8,2/4/2009,2,BUN,blood urea nitrogen,,,
adverseReaction,0f131f23-80dd-4a42-893a-b7d86cd0e037,7/13/2011,18,EPS,extrapyramidal symptoms,,,
adverseReaction,0f131f23-80dd-4a42-893a-b7d86cd0e037,7/13/2011,18,SJS,Stevens-Johnson syndrome,,,
adverseReaction,0f131f23-80dd-4a42-893a-b7d86cd0e037,7/13/2011,18,CBC,complete blood count,,,
adverseReaction,0f131f23-80dd-4a42-893a-b7d86cd0e037,7/13/2011,18,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,285e60f8-2404-47d0-a171-a4f075d6f418,1/13/2012,1,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,LDH,lactic dehydrogenase,,,
adverseReaction,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,TTP/HUS,thrombocytopenic purpura/hemolytic uremic syndrome,,,
adverseReaction,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,CMV,cytomegalovirus,,,
adverseReaction,304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e,3/8/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,153d3376-4e38-4f5e-8bf7-4b77bcbb2ebe,11/3/2011,1,GI,gastrointestinal,,,
adverseReaction,3231dc15-5ce2-cf61-7d1f-bd86704269ae,10/20/2011,6,ANLL,acute non-lymphocytic leukemia,,,
adverseReaction,922d17f7-58c7-7b82-5f80-b808a9db5da2,8/1/2011,9,RLS,restless leg syndrome,,,
adverseReaction,922d17f7-58c7-7b82-5f80-b808a9db5da2,8/1/2011,9,NPN,nonprotein nitrogen,,,
adverseReaction,b136813b-7831-4d7c-b68d-f646200905e3,7/1/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,9c72d2f4-c586-4456-80b3-cec69b7d9ee0,3/23/2012,7,BUN,blood urea increased,,,
adverseReaction,254d072d-c684-4a5c-aa19-a40d76f8385a,11/30/2010,3,ALT,alanine aminotransferase,,,
adverseReaction,254d072d-c684-4a5c-aa19-a40d76f8385a,11/30/2010,3,AST,aspartate aminotransferase,,,
adverseReaction,a6292311-9cb2-49ff-b8bf-12e2dbd196cd,3/6/2012,1,BUN,blood urea increased,,,
adverseReaction,9e58806e-08ba-4813-885a-bde5cf82b26d,1/9/2012,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,rare,Renal Failure,,,
adverseReaction,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,36087b99-a193-4dee-a103-8739484f4591,4/20/2010,2,GI,gastrointestinal,,,
adverseReaction,5914ef00-19b1-4e22-9ad3-2b62b455af9d,9/29/2010,1,GI,gastrointestinal,,,
adverseReaction,24998e63-f01e-4a07-be5b-203aadd46941,3/23/2012,3702,rare,Renal Failure,,,
adverseReaction,79000ef8-702c-47ec-aafc-9bc1dfd83e77,5/24/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,cd4f6a14-a2eb-4157-83a7-91ab4e9926e5,9/10/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,82effea8-5782-4aa5-969e-b635423ae3c6,10/22/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,EBV,Epstein Barr Virus,,,
adverseReaction,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,cUTI,complicated urinary tract infections,,,
adverseReaction,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,ALT,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGPT",,,
adverseReaction,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,AST,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGOT",,,
adverseReaction,7ccd3733-c3af-4a11-8500-0f99194c1472,1/12/2012,4,DRESS,drug rash with eosinophilia and systemic symptoms,,,
adverseReaction,7ccd3733-c3af-4a11-8500-0f99194c1472,1/12/2012,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,51c9a29c-a285-40d0-bf3a-7e8c944ee39c,3/7/2011,1,WHO,World Health Organization,,,
adverseReaction,51c9a29c-a285-40d0-bf3a-7e8c944ee39c,3/7/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,1eb2ffc4-d6d9-4efb-9f88-8434214d047e,7/14/2011,7,URI,Upper Respiratory Tract Infection,,,
adverseReaction,1eb2ffc4-d6d9-4efb-9f88-8434214d047e,7/14/2011,7,SAR,seasonal allergic rhinitis,,,
adverseReaction,4bc249f2-7e8b-05cb-38ad-3085e947e0f1,11/18/2011,9,ALT,"align=""left"" colspan=""1"" rowspan=""1"">SGPT",,,
adverseReaction,4bc249f2-7e8b-05cb-38ad-3085e947e0f1,11/18/2011,9,AST,"align=""left"" colspan=""1"" rowspan=""1"">SGOT",,,
adverseReaction,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,HDL,high-density lipoprotein,,,
adverseReaction,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,GI,Gastrointestinal,,,
adverseReaction,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,cUTI,complicated urinary tract infections,,,
adverseReaction,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,i.e.,into a limited,,,
adverseReaction,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,EEG,electroencephalogram,,,
adverseReaction,4c149192-bfdf-4da2-abac-be4fa3e17c56,3/14/2011,4,WHO,World Health Organization,,,
adverseReaction,4c149192-bfdf-4da2-abac-be4fa3e17c56,3/14/2011,4,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,aa530dfd-3a48-46b9-9678-a7bc48316e41,10/1/2009,3,TSS,toxic shock syndrome,,,
adverseReaction,837a54d9-e335-4af2-b3c7-a993af619a6d,12/1/2011,1,HDL,High Density Lipoprotein,,,
adverseReaction,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,TC,total cholesterol,,,
adverseReaction,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,TG,triglycerides,,,
adverseReaction,760d589c-24f1-c89a-bc01-ea57101b2f20,11/1/2003,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,27bee6c9-118a-4609-8949-2eb161b0c5c4,2/28/2012,3593,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,71bdbbb9-8696-416d-bed4-7259929c0161,5/18/2011,5,URI,upper respiratory tract infection,,,
adverseReaction,71bdbbb9-8696-416d-bed4-7259929c0161,5/18/2011,5,SAR,seasonal allergic rhinitis,,,
adverseReaction,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,ALT,at baseline <3 times ULN,,,
adverseReaction,29b69da9-3f02-4863-ad22-6cbffba4291e,1/18/2012,1,ALT,alanine aminotransferase,,,
adverseReaction,29b69da9-3f02-4863-ad22-6cbffba4291e,1/18/2012,1,AST,aspartate aminotransferase,,,
adverseReaction,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,ELISAs,Enzyme?linked immunosorbent assays,,,
adverseReaction,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,EEG,electroencephalogram,,,
adverseReaction,6f6f6cc7-0833-410c-8889-206addebbfa3,4/1/2010,1,JRA,Juvenile Rheumatoid Arthritis,,,
adverseReaction,c129f662-9ae7-45b6-9a02-15b569e051fc,6/1/2010,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,dfecf849-5261-438a-bd1c-68a7a72c6e3a,4/6/2012,3,TEN,Toxic epidermal necrolysis,,,
adverseReaction,087507ee-8b55-4897-a888-ce363087659b,9/10/2010,1,URI,Upper Respiratory Tract Infection,,,
adverseReaction,087507ee-8b55-4897-a888-ce363087659b,9/10/2010,1,SAR,seasonal allergic rhinitis,,,
adverseReaction,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,MAS,macrophage activation syndrome,,,
adverseReaction,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
adverseReaction,076da359-b3d0-44f7-8c0e-662f5b7a8668,3/12/2010,2,Table 3,the laboratory abnormalities described for Study 934,,,
adverseReaction,be478f3c-40f6-47cc-8ab9-f420a9372b1c,10/24/2010,1,TEN,Toxic epidermal necrolysis,,,
adverseReaction,be478f3c-40f6-47cc-8ab9-f420a9372b1c,10/24/2010,1,ADH,antidiuretic hormone,,,
adverseReaction,be478f3c-40f6-47cc-8ab9-f420a9372b1c,10/24/2010,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,4633eab3-2c9e-4a5f-a282-108445b7cea7,9/16/2010,28,BUN,libido<br/>Rhinorrhea<br/>Flushing<br/>Hyperuricemia<br/>Hyperglycemia<br/>Hyponatremia<br/>Hypochloremia<br/>Increase  in serum urea nitrogen,,,
adverseReaction,a293cece-e97a-4e67-be72-b187568e3b11,1/1/2010,1,IBS,irritable bowel syndrome,,,
adverseReaction,a293cece-e97a-4e67-be72-b187568e3b11,1/1/2010,1,BPH,benign prostatic hypertrophy,,,
adverseReaction,a293cece-e97a-4e67-be72-b187568e3b11,1/1/2010,1,AUR,Acute urinary retention,,,
adverseReaction,a293cece-e97a-4e67-be72-b187568e3b11,1/1/2010,1,OAB,overactive bladder,,,
adverseReaction,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,AST,aspartate transaminase,,,
adverseReaction,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,ALT,alanine transaminase,,,
adverseReaction,c4597231-fec0-435d-a0c6-8c237e3d60a9,10/20/2009,3,BUN,blood urea increased,,,
adverseReaction,679af699-714d-a3a3-674b-fc9ae4474a9a,8/25/2010,1,I.V./P.O.,involving more than 750 patients treated with azithromycin,,,
adverseReaction,10360cf0-1671-3cbe-cd7c-2c8e8753bd1b,1/1/2009,2,LMWH,low molecular weight heparin,,,
adverseReaction,457d7810-23f1-4318-9561-2cd58a9cf973,11/15/2011,4,gGT,gamma-glutamyl transpeptidase,,,
adverseReaction,ADA307F1-B6B1-4B64-A060-5C254B1948F2,3/28/2006,1,BUN,blood urea increased,,,
adverseReaction,189b7b6a-9717-44eb-b87b-fd3e985b2268,5/9/2012,3,EE,Erosive Esophagitis,,,
adverseReaction,189b7b6a-9717-44eb-b87b-fd3e985b2268,5/9/2012,3,TEN,toxic epidermal necrolysis,,,
adverseReaction,189b7b6a-9717-44eb-b87b-fd3e985b2268,5/9/2012,3,CK,creatine kinase,,,
adverseReaction,5d1e0e59-f3af-496d-a878-547b5467cd99,2/3/2010,8,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,15c0c2df-f195-45f9-a1e4-1ed2a43c2216,1/26/2012,4,ANA,antinuclear antibodies,,,
adverseReaction,44c45bfe-461f-4398-8f20-ea771b2403ee,7/13/2012,6,HR,hazard ratios,,,
adverseReaction,44c45bfe-461f-4398-8f20-ea771b2403ee,7/13/2012,6,CI,confidence intervals,,,
adverseReaction,44c45bfe-461f-4398-8f20-ea771b2403ee,7/13/2012,6,ADHF,acute decompensated heart failure,,,
adverseReaction,05adc16c-4c2b-46f0-b810-bb18d4106dc5,9/4/2009,2,TSH,thyrotropin stimulating hormone,,,
adverseReaction,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,GI,Gastrointestinal,,,
adverseReaction,c1b5d801-336f-4541-a7d9-a8d4a110a4cc,9/29/2010,3,SAEs,Serious adverse events,,,
adverseReaction,4899b6d9-c080-4209-93fc-5b08394895e7,3/1/2012,2,BUN,blood urea nitrogen,,,
adverseReaction,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,97ec87b2-322a-438b-ba95-69040c580eb6,8/18/2010,3,ANA,antinuclear antibodies,,,
adverseReaction,f639b9fe-0eb9-49bc-ab1d-a867c8b26b91,5/17/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,HVOD,Hepatic veno-occlusive disease,,,
adverseReaction,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,AML,a mixed population of hematological malignancies,,,
adverseReaction,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,TMA,thrombotic micro-angiopathy,,,
adverseReaction,6c95caa4-812e-4e47-bcfc-c641c00db3f7,11/28/2011,3,TSH,thyrotropin stimulating hormone,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,PT,prothrombin time,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,INR,international normalized ratio,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,cIAI,complicated intra-abdominal infections,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,CABP,community-acquired bacterial pneumonia,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,aPTT,and Lymphatic System: partial thromboplastin time,,,
adverseReaction,2ccdb48e-c14a-4eeb-348c-4920ccfd7465,1/12/2011,18,cSSSI,complicated skin and skin structure infections,,,
adverseReaction,61dee012-43af-0e9a-3843-9b9b91e022c4,3/21/2012,3,AZA,Azathioprine,,,
adverseReaction,61dee012-43af-0e9a-3843-9b9b91e022c4,3/21/2012,3,PTDM,Post-Transplant Diabetes Mellitus,,,
adverseReaction,61dee012-43af-0e9a-3843-9b9b91e022c4,3/21/2012,3,AZA,Tacrolimus/Azathioprine,,,
adverseReaction,1cc22d45-f09a-49e1-896c-01ef9f80822f,6/6/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,e4e9610a-765b-4237-a598-0f4b27a4553e,6/1/2010,1,ALT,Abnormalities                                                Increases in serum transaminase,,,
adverseReaction,a58fe03c-2b5c-40dc-b592-3e376b2dc9f0,10/10/2010,4,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,i.e.,into a limited,,,
adverseReaction,805cecd0-fd1f-11dd-87af-0800200c9a66,2/29/2012,4,MMPs,matrix metalloproteinases,,,
adverseReaction,e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01,6/19/2012,10,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
adverseReaction,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,84a1f925-c2f6-402e-bf35-dd65dad9545d,11/10/2010,1,ALT,ACEON® Tablets vs 0.9% placebo,,,
adverseReaction,a5fcb10d-31f6-40bd-8e0e-f01e2eb8ef7f,9/2/2010,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,c33d82ae-7991-443f-8e48-5832c02ea450,10/19/2010,4,PGTC,primary generalized tonic-clonic,,,
adverseReaction,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,GI,Gastrointestinal,,,
adverseReaction,c7bc9486-8e61-4ba1-827f-2cd8c304b454,12/28/2010,1,U/L,upper limit of normal,,,
adverseReaction,c7bc9486-8e61-4ba1-827f-2cd8c304b454,12/28/2010,1,ALT,alanine aminotransferase,,,
adverseReaction,c7bc9486-8e61-4ba1-827f-2cd8c304b454,12/28/2010,1,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,ebddb745-81f9-4b25-8739-b2886032ed26,7/28/2009,1,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,ebddb745-81f9-4b25-8739-b2886032ed26,7/28/2009,1,PDE5,phosphodiesterase type 5,,,
adverseReaction,42ae28da-a613-4db4-b471-efa4e2638dc8,1/28/2009,2,Angioedema,Angiodema and Intestinal Angiodema,,,
adverseReaction,0b781118-9a91-4855-ab7c-669ed73068e9,10/20/2011,2,see,suicide among untreated patients,,,
adverseReaction,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
adverseReaction,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,GI,are:Gastrointestinal,,,
adverseReaction,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,GI,patients.Gastrointestinal,,,
adverseReaction,a8126e6d-33f3-4357-92de-f921d4e8f26f,3/5/2012,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,96a24e36-8580-4219-9150-c1937be7572e,6/1/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,27fbf6d5-2853-4f26-bf50-9eac8bb82785,3/1/2012,1,Jaundice,jaundice,,,
adverseReaction,fc01bdbd-9958-4a87-b59f-962a1f697740,11/9/2011,20,EPS,extrapyramidal symptoms,,,
adverseReaction,fc01bdbd-9958-4a87-b59f-962a1f697740,11/9/2011,20,SJS,Stevens-Johnson syndrome,,,
adverseReaction,fc01bdbd-9958-4a87-b59f-962a1f697740,11/9/2011,20,CBC,complete blood count,,,
adverseReaction,fc01bdbd-9958-4a87-b59f-962a1f697740,11/9/2011,20,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,see,serious hepatotoxicity,,,
adverseReaction,087ff0d3-1761-47ea-a8c1-7c4cb679af97,5/4/2012,6,RLS,restless legs syndrome,,,
adverseReaction,087ff0d3-1761-47ea-a8c1-7c4cb679af97,5/4/2012,6,NPN,non-protein nitrogen,,,
adverseReaction,d17d767b-08c4-4a25-ad73-03a36d56902a,8/16/2011,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,6a11f61b-2318-4382-2b91-4366e4bb53fa,7/5/2011,11,AST,aspartate transaminase,,,
adverseReaction,6a11f61b-2318-4382-2b91-4366e4bb53fa,7/5/2011,11,ALT,alanine transaminase,,,
adverseReaction,079ed521-3ff0-47fa-86d5-a336732056cc,6/7/2010,1,LMWH,low molecular weight heparin,,,
adverseReaction,5abbc5cd-7c71-467e-ab9b-74ff29778420,11/11/2011,1,see,suicide among untreated patients,,,
adverseReaction,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,EPS,extrapyramidal symptoms,,,
adverseReaction,713b5ac7-53d6-4139-8599-3028f789de4b,1/11/2012,7,EPS,extrapyramidal symptoms,,,
adverseReaction,4ae433f5-52bb-4403-984c-32f0fad50dd1,12/10/2010,1,URI,upper respiratory infection,,,
adverseReaction,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,WBC,white blood cell,,,
adverseReaction,026da3c7-c865-4eff-a6e5-381f9645f717,12/6/2010,121,G.I.,gastrointestinal,,,
adverseReaction,bf2e0dfa-d6ca-4961-9627-b666266f58f1,5/10/2010,2,ADH,antidiuretic hormone,,,
adverseReaction,bf2e0dfa-d6ca-4961-9627-b666266f58f1,5/10/2010,2,SJS,Stevens-Johnson syndrome,,,
adverseReaction,e03d1378-6889-43d5-a34c-f96132cffa88,4/1/2012,3,AML,Acute Myeloid Leukemia,,,
adverseReaction,44146b18-78ee-406e-be8d-89a6afa15454,4/19/2011,3,SLE,Systemic lupus erythematosus,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,TNT,to New Targets Study,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,TIA,transient ischemic attack,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,fb8ef96b-ed37-4439-9294-834ef2e2a7c6,1/9/2012,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,a3a7d398-59a7-468b-b05e-fb87e8311b32,5/11/2010,1,ALT,alanine  aminotransferase,,,
adverseReaction,a3a7d398-59a7-468b-b05e-fb87e8311b32,5/11/2010,1,AST,aspartate aminotransferase,,,
adverseReaction,04c1b5e1-1cd4-4aae-9459-0091efe15c2d,6/22/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,027c7db2-2a36-477f-90bf-608ff3a0e14e,7/15/2011,1,RLS,restless legs syndrome,,,
adverseReaction,027c7db2-2a36-477f-90bf-608ff3a0e14e,7/15/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,cad3d03b-4e1b-434f-90f1-cca2789e96ab,1/11/2012,1,ANA,antinuclear antibodies,,,
adverseReaction,42a5ed18-0ea9-4fb0-87b7-62b3af79f85c,10/22/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,EPS,extrapyramidal symptoms,,,
adverseReaction,cb1ce9ec-4f07-4cc9-85bb-663ee1f2ccc7,6/7/2011,1,LMWH,low molecular weight heparin,,,
adverseReaction,050bd2a2-a125-721a-e366-255c5466f018,1/26/2012,5,BUN,blood urea nitrogen,,,
adverseReaction,050bd2a2-a125-721a-e366-255c5466f018,1/26/2012,5,BSP,bromsulphalein,,,
adverseReaction,9d71d7fd-2b25-4163-922f-018ed8c5171f,2/20/2007,1,IOP,intraocular pressure,,,
adverseReaction,9bc08d7b-13da-444f-ac8a-3714a05176cc,11/9/2011,25,WBC,white blood cell,,,
adverseReaction,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,RLS,restless legs  syndrome,,,
adverseReaction,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,NPN,non-protein nitrogen,,,
adverseReaction,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,WHO,World Health Organization,,,
adverseReaction,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,cUTI,complicated urinary tract infections,,,
adverseReaction,b6f298ba-2d7e-4a3c-9edb-8b60aba716d6,1/19/2012,7,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,A7C486DA-1104-4566-A0BB-B8FFE5B964C4,11/17/2008,1,TEAE,treatment-emergent adverse events,,,
adverseReaction,20cc66c0-a00b-4643-9819-6e0daed51e5f,4/14/2011,1,HDL,High Density Lipoprotein,,,
adverseReaction,983ce15f-cd37-4f3a-9e51-205860e80976,6/4/2010,3,BUN,blood urea  nitrogen,,,
adverseReaction,9ce19944-dd88-4a7b-84ca-b07f4ec23bad,3/8/2010,3,AST,aspartate transaminase,,,
adverseReaction,9ce19944-dd88-4a7b-84ca-b07f4ec23bad,3/8/2010,3,ALT,alanine transaminase,,,
adverseReaction,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HPS,Heart Protection Study,,,
adverseReaction,1d111239-79a0-4159-965e-f3a644b60360,2/1/2011,2,EEG,electroencephalogram,,,
adverseReaction,7b6f6f55-aef9-4521-b0b5-1f4e17ee7ad3,9/30/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,2a97ef74-b338-4655-a60b-923f86720179,10/23/2009,2,CPK,creatine phosphokinase levels,,,
adverseReaction,2a97ef74-b338-4655-a60b-923f86720179,10/23/2009,2,PROactive,Prospective Pioglitazone Clinical  Trial In Macrovascular Events,,,
adverseReaction,3ff75342-03b6-462f-b6db-80bc1a52fe6c,4/11/2012,1,ALT,Abnormalities                                                Increases in serum transaminase,,,
adverseReaction,1612d931-d86e-4dba-bbd7-0aac3eaee131,2/28/2006,1,IOP,intraocular pressure,,,
adverseReaction,1612d931-d86e-4dba-bbd7-0aac3eaee131,2/28/2006,1,bacterial,been reported following local use of corticosteroids.The development of secondary ocular infection,,,
adverseReaction,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,i.e.,into a limited,,,
adverseReaction,a55773f1-bcc8-4b15-a137-1d5377f639c3,3/7/2012,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,34b91547-31f6-4043-b91c-16c9ebd81349,2/4/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,BUN,blood urea nitrogen,,,
adverseReaction,72d1ad20-a10d-4c1e-8a4a-a125426d400f,7/1/2011,1,JRA,Juvenile Rheumatoid Arthritis,,,
adverseReaction,97a9dfe0-4c36-4733-aa06-c2cd2a1f1ca6,9/13/2011,1,Anemia,anemias progressing on therapy,,,
adverseReaction,45af3eda-caaa-4478-9372-95aa65adc9b3,5/29/2009,2,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,45af3eda-caaa-4478-9372-95aa65adc9b3,5/29/2009,2,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,d579b480-0e49-461c-b784-a51a5272849f,10/16/2009,1,i.e.,into a limited,,,
adverseReaction,e7bfb636-4b0a-440c-a4d3-d26393a14ac5,2/7/2011,1,AP,alkaline phosphatase,,,
adverseReaction,e7bfb636-4b0a-440c-a4d3-d26393a14ac5,2/7/2011,1,GGT,gamma glutamyltransferase,,,
adverseReaction,93B19AE0-C0A1-4400-9A56-6827939B7E7A,10/6/2006,1,ADH,antidiuretic hormone,,,
adverseReaction,6eeef664-ace1-47b3-9193-06ae7eb8e459,10/13/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,6eeef664-ace1-47b3-9193-06ae7eb8e459,10/13/2011,2,SJS,Stevens-Johnson syndrome,,,
adverseReaction,6eeef664-ace1-47b3-9193-06ae7eb8e459,10/13/2011,2,CBC,complete blood count,,,
adverseReaction,6eeef664-ace1-47b3-9193-06ae7eb8e459,10/13/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,BMD,bone mineral density,,,
adverseReaction,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,baf9f88a-776a-44e7-82cc-8f0ca419572f,12/15/2009,3,i.e.,in serum glucose,,,
adverseReaction,8143a6cf-dadc-4ef7-a8db-d16d7150ad34,12/8/2010,1,AST,and increased SGOT,,,
adverseReaction,d931b294-8834-4c7f-ac05-9aeb078cd86e,12/22/2011,5,AST,aspartate transaminase,,,
adverseReaction,d931b294-8834-4c7f-ac05-9aeb078cd86e,12/22/2011,5,ALT,alanine transaminase,,,
adverseReaction,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,WHO,World Health Organization,,,
adverseReaction,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,PSA,prostate-specific antigen,,,
adverseReaction,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,HSRs,hypersensitivity reactions,,,
adverseReaction,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,ECOG,Eastern Cooperative                                 Oncology Group,,,
adverseReaction,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,HSR,hypersensitivity reaction,,,
adverseReaction,f9a93841-f097-472a-b4a5-ee7a2aa74164,11/30/2011,6,ALL,acute lymphoid leukemia,,,
adverseReaction,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox®,ceftizoxime for injection,,,
adverseReaction,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,GI,Gastrointestinal,,,
adverseReaction,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,WHO,World Health Organization,,,
adverseReaction,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,52a03dbc-0510-40ec-8a33-15bf1c404622,7/1/2010,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,716ab835-584e-4bdc-ac7c-f685d88b4dad,12/10/2010,1,BUN,blood urea nitrogen,,,
adverseReaction,3801e8f0-755d-4b05-a5f7-6e14f8cff2ea,10/11/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,3ea59594-8a2b-4b64-9aa8-1d53d9027bb0,11/9/2011,19,EPS,extrapyramidal symptoms,,,
adverseReaction,3ea59594-8a2b-4b64-9aa8-1d53d9027bb0,11/9/2011,19,SJS,Stevens-Johnson syndrome,,,
adverseReaction,3ea59594-8a2b-4b64-9aa8-1d53d9027bb0,11/9/2011,19,CBC,complete blood count,,,
adverseReaction,3ea59594-8a2b-4b64-9aa8-1d53d9027bb0,11/9/2011,19,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,GI,are:Gastrointestinal,,,
adverseReaction,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,GI,patients.Gastrointestinal,,,
adverseReaction,573eefd9-3f28-4053-a8ed-1fb531c38e15,5/31/2011,10,ALL,acute lymphoid leukemia,,,
adverseReaction,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,EPS,Extrapyramidal Reactions,,,
adverseReaction,b8fdcb32-b571-43b4-91e9-b4e9f75d86ae,2/28/2011,6,ED,erectile dysfunction,,,
adverseReaction,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,TNT,to New Targets Study,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,SPARCL,Stroke Prevention by Aggressive Reduction in  Cholesterol Levels,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,TIA,transient ischemic attack,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,IDEAL,Incremental Decrease in Endpoints through  Aggressive Lipid Lowering Study,,,
adverseReaction,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,26672A97-ADF3-9F1D-4BDC-B2606747BBF5,1/30/2007,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,for EPS,from  those trials on the Simpson-Angus Rating Scale,,,
adverseReaction,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,EPS,extrapyramidal syndrome,,,
adverseReaction,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,BMI,body mass index,,,
adverseReaction,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,EPS,Extrapyramidal Symptoms,,,
adverseReaction,cdd50dc7-f712-4248-b0e3-ba247cf08cee,8/22/2011,10,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,f0892106-399d-4e53-ae8d-8797c50ce7bf,12/14/2011,11,EPS,Extrapyramidal Syndromes,,,
adverseReaction,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,EMD,arrest/electromechanical dissociation,,,
adverseReaction,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,55f21004-9ce6-4648-94d9-73ab2c7873e8,6/21/2010,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,b7bf2897-8272-4c7d-84e9-6fbba0ea63fa,2/1/2012,1,GOT,glutamic oxaloacetic transaminase,,,
adverseReaction,b7bf2897-8272-4c7d-84e9-6fbba0ea63fa,2/1/2012,1,SGOT,serum glutamic oxaloacetic transaminase,,,
adverseReaction,89967042-5a78-451a-af91-bab38afa7a4d,8/2/2010,5,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,f90f8801-e566-4288-b661-f31450aff84a,5/18/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,6220496a-b651-4e7b-9a41-0ea949de3df0,2/29/2012,3,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
adverseReaction,701e1cd8-2868-4d29-85a9-a2212c88165f,9/30/2011,7,EPS,extrapyramidal  symptoms,,,
adverseReaction,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,i.e.,into a limited,,,
adverseReaction,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,WHO,World Health Organization,,,
adverseReaction,f3b11f4f-936b-4b75-9cb5-9ef14ee95144,5/7/2012,5,ED,erectile dysfunction,,,
adverseReaction,783c8a4c-53af-4a58-b3ee-58184d2e9549,1/18/2012,1,ALT,alanine aminotransferase,,,
adverseReaction,783c8a4c-53af-4a58-b3ee-58184d2e9549,1/18/2012,1,AST,aspartate aminotransferase,,,
adverseReaction,5f4fc5df-5077-4cad-a5dc-1b54a73904cc,4/25/2012,7,BUN,blood urea increased,,,
adverseReaction,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,10/7/2009,5,HDL,High Density Lipoprotein,,,
adverseReaction,51b65970-02e6-4558-a4b3-38e56e0c073c,5/20/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,675cb354-9d13-482e-8ac2-22f709c58b4f,1/6/2012,5,MNA,mouse neutralization assay,,,
adverseReaction,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,70b8c470-3137-47ba-a8bd-f5fe141f6d66,5/11/2006,1,LE,lupus erythematosus,,,
adverseReaction,70b8c470-3137-47ba-a8bd-f5fe141f6d66,5/11/2006,1,PVCs,premature ventricular contractions,,,
adverseReaction,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,ICH,intracranial hemorrhage,,,
adverseReaction,94153dc5-9939-4409-ae13-e7ce785ac430,7/1/2010,2,AST,and increased SGOT,,,
adverseReaction,94153dc5-9939-4409-ae13-e7ce785ac430,7/1/2010,2,Cough:,Cough.,,,
adverseReaction,5cfbc0e9-cfe5-4eac-8a2a-79108e48c25a,7/8/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,32fd2bb2-1cfa-4250-feb8-d7956c794e05,4/19/2010,3,VOD,veno-occlusive disease,,,
adverseReaction,32fd2bb2-1cfa-4250-feb8-d7956c794e05,4/19/2010,3,ESI,“events of special interest”,,,
adverseReaction,012a7f03-269d-402c-923d-e5c317a795d2,6/9/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,1e4fe8ef-b215-be45-0793-c55af24db6bb,2/17/2011,4,EPS,extrapyramidal symptoms,,,
adverseReaction,b1b95503-1c7a-44e8-b5e0-d50b61db99d5,7/20/2011,1,MI,myocardial infarction,,,
adverseReaction,b1b95503-1c7a-44e8-b5e0-d50b61db99d5,7/20/2011,1,CVA,cerebrovascular accident,,,
adverseReaction,f36d4ed3-dcbb-4465-9fa6-1da811f555e6,7/10/2007,1,ANA,antinuclear antibodies,,,
adverseReaction,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,8d0575c8-5556-41ce-9b94-8c013ff69066,11/11/2011,2,see,suicide among untreated patients,,,
adverseReaction,3518853a-4c5b-4161-a178-8da7f656f009,5/13/2011,4,about 1%,about 1.5% of patients and was not significantly different                         from placebo,,,
adverseReaction,740e054b-faac-7c27-f06d-a56efb699355,1/26/2012,5,BUN,blood urea nitrogen,,,
adverseReaction,740e054b-faac-7c27-f06d-a56efb699355,1/26/2012,5,BSP,bromsulphalein,,,
adverseReaction,b8351a60-1000-4656-90ae-1fa666030dd4,6/4/2010,1,SOC,system organ class,,,
adverseReaction,4b4edc09-bbfd-471f-ac16-6118937a6e7e,11/15/2011,2,TEN,toxic epidermal necrolysis,,,
adverseReaction,9f41c976-a6d5-4e10-bf62-6e2898be8d8b,10/6/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,WHO,World Health Organization,,,
adverseReaction,9dac97a5-c992-4601-af93-138bfe2302a8,3/15/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,WBC,white blood cell,,,
adverseReaction,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,RBC,red blood cell,,,
adverseReaction,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,ALL,acute lymphoid leukemia,,,
adverseReaction,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,AML/MDS,acute myelogenous leukemia or myelodysplastic syndrome,,,
adverseReaction,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,WHO,World Health Organization,,,
adverseReaction,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,5e99755f-e72d-4865-a272-a4eb1e940107,11/29/2011,3263,EE,Erosive Esophagitis,,,
adverseReaction,5e99755f-e72d-4865-a272-a4eb1e940107,11/29/2011,3263,TEN,toxic epidermal necrolysis,,,
adverseReaction,5e99755f-e72d-4865-a272-a4eb1e940107,11/29/2011,3263,CK,creatine kinase,,,
adverseReaction,26610bfe-4c3c-4c20-8b6d-b7c18cd6fe23,12/7/2011,15,BUN,blood urea increased,,,
adverseReaction,01735685-40e0-4323-af5a-91db399f6451,4/2/2012,3,ANF,antinuclear factor,,,
adverseReaction,24bc527e-c682-4c66-964e-c21d31eca5dd,12/12/2011,2,TSH,thyrotropin stimulating hormone,,,
adverseReaction,73673E2D-8D33-4719-92CE-AB619DE343B0,1/4/2006,2,AST,aspartate transaminase,,,
adverseReaction,73673E2D-8D33-4719-92CE-AB619DE343B0,1/4/2006,2,ALT,alanine transaminase,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,TNT,to New Targets Study,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,TIA,transient ischemic attack,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,TTP,thrombocytopenic purpura,,,
adverseReaction,b13e343b-ff5f-4f1e-ae8f-0868148d58c6,6/17/2010,2,RBS,Registry-Based Study,,,
adverseReaction,b13e343b-ff5f-4f1e-ae8f-0868148d58c6,6/17/2010,2,SAEs,serious adverse events,,,
adverseReaction,b13e343b-ff5f-4f1e-ae8f-0868148d58c6,6/17/2010,2,RBS,Registry Based Study,,,
adverseReaction,ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9,3/8/2010,1,AIDS,Acquired                                                                                                            Immunodeficiency Syndrome,,,
adverseReaction,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,NPN,non-protein nitrogen,,,
adverseReaction,b1174730-7a95-4bf6-a425-a5bc1836a17a,10/6/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,fc0a61a2-78b2-46f7-9933-63fed2c1cebc,10/1/2010,1,TC,total cholesterol,,,
adverseReaction,fc0a61a2-78b2-46f7-9933-63fed2c1cebc,10/1/2010,1,BMD,bone mineral density,,,
adverseReaction,fc0a61a2-78b2-46f7-9933-63fed2c1cebc,10/1/2010,1,TG,triglycerides,,,
adverseReaction,20f8c35b-bf1c-44cf-bdd7-01b56b85bc0c,12/28/2010,1,TEN,Toxic epidermal necrolysis,,,
adverseReaction,0626b548-c908-4c54-a609-50758b93df37,4/18/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,GI,gastrointestinal,,,
adverseReaction,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,RLS,restless legs syndrome,,,
adverseReaction,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,NPN,non-protein nitrogen,,,
adverseReaction,60aa95a1-5f7d-4438-bf78-fba6127a022b,8/24/2011,1,dyspepsia,dyspeptic signs and symptoms,,,
adverseReaction,1ec7ef4d-8ea8-4189-b1ac-b8ac57d7ebe2,5/9/2012,2,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,d73a7aa3-5b5f-4532-9936-752366a2430d,7/22/2011,1,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,35940480-76d8-11de-9eb4-0002a5d5c51b,8/18/2011,4,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,PSA,prostate-specific antigen,,,
adverseReaction,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,ASR,application site reaction,,,
adverseReaction,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,777be0dc-5961-4fa8-aa7c-3b136db627a0,11/2/2011,1,HDL,High Density Lipoprotein,,,
adverseReaction,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,b701aef5-3f70-4bc2-abe7-7047b6a6e2a5,10/21/2011,1,GI,gastrointestinal,,,
adverseReaction,f4b2b88c-946c-4670-8538-84f858b7af33,5/2/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,01b14603-8f29-4fa3-8d7e-9d523f802e0b,12/31/2011,14,LMWH,low molecular weight heparin,,,
adverseReaction,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,Trials 1,Trials:                   Among 1554 patients treated with FROVA in four placebo-controlled  trials,,,
adverseReaction,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,a4de4fbc-56d2-40ac-814e-0546bca5ca7c,8/5/2011,1,WHO,World Health Organization,,,
adverseReaction,a4de4fbc-56d2-40ac-814e-0546bca5ca7c,8/5/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,HSRs,hypersensitivity reactions,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,ECG,Electrocardiogram,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,GI,Gastrointestinal,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,HSR,hypersensitivity reaction,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,HSRs,Hypersensitivity Reactions,,,
adverseReaction,3ca226a5-b121-47d4-967f-bc2b40687dac,9/19/2011,2,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,53a18eb5-4be6-40ac-aabe-d9290b483b22,9/1/2011,12,EPS,extrapyramidal symptoms,,,
adverseReaction,c7961b19-3f23-4372-b071-34423124d801,3/24/2011,2,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,3eb971cf-ab82-49f3-a46c-4d76a8ce599e,9/27/2010,2,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,fc0cbcd4-5400-4b71-a239-39e451b4c7b3,4/19/2010,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,0664309d-1342-4a63-ba5f-4b899cdf3bec,12/31/2011,10,CK,creatine kinase,,,
adverseReaction,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,NPN,non-protein nitrogen,,,
adverseReaction,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,40dd071a-d07f-452f-bf1a-2a23b9d22ca4,10/27/2010,2,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,24a02cd6-667c-4e03-8055-aaa094567864,5/11/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,24a02cd6-667c-4e03-8055-aaa094567864,5/11/2012,3,TTP,Thrombocytopenic Purpura,,,
adverseReaction,eec8727b-c98c-41a4-90b8-d49a8e01e63c,9/28/2009,10,SOCA,Studies of the Ocular Complications of AIDS,,,
adverseReaction,66b1190e-a11d-4005-bb95-fa32a0e2de1e,10/20/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,b18a36bc-1697-4b3c-a1bd-d76d2a543d8c,10/20/2011,14,PGTC,primary generalized tonic-clonic,,,
adverseReaction,d9b3e380-734b-5b0d-f8cb-e50172910c99,5/1/2010,1,i.e.,into a limited,,,
adverseReaction,0c40521f-99e3-4546-a71b-64749c3e8c16,10/22/2009,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,EPS,extrapyramidal symptoms,,,
adverseReaction,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,SJS,Stevens-Johnson syndrome,,,
adverseReaction,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,CBC,complete blood count,,,
adverseReaction,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,ESRD,end-stage renal disease,,,
adverseReaction,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,TZD,thiazolidinedione,,,
adverseReaction,83864c82-9114-4523-bab8-2b47beb88d4e,3/12/2010,2,rare,Renal Failure,,,
adverseReaction,c1e38416-5ece-4b88-8793-b49032c13672,9/1/2010,6,WHO,World Health Organization,,,
adverseReaction,c1e38416-5ece-4b88-8793-b49032c13672,9/1/2010,6,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,d564f2b1-9fc7-4201-8066-d745ac3a671f,7/6/2011,5,i.e.,in the urea cycle,,,
adverseReaction,0ae10bc4-6b65-402f-9db5-2d7753054922,12/14/2010,6,IgG,immunoglobulin G,,,
adverseReaction,0ae10bc4-6b65-402f-9db5-2d7753054922,12/14/2010,6,IgE,immunoglobulin E,,,
adverseReaction,59341250-deac-ed71-3823-a4f5d64dbd77,4/28/2011,2,GAG,glycosaminoglycan,,,
adverseReaction,6cef2a80-c7e5-44a2-92db-06082092bb35,12/10/2010,1,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,6cef2a80-c7e5-44a2-92db-06082092bb35,12/10/2010,1,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,cUTI,complicated urinary tract infections,,,
adverseReaction,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,HAMA,Human anti-mouse antibody,,,
adverseReaction,37b5287d-d520-4853-88f4-6f4cbde5a321,5/31/2012,3827,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,1fd9de6d-783b-47f3-b2b7-cb633b939494,6/8/2010,3,EPS,extrapyramidal symptoms,,,
adverseReaction,f1d77dba-9dae-4f30-b3e3-b4898993f865,1/12/2012,3,LMWH,low molecular weight heparin,,,
adverseReaction,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,cUTI,complicated urinary tract infections,,,
adverseReaction,4c222831-90af-4336-8bf6-5628ddf24326,1/13/2012,2,EEG,electroencephalogram,,,
adverseReaction,4c222831-90af-4336-8bf6-5628ddf24326,1/13/2012,2,ACEI,angiotensin-converting enzyme inhibitor,,,
adverseReaction,4c222831-90af-4336-8bf6-5628ddf24326,1/13/2012,2,BUN,blood urea nitrogen,,,
adverseReaction,4c222831-90af-4336-8bf6-5628ddf24326,1/13/2012,2,GI,gastrointestinal,,,
adverseReaction,CA26071D-1FF4-4000-8104-17F211CC6B71,5/11/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,367B47D7-C4DE-4B39-BD3A-69C29D80396F,11/6/2006,1,SIADH,syndrome of inappropriate ADH secretion,,,
adverseReaction,E1FF4C1F-5D6F-44A6-A0F6-D7CA2A94ADB9,11/5/2007,2,BUN,blood urea nitrogen,,,
adverseReaction,a73cf8ee-f99b-4972-8939-0d394a527134,11/10/2010,1,NPN,non-protein nitrogen,,,
adverseReaction,93285568-950e-4cdd-973e-0b714a536223,11/10/2011,3133,i.e.,is being  recommended,,,
adverseReaction,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,ARDS,adult respiratory distress syndrome,,,
adverseReaction,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,ALT,alanine aminotransferase,,,
adverseReaction,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,GGT,gamma-glutamyl transferase,,,
adverseReaction,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,AST,aspartate aminotransferase,,,
adverseReaction,ea2d1275-8437-4979-8199-24eb9678be94,6/1/2010,1,ALT,Abnormalities                                                Increases in serum transaminase,,,
adverseReaction,af2385dd-0a2d-4e64-86c8-d6616f48fb9d,10/10/2010,3,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,313ccc9f-7b3e-4e42-b5d8-0e27c3c72d8e,3/7/2011,8,WHO,World Health Organization,,,
adverseReaction,313ccc9f-7b3e-4e42-b5d8-0e27c3c72d8e,3/7/2011,8,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,6c587586-b966-49a8-913b-7fafbca2127a,5/7/2012,6,ED,erectile dysfunction,,,
adverseReaction,54c6ab59-6645-ae3e-810c-9c1a698feefb,11/15/2011,1,EEG,electroencephalogram,,,
adverseReaction,fa3cbd5d-677c-4b19-9032-d9182cb69a83,5/1/2012,4,ADA,anti-drug antibodies,,,
adverseReaction,ea4bf1f5-acb3-4da7-9b54-d4c97f31a964,7/20/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,7551b0a2-bfbd-4a9e-9348-654724c13a29,7/1/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,i.e.,into a limited,,,
adverseReaction,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,WHO,World  Health Organization,,,
adverseReaction,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,e7d690ab-d74a-4ee5-8927-e939a9d78453,3/31/2011,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,NPN,non-protein nitrogen,,,
adverseReaction,5ad67ea2-409c-4f52-a9b8-38216209609a,2/27/2012,1412,AST,and Endocrine                                                           Increased SGOT,,,
adverseReaction,b9ee689a-ea12-435d-b01c-70d45891e62f,9/9/2011,4,URI,upper respiratory infection,,,
adverseReaction,e94c15f7-7115-4c9e-b5e5-6b8f275882a1,2/15/2012,2,TSH,thyrotropin stimulating hormone,,,
adverseReaction,2c62c65f-527e-44ed-8491-30db3eb8b902,7/22/2011,4,EPS,extrapyramidal symptoms,,,
adverseReaction,271e9fb7-3c70-43fc-8279-5adf189f3c22,3/27/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,BUN,blood urea nitrogen,,,
adverseReaction,27badbda-3635-444e-8005-5d5ee16f8c3c,4/13/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,2e736bd6-01cc-4180-b97c-dd10b2250630,7/30/2010,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,i.e.,into a limited,,,
adverseReaction,70e73a11-5951-43db-9cd2-dc851cd5fa7b,11/11/2009,1005,GI,Gastrointestinal,,,
adverseReaction,6f25ed16-e5e9-4170-b4b4-3b460887779d,1/1/2011,1,AST,and increased SGOT,,,
adverseReaction,d466910c-9a76-44e8-8759-4717ec2c591f,12/15/2011,3,TURP,transurethral resection of the prostate,,,
adverseReaction,d466910c-9a76-44e8-8759-4717ec2c591f,12/15/2011,3,DVT,deep vein thrombosis,,,
adverseReaction,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,GI,Gastrointestinal,,,
adverseReaction,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,GI,Gastrointestinal,,,
adverseReaction,73290450-b243-4127-a07b-6835c5eb44ec,5/15/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,REACTIONS,reactions are underlined.,,,
adverseReaction,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,HPS,Heart Protection Study,,,
adverseReaction,b4fb7c77-1e82-48b7-83c5-dd04ec7c5c4e,12/15/2009,3,i.e.,in serum glucose,,,
adverseReaction,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,5f742224-618e-4f4c-bdec-7693be99c697,5/29/2009,1,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,5f742224-618e-4f4c-bdec-7693be99c697,5/29/2009,1,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,B4DC473F-FBD3-4AD9-83AF-5ED2A33E6EAE,6/13/2006,1,REM,rapid eye movement,,,
adverseReaction,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,SAEs,Serious Adverse Events,,,
adverseReaction,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,cUTI,complicated urinary tract infections,,,
adverseReaction,a1d55e87-41f7-4556-95af-0854c1b1c1bd,10/6/2010,417,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,9444ca88-e119-4027-a8bf-9f8eef7453a2,10/5/2009,1,rare,Renal Failure,,,
adverseReaction,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,EPS,.Extrapyramidal Reactions,,,
adverseReaction,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,f3cb9331-a57d-428c-a13c-7ba5f2eeab14,12/13/2011,3378,LMWH,low molecular weight heparin,,,
adverseReaction,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,WHO,World Health Organization,,,
adverseReaction,e2857ea0-df36-4d91-a705-a574fa323b2e,8/26/2010,1,AV,atrioventricular,,,
adverseReaction,e2857ea0-df36-4d91-a705-a574fa323b2e,8/26/2010,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,492dbdb2-077e-4064-bff3-372d6af0a7a2,10/26/2010,3,ELISA,enzyme?linked immunosorbent assay,,,
adverseReaction,492dbdb2-077e-4064-bff3-372d6af0a7a2,10/26/2010,3,AC?TH,AC?T but not to TCH [44%,,,
adverseReaction,492dbdb2-077e-4064-bff3-372d6af0a7a2,10/26/2010,3,HAHA,human anti?human antibody,,,
adverseReaction,508fda39-e503-4ff5-876d-726cddc4dfa6,9/1/2010,2,WHO,World Health Organization,,,
adverseReaction,c77ababd-a449-4e89-a9c6-b7e401120ba1,12/28/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,8a0a454e-b18e-4d89-bf16-943c4c968fe2,6/3/2011,5,WHO,World Health Organization,,,
adverseReaction,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,CBC,complete blood count,,,
adverseReaction,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,cUTI,complicated urinary tract infections,,,
adverseReaction,b1eee648-907a-439c-8e45-bd632364cbc3,12/28/2011,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,for EPS,from  those trials on the Simpson-Angus Rating Scale,,,
adverseReaction,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,EPS,extrapyramidal syndrome,,,
adverseReaction,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,BMI,body mass index,,,
adverseReaction,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,EPS,Extrapyramidal Symptoms,,,
adverseReaction,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,WHO,World Health Organization,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,TNT,to New Targets Study,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,TIA,transient ischemic attack,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,GI,gastrointestinal,,,
adverseReaction,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,PGTC,primary generalized tonic-clonic,,,
adverseReaction,7e117c7e-02fc-4343-92a1-230061dfc5e0,9/1/2011,12,EPS,extrapyramidal symptoms,,,
adverseReaction,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,ARDS,Acute Respiratory Distress Syndrome,,,
adverseReaction,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,TAAEs,temporally associated adverse events,,,
adverseReaction,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,TRALI,Transfusion Related Acute Lung Injury,,,
adverseReaction,b2503fff-c978-4efa-b1b4-d7740b6b26f2,3/6/2012,7,TSH,thyrotropin stimulating hormone,,,
adverseReaction,AF99AA0C-D891-4327-B406-4733F8DAC7BA,9/15/2008,1,Diarrhea,diarrhea,,,
adverseReaction,a96e22b2-eca3-4438-b959-dc5381085d31,9/3/2011,4,TC,total cholesterol,,,
adverseReaction,a96e22b2-eca3-4438-b959-dc5381085d31,9/3/2011,4,TG,triglycerides,,,
adverseReaction,f0c765e9-edc1-4944-a4e6-91b82a29a8d7,10/29/2009,5,TTP,Thrombocytopenic Purpura,,,
adverseReaction,29c0e001-4855-4903-aa1d-64e4dd155b8a,1/25/2012,9,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,9ca0ff77-6658-42ef-95ab-5896d7f947ed,1/6/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,EEG,electroencephalogram,,,
adverseReaction,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,ECG,electrocardiogram,,,
adverseReaction,27c29f1d-a908-41fb-86bd-a0370b3117ef,3/18/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,34404a9e-9349-4cd2-a80d-1a391c0eed3d,4/25/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,GI,Gastrointestinal,,,
adverseReaction,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,BUN,blood urea nitrogen,,,
adverseReaction,a41b7601-34f2-4a88-a406-f53011fb7de1,2/16/2012,5,TIV,Trivalent Inactivated Influenza Vaccine,,,
adverseReaction,7e38b09c-da41-4ee3-8f99-812d3276d551,5/3/2012,2,AST,aspartate transaminase,,,
adverseReaction,7e38b09c-da41-4ee3-8f99-812d3276d551,5/3/2012,2,ALT,alanine transaminase,,,
adverseReaction,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,ALL,acute lymphoid leukemia,,,
adverseReaction,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,1ac3b68a-ca60-43c5-a208-f92f10008521,3/23/2012,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,E.,Escherichia,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,CNS,central nervous system,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,NCI CTC,National Cancer Institute Common Toxicity Criteria,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,E.,.Escherichia,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,CCG,Cancer Group,,,
adverseReaction,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,ELISA,enzyme-linked immunosorbent assay,,,
adverseReaction,ec524b62-3b42-4c36-bca6-7ef442fcd477,12/15/2011,2,URI,upper respiratory infection,,,
adverseReaction,973efa93-7f9d-440a-a09f-521cf331b5e7,11/23/2011,4,HSRs,hypersensitivity reactions,,,
adverseReaction,973efa93-7f9d-440a-a09f-521cf331b5e7,11/23/2011,4,HSR,hypersensitivity reaction,,,
adverseReaction,a0ec4bcc-93ea-4c41-a4b6-95ec19491807,11/9/2011,17,AML,Acute Myeloid Leukemia,,,
adverseReaction,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,HDL,High Density Lipoprotein,,,
adverseReaction,eb701085-3646-4129-ab01-561e4ef1ca8b,8/9/2011,6,EPS,extrapyramidal symptoms,,,
adverseReaction,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,cUTI,complicated urinary tract infections,,,
adverseReaction,b4332b67-833d-4838-9594-b2b76f98d1ab,7/21/2010,1,AST,aspartate  transaminase,,,
adverseReaction,b4332b67-833d-4838-9594-b2b76f98d1ab,7/21/2010,1,ALT,alanine transaminase,,,
adverseReaction,1cf82d42-5ad0-4b86-838e-9230c61cf3d4,3/18/2010,3,NOS,not otherwise specified,,,
adverseReaction,aca7768e-28a7-4027-b1d8-e66247665f79,3/20/2012,2,IVF,in vitro fertilization,,,
adverseReaction,aca7768e-28a7-4027-b1d8-e66247665f79,3/20/2012,2,ICSI,intracytoplasmic sperm injection,,,
adverseReaction,4a246ce7-c04e-4119-9201-23e5f90152a8,6/30/2010,4,i.e.,incidences of methotrexate attributed,,,
adverseReaction,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,TEN,toxic epidermal necrolysis,,,
adverseReaction,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
adverseReaction,20dc1daf-4732-404d-9904-e046991ce59e,3/5/2011,1,WHO,World Health Organization,,,
adverseReaction,20dc1daf-4732-404d-9904-e046991ce59e,3/5/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,PSA,prostate-specific antigen,,,
adverseReaction,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,WHO,World Health Organization,,,
adverseReaction,a6008865-7f09-c535-f031-a6a9f40b5ff4,2/4/2011,9,EPS,extrapyramidal symptoms,,,
adverseReaction,4A8AE85C-66A0-48BE-4099-B3C72C838176,5/11/2009,2,EBV,Epstein Barr Virus,,,
adverseReaction,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,BUN,blood urea nitrogen,,,
adverseReaction,a3201369-1c77-4a05-bbd0-0dd333305ace,1/11/2011,2,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,HSRs,hypersensitivity reactions,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,ECG,Electrocardiogram,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,GI,Gastrointestinal,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,HSR,hypersensitivity reaction,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,HSRs,Hypersensitivity Reactions,,,
adverseReaction,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,ULN,upper limit of normal,,,
adverseReaction,c96afe62-f0cf-4d4b-b57d-194a8ec12389,7/1/2009,2,AML,acute myelogenous leukemia,,,
adverseReaction,c96afe62-f0cf-4d4b-b57d-194a8ec12389,7/1/2009,2,SC,subcutaneous injection,,,
adverseReaction,6dbf24ce-1200-49ea-95ad-9a06f6db3c1b,2/3/2010,8,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,7c3d8c2c-ece6-4aba-8b5a-3865402cffcf,3/15/2010,2,ALT,as follows:  Hepatic – elevated SGPT,,,
adverseReaction,4e07adb4-7807-47d3-b9a9-2332a3047410,4/11/2012,16,MTOPS,Medical Therapy of Prostatic Symptoms,,,
adverseReaction,4e07adb4-7807-47d3-b9a9-2332a3047410,4/11/2012,16,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,4e07adb4-7807-47d3-b9a9-2332a3047410,4/11/2012,16,PLESS,PROSCAR Long-Term Efficacy and Safety Study,,,
adverseReaction,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,PGTC,primary generalized tonic-clonic,,,
adverseReaction,e6238767-90da-4176-8ac6-d71c2025dcb5,6/22/2011,1,EE,Erosive Esophagitis,,,
adverseReaction,e6238767-90da-4176-8ac6-d71c2025dcb5,6/22/2011,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,e6238767-90da-4176-8ac6-d71c2025dcb5,6/22/2011,1,CK,creatine kinase,,,
adverseReaction,696f9e80-9cae-403b-de9e-078343ce4713,7/6/2012,13,PONV,postoperative nausea and vomiting,,,
adverseReaction,53664f8d-3a93-9f2b-daee-380707e4062c,4/1/2009,3,i.e.,into a limited,,,
adverseReaction,2e8fb017-8754-421a-a76a-c41b8f48070b,11/11/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,84e9de8f-27c3-4177-827a-6992495511ac,5/28/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,b1447b82-9e72-4e93-97c3-51fe7484517f,3/6/2012,2,AST,aspartate transaminase,,,
adverseReaction,b1447b82-9e72-4e93-97c3-51fe7484517f,3/6/2012,2,ALT,alanine transaminase,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,TNT,to New Targets Study,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,TIA,transient ischemic attack,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,TZD,thiazolidinedione,,,
adverseReaction,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,i.e.,into a limited,,,
adverseReaction,e18d23e3-b4b2-483f-9523-fdc2b10c6978,1/4/2012,3474,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,i.e.,into a limited,,,
adverseReaction,bc62b38c-4cc9-4e64-8852-1a0be6d36d8e,8/30/2011,1,Anemia,anemias progressing on therapy,,,
adverseReaction,3bc17845-11ff-48b5-9a29-4b349df04f6f,12/20/2011,19,URI,upper respiratory infection,,,
adverseReaction,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,ESRD,end-stage renal disease,,,
adverseReaction,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,TZD,thiazolidinedione,,,
adverseReaction,ffb4c507-59e5-470b-9705-6d4e854dc77a,2/16/2012,3571,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,2a569ec5-08d7-44ab-b649-384a496e173c,5/26/2010,9,CHO,Chinese Hamster Ovary,,,
adverseReaction,2a569ec5-08d7-44ab-b649-384a496e173c,5/26/2010,9,PTP,Previously Treated Patients,,,
adverseReaction,2a569ec5-08d7-44ab-b649-384a496e173c,5/26/2010,9,PUP,Previously Untreated Patients,,,
adverseReaction,2a569ec5-08d7-44ab-b649-384a496e173c,5/26/2010,9,SOC,System Organ Class,,,
adverseReaction,7cd48453-9303-4d63-825a-274ad54ba695,12/8/2011,2,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,c84ad6a2-1b52-4df0-b6c5-21a5e7cd047e,8/1/2011,1,AST,aspartate transaminase,,,
adverseReaction,c84ad6a2-1b52-4df0-b6c5-21a5e7cd047e,8/1/2011,1,ALT,alanine transaminase,,,
adverseReaction,9b993fc7-e026-4749-b785-cbd3b9c29003,3/31/2011,3,BUN,blood urea nitrogen,,,
adverseReaction,d45418b5-ba22-40b0-e29f-842d11bb09ae,4/23/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,RLS,restless legs  syndrome,,,
adverseReaction,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,NPN,non-protein nitrogen,,,
adverseReaction,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,WHO,World Health Organization,,,
adverseReaction,483bd97f-c4d0-4e23-aaa8-6334f4471e0c,4/24/2012,7,RLS,restless legs syndrome,,,
adverseReaction,483bd97f-c4d0-4e23-aaa8-6334f4471e0c,4/24/2012,7,NPN,non-protein nitrogen,,,
adverseReaction,468bc2c3-9af3-4db1-b079-f2b5b98e951d,10/29/2010,1,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,BMD,bone mineral density,,,
adverseReaction,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,805af56e-c180-47af-b9ab-ae25f61736c2,5/26/2010,1,ie,infrequently,,,
adverseReaction,35f9e465-76c0-435c-9e81-8fd9bb16cedf,8/30/2011,1,GI,Gastrointestinal,,,
adverseReaction,2b122216-be4b-4c2a-9ee6-26751266640e,8/2/2011,56,HF,Heart Failure,,,
adverseReaction,2b122216-be4b-4c2a-9ee6-26751266640e,8/2/2011,56,Trial,Treated With Carvedilol,,,
adverseReaction,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox®,ceftizoxime for injection,,,
adverseReaction,dc122a02-865a-4ffe-9f57-3e02e8d2a810,4/25/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,TNT,to New Targets Study,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,TIA,transient ischemic attack,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,7217ffdd-bcd2-48b7-a397-da966ea533bd,9/17/2009,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,7217ffdd-bcd2-48b7-a397-da966ea533bd,9/17/2009,2,cUTI,complicated urinary tract infections,,,
adverseReaction,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,CTC,Common Toxicity Criteria,,,
adverseReaction,d6d6c0df-adbf-46a4-a709-091183a56ec2,10/10/2020,429,SU,sulfonylurea drugs,,,
adverseReaction,44f634f4-b794-4d55-8ab7-037fdef8ff0f,3/21/2011,14,PONV,postoperative nausea and vomiting,,,
adverseReaction,44f634f4-b794-4d55-8ab7-037fdef8ff0f,3/21/2011,14,MEC,Moderately Emetogenic Chemotherapy,,,
adverseReaction,44f634f4-b794-4d55-8ab7-037fdef8ff0f,3/21/2011,14,CINV,chemotherapy induced nausea and vomiting,,,
adverseReaction,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,i.e.,into a limited,,,
adverseReaction,ddef12df-a0bd-4f58-bd3e-da975581d01b,8/4/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,PH,pulmonary hypertension,,,
adverseReaction,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,PDE5,phosphodiesterase type 5,,,
adverseReaction,eb0cd037-1e48-42b1-92ef-4d4ede585bb8,5/14/2010,6,HDL,High Density  Lipoprotein,,,
adverseReaction,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,tamoxifen.Ductal Carcinoma in Situ,,,
adverseReaction,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,c0c3eeb6-8a75-0b20-2008-396e63cddcdb,5/31/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,c0c3eeb6-8a75-0b20-2008-396e63cddcdb,5/31/2010,1,TTP,Thrombocytopenic Purpura,,,
adverseReaction,b078dae2-664d-4144-847a-3b9d9b557402,1/27/2012,13,BUN,Blood Urea Nitrogen,,,
adverseReaction,b078dae2-664d-4144-847a-3b9d9b557402,1/27/2012,13,HCT,hydrochlorothiazide,,,
adverseReaction,2b28ca1b-673e-491b-9421-678c999261b0,10/31/2011,6,ACEi,angiotensin converting enzyme inhibitor,,,
adverseReaction,656756de-2404-4845-a8a7-c0ffa2d61c90,10/5/2009,4,PGTC,primary generalized tonic-clonic,,,
adverseReaction,2cc75d23-408a-407a-93dd-640d49453292,12/21/2010,161,NMS,Neuroleptic malignant syndrome,,,
adverseReaction,2cc75d23-408a-407a-93dd-640d49453292,12/21/2010,161,EPS,EffectsExtrapyramidal Symptoms,,,
adverseReaction,5498f6aa-f4c1-49a3-b969-0711077dde81,8/23/2010,1,AV,atrioventricular,,,
adverseReaction,5498f6aa-f4c1-49a3-b969-0711077dde81,8/23/2010,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,5498f6aa-f4c1-49a3-b969-0711077dde81,8/23/2010,1,EPS,Extrapyramidal Reactions,,,
adverseReaction,d514ac98-2895-40f1-b1d2-00f3701434b5,9/22/2010,43,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,TC,total cholesterol,,,
adverseReaction,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,BMD,bone mineral density,,,
adverseReaction,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,TG,triglycerides,,,
adverseReaction,e11e41a1-56e3-4505-b3a5-159e03e2daba,10/4/2011,1,ie,infrequently,,,
adverseReaction,601dffbd-5987-4786-92af-853f7e60062e,1/11/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,2d6a6ff9-3f12-4a6e-bba3-3f85fd54ffac,6/29/2011,4,Jaundice,jaundice,,,
adverseReaction,f0a096a0-bde2-494f-a1af-2f778bb7c5c1,8/1/2011,17,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,e1431edd-0fc5-4ebc-8c10-53deb0db0d23,9/30/2011,4,DIOS,distal intestinal obstruction syndrome,,,
adverseReaction,70047724-e16b-4ef7-be24-06e651d004d2,10/5/2009,4,rare,Renal Failure,,,
adverseReaction,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,RLS,restless legs syndrome,,,
adverseReaction,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,HPS,Heart Protection Study,,,
adverseReaction,2cc8b659-bd69-4ecc-9b7f-9968ece05357,8/10/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,d2a87691-c9ad-4753-97a1-311fccfe6515,4/13/2011,3,MTC,medullary thyroid cancer,,,
adverseReaction,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,8da31a19-855d-4511-8365-edf70ca37272,5/19/2010,1,BUN,libido<br/>Rhinorrhea<br/>Flushing<br/>Hyperuricemia<br/>Hyperglycemia<br/>Hyponatremia<br/>Hypochloremia<br/>Increase  in serum urea nitrogen,,,
adverseReaction,2a09af01-3983-466f-8ed8-c849af848b56,4/5/2010,1,AST,aspartate transaminase,,,
adverseReaction,2a09af01-3983-466f-8ed8-c849af848b56,4/5/2010,1,ALT,alanine transaminase,,,
adverseReaction,cc5fed6e-37b5-415c-af2c-31e2bfb83c7c,3/5/2012,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,MedDRA,Medical Dictionary for Regulatory Activities,,,
adverseReaction,7efc3d9c-12f5-43f6-9a22-88d66cbe6f62,12/15/2010,5,AST,aspartate transaminase,,,
adverseReaction,7efc3d9c-12f5-43f6-9a22-88d66cbe6f62,12/15/2010,5,BUN,blood urea nitrogen,,,
adverseReaction,7efc3d9c-12f5-43f6-9a22-88d66cbe6f62,12/15/2010,5,ALT,alanine                                     transaminase,,,
adverseReaction,10d4a5d9-9cb8-4dcf-9836-34c377990128,8/18/2011,8,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,PGTC,primary generalized tonic-clonic,,,
adverseReaction,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,RLS,restless legs syndrome,,,
adverseReaction,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,NPN,non-protein nitrogen,,,
adverseReaction,cb1505f6-4b09-4e7b-a225-735f3a1a0e4b,12/19/2011,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,4710e965-7e92-4fef-b7fa-d4ecece6a606,7/18/2011,1,dyspepsia,dyspeptic signs and symptoms,,,
adverseReaction,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HPS,Heart Protection Study,,,
adverseReaction,f15b043d-fcfa-4ade-a3da-76700c0c5c2a,12/28/2010,1,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,f15b043d-fcfa-4ade-a3da-76700c0c5c2a,12/28/2010,1,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,ede15ef7-a3b3-4b3b-9392-b7fc44109f24,7/13/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,AF8317D7-B280-4F40-AD88-802F99D33D78,10/29/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,AZA,Prograf/Azathioprine,,,
adverseReaction,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,NODAT,New Onset Diabetes After Transplant,,,
adverseReaction,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,AZA,azathioprine,,,
adverseReaction,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,PTDM,Post-Transplant Diabetes Mellitus,,,
adverseReaction,6ffd38bc-0fa1-4ed5-8391-98487b7823d4,9/21/2011,15,i.e.,into a limited,,,
adverseReaction,7cd68095-12a7-446d-8ee6-4301cdf3f934,10/6/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,6/17/2011,2,BE,Barrett's Esophagus,,,
adverseReaction,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,6/17/2011,2,FMH,fatal massive hemoptysis,,,
adverseReaction,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,6/17/2011,2,HGD,High-Grade Dysplasia,,,
adverseReaction,a3294d91-4aa9-4a94-be6a-28ccf2d74326,1/11/2011,1,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,b1dfcac3-ef66-4d3e-9d58-37d3f516eb31,1/3/2012,2,one patient,of >3.5 x ULN occurred in 0.1% of patients taking TEVETEN®,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,TNT,to New Targets Study,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,TIA,transient ischemic attack,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d,3/5/2012,5,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,6ed2d03e-0c8f-4ec7-b836-0683a848a762,6/1/2012,5,SIADH,mellitus, syndrome of inappropriate antidiuretic hormone secretion,,
adverseReaction,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,PGTC,primary generalized tonic-clonic,,,
adverseReaction,97cc73cc-b5b7-458a-a933-77b00523e193,3/2/2010,102,BMT,bone marrow transplant,,,
adverseReaction,97cc73cc-b5b7-458a-a933-77b00523e193,3/2/2010,102,ARDS,acute respiratory distress syndrome,,,
adverseReaction,a7791982-48e3-4a8a-afd2-f6977048c17c,8/23/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,TNT,to New Targets Study,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,SPARCL,Stroke Prevention by Aggressive Reduction in  Cholesterol Levels,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,about 1%,about 1.5% of patients and was not significantly  different from placebo,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,TIA,transient ischemic attack,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive  Lipid Lowering Study,,,
adverseReaction,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,d0c236d5-7ca2-11e0-819a-0800200c9a66,3/30/2012,3,PRCA,pure red cell aplasia,,,
adverseReaction,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,bone,"<br/>3.0<br/>2.2<br/>2.4<br/>2.4<br/>1.4<br/>1.6<br/>1.6<br/>1.1<br/>1.1</td>                         </tr>                         <tr>                            <td>                               <content styleCode=""italics"">Musculoskeletal  </content>                               <br/>&#160;&#160;&#160;&#160;&#160;musculoskeletal",,,
adverseReaction,95dd7d8e-faa9-ab7e-3ba7-c2f027faf59b,3/2/2011,4,BUN,blood urea nitrogen,,,
adverseReaction,81e8ece1-ab0b-4deb-8f84-79f21419b328,1/22/2010,1,AOM TT,Acute Otitis Media with Tympanostomy Tubes,,,
adverseReaction,81e8ece1-ab0b-4deb-8f84-79f21419b328,1/22/2010,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,d28b7f1a-e287-47d7-a67f-3e3795c70032,9/9/2010,1,AST,aspartate transaminase,,,
adverseReaction,d28b7f1a-e287-47d7-a67f-3e3795c70032,9/9/2010,1,ALT,alanine treatment transaminase and hemorrhage,,,
adverseReaction,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,0121363e-dcd9-4c24-940b-ea890ab762e7,7/13/2010,2037,0.90%, N=5,insomnia (0.9%, N=5); nausea,
adverseReaction,0121363e-dcd9-4c24-940b-ea890ab762e7,7/13/2010,2037,0.60%, N=3,pain (0.6%, N=3); fatigue,
adverseReaction,34dddfc8-badd-4371-86a5-e9ee31a66531,3/4/2011,2,HDL,High Density Lipoprotein,,,
adverseReaction,865ea555-ba24-4f2c-8791-cf681b76ad3f,11/2/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,cUTI,complicated urinary tract infections,,,
adverseReaction,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,WHO,World Health Organization,,,
adverseReaction,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,EPS,extrapyramidal symptoms,,,
adverseReaction,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,TTP,Thrombocytopenic Purpura,,,
adverseReaction,4b21af6c-486c-4b45-8adb-ae67f7e77ac6,8/11/2010,6,EE,Erosive Esophagitis,,,
adverseReaction,4b21af6c-486c-4b45-8adb-ae67f7e77ac6,8/11/2010,6,TEN,toxic epidermal necrolysis,,,
adverseReaction,4b21af6c-486c-4b45-8adb-ae67f7e77ac6,8/11/2010,6,CK,creatine kinase,,,
adverseReaction,24259865-233b-4258-a01b-e895a873f2c4,10/28/2009,2,TSH,thyrotropin stimulating hormone,,,
adverseReaction,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,PGTC,primary generalized tonic-clonic,,,
adverseReaction,6ce1d9b9-3a71-4c10-9c09-6259088baafb,7/15/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,cd6cbf0b-34b8-43aa-8037-360480a19cf8,1/27/2012,10,U/L,upper limit of normal,,,
adverseReaction,cd6cbf0b-34b8-43aa-8037-360480a19cf8,1/27/2012,10,ALT,alanine aminotransferase,,,
adverseReaction,cd6cbf0b-34b8-43aa-8037-360480a19cf8,1/27/2012,10,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,24d75b58-bafb-4440-b8d7-4f4079c08b0b,11/13/2007,4,BUN,blood urea increased,,,
adverseReaction,5a89f93f-db62-846e-336e-ebbdb171056d,9/23/2010,3,GGT,gamma-glutamyltransferase,,,
adverseReaction,969dd35d-fbf5-4a26-b083-d68f10085445,3/19/2008,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,a80ac249-cae4-41f3-88bb-344088b20e60,7/18/2011,4,OD/uL,optical density units per uL,,,
adverseReaction,a80ac249-cae4-41f3-88bb-344088b20e60,7/18/2011,4,RIP,radio-immunoprecipitation,,,
adverseReaction,a80ac249-cae4-41f3-88bb-344088b20e60,7/18/2011,4,ELISA,enzyme-linked immunosorbent assay,,,
adverseReaction,ac724f97-5941-47c1-bcc9-eb5e64be815a,1/26/2012,1,rare,Renal Failure,,,
adverseReaction,3dab9411-df12-4073-9cc1-3273e2aee7e7,6/29/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,e0a5dcf8-a49c-49b3-8dc9-4bbad603008a,11/22/2011,2,GOT,glutamic oxaloacetic transaminase,,,
adverseReaction,e0a5dcf8-a49c-49b3-8dc9-4bbad603008a,11/22/2011,2,SGOT,serum glutamic oxaloacetic transaminase,,,
adverseReaction,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,cUTI,complicated urinary tract infections,,,
adverseReaction,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,43aab72d-0160-3cc0-0069-8d2a98703364,1/5/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,e77a8504-b49f-4343-beaf-6e4c2c59ab45,4/3/2012,4,PY,patient-years,,,
adverseReaction,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,PDE5,phosphodiesterase type 5,,,
adverseReaction,768a363a-c814-4ef5-a37f-90fddf690c07,6/1/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,f3bc8ede-13a3-4119-a47a-8234c80bbc05,3/29/2010,1,i.e.,is being recommended,,,
adverseReaction,827d60e8-7e07-41b7-c28b-49ef1c4a5a41,2/17/2010,5,ILD,interstitial lung disease,,,
adverseReaction,827d60e8-7e07-41b7-c28b-49ef1c4a5a41,2/17/2010,5,INR,Interactions                             sections,,,
adverseReaction,827d60e8-7e07-41b7-c28b-49ef1c4a5a41,2/17/2010,5,INR,International Normalized Ratio,,,
adverseReaction,a480fe5d-68e0-471c-85cf-a9824bd7a0ae,5/8/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,a480fe5d-68e0-471c-85cf-a9824bd7a0ae,5/8/2012,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,a480fe5d-68e0-471c-85cf-a9824bd7a0ae,5/8/2012,1,CBC,complete blood count,,,
adverseReaction,a480fe5d-68e0-471c-85cf-a9824bd7a0ae,5/8/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,b40932cc-7867-4c87-8a82-402e95b3a1fc,3/27/2007,1,ALT,alanine aminotransferase,,,
adverseReaction,b40932cc-7867-4c87-8a82-402e95b3a1fc,3/27/2007,1,AST,aspartate aminotransferase,,,
adverseReaction,b5e88a0b-5504-4a69-8c72-02311c70e9c9,4/13/2012,1,CNS,central nervous system,,,
adverseReaction,8db221b1-32f3-f6ca-e404-71f56a860d08,6/22/2012,1,AOM TT,Acute Otitis Media with Tympanostomy Tubes,,,
adverseReaction,8db221b1-32f3-f6ca-e404-71f56a860d08,6/22/2012,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,6afd70a6-fe7b-4096-894e-86c89c3b463f,9/1/2011,12,EPS,extrapyramidal symptoms,,,
adverseReaction,d267425d-4e5f-4e7a-a27e-fe8814f0e225,8/1/2011,9,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,ec0e596c-baca-417d-8aa4-a1878100064d,10/11/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,b5603084-dda6-4147-9d88-3818877b5f62,8/11/2011,1,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,545cea18-11ad-4881-b184-6f8bcc7908e4,7/16/2012,5,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,c621d002-b7bf-4f3a-af68-4f70fd298d05,3/12/2012,3,INR,International normalized ratio,,,
adverseReaction,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,WHO,World Health Organization,,,
adverseReaction,1873bce1-172f-4eb0-b5bc-cb7d444a8d8e,4/25/2012,14,ALT,Alanine Aminotransferase,,,
adverseReaction,1873bce1-172f-4eb0-b5bc-cb7d444a8d8e,4/25/2012,14,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,c550dd16-a5e8-44be-87f2-210c15bbb513,3/2/2012,10,CTC,Common Toxicity Criteria,,,
adverseReaction,86530199-999b-9f92-b1bc-b8515ec829f3,9/26/2011,2,EEG,electroencephalogram,,,
adverseReaction,a71a83c2-2289-4e9a-b15f-1bea81d49aa0,6/15/2008,2,ALA,aminolevulinic acid,,,
adverseReaction,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,GI,Gastrointestinal,,,
adverseReaction,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,PEA,arrest/pulseless electrical activity,,,
adverseReaction,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,33f60b40-3fca-11de-8f56-0002a5d5c51b,3/21/2011,16,general,General Disorders and Administrative Site Conditions: Infrequent – edema,,,
adverseReaction,4d0f0f1a-31af-40fa-9c64-e90891fa6ce4,6/15/2012,4,ANLL,acute nonlymphocytic leukemia,,,
adverseReaction,a28547a9-0831-488b-bfdf-7ae8bed82da9,11/17/2010,466,G.I.,gastrointestinal,,,
adverseReaction,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,4b1e7c09-c393-4f1e-be68-8a662ceda185,1/9/2012,1,i.e.,into a limited,,,
adverseReaction,f85aba16-6b3e-476a-a193-f266c4bdfef4,11/30/2010,112,ANF,antinuclear factor,,,
adverseReaction,f2e8b588-fae5-476a-b7c5-f27e72db56e3,5/17/2012,2,EPS,extrapyramidal symptoms,,,
adverseReaction,ceac1ae3-c343-28ca-c083-b748d21a15e6,10/18/2011,3,BUN,blood urea increased,,,
adverseReaction,33068ad0-3654-4b5a-a081-5ce89075b307,5/16/2011,1,TEN,Toxic epidermal necrolysis,,,
adverseReaction,33068ad0-3654-4b5a-a081-5ce89075b307,5/16/2011,1,ADH,antidiuretic hormone,,,
adverseReaction,33068ad0-3654-4b5a-a081-5ce89075b307,5/16/2011,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,c851ac17-0068-4320-94d4-fd955a26e1ac,11/16/2011,1,AST,aspartate transaminase,,,
adverseReaction,c851ac17-0068-4320-94d4-fd955a26e1ac,11/16/2011,1,ALT,alanine transaminase,,,
adverseReaction,893c95d7-d9b6-4064-db97-91dd21ce7e40,12/6/2011,7,T-LBL,/T-cell lymphoblastic lymphoma,,,
adverseReaction,893c95d7-d9b6-4064-db97-91dd21ce7e40,12/6/2011,7,T-ALL,T-cell acute lymphoblastic leukemia,,,
adverseReaction,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,RLS,restless legs syndrome,,,
adverseReaction,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,NPN,non-protein nitrogen,,,
adverseReaction,e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3,11/11/2011,5,PBI,protein bound iodine,,,
adverseReaction,d5b85158-b0d6-4855-9d07-8d1b3ad9ab71,10/18/2010,7,SOC,System Order Class,,,
adverseReaction,53132901-2adb-48b9-9158-5ae585c759bd,4/28/2011,1,SLE,Systemic lupus erythematosus,,,
adverseReaction,1cd37c76-84d0-4091-b68c-e2f67127a2e0,12/17/2010,2,AST,aspartate transaminase,,,
adverseReaction,1cd37c76-84d0-4091-b68c-e2f67127a2e0,12/17/2010,2,ALT,alanine transaminase,,,
adverseReaction,bcaffc12-69af-46a8-a092-b3f66a0508d5,2/14/2012,2,AST,and Endocrine                                                           Increased SGOT,,,
adverseReaction,8ebda73d-82a3-4b17-8a81-a1f258003d32,2/17/2012,2,BMD,bone mineral density,,,
adverseReaction,f916dfb5-15fc-408f-b874-5656aeb80743,4/4/2011,1,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,9dfc5f4b-3936-4607-8495-439a27433e81,4/7/2011,4,BUN,blood urea increased,,,
adverseReaction,826c77fa-d8b2-48df-8028-720b15912d92,12/19/2011,2,COPD,chronic obstructive pulmonary disease,,,
adverseReaction,826c77fa-d8b2-48df-8028-720b15912d92,12/19/2011,2,MI,myocardial infarction,,,
adverseReaction,826c77fa-d8b2-48df-8028-720b15912d92,12/19/2011,2,PVD,peripheral vascular disease,,,
adverseReaction,826c77fa-d8b2-48df-8028-720b15912d92,12/19/2011,2,CVA,cerebrovascular accident,,,
adverseReaction,eabf8701-5661-49e5-8b66-29b9be3fd265,12/16/2010,150,NMS,Neuroleptic Malignant  Syndrome,,,
adverseReaction,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,WHO,World Health Organization,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,HSRs,hypersensitivity reactions,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,ECG,Electrocardiogram,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,GI,Gastrointestinal,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,HSR,hypersensitivity reaction,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,HSRs,Hypersensitivity Reactions,,,
adverseReaction,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,ARDS,adult respiratory distress syndrome,,,
adverseReaction,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,ALT,alanine aminotransferase,,,
adverseReaction,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,GGT,gamma-glutamyl transferase,,,
adverseReaction,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,AST,aspartate aminotransferase,,,
adverseReaction,66146d45-0fe4-46b9-b2b1-b67c219088b7,2/1/2012,1,GOT,glutamic oxaloacetic transaminase,,,
adverseReaction,66146d45-0fe4-46b9-b2b1-b67c219088b7,2/1/2012,1,SGOT,serum glutamic oxaloacetic transaminase,,,
adverseReaction,f3182470-1965-4e20-dbaf-e3506f893ea5,6/8/2012,7,SAEs,Serious Adverse Events,,,
adverseReaction,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,6a8621eb-7415-42a6-9432-630751d34c6b,8/30/2010,1,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,6a8621eb-7415-42a6-9432-630751d34c6b,8/30/2010,1,PDE5,phosphodiesterase type 5,,,
adverseReaction,1866bcff-0cb2-469c-8952-84179643ae5f,12/1/2011,3289,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,87e10b06-773c-4d7b-97a7-34b2437c2b53,12/15/2010,2,CNS,Central Nervous System,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,HSRs,hypersensitivity reactions,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,ECG,Electrocardiogram,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,GI,Gastrointestinal,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,HSR,hypersensitivity reaction,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,HSRs,Hypersensitivity Reactions,,,
adverseReaction,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,WHO,World Health Organization,,,
adverseReaction,c7bdf6cc-ef15-4ea8-a4a9-86f5434ebf09,4/21/2011,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,3F82E6B5-C6B6-4D96-8295-948FEC7E7FDB,2/12/2009,4,TEAE,treatment-emergent adverse events,,,
adverseReaction,19ebf09d-cf0d-4744-a874-a3a9f0b624b4,9/4/2009,1,TTP,thrombocytopenic purpura,,,
adverseReaction,19ebf09d-cf0d-4744-a874-a3a9f0b624b4,9/4/2009,1,NPN,non-protein nitrogen,,,
adverseReaction,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,EPS,extrapyramidal symptoms,,,
adverseReaction,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,AEs,adverse effects,,,
adverseReaction,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,URI,upper respiratory infection,,,
adverseReaction,473a3ac4-67f4-4782-baa9-7f9bdd8761f4,11/9/2011,18,BARS,Barnes Akathisia Rating Scale,,,
adverseReaction,473a3ac4-67f4-4782-baa9-7f9bdd8761f4,11/9/2011,18,EPS,Extrapyramidal Symptoms,,,
adverseReaction,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,i.e.,is being recommended,,,
adverseReaction,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,cUTI,complicated urinary tract infections,,,
adverseReaction,42abd7f6-d3b0-4133-b9ca-258f699f7162,7/7/2011,10,AST,aspartate transaminase,,,
adverseReaction,42abd7f6-d3b0-4133-b9ca-258f699f7162,7/7/2011,10,ALT,alanine transaminase,,,
adverseReaction,539cdfb4-b920-48fb-8176-fe23841e3d32,2/14/2012,2,BUN,Blood Urea Nitrogen,,,
adverseReaction,539cdfb4-b920-48fb-8176-fe23841e3d32,2/14/2012,2,HCT,hydrochlorothiazide,,,
adverseReaction,6814cd6d-fbb7-4504-8c01-45b31df7b566,7/21/2010,1,EE,Erosive Esophagitis,,,
adverseReaction,6814cd6d-fbb7-4504-8c01-45b31df7b566,7/21/2010,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,6814cd6d-fbb7-4504-8c01-45b31df7b566,7/21/2010,1,CK,creatine kinase,,,
adverseReaction,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,ECG,electrocardiogram,,,
adverseReaction,564709e8-358f-c185-4ecb-b3849c3fe59c,11/25/2011,7,TEN,toxic epidermal necrolysis,,,
adverseReaction,5fc4f89c-cf94-4e7a-bf31-d3d86a242efa,3/19/2007,1,ALT,alanine aminotransferase,,,
adverseReaction,5fc4f89c-cf94-4e7a-bf31-d3d86a242efa,3/19/2007,1,AST,aspartate aminotransferase,,,
adverseReaction,7BFF901E-0496-4818-813A-108B762B83A8,4/7/2006,1,IOP,intraocular pressure,,,
adverseReaction,0005e2a8-3ab9-4173-a46f-9c53881379e2,8/19/2010,2,LMWH,low molecular weight heparin,,,
adverseReaction,d1329893-a8bc-4f31-a31b-76690d111035,12/28/2010,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,WHO,World Health Organization,,,
adverseReaction,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,NPN,non-protein nitrogen,,,
adverseReaction,A784F545-F209-46D4-9350-AE64FAD9E07C,1/12/2009,4,AST,aspartate transaminase,,,
adverseReaction,A784F545-F209-46D4-9350-AE64FAD9E07C,1/12/2009,4,ALT,alanine transaminase,,,
adverseReaction,3cae0c4c-faaa-43f5-a186-91b2c8bd0a13,5/10/2007,2,BUN,Blood urea nitrogen,,,
adverseReaction,3cae0c4c-faaa-43f5-a186-91b2c8bd0a13,5/10/2007,2,MCV,Mean Cell Volume,,,
adverseReaction,ef08d90f-ba26-4b68-8e3a-d0320e4b0f8e,4/12/2012,2,ISMN,Isosorbide Mononitrate,,,
adverseReaction,e7705bf6-e473-4b9c-bb5d-57e26ffe7b97,6/8/2012,7,TEN,toxic epidermal necrolysis,,,
adverseReaction,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,TEN,Toxic epidermal necrolysis,,,
adverseReaction,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,ADH,antidiuretic hormone,,,
adverseReaction,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,SJS,Stevens-Johnson syndrome,,,
adverseReaction,967bd870-7517-43bc-90eb-05e831d688ae,2/17/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,b3efaffa-9ef9-4a4f-998e-aa7d2eb61fc9,6/28/2011,10,SGOT,significant increase was observed in median AST,,,
adverseReaction,dd8d7ec8-79b0-4152-8789-d247c77232ce,7/22/2009,2,PY,patient-years,,,
adverseReaction,b5412eeb-f638-4fac-9c4d-605a43e5b4c4,11/14/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,ff316953-15c5-434d-abbf-7b675492e2cc,4/19/2012,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,56bac591-9f78-4958-8a3b-878d36d3ceca,6/30/2010,5,IVF,in vitro fertilization therapy,,,
adverseReaction,56bac591-9f78-4958-8a3b-878d36d3ceca,6/30/2010,5,GnRH,gonadotropin release hormone,,,
adverseReaction,616224ff-a925-4b38-9ca2-00fbf669380f,12/6/2011,9,CLD,chronic liver disease,,,
adverseReaction,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,RLS,restless legs syndrome,,,
adverseReaction,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,NPN,non-protein nitrogen,,,
adverseReaction,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,Trials,trials,,,
adverseReaction,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,i.e.,into a limited,,,
adverseReaction,fe8bea43-9144-41c7-9c12-52e910008e28,4/18/2011,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,fe8bea43-9144-41c7-9c12-52e910008e28,4/18/2011,1,SS,serotonin syndrome,,,
adverseReaction,c9c3fa3e-af0c-42b9-a7c0-181642d2b1ea,12/17/2009,3,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,TNT,to New Targets Study,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,TIA,transient ischemic attack,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,cc9e1c8c-0e2b-44e2-878b-27057f786be9,5/2/2012,13,RRMS,relapsing remitting MS,,,
adverseReaction,62186279-2814-453e-8256-5592db6aa66f,5/23/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,6eeb14df-6fcf-a737-5359-5744eb4accea,5/15/2009,2,i.e.,into a limited,,,
adverseReaction,c3f47985-0027-4fa7-aab2-5bc6ca79a6e8,8/1/2011,7,GI,Gastrointestinal,,,
adverseReaction,77c8c6c2-cf86-4795-b035-0501e6635f27,10/29/2010,2,AST,aspartate transaminase,,,
adverseReaction,77c8c6c2-cf86-4795-b035-0501e6635f27,10/29/2010,2,ALT,alanine transaminase,,,
adverseReaction,87d39a93-7a51-4662-8e57-f9950c995caa,11/11/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,TNT,to New Targets Study,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,TIA,transient ischemic attack,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,4743a48b-d4b5-4054-85e1-9d64cc40de25,10/18/2011,1,U/L,upper limit of normal,,,
adverseReaction,4743a48b-d4b5-4054-85e1-9d64cc40de25,10/18/2011,1,ALT,alanine aminotransferase,,,
adverseReaction,4743a48b-d4b5-4054-85e1-9d64cc40de25,10/18/2011,1,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,7aad4b60-41ac-424f-b1ae-5e7212b312e6,11/21/2011,18,BUN,blood urea nitrogen,,,
adverseReaction,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,7a8c0140-f34f-4018-956e-1834a9a2abe1,3/13/2012,1,ED,erectile dysfunction,,,
adverseReaction,36199637-6267-43d6-9304-d77e8948c4fd,12/10/2009,2,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,93902b00-6cbf-477d-9a3a-e47b2c45ff96,4/18/2012,3761,MedDRA,Medical Dictionary for Regulatory Activities,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,TNT,to New Targets Study,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,TIA,transient ischemic attack,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,5cb7fd36-ae36-409b-af79-9c432e1cf5d9,6/1/2011,7,EEG,electroencephalogram,,,
adverseReaction,6408f6b7-8794-4dd5-2db6-0b44660c586d,1/7/2011,5,vWF,Von Willebrand factor,,,
adverseReaction,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,aa5028d6-fd0a-4cf1-b708-c93bb2a7c76a,6/22/2012,4,NMS,Neuroleptic malignant syndrome,,,
adverseReaction,2fcc87a4-74ef-46bd-8ee9-bd2f3cf3d0c2,8/1/2011,7,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,854148e7-53c2-c4c3-a5b1-2397a0b06be4,7/8/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,854148e7-53c2-c4c3-a5b1-2397a0b06be4,7/8/2011,2,SJS,Stevens-Johnson syndrome,,,
adverseReaction,854148e7-53c2-c4c3-a5b1-2397a0b06be4,7/8/2011,2,CBC,complete blood count,,,
adverseReaction,854148e7-53c2-c4c3-a5b1-2397a0b06be4,7/8/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,b52dfa36-f90b-4e19-9b5e-26db9d04df2b,8/1/2008,8,FLS,flu-like symptoms,,,
adverseReaction,23b73332-cbb3-4155-8ad8-b24619cdea85,4/4/2012,1,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,23b73332-cbb3-4155-8ad8-b24619cdea85,4/4/2012,1,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,eadf575d-7561-4020-b88f-a280e58d10ba,6/1/2011,1,ALT,as follows: Hepatic - elevated SGPT,,,
adverseReaction,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,10/31/2011,6,ANA,antinuclear antibodies,,,
adverseReaction,1842bb9f-60ab-4af9-95a4-1cfc3645ee6b,11/22/2011,2,GOT,glutamic oxaloacetic transaminase,,,
adverseReaction,1842bb9f-60ab-4af9-95a4-1cfc3645ee6b,11/22/2011,2,SGOT,serum glutamic oxaloacetic transaminase,,,
adverseReaction,63b36274-89f0-42d8-9f09-f9e78e179af4,1/11/2012,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,910fae46-5eaf-427f-b137-e4e775b065c7,5/31/2012,3831,NOS,not otherwise specified,,,
adverseReaction,c957df9a-eb66-432f-a280-9cd74389d667,8/1/2011,13,GI,Gastrointestinal,,,
adverseReaction,abfeded8-9da9-4884-8429-bed89763d873,2/22/2012,11,BUN,Creatinine/Blood Urea Nitrogen,,,
adverseReaction,dc429f91-5de5-4a4a-9943-422ec2331694,8/10/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,172e2eed-2086-4cc2-8a13-c3f25f3995d6,7/29/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,36202145-15cc-47b9-9706-b7102da8586f,2/14/2012,1,WHO,World Health Organization,,,
adverseReaction,36202145-15cc-47b9-9706-b7102da8586f,2/14/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,1f21097c-7d48-47e5-ab09-8dc7f7e06e9d,8/31/2009,5,EPS,extrapyramidal symptoms,,,
adverseReaction,c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f,5/2/2012,22,TURP,transurethral resection of the prostate,,,
adverseReaction,c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f,5/2/2012,22,DVT,deep vein thrombosis,,,
adverseReaction,751747da-7c1f-41ad-b1a6-a6d920f70599,12/31/2011,14,INR,International normalized ratio,,,
adverseReaction,dffb4544-0e47-40cd-9baa-d622075838cc,1/12/2006,1,TEN,,,,
adverseReaction,02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55,9/26/2011,3,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,e0c27a29-b895-4132-a2c2-8da4c0722d03,8/17/2010,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,e28b0df4-b052-4588-8a45-d17797116c3f,9/1/2010,2,WHO,World Health Organization,,,
adverseReaction,3796bad0-85ff-409f-be43-28884bbc115e,5/29/2012,4,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,635f8a00-0048-4421-9f5f-f8e38034f230,8/17/2011,1,GI,Gastrointestinal,,,
adverseReaction,b695b4cc-f3b0-4704-910c-bd840efaf443,5/13/2011,2,GI,Gastrointestinal,,,
adverseReaction,A32ECCC4-16D1-47A5-9E61-261F5D38638C,3/2/2007,1,ANA,antinuclear antibodies,,,
adverseReaction,1f1490cd-b11b-40cb-96be-865730c989e1,2/11/2008,2,WHO,World Health Organization,,,
adverseReaction,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,BMD,bone mineral density,,,
adverseReaction,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,3b433650-0dca-4714-bb72-341036d3972e,4/15/2009,1,ALL,acute lymphoid leukemia,,,
adverseReaction,45e6dce4-92e2-4ad1-bf11-bbcefb753636,1/5/2012,8,AML,Acute Myeloid Leukemia,,,
adverseReaction,a430577c-f233-40a7-bfd8-3d2bc6f98aa2,3/18/2011,7,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,1c3250f3-d291-4280-97d5-da3bb171e2b6,9/19/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,i.e.,"styleCode=""bold"">infusion rate",,,
adverseReaction,acd53964-52dc-4534-b20f-14a7561b8a6c,10/23/2009,1,SS,serotonin syndrome,,,
adverseReaction,7a7daacf-cfc1-464f-8841-c9a27d7b3529,7/8/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,PH,pulmonary hypertension,,,
adverseReaction,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,PDE5,phosphodiesterase type 5,,,
adverseReaction,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,EEG,electroencephalogram,,,
adverseReaction,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,BARS,Barnes Akathisia Rating Scale,,,
adverseReaction,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,SJS,Stevens-Johnson syndrome,,,
adverseReaction,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,CBC,complete blood count,,,
adverseReaction,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,EPS,Extrapyramidal Symptoms,,,
adverseReaction,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,GI,Gastrointestinal,,,
adverseReaction,2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a,9/11/2006,1,IOP,intraocular pressure,,,
adverseReaction,2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a,9/11/2006,1,bacterial,been reported following local use of corticosteroids.The development of secondary ocular infection,,,
adverseReaction,1c572c5b-24f6-46c6-bdd2-6774ebefbb42,6/22/2012,12,EPS,extrapyramidal symptoms,,,
adverseReaction,ef4d3d9f-4976-4eae-92b1-77749de3c63c,2/6/2006,2,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,BUN,blood urea nitrogen,,,
adverseReaction,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,COSTART,Coding Symbols for Thesaurus of Adverse Reaction Terms,,,
adverseReaction,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,HPA,Hypothalamic-pituitary-adrenal,,,
adverseReaction,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,MedDRA,Medical Dictionary for Regulatory Activities terminology,,,
adverseReaction,763213c9-3e4b-4ea1-a544-f7d3720568ad,12/28/2011,3,GI,Gastrointestinal,,,
adverseReaction,8d9a17e9-fd2d-4976-9704-42c6e1760db4,5/14/2010,401,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,RLS,restless legs  syndrome,,,
adverseReaction,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,NPN,non-protein nitrogen,,,
adverseReaction,1eee14d3-acfc-4002-b457-6bd69afbd2c7,8/4/2011,1,SLE,Systemic lupus erythematosus,,,
adverseReaction,2315d6e5-144d-4163-9711-f855c759cf8e,2/10/2011,1,EEG,electroencephalogram,,,
adverseReaction,4b43f23c-3354-41e7-a1ec-81f6fe341f86,3/22/2012,1,SIADH,syndrome of  inappropriate antidiuretic hormone,,,
adverseReaction,a5a77f2d-2833-4dd9-8839-95f0e63b1606,3/8/2011,1,GI,Gastrointestinal,,,
adverseReaction,d99348b1-edad-41de-aed9-903a6f9f279f,10/1/2010,8,CHO,Chinese                                     Hamster Ovary,,,
adverseReaction,d99348b1-edad-41de-aed9-903a6f9f279f,10/1/2010,8,PUP,Previously Untreated                                     Patients,,,
adverseReaction,d99348b1-edad-41de-aed9-903a6f9f279f,10/1/2010,8,PTP,Previously Treated Patients,,,
adverseReaction,d99348b1-edad-41de-aed9-903a6f9f279f,10/1/2010,8,SOC,System Organ Class,,,
adverseReaction,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,0d83cde7-4604-4bdd-a7cd-c31a5830514d,1/12/2010,1,WHO,World Health Organization,,,
adverseReaction,0d83cde7-4604-4bdd-a7cd-c31a5830514d,1/12/2010,1,SSRI-,selective serotonin reuptake inhibitor-,,,
adverseReaction,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,BMD,bone mineral density,,,
adverseReaction,1f3c04d9-cccb-06a3-a0f3-f7c9228ee743,2/10/2012,6,PGTC,primary generalized tonic-clonic,,,
adverseReaction,c8c74af4-cac5-4cde-ab68-3f3647c5cb99,8/17/2011,10,TEN,Toxic epidermal necrolysis,,,
adverseReaction,c8c74af4-cac5-4cde-ab68-3f3647c5cb99,8/17/2011,10,ADH,antidiuretic hormone,,,
adverseReaction,c8c74af4-cac5-4cde-ab68-3f3647c5cb99,8/17/2011,10,SJS,Stevens-Johnson syndrome,,,
adverseReaction,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,AEs,adverse events,,,
adverseReaction,8290add3-4449-4e58-6c97-8fe1eec972e3,5/30/2012,1416,TEN,Toxic epidermal necrolysis,,,
adverseReaction,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,AST,aspartate transaminase,,,
adverseReaction,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,ALT,alanine transaminase,,,
adverseReaction,2837a082-3a34-6f81-5e43-45a70295686b,8/22/2008,3,G.I.,gastrointestinal,,,
adverseReaction,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,4fa83401-321d-4fb9-bd7f-8cfa966782e3,10/20/2011,4,i.e.,into a limited,,,
adverseReaction,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,PONV,postoperative nausea and vomiting,,,
adverseReaction,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,PH,pulmonary hypertension,,,
adverseReaction,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,PDE5,phosphodiesterase type 5,,,
adverseReaction,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,BUN,blood urea nitrogen,,,
adverseReaction,238176e5-df10-457b-a5cf-c950a583e748,3/30/2011,6,URI,upper respiratory infection,,,
adverseReaction,558a2e6f-fbc0-4bac-abcb-7117018bc919,4/3/2012,3,TSH,thyrotropin stimulating hormone,,,
adverseReaction,45c45f61-b20b-41ba-af07-1f977163d39b,6/25/2010,4,BUN,blood urea nitrogen,,,
adverseReaction,bac2c9a1-0300-412c-964b-eba3ed73d8cb,5/22/2012,3,HITT,Heparin-induced Thrombocytopenia and Thrombosis,,,
adverseReaction,bac2c9a1-0300-412c-964b-eba3ed73d8cb,5/22/2012,3,HIT,Heparin-induced Thrombocytopenia,,,
adverseReaction,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,CPK,creatinine phosphokinase,,,
adverseReaction,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,BSP,Bromsulphalein,,,
adverseReaction,82731db6-92fc-483b-9d73-9b2aed79b104,12/13/2011,9,AML,Acute Myeloid Leukemia,,,
adverseReaction,e2f854cb-7f91-4269-ba67-97065ac8b4a0,3/3/2011,1405,TEN,Toxic epidermal necrolysis,,,
adverseReaction,2d77412a-e084-4406-ac33-d882aece9354,3/12/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,2d77412a-e084-4406-ac33-d882aece9354,3/12/2012,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,2d77412a-e084-4406-ac33-d882aece9354,3/12/2012,1,CBC,complete blood count,,,
adverseReaction,2d77412a-e084-4406-ac33-d882aece9354,3/12/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,78b374f8-0e16-4c15-85c1-16609ac3aca2,10/1/2010,6,ANA,antinuclear antibodies,,,
adverseReaction,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,HCl,hydrochloride Tablets Product Information for details,,,
adverseReaction,b0d3df23-9450-4ae8-b626-d14d8b9ef481,9/1/2011,3,URI,upper respiratory infection,,,
adverseReaction,1123d56c-16f0-4f81-b56f-67b1f343ae1e,3/31/2011,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,e8593016-2bec-4c62-a10f-e7e944c26755,8/22/2008,3,G.I.,gastrointestinal,,,
adverseReaction,49be5b16-dab5-4a95-b202-bfb13d730d83,4/30/2011,6,NCCTG,North Central Cancer Treatment Group,,,
adverseReaction,7073b706-1946-4ff2-8788-fb9452a59cae,4/15/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,0a5c7e83-3b17-4412-89fb-ff2235cbe77c,3/30/2012,13,EEG,electroencephalogram,,,
adverseReaction,0a5c7e83-3b17-4412-89fb-ff2235cbe77c,3/30/2012,13,GI,gastrointestinal,,,
adverseReaction,0a5c7e83-3b17-4412-89fb-ff2235cbe77c,3/30/2012,13,BUN,Blood Urea Nitrogen,,,
adverseReaction,30bbeb12-0141-4a86-8928-206e8f963a67,6/1/2011,1,PY,patient-years,,,
adverseReaction,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,BMD,bone mineral density,,,
adverseReaction,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,cUTI,complicated urinary tract infections,,,
adverseReaction,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,BMD,bone mineral density,,,
adverseReaction,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,0396bfec-afe1-460c-8141-e8ad877b4bc0,4/1/2010,1,PCR,"styleCode=""italics"">Probable Causal Relationship",,,
adverseReaction,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,b891bd9f-fdb8-4862-89c5-ecdd700398a3,1/7/2010,2,ECGs,Electrocardiograms,,,
adverseReaction,3dc79540-2f24-4920-99cd-ef6482f68eb2,12/27/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,3dc79540-2f24-4920-99cd-ef6482f68eb2,12/27/2010,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,3dc79540-2f24-4920-99cd-ef6482f68eb2,12/27/2010,1,CBC,complete blood count,,,
adverseReaction,3dc79540-2f24-4920-99cd-ef6482f68eb2,12/27/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,dae5ec58-85c1-4503-a6b8-56696dd1e6fc,5/31/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,f713500a-20b8-8e20-c4cc-956805170335,4/20/2010,1,GI,gastrointestinal,,,
adverseReaction,e61ae711-e6d2-44e4-b7d7-943a9d06f985,3/17/2011,1,G.I.,gastrointestinal,,,
adverseReaction,B1E6C7AB-EEFE-4089-B403-EDEAAB4F6E36,1/3/2007,1,ANF,antinuclear factor,,,
adverseReaction,f11dae15-b057-4258-9229-3819d0c980fe,7/28/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,92FE06D1-9AEC-47B4-B7FC-AEA6434CBE10,6/1/2006,1,DIC,disseminated intravascular coagulation,,,
adverseReaction,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,i.e.,into a limited,,,
adverseReaction,21b73946-d12e-4a61-8eaa-4bf10bb31b98,10/4/2011,1,SU,sulfonylurea drugs,,,
adverseReaction,21b73946-d12e-4a61-8eaa-4bf10bb31b98,10/4/2011,1,Events,events,,,
adverseReaction,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,ART,Assisted Reproductive                 Technologies,,,
adverseReaction,db801706-1362-44c7-92ab-f584f96c7e1c,9/22/2011,5,ANA,antinuclear antibodies,,,
adverseReaction,820839ef-e53d-47e8-a3b9-d911ff92e6a9,3/30/2012,15,NOS,not otherwise specified,,,
adverseReaction,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,MAC,Monitored Anesthesia Care,,,
adverseReaction,fbf67fc8-8d29-4ae2-a533-75461754c5b1,3/14/2012,4,ADH,antidiuretic hormone,,,
adverseReaction,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,RLS,restless legs  syndrome,,,
adverseReaction,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,NPN,non-protein nitrogen,,,
adverseReaction,46b2ddff-d40a-43ac-b027-4fac9fc2f4b9,7/15/2011,6,Spray,sprays/nostril twice daily,,,
adverseReaction,0fb9f3ab-45d1-405e-a14e-4cb4b1a28c55,10/27/2009,2,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,f08efff4-861d-43ef-9eb3-92608b32d24e,6/29/2010,4,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,c8b18a0b-b4f7-4f88-8732-1fa4736c3046,3/15/2012,3665,BUN,Blood Urea Nitrogen,,,
adverseReaction,c8b18a0b-b4f7-4f88-8732-1fa4736c3046,3/15/2012,3665,HCT,hydrochlorothiazide,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,TNT,to New Targets Study,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,TIA,transient ischemic attack,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,2f4c571b-a27e-40ef-b0cd-e6e44ac9a15e,3/15/2010,5,ALT,as follows:  Hepatic – elevated SGPT,,,
adverseReaction,14d37c59-0b0c-4507-9f15-481bd7f5f4d2,12/2/2011,2,TEN,toxic epidermal necrolysis,,,
adverseReaction,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,i.e.,into a limited,,,
adverseReaction,ba5527fb-76fc-4ee5-b62e-a141c58c957d,1/17/2008,2,lorazepam,Lorazepam,,,
adverseReaction,af38711e-8873-4790-a92d-4d583e23fb89,12/15/2007,4,GGT,gamma-glutamyltransferase,,,
adverseReaction,179b9b4f-74b2-4b51-bdea-e77afd15c50a,7/19/2011,6,URI,upper respiratory infection,,,
adverseReaction,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,RLS,restless legs syndrome,,,
adverseReaction,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,NPN,non-protein nitrogen,,,
adverseReaction,939e28c5-f3a9-42c0-9a2d-8d471d82a6e0,4/11/2012,2,ASRs,application site reactions,,,
adverseReaction,d0ef6df3-67e5-47b1-bcf7-f67aa030caca,5/17/2012,13,EPS,extrapyramidal symptoms,,,
adverseReaction,a9abe8f4-0b0b-42f7-b3d7-c678a9fcf39f,6/9/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,SAE,serious adverse event,,,
adverseReaction,d0b31508-de7c-4203-be0f-5954d4e71813,9/27/2011,2,URI,upper respiratory infection,,,
adverseReaction,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,EEG,electroencephalogram,,,
adverseReaction,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,RLS,restless legs  syndrome,,,
adverseReaction,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,NPN,non-protein nitrogen,,,
adverseReaction,a1c8ee2a-6a76-435e-ad38-8a9c99046ad9,1/27/2012,1,INR,international normalized ratio,,,
adverseReaction,dce12085-d6c4-48a5-959b-e771c413c9c5,4/10/2012,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,98dc2482-ec98-48dc-9449-93ac202e5679,9/13/2011,5,PGTC,primary generalized tonic-clonic,,,
adverseReaction,37A18BD1-034F-4366-8323-EC4E1C52AC1E,7/21/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,d34336b1-7041-4078-beda-94bc9d9f771e,12/4/2009,3,WHO,World Health Organization,,,
adverseReaction,d34336b1-7041-4078-beda-94bc9d9f771e,12/4/2009,3,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,B52BDAF7-3B54-4165-9AB0-9DFA08170E47,12/1/2008,1,AUCs,affords minimal peak serum levels and systemic exposure,,,
adverseReaction,a9a3c560-2408-4dd0-9f83-ee3e3a549c7b,3/9/2012,2,LMWH,low molecular weight heparin,,,
adverseReaction,e5f93bf7-6f27-4963-a508-11f317f030a0,4/19/2011,2,SLE,Systemic lupus erythematosus,,,
adverseReaction,daf11e04-d69c-4aaa-80e6-a4bac692736c,5/21/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,4770e42e-9ce7-42e0-a880-0908df244606,9/1/2011,12,EPS,extrapyramidal symptoms,,,
adverseReaction,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SD,standard  deviation,,,
adverseReaction,9be700c1-937a-180d-fb38-bc2aa85d20cf,6/26/2006,1,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,ARDS,adult respiratory distress syndrome,,,
adverseReaction,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,ALT,alanine aminotransferase,,,
adverseReaction,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,GGT,gamma-glutamyl transferase,,,
adverseReaction,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,AST,aspartate aminotransferase,,,
adverseReaction,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,WHO,World Health Organization,,,
adverseReaction,9b711ce9-f8cb-4ef0-b0c8-9477b1b30230,10/11/2010,50,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,for EPS,from  those trials on the Simpson-Angus Rating Scale,,,
adverseReaction,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,EPS,extrapyramidal syndrome,,,
adverseReaction,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,BMI,body mass index,,,
adverseReaction,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,EPS,Extrapyramidal Symptoms,,,
adverseReaction,f66b58cd-5d9d-416e-a41d-bad80a306681,3/30/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,b63c4c7d-3dbf-419d-84cc-2c1957b92be7,4/13/2012,11,SIDS,Sudden Infant Death Syndrome,,,
adverseReaction,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,c10f83e7-3aca-4087-8208-8c0a93413b01,5/24/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,f931d3af-c32a-4406-8799-9b097f41594b,6/16/2010,2,NMS,neuroleptic malignant syndrome,,,
adverseReaction,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,WHO,World Health Organization,,,
adverseReaction,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,ALT,as follows:Hepatic - elevated SGPT,,,
adverseReaction,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,EPS,extrapyramidal symptoms,,,
adverseReaction,78470162-0f92-4f46-a9c8-902f94ddcc7f,2/14/2012,1,ANA,antinuclear antibodies,,,
adverseReaction,782af2da-7092-4e55-8f07-9e67c283bf84,2/10/2011,1,ALT,Abnormalities                                                Increases in serum transaminase,,,
adverseReaction,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,EMD,arrest/electromechanical dissociation,,,
adverseReaction,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,TNT,to New Targets Study,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,TIA,transient ischemic attack,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,GI,Gastrointestinal,,,
adverseReaction,F7EC5EC1-FB05-4C78-B821-9AEA638CF144,6/11/2008,1,ALL,acute lymphoid leukemia,,,
adverseReaction,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,TTP,thrombocytopenic purpura,,,
adverseReaction,fbc54fbc-a886-4b25-b879-fbbc95b46cf1,11/7/2011,2,WBC,white blood cell count,,,
adverseReaction,87ecfffe-4b46-4e06-84eb-d2eaed45062e,8/10/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,HSRs,hypersensitivity reactions,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,ECG,Electrocardiogram,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,GI,Gastrointestinal,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,HSR,hypersensitivity reaction,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,HSRs,Hypersensitivity Reactions,,,
adverseReaction,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,ddI,didanosine,,,
adverseReaction,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
adverseReaction,3202b686-e944-4b52-a226-9297fe899606,6/28/2011,1,EEG,electroencephalogram,,,
adverseReaction,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,ba20f010-1866-4763-b859-d54eac59c481,11/15/2011,2,TEN,toxic epidermal necrolysis,,,
adverseReaction,94d644b9-9ad1-4c21-9c88-c39796b3e3e6,10/27/2009,1,TSH,thyrotropin stimulating  hormone,,,
adverseReaction,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,ESAs,erythropoiesis stimulating agents,,,
adverseReaction,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,MPM,Malignant Pleural Mesothelioma,,,
adverseReaction,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,NSCLC,Non-Small Cell Lung Cancer,,,
adverseReaction,e6183e05-b9b6-460e-b7bd-e6885bd0b696,1/12/2012,2,TSS,toxic shock syndrome,,,
adverseReaction,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,154af0be-18fb-413e-a702-012bb259962d,2/9/2012,3,GI,gastrointestinal,,,
adverseReaction,320f63f2-fac3-4aee-aff8-85724e00ef52,9/14/2010,6,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,6e808a2e-c49c-48ee-a64d-fb2e0aefbaf5,7/28/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,7026f0a7-3f08-4116-aa0b-eb61dc3804ab,2/28/2012,3594,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,TTP,thrombocytopenic purpura,,,
adverseReaction,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,NPN,non-protein nitrogen,,,
adverseReaction,3b1f8ee3-d582-4faa-a7f2-0fbc45721298,7/13/2011,1,Anemia,anemias progressing on therapy,,,
adverseReaction,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,NPN,non-protein nitrogen,,,
adverseReaction,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,AML,acute myelogenous leukemia,,,
adverseReaction,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,SC,subcutaneous injection,,,
adverseReaction,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,i.e.,is being  recommended,,,
adverseReaction,0800d19b-bdd8-47c9-81c3-67a92b81d07a,2/1/2011,5,BMD,bone mineral density,,,
adverseReaction,ACBCE0E8-5098-4785-943B-8BDB5FF17FAB,3/18/2008,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,1e528336-c1a6-4657-96a6-5eb5121e757b,6/24/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,ae7bbf44-c5af-4bda-bc22-2388498ad529,11/16/2011,4,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,d17e3be5-514f-454a-8347-d804cd5ec37f,10/8/2011,1,i.e.,in serum glucose,,,
adverseReaction,b186bdcd-5a50-41a5-818e-5bb45b6008b1,8/29/2011,1,ANF,antinuclear factor,,,
adverseReaction,d3a4788f-6ff4-4804-9b41-7d6f0b27cd5c,8/11/2011,5,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,83c20b13-f3ee-4724-8c8b-18a42460680f,7/3/2012,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,fcc8658c-761a-443f-8c32-1499d86028ec,5/11/2010,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,RLS,restless legs syndrome,,,
adverseReaction,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,dd0ca36d-1f54-4568-8d19-a7152addcd52,9/9/2011,6,AML,Acute Myeloid Leukemia,,,
adverseReaction,8e4382de-df78-4821-b11e-c423442a7ff8,4/1/2011,7,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,cUTI,complicated urinary tract infections,,,
adverseReaction,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,PMNs,<tr><td/><td>&#8593;Polymorphonuclear neutrophils,,,
adverseReaction,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,ALT,<tr><td/><td>&#8593;Alanine aminotransferase,,,
adverseReaction,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,BUN,<tr><td/><td>&#8593;Blood urea nitrogen,,,
adverseReaction,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,AST,<tr><td/><td>&#8593;Aspartate aminotransferase,,,
adverseReaction,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,48f4d638-d2a1-47fa-9a81-3acda1b1b1e3,1/11/2012,21,TEN,toxic epidermal necrolysis,,,
adverseReaction,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,AV,atrioventricular,,,
adverseReaction,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,NMS,neuroleptic malignant syndrome,,,
adverseReaction,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,EPS,Extrapyramidal Reactions,,,
adverseReaction,88e7a888-1464-491a-a439-9a9c127c3702,7/20/2011,1,mg/day,mg/dayTopiramate Group Topiramate Dosage,,,
adverseReaction,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,WHO,World Health Organization,,,
adverseReaction,308c0bb7-e8cc-4920-8f23-cf8e7c004341,7/6/2011,3,ANA,antinuclear antibodies,,,
adverseReaction,beb15c4c-9ad8-4fa4-d28c-cef6ed9871b5,2/29/2012,15,RLS,restless legs syndrome,,,
adverseReaction,beb15c4c-9ad8-4fa4-d28c-cef6ed9871b5,2/29/2012,15,NPN,non-protein nitrogen,,,
adverseReaction,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,NPN,non-protein nitrogen,,,
adverseReaction,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,RLS,porphyria,restless legs syndrome,,
adverseReaction,88603d5f-4ad0-46ab-999f-740312dc35dc,1/14/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,cUTI,complicated urinary tract infections,,,
adverseReaction,5d344c39-175b-4819-b9da-8ba630530ad7,4/7/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,BUN,blood urea nitrogen,,,
adverseReaction,df3c1900-a076-4a3a-a2a8-5939d818451f,10/1/2011,14,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,a6794dfa-adbb-491b-9d48-f89a44e866c5,10/1/2010,6,ANA,antinuclear antibodies,,,
adverseReaction,8e35c4c8-bf56-458f-a73c-8f5733829788,4/16/2012,20,ECL,electrochemical luminescence,,,
adverseReaction,8e35c4c8-bf56-458f-a73c-8f5733829788,4/16/2012,20,ELISA,enzyme-linked immunosorbent assay,,,
adverseReaction,377EEFB1-E588-4D23-BBFC-F9ED877124B0,11/12/2008,3,ANA,antinuclear antibodies,,,
adverseReaction,9fd7a181-ab26-4e68-8404-20ce339b0844,9/30/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,8f0ff905-5eb3-4ad0-ad31-fe35b924211f,10/27/2009,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,8f0ff905-5eb3-4ad0-ad31-fe35b924211f,10/27/2009,1,i.e.,into a limited,,,
adverseReaction,47a00976-3625-4d19-8418-b88b8693f968,4/21/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,G.I.,gastrointestinal,,,
adverseReaction,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,GI,gastrointestinal,,,
adverseReaction,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,BUN,blood urea nitrogen,,,
adverseReaction,819571ea-b808-4fd8-93c7-1ea2e33d71cf,2/9/2011,1,MTIC,5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide,,,
adverseReaction,819571ea-b808-4fd8-93c7-1ea2e33d71cf,2/9/2011,1,PCP,Pneumocystis carinii pneumonia,,,
adverseReaction,819571ea-b808-4fd8-93c7-1ea2e33d71cf,2/9/2011,1,CTC,Common Toxicity Criteria,,,
adverseReaction,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,BE,Barrett’s Esophagus,,,
adverseReaction,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,HGD,High-Grade Dysplasia,,,
adverseReaction,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,PSA,prostate-specific antigen,,,
adverseReaction,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,a990373a-fad0-4ed5-aa56-7a065d092caa,8/10/2011,4,ANA,antinuclear antibodies,,,
adverseReaction,a0ce563a-8a78-4692-bcf5-620b74d84cdd,1/24/2007,1,NMS,neuroleptic malignant syndrome,,,
adverseReaction,23271cee-8b35-47e7-ae97-cb2ff8a48f02,9/1/2010,1,AST,aspartate transaminase,,,
adverseReaction,23271cee-8b35-47e7-ae97-cb2ff8a48f02,9/1/2010,1,ALT,alanine treatment transaminase and hemorrhage,,,
adverseReaction,16026409-e821-4680-a114-24c1761d6690,1/30/2008,3,TEN,Toxic epidermal necrolysis,,,
adverseReaction,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,i.e.,is being recommended,,,
adverseReaction,b1918b4e-2238-4cbd-81be-61cae5481c88,5/7/2012,7,PGTC,primary generalized tonic-clonic,,,
adverseReaction,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,WHO,World Health Organization,,,
adverseReaction,ff6c0109-e6f3-4920-83f3-6e39fd28a118,5/20/2011,7,WHO,World Health Organization,,,
adverseReaction,ff6c0109-e6f3-4920-83f3-6e39fd28a118,5/20/2011,7,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,GI,Gastrointestinal,,,
adverseReaction,e2902ed1-cfeb-4815-adc3-129c577917a1,1/15/2012,12,i.e.,into the maintenance phase,,,
adverseReaction,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,EEG,electroencephalogram,,,
adverseReaction,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,ECG,electrocardiogram,,,
adverseReaction,268fe552-b8f0-45ab-658a-39616c40c9d4,6/5/2012,7,AST,and Endocrine                                                           Increased SGOT,,,
adverseReaction,85522c25-1d1c-477c-8aa7-895ec3dfc3dc,4/18/2012,3762,EPS,extrapyramidal symptoms,,,
adverseReaction,85522c25-1d1c-477c-8aa7-895ec3dfc3dc,4/18/2012,3762,SJS,Stevens-Johnson syndrome,,,
adverseReaction,85522c25-1d1c-477c-8aa7-895ec3dfc3dc,4/18/2012,3762,CBC,complete blood count,,,
adverseReaction,85522c25-1d1c-477c-8aa7-895ec3dfc3dc,4/18/2012,3762,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,284b5dac-2b8d-46bf-95fe-80ce03fa178a,11/23/2010,4,AIDS,Acquired  Immunodeficiency Syndrome,,,
adverseReaction,6f25ed16-e5e9-4170-b4b4-3b460887779e,12/16/2011,9,AST,and increased SGOT,,,
adverseReaction,bc09674c-221f-40d8-9fd4-6da672496b3a,3/27/2012,1,WHO,World Health Organization,,,
adverseReaction,bc09674c-221f-40d8-9fd4-6da672496b3a,3/27/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,d5e13c3c-2ca8-4989-aba0-4a5e8a75c383,4/14/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,cUTI,complicated urinary tract infections,,,
adverseReaction,d0708534-89cb-4c2c-a076-c19e7f57ffcf,9/26/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,LDH,lactic dehydrogenase,,,
adverseReaction,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,TTP/HUS,thrombocytopenic purpura/hemolytic uremic syndrome,,,
adverseReaction,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,CMV,cytomegalovirus,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,HSRs,hypersensitivity reactions,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,ECG,Electrocardiogram,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,GI,Gastrointestinal,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,HSR,hypersensitivity reaction,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,HSRs,Hypersensitivity Reactions,,,
adverseReaction,2DEEE7BA-BBD9-4827-8265-9E770E9D93BC,8/20/2007,1,RDA,Recommended Dietary Allowance,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,TNT,to New Targets Study,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,TIA,transient ischemic attack,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,481eec00-9abf-11dd-b71c-0002a5d5c51b,5/30/2012,7,DIOS,distal intestinal obstruction syndrome,,,
adverseReaction,289bda32-6198-4072-a9f3-283438bda707,9/13/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,TNT,to New Targets Study,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,TIA,transient ischemic attack,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,95b03516-34b0-4438-a05c-918d80f70091,3/30/2012,3,NODAT,New Onset Diabetes After Transplant,,,
adverseReaction,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,23993d21-80bf-41c4-b57d-88a620173b6b,1/27/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,0c3354b5-a1d8-4f98-ad55-2eafe4265c4e,9/29/2010,7,COPD,chronic obstructive pulmonary disease,,,
adverseReaction,b78499dc-4d24-4226-be97-dc618d9da0cf,4/17/2012,2,AV,atrioventricular,,,
adverseReaction,b78499dc-4d24-4226-be97-dc618d9da0cf,4/17/2012,2,NMS,neuroleptic malignant syndrome,,,
adverseReaction,2D367E16-FC74-4A63-AC6D-85E038164DE5,7/11/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,c5484f1a-2321-453f-9469-dfcf709e2e2e,2/8/2012,4,AOM TT,Acute Otitis Media with Tympanostomy Tubes,,,
adverseReaction,c5484f1a-2321-453f-9469-dfcf709e2e2e,2/8/2012,4,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,ee1eaaf6-050b-48af-942b-5e3451edc164,3/31/2010,2,BUN,blood urea nitrogen,,,
adverseReaction,75d8099b-4e08-43c0-811e-589d4fb52932,9/13/2011,1,AOM TT,Acute Otitis Media with Tympanostomy Tubes,,,
adverseReaction,75d8099b-4e08-43c0-811e-589d4fb52932,9/13/2011,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,2a169bec-aa08-44e8-b6fa-f412f5be3b07,4/15/2011,3,TSH,thyrotropin stimulating hormone,,,
adverseReaction,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,PH,pulmonary hypertension,,,
adverseReaction,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,PDE5,phosphodiesterase type 5,,,
adverseReaction,8e456333-5a25-4484-84bf-53ece67c000a,5/9/2012,6,MEDWATCH,www.fda.gov/medwatch,,,
adverseReaction,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,TEN,toxic epidermal necrolysis,,,
adverseReaction,b2608b36-03d1-46b6-9633-88d21306a317,11/18/2011,3218,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,ea2067bd-1622-4d98-8012-2c09405aa88d,8/22/2011,10,WHO,World Health Organization,,,
adverseReaction,ea2067bd-1622-4d98-8012-2c09405aa88d,8/22/2011,10,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,8b682a09-ad34-452d-95a4-58a0a35470f1,12/1/2011,3291,SS,serotonin syndrome,,,
adverseReaction,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,PSA,prostate-specific antigen,,,
adverseReaction,c135323a-33dd-49d5-b55a-33e1ff1b78fd,10/25/2010,2,AIDS,Acquired                                                                                                            Immunodeficiency Syndrome,,,
adverseReaction,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,i.e.,inappropriately,,,
adverseReaction,cc2f489e-a75d-47dc-96d1-7f05bc6b7197,9/12/2006,1,IOP,intraocular pressure,,,
adverseReaction,610b905a-50d3-48f0-919a-69cc99aab5a8,11/8/2010,5,TRALI,Transfusion-Related Acute Lung Injury,,,
adverseReaction,610b905a-50d3-48f0-919a-69cc99aab5a8,11/8/2010,5,ARDS,Acute Respiratory Distress Syndrome,,,
adverseReaction,3d71cd67-1e4f-4db5-8e05-edaaec50e6d2,5/16/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,19592ac2-e193-47c4-b93e-e1d124d005d6,3/28/2011,3,ED,erectile dysfunction,,,
adverseReaction,eed26501-890d-4ff6-88e7-6dbea4726e53,6/27/2012,15,PVAN,Polyomavirus associated nephropathy,,,
adverseReaction,eed26501-890d-4ff6-88e7-6dbea4726e53,6/27/2012,15,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,eed26501-890d-4ff6-88e7-6dbea4726e53,6/27/2012,15,PRCA,pure red cell aplasia,,,
adverseReaction,eed26501-890d-4ff6-88e7-6dbea4726e53,6/27/2012,15,MMF,mycophenolate mofetil,,,
adverseReaction,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,PSA,prostate-specific antigen,,,
adverseReaction,cc11b09d-e6cc-4cf8-1495-5ac64d5aae5f,3/27/2012,8,TSH,thyrotropin stimulating hormone,,,
adverseReaction,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,CNS,central nervous system,,,
adverseReaction,487193e9-b9ab-443e-a1c5-26aa14cb2641,3/30/2012,1,ALT,alanine aminotransferase,,,
adverseReaction,487193e9-b9ab-443e-a1c5-26aa14cb2641,3/30/2012,1,AST,aspartate aminotransferase,,,
adverseReaction,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,ARDS,adult respiratory distress syndrome,,,
adverseReaction,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,ALT,alanine aminotransferase,,,
adverseReaction,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,GGT,gamma-glutamyl transferase,,,
adverseReaction,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,AST,aspartate aminotransferase,,,
adverseReaction,cdf1487b-9f1d-42c6-9184-0015fff0b48f,10/28/2010,10,IBS,irritable bowel syndrome,,,
adverseReaction,cdf1487b-9f1d-42c6-9184-0015fff0b48f,10/28/2010,10,BPH,benign prostatic hypertrophy,,,
adverseReaction,cdf1487b-9f1d-42c6-9184-0015fff0b48f,10/28/2010,10,AUR,Acute urinary retention,,,
adverseReaction,cdf1487b-9f1d-42c6-9184-0015fff0b48f,10/28/2010,10,OAB,overactive bladder,,,
adverseReaction,3e2c9a35-6a39-41d7-ad84-3c0bb8894b09,12/19/2011,16,i.e.,increased relative to placebo,,,
adverseReaction,2fa7a133-ad57-4e3e-8e92-8c678d5fe68d,8/9/2011,7,N=496,<td>&#160;PLACEBO<br/>(N=496)<br/>                            </td>                            <td>&#160;PLACEBO<br/>,,,
adverseReaction,47dc96cb-e586-44dd-a002-1b1d1bf48d3d,3/27/2012,2,EPS,extrapyramidal symptoms,,,
adverseReaction,47dc96cb-e586-44dd-a002-1b1d1bf48d3d,3/27/2012,2,SJS,Stevens-Johnson syndrome,,,
adverseReaction,47dc96cb-e586-44dd-a002-1b1d1bf48d3d,3/27/2012,2,CBC,complete blood count,,,
adverseReaction,47dc96cb-e586-44dd-a002-1b1d1bf48d3d,3/27/2012,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,727a5eb4-ac82-444d-8381-44c34ee3b895,5/12/2010,2,i.e.,into a limited,,,
adverseReaction,32e2b197-e171-444d-86ca-198d4c84d7a5,11/23/2010,2,AIDS,Acquired  Immunodeficiency Syndrome,,,
adverseReaction,8e49409b-6bb1-4b8a-8a5b-4cb1a291660e,2/2/2012,1,BUN,blood urea increased,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,TNT,to New Targets Study,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,TIA,transient ischemic attack,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,WHO,World  Health Organization,,,
adverseReaction,5ce42a9d-cdce-4889-9def-cb7be2cb8d7b,3/10/2010,1002,ALT,as follows:                                         Hepatic elevated SGPT,,,
adverseReaction,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,ALT,as follows:Hepatic - elevated SGPT,,,
adverseReaction,9B59DC6E-4AE6-4D5A-A313-7732A0CE4380,11/19/2007,3,CNS,drowsiness/confusion/depression/anxiety/nervousness,,,
adverseReaction,3605a8c6-13db-409b-9e5c-19936fef9076,7/12/2010,2036,ALT,at  baseline less than 3X ULN,,,
adverseReaction,d91179bf-48ce-423c-822d-cd06b60caabe,5/30/2011,1,rare,Renal Failure,,,
adverseReaction,2ec6bd57-96df-47ac-b218-1469801868b7,10/26/2009,1,AOM TT,Acute Otitis Media with Tympanostomy Tubes,,,
adverseReaction,2ec6bd57-96df-47ac-b218-1469801868b7,10/26/2009,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,A5C67C7A-0FFD-4C51-BADB-B5109D4D25B6,3/8/2006,1,ANA,antinuclear antibodies,,,
adverseReaction,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,REACTIONS,reactions are underlined.,,,
adverseReaction,56747ded-19ce-4401-a7f2-1cd4714c2f02,8/18/2010,2,ALT,alanine aminotransferase,,,
adverseReaction,56747ded-19ce-4401-a7f2-1cd4714c2f02,8/18/2010,2,AST,aspartate aminotransferase,,,
adverseReaction,A586B484-1B46-40B9-9508-FD28002AD383,2/8/2007,1,CPK,creatinine phosphokinase,,,
adverseReaction,8de51bf0-68c4-47c1-a5a2-1a06b7215ed0,6/4/2010,2,ALT,alanine aminotransferase,,,
adverseReaction,8de51bf0-68c4-47c1-a5a2-1a06b7215ed0,6/4/2010,2,AST,aspartate aminotransferase,,,
adverseReaction,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,RLS,restless legs  syndrome,,,
adverseReaction,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,NPN,non-protein nitrogen,,,
adverseReaction,ec1de664-3135-4498-a0c9-1a9c0d3d0775,12/17/2009,3,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,ALT,AbnormalitiesIncreases in serum transaminase,,,
adverseReaction,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,BMD,bone mineral density,,,
adverseReaction,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,dce4437a-bf43-483c-8db2-5eb58fa8a559,5/20/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,73861076-218d-4f8e-872d-0e0690c374a8,3/5/2012,1,DIOS,distal intestinal obstruction syndrome,,,
adverseReaction,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,Trials,trials,,,
adverseReaction,1d2cd01c-05e7-44cf-a71d-0f474e826b7e,5/1/2009,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,9b6e29b3-7286-4408-9a44-7d8589d1d958,6/11/2012,1,MSDS,Material Safety Data Sheet,,,
adverseReaction,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,PGTC,primary generalized tonic-clonic,,,
adverseReaction,f3637209-303e-4232-ae79-07315a990973,1/9/2012,1,Anemia,anemias progressing on therapy,,,
adverseReaction,fcb8ef8a-f770-4416-8fc5-fa01d98c8eee,5/5/2011,2,NCI,National Cancer Institute,,,
adverseReaction,01859e07-1262-4cc6-b7ed-5a273cbf0c36,12/27/2010,2,EPS,extrapyramidal symptoms,,,
adverseReaction,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,TFR,tumor flare reaction,,,
adverseReaction,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,TLS,tumor lysis syndrome,,,
adverseReaction,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,EMD,arrest/electromechanical dissociation,,,
adverseReaction,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,44a07041-456a-4b0b-9a8a-9e1715327d33,1/24/2012,1,ALT,Abnormalities                                                Increases in serum transaminase,,,
adverseReaction,70adfac7-f8b7-405c-86aa-b1f30343d38b,6/26/2012,4,ie,infrequently,,,
adverseReaction,545776FE-63DF-44AB-ACE3-F3D73D2E0092,5/11/2006,1,IOP,intraocular pressure,,,
adverseReaction,9a14cb3d-cf49-4d72-ae38-86f847036a58,6/4/2010,4,ALT,alanine aminotransferase,,,
adverseReaction,9a14cb3d-cf49-4d72-ae38-86f847036a58,6/4/2010,4,AST,aspartate aminotransferase,,,
adverseReaction,e185959e-d360-4ecc-8690-e62256f696cd,5/1/2012,1,ALT,"align=""left"" colspan=""1"" rowspan=""1"">SGPT",,,
adverseReaction,e185959e-d360-4ecc-8690-e62256f696cd,5/1/2012,1,AST,"align=""left"" colspan=""1"" rowspan=""1"">SGOT",,,
adverseReaction,69e575b9-f8a5-494f-b736-2520ef505cb0,2/1/2011,1,NMS,Neuroleptic malignant syndrome,,,
adverseReaction,bc0a3a39-4ac3-47de-a388-9c3672e3e130,11/15/2011,4,AML/MDS,acute myelogenous leukemia or myelodysplastic syndrome,,,
adverseReaction,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,ICU,Intensive Care Unit,,,
adverseReaction,f4f54d5b-32f7-4765-8702-50a78c9d657e,8/23/2011,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,accf9569-4b57-4e83-a7db-4e890a75d1ba,6/19/2012,11,ANLL,acute non-lymphocytic leukemia,,,
adverseReaction,e4f3014d-381e-4a74-bc6c-5aaa12fcfc2d,8/10/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,cUTI,complicated urinary tract infections,,,
adverseReaction,3fd850a2-af0f-4291-af5d-52c8d6094e64,11/1/2011,4,URI,Upper Respiratory Tract Infection,,,
adverseReaction,3fd850a2-af0f-4291-af5d-52c8d6094e64,11/1/2011,4,SAR,seasonal allergic rhinitis,,,
adverseReaction,725d4e73-6c83-477a-adc6-0ae4a133a844,2/24/2012,13,ULN,upper limit of normal,,,
adverseReaction,725d4e73-6c83-477a-adc6-0ae4a133a844,2/24/2012,13,PDE5,phosphodiesterase type 5,,,
adverseReaction,725d4e73-6c83-477a-adc6-0ae4a133a844,2/24/2012,13,ERA,Endothelin Receptor Antagonist,,,
adverseReaction,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,i.e.,into a limited,,,
adverseReaction,96118395-557e-4998-842d-424a59d574b6,9/14/2011,3,ART,Assisted Reproductive Technology,,,
adverseReaction,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,cont.,"<tr><td><content styleCode=""underline"">Cardiovascular",,,
adverseReaction,c04b1b2c-5484-4a5d-887a-3f7ace8388a1,3/6/2012,2,AE,adverse event,,,
adverseReaction,c04b1b2c-5484-4a5d-887a-3f7ace8388a1,3/6/2012,2,SAEs,serious adverse events,,,
adverseReaction,c04b1b2c-5484-4a5d-887a-3f7ace8388a1,3/6/2012,2,BSS,baseline signs and symptoms,,,
adverseReaction,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,0193ddae-c600-4e80-a578-4fe271231991,6/28/2010,1,BMD,bone mineral density,,,
adverseReaction,208db529-ae52-462d-8fd2-775b11ce6350,9/18/2008,1,WHO,World Health Organization,,,
adverseReaction,208db529-ae52-462d-8fd2-775b11ce6350,9/18/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,PGTC,primary generalized tonic-clonic,,,
adverseReaction,d1a26230-80ab-4892-9db3-ac7a1b85c636,3/16/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,d933e1d1-06b7-4d70-981f-3e8984b0683f,6/8/2012,2,E.,Escherichia,,,
adverseReaction,d933e1d1-06b7-4d70-981f-3e8984b0683f,6/8/2012,2,NCI CTC,National Cancer Institute Common Toxicity Criteria,,,
adverseReaction,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,GI,gastrointestinal,,,
adverseReaction,e9f89260-97fb-484a-af52-5d1be77fee76,5/24/2010,1,TSH,thyrotropin stimulating  hormone,,,
adverseReaction,dc02a23b-3ff9-4441-aa91-8e9e629a7315,7/20/2011,8,ARDS,adult respiratory distress syndrome,,,
adverseReaction,dc02a23b-3ff9-4441-aa91-8e9e629a7315,7/20/2011,8,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,dc02a23b-3ff9-4441-aa91-8e9e629a7315,7/20/2011,8,ALT,alanine aminotransferase,,,
adverseReaction,dc02a23b-3ff9-4441-aa91-8e9e629a7315,7/20/2011,8,GGT,gamma-glutamyl transferase,,,
adverseReaction,dc02a23b-3ff9-4441-aa91-8e9e629a7315,7/20/2011,8,AST,aspartate aminotransferase,,,
adverseReaction,39e19789-de4b-4fd1-ab1c-92f59496f496,1/25/2012,2,i.e.,in electrolytes,,,
adverseReaction,d74e59ba-bfeb-4c48-9596-da44328561a9,5/26/2010,7,CHO,Chinese Hamster Ovary,,,
adverseReaction,d74e59ba-bfeb-4c48-9596-da44328561a9,5/26/2010,7,PTP,Previously Treated Patients,,,
adverseReaction,d74e59ba-bfeb-4c48-9596-da44328561a9,5/26/2010,7,PUP,Previously Untreated Patients,,,
adverseReaction,d74e59ba-bfeb-4c48-9596-da44328561a9,5/26/2010,7,SOC,System Organ Class,,,
adverseReaction,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,ddI,didanosine,,,
adverseReaction,556265b0-8757-11de-8a39-0800200c9a66,7/29/2011,10,DIOS,distal intestinal obstruction syndrome,,,
adverseReaction,7bb90096-14d3-400e-94d3-048bff6b1292,11/30/2010,4,ALT,alanine aminotransferase,,,
adverseReaction,7bb90096-14d3-400e-94d3-048bff6b1292,11/30/2010,4,AST,aspartate aminotransferase,,,
adverseReaction,a951cd63-d329-47c9-965a-582fa73a07c6,3/27/2012,6,EPS,extrapyramidal symptoms,,,
adverseReaction,6d988699-95c2-46b9-8266-23fe7016f33b,3/31/2011,5,U/L,upper limit of normal,,,
adverseReaction,6d988699-95c2-46b9-8266-23fe7016f33b,3/31/2011,5,ALT,alanine aminotransferase,,,
adverseReaction,6d988699-95c2-46b9-8266-23fe7016f33b,3/31/2011,5,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,ba1a46f0-61b0-4204-a2a0-c94f861fccc6,12/6/2011,1,SS,serotonin syndrome,,,
adverseReaction,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,RLS,restless legs  syndrome,,,
adverseReaction,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,NPN,non-protein nitrogen,,,
adverseReaction,ef3a204e-1209-67d8-038b-bfd04f7210a2,9/25/2000,1,URI,upper respiratory infection,,,
adverseReaction,18d7820d-471f-4ee2-9ec6-25d8d27c77de,2/22/2012,9,BUN,Blood Urea Nitrogen,,,
adverseReaction,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,TEN,Toxic epidermal necrolysis,,,
adverseReaction,47fdef53-4060-4372-9b48-fdb39a7e3fd3,4/6/2012,2,TEN,Toxic epidermal necrolysis,,,
adverseReaction,25a72ec9-de0f-44e5-90b8-da1aab0d3588,9/30/2011,7,ANA,antinuclear antibodies,,,
adverseReaction,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,TC,total cholesterol,,,
adverseReaction,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,BMD,bone mineral density,,,
adverseReaction,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,TG,triglycerides,,,
adverseReaction,60aad237-e1da-4705-cbbb-b3ca79e89ad8,4/4/2012,1419,QDR,quantitative digital radiography,,,
adverseReaction,60aad237-e1da-4705-cbbb-b3ca79e89ad8,4/4/2012,1419,DEXA,dual energy x-ray absorptiometry,,,
adverseReaction,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,RLS,restless legs syndrome,,,
adverseReaction,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,NPN,non-protein nitrogen,,,
adverseReaction,b426b6bf-f07e-4580-97ae-dfca1ddf5b8f,12/15/2011,5,ALT,abnormalities in measures of hepatocellular function,,,
adverseReaction,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,c13bc0b8-7900-4ef4-98ed-e1315a08d95d,1/29/2008,3,TEN,Toxic epidermal necrolysis,,,
adverseReaction,c13bc0b8-7900-4ef4-98ed-e1315a08d95d,1/29/2008,3,ADH,antidiuretic hormone,,,
adverseReaction,c13bc0b8-7900-4ef4-98ed-e1315a08d95d,1/29/2008,3,SJS,Stevens-Johnson syndrome,,,
adverseReaction,6bd94a89-f18a-45e5-d0a4-b343a4f0f03d,12/31/2010,11,BMD,bone mineral density,,,
adverseReaction,6bd94a89-f18a-45e5-d0a4-b343a4f0f03d,12/31/2010,11,OHSS,ovarian hyperstimulation syndrome,,,
adverseReaction,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,GI,Gastrointestinal,,,
adverseReaction,99721d00-0a3e-4966-8bce-7cfa8a9146b2,9/1/2011,3,ANA,antinuclear antibodies,,,
adverseReaction,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,NTG,nitroglycerin,,,
adverseReaction,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,SNP,sodium nitroprusside,,,
adverseReaction,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,NIC,nicardipine,,,
adverseReaction,efa614a9-e857-45a7-a8c3-faa6195fa1ec,9/10/2010,2,BUN,blood urea increased,,,
adverseReaction,a55a39ff-1bd5-428b-a64f-c44262e2f3ed,3/31/2011,5,U/L,upper limit of normal,,,
adverseReaction,a55a39ff-1bd5-428b-a64f-c44262e2f3ed,3/31/2011,5,ALT,alanine aminotransferase,,,
adverseReaction,a55a39ff-1bd5-428b-a64f-c44262e2f3ed,3/31/2011,5,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,ULN,upper limit of normal,,,
adverseReaction,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,CAP,community-acquired pneumonia,,,
adverseReaction,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,SOC,System Organ Class,,,
adverseReaction,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,INR,International Normalized Ratio,,,
adverseReaction,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,WHO,World Health Organization,,,
adverseReaction,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,GI,Gastrointestinal,,,
adverseReaction,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,i.e.,into a limited,,,
adverseReaction,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,bc747f6d-f52c-4dcb-bda5-2d0a9f954147,5/17/2012,1,LMWH,low molecular weight heparin,,,
adverseReaction,b900115a-faac-4244-94bc-c1ef2f88aa38,11/30/2011,12,ANA,antinuclear antibodies,,,
adverseReaction,b8d8c29a-414d-4622-bffd-b742725b20f0,4/4/2011,1,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,i.e.,is being  recommended,,,
adverseReaction,aaf16572-f861-452f-8096-0adca3e40d8d,12/6/2010,123,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,10db92f9-2300-4a80-836b-673e1ae91610,12/8/2011,4,ADRs,adverse drug reactions,,,
adverseReaction,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,27355e18-e832-4639-93dc-d6995ff193d6,3/8/2012,4,BMD,bone mineral density,,,
adverseReaction,2f21f0d5-ed6c-44b8-8368-b754d77dc508,12/16/2010,153,SS,serotonin syndrome,,,
adverseReaction,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,PDE5,phosphodiesterase type 5,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,DAT,direct antiglobulin test,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,B19V,B19 virus,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,HBV,hepatitis B virus,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,ARDS,Acute Respiratory Distress Syndrome,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,HIV,human immunodeficiency virus,,,
adverseReaction,6c3ce068-59f0-413b-9f93-85fb597d55e5,6/24/2010,4,HCV,hepatitis C virus,,,
adverseReaction,1982fbca-fb5f-4e14-b837-e0c59028dad7,11/3/2010,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,6e76d0ef-93ca-4be9-8384-65656fe8bd47,12/5/2009,1,AST,aspartate transaminase,,,
adverseReaction,6e76d0ef-93ca-4be9-8384-65656fe8bd47,12/5/2009,1,ALT,alanine transaminase,,,
adverseReaction,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,IVF,in vitro fertilization,,,
adverseReaction,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,GnRH,gonadotropin releasing hormone,,,
adverseReaction,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,ICSI,intracytoplasmic sperm injection,,,
adverseReaction,7494496c-02fc-4509-ae9e-cbd000fa45a1,4/1/2011,7,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,MTOPS,Medical Therapy of Prostatic Symptoms,,,
adverseReaction,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,688f5dec-a6db-43c6-a1f8-5df99d08d395,4/20/2010,2,GI,gastrointestinal,,,
adverseReaction,ac4a002d-c143-460f-8cb9-37c70c65a9eb,5/27/2005,1,BUN,blood urea nitrogen,,,
adverseReaction,4306730b-e894-45ca-b4e9-3fe7f65b7b1d,5/11/2010,1,ALT,alanine aminotransferase,,,
adverseReaction,4306730b-e894-45ca-b4e9-3fe7f65b7b1d,5/11/2010,1,AST,aspartate aminotransferase,,,
adverseReaction,240118ae-2cf5-4e48-a182-7c37026d59b5,12/31/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,EF56C531-A1CA-B94C-23DE-A0BA617AE2B4,5/29/2007,1,WHO,World Health Organization,,,
adverseReaction,EF56C531-A1CA-B94C-23DE-A0BA617AE2B4,5/29/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,21f82a95-c283-4c18-b47d-f6ba26e34299,6/9/2011,1,GI,Gastrointestinal,,,
adverseReaction,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,GI,are:Gastrointestinal,,,
adverseReaction,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,GI,patients.Gastrointestinal,,,
adverseReaction,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,ALT,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGPT",,,
adverseReaction,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,AST,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGOT",,,
adverseReaction,019ac336-0dc3-ec89-3e0a-09110e0fc30b,10/2/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,b7e18194-8d57-473d-904c-bb2e576c132b,1/19/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,2139632a-49b6-44cc-b01d-97f6c293e237,7/13/2011,1,TEN,Toxic epidermal necrolysis,,,
adverseReaction,2139632a-49b6-44cc-b01d-97f6c293e237,7/13/2011,1,ADH,antidiuretic hormone,,,
adverseReaction,2139632a-49b6-44cc-b01d-97f6c293e237,7/13/2011,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,0c4ef9ad-ac23-4f48-8eb8-f5931333deaf,1/5/2012,3485,COPD,chronic obstructive pulmonary disease,,,
adverseReaction,0c4ef9ad-ac23-4f48-8eb8-f5931333deaf,1/5/2012,3485,MI,myocardial infarction,,,
adverseReaction,0c4ef9ad-ac23-4f48-8eb8-f5931333deaf,1/5/2012,3485,PVD,peripheral vascular disease,,,
adverseReaction,0c4ef9ad-ac23-4f48-8eb8-f5931333deaf,1/5/2012,3485,CVA,cerebrovascular accident,,,
adverseReaction,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,GI,gastrointestinal,,,
adverseReaction,68e860d7-4adc-418a-ba12-233ccdf85d0a,9/27/2010,35,torsade,torsades,,,
adverseReaction,68e860d7-4adc-418a-ba12-233ccdf85d0a,9/27/2010,35,TEN,Toxic epidermal necrolysis,,,
adverseReaction,08982e49-d2eb-4b25-b01a-1be52fd669ef,4/11/2012,7,ICH,intracranial hemorrhage,,,
adverseReaction,742ca9f4-9fba-44d4-29a8-1fe3a04f1af6,9/30/2010,9,EE,Erosive Esophagitis,,,
adverseReaction,742ca9f4-9fba-44d4-29a8-1fe3a04f1af6,9/30/2010,9,TEN,toxic epidermal necrolysis,,,
adverseReaction,742ca9f4-9fba-44d4-29a8-1fe3a04f1af6,9/30/2010,9,CK,creatine kinase,,,
adverseReaction,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,TC,total cholesterol,,,
adverseReaction,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,TG,triglycerides,,,
adverseReaction,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,ADOPT,AVANDIA as  Monotherapy                                      A 4- to 6-year study,,,
adverseReaction,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,PY,patient-years,,,
adverseReaction,6c47a65b-2665-4391-ad69-25c4f5a8b010,2/18/2009,3,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,6c47a65b-2665-4391-ad69-25c4f5a8b010,2/18/2009,3,NPN,non-protein nitrogen,,,
adverseReaction,e8323922-191d-4bfc-8871-fbe15a8a7b58,2/7/2012,2,U/L,upper limit of normal,,,
adverseReaction,e8323922-191d-4bfc-8871-fbe15a8a7b58,2/7/2012,2,ALT,alanine aminotransferase,,,
adverseReaction,e8323922-191d-4bfc-8871-fbe15a8a7b58,2/7/2012,2,GGT,gamma glutamyl transpeptidase,,,
adverseReaction,cbdf11f4-d84c-4c4a-aac2-f8c23304fb02,9/21/2006,1,IOP,intraocular pressure,,,
adverseReaction,879519b4-37a2-4bf4-8a7a-dc17a29a6f1c,1/7/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,aaba92a9-65fb-4150-aec0-9d9f721ca5a5,1/1/2011,3,HPA,hypothalamic-pituitary-adrenal,,,
adverseReaction,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,MTOPS,Medical Therapy of Prostatic Symptoms,,,
adverseReaction,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,ED,erectile dysfunction,,,
adverseReaction,938d167b-bf6d-4c29-8848-fc76aba3cbd0,11/10/2011,2,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,c325bbfc-46f3-471e-7bbc-ed0d6965d13b,1/20/2012,16,TEN,toxic epidermal necrolysis,,,
adverseReaction,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,7c958802-daad-4c7e-88eb-73be7d2261d8,3/31/2009,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,27615b77-2550-4e46-87d9-b4d007a0e79f,2/14/2012,3558,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,d76a0419-05ee-437e-884c-65807aea9569,2/22/2012,11,BUN,Creatinine/Blood Urea Nitrogen,,,
adverseReaction,bf95521a-a636-4f4e-a0a0-5fcd469dbb09,9/21/2011,2,NMS,neuroleptic malignant syndrome,,,
adverseReaction,ac47efbe-025b-4688-bcd3-a10a0b012b34,11/19/2009,2,PSA,prostate specific antigen,,,
adverseReaction,0f55b9ec-2de6-431d-8bc3-1ed418051cd8,3/30/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,f9be442d-0782-4b93-828f-9ebbf67dbced,6/29/2010,2,AUCs,affords minimal peak serum levels and systemic exposure,,,
adverseReaction,a4d07b57-09e1-4732-a135-559febcab3ef,11/12/2008,7,HDL,High Density Lipoprotein,,,
adverseReaction,c62e99a1-0612-4c76-9c72-80c6b78e3567,5/10/2011,10,LMWH,low molecular weight heparin,,,
adverseReaction,d3e434b9-2f56-4dec-8cbf-a61e23abcc6a,11/21/2011,18,BUN,blood urea nitrogen,,,
adverseReaction,46ac55cf-d85e-4c34-bb33-f49e078c4a03,3/14/2012,5,NODAT,New Onset Diabetes After Transplant,,,
adverseReaction,46ac55cf-d85e-4c34-bb33-f49e078c4a03,3/14/2012,5,PTDM,Post-Transplant Diabetes Mellitus,,,
adverseReaction,46ac55cf-d85e-4c34-bb33-f49e078c4a03,3/14/2012,5,AZA,tacrolimus/Azathioprine,,,
adverseReaction,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,BMT,bone  marrow transplant,,,
adverseReaction,3d5a25e6-a117-47fd-b23e-d67597552c0f,6/9/2011,2,GI,gastrointestinal,,,
adverseReaction,99ae0271-47d8-4321-96e0-55124811df1a,1/4/2010,2,ANA,antinuclear antibodies,,,
adverseReaction,a41b9710-a1ec-41be-8417-b03c5d802ae2,4/11/2012,1,G.I.,gastrointestinal,,,
adverseReaction,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,RPLS,Reversible Posterior Leukoencephalopathy Syndrome,,,
adverseReaction,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,Patients,patients,,,
adverseReaction,2e97aa6d-09f7-46df-9499-63db7e9bac35,6/22/2012,11,Table 3,the laboratory abnormalities described for Study 934,,,
adverseReaction,710bede3-2742-4413-8772-63b2a955fab5,4/6/2012,1,LMWH,low molecular weight heparin,,,
adverseReaction,b35e3633-8893-4b0b-af1e-92e342557199,8/22/2011,6,LFTs,liver function tests,,,
adverseReaction,3fdb96fd-eab2-40c8-9695-95a26e613fc8,10/12/2011,12,PY,patient-years,,,
adverseReaction,26ec6e6d-10bc-4ce9-b602-64077d7eaa40,11/11/2011,1,see,suicide among untreated patients,,,
adverseReaction,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,AST,aspartate transaminase,,,
adverseReaction,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,ALT,alanine transaminase,,,
adverseReaction,44df7cdc-fa24-4e52-800b-63589cf49706,4/27/2012,8,EPS,extrapyramidal symptoms,,,
adverseReaction,42308dd9-57c2-4416-a394-681f6733f566,3/18/2011,7,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,7dbc22e1-b4c7-4794-8277-7d3814b924d2,4/19/2011,1,SLE,Systemic lupus erythematosus,,,
adverseReaction,a6347895-5f16-43b4-92a0-b9904ac81937,9/13/2011,8,EPS,extrapyramidal symptoms,,,
adverseReaction,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,GI,Gastrointestinal,,,
adverseReaction,4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525,4/11/2011,5,MTC,medullary thyroid cancer,,,
adverseReaction,c4b40689-96e9-4140-a9f9-0c73d4c1d825,1/21/2011,2,TSH,thyrotropin stimulating hormone,,,
adverseReaction,90593214-5e4d-4b91-b308-a82311a3e4f9,6/22/2009,1,TEAEs,treatment-emergent adverse event,,,
adverseReaction,89783608-d4fa-4f57-949a-e4a30366ee51,6/28/2012,4,TEAEs,treatment-emergent adverse event,,,
adverseReaction,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,BMD,bone mineral density,,,
adverseReaction,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,HPS,Heart Protection Study,,,
adverseReaction,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HPS,Heart Protection Study,,,
adverseReaction,d9680c5a-df82-407c-9729-a9c9c59bda78,11/19/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,TNT,to New Targets Study,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,TIA,transient ischemic attack,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,ea28753a-8631-460a-bfdc-b101eb8ac84a,2/8/2010,10,HSRs,hypersensitivity reactions,,,
adverseReaction,235f367b-544a-4523-a7bf-a9e2b3aa6fa0,2/6/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,235f367b-544a-4523-a7bf-a9e2b3aa6fa0,2/6/2012,3,SJS,Stevens-Johnson syndrome,,,
adverseReaction,235f367b-544a-4523-a7bf-a9e2b3aa6fa0,2/6/2012,3,CBC,complete blood count,,,
adverseReaction,235f367b-544a-4523-a7bf-a9e2b3aa6fa0,2/6/2012,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,WHO,World Health Organization,,,
adverseReaction,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,SSRI,selective serotonin reuptake inhibitor-,,,
adverseReaction,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,ALT,Abnormalities Increases in serum transaminase,,,
adverseReaction,a2360c52-f2b3-43c6-8485-292d828a7488,6/9/2006,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,SJS,Stevens-Johnson syndrome,,,
adverseReaction,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,CBC,complete blood count,,,
adverseReaction,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,47cb9a03-7946-4142-b97b-be035dc51f7d,5/11/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,B221B509-EA5C-427C-94F7-27939957ED97,7/25/2006,1,AST,aspartate transaminase,,,
adverseReaction,B221B509-EA5C-427C-94F7-27939957ED97,7/25/2006,1,ALT,alanine transaminase,,,
adverseReaction,95de7015-932f-48d4-8734-5906aaee697e,2/24/2012,1,rare,Renal Failure,,,
adverseReaction,e5929809-f517-4383-a754-ba8afc00e5c4,6/24/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,afad3051-9df2-4c54-9684-e8262a133af8,4/30/2012,11,EPS,extrapyramidal symptoms,,,
adverseReaction,afad3051-9df2-4c54-9684-e8262a133af8,4/30/2012,11,LATUDA,LATUDA-treated patients versus placebo for the BAS,,,
adverseReaction,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,4818abc4-2797-4248-b7d7-5cb4b5cdcf6a,12/14/2010,1,BMD,bone mineral density,,,
adverseReaction,1ac2687d-1a70-4a69-b84c-22840925db09,1/4/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,a360d43c-bed8-4f41-ab36-e2aa77dfbff2,8/15/2011,1,AST,aspartate transaminase,,,
adverseReaction,a360d43c-bed8-4f41-ab36-e2aa77dfbff2,8/15/2011,1,ALT,alanine transaminase,,,
adverseReaction,aa4d77fb-8d49-4212-8535-9ab8ea7e30d5,1/17/2011,2094,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,JRA,Juvenile Rheumatoid Arthritis,,,
adverseReaction,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,GI,Gastrointestinal,,,
adverseReaction,5ddba454-f3e6-43c2-a7a6-58365d297213,2/29/2012,10,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,3e463126-78a9-4ec5-904c-0424a64d8ae8,5/24/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,i.e.,into a limited,,,
adverseReaction,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,i.e.,into a limited,,,
adverseReaction,6e71e169-bc37-4a1f-bb7d-05bb55345742,1/23/2012,1,rare,Renal Failure,,,
adverseReaction,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,f85a48d0-0407-4c50-b0fa-7673a160bf01,4/25/2012,29,WBC,white blood cell count,,,
adverseReaction,7b1d9124-5fde-4f57-9fca-ee061750fcc3,3/23/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,b375a2fb-7bd4-486c-87f6-72237713d528,4/7/2011,5,PCC,Partial Coagulation Complex,,,
adverseReaction,bd447ffa-9196-4c3c-accf-5adf29b84665,6/4/2011,1,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,bd447ffa-9196-4c3c-accf-5adf29b84665,6/4/2011,1,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,5e21f8fc-b32c-4100-a664-15737bdeb32c,4/18/2012,3763,EPS,extrapyramidal symptoms,,,
adverseReaction,5e21f8fc-b32c-4100-a664-15737bdeb32c,4/18/2012,3763,SJS,Stevens-Johnson syndrome,,,
adverseReaction,5e21f8fc-b32c-4100-a664-15737bdeb32c,4/18/2012,3763,CBC,complete blood count,,,
adverseReaction,5e21f8fc-b32c-4100-a664-15737bdeb32c,4/18/2012,3763,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,e96e6f6b-d7e6-48f4-bae8-2d878a5b7694,11/10/2010,77,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,4e92bf71-0ba2-4276-af81-5e61b9122044,6/3/2011,1,BMD,bone mineral density,,,
adverseReaction,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,see,serum sickness,,,
adverseReaction,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,EEG,electroencephalogram,,,
adverseReaction,bf588f7e-89de-4b4e-8d33-c1ff2be1b34e,2/8/2012,7,SGOT,significant increase was observed in median AST,,,
adverseReaction,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,i.e.,into a limited,,,
adverseReaction,463cb005-7ba6-4f8c-835d-ba8f1714a6e1,8/22/2008,3,G.I.,gastrointestinal,,,
adverseReaction,d31a6e7d-31b1-474e-bc7b-821b08115109,10/6/2011,3,rare,Renal Failure,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,TNT,to New Targets Study,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,TIA,transient ischemic attack,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,2150f73a-179b-4afc-b8ce-67c85cc72f04,4/30/2012,24,ANC,absolute neutrophil count,,,
adverseReaction,2150f73a-179b-4afc-b8ce-67c85cc72f04,4/30/2012,24,AST,aspartate transaminase,,,
adverseReaction,2150f73a-179b-4afc-b8ce-67c85cc72f04,4/30/2012,24,ALT,alanine transaminase,,,
adverseReaction,3f4703c0-0b9e-41a0-8b70-da26683d9ed2,1/4/2012,4,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,PRCA,pure red cell aplasia,,,
adverseReaction,1bec1223-5239-4eb6-a9e8-62444106d2c0,3/31/2010,3,SCT,symbol copying test,,,
adverseReaction,1bec1223-5239-4eb6-a9e8-62444106d2c0,3/31/2010,3,VAS,visual analog scale,,,
adverseReaction,1bec1223-5239-4eb6-a9e8-62444106d2c0,3/31/2010,3,DSST,digit-symbol substitution test,,,
adverseReaction,9f4e2f54-274a-4ecd-9f42-c16437018fdb,3/9/2012,3631,WBC,white blood cell count,,,
adverseReaction,26404e50-011e-4068-9745-647d2de681a3,4/18/2012,5,AST,and Endocrine: increased SGOT,,,
adverseReaction,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,BMD,bone mineral density,,,
adverseReaction,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,NATO,Nolvadex Adjuvant Trial Organization,,,
adverseReaction,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,2D9D9660-EF3A-4ABF-C291-DB8D844FF658,1/15/2008,5,SLE,Systemic lupus erythematosus,,,
adverseReaction,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,female,SystemNausea31%12%Constipation8%5%Anorexia8%4%Vomiting4%2%Flatulence4%3%Metabolic/NutritionalWeight Loss3%0%Nervous SystemDizziness20%9%Somnolence17%8%Insomnia17%11%Dry Mouth12%6%Nervousness10%5%Abnormal Dreams47%2%Tremor5%2%Depression3%<1%Paresthesia3%1%Libido Decreased3%<1%Agitation3%1%Respiratory SystemPharyngitis7%6%Yawn3%0%SkinSweating14%3%Special SensesAbnormal Vision54%<1%Urogenital SystemAbnormal Ejaculation16%<1%(male)6,7Impotence74%<1%Anorgasmia,,
adverseReaction,903a60c9-d464-4665-8575-553218f97186,5/18/2011,1,TEN,toxic epidermal necrolysis,,,
adverseReaction,046a9011-3911-4d3f-a15f-fbb56d5aad56,2/9/2011,11,MTIC,5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide,,,
adverseReaction,046a9011-3911-4d3f-a15f-fbb56d5aad56,2/9/2011,11,PCP,Pneumocystis carinii pneumonia,,,
adverseReaction,046a9011-3911-4d3f-a15f-fbb56d5aad56,2/9/2011,11,CTC,Common Toxicity Criteria,,,
adverseReaction,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,CPK,creatinine phosphokinase,,,
adverseReaction,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,ALT,alanine aminotransferase,,,
adverseReaction,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,BSP,bromsulfophthalein,,,
adverseReaction,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,AST,aspartate aminotransferase,,,
adverseReaction,0566df92-8e8d-4849-ae1c-46eb13fef34a,9/26/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,515f735c-5dba-43d9-8a58-97a319cafd56,4/11/2011,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,ARDS,adult respiratory distress syndrome,,,
adverseReaction,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,HUS,Hemolytic Uremic Syndrome,,,
adverseReaction,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,ALT,alanine aminotransferase,,,
adverseReaction,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,GGT,gamma-glutamyl transferase,,,
adverseReaction,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,AST,aspartate aminotransferase,,,
adverseReaction,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,DMA,Dimethylacetamide,,,
adverseReaction,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,HVOD,disease:Hepatic veno-occlusive disease,,,
adverseReaction,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,AML,a mixed population of hematological malignancies,,,
adverseReaction,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,MTD,maximum tolerated dose,,,
adverseReaction,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,busulfan,BUSULFEX Clinical Trials In the BUSULFEX,,,
adverseReaction,b0edc273-fd24-46b4-9e30-ee01277ef98f,6/10/2011,3,RLS,restless leg syndrome,,,
adverseReaction,b0edc273-fd24-46b4-9e30-ee01277ef98f,6/10/2011,3,NPN,nonprotein nitrogen,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,TNT,to New Targets Study,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,TIA,transient ischemic attack,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,d9adb9e4-c495-9530-e5e3-7e3b01d53e4c,6/4/2012,6,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,8634a53f-fba5-4433-87bf-e6cf72acf869,5/19/2011,6,BUN,blood urea nitrogen,,,
adverseReaction,f82dcff5-4afa-45d8-bc8c-f0f7c0c96272,12/28/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,27c6abf0-6551-4333-980d-309b9c1eeba3,2/23/2012,3589,COPD,chronic obstructive pulmonary disease,,,
adverseReaction,27c6abf0-6551-4333-980d-309b9c1eeba3,2/23/2012,3589,MI,myocardial infarction,,,
adverseReaction,27c6abf0-6551-4333-980d-309b9c1eeba3,2/23/2012,3589,PVD,peripheral vascular disease,,,
adverseReaction,27c6abf0-6551-4333-980d-309b9c1eeba3,2/23/2012,3589,CVA,cerebrovascular accident,,,
adverseReaction,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,WHO,World Health Organization,,,
adverseReaction,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,d370635f-5530-4d42-a019-d76b61639787,9/9/2011,14,SJS, Stevens-Johnson Syndrome,,,
adverseReaction,d370635f-5530-4d42-a019-d76b61639787,9/9/2011,14,TEN, Toxic epidermal necrolysis,,,
adverseReaction,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,BUN,blood urea nitrogen,,,
adverseReaction,34c02bcc-d6ff-99d4-8e6a-4a91908adca8,7/30/2011,8,Anemia,anemias progressing on therapy,,,
adverseReaction,98378b91-786e-7e31-6e2e-801cb224f273,10/27/2010,3,BUN,blood urea nitrogen,,,
adverseReaction,7cde57a7-eded-4c22-b1c7-98afc5546997,2/8/2012,1408,one patient,of >3.5 x ULN occurred in 0.1% of patients taking TEVETEN®,,,
adverseReaction,93d03943-0655-44f6-b494-57bd1e336a34,4/12/2012,2,NODAT,New Onset Diabetes After Transplant,,,
adverseReaction,93d03943-0655-44f6-b494-57bd1e336a34,4/12/2012,2,PTDM,Post-Transplant Diabetes Mellitus,,,
adverseReaction,93d03943-0655-44f6-b494-57bd1e336a34,4/12/2012,2,AZA,tacrolimus/Azathioprine,,,
adverseReaction,6b32b31b-e99e-4c6b-9082-5274f3510816,9/2/2011,4,AST,and increased SGOT,,,
adverseReaction,091d865c-6881-43fc-b7e9-4b1abdd6b055,3/5/2012,2,AST,aspartate transaminase,,,
adverseReaction,091d865c-6881-43fc-b7e9-4b1abdd6b055,3/5/2012,2,ALT,alanine transaminase,,,
adverseReaction,f72a1419-0df4-4aaa-84cf-606a17cac493,8/1/2011,3,NMS,neuroleptic malignant syndrome,,,
adverseReaction,f72a1419-0df4-4aaa-84cf-606a17cac493,8/1/2011,3,SS,serotonin syndrome,,,
adverseReaction,e5ec2af6-7777-4dc2-9cea-eefc2629d5ad,3/20/2012,5,EPS,extrapyramidal symptoms,,,
adverseReaction,16f9e4d1-6953-4d4f-b4cf-ad95a856ac25,1/20/2012,2,NMS,Neuroleptic malignant syndrome,,,
adverseReaction,d337b07d-5d72-428d-ac31-d8afbfd3b44b,6/6/2011,1,AST,aspartate transaminase,,,
adverseReaction,d337b07d-5d72-428d-ac31-d8afbfd3b44b,6/6/2011,1,ALT,alanine transaminase,,,
adverseReaction,5e14c50e-27da-470b-a519-b26fd74cc501,11/16/2011,3181,WHO,World Health Organization,,,
adverseReaction,5e14c50e-27da-470b-a519-b26fd74cc501,11/16/2011,3181,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,42d81ec3-0788-40c3-8eec-e50403f0ab58,4/20/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,e007e7c6-7d5d-4d5c-9a6c-c82d9e9cfaf7,11/19/2010,1,ALT,Abnormalities                                      Increases in serum transaminase,,,
adverseReaction,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,GI,Gastrointestinal,,,
adverseReaction,ae85b9c3-e7eb-4981-a5d9-346050e8f189,3/23/2010,2,ART,Assisted Reproductive Technology,,,
adverseReaction,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,GI,are:Gastrointestinal,,,
adverseReaction,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,GI,Gastrointestinal,,,
adverseReaction,00bf4e02-633e-453b-8c3c-fb8b1d829887,3/21/2012,2,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,see,serum sickness,,,
adverseReaction,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,EEG,electroencephalogram,,,
adverseReaction,994244cf-6198-41f0-a9b0-75ee9bbd629e,11/17/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,c4c5d38c-139a-4bff-b152-fe5ef17164ba,9/29/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,03325ca1-4f51-41a1-92f3-ff7f96e01cc8,1/9/2012,1,EPS,extrapyramidal symptoms,,,
adverseReaction,03325ca1-4f51-41a1-92f3-ff7f96e01cc8,1/9/2012,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,03325ca1-4f51-41a1-92f3-ff7f96e01cc8,1/9/2012,1,CBC,complete blood count,,,
adverseReaction,03325ca1-4f51-41a1-92f3-ff7f96e01cc8,1/9/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,faaf13ce-5d8d-4c57-a49f-a7a73daa41a5,2/4/2012,2,HDL,High Density Lipoprotein,,,
adverseReaction,fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0,6/9/2010,2,ie,in serum glucose,,,
adverseReaction,ee862463-77c0-4694-bba8-97274f13963f,3/31/2010,1,HDL,high-density lipoprotein,,,
adverseReaction,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,BMD,bone mineral density,,,
adverseReaction,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,d7d7dcc9-c3e0-45e5-abcd-135a6d8c8dab,12/12/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,BMD,bone mineral density,,,
adverseReaction,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,NATO,NOLVADEX Adjuvant Trial Organization,,,
adverseReaction,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,ECOG,Eastern Cooperative Oncology Group,,,
adverseReaction,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,Ductal Carcinoma in Situ,,,
adverseReaction,983bd055-d289-4fb1-a69c-5a7f178a07d1,5/4/2011,1,ED,erectile dysfunction,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,TNT,to New Targets Study,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,TIA,transient ischemic attack,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,901550e6-22be-68c9-eb86-f85a9c9dd998,3/2/2012,5,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,215fc8cf-92a0-98d6-c084-3575882f0a66,12/1/1995,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,734e21f5-42e6-4493-8a69-b3ebfa7357c3,9/14/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,3c6194c0-ba69-4b16-b882-caf736a02348,2/17/2012,12,FAMVIR,FAMVIR-treated patients with herpes zoster,,,
adverseReaction,3c6194c0-ba69-4b16-b882-caf736a02348,2/17/2012,12,FAMVIR,FAMVIR-treated patients with recurrent genital herpes,,,
adverseReaction,3c6194c0-ba69-4b16-b882-caf736a02348,2/17/2012,12,FAMVIR,FAMVIR-treated patients with herpes labialis,,,
adverseReaction,bc55f60a-8121-44bb-bdfc-1d311879ba4f,5/31/2011,5,EPS,extrapyramidal symptoms,,,
adverseReaction,a8d6fbb8-bde9-4346-8d9f-d0e785f66c1a,4/28/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,753453c5-8a7a-878e-3ce7-1d1edce718a9,9/16/2011,2,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,ULN,upper limit of normal,,,
adverseReaction,6d8304ba-1f38-428c-afc6-63a132e559ca,8/3/2007,1,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,EPS,extrapyramidal symptoms,,,
adverseReaction,39f4fcea-a586-4c79-a47e-d38c10601fd7,7/7/2011,1,EPS,extrapyramidal symptoms,,,
adverseReaction,39f4fcea-a586-4c79-a47e-d38c10601fd7,7/7/2011,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,39f4fcea-a586-4c79-a47e-d38c10601fd7,7/7/2011,1,CBC,complete blood count,,,
adverseReaction,39f4fcea-a586-4c79-a47e-d38c10601fd7,7/7/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,253b9eeb-3be5-47d6-a76b-9889bd3c55ed,7/29/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,AAE8B7A4-742A-4BEC-A283-31B9408EE1AA,4/11/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,WHO,World Health Organization,,,
adverseReaction,8e26d49b-f0ba-4fd1-b863-4bd68e65ee88,4/7/2010,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,9a5f6cd0-fe92-47ae-9f18-0bf1b51839f1,8/10/2011,1,ANA,antinuclear antibodies,,,
adverseReaction,276e53bf-d3c0-4457-a76e-ee39c1cd2a3d,6/1/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,276e53bf-d3c0-4457-a76e-ee39c1cd2a3d,6/1/2010,1,SJS,Stevens-Johnson syndrome,,,
adverseReaction,276e53bf-d3c0-4457-a76e-ee39c1cd2a3d,6/1/2010,1,CBC,complete blood count,,,
adverseReaction,276e53bf-d3c0-4457-a76e-ee39c1cd2a3d,6/1/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,ac768bab-8afa-4446-bc7f-caeeffec0cda,5/1/2011,6,ALT,alanine aminotransferase,,,
adverseReaction,ac768bab-8afa-4446-bc7f-caeeffec0cda,5/1/2011,6,AST,aspartate aminotransferase,,,
adverseReaction,ac768bab-8afa-4446-bc7f-caeeffec0cda,5/1/2011,6,EPS,Extrapyramidal Symptoms,,,
adverseReaction,df9f2e2e-01d4-4d25-8dc0-0533681828d9,4/14/2011,1,H2RAs,histamine-2-receptor antagonists,,,
adverseReaction,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,EBV,Epstein Barr Virus,,,
adverseReaction,d0b36326-e17d-4fff-aa12-a86f5284669f,6/2/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,56803c6d-444a-4c1f-a936-790720b27b22,10/11/2011,2,HDL,High Density Lipoprotein,,,
adverseReaction,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,RLS,restless legs  syndrome,,,
adverseReaction,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,NPN,non-protein nitrogen,,,
adverseReaction,fcca49a1-8009-4375-47b3-543a4f437e02,6/6/2012,11,ALL,acute lymphoid leukemia,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,TNT,to New Targets Study,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,TIA,transient ischemic attack,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,481cb8c7-578d-4db0-862e-a010b1af47d7,9/11/2008,1,ALT,Abnormalities                                               Increases in serum transaminase,,,
adverseReaction,bf6bebde-81ef-4a49-bd8b-2b7444f7adbf,8/2/2011,1,LDH,lactic dehydrogenase,,,
adverseReaction,63c0d87a-cfec-4c49-a03d-59e62732d0ca,9/26/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,018a7a0d-4b38-4e59-bc37-621ae8786f51,6/30/2011,5,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,3400D26A-41CB-40E4-99B4-780E1E0EC561,3/30/2007,1,AST,aspartate transaminase,,,
adverseReaction,3400D26A-41CB-40E4-99B4-780E1E0EC561,3/30/2007,1,ALT,alanine transaminase,,,
adverseReaction,6aee7760-c378-4bc0-a5ca-15216aa02ca9,10/13/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,ae1e0d8a-03fc-419b-9d44-afa68fbd5681,12/27/2010,1,LDL,low density lipoprotein,,,
adverseReaction,ae1e0d8a-03fc-419b-9d44-afa68fbd5681,12/27/2010,1,CPK,creatine phosphokinase,,,
adverseReaction,ae1e0d8a-03fc-419b-9d44-afa68fbd5681,12/27/2010,1,APTC,Anti-Platelet Trialists' Collaborations,,,
adverseReaction,7306dad3-30ed-47ed-9fb9-d5d9e1ec5247,12/20/2010,1,BUN,blood urea nitrogen,,,
adverseReaction,c4b45105-6b8a-45f7-bf50-9fc83b84d048,6/28/2011,1,GI,Gastrointestinal,,,
adverseReaction,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,cUTI,complicated urinary tract infections,,,
adverseReaction,89db8bac-b418-4c84-b0f2-a56c6b2848f4,8/1/2011,10,HDL,High Density Lipoprotein,,,
adverseReaction,f59f7811-70b7-4c44-99f7-4f4fdce3ed22,6/27/2011,1,AML,Acute Myeloid Leukemia,,,
adverseReaction,e80642ad-bb06-4546-ae33-5bc70cf05cee,1/9/2012,3,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,d2af616e-673a-4fdd-ace8-db2d0f154604,11/24/2011,6,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,0b126fcd-2385-409f-9269-5bf886649c1a,3/6/2012,1,TEN,Toxic epidermal necrolysis,,,
adverseReaction,e7ea978d-00a1-4c60-97bc-bb1d37d776e9,5/19/2010,1,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,e7ea978d-00a1-4c60-97bc-bb1d37d776e9,5/19/2010,1,PDE5,phosphodiesterase type 5,,,
adverseReaction,2e5c6b7f-1d57-4114-9067-79dca009c4cc,8/25/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,2265ef30-253e-11df-8a39-0800200c9a66,3/25/2011,5,ECL,electrochemiluminescent,,,
adverseReaction,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,GERD,Gastroesophageal  Reflux Disease,,,
adverseReaction,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,RAC,rabeprazole plus amoxicillin and clarithromycin,,,
adverseReaction,51772745-9ea9-42cd-97e6-7266f41ae3ca,2/22/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,TNT,to New Targets Study,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,TIA,transient ischemic attack,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,PDE5,phosphodiesterase type 5,,,
adverseReaction,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,PSA,prostate-specific antigen,,,
adverseReaction,833c7a0b-5f64-4363-94d5-9a179049113a,3/30/2012,16,EEG,electroencephalogram,,,
adverseReaction,833c7a0b-5f64-4363-94d5-9a179049113a,3/30/2012,16,BUN,blood urea nitrogen,,,
adverseReaction,833c7a0b-5f64-4363-94d5-9a179049113a,3/30/2012,16,GI,gastrointestinal,,,
adverseReaction,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,WHO,World Health Organization,,,
adverseReaction,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,NPN,non-protein nitrogen,,,
adverseReaction,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,RLS,porphyria,restless legs syndrome,,
adverseReaction,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,HF,Heart Failure,,,
adverseReaction,1cec7a02-b7a5-49e1-ab64-3a4dab4149d2,4/30/2012,2,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,CBS,cystathionine beta-synthase,,,
adverseReaction,12084cb5-13db-42ea-b91c-1d361960fba7,6/25/2012,3,VALIANT,Valsartan in Acute Myocardial Infarction Trial,,,
adverseReaction,afde17e7-b95b-4cd5-97eb-e361724014bd,2/15/2012,2,SGOT,significant increase was observed in median AST,,,
adverseReaction,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,NMS,Neuroleptic Malignant Syndrome,,,
adverseReaction,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,RLS,restless legs syndrome,,,
adverseReaction,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,NPN,non-protein nitrogen,,,
adverseReaction,e617f7f2-585c-4eb5-8d35-1fc6d02ef57d,2/9/2012,1,WHO,World Health Organization,,,
adverseReaction,e617f7f2-585c-4eb5-8d35-1fc6d02ef57d,2/9/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,SIADH,syndrome of inappropriate antidiuretic                                     hormone secretion,,,
adverseReaction,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,cUTI,complicated urinary tract infections,,,
adverseReaction,27522eb0-9e11-45cb-9137-fc50dc78ba80,9/19/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,GI,Gastrointestinal,,,
adverseReaction,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,cUTI,complicated urinary tract infections,,,
adverseReaction,87768fbf-7c63-47da-8925-0316f343d6ef,10/29/2011,5,ESR,erythrocyte sedimentation rate,,,
adverseReaction,87768fbf-7c63-47da-8925-0316f343d6ef,10/29/2011,5,ANA,antinuclear antibody,,,
adverseReaction,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,i.e.,into a limited,,,
adverseReaction,f0cdfa57-95e5-416b-bc2f-cde2491c2fd0,3/17/2012,17,APR,acute phase reaction,,,
adverseReaction,f0cdfa57-95e5-416b-bc2f-cde2491c2fd0,3/17/2012,17,HCM,hypercalcemia of malignancy,,,
adverseReaction,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
adverseReaction,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,RLS,restless legs  syndrome,,,
adverseReaction,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,NPN,non-protein nitrogen,,,
adverseReaction,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,PGTC,primary generalized tonic-clonic,,,
adverseReaction,71359f14-0f8f-4e90-af1d-426e8c21bd61,8/1/2011,12,EEG,electroencephalogram,,,
adverseReaction,71359f14-0f8f-4e90-af1d-426e8c21bd61,8/1/2011,12,ECG,electrocardiogram,,,
adverseReaction,f0c8d2e8-216d-4605-9040-27d01bbba9ac,1/30/2012,1,WHO,World Health Organization,,,
adverseReaction,f0c8d2e8-216d-4605-9040-27d01bbba9ac,1/30/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,0679dd4c-fece-4c6d-b273-2c62237e8973,1/22/2010,3,LDH,lactic dehydrogenase,,,
adverseReaction,0679dd4c-fece-4c6d-b273-2c62237e8973,1/22/2010,3,SGPT,serum glutamate pyruvate transaminase,,,
adverseReaction,0679dd4c-fece-4c6d-b273-2c62237e8973,1/22/2010,3,SGOT,serum glutamate oxaloacetic transaminase,,,
adverseReaction,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HPS,Heart Protection Study,,,
adverseReaction,a5627eb8-eedb-49d7-84d4-bbc72fb9376e,8/23/2011,1,SGOT,significant increase was observed in median AST,,,
adverseReaction,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,MTOPS,Medical Therapy of Prostatic Symptoms,,,
adverseReaction,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,PCPT,Prostate Cancer Prevention Trial,,,
adverseReaction,eac8c44f-cf77-6a30-cfd7-7cffffc79bd6,10/2/2006,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,fe8480c4-b176-45ae-b4d6-fa59912fe286,7/22/2010,4,GI,Gastrointestinal,,,
adverseReaction,5eadda0e-faf8-4b3c-851e-da5a5a127242,6/27/2012,3,EPS,extrapyramidal symptoms,,,
adverseReaction,eed99b60-d043-4249-9b2a-f05e46fb588d,3/28/2011,7,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,0584dda8-bc3c-48fe-1a90-79608f78e8a0,11/9/2011,20,EPS,extrapyramidal symptoms,,,
adverseReaction,0584dda8-bc3c-48fe-1a90-79608f78e8a0,11/9/2011,20,SJS,Stevens-Johnson syndrome,,,
adverseReaction,0584dda8-bc3c-48fe-1a90-79608f78e8a0,11/9/2011,20,CBC,complete blood count,,,
adverseReaction,0584dda8-bc3c-48fe-1a90-79608f78e8a0,11/9/2011,20,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,f0ff4f27-5185-4881-a749-c6b7a0ca5696,12/15/2011,17,COPD,chronic obstructive pulmonary disease,,,
adverseReaction,f0ff4f27-5185-4881-a749-c6b7a0ca5696,12/15/2011,17,MI,myocardial infarction,,,
adverseReaction,f0ff4f27-5185-4881-a749-c6b7a0ca5696,12/15/2011,17,PVD,peripheral vascular disease,,,
adverseReaction,f0ff4f27-5185-4881-a749-c6b7a0ca5696,12/15/2011,17,CVA,cerebrovascular accident,,,
adverseReaction,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,i.e.,is being  recommended,,,
adverseReaction,f927b041-1d05-478c-ac26-066d9c782c5e,11/2/2010,2,AST,aspartate transaminase,,,
adverseReaction,f927b041-1d05-478c-ac26-066d9c782c5e,11/2/2010,2,ALT,alanine transaminase,,,
adverseReaction,294948d9-3cf2-4c75-85c7-2f14ae04e6e8,6/1/2009,1,EEG,electroencephalogram,,,
adverseReaction,441274d3-61d6-4854-be15-5d8b6a9fef62,4/20/2011,1,WHO,World Health Organization,,,
adverseReaction,aaadccea-4842-493b-a0bd-0ee7645fc250,5/21/2010,3,WBC,white blood cell count,,,
adverseReaction,8dd93a47-d14c-49be-9c22-97c0cdbec75a,10/15/2010,2,ANA,antinuclear antibodies,,,
adverseReaction,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,SCLC,small cell lung cancer,,,
adverseReaction,0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd,2/22/2011,4,PY,patient-years,,,
adverseReaction,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,COSTART,classified into standard dictionary,,,
adverseReaction,bda524fd-6c95-45a4-87e4-49f3f9d18f0d,8/1/2010,6,WHO,World Health Organization,,,
adverseReaction,bda524fd-6c95-45a4-87e4-49f3f9d18f0d,8/1/2010,6,SSRI,selective serotonin reuptake inhibitor,,,
adverseReaction,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,male,"valign=""middle"">&#160;</td>                                           </tr>                                           <tr>                                              <td>&#160;&#160;&#160;Abnormal Ejaculation",,,
adverseReaction,88a244d1-eddb-499c-bee2-e1f49056e78f,11/18/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,88a244d1-eddb-499c-bee2-e1f49056e78f,11/18/2010,1,LATUDA,LATUDA-treated patients versus placebo for the BAS,,,
adverseReaction,4d586471-8b20-4899-94ad-31e0a519e99e,1/17/2012,1,HAM-D,Hamilton Depression Rating Scale,,,
adverseReaction,21b3b8a2-bfed-4945-954d-6a42ea61888f,5/17/2011,3,RLS,restless leg syndrome,,,
adverseReaction,21b3b8a2-bfed-4945-954d-6a42ea61888f,5/17/2011,3,NPN,nonprotein nitrogen,,,
adverseReaction,69d0449f-95ba-dbf6-efde-6b80edee7bad,7/29/2009,1,EPS,extrapyramidal symptoms,,,
adverseReaction,a00f9c78-ebe9-4afd-b4c4-dceaa7eb27e9,10/15/2009,1,AHS,Anticonvulsant Hypersensitivity Syndrome,,,
adverseReaction,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,for EPS,from those trials on the Simpson-Angus Rating Scale,,,
adverseReaction,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,EPS,extrapyramidal syndrome,,,
adverseReaction,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,BMI,body mass index,,,
adverseReaction,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,EPS,Extrapyramidal Symptoms,,,
adverseReaction,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,PTT,partial thromboplastin time,,,
adverseReaction,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,MI,myocardial infarction,,,
adverseReaction,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,celite ACT,celite Activated Clotting Time,,,
adverseReaction,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,EPS,extrapyramidal symptoms,,,
adverseReaction,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,TTP,Thrombocytopenic Purpura,,,
adverseReaction,f91f551e-926f-440d-83d2-357e9d7484fe,8/18/2010,2,EPS,extrapyramidal symptoms,,,
adverseReaction,c1302f06-f0f0-407e-817a-52ceb53abb3c,3/1/2010,2,BUN,blood urea nitrogen,,,
adverseReaction,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,ALT,as follows:                   Hepatic–elevated SGPT,,,
adverseReaction,92ae1de4-6b27-4f03-acb5-7170664f67cb,9/11/2006,1,IOP,intraocular pressure,,,
adverseReaction,92ae1de4-6b27-4f03-acb5-7170664f67cb,9/11/2006,1,bacterial,been reported following local use of corticosteroids.The development of secondary ocular infection,,,
adverseReaction,de358060-f54a-4f36-a0d5-3f34122aba53,3/12/2012,1415,one patient,of >3.5 x ULN occurred in 0.1% of patients taking TEVETEN®,,,
adverseReaction,9a3ca129-d6f0-47e4-9f79-f7f9b3fd8692,4/21/2010,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,TTP,thrombocytopenic purpura,,,
adverseReaction,5958bb43-6967-4f15-9bd1-7f06340527ff,10/1/2011,4,EPS,extrapyramidal symptoms,,,
adverseReaction,db16d6b9-3b89-431d-97f9-9b4a8300e913,3/19/2010,3,PONV,postoperative nausea and vomiting,,,
adverseReaction,b4cfa459-c1c3-4fe2-ac2d-afeea2b96cca,8/29/2011,3,ANA,antinuclear antibodies,,,
adverseReaction,4AD759F3-72DD-412E-9500-055335CDA6CF,5/3/2007,1,ALT,alanine aminotransferase,,,
adverseReaction,4AD759F3-72DD-412E-9500-055335CDA6CF,5/3/2007,1,AST,aspartate aminotransferase,,,
adverseReaction,4db25db3-0494-4b5d-a5e1-c55a12395bb2,6/9/2010,1,IOP,intraocular  pressure,,,
adverseReaction,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,Syndrome,Syndromeand PRECAUTIONS: Information for the Patients,,,
adverseReaction,e0917960-87bf-4650-b60b-64bef2ccc4d6,2/15/2012,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,4b114460-7a1c-11df-8b19-0002a5d5c51b,6/22/2010,1,Spray,sprays/nostril twice daily,,,
adverseReaction,2ab4878e-cbe0-46f8-a9fc-e70945a352ed,5/4/2010,1,EEG,electroencephalogram,,,
adverseReaction,f0eaf0b6-a300-47e3-ad5d-b0b5779efa87,9/27/2011,6,BUN,blood urea nitrogen,,,
adverseReaction,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,NAION,Non-arteritic anterior ischemic optic neuropathy,,,
adverseReaction,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,PH,pulmonary hypertension,,,
adverseReaction,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,PDE5,phosphodiesterase type 5,,,
adverseReaction,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,GI,Gastrointestinal,,,
adverseReaction,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,EPS,extrapyramidal symptoms,,,
adverseReaction,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,TTP,Thrombocytopenic Purpura,,,
adverseReaction,99b9019c-f650-5465-5edf-80f656d06611,6/29/2009,2,see,should be monitored frequently,,,
adverseReaction,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,GI,Gastrointestinal,,,
adverseReaction,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,rare,rechallenge of drug after withdrawal due to rash,,,
adverseReaction,2af28649-2553-4bcc-9cb1-c73f7cec76d5,6/22/2012,4,AST,aspartate transaminase,,,
adverseReaction,2af28649-2553-4bcc-9cb1-c73f7cec76d5,6/22/2012,4,ALT,alanine transaminase,,,
adverseReaction,944349ca-7cdb-441a-8fd0-b8616857d338,5/18/2010,1,Spray,sprays/nostril twice daily,,,
adverseReaction,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,cUTI,complicated urinary tract infections,,,
adverseReaction,b52e2905-f906-4c46-bb24-2c7754c5d75b,12/15/2008,1,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,EEG,electroencephalogram,,,
adverseReaction,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,ECG,electrocardiogram,,,
adverseReaction,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,cUTI,complicated urinary tract infections,,,
adverseReaction,0e39a110-6e65-ee4c-1d8d-eac2ae62225a,4/13/2011,5,TEN,toxic epidermal necrolysis,,,
adverseReaction,A3C3048F-81A7-4A86-8A06-F1F00909F6D1,12/21/2006,2,AST,aspartate transaminase,,,
adverseReaction,A3C3048F-81A7-4A86-8A06-F1F00909F6D1,12/21/2006,2,ALT,alanine transaminase,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,SAEs,serious AEs,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,B19V,B19 virus,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,HBV,hepatitis B virus,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,ARDS,Acute Respiratory Distress Syndrome,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,HIV,human immunodeficiency virus,,,
adverseReaction,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,HCV,hepatitis C virus,,,
adverseReaction,a7048c81-6769-436b-8397-fbaa7489fcdf,7/16/2008,3,ANA,antinuclear antibodies,,,
adverseReaction,cd742c16-c003-4c4c-8fa0-a3b4d0158383,7/9/2010,3,EPS,extrapyramidal symptoms,,,
adverseReaction,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
adverseReaction,fae9b5cc-f32f-4e60-91f0-efbb53c1c880,1/7/2010,3,NMS,neuroleptic malignant syndrome,,,
adverseReaction,fae9b5cc-f32f-4e60-91f0-efbb53c1c880,1/7/2010,3,EPS,Extrapyramidal Reactions,,,
adverseReaction,77589cc3-c440-4695-800c-82a0e5128a6c,5/18/2012,6,MTOPS,Medical Therapy of Prostatic Symptoms,,,
adverseReaction,2096a07e-8601-4bdc-ba5a-338a40cd02e9,5/1/2012,1,Table 3,the laboratory abnormalities described for Study 934,,,
adverseReaction,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,TEN,toxic epidermal necrolysis,,,
adverseReaction,e5407ed7-794c-401c-9a5d-b221722aa22f,9/1/2011,12,EPS,extrapyramidal symptoms,,,
adverseReaction,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,f56aec67-c662-477c-b866-bfc23e8809cf,8/18/2011,2,ECL,electrochemiluminescence,,,
adverseReaction,0b46314b-604d-48ed-9d31-83a18ef4134c,2/25/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,2fbc01fb-b787-4ff1-bb9f-280dfe975531,9/22/2010,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,ee03507b-cb35-4fe9-ae7b-85ea89f876f0,2/10/2012,6,PGTC,primary generalized tonic-clonic,,,
adverseReaction,f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6,5/18/2012,12,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,739dcf8a-ed73-5eb0-899b-7e51cb73c335,10/23/2011,8,EPS,extrapyramidal symptoms,,,
adverseReaction,9a6df709-e016-44e1-8e1d-dea46689c3c8,9/21/2010,2,GI,gastrointestinal,,,
adverseReaction,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,BUN,blood urea nitrogen,,,
adverseReaction,424c69ef-b5a4-4480-98f1-6c8bed9cbcf2,12/15/2010,147,i.e.,is being recommended,,,
adverseReaction,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,EPS,extrapyramidal symptoms,,,
adverseReaction,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,TTP,Thrombocytopenic Purpura,,,
adverseReaction,e9cf9dc8-ed41-47d7-9314-7e09e163f8f0,5/18/2012,16,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,WHO,World Health Organization,,,
adverseReaction,d7962180-0c2b-ad3a-2404-05ef6400aac7,11/1/2003,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,EPS,extrapyramidal symptoms,,,
adverseReaction,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,TTP,Thrombocytopenic Purpura,,,
adverseReaction,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,EEG,electroencephalogram,,,
adverseReaction,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,ECG,electrocardiogram,,,
adverseReaction,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,GI,Gastrointestinal,,,
adverseReaction,187cee88-8cdb-48b9-bd2d-5144ad322f1c,8/12/2011,13,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,5aa18b0b-4688-493a-a5ae-cb056ea6c0e3,4/23/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,4F266BF9-05BA-45BD-F683-D156C06D9ACC,11/9/2006,1,ANA,antinuclear antibodies,,,
adverseReaction,aa756b80-11eb-4f67-abb8-8babcee728b2,7/8/2010,4,PML,progressive multifocal leukoencephalopathy,,,
adverseReaction,aa756b80-11eb-4f67-abb8-8babcee728b2,7/8/2010,4,PRES,posterior reversible encephalopathy syndrome,,,
adverseReaction,2d8fbab4-d7a7-4f4f-bbcc-56e603f72f73,3/14/2012,2,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,INR,international normalized ratio,,,
adverseReaction,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,ABECB,acute bacterial exacerbation of chronic bronchitis,,,
adverseReaction,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,CAP,community acquired pneumonia,,,
adverseReaction,300946bf-2f83-471d-868d-9820b65c52bb,7/23/2011,1,i.e.,increased relative to placebo,,,
adverseReaction,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,WHO,World Health Organization,,,
adverseReaction,16ef6920-00cf-4c98-b449-c781d84b5dcc,3/11/2010,2,BUN,blood urea nitrogen,,,
adverseReaction,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,cUTI,complicated urinary tract infections,,,
adverseReaction,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,RLS,restless legs syndrome,,,
adverseReaction,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,NPN,non-protein nitrogen,,,
adverseReaction,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,0.90%, N=5,insomnia (0.9%, N=5); nausea,
adverseReaction,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,0.60%, N=3,pain (0.6%, N=3); fatigue,
adverseReaction,28eefc95-d92e-4555-b6c5-2933860b0610,7/2/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
adverseReaction,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,cUTI,complicated urinary tract infections,,,
adverseReaction,23c702e2-3abc-4d7d-b88f-a089e2179f42,8/9/2011,2,0.90%, N=5,insomnia (0.9%, N=5); nausea,
adverseReaction,23c702e2-3abc-4d7d-b88f-a089e2179f42,8/9/2011,2,0.60%, N=3,pain (0.6%, N=3); fatigue,
adverseReaction,e6e34c18-fbc6-4cab-9aed-0905d93c2ab6,7/16/2012,3,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,6ed06682-7507-4c11-a782-42e694c21b53,2/21/2012,1,GI,Gastrointestinal,,,
adverseReaction,8cf65b07-115e-4499-92c4-5f16792a954d,8/11/2010,1,ALT,alanine aminotransferase,,,
adverseReaction,8cf65b07-115e-4499-92c4-5f16792a954d,8/11/2010,1,AST,aspartate aminotransferase,,,
adverseReaction,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,BUN,blood urea nitrogen,,,
adverseReaction,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,RLS,restless legs  syndrome,,,
adverseReaction,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,NPN,non-protein nitrogen,,,
adverseReaction,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,BUN,blood urea nitrogen,,,
adverseReaction,302da2e0-3538-42fd-b712-45725a790fb0,11/16/2011,4,AST,aspartate transaminase,,,
adverseReaction,302da2e0-3538-42fd-b712-45725a790fb0,11/16/2011,4,ALT,alanine transaminase,,,
adverseReaction,d7c6da26-42a7-4743-be02-3a233434eef2,5/14/2012,6,NMS,Neuroleptic malignant syndrome,,,
adverseReaction,e5073974-ff27-4620-8b4b-79729a957b11,7/28/2011,4,i.e.,into a limited,,,
adverseReaction,3e1a6613-bdd3-4261-93b3-d7f5cc09064b,3/14/2011,7,SOC,system organ class,,,
adverseReaction,a31fd109-d0fd-4ab9-ba98-a3d64333c18d,3/31/2010,2,HDL,high-density lipoprotein,,,
adverseReaction,08098cb2-c048-4640-f387-6beec4a38936,10/29/2011,13,EE,Erosive Esophagitis,,,
adverseReaction,08098cb2-c048-4640-f387-6beec4a38936,10/29/2011,13,TEN,toxic epidermal necrolysis,,,
adverseReaction,08098cb2-c048-4640-f387-6beec4a38936,10/29/2011,13,CK,creatine kinase,,,
adverseReaction,2492d5f6-00b0-42c9-a793-2be83ea81ad1,9/21/2011,3,ANA,antinuclear antibodies,,,
adverseReaction,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,IPSC,Independent Pediatric Safety Committee,,,
adverseReaction,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,Trials,trials,,,
adverseReaction,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,i.e.,into a limited,,,
adverseReaction,b8b4539b-31d1-40cb-b284-86cf8b16522a,1/7/2010,2,LDL,low-density lipoprotein,,,
adverseReaction,b8b4539b-31d1-40cb-b284-86cf8b16522a,1/7/2010,2,HDL,high-density lipoprotein,,,
adverseReaction,d4243a76-516c-417e-80ba-444a21ecc688,9/1/2011,3,URI,upper respiratory infection,,,
adverseReaction,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,PGTC,primary generalized tonic-clonic,,,
adverseReaction,3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1,2/21/2007,1,LE,lupus erythematosus,,,
adverseReaction,627146d8-fa8e-4c8b-b703-29ee080a6d5b,3/30/2012,20,Edema,edema,,,
adverseReaction,54b203a6-0a3e-4990-906e-50a2e1fd0b6f,12/14/2011,3,MedDRA’s,Medical Dictionary for Regulatory Activities,,,
adverseReaction,13b059c6-0c6c-49a5-b985-a4b05caf9ac9,4/10/2012,1423,TEN,Toxic epidermal necrolysis,,,
adverseReaction,6b098fd2-b0ee-42f9-97bc-837768dc4788,9/27/2011,2,BUN,blood urea nitrogen,,,
adverseReaction,0d3e4f7c-0ce1-4631-a801-e3812f7dd456,1/9/2012,1,NPN,non-protein nitrogen,,,
adverseReaction,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,BUN,blood urea nitrogen,,,
adverseReaction,8198f921-5dea-4077-938e-010269fb7abe,5/26/2010,9,CHO,Chinese Hamster Ovary,,,
adverseReaction,8198f921-5dea-4077-938e-010269fb7abe,5/26/2010,9,PTP,Previously Treated Patients,,,
adverseReaction,8198f921-5dea-4077-938e-010269fb7abe,5/26/2010,9,PUP,Previously Untreated Patients,,,
adverseReaction,8198f921-5dea-4077-938e-010269fb7abe,5/26/2010,9,SOC,System Organ Class,,,
adverseReaction,697948e4-9807-4dc0-acc9-b9a3b5fa2f12,5/16/2012,2,ALT,abnormalities in measures of hepatocellular function,,,
adverseReaction,EA623E21-E9FD-4EF1-843B-82CBC05AF5BF,3/31/2007,1,rare,ReactionsHematologic Reactionsaplastic anemia,,,
adverseReaction,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,ddI,didanosine,,,
adverseReaction,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,ZDV,zidovudine,,,
adverseReaction,a21163d6-e1b9-4490-bce3-751e0823797c,11/1/2011,8,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,924413e8-924e-4001-ba9c-b86a3dab9b21,12/16/2010,151,NMS,Neuroleptic Malignant  Syndrome,,,
adverseReaction,9ac8b9fe-dfb9-0151-30b3-f9da72d74ac2,2/9/2012,10,HCTZ,hydrochlorothiazide,,,
adverseReaction,9ac8b9fe-dfb9-0151-30b3-f9da72d74ac2,2/9/2012,10,BUN,blood urea nitrogen,,,
adverseReaction,a2d29601-21aa-4e78-a725-6c1ea982e3ac,4/7/2010,1,ANA,antinuclear antibodies,,,
adverseReaction,1c5178c9-270f-4a5b-a52b-68a56972f035,5/29/2012,13,HPS,Heart Protection Study,,,
adverseReaction,59bfb7f9-400c-4bcd-88cc-edde4b1e8189,4/27/2010,1,CSOM,Chronic Suppurative Otitis Media,,,
adverseReaction,6E9A6C82-9F25-4C71-B09A-929BD5D7B1CF,1/23/2008,1,about 1%,about 1.5% of patients and was not significantly different from placebo,,,
adverseReaction,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,WHO,World Health Organization,,,
adverseReaction,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,BUN,blood urea nitrogen,,,
adverseReaction,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,TNT,to New Targets Study,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,TIA,transient ischemic attack,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,24d10449-2936-4cd3-b7db-a7683db721e4,6/6/2012,14,ECG,Electrocardiogram,,,
adverseReaction,24d10449-2936-4cd3-b7db-a7683db721e4,6/6/2012,14,GI,Gastrointestinal,,,
adverseReaction,24d10449-2936-4cd3-b7db-a7683db721e4,6/6/2012,14,HSRs,Hypersensitivity Reactions,,,
adverseReaction,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
adverseReaction,91666161-880e-4a69-95f0-6f18314ea999,8/31/2010,1,HDL,High Density Lipoprotein,,,
adverseReaction,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,COSTART,classified into standard dictionary,,,
adverseReaction,deafd195-7a1b-4ad8-a371-2cd9f433dea5,9/29/2011,5,BUN,blood urea nitrogen,,,
adverseReaction,b5d286ce-e23f-4dde-b400-cb4832172ece,1/4/2012,3472,EEG,electroencephalogram,,,
adverseReaction,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,NAT,nucleic acid testing,,,
adverseReaction,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,PE,pulmonary embolism,,,
adverseReaction,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,ARDS,Acute Respiratory Distress Syndrome,,,
adverseReaction,cec47488-ebad-4a3a-904c-e916b432e2cf,3/5/2012,3613,IBS,irritable bowel syndrome,,,
adverseReaction,cec47488-ebad-4a3a-904c-e916b432e2cf,3/5/2012,3613,BPH,benign prostatic hypertrophy,,,
adverseReaction,cec47488-ebad-4a3a-904c-e916b432e2cf,3/5/2012,3613,AUR,Acute urinary retention,,,
adverseReaction,cec47488-ebad-4a3a-904c-e916b432e2cf,3/5/2012,3613,OAB,overactive bladder,,,
adverseReaction,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,PSA,prostate-specific antigen,,,
adverseReaction,424a34e0-9100-4232-8de6-bc90c21e6b3f,9/1/2011,2,ANA,antinuclear antibodies,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,TNT,to New Targets Study,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,TIA,transient ischemic attack,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial,,,
adverseReaction,634ec8e3-6d83-4cb2-90a3-fc9c973b06bf,6/25/2012,6,CARDS,Collaborative Atorvastatin Diabetes Study,,,
adverseReaction,e72a2768-815f-47bf-b2f9-16a93dd10684,6/23/2010,1,EPS,extrapyramidal symptoms,,,
adverseReaction,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,i.e.,into a limited,,,
adverseReaction,9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387,11/4/2010,448,about 1%,about 1.5% of patients and was not  significantly different from placebo,,,
adverseReaction,a591e33a-52f0-41c8-a00b-4a1afcc3dc4c,1/4/2011,4,EEG,electroencephalogram,,,
adverseReaction,ca37f71a-6261-4ada-9d4b-368329aa439a,6/2/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,8438b406-9259-46d1-b26a-90fdcb5cbc50,5/11/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone,,,
adverseReaction,4c8a0544-5e03-47e3-9236-c9646a841e9b,1/24/2011,2,TEN,toxic epidermal necrolysis,,,
adverseReaction,b7db52f1-1fed-480e-84d8-4d1adaa8c32b,8/16/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,c7750b68-b3d8-45fa-b134-bf75f6ac510e,1/19/2010,2,HCTZ,hydrochlorothiazide,,,
adverseReaction,c7750b68-b3d8-45fa-b134-bf75f6ac510e,1/19/2010,2,BUN,blood urea nitrogen,,,
adverseReaction,72f82e7c-fdfb-4d54-8161-944ba00b700e,12/21/2011,3,EE,Erosive Esophagitis,,,
adverseReaction,72f82e7c-fdfb-4d54-8161-944ba00b700e,12/21/2011,3,TEN,toxic epidermal necrolysis,,,
adverseReaction,72f82e7c-fdfb-4d54-8161-944ba00b700e,12/21/2011,3,CK,creatine kinase,,,
adverseReaction,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,WHO,World Health Organization,,,
adverseReaction,96425d91-cfe1-477d-a130-b58c330ca8a3,2/15/2012,3,IFIS,Intraoperative Floppy Iris Syndrome,,,
adverseReaction,9485cc30-15e8-4b53-876d-db317145474b,8/12/2009,1,TSH,thyrotropin stimulating hormone,,,
adverseReaction,1086a7b4-b89b-4bee-8120-5f752626c046,12/28/2010,1,LMWH,low molecular weight heparin,,,
adverseReaction,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,WHO,World Health Organization,,,
adverseReaction,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
boxedWarning,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,NSAID,nonsteroidal anti-inflammatory drug,,,
boxedWarning,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,CABG,coronary artery bypass graft,,,
boxedWarning,d471d6b5-2a16-41a0-9058-cbe5dfa3011f,5/27/2008,3,MI,myocardial infarction,,,
boxedWarning,d471d6b5-2a16-41a0-9058-cbe5dfa3011f,5/27/2008,3,GI,gastrointestinal,,,
boxedWarning,d471d6b5-2a16-41a0-9058-cbe5dfa3011f,5/27/2008,3,CABG,coronary artery bypass graft,,,
boxedWarning,c8c74af4-cac5-4cde-ab68-3f3647c5cb99,8/17/2011,10,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,c8c74af4-cac5-4cde-ab68-3f3647c5cb99,8/17/2011,10,TEN,TOXIC EPIDERMAL NECROLYSIS,,,
boxedWarning,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,CAF,chronic atrial fibrillation,,,
boxedWarning,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PAF,paroxysmal atrial fibrillation/flutter,,,
boxedWarning,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,VF,ventricular fibrillation,,,
boxedWarning,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,CAST,Cardiac Arrhythmia Suppression Trial,,,
boxedWarning,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,MDD,major depressive disorder,,,
boxedWarning,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,MDD,major depressive disorder,,,
boxedWarning,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,OCD,obsessive compulsive disorder,,,
boxedWarning,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,MDD,major depressive disorder,,,
boxedWarning,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,OCD,obsessive compulsive disorder,,,
boxedWarning,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,MDD,major depressive disorder,,,
boxedWarning,36d4f6c4-4946-4baa-8f9d-42a03926eeb7,4/11/2012,2,NSAIDs,nonsteroidal antiinflammatory drugs,,,
boxedWarning,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,WHI,Women’s Health Initiative,,,
boxedWarning,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,DVT,deep vein thrombosis,,,
boxedWarning,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,MDD,major depressive disorder,,,
boxedWarning,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,MDD,major depressive disorder,,,
boxedWarning,41999580-5495-4b5d-9a41-9b4466c65eda,9/20/2011,1,MDD,major depressive disorder,,,
boxedWarning,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,MDD,major depressive disorder,,,
boxedWarning,b40bfd2b-9ff1-45bf-a40f-e9812f1df228,6/3/2010,323,MDD,major depressive disorder,,,
boxedWarning,1ec26930-abe6-4db3-9315-aa896f7d5232,5/18/2009,3,CABG,coronary artery bypass graft,,,
boxedWarning,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,CABG,coronary artery bypass graft,,,
boxedWarning,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,CABG,coronary artery bypass graft,,,
boxedWarning,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,CHF,congestive heart failure,,,
boxedWarning,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,AML,acute myelogenous leukemia,,,
boxedWarning,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,MDS,myelodysplastic syndrome,,,
boxedWarning,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,MDD,major depressive disorder,,,
boxedWarning,e61ae711-e6d2-44e4-b7d7-943a9d06f985,3/17/2011,1,CABG,coronary artery bypass graft,,,
boxedWarning,a41b9710-a1ec-41be-8417-b03c5d802ae2,4/11/2012,1,CABG,coronary artery bypass graft,,,
boxedWarning,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,HBV,hepatitis B virus,,,
boxedWarning,02500709-7f2c-4251-bd8c-94ab6cdadd4c,8/26/2010,1,MDD,major depressive disorder,,,
boxedWarning,89b11e03-4921-4c59-ac5d-082bf755eab7,12/2/2010,116,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,6eebe6be-34a5-41c5-a63f-53fddc8bd0c0,12/7/2010,126,MDD,major depressive disorder,,,
boxedWarning,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,MDD,major depressive disorder,,,
boxedWarning,4a246ce7-c04e-4119-9201-23e5f90152a8,6/30/2010,4,NSAIDs,non-steroidal anti-inflammatory drugs,,,
boxedWarning,f38feadf-3fa4-430c-99ed-374023f8132c,5/10/2010,2,TEN,TOXIC EPIDERMAL  NECROLYSIS,,,
boxedWarning,f38feadf-3fa4-430c-99ed-374023f8132c,5/10/2010,2,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,MDD,major depressive disorder,,,
boxedWarning,14496afb-a541-4b01-a672-fcd411292b8d,4/2/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,b602edb3-45eb-42f4-8e75-1530c1f4355c,9/21/2011,1,MDD,major depressive disorder,,,
boxedWarning,ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,2/27/2012,2,Sr-82,STRONTIUM-82,,,
boxedWarning,ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,2/27/2012,2,Sr-85,STRONTIUM-85,,,
boxedWarning,10644068-fa47-4e3b-9e93-f57ebac3dd17,4/1/2010,1,NSAIDS,NON-STEROIDAL ANTI-INFLAMMATORY DRUGS,,,
boxedWarning,4A8AE85C-66A0-48BE-4099-B3C72C838176,5/11/2009,2,CLL,chronic lymphocytic leukemia,,,
boxedWarning,37204b95-bd46-4b12-b5b7-2c4b128b7203,11/17/2010,1,ESAs,erythropoiesis-stimulating agents,,,
boxedWarning,C1DFE613-D8AC-4F18-9AAF-5F11044DE2B1,11/4/2008,1,MDD,major depressive disorder,,,
boxedWarning,ced93eb0-e8b6-44b8-9d2c-e2afa92500f7,1/4/2008,1,MDD,major depressive disorder,,,
boxedWarning,6ec3eda9-d415-4796-8cfd-9225052f6b1b,11/16/2010,91,MDD,major depressive disorder,,,
boxedWarning,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,DES,diethylstilbestrol,,,
boxedWarning,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,OCD,Obsessive Compulsive Disorder,,,
boxedWarning,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,MDD,Major Depressive Disorder,,,
boxedWarning,097d95e4-707e-47aa-b18e-aad18fecd42a,3/28/2011,1,MDD,major depressive disorder,,,
boxedWarning,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,MDD,major depressive disorder,,,
boxedWarning,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
boxedWarning,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,CV,cardiovascular,,,
boxedWarning,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,WHI,Women’s Health Initiative,,,
boxedWarning,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,DVT,deep vein thrombosis,,,
boxedWarning,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,PE,pulmonary embolism,,,
boxedWarning,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,WHIMS,WHI Memory Study,,,
boxedWarning,e18ac1f5-4815-4123-b4c2-edfc2f73763b,7/13/2010,340,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
boxedWarning,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,MDD,major depressive disorder,,,
boxedWarning,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,MDD,major depressive disorder,,,
boxedWarning,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,OCD,obsessive compulsive disorder,,,
boxedWarning,bc62b38c-4cc9-4e64-8852-1a0be6d36d8e,8/30/2011,1,HIV,HUMAN IMMUNODEFICIENCY VIRUS,,,
boxedWarning,EABD3C7F-028D-4299-4B9B-60C75AF7EE01,5/23/2008,2,CDAD,Clostridium difficile associated diarrhea,,,
boxedWarning,f15b41bd-ed36-4908-aba5-f0a019b7a26e,4/15/2010,2,NSAIDS,NON-STEROIDAL ANTI-INFLAMMATORY DRUGS,,,
boxedWarning,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,CLL,chronic lymphocytic leukemia,,,
boxedWarning,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,MDD,major depressive disorder,,,
boxedWarning,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,WHI,Women’s Health Initiative,,,
boxedWarning,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,MDD,major depressive disorder,,,
boxedWarning,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,OCD,obsessive compulsive disorder,,,
boxedWarning,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,MDD,major depressive disorder,,,
boxedWarning,bd9a5180-1773-11e0-980a-0002a5d5c51b,2/16/2012,2,DMSO,dimethyl sulfoxide,,,
boxedWarning,885A90B0-7C9F-4BC9-9F22-2C16F15EB108,10/17/2007,2,MI,myocardial infarction,,,
boxedWarning,885A90B0-7C9F-4BC9-9F22-2C16F15EB108,10/17/2007,2,GI,gastrointestinal,,,
boxedWarning,885A90B0-7C9F-4BC9-9F22-2C16F15EB108,10/17/2007,2,CABG,coronary artery bypass graft,,,
boxedWarning,751887d9-71da-4226-8ae1-d7ca59259cbe,3/4/2009,1,CABG,coronary artery bypass graft,,,
boxedWarning,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,WHI,Women’s Health Initiative,,,
boxedWarning,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,DVT,deep vein thrombosis,,,
boxedWarning,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,WHI,Women’s Health Initiative,,,
boxedWarning,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,A72329C8-A565-42F7-9640-05E712703D42,1/20/2007,1,MDD,Major Depressive Disorder,,,
boxedWarning,A72329C8-A565-42F7-9640-05E712703D42,1/20/2007,1,MDD,major depressive disorder,,,
boxedWarning,A72329C8-A565-42F7-9640-05E712703D42,1/20/2007,1,OCD,obsessive compulsive disorder,,,
boxedWarning,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,MDD,major depressive disorder,,,
boxedWarning,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,OCD,obsessive compulsive disorder,,,
boxedWarning,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,CABG,coronary artery bypass graft,,,
boxedWarning,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,MDD,major depressive disorder,,,
boxedWarning,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
boxedWarning,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,WHI,Women's Health Initiative,,,
boxedWarning,468a972c-cb14-47c3-bdf6-4f7b64509e5c,6/7/2011,1,WHIMS,Women's Health Initiative Memory Study,,,
boxedWarning,468a972c-cb14-47c3-bdf6-4f7b64509e5c,6/7/2011,1,DVT,deep vein thrombosis,,,
boxedWarning,468a972c-cb14-47c3-bdf6-4f7b64509e5c,6/7/2011,1,WHI,Women's Health Initiative,,,
boxedWarning,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,MDD,major depressive disorder,,,
boxedWarning,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,OCD,obsessive compulsive disorder,,,
boxedWarning,9c6e2044-c040-403c-bcd6-99ca1e6bba73,1/19/2012,3,MDD,major depressive disorder,,,
boxedWarning,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,MDD,Major Depressive Disorder,,,
boxedWarning,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,MDD,major depressive disorder,,,
boxedWarning,A551FAC0-8738-40B3-9B03-602F794A4B66,6/12/2008,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
boxedWarning,b007bac6-a207-481c-8aba-03ade1dd6a88,7/8/2010,330,MDD,major depressive disorder,,,
boxedWarning,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,MPA,medroxyprogesterone acetate,,,
boxedWarning,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,DVT,deep vein thrombosis,,,
boxedWarning,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,WHI,Women's Health Initiative,,,
boxedWarning,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,CE,conjugated  estrogens,,,
boxedWarning,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,Ductal Carcinoma in Situ,,,
boxedWarning,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,NSAID,nonsteroidal                                 anti-inflammatory drug,,,
boxedWarning,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,NSAIDs,nonsteroidal                                         anti-inflammatory drugs,,,
boxedWarning,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,busulfan,BUSULFAN-INDUCED PANCYTOPENIA IN HUMANS.®,,,
boxedWarning,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
boxedWarning,396686ba-ab8d-4223-80e7-9c4f7ddb7852,1/18/2010,2,WHI,Women’s Health Initiative,,,
boxedWarning,396686ba-ab8d-4223-80e7-9c4f7ddb7852,1/18/2010,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,CLL,chronic lymphocytic leukemia,,,
boxedWarning,f72a1419-0df4-4aaa-84cf-606a17cac493,8/1/2011,3,MDD,major depressive disorder,,,
boxedWarning,8E6E1AEA-D1C9-F6BF-2A8C-0504437BE95C,2/12/2009,1,CABG,coronary artery bypass graft,,,
boxedWarning,3b1f8ee3-d582-4faa-a7f2-0fbc45721298,7/13/2011,1,HIV,HUMAN IMMUNODEFICIENCY VIRUS,,,
boxedWarning,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,MDD,major depressive disorder,,,
boxedWarning,405d2b6c-b465-41de-ad93-1e009825cd3b,6/20/2011,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
boxedWarning,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,4789c1dd-ae52-4962-be54-6ae7e08ac0e4,5/1/2007,1,ANA,anti-nuclear antibody,,,
boxedWarning,197c0496-3910-44ed-b8fb-df01b0f925a8,5/12/2011,125,CABG,coronary artery bypass graft,,,
boxedWarning,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,MDD,Major Depressive Disorder,,,
boxedWarning,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,WHI,Women’s Health Initiative,,,
boxedWarning,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,96a9f4c5-de60-49ca-aa93-abf3258c2662,12/23/2010,167,MDD,major depressive disorder,,,
boxedWarning,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,MDD,major depressive disorder,,,
boxedWarning,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,MDD,major depressive disorder,,,
boxedWarning,552ba162-76ed-4bc9-8c2c-fac7a1804da0,2/23/2012,11,TIRF,Transmucosal Immediate Release Fentanyl,,,
boxedWarning,552ba162-76ed-4bc9-8c2c-fac7a1804da0,2/23/2012,11,REMS,Risk Evaluation and Mitigation Strategy,,,
boxedWarning,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,Ductal Carcinoma in Situ,,,
boxedWarning,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,Ductal Carcinoma in Situ,,,
boxedWarning,a767e888-f825-4429-b3a4-05580ea6d157,9/19/2011,1,MDD,major depressive disorder,,,
boxedWarning,4b52487b-dfed-402e-ba8b-766f96313b67,4/21/2011,1,CABG,coronary artery bypass graft,,,
boxedWarning,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,CABG,coronary artery bypass graft,,,
boxedWarning,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,MDD,major depressive disorder,,,
boxedWarning,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,OCD,obsessive compulsive disorder,,,
boxedWarning,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,MDD,major depressive disorder,,,
boxedWarning,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,MDD,major depressive disorder,,,
boxedWarning,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,MDD,major depressive disorder,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,CHF,congestive heart failure,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,AML,acute myelogenous leukemia,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,MUGA,multi-gated radionuclide angiography,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,CHF,Congestive heart failure,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,LVEF,left ventricular ejection fraction,,,
boxedWarning,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,AML,acute myelogeneous leukemia,,,
boxedWarning,cf3630b8-7deb-48ee-9c99-b51b38934d7e,1/17/2012,3,MDD,major depressive disorder,,,
boxedWarning,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,PEP,post-exposure prophylaxis,,,
boxedWarning,4c55ccfb-c4cf-11df-851a-0800200c9a66,4/29/2011,1,MDD,major depressive disorder,,,
boxedWarning,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,WHI,Women’s Health Initiative,,,
boxedWarning,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,DVT,deep vein thrombosis,,,
boxedWarning,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,CLL,chronic lymphocytic leukemia,,,
boxedWarning,967ef131-3dce-4c05-8f17-a5c9e01ca9a0,6/9/2011,1,CABG,coronary artery bypass graft,,,
boxedWarning,e0f4ad87-07c0-41b7-85d2-ddf66e0840ad,7/11/2011,1,MDD,major depressive disorder,,,
boxedWarning,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,WHI,Women’s Health Initiative,,,
boxedWarning,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,386b8c18-5be1-4cef-90a8-28096293bffb,6/16/2011,4,MDD,major depressive disorder,,,
boxedWarning,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,MDD,major depressive disorder,,,
boxedWarning,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,MDD,Major Depressive Disorder,,,
boxedWarning,8f0ff905-5eb3-4ad0-ad31-fe35b924211f,10/27/2009,1,OCD,obsessive compulsive disorder,,,
boxedWarning,5e46b7e9-e640-4db5-882f-73a5dd2482d2,6/2/2010,1,CABG,coronary artery bypass graft,,,
boxedWarning,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,MDD,major depressive disorder,,,
boxedWarning,026da3c7-c865-4eff-a6e5-381f9645f717,12/6/2010,121,CABG,coronary artery bypass graft,,,
boxedWarning,bf2e0dfa-d6ca-4961-9627-b666266f58f1,5/10/2010,2,TEN,TOXIC EPIDERMAL  NECROLYSIS,,,
boxedWarning,bf2e0dfa-d6ca-4961-9627-b666266f58f1,5/10/2010,2,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,0121363e-dcd9-4c24-940b-ea890ab762e7,7/13/2010,2037,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
boxedWarning,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,MDD,major depressive disorder,,,
boxedWarning,c4b45105-6b8a-45f7-bf50-9fc83b84d048,6/28/2011,1,CABG,coronary artery bypass graft,,,
boxedWarning,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,MDD,major depressive disorder,,,
boxedWarning,3614d085-c313-4ce8-8a70-888899b6406e,7/21/2011,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
boxedWarning,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,DES,diethylstilbestrol,,,
boxedWarning,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
boxedWarning,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,WHI,Women’s Health Initiative,,,
boxedWarning,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,DVT,deep vein thrombosis,,,
boxedWarning,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,MDD,major depressive disorder,,,
boxedWarning,6436dfa0-5f27-456a-83b9-c0485a40d9cc,4/10/2012,2,NSAIDs,nonsteroidal antiinflammatory drugs,,,
boxedWarning,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,f56be63c-88e4-4b78-b12d-d80e3e8b3893,8/9/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,MDD,Major Depressive Disorder,,,
boxedWarning,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,WHI,Women’s Health Initiative,,,
boxedWarning,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,MDD,major  depressive disorder,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,MPA,medroxyprogesterone acetate,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHI,Women’s Health Initiative,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,DVT,deep vein thrombosis,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,CE,conjugated estrogen,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,DVT,deep vein  thrombosis,,,
boxedWarning,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHIMS,WHI  Memory Study,,,
boxedWarning,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,MDD,major depressive disorder,,,
boxedWarning,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,OCD,obsessive compulsive disorder,,,
boxedWarning,97a9dfe0-4c36-4733-aa06-c2cd2a1f1ca6,9/13/2011,1,HIV,HUMAN IMMUNODEFICIENCY VIRUS,,,
boxedWarning,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
boxedWarning,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,DVT,deep vein thrombosis,,,
boxedWarning,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,WHI,Women's Health Initiative,,,
boxedWarning,A8207FBD-F307-4120-95F7-4276A63BD4A1,5/3/2007,2,CABG,coronary artery bypass graft,,,
boxedWarning,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,MDD,Major Depressive Disorder,,,
boxedWarning,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,MDD,major depressive disorder,,,
boxedWarning,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,OCD,obsessive compulsive disorder,,,
boxedWarning,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,MDD,major depressive disorder,,,
boxedWarning,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,MDD,major depressive disorder,,,
boxedWarning,cec41945-8d64-4793-8784-4c2b8ec37b0f,12/2/2010,8,MDD,major depressive disorder,,,
boxedWarning,1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5,6/24/2011,102,RBC,red blood cell,,,
boxedWarning,1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5,6/24/2011,102,ESAs,erythropoiesis-stimulating agents,,,
boxedWarning,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,a28547a9-0831-488b-bfdf-7ae8bed82da9,11/17/2010,466,CABG,coronary artery bypass graft,,,
boxedWarning,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,CABG,coronary artery bypass graft,,,
boxedWarning,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,MDD,major depressive disorder,,,
boxedWarning,33068ad0-3654-4b5a-a081-5ce89075b307,5/16/2011,1,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,33068ad0-3654-4b5a-a081-5ce89075b307,5/16/2011,1,TEN,TOXIC EPIDERMAL NECROLYSIS,,,
boxedWarning,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,CABG,coronary artery bypass graft,,,
boxedWarning,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,NSAIDs,non steroidal anti-inflammatory drugs,,,
boxedWarning,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,MDD,major depressive disorder,,,
boxedWarning,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,OCD,obsessive compulsive disorder,,,
boxedWarning,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,WHIMS,Women&#8217;s Health Initiative Memory Study,,,
boxedWarning,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,WHI,Women&#8217;s Health Initiative,,,
boxedWarning,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,MDD,major depressive disorder,,,
boxedWarning,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,OCD,obsessive compulsive disorder,,,
boxedWarning,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,MDD,major depressive disorder,,,
boxedWarning,88c45123-f475-4dd0-bbac-c261868924ef,7/19/2011,7,MDD,major depressive disorder,,,
boxedWarning,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,MDD,Major Depressive Disorder,,,
boxedWarning,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,MDD,major depressive disorder,,,
boxedWarning,47499f96-d382-4ed5-a658-525196c49538,9/21/2011,2,MDD,major depressive disorder,,,
boxedWarning,146f7be7-5cd4-4279-a482-794d0cd554e1,3/28/2006,1,Dantrium,dantrolene sodium,,,
boxedWarning,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHI,Women’s Health Initiative,,,
boxedWarning,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,dfd184f0-2e52-454c-8ef2-3153be7dd4c9,9/8/2011,1,CABG,coronary artery bypass graft,,,
boxedWarning,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,MDD,major depressive disorder,,,
boxedWarning,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,OCD,obsessive compulsive disorder,,,
boxedWarning,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,MDD,major depressive disorcer,,,
boxedWarning,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,COC,contraceptive,,,
boxedWarning,ad436213-ad9b-42cd-8836-ade94ad990d8,6/5/2012,1,CABG,coronary artery bypass graft,,,
boxedWarning,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,RBC,red blood cell,,,
boxedWarning,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,ESAs,erythropoiesis-stimulating agents,,,
boxedWarning,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,MDD,major depressive disorder,,,
boxedWarning,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,MDD,major depressive disorder,,,
boxedWarning,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,MDD,major depressive disorder,,,
boxedWarning,a697e731-8d19-4845-8f31-16c4b19bb338,10/27/2009,2,CABG,coronary artery bypass  graft,,,
boxedWarning,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,WHI,Women’s Health Initiative,,,
boxedWarning,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,MDD,major depressive disorder,,,
boxedWarning,01e537e6-f19c-4259-952d-22224c10c74c,12/23/2010,166,MDD,major depressive disorder,,,
boxedWarning,953CEE06-5C26-4F30-870A-46B9FBB66E79,3/8/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DCIS,Ductal Carcinoma in Situ,,,
boxedWarning,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,OCD,obsessive  compulsive disorder,,,
boxedWarning,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,MDD,major depressive disorder,,,
boxedWarning,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,MDD,Major Depressive Disorder,,,
boxedWarning,2ab4878e-cbe0-46f8-a9fc-e70945a352ed,5/4/2010,1,MDD,major depressive disorder,,,
boxedWarning,e35aa027-aef2-485d-927c-ab350f51f977,2/16/2006,1,CAST,Cardiac Arrhythmia Suppression Trial,,,
boxedWarning,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,WHI,Women’s Health Initiative,,,
boxedWarning,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,DVT,deep vein thrombosis,,,
boxedWarning,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,WHIMS,Women’s Health Initiative Memory Study,,,
boxedWarning,c17aa1e0-8b69-4c46-8502-9e3e07d461b3,7/7/2010,329,MDD,major depressive disorder,,,
boxedWarning,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,PCI,percutaneous coronary intervention,,,
boxedWarning,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,CYP,cytochrome P450,,,
boxedWarning,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,ACS,acute coronary syndrome,,,
boxedWarning,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,CABG,coronary artery bypass graft,,,
boxedWarning,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,OCD,obsessive compulsive disorder,,,
boxedWarning,079fdde2-8b69-42c4-88f5-830ed7d2ba5f,6/7/2011,1,MDD,major depressive disorder,,,
boxedWarning,62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,7/17/2008,1,CABG,coronary artery bypass graft,,,
boxedWarning,d1b9dd40-8140-40df-8083-7255f1035cbc,6/17/2011,1,MDD,major depressive disorder,,,
boxedWarning,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,MDD,major depressive disorder,,,
boxedWarning,91f37277-4aa2-44e0-a1ea-f47e9144c567,8/27/2010,1,MDD,major depressive disorder,,,
boxedWarning,F4FA5E60-5F70-46D7-8E29-DFCF8B783F2C,8/9/2007,1,i.e.,interval,,,
boxedWarning,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,MDD,major depressive disorder,,,
boxedWarning,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MDD,major  depressive disorder,,,
boxedWarning,AA447BAC-DFBD-44AE-B1D1-3E1BE6D7EF9E,2/21/2008,2,CABG,coronary artery bypass graft,,,
boxedWarning,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,MDD,major depressive disorder,,,
boxedWarning,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,MDD,major depressive disorder,,,
boxedWarning,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,GI,gastrointestinal,,,
boxedWarning,bd55dd57-348c-4d78-b322-d1ae10279298,4/20/2012,2,HBV,hepatitis B virus,,,
boxedWarning,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,MDD,major depressive disorder,,,
boxedWarning,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,MDD,Major Depressive Disorder,,,
boxedWarning,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,ADHD,Attention–Deficit/Hyperactivity Disorder,,,
boxedWarning,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,NSF,NEPHROGENIC SYSTEMIC FIBROSIS,,,
boxedWarning,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,NSF,nephrogenic systemic fibrosis,,,
boxedWarning,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,MRI,magnetic resonance imaging,,,
boxedWarning,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,MDD,major depressive disorder,,,
boxedWarning,743d1398-942d-4d2f-9547-79c395238447,11/18/2009,1,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,743d1398-942d-4d2f-9547-79c395238447,11/18/2009,1,TEN,TOXIC EPIDERMAL NECROLYSIS,,,
boxedWarning,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,MDD,major depressive disorder,,,
boxedWarning,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,OCD,obsessive compulsive disorder,,,
boxedWarning,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,MDD,major  depressive disorder,,,
boxedWarning,0306cdb2-f143-4f55-9d63-f0508c842609,12/2/2010,145,MDD,major depressive disorder,,,
boxedWarning,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,MDD,major depressive disorder,,,
boxedWarning,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,OCD,obsessive compulsive disorder,,,
boxedWarning,b77dd52f-3506-445c-989b-916f844633f6,3/15/2012,1,HBV,hepatitis B virus,,,
boxedWarning,a203a396-f64b-4e2d-a57e-47ea7e83c3bf,12/12/2011,1,MDD,major depressive disorder,,,
boxedWarning,ba1a46f0-61b0-4204-a2a0-c94f861fccc6,12/6/2011,1,MDD,major depressive disorder,,,
boxedWarning,b93d1bcd-91b6-42fe-a668-2e0dcfc78bfe,8/10/2011,1,MDD,major depressive disorder,,,
boxedWarning,debf74d1-3250-4858-8a9d-638262f3a7d5,10/12/2011,1,MDD,major depressive disorder,,,
boxedWarning,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,MDD,Major Depressive Disorder,,,
boxedWarning,7d359680-2a9e-426a-a033-6906f51af1b5,9/13/2011,1,MDD,major depressive disorder,,,
boxedWarning,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,MDD,major depressive disorder,,,
boxedWarning,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,OCD,obsessive compulsive disorder,,,
boxedWarning,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,HBV,hepatitis B virus,,,
boxedWarning,70a2ac22-7fab-4383-8c34-b6793915a79c,3/29/2011,1,MDD,major depressive disorder,,,
boxedWarning,3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1,2/21/2007,1,CAST,Cardiac Arrhythmia Suppression Trial,,,
boxedWarning,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,CAST,Cardiac Arrhythmia Suppression Trial,,,
boxedWarning,c13bc0b8-7900-4ef4-98ed-e1315a08d95d,1/29/2008,3,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,c13bc0b8-7900-4ef4-98ed-e1315a08d95d,1/29/2008,3,TEN,TOXIC EPIDERMAL NECROLYSIS,,,
boxedWarning,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,MDD,major depressive disorder,,,
boxedWarning,54c6ab59-6645-ae3e-810c-9c1a698feefb,11/15/2011,1,MDD,major depressive disorder,,,
boxedWarning,74ae4775-8190-4bab-93d0-0f209023f973,5/10/2010,1,NSAIDs,NONSTEROIDAL  ANTI-INFLAMMATORY DRUGS,,,
boxedWarning,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,MDD,Major Depressive Disorder,,,
boxedWarning,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,MDD,major depressive disorder,,,
boxedWarning,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,OCD,obsessive complusive disorder,,,
boxedWarning,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,MDD,major depressive disorder,,,
boxedWarning,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,MDD,major depressive disorder,,,
boxedWarning,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,OCD,obsessive compulsive disorder,,,
boxedWarning,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,MDD,major depressive disorder,,,
boxedWarning,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,OCD,obsessive compulsive disorder,,,
boxedWarning,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,MDD,major depressive disorder,,,
boxedWarning,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,OCD,Obsessive  Compulsive Disorder,,,
boxedWarning,AA69C63C-CED6-4676-A16B-554F1AF7D210,10/25/2007,13,MDD,major depressive disorder,,,
boxedWarning,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,MDD,major depressive disorder,,,
boxedWarning,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MDD,Major Depressive Disorder,,,
boxedWarning,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MDD,major depressive disorder,,,
boxedWarning,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,MDD,major depressive disorder,,,
boxedWarning,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,MDD,major depressive disorder,,,
boxedWarning,b5d286ce-e23f-4dde-b400-cb4832172ece,1/4/2012,3472,MDD,major depressive disorder,,,
boxedWarning,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,MDD,major depressive disorder,,,
boxedWarning,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,OCD,obsessive compulsive disorder,,,
boxedWarning,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,MDD,major depressive disorder,,,
boxedWarning,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,b99a44df-ff38-4602-68ab-9bef1ff3af83,8/12/2011,11,i.e.,interval,,,
boxedWarning,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,CABG,coronary artery bypass graft,,,
boxedWarning,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,MDD,major depressive disorder,,,
boxedWarning,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,CABG,coronary artery bypass graft,,,
boxedWarning,2139632a-49b6-44cc-b01d-97f6c293e237,7/13/2011,1,SJS,STEVENS-JOHNSON SYNDROME,,,
boxedWarning,2139632a-49b6-44cc-b01d-97f6c293e237,7/13/2011,1,TEN,TOXIC EPIDERMAL NECROLYSIS,,,
clinicalPharmacology,fcabfaee-df20-4e7c-b951-8a454f0d355e,4/8/2011,2,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,V?,volume,,,
clinicalPharmacology,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,min,"Rrule"">T<sub>max</sub><footnote>Time-to-peak plasma concentration</footnote>",,,
clinicalPharmacology,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,Vss,volume of distribution at steady state,,,
clinicalPharmacology,aebbf53e-43d2-4d44-8838-481723c4749e,11/9/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,15ca7e87-e640-4788-b3d5-a15a0e3aa034,10/27/2010,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,22191eca-c98d-4a07-844e-11edb0f04b8d,8/31/2009,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,22191eca-c98d-4a07-844e-11edb0f04b8d,8/31/2009,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,9c7bb7e7-a775-4f93-bd77-d08c48a86f7c,7/10/2007,2,AUC,area under the curve,,,
clinicalPharmacology,5626e08c-de45-48ff-b85f-21abdfae6574,7/18/2012,2,i.e.,improvement from baseline,,,
clinicalPharmacology,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalPharmacology,6b76b5bb-1d69-43f9-99c6-f39a0b6d8a26,6/7/2012,3,FUPA,5-fluoro-ureido-propionic acid,,,
clinicalPharmacology,a0a40104-2196-4ea2-9577-63b86d6acb65,6/30/2010,1,IV,intravenous,,,
clinicalPharmacology,70e213e7-473a-464c-8e58-26bf921d5c40,6/15/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1c245363-51bb-452c-a2bb-e43811e98894,5/25/2011,7,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,BMI,body mass index,,,
clinicalPharmacology,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,GIR,Glucose Infusion Rate,,,
clinicalPharmacology,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,DCT,demethylcitalopram,,,
clinicalPharmacology,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,CT,citalopram,,,
clinicalPharmacology,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,HAMD,Hamilton Depression Rating  Scale,,,
clinicalPharmacology,d77f1654-4423-464f-a846-6767a2377ce1,1/14/2011,1,V/F,Volume of Distribution,,,
clinicalPharmacology,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,bbe6bcf4-f7d3-4067-93af-218c641059dc,9/14/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,b6c4b64a-2f0c-47ce-b423-b74d705b2de8,3/15/2012,3657,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,b6c4b64a-2f0c-47ce-b423-b74d705b2de8,3/15/2012,3657,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,24284954-0c29-458f-a9f8-97a7ad418ca7,2/10/2012,1,i.e.,improvement from baseline,,,
clinicalPharmacology,400136c4-2d2a-4c25-acaf-0c8878378e64,7/11/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,IV,intravenous,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,ie,its active metabolites,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,TSO,to sleep onset,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,CYP,cytochrome P450,,,
clinicalPharmacology,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,LPS,latency to persistent sleep,,,
clinicalPharmacology,206ea94a-8386-4d65-a74e-8abd52e1bfc3,3/5/2012,1,AUC,area under the concentration-time,,,
clinicalPharmacology,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,821309e9-249a-4eac-a20c-e1d9978a82d7,9/20/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,STH,somatotropic hormone,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,ECL,Enterochromaffin                            -like,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,FSH,follicle stimulating hormone,,,
clinicalPharmacology,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,LH,luteinizing hormone,,,
clinicalPharmacology,dbc611aa-8fbd-4142-b3e1-82fde917a06a,4/13/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,c6d4e685-d1b3-4e81-b6f5-47db218ed117,12/7/2010,7,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c6c7322b-6a89-4d23-90d1-bf9327bd6d91,4/13/2012,10,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,c6c7322b-6a89-4d23-90d1-bf9327bd6d91,4/13/2012,10,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,ICP,intracranial pressure,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,ICU,Intensive Care Unit,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,IV,intravenous,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,CABG,coronary artery bypass graft,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,MAC,monitored anesthesia care,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,SSA,standard sedative agents,,,
clinicalPharmacology,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,ACTH,adrenocorticotropic hormone,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,CPS,complex partial seizures,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,AED,antiepilepsy drug,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,TID,three divided doses,,,
clinicalPharmacology,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,MRS,Manic Rating Scale,,,
clinicalPharmacology,de69eafe-b9d3-4dd3-915d-ff2edafc14f4,12/10/2009,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,35db0a86-76af-4f5e-a5c6-0a664f53f6da,6/1/2011,2,INRWA,INR for co-therapy of warfarin and argatroban,,,
clinicalPharmacology,35db0a86-76af-4f5e-a5c6-0a664f53f6da,6/1/2011,2,INRW,INR for warfarin alone,,,
clinicalPharmacology,35db0a86-76af-4f5e-a5c6-0a664f53f6da,6/1/2011,2,INRW,INR on warfarin alone,,,
clinicalPharmacology,35db0a86-76af-4f5e-a5c6-0a664f53f6da,6/1/2011,2,INR,International Normalized Ratio,,,
clinicalPharmacology,Lb28113c1-3d01-4084-a69e-df8f481488d6,10/13/2006,1,MICs,minimum,,,
clinicalPharmacology,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,FPG,fasting plasma glucose,,,
clinicalPharmacology,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,V/F,volume of distribution,,,
clinicalPharmacology,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,AUC,area under the curve,,,
clinicalPharmacology,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,IR,immediate-release,,,
clinicalPharmacology,f986164c-51a7-41c2-8952-511b8f46d593,8/9/2011,4,AUC,area under the concentration-time curve,,,
clinicalPharmacology,21bfd9fb-6963-4149-ba3d-e2c79f8b05d8,3/27/2012,2,Cl-,chloride,,,
clinicalPharmacology,21bfd9fb-6963-4149-ba3d-e2c79f8b05d8,3/27/2012,2,Cl-,Chloride,,,
clinicalPharmacology,df4b6775-4337-41e0-815a-b064d98c3fe1,2/8/2012,3,5-HT3,5-hydroxytryptamine3,,,
clinicalPharmacology,df4b6775-4337-41e0-815a-b064d98c3fe1,2/8/2012,3,IV,intravenous,,,
clinicalPharmacology,e8f5aad8-8984-4f1e-8ab0-72f7af5e42ea,10/5/2010,413,PET,Positron Emission Tomographic,,,
clinicalPharmacology,e8f5aad8-8984-4f1e-8ab0-72f7af5e42ea,10/5/2010,413,DBP,diastolic blood  pressure,,,
clinicalPharmacology,e8f5aad8-8984-4f1e-8ab0-72f7af5e42ea,10/5/2010,413,SBP,systolic blood pressure,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,STH,somatotropic hormone,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,FSH,follicle stimulating hormone,,,
clinicalPharmacology,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,LH,luteinizing hormone,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,42e16ddf-4eb1-447e-9c90-06844f9e1246,10/6/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,EM,extensive metabolizers,,,
clinicalPharmacology,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,Tmax,to maximum concentration,,,
clinicalPharmacology,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,f2bc3c76-fd41-4a79-aa5d-3eb45133c1ee,3/11/2010,1,NAPQI,N-acetyl-p-benzoquinone imine,,,
clinicalPharmacology,caf7c3af-8256-4557-af40-e8143e9af9f1,3/12/2012,4,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,b1f9a948-f807-4256-b221-e431167f9d54,4/27/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,e82de7ec-0ca3-4afb-aa09-5ec5e7895b9d,2/1/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,A699614A-8E5B-4BEC-81C9-49305129EB39,12/18/2006,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,A699614A-8E5B-4BEC-81C9-49305129EB39,12/18/2006,2,IV,intravenous,,,
clinicalPharmacology,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,MAO,monoamine oxidase,,,
clinicalPharmacology,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,b60a9829-f356-4e43-97d5-7666fe11588c,9/28/2010,42,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,b60a9829-f356-4e43-97d5-7666fe11588c,9/28/2010,42,mCPP,m-chlorophenylpiperazine,,,
clinicalPharmacology,149f17ea-98b4-46cc-a80b-e56d18c8b266,10/24/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,149f17ea-98b4-46cc-a80b-e56d18c8b266,10/24/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,149f17ea-98b4-46cc-a80b-e56d18c8b266,10/24/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,149f17ea-98b4-46cc-a80b-e56d18c8b266,10/24/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,149f17ea-98b4-46cc-a80b-e56d18c8b266,10/24/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,506faddb-9f97-4019-85fc-f053d3e892b0,5/18/2011,3,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,a9c5062d-e8ad-44e7-a709-af0092f73d52,9/12/2011,1,LDL,low density lipoprotein,,,
clinicalPharmacology,a9c5062d-e8ad-44e7-a709-af0092f73d52,9/12/2011,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,a9c5062d-e8ad-44e7-a709-af0092f73d52,9/12/2011,1,TG,triglyceride,,,
clinicalPharmacology,500be4f9-1ce7-4a40-b6b1-d0b12f0856dd,12/9/2011,3347,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1d3e46c4-6652-44c9-8aa6-2bae30d4b246,11/18/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,i.e.,in pharmacokinetics,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,CL,clearance,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,MAP,mean arterial blood pressure,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,IBW,ideal body weight,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,HR,heart rate,,,
clinicalPharmacology,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,i.e.,infusion requirements,,,
clinicalPharmacology,833cd52c-6470-49c4-937f-1393971f4db9,9/1/2009,5,GX,glycinexylidide,,,
clinicalPharmacology,833cd52c-6470-49c4-937f-1393971f4db9,9/1/2009,5,tmax,to reach maximum concentration,,,
clinicalPharmacology,833cd52c-6470-49c4-937f-1393971f4db9,9/1/2009,5,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,833cd52c-6470-49c4-937f-1393971f4db9,9/1/2009,5,PK,pharmacokinetic,,,
clinicalPharmacology,73aea9e0-ff14-4eac-97bd-3d3b6b7ed524,1/18/2012,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1cf306eb-367b-4ccc-a15f-bea996015332,4/18/2007,1,AUCs,areas under plasma concentration-time curves,,,
clinicalPharmacology,1cf306eb-367b-4ccc-a15f-bea996015332,4/18/2007,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,4e66ad5c-572c-4819-8b6e-6930c33cc210,10/27/2011,1,ERG,electroretinogram,,,
clinicalPharmacology,4e66ad5c-572c-4819-8b6e-6930c33cc210,10/27/2011,1,CAD,Coronary Artery Disease,,,
clinicalPharmacology,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,254d072d-c684-4a5c-aa19-a40d76f8385a,11/30/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,254d072d-c684-4a5c-aa19-a40d76f8385a,11/30/2010,3,IM,intramuscular,,,
clinicalPharmacology,91fb6442-1059-4aeb-b562-62ded3932433,11/2/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,91fb6442-1059-4aeb-b562-62ded3932433,11/2/2009,5,IV,intravenous,,,
clinicalPharmacology,9af42271-1846-496e-ae33-f566e11e75fc,2/17/2009,1,V/F,volume of distribution,,,
clinicalPharmacology,9e58806e-08ba-4813-885a-bde5cf82b26d,1/9/2012,1,min,median,,,
clinicalPharmacology,5fbfe9da-26e8-4705-98f3-42acd3d7b439,2/2/2012,2,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,8265c67f-55bc-40f0-9ede-3e4b4bb178f4,11/16/2011,1,SD,subjects resulted in mean,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,SMAP,2–sulfamoylacetyl phenol,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,RBC,red blood cells,,,
clinicalPharmacology,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,CI,confidence intervals,,,
clinicalPharmacology,7AB1EB1E-F070-4C2A-B084-F3E632A41958,6/13/2006,1,Cl?,Chloride,,,
clinicalPharmacology,7AB1EB1E-F070-4C2A-B084-F3E632A41958,6/13/2006,1,Cl?,chloride,,,
clinicalPharmacology,9647db9a-065f-46a7-acfe-b74aeb532789,12/17/2009,4,Tmax,to maximum concentration,,,
clinicalPharmacology,abbf31eb-9966-411a-9c5d-91025ff7a782,9/9/2010,4,CyP3A4,Cytochrome P450 3A4,,,
clinicalPharmacology,abbf31eb-9966-411a-9c5d-91025ff7a782,9/9/2010,4,CBG,corticosteroid binding globulin,,,
clinicalPharmacology,abbf31eb-9966-411a-9c5d-91025ff7a782,9/9/2010,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,WHI,Women’s Health Initiative,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,PE,pulmonary embolism,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CHD,coronary heart disease,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CE,conjugated equine estrogens,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,LH,luteinizing hormone,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CPS,complex partial seizures,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,AED,antiepilepsy drug,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,i.e.,improvement,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,TID,three divided doses,,,
clinicalPharmacology,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,1a88218c-5b18-4220-8f56-526de1a276cd,11/1/2010,5,PPAA,?-phenyl-piperidine acetic acid,,,
clinicalPharmacology,1a88218c-5b18-4220-8f56-526de1a276cd,11/1/2010,5,MPH,methylphenidate,,,
clinicalPharmacology,bfbc4b74-509b-4df8-be2b-d665c6a070af,5/25/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,bfbc4b74-509b-4df8-be2b-d665c6a070af,5/25/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,bf7d0367-df73-47d2-b4a0-66bbf5e119a2,4/25/2011,2,ICU,Intensive Care Unit,,,
clinicalPharmacology,d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2,11/28/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,ITT,intent-to-treat,,,
clinicalPharmacology,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,CLr,clearance,,,
clinicalPharmacology,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,PHN,postherpetic neuralgia,,,
clinicalPharmacology,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,60e29e4c-7512-4aba-95a9-be987129ad63,2/6/2012,3533,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bd58b065-5926-4671-8328-7cdc662b6988,4/23/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,4021a77c-36ad-4f3a-bb4b-b44de96173b2,12/8/2009,1,Tmax,to maximum concentration,,,
clinicalPharmacology,4bc249f2-7e8b-05cb-38ad-3085e947e0f1,11/18/2011,9,CI,confidence interval,,,
clinicalPharmacology,54480d98-5ad3-492b-a63c-d3a39187e82c,7/17/2006,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,be26ff29-b06e-4ae6-bd17-65ab2730a014,11/8/2010,452,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,f5766e3f-374d-47b5-b141-2767cb7a4693,4/27/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,ae3defca-06d5-49ac-8a27-be5c4e9304d1,2/13/2007,1,MBC,minimum bactericidal concentration,,,
clinicalPharmacology,ae3defca-06d5-49ac-8a27-be5c4e9304d1,2/13/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,3b631aa1-2d46-40bc-a614-d698301ea4f9,10/5/2011,7,MN,mononuclear,,,
clinicalPharmacology,3b631aa1-2d46-40bc-a614-d698301ea4f9,10/5/2011,7,PMN,polymorphonuclear,,,
clinicalPharmacology,706e50a5-1998-46ab-a635-402fc5489865,7/13/2012,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,722a733e-60ee-4ef8-83d8-a3196160ac76,12/21/2009,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,ee89d63b-123d-4995-b7cc-822c5bee16aa,10/5/2011,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,8f54731f-c5b7-492c-acb0-444c5fbb7029,3/5/2011,6,i.e.,its active metabolites,,,
clinicalPharmacology,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,CYP,cytochrome P450,,,
clinicalPharmacology,29b69da9-3f02-4863-ad22-6cbffba4291e,1/18/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7c50bb9c-7c49-4ba7-a3e5-c28ff0719ce5,5/19/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,3b3d22dc-df09-4910-8c9b-1204eeedbd68,1/18/2012,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,78cabf7c-f342-4285-bc5a-9f24789d44ed,6/7/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,05393315-da87-4679-9ab1-7b3a289e5638,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,05393315-da87-4679-9ab1-7b3a289e5638,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,30a70882-b40a-4782-b227-cd0d35e50a26,7/25/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,e84ca5ed-dff5-4a13-a04f-6aeee4be4bb0,5/21/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e84ca5ed-dff5-4a13-a04f-6aeee4be4bb0,5/21/2010,3,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,e84ca5ed-dff5-4a13-a04f-6aeee4be4bb0,5/21/2010,3,PBP,penicillin binding proteins,,,
clinicalPharmacology,e84ca5ed-dff5-4a13-a04f-6aeee4be4bb0,5/21/2010,3,IM,intramuscular,,,
clinicalPharmacology,212167a8-13f1-4103-9837-fd7e40e8d1d6,2/22/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,65D8ADAA-04C8-4C5E-AE57-2FBAE0979178,5/7/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,65D8ADAA-04C8-4C5E-AE57-2FBAE0979178,5/7/2009,1,MN,mononuclear,,,
clinicalPharmacology,65D8ADAA-04C8-4C5E-AE57-2FBAE0979178,5/7/2009,1,PMN,polymorphonuclear,,,
clinicalPharmacology,d2690b7a-94d7-42f9-acb5-9556f70fe364,1/6/2012,1,ADCS-CGIC,Alzheimer’s Disease Cooperative Study—Clinicians Global Impression of Change,,,
clinicalPharmacology,62379cd5-a314-43eb-a1ee-33997623bfa3,3/5/2011,6,i.e.,its active metabolites,,,
clinicalPharmacology,49E5A402-A084-4B48-9ADE-1E123F49391E,1/23/2008,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,7e14591f-0062-4159-b9d3-095b4ad68f00,11/17/2010,4,GER,gastroesophageal reflux,,,
clinicalPharmacology,7e14591f-0062-4159-b9d3-095b4ad68f00,11/17/2010,4,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,0799b639-1d06-4ad4-8bcd-4922db100717,3/30/2010,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,679af699-714d-a3a3-674b-fc9ae4474a9a,8/25/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,679af699-714d-a3a3-674b-fc9ae4474a9a,8/25/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,679af699-714d-a3a3-674b-fc9ae4474a9a,8/25/2010,1,MN,mononuclear,,,
clinicalPharmacology,679af699-714d-a3a3-674b-fc9ae4474a9a,8/25/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,4906457e-30ad-4da7-b3ac-bb9e6651a670,2/29/2012,2,Vss,volume of distribution at steady state,,,
clinicalPharmacology,ADA307F1-B6B1-4B64-A060-5C254B1948F2,3/28/2006,1,PT,pharmacologic effects,,,
clinicalPharmacology,ADA307F1-B6B1-4B64-A060-5C254B1948F2,3/28/2006,1,cAMP,Cilostazol and several of its metabolites arecyclic AMP,,,
clinicalPharmacology,ADA307F1-B6B1-4B64-A060-5C254B1948F2,3/28/2006,1,PAD,peripheral arterial disease,,,
clinicalPharmacology,1daf9566-168f-4e05-b23e-fdcb09183171,8/1/2011,9,QC,Quality control,,,
clinicalPharmacology,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,CGI,Clinical Global Impression,,,
clinicalPharmacology,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,00866401-6936-478e-8848-bb1cfe83e82e,8/7/2009,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fa04ba45-0439-4c97-ecba-2db7f27314ce,6/7/2011,4,IM,intramuscular,,,
clinicalPharmacology,067ea8ec-99a3-4a0b-9116-4ffd6160b24b,3/18/2010,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,LDL-C,low-density lipoprotein cholesterol,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,HDL,high density lipoprotein,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,apo B,apolipoprotein B,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,TC,total cholesterol,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,HDL-C,high-density lipoprotein cholesterol,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,TG,triglycerides,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,CYP,cytochrome P450,,,
clinicalPharmacology,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,PPAR?,peroxisome proliferator activated receptor ?,,,
clinicalPharmacology,1b87c5c3-6a4d-41f1-b504-60004366e613,6/1/2012,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,mCPP,m-chlorophenylpiperazine,,,
clinicalPharmacology,3330ea92-fc9d-4541-b378-be399b0995d3,9/19/2011,4,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,A6EB861C-085E-442A-8E71-722587493D5D,9/11/2008,1,AUC,area under the curve,,,
clinicalPharmacology,7aae16cb-addc-468a-be00-6c5be248da29,1/20/2012,2,CgA,Chromogranin A,,,
clinicalPharmacology,7aae16cb-addc-468a-be00-6c5be248da29,1/20/2012,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,CLSI,Clinical Laboratory and Standards Institute,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,broth,based on a microdilution method,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,Inhibitors,inhibitors,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,7951139c-b271-45a4-b523-34b23800917b,4/27/2012,14,N-Ac-5-ASA,N-acetyl-5-aminosalicylic acid,,,
clinicalPharmacology,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,LDL,low density lipoprotein,,,
clinicalPharmacology,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,VLDL,very low density lipoprotein,,,
clinicalPharmacology,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,TG,triglyceride,,,
clinicalPharmacology,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,MN,mononuclear,,,
clinicalPharmacology,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,PMN,polymorphonuclear,,,
clinicalPharmacology,744790b9-1b0d-4424-a4aa-9726705281de,11/15/2010,86,B.  fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,150b4d91-7a2a-4c01-877d-bbafd3a7a74e,10/29/2009,5,GU,gastric ulcer,,,
clinicalPharmacology,150b4d91-7a2a-4c01-877d-bbafd3a7a74e,10/29/2009,5,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,bd7c11f5-340c-84e1-10d2-3f7100e74048,11/30/2009,1,YMRS,Young Mania Rating Scale,,,
clinicalPharmacology,bd7c11f5-340c-84e1-10d2-3f7100e74048,11/30/2009,1,i.e.,improvement,,,
clinicalPharmacology,bd7c11f5-340c-84e1-10d2-3f7100e74048,11/30/2009,1,GAS,Global Assessment Scale,,,
clinicalPharmacology,bd7c11f5-340c-84e1-10d2-3f7100e74048,11/30/2009,1,BPRS-A,Brief Psychiatric Rating Scale,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,ISH,isolated systolic hypertension,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,DBP,diastolic blood pressure,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,ITT,intention-to-treat,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,ESRD,end-stage renal disease,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,CVD,cardiovascular disease,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,SBP,systolic blood pressure,,,
clinicalPharmacology,9ccd6823-e813-472c-99cd-c6ef25e74bed,1/18/2012,4,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,AMD,Age-Related Macular Degeneration,,,
clinicalPharmacology,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,CNV,choroidal neovascularization,,,
clinicalPharmacology,df63e944-bfb7-453d-bbd8-63f545826784,9/1/2011,4,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,8bcc115b-88da-4ff0-b4e1-ef10d5287e54,11/5/2010,1,cGMP,cyclic  guanosine monophosphate,,,
clinicalPharmacology,8bcc115b-88da-4ff0-b4e1-ef10d5287e54,11/5/2010,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,CYP,cytochrome P450,,,
clinicalPharmacology,39ae3070-9b9b-41f3-b058-2e240b4ac18e,2/16/2012,1,DF,disoproxil fumarate,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,CPS,complex partial seizures,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,AED,antiepilepsy drug,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,i.e.,improvement,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,TID,three divided doses,,,
clinicalPharmacology,ec5ec477-2d6e-42dc-8620-66f1e51010c0,4/18/2011,2,MRS,Manic Rating Scale,,,
clinicalPharmacology,41b6dbdc-a41a-426e-8ad4-c5d52ee87ae8,10/27/2010,2,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,e0f4ad87-07c0-41b7-85d2-ddf66e0840ad,7/11/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,e0f4ad87-07c0-41b7-85d2-ddf66e0840ad,7/11/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,e0f4ad87-07c0-41b7-85d2-ddf66e0840ad,7/11/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,4ab8ddab-8226-4b5a-8774-308ed49d6bc4,4/18/2012,2,GER,gastroesophageal reflux,,,
clinicalPharmacology,4ab8ddab-8226-4b5a-8774-308ed49d6bc4,4/18/2012,2,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,CPS,complex partial seizures,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,AED,antiepilepsy drug,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,i.e.,improvement,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,TID,three divided doses,,,
clinicalPharmacology,f738ddad-fef0-43cb-b791-b046fdcec311,5/24/2010,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,2a84c550-aed8-4058-961f-351a5e4cf7a1,7/28/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,1e80b790-a57e-46ee-a257-4f59ca6502ce,11/23/2009,1,AUC,area under the curve,,,
clinicalPharmacology,4d0ba36c-0a4a-4faf-9f1d-79e5273808d5,12/15/2011,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,756d627b-021d-4609-aa08-af6cab80a812,11/30/2010,3,HTM,Haemophilus Test Media,,,
clinicalPharmacology,756d627b-021d-4609-aa08-af6cab80a812,11/30/2010,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,756d627b-021d-4609-aa08-af6cab80a812,11/30/2010,3,AUC,area under the curve,,,
clinicalPharmacology,756d627b-021d-4609-aa08-af6cab80a812,11/30/2010,3,V/F,volume of distribution,,,
clinicalPharmacology,756d627b-021d-4609-aa08-af6cab80a812,11/30/2010,3,MEF,Middle-ear fluid,,,
clinicalPharmacology,f65dbfca-bfb4-42ed-9b05-34769d81d04c,1/31/2012,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,f1193f10-c625-4e24-a506-3c101c6ee09b,4/27/2011,4,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,NK,natural killer,,,
clinicalPharmacology,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,AUC,area under the curve,,,
clinicalPharmacology,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,ELISA,enzyme-linked immunosorbent assay,,,
clinicalPharmacology,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,2'5'OAS,2'5' oligoadenylate synthetase,,,
clinicalPharmacology,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,i.e.,identified,,,
clinicalPharmacology,026da3c7-c865-4eff-a6e5-381f9645f717,12/6/2010,121,Vss,volume of distribution at steady state,,,
clinicalPharmacology,039c413c-acd2-4e8c-a619-2f48c58ae3c2,6/18/2010,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,039c413c-acd2-4e8c-a619-2f48c58ae3c2,6/18/2010,1,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,d61c7acb-a64f-46ee-b125-0c80d3b35585,8/18/2010,1,B17P,betamethasone  17-propionate,,,
clinicalPharmacology,d61c7acb-a64f-46ee-b125-0c80d3b35585,8/18/2010,1,B17P,Betamethasone 17-propionate,,,
clinicalPharmacology,bd83abef-db50-4176-9e6c-b6653a85f44d,6/1/2012,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,bd83abef-db50-4176-9e6c-b6653a85f44d,6/1/2012,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,bd83abef-db50-4176-9e6c-b6653a85f44d,6/1/2012,2,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,i.e.,insufficiency,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PT,Prothrombin time,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,DVT,deep vein thrombosis,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PE,pulmonary embolism,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,IU,IU/kg,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PK,pharmacokinetic,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,BMI,body mass index,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,UFH,unfractionated heparin,,,
clinicalPharmacology,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,aPTT,Activated partial thromboplastin time,,,
clinicalPharmacology,33529ede-844c-4dcf-9fc4-93962535981a,10/7/2011,12,HTM,Haemophilus Test Media,,,
clinicalPharmacology,77702d60-d1ea-4e4c-a837-aaa813b66064,6/9/2011,2,MUGA,multigated nuclear medicine,,,
clinicalPharmacology,77702d60-d1ea-4e4c-a837-aaa813b66064,6/9/2011,2,LVEF,left ventricular ejection fraction,,,
clinicalPharmacology,cf6676ff-1122-4495-b64d-f70771a09633,1/22/2010,1,Tmax,to maximum concentration,,,
clinicalPharmacology,ccdcd2b7-160d-465d-acd4-9002bf86989e,4/28/2011,1,MI,myocardial infarction,,,
clinicalPharmacology,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,16348d76-055f-4a7a-9de9-00144c9ee339,12/29/2011,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,a7c8f090-c48c-44f7-9973-2cf4b491e35c,7/13/2009,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,a7c8f090-c48c-44f7-9973-2cf4b491e35c,7/13/2009,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,a7c8f090-c48c-44f7-9973-2cf4b491e35c,7/13/2009,1,PVCs,premature ventricular contractions,,,
clinicalPharmacology,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,DCT,demethylcitalopram,,,
clinicalPharmacology,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,CT,citalopram,,,
clinicalPharmacology,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,A7C486DA-1104-4566-A0BB-B8FFE5B964C4,11/17/2008,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,db39f510-b247-46a4-a5ad-8da13697ec0c,3/15/2012,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,ICU,Intensive Care Unit,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,HR,Heart Rate,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,PK/PD,pharmacokinetic/pharmacodynamic,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,Vss,volume of distribution at steady state,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,CL,clearance,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,MAP,mean arterial blood pressure,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,TOF,train-of-four,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,29 minutes,29 minutes and were consistent with the t½? of cisatracurium in vitro,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,MQA,monoquaternary alcohol,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,HR,heart rate,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,MAP,Mean Arterial Pressure,,,
clinicalPharmacology,3db3b76c-3e5a-456e-46a8-456fde1e6195,12/15/2010,1403,CABG,coronary artery bypass grafting,,,
clinicalPharmacology,676b8fd6-b611-4df1-a52c-2f08b0f4d031,6/14/2012,3866,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,676b8fd6-b611-4df1-a52c-2f08b0f4d031,6/14/2012,3866,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,dd975843-c3e4-44f4-bb0d-33b294c1f6fb,5/20/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,57CEBFF0-1C66-4FD1-96EC-45AB7A4B801B,12/9/2008,2,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,57CEBFF0-1C66-4FD1-96EC-45AB7A4B801B,12/9/2008,2,C1EI,C1 esterase inhibitor,,,
clinicalPharmacology,57CEBFF0-1C66-4FD1-96EC-45AB7A4B801B,12/9/2008,2,LH,luteinizing hormone,,,
clinicalPharmacology,90d35dd6-a918-c4ab-bc7e-43652ce9b3b4,5/29/2012,12,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,90d35dd6-a918-c4ab-bc7e-43652ce9b3b4,5/29/2012,12,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,90d35dd6-a918-c4ab-bc7e-43652ce9b3b4,5/29/2012,12,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,3ff75342-03b6-462f-b6db-80bc1a52fe6c,4/11/2012,1,min,median,,,
clinicalPharmacology,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,TCA,tricyclic antidepressant,,,
clinicalPharmacology,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,442AED6E-6242-4A96-90AA-D988B62D55E8,2/25/2008,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,442AED6E-6242-4A96-90AA-D988B62D55E8,2/25/2008,3,CT,computerized tomographic,,,
clinicalPharmacology,a373596c-9fb3-426e-bf92-54cdd6dfc3ec,1/4/2012,2,CgA,Chromogranin A,,,
clinicalPharmacology,a373596c-9fb3-426e-bf92-54cdd6dfc3ec,1/4/2012,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,0593fa48-8a47-4a0e-a9c6-2ef244470b4e,7/17/2012,1,AD,Alzheimer's disease,,,
clinicalPharmacology,0593fa48-8a47-4a0e-a9c6-2ef244470b4e,7/17/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,4d19753e-8525-4c67-9657-70ba571f7e74,6/4/2010,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,034c35a5-c037-4ad8-82d1-aec4feac4c97,5/14/2010,1,CLD,chronic liver disease,,,
clinicalPharmacology,034c35a5-c037-4ad8-82d1-aec4feac4c97,5/14/2010,1,FPG,fasting plasma glucose,,,
clinicalPharmacology,034c35a5-c037-4ad8-82d1-aec4feac4c97,5/14/2010,1,PPG,post-prandial glucose,,,
clinicalPharmacology,45af3eda-caaa-4478-9372-95aa65adc9b3,5/29/2009,2,AUC,area under the curve,,,
clinicalPharmacology,d9f571b7-0933-4efa-9c0f-402b83c060cf,11/18/2010,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f0fcfef0-231b-4ba2-b5b4-ae11c8879b32,1/6/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f0fcfef0-231b-4ba2-b5b4-ae11c8879b32,1/6/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,615a4d38-a235-bb1f-a0ef-1909dcfe7b2a,5/6/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,615a4d38-a235-bb1f-a0ef-1909dcfe7b2a,5/6/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,615a4d38-a235-bb1f-a0ef-1909dcfe7b2a,5/6/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,615a4d38-a235-bb1f-a0ef-1909dcfe7b2a,5/6/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,Total-C,total cholesterol,,,
clinicalPharmacology,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,a4cf4b57-c468-4782-8d41-2f74f89fa4e8,12/28/2009,5,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,a4cf4b57-c468-4782-8d41-2f74f89fa4e8,12/28/2009,5,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,CI,confidence interval,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,LCIS,lobular carcinoma in situ,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,RR,relative risk,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,BMD,bone mineral density,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,RMT,Royal Marsden Trial,,,
clinicalPharmacology,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,8750bc89-340d-4abf-b0b8-b83012ab7cae,4/23/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8750bc89-340d-4abf-b0b8-b83012ab7cae,4/23/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8750bc89-340d-4abf-b0b8-b83012ab7cae,4/23/2012,3,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,8750bc89-340d-4abf-b0b8-b83012ab7cae,4/23/2012,3,CYP,cytochrome P450,,,
clinicalPharmacology,fbc1ff07-701e-4b7f-93a3-f4309e238e5a,12/20/2011,2,IRI,Immunoreactive Insulin,,,
clinicalPharmacology,52c09a36-879b-4b0e-b3a5-f4a4bba9bde5,5/16/2012,6,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,52c09a36-879b-4b0e-b3a5-f4a4bba9bde5,5/16/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,52c09a36-879b-4b0e-b3a5-f4a4bba9bde5,5/16/2012,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,11882E93-AA62-4D24-895C-6F01D97FC730,5/13/2008,1,ICU,Intensive Care Unit,,,
clinicalPharmacology,980b3c11-a502-4235-bbff-af83a17ebcdf,1/2/2012,6,IV,intravenous,,,
clinicalPharmacology,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,CI,confidence intervals,,,
clinicalPharmacology,D01C8FD1-25D4-49AB-8637-856843649B87,9/26/2008,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5,6/24/2011,102,CL,clearance,,,
clinicalPharmacology,4FEA5871-B515-4F69-A297-11507DDD7817,12/11/2007,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,392fc0f1-b910-4d97-9b6d-00e1b2bc9d78,4/3/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,392fc0f1-b910-4d97-9b6d-00e1b2bc9d78,4/3/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,392fc0f1-b910-4d97-9b6d-00e1b2bc9d78,4/3/2012,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,CUE,cumulative urinary excretion,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,CV,coefficient of variation,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,Total-C,total cholesterol,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,57517a0e-ec1b-4605-a7cc-7e3801158ec9,6/21/2011,7,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,57517a0e-ec1b-4605-a7cc-7e3801158ec9,6/21/2011,7,PBP,penicillin binding proteins,,,
clinicalPharmacology,33f3b99b-fa82-42e0-26bf-f49891ae3d22,2/17/2012,19,PBPs,penicillin binding proteins,,,
clinicalPharmacology,33f3b99b-fa82-42e0-26bf-f49891ae3d22,2/17/2012,19,CYP,cytochrome p450,,,
clinicalPharmacology,4e45cd6c-a777-4100-943b-985058bff75a,2/2/2012,4,GX,glycinexylidide,,,
clinicalPharmacology,4e45cd6c-a777-4100-943b-985058bff75a,2/2/2012,4,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,STH,somatotropic hormone,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,ECL,Enterochromaffin-like,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,FSH,follicle stimulating hormone,,,
clinicalPharmacology,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,LH,luteinizing hormone,,,
clinicalPharmacology,21e8592c-ea81-4604-b694-8e095b046593,6/8/2011,1,MI,myocardial infarction,,,
clinicalPharmacology,85532a0e-24fa-4a4f-9a0e-721502fa7d7e,7/11/2011,15,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,45f027f5-3bd9-4f2e-8626-1526bc559abf,3/16/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5fa71668-364e-467a-929c-ae2c9acd66ac,8/2/2007,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,88ac83d9-798a-4610-b242-c443b43bdc88,8/3/2010,2,AUC,area under the curve,,,
clinicalPharmacology,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,TT,thrombin time,,,
clinicalPharmacology,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,PT,prothrombin time,,,
clinicalPharmacology,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,APTT,activated partial thromboplastin time,,,
clinicalPharmacology,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,s.c.,Subcutaneous,,,
clinicalPharmacology,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,PF4,Platelet Factor 4,,,
clinicalPharmacology,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,25b87a16-3e28-45b5-9ae8-98053f1f387a,8/25/2009,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,4aa0642b-5de8-5048-a02b-28e4787f7013,10/6/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,4aa0642b-5de8-5048-a02b-28e4787f7013,10/6/2009,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,553de8e9-fa76-4983-84aa-3a6a0df8f165,5/21/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,553de8e9-fa76-4983-84aa-3a6a0df8f165,5/21/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,55f1ee88-a455-44ba-b51a-2fcefe8eda65,8/31/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,55f1ee88-a455-44ba-b51a-2fcefe8eda65,8/31/2010,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,0fcdd59a-906b-43df-9c65-97d8a736b4f1,6/9/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,b989cb92-dbe5-4325-bcd3-43fe8a5f13b7,10/10/2010,46,B.  fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,b989cb92-dbe5-4325-bcd3-43fe8a5f13b7,10/10/2010,46,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,IDL-C,intermediate density lipoprotein  cholesterol,,,
clinicalPharmacology,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,IDL,intermediate density lipoprotein,,,
clinicalPharmacology,6d2f9c84-a597-4055-8815-8fbcdf4c4876,1/19/2011,5,i.e.,improvement from baseline,,,
clinicalPharmacology,7aa8637a-2b2f-4a24-b1c2-b2eba8b008cf,2/22/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,D2,dopamine type 2,,,
clinicalPharmacology,3bc870c2-e1db-44ca-9552-ea5981fd3c33,7/13/2012,1,Cl-,chloride,,,
clinicalPharmacology,ef12dce1-5259-40bf-84f3-2db4859c560b,3/30/2012,1,HETEs,hydroxyeicosatetraenoic acids,,,
clinicalPharmacology,ef12dce1-5259-40bf-84f3-2db4859c560b,3/30/2012,1,LTs,leukotrienes,,,
clinicalPharmacology,ef12dce1-5259-40bf-84f3-2db4859c560b,3/30/2012,1,AA,arachidonic acid,,,
clinicalPharmacology,ef12dce1-5259-40bf-84f3-2db4859c560b,3/30/2012,1,PG,prostaglandin,,,
clinicalPharmacology,b8fc7086-c034-41c2-aa24-ca30c45753f5,4/21/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,71dc3f3d-7ecf-40d6-9050-29f07ed268be,5/20/2011,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,89967042-5a78-451a-af91-bab38afa7a4d,8/2/2010,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,89967042-5a78-451a-af91-bab38afa7a4d,8/2/2010,5,IV,intravenous,,,
clinicalPharmacology,f00b6da7-3f74-4ef6-a1ac-343029cf97ea,4/11/2011,10,SREs,skeletal-related events,,,
clinicalPharmacology,ed71d7ea-f5af-4406-8b0d-68e17cb1e61e,12/15/2010,6,V/F,volume of distribution,,,
clinicalPharmacology,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,Y-BOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,CGI,Clinical Global Impressions,,,
clinicalPharmacology,50972F39-A15B-4C90-B9E6-CF7F76CD6E99,10/9/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,f3b11f4f-936b-4b75-9cb5-9ef14ee95144,5/7/2012,5,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,783c8a4c-53af-4a58-b3ee-58184d2e9549,1/18/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,10/7/2009,5,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,10/7/2009,5,PM,poor metabolizers,,,
clinicalPharmacology,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,LDL,low density lipoprotein,,,
clinicalPharmacology,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,VLDL,very low density lipoprotein,,,
clinicalPharmacology,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,TG,triglyceride,,,
clinicalPharmacology,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,ICH,intracranial hemorrhage,,,
clinicalPharmacology,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,PT,prothrombin time,,,
clinicalPharmacology,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,CT,computerized tomography,,,
clinicalPharmacology,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,aPTT,activated partial thromboplastin time,,,
clinicalPharmacology,c669f77c-fa48-478b-a14b-80b20a0139c2,3/8/2012,2,NIHSS,National Institutes of Health Stroke Scale,,,
clinicalPharmacology,0feb7a22-7416-4502-bf6e-6341782d11ab,4/5/2012,3,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,9467f6c9-3e59-45c6-a1be-77200f2d4554,12/2/2010,10,HTM,Haemophilus Test Media,,,
clinicalPharmacology,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,CNS,central nervous system,,,
clinicalPharmacology,017021a4-25a4-4914-aab3-c21daf97ea50,3/15/2012,3,CNS,central nervous system,,,
clinicalPharmacology,017021a4-25a4-4914-aab3-c21daf97ea50,3/15/2012,3,AV,atrioventricular,,,
clinicalPharmacology,017021a4-25a4-4914-aab3-c21daf97ea50,3/15/2012,3,DIG,Digitalis Investigation Group,,,
clinicalPharmacology,fac07cd0-f208-4dec-bcc7-26c46181baff,8/5/2009,2,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,5a96f4e1-6b80-42a2-8d85-95a1ff892099,5/29/2012,2,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,5a96f4e1-6b80-42a2-8d85-95a1ff892099,5/29/2012,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,5a96f4e1-6b80-42a2-8d85-95a1ff892099,5/29/2012,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,f5c534e8-656c-406d-b3dc-b562576ba4eb,2/24/2010,2,V/F,volume of distribution,,,
clinicalPharmacology,d36b7894-2152-452d-9bba-38067c52c79e,12/31/2006,1,AUC,[area under the curve,,,
clinicalPharmacology,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,ab2edabd-e57d-4754-9822-93bd17af9e88,6/14/2007,2,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,9dac97a5-c992-4601-af93-138bfe2302a8,3/15/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,MN,mononuclear,,,
clinicalPharmacology,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,422811d6-915c-41a5-be70-212e65d6f647,6/21/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,i.e.,improvement,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,TID,three divided doses,,,
clinicalPharmacology,4e238105-e53f-4e2f-a023-1f966cf14c60,3/18/2011,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,ISH,isolated systolic hypertension,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,DBP,diastolic blood pressure,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,ITT,intention-to-treat,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,ESRD,end-stage renal disease,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,CVD,cardiovascular disease,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,SBP,systolic blood pressure,,,
clinicalPharmacology,d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4,1/13/2012,7,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,686B528E-5480-4CAA-8FF4-B1BAAF5983EC,12/7/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,1448e72e-dc7f-4618-9b37-a82c59823839,7/22/2010,2,triazole,Three metabolites of  anastrozole,,,
clinicalPharmacology,13916cd3-6fe6-401e-af71-07ae2686bce0,4/7/2006,1,calcitriol,calcipotriene is expected to be similar to that of the naturally occurring vitamin.3,,,
clinicalPharmacology,83a2a183-7354-4ba8-bd8d-9b6fd1d1a351,1/11/2010,1,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,a498f39c-7385-4bec-884d-ee33968171cb,2/25/2011,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,1e1e306f-c1d2-4ce8-bc70-228adf4c3102,7/17/2012,9,cGMP,cyclic guanosine monophosphate,,,
clinicalPharmacology,705f45f0-0be4-45f6-8268-3db0c8e8950a,1/12/2012,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,ffa394f7-2e07-4455-9ed9-4271e05cd762,11/30/2011,5,AUC,area under the concentration time curve,,,
clinicalPharmacology,b367d81d-4eca-4e28-b490-34be4c003561,4/30/2010,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9D7666AB-D48A-4507-A120-D7E1229543FD,2/15/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9D7666AB-D48A-4507-A120-D7E1229543FD,2/15/2008,1,broth,be interpreted according to the following criteria:1,,,
clinicalPharmacology,C6DBB330-4926-49D3-936D-488975985484,12/11/2008,5,Tmax,to maximum plasma concentration,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,ISH,isolated systolic hypertension,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,DBP,diastolic blood pressure,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,ITT,intention-to-treat,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,CVD,cardiovascular disease,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,SBP,systolic blood pressure,,,
clinicalPharmacology,7f3b370c-ca97-e0a5-dbd2-870d7c7782cf,10/19/2011,4,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9,3/8/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9,3/8/2010,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,PNS,peripheral  nervous system,,,
clinicalPharmacology,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,CNS,central nervous system,,,
clinicalPharmacology,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,LH,luteinizing  hormone,,,
clinicalPharmacology,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,GH,growth hormone,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,MTSS,mean total symptom scores,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,SAR,Seasonal allergic rhinitis,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,MNW,mean number of wheals,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,MPS,mean pruritus scores,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,AUC,area under the curve,,,
clinicalPharmacology,FC990447-E652-456D-B59D-67F586212F19,10/12/2006,1,CIU,chronic idiopathic urticaria,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,CPS,complex partial seizures,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,i.e.,improvement,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,TID,three divided doses,,,
clinicalPharmacology,33798a7c-c5a9-49a5-be5d-1312910ef468,4/18/2011,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,20f8c35b-bf1c-44cf-bdd7-01b56b85bc0c,12/28/2010,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,20f8c35b-bf1c-44cf-bdd7-01b56b85bc0c,12/28/2010,1,msec,mseconds,,,
clinicalPharmacology,20f8c35b-bf1c-44cf-bdd7-01b56b85bc0c,12/28/2010,1,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,6cc898bd-f6c7-4d44-b2f7-a5f9410c4d0b,7/12/2010,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,6cc898bd-f6c7-4d44-b2f7-a5f9410c4d0b,7/12/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,6cc898bd-f6c7-4d44-b2f7-a5f9410c4d0b,7/12/2010,1,IV,intravenous,,,
clinicalPharmacology,6cc898bd-f6c7-4d44-b2f7-a5f9410c4d0b,7/12/2010,1,IM,intramuscular,,,
clinicalPharmacology,78c4d20c-9d9b-4f26-bc11-ff193c6c53ca,12/27/2010,2,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,V/F,volume of distribution,,,
clinicalPharmacology,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,7a83e68b-0c37-4e1a-9648-ce21fb4aff00,8/8/2006,1,IV,intravenous,,,
clinicalPharmacology,6056b480-a27f-403f-b92b-b0bc6e5e7b0e,12/13/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,MES,maximal electroshock seizure,,,
clinicalPharmacology,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,SER,spontaneous epileptic rat,,,
clinicalPharmacology,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,Tmax,to maximum  concentration,,,
clinicalPharmacology,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,EM,extensive metabolizers,,,
clinicalPharmacology,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,08AFDA78-EB23-4C0E-BA02-690598E5AF9C,10/22/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,ITT,intention-to-treat,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,ESRD,end-stage renal disease,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,CVD,cardiovascular disease,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,SBP,systolic blood pressure,,,
clinicalPharmacology,d8a91143-7f4c-47d6-916e-b239dc23ae6a,4/24/2012,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,MES,maximal electroshock seizure,,,
clinicalPharmacology,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,SER,spontaneous epileptic rat,,,
clinicalPharmacology,e2d6d072-b0fe-5d01-99c5-9fdb8a7ec079,10/22/1997,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,MN,mononuclear,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,MAO,monoamine oxidase,,,
clinicalPharmacology,efcb06dc-c131-4c89-b441-f0aadb03c7cc,5/15/2012,2,Cl?,Chloride,,,
clinicalPharmacology,efcb06dc-c131-4c89-b441-f0aadb03c7cc,5/15/2012,2,Cl?,chloride,,,
clinicalPharmacology,2a3b79e8-f14c-4b44-9d3e-3c92a82269bd,4/16/2012,3748,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,RIA,radioimmunoassay,,,
clinicalPharmacology,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,GC-MF,gas chromatography-mass fragmentography,,,
clinicalPharmacology,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,HPLC,high pressure liquid chromato-graphy,,,
clinicalPharmacology,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,AUC,area under the concentration time-curve,,,
clinicalPharmacology,0609253c-505b-c6d0-241e-90ffdba25ca2,1/2/1998,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,b749df83-49b0-433e-8a62-589a048dd716,3/21/2011,6,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,b749df83-49b0-433e-8a62-589a048dd716,3/21/2011,6,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,b749df83-49b0-433e-8a62-589a048dd716,3/21/2011,6,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,3494332D-3E3F-4EC5-82E9-38FD6107F32A,10/25/2007,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,PES,programmed electrical stimulation,,,
clinicalPharmacology,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,LVEF,left ventricular ejection fraction,,,
clinicalPharmacology,df7ddf4f-d569-431e-81f1-9129d7043150,10/27/2010,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
clinicalPharmacology,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,PMs,poor metabolizers,,,
clinicalPharmacology,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,EMs,[extensive metabolizers,,,
clinicalPharmacology,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,EC09AB1C-52FA-4F41-BF65-A632DCE8F097,3/31/2007,1,ISDN,isosorbide dinitrate,,,
clinicalPharmacology,EC09AB1C-52FA-4F41-BF65-A632DCE8F097,3/31/2007,1,preload,pressure and,,,
clinicalPharmacology,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,D2,dopamine Type 2,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,OADC,oleic acid-albumin dextrose-catalase,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,eec8727b-c98c-41a4-90b8-d49a8e01e63c,9/28/2009,10,CL,clearance,,,
clinicalPharmacology,b32fcb1b-fee4-44b8-a91c-10dfdd3f84ea,3/30/2010,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,b32fcb1b-fee4-44b8-a91c-10dfdd3f84ea,3/30/2010,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,SMAP,2–sulfamoylacetyl phenol,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,V/F,volume of distribution,,,
clinicalPharmacology,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,RBC,red blood cells,,,
clinicalPharmacology,3da5f41d-5200-45ac-b89d-00881237ec85,11/28/2011,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,CLSI,Clinical Laboratory and Standards Institute,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,broth,based on a microdilution method,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,Inhibitors,inhibitors,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,a09299d5-9c55-4cef-aed0-3a6a45532289,2/21/2012,5,CL,clearance,,,
clinicalPharmacology,e2015ac5-0441-43fd-b864-a1b1fe944450,9/30/2010,6,CSF,cerebrospinal fluid,,,
clinicalPharmacology,ddcfb616-78c1-42eb-9dcb-2cc41291a2ac,6/1/2009,2,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,efbb228b-7b38-4176-8bae-826103178c35,12/14/2010,1,CVP,central venous pressure,,,
clinicalPharmacology,a1f49fe1-b511-4f6b-a912-8ae8662d95a5,7/10/2009,3,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,384848CD-55EA-4107-89D3-CE0B819F4DD2,8/28/2008,1,SREs,skeletal-related events,,,
clinicalPharmacology,384848CD-55EA-4107-89D3-CE0B819F4DD2,8/28/2008,1,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,ITT,intention-to-treat,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,CVD,cardiovascular disease,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,SBP,systolic blood pressure,,,
clinicalPharmacology,00c34d67-720a-ccc7-d545-d5448f8b108e,10/4/2010,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,3b453b16-b050-4dda-8e2f-40924e7f7d1c,7/17/2012,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,3b453b16-b050-4dda-8e2f-40924e7f7d1c,7/17/2012,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,b85c7258-f5a2-4baa-b2e5-f951da7589e9,4/13/2010,1,IV,intravenous,,,
clinicalPharmacology,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,AV,atrioventricular,,,
clinicalPharmacology,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,PAF,[paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,WPW,Wolf Parkinson’s White,,,
clinicalPharmacology,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6fabbc1e-4fa9-4830-8740-e6a878c64adf,4/27/2010,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,e15905e0-e0f6-4c8b-ac19-59724d6c4bf0,7/23/2012,6,GER,gastroesophageal reflux,,,
clinicalPharmacology,e15905e0-e0f6-4c8b-ac19-59724d6c4bf0,7/23/2012,6,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,93285568-950e-4cdd-973e-0b714a536223,11/10/2011,3133,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,93285568-950e-4cdd-973e-0b714a536223,11/10/2011,3133,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,f1c40164-4626-4290-9012-c00e33420a33,2/25/2010,2,GX,glycinexylidide,,,
clinicalPharmacology,f1c40164-4626-4290-9012-c00e33420a33,2/25/2010,2,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,ea2d1275-8437-4979-8199-24eb9678be94,6/1/2010,1,min,median,,,
clinicalPharmacology,f1076019-6f2c-4c90-9f3c-ab0c7cdd9315,5/1/2006,3,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,f1076019-6f2c-4c90-9f3c-ab0c7cdd9315,5/1/2006,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,cb723a07-f9de-414a-b438-27fa3e6337b4,10/4/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,cb723a07-f9de-414a-b438-27fa3e6337b4,10/4/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,5d9cf81e-8271-4d56-9d68-4b24dc54715a,5/23/2011,1,PT,prothrombin time,,,
clinicalPharmacology,c68204a7-d00c-4ce7-bfda-bff58b2ed67e,6/3/2011,1,AUC,area under the concentration-time,,,
clinicalPharmacology,46fb9dbc-5345-48a4-a0ec-75039622c76c,5/21/2010,1,RT,reverse transcriptase,,,
clinicalPharmacology,46fb9dbc-5345-48a4-a0ec-75039622c76c,5/21/2010,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,CNS,central nervous system,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,CGI,Clinical Global Impression,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,DCT,demethylcitalopram,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,DDCT,didemethylcitalopram,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,DA,dopamine,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,NE,norepinephrine,,,
clinicalPharmacology,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,CT,citalopram ,,,
clinicalPharmacology,0f079187-1cdf-48c4-a217-9a0e25eb4c92,4/13/2010,1,IV,intravenous,,,
clinicalPharmacology,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,MN,mononuclear,,,
clinicalPharmacology,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,MN,mononuclear,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,Drugs,Drug Interactions.,,,
clinicalPharmacology,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,PMN,polymorphonuclear,,,
clinicalPharmacology,f22c1b09-fee6-4051-be7c-7fd5260db62f,4/13/2012,1,Cl-,chloride,,,
clinicalPharmacology,58b181b0-8c2f-4caf-95e8-123719aa164c,1/20/2011,2,LES,lower esophageal sphincter,,,
clinicalPharmacology,e94c15f7-7115-4c9e-b5e5-6b8f275882a1,2/15/2012,2,MAOI,monoamine oxidase inhibitors,,,
clinicalPharmacology,e94c15f7-7115-4c9e-b5e5-6b8f275882a1,2/15/2012,2,MAO,monoamine oxidase,,,
clinicalPharmacology,e94c15f7-7115-4c9e-b5e5-6b8f275882a1,2/15/2012,2,IAA,indole acetic acid,,,
clinicalPharmacology,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,Tmax,time of maximum plasma concentration,,,
clinicalPharmacology,151d1497-7655-44ce-8e97-dd1cd91f686a,11/15/2010,2,PAD,peripheral arterial disease,,,
clinicalPharmacology,DF687429-C3D0-4987-9CF0-B958B8EE6290,1/4/2006,1,e.g.,exogenous amines,,,
clinicalPharmacology,DF687429-C3D0-4987-9CF0-B958B8EE6290,1/4/2006,1,MAO,monoamine oxidase,,,
clinicalPharmacology,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,GI,gastrointestinal,,,
clinicalPharmacology,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,rT3,reverse T3,,,
clinicalPharmacology,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,TBPA,thyroxine-binding  prealbumin,,,
clinicalPharmacology,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,TBG,thyroxine-binding globulin,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,CPS,complex partial seizures,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,AED,antiepilepsy drug,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,i.e.,improvement,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,TID,three divided doses,,,
clinicalPharmacology,a221e493-2e44-4398-90dd-80b348f3f0c2,4/22/2011,2,MRS,Manic Rating Scale,,,
clinicalPharmacology,2e736bd6-01cc-4180-b97c-dd10b2250630,7/30/2010,1,min,median,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,IV,intravenous,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,TSO,to sleep onset,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,i.e.,its active metabolites,,,
clinicalPharmacology,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,LPS,latency to persistent sleep,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,ICU,Intensive Care Unit,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,HR,Heart Rate,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,PK/PD,pharmacokinetic/pharmacodynamic,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,CL,clearance,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,MAP,mean arterial blood pressure,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,TOF,train-of-four,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,29 minutes,29 minutes and were consistent with the t½? of cisatracurium in vitro,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,MQA,monoquaternary alcohol,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,HR,heart rate,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,MAP,Mean Arterial Pressure,,,
clinicalPharmacology,2ee0358e-2cce-40d3-9fcf-1b9088815c98,7/13/2012,1,CABG,coronary artery bypass grafting,,,
clinicalPharmacology,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,TCA,tricyclic antidepressant,,,
clinicalPharmacology,8362b919-efa6-4451-8c44-49380f81b5db,7/8/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,HRT,estrogen/hormone replacement therapy,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,mean,men between the ages of 38 and 91,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,U.S.,United States,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,FIT,Fracture Intervention Trial,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,IV,intravenous,,,
clinicalPharmacology,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,mean,men between the ages of 31 and 87,,,
clinicalPharmacology,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,CHF,.Congestive Heart Failure,,,
clinicalPharmacology,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,i.e.,initial clearance rates,,,
clinicalPharmacology,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,D2,dopamine Type 2,,,
clinicalPharmacology,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,f77f9742-9100-4b64-ac73-dff94079b888,6/4/2010,1,ABPM,ambulatory  blood pressure monitoring,,,
clinicalPharmacology,5f742224-618e-4f4c-bdec-7693be99c697,5/29/2009,1,AUC,area under the curve,,,
clinicalPharmacology,c48c8351-ee27-47c6-a88b-c642c6baf5e1,3/23/2007,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,13DDBD97-DA1A-D20D-FEEF-8F8B737126F0,1/12/2007,1,PRA,plasma renin activity,,,
clinicalPharmacology,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,429a2f62-9fe6-4299-b314-92a9d22b1381,10/7/2011,8,CSF,cerebrospinal fluid,,,
clinicalPharmacology,98ea197c-b3ff-47bc-8d0f-fce91b539959,2/8/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,CNS,central nervous system,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,CGI,Clinical Global Impression,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,DCT,demethylcitalopram,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,DDCT,didemethylcitalopram,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,CT,citalopram,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,DA,dopamine,,,
clinicalPharmacology,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,NE,norepinephrine,,,
clinicalPharmacology,1AA8A109-8AB9-4CC6-A945-401FFDECD32E,2/26/2008,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,e2d3f96d-7e36-4b80-8fa5-7a4e606148c3,9/14/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,28f698df-b584-4455-2e94-6efc41313960,11/10/2010,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,d823148f-9c5a-4c4b-962f-633f0b2e1dd8,8/26/2010,1,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,d823148f-9c5a-4c4b-962f-633f0b2e1dd8,8/26/2010,1,LES,lower esophageal sphincter,,,
clinicalPharmacology,b1eee648-907a-439c-8e45-bd632364cbc3,12/28/2011,1,SDD,Susceptible-Dose Dependent,,,
clinicalPharmacology,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,D2,dopamine type 2,,,
clinicalPharmacology,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,PPG,postprandial plasma glucose,,,
clinicalPharmacology,dd7f12a7-7fe5-470b-b151-6ccf19945638,8/3/2010,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,STH,somatotropic hormone,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,ECL,Enterochromaffin-like,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,FSH,follicle stimulating hormone,,,
clinicalPharmacology,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,LH,luteinizing hormone,,,
clinicalPharmacology,cbf74e0d-3254-4ed4-b5bd-d6eeaa1efec0,3/14/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b38a3332-5c54-453f-aeb7-070f830955c2,12/16/2009,3,IV,intravenous,,,
clinicalPharmacology,1eb9a361-cd8d-44b0-bf40-42b97a470ddd,3/12/2010,1,cAMP,cyclic AMP,,,
clinicalPharmacology,e97fa417-643a-4f78-94f4-a3b554843a19,12/30/2009,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,4a3f1deb-13b0-4253-b0af-7374880655d8,11/30/2009,3,PPAA,?-phenyl-piperidine acetic acid,,,
clinicalPharmacology,4a3f1deb-13b0-4253-b0af-7374880655d8,11/30/2009,3,MPH,methylphenidate,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,PT,prothrombin time,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,CL,clearance,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,Vd,volume of distribution,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,IV,intravenous,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,CYP,cytochrome P450,,,
clinicalPharmacology,b019bfc3-5a3b-4b8f-9962-d885447639db,4/4/2012,2,BMI,body mass index,,,
clinicalPharmacology,b40bfd2b-9ff1-45bf-a40f-e9812f1df228,6/3/2010,323,EM,extensive metabolizers,,,
clinicalPharmacology,b40bfd2b-9ff1-45bf-a40f-e9812f1df228,6/3/2010,323,PM,poor metabolizers,,,
clinicalPharmacology,b32d82ee-7727-4501-a858-a8304135b11b,1/12/2011,1,NO,nitric oxide,,,
clinicalPharmacology,37061e3e-5e7f-4958-aab8-462846dd6fc0,5/30/2012,3,CLD,chronic liver disease,,,
clinicalPharmacology,37061e3e-5e7f-4958-aab8-462846dd6fc0,5/30/2012,3,FPG,fasting plasma glucose,,,
clinicalPharmacology,37061e3e-5e7f-4958-aab8-462846dd6fc0,5/30/2012,3,PPG,post-prandial glucose,,,
clinicalPharmacology,e6c549a7-774f-4274-9bc5-1149fed5c526,10/20/2011,3,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,ISH,isolated systolic hypertension,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,DBP,diastolic blood pressure,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,ITT,intention-to-treat,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,CVD,cardiovascular disease,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,SBP,systolic blood pressure,,,
clinicalPharmacology,a092eef4-78b8-43b9-80fc-61341c37ea43,9/28/2010,3,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,442471c7-65eb-454c-a5ff-ac6134cbc8bb,7/13/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,442471c7-65eb-454c-a5ff-ac6134cbc8bb,7/13/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,442471c7-65eb-454c-a5ff-ac6134cbc8bb,7/13/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,442471c7-65eb-454c-a5ff-ac6134cbc8bb,7/13/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,442471c7-65eb-454c-a5ff-ac6134cbc8bb,7/13/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,GX,glycinexylidide,,,
clinicalPharmacology,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,PD,pain threshold depth,,,
clinicalPharmacology,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,SD,sensory penetration depth,,,
clinicalPharmacology,6e8f7981-f2ca-4b56-8759-4f18cf9706c8,9/8/2010,3,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,6e8f7981-f2ca-4b56-8759-4f18cf9706c8,9/8/2010,3,B-21-MP,beclomethasone-21-monopropionate,,,
clinicalPharmacology,6e8f7981-f2ca-4b56-8759-4f18cf9706c8,9/8/2010,3,BOH,beclomethasone,,,
clinicalPharmacology,b3e740ad-46d9-48f5-85ab-7c319919ceb1,3/1/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,b3e740ad-46d9-48f5-85ab-7c319919ceb1,3/1/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,4d68df6a-6e96-47a4-abeb-6afc7cc84bbc,9/10/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c0d505ad-eba0-498d-890c-ebcab8386c62,5/1/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e4e9a872-2bda-4e9e-9803-eb4782489978,5/12/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f5d7ae2f-5485-42e2-af2b-bd7f06df85d7,2/22/2010,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,7ea1db43-40fa-417b-8911-ae98092070a0,6/20/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,7ea1db43-40fa-417b-8911-ae98092070a0,6/20/2011,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,89c78896-7b10-4612-90dd-60f952937685,7/1/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,89c78896-7b10-4612-90dd-60f952937685,7/1/2011,2,LES,lower esophageal sphincter,,,
clinicalPharmacology,be5f8ca6-7232-423a-a2d5-cccb7abe7921,12/8/2011,6,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,be5f8ca6-7232-423a-a2d5-cccb7abe7921,12/8/2011,6,PBP,penicillin binding proteins,,,
clinicalPharmacology,1ceb560b-1a62-408d-8e30-23113e8c9dd3,10/25/2011,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,1ceb560b-1a62-408d-8e30-23113e8c9dd3,10/25/2011,1,EM,extensive metabolizers,,,
clinicalPharmacology,1ceb560b-1a62-408d-8e30-23113e8c9dd3,10/25/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,db303d11-eba4-49f7-bf9c-7d944ddb43e7,2/14/2012,1,HPA,hypothalamic-pituitary- adrenal,,,
clinicalPharmacology,db303d11-eba4-49f7-bf9c-7d944ddb43e7,2/14/2012,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,PIs,protease inhibitors,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,NNRTIs,non-nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,TAMs,Thymidine analogue mutations,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,NRTIs,nucleoside reverse transcriptase  inhibitors,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,AMT,3?-amino-3?-deoxythymidine,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,AUC,area under the  curve,,,
clinicalPharmacology,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,0.011 µM,0.005 to 0.110 µM,,,
clinicalPharmacology,78ad1221-f07d-4afc-9ce7-5a0418101ff9,11/3/2009,4,i.e.,improvement from baseline,,,
clinicalPharmacology,4a246ce7-c04e-4119-9201-23e5f90152a8,6/30/2010,4,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,4a246ce7-c04e-4119-9201-23e5f90152a8,6/30/2010,4,NSAIDs,non-steroidal anti-inflammatory drugs,,,
clinicalPharmacology,3af8cfe6-1c0d-4b57-ae31-05cffa64132e,12/9/2010,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,3af8cfe6-1c0d-4b57-ae31-05cffa64132e,12/9/2010,2,Inhibitors,inhibitors,,,
clinicalPharmacology,3af8cfe6-1c0d-4b57-ae31-05cffa64132e,12/9/2010,2,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,NE,neuroendocrine,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,EE,erosive esophagitis,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,b19238be-9962-478c-bd29-0f5f8d0abef3,5/25/2012,6,CYP,cytochrome P450,,,
clinicalPharmacology,e174c804-fe33-4cd8-809a-d107b5200064,12/29/2009,2,PIC,Polysaccharide iron complex,,,
clinicalPharmacology,89245260-c470-4a4c-8ef6-12598dc28e4c,6/23/2009,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,ITT,intention-to-treat,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,CVD,cardiovascular disease,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,SBP,systolic blood pressure,,,
clinicalPharmacology,69605072-f130-4054-95b0-ff3c34554fb9,1/21/2010,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,CYP450,cytochrome P450,,,
clinicalPharmacology,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,NRTIs,nucleoside/nucleotide reverse transcriptase inhibitors,,,
clinicalPharmacology,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,HIV-1,HIV type 1,,,
clinicalPharmacology,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,rt,reverse transcriptase,,,
clinicalPharmacology,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,IV,intravenous,,,
clinicalPharmacology,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,7c6b995b-264f-494c-8c10-6c12b02c214e,5/14/2010,10,HTM,Haemophilus Test Media,,,
clinicalPharmacology,7c6b995b-264f-494c-8c10-6c12b02c214e,5/14/2010,10,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,7c6b995b-264f-494c-8c10-6c12b02c214e,5/14/2010,10,CLSI,control  strainsClinical and Laboratory Standards Institute,,,
clinicalPharmacology,7c6b995b-264f-494c-8c10-6c12b02c214e,5/14/2010,10,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,0ae0e103-5250-4745-8ae2-74fa47fbf973,1/3/2011,1,CNS,central nervous system,,,
clinicalPharmacology,0ae0e103-5250-4745-8ae2-74fa47fbf973,1/3/2011,1,PNS,peripheral nervous system,,,
clinicalPharmacology,2564646d-183c-4759-8726-155a4c22aa2b,1/11/2012,5,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,2564646d-183c-4759-8726-155a4c22aa2b,1/11/2012,5,AWR,airways resistance,,,
clinicalPharmacology,d6fc590a-7ff9-488c-9898-eec926303b76,4/4/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,d6fc590a-7ff9-488c-9898-eec926303b76,4/4/2011,1,MHPG,3-methoxy- 4-hydroxyphenyl glycol,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,CPS,complex partial seizures,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,AED,antiepilepsy drug,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,i.e.,improvement,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,TID,three divided doses,,,
clinicalPharmacology,7981f586-89c2-4ed3-874f-952c28c31cb1,4/22/2011,3,MRS,Manic Rating Scale,,,
clinicalPharmacology,AADEE2AB-113B-4CD4-8184-575C3F496990,1/8/2007,3,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,120b912d-87d4-4463-ae46-5e48ca33db49,2/8/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,10a557fe-6620-4b15-862a-d3ff5dece612,3/13/2012,2,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,7a5a367f-8461-4b15-99fc-f89aa7d5936e,9/28/2010,2,see,sustained fever,,,
clinicalPharmacology,7a5a367f-8461-4b15-99fc-f89aa7d5936e,9/28/2010,2,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,7a5a367f-8461-4b15-99fc-f89aa7d5936e,9/28/2010,2,see and,serum theophylline concentrations are required in pediatric patients,,,
clinicalPharmacology,7a5a367f-8461-4b15-99fc-f89aa7d5936e,9/28/2010,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,7a5a367f-8461-4b15-99fc-f89aa7d5936e,9/28/2010,2,CHF,Congestive Heart Failure,,,
clinicalPharmacology,8aa4f3fc-720b-448b-ae8b-9bb3a9ff6d42,2/8/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,8aa4f3fc-720b-448b-ae8b-9bb3a9ff6d42,2/8/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8aa4f3fc-720b-448b-ae8b-9bb3a9ff6d42,2/8/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,cfb4ae70-0bd4-4585-bbaf-507b18437866,1/20/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a194b8f8-163c-4e48-bc8b-871391010bab,11/29/2011,1,ECG,electrocardiogram,,,
clinicalPharmacology,17281FD4-F7B3-44CF-971F-491EBA72D5D7,5/18/2007,2,Vd,volume of distribution,,,
clinicalPharmacology,17281FD4-F7B3-44CF-971F-491EBA72D5D7,5/18/2007,2,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,0FB7864F-BE1C-4992-A996-556AEF29981F,6/25/2008,2,GX,glycinexylidide,,,
clinicalPharmacology,0FB7864F-BE1C-4992-A996-556AEF29981F,6/25/2008,2,GX,and glycinexylidide,,,
clinicalPharmacology,0FB7864F-BE1C-4992-A996-556AEF29981F,6/25/2008,2,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,4AA4EE5B-B5BE-4A98-5B8C-6F75E2B59E51,4/13/2006,1,Cl¯,Chloride,,,
clinicalPharmacology,4AA4EE5B-B5BE-4A98-5B8C-6F75E2B59E51,4/13/2006,1,LES,lower esophageal sphincter,,,
clinicalPharmacology,4AA4EE5B-B5BE-4A98-5B8C-6F75E2B59E51,4/13/2006,1,Cl¯,chloride,,,
clinicalPharmacology,11939A69-D373-42DF-BABB-9FB7B9C8F6CB,3/7/2007,1,IV,intravenous,,,
clinicalPharmacology,85cbba14-ab8e-43b1-9f7d-3a0e6a28b0fc,1/12/2010,1,PT,prothrombin time,,,
clinicalPharmacology,b04c23ee-3165-4eb7-86a9-ca457747539e,5/24/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b04c23ee-3165-4eb7-86a9-ca457747539e,5/24/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,b04c23ee-3165-4eb7-86a9-ca457747539e,5/24/2012,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,b04c23ee-3165-4eb7-86a9-ca457747539e,5/24/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,ecb298ce-4817-4530-9aee-cf5f3041b836,2/28/2012,3599,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,ecb298ce-4817-4530-9aee-cf5f3041b836,2/28/2012,3599,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,ecb298ce-4817-4530-9aee-cf5f3041b836,2/28/2012,3599,AUC,area under the concentration-time curve,,,
clinicalPharmacology,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,TCA,tricyclic antidepressant,,,
clinicalPharmacology,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,445fbfa9-ef9a-42d3-a7d5-5a48f8b0af21,8/4/2011,1,LVEDP,left ventricular  end diastolic pressure,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,ISH,isolated systolic hypertension,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,DBP,diastolic blood pressure,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,ITT,intention-to-treat,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,ESRD,end-stage renal disease,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,CVD,cardiovascular disease,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,SBP,systolic blood pressure,,,
clinicalPharmacology,9199238d-8b24-4ca8-bd24-c200853416f6,12/19/2011,3,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,4afee435-ae60-4260-a1df-e52abf7a043d,12/29/2010,1,CNS,central nervous system,,,
clinicalPharmacology,4afee435-ae60-4260-a1df-e52abf7a043d,12/29/2010,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,baf1bea8-c573-4ef8-8630-7b51a8e53cac,3/27/2009,1,ACh,acetylcholine,,,
clinicalPharmacology,bc62b38c-4cc9-4e64-8852-1a0be6d36d8e,8/30/2011,1,TMP/SMX,trimethoprim/sulfamethoxazole,,,
clinicalPharmacology,bc62b38c-4cc9-4e64-8852-1a0be6d36d8e,8/30/2011,1,IV,intravenous,,,
clinicalPharmacology,9321c20d-04f4-2bcd-a080-43c9e45025b2,6/19/2006,2,AF,Atrial Fibrillation,,,
clinicalPharmacology,9321c20d-04f4-2bcd-a080-43c9e45025b2,6/19/2006,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,Tmax,to maximum concentration,,,
clinicalPharmacology,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,CYP3A4/5,cytochrome P450 3A4/5,,,
clinicalPharmacology,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,BMI,body mass index,,,
clinicalPharmacology,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,P-gp,P-glycoprotein,,,
clinicalPharmacology,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,0f026966-e6ed-4b5b-a8e4-1b383b010813,3/13/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,0f026966-e6ed-4b5b-a8e4-1b383b010813,3/13/2012,3,IV,intravenous,,,
clinicalPharmacology,39531d0c-db12-4627-81c9-6563076b637b,6/15/2012,4,Vss,volume of distribution at steady state,,,
clinicalPharmacology,39531d0c-db12-4627-81c9-6563076b637b,6/15/2012,4,seasonal,study to evaluate differences in Lazanda absorption in individuals with induced allergic,,,
clinicalPharmacology,C07DF5A8-A4ED-4A2F-AC97-BF5F4E55D80D,4/4/2008,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,a4ff77b8-04bc-4edb-a085-8d6d8687f8d1,8/17/2011,5,NET,norethindrone,,,
clinicalPharmacology,a4ff77b8-04bc-4edb-a085-8d6d8687f8d1,8/17/2011,5,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,a4ff77b8-04bc-4edb-a085-8d6d8687f8d1,8/17/2011,5,EE,ethinyl estradiol,,,
clinicalPharmacology,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,40dcf270-64bb-bca0-db08-6b233a3430f8,4/13/2007,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,b0af5ca1-9189-4c62-bdf1-f1124ec337e7,10/17/2011,17,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,6e3e5317-14b0-4786-90e7-6ed86eb4d8f5,2/15/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,6e3e5317-14b0-4786-90e7-6ed86eb4d8f5,2/15/2010,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,51abd2ce-6be1-412d-b806-5f24935ac5e3,2/15/2012,8,AMT,3'-amino-3'-deoxythymidine,,,
clinicalPharmacology,51abd2ce-6be1-412d-b806-5f24935ac5e3,2/15/2012,8,IV,intravenous,,,
clinicalPharmacology,51abd2ce-6be1-412d-b806-5f24935ac5e3,2/15/2012,8,TAMs,Thymidine analogue mutations,,,
clinicalPharmacology,51abd2ce-6be1-412d-b806-5f24935ac5e3,2/15/2012,8,CrCl,creatinine clearance,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,CE,conjugated estrogens,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,WHI,Women’s Health Initiative,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,PE,pulmonary embolism,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,CHD,coronary heart disease,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,LH,luteinizing hormone,,,
clinicalPharmacology,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,CI,confidence intervals,,,
clinicalPharmacology,a5215931-3385-4d8e-b121-47aa1c20420c,2/7/2008,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,f7cadf45-ffe6-43d1-d5aa-a880506bb782,10/26/2010,10,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,bac9ca81-db70-41aa-82af-6c5bb8496846,6/28/2010,2,MMSE,Mini-Mental State Examination,,,
clinicalPharmacology,bac9ca81-db70-41aa-82af-6c5bb8496846,6/28/2010,2,GDS,Global Deterioration Scale,,,
clinicalPharmacology,bac9ca81-db70-41aa-82af-6c5bb8496846,6/28/2010,2,ADCS-CGIC,Alzheimer’s Disease Cooperative Study—Clinicians Global Impression of Change,,,
clinicalPharmacology,bac9ca81-db70-41aa-82af-6c5bb8496846,6/28/2010,2,CIBIC,Clinician’s Interview Based Impression of Change,,,
clinicalPharmacology,f35e3310-0246-446a-aabe-c17f9000ce26,10/6/2006,1,that is,three inhalations of Alupent,,,
clinicalPharmacology,f35e3310-0246-446a-aabe-c17f9000ce26,10/6/2006,1,c-AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,f35e3310-0246-446a-aabe-c17f9000ce26,10/6/2006,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,c738fb6a-bdde-4149-97e4-de8e63236e7a,11/23/2011,3254,AUC,area  under the concentration-time,,,
clinicalPharmacology,166abd26-675e-4832-9d18-0567f2a9d4e4,9/24/2010,1,ddI,didanosine,,,
clinicalPharmacology,166abd26-675e-4832-9d18-0567f2a9d4e4,9/24/2010,1,RT,reverse transcriptase,,,
clinicalPharmacology,166abd26-675e-4832-9d18-0567f2a9d4e4,9/24/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,35f9e465-76c0-435c-9e81-8fd9bb16cedf,8/30/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d7214539-6c3d-466a-a474-6fde096fa182,2/3/2011,3,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox,ceftizoxime for injection,,,
clinicalPharmacology,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8351aa37-552d-471d-b293-c564dcb6ec29,11/6/2009,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,25c2a91c-dfc2-4596-8a24-63acf04a2568,7/9/2010,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,7e2462b2-bfed-4da4-8c47-46838d6153f8,11/28/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,54233F16-400F-41B8-BAAF-3A963DB8D129,10/6/2006,1,Cl?,Chloride,,,
clinicalPharmacology,54233F16-400F-41B8-BAAF-3A963DB8D129,10/6/2006,1,Cl?,chloride,,,
clinicalPharmacology,54233F16-400F-41B8-BAAF-3A963DB8D129,10/6/2006,1,Mg++,magnesium,,,
clinicalPharmacology,7aa0ce90-156c-4583-ae6d-9ed3595960c8,5/31/2011,1,PBPs,penicillin binding proteins,,,
clinicalPharmacology,22991030-8116-4CBA-8A99-BDC708F0F524,12/4/2006,1,APTTs,activated partial thromboplastin times,,,
clinicalPharmacology,22991030-8116-4CBA-8A99-BDC708F0F524,12/4/2006,1,Cl?,Chloride,,,
clinicalPharmacology,22991030-8116-4CBA-8A99-BDC708F0F524,12/4/2006,1,Cl?,chloride,,,
clinicalPharmacology,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,Inhibitors,inhibitors,,,
clinicalPharmacology,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,244DA533-0B72-4015-37B0-A16744490B28,6/12/2008,2,Vd,volume of distribution,,,
clinicalPharmacology,ddef12df-a0bd-4f58-bd3e-da975581d01b,8/4/2011,1,AUC,Area Under Curve,,,
clinicalPharmacology,78794e3d-f293-4eeb-22ac-8f536d5947eb,5/2/2012,11,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,78794e3d-f293-4eeb-22ac-8f536d5947eb,5/2/2012,11,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,CABG,coronary artery bypass graft,,,
clinicalPharmacology,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,ED,erectile dysfunction,,,
clinicalPharmacology,b6c0ff30-03f5-4c1b-9077-f0918cf40a91,11/11/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,f3217d4f-d4c0-4289-b5ac-949628f4138e,9/1/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,f3217d4f-d4c0-4289-b5ac-949628f4138e,9/1/2009,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,CgA,Chromogranin A,,,
clinicalPharmacology,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,CYP,cytochrome P450,,,
clinicalPharmacology,117ec4c4-07d6-42b1-a537-43fbc93d901d,7/12/2012,5,CL,clearance,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,ER,estrogen receptor,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,CI,confidence interval,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,RR,relative risk,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DMBA,dimethylbenzanthracene,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,RMT,Royal Marsden Trial,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,EBCTCG,Early Breast Cancer Trialists' Collaborative Group,,,
clinicalPharmacology,eb558270-1b12-4704-9b09-39f668f30529,12/7/2010,1,AI,1-aminoindan,,,
clinicalPharmacology,eb558270-1b12-4704-9b09-39f668f30529,12/7/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,GI,gastrointestinal,,,
clinicalPharmacology,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,AUC,and                       bioequivalence,,,
clinicalPharmacology,A694C480-76F3-42C3-BB67-BED50E12C1AE,2/19/2009,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,42e49120-6f3f-11db-9fe1-0800200c9a66,5/31/2012,9,AUC,area under the curve,,,
clinicalPharmacology,a03f40f5-068e-41f2-826d-6ed627dd8776,4/6/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,dc420d50-6192-482d-b3da-3be55870a79a,1/2/2012,2,AUC,area under the concentration time curve,,,
clinicalPharmacology,F133FE04-1550-4FA4-9DC4-652C27936BF2,1/4/2006,1,GABA,gamma-amino-butyric acid,,,
clinicalPharmacology,9498a2f4-6b05-4811-80d7-9acaa9cf59a5,1/17/2011,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,BMI,Body Mass Index,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,BSA,body surface area,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,PACTG,Pediatric AIDS Clinical Trials Group,,,
clinicalPharmacology,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,e3e96f8d-31a6-4457-8e05-02579b539b8a,3/30/2011,1,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,e3e96f8d-31a6-4457-8e05-02579b539b8a,3/30/2011,1,AUC,area under the concentration  time-curve,,,
clinicalPharmacology,ae50721d-ee15-4ee7-9fe7-afd98c56461b,11/16/2011,13,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,91bd0351-f33c-43ca-bd77-7da97969985b,12/13/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,91bd0351-f33c-43ca-bd77-7da97969985b,12/13/2010,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,6a73336d-216b-4070-bedc-f2c05bcc2d83,8/13/2010,350,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,5ec05500-6333-4bd0-ac83-464fad0d5162,11/16/2011,11,RT,reverse transcriptase,,,
clinicalPharmacology,5ec05500-6333-4bd0-ac83-464fad0d5162,11/16/2011,11,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,675d87cb-195c-4d28-8c10-db677e16c656,8/8/2011,3061,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,468AF59B-81E9-4876-9903-EACAECD28B3B,11/5/2007,2,V/F,volume of distribution,,,
clinicalPharmacology,468AF59B-81E9-4876-9903-EACAECD28B3B,11/5/2007,2,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,468AF59B-81E9-4876-9903-EACAECD28B3B,11/5/2007,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,93d73c30-f90d-435b-a31b-036884caa7b4,10/12/2007,1,BHPM,[bis-(p-hydroxyphenyl) pyridyl-2 methane;,,,
clinicalPharmacology,ad7ac196-4c6e-4aab-8742-bdb9f38f4be6,1/14/2011,5,PID,Pain Intensity Difference,,,
clinicalPharmacology,be64cd87-af1b-4beb-957f-963b61fd95bf,1/15/2010,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,be64cd87-af1b-4beb-957f-963b61fd95bf,1/15/2010,1,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,be64cd87-af1b-4beb-957f-963b61fd95bf,1/15/2010,1,MEF,middle ear fluid,,,
clinicalPharmacology,7d82aa5d-aee9-4c72-9b9b-af7adad21f4c,10/18/2011,2,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,7d82aa5d-aee9-4c72-9b9b-af7adad21f4c,10/18/2011,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,e.g.,enzyme-inducing AED,,,
clinicalPharmacology,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,9013ca48-15f2-43cd-a51d-91cf65c72a7c,11/29/2011,4,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,ADB54FE50FCC4A01AFC64AA3D3DB45BB,11/7/2006,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,IV,intravenous,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,TSO,to sleep onset,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,i.e.,its active metabolites,,,
clinicalPharmacology,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,LPS,latency to persistent sleep,,,
clinicalPharmacology,5386fb7c-f4d8-4ee6-b914-780e2da5411b,6/1/2010,1,IV,intravenous,,,
clinicalPharmacology,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,MN,mononuclear,,,
clinicalPharmacology,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,PMN,polymorphonuclear,,,
clinicalPharmacology,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,e.g.,enzyme-inducing AED,,,
clinicalPharmacology,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,2e84d479-5536-471f-93ef-34c353aff071,1/26/2012,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,a4d555fa-787c-40fb-bb7d-b0d4f7318fd0,6/21/2012,8,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,83cb43e7-325c-4afc-9bc5-93a1fbbadff4,7/7/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,040d8193-0ca7-33cd-e300-44bb5b5ee0e4,10/11/2011,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,cb1505f6-4b09-4e7b-a225-735f3a1a0e4b,12/19/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,cb1505f6-4b09-4e7b-a225-735f3a1a0e4b,12/19/2011,1,SDD,Susceptible-Dose Dependent,,,
clinicalPharmacology,994dfdaa-6cf7-4177-8cea-b20b56f1512a,1/11/2010,3,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,C3F7CD94-D842-4F6B-A582-A38C751A790A,6/26/2008,2,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,f15b043d-fcfa-4ade-a3da-76700c0c5c2a,12/28/2010,1,AUC,area under the curve,,,
clinicalPharmacology,f21494ed-c5e8-4ddf-b140-ecd68c5c312b,8/8/2008,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,f21494ed-c5e8-4ddf-b140-ecd68c5c312b,8/8/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f21494ed-c5e8-4ddf-b140-ecd68c5c312b,8/8/2008,1,Groups C,group streptococciStreptococcus agalactiae  Streptococci,,,
clinicalPharmacology,30a73005-ac90-467c-bedd-59d528e7930e,8/12/2010,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,30a73005-ac90-467c-bedd-59d528e7930e,8/12/2010,1,Tmax,to reach maximum plasma concentration,,,
clinicalPharmacology,3b90b6e6-88b9-4774-884a-f30049226466,12/31/2009,2,FVC,forced  vital capacity,,,
clinicalPharmacology,9bced3c4-f450-4e21-9baa-ab2efd0ed4bd,10/5/2011,1,Vd?,volume of distribution,,,
clinicalPharmacology,4ec4c8ca-ce83-4948-8626-21eb82ae5c19,1/17/2012,8,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,STH,somatotropic hormone,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,ECL,Enterochromaffin-like,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,FSH,follicle stimulating hormone,,,
clinicalPharmacology,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,LH,luteinizing hormone,,,
clinicalPharmacology,484e0918-3442-49dc-8ccf-177f1f3ee9f3,8/1/2011,3,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,3f08b127-1c61-4608-aa23-9ef72d2b5361,3/24/2010,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,d2d9e4a0-6c8a-45fa-82e7-297721a98545,2/21/2011,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,e607b0e3-e22e-429f-b40a-0567ded993a7,4/27/2011,7,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,e3e27c8f-64d5-4e6e-bb2d-5dd3a2e3daa1,3/2/2011,2,MIC's,minimum  inhibitory concentrations,,,
clinicalPharmacology,7dfd3fdd-efa4-4239-8cd7-ddf2de682328,4/5/2011,2,HCV-RNS,HCV replicon cells,,,
clinicalPharmacology,92da8862-a021-45e3-acdd-6cf6e0c8dc94,1/25/2012,2,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,92da8862-a021-45e3-acdd-6cf6e0c8dc94,1/25/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,038ae416-4bd5-411b-bd28-d4f0af5c2ab7,5/16/2011,2,PPAA,?-phenyl-piperidine acetic acid,,,
clinicalPharmacology,038ae416-4bd5-411b-bd28-d4f0af5c2ab7,5/16/2011,2,MPH,methylphenidate,,,
clinicalPharmacology,9907acb2-e4a0-46f9-93c0-a8d7b7ce98cf,11/16/2010,5,TAMs,Thymidine analogue mutations,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,apo B,apolipoprotein B,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,LDL,low-density lipoprotein,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,VLDL,very-low-density  lipoprotein,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,see above,significantly different from the bioavailability of amlodipine and atorvastatin  administered separately,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,IDL,intermediate density lipoprotein,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,TG,Triglycerides,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,IDL-C,intermediate density lipoprotein cholesterol,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,FH,familial hypercholesterolemia,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,LDL-C,LDL-cholesterol,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,total-C,total  cholesterol,,,
clinicalPharmacology,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,IDL,intermediate-density  lipoprotein,,,
clinicalPharmacology,4fc5df6d-9253-409c-9c4f-26159aa651bd,2/28/2012,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,LDL,low density lipoprotein,,,
clinicalPharmacology,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,TG,triglyceride,,,
clinicalPharmacology,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,IV,intravenous,,,
clinicalPharmacology,baacecf3-b371-42c6-bf58-bd4141ddb665,2/27/2012,2,GER,gastroesophageal reflux,,,
clinicalPharmacology,baacecf3-b371-42c6-bf58-bd4141ddb665,2/27/2012,2,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,MN,mononuclear,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,CNS,central nervous system,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,DCT,demethylcitalopram,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,CT,citalopram,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,DA,dopamine,,,
clinicalPharmacology,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,NE,norepinephrine,,,
clinicalPharmacology,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,7/20/2012,3,CNS,central nervous system,,,
clinicalPharmacology,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,7/20/2012,3,CGI,Clinical Global Impressions,,,
clinicalPharmacology,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,CYP,cytochrome P450,,,
clinicalPharmacology,7dd162fc-f208-4746-b2da-92747fa2f3d5,8/17/2011,5,NET,norethindrone,,,
clinicalPharmacology,7dd162fc-f208-4746-b2da-92747fa2f3d5,8/17/2011,5,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,7dd162fc-f208-4746-b2da-92747fa2f3d5,8/17/2011,5,EE,ethinyl estradiol,,,
clinicalPharmacology,bfbc2cfb-8e96-4cf2-81c7-d63a1b7365c4,12/17/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,4655fb97-a1e0-4a6d-964e-800327847846,6/24/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,Tmax,time to peak exposure,,,
clinicalPharmacology,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,AUC,area under the curve,,,
clinicalPharmacology,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,e.g.,experience changes in mood,,,
clinicalPharmacology,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,CNS,central nervous system,,,
clinicalPharmacology,3c5e2c32-58ff-48da-aabe-93562868a390,2/16/2011,3,HTM,Haemophilus Test Media,,,
clinicalPharmacology,3c5e2c32-58ff-48da-aabe-93562868a390,2/16/2011,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,f63abe56-46d9-4e32-afb1-f4e22370717d,10/5/2011,4,CAD,coronary artery disease,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,NE,neuroendocrine,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,EE,erosive esophagitis,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,a81dc60e-af42-4d5a-ba21-865fec74ce05,1/3/2011,1,CYP,cytochrome P450,,,
clinicalPharmacology,9df717ae-2d95-4ae3-bb5d-d1d285e15d26,5/21/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9df717ae-2d95-4ae3-bb5d-d1d285e15d26,5/21/2010,2,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,9df717ae-2d95-4ae3-bb5d-d1d285e15d26,5/21/2010,2,PBP,penicillin binding proteins,,,
clinicalPharmacology,9df717ae-2d95-4ae3-bb5d-d1d285e15d26,5/21/2010,2,IM,intramuscular,,,
clinicalPharmacology,6fafbe75-fcae-4afd-9745-02e641cefb31,1/3/2011,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,CABG,coronary artery bypass graft,,,
clinicalPharmacology,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,ED,erectile dysfunction,,,
clinicalPharmacology,3d6164d7-3083-41c5-a6a6-7e144fe29f7d,8/17/2007,1,MI,myocardial infarction,,,
clinicalPharmacology,3d6164d7-3083-41c5-a6a6-7e144fe29f7d,8/17/2007,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,abe0d2d5-4879-4b4e-9b57-47ea83a17ba0,9/29/2009,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a086ceb6-7796-437f-865d-e25b39bd1a23,2/28/2012,3,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,31c12a11-7bce-4457-b413-feaad0da9c49,7/1/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1f1af798-17d5-47d0-b129-21d4aa1eb125,7/9/2012,1,AIDS,Acquired Immune Deficiency Syndrome,,,
clinicalPharmacology,7f888a0c-189e-4c76-86d8-7bc6f21e3b16,2/21/2012,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,7f888a0c-189e-4c76-86d8-7bc6f21e3b16,2/21/2012,1,AWR,airways resistance,,,
clinicalPharmacology,f62cabe9-2651-4eb4-a3fe-bc26a5c4fc23,1/9/2010,1,IV,intravenous,,,
clinicalPharmacology,b58b9f95-6886-40a9-a443-ad95eebebcf0,6/27/2012,2,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,MN,mononuclear,,,
clinicalPharmacology,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,06fbdb63-d32f-4212-9962-f1de15597dda,12/16/2009,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,CNS,central nervous system,,,
clinicalPharmacology,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,DA,dopamine,,,
clinicalPharmacology,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,NE,norepinephrine,,,
clinicalPharmacology,a28d52ce-70b4-4d74-b78c-4964bbd884ab,9/1/2010,3,BALs,Bronchoalveolar lavages,,,
clinicalPharmacology,a28d52ce-70b4-4d74-b78c-4964bbd884ab,9/1/2010,3,ELF,epithelial lining fluid,,,
clinicalPharmacology,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,GFR,glomerular filtration rate,,,
clinicalPharmacology,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,GNG,guanines separated by an intervening nucleotide,,,
clinicalPharmacology,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,AG,adenine-guanines,,,
clinicalPharmacology,173018F5-FD76-4480-90F8-4B7EFE328444,5/11/2006,1,MBC,minimum bactericidal concentration,,,
clinicalPharmacology,173018F5-FD76-4480-90F8-4B7EFE328444,5/11/2006,1,Cmax,changes in rate or extent of lomefloxacin exposure,,,
clinicalPharmacology,173018F5-FD76-4480-90F8-4B7EFE328444,5/11/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,173018F5-FD76-4480-90F8-4B7EFE328444,5/11/2006,1,broth,be interpreted according to the following criteria:2,,,
clinicalPharmacology,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,dca63476-c4a7-4857-84fe-7cb602e6393f,4/21/2011,2,Met,Metformin,,,
clinicalPharmacology,dca63476-c4a7-4857-84fe-7cb602e6393f,4/21/2011,2,Comb,Combined Metformin/Glyburide,,,
clinicalPharmacology,dca63476-c4a7-4857-84fe-7cb602e6393f,4/21/2011,2,Glyb,Glyburide,,,
clinicalPharmacology,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
clinicalPharmacology,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,PMs,poor metabolizers,,,
clinicalPharmacology,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,EMs,[extensive metabolizers,,,
clinicalPharmacology,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,8da31eca-51cf-4a01-9159-740f772b0f15,4/29/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9FC0BDC2-5BA2-48DD-AA87-7B0050A2D6CE,3/30/2007,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,f1311278-6ea6-44de-8a0c-9131a6882d15,5/16/2011,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,f1311278-6ea6-44de-8a0c-9131a6882d15,5/16/2011,1,LESP,lower esophageal sphincter pressure,,,
clinicalPharmacology,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,PMDD,Premenstrual Dysphoric Disorder,,,
clinicalPharmacology,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,LLPDD,Luteal Phase Dysphoric Disorder,,,
clinicalPharmacology,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,e17d7cc3-e193-4f41-a457-4b6b32a9201d,3/23/2007,1,V/F,volume of distribution,,,
clinicalPharmacology,a5e522b5-bc59-4010-a658-6e0c0884b234,8/9/2009,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,92c6c41b-21b8-44e6-89eb-8e8c9170f4db,11/22/2011,2,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,CPS,complex partial seizures,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,AED,antiepilepsy drug,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,TID,three divided doses,,,
clinicalPharmacology,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,9b52e0a7-f024-4d8a-a59e-374946e60b44,7/22/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,67044E85-DD05-4AB4-BB85-D56679372599,10/18/2006,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,CGI,Clinical Global Impression,,,
clinicalPharmacology,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,619e10bb-6e5d-4ec3-a85a-6270965f5389,8/1/2011,6,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,3bbb25db-ec98-4469-6e9c-8685ab20b0cc,6/7/2011,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1971e893-5fdb-41e3-a1e9-5e52deed03d1,3/23/2009,5,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,9ca35e18-c823-4e4c-bd69-09d333a7f851,1/23/2006,1,PSVT,paroxysmal supraventricular tachycardias,,,
clinicalPharmacology,5517349a-4f7f-4c8d-9c4b-5cbb8c5996f8,12/3/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c59f8018-fff8-4884-a3c8-bc306e2c8f64,7/15/2010,4,MRI,magnetic resonance imaging,,,
clinicalPharmacology,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,FEV1,forced expiratory volume 1 second,,,
clinicalPharmacology,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,GFR,glomerular filtration rate,,,
clinicalPharmacology,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,RPF,renal plasma flow,,,
clinicalPharmacology,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,FVC,forced vital capacity,,,
clinicalPharmacology,a06f4905-2c1b-42ae-9c47-5d95e532c2a2,3/4/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1c82c808-fc1d-4564-8120-ce2532092514,6/15/2011,2,GER,gastroesophageal reflux,,,
clinicalPharmacology,1c82c808-fc1d-4564-8120-ce2532092514,6/15/2011,2,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,57016639-89fe-43ad-89c4-5e7a756dddec,11/21/2011,1,NET,norethindrone,,,
clinicalPharmacology,57016639-89fe-43ad-89c4-5e7a756dddec,11/21/2011,1,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,57016639-89fe-43ad-89c4-5e7a756dddec,11/21/2011,1,EE,ethinyl estradiol,,,
clinicalPharmacology,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,ND,NDMinor Bleedingd391031333.21a,,,
clinicalPharmacology,eac3e17d-aac3-482b-98a0-c2258255d180,8/3/2011,1,mm,MicroorganismZone Diameter,,,
clinicalPharmacology,eac3e17d-aac3-482b-98a0-c2258255d180,8/3/2011,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,0c7adf7f-d2c3-4b3a-b81b-dcaae7cc3036,6/4/2010,3,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,Total-C,total cholesterol,,,
clinicalPharmacology,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,1577bc9c-24d3-450e-b438-d4f1b5db6485,6/7/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1577bc9c-24d3-450e-b438-d4f1b5db6485,6/7/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1577bc9c-24d3-450e-b438-d4f1b5db6485,6/7/2010,1,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,1577bc9c-24d3-450e-b438-d4f1b5db6485,6/7/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,082A3791-20C6-4FFA-A113-B60128344381,10/28/2008,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,082A3791-20C6-4FFA-A113-B60128344381,10/28/2008,1,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,96af95c4-ed8b-450b-920b-bc12678f3584,3/15/2012,2,CBG,corticosteroid binding globulin,,,
clinicalPharmacology,96af95c4-ed8b-450b-920b-bc12678f3584,3/15/2012,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,892aa268-0790-4e2c-8faa-d8cbeb200abd,12/21/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,ULN,upper limit of normal,,,
clinicalPharmacology,882bbf32-8a87-4479-a2a8-92637abfdd75,11/2/2010,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,882bbf32-8a87-4479-a2a8-92637abfdd75,11/2/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,882bbf32-8a87-4479-a2a8-92637abfdd75,11/2/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6a8621eb-7415-42a6-9432-630751d34c6b,8/30/2010,1,QTc,QT correction,,,
clinicalPharmacology,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,ULN,upper limit of normal,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,CNS,central nervous system,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,DCT,demethylcitalopram,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,CT,citalopram,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,DA,dopamine,,,
clinicalPharmacology,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,NE,norepinephrine,,,
clinicalPharmacology,3F82E6B5-C6B6-4D96-8295-948FEC7E7FDB,2/12/2009,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,CE,conjugated estrogens,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,MPA,medroxyprogesterone  acetate,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,WHI,Women’s Health Initiative,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,PE,pulmonary embolism,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,CHD,coronary heart disease,,,
clinicalPharmacology,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,471fde4e-1661-4ca0-9d3e-18522139687a,4/3/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,471fde4e-1661-4ca0-9d3e-18522139687a,4/3/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,471fde4e-1661-4ca0-9d3e-18522139687a,4/3/2012,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,5c827776-912a-40ce-a57d-d941c3d7d9f6,10/3/2011,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,176A1E12-A9A1-4901-8900-A530F7937F03,11/14/2008,1,SREs,skeletal-related events,,,
clinicalPharmacology,176A1E12-A9A1-4901-8900-A530F7937F03,11/14/2008,1,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,75b4e52e-84d0-4f3b-568e-2bc1d0ce9ae1,10/31/2011,10,Cl?,Chloride,,,
clinicalPharmacology,75b4e52e-84d0-4f3b-568e-2bc1d0ce9ae1,10/31/2011,10,Cl?,chloride,,,
clinicalPharmacology,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,AWR,airway resistance,,,
clinicalPharmacology,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,PIC,Polysaccharide iron complex,,,
clinicalPharmacology,3d9aa97a-665a-44d4-990f-3d1a54c04174,3/29/2012,14,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c337bce8-27e9-48fd-85fa-381d0242a36a,8/31/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,7b5c59ae-e4c1-4097-9db1-f6837b7c3688,12/22/2009,1,IV,intravenous,,,
clinicalPharmacology,5fc4f89c-cf94-4e7a-bf31-d3d86a242efa,3/19/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,ISH,isolated systolic hypertension,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,DBP,diastolic blood pressure,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,ITT,intention-to-treat,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,ESRD,end-stage renal disease,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,CVD,cardiovascular disease,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,SBP,systolic blood pressure,,,
clinicalPharmacology,2410e0c7-8166-403b-8c55-89ed084c2955,11/21/2011,15,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,23b776e0-7a03-4946-0110-6f70e70031e8,3/29/2010,1,IV,intravenous,,,
clinicalPharmacology,23b776e0-7a03-4946-0110-6f70e70031e8,3/29/2010,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,bcf72938-7043-4d66-9edc-29a4599021a1,3/20/2007,1,PRA,plasma renin activity,,,
clinicalPharmacology,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,ADP,adenosine diphosphate,,,
clinicalPharmacology,b34da4a3-f25e-46d3-b86a-7167d7546092,3/28/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2dcdd1c3-6728-45fb-97aa-de21f1f5ccad,1/4/2006,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,93983865-362f-40a8-ba41-a8bcb99e35cb,4/26/2011,1,AUC,area under the curve,,,
clinicalPharmacology,dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078,8/16/2010,6,GCV,ganciclovir,,,
clinicalPharmacology,dc548ff9-e8ea-4d6e-b9b4-e31f53ac4078,8/16/2010,6,VGCV,valganciclovir,,,
clinicalPharmacology,35019655-9a30-4305-a262-936ad0e73071,7/22/2010,4,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,M-1,model.11A pentapeptide,,,
clinicalPharmacology,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,IV,intravenous,,,
clinicalPharmacology,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,LH,luteinizing hormone,,,
clinicalPharmacology,038c2b07-8028-4dc4-847c-adafe1b0e81a,12/25/2009,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,MN,mononuclear,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,cafe4650-6aa4-4466-9beb-064ee5a0e401,11/1/2011,1,AUC,Area Under the Curve,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,GAD,generalized anxiety disorder,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,PD,panic disorder,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,2d4f6e4f-e385-b872-38c6-b7d1a9e8f9b9,3/13/2012,2,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,c61229e8-75cb-4776-9883-c5630bc38a32,1/26/2011,1,QC,Quality control,,,
clinicalPharmacology,5cf490d1-edb7-4b3f-9a01-a44ec7e8369c,11/25/2010,1,V/F,volume of distribution,,,
clinicalPharmacology,5cf490d1-edb7-4b3f-9a01-a44ec7e8369c,11/25/2010,1,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,5cf490d1-edb7-4b3f-9a01-a44ec7e8369c,11/25/2010,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,0527eaca-7774-42de-aeca-bb23f05fbe02,3/1/2007,1,SRS-A,slow-reacting substance of anaphylaxis,,,
clinicalPharmacology,57d438aa-eee7-4403-9ecf-04730fa32f2f,7/11/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,f27aa99b-2b77-48d6-8af4-3ae26c04d5b6,1/3/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,Lf69f100f-c766-490f-9143-5e8e0c8cb7c9,9/14/2007,1,cyclic GMP,cyclic guanosine monophosphate,,,
clinicalPharmacology,Lf69f100f-c766-490f-9143-5e8e0c8cb7c9,9/14/2007,1,FVC,forced vital capacity,,,
clinicalPharmacology,1c3ba0b0-0352-49e8-b5cd-9df698194988,3/31/2011,2,ddI,didanosine,,,
clinicalPharmacology,1c3ba0b0-0352-49e8-b5cd-9df698194988,3/31/2011,2,RT,reverse transcriptase,,,
clinicalPharmacology,1c3ba0b0-0352-49e8-b5cd-9df698194988,3/31/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,CF16BFB8-CD72-49E7-B74F-C99292CAB53B,2/8/2008,1,Cl-,chloride,,,
clinicalPharmacology,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,ddI,"rowspan=""1"">didanosine",,,
clinicalPharmacology,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,9daf95f8-f326-4fb0-8a14-022999c9fdeb,3/12/2012,5,GER,gastroesophageal reflux,,,
clinicalPharmacology,9daf95f8-f326-4fb0-8a14-022999c9fdeb,3/12/2012,5,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,67f778f2-8af3-4d4e-850a-e8f3a54743b7,10/13/2010,2,MRI,magnetic resonance imaging,,,
clinicalPharmacology,69f5bc4b-758d-471b-ad8d-17c94f8e0963,7/5/2011,4,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,bd55dd57-348c-4d78-b322-d1ae10279298,4/20/2012,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,I.V.,intravenous,,,
clinicalPharmacology,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,AF,ATRIAL FIBRILLATION,,,
clinicalPharmacology,2b55e178-987d-4ab7-b12b-be9ab2588292,4/3/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,2b55e178-987d-4ab7-b12b-be9ab2588292,4/3/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2b55e178-987d-4ab7-b12b-be9ab2588292,4/3/2012,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,9e5b9309-e835-4863-ab6f-e3018e38fc64,12/31/2009,1,PIC,Polysaccharide iron complex,,,
clinicalPharmacology,48850874-2b01-404a-bbd9-eb83b15c69fb,11/19/2010,3,AUC,area under the  concentration time curve,,,
clinicalPharmacology,036ab68e-5085-4edc-bd83-784b43d64eab,11/16/2010,7,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,CYP,cytochrome P450,,,
clinicalPharmacology,a6355634-dab6-4995-b608-898988d14ad9,11/3/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,LDL,low density lipoprotein,,,
clinicalPharmacology,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,VLDL,very low density lipoprotein,,,
clinicalPharmacology,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,TG,triglyceride,,,
clinicalPharmacology,046da5ed-06d5-46fc-b734-de5c2978d261,11/22/2010,1,NA,<td>Not applicable,,,
clinicalPharmacology,046da5ed-06d5-46fc-b734-de5c2978d261,11/22/2010,1,HTM,Haemophilus  Test Medium,,,
clinicalPharmacology,046da5ed-06d5-46fc-b734-de5c2978d261,11/22/2010,1,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,MAO,monoamine oxidase,,,
clinicalPharmacology,7a8c0140-f34f-4018-956e-1834a9a2abe1,3/13/2012,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1,1/9/2012,11,HTM,Haemophilus Test Media,,,
clinicalPharmacology,4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1,1/9/2012,11,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,436391ed-1bf9-407b-1854-9796537bdf50,3/13/2009,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,436391ed-1bf9-407b-1854-9796537bdf50,3/13/2009,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,2c7f7c84-da53-4fba-ac29-1c3652dd5b3a,11/16/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,2c7f7c84-da53-4fba-ac29-1c3652dd5b3a,11/16/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,dbeb646f-dc6c-40f2-803c-68858d6ac080,3/21/2012,1,MAC,minimum alveolar concentration,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,MN,mononuclear,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,4ab12da7-5731-4e06-bf1c-bc3f2e711f12,3/1/2011,4,GU,gastric ulcer,,,
clinicalPharmacology,4ab12da7-5731-4e06-bf1c-bc3f2e711f12,3/1/2011,4,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,NE,neuroendocrine,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,EE,erosive esophagitis,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,ee114ab9-db51-4a71-90b9-cd9865e4fced,1/21/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,59e94a55-08b6-4d04-bc10-9911e5a585e0,11/11/2011,3142,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,MN,mononuclear,,,
clinicalPharmacology,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,PMN,polymorphonuclear,,,
clinicalPharmacology,a27ce7d2-0b75-47e8-9a7e-1e561b603216,4/9/2010,5,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a27ce7d2-0b75-47e8-9a7e-1e561b603216,4/9/2010,5,PBP,penicillin binding proteins,,,
clinicalPharmacology,a27ce7d2-0b75-47e8-9a7e-1e561b603216,4/9/2010,5,MRSA,methicillin-resistant staphylococci,,,
clinicalPharmacology,a27ce7d2-0b75-47e8-9a7e-1e561b603216,4/9/2010,5,PBP,penicillin-binding-protein,,,
clinicalPharmacology,46eb2941-bda1-4553-84e4-7ac37a60db07,9/13/2011,2,Tmax,to maximum concentration,,,
clinicalPharmacology,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,i.e.,initial clearance rates,,,
clinicalPharmacology,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,CHF,.Congestive heart failure,,,
clinicalPharmacology,abcfeec6-7f3a-4139-a6e6-fa42dafd8264,4/27/2012,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,e38c48f6-4d07-422b-9bb2-3c1025946e86,8/26/2009,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,3f3a870e-f325-475b-8453-fe3d1bb8f54a,3/19/2010,1,GH,growth  hormone,,,
clinicalPharmacology,3f3a870e-f325-475b-8453-fe3d1bb8f54a,3/19/2010,1,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,3f3a870e-f325-475b-8453-fe3d1bb8f54a,3/19/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,1f1490cd-b11b-40cb-96be-865730c989e1,2/11/2008,2,BZ,benzodiazepine,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,CI,confidence interval,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,LCIS,lobular carcinoma in situ,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,RR,relative risk,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,BMD,bone mineral density,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,RMT,Royal Marsden Trial,,,
clinicalPharmacology,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,0c160018-e3fb-4f04-9475-c4cf2cceb1b7,2/22/2012,1,i.e.,improvement from baseline,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,LDL,low density lipoprotein,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,HDL,high density lipoprotein,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,apo B,apolipoprotein B,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,TG,triglyceride,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,total-C,total cholesterol,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,TG,triglycerides,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,HDL-C,high density lipoprotein cholesterol,,,
clinicalPharmacology,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,PPAR?,peroxisome proliferator activated receptor ?,,,
clinicalPharmacology,918cb226-3f1e-479e-8058-dfe60ae14fb2,12/8/2009,1,SREs,skeletal-related events,,,
clinicalPharmacology,918cb226-3f1e-479e-8058-dfe60ae14fb2,12/8/2009,1,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,CSF,cerebrospinal fluid,,,
clinicalPharmacology,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,CYP,cytochrome P450,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,CPS,complex partial seizures,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,AED,antiepilepsy drug,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,TID,three divided doses,,,
clinicalPharmacology,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,MRS,Manic Rating Scale,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,CPS,complex partial seizures,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,AED,antiepilepsy drug,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,i.e.,improvement,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,TID,three divided doses,,,
clinicalPharmacology,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,MRS,Manic Rating Scale,,,
clinicalPharmacology,053a7300-0bce-11e0-9d16-0002a5d5c51b,4/11/2011,2,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,CABG,coronary artery bypass graft,,,
clinicalPharmacology,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,ED,erectile dysfunction,,,
clinicalPharmacology,f20685e4-71c5-40ba-a5ca-f0eb345a8bc5,3/6/2012,7,GER,gastroesophageal reflux,,,
clinicalPharmacology,f20685e4-71c5-40ba-a5ca-f0eb345a8bc5,3/6/2012,7,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,bf92a7d7-395b-4e2c-a3c4-66ebdbfd1052,1/10/2012,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,47c21109-6e7e-4647-9963-d2151f5ef820,10/13/2011,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,CNS,central nervous system,,,
clinicalPharmacology,bfdc6d04-2859-4a0c-add9-81ab131526ca,7/7/2011,3,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,bfdc6d04-2859-4a0c-add9-81ab131526ca,7/7/2011,3,PPG,postprandial plasma glucose,,,
clinicalPharmacology,18f7f458-9276-4e9d-94b2-99ca8dd4cebf,8/3/2010,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,RA,rheumatoid arthritis,,,
clinicalPharmacology,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,Tmax,to maximum concentration,,,
clinicalPharmacology,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,INR,International Normalized Ratio,,,
clinicalPharmacology,55fec4f1-0429-4913-8e9e-be1cb537bb68,3/30/2010,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,7cab718d-2a6f-4792-b94c-be87ebed5cf3,6/22/2010,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,c3ef4853-96d8-4032-b390-060dc8a32148,5/24/2010,11,PK,pharmacokinetic,,,
clinicalPharmacology,674d17c2-1fd4-4e14-892f-d88091b2b6d7,1/16/2012,2,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,Vd,volume of distribution,,,
clinicalPharmacology,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,HPA,Hypothalamic-Pituitary-Adrenal,,,
clinicalPharmacology,68e22782-f3a6-4e2c-8612-3f1608547919,5/24/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,83484e4b-9a8c-4125-9897-715971c7dc8c,9/30/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,8d9a17e9-fd2d-4976-9704-42c6e1760db4,5/14/2010,401,Tmax,to maximum concentration,,,
clinicalPharmacology,284f1e3c-45e4-40fc-a56a-bfacec331016,8/4/2011,1,MIC’s,minimum inhibitory concentrations,,,
clinicalPharmacology,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,AUC,area under the curve,,,
clinicalPharmacology,ac323b5b-132a-4513-927e-2c38b6d33d71,4/12/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,04d9fe8b-6d44-f46f-732a-5583a7118b91,6/28/2011,16,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,04d9fe8b-6d44-f46f-732a-5583a7118b91,6/28/2011,16,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,04d9fe8b-6d44-f46f-732a-5583a7118b91,6/28/2011,16,ECL,Enterochromaffin-like,,,
clinicalPharmacology,04d9fe8b-6d44-f46f-732a-5583a7118b91,6/28/2011,16,CYP,cytochrome P450,,,
clinicalPharmacology,4f4ce896-7f63-44c7-b080-59bd161b44e7,11/6/2009,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4f4ce896-7f63-44c7-b080-59bd161b44e7,11/6/2009,7,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,4165ef14-8dfc-4165-859c-dcf06174d69c,3/2/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,4165ef14-8dfc-4165-859c-dcf06174d69c,3/2/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,BMI,Body Mass Index,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,BSA,body surface area,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,PACTG,Pediatric AIDS Clinical Trials Group,,,
clinicalPharmacology,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,c4cbe7cc-c160-4d46-aad3-61aefe90b3d8,12/15/2009,1,HGPRTase,hypoxanthineguanine phosphoribosyltransferase,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,c66550cd-4bee-4507-8f2d-2cff68cca8cd,7/1/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,CSF,cerebrospinal fluid,,,
clinicalPharmacology,1f71920c-0e54-46e8-82c8-3ea5d212d469,4/23/2012,3,Tmax,the maximum concentration in serum,,,
clinicalPharmacology,0e198d28-4986-4b93-833f-17c7ed4ce13e,3/1/2011,1,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,0e198d28-4986-4b93-833f-17c7ed4ce13e,3/1/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,D8CF50D4-0448-4527-A498-CDDD511213F0,10/2/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,e2f53384-6c90-4a9f-aacf-281233581742,11/4/2010,1,PGE2,prostaglandin E2,,,
clinicalPharmacology,8290add3-4449-4e58-6c97-8fe1eec972e3,5/30/2012,1416,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,8290add3-4449-4e58-6c97-8fe1eec972e3,5/30/2012,1416,msec,mseconds,,,
clinicalPharmacology,8290add3-4449-4e58-6c97-8fe1eec972e3,5/30/2012,1416,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,1/31/2012,15,BMI,Body Mass Index,,,
clinicalPharmacology,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,1/31/2012,15,V/F,volume of distribution,,,
clinicalPharmacology,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,1/31/2012,15,P-gp,P-glycoprotein,,,
clinicalPharmacology,e110f879-98e6-49cb-a3b0-68805cdf602a,4/13/2012,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,a5fa252a-d39e-4099-a230-b665fbb97a80,5/21/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,10a7bd47-d6fe-4e10-8d2a-30c81cee4c2d,4/25/2010,9,GER,gastroesophageal reflux,,,
clinicalPharmacology,10a7bd47-d6fe-4e10-8d2a-30c81cee4c2d,4/25/2010,9,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,b41ecd6b-4c54-44c8-aa3f-1868faad07c6,12/1/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f8e8a69e-a018-469a-af56-e20f61fe4e06,1/10/2012,5,PK,pharmacokinetic,,,
clinicalPharmacology,36d4f6c4-4946-4baa-8f9d-42a03926eeb7,4/11/2012,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,ISH,isolated systolic hypertension,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,DBP,diastolic blood pressure,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,CVD,cardiovascular disease,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,SBP,systolic blood pressure,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,AUCs,area under the plasma concentration curves,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,INR,International Normalized Ratio,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,STH,somatotropic hormone,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,FSH,follicle stimulating hormone,,,
clinicalPharmacology,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,LH,luteinizing hormone,,,
clinicalPharmacology,fbf22eeb-27f5-46aa-be39-5aef43101369,10/25/2010,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,ce566d2e-a158-43d7-a18f-b373e1648645,7/8/2011,1,DNA,deoxyribonu cleic acid,,,
clinicalPharmacology,1123d56c-16f0-4f81-b56f-67b1f343ae1e,3/31/2011,1,min,median,,,
clinicalPharmacology,8878F134-42B9-4C30-B240-2761B6B3AA5F,5/11/2006,1,drying,Diphenhydramine hydrochloride is an antihistamine with anticholinergic,,,
clinicalPharmacology,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,NET,norethindrone,,,
clinicalPharmacology,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,MES,maximal electroshock seizure,,,
clinicalPharmacology,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,SER,spontaneous epileptic rat,,,
clinicalPharmacology,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,EE,ethinyl estradiol,,,
clinicalPharmacology,d5a99052-a939-4d9e-a401-0f106d8b5893,4/13/2007,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,00c96589-6998-4088-a312-ba831433ded6,7/22/2011,7,HTM,Haemophilus Test Media,,,
clinicalPharmacology,00c96589-6998-4088-a312-ba831433ded6,7/22/2011,7,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,00c96589-6998-4088-a312-ba831433ded6,7/22/2011,7,IV,intravenous,,,
clinicalPharmacology,00c96589-6998-4088-a312-ba831433ded6,7/22/2011,7,IM,intramuscular,,,
clinicalPharmacology,3aec64f1-c9eb-4550-9b0d-4410071b7948,4/2/2012,1,Cl-,chloride,,,
clinicalPharmacology,1a56c82e-7ecd-43b0-2899-f89e47adf7db,10/26/2009,5,D/C,discontinuations,,,
clinicalPharmacology,82262fea-91ef-4905-9e25-10b287cd6456,9/9/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,a6182855-6287-45e9-b6b4-7b57efc9c76e,4/6/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a6182855-6287-45e9-b6b4-7b57efc9c76e,4/6/2012,4,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,EM,extensive metabolizers,,,
clinicalPharmacology,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,PM,poor metabolizers,,,
clinicalPharmacology,9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23,6/23/2011,11,SREs,skeletal-related events,,,
clinicalPharmacology,e61ae711-e6d2-44e4-b7d7-943a9d06f985,3/17/2011,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,750fdf6b-e2b1-4d28-a8b1-81b326c714a2,5/30/2011,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,750fdf6b-e2b1-4d28-a8b1-81b326c714a2,5/30/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,4259d9b1-de34-43a4-85a8-41dd214e9177,3/28/2012,12,CGI,Clinical Global Impression,,,
clinicalPharmacology,4259d9b1-de34-43a4-85a8-41dd214e9177,3/28/2012,12,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,86ec0a92-a552-4a6d-9125-a54f95e43392,5/18/2012,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,86ec0a92-a552-4a6d-9125-a54f95e43392,5/18/2012,3,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,dee07488-7a2b-4d45-89e1-d65ab895fd52,12/2/2011,3306,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,A48FB550-390F-4579-8514-D85DB7421721,3/31/2007,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,6b7fb6b7-2f58-4cb6-b48f-e9b4cf292365,7/22/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,0edf8afb-4af8-4dc9-8d9d-7f233f442736,6/6/2011,2,IV,intravenous,,,
clinicalPharmacology,21b73946-d12e-4a61-8eaa-4bf10bb31b98,10/4/2011,1,AUC,area under the time/plasma concentration curve,,,
clinicalPharmacology,21b73946-d12e-4a61-8eaa-4bf10bb31b98,10/4/2011,1,FPG,fasting plasma glucose,,,
clinicalPharmacology,21b73946-d12e-4a61-8eaa-4bf10bb31b98,10/4/2011,1,PPG,post-prandial glucose,,,
clinicalPharmacology,2b8b5145-77ad-4817-8f9e-77fd7938242e,6/30/2011,4,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,2b8b5145-77ad-4817-8f9e-77fd7938242e,6/30/2011,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,df26edb0-9bd6-449c-a187-0be0c9e2600c,12/2/2010,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f154afd2-7732-46cf-aeee-bc16a31e49e8,11/21/2011,4,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,2f36d6b4-1175-4127-b3e5-2be95b710014,2/28/2012,7,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,hCG,human chorionic gonadotropin,,,
clinicalPharmacology,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,ART,Assisted                   Reproductive Technologies,,,
clinicalPharmacology,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,AUC,area under the curve,,,
clinicalPharmacology,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,ART,Assisted Reproductive Technologies,,,
clinicalPharmacology,14d06124-1eef-4f97-b1f3-18620819ae1a,6/26/2009,1,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,14d06124-1eef-4f97-b1f3-18620819ae1a,6/26/2009,1,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,14d06124-1eef-4f97-b1f3-18620819ae1a,6/26/2009,1,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,14496afb-a541-4b01-a672-fcd411292b8d,4/2/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,291512ba-6e0e-4cd0-9e1c-9c6277372f78,4/9/2012,1,B17P,Betamethasone 17-propionate,,,
clinicalPharmacology,0878bdc2-0410-4938-9890-96523aa81c2f,7/21/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a313c111-e539-47bc-9d57-c3767f74bcca,8/26/2011,6,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,a313c111-e539-47bc-9d57-c3767f74bcca,8/26/2011,6,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,85f11b74-a88d-45a1-9ef1-6007e1bbedf7,11/2/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,85f11b74-a88d-45a1-9ef1-6007e1bbedf7,11/2/2009,5,IV,intravenous,,,
clinicalPharmacology,10644068-fa47-4e3b-9e93-f57ebac3dd17,4/1/2010,1,GU,gastric ulcer,,,
clinicalPharmacology,10644068-fa47-4e3b-9e93-f57ebac3dd17,4/1/2010,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,ICU,Intensive Care Unit,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,HR,Heart Rate,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,PK/PD,pharmacokinetic/pharmacodynamic,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,Vss,volume of distribution at steady state,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,CL,clearance,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,MAP,mean arterial blood pressure,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,TOF,train-of-four,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,29 minutes,29 minutes and were consistent with the t½? of cisatracurium in vitro,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,MQA,monoquaternary alcohol,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,HR,heart rate,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,MAP,Mean Arterial Pressure,,,
clinicalPharmacology,291a55dd-ab45-4660-b513-4ecb729eb051,4/16/2012,2,CABG,coronary artery bypass grafting,,,
clinicalPharmacology,7b891df0-add4-4f0c-a3ab-d53e864eced7,11/8/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,7b891df0-add4-4f0c-a3ab-d53e864eced7,11/8/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7b891df0-add4-4f0c-a3ab-d53e864eced7,11/8/2011,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,7b891df0-add4-4f0c-a3ab-d53e864eced7,11/8/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,61caf965-1172-4200-ad56-a3815388c044,10/17/2010,52,RR,risk reductions,,,
clinicalPharmacology,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,MAC,monitored anesthesia care,,,
clinicalPharmacology,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,ITT,intent-to-treat,,,
clinicalPharmacology,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,CLr,clearance,,,
clinicalPharmacology,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,PHN,postherpetic neuralgia,,,
clinicalPharmacology,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,fbf67fc8-8d29-4ae2-a533-75461754c5b1,3/14/2012,4,CBZ,Carbamazepine,,,
clinicalPharmacology,fbf67fc8-8d29-4ae2-a533-75461754c5b1,3/14/2012,4,CBZ-E,Carbamazepine-10,11-epoxide,,
clinicalPharmacology,7F11BE5C-6112-C93E-4D0F-D3A085AC698A,4/2/2009,1,e.g.,exogenous amines,,,
clinicalPharmacology,7F11BE5C-6112-C93E-4D0F-D3A085AC698A,4/2/2009,1,MAO,monoamine oxidase,,,
clinicalPharmacology,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,MAO,monoamine oxidase,,,
clinicalPharmacology,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,CGI,Clinical Global Impressions,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,MN,mononuclear,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,Drugs,Drug Interactions.,,,
clinicalPharmacology,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,PMN,polymorphonuclear,,,
clinicalPharmacology,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,CLr,clearance,,,
clinicalPharmacology,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,ITT,intent-to-treat,,,
clinicalPharmacology,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,CLr,clearance,,,
clinicalPharmacology,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,5/18/2012,22,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d970b074-957a-4036-92d3-1712386f3858,2/19/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d970b074-957a-4036-92d3-1712386f3858,2/19/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,34c30372-08b0-4060-8aba-779b5bc1e5dd,10/26/2011,1,ERG,electroretinogram,,,
clinicalPharmacology,34c30372-08b0-4060-8aba-779b5bc1e5dd,10/26/2011,1,CAD,Coronary Artery Disease,,,
clinicalPharmacology,0fb9f3ab-45d1-405e-a14e-4cb4b1a28c55,10/27/2009,2,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,8df6c027-eb7e-4f8d-9f06-61da861b660c,4/1/2009,1,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,14d37c59-0b0c-4507-9f15-481bd7f5f4d2,12/2/2011,2,NE,neuroendocrine,,,
clinicalPharmacology,9843b969-33e1-4859-8eae-0055bb71d933,6/8/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6a9cbc29-9f15-4b24-8d86-206b82887f3d,3/30/2012,8,PSS,phenotypic susceptibility score,,,
clinicalPharmacology,6a9cbc29-9f15-4b24-8d86-206b82887f3d,3/30/2012,8,HLMs,human liver microsomes,,,
clinicalPharmacology,aa34bfca-06c3-4916-bb51-4bfbfc0ee371,12/18/2009,2,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,i.e.,improvement from baseline,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,SMAP,2-sulfamoylacetyl phenol,,,
clinicalPharmacology,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,RBC,red blood cells,,,
clinicalPharmacology,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,Total-C,total cholesterol,,,
clinicalPharmacology,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,CHF,.Congestive Heart Failure,,,
clinicalPharmacology,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,i.e.,initial clearance rates,,,
clinicalPharmacology,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,a121fa30-2aaf-4dde-a08e-a67381333751,1/31/2012,11,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,a121fa30-2aaf-4dde-a08e-a67381333751,1/31/2012,11,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,ITT,intent-to-treat,,,
clinicalPharmacology,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,CLr,clearance,,,
clinicalPharmacology,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,EABD3C7F-028D-4299-4B9B-60C75AF7EE01,5/23/2008,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4E9A1841-B44D-413E-6B98-C33C25095BA1,12/22/2006,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,99EB1A81-8472-4CFB-BAD8-739636AB5BEC,4/5/2007,1,V/F,volume of distribution,,,
clinicalPharmacology,99EB1A81-8472-4CFB-BAD8-739636AB5BEC,4/5/2007,1,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,99EB1A81-8472-4CFB-BAD8-739636AB5BEC,4/5/2007,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,1bc56a86-735c-4787-826a-9bb59027fa09,12/22/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a1c8ee2a-6a76-435e-ad38-8a9c99046ad9,1/27/2012,1,BMI,body mass indices,,,
clinicalPharmacology,a1c8ee2a-6a76-435e-ad38-8a9c99046ad9,1/27/2012,1,QTcP,QTc based on population correction method,,,
clinicalPharmacology,a1c8ee2a-6a76-435e-ad38-8a9c99046ad9,1/27/2012,1,OC,oral contraceptive,,,
clinicalPharmacology,4f015e1d-af11-47a6-92bb-4bceaa5db3ee,11/16/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,eef30745-075c-4430-8271-2c3f353f40a2,6/1/2010,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,32b0e320-a739-11dc-a704-0002a5d5c51b,11/4/2011,8,CL,clearance,,,
clinicalPharmacology,32b0e320-a739-11dc-a704-0002a5d5c51b,11/4/2011,8,PK,pharmacokinetic,,,
clinicalPharmacology,32b0e320-a739-11dc-a704-0002a5d5c51b,11/4/2011,8,tmax,time of maximum concentration,,,
clinicalPharmacology,32b0e320-a739-11dc-a704-0002a5d5c51b,11/4/2011,8,Vd,Volume of distribution,,,
clinicalPharmacology,d9fdc4b4-5b00-46dd-8700-6e36ceaafb0e,12/14/2010,2,AUC,area under the concentration-time curve,,,
clinicalPharmacology,955cae30-8bfb-46a5-9878-bbc9578493d0,1/19/2012,3,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,ba1dfe30-7ea1-4662-8a70-add5670b1c7a,3/2/2012,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,f3a50f13-b028-4135-8f20-bfb62a9bc0a9,9/15/2010,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,f3a50f13-b028-4135-8f20-bfb62a9bc0a9,9/15/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,AC0289A6-9533-4F8C-B46C-506DCE1B90B5,3/10/2008,2,NYHA,New York Heart Association,,,
clinicalPharmacology,AC0289A6-9533-4F8C-B46C-506DCE1B90B5,3/10/2008,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,29c4305a-7d8e-44c6-9e6f-408f6d1b8f37,7/14/2011,1,sc,StimulantStimulant DoseCimetidine% InhibitionBetazole1.5 mg/kg,,,
clinicalPharmacology,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,ie,its active metabolites,,,
clinicalPharmacology,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,i.e.,improvement,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,TID,three divided doses,,,
clinicalPharmacology,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,D2,dopamine Type 2,,,
clinicalPharmacology,a791c769-f859-4b01-a8bf-4f8ccb2ab8c1,3/17/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,a791c769-f859-4b01-a8bf-4f8ccb2ab8c1,3/17/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,3ad7567d-b11c-407b-9c0b-a198406b7102,10/27/2009,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,b9bbf9ed-4781-42a9-bc3e-deda9f05e810,9/25/2009,2,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,b9bbf9ed-4781-42a9-bc3e-deda9f05e810,9/25/2009,2,AWR,airways resistance,,,
clinicalPharmacology,6600e2b3-65df-4fc3-8081-d574537d27e3,9/30/2011,7,AUC,area under the curve,,,
clinicalPharmacology,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,PTZ,pentylenetetrazol,,,
clinicalPharmacology,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,GEPR,genetically epilepsy-prone rats,,,
clinicalPharmacology,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,e.g.,enzyme-inducing agents,,,
clinicalPharmacology,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,ADP,adenosine diphosphate,,,
clinicalPharmacology,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,PPI,pump inhibitors,,,
clinicalPharmacology,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,ULN,upper limit of normal,,,
clinicalPharmacology,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,857be233-613e-4a2a-aab5-c53c55eec8e6,7/3/2012,1,IV,intravenous,,,
clinicalPharmacology,03dc63f5-78cc-495a-a80b-fb77aeed8815,2/14/2012,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,2F-ara-ATP,2-fluoro-ara-ATP,,,
clinicalPharmacology,bb65f952-284f-46f9-8cfc-4aff59ba5dcd,5/28/2012,3,DDC,dopa decarboxylase,,,
clinicalPharmacology,bb65f952-284f-46f9-8cfc-4aff59ba5dcd,5/28/2012,3,UPDRS,Unified Parkinson’s Disease Rating Scale,,,
clinicalPharmacology,bb65f952-284f-46f9-8cfc-4aff59ba5dcd,5/28/2012,3,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,77272416-32ed-45c4-99bd-5d0e5620cf04,4/7/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,42c535b9-c55e-4fe4-be69-0fc76831bc92,11/8/2010,71,p-gp,p-glycoprotein,,,
clinicalPharmacology,42c535b9-c55e-4fe4-be69-0fc76831bc92,11/8/2010,71,PMs,poor metabolizers,,,
clinicalPharmacology,42c535b9-c55e-4fe4-be69-0fc76831bc92,11/8/2010,71,EMs,extensive  metabolizers,,,
clinicalPharmacology,c7fc2d1e-802e-4da1-9763-3355f8aafe3a,4/13/2010,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,c7fc2d1e-802e-4da1-9763-3355f8aafe3a,4/13/2010,1,msec,mseconds,,,
clinicalPharmacology,c7fc2d1e-802e-4da1-9763-3355f8aafe3a,4/13/2010,1,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,MAO,Maximum acid output,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,NE,neuroendocrine,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,BAO,basal acid output,,,
clinicalPharmacology,3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b,5/9/2012,3,GERD,Gastroesophageal reflux disease,,,
clinicalPharmacology,94d644b9-9ad1-4c21-9c88-c39796b3e3e6,10/27/2009,1,MAOI,monoamine oxidase inhibitors,,,
clinicalPharmacology,94d644b9-9ad1-4c21-9c88-c39796b3e3e6,10/27/2009,1,MAO,monoamine oxidase,,,
clinicalPharmacology,94d644b9-9ad1-4c21-9c88-c39796b3e3e6,10/27/2009,1,IAA,indole  acetic acid,,,
clinicalPharmacology,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,OAT3,organic anion transporter 3,,,
clinicalPharmacology,e58e52c4-50f9-4727-9950-bfefadabb2d0,12/31/2009,2,CNS,central nervous system,,,
clinicalPharmacology,80fb18a3-824a-4360-947e-63f0a167245b,6/7/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,D2,dopamine Type 2,,,
clinicalPharmacology,dac396fb-748d-45ea-9830-17c6eeb8834f,6/8/2011,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,dac396fb-748d-45ea-9830-17c6eeb8834f,6/8/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,aeec0560-3079-4da6-9c49-c87b5f36d2da,8/1/2011,3,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,3/6/2012,6,FA,following termination of anesthesia,,,
clinicalPharmacology,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,3/6/2012,6,MAC,Minimum alveolar concentration,,,
clinicalPharmacology,015bebfb-55a7-4b44-a94d-b032231058b4,2/11/2011,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,IV,intravenous,,,
clinicalPharmacology,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,631dc216-df9e-4126-b59e-c8079ba6e287,8/12/2010,1,APTTs,activated partial thromboplastin  times,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,MN,mononuclear,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,3b1f8ee3-d582-4faa-a7f2-0fbc45721298,7/13/2011,1,TMP/SMX,trimethoprim/sulfamethoxazole,,,
clinicalPharmacology,3b1f8ee3-d582-4faa-a7f2-0fbc45721298,7/13/2011,1,IV,intravenous,,,
clinicalPharmacology,d75b0a7e-cb9b-4102-bcac-097403b25129,1/23/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,0fb2e3cc-b9b5-48a6-b487-1e558dfd56db,8/12/2010,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,611e1f43-1442-4cbb-b7eb-b65de15c6c70,1/4/2011,1,triazole,Three metabolites of anastrozole,,,
clinicalPharmacology,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,SC,subcutaneous injection,,,
clinicalPharmacology,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,b32d180f-f8d6-4535-a3b6-45045663a96f,9/30/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,MIC,minimum  inhibitory concentration,,,
clinicalPharmacology,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,PVL,Panton-Valentine Leukocidin,,,
clinicalPharmacology,54981774-1689-481a-9840-becf1d0dfaf8,2/8/2011,2,NE,neuroendocrine,,,
clinicalPharmacology,54981774-1689-481a-9840-becf1d0dfaf8,2/8/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,54981774-1689-481a-9840-becf1d0dfaf8,2/8/2011,2,EE,erosive esophagitis,,,
clinicalPharmacology,54981774-1689-481a-9840-becf1d0dfaf8,2/8/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,e780534f-5b33-42f8-ae35-ccf8ee652035,9/19/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,fc61fd7e-63ca-4714-851f-31b2a045903d,5/25/2010,1,i.e.,initial clearance rates,,,
clinicalPharmacology,fc61fd7e-63ca-4714-851f-31b2a045903d,5/25/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9251e824-4aad-4a27-bd5b-041b42f68ba5,1/21/2010,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,9251e824-4aad-4a27-bd5b-041b42f68ba5,1/21/2010,2,CVD,cardiovascular disease,,,
clinicalPharmacology,fcc8658c-761a-443f-8c32-1499d86028ec,5/11/2010,3,DEA,N-desethylamiodarone,,,
clinicalPharmacology,fcc8658c-761a-443f-8c32-1499d86028ec,5/11/2010,3,VT,ventricular tachycardia,,,
clinicalPharmacology,fcc8658c-761a-443f-8c32-1499d86028ec,5/11/2010,3,VF,ventricular fibrillation,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,CGI,Clinical Global Impression,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,b7d5e4f6-8798-4385-97c7-cf22c8fcc66f,11/30/2010,5,CL,clearance,,,
clinicalPharmacology,b7d5e4f6-8798-4385-97c7-cf22c8fcc66f,11/30/2010,5,MAP,mean arterial blood pressure,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,HDL,high density lipoprotein,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,apo B,apolipoprotein B,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,total-C,total cholesterol,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,TG,triglycerides,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,HDL-C,high density lipoprotein cholesterol,,,
clinicalPharmacology,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,PPAR?,peroxisome proliferator activated receptor ?,,,
clinicalPharmacology,a401a44e-2c5c-4c4a-81d8-56a3ef9d57f7,10/19/2010,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,59C9BF80-B46E-E302-4EB7-4F751ECD1FEE,4/3/2009,1,e.g.,exogenous amines,,,
clinicalPharmacology,59C9BF80-B46E-E302-4EB7-4F751ECD1FEE,4/3/2009,1,MAO,monoamine oxidase,,,
clinicalPharmacology,A4E9183F-D0EB-4BA7-9204-760B1FD62010,1/1/2007,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,de477f37-40f6-4295-ae72-a2ee36a8922e,3/31/2012,9,IM,intramuscular,,,
clinicalPharmacology,b861fdd9-e134-436e-8c0c-a60dd0006dd3,1/5/2010,2,BMI,Body Mass Index,,,
clinicalPharmacology,dc6c7600-454b-449f-af1c-ff1a8e1b8109,6/9/2010,1,MBC,minimum bactericidal concentration,,,
clinicalPharmacology,dc6c7600-454b-449f-af1c-ff1a8e1b8109,6/9/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d42fbeff-dcca-447c-83e2-c59690b7dc1a,2/8/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b14ef252-fe31-4dfd-840d-2588f591cb7c,2/27/2009,4,V/F,volume of distribution,,,
clinicalPharmacology,b14ef252-fe31-4dfd-840d-2588f591cb7c,2/27/2009,4,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,b14ef252-fe31-4dfd-840d-2588f591cb7c,2/27/2009,4,PPG,postprandial plasma glucose,,,
clinicalPharmacology,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,IV,intravenous,,,
clinicalPharmacology,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,a06ea7d8-a884-4b62-a87f-c36d824f2aa4,3/6/2012,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,a06ea7d8-a884-4b62-a87f-c36d824f2aa4,3/6/2012,2,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,CYP,cytochrome P450,,,
clinicalPharmacology,87315917-3e54-44e6-bb64-2f722501c11b,1/18/2011,1,IV,intravenous,,,
clinicalPharmacology,87315917-3e54-44e6-bb64-2f722501c11b,1/18/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,28fd7158-a617-436a-8f5c-71ffbaafe527,9/14/2005,2,LES,lower esophageal sphincter,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,MN,mononuclear,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,Drugs,Drug Interactions.,,,
clinicalPharmacology,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,PMN,polymorphonuclear,,,
clinicalPharmacology,2f44db39-e1d9-451e-ba31-e4b10366a430,12/1/2010,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,803338bc-9375-11dd-9d53-0ff1e074fd46,10/14/2008,1,GFR,glomerular filtration rate,,,
clinicalPharmacology,8c0c49c9-aa28-4587-869e-b40368152540,12/28/2010,2,HPA,hypothalamic-pituitary- adrenal,,,
clinicalPharmacology,8c0c49c9-aa28-4587-869e-b40368152540,12/28/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,6d8c343b-30d9-4cdb-8f55-2a20983a71c1,7/29/2010,1,MIC's,minimal inhibitory  concentrations,,,
clinicalPharmacology,6d8c343b-30d9-4cdb-8f55-2a20983a71c1,7/29/2010,1,MIC's,minimum  inhibitory concentrations,,,
clinicalPharmacology,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,CNS,Central Nervous System,,,
clinicalPharmacology,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,GH,growth hormone,,,
clinicalPharmacology,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,LH,luteinizing hormone,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,CGI,Clinical Global Impression,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,65ee7ef8-cc68-41d1-cc8b-c01a056409a9,2/29/2012,14,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,f884225c-7845-4df1-ba35-dc53010ed0b0,3/30/2010,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,f884225c-7845-4df1-ba35-dc53010ed0b0,3/30/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,bcd8f8ab-81a2-4891-83db-24a0b0e25895,12/12/2011,22,QTc,QT correction,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,BMI,Body Mass Index,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,BSA,body surface area,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,PACTG,Pediatric AIDS Clinical Trials Group,,,
clinicalPharmacology,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,7259652f-81bc-4ad1-bba5-d01f9fac1b80,6/12/2012,1413,HD,hemodialysis,,,
clinicalPharmacology,7259652f-81bc-4ad1-bba5-d01f9fac1b80,6/12/2012,1413,PD,peritoneal dialysis,,,
clinicalPharmacology,9ccf0781-4fb3-496e-bd58-54381ea33510,12/29/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b910cff4-22a4-4b39-b872-0bd1312f4d8b,3/17/2011,2,Vss,volume of  distribution at steady state,,,
clinicalPharmacology,b910cff4-22a4-4b39-b872-0bd1312f4d8b,3/17/2011,2,GH,growth  hormone,,,
clinicalPharmacology,b910cff4-22a4-4b39-b872-0bd1312f4d8b,3/17/2011,2,Tmax,time of maximum  plasma concentration,,,
clinicalPharmacology,b910cff4-22a4-4b39-b872-0bd1312f4d8b,3/17/2011,2,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,b910cff4-22a4-4b39-b872-0bd1312f4d8b,3/17/2011,2,LH,luteinizing hormone,,,
clinicalPharmacology,4799261f-9fac-4b0a-a470-daa709569405,9/10/2009,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,9fd7a181-ab26-4e68-8404-20ce339b0844,9/30/2010,2,AV,atrioventricular,,,
clinicalPharmacology,326fa31a-5420-429b-9f7f-170cb38f64bd,7/22/2011,4,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,326fa31a-5420-429b-9f7f-170cb38f64bd,7/22/2011,4,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,CNS,central nervous system,,,
clinicalPharmacology,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,HO-NEF,hydroxynefazodone,,,
clinicalPharmacology,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,mCPP,meta-chlorophenylpiperazine,,,
clinicalPharmacology,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,b34eb07b-d8a7-4762-a457-9d64dd86b205,3/10/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5efa48e3-1f8e-4a69-b41f-bf1adc754f94,12/8/2006,1,broth,be interpreted according to the following criteria:2,,,
clinicalPharmacology,5efa48e3-1f8e-4a69-b41f-bf1adc754f94,12/8/2006,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,5e29f133-270c-4e5a-8493-e038c163a891,6/28/2012,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,5e29f133-270c-4e5a-8493-e038c163a891,6/28/2012,3,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,5e29f133-270c-4e5a-8493-e038c163a891,6/28/2012,3,AUC,area under the concentration-time curve,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,ad03e5cc-c36d-4ff0-9b25-5d13e2909230,1/27/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,c4fe14fb-0a43-4c31-9cd6-29eb0d156705,10/15/2009,3,GU,gastric ulcer,,,
clinicalPharmacology,c4fe14fb-0a43-4c31-9cd6-29eb0d156705,10/15/2009,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,PRA,plasma renin  activity,,,
clinicalPharmacology,3814cfed-029f-4231-bba3-89b2b4e01392,2/14/2012,3,V/F,volume of distribution,,,
clinicalPharmacology,3814cfed-029f-4231-bba3-89b2b4e01392,2/14/2012,3,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,3814cfed-029f-4231-bba3-89b2b4e01392,2/14/2012,3,PPG,postprandial plasma glucose,,,
clinicalPharmacology,c6b4fe73-ce77-4adf-b787-2bdb2dd74f84,1/23/2009,3,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,c6b4fe73-ce77-4adf-b787-2bdb2dd74f84,1/23/2009,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c6b4fe73-ce77-4adf-b787-2bdb2dd74f84,1/23/2009,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,c1694b2d-6fbb-b800-370b-0bf31220cb35,10/1/2010,1,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,c1694b2d-6fbb-b800-370b-0bf31220cb35,10/1/2010,1,LES,lower esophageal sphincter,,,
clinicalPharmacology,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,Tmax,to maximum  concentration,,,
clinicalPharmacology,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,EM,extensive metabolizers,,,
clinicalPharmacology,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,dc676bc5-f3f7-4755-92e1-1814498c1f4f,12/31/2010,8,iPTH,intact parathyroid                                             hormone,,,
clinicalPharmacology,6136dcbf-9bde-4b5b-82b3-d7cb8bdb817b,7/1/2011,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,i.e.,initial clearance rates,,,
clinicalPharmacology,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,CHF,Congestive Heart Failure,,,
clinicalPharmacology,7bf48c44-6db5-434f-a60a-a41aed6dbc08,11/10/2011,3131,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,b89b5502-ce87-45a6-a43c-9891da3cfca4,3/28/2012,4,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,546130a3-e5f2-422d-88f0-66de19540ecb,1/19/2012,3,NET,norethindrone,,,
clinicalPharmacology,546130a3-e5f2-422d-88f0-66de19540ecb,1/19/2012,3,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,546130a3-e5f2-422d-88f0-66de19540ecb,1/19/2012,3,EE,ethinyl estradiol,,,
clinicalPharmacology,D59FA254-7959-47C9-BB77-AB7946A1A127,8/13/2008,1,ACh,acetylcholine,,,
clinicalPharmacology,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,4d1ad77f-2c6b-4250-82e5-ab3574444e08,1/4/2011,9,HTM,Haemophilus Test Media,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,CNS,central nervous system,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,DCT,demethylcitalopram,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,DA,dopamine,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,NE,norepinephrine,,,
clinicalPharmacology,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,CT,citalopram ,,,
clinicalPharmacology,A719EC72-771F-49C9-B93D-9D5F585176A4,8/7/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,Tmax,to maximum concentration,,,
clinicalPharmacology,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,MAO,monoamine oxidase,,,
clinicalPharmacology,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,375c42d4-e222-45a5-a0f3-34c871abca42,6/1/2012,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,375c42d4-e222-45a5-a0f3-34c871abca42,6/1/2012,5,broth,be determined using a standardized procedure based on dilution methods,,,
clinicalPharmacology,944c0e5f-88ff-4a46-95ef-2ea7d55063ce,3/29/2012,4,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,86071c7f-9f11-4783-9492-22beb55682e6,3/31/2011,5,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,86071c7f-9f11-4783-9492-22beb55682e6,3/31/2011,5,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,86071c7f-9f11-4783-9492-22beb55682e6,3/31/2011,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,ITT,intent-to-treat,,,
clinicalPharmacology,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,CLr,clearance,,,
clinicalPharmacology,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,PHN,postherpetic neuralgia,,,
clinicalPharmacology,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,MAO,monoamine oxidase,,,
clinicalPharmacology,84f7c21f-d0af-4ae6-9cd5-d5af96ade329,12/10/2010,9,SAM,S-adenosylmethionine,,,
clinicalPharmacology,58b72e4c-f419-4a70-b894-93a5804d9993,9/9/2010,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,58b72e4c-f419-4a70-b894-93a5804d9993,9/9/2010,2,MN,mononuclear,,,
clinicalPharmacology,58b72e4c-f419-4a70-b894-93a5804d9993,9/9/2010,2,PMN,polymorphonuclear,,,
clinicalPharmacology,b92f9206-325e-4454-9518-4f7464b23f47,12/15/2011,3,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,e1aba7cf-52f5-461d-a8f5-9bb580da99d0,10/6/2010,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,e7f6b25b-ec4c-4c3a-a541-617d2d9ab393,4/12/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,af1fef85-fb8e-478d-999a-5a8adc42baa3,2/1/2011,4,TK,thymidine kinase,,,
clinicalPharmacology,6044028a-26d0-4e48-9cfa-8d045c36661a,4/8/2011,1,NYHA,New York Heart Association,,,
clinicalPharmacology,b78499dc-4d24-4226-be97-dc618d9da0cf,4/17/2012,2,GER,gastroesophageal reflux,,,
clinicalPharmacology,b78499dc-4d24-4226-be97-dc618d9da0cf,4/17/2012,2,mean age,minutes to nine pediatric cancer patients  receiving chemotherapy,,,
clinicalPharmacology,e3d77513-723a-4612-a52c-4f4cfefc8763,12/16/2010,150,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,e3d77513-723a-4612-a52c-4f4cfefc8763,12/16/2010,150,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,d62d754e-2310-4912-b022-603ae925710d,2/8/2012,2,CV%,coefficient of variation,,,
clinicalPharmacology,da457b34-ca08-60df-045b-1ae80d2f7e71,3/17/2010,2,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,4a5120c7-2436-43f2-a12f-361224296907,3/13/2012,3,MEF,middle ear fluid,,,
clinicalPharmacology,6052C707-A8A3-43A7-80C2-7AD1AD9391A4,12/18/2006,1,ALAD,metalloenzyme-?-aminolevulinic acid dehydrase,,,
clinicalPharmacology,6052C707-A8A3-43A7-80C2-7AD1AD9391A4,12/18/2006,1,Mn,manganese,,,
clinicalPharmacology,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,IV,intravenous,,,
clinicalPharmacology,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,3a73b934-ea39-43c2-86bf-dfb88353b8bd,7/10/2012,1,Cl-,chloride,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,ISH,isolated systolic hypertension,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,DBP,diastolic blood pressure,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,ITT,intention-to-treat,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,ESRD,end-stage renal disease,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,CVD,cardiovascular disease,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,SBP,systolic blood pressure,,,
clinicalPharmacology,3233c707-70b6-4c29-8210-913eeb2a38ed,1/13/2012,7,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,4f1992ef-d1c8-4219-b3c4-33c608fce28c,10/26/2010,10,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,b8f4d730-fd8e-4692-aabd-e2b7e63fabe1,11/15/2006,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,MN,mononuclear,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,Drugs,Drug Interactions.,,,
clinicalPharmacology,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,PMN,polymorphonuclear,,,
clinicalPharmacology,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,CABG,coronary artery bypass graft,,,
clinicalPharmacology,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,ED,erectile dysfunction,,,
clinicalPharmacology,3fa5b81e-81fd-4017-8e87-a4a4c08119fd,10/14/2009,1,SHBG,sex hormone  binding globulin,,,
clinicalPharmacology,3fa5b81e-81fd-4017-8e87-a4a4c08119fd,10/14/2009,1,DHT,dihydrotestosterone,,,
clinicalPharmacology,3fa5b81e-81fd-4017-8e87-a4a4c08119fd,10/14/2009,1,BT,Bioactive serum testosterone concentrations,,,
clinicalPharmacology,09325220-e4c5-4fac-aefd-ee3e42602198,9/14/2011,5,i.e.,initial clearance rates,,,
clinicalPharmacology,09325220-e4c5-4fac-aefd-ee3e42602198,9/14/2011,5,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,LDL,low density lipoprotein,,,
clinicalPharmacology,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,TG,triglyceride,,,
clinicalPharmacology,240bcdcb-31d9-40a0-87e1-bd16264a2e20,9/28/2009,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,EM,extensive metabolizers,,,
clinicalPharmacology,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,Tmax,to maximum concentration,,,
clinicalPharmacology,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,PM,poor metabolizers,,,
clinicalPharmacology,c135323a-33dd-49d5-b55a-33e1ff1b78fd,10/25/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c135323a-33dd-49d5-b55a-33e1ff1b78fd,10/25/2010,2,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,83221ce8-38f3-4529-2994-333379b77d05,9/28/2011,8,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,Tmax,to maximum  concentration,,,
clinicalPharmacology,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,EM,extensive metabolizers,,,
clinicalPharmacology,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,CNS,Central Nervous System,,,
clinicalPharmacology,487193e9-b9ab-443e-a1c5-26aa14cb2641,3/30/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,11d1e166-9577-47b0-a338-d11ab3ba44aa,8/9/2011,1,TK,thymidine kinase,,,
clinicalPharmacology,11d1e166-9577-47b0-a338-d11ab3ba44aa,8/9/2011,1,HSV-1,HSV types 1,,,
clinicalPharmacology,2fa7a133-ad57-4e3e-8e92-8c678d5fe68d,8/9/2011,7,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,ac7242ec-1830-404e-9269-fe2409ce233c,1/19/2011,1,PAF,[paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,ac7242ec-1830-404e-9269-fe2409ce233c,1/19/2011,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,ac7242ec-1830-404e-9269-fe2409ce233c,1/19/2011,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,ERG,electroretinogram,,,
clinicalPharmacology,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,CAD,Coronary Artery Disease,,,
clinicalPharmacology,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,NTG,nitroglycerin,,,
clinicalPharmacology,32e2b197-e171-444d-86ca-198d4c84d7a5,11/23/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,32e2b197-e171-444d-86ca-198d4c84d7a5,11/23/2010,2,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,CNS,central nervous system,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,DCT,demethylcitalopram,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,DA,dopamine,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,NE,norepinephrine,,,
clinicalPharmacology,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,CT,citalopram ,,,
clinicalPharmacology,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,MAC,Mycobacterium avium Complex,,,
clinicalPharmacology,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,AUC,area under the plasma concentrationtime curve,,,
clinicalPharmacology,21628112-0c47-11df-95b3-498d55d89593,1/18/2012,7,NET,norethindrone,,,
clinicalPharmacology,21628112-0c47-11df-95b3-498d55d89593,1/18/2012,7,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,21628112-0c47-11df-95b3-498d55d89593,1/18/2012,7,EE,ethinyl estradiol,,,
clinicalPharmacology,1781fc07-5a2a-4b31-aad9-d0457eb704f4,2/9/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,1781fc07-5a2a-4b31-aad9-d0457eb704f4,2/9/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,c3122a02-0a44-49f8-947f-109092c38a13,3/30/2010,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,CPS,complex partial seizures,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,AED,antiepilepsy drug,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,CSF,cerebrospinal fluid,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,i.e.,improvement,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,TID,three divided doses,,,
clinicalPharmacology,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,5b03bc3e-a672-e66b-88d7-f63c748851ab,4/13/2011,4,PT,prothrombin time,,,
clinicalPharmacology,aee04f17-8ee9-42f5-861f-b6ba17220ca4,3/31/2011,3,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,aee04f17-8ee9-42f5-861f-b6ba17220ca4,3/31/2011,3,AUCs,areas under plasma concentration-time curves,,,
clinicalPharmacology,a61b7e77-ed45-42dd-a97f-b12a0dcca8da,11/6/2009,1001,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,a61b7e77-ed45-42dd-a97f-b12a0dcca8da,11/6/2009,1001,MIC,minimum inhibitory concentrations,,,
clinicalPharmacology,8de51bf0-68c4-47c1-a5a2-1a06b7215ed0,6/4/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,276c3f70-890e-4afa-af48-8630f9689785,5/28/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,276c3f70-890e-4afa-af48-8630f9689785,5/28/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,276c3f70-890e-4afa-af48-8630f9689785,5/28/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,276c3f70-890e-4afa-af48-8630f9689785,5/28/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,CGI,Clinical Global Impression,,,
clinicalPharmacology,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,b5a8f864-a53d-48d9-aca6-6b64017fb168,11/15/2011,4,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,CV,coefficient of variation,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,AUC,area under the concentration-time  curve,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,CUE,cumulative urinary  excretion,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,Total-C,total  cholesterol,,,
clinicalPharmacology,878064ef-6a81-4999-8902-9da151e9c22d,4/3/2012,3739,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,878064ef-6a81-4999-8902-9da151e9c22d,4/3/2012,3739,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,878064ef-6a81-4999-8902-9da151e9c22d,4/3/2012,3739,ECL,Enterochromaffin-like,,,
clinicalPharmacology,878064ef-6a81-4999-8902-9da151e9c22d,4/3/2012,3739,CYP,cytochrome P450,,,
clinicalPharmacology,91431bad-6a95-4cea-b5b1-a0160d19ef5a,10/3/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fac9b9c0-7ea2-4986-9552-dc46a32b7c99,6/9/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bf667704-f439-4e8a-a4a5-dd150462a125,2/9/2007,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a5c04015-454e-456b-8637-4342c8c9b54e,3/28/2010,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8,2/17/2011,8,FUPA,5-fluoro-ureido-propionic acid,,,
clinicalPharmacology,8f7cba0f-cfcc-cb98-8657-20bd604165d5,1/1/2009,4,CR,Carbidopa-Levodopa,,,
clinicalPharmacology,6339bcdb-060f-4558-9f42-6bf7f935e138,8/10/2010,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6339bcdb-060f-4558-9f42-6bf7f935e138,8/10/2010,5,MEF,middle ear fluid,,,
clinicalPharmacology,11fa7725-cb19-46f6-9468-01a0a430492c,10/8/2006,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,5B3535D5-B1E2-409F-BF82-DECDE34ABF0C,2/13/2009,1,AD,Alzheimer's disease,,,
clinicalPharmacology,5B3535D5-B1E2-409F-BF82-DECDE34ABF0C,2/13/2009,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,65b28775-ee59-88cf-e4d8-372c6c79ad14,3/1/2011,2,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,65b28775-ee59-88cf-e4d8-372c6c79ad14,3/1/2011,2,AUC,area under the concentration-time curve,,,
clinicalPharmacology,96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,1/18/2010,3,MBL,menstrual blood loss,,,
clinicalPharmacology,96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,1/18/2010,3,see Table,species of meclofenamic acid and Metabolite I,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,IV,intravenous,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,ie,its active metabolites,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,TSO,to sleep onset,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,CYP,cytochrome P450,,,
clinicalPharmacology,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,LPS,latency to persistent sleep,,,
clinicalPharmacology,caf12ea3-06c8-44c1-9e89-3ecaff89a22b,6/11/2012,1,i.e.,improvement,,,
clinicalPharmacology,a40db6da-17c6-430c-a247-9900f5863f7c,3/6/2012,4,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,a40db6da-17c6-430c-a247-9900f5863f7c,3/6/2012,4,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,c17aa1e0-8b69-4c46-8502-9e3e07d461b3,7/7/2010,329,D2,dopamine type 2,,,
clinicalPharmacology,ec86b651-d77d-4a42-b493-24244456b3f6,3/23/2009,3,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,e185959e-d360-4ecc-8690-e62256f696cd,5/1/2012,1,CI,confidence interval,,,
clinicalPharmacology,a0135a49-0c38-4235-908e-cf773e34dc62,4/12/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,6a7f6c20-d878-409f-aadb-8c5c63df61d0,4/25/2012,1,i.e.,improvement,,,
clinicalPharmacology,5742fd25-09c5-4264-99c1-249ab823d3cd,6/7/2010,1,V/F,volume of distribution,,,
clinicalPharmacology,5742fd25-09c5-4264-99c1-249ab823d3cd,6/7/2010,1,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,5742fd25-09c5-4264-99c1-249ab823d3cd,6/7/2010,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,CPS,complex partial seizures,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,AED,antiepilepsy drug,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,i.e.,improvement,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,TID,three divided doses,,,
clinicalPharmacology,c8d9cd69-ceca-3057-9d1c-12c44b19f767,7/29/2008,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,abf3db95-913b-432a-984f-caaef72088b8,2/14/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,abf3db95-913b-432a-984f-caaef72088b8,2/14/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,abf3db95-913b-432a-984f-caaef72088b8,2/14/2012,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,abf3db95-913b-432a-984f-caaef72088b8,2/14/2012,3,CYP,cytochrome P450,,,
clinicalPharmacology,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,Tmax,to Cmax,,,
clinicalPharmacology,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,GH,growth hormone,,,
clinicalPharmacology,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,ACTH,adrenocorticotropic hormone,,,
clinicalPharmacology,81d1bed6-8fb5-4191-9396-234366667fad,5/17/2010,5,RA,rheumatoid arthritis,,,
clinicalPharmacology,81d1bed6-8fb5-4191-9396-234366667fad,5/17/2010,5,OA,osteoarthritis,,,
clinicalPharmacology,363d2275-fca2-4c6d-940c-137e89d9d78c,10/22/2010,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,67153914-16bc-490d-82d7-638061618467,11/16/2011,10,HTM,Haemophilus Test Media,,,
clinicalPharmacology,67153914-16bc-490d-82d7-638061618467,11/16/2011,10,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,TCA,tricyclic antidepressant,,,
clinicalPharmacology,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,9b73c97f-b898-471f-be8a-96324a3e3b86,12/29/2010,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,ca37556e-b7f9-4e36-b82e-10cc9d0feee8,10/28/2010,2007,MES,maximal  electroshock seizure,,,
clinicalPharmacology,ca37556e-b7f9-4e36-b82e-10cc9d0feee8,10/28/2010,2007,SER,spontaneous epileptic rat,,,
clinicalPharmacology,bcfd6a3d-66eb-4844-bede-6ec671985b2c,7/24/2012,3944,i.e.,its active metabolites,,,
clinicalPharmacology,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,D2,dopamine Type 2,,,
clinicalPharmacology,533260c1-3d9f-4414-a097-068a215876d5,2/10/2012,4,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,533260c1-3d9f-4414-a097-068a215876d5,2/10/2012,4,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,6c4d4603-190a-496f-a40f-bc09853b9820,5/4/2011,5,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,6c4d4603-190a-496f-a40f-bc09853b9820,5/4/2011,5,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,76635b0d-0a20-44b7-a076-b8f3c689c2ce,4/19/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,f585bcf6-78b0-4077-b93c-7876573cc5d6,3/25/2011,1,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,34878e92-c843-4cce-812e-a82cbb96df2b,9/1/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,19b4ff5c-adb7-a0d0-7ef2-4ae05047fd94,3/4/2011,3,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,39e19789-de4b-4fd1-ab1c-92f59496f496,1/25/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,39e19789-de4b-4fd1-ab1c-92f59496f496,1/25/2012,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,39e19789-de4b-4fd1-ab1c-92f59496f496,1/25/2012,2,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,dabb7f5d-03b3-4d46-951a-e41a1f8d69cc,5/28/2012,3,DDC,dopa decarboxylase,,,
clinicalPharmacology,dabb7f5d-03b3-4d46-951a-e41a1f8d69cc,5/28/2012,3,UPDRS,Unified Parkinson’s Disease Rating Scale,,,
clinicalPharmacology,dabb7f5d-03b3-4d46-951a-e41a1f8d69cc,5/28/2012,3,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,f2c7e54b-ed7c-4d8f-a86d-5099a8b52f28,4/7/2010,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,AUC,area under the curve,,,
clinicalPharmacology,6fdcebac-0a5a-4858-b0e6-87f77ba53bf1,4/17/2003,3,AUC,area under the concentration-time curve,,,
clinicalPharmacology,3049c71a-a422-4c02-bafb-d876f068911a,7/13/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,3049c71a-a422-4c02-bafb-d876f068911a,7/13/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,3049c71a-a422-4c02-bafb-d876f068911a,7/13/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,3049c71a-a422-4c02-bafb-d876f068911a,7/13/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,3049c71a-a422-4c02-bafb-d876f068911a,7/13/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,a5c46194-3692-cd26-0d85-6371974ccc44,3/2/2011,5,TK,thymidine kinase,,,
clinicalPharmacology,a5c46194-3692-cd26-0d85-6371974ccc44,3/2/2011,5,HSV-1,herpes simplex virus types 1,,,
clinicalPharmacology,a5c46194-3692-cd26-0d85-6371974ccc44,3/2/2011,5,Vd?,volume of distribution,,,
clinicalPharmacology,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,SAH,subarachnoid hemorrhage,,,
clinicalPharmacology,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,III,initial bleed,,,
clinicalPharmacology,665ABE12-209D-4B80-8020-EF9E3F9BDADE,5/28/2009,3,thiazide,The diuretic effects of chlorthalidone and the benzothiadiazine,,,
clinicalPharmacology,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,CGI,Clinical Global Impression,,,
clinicalPharmacology,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,c702df3b-584f-4a8e-8554-aa611e18ac4f,11/16/2011,3190,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,COX-2,cyclooxygenase-2,,,
clinicalPharmacology,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,COX-1,cyclooxygenase-1,,,
clinicalPharmacology,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,Vdss,volume of distribution at steady state,,,
clinicalPharmacology,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,DHFR,dihydrofolate reductase,,,
clinicalPharmacology,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,5aba19da-663f-4901-94e2-f438dba4841f,6/20/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5aba19da-663f-4901-94e2-f438dba4841f,6/20/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5aba19da-663f-4901-94e2-f438dba4841f,6/20/2011,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,5aba19da-663f-4901-94e2-f438dba4841f,6/20/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,829dbd3d-5c2b-47b8-96a5-423af78c93b9,5/19/2011,2,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,5B555346-57CD-44BB-8A60-BF7124B62C30,5/11/2006,1,NAPR,nonallergic perennial rhinitis,,,
clinicalPharmacology,5B555346-57CD-44BB-8A60-BF7124B62C30,5/11/2006,1,APR,allergic perennial rhinitis,,,
clinicalPharmacology,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,CGI,Clinical Global Impression,,,
clinicalPharmacology,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7,8/1/2011,6,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,5ad82e30-50d8-450c-8a2a-b4b507ed1ce2,12/19/2011,6,PT,prothrombin time,,,
clinicalPharmacology,5ad82e30-50d8-450c-8a2a-b4b507ed1ce2,12/19/2011,6,aPTT,activated partial thromboplastin time,,,
clinicalPharmacology,4cb11585-a53f-4ef6-a52d-8cff3a4fd8eb,3/8/2011,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,ded64147-7a43-4055-accc-2c011828079d,6/8/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,575ef8ab-ff4a-4ccf-8de8-678ea0895b61,7/11/2012,11,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,575ef8ab-ff4a-4ccf-8de8-678ea0895b61,7/11/2012,11,cGMP,cyclic guanosine monophosphate,,,
clinicalPharmacology,87fce959-ba71-46b8-911d-2004658196ce,2/9/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,AUCs,area under the plasma concentration curves,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,INR,International Normalized Ratio,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,STH,somatotropic hormone,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,FSH,follicle stimulating hormone,,,
clinicalPharmacology,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,LH,luteinizing hormone,,,
clinicalPharmacology,88c9d1ca-f3a8-4078-8de7-21fd9040dd20,2/14/2012,2,NET,norethindrone,,,
clinicalPharmacology,88c9d1ca-f3a8-4078-8de7-21fd9040dd20,2/14/2012,2,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,88c9d1ca-f3a8-4078-8de7-21fd9040dd20,2/14/2012,2,EE,ethinyl estradiol,,,
clinicalPharmacology,2402ba3b-e06e-4974-0b99-cfff5cb2cb21,6/9/2011,8,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,09BAFC2D-1893-4618-86DC-E9403407CD41,2/6/2006,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,09BAFC2D-1893-4618-86DC-E9403407CD41,2/6/2006,1,LH,luteinizing hormone,,,
clinicalPharmacology,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,V?,volume,,,
clinicalPharmacology,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,Vss,volume of distribution at steady state,,,
clinicalPharmacology,91da40ab-cfd7-4e2a-8ef9-84809176d850,8/17/2011,2,HETEs,hydroxyeicosatetraenoic acids,,,
clinicalPharmacology,91da40ab-cfd7-4e2a-8ef9-84809176d850,8/17/2011,2,LTs,leukotrienes,,,
clinicalPharmacology,91da40ab-cfd7-4e2a-8ef9-84809176d850,8/17/2011,2,AA,arachidonic acid,,,
clinicalPharmacology,91da40ab-cfd7-4e2a-8ef9-84809176d850,8/17/2011,2,PG,prostaglandin,,,
clinicalPharmacology,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,a4f82a4c-bc7e-4927-936e-add854812559,1/1/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,5d86f813-e784-4490-a842-bcb78eb0d9a4,8/1/2011,4,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,MN,mononuclear,,,
clinicalPharmacology,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,MIC,minimum inhibitory                         concentration,,,
clinicalPharmacology,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,PMN,polymorphonuclear,,,
clinicalPharmacology,e2edf92b-e06d-43df-b82f-875fd5d4ad42,9/16/2010,29,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,86e1102c-47bc-4f27-a4d0-7261b3deba63,3/5/2012,7,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,86e1102c-47bc-4f27-a4d0-7261b3deba63,3/5/2012,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e41e7bf5-86b4-4b25-b061-407c88449372,7/1/2011,15,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e41e7bf5-86b4-4b25-b061-407c88449372,7/1/2011,15,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e41e7bf5-86b4-4b25-b061-407c88449372,7/1/2011,15,ECL,Enterochromaffin-like,,,
clinicalPharmacology,e41e7bf5-86b4-4b25-b061-407c88449372,7/1/2011,15,CYP,cytochrome P450,,,
clinicalPharmacology,d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2,7/13/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2,7/13/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2,7/13/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2,7/13/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2,7/13/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,ITT,intent-to-treat,,,
clinicalPharmacology,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,CLr,clearance,,,
clinicalPharmacology,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,aaf16572-f861-452f-8096-0adca3e40d8d,12/6/2010,123,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,aaf16572-f861-452f-8096-0adca3e40d8d,12/6/2010,123,IV,intravenous,,,
clinicalPharmacology,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,4/19/2012,5,Tmax,to maximum concentration,,,
clinicalPharmacology,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,4/19/2012,5,GIR,Glucose infusion rates,,,
clinicalPharmacology,e7af6a7a-8046-4fb4-9979-4ec4230b23aa,4/19/2012,5,BMI,body mass index,,,
clinicalPharmacology,dfc41fcd-c5ba-4b25-b647-cf04d3988b3e,2/22/2012,4,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,dfc41fcd-c5ba-4b25-b647-cf04d3988b3e,2/22/2012,4,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,PDSS,Panic Disorder Severity Scale,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,CGI,Clinical Global  Impressions,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,LSAS,Liebowitz Social Anxiety  Scale,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,CGI,Clinical Global Impressions,,,
clinicalPharmacology,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,18e420b9-0fd1-48d9-9a23-c1e29a5f629f,2/1/2010,1,GX,glycinexylidide,,,
clinicalPharmacology,18e420b9-0fd1-48d9-9a23-c1e29a5f629f,2/1/2010,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,e3381145-ab3b-4f5a-8c45-9eadd53943a4,7/19/2011,1,NTD,neural tube defects,,,
clinicalPharmacology,e3381145-ab3b-4f5a-8c45-9eadd53943a4,7/19/2011,1,PIC,Polysaccharide Iron Complex,,,
clinicalPharmacology,787cda7d-7aa4-4909-8e5c-f2fcf68828e4,6/29/2010,1,CNS,central nervous system,,,
clinicalPharmacology,4471223e-9023-457e-be2e-8e4e0c2d94d1,12/20/2010,5,cMLSB,constitutive macrolide-lincosamide-streptogramin B,,,
clinicalPharmacology,4471223e-9023-457e-be2e-8e4e0c2d94d1,12/20/2010,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4471223e-9023-457e-be2e-8e4e0c2d94d1,12/20/2010,5,Chlamydia,Chlamydophila,,,
clinicalPharmacology,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,IV,intravenous,,,
clinicalPharmacology,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,AUC,area under the curve,,,
clinicalPharmacology,49151A62-191A-4BA8-8B8C-BD8535F2FDB3,3/11/2008,1,NCCLS,National Committee for Clinical Laboratory Standards,,,
clinicalPharmacology,49151A62-191A-4BA8-8B8C-BD8535F2FDB3,3/11/2008,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,58b66be7-e0ec-42c5-1383-45aadcd6c307,4/18/2012,10,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,58b66be7-e0ec-42c5-1383-45aadcd6c307,4/18/2012,10,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,STH,somatotropic hormone,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,FSH,follicle stimulating hormone,,,
clinicalPharmacology,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,LH,luteinizing hormone,,,
clinicalPharmacology,01a8bfdf-0fac-4e86-a299-daf64a2e885e,5/29/2009,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,01a8bfdf-0fac-4e86-a299-daf64a2e885e,5/29/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,D1915D2E-056B-44BD-4A9C-FC9E41AB10CE,6/23/2008,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,D1915D2E-056B-44BD-4A9C-FC9E41AB10CE,6/23/2008,1,mm,Microorganism Zone Diameter,,,
clinicalPharmacology,D1915D2E-056B-44BD-4A9C-FC9E41AB10CE,6/23/2008,1,mm,strains:Microorganism Zone Diameter,,,
clinicalPharmacology,f1a64637-6143-4543-a785-12e006cba849,5/17/2011,4,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,f1a64637-6143-4543-a785-12e006cba849,5/17/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f1a64637-6143-4543-a785-12e006cba849,5/17/2011,4,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,60979ac0-024e-4dc8-9a84-c9195093c08d,4/19/2012,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,LDL,low density lipoprotein,,,
clinicalPharmacology,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,TG,triglyceride,,,
clinicalPharmacology,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,ND,NDMinor Bleedingd391031333.21a,,,
clinicalPharmacology,73bd377e-cd9a-4d34-aa6e-7a1e44b47b89,3/29/2012,7,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,73bd377e-cd9a-4d34-aa6e-7a1e44b47b89,3/29/2012,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,73bd377e-cd9a-4d34-aa6e-7a1e44b47b89,3/29/2012,7,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,82CEB312-3AAA-4A5C-9849-7F246CC06DED,3/10/2008,1,RES,reticuloendothelial system,,,
clinicalPharmacology,82CEB312-3AAA-4A5C-9849-7F246CC06DED,3/10/2008,1,MRI,magnetic resonance imaging,,,
clinicalPharmacology,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,CSF,Cerebrospinal fluid,,,
clinicalPharmacology,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,33574801-581a-4028-befd-8e0cc8b6a892,9/30/2009,1,NO,nitric oxide,,,
clinicalPharmacology,c5604b48-d58f-45ac-8602-72241ed4b906,12/27/2011,1,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,c8c3f5ad-eb5a-4e30-afaf-9149c014c2c3,6/16/2011,1,PRA,plasma renin activity,,,
clinicalPharmacology,192733b3-7b22-4237-80c1-3fc10e3e71a3,5/12/2011,1,CNS,central nervous system,,,
clinicalPharmacology,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,ITT,intent-to-treat,,,
clinicalPharmacology,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,CLr,clearance,,,
clinicalPharmacology,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,c68734cc-d998-4909-922d-8e55cdd780e2,10/19/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,i.e.,initial clearance rates,,,
clinicalPharmacology,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,CSF,cerebrospinal fluid,,,
clinicalPharmacology,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,CHF,Congestive Heart Failure,,,
clinicalPharmacology,8bcdd16b-18f0-4478-8699-85edb1acb17c,4/7/2010,2,2 ?g/kg,2 micrograms per kilogram,,,
clinicalPharmacology,8bcdd16b-18f0-4478-8699-85edb1acb17c,4/7/2010,2,MAC,minimum alveolar concentration,,,
clinicalPharmacology,08982e49-d2eb-4b25-b01a-1be52fd669ef,4/11/2012,7,TPV,Tipranavir,,,
clinicalPharmacology,08982e49-d2eb-4b25-b01a-1be52fd669ef,4/11/2012,7,CYP 3A,cytochrome P450 3A,,,
clinicalPharmacology,08982e49-d2eb-4b25-b01a-1be52fd669ef,4/11/2012,7,IQ,Inhibitory Quotient,,,
clinicalPharmacology,5ceed28f-2cb1-4eef-b1ce-3cc83b8f49aa,2/3/2010,1,CI,confidence interval,,,
clinicalPharmacology,524a0dac-6e2b-2c0c-04b4-76d85dba63c5,8/1/2011,2,TRF,thyroid release factor,,,
clinicalPharmacology,524a0dac-6e2b-2c0c-04b4-76d85dba63c5,8/1/2011,2,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,706e938f-a0a0-42f6-b99b-60c31cbfb441,1/4/2006,1,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,706e938f-a0a0-42f6-b99b-60c31cbfb441,1/4/2006,1,GH,growth hormone,,,
clinicalPharmacology,706e938f-a0a0-42f6-b99b-60c31cbfb441,1/4/2006,1,LH,luteinizing hormone,,,
clinicalPharmacology,ea79f802-e9ac-480b-91e6-1e3900b11803,1/3/2011,1,CgA,Chromogranin A,,,
clinicalPharmacology,ea79f802-e9ac-480b-91e6-1e3900b11803,1/3/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,5d8db96a-c0f5-44c5-aadd-72433ea30e46,3/2/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,81df83d0-088c-4a13-9538-f362a0f35456,9/28/2011,6,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,81df83d0-088c-4a13-9538-f362a0f35456,9/28/2011,6,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,81df83d0-088c-4a13-9538-f362a0f35456,9/28/2011,6,AUC,area under the concentration-time curve,,,
clinicalPharmacology,f39821c1-60f1-4b72-809a-b76b3deffa5b,4/22/2011,1,NYHA,New York Heart Association,,,
clinicalPharmacology,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,DHT,5?-dihydrotestosterone,,,
clinicalPharmacology,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,IV,intravenous,,,
clinicalPharmacology,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,AUC,area under the curve,,,
clinicalPharmacology,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,LH,luteinizing hormone,,,
clinicalPharmacology,acdb3ee0-006e-4799-8732-5488ef72f90e,11/16/2011,13,GER,gastroesophageal reflux,,,
clinicalPharmacology,acdb3ee0-006e-4799-8732-5488ef72f90e,11/16/2011,13,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,1fd148fb-0fbc-4b6f-b790-23546fb46a71,10/4/2011,8,AC,and cyclophosphamide,,,
clinicalPharmacology,0034fc51-706c-4b03-b8f4-6255a329dd9b,3/1/2012,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,c325bbfc-46f3-471e-7bbc-ed0d6965d13b,1/20/2012,16,CgA,Chromogranin A,,,
clinicalPharmacology,c325bbfc-46f3-471e-7bbc-ed0d6965d13b,1/20/2012,16,ECL,Enterochromaffin-like,,,
clinicalPharmacology,c325bbfc-46f3-471e-7bbc-ed0d6965d13b,1/20/2012,16,CYP,cytochrome P450,,,
clinicalPharmacology,3e99052d-4442-4283-8915-c9a796c77008,12/31/2011,5,AIDS,Acquired Immunodeficiency,,,
clinicalPharmacology,3e99052d-4442-4283-8915-c9a796c77008,12/31/2011,5,EMC,encephalomyocarditis virus,,,
clinicalPharmacology,3e99052d-4442-4283-8915-c9a796c77008,12/31/2011,5,HAV,hepatitis A virus,,,
clinicalPharmacology,3e99052d-4442-4283-8915-c9a796c77008,12/31/2011,5,VSV,vesicular stomatitis virus,,,
clinicalPharmacology,3e99052d-4442-4283-8915-c9a796c77008,12/31/2011,5,HIV,human immunodeficiency virus,,,
clinicalPharmacology,cd989627-71ff-479d-a103-c1a22aa9e5e2,5/26/2010,1,Tmax,to maximum concentration,,,
clinicalPharmacology,23452a86-8ae2-4165-aca6-056b3d2c6462,7/29/2011,70,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,ba72b914-1252-4370-9b4b-0105186ffb42,5/6/2010,1,PRA,plasma renin activity,,,
clinicalPharmacology,17a1975e-ce3b-4057-ae5b-8d191319caa7,11/15/2011,3,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,b1397a52-d99f-44f0-8649-8ceb8e7b9b85,4/26/2012,1,HCV-RNS,HCV replicon cells,,,
clinicalPharmacology,f1e5977e-31d2-11df-b51e-3b5856d89593,1/15/2009,1,diazepam,diazepamVALIUM®,,,
clinicalPharmacology,f1e5977e-31d2-11df-b51e-3b5856d89593,1/15/2009,1,AUC,area under the concentration-time,,,
clinicalPharmacology,bf95521a-a636-4f4e-a0a0-5fcd469dbb09,9/21/2011,2,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,bf95521a-a636-4f4e-a0a0-5fcd469dbb09,9/21/2011,2,LESP,lower esophageal sphincter pressure,,,
clinicalPharmacology,ac47efbe-025b-4688-bcd3-a10a0b012b34,11/19/2009,2,DHT,dihydrotestosterone,,,
clinicalPharmacology,ac47efbe-025b-4688-bcd3-a10a0b012b34,11/19/2009,2,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,a64496be-bf43-4ba9-a4b1-bd632965c1a0,10/12/2011,2,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,a4d07b57-09e1-4732-a135-559febcab3ef,11/12/2008,7,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,a4d07b57-09e1-4732-a135-559febcab3ef,11/12/2008,7,PM,poor metabolizers,,,
clinicalPharmacology,36a919ce-7a21-40c0-9af5-2299bf2b1f97,12/1/2010,2,AF,Atrial Fibrillation,,,
clinicalPharmacology,36a919ce-7a21-40c0-9af5-2299bf2b1f97,12/1/2010,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,a075cffe-6aeb-43f7-9533-de978a962b77,11/18/2010,5,mean age,minutes,,,
clinicalPharmacology,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,8/3/2007,1,CFTR,cystic fibrosis transmembrane conductance regulator,,,
clinicalPharmacology,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,1bee6f20-2d81-4e03-908f-ec9b004f49d8,1/19/2012,3,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,GFR,glomerular filtration rate,,,
clinicalPharmacology,17e47845-daad-434c-a784-6d3875b0d704,7/15/2011,10,NAPA,N-acetylprocainamide,,,
clinicalPharmacology,c9b57101-2455-463d-b8d7-b2316cecd67a,5/29/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,c9b57101-2455-463d-b8d7-b2316cecd67a,5/29/2010,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,c9b57101-2455-463d-b8d7-b2316cecd67a,5/29/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,c9b57101-2455-463d-b8d7-b2316cecd67a,5/29/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,ECG,electrocardiogram,,,
clinicalPharmacology,30f2dc3f-a5da-40da-9314-12935cbdac7d,4/7/2011,1,CNS,central nervous system,,,
clinicalPharmacology,30f2dc3f-a5da-40da-9314-12935cbdac7d,4/7/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,e4412a6a-ed4d-410d-8abb-86e1d7b72a3c,4/13/2011,1,ERAFT,[(European Rythmonorm SR Atrial Fibrillation Trial,,,
clinicalPharmacology,ca7a8abd-9301-40f5-9300-6398f4d467b3,7/31/2009,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,67dcdd6e-48bc-418e-a887-805929d83ce0,10/14/2011,4,NET,norethindrone,,,
clinicalPharmacology,67dcdd6e-48bc-418e-a887-805929d83ce0,10/14/2011,4,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,67dcdd6e-48bc-418e-a887-805929d83ce0,10/14/2011,4,EE,ethinyl estradiol,,,
clinicalPharmacology,c5a906d1-b276-48d0-b58e-b45f4c5aa067,8/19/2011,6,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,4a0166c7-7097-4e4a-9036-6c9a60d08fc6,11/11/2011,5,V/F,volume of distribution,,,
clinicalPharmacology,4a0166c7-7097-4e4a-9036-6c9a60d08fc6,11/11/2011,5,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,4a0166c7-7097-4e4a-9036-6c9a60d08fc6,11/11/2011,5,PPG,postprandial plasma glucose,,,
clinicalPharmacology,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,V?,volume,,,
clinicalPharmacology,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,Vss,volume of distribution at steady state,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,STH,somatotropic hormone,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,FSH,follicle stimulating hormone,,,
clinicalPharmacology,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,LH,luteinizing hormone,,,
clinicalPharmacology,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,a87e6e9b-d368-4f6b-aaf2-6b41d6b46888,3/26/2012,1,Cl-,chloride,,,
clinicalPharmacology,f4797359-d4a0-4967-86d3-d348518b3fe4,4/25/2011,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1154688c-1383-442b-a3a5-ec01e038795c,10/12/2010,5,AUC,area under the concentration-time,,,
clinicalPharmacology,90593214-5e4d-4b91-b308-a82311a3e4f9,6/22/2009,1,PBC,primary biliary cirrhosis,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,CPS,complex partial seizures,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,AED,antiepilepsy drug,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,i.e.,improvement,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,TID,three divided doses,,,
clinicalPharmacology,9fef0f9c-e6ed-4b29-a473-525f2aba70bd,10/14/2009,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,790d3557-0b33-4b92-974a-14dc3e95d62b,11/2/2010,12,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,790d3557-0b33-4b92-974a-14dc3e95d62b,11/2/2010,12,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,ETT,exercise tolerance time,,,
clinicalPharmacology,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,SAVE,Survival and Ventricular Enlargement,,,
clinicalPharmacology,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,PRA,plasma renin activity,,,
clinicalPharmacology,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,LVD,left ventricular dysfunction,,,
clinicalPharmacology,03a1429b-cd24-4cb7-84bb-5ec7a7b2b687,11/16/2011,1,CYP450,Cytochrome P450,,,
clinicalPharmacology,be59c773-1d4f-4843-a326-1eca9a494d2c,12/2/2011,1,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,be59c773-1d4f-4843-a326-1eca9a494d2c,12/2/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,3aada4c2-0c2a-4afb-8df1-bdac68972111,11/28/2006,3,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,STH,somatotropic hormone,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,B.  fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,ie,its active metabolites,,,
clinicalPharmacology,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,33C9CD03-A005-476A-9A57-50BFE913674A,8/2/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,D2,dopamine type 2,,,
clinicalPharmacology,b69917c0-95d5-4b29-b0e3-07054a4fd79f,6/22/2011,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2527f4de-4bab-4c25-a624-3884ecd906bf,6/26/2012,3,placebo,placebo-controlled study in 207 patients,,,
clinicalPharmacology,2527f4de-4bab-4c25-a624-3884ecd906bf,6/26/2012,3,placebo,placebo-controlled studies in 629 patients,,,
clinicalPharmacology,2527f4de-4bab-4c25-a624-3884ecd906bf,6/26/2012,3,AUC,Area Under the Curve,,,
clinicalPharmacology,5824c578-160e-4514-8332-a93c4a9d627c,5/13/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,9ed8b5a6-4bbe-49dd-901b-1d86e8378bd3,6/3/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,95e06935-8788-420c-b4a4-dc6ea339c7d0,7/1/2010,5,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,95e06935-8788-420c-b4a4-dc6ea339c7d0,7/1/2010,5,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,976916CA-85FA-4099-9607-FD377E9CF319,10/25/2007,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,097d95e4-707e-47aa-b18e-aad18fecd42a,3/28/2011,1,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,097d95e4-707e-47aa-b18e-aad18fecd42a,3/28/2011,1,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,RA,rheumatoid arthritis,,,
clinicalPharmacology,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,Tmax,to maximum concentration,,,
clinicalPharmacology,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,INR,International Normalized Ratio,,,
clinicalPharmacology,6414f16f-c3e0-4ca1-ad58-ed081a9c0b09,3/30/2012,10,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,ARB,angiotensin receptor blocker,,,
clinicalPharmacology,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,SD,standard deviation,,,
clinicalPharmacology,47ef5501-1408-41fa-b0e5-f078f18129f5,7/30/2009,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,31392b3b-5d64-4a68-afab-4ef80704dd87,9/17/2010,393,GH,growth  hormone,,,
clinicalPharmacology,31392b3b-5d64-4a68-afab-4ef80704dd87,9/17/2010,393,Vd,volume of distribution,,,
clinicalPharmacology,31392b3b-5d64-4a68-afab-4ef80704dd87,9/17/2010,393,Css,concentration  of morphine at steady state,,,
clinicalPharmacology,31392b3b-5d64-4a68-afab-4ef80704dd87,9/17/2010,393,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,31392b3b-5d64-4a68-afab-4ef80704dd87,9/17/2010,393,LH,luteinizing hormone,,,
clinicalPharmacology,f0ac27f6-d7e1-42e4-8cf1-95a0db50dcbf,5/25/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,3cacd754-73f4-496e-a529-9ca39fa6692d,5/30/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,53e2801a-323d-448e-8278-92d672904b0f,10/3/2011,2,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,53e2801a-323d-448e-8278-92d672904b0f,10/3/2011,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,53e2801a-323d-448e-8278-92d672904b0f,10/3/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,CI,confidence intervals,,,
clinicalPharmacology,d470695c-c0d7-4361-8783-45f58a932ac4,8/24/2010,6,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,d470695c-c0d7-4361-8783-45f58a932ac4,8/24/2010,6,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,d470695c-c0d7-4361-8783-45f58a932ac4,8/24/2010,6,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,df4136c0-9efd-42c3-a487-e728e8b91275,1/17/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,df4136c0-9efd-42c3-a487-e728e8b91275,1/17/2012,1,MEF,middle ear fluid,,,
clinicalPharmacology,408eda31-0188-4f1d-96b9-8224dfe1bbc7,8/17/2009,1001,GH,growth  hormone,,,
clinicalPharmacology,408eda31-0188-4f1d-96b9-8224dfe1bbc7,8/17/2009,1001,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,408eda31-0188-4f1d-96b9-8224dfe1bbc7,8/17/2009,1001,LH,luteinizing hormone,,,
clinicalPharmacology,fef7f0c9-48a1-46b4-a19c-c23d272a8ca2,3/29/2012,14,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,520428f1-2cd5-447f-8782-c8505ce65b72,2/28/2012,10,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,cabd1834-7398-497e-b11f-221a25f21a4e,1/4/2011,1,CNS,central nervous system,,,
clinicalPharmacology,cabd1834-7398-497e-b11f-221a25f21a4e,1/4/2011,1,AV,atrioventricular,,,
clinicalPharmacology,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,ddI,"rowspan=""1"">didanosine",,,
clinicalPharmacology,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,e90dac00-81f3-4d67-8718-c290136ebd12,3/12/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,e6898cf8-34c8-44d5-8a86-fbe3be847b16,7/28/2011,1,MI,myocardial infarction,,,
clinicalPharmacology,bf588f7e-89de-4b4e-8d33-c1ff2be1b34e,2/8/2012,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,45d5d3f1-43e6-41e4-b2b4-51ba9085a526,6/23/2010,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,87a1d553-5c18-4f74-8298-933a2069d336,6/14/2011,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,TSO,to  sleep onset,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,IV,intravenous,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,ie,its active metabolites,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,CYP,cytochrome P450,,,
clinicalPharmacology,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,LPS,latency to persistent sleep,,,
clinicalPharmacology,c674e1bc-5c8e-4c59-8de5-c7fa5306706d,1/26/2011,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,c674e1bc-5c8e-4c59-8de5-c7fa5306706d,1/26/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,PAAS,Panic and Anticipatory Anxiety Scale,,,
clinicalPharmacology,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,PDSS,Panic Disorder Severity Scale,,,
clinicalPharmacology,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,CGI,Clinical Global Impressions,,,
clinicalPharmacology,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee,5/25/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,A551FAC0-8738-40B3-9B03-602F794A4B66,6/12/2008,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,A551FAC0-8738-40B3-9B03-602F794A4B66,6/12/2008,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,c8b8c294-57b1-4285-b230-fb5ba1cfcfac,2/15/2011,1,Tmax,time of maximum plasma concentration,,,
clinicalPharmacology,499df918-9c97-4e13-ab56-0bec5d61d652,11/2/2010,3,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,499df918-9c97-4e13-ab56-0bec5d61d652,11/2/2010,3,DBP,diastolic blood pressure,,,
clinicalPharmacology,499df918-9c97-4e13-ab56-0bec5d61d652,11/2/2010,3,ITT,intention-to-treat,,,
clinicalPharmacology,499df918-9c97-4e13-ab56-0bec5d61d652,11/2/2010,3,SBP,systolic blood pressure,,,
clinicalPharmacology,499df918-9c97-4e13-ab56-0bec5d61d652,11/2/2010,3,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,d99086c9-41a4-4c69-b41a-80054e828095,5/10/2010,1,DF,disoproxil fumarate,,,
clinicalPharmacology,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,GST,glutathione S-transferase,,,
clinicalPharmacology,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,CL,clearance,,,
clinicalPharmacology,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,PPK,population pharmacokinetic,,,
clinicalPharmacology,7e7e03ba-5035-4e6d-9aa0-a00c8d3e0d87,11/17/2011,3,GX,glycinexylidide,,,
clinicalPharmacology,7e7e03ba-5035-4e6d-9aa0-a00c8d3e0d87,11/17/2011,3,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,CE,conjugated estrogens,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,PE,pulmonary embolism,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,CHD,coronary heart disease,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,WHI,Women's Health Initiative,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,fd2fa2af-5929-4152-afd3-55e4e162f765,6/13/2011,1,IM,intramuscular,,,
clinicalPharmacology,f3abe0c2-2029-4d89-b413-606a421491e4,4/7/2011,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,869349b7-a037-47b5-9da6-e061cefc3ced,6/9/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,869349b7-a037-47b5-9da6-e061cefc3ced,6/9/2010,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,OCT,organic cationic transporter,,,
clinicalPharmacology,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,BMI,Body Mass Index,,,
clinicalPharmacology,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,AUC,area under the curve,,,
clinicalPharmacology,34c02bcc-d6ff-99d4-8e6a-4a91908adca8,7/30/2011,8,ddI,didanosine,,,
clinicalPharmacology,34c02bcc-d6ff-99d4-8e6a-4a91908adca8,7/30/2011,8,RT,reverse transcriptase,,,
clinicalPharmacology,34c02bcc-d6ff-99d4-8e6a-4a91908adca8,7/30/2011,8,CSF,cerebrospinal fluid,,,
clinicalPharmacology,f6a79b4e-d7b3-4849-a552-7a37017e0a7a,12/28/2009,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,61b34d13-3b8b-4491-b5a3-e9740b2aaccb,4/27/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,61b34d13-3b8b-4491-b5a3-e9740b2aaccb,4/27/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,61b34d13-3b8b-4491-b5a3-e9740b2aaccb,4/27/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,61b34d13-3b8b-4491-b5a3-e9740b2aaccb,4/27/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,09e383a8-e912-4cf7-8fb3-05545af80dd0,9/30/2011,8,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,13cbc9d9-4e59-4731-b9ef-41084859fecf,9/1/2011,2,MN,mononuclear,,,
clinicalPharmacology,13cbc9d9-4e59-4731-b9ef-41084859fecf,9/1/2011,2,PMN,polymorphonuclear,,,
clinicalPharmacology,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,IV,intravenous,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,CE,conjugated estrogens,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,WHI,Women’s Health Initiative,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,PE,pulmonary embolism,,,
clinicalPharmacology,50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd,7/16/2012,2,CHD,coronary heart disease,,,
clinicalPharmacology,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,553777EE-8ECA-4A89-89B7-317A3E9084F6,9/16/2007,1,V/F,volume of distribution,,,
clinicalPharmacology,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,Tmax,to maximal naproxen levels,,,
clinicalPharmacology,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,AD59F90A-B81B-401B-9B5E-34DFA988034C,4/27/2009,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,a65325a7-ae0a-4704-99c4-a3a2e4e1dcf2,1/27/2012,14,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,a65325a7-ae0a-4704-99c4-a3a2e4e1dcf2,1/27/2012,14,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,ESRD,end stage renal disease,,,
clinicalPharmacology,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,205c4672-2006-4999-9897-33079fefa3a1,7/10/2012,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,CI,confidence interval,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,LCIS,lobular carcinoma in situ,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,RR,relative risk,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,BMD,bone mineral density,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,RMT,Royal Marsden Trial,,,
clinicalPharmacology,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,426a574a-a832-4723-beb1-4e869b6539af,11/18/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c36f2137-98bb-4583-89f7-6bce9582c465,6/23/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4252d631-03d0-4b37-8a0e-c7dc8fc5438a,3/9/2012,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,4252d631-03d0-4b37-8a0e-c7dc8fc5438a,3/9/2012,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,ER,estrogen receptor,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,CI,confidence interval,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,RR,relative risk,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,BMD,bone mineral density,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DMBA,dimethylbenzanthracene,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,RMT,Royal Marsden Trial,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,HR,[Hazard Ratio,,,
clinicalPharmacology,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,EBCTCG,Early Breast Cancer Trialists’ Collaborative Group,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,STH,somatotropic hormone,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,ECL,Enterochromaffin-like,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,FSH,follicle stimulating hormone,,,
clinicalPharmacology,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,LH,luteinizing hormone,,,
clinicalPharmacology,e2f051ce-c4e4-43a1-9732-fe0a777a6951,10/20/2011,12,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,e2f051ce-c4e4-43a1-9732-fe0a777a6951,10/20/2011,12,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,e2f051ce-c4e4-43a1-9732-fe0a777a6951,10/20/2011,12,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,da574350-be6b-49f3-b2ef-64da06af9b9d,2/4/2009,1,mL/min,"valign=""middle"">Percent of dose excreted in urine</td><td align=""center"" styleCode=""Botrule"" valign=""middle"">Total Clearance",,,
clinicalPharmacology,da574350-be6b-49f3-b2ef-64da06af9b9d,2/4/2009,1,SREs,skeletal-related events,,,
clinicalPharmacology,da574350-be6b-49f3-b2ef-64da06af9b9d,2/4/2009,1,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,e6d22e3b-9343-408f-9a86-59097f6e8983,10/18/2011,2,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,753453c5-8a7a-878e-3ce7-1d1edce718a9,9/16/2011,2,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,753453c5-8a7a-878e-3ce7-1d1edce718a9,9/16/2011,2,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,753453c5-8a7a-878e-3ce7-1d1edce718a9,9/16/2011,2,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,520b05ef-420e-47d5-9491-63a7ba9e5423,2/2/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,62aace29-36a3-4a2a-aae0-61f7480095c1,7/7/2009,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,c5c5c629-8f85-440a-b8c9-f702272c2854,12/4/2009,3,HPLC,high pressure liquid chromatographic,,,
clinicalPharmacology,502fac46-67a6-4c4d-a666-65305d50d7a1,8/29/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,f3c5895f-f54b-43d4-9b38-7bfbdf8335b7,11/20/2009,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,46b5dc53-802a-42c6-bb6d-370b32f74457,2/11/2011,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a712f252-16d9-47df-b2bf-6794228f3a88,3/21/2012,6,PMs,poor metabolizers,,,
clinicalPharmacology,a712f252-16d9-47df-b2bf-6794228f3a88,3/21/2012,6,EMs,extensive metabolizers,,,
clinicalPharmacology,a712f252-16d9-47df-b2bf-6794228f3a88,3/21/2012,6,ii,in the dihydrobenzofuran ring;,,,
clinicalPharmacology,1ab5ae3e-e303-4499-4c89-472d7cc1e46c,3/5/2012,11,IM,intramuscular,,,
clinicalPharmacology,8cdd6af4-7124-4ea5-b822-92b8edd3a442,5/17/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,8cdd6af4-7124-4ea5-b822-92b8edd3a442,5/17/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,4PY,N-methyl-4-pyridone-5-carboxamide,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,NNO,nicotinamide-N-oxide,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,MNA,N-methylnicotinamide,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,2PY,N-methyl-2-pyridone-5-carboxamide,,,
clinicalPharmacology,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,NUA,nicotinuric acid,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,RNA,ribonucleic acid,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,CALGB,Cancer and Leukemia Group B,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,SDS,Symptom Distress Scale,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,NPCP,National Prostate Cancer Project,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,PSA,prostate-specific antigen,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,ANLL,acute nonlymphocytic leukemia,,,
clinicalPharmacology,13c80d46-429e-4007-8f89-eed2ed96eccf,6/17/2010,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,3fe3d468-d283-4dd0-a1a7-29291a9b2d0b,2/26/2010,5,CVP,central venous pressure,,,
clinicalPharmacology,56803c6d-444a-4c1f-a936-790720b27b22,10/11/2011,2,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,56803c6d-444a-4c1f-a936-790720b27b22,10/11/2011,2,PM,poor metabolizers,,,
clinicalPharmacology,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,07f245c5-fcb0-3008-d69e-10290cadbfa6,4/13/2007,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,LDL,low density lipoprotein,,,
clinicalPharmacology,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,VLDL,very low density lipoprotein,,,
clinicalPharmacology,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,TG,triglyceride,,,
clinicalPharmacology,ce2ffee3-3048-43a0-ac45-ee32ce0c4c33,3/18/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,ce2ffee3-3048-43a0-ac45-ee32ce0c4c33,3/18/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,5a33d7f7-6a79-62df-baaa-57950e256842,2/25/2011,3,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,481cb8c7-578d-4db0-862e-a010b1af47d7,9/11/2008,1,min,median,,,
clinicalPharmacology,d356b7bb-929e-4cc0-98f7-bcf081c9c3b6,1/12/2012,7,RT,reverse transcriptase,,,
clinicalPharmacology,d356b7bb-929e-4cc0-98f7-bcf081c9c3b6,1/12/2012,7,CI,confidence interval,,,
clinicalPharmacology,d356b7bb-929e-4cc0-98f7-bcf081c9c3b6,1/12/2012,7,TAMs,thymidine analogue mutations,,,
clinicalPharmacology,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,AF,Atrial Fibrillation,,,
clinicalPharmacology,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalPharmacology,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,IV,intravenous,,,
clinicalPharmacology,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,59050278-167e-4641-a253-4e57653f8b6b,3/5/2010,1,AMS,acute  mountain sickness,,,
clinicalPharmacology,AE8F74F0-E600-4452-8557-958B603E2709,12/30/2008,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,AE8F74F0-E600-4452-8557-958B603E2709,12/30/2008,1,ISDN,isosorbide dinitrate,,,
clinicalPharmacology,2970fe7e-9e1f-47aa-85ad-663ee15c7e06,7/20/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,MCE,major coronary events,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,LDL-C,low-density lipoprotein cholesterol,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,HPS,Heart Protection Study,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,HDL-C,high-density lipoprotein cholesterol,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,hCG,human chorionic gonadotropin,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,MVE,major vascular events,,,
clinicalPharmacology,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,total-C,total cholesterol,,,
clinicalPharmacology,8489416f-61b4-4711-99d4-d409fab43cfd,10/11/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8489416f-61b4-4711-99d4-d409fab43cfd,10/11/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8489416f-61b4-4711-99d4-d409fab43cfd,10/11/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,8489416f-61b4-4711-99d4-d409fab43cfd,10/11/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,AB73778B-6794-441C-B127-610A6D0733EA,4/29/2008,2,ERP,effective refractory period,,,
clinicalPharmacology,AB73778B-6794-441C-B127-610A6D0733EA,4/29/2008,2,APD,action potential duration,,,
clinicalPharmacology,ee80603a-7d4c-4172-aef4-286185b69acd,3/14/2012,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,407e0758-9e2e-4e45-8c1b-10cfd2115b1f,3/15/2012,1,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,407e0758-9e2e-4e45-8c1b-10cfd2115b1f,3/15/2012,1,LV,leucovorin,,,
clinicalPharmacology,407e0758-9e2e-4e45-8c1b-10cfd2115b1f,3/15/2012,1,5-FU,5-fluorouracil,,,
clinicalPharmacology,407e0758-9e2e-4e45-8c1b-10cfd2115b1f,3/15/2012,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,05e16c10-ff0a-4238-8181-f3e84379ed6a,2/21/2012,2,i.e.,improvement,,,
clinicalPharmacology,a49ba8e3-e379-44f1-8ad2-b6dae53bbdf8,5/26/2010,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,a49ba8e3-e379-44f1-8ad2-b6dae53bbdf8,5/26/2010,2,LES,lower esophageal sphincter,,,
clinicalPharmacology,10cc918f-aa44-415b-932d-2404695ac449,1/12/2010,1,ALOPRIM,allopurinol sodium,,,
clinicalPharmacology,d2af616e-673a-4fdd-ace8-db2d0f154604,11/24/2011,6,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,00332c65-edad-a153-9c78-628931daa732,5/31/2012,4,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d5067b09-62cf-4955-b384-64fd17410e12,3/11/2009,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,78581094-bd77-4276-8416-246293907165,12/14/2011,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,78581094-bd77-4276-8416-246293907165,12/14/2011,2,mm,MicroorganismZone Diameter Ranges,,,
clinicalPharmacology,2fc288bd-b176-42d5-945f-7f4ff370a57e,3/17/2011,6,GER,gastroesophageal reflux,,,
clinicalPharmacology,2fc288bd-b176-42d5-945f-7f4ff370a57e,3/17/2011,6,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,871E2A73-A1E9-4952-8CF2-15DA430117CE,2/26/2008,1,CYP450,Cytochrome P450,,,
clinicalPharmacology,b2fbd294-5fb9-45bc-baf0-8c5b72bddb74,10/22/2010,1,ODC,ornithine decarboxylase,,,
clinicalPharmacology,b85f71ac-7c97-4c92-a230-95a1d8efc132,1/13/2009,2,AUC,area under the concentration time curve,,,
clinicalPharmacology,88f1abdc-f53e-4ff9-b4c1-3cfbc2609b79,7/7/2010,1,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,88f1abdc-f53e-4ff9-b4c1-3cfbc2609b79,7/7/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,CYP3A,cytochromes P450 3A,,,
clinicalPharmacology,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,CYP2C19,cytochrome P450 2C19,,,
clinicalPharmacology,39988aa6-8f68-40e8-9bdd-c40a3bdaad61,4/17/2012,5,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,F5EA346B-F507-4224-88A6-4C891C4B1AD5,8/6/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,ETT,exercise tolerance time,,,
clinicalPharmacology,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,SAVE,Survival and Ventricular Enlargement,,,
clinicalPharmacology,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,PRA,plasma renin activity,,,
clinicalPharmacology,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,LVD,left ventricular dysfunction,,,
clinicalPharmacology,8828d4c9-6e71-4d0a-9ca1-bd0d231184ab,6/20/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,8828d4c9-6e71-4d0a-9ca1-bd0d231184ab,6/20/2011,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,8b59207a-ea5c-4697-a8b6-94c3015a00de,7/23/2008,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,CABG,coronary artery bypass graft,,,
clinicalPharmacology,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,ED,erectile dysfunction,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,CNS,central nervous system,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,DCT,demethylcitalopram,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,DA,dopamine,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,NE,norepinephrine,,,
clinicalPharmacology,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,CT,citalopram ,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,40226242-da82-4dd7-bca2-eebb14501264,1/5/2012,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,b9cb34bb-14b5-4b98-bba0-3326e58362e0,8/10/2011,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,61364915-3b0b-427d-9fef-29cdcc427ec5,4/10/2012,4,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,61364915-3b0b-427d-9fef-29cdcc427ec5,4/10/2012,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,13d9563f-17e7-418e-8866-b849c9e74787,11/30/2011,2,AED,antiepilepsy drug,,,
clinicalPharmacology,13d9563f-17e7-418e-8866-b849c9e74787,11/30/2011,2,TID,three divided doses,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,BSPS,Brief Social Phobia Scale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,PMDD,Premenstrual Dysphoric Disorder,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,OCD,Obsessive-Compulsive Disorder,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CAPS,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,IES,Impact of Event Scale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CGI,Clinical Global Impressions,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CYBOCS,Children’s Yale-Brown Obsessive-Compulsive Scale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,FQ-SPS,Fear Questionnaire Social Phobia Subscale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,YBOCS,Yale–Brown Obsessive-Compulsive Scale,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,LLPDD,Luteal Phase Dysphoric Disorder,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CGI-S,Clinical Global Impression – Severity of Illness,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CGI-I,Clinical Global Impression of Improvement,,,
clinicalPharmacology,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,CI,confidence intervals,,,
clinicalPharmacology,afde17e7-b95b-4cd5-97eb-e361724014bd,2/15/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,CGI,Clinical Global Impression,,,
clinicalPharmacology,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,0dc024ce-efc8-4690-7cb5-639c728fccac,8/23/2011,1406,CSF,cerebrospinal fluid,,,
clinicalPharmacology,dd02a11f-6ea6-42e7-b168-bf2b9f4d54ae,12/20/2011,2,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,IV,intravenous,,,
clinicalPharmacology,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,b43f6b44-9de3-4efb-a467-487aee28f6a0,8/25/2009,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b43f6b44-9de3-4efb-a467-487aee28f6a0,8/25/2009,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,b43f6b44-9de3-4efb-a467-487aee28f6a0,8/25/2009,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,b43f6b44-9de3-4efb-a467-487aee28f6a0,8/25/2009,2,CYP,cytochrome P450,,,
clinicalPharmacology,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,MMEF,maximal midexpiratory flow rate,,,
clinicalPharmacology,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,7F60424F-B90C-459C-AE53-B732EE3D67B5,11/27/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,TCA,tricyclic antidepressant,,,
clinicalPharmacology,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,87859aea-e6d8-4d68-8ce3-135163a7fdd8,7/27/2011,5,HTM,Haemophilus Test Media,,,
clinicalPharmacology,87859aea-e6d8-4d68-8ce3-135163a7fdd8,7/27/2011,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,87859aea-e6d8-4d68-8ce3-135163a7fdd8,7/27/2011,5,IV,intravenous,,,
clinicalPharmacology,87859aea-e6d8-4d68-8ce3-135163a7fdd8,7/27/2011,5,IM,intramuscular,,,
clinicalPharmacology,9781f06d-485e-41f0-84aa-ee177f0ad137,10/11/2011,10,MAC,monitored anesthesia care,,,
clinicalPharmacology,42f6c7bd-9bd3-42d1-9f7e-e762cab1e0f0,2/25/2011,7,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,673ac9dd-472a-4936-ad22-d9f6298b0106,2/28/2012,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,CHF,.Congestive Heart Failure,,,
clinicalPharmacology,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,i.e.,initial clearance rates,,,
clinicalPharmacology,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,605c1d23-c97c-4ea4-92d0-fed351de9d2e,4/11/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,9448e8ba-b73a-4d2a-b58c-afdcd19f8e12,8/4/2010,18,BHPM,[bis-(p-hydroxyphenyl) pyridyl-2 methane;,,,
clinicalPharmacology,60f0fb82-d870-4f07-82af-e4aeb79ed023,3/28/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,cccf04bd-7463-40b8-a41f-cb1093c358d7,6/7/2011,4,GER,gastroesophageal reflux,,,
clinicalPharmacology,cccf04bd-7463-40b8-a41f-cb1093c358d7,6/7/2011,4,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,b21683fc-1126-8ead-2742-1fe93a83c1e4,11/22/2011,3,ISH,isolated systolic hypertension,,,
clinicalPharmacology,b21683fc-1126-8ead-2742-1fe93a83c1e4,11/22/2011,3,CVD,cardiovascular disease,,,
clinicalPharmacology,d6599395-3944-44f9-97f2-e0424c6b6a1f,12/5/2011,5,DF,disoproxil fumarate,,,
clinicalPharmacology,ca1b6a78-739b-4e2a-9332-145c887fb2ff,8/18/2010,2,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,A547CC0A-6AF0-49C7-A5EA-C41684CC36AE,9/30/2008,1,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,A547CC0A-6AF0-49C7-A5EA-C41684CC36AE,9/30/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,A547CC0A-6AF0-49C7-A5EA-C41684CC36AE,9/30/2008,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,9CF04DAD-E312-4B8F-A297-1E002D43E151,10/6/2006,1,ACTG,AIDS Clinical Trials Group,,,
clinicalPharmacology,9CF04DAD-E312-4B8F-A297-1E002D43E151,10/6/2006,1,KS,Kaposi’s sarcoma,,,
clinicalPharmacology,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,EEAD,evoked after-discharge,,,
clinicalPharmacology,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,MES,maximum electroshock,,,
clinicalPharmacology,462dce28-bed1-4885-972b-a6e1028fcead,4/12/2012,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,815270f2-1bb2-4a77-a8ba-3410dc6ae104,7/21/2008,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,MN,mononuclear,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,9b653e01-81f3-49b1-89a2-a56988ad94a3,1/4/2012,3473,ECL,Enterochromaffin-like,,,
clinicalPharmacology,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,4d04a96c-8dee-49f1-be92-f410afc23a68,1/25/2012,1,PT,prothrombin time,,,
clinicalPharmacology,29157995-fa61-4425-86a5-5bd0e4718cd8,11/15/2011,9,IOP,intraocular pressure,,,
clinicalPharmacology,29157995-fa61-4425-86a5-5bd0e4718cd8,11/15/2011,9,CA-II,carbonic anhydrase II,,,
clinicalPharmacology,29157995-fa61-4425-86a5-5bd0e4718cd8,11/15/2011,9,CA,Carbonic anhydrase,,,
clinicalPharmacology,29157995-fa61-4425-86a5-5bd0e4718cd8,11/15/2011,9,RBCs,red blood cells,,,
clinicalPharmacology,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7,7/19/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc,3/30/2011,3,AD,Alzheimer's disease,,,
clinicalPharmacology,4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc,3/30/2011,3,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,HRT,estrogen/hormone replacement therapy,,,
clinicalPharmacology,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,mean,men between the ages of 38 and 91,,,
clinicalPharmacology,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,mean,men between the ages of 31 and 87,,,
clinicalPharmacology,35b5ddb5-1729-4588-b2a2-ead56d78b6f9,3/12/2012,6,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,517fbb02-8793-4647-83c7-25a91be49622,7/8/2010,8,ERG,electroretinogram,,,
clinicalPharmacology,517fbb02-8793-4647-83c7-25a91be49622,7/8/2010,8,CAD,Coronary Artery Disease,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,ISH,isolated systolic hypertension,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,DBP,diastolic blood pressure,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,ITT,intention-to-treat,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,ESRD,end-stage renal disease,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,CVD,cardiovascular disease,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,SBP,systolic blood pressure,,,
clinicalPharmacology,db36c4f9-a1b7-48ad-b516-b78b224a5ac5,10/25/2010,3,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,f180e621-7bc1-4581-b34f-04c38a47d219,8/24/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,23bee05f-4161-4281-9f99-3d64be335c7b,11/24/2008,2,AUC,area under the curve,,,
clinicalPharmacology,3F7F39A5-D5F9-40B3-B20B-55E2C2D4EF3E,5/11/2006,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
clinicalPharmacology,1513b960-d9d1-11de-8a1e-0002a5d5c51b,10/5/2010,5,UFH,unfractionated heparin,,,
clinicalPharmacology,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,SIR,systemic inflammatory response,,,
clinicalPharmacology,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,CPB,cardiopulmonary bypass,,,
clinicalPharmacology,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,IV,intravenous,,,
clinicalPharmacology,6e88b4d2-223e-44ac-8b9c-3eecf4d573a5,1/15/2008,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,6e88b4d2-223e-44ac-8b9c-3eecf4d573a5,1/15/2008,1,MIC,minimum inhibitory concentrations,,,
clinicalPharmacology,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,D2,dopamine Type 2,,,
clinicalPharmacology,b95cd483-64ca-4840-948d-eaf1e13e58b2,7/19/2010,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,f32d6e27-5b7b-4b17-af2e-0250447ee560,10/4/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MAC,Mycobacterium avium Complex,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MICs,minimum inhibitory  concentrations,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MAC,Mycobacterium avium  complex,,,
clinicalPharmacology,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,OADC,oleic  acid-albumin-dextrose-catalase,,,
clinicalPharmacology,0e5139d8-bf61-4f21-a36b-81b96b9b07d1,7/11/2012,2,Tmax,the maximum concentration in serum,,,
clinicalPharmacology,4AD759F3-72DD-412E-9500-055335CDA6CF,5/3/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,PSA,prostate-specific antigen,,,
clinicalPharmacology,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,IV,intravenous,,,
clinicalPharmacology,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,AUC,area under the curve,,,
clinicalPharmacology,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,MRI,magnetic resonance imaging,,,
clinicalPharmacology,fa5f39f7-3b15-4947-81c9-a7081798b6cf,4/16/2009,2,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,2DA604EA-01C4-44F3-852F-E6E55F140360,3/30/2007,1,broth,be interpreted according to the following criteria:4,,,
clinicalPharmacology,2DA604EA-01C4-44F3-852F-E6E55F140360,3/30/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,TBG,thyroxine-binding  globulin,,,
clinicalPharmacology,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,TBPA,thyroxine-binding prealbumin,,,
clinicalPharmacology,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,GI,gastrointestinal,,,
clinicalPharmacology,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,rT3,reverse T3,,,
clinicalPharmacology,d95bdf63-69a2-47b9-b909-97c74b6d7731,2/17/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2F44755A-2661-475D-83C5-8923101EB7A3,6/13/2007,1,CNS,central nervous system,,,
clinicalPharmacology,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,CABG,coronary artery bypass graft,,,
clinicalPharmacology,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,ED,erectile dysfunction,,,
clinicalPharmacology,2554e49e-97a6-4543-b844-e60f05f7ae8e,3/7/2012,3622,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5b3a75f7-9cc2-48a7-9b2e-35f666bdc992,5/21/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,Tmax,to maximum concentration,,,
clinicalPharmacology,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,ITT,intent-to-treat,,,
clinicalPharmacology,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,CLr,clearance,,,
clinicalPharmacology,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,D2,dopamine Type 2,,,
clinicalPharmacology,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,5edfc3e7-f80d-47ee-897a-c02ff4eb3e74,4/6/2011,9,DDC,dopa decarboxylase,,,
clinicalPharmacology,5edfc3e7-f80d-47ee-897a-c02ff4eb3e74,4/6/2011,9,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,f1bf6b2f-d00a-4c3c-a55c-46bb0ad6d5c6,7/1/2011,10,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,CNS,central nervous system,,,
clinicalPharmacology,7e3a4517-1934-4e03-b96b-4ad65ab076c5,5/22/2012,9,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e563b079-a892-4505-a4ab-e6c9c8c02a51,4/30/2012,4,TK,thymidine kinase,,,
clinicalPharmacology,e563b079-a892-4505-a4ab-e6c9c8c02a51,4/30/2012,4,HSV-1,herpes simplex virus types 1,,,
clinicalPharmacology,e563b079-a892-4505-a4ab-e6c9c8c02a51,4/30/2012,4,Vd?,volume of distribution,,,
clinicalPharmacology,e563b079-a892-4505-a4ab-e6c9c8c02a51,4/30/2012,4,L/hr,L/hr/kg,,,
clinicalPharmacology,ad6397ff-8109-4f0e-b57d-d7cfd525c2d3,1/6/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ad6397ff-8109-4f0e-b57d-d7cfd525c2d3,1/6/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,c2126e2d-3b46-40dd-8168-6d0368e5d233,12/27/2011,4,NTS,nicotine transdermal system,,,
clinicalPharmacology,c2126e2d-3b46-40dd-8168-6d0368e5d233,12/27/2011,4,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalPharmacology,a0c0811e-9b05-4434-21a3-a25ebb27681f,7/16/2012,1049,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,a0c0811e-9b05-4434-21a3-a25ebb27681f,7/16/2012,1049,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,AF0C5240-4A98-4B25-B805-D6D3889BDC62,9/10/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,fae9b5cc-f32f-4e60-91f0-efbb53c1c880,1/7/2010,3,GER,gastroesophageal reflux,,,
clinicalPharmacology,fae9b5cc-f32f-4e60-91f0-efbb53c1c880,1/7/2010,3,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,MCVE,major cardiovascular events,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,TNT,to New Targets Study,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,min,median,,,
clinicalPharmacology,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalPharmacology,2E129105-0F1F-4E64-8D93-81399D744619,3/31/2007,2,MIC’s,minimum inhibitory concentrations,,,
clinicalPharmacology,ca09dd2c-02ed-4d26-af3c-aaff4120887e,8/20/2010,2,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,73667241-b95a-49b0-9c51-a4289f20d5c2,7/28/2010,1,PSS,phenotypic susceptibility score,,,
clinicalPharmacology,73667241-b95a-49b0-9c51-a4289f20d5c2,7/28/2010,1,HLMs,human liver microsomes,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,NE,neuroendocrine,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,EE,erosive esophagitis,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,9c983da1-a8e0-479e-8816-5d5668ea242e,9/5/2011,4,CYP,cytochrome P450,,,
clinicalPharmacology,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,DHD,10,11-dihydroxy metabolite,,
clinicalPharmacology,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,MHD,10-monohydroxy metabolite,,,
clinicalPharmacology,f56aec67-c662-477c-b866-bfc23e8809cf,8/18/2011,2,aPTT,activated partial thromboplastin time,,,
clinicalPharmacology,f56aec67-c662-477c-b866-bfc23e8809cf,8/18/2011,2,HMW,High Molecular Weight,,,
clinicalPharmacology,AA447BAC-DFBD-44AE-B1D1-3E1BE6D7EF9E,2/21/2008,2,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,424c69ef-b5a4-4480-98f1-6c8bed9cbcf2,12/15/2010,147,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,D2,dopamine Type 2,,,
clinicalPharmacology,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,LDL,low density lipoprotein,,,
clinicalPharmacology,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,TG,triglyceride,,,
clinicalPharmacology,aa756b80-11eb-4f67-abb8-8babcee728b2,7/8/2010,4,AUC,area under the curve,,,
clinicalPharmacology,3fc60483-3dd9-4d52-a0eb-fceba330e019,5/20/2010,10,TK,thymidine kinase,,,
clinicalPharmacology,3fc60483-3dd9-4d52-a0eb-fceba330e019,5/20/2010,10,HSV-1,HSV types 1,,,
clinicalPharmacology,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,CNS,central nervous system,,,
clinicalPharmacology,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,DA,dopamine,,,
clinicalPharmacology,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,NE,norepinephrine,,,
clinicalPharmacology,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,AUC,Area Under Curve,,,
clinicalPharmacology,8865ccfb-6ab7-45f2-807f-11c9aa681836,6/1/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,99103779-6d2f-4e4b-9b7f-0b24d7c6bf4e,5/22/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b34ef1e1-9679-4c56-8a88-bf45faf3594c,6/25/2009,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,9bec8131-d420-41ea-809c-6607bf5351ea,1/3/2011,1,AUC,area-under-the-curve,,,
clinicalPharmacology,e563332a-f866-4395-85d3-5ccd217d1ebf,8/10/2009,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,26d01204-4002-4f4e-9c50-49c5a74858db,11/1/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8cf65b07-115e-4499-92c4-5f16792a954d,8/11/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,CGI,Clinical Global Impression,,,
clinicalPharmacology,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,a6bb4f0a-1555-4550-a7a4-99609674b1e7,2/16/2012,4,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,LDL,low density lipoprotein,,,
clinicalPharmacology,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,VLDL,very low density lipoprotein,,,
clinicalPharmacology,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,TG,triglyceride,,,
clinicalPharmacology,6f400537-0d6b-3800-4803-53536250f511,1/25/2006,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,LDL-C,low-density lipoprotein cholesterol,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,HDL,high density lipoprotein,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,apo B,apolipoprotein B,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,TC,total cholesterol,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,HDL-C,high-density lipoprotein cholesterol,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,TG,triglycerides,,,
clinicalPharmacology,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,CYP,cytochrome P450,,,
clinicalPharmacology,F103B9F9-E081-419D-A2D8-B86ACDA834DD,6/30/2008,1,NYHA,New York Heart Association,,,
clinicalPharmacology,F103B9F9-E081-419D-A2D8-B86ACDA834DD,6/30/2008,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,4ac6d01a-af26-44e7-ae2e-3618de0080aa,12/2/2010,5,V/F,volume of distribution,,,
clinicalPharmacology,4ac6d01a-af26-44e7-ae2e-3618de0080aa,12/2/2010,5,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,4ac6d01a-af26-44e7-ae2e-3618de0080aa,12/2/2010,5,PPG,postprandial plasma glucose,,,
clinicalPharmacology,942008d0-dd1a-48cd-8736-80872a04e0e0,3/28/2012,3,NO,nitric oxide,,,
clinicalPharmacology,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,TCA,tricyclic antidepressant,,,
clinicalPharmacology,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,4d05bbff-0adf-4d29-a4b9-c15979e9ce39,3/30/2012,1,Cl-,chloride,,,
clinicalPharmacology,0ae5f19b-e8d5-4ec7-bcf1-697e88c0e66c,4/18/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,0ae5f19b-e8d5-4ec7-bcf1-697e88c0e66c,4/18/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,0ae5f19b-e8d5-4ec7-bcf1-697e88c0e66c,4/18/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,c6f64190-4911-4cfc-a9b1-bf86d4e58ed0,7/20/2012,4,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,c6f64190-4911-4cfc-a9b1-bf86d4e58ed0,7/20/2012,4,EM,extensive metabolizers,,,
clinicalPharmacology,c6f64190-4911-4cfc-a9b1-bf86d4e58ed0,7/20/2012,4,PM,poor metabolizers,,,
clinicalPharmacology,d0d87f37-70f7-4cbd-a687-a7296700773f,7/7/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2288e08f-f7e0-423f-abeb-1995b0610049,4/1/2009,1,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,79d6a5ea-77d3-4547-aa67-1b465141b1f5,12/8/2009,1,CI,confidence interval,,,
clinicalPharmacology,10cd5ca5-6f8b-417c-af11-a2054a2dde34,3/1/2010,1,EIB,exercise-induced bronchoconstriction,,,
clinicalPharmacology,10cd5ca5-6f8b-417c-af11-a2054a2dde34,3/1/2010,1,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalPharmacology,80971965-5c77-4950-b65d-7996b802d2cd,7/8/2010,8,ERG,electroretinogram,,,
clinicalPharmacology,80971965-5c77-4950-b65d-7996b802d2cd,7/8/2010,8,CAD,Coronary Artery Disease,,,
clinicalPharmacology,A69EC903-874E-4FEF-9E71-81E608DEB6A7,12/11/2008,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,3071978c-a77f-43ff-b68b-a951f1fd0816,4/1/2010,3,PPG,postprandial plasma glucose,,,
clinicalPharmacology,4acf51de-26f7-42b2-8acc-61b800627ef3,12/13/2010,2,TK,thymidine kinase,,,
clinicalPharmacology,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,i.e.,improvement from baseline,,,
clinicalPharmacology,782c1bb9-75c4-4258-97b6-fd776ca970f5,11/2/2011,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,782c1bb9-75c4-4258-97b6-fd776ca970f5,11/2/2011,2,MN,mononuclear,,,
clinicalPharmacology,782c1bb9-75c4-4258-97b6-fd776ca970f5,11/2/2011,2,PMN,polymorphonuclear,,,
clinicalPharmacology,d1697161-ebe8-42b0-83e7-c9de4412546c,2/9/2011,1,AD,Alzheimer's disease,,,
clinicalPharmacology,d1697161-ebe8-42b0-83e7-c9de4412546c,2/9/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desmethyl venlafaxine,,,
clinicalPharmacology,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,MAO,monoamine oxidase,,,
clinicalPharmacology,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,2298ed2a-e01b-4f7c-9902-7c58a6e06b7a,4/13/2011,3,HGPRTase,hypoxanthine-guanine phosphoribosyltransferase,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,ISH,isolated systolic hypertension,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,DBP,diastolic blood pressure,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,CVD,cardiovascular disease,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,SBP,systolic blood pressure,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,be716692-6b4f-47b6-83d1-01665861626b,4/26/2011,1,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,be716692-6b4f-47b6-83d1-01665861626b,4/26/2011,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,MCVE,major cardiovascular events,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,DBP,diastolic blood pressure,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,TNT,to New Targets Study,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,CVD,cardiovascular disease,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,SBP,systolic blood pressure,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,min,median,,,
clinicalPharmacology,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalPharmacology,1d480bbc-9716-427e-a558-e6dd48a90edf,11/27/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e6634d24-08af-44bc-8e76-e759619857fa,2/15/2011,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,e6634d24-08af-44bc-8e76-e759619857fa,2/15/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,LDL-C,low-density lipoprotein cholesterol,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,HDL-C,high-density lipoprotein cholesterol,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,EXCEL,agents.EXPANDED CLINICAL EVALUATION OF LOVASTATIN,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,AUC,area under the curve,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,total-C,total cholesterol,,,
clinicalPharmacology,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,TG,triglycerides,,,
clinicalPharmacology,c22dfa61-ca2e-419c-9ff6-484023793699,7/1/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c22dfa61-ca2e-419c-9ff6-484023793699,7/1/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c22dfa61-ca2e-419c-9ff6-484023793699,7/1/2011,4,ECL,Enterochromaffin-like,,,
clinicalPharmacology,c22dfa61-ca2e-419c-9ff6-484023793699,7/1/2011,4,CYP,cytochrome P450,,,
clinicalPharmacology,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,EEAD,evoked after-discharge,,,
clinicalPharmacology,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,MES,maximum electroshock,,,
clinicalPharmacology,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,CI,confidence intervals,,,
clinicalPharmacology,897e4438-ba93-4d47-9d33-6ad1afcd7c25,8/19/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,91666161-880e-4a69-95f0-6f18314ea999,8/31/2010,1,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,91666161-880e-4a69-95f0-6f18314ea999,8/31/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,ie,its active metabolites,,,
clinicalPharmacology,A3878E6A-ABB9-4994-8D5A-EA4DC2E85226,3/28/2007,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,26fcc267-c8d7-e059-1bcf-830dded43690,6/9/2011,7,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,SC,Subcutaneous,,,
clinicalPharmacology,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,Tmax,to maximum  concentration,,,
clinicalPharmacology,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,EM,extensive metabolizers,,,
clinicalPharmacology,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,PM,poor metabolizers,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,ICP,intracranial pressure,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,Sevo/O2,sevoflurane-O2,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,HFIP,hexafluoroisopropanol,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,Sevo/N2O/O2,sevoflurane-N2O/O2,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,FA,following termination of anesthesia,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,CABG,Coronary Artery Bypass Graft,,,
clinicalPharmacology,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,MAC,Minimum alveolar concentration,,,
clinicalPharmacology,04d2b6f4-bd9b-4871-9527-92c81aa2d4d0,10/27/2011,9,HCV-RNS,HCV replicon cells,,,
clinicalPharmacology,d7b4d497-0b70-49e8-b17b-643fa82a0d8c,6/28/2010,3,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,d7b4d497-0b70-49e8-b17b-643fa82a0d8c,6/28/2010,3,LES,lower esophageal sphincter,,,
clinicalPharmacology,27e63200-c82c-47cd-a212-a2b5edc343bf,1/3/2011,1,CNS,central nervous system,,,
clinicalPharmacology,27e63200-c82c-47cd-a212-a2b5edc343bf,1/3/2011,1,PNS,peripheral nervous system,,,
clinicalPharmacology,a591e33a-52f0-41c8-a00b-4a1afcc3dc4c,1/4/2011,4,NTS,nicotine transdermal system,,,
clinicalPharmacology,a591e33a-52f0-41c8-a00b-4a1afcc3dc4c,1/4/2011,4,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalPharmacology,a35fa709-5eb5-4429-b38f-f1e0019bf0ee,2/2/2010,2,Moderate,moderately darker than the surrounding normal skin,,,
clinicalPharmacology,a56b1b78-0ae2-41b4-9c76-98ad9d439199,8/12/2010,5,CLCR,clearance and creatinine clearance,,,
clinicalPharmacology,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,a1b077e6-b070-43f2-a98e-380cc635419d,1/20/2012,19,CgA,Chromogranin A,,,
clinicalPharmacology,a1b077e6-b070-43f2-a98e-380cc635419d,1/20/2012,19,ECL,Enterochromaffin-like,,,
clinicalPharmacology,a1b077e6-b070-43f2-a98e-380cc635419d,1/20/2012,19,CYP,cytochrome P450,,,
clinicalPharmacology,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,MN,mononuclear,,,
clinicalPharmacology,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,PMN,polymorphonuclear,,,
clinicalPharmacology,71f63741-cad4-43b5-bb3e-c63a188d10a2,7/19/2011,1,PIC,Polysaccharide Iron Complex,,,
clinicalPharmacology,92ae2611-637c-4a9e-8e95-2d8fa8191f03,2/1/2012,3,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,92ae2611-637c-4a9e-8e95-2d8fa8191f03,2/1/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,Tmax,to Cmax,,,
clinicalPharmacology,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,GH,growth hormone,,,
clinicalPharmacology,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,LH,luteinizing hormone,,,
clinicalPharmacology,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,ACTH,adrenocorticotropic hormone,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,DCT,demethylcitalopram,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,CT,citalopram,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,DA,dopamine,,,
clinicalPharmacology,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,NE,norepinephrine,,,
clinicalPharmacology,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,ie,its active metabolites,,,
clinicalPharmacology,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,5314ab7a-e750-4e6b-8ef2-e37f831e088b,6/21/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,67464901-d29e-4706-b337-e3e27707fdbe,8/1/2009,5,CV%,coefficient of variation,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,PT,prothrombin time,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,CL,clearance,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,Vd,volume of distribution,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,IV,intravenous,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,CYP,cytochrome P450,,,
clinicalPharmacology,31b5d407-cce4-456f-6da1-825c74c1db7d,10/11/2011,12,BMI,body mass index,,,
clinicalPharmacology,346a77ce-d326-4cda-b7da-0d51c6d11307,2/8/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,346a77ce-d326-4cda-b7da-0d51c6d11307,2/8/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,346a77ce-d326-4cda-b7da-0d51c6d11307,2/8/2012,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,346a77ce-d326-4cda-b7da-0d51c6d11307,2/8/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,b5349a88-9275-489e-8c71-2bd22eb9e520,11/4/2010,69,B.  fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,b5349a88-9275-489e-8c71-2bd22eb9e520,11/4/2010,69,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,CHF,congestive heart failure,,,
clinicalPharmacology,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,AV,atrioventricular,,,
clinicalPharmacology,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PVCs,premature ventricular contractions,,,
clinicalPharmacology,95a33c9b-79a6-47c7-8433-fc217950b88f,3/30/2010,1,CNS,central nervous system,,,
clinicalPharmacology,95a33c9b-79a6-47c7-8433-fc217950b88f,3/30/2010,1,Butalbital,butalbital component of ASCOMP® with Codeine,,,
clinicalPharmacology,e83f43dd-f79e-4166-9bee-9427e235c876,11/15/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e83f43dd-f79e-4166-9bee-9427e235c876,11/15/2011,4,MEF,middle ear fluid,,,
clinicalPharmacology,55816042-946d-4bec-9461-bd998628ff45,2/7/2011,3,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,GFR,glomerular filtration rate,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,AUC,area under the curve,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,RPF,renal plasma flow,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,FVC,forced vital capacity,,,
clinicalPharmacology,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,FEV 1,forced expiratory volume 1 second,,,
clinicalPharmacology,AEC0308F-F583-4E27-9BB8-21800BDE7FAA,11/16/2007,1,e.g.,ergot alkaloids,,,
clinicalPharmacology,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,XO,xanthine oxidase,,,
clinicalPharmacology,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,6-TGNs,6-thioguanine nucleotides,,,
clinicalPharmacology,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,TPMT,thiopurine S-methyltransferase,,,
clinicalPharmacology,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,6-MP,6-mercaptopurine,,,
clinicalPharmacology,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,HGPRT,hypoxanthine-guanine phosphoribosyltransferase,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,CSF,cerebrospinal fluid,,,
clinicalPharmacology,0e15feec-d27e-4861-8152-c5a8b8ccacd4,7/23/2012,5,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,9a8cd40a-6fb6-46b6-b692-da8669097e02,7/2/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a136e22d-ad97-4f4d-b28b-347a3d2a994b,2/22/2012,3,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,a136e22d-ad97-4f4d-b28b-347a3d2a994b,2/22/2012,3,CV,coefficient of variances,,,
clinicalPharmacology,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,a90897e7-4352-44db-891b-763ac4c3bebe,12/8/2010,134,Fluid,"Fluid</content>                            </td>                            <td>                               <content styleCode=""bold"">Ratio of Fluconazole Tissue",,,
clinicalPharmacology,1ec26930-abe6-4db3-9315-aa896f7d5232,5/18/2009,3,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,77523882-3a1e-48ea-9bbb-9fffdd7aa415,6/28/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,77523882-3a1e-48ea-9bbb-9fffdd7aa415,6/28/2011,1,IAA,indole  acetic acid,,,
clinicalPharmacology,7B5F7DD0-0BFC-4DA4-9619-4FD0AFEB98A7,1/8/2007,1,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,fe9a82be-dbf0-b51e-055e-139c35b00898,7/27/2011,2,MN,mononuclear,,,
clinicalPharmacology,fe9a82be-dbf0-b51e-055e-139c35b00898,7/27/2011,2,PMN,polymorphonuclear,,,
clinicalPharmacology,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,CGI,Clinical Global Impression,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,584ace29-6e40-432f-950f-ab7e98653d32,4/25/2012,5,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,6281ca7c-2aec-4f14-b7e4-82401a701c96,9/19/2006,3,ER,Extended-release,,,
clinicalPharmacology,5dc0f75a-1e14-469f-af4f-c668a32f2328,7/5/2012,12,Groups C,gonorrhoeae Peptostreptococcus species Streptococci,,,
clinicalPharmacology,c6754623-b14c-4fc3-8719-48eee3119156,12/30/2011,3,DEO,N-desethyloxybutynin,,,
clinicalPharmacology,37ce0483-afde-4859-b160-e81c0ecd5506,11/23/2009,4,see,seizure,,,
clinicalPharmacology,14527f4a-ce99-449d-a5a5-9edd7fb28dee,3/27/2011,2,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,Ac-5-ASA,N-acetyl-5-ASA,,,
clinicalPharmacology,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,AA,arachidonic acid,,,
clinicalPharmacology,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,5-ASA,5-aminosalicylic acid,,,
clinicalPharmacology,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,PG,prostaglandin,,,
clinicalPharmacology,d5574dfc-203f-4540-bce2-c5f83aefc6bd,2/5/2009,3,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,d5574dfc-203f-4540-bce2-c5f83aefc6bd,2/5/2009,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d5574dfc-203f-4540-bce2-c5f83aefc6bd,2/5/2009,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,25994fad-388d-4f9c-950e-14b7f8073b8c,1/14/2010,1,PMs,poor metabolizers,,,
clinicalPharmacology,25994fad-388d-4f9c-950e-14b7f8073b8c,1/14/2010,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,25994fad-388d-4f9c-950e-14b7f8073b8c,1/14/2010,1,5-HMT,5-hydroxymethyl tolterodine,,,
clinicalPharmacology,25994fad-388d-4f9c-950e-14b7f8073b8c,1/14/2010,1,ECG,electrocardiographic,,,
clinicalPharmacology,25994fad-388d-4f9c-950e-14b7f8073b8c,1/14/2010,1,EMs,extensive metabolizers,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,61b1a335-fca5-4a57-b24f-ae7d081d06ed,5/13/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,ebfd2c46-8635-4cb3-8523-852b425feedd,5/26/2010,3,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,ebfd2c46-8635-4cb3-8523-852b425feedd,5/26/2010,3,LES,lower esophageal sphincter,,,
clinicalPharmacology,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,V/F,volume of distribution,,,
clinicalPharmacology,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,PPG,postprandial plasma glucose,,,
clinicalPharmacology,963e7bea-ff5d-420a-9cb2-e4aefb534b33,11/16/2011,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,628efd34-8121-4f8d-8006-f8f659b5dd29,4/25/2011,2,ICU,Intensive Care Unit,,,
clinicalPharmacology,e518dfc6-7e93-4fee-a66c-51e1ab71c056,10/31/2011,13,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,e518dfc6-7e93-4fee-a66c-51e1ab71c056,10/31/2011,13,LV,leucovorin,,,
clinicalPharmacology,e518dfc6-7e93-4fee-a66c-51e1ab71c056,10/31/2011,13,5-FU,5-fluorouracil,,,
clinicalPharmacology,e518dfc6-7e93-4fee-a66c-51e1ab71c056,10/31/2011,13,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,6ebf24fd-41cd-4b3c-8176-a1436253ba2d,2/9/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a89d439e-7ac5-48e4-b0a7-688518458611,9/8/2010,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,1979fd2a-7e2b-4d9a-9286-1066a0da944c,8/19/2010,3,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,1979fd2a-7e2b-4d9a-9286-1066a0da944c,8/19/2010,3,MI,myocardial infarction,,,
clinicalPharmacology,5cf93bc5-9e4c-4734-bc02-c7d0ac071022,6/24/2011,4,HTM,Haemophilus Test Media,,,
clinicalPharmacology,4b0c8bda-2ee3-4e57-8637-aef38410ef21,2/17/2012,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,4b0c8bda-2ee3-4e57-8637-aef38410ef21,2/17/2012,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,4b0c8bda-2ee3-4e57-8637-aef38410ef21,2/17/2012,1,ITT,intention-to-treat,,,
clinicalPharmacology,4b0c8bda-2ee3-4e57-8637-aef38410ef21,2/17/2012,1,SBP,systolic blood pressure,,,
clinicalPharmacology,4b0c8bda-2ee3-4e57-8637-aef38410ef21,2/17/2012,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,aae18c5d-5d4b-4fe2-930b-dbc58dc59665,4/25/2012,4,TSO,to sleep onset,,,
clinicalPharmacology,aae18c5d-5d4b-4fe2-930b-dbc58dc59665,4/25/2012,4,i.e.,its active metabolites,,,
clinicalPharmacology,aae18c5d-5d4b-4fe2-930b-dbc58dc59665,4/25/2012,4,LPS,latency to persistent sleep,,,
clinicalPharmacology,d9a049bd-2161-4a9b-8f6d-0c7d2bfdb0ed,3/10/2010,1,MIC,minimal  inhibitory concentration,,,
clinicalPharmacology,82a362e8-65e7-4270-b11c-2be167618964,5/20/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,476e704c-95ae-4591-94f7-ee4ab827ff13,2/23/2007,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,9a2b64bb-011a-4b23-b097-7dce576c57f8,10/12/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,9a2b64bb-011a-4b23-b097-7dce576c57f8,10/12/2011,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,b073b082-7b57-4423-8c06-4fd4263d6f84,9/10/2010,4,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,3391de8b-7bc9-4624-a5c4-836135b39d99,5/12/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,189d8bed-8a53-4126-9409-41ef48678dc9,5/5/2010,1,Tmax,to reach maximum verapamil concentrations,,,
clinicalPharmacology,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,ab047628-67d0-4a64-8d77-36b054969b44,6/6/2011,1,IV,intravenous,,,
clinicalPharmacology,ab047628-67d0-4a64-8d77-36b054969b44,6/6/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,11d14362-8f69-4c30-b487-5d05f6462bd7,5/7/2012,4,3HQ,3–hydroxy–quinidine,,,
clinicalPharmacology,496e258d-a5fd-42da-9a86-73afc8be359b,11/8/2011,3,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,496e258d-a5fd-42da-9a86-73afc8be359b,11/8/2011,3,LES,lower esophageal sphincter,,,
clinicalPharmacology,fb120098-b007-4a33-80b8-b7279c7668ee,8/31/2011,4,EM,extensive metabolizers,,,
clinicalPharmacology,fb120098-b007-4a33-80b8-b7279c7668ee,8/31/2011,4,PM,poor metabolizers,,,
clinicalPharmacology,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,NE,neuroendocrine,,,
clinicalPharmacology,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,PPI,pump inhibitor,,,
clinicalPharmacology,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,EE,erosive esophagitis,,,
clinicalPharmacology,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,93ec1327-22b1-4a5d-a793-e014f6dffd33,2/28/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,93ec1327-22b1-4a5d-a793-e014f6dffd33,2/28/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,93ec1327-22b1-4a5d-a793-e014f6dffd33,2/28/2012,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,93ec1327-22b1-4a5d-a793-e014f6dffd33,2/28/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e,3/8/2012,1,DEA,N-desethylamiodarone,,,
clinicalPharmacology,304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e,3/8/2012,1,VT,ventricular tachycardia,,,
clinicalPharmacology,304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e,3/8/2012,1,VF,ventricular fibrillation,,,
clinicalPharmacology,42fcf2b5-3466-4493-8a47-c4675538ece3,1/14/2011,1,V/F,Volume of<br/>Distribution,,,
clinicalPharmacology,3231dc15-5ce2-cf61-7d1f-bd86704269ae,10/20/2011,6,ALL,acute lymphoblastic leukemia,,,
clinicalPharmacology,3231dc15-5ce2-cf61-7d1f-bd86704269ae,10/20/2011,6,ALL,acute lymphocytic leukemia,,,
clinicalPharmacology,3231dc15-5ce2-cf61-7d1f-bd86704269ae,10/20/2011,6,CV%,coefficients of variation,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,OADC,oleic acid-albumin dextrose-catalase,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,bcf04f49-8d0b-4563-9d0f-93939cdf6a6c,7/6/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,42C69D40-E716-4347-9351-F8D8E1E65085,11/28/2006,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,c8806b45-493a-4373-bce7-736e97f9f876,4/4/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,c8806b45-493a-4373-bce7-736e97f9f876,4/4/2011,1,i.e.,improvement,,,
clinicalPharmacology,c8806b45-493a-4373-bce7-736e97f9f876,4/4/2011,1,TID,three divided doses,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,UGT,UDP-glucuronosyltransferase,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,M6G,morphine-6-glucuronide,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,TSH,Thyroid stimulating  hormone,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,M3G,morphine-3-glucuronide,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,C6G,codeine-6-glucuronide,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,GH,growth hormone,,,
clinicalPharmacology,f317cd06-2851-4a52-86d3-6efde3a4c243,10/22/2009,1,LH,luteinizing hormone,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,IMT,intimalmedial thickness,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,QCA,quantitative coronary angiography,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,RR,risk reductions,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,AUC,area under the curve,,,
clinicalPharmacology,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,CCAIT,Canadian Coronary Atherosclerosis Intervention Trial,,,
clinicalPharmacology,8c9f9094-e043-4762-9cd5-90c859e09668,4/20/2010,5,BALs,Bronchoalveolar lavages,,,
clinicalPharmacology,8c9f9094-e043-4762-9cd5-90c859e09668,4/20/2010,5,ELF,epithelial lining fluid,,,
clinicalPharmacology,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,HETEs,hydroxyeicosatetraenoic acids,,,
clinicalPharmacology,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,LTs,leukotrienes,,,
clinicalPharmacology,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,AA,arachidonic acid,,,
clinicalPharmacology,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,PG,prostaglandin,,,
clinicalPharmacology,748977db-fd10-46b8-a219-381ba34e55cd,5/28/2007,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,a66d2f97-8d22-482d-b18b-f58f1d882f42,5/7/2010,1,CYP450,Cytochrome P450,,,
clinicalPharmacology,73f92f9b-3715-4699-ba60-1ffecd677e23,3/22/2012,5,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,d3620ebe-87e1-4a93-96cc-ff20ddbb30b2,12/13/2011,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,6f9d59e3-d10d-48f3-af01-83ba3e1e3a2b,11/30/2011,3,NET,norethindrone,,,
clinicalPharmacology,6f9d59e3-d10d-48f3-af01-83ba3e1e3a2b,11/30/2011,3,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,6f9d59e3-d10d-48f3-af01-83ba3e1e3a2b,11/30/2011,3,EE,ethinyl estradiol,,,
clinicalPharmacology,93374337-1499-4225-9585-3b3d20371d84,5/22/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,d9db2fd3-a668-4d37-9082-18f6ceb8c3cb,2/2/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,d9db2fd3-a668-4d37-9082-18f6ceb8c3cb,2/2/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,dd332944-d610-4338-9e5e-9b2e5e90e399,1/22/2010,1,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,dd332944-d610-4338-9e5e-9b2e5e90e399,1/22/2010,1,MA,megestrol acetate,,,
clinicalPharmacology,dd332944-d610-4338-9e5e-9b2e5e90e399,1/22/2010,1,AUC,area under the concentration  time-curve,,,
clinicalPharmacology,5fbef611-39db-4a8e-8f46-090c95a27042,7/1/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,CE,conjugated estrogens,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,WHI,Women’s Health Initiative,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,ESRD,end stage renal disease,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,PE,pulmonary embolism,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,CHD,coronary heart disease,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,e7e6da3b-8485-1382-61c9-e9b369018b98,9/1/2009,3,BMD,bone mineral density,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,CPS,complex partial seizures,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,i.e.,improvement,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,TID,three divided doses,,,
clinicalPharmacology,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,4d7cf836-d115-456c-a636-6f05eae043cd,4/4/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,98C0C097-C253-4CC2-939E-6C172752D394,6/7/2006,1,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,98C0C097-C253-4CC2-939E-6C172752D394,6/7/2006,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,7D8688B0-BB99-45f6-A4E4-DE0236E5E22B,8/15/2006,1,July,J: Urology 10:23-24,,,
clinicalPharmacology,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,1b5826d4-5177-42b9-8ac2-d35071b4bccb,7/24/2006,1,GX,glycine xylidide,,,
clinicalPharmacology,1b5826d4-5177-42b9-8ac2-d35071b4bccb,7/24/2006,1,MEGX,mono-ethylglyciniexylidide,,,
clinicalPharmacology,676f6a52-8d82-4289-ae35-28eb4fbbc184,1/10/2012,2,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,676f6a52-8d82-4289-ae35-28eb4fbbc184,1/10/2012,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,5878bfaf-66b2-4a78-b6b0-f6405d44ebef,4/22/2011,2,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,5878bfaf-66b2-4a78-b6b0-f6405d44ebef,4/22/2011,2,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,24f6a14a-a3e8-2096-11a3-c0cc8d67bb78,12/23/2008,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,24f6a14a-a3e8-2096-11a3-c0cc8d67bb78,12/23/2008,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,563e576e-6966-4f8d-91bb-0a1a951de324,4/30/2007,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,563e576e-6966-4f8d-91bb-0a1a951de324,4/30/2007,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,563e576e-6966-4f8d-91bb-0a1a951de324,4/30/2007,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,563e576e-6966-4f8d-91bb-0a1a951de324,4/30/2007,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,a01def95-c0ef-43b9-bd9e-5565b2385ad3,7/12/2012,3,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
clinicalPharmacology,a01def95-c0ef-43b9-bd9e-5565b2385ad3,7/12/2012,3,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,a01def95-c0ef-43b9-bd9e-5565b2385ad3,7/12/2012,3,mmHg,maximal change in baseline in systolic blood pressure,,,
clinicalPharmacology,a01def95-c0ef-43b9-bd9e-5565b2385ad3,7/12/2012,3,mmHg,maximal change from baseline in systolic blood pressure,,,
clinicalPharmacology,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,VLDL,very-low-density lipoproteins,,,
clinicalPharmacology,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,IDL,intermediate-density lipoproteins,,,
clinicalPharmacology,98e9274c-c02e-44d9-8cc5-17536ef03a77,1/28/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,46f36a92-9049-45b8-acee-2b491fd38683,11/9/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bcfc31a1-b604-4cd1-a9e0-681e60d4cd2e,4/18/2012,5,TK,thymidine kinase,,,
clinicalPharmacology,bcfc31a1-b604-4cd1-a9e0-681e60d4cd2e,4/18/2012,5,HSV-1,HSV types 1,,,
clinicalPharmacology,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,ATP,adenosine triphosphate,,,
clinicalPharmacology,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,FEV1,forced expiratory volume in 1 second,,,
clinicalPharmacology,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,MMEF,maximum midexpiratory flow rate,,,
clinicalPharmacology,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,cyclic AMP,cyclic-3',5'- adenosine monophosphate,,
clinicalPharmacology,A4FD2D68-019F-4C89-8923-4E61262F6EEE,8/30/2006,1,AUC,area-under-the plasma-concentration curve,,,
clinicalPharmacology,A4FD2D68-019F-4C89-8923-4E61262F6EEE,8/30/2006,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,49fd02f8-12b8-460c-ae1f-f26738d86998,6/21/2007,2,Vc,volumes of distribution centrally,,,
clinicalPharmacology,49fd02f8-12b8-460c-ae1f-f26738d86998,6/21/2007,2,IM,intra-muscularly,,,
clinicalPharmacology,49fd02f8-12b8-460c-ae1f-f26738d86998,6/21/2007,2,ESRD,end-stage renal                                             disease,,,
clinicalPharmacology,49fd02f8-12b8-460c-ae1f-f26738d86998,6/21/2007,2,SC,subcutaneously,,,
clinicalPharmacology,357e0e6b-cfbd-454c-82d7-cfc460dc0d68,8/23/2010,1,KCS,Keratoconjunctivitis sicca,,,
clinicalPharmacology,b630824c-bee7-4a78-9349-d995c1eb0f16,3/12/2009,1,PRA,plasma renin activity,,,
clinicalPharmacology,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,NO,nitric oxide,,,
clinicalPharmacology,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,T½?,the nitroglycerin,,,
clinicalPharmacology,0a99a222-580b-4d80-8aaf-1c74d9a6caab,10/26/2009,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,15b91de7-1954-4055-aef6-fb57d8568a80,7/12/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,15b91de7-1954-4055-aef6-fb57d8568a80,7/12/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,MN,mononuclear,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,Drugs,Drug Interactions.,,,
clinicalPharmacology,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,PMN,polymorphonuclear,,,
clinicalPharmacology,bcd26183-313e-e4e1-092b-49b35b12863f,8/31/2009,10,mcg/mL,"underline"">Microorganism</content>                                                 </content>                                              </td>                                              <td align=""center"">                                                 <content styleCode=""bold"">                                                    <content styleCode=""bold underline"">MIC",,,
clinicalPharmacology,bcd26183-313e-e4e1-092b-49b35b12863f,8/31/2009,10,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,bcd26183-313e-e4e1-092b-49b35b12863f,8/31/2009,10,PBP3,penicillin binding protein 3,,,
clinicalPharmacology,542c7f49-abdc-4937-bca2-f51c553c5286,9/16/2008,2,V/F,volume of distribution,,,
clinicalPharmacology,407d9920-7110-4299-b0fa-36661070f076,11/7/1984,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,3e48217f-8175-4e9b-9fd0-909be4bbba95,11/3/2010,2,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,5f6565b7-3d3e-4f5b-bf92-8d9f8002a36a,3/1/2011,4,GU,gastric ulcer,,,
clinicalPharmacology,5f6565b7-3d3e-4f5b-bf92-8d9f8002a36a,3/1/2011,4,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,fcbea233-0aa2-462e-9254-7c970936e44c,6/23/2010,5,NET,norethindrone,,,
clinicalPharmacology,fcbea233-0aa2-462e-9254-7c970936e44c,6/23/2010,5,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,fcbea233-0aa2-462e-9254-7c970936e44c,6/23/2010,5,EE,ethinyl estradiol,,,
clinicalPharmacology,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,ECG,electrocardiogram,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,MN,mononuclear,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,76f677b5-48f0-4fda-90c5-34756d7ea87b,7/1/2010,1,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,76f677b5-48f0-4fda-90c5-34756d7ea87b,7/1/2010,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,13fb5b4c-e9c3-a92d-94bc-a3c6c55812cd,8/26/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,8E6E1AEA-D1C9-F6BF-2A8C-0504437BE95C,2/12/2009,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,8E6E1AEA-D1C9-F6BF-2A8C-0504437BE95C,2/12/2009,1,V/F,volume of distribution,,,
clinicalPharmacology,af653650-1825-475d-af3a-fe4d03e552fd,3/8/2012,5,IV,intravenous,,,
clinicalPharmacology,ac5d715d-6b6e-40d5-a5df-e3b884c3ef84,6/1/2012,2,AF,Atrial Fibrillation,,,
clinicalPharmacology,ac5d715d-6b6e-40d5-a5df-e3b884c3ef84,6/1/2012,2,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,MAO,monoamine oxidase,,,
clinicalPharmacology,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,d58c0b66-475f-46b3-949d-cda5343e7239,12/10/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d58c0b66-475f-46b3-949d-cda5343e7239,12/10/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d58c0b66-475f-46b3-949d-cda5343e7239,12/10/2009,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d58c0b66-475f-46b3-949d-cda5343e7239,12/10/2009,1,CYP,cytochrome P450,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,MN,mononuclear,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,ND,NDMinor Bleedingd391031333.21a,,,
clinicalPharmacology,430c343b-bad6-4584-8c63-05bca0b203a2,6/2/2008,2,mL/kg,meglumine/kg,,,
clinicalPharmacology,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,CI,confidence intervals,,,
clinicalPharmacology,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,GST,glutathione S-transferase,,,
clinicalPharmacology,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,CL,clearance,,,
clinicalPharmacology,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,PPK,population pharmacokinetic,,,
clinicalPharmacology,929126e0-302f-47a5-b1a9-3474ff9befc7,1/27/2012,3,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,7ab30afe-4de2-4fe5-9e62-a484683fb93f,7/21/2011,1,GX,glycinexylidide,,,
clinicalPharmacology,7ab30afe-4de2-4fe5-9e62-a484683fb93f,7/21/2011,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,70c96b78-3702-4216-819f-1071770494bf,4/12/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,E177C228-33E1-4074-3E98-7D484C370E58,10/31/2007,4,CL,clearance,,,
clinicalPharmacology,e4e9610a-765b-4237-a598-0f4b27a4553e,6/1/2010,1,min,median,,,
clinicalPharmacology,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01,6/19/2012,10,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,IV,intravenous,,,
clinicalPharmacology,1e99efc7-cf3f-4368-7afb-41d8dfaeffcf,1/13/2011,6,i.e.,improvement from baseline,,,
clinicalPharmacology,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,KGF,Keratinocyte growth factor,,,
clinicalPharmacology,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,CL,clearance,,,
clinicalPharmacology,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,FGF,fibroblast growth factor,,,
clinicalPharmacology,b9111a81-07c4-4458-b994-a4ad504986d8,6/10/2010,3,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,b9111a81-07c4-4458-b994-a4ad504986d8,6/10/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b9111a81-07c4-4458-b994-a4ad504986d8,6/10/2010,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,ER,estrogen receptor,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,CI,confidence interval,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,RR,relative risk,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DMBA,dimethylbenzanthracene,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,RMT,Royal Marsden Trial,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,EBCTCG,Early Breast Cancer Trialists' Collaborative Group,,,
clinicalPharmacology,b5e516a0-d0f4-4613-ab56-b1bb440fcb78,5/8/2012,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,9af7a792-d38a-4b2a-b5d6-855d2183b029,9/4/2009,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,RA,rheumatoid arthritis,,,
clinicalPharmacology,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,Tmax,to maximum concentration,,,
clinicalPharmacology,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,INR,International Normalized Ratio,,,
clinicalPharmacology,4e4d8017-9c1d-41eb-affb-8046e3548be9,4/5/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,ebddb745-81f9-4b25-8739-b2886032ed26,7/28/2009,1,QTc,QT correction,,,
clinicalPharmacology,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,CGI,Clinical Global Impressions,,,
clinicalPharmacology,1153e9d4-e621-4c08-914a-69f0f8691824,6/6/2011,2,IV,intravenous,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,NE,neuroendocrine,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,EE,erosive esophagitis,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,b341ddf9-a539-4e29-b72c-e8f5cc247172,1/21/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,LDL,low density lipoprotein,,,
clinicalPharmacology,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,VLDL,very low density lipoprotein,,,
clinicalPharmacology,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,TG,triglyceride,,,
clinicalPharmacology,42ae28da-a613-4db4-b471-efa4e2638dc8,1/28/2009,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,41aa6cd8-2243-4c7a-aa91-12424c29717b,4/9/2012,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,2ed81194-be24-45a0-8dde-fbc6ad3d7abe,4/19/2012,4,i.e.,its active metabolites,,,
clinicalPharmacology,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,Y-BOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,41a61cf1-30a3-472b-a592-b17a610daaba,9/21/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,QCA,quantitative coronary angiography,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,RR,risk reductions,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,AUC,area under the curve,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,TG,triglycerides,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,IMT,intimal-medial thickness,,,
clinicalPharmacology,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,CCAIT,Canadian Coronary Atherosclerosis Intervention Trial,,,
clinicalPharmacology,e2c1bea3-3c6d-4fe9-9bfd-09dbbce0fd7c,3/7/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,302a6fd7-ed02-4be6-a35f-35e1d648165b,1/10/2011,1,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,302a6fd7-ed02-4be6-a35f-35e1d648165b,1/10/2011,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,84dba679-a118-47c1-8c44-7a3a1e1ed725,7/28/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,9ea9486c-822a-a38b-7eed-8d3740ee502b,8/9/2011,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a8126e6d-33f3-4357-92de-f921d4e8f26f,3/5/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,38f42bad-6b2a-423d-af66-0e526ba03da1,4/28/2010,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,38f42bad-6b2a-423d-af66-0e526ba03da1,4/28/2010,1,ETEC,enterotoxigenic  strains of Escherichia coli,,,
clinicalPharmacology,202b1a2a-11dc-4c3d-aa53-27512a98a042,12/27/2010,1,NET,norethindrone,,,
clinicalPharmacology,202b1a2a-11dc-4c3d-aa53-27512a98a042,12/27/2010,1,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,202b1a2a-11dc-4c3d-aa53-27512a98a042,12/27/2010,1,EE,ethinyl estradiol,,,
clinicalPharmacology,9b73979c-c95a-4433-0a9d-f9cea3cb557f,3/5/2012,11,IM,intramuscular,,,
clinicalPharmacology,8379f1db-4255-4285-abd3-8ecdcaf03372,11/22/2010,6,AKs,actinic keratoses,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,ISH,isolated systolic hypertension,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,DBP,diastolic blood pressure,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,ITT,intention-to-treat,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,ESRD,end-stage renal disease,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,CVD,cardiovascular disease,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,SBP,systolic blood pressure,,,
clinicalPharmacology,5ac32c20-169d-475a-fc8a-934f758d6ab0,11/21/2011,15,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,B5C93AB1-317E-4F99-9EC5-E47B30FAF650,4/9/2009,1,TRH,Thyrotropin-releasing hormone,,,
clinicalPharmacology,e99d91ef-e189-4556-9343-5c8c9e1b6e1a,5/30/2012,3823,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,e08bcb41-21de-462e-b8f1-1c3968d97356,5/24/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a0f5c480-7ada-4593-83c4-4cf15eaabd7d,3/4/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0826c44b-2955-45c4-aae2-3f08fdb3486e,1/18/2012,6,GER,gastroesophageal reflux,,,
clinicalPharmacology,0826c44b-2955-45c4-aae2-3f08fdb3486e,1/18/2012,6,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,10124262-e443-49a5-a1cc-8cc34c74d953,11/29/2010,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,10124262-e443-49a5-a1cc-8cc34c74d953,11/29/2010,1,mCPP,m-chlorophenylpiperazine,,,
clinicalPharmacology,ab1dbe70-696f-4ff9-a0c7-7406bff590ae,12/21/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,53df951b-2eee-44b1-bae2-df7ed85bc0ed,8/4/2011,16,HTM,Haemophilus Test Media,,,
clinicalPharmacology,73f4a334-66d7-4e06-82f1-562bd7cb601a,1/7/2010,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,73f4a334-66d7-4e06-82f1-562bd7cb601a,1/7/2010,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,a3a7d398-59a7-468b-b05e-fb87e8311b32,5/11/2010,1,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,3614d085-c313-4ce8-8a70-888899b6406e,7/21/2011,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,3614d085-c313-4ce8-8a70-888899b6406e,7/21/2011,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
clinicalPharmacology,f7485b07-7ac0-44fe-a713-1e066c9043a8,3/22/2011,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,579fcb4d-1b2c-4a76-9ff7-0ee76ddd1041,9/23/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,D2,dopamine Type 2,,,
clinicalPharmacology,4654adbd-c107-4846-9ee6-13f314bc2798,6/6/2011,4,IV,intravenous,,,
clinicalPharmacology,447aaf48-3bea-4047-8032-a3c878576093,12/21/2010,12,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,447aaf48-3bea-4047-8032-a3c878576093,12/21/2010,12,MN,mononuclear,,,
clinicalPharmacology,447aaf48-3bea-4047-8032-a3c878576093,12/21/2010,12,PMN,polymorphonuclear,,,
clinicalPharmacology,e358437f-7c6b-4e49-957d-d7f5b8f4b8f5,9/7/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e38c7741-6d25-46d7-aeee-c14f7ee7aac3,11/29/2010,3,GX,glycinexylidide,,,
clinicalPharmacology,e38c7741-6d25-46d7-aeee-c14f7ee7aac3,11/29/2010,3,tmax,to reach maximum concentration,,,
clinicalPharmacology,e38c7741-6d25-46d7-aeee-c14f7ee7aac3,11/29/2010,3,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,e38c7741-6d25-46d7-aeee-c14f7ee7aac3,11/29/2010,3,PK,pharmacokinetic,,,
clinicalPharmacology,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,20cc66c0-a00b-4643-9819-6e0daed51e5f,4/14/2011,1,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,20cc66c0-a00b-4643-9819-6e0daed51e5f,4/14/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,8c5a4a2a-234e-4702-9ba0-844ea86ec8b9,4/10/2012,2,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalPharmacology,8c5a4a2a-234e-4702-9ba0-844ea86ec8b9,4/10/2012,2,ESRD,end-stage renal disease,,,
clinicalPharmacology,1D7E21F7-00C1-4737-B663-C240BADCC206,6/20/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,2a97ef74-b338-4655-a60b-923f86720179,10/23/2009,2,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,d19c57bd-56f8-4640-b891-18f9c365e372,4/23/2012,6,RT,reverse transcriptase,,,
clinicalPharmacology,d19c57bd-56f8-4640-b891-18f9c365e372,4/23/2012,6,CI,confidence interval,,,
clinicalPharmacology,2bfb390f-ba99-4d21-8a9e-50fa8ec217c0,5/16/2011,1,PPAA,?-phenyl-piperidine acetic acid,,,
clinicalPharmacology,2bfb390f-ba99-4d21-8a9e-50fa8ec217c0,5/16/2011,1,MPH,methylphenidate,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,ISH,isolated systolic hypertension,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,DBP,diastolic blood pressure,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,ITT,intention-to-treat,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,ESRD,end-stage renal disease,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,CVD,cardiovascular disease,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,SBP,systolic blood pressure,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,e4886adf-199d-4b19-a4ef-75f8f94cb54e,10/19/2011,4,NET,norethindrone,,,
clinicalPharmacology,e4886adf-199d-4b19-a4ef-75f8f94cb54e,10/19/2011,4,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,e4886adf-199d-4b19-a4ef-75f8f94cb54e,10/19/2011,4,EE,ethinyl estradiol,,,
clinicalPharmacology,97a9dfe0-4c36-4733-aa06-c2cd2a1f1ca6,9/13/2011,1,TMP/SMX,trimethoprim/sulfamethoxazole,,,
clinicalPharmacology,97a9dfe0-4c36-4733-aa06-c2cd2a1f1ca6,9/13/2011,1,IV,intravenous,,,
clinicalPharmacology,6A105E44-B558-45C1-9C91-FE1F3DFC5BD5,3/30/2007,1,e.g.,ergotamine and macrolide antibiotics,,,
clinicalPharmacology,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,RARs,retinoic acid receptors,,,
clinicalPharmacology,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,RXR?,retinoid X                                     receptor subtypes,,,
clinicalPharmacology,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,CTCL,cutaneous T-cell lymphoma,,,
clinicalPharmacology,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,PPARs,peroxisome proliferator activator receptors,,,
clinicalPharmacology,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,CTCL,cutaneous T-cell                                     lymphoma,,,
clinicalPharmacology,3676af6a-198b-4453-b43a-039fb26817dd,2/16/2012,13,i.e.,improvement from baseline,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,CVP,central venous pressure,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,SVR,systemic vascular resistance,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,RAP,right atrial pressure,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,PVR,pulmonary vascular resistance,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,PCWP,pulmonary-capillary wedge pressure,,,
clinicalPharmacology,7ea5a071-6f92-4a8a-8e3f-72b74fb2810a,2/20/2012,3,PAP,pulmonary arterial pressure,,,
clinicalPharmacology,EB02166C-18F6-4BE0-F493-AC89D65DA759,5/30/2006,1,NCCLS,National Committee for Clinical Laboratory Standards,,,
clinicalPharmacology,EB02166C-18F6-4BE0-F493-AC89D65DA759,5/30/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,CNS,central nervous system,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,DCT,demethylcitalopram,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,DA,dopamine,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,NE,norepinephrine,,,
clinicalPharmacology,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,CT,citalopram ,,,
clinicalPharmacology,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,CYP450,cytochrome P450,,,
clinicalPharmacology,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,DEA,N-desethylamiodarone,,,
clinicalPharmacology,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,VT,ventricular tachycardia,,,
clinicalPharmacology,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,VF,ventricular fibrillation,,,
clinicalPharmacology,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,EM,extensive metabolizers,,,
clinicalPharmacology,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,Tmax,to maximum concentration,,,
clinicalPharmacology,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,PM,poor metabolizers,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,PT,prothrombin time,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,FPG,fasting plasma glucose,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,CL,clearance,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,Vd,volume of distribution,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,IV,intravenous,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,AUC,area under the curve,,,
clinicalPharmacology,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,FBG,fasting blood glucose,,,
clinicalPharmacology,6f598b07-62d9-4220-9378-830f3a9487ba,1/4/2012,3471,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,4c6791a0-e7ef-4645-a460-8f9a13f3d166,6/28/2010,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d6f37813-40bb-4fe8-99e2-ad2339b8e04a,1/9/2012,5,PRA,plasma renin  activity,,,
clinicalPharmacology,d6f37813-40bb-4fe8-99e2-ad2339b8e04a,1/9/2012,5,ACE,angiotensin  converting enzyme,,,
clinicalPharmacology,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a17e415e-a559-4a8d-a455-699184a01523,2/13/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a17e415e-a559-4a8d-a455-699184a01523,2/13/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a17e415e-a559-4a8d-a455-699184a01523,2/13/2012,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,a17e415e-a559-4a8d-a455-699184a01523,2/13/2012,3,CYP,cytochrome P450,,,
clinicalPharmacology,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,Tmax,to maximum concentration,,,
clinicalPharmacology,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,i.e.,its active metabolites,,,
clinicalPharmacology,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,30dadf97-4e8c-4630-b362-940313a8852e,9/4/2009,4,i.e.,its active  metabolites,,,
clinicalPharmacology,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,SD,"styleCode=""bold"">Mean",,,
clinicalPharmacology,08a35bfc-3945-4f95-948a-8af36cda715c,4/2/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,STH,somatotropic hormone,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,LH,luteinizing hormone,,,
clinicalPharmacology,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,PTZ,pentylenetetrazol,,,
clinicalPharmacology,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,GEPR,genetically epilepsy-prone rats,,,
clinicalPharmacology,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,e.g.,enzyme-inducing agents,,,
clinicalPharmacology,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,f8b0c917-3fdd-4a28-a47d-6225b8195458,8/9/2011,7,CL,clearance,,,
clinicalPharmacology,f8b0c917-3fdd-4a28-a47d-6225b8195458,8/9/2011,7,IV,intravenous,,,
clinicalPharmacology,f8b0c917-3fdd-4a28-a47d-6225b8195458,8/9/2011,7,Cmax,concentration of glimepiride or pioglitazone or peak exposure,,,
clinicalPharmacology,573eefd9-3f28-4053-a8ed-1fb531c38e15,5/31/2011,10,ITT,intent-to-treat,,,
clinicalPharmacology,573eefd9-3f28-4053-a8ed-1fb531c38e15,5/31/2011,10,RFS,relapse-free survival,,,
clinicalPharmacology,573eefd9-3f28-4053-a8ed-1fb531c38e15,5/31/2011,10,OS,overall survival,,,
clinicalPharmacology,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,LESP,lower  esophageal sphincter pressure,,,
clinicalPharmacology,22f41e83-b9fb-4c9e-8cc3-f457034191a8,2/10/2012,10,i.e.,dose-independent,,,
clinicalPharmacology,d63a086a-32e2-49e2-949e-64e4c922775a,5/18/2010,5,ADHD,Attention Deficit  Hyperactivity Disorder,,,
clinicalPharmacology,b8fdcb32-b571-43b4-91e9-b4e9f75d86ae,2/28/2011,6,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,ITT,intention-to-treat,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,CVD,cardiovascular disease,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,SBP,systolic blood pressure,,,
clinicalPharmacology,a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d,10/4/2010,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,269fa5f9-974e-4cea-8f6b-a2913a6dc1cb,3/22/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,33bc102c-31a3-4fd9-9702-c1193d7699a3,10/27/2009,2,MA,megestrol acetate,,,
clinicalPharmacology,33bc102c-31a3-4fd9-9702-c1193d7699a3,10/27/2009,2,lb.,<td>Lean Body Mass,,,
clinicalPharmacology,cdd50dc7-f712-4248-b0e3-ba247cf08cee,8/22/2011,10,DEA,N-desethylamiodarone,,,
clinicalPharmacology,cdd50dc7-f712-4248-b0e3-ba247cf08cee,8/22/2011,10,VT,ventricular tachycardia,,,
clinicalPharmacology,cdd50dc7-f712-4248-b0e3-ba247cf08cee,8/22/2011,10,VF,ventricular fibrillation,,,
clinicalPharmacology,f5c2fe10-c61f-4cbe-bc45-7ab14baa691c,12/31/2008,1,IPPB,intermittent positive-pressure breathing,,,
clinicalPharmacology,f5c2fe10-c61f-4cbe-bc45-7ab14baa691c,12/31/2008,1,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,f5c2fe10-c61f-4cbe-bc45-7ab14baa691c,12/31/2008,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,CYP450,cytochrome P450,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,AV,atrioventricular,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,VT,ventricular tachycardia,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,SCL,sinus cycle length,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,DEA,.N-desethylamiodarone,,,
clinicalPharmacology,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,VF,ventricular fibrillation,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,i.e.,improvement from baseline,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,SMAP,2-sulfamoylacetyl phenol,,,
clinicalPharmacology,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,RBC,red blood cells,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHI,Women’s Health Initiative,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CE/MPA,conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,PE,pulmonary embolism,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CHD,coronary heart disease,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CE,conjugated equine estrogens,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
clinicalPharmacology,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,i.e.,improvement from baseline,,,
clinicalPharmacology,6f650345-0bca-4fe9-96eb-4d7ac80928ec,7/21/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d4ff7c80-f38f-484e-8c95-2fb322500530,2/1/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,d4ff7c80-f38f-484e-8c95-2fb322500530,2/1/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,AUC,area under the curve,,,
clinicalPharmacology,a697e731-8d19-4845-8f31-16c4b19bb338,10/27/2009,2,V/F,volume of distribution,,,
clinicalPharmacology,98d84849-4796-4483-9fe7-bf617fcd555f,1/10/2012,2,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,98d84849-4796-4483-9fe7-bf617fcd555f,1/10/2012,2,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,bae70c53-6ef4-4d0e-afd5-7d6c20a952ef,5/10/2011,3,CNS,central nervous system,,,
clinicalPharmacology,0f342e3a-189f-41ec-9583-1733d2437ad2,10/24/2011,13,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,596c7a8f-27cd-4de2-9491-476f43570b8b,5/17/2007,1,A-V,atrioventricular,,,
clinicalPharmacology,596c7a8f-27cd-4de2-9491-476f43570b8b,5/17/2007,1,e.g.,effector organ,,,
clinicalPharmacology,740e054b-faac-7c27-f06d-a56efb699355,1/26/2012,5,ESRD,end-stage renal disease,,,
clinicalPharmacology,fda80325-8082-4222-8b17-bcd9f38011e6,6/1/2011,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,fda80325-8082-4222-8b17-bcd9f38011e6,6/1/2011,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,CNS,central nervous system,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,DCT,demethylcitalopram,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,CT,citalopram,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,DA,dopamine,,,
clinicalPharmacology,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,NE,norepinephrine,,,
clinicalPharmacology,BBDAF2F2-14E6-45C4-B807-5B22955444B0,9/9/2008,1,AD,Alzheimer's disease,,,
clinicalPharmacology,BBDAF2F2-14E6-45C4-B807-5B22955444B0,9/9/2008,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,570e7625-d5ee-4502-b0d8-76c547cf5ed7,3/12/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,STH,somatotropic hormone,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,ie,its active metabolites,,,
clinicalPharmacology,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,EDRF,endothelium-derived relaxing factor,,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,ADP,adenosine diphosphate,,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,PDE,phosphodiesterase,,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,PAF,platelet activating factor,,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,cGMP-PDE,cyclic-3',5'-guanosine monophosphate-PDE,,
clinicalPharmacology,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,cAMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,f484218e-4265-7a3f-fda0-07e9c6f24dd5,4/27/2011,1,i.e.,improvement from baseline,,,
clinicalPharmacology,dbe07049-223d-4e54-b1ab-5b57bb9ad8ae,5/16/2011,9,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,b3eee508-8bf3-4bd3-9a71-47ee6ea87f95,3/2/2012,2,GX,glycinexylidide,,,
clinicalPharmacology,b3eee508-8bf3-4bd3-9a71-47ee6ea87f95,3/2/2012,2,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,24e1525f-a347-4745-b577-5dad60ef9f45,7/14/2010,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,IV,intravenous,,,
clinicalPharmacology,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,MAC,monitored anesthesia care,,,
clinicalPharmacology,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,PPI,pump inhibitors,,,
clinicalPharmacology,d6a81f9f-3a51-4e86-aeb3-8352186b3528,11/20/2008,3,ETT,Exercise Tolerance Test,,,
clinicalPharmacology,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,MMEF,maximal midexpiratory flow rate,,,
clinicalPharmacology,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,a1c53a0c-78b0-4c6e-b2bc-0ee90cbe9e73,8/30/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,IV,intravenous,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,ie,its active metabolites,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,TSO,to sleep onset,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,CYP,cytochrome P450,,,
clinicalPharmacology,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,LPS,latency to persistent sleep,,,
clinicalPharmacology,a9fef8f6-b823-4b8a-84b8-2b916374adb5,12/17/2009,1,IV,intravenous,,,
clinicalPharmacology,72ddd1c9-ddbd-4c95-acd9-003189a353a3,10/23/2006,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
clinicalPharmacology,67cb9ea4-5adb-4a3a-9568-266b6f472078,9/7/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,01655AF6-E754-49B5-B130-DD2416A7CF1C,3/28/2008,1,PRA,plasma renin activity,,,
clinicalPharmacology,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,f235ee45-9517-45de-8df7-9a06fdb43380,6/3/2011,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,1ec7ef4d-8ea8-4189-b1ac-b8ac57d7ebe2,5/9/2012,2,min,median,,,
clinicalPharmacology,0f30f885-d0cd-4fa6-a8e0-142f08a56792,2/28/2012,1,LAAM,levo-alpha-acetyl-methadol,,,
clinicalPharmacology,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,CYP3A4,cytochrome P450 3A4 enzyme,,,
clinicalPharmacology,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,PES,programmed electrical stimulation,,,
clinicalPharmacology,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,LVEF,left ventricular ejection fraction,,,
clinicalPharmacology,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,NET,norethindrone,,,
clinicalPharmacology,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,EE,ethinyl estradiol,,,
clinicalPharmacology,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,CBZ,ConcentrationPhenytoinNC or 25% increasea48% decreaseCarbamazepine,,,
clinicalPharmacology,08f9eb0a-3797-49f6-90e4-9b8732bfc63f,12/1/2009,3,ADHD,Attention Deficit  Hyperactivity Disorder,,,
clinicalPharmacology,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,MAO,monoamine oxidase,,,
clinicalPharmacology,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,066f4be0-054c-4b34-aa0d-941ddc529610,4/9/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,066f4be0-054c-4b34-aa0d-941ddc529610,4/9/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,066f4be0-054c-4b34-aa0d-941ddc529610,4/9/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,ULN,upper limit of normal,,,
clinicalPharmacology,4A423BBA-3BC1-4323-ABBB-EF6C5C315784,11/17/2006,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,26b65fec-9a5d-4b9b-9b87-c3d328c58cd0,7/30/2009,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,7bb07118-4b39-4b0b-914a-a4675f732c11,9/2/2009,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,7bb07118-4b39-4b0b-914a-a4675f732c11,9/2/2009,2,MN,mononuclear,,,
clinicalPharmacology,7bb07118-4b39-4b0b-914a-a4675f732c11,9/2/2009,2,PMN,polymorphonuclear,,,
clinicalPharmacology,f1991013-5fdf-4a5b-940a-0ae68a2462d1,12/21/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=23,"Botrule"">0.90<br/>(&#177;0.24)<br/>(n=23)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">24.1<br/>(&#177;12.1)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=11,"Botrule"">1.8<br/>(&#177;1.3)<br/>(n=11)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">11.5<br/>(&#177;6.8)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=129,"Botrule"">0.80<br/>(&#177;0.36)<br/>(n=129)</td>                                        <td styleCode=""Lrule Botrule"">24.5<br/>(&#177;9.5)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=20,"Botrule"">1.15<br/>(&#177;0.432)<br/>(n=20)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">13.1<br/>(&#177;6.76)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=27,"Botrule"">1.21<br/>(&#177;0.81)<br/>(n=27)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">13.5<br/>(&#177;8.18)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=31,"Botrule"">1.33<br/>(&#177;1.05)<br/>(n=31)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">10.7<br/>(&#177;4.83)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=31,"Botrule"">1.58<br/>(&#177;0.46)<br/>(n=31)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">12.0<br/>(&#177;3.82)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=25,"Botrule"">1.31<br/>(&#177;0.76)<br/>(n=25)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">8.16<br/>(&#177;4.50)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=52,"Botrule"">1.1<br/>(&#177;0.7)<br/>(n=52)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">20.0<br/>(&#177;9.4)<br/>",,,
clinicalPharmacology,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,n=22,"Botrule"">1.50<br/>(&#177;0.517)<br/>(n=22)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">17.0<br/>(&#177;12.7)<br/>",,,
clinicalPharmacology,b4509afc-539b-4d7f-97d4-5e9c98c2f65a,7/1/2011,1,PAD,peripheral arterial disease,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PTSD,posttraumatic stress disorder,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,GAD,generalized anxiety disorder,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PD,panic disorder,,,
clinicalPharmacology,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,BPH,BENIGN PROSTATIC HYPERPLASIA,,,
clinicalPharmacology,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,BPH,Benign prostatic hyperplasia,,,
clinicalPharmacology,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,D2,dopamine type 2,,,
clinicalPharmacology,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,Tmax,to maximum concentration,,,
clinicalPharmacology,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,CYP3A4/5,cytochrome P450 3A4/5,,,
clinicalPharmacology,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,BMI,body mass index,,,
clinicalPharmacology,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,P-gp,P-glycoprotein,,,
clinicalPharmacology,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,7cf101d0-6515-4474-b451-c58e119ad72c,7/10/2011,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,4bf994a4-6cc5-4941-8a81-6cf4c7ee235a,8/19/2010,359,LH,luteinizing  hormone,,,
clinicalPharmacology,4bf994a4-6cc5-4941-8a81-6cf4c7ee235a,8/19/2010,359,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,4bf994a4-6cc5-4941-8a81-6cf4c7ee235a,8/19/2010,359,GH,growth hormone,,,
clinicalPharmacology,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,4b9d7052-a54f-3ee1-ab0e-633b087f4802,4/18/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,4b9d7052-a54f-3ee1-ab0e-633b087f4802,4/18/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4b9d7052-a54f-3ee1-ab0e-633b087f4802,4/18/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6cef2a80-c7e5-44a2-92db-06082092bb35,12/10/2010,1,AUC,area under the curve,,,
clinicalPharmacology,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,CSF,cerebrospinal fluid,,,
clinicalPharmacology,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,PMNs,polymorphonuclear neutrophils,,,
clinicalPharmacology,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,CD15,cluster of differentiation 15,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,mcg/mL,MicroorganismsAntimicrobialMIC,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,mm,MicroorganismZone diameter,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,HTM,Haemophilus Testing Medium,,,
clinicalPharmacology,F0FC4960-8262-48E1-805C-DAE63FD045B0,3/27/2007,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
clinicalPharmacology,AE6C88E4-C6E6-4C5F-8248-F1D01D73DAB2,12/18/2008,2,BPH,:Benign prostatic hyperplasia,,,
clinicalPharmacology,AE6C88E4-C6E6-4C5F-8248-F1D01D73DAB2,12/18/2008,2,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,a637c1ac-78d1-4d44-9c79-b6da9a8f2fb9,2/25/2011,6,GER,gastroesophageal reflux,,,
clinicalPharmacology,a637c1ac-78d1-4d44-9c79-b6da9a8f2fb9,2/25/2011,6,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,6c587586-b966-49a8-913b-7fafbca2127a,5/7/2012,6,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,74ae4775-8190-4bab-93d0-0f209023f973,5/10/2010,1,GU,gastric ulcer,,,
clinicalPharmacology,74ae4775-8190-4bab-93d0-0f209023f973,5/10/2010,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,599dcdd0-df9b-41e2-a767-b1f44f466fbd,7/2/2012,26,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,b8004451-7b26-425b-b5ea-cbb1b08e30e3,6/1/2012,4,Met,Metformin Hydrochloride,,,
clinicalPharmacology,b8004451-7b26-425b-b5ea-cbb1b08e30e3,6/1/2012,4,Comb,Combined Metformin/Glyburide,,,
clinicalPharmacology,b8004451-7b26-425b-b5ea-cbb1b08e30e3,6/1/2012,4,Glyb,Glyburide,,,
clinicalPharmacology,9483c4be-f0c7-49ea-95d6-d4de6f79ef79,10/10/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,9483c4be-f0c7-49ea-95d6-d4de6f79ef79,10/10/2011,2,LES,lower esophageal sphincter,,,
clinicalPharmacology,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,128bb292-d174-4769-b3e6-9f16617f31e3,10/7/2011,12,HTM,Haemophilus Test Media,,,
clinicalPharmacology,cab63f24-8728-4927-aba5-53e8d2e44cdb,2/29/2012,5,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,1742C476-E7DD-4BC5-BF4B-9935612A96C9,2/22/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5d29dc3b-e19a-4924-8ad4-85018f0ab395,4/9/2012,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,5d29dc3b-e19a-4924-8ad4-85018f0ab395,4/9/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,b18eca1d-0133-4266-829b-9a0bd925c4f2,10/30/2009,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6ca166e5-8591-4eb1-b6dd-ade7f6f4c1bf,3/21/2008,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MAO,monoamine oxidase,,,
clinicalPharmacology,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,347c802f-4ea9-41d4-80d6-e4a183f22179,1/3/2011,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,dd11e4b9-7730-4d3a-81ca-16f15de09759,12/3/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,878f5bb7-1fda-4ac9-8190-c7e5571993e2,4/5/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,89226149-47fa-4f7d-bb1f-1aa7034486b8,12/9/2011,3,ddI,didanosine,,,
clinicalPharmacology,89226149-47fa-4f7d-bb1f-1aa7034486b8,12/9/2011,3,RT,reverse transcriptase,,,
clinicalPharmacology,89226149-47fa-4f7d-bb1f-1aa7034486b8,12/9/2011,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,19df63de-9f44-40ce-9a4f-0c96345b8a23,12/16/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b897c800-24a2-4e76-8668-498c5515c3d0,5/1/2008,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,931d5b4d-8749-4d00-bf51-2f5b42fd694c,7/11/2012,1,Cl-,chloride,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,CPS,complex partial seizures,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,AED,antiepilepsy drug,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,i.e.,improvement,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,TID,three divided doses,,,
clinicalPharmacology,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,MRS,Manic Rating Scale,,,
clinicalPharmacology,daa89601-3e7c-4d9e-9bed-fd6abf20348e,2/8/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d6ff6f94-5cb4-44c3-a9e5-65c1625e6a1f,4/23/2012,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,da057d69-00a3-4f65-8cc8-9f08042a95a2,12/15/2011,1,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,6adc5bb0-69a5-4c9f-b569-1eee446afcd2,5/3/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a61cf5cb-351d-4b31-b731-6154a27aeb56,1/13/2012,3,CI,confidence interval,,,
clinicalPharmacology,b58ec5f9-0715-4562-9aeb-915329a4eef8,9/14/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,cfd96e4b-fcf1-4959-aaf4-7aabe0d80ab5,11/13/2008,2,AUCs,areas under plasma concentration- time curves,,,
clinicalPharmacology,cfd96e4b-fcf1-4959-aaf4-7aabe0d80ab5,11/13/2008,2,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,6b2db776-4f30-4a17-a250-79654b86eca0,4/13/2011,2,TK,thymidine kinase,,,
clinicalPharmacology,6b2db776-4f30-4a17-a250-79654b86eca0,4/13/2011,2,HSV-1,HSV types 1,,,
clinicalPharmacology,13ca868d-a734-4c2f-88f0-ac1071ba7311,4/13/2010,1,ddI,didanosine,,,
clinicalPharmacology,13ca868d-a734-4c2f-88f0-ac1071ba7311,4/13/2010,1,RT,reverse transcriptase,,,
clinicalPharmacology,13ca868d-a734-4c2f-88f0-ac1071ba7311,4/13/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,Tmax,to maximum concentration,,,
clinicalPharmacology,801e4da1-5459-47d2-b67b-009f0a3247cc,6/3/2010,1,IV,intravenous,,,
clinicalPharmacology,801e4da1-5459-47d2-b67b-009f0a3247cc,6/3/2010,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,CNS,central nervous system,,,
clinicalPharmacology,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,adrenergic,and nasal passages.Pseudoephedrine: Pseudoephedrine acts as an indirect sympathomimetic agent by stimulating sympathetic,,,
clinicalPharmacology,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,DHT,5?-dihydrotestosterone,,,
clinicalPharmacology,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,LH,luteinizing hormone,,,
clinicalPharmacology,2f6bbff2-8855-4903-be12-11b9c8b9aae9,10/14/2011,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,89b6f044-fe14-4e38-b5ea-a3c525d29dd6,4/14/2010,1,ddI,didanosine,,,
clinicalPharmacology,89b6f044-fe14-4e38-b5ea-a3c525d29dd6,4/14/2010,1,RT,reverse transcriptase,,,
clinicalPharmacology,89b6f044-fe14-4e38-b5ea-a3c525d29dd6,4/14/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,LESP,lower esophageal sphincter pressure,,,
clinicalPharmacology,7332ea0c-a7ff-cca0-4c47-39c721b47edd,2/21/2011,4,AUC,area under the concentration-time curve,,,
clinicalPharmacology,24845e58-5bfe-4a74-beec-696a564fb68c,7/1/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,MN,mononuclear,,,
clinicalPharmacology,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,PMN,polymorphonuclear,,,
clinicalPharmacology,dd4944b6-9d6e-4180-bb68-c0516a27a379,8/31/2010,1,Cl-,chloride,,,
clinicalPharmacology,dd4944b6-9d6e-4180-bb68-c0516a27a379,8/31/2010,1,Cl-,Chloride,,,
clinicalPharmacology,6fe6fe2d-4405-4e7a-a2ed-5eb367d52842,4/12/2007,1,drying,Diphenhydramine hydrochloride is an antihistamine with anticholinergic,,,
clinicalPharmacology,6467d400-d373-4137-af06-568b98813c8e,8/13/2010,1,APTTs,activated partial thromboplastin  times,,,
clinicalPharmacology,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,D2,dopamine type 2,,,
clinicalPharmacology,d16d449a-a345-4b7c-8ab5-e18fb37dcb6a,1/17/2012,2,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,8e80f9d8-2577-4fd9-a455-e6c6dc244c3a,9/27/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ee98f923-8961-4f9f-8fa1-dcd934df89ac,6/9/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,ee98f923-8961-4f9f-8fa1-dcd934df89ac,6/9/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,CNS,central nervous system,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,DCT,demethylcitalopram,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,CT,citalopram,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,DA,dopamine,,,
clinicalPharmacology,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,NE,norepinephrine,,,
clinicalPharmacology,3c8fccb9-ebcf-4891-a1e5-e07a3fa30ae0,11/15/2011,3176,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,3c8fccb9-ebcf-4891-a1e5-e07a3fa30ae0,11/15/2011,3176,CYP3A,cytochrome  P450 3A,,,
clinicalPharmacology,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,IgG,immunoglobulin G,,,
clinicalPharmacology,30fbaf9e-01cf-492a-b44f-dc81c17d7647,8/9/2011,9,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,b2503fff-c978-4efa-b1b4-d7740b6b26f2,3/6/2012,7,MAOI,monoamine oxidase inhibitors,,,
clinicalPharmacology,b2503fff-c978-4efa-b1b4-d7740b6b26f2,3/6/2012,7,MAO,monoamine oxidase,,,
clinicalPharmacology,b2503fff-c978-4efa-b1b4-d7740b6b26f2,3/6/2012,7,IAA,indole acetic acid,,,
clinicalPharmacology,feaa5f6f-9753-4f37-ab81-04c9c6b45e6a,6/6/2011,1,IV,intravenous,,,
clinicalPharmacology,feaa5f6f-9753-4f37-ab81-04c9c6b45e6a,6/6/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,MN,mononuclear,,,
clinicalPharmacology,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,PMN,polymorphonuclear,,,
clinicalPharmacology,31b9b263-11fd-4495-83dd-ababf0d70e9e,10/30/2006,1,FVC,Forced Vital Capacity,,,
clinicalPharmacology,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,CNS,central nervous system,,,
clinicalPharmacology,c628d376-4b65-4f05-b6fa-eabb1d96a7df,7/30/2009,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,f41d8abd-7792-4918-1b93-bd83ea01955e,4/16/2012,15,PBPs,penicillin binding proteins,,,
clinicalPharmacology,0a5ce8f7-2f8e-4944-7692-5a1c549f451a,10/12/2010,6,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,2ac09b93-d769-4f04-af3c-b0f3ce0bd991,5/6/2011,4,topiramate,to 4250 mg DivalproexSodium Delayed-Release TabletsConcomitant antiepilepsy drugs,,,
clinicalPharmacology,5b3201f8-fa99-41bf-84c1-4e9355a58ce6,5/16/2012,4,IV,intravenous,,,
clinicalPharmacology,3fed77ce-ad29-48e2-a28b-6d1501d0b090,2/8/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,3fed77ce-ad29-48e2-a28b-6d1501d0b090,2/8/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,3fed77ce-ad29-48e2-a28b-6d1501d0b090,2/8/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,RDS,Respiratory Distress Syndrome,,,
clinicalPharmacology,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,ITT,intent-to-treat,,,
clinicalPharmacology,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,RFS,relapse-free survival,,,
clinicalPharmacology,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,OS,overall survival,,,
clinicalPharmacology,37045a6a-defa-4041-9bc1-18784f49e3f1,5/25/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bd06f321-bb42-4748-92f3-d59626b540e0,9/19/2008,1,Tmax,to maximum concentration,,,
clinicalPharmacology,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,488796b3-3760-4563-b662-ade3d6637ec5,9/29/2010,3,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,c7ef31c4-e3d9-4a9b-98bd-46b609f7f3aa,2/21/2006,1,c-AMP,cyclic-3?,5?-adenosine monophosphate,,
clinicalPharmacology,c7ef31c4-e3d9-4a9b-98bd-46b609f7f3aa,2/21/2006,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,Comb,Combined Metformin Hydrochloride Tablets/Glyburide,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,MET,Metformin Hydrochloride Tablets,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,Glyb,Glyburide,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,45fc03d1-cdba-4c96-a809-ae6703c2408b,5/16/2011,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,e118df30-a578-4cf0-93c8-689d15415ec2,9/15/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,CSF,cerebrospinal fluid,,,
clinicalPharmacology,f2ec923a-2b88-43c0-ac2a-7ae20c053039,8/27/2009,1,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,cd24a261-9c15-42b4-8040-89d2dbda174e,10/1/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5747157d-7bcd-4021-83f1-289f348e9c3f,3/4/2010,2,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,d8684144-6c2d-4664-943a-2d3d2b46b1fc,5/3/2011,5,AUC,area under the curve,,,
clinicalPharmacology,d1f29fda-6ea3-4c53-bf2e-1128cc19d3e2,4/14/2008,2,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,d1f29fda-6ea3-4c53-bf2e-1128cc19d3e2,4/14/2008,2,SD,"styleCode=""bold"">Mean",,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,QCA,quantitative coronary angiography,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,AUC,area under the curve,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,TG,triglycerides,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,CCAIT,Canadian Coronary Atherosclerosis Intervention Trial,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,IMT,intimal-medial thickness,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,RR,risk reductions,,,
clinicalPharmacology,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalPharmacology,8d8aaac5-3203-4ade-ae74-e2ea469dae18,4/20/2011,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,8d8aaac5-3203-4ade-ae74-e2ea469dae18,4/20/2011,1,LOQ,limit of quantitation,,,
clinicalPharmacology,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,Tmax,to maximum  concentration,,,
clinicalPharmacology,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,EM,extensive metabolizers,,,
clinicalPharmacology,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,PM,poor metabolizers,,,
clinicalPharmacology,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,CNS,central nervous system,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,OADC,oleic acid-albumin dextrose-catalase,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,4A8AE85C-66A0-48BE-4099-B3C72C838176,5/11/2009,2,SWOG,Southwest Oncology Group,,,
clinicalPharmacology,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,ULN,upper limit of normal,,,
clinicalPharmacology,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,CVP,central venous pressure,,,
clinicalPharmacology,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,CHF,.Congestive Heart Failure,,,
clinicalPharmacology,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,i.e.,initial clearance rates,,,
clinicalPharmacology,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,b73e7993-b5fb-4147-8bbe-eba686a5d051,3/25/2011,3,GER,gastroesophageal reflux,,,
clinicalPharmacology,b73e7993-b5fb-4147-8bbe-eba686a5d051,3/25/2011,3,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,d6de628c-bbe5-437e-9338-6f54cd661be1,4/6/2012,3,Vd,volume of distribution,,,
clinicalPharmacology,d6de628c-bbe5-437e-9338-6f54cd661be1,4/6/2012,3,Cl,clearance,,,
clinicalPharmacology,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,bb6708c0-0446-40a9-8b68-a8785c7ab061,6/8/2011,5,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,adaa3246-d0fc-417c-9a16-81d76f153903,6/7/2010,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,e889f164-a92c-412d-960a-59391e4151fe,7/3/2012,2,AUC,area under the concentration-time curve,,,
clinicalPharmacology,9ab4e06f-2d51-4247-bf43-4636b416e96a,5/31/2011,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,OADC,oleic  acid-albumin-dextrose-catalase,,,
clinicalPharmacology,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,MAC,Mycobacterium avium                    Complex,,,
clinicalPharmacology,2dd58c88-142f-41ad-bc31-0a4fff074970,1/12/2010,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,2dd58c88-142f-41ad-bc31-0a4fff074970,1/12/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2dd58c88-142f-41ad-bc31-0a4fff074970,1/12/2010,1,AUC,area under the curve,,,
clinicalPharmacology,2dd58c88-142f-41ad-bc31-0a4fff074970,1/12/2010,1,V/F,volume of distribution,,,
clinicalPharmacology,2dd58c88-142f-41ad-bc31-0a4fff074970,1/12/2010,1,MEF,Middle-ear fluid,,,
clinicalPharmacology,42CD4847-B706-4D51-97E3-B736839C2D24,10/11/2006,1,c-AMP,cyclic adenosine monophosphate,,,
clinicalPharmacology,473ab78d-5015-4a4a-8a2c-8f594b8de41d,1/17/2011,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,473ab78d-5015-4a4a-8a2c-8f594b8de41d,1/17/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,346af8fe-3816-49de-bfd3-5a7425e728f9,3/30/2007,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalPharmacology,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,ESRD,end-stage renal disease,,,
clinicalPharmacology,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,RAS,renin-angiotensin system,,,
clinicalPharmacology,508248c9-fc88-4be0-b509-591001be04e8,10/11/2011,2,V/F,volume of distribution,,,
clinicalPharmacology,508248c9-fc88-4be0-b509-591001be04e8,10/11/2011,2,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,508248c9-fc88-4be0-b509-591001be04e8,10/11/2011,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,e.g.,enzyme-inducing AED,,,
clinicalPharmacology,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,c83616c9-c222-4e3e-91bd-c7839406bb2a,1/11/2010,1,CV%,coefficient of variation,,,
clinicalPharmacology,e8f94df9-0692-4462-a7f0-fe019a0a3f07,2/22/2012,6,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,e8f94df9-0692-4462-a7f0-fe019a0a3f07,2/22/2012,6,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,897e946d-075f-4048-bc32-ec5d6da9c388,9/23/2010,4,PT,prothrombin time,,,
clinicalPharmacology,787c1115-61fa-41d1-a0b2-32318f1e20f5,8/1/2011,8,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,D2,dopamine Type 2,,,
clinicalPharmacology,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,V/F,volume of distribution,,,
clinicalPharmacology,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,Tmax,to maximum concentration,,,
clinicalPharmacology,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,CYP3A4/5,cytochrome P450 3A4/5,,,
clinicalPharmacology,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,BMI,body mass index,,,
clinicalPharmacology,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,P-gp,P-glycoprotein,,,
clinicalPharmacology,a24e8e53-07b3-49be-87e4-124f7d3aeac1,8/18/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,36ab49ab-ed1e-4e1b-8a9a-d74f6c62619a,5/5/2010,1,SAR,Seasonal Allergic Rhinitis,,,
clinicalPharmacology,1fdf16e5-145d-4c19-a318-fc6c10794b50,1/25/2012,1,GERD,GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalPharmacology,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,Y-BOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,CGI,Clinical Global Impressions,,,
clinicalPharmacology,a6195532-388b-47f7-a984-89ed10e29bc6,3/26/2010,2,Css,concentration  of morphine at steady-state,,,
clinicalPharmacology,a6195532-388b-47f7-a984-89ed10e29bc6,3/26/2010,2,GH,growth  hormone,,,
clinicalPharmacology,a6195532-388b-47f7-a984-89ed10e29bc6,3/26/2010,2,Vd,volume of distribution,,,
clinicalPharmacology,a6195532-388b-47f7-a984-89ed10e29bc6,3/26/2010,2,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,a6195532-388b-47f7-a984-89ed10e29bc6,3/26/2010,2,LH,luteinizing hormone,,,
clinicalPharmacology,59abd52d-8172-44a3-baa2-fe1fe20f78c0,4/21/2011,4,GER,gastroesophageal reflux,,,
clinicalPharmacology,59abd52d-8172-44a3-baa2-fe1fe20f78c0,4/21/2011,4,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,7a51d289-2013-4d37-adf2-91ea49df7932,1/20/2010,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,ee94dfa0-2ddd-48a1-b241-881c22a600bb,11/15/2010,83,MI,myocardial infarction,,,
clinicalPharmacology,917494a9-cff1-4ee6-9523-e112120373c5,10/3/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,917494a9-cff1-4ee6-9523-e112120373c5,10/3/2011,1,mean age,minutes to nine pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,CNS,central nervous system,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,DCT,demethylcitalopram,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,CT,citalopram,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,DA,dopamine,,,
clinicalPharmacology,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,NE,norepinephrine,,,
clinicalPharmacology,58240A50-5E29-4168-A7D7-00BE1540AF1D,5/14/2007,1,EFAD,essential fatty acid deficiency,,,
clinicalPharmacology,ea2a9cd6-1b03-4d96-9081-5cbc45473020,1/6/2012,14,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,ea2a9cd6-1b03-4d96-9081-5cbc45473020,1/6/2012,14,BPH,Benign prostatic hyperplasia,,,
clinicalPharmacology,3E28CF99-2B70-4FD7-7988-A808DFAC54C4,8/28/2007,2,MAC,minimum alveolar concentration,,,
clinicalPharmacology,25e641d0-a5de-4163-938a-ea52c4bfa48e,7/11/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,LDL,low density lipoprotein,,,
clinicalPharmacology,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,VLDL,very low density lipoprotine,,,
clinicalPharmacology,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,TG,triglyceride,,,
clinicalPharmacology,1dc5c813-501a-43fe-ac86-ce5257f51410,4/26/2011,3,HPPH,5-(p-hydroxyphenyl)-5-phenylhydantoin,,,
clinicalPharmacology,9b74fbac-9e04-4927-9981-1e3dace89c6d,1/7/2011,1,PT,prothrombin time,,,
clinicalPharmacology,b8d95ad1-4725-fec7-e7e2-062cbb46d873,3/1/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,b8d95ad1-4725-fec7-e7e2-062cbb46d873,3/1/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,f95f01c5-22f8-43c2-aaf4-0840aa256486,4/13/2011,3,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,A8DF90D8-78B3-48C3-B42E-1E651D81454B,3/4/2009,2,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,A8DF90D8-78B3-48C3-B42E-1E651D81454B,3/4/2009,2,ETEC,enterotoxigenic strains of Escherichia coli,,,
clinicalPharmacology,4a48e24c-9280-47fe-b200-9b79a7f6bd96,10/31/2011,3,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,4a48e24c-9280-47fe-b200-9b79a7f6bd96,10/31/2011,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,DHT,5?-dihydrotestosterone,,,
clinicalPharmacology,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,IV,intravenous,,,
clinicalPharmacology,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,AUC,area under the curve,,,
clinicalPharmacology,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,TG,triglycerides,,,
clinicalPharmacology,260e7bba-36c7-4d29-8781-48b25e75cf60,10/25/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,CPS,complex partial seizures,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,AED,antiepilepsy drug,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,i.e.,improvement,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,TID,three divided doses,,,
clinicalPharmacology,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,cf10d256-dd89-4a91-a3ed-81db505a79c2,10/31/2011,6,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,TCA,tricyclic antidepressant,,,
clinicalPharmacology,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,GFR,glomerular filtration rate,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,AUC,area under the curve,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,RPF,renal plasma flow,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,FVC,forced vital capacity,,,
clinicalPharmacology,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,FEV 1,forced expiratory volume 1 second,,,
clinicalPharmacology,eb0cd037-1e48-42b1-92ef-4d4ede585bb8,5/14/2010,6,CYP2D6,cytochrome P450  isoform 2D6,,,
clinicalPharmacology,eb0cd037-1e48-42b1-92ef-4d4ede585bb8,5/14/2010,6,PM,poor metabolizers,,,
clinicalPharmacology,de8990a6-f3b6-478f-acbe-eda961b6da4b,4/4/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,02fddbda-e9e1-41f0-b1a9-b46f4f24705c,9/21/2011,1,IV,intravenous,,,
clinicalPharmacology,02fddbda-e9e1-41f0-b1a9-b46f4f24705c,9/21/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,2e2313cf-ee59-4b22-acb1-530c50c17ff2,9/14/2009,1,DNA,deoxyribonu cleic acid,,,
clinicalPharmacology,880b3ae3-99e5-4d4c-935c-ee232f1f2a45,3/21/2012,4,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,60bc6eab-fc04-476f-a894-d3cd56fe8f6f,5/5/2011,3,HTM,Haemophilus Test Media,,,
clinicalPharmacology,4bec3923-6221-4b8b-9a72-872a63680de1,6/4/2012,2,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,d86e48ca-7e98-4e9c-9b1e-f80fef1c7c2a,8/2/2010,1,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,d86e48ca-7e98-4e9c-9b1e-f80fef1c7c2a,8/2/2010,1,Tmax,to reach maximum plasma concentration,,,
clinicalPharmacology,fffebd01-3815-425f-8293-1ad909d0d0ab,4/23/2012,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,ETT,exercise tolerance time,,,
clinicalPharmacology,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,PRA,plasma renin activity,,,
clinicalPharmacology,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,ITT,intent-to-treat,,,
clinicalPharmacology,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,CLr,clearance,,,
clinicalPharmacology,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,triazole,Three metabolites of anastrozole,,,
clinicalPharmacology,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,d5d05b1f-9f45-4f66-9f75-3c67934105de,2/15/2012,2,N-Ac-5-ASA,N-acetyl-5-aminosalicylic acid,,,
clinicalPharmacology,338c1b5f-1bb9-43f4-a5db-00e9bf3f7845,7/6/2010,8,HTM,Haemophilus Test Media,,,
clinicalPharmacology,338c1b5f-1bb9-43f4-a5db-00e9bf3f7845,7/6/2010,8,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,e11e41a1-56e3-4505-b3a5-159e03e2daba,10/4/2011,1,HETEs,hydroxyeicosatetraenoic acids,,,
clinicalPharmacology,e11e41a1-56e3-4505-b3a5-159e03e2daba,10/4/2011,1,PG,prostagladin,,,
clinicalPharmacology,e11e41a1-56e3-4505-b3a5-159e03e2daba,10/4/2011,1,LTs,leukotrienes,,,
clinicalPharmacology,e11e41a1-56e3-4505-b3a5-159e03e2daba,10/4/2011,1,AA,arachidonic acid,,,
clinicalPharmacology,b3bbc16e-8305-469a-9dc3-8e698339a98b,7/8/2010,1,ERG,electroretinogram,,,
clinicalPharmacology,b3bbc16e-8305-469a-9dc3-8e698339a98b,7/8/2010,1,CAD,Coronary Artery Disease,,,
clinicalPharmacology,e424b30d-8f40-48b7-bb99-415f92d84ed0,4/19/2012,3,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,A1DA5A84-7529-4F62-867F-808A6CAB40B8,1/1/2007,1,LDL,low density lipoprotein,,,
clinicalPharmacology,A1DA5A84-7529-4F62-867F-808A6CAB40B8,1/1/2007,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,A1DA5A84-7529-4F62-867F-808A6CAB40B8,1/1/2007,1,HDL,high density lipoprotein,,,
clinicalPharmacology,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,MN,mononuclear,,,
clinicalPharmacology,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,PMN,polymorphonuclear,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,GAD,generalized anxiety disorder,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,PD,panic disorder,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,405d2b6c-b465-41de-ad93-1e009825cd3b,6/20/2011,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,405d2b6c-b465-41de-ad93-1e009825cd3b,6/20/2011,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
clinicalPharmacology,c3bd674c-cf21-4957-bbaf-ddd4b0770ff4,8/23/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,4789c1dd-ae52-4962-be54-6ae7e08ac0e4,5/1/2007,1,PA,Procainamide,,,
clinicalPharmacology,4789c1dd-ae52-4962-be54-6ae7e08ac0e4,5/1/2007,1,A-V,atrioventricular,,,
clinicalPharmacology,4789c1dd-ae52-4962-be54-6ae7e08ac0e4,5/1/2007,1,NAPA,N-acetylprocainamide,,,
clinicalPharmacology,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,IV,intravenous,,,
clinicalPharmacology,35744538-1704-4ee0-954d-52710cf3456d,3/29/2010,1,ADHD-RS,Attention Deficit Hyperactivity Disorder-Rating Scale,,,
clinicalPharmacology,35744538-1704-4ee0-954d-52710cf3456d,3/29/2010,1,ADHD,Attention Deficit  Hyperactivity Disorder,,,
clinicalPharmacology,35744538-1704-4ee0-954d-52710cf3456d,3/29/2010,1,AUC?,area under the curve to infinity,,,
clinicalPharmacology,35744538-1704-4ee0-954d-52710cf3456d,3/29/2010,1,Tmax,to reach maximum plasma concentration,,,
clinicalPharmacology,9378d186-5b25-49bc-8563-a659fa1194c2,2/24/2011,6,GX,glycinexylidide,,,
clinicalPharmacology,9378d186-5b25-49bc-8563-a659fa1194c2,2/24/2011,6,tmax,to reach maximum concentration,,,
clinicalPharmacology,9378d186-5b25-49bc-8563-a659fa1194c2,2/24/2011,6,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,9378d186-5b25-49bc-8563-a659fa1194c2,2/24/2011,6,PK,pharmacokinetic,,,
clinicalPharmacology,b3ad0449-fd60-482a-9ba7-afd8f5555b83,1/13/2012,8,CI,confidence interval,,,
clinicalPharmacology,b40ec321-1181-4e8d-8914-d30772b30cad,7/23/2010,1,i.e.,improvement from baseline,,,
clinicalPharmacology,9d4fa3ac-5a6d-460c-bc89-1c83fd436e90,5/12/2010,1,HDL,high density lipoprotein,,,
clinicalPharmacology,9d4fa3ac-5a6d-460c-bc89-1c83fd436e90,5/12/2010,1,TG,triglycerides,,,
clinicalPharmacology,5681d4d2-9b67-4cac-9b94-8368f9978231,3/9/2007,1,broth,be interpreted according to the following criteria:2,,,
clinicalPharmacology,5681d4d2-9b67-4cac-9b94-8368f9978231,3/9/2007,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,67b6d8b9-5944-4961-894a-13d214cc3229,3/1/2012,3,CNS,central nervous systems,,,
clinicalPharmacology,adc92303-b62b-41c8-becf-9c3a4e8c3a6b,2/10/2012,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,CVP,central venous pressure,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,SVR,systemic vascular resistance,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,PCWP,pulmonary-capillary wedge pressure,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,PVR,pulmonary vascular                                     resistance,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,preload,pressure and pulmonary capillary                             wedge pressure,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,PAP,pulmonary arterial pressure,,,
clinicalPharmacology,457a026c-ebce-4701-9deb-2d7652759a99,4/7/2006,1,RAP,right                                     atrial pressure,,,
clinicalPharmacology,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,PIs,protease inhibitors,,,
clinicalPharmacology,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,NNRTIs,non-nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,GH,growth hormone,,,
clinicalPharmacology,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,NRTIs,Nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,LH,luteinizing hormone,,,
clinicalPharmacology,58896863-63AC-4B99-9D3C-97CA472357C7,4/21/2008,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,e6c0ee96-5d2a-4725-a460-5ca62f2b6c36,2/13/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,e6c0ee96-5d2a-4725-a460-5ca62f2b6c36,2/13/2012,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,3cd2e7f1-cbdb-47f6-b37f-830aaaef2482,3/21/2011,1,TK,thymidine kinase,,,
clinicalPharmacology,3cd2e7f1-cbdb-47f6-b37f-830aaaef2482,3/21/2011,1,HSV-1,herpes simplex virus types 1,,,
clinicalPharmacology,3cd2e7f1-cbdb-47f6-b37f-830aaaef2482,3/21/2011,1,Vd?,volume of distribution,,,
clinicalPharmacology,3cd2e7f1-cbdb-47f6-b37f-830aaaef2482,3/21/2011,1,VZV,varicella zoster virus,,,
clinicalPharmacology,fdebf4d8-8171-4e56-9aac-89d9c61f0929,12/2/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,MCVE,major cardiovascular events,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,TNT,to New Targets Study,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,CVD,cardiovascular disease,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,min,median,,,
clinicalPharmacology,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalPharmacology,111F628A-7E1E-4D47-8AC1-F898CBFC9B74,8/3/2007,2,e.g.,ergot alkaloids,,,
clinicalPharmacology,9fde45b1-b40c-4374-81ad-f2bf1015950b,1/28/2011,1,LES,lower esophageal sphincter,,,
clinicalPharmacology,a767e888-f825-4429-b3a4-05580ea6d157,9/19/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,a767e888-f825-4429-b3a4-05580ea6d157,9/19/2011,1,MHPG,3-methoxy- 4-hydroxyphenyl glycol,,,
clinicalPharmacology,6077eae6-aea0-427f-be15-9f1b3f33db0c,3/22/2012,3694,AUC,area under the concentration time curve,,,
clinicalPharmacology,f08671b6-dc76-450a-8c8c-9d54f9611c00,12/3/2010,4,GER,gastroesophageal reflux,,,
clinicalPharmacology,f08671b6-dc76-450a-8c8c-9d54f9611c00,12/3/2010,4,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,4908849a-c727-49a6-b936-e9d935374d74,1/7/2010,2,PRA,plasma renin activity,,,
clinicalPharmacology,81167e87-b1d5-44df-99aa-a033825634dd,12/2/2010,119,HGPRTase,hypoxanthine guanine phosphoribosyltransferase,,,
clinicalPharmacology,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
clinicalPharmacology,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,ISH,isolated systolic hypertension,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,DBP,diastolic blood pressure,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,ITT,intention-to-treat,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,ESRD,end-stage renal disease,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,CVD,cardiovascular disease,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,SBP,systolic blood pressure,,,
clinicalPharmacology,d87866fd-62c9-4b0a-b8a8-e62516cae0a9,4/24/2012,6,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,201e71d6-6a69-4ca8-9eb6-9821f45f8d18,11/10/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,201e71d6-6a69-4ca8-9eb6-9821f45f8d18,11/10/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,50a58159-9572-4445-9859-b392632597da,12/8/2011,6,PRA,plasma renin activity,,,
clinicalPharmacology,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,BCC2D379-83D6-4B10-BA7F-729AE87FE57E,2/7/2007,1,AMS,acute mountain sickness,,,
clinicalPharmacology,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,GI,gastrointestinal,,,
clinicalPharmacology,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,rT3,reverse T3,,,
clinicalPharmacology,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,TBPA,thyroxine-binding  prealbumin,,,
clinicalPharmacology,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,TBG,thyroxine-binding globulin,,,
clinicalPharmacology,92123CFA-5BD5-4554-8D5D-B877D5CB9C02,6/19/2007,1,CNS,central nervous system,,,
clinicalPharmacology,fe8b7729-d870-4e61-a5a4-91e28bdd5a94,12/8/2010,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,fe8b7729-d870-4e61-a5a4-91e28bdd5a94,12/8/2010,1,MICs,minimal inhibitory  concentrations,,,
clinicalPharmacology,fe8b7729-d870-4e61-a5a4-91e28bdd5a94,12/8/2010,1,MIC,minimum inhibitory concentrations,,,
clinicalPharmacology,1893ed5d-eddc-49ea-94d0-b839e0b1bfc9,1/23/2012,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,6339395b-0125-4b18-8743-894e8a97f11b,11/24/2010,6,PD,pocket depth,,,
clinicalPharmacology,6339395b-0125-4b18-8743-894e8a97f11b,11/24/2010,6,SRP,scaling and root planing,,,
clinicalPharmacology,6339395b-0125-4b18-8743-894e8a97f11b,11/24/2010,6,BOP,bleeding-on-probing,,,
clinicalPharmacology,6339395b-0125-4b18-8743-894e8a97f11b,11/24/2010,6,ALv,attachment level,,,
clinicalPharmacology,8d53dc31-a51f-4326-a6cd-5aa6aebda3ed,5/22/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,A1A8067E-2C0A-4161-A299-1DF7C9C8D84C,11/29/2007,2,ACE,angiotensin-coverting enzyme,,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,EDRF,endothelium-derived relaxing factor,,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,ADP,adenosine diphosphate,,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,PDE,phosphodiesterase,,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,PAF,platelet activating factor,,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,cGMP-PDE,cyclic-3',5'-guanosine monophosphate-PDE,,
clinicalPharmacology,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,cAMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,2e899f4a-a2e9-445c-a0ed-6ad811e997e6,2/22/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,2e899f4a-a2e9-445c-a0ed-6ad811e997e6,2/22/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2e899f4a-a2e9-445c-a0ed-6ad811e997e6,2/22/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,AUC,Area Under Curve,,,
clinicalPharmacology,a086ead1-b906-4198-af19-5423957c9e2a,2/7/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,D2,dopamine Type 2,,,
clinicalPharmacology,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,e.g.,enzyme-inducing AED,,,
clinicalPharmacology,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,041ae7f6-7e42-4803-a015-f3bfcce277ba,6/9/2011,4,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,42033007-1d59-4b83-9908-7b66f5519a14,11/7/2011,4,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,CgA,Chromogranin A,,,
clinicalPharmacology,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,ECL,Enterochromaffin-like,,,
clinicalPharmacology,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,CYP,cytochrome P450,,,
clinicalPharmacology,8357fbc6-9a5b-4d06-bb99-0bc21ddbdc7d,12/7/2010,135,HGPRTase,hypoxanthine-guanine phosphoribosyltransferase,,,
clinicalPharmacology,686cd696-0011-47b2-b342-142c20169ac6,11/7/2008,1,broth,be interpreted according to the following criteria.2,,,
clinicalPharmacology,19e1d930-20b3-81e3-0c6d-3e4979460444,4/21/1987,1,i.e.,its active metabolites,,,
clinicalPharmacology,6118E185-5226-4676-1DBC-42554FD53D50,6/3/2008,2,DOPA,dihydroxyphenylalanine,,,
clinicalPharmacology,dac26bcd-7a59-401f-9f66-a0649767cece,7/6/2011,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,dac26bcd-7a59-401f-9f66-a0649767cece,7/6/2011,2,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,578a6b9f-a77a-4619-8d13-7810f30fa04b,3/1/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,2e1f1640-c6ff-456f-8bec-ec3251065f46,1/3/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,MPA,MEDROXYPROGESTERONE ACETATE,,,
clinicalPharmacology,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,SHBG,sex hormone?binding globulin,,,
clinicalPharmacology,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,FSH,follicle stimulating hormone,,,
clinicalPharmacology,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,LH,luteinizing hormone,,,
clinicalPharmacology,ceccf36f-d165-4c2f-bed6-07ff1f5a70bc,2/22/2011,2,MAO,monoamine oxidase,,,
clinicalPharmacology,ceccf36f-d165-4c2f-bed6-07ff1f5a70bc,2/22/2011,2,CAD,coronary artery disease,,,
clinicalPharmacology,ADF16E64-345F-469A-B987-3FBDD17E0AC2,3/31/2007,1,RSV,respiratory syncytial virus,,,
clinicalPharmacology,cb4f1002-9372-4fac-aea3-99142f93dd37,10/30/2009,1,CFCs,chlorofluorocarbons,,,
clinicalPharmacology,cb4f1002-9372-4fac-aea3-99142f93dd37,10/30/2009,1,Tmax,to maximum plasma concentration,,,
clinicalPharmacology,5200ae31-8a79-45f9-84fc-98f8448483a7,12/21/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5200ae31-8a79-45f9-84fc-98f8448483a7,12/21/2011,2,MEF,middle ear fluid,,,
clinicalPharmacology,a6e402d9-623d-444d-94f0-21f4977d3d40,12/20/2010,3,GER,gastroesophageal reflux,,,
clinicalPharmacology,a6e402d9-623d-444d-94f0-21f4977d3d40,12/20/2010,3,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,LDL,low density lipoprotein,,,
clinicalPharmacology,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,TG,triglyceride,,,
clinicalPharmacology,7d5cb52e-37dd-4dfa-a6f4-09f9548846c6,7/18/2012,4,i.e.,improvement,,,
clinicalPharmacology,f3bc8ede-13a3-4119-a47a-8234c80bbc05,3/29/2010,1,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,efd1106b-d369-4651-b703-b0985ce93b79,12/22/2011,3,NET,norethindrone,,,
clinicalPharmacology,efd1106b-d369-4651-b703-b0985ce93b79,12/22/2011,3,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,efd1106b-d369-4651-b703-b0985ce93b79,12/22/2011,3,EE,ethinyl estradiol,,,
clinicalPharmacology,b40932cc-7867-4c87-8a82-402e95b3a1fc,3/27/2007,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,CLSI,Clinical Laboratory and Standards Institute,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,broth,based on a microdilution method,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,Inhibitors,inhibitors,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,63777889-d306-4fc3-88da-b24859040ef4,6/21/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,18b22092-605b-4ae7-8bc8-7f213d7d02eb,6/6/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,18b22092-605b-4ae7-8bc8-7f213d7d02eb,6/6/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,18b22092-605b-4ae7-8bc8-7f213d7d02eb,6/6/2011,1,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,18b22092-605b-4ae7-8bc8-7f213d7d02eb,6/6/2011,1,CYP,cytochrome P450,,,
clinicalPharmacology,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,CgA,Chromogranin A,,,
clinicalPharmacology,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,ECL,Enterochromaffin-like,,,
clinicalPharmacology,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,CYP,cytochrome P450,,,
clinicalPharmacology,d267425d-4e5f-4e7a-a27e-fe8814f0e225,8/1/2011,9,IV,intravenous,,,
clinicalPharmacology,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,ESVEM,[Electrophysiologic Study Versus Electrocardiographic Monitoring,,,
clinicalPharmacology,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,PES,programmed electrical stimulation,,,
clinicalPharmacology,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,NSVT,non-sustained ventricular tachycardia,,,
clinicalPharmacology,b5603084-dda6-4147-9d88-3818877b5f62,8/11/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,b5603084-dda6-4147-9d88-3818877b5f62,8/11/2011,1,IV,intravenous,,,
clinicalPharmacology,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,DEA,N-desethylamiodarone,,,
clinicalPharmacology,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,VT,ventricular tachycardia,,,
clinicalPharmacology,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,SCL,sinus cycle length,,,
clinicalPharmacology,ab4a4e86-bc2b-42d5-bc47-1a73f872217b,7/21/2011,2,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,ab4a4e86-bc2b-42d5-bc47-1a73f872217b,7/21/2011,2,ADH,antidiuretic hormone,,,
clinicalPharmacology,7813e1fc-0081-0e69-136e-a7c7dc4ed589,7/15/2010,7,MRI,magnetic resonance imaging,,,
clinicalPharmacology,53eb28f5-41c5-4470-8878-1c5085c27166,12/3/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,cffcb7cd-1459-4293-8b22-81b077b0f4df,9/26/2008,1,V/F,volume of distribution,,,
clinicalPharmacology,82598cb3-a0eb-4ff2-8b8d-d8da96c25388,11/17/2011,3,RT,reverse transcriptase,,,
clinicalPharmacology,82598cb3-a0eb-4ff2-8b8d-d8da96c25388,11/17/2011,3,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,454f2f4c-5bdd-4aff-b49e-792962dd1a94,7/19/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,CPS,complex partial seizures,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,AED,antiepilepsy drug,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,i.e.,improvement,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,TID,three divided doses,,,
clinicalPharmacology,1ec1a441-218a-4c80-a0cb-69bcc327f472,10/18/2011,5,MRS,Manic Rating Scale,,,
clinicalPharmacology,de55c133-eb08-4a35-91a2-5dc093027397,7/5/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,de55c133-eb08-4a35-91a2-5dc093027397,7/5/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,3e43d8e1-94be-476f-a521-065bee4b02ea,7/30/2010,4,IV,intravenous,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,PT,prothrombin time,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,FPG,fasting plasma glucose,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,CL,clearance,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,Vd,volume of distribution,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,IV,intravenous,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,AUC,area under the curve,,,
clinicalPharmacology,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,FBG,fasting blood glucose,,,
clinicalPharmacology,ea326682-b06d-41e8-b457-85e39ee51034,5/28/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,ea326682-b06d-41e8-b457-85e39ee51034,5/28/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A,5/11/2006,1,that is,the renin-angiotensin system,,,
clinicalPharmacology,0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A,5/11/2006,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,c07b1c7a-510c-48cd-8eda-42397c41f893,11/29/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c07b1c7a-510c-48cd-8eda-42397c41f893,11/29/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c07b1c7a-510c-48cd-8eda-42397c41f893,11/29/2011,4,ECL,Enterochromaffin-like,,,
clinicalPharmacology,c07b1c7a-510c-48cd-8eda-42397c41f893,11/29/2011,4,CYP,cytochrome P450,,,
clinicalPharmacology,0ff1ba75-3c86-4baf-a6b1-1bb883839866,7/24/2012,6,V/F,volume of distribution,,,
clinicalPharmacology,0ff1ba75-3c86-4baf-a6b1-1bb883839866,7/24/2012,6,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,0ff1ba75-3c86-4baf-a6b1-1bb883839866,7/24/2012,6,PPG,postprandial plasma glucose,,,
clinicalPharmacology,2d821387-4b4f-4fe3-825e-750f49755baf,12/28/2010,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,A37E08C3-92CB-4BFB-901F-219C6CDCFFE2,4/7/2006,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,194cd14a-d952-4507-91be-3f1d5371d3b8,11/18/2009,2,LDL,low density lipoprotein,,,
clinicalPharmacology,194cd14a-d952-4507-91be-3f1d5371d3b8,11/18/2009,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,194cd14a-d952-4507-91be-3f1d5371d3b8,11/18/2009,2,TG,triglyceride,,,
clinicalPharmacology,8d24d1ab-8701-42c1-9537-81526b7adf7a,11/24/2010,107,LES,lower esophageal sphincter,,,
clinicalPharmacology,fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343,3/10/2011,6,Vd?,volume of distribution,,,
clinicalPharmacology,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,eg,emergency                                                   setting,,,
clinicalPharmacology,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,QRDRs,Quinolone-  Resistance Determining Regions,,,
clinicalPharmacology,780f5a28-9b5c-4b5f-958e-d1a07f1ba2ec,3/29/2012,1,IV,intravenous,,,
clinicalPharmacology,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,a8ba3ed0-7047-400e-8037-ebc058024637,2/25/2011,2,SREs,skeletal-related events,,,
clinicalPharmacology,a8ba3ed0-7047-400e-8037-ebc058024637,2/25/2011,2,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,IV,intravenous,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,TSO,to sleep onset,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,CYP,cytochrome P450,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,i.e.,its active metabolites,,,
clinicalPharmacology,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,LPS,latency to persistent sleep,,,
clinicalPharmacology,dfe97a3d-247d-4dda-a641-1a95196cd8d8,1/22/2010,1,M6G,morphine-6-glucuronide,,,
clinicalPharmacology,dfe97a3d-247d-4dda-a641-1a95196cd8d8,1/22/2010,1,M3G,morphine-3-glucuronide,,,
clinicalPharmacology,434511bb-ebf9-4e25-9ef8-90e4c6786361,10/2/2008,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,434511bb-ebf9-4e25-9ef8-90e4c6786361,10/2/2008,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,434511bb-ebf9-4e25-9ef8-90e4c6786361,10/2/2008,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,434511bb-ebf9-4e25-9ef8-90e4c6786361,10/2/2008,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,1a5ce8d6-92d6-4f78-80b4-cf9a11e147ed,6/22/2010,2,GI,gastrointestinal,,,
clinicalPharmacology,1a5ce8d6-92d6-4f78-80b4-cf9a11e147ed,6/22/2010,2,AUC,and bioequivalence,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,MCVE,major cardiovascular events,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,DBP,diastolic blood pressure,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,TNT,to New Targets Study,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,CVD,cardiovascular disease,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,SBP,systolic blood pressure,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,min,median,,,
clinicalPharmacology,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalPharmacology,c4936878-1643-4e7f-9b0d-e4957935aef2,1/18/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,c4936878-1643-4e7f-9b0d-e4957935aef2,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,CYP,cytochrome P450,,,
clinicalPharmacology,ee77db05-991c-4467-a299-5e79554c7f5d,7/24/2012,5,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,ee77db05-991c-4467-a299-5e79554c7f5d,7/24/2012,5,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ee77db05-991c-4467-a299-5e79554c7f5d,7/24/2012,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,6ad768fe-10ec-47d5-9f98-4e396bc6aedb,5/26/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6ad768fe-10ec-47d5-9f98-4e396bc6aedb,5/26/2011,1,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,6ad768fe-10ec-47d5-9f98-4e396bc6aedb,5/26/2011,1,PBP,penicillin binding proteins,,,
clinicalPharmacology,6ad768fe-10ec-47d5-9f98-4e396bc6aedb,5/26/2011,1,IM,intramuscular,,,
clinicalPharmacology,5b6f93c9-43b2-40a9-9f10-054c1145b4cc,3/1/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,d5ab4f08-1d12-4c64-b3bf-e72c705aeca8,12/5/2011,2,logP,log partition coefficient,,,
clinicalPharmacology,2a0092d8-f782-45ec-b8a8-c72156bbd5d5,9/1/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,SSRI,selective  serotonin reuptake inhibitor,,,
clinicalPharmacology,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,CNS,central nervous system,,,
clinicalPharmacology,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,S-DDCT,S-didemethylcitalopram,,,
clinicalPharmacology,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,S-DCT,S-demethylcitalopram,,,
clinicalPharmacology,bf5e6bcd-e935-40c2-870a-b097e7a2ef7f,1/19/2012,9,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,9558e870-aa8b-4646-a701-1e9416c02f11,11/8/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,9558e870-aa8b-4646-a701-1e9416c02f11,11/8/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,44D8F56C-E1ED-4761-A138-CAC1027C1852,3/31/2007,2,V/F,volume of distribution,,,
clinicalPharmacology,44D8F56C-E1ED-4761-A138-CAC1027C1852,3/31/2007,2,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,44D8F56C-E1ED-4761-A138-CAC1027C1852,3/31/2007,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,TG,triglycerides,,,
clinicalPharmacology,c7bdf6cc-ef15-4ea8-a4a9-86f5434ebf09,4/21/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c7bdf6cc-ef15-4ea8-a4a9-86f5434ebf09,4/21/2011,1,SDD,Susceptible-Dose Dependent,,,
clinicalPharmacology,c6fa0c7b-eea6-48f0-9ae9-c19eb088b271,9/7/2011,3,NET,norethindrone,,,
clinicalPharmacology,c6fa0c7b-eea6-48f0-9ae9-c19eb088b271,9/7/2011,3,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,c6fa0c7b-eea6-48f0-9ae9-c19eb088b271,9/7/2011,3,EE,ethinyl estradiol,,,
clinicalPharmacology,f7f84d2a-d740-4414-9bfe-fccee9e73da0,4/20/2010,5,BALs,Bronchoalveolar lavages,,,
clinicalPharmacology,f7f84d2a-d740-4414-9bfe-fccee9e73da0,4/20/2010,5,ELF,epithelial lining fluid,,,
clinicalPharmacology,09b3a912-97f9-45ae-a162-9f45c860dc22,8/17/2011,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,3895e5cb-14d0-4676-9e57-3c224806bf3e,3/21/2012,17,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,HCTZ/TA,hydrochlorothiazide/triamterene,,,
clinicalPharmacology,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,b1a9ef34-092b-409b-a6b0-59cb079bad0a,3/31/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,CNS,central nervous system,,,
clinicalPharmacology,b0e6fa63-7b34-4453-a259-34ffd917f4d7,3/22/2012,1,TK,thymidine kinase,,,
clinicalPharmacology,b0e6fa63-7b34-4453-a259-34ffd917f4d7,3/22/2012,1,HSV-1,HSV types 1,,,
clinicalPharmacology,0b0ba593-fe54-456c-a3d7-651c50036e3e,2/28/2011,9,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,e3485086-7a10-45fa-aa83-ee6fbbf39c59,4/3/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,e3485086-7a10-45fa-aa83-ee6fbbf39c59,4/3/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,e3485086-7a10-45fa-aa83-ee6fbbf39c59,4/3/2012,1,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,e35aa027-aef2-485d-927c-ab350f51f977,2/16/2006,1,ERP,effective refractory period,,,
clinicalPharmacology,e35aa027-aef2-485d-927c-ab350f51f977,2/16/2006,1,APD,action potential duration,,,
clinicalPharmacology,3cae0c4c-faaa-43f5-a186-91b2c8bd0a13,5/10/2007,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d908e334-b74b-4b4d-b159-c592c2ecc7f9,2/14/2012,3560,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,CBZ,Carbamazepine,,,
clinicalPharmacology,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,CBZ-E,Carbamazepine-10,11-epoxide,,
clinicalPharmacology,0d1d5797-6a7f-4a25-b13d-009224cc59c1,9/8/2011,4,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,CVP,central venous pressure,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,SVR,systemic vascular resistance,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,RAP,right atrial pressure,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,PVR,pulmonary vascular resistance,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,PCWP,pulmonary-capillary wedge pressure,,,
clinicalPharmacology,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,PAP,pulmonary arterial pressure,,,
clinicalPharmacology,967bd870-7517-43bc-90eb-05e831d688ae,2/17/2012,1,DDC,dopa decarboxylase,,,
clinicalPharmacology,967bd870-7517-43bc-90eb-05e831d688ae,2/17/2012,1,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,ac7391da-1789-493d-a025-dbc697f32e60,8/1/2011,4,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,b3efaffa-9ef9-4a4f-998e-aa7d2eb61fc9,6/28/2011,10,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,TMS,"styleCode=""italics"">&#945;</content>-(thiomethyl) spirolactone",,,
clinicalPharmacology,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,HTMS,"styleCode=""italics"">&#946;</content>-hydroxy-7-<content styleCode=""italics"">&#945;</content>-(thiomethyl) spirolactone",,,
clinicalPharmacology,165d8988-4489-4749-83f0-b68b8e69f43d,4/20/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,165d8988-4489-4749-83f0-b68b8e69f43d,4/20/2011,1,TID,three divided doses,,,
clinicalPharmacology,63a0466c-af7d-4696-a950-19b73b55a65a,6/24/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,63a0466c-af7d-4696-a950-19b73b55a65a,6/24/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2df7349c-f5d7-47b5-d29b-1b6b31985591,12/13/2011,8,TMP/SMX,trimethoprim/sulfamethoxazole,,,
clinicalPharmacology,786992bd-13a0-4a00-dfb2-6c135ecd349b,1/11/2011,5,ddI,didanosine,,,
clinicalPharmacology,786992bd-13a0-4a00-dfb2-6c135ecd349b,1/11/2011,5,RT,reverse transcriptase,,,
clinicalPharmacology,786992bd-13a0-4a00-dfb2-6c135ecd349b,1/11/2011,5,CSF,cerebrospinal fluid,,,
clinicalPharmacology,07c99997-31c7-4c03-ae35-49788213b43e,4/13/2010,1,MCE,major coronary events,,,
clinicalPharmacology,07c99997-31c7-4c03-ae35-49788213b43e,4/13/2010,1,MVE,major vascular events,,,
clinicalPharmacology,6d9d13e6-246c-435c-b8c2-823eac283463,3/28/2011,1,mm,MicroorganismZone Diameter,,,
clinicalPharmacology,6d9d13e6-246c-435c-b8c2-823eac283463,3/28/2011,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,5e2dbda9-aceb-4bfb-9c3f-e7b6118f580c,10/27/2009,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,MPA,medroxyprogesterone acetate,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,CE,conjugated estrogens,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,ESRD,end stage renal disease,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,CHD,coronary heart disease,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,WHI,Women's Health Initiative,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,PB,pulmonary embolism,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,BMD,bone mineral density,,,
clinicalPharmacology,e2a38bbb-7505-407f-ba38-469500347697,4/13/2011,3,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,bb934a63-ed66-433a-a9a7-b9c5e9963f73,10/25/2010,38,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,bb934a63-ed66-433a-a9a7-b9c5e9963f73,10/25/2010,38,IV,intravenous,,,
clinicalPharmacology,e9ea2ae7-1b98-4034-9fba-8ce2225e0145,3/8/2012,6,CA-II,carbonic anhydrase II,,,
clinicalPharmacology,0d592c37-b38c-4fb6-a1d3-96531384ae8d,6/9/2011,1,LVEDP,left ventricular end diastolic pressure,,,
clinicalPharmacology,091c71be-dd6c-4f7a-9af0-3222686345a5,6/1/2009,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a7c456e6-403b-4aae-a576-60b106bf66a7,10/4/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,38b56b76-33c0-69d5-ddab-b25fa19cae52,10/6/2006,11,Cl?,Chloride,,,
clinicalPharmacology,38b56b76-33c0-69d5-ddab-b25fa19cae52,10/6/2006,11,Cl?,chloride,,,
clinicalPharmacology,38b56b76-33c0-69d5-ddab-b25fa19cae52,10/6/2006,11,Mg++,magnesium,,,
clinicalPharmacology,03646015-2d86-4d6d-958f-94687899b838,1/27/2012,1,ITT,intent-to-treat,,,
clinicalPharmacology,03646015-2d86-4d6d-958f-94687899b838,1/27/2012,1,CLr,clearance,,,
clinicalPharmacology,03646015-2d86-4d6d-958f-94687899b838,1/27/2012,1,PHN,postherpetic neuralgia,,,
clinicalPharmacology,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,MED,minimum erythematous dose,,,
clinicalPharmacology,5683ec23-d01d-493c-b5a9-00a3e240bb07,3/29/2012,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,5683ec23-d01d-493c-b5a9-00a3e240bb07,3/29/2012,1,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,d9243be5-bd27-4f37-ba8b-9f6f55f8b3e4,12/16/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,PR,partial responses,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,CR,[complete responses,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,PCR,polymerase chain reaction,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,SR,sustained response,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,CML,Chronic Myelogenous Leukemia,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,CR+PR,cytogenetic response rate,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,ALT,alanine aminotransferase,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,SC,subcutaneous,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,tiw,times a week,,,
clinicalPharmacology,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,IM,intramuscular,,,
clinicalPharmacology,3F89FB83-49EA-467F-6E9A-68FD1EE12ED7,11/19/2007,1,RNA,ribonucleic acid,,,
clinicalPharmacology,3F89FB83-49EA-467F-6E9A-68FD1EE12ED7,11/19/2007,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,a5e5413d-bc22-4ae1-959b-0eb0430dbd38,1/19/2012,2,GU,gastric ulcer,,,
clinicalPharmacology,a5e5413d-bc22-4ae1-959b-0eb0430dbd38,1/19/2012,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,09be2cbc-73bf-4894-add6-10e46c4471c9,12/7/2011,3335,GX,glycinexylidide,,,
clinicalPharmacology,09be2cbc-73bf-4894-add6-10e46c4471c9,12/7/2011,3335,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,23ba1d84-686f-41f6-ac83-8d839ae25350,1/9/2012,2,QTc,QT and mean corrected QT interval,,,
clinicalPharmacology,540eaf0a-da8d-41ce-b9c5-0c4e0733a179,10/13/2011,2,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,LDL,low density lipoprotein,,,
clinicalPharmacology,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,VLDL,very low density lipoprotein,,,
clinicalPharmacology,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,TG,triglyceride,,,
clinicalPharmacology,6c7e9485-1ede-411c-8c46-911439332864,10/13/2011,11,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,c3f47985-0027-4fa7-aab2-5bc6ca79a6e8,8/1/2011,7,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,34f6e21e-f6fc-4426-b5fb-1abe97faa7ac,9/20/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,34f6e21e-f6fc-4426-b5fb-1abe97faa7ac,9/20/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,1aa34beb-b06b-410c-b483-ba0bd903944a,5/24/2010,1,TK,thymidine kinase,,,
clinicalPharmacology,1aa34beb-b06b-410c-b483-ba0bd903944a,5/24/2010,1,HSV-1,HSV types 1,,,
clinicalPharmacology,b1ceb35b-25e0-4b7d-bea0-18099464d168,3/29/2012,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,0e747223-2740-4e45-9bef-ae5f7798064a,12/15/2011,2,QTc,QT correction,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,MCVE,major cardiovascular events,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,TNT,to New Targets Study,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,min,median,,,
clinicalPharmacology,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalPharmacology,d02af310-d097-4886-86e5-adcf6bca0533,9/26/2007,1,PDT,photodynamic therapy,,,
clinicalPharmacology,d02af310-d097-4886-86e5-adcf6bca0533,9/26/2007,1,PAP,photoactive porphyrins,,,
clinicalPharmacology,d02af310-d097-4886-86e5-adcf6bca0533,9/26/2007,1,AKs,actinic keratoses,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,ITT,intention-to-treat,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,CVD,cardiovascular disease,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,SBP,systolic blood pressure,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,110aada7-dfe8-4ecf-80c7-4dac8907ad29,5/4/2011,1,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,ISH,isolated systolic hypertension,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,DBP,diastolic blood pressure,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,ITT,intention-to-treat,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,ESRD,end-stage renal disease,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,CVD,cardiovascular disease,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,SBP,systolic blood pressure,,,
clinicalPharmacology,f51fd4fa-ea55-487e-b886-ae105dd5a854,12/29/2011,6,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,b506bc93-f0c9-4483-a7e8-a4e3f6b54282,6/29/2010,1,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,b506bc93-f0c9-4483-a7e8-a4e3f6b54282,6/29/2010,1,LES,lower esophageal sphincter,,,
clinicalPharmacology,ffb158a1-83ba-4100-9221-175aa986dc3e,1/21/2012,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,PIs,protease inhibitors,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,NNRTIs,non-nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,ZDV-TP,zidovudine triphosphate,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,AMT,3’-amino-3’-deoxythymidine,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,AUC,area under the curve,,,
clinicalPharmacology,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,TAMs,Thymidine analogue mutations,,,
clinicalPharmacology,2ffbec78-5bd4-4647-b282-d6edf8e22ccc,7/15/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2ffbec78-5bd4-4647-b282-d6edf8e22ccc,7/15/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,fead084a-a376-4d57-bdf0-aa7ed3655505,6/9/2010,1,ADCS-CGIC,Alzheimer’s  Disease Cooperative Study - Clinician’s Global Impression of Change,,,
clinicalPharmacology,fead084a-a376-4d57-bdf0-aa7ed3655505,6/9/2010,1,ADCS-CGIC,Alzheimer’s Disease Cooperative Study – Clinician’s Global  Impression of Change,,,
clinicalPharmacology,fead084a-a376-4d57-bdf0-aa7ed3655505,6/9/2010,1,CIBIC,Clinician's Interview-Based Impression of Change,,,
clinicalPharmacology,23b73332-cbb3-4155-8ad8-b24619cdea85,4/4/2012,1,AUC,area under the curve,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,STH,somatotropic hormone,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,c5774511-bee9-4ebb-a9aa-9e74de8d840e,2/4/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,HDRS,Hamilton  Depression Rating Scale,,,
clinicalPharmacology,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,CGI,Clinical Global Impressions,,,
clinicalPharmacology,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,MN,mononuclear,,,
clinicalPharmacology,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,6242b7ad-eaa0-a524-b6e0-ec33e63407db,6/21/2012,7,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,de028434-46cf-44f6-8ac6-889c7c6943b3,10/7/2011,13,HTM,Haemophilus Test Media,,,
clinicalPharmacology,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,CNS,Central Nervous System,,,
clinicalPharmacology,743fca6d-9482-4e9d-b072-ea9d18da2a23,11/28/2006,3,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,49040b3a-0802-4a7d-b0c9-c7f47c1bbe10,5/18/2010,2,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,4ae0ff63-c577-478e-9fa0-b7c22a8e7de4,6/4/2012,6,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,4ae0ff63-c577-478e-9fa0-b7c22a8e7de4,6/4/2012,6,TRNG,tetracycline-resistant Neisseria gonorrhoae,,,
clinicalPharmacology,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,ab02fb34-932c-43d6-a82c-9825957c6468,11/10/2011,3130,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,e135bf9d-b8f1-49e1-9b43-afdcd2b9c8f0,11/21/2011,12,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,e135bf9d-b8f1-49e1-9b43-afdcd2b9c8f0,11/21/2011,12,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,e135bf9d-b8f1-49e1-9b43-afdcd2b9c8f0,11/21/2011,12,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,1881d0ef-38d3-4ecc-bd51-d20679b7dc2f,5/2/2012,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8,2/29/2008,1,M-I,metabolite,,,
clinicalPharmacology,319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8,2/29/2008,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8,2/29/2008,1,LH,luteinizing hormone,,,
clinicalPharmacology,4c2347db-79a3-4279-87f8-9fa91e6d00e3,1/19/2012,6,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,4c2347db-79a3-4279-87f8-9fa91e6d00e3,1/19/2012,6,DBP,diastolic blood pressure,,,
clinicalPharmacology,4c2347db-79a3-4279-87f8-9fa91e6d00e3,1/19/2012,6,ITT,intention-to-treat,,,
clinicalPharmacology,4c2347db-79a3-4279-87f8-9fa91e6d00e3,1/19/2012,6,SBP,systolic blood pressure,,,
clinicalPharmacology,4c2347db-79a3-4279-87f8-9fa91e6d00e3,1/19/2012,6,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,CVP,central venous pressure,,,
clinicalPharmacology,C89D3ECC-4F4C-4566-8808-79152344194D,10/2/2008,1,MIHA,m-iodohippuric acid,,,
clinicalPharmacology,C89D3ECC-4F4C-4566-8808-79152344194D,10/2/2008,1,NE,norepinephrine,,,
clinicalPharmacology,de06a4da-ea70-441e-bba2-e40eb51a8c3a,6/2/2006,1,AUC,area-under-the-curve,,,
clinicalPharmacology,3e823928-c853-4617-acad-21b27174aa7b,7/29/2010,2,MIC's,minimal inhibitory  concentrations,,,
clinicalPharmacology,3e823928-c853-4617-acad-21b27174aa7b,7/29/2010,2,MIC's,minimum  inhibitory concentrations,,,
clinicalPharmacology,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,Vd,volume of distribution,,,
clinicalPharmacology,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,CPB,Cardiopulmonary Bypass,,,
clinicalPharmacology,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,PDT,photodynamic therapy,,,
clinicalPharmacology,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,BLU-U,Blue Light Photodynamic Therapy Illuminator,,,
clinicalPharmacology,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,PpIX,protoporphyrin IX,,,
clinicalPharmacology,cdad645a-c939-496e-973c-d1a22ffe6b29,5/19/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5fb7c70d-410f-46a6-9906-edd5106c34d0,6/8/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,4383c6ec-53ad-4c79-b0af-316b3284b2fb,4/30/2011,14,Ratio,ratio with/without coadministered drug,,,
clinicalPharmacology,96424d21-3fa4-4a32-8b98-fd593748f236,2/7/2012,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,96424d21-3fa4-4a32-8b98-fd593748f236,2/7/2012,2,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,1CBEB5ED-32B4-43D7-9A50-7464D11A5CF2,9/11/2007,2,Vd,volume of distribution,,,
clinicalPharmacology,cc445a39-d84c-4b76-9fb8-ae302e7cd96b,11/16/2011,5,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2A4CD065-A1DD-4B88-9F7A-7BA93502F972,10/26/2006,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,STH,somatotropic hormone,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,CGI,Clinical Global Impression,,,
clinicalPharmacology,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,49d3b871-f9fd-4d58-8405-8682c0c6e238,6/1/2012,11,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,09660a95-a7b3-4d1f-832c-a4fa7a5b7ddd,11/27/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d8d3b5b9-7ac7-445a-96c7-b5218417d9f8,2/15/2012,2,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681,6/24/2008,2,PRA,plasma renin activity,,,
clinicalPharmacology,4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681,6/24/2008,2,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,a5a77f2d-2833-4dd9-8839-95f0e63b1606,3/8/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,d567412a-e5ed-4c7f-90f0-ea3039786480,11/22/2010,3,MICs,minimal inhibitory  concentrations,,,
clinicalPharmacology,cc12443a-26f3-4a6d-8569-62494c0841c4,10/12/2010,430,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,cc12443a-26f3-4a6d-8569-62494c0841c4,10/12/2010,430,ECL,Enterochromaffin-like,,,
clinicalPharmacology,cc12443a-26f3-4a6d-8569-62494c0841c4,10/12/2010,430,CYP,cytochrome P450,,,
clinicalPharmacology,dba16dd8-5a2e-4914-a09d-2e4af18ee432,10/8/2010,2008,GH,growth  hormone,,,
clinicalPharmacology,dba16dd8-5a2e-4914-a09d-2e4af18ee432,10/8/2010,2008,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,dba16dd8-5a2e-4914-a09d-2e4af18ee432,10/8/2010,2008,LH,luteinizing hormone,,,
clinicalPharmacology,87f388c6-c942-47f5-b685-0f7ce0e431f4,4/18/2012,1,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,0750d877-b6f0-46bb-8c1a-46a7c27ebefb,4/28/2011,1,AF,Atrial Fibrillation,,,
clinicalPharmacology,0750d877-b6f0-46bb-8c1a-46a7c27ebefb,4/28/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,ECG,electrocardiogram,,,
clinicalPharmacology,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,CI,confidence intervals,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,ESRD,end-stage renal disease,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,ac389683-9906-42b6-864f-aad2f3be62b6,9/27/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,CABG,coronary artery bypass graft,,,
clinicalPharmacology,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,ED,erectile dysfunction,,,
clinicalPharmacology,719ef928-c061-49d3-83d3-6e7482462679,6/28/2010,1,MMSE,Mini-Mental State Examination,,,
clinicalPharmacology,719ef928-c061-49d3-83d3-6e7482462679,6/28/2010,1,GDS,Global Deterioration Scale,,,
clinicalPharmacology,719ef928-c061-49d3-83d3-6e7482462679,6/28/2010,1,ADCS-CGIC,Alzheimer’s Disease Cooperative Study—Clinicians Global Impression of Change,,,
clinicalPharmacology,719ef928-c061-49d3-83d3-6e7482462679,6/28/2010,1,CIBIC,Clinician’s Interview Based Impression of Change,,,
clinicalPharmacology,f94b2ba4-024f-4068-8759-da6c8d31c546,1/30/2012,8,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,FAC0C875-111E-4AF2-D186-ED4D4EE9DE59,4/24/2007,2,AUC,area under the curve,,,
clinicalPharmacology,13ac45e5-59b1-456a-87fc-8e60107818a1,4/3/2012,3,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,e2f854cb-7f91-4269-ba67-97065ac8b4a0,3/3/2011,1405,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,e2f854cb-7f91-4269-ba67-97065ac8b4a0,3/3/2011,1405,msec,mseconds,,,
clinicalPharmacology,e2f854cb-7f91-4269-ba67-97065ac8b4a0,3/3/2011,1405,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,NET,norethindrone,,,
clinicalPharmacology,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,EE,ethinyl estradiol,,,
clinicalPharmacology,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,A-V,atrioventricular,,,
clinicalPharmacology,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,ISA,in animals with minimal beta1-agonist,,,
clinicalPharmacology,1a4ce717-7a29-4308-8180-91f923d45a03,3/27/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,adea2968-68fa-435e-9c8c-dfa0f9903b00,6/19/2012,1035,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,adea2968-68fa-435e-9c8c-dfa0f9903b00,6/19/2012,1035,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,MN,mononuclear,,,
clinicalPharmacology,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,fe44d24d-55cd-439c-895b-00a38cd59f65,3/10/2012,20,MBC,minimum bactericidal concentration,,,
clinicalPharmacology,fe44d24d-55cd-439c-895b-00a38cd59f65,3/10/2012,20,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fe44d24d-55cd-439c-895b-00a38cd59f65,3/10/2012,20,PBPs,penicillin binding proteins,,,
clinicalPharmacology,4c1c212f-71a5-4dd3-81b2-cd9e2148774c,9/9/2011,6,CLD,chronic liver disease,,,
clinicalPharmacology,4c1c212f-71a5-4dd3-81b2-cd9e2148774c,9/9/2011,6,FPG,fasting plasma glucose,,,
clinicalPharmacology,4c1c212f-71a5-4dd3-81b2-cd9e2148774c,9/9/2011,6,PPG,post-prandial glucose,,,
clinicalPharmacology,c4572a72-e49a-4c29-b121-a530a6b5fd4f,4/5/2011,2,AD,Alzheimer's disease,,,
clinicalPharmacology,c4572a72-e49a-4c29-b121-a530a6b5fd4f,4/5/2011,2,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,6588514f-84fe-4608-99e6-e3a7ecd338c3,4/18/2011,2,AUC,area under the curve,,,
clinicalPharmacology,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,CSF,cerebrospinal fluid,,,
clinicalPharmacology,aa44552c-3cfe-4111-8aa5-4251aeed9be9,7/19/2012,1434,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,aa44552c-3cfe-4111-8aa5-4251aeed9be9,7/19/2012,1434,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8895a5a9-ea0a-406a-8c92-e03bbc3d0bd8,12/13/2011,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,4700340f-4f77-48f2-bef2-bf6391bc25da,9/22/2009,5,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,CPS,complex partial seizures,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,AED,antiepilepsy drug,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,i.e.,improvement,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,TID,three divided doses,,,
clinicalPharmacology,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,MRS,Manic Rating Scale,,,
clinicalPharmacology,afbcbf79-e7cd-4615-a999-9941573882b5,1/19/2010,1,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,afbcbf79-e7cd-4615-a999-9941573882b5,1/19/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8e8612cd-9f21-4348-a06c-ca7ea151f848,8/23/2011,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,8e8612cd-9f21-4348-a06c-ca7ea151f848,8/23/2011,1,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,1C3A94FF-91F0-4BC1-8BC8-1B6AA87E8026,4/5/2007,1,AUC,area-under-the-plasma-concentration curve,,,
clinicalPharmacology,1C3A94FF-91F0-4BC1-8BC8-1B6AA87E8026,4/5/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,95905ef9-1de6-41eb-aa34-ac750e93e292,12/1/2011,3282,V/F,volume of distribution,,,
clinicalPharmacology,95905ef9-1de6-41eb-aa34-ac750e93e292,12/1/2011,3282,HbA1c,hemoglobin A1c,,,
clinicalPharmacology,95905ef9-1de6-41eb-aa34-ac750e93e292,12/1/2011,3282,PPG,postprandial plasma glucose,,,
clinicalPharmacology,B1E6C7AB-EEFE-4089-B403-EDEAAB4F6E36,1/3/2007,1,ISA,in animals with minimal beta1-agonist,,,
clinicalPharmacology,f8bb3384-355a-45fa-ad59-b7402a9f5533,3/22/2007,1,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,f8bb3384-355a-45fa-ad59-b7402a9f5533,3/22/2007,1,BPH,Benign prostatic hyperplasia,,,
clinicalPharmacology,13a33420-b1e1-4b7e-8e59-4d5badafe654,5/11/2012,7,MIC,minimum inhibitory concentrations,,,
clinicalPharmacology,8f935afa-f845-46cd-b61a-db7a48e559c0,4/22/2011,1,ERG,electroretinogram,,,
clinicalPharmacology,8f935afa-f845-46cd-b61a-db7a48e559c0,4/22/2011,1,CAD,Coronary Artery Disease,,,
clinicalPharmacology,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,i.e.,improvement from baseline,,,
clinicalPharmacology,b95b7647-d6c0-4470-fba0-680256661dd2,10/27/2011,10,TPN,total parenteral nutrition,,,
clinicalPharmacology,f4853677-1622-4037-688b-fdf533a11d96,1/20/2012,29,CgA,Chromogranin A,,,
clinicalPharmacology,f4853677-1622-4037-688b-fdf533a11d96,1/20/2012,29,ECL,Enterochromaffin-like,,,
clinicalPharmacology,fa952140-c9f6-472d-a04f-96c44fe9bca8,6/7/2010,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,6742732c-80a5-460c-b6e3-81446c565706,6/1/2011,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,A7C056ED-BE64-4AFA-AD79-D90EA4352BED,11/8/2006,1,GERD,patients.Gastroesophageal Reflux Disease,,,
clinicalPharmacology,A7C056ED-BE64-4AFA-AD79-D90EA4352BED,11/8/2006,1,GERD,therapy.Gastroesophageal Reflux Disease,,,
clinicalPharmacology,A7C056ED-BE64-4AFA-AD79-D90EA4352BED,11/8/2006,1,IV,intravenous,,,
clinicalPharmacology,7d485d38-5d43-4a54-bc63-82734035c66a,10/6/2007,1,AUC,area under the curve,,,
clinicalPharmacology,9250d33e-3429-4ad5-398b-b9b7943d9ff9,6/9/2011,11,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,13e256ae-8b78-49ff-8ad7-bd38bbf5e166,1/23/2012,3,i.e.,inhibited by muscarine,,,
clinicalPharmacology,13e256ae-8b78-49ff-8ad7-bd38bbf5e166,1/23/2012,3,A-V,atrioventricular,,,
clinicalPharmacology,13e256ae-8b78-49ff-8ad7-bd38bbf5e166,1/23/2012,3,e.g.,effector organ,,,
clinicalPharmacology,13e256ae-8b78-49ff-8ad7-bd38bbf5e166,1/23/2012,3,Cl¯,chloride,,,
clinicalPharmacology,50b7fc3e-de79-4b08-a2b7-b05110ec70fb,4/27/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,6737ed97-9559-44c7-889b-6bc0e20eb36b,10/7/2010,3,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,6737ed97-9559-44c7-889b-6bc0e20eb36b,10/7/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,453ac443-4fd4-4b5c-b7b4-06d34dc38e0d,2/23/2012,5,LVEDP,left ventricular end diastolic pressure,,,
clinicalPharmacology,b1fe2ec1-8604-45ea-8b45-15f01c9fe309,3/9/2012,3,Cl¯,chloride,,,
clinicalPharmacology,1c0525fc-2d95-4682-a459-7ea4fbe95c72,6/13/2011,8,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,473d1684-944c-4a65-aef4-6379f97a0178,6/23/2011,2,AUC,area under the curve,,,
clinicalPharmacology,330cc74e-0f50-477d-85b1-fec1438c81f6,9/14/2010,2,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,CYP,cytochrome P450,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,IV,intravenous,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,GABA-BZ,gamma-aminobutyric acid-benzodiazepine,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,ie,its active metabolites,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,TSO,to sleep onset,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,CYP,cytochrome P450,,,
clinicalPharmacology,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,LPS,latency to persistent sleep,,,
clinicalPharmacology,2342cfb7-6ac2-471e-8b69-44d4e9bfe765,5/8/2012,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,2342cfb7-6ac2-471e-8b69-44d4e9bfe765,5/8/2012,2,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,A2DE6991-EEB8-45A8-E0A7-B635C90A384A,12/4/2006,1,APTTs,activated partial thromboplastin times,,,
clinicalPharmacology,A2DE6991-EEB8-45A8-E0A7-B635C90A384A,12/4/2006,1,Cl?,Chloride,,,
clinicalPharmacology,A2DE6991-EEB8-45A8-E0A7-B635C90A384A,12/4/2006,1,Cl?,chloride,,,
clinicalPharmacology,2bcde264-5f6f-47f6-ae2e-1b7010deacf7,1/5/2012,6,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,2bcde264-5f6f-47f6-ae2e-1b7010deacf7,1/5/2012,6,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,5c527c2e-9062-4afe-dbbb-f650db3a340f,4/18/2012,10,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,5c527c2e-9062-4afe-dbbb-f650db3a340f,4/18/2012,10,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,ITT,intention-to-treat,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,CVD,cardiovascular disease,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,SBP,systolic blood pressure,,,
clinicalPharmacology,f88c39fa-ed74-42f4-a886-c268daf8f3a6,12/28/2010,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,3ec55c0a-1456-412e-972f-352b3135c8f2,4/1/2011,2,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,CGI,Clinical Global Impression,,,
clinicalPharmacology,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,c0acc97d-3d8d-4a7f-8acd-99050b0af2f1,2/16/2012,4,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,06c0a509-026f-44e0-9975-a94a8de51d43,9/14/2005,3,LES,lower esophageal sphincter,,,
clinicalPharmacology,14710a71-e2e9-4e4e-bd65-1c296f70c166,12/8/2009,5,Tmax,to maximum concentration,,,
clinicalPharmacology,de6a969a-7e0f-4e5f-8d12-de5c7129d39c,8/26/2010,1,Cl–,chloride,,,
clinicalPharmacology,4fe9ed32-0843-4a05-a5f2-d2e6325bbb9a,5/29/2012,4,B17P,Betamethasone 17-propionate,,,
clinicalPharmacology,06d55c37-5b80-45b6-bfea-6b00fd960ed4,1/18/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fbfa1874-a710-49da-9e79-56cfaad69080,3/18/2010,1,Css,concentration  of morphine at steady-state,,,
clinicalPharmacology,fbfa1874-a710-49da-9e79-56cfaad69080,3/18/2010,1,GH,growth  hormone,,,
clinicalPharmacology,fbfa1874-a710-49da-9e79-56cfaad69080,3/18/2010,1,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,fbfa1874-a710-49da-9e79-56cfaad69080,3/18/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,7d028b83-5166-4b2e-b442-ba6cbfefbfd6,1/31/2008,2,TBPA,thyroid-binding prealbumin,,,
clinicalPharmacology,7d028b83-5166-4b2e-b442-ba6cbfefbfd6,1/31/2008,2,TRH,thyrotropin releasing hormone,,,
clinicalPharmacology,7d028b83-5166-4b2e-b442-ba6cbfefbfd6,1/31/2008,2,TBg,thyroid-binding globulin,,,
clinicalPharmacology,9a4229fd-fecd-4ac1-9c4f-6d442533457f,3/2/2010,2,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,9a4229fd-fecd-4ac1-9c4f-6d442533457f,3/2/2010,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,4fecb867-7213-49ce-9d8f-433f157635d1,4/25/2011,2,HPPH,5-(p-hydroxyphenyl)-5-phenylhydantoin,,,
clinicalPharmacology,2c592fc1-ccb3-4bff-9087-54834bca7446,4/20/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,2c592fc1-ccb3-4bff-9087-54834bca7446,4/20/2011,1,TID,three divided doses,,,
clinicalPharmacology,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,TCA,tricyclic antidepressant,,,
clinicalPharmacology,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,SSRIs,selective serotonin  reuptake inhibitors,,,
clinicalPharmacology,ae5682dc-61f0-48ff-9d0d-7ce1aa1c39de,1/18/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b8910797-9aa9-48f1-8d61-d35be37e860d,10/4/2011,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,8809c12d-06de-4ccb-95d3-5108d2a955fb,8/5/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,8809c12d-06de-4ccb-95d3-5108d2a955fb,8/5/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,8809c12d-06de-4ccb-95d3-5108d2a955fb,8/5/2011,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,8809c12d-06de-4ccb-95d3-5108d2a955fb,8/5/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,07FE9CC3-1EF2-420C-B45D-7F1E894B6EF9,10/31/2006,1,ISA,intrinsic sympathomimetic activity,,,
clinicalPharmacology,A9758BEA-B15B-42E5-938C-03E3F042B290,3/31/2007,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,A9758BEA-B15B-42E5-938C-03E3F042B290,3/31/2007,1,LH,luteinizing hormone,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,CL,clearance,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,Vd,volume of distribution,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,IV,intravenous,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,GI,gastrointestinal,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,PK,pharmacokinetics,,,
clinicalPharmacology,a02a3bfc-8e79-4e59-953e-361f92a3b3f1,10/7/2011,17,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,a02a3bfc-8e79-4e59-953e-361f92a3b3f1,10/7/2011,17,PBP,penicillin binding proteins,,,
clinicalPharmacology,a02a3bfc-8e79-4e59-953e-361f92a3b3f1,10/7/2011,17,IM,intramuscular,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,CGI,Clinical Global Impression,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,GAD,generalized anxiety disorder,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,PD,panic disorder,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,aa8e14c1-fbfd-4e4d-b59e-2d4ae1ca815f,1/10/2012,1,EDDP,2-ethylidene-1,5-dimethyl-3,3¬diphenylpyrrolidene,
clinicalPharmacology,08b737e8-9d9c-4d04-b91b-1f0c5fe065c7,4/12/2011,3,Tmax,the maximum concentration in serum,,,
clinicalPharmacology,05d4df4b-dfe8-4828-b423-a3d4f2c4114a,6/8/2010,3,V/F,volume of distribution,,,
clinicalPharmacology,da74aee2-4596-4a41-a061-b9a2a487adb0,6/7/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,da74aee2-4596-4a41-a061-b9a2a487adb0,6/7/2012,4,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,c73da51a-1899-45ad-b6cf-9c52c36a25dd,6/19/2012,24,IRI,Immunoreactive Insulin,,,
clinicalPharmacology,7fce939e-c38e-497f-ba3f-e7b6ba44bfd9,8/25/2010,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,ffa97984-f7e1-4be6-a0fd-5998b18c42cd,10/8/2009,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,CGI,Clinical Global Impression,,,
clinicalPharmacology,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,6d5fcdb2-4d84-4b20-87e3-58a43e567500,2/18/2012,4,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,MMSE,Mini-Mental State Examination,,,
clinicalPharmacology,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,ADCS-CGIC,Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression of Change,,,
clinicalPharmacology,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,GDS,Global Deterioration Scale,,,
clinicalPharmacology,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinician’s Global Impression of Change,,,
clinicalPharmacology,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,CIBIC,Clinician's Interview-Based Impression of Change,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,GFR,glomerular filtration rate,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,IRF,immediate-release formulation,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,CCK,cholecystokinin,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,SSTR,somatostatin receptors,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,MRT,mean residence time,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,PK,pharmacokinetics,,,
clinicalPharmacology,dce12085-d6c4-48a5-959b-e771c413c9c5,4/10/2012,1,CgA,Chromogranin A,,,
clinicalPharmacology,dce12085-d6c4-48a5-959b-e771c413c9c5,4/10/2012,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,dce12085-d6c4-48a5-959b-e771c413c9c5,4/10/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MAC,Mycobacterium avium                          Complex,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MAC,Mycobacterium avium  complex,,,
clinicalPharmacology,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,HTM,Haemophilus Testing Medium,,,
clinicalPharmacology,03283208-8616-4117-9d2b-aa8046017a4f,10/7/2011,12,HTM,Haemophilus Test Media,,,
clinicalPharmacology,a9241f0b-e1d0-4782-98e6-7f1eaf9ccc85,2/23/2010,4,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,STH,somatotropic hormone,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,FSH,follicle stimulating hormone,,,
clinicalPharmacology,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,LH,luteinizing hormone,,,
clinicalPharmacology,2b55a812-a862-4f35-a6ce-25cff716e63d,7/12/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f68a34ae-e17e-45b3-8c8e-8d7194b2124a,7/12/2012,8,MUGA,multigated nuclear medicine,,,
clinicalPharmacology,f68a34ae-e17e-45b3-8c8e-8d7194b2124a,7/12/2012,8,LVEF,left ventricular ejection fraction,,,
clinicalPharmacology,95b9fc17-9c94-4762-910c-df0bb0b2aa85,7/23/2012,7,AUC,area under the curve,,,
clinicalPharmacology,86d1eec6-fb4d-42da-86f4-16ecd9f6a0df,9/25/2009,5,CYP3A,cytochrome  P450 3A,,,
clinicalPharmacology,86d1eec6-fb4d-42da-86f4-16ecd9f6a0df,9/25/2009,5,Cyp3A4,cytochrome P450 3A4,,,
clinicalPharmacology,d73713c3-3c48-4cce-8437-1723ca54d077,2/2/2010,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,a41b3e0c-8f43-49a5-90ea-0509e5fc18e2,8/10/2010,1,Cl–,chloride,,,
clinicalPharmacology,2a9976e3-4595-4bc5-b7f9-f4a9bd59e55d,10/1/2010,1,GX,glycinexylidide,,,
clinicalPharmacology,2a9976e3-4595-4bc5-b7f9-f4a9bd59e55d,10/1/2010,1,tmax,to reach maximum concentration,,,
clinicalPharmacology,2a9976e3-4595-4bc5-b7f9-f4a9bd59e55d,10/1/2010,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,2a9976e3-4595-4bc5-b7f9-f4a9bd59e55d,10/1/2010,1,PK,pharmacokinetic,,,
clinicalPharmacology,7cc14b86-0833-4c3c-91f3-7963d7052fd5,8/18/2011,11,AUC,area under the curve,,,
clinicalPharmacology,0d543ed4-ff0d-407c-9c78-c416bd0c4eee,6/7/2011,2,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,PWS,Prader-Willi syndrome,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,TS,Turner syndrome,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,IGF-I,Insulin-like Growth  Factor-I/Somatomedin C,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,ISS,Idiopathic short stature,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,GHD,growth hormone deficiency,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SC,subcutaneous,,,
clinicalPharmacology,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SGA,small for gestational age,,,
clinicalPharmacology,E16D8FE7-4480-40D1-8951-AD65F7F15438,1/4/2008,3,TRF,thyroid releasing factor,,,
clinicalPharmacology,E16D8FE7-4480-40D1-8951-AD65F7F15438,1/4/2008,3,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,7e7a04d3-c010-4416-932a-0a7857f6b00c,7/23/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,4ccb8d3d-31ef-49ff-8567-c620b9d74f8c,8/31/2011,1,TBPS,t-butyl-bicyclophosphorothionate,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,CPS,complex partial seizures,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,AED,antiepilepsy drug,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,i.e.,improvement,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,TID,three divided doses,,,
clinicalPharmacology,9fb17714-bdb1-4bfa-bc04-d9c011604cde,5/24/2010,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,CE,conjugated estrogens,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,MPA,medroxyprogesterone  acetate,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,PE,pulmonary embolism,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,CHD,coronary heart disease,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,WHI,Women's Health Initiative,,,
clinicalPharmacology,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,cyclical,"<content styleCode=""bold"">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg",,,
clinicalPharmacology,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,LDL,low density lipoprotein,,,
clinicalPharmacology,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,VLDL,very low density lipoprotein,,,
clinicalPharmacology,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,TG,triglyceride,,,
clinicalPharmacology,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,D2,dopamine type 2,,,
clinicalPharmacology,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,CI,confidence intervals,,,
clinicalPharmacology,5a205e32-ce63-491c-a1e4-0e45635090af,6/27/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,6beb0c1a-9801-40d9-97d5-3488e603cc1a,3/22/2011,2,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,CgA,Chromogranin A,,,
clinicalPharmacology,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,CYP,cytochrome P450,,,
clinicalPharmacology,f931d3af-c32a-4406-8799-9b097f41594b,6/16/2010,2,ER,Extended-release,,,
clinicalPharmacology,6e030b0f-8ee6-4b23-9345-7193d4280e88,3/12/2012,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,0d4fb45b-e45b-4519-96a3-a8a106450f87,1/4/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,MycobacteriaMycobacteriaMycobacterium avium complex,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,Mycobacterium avium Complex,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,OADC,oleic acid-albumin-dextrose-catalase,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,of:Mycobacterium avium complex,,,
clinicalPharmacology,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,Groups C,Gram-positive MicroorganismsStreptococcus agalactiaeStreptococcus agalactiaeStreptococci,,,
clinicalPharmacology,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,HPS,Heart Protection Study,,,
clinicalPharmacology,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,95% CI,278.6(51.8)211.9(49)46.9(11.9)90(50.7)186.3(38.1)Simvastatin24 Weeks106% Change from Baseline,,,
clinicalPharmacology,782af2da-7092-4e55-8f07-9e67c283bf84,2/10/2011,1,min,median,,,
clinicalPharmacology,b007bac6-a207-481c-8aba-03ade1dd6a88,7/8/2010,330,D2,dopamine type 2,,,
clinicalPharmacology,4a81b757-0a64-4ed4-86f4-57aeb349105f,1/20/2012,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,AV,atrioventricular,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,CYP3A,cytochrome P-450 3A,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,VT,ventricular tachycardia,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,SCL,sinus cycle length,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,DEA,.N-desethylamiodarone,,,
clinicalPharmacology,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,VF,ventricular fibrillation,,,
clinicalPharmacology,d09dd18f-8db4-4fee-b51c-6aba56850103,12/16/2010,14,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,QRDRs,Quinolone-Resistance Determining Regions,,,
clinicalPharmacology,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,AUC,area under the curve,,,
clinicalPharmacology,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,KS,Kaposi's sarcoma,,,
clinicalPharmacology,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,MPS,mononuclear phagocyte system,,,
clinicalPharmacology,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,MPEG,methoxypolyethylene glycol,,,
clinicalPharmacology,56fc2167-ceb6-4e3e-8ff7-5e400dfbd533,7/13/2010,2,i.e.,initial clearance rates,,,
clinicalPharmacology,56fc2167-ceb6-4e3e-8ff7-5e400dfbd533,7/13/2010,2,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,56fc2167-ceb6-4e3e-8ff7-5e400dfbd533,7/13/2010,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,56fc2167-ceb6-4e3e-8ff7-5e400dfbd533,7/13/2010,2,CHF,Congestive Heart Failure,,,
clinicalPharmacology,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,study 2,Rate      STUDY 2 Maximum Flow RateIn one fixed dose study,,,
clinicalPharmacology,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,BPH,Benign prostatic hyperplasia,,,
clinicalPharmacology,9ad1b5f4-fbb7-46b5-a719-796d85cd4c54,5/25/2011,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,9ad1b5f4-fbb7-46b5-a719-796d85cd4c54,5/25/2011,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,9ad1b5f4-fbb7-46b5-a719-796d85cd4c54,5/25/2011,1,PVCs,premature ventricular contractions,,,
clinicalPharmacology,4144009e-e956-4fec-b5b7-a4950168e055,9/16/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,18c897d3-47c2-461a-a0e7-0926453d45e3,12/30/2009,1,CAPD,continuous ambulatory peritoneal  dialysis,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,c99c5895-c3a0-4c44-9e42-59c4ef11d75c,3/11/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,cd6bb11b-3b9d-4d73-a093-d198913c4bff,12/13/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,cd6bb11b-3b9d-4d73-a093-d198913c4bff,12/13/2010,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8,3/31/2011,3,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8,3/31/2011,3,CYP,cytochrome P450,,,
clinicalPharmacology,15638656-0430-4157-bb13-32ede85131e1,9/10/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,154af0be-18fb-413e-a702-012bb259962d,2/9/2012,3,PPG,postprandial plasma glucose,,,
clinicalPharmacology,320f63f2-fac3-4aee-aff8-85724e00ef52,9/14/2010,6,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,320f63f2-fac3-4aee-aff8-85724e00ef52,9/14/2010,6,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,320f63f2-fac3-4aee-aff8-85724e00ef52,9/14/2010,6,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,c9fc6a64-cd68-46bd-a470-843b5d44eb2b,11/4/2010,70,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,ADP,adenosine diphosphate,,,
clinicalPharmacology,bedf8a82-48e9-44a4-8a1f-264ea194d45f,12/8/2009,5,SREs,skeletal-related events,,,
clinicalPharmacology,bedf8a82-48e9-44a4-8a1f-264ea194d45f,12/8/2009,5,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,67c174da-41b8-4738-8a22-dd814b8e96b8,12/22/2011,6,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,67c174da-41b8-4738-8a22-dd814b8e96b8,12/22/2011,6,Inhibitors,inhibitors,,,
clinicalPharmacology,67c174da-41b8-4738-8a22-dd814b8e96b8,12/22/2011,6,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,A2505576-801A-4DC5-9AC6-423664406481,6/12/2008,1,RNA,ribonucleic acid,,,
clinicalPharmacology,A2505576-801A-4DC5-9AC6-423664406481,6/12/2008,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,9001fa88-7b48-4be7-ba95-000ba1db48b4,10/13/2011,11,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,9001fa88-7b48-4be7-ba95-000ba1db48b4,10/13/2011,11,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,af154048-4130-46b6-ac1e-5389dfe68cb4,11/6/2009,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,af154048-4130-46b6-ac1e-5389dfe68cb4,11/6/2009,6,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,b28980df-064b-4fd4-8bf3-1589987671ab,1/3/2012,7,TK,thymidine kinase,,,
clinicalPharmacology,b28980df-064b-4fd4-8bf3-1589987671ab,1/3/2012,7,HSV-1,HSV types 1,,,
clinicalPharmacology,a81b956b-f004-4426-ba20-375ccf21eb71,10/1/2010,6,AUC,area under the concentration-time curve,,,
clinicalPharmacology,ACBCE0E8-5098-4785-943B-8BDB5FF17FAB,3/18/2008,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,55be87b4-a69b-4bfd-bf92-2949ec5e5dab,10/5/2011,1,GX,glycinexylidide,,,
clinicalPharmacology,55be87b4-a69b-4bfd-bf92-2949ec5e5dab,10/5/2011,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,c5f32941-3427-4a38-bc3d-38337b41d9d3,1/27/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalPharmacology,c5f32941-3427-4a38-bc3d-38337b41d9d3,1/27/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,6567dfb0-b220-40ea-9c00-551f873ffcf2,5/18/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,6567dfb0-b220-40ea-9c00-551f873ffcf2,5/18/2011,1,IV,intravenous,,,
clinicalPharmacology,1709ae09-e613-4d66-afad-47c0449f62aa,9/25/2009,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,A8454E30-AAE5-43AC-9184-953406E0F3B8,11/8/2007,1,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,A8454E30-AAE5-43AC-9184-953406E0F3B8,11/8/2007,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,A8454E30-AAE5-43AC-9184-953406E0F3B8,11/8/2007,1,PFR,peak flow rate,,,
clinicalPharmacology,5ffefcdc-ebfa-4dc8-b484-719658da9d6d,5/24/2010,2,GX,glycinexylidide,,,
clinicalPharmacology,5ffefcdc-ebfa-4dc8-b484-719658da9d6d,5/24/2010,2,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,A2C1F1B7-70B0-416B-8BDF-9EAED156E34B,4/12/2006,1,Css,concentration of morphine at steady state,,,
clinicalPharmacology,A2C1F1B7-70B0-416B-8BDF-9EAED156E34B,4/12/2006,1,Vd,volume of distribution,,,
clinicalPharmacology,d3a4788f-6ff4-4804-9b41-7d6f0b27cd5c,8/11/2011,5,CAPD,chronic ambulatory peritoneal dialysis,,,
clinicalPharmacology,d3a4788f-6ff4-4804-9b41-7d6f0b27cd5c,8/11/2011,5,JRA,Juvenile Rheumatoid Arthritis,,,
clinicalPharmacology,d3a4788f-6ff4-4804-9b41-7d6f0b27cd5c,8/11/2011,5,TFMA,4-trifluoromethylaniline,,,
clinicalPharmacology,159B5FAC-255C-4A22-98AD-891ABA73EAE1,11/24/2006,1,GERD,.GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,GAD,generalized anxiety disorder,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,PD,panic disorder,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,ad94cde9-4f4d-438a-bb95-d4350be8653b,4/13/2011,1,HDL,high density lipoprotein,,,
clinicalPharmacology,f9edc9b3-12e7-4917-a27c-8dbf6ac654ce,12/22/2009,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,09aee1f2-d5f0-4544-9949-14e425219220,12/8/2009,1,CI,confidence interval,,,
clinicalPharmacology,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,PT,prothrombin time,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,FPG,fasting plasma glucose,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,CL,clearance,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,Vd,volume of distribution,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,IV,intravenous,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,AUC,area under the curve,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,FBG,fasting blood glucose,,,
clinicalPharmacology,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,Tmax,to reach Cmax,,,
clinicalPharmacology,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,AIDS,acquired immunodeficiency syndrome,,,
clinicalPharmacology,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,RIA,radioimmunoassay,,,
clinicalPharmacology,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,GC-MF,gas chromatography-mass fragmentography,,,
clinicalPharmacology,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,AUC,area under the concentration time-curve,,,
clinicalPharmacology,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,HPLC,high pressure liquid chromatography,,,
clinicalPharmacology,9FCA10EE-973E-4FE0-AAF5-A0416918A397,12/18/2006,1,EEF,enhancement factor,,,
clinicalPharmacology,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,LDL,low density lipoprotein,,,
clinicalPharmacology,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,VLDL,very low density lipoprotein,,,
clinicalPharmacology,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,TG,triglyceride,,,
clinicalPharmacology,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,GER,gastroesophageal reflux,,,
clinicalPharmacology,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,mean age,minutes to nine pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,LESP,lower esophageal sphincter pressure,,,
clinicalPharmacology,1b11750e-4db4-4dd3-8b21-c9917b00aeaa,4/15/2010,4,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,1b11750e-4db4-4dd3-8b21-c9917b00aeaa,4/15/2010,4,PBP3,penicillin binding protein 3,,,
clinicalPharmacology,4d6b509c-7b9c-4c53-d8b1-ef9539f17039,3/5/2012,1413,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,CNS,central nervous system,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,DCT,demethylcitalopram,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,DA,dopamine,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,NE,norepinephrine,,,
clinicalPharmacology,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,CT,citalopram ,,,
clinicalPharmacology,50a26e9a-42d5-4d91-a346-57ef3a1e935f,11/11/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,756e6ebc-36fa-b6ac-a228-9d86d0ab8256,9/1/2011,9,NET,norethindrone,,,
clinicalPharmacology,756e6ebc-36fa-b6ac-a228-9d86d0ab8256,9/1/2011,9,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,756e6ebc-36fa-b6ac-a228-9d86d0ab8256,9/1/2011,9,EE,ethinyl estradiol,,,
clinicalPharmacology,8e9e8cb6-d28a-475a-9584-a1dee4899c4f,9/8/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,CNS,central nervous system,,,
clinicalPharmacology,a3ce5125-62ba-4983-93f0-91f254271605,7/1/2011,2,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,CSF,cerebrospinal fluid,,,
clinicalPharmacology,d93bc81a-650f-4070-beb4-3a5fa4d27a7d,8/1/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d93bc81a-650f-4070-beb4-3a5fa4d27a7d,8/1/2010,4,NMP,N-methylpyrrolidine,,,
clinicalPharmacology,d93bc81a-650f-4070-beb4-3a5fa4d27a7d,8/1/2010,4,PBP,penicillin binding proteins,,,
clinicalPharmacology,d93bc81a-650f-4070-beb4-3a5fa4d27a7d,8/1/2010,4,IM,intramuscular,,,
clinicalPharmacology,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalPharmacology,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,ESRD,end-stage renal disease,,,
clinicalPharmacology,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,RAS,renin-angiotensin system,,,
clinicalPharmacology,cb52fd1e-2ddf-4f45-b5c3-3d56b907270e,2/1/2012,2,HTM,Haemophilus Test Media,,,
clinicalPharmacology,967ef131-3dce-4c05-8f17-a5c9e01ca9a0,6/9/2011,1,6MNA,6- methoxy-2-naphthylacetic acid,,,
clinicalPharmacology,95976f1d-1b36-4f08-a98f-36d5d7883d7b,11/18/2011,3,UPDRS,Unified Parkinson’s Disease Rating Scale,,,
clinicalPharmacology,95976f1d-1b36-4f08-a98f-36d5d7883d7b,11/18/2011,3,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,95976f1d-1b36-4f08-a98f-36d5d7883d7b,11/18/2011,3,AUC,area under the curve,,,
clinicalPharmacology,a526ee23-eb4b-4bf4-a815-61ae171d182b,7/1/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,cd23e09f-0565-4592-90fe-624ca283188b,6/19/2012,1,Cl-,chloride,,,
clinicalPharmacology,d286d935-e409-452a-b7c2-84a446a6042b,4/9/2012,4,NET,norethindrone,,,
clinicalPharmacology,d286d935-e409-452a-b7c2-84a446a6042b,4/9/2012,4,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,d286d935-e409-452a-b7c2-84a446a6042b,4/9/2012,4,EE,ethinyl estradiol,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,CE,conjugated estrogens,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,MPA,medroxyprogesterone  acetate,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,WHI,Women’s Health Initiative,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,PE,pulmonary embolism,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,CHD,coronary heart disease,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,c56b20d8-eeee-4d87-94a1-ae186f9b550e,10/18/2011,7,IHSS,Idiopathic Hypertrophic Subaortic Stenosis,,,
clinicalPharmacology,6336b9ee-a2f3-44cc-ae6a-43a5f68745f6,3/30/2012,10,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,i.e.,improvement from baseline,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,SMAP,2–sulfamoylacetyl phenol,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,V/F,volume of distribution,,,
clinicalPharmacology,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,RBC,red blood cells,,,
clinicalPharmacology,690730ea-bd69-4b57-ab9e-2e76309c8d50,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,690730ea-bd69-4b57-ab9e-2e76309c8d50,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,5b6288fa-49da-4f44-b779-86e8404921db,10/7/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5b6288fa-49da-4f44-b779-86e8404921db,10/7/2008,1,broth,be interpreted according to the following criteria:1,,,
clinicalPharmacology,b6b16acc-608a-418a-bf53-f0e44d7f123a,4/7/2010,1,TK,thymidine kinase,,,
clinicalPharmacology,A57FD3FC-4C8F-4EB4-8BE0-9C7E243624BC,1/24/2008,1,V/F,volume of distribution,,,
clinicalPharmacology,efb1fc6e-2f9e-400a-8069-569d1c0894a5,5/31/2012,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a92428d1-b8a5-4b3d-965d-50fd333bd743,11/30/2011,8,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,CLr,clearance,,,
clinicalPharmacology,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,58ba2dc8-10c2-4532-92e2-40ec2fee3378,11/24/2010,1,Scores,scores of nasal and non-nasal symptoms,,,
clinicalPharmacology,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,PMDD,Premenstrual Dysphoric Disorder,,,
clinicalPharmacology,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,LLPDD,Luteal Phase Dysphoric Disorder,,,
clinicalPharmacology,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,V?,volume,,,
clinicalPharmacology,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,i.e.,improvement from baseline,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,SMAP,2–sulfamoylacetyl phenol,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,V/F,volume of distribution,,,
clinicalPharmacology,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,RBC,red blood cells,,,
clinicalPharmacology,373ba08b-33ad-49fc-28a7-928e89a65314,7/12/2011,10,GER,gastroesophageal reflux,,,
clinicalPharmacology,373ba08b-33ad-49fc-28a7-928e89a65314,7/12/2011,10,mean age,minutes to nine pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,d3f7c414-db83-4a7a-a7aa-745c5606cdba,6/7/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,BSPS,Brief Social Phobia Scale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PMDD,Premenstrual Dysphoric Disorder,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,OCD,Obsessive-Compulsive Disorder,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CAPS,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,DRSP,Daily Record of Severity of Problems,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CGI-S,Clinical Global Impression Severity of Illness,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,IES,Impact of Event Scale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CGI,Clinical Global Impressions,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CYBOCS,Children’s Yale-Brown Obsessive-Compulsive Scale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,FQ-SPS,Fear Questionnaire Social Phobia Subscale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,YBOCS,Yale–Brown Obsessive-Compulsive Scale,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,LLPDD,Luteal Phase Dysphoric Disorder,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CGI-S,Clinical Global Impression – Severity of Illness,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CGI-I,Clinical Global Impression of Improvement,,,
clinicalPharmacology,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,CI,confidence intervals,,,
clinicalPharmacology,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalPharmacology,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalPharmacology,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,TG,triglycerides,,,
clinicalPharmacology,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,PLAC I,Pravastatin Limitation of Atherosclerosis in the Coronary Arteries,,,
clinicalPharmacology,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,min,median,,,
clinicalPharmacology,b1c5c06b-9ce2-4bf7-9693-e37608055a14,7/20/2012,2,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,b1c5c06b-9ce2-4bf7-9693-e37608055a14,7/20/2012,2,SHBG,sex-hormone-binding globulin,,,
clinicalPharmacology,fcab4c61-9bfd-40ad-8389-65e077abd787,6/23/2011,1,i.e.,dose-independent,,,
clinicalPharmacology,ace72ca5-277c-4031-85f0-29b0bbe9b504,12/17/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,ace72ca5-277c-4031-85f0-29b0bbe9b504,12/17/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,3b33023e-974a-40fa-b2ad-f095b8dec4e8,2/5/2010,10,PBPs,penicillin-binding proteins,,,
clinicalPharmacology,3b33023e-974a-40fa-b2ad-f095b8dec4e8,2/5/2010,10,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,CNS,central nervous system,,,
clinicalPharmacology,04a413fe-95f4-47a7-42ac-283a9e78297d,4/27/2011,5,PAS,para-aminosalicylic acid,,,
clinicalPharmacology,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,CrCl,creatinine clearance,,,
clinicalPharmacology,cd288b01-b95c-6398-fdff-b9ead9f324fa,3/1/2012,11,MAOI,monoamine oxidase inhibitors,,,
clinicalPharmacology,cd288b01-b95c-6398-fdff-b9ead9f324fa,3/1/2012,11,MAO,monoamine oxidase,,,
clinicalPharmacology,cd288b01-b95c-6398-fdff-b9ead9f324fa,3/1/2012,11,IAA,indole acetic acid,,,
clinicalPharmacology,b98b02bb-2609-49a0-b29f-e5911aa0cbc1,1/25/2012,11,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,b98b02bb-2609-49a0-b29f-e5911aa0cbc1,1/25/2012,11,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,60f13170-9706-4f17-b890-44737c4d3a8d,12/19/2011,3395,GH,growth  hormone,,,
clinicalPharmacology,60f13170-9706-4f17-b890-44737c4d3a8d,12/19/2011,3395,Vd,volume of distribution,,,
clinicalPharmacology,60f13170-9706-4f17-b890-44737c4d3a8d,12/19/2011,3395,Css,concentration  of morphine at steady state,,,
clinicalPharmacology,60f13170-9706-4f17-b890-44737c4d3a8d,12/19/2011,3395,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,60f13170-9706-4f17-b890-44737c4d3a8d,12/19/2011,3395,LH,luteinizing hormone,,,
clinicalPharmacology,c95f0b0d-77ef-e753-be04-2228139df2d3,6/19/2006,1,AF,Atrial Fibrillation,,,
clinicalPharmacology,c95f0b0d-77ef-e753-be04-2228139df2d3,6/19/2006,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,8fe7a7f5-289d-4546-8d08-33dd0664c5f6,10/1/2009,1,bone,by examination of additional  tissues and fluids,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,CGI-I,Clinical Global Impression-Global Improvement,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,IRLS scale,International RLS Rating Scale,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,L-dopa,levodopa,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,Part I,4-part multi-item rating scale intended to evaluate mentation,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,PET,Positron emission tomographic,,,
clinicalPharmacology,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,MPTP,1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
clinicalPharmacology,284b5dac-2b8d-46bf-95fe-80ce03fa178a,11/23/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,284b5dac-2b8d-46bf-95fe-80ce03fa178a,11/23/2010,4,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,85d69d02-c5ef-467e-94aa-903100218795,6/6/2012,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,85d69d02-c5ef-467e-94aa-903100218795,6/6/2012,1,ITT,intention-to-treat,,,
clinicalPharmacology,85d69d02-c5ef-467e-94aa-903100218795,6/6/2012,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,85d69d02-c5ef-467e-94aa-903100218795,6/6/2012,1,CVD,cardiovascular disease,,,
clinicalPharmacology,3c11c1c2-8e62-4f63-8293-2f8b8d845f7e,6/11/2008,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,STH,somatotropic hormone,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,ECL,Enterochromaffin-like,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,FSH,follicle stimulating hormone,,,
clinicalPharmacology,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,LH,luteinizing hormone,,,
clinicalPharmacology,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,MN,mononuclear,,,
clinicalPharmacology,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,PMN,polymorphonuclear,,,
clinicalPharmacology,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,MIC’s,minimal inhibitory concentrations,,,
clinicalPharmacology,37992a25-68bd-4050-b936-596ddedc25a3,1/31/2009,1,NTD's,Neural tube defects,,,
clinicalPharmacology,37992a25-68bd-4050-b936-596ddedc25a3,1/31/2009,1,PIC,Polysaccharide iron complex,,,
clinicalPharmacology,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,ULN,upper limit of normal,,,
clinicalPharmacology,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,AUC,area under the curve,,,
clinicalPharmacology,938ab0b5-8377-404a-8f61-5c630bda5932,12/13/2011,10,i.v.,intravenous,,,
clinicalPharmacology,eb40a594-d58d-4214-b766-9e7a815b2de8,8/8/2011,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,2DEEE7BA-BBD9-4827-8265-9E770E9D93BC,8/20/2007,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,4D705C57-FA98-46E0-97F3-38E1B0ADA76B,2/19/2008,1,CNS,central nervous system,,,
clinicalPharmacology,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,e.g.,enzyme-inducing AED,,,
clinicalPharmacology,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,fd3c2497-ab34-4e19-a7c8-e599025435c8,8/2/2009,1,CV%,coefficient of variation,,,
clinicalPharmacology,da930058-8908-4fa3-8035-303abc9624fa,7/23/2012,4,V/F,volume of distribution,,,
clinicalPharmacology,00088ecd-e45d-4080-b124-e66376ad7694,10/18/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,95b03516-34b0-4438-a05c-918d80f70091,3/30/2012,3,AUC,area under the curve,,,
clinicalPharmacology,eff16712-d4c4-4e7b-bf38-c467de1095f4,6/11/2010,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,0c01acd6-123b-43f3-b639-b039e83baa27,5/12/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,0c01acd6-123b-43f3-b639-b039e83baa27,5/12/2011,3,broth,be determined using a standardized procedure based on dilution methods,,,
clinicalPharmacology,3b36beb7-db94-4b07-8c81-bd2b601a6601,3/2/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,3b36beb7-db94-4b07-8c81-bd2b601a6601,3/2/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,d79fa307-a4fa-4ded-af53-31df482510dc,3/11/2010,1,IV,intravenous,,,
clinicalPharmacology,64392954-0d2d-4946-bb5c-05d4b81dc319,1/9/2012,2,RT,reverse transcriptase,,,
clinicalPharmacology,64392954-0d2d-4946-bb5c-05d4b81dc319,1/9/2012,2,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,a88d9010-55fb-4a02-baff-042cd27688ea,11/10/2010,7,CYP450,cytochrome P450,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,STH,somatotropic hormone,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,1c1b1efe-735d-4ddb-aafe-ff1ece78ecc4,4/13/2011,7,B. fragilis,Bacteroides fragilis group,,,
clinicalPharmacology,025fee85-53a8-4161-a806-44fd95d0ca74,12/31/2009,1,PIC,Polysaccharide iron complex,,,
clinicalPharmacology,3f6b53fb-8ce9-4897-ae13-52a8a451d48c,8/6/2009,1,eg,emergency setting,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,i.e.,improvement from baseline,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,V/F,volume of distribution,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,SMAP,2-sulfamoylacetyl phenol,,,
clinicalPharmacology,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,RBC,red blood cells,,,
clinicalPharmacology,f704dd21-68d1-4697-b07f-4e07a8a9c29c,10/4/2011,1,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,cafb55ed-f2fb-4462-8b5c-c0e34cd83cbc,2/4/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,cafb55ed-f2fb-4462-8b5c-c0e34cd83cbc,2/4/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,a17c90f9-3d5d-4503-ba2c-754b45decbf8,5/16/2012,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,c9676c8a-4597-4dcf-8944-18ecc96004e2,10/13/2011,2,HTM,Haemophilus Test Medium,,,
clinicalPharmacology,3537dd95-954c-459f-97a9-54a861bed265,8/28/2006,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,EEAD,evoked after-discharge,,,
clinicalPharmacology,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,MES,maximum electroshock,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,NE,neuroendocrine,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,GERD,gastroesophageal reflux disease,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,EE,erosive esophagitis,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,TSH,thyroid-stimulating hormone,,,
clinicalPharmacology,f9be6294-9a16-4de1-b346-af0d09a97482,1/4/2012,2,CYP,cytochrome P450,,,
clinicalPharmacology,56d13a1c-b289-4528-b23c-60f5427b4552,12/12/2008,1,V/F,volume of distribution,,,
clinicalPharmacology,56d13a1c-b289-4528-b23c-60f5427b4552,12/12/2008,1,HbA1c,hemoglobin  A1c,,,
clinicalPharmacology,56d13a1c-b289-4528-b23c-60f5427b4552,12/12/2008,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,EAE,encephalomyelitis,,,
clinicalPharmacology,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,MS,Multiple Sclerosis,,,
clinicalPharmacology,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,RR MS,Relapsing-Remitting Multiple Sclerosis,,,
clinicalPharmacology,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,i.e.,intent-to-treat                                     population,,,
clinicalPharmacology,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,DSS,Disability Scale Score,,,
clinicalPharmacology,7a0bba98-8f39-4020-b2a5-c487278a057a,4/29/2010,1,TMS,&#945;-(thiomethyl)<br/>spironolactone,,,
clinicalPharmacology,7af84664-7e3b-43f3-a43e-beba36ffb739,12/29/2010,6,i.e.,improvement,,,
clinicalPharmacology,b61c6a09-7764-4a92-93a9-a1356aeeaa9c,10/1/2010,1,GX,glycinexylidide,,,
clinicalPharmacology,b61c6a09-7764-4a92-93a9-a1356aeeaa9c,10/1/2010,1,tmax,to reach maximum concentration,,,
clinicalPharmacology,b61c6a09-7764-4a92-93a9-a1356aeeaa9c,10/1/2010,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,b61c6a09-7764-4a92-93a9-a1356aeeaa9c,10/1/2010,1,PK,pharmacokinetic,,,
clinicalPharmacology,11bf60e0-d81d-4bd3-ac1b-376151d2754d,7/3/2006,1,OPHTHALMIC®,ophthalmic solution,,,
clinicalPharmacology,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,A-V,atrioventricular,,,
clinicalPharmacology,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,e.g.,effector organ,,,
clinicalPharmacology,2caaf94b-b382-4573-8614-57815776b659,2/17/2010,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a384641c-04e3-4ab5-b152-7408cd07b64d,12/14/2009,2,NCCLS,National Committee for Clinical Laboratory Standards,,,
clinicalPharmacology,a384641c-04e3-4ab5-b152-7408cd07b64d,12/14/2009,2,MIC,minimum inhibitory concentrations,,,
clinicalPharmacology,6982a931-15b8-482a-bfe0-05d61f37b462,6/17/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,6982a931-15b8-482a-bfe0-05d61f37b462,6/17/2011,1,TG,triglycerides,,,
clinicalPharmacology,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,ee4c9c41-8ac4-4647-a765-731d8376c2d2,11/16/2011,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,EE2B4869-CD13-489B-B12F-1CE4FE081157,9/15/2006,1,SH,sulfhydryl,,,
clinicalPharmacology,EE2B4869-CD13-489B-B12F-1CE4FE081157,9/15/2006,1,IM,Intramuscular Solution,,,
clinicalPharmacology,c37c3d9f-8fdd-4e14-87d5-08d98cf5f61f,10/31/2011,4,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,a0cfad4b-043e-451e-bfd6-1fe1ac1bd0d6,5/11/2011,5,IV,intravenous,,,
clinicalPharmacology,a0cfad4b-043e-451e-bfd6-1fe1ac1bd0d6,5/11/2011,5,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,D61BE7A2-0F54-44C2-9ED0-2316F4CB6128,4/23/2009,3,NCCLS,National Committee for Clinical Laboratory Standards,,,
clinicalPharmacology,D61BE7A2-0F54-44C2-9ED0-2316F4CB6128,4/23/2009,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,NET,norethindrone,,,
clinicalPharmacology,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,MES,maximal electroshock seizure,,,
clinicalPharmacology,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,SER,spontaneous epileptic rat,,,
clinicalPharmacology,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,EE,ethinyl estradiol,,,
clinicalPharmacology,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,MN,mononuclear,,,
clinicalPharmacology,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,PMN,polymorphonuclear,,,
clinicalPharmacology,AD90767E-829A-4E26-BB33-2585BC0B72DD,9/24/2008,1,CNS,central nervous system,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICP,intracranial pressure,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICU,Intensive Care Unit,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,CSFP,cerebrospinal fluid pressure,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,MAC,Monitored Anesthesia Care,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,CABG,coronary artery bypass graft,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICU,pressure.Intensive Care Unit,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,MAC,monitored anesthesia care,,,
clinicalPharmacology,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ACTH,adrenocorticotropic hormone,,,
clinicalPharmacology,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,MN,mononuclear,,,
clinicalPharmacology,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,8debb03e-a237-4e0d-be06-8ae17eaa14fa,4/25/2012,1,GX,glycinexylidide,,,
clinicalPharmacology,8debb03e-a237-4e0d-be06-8ae17eaa14fa,4/25/2012,1,tmax,to reach maximum concentration,,,
clinicalPharmacology,8debb03e-a237-4e0d-be06-8ae17eaa14fa,4/25/2012,1,MEGX,monoethylglycinexylidide,,,
clinicalPharmacology,8debb03e-a237-4e0d-be06-8ae17eaa14fa,4/25/2012,1,PK,pharmacokinetic,,,
clinicalPharmacology,73cd79c1-6bab-4d7b-ae8b-0176efbaf5b9,12/6/2011,3,HGPRTase,hypoxanthineguanine phosphoribosyltransferase,,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,CBG,corticosteroid-binding globulin,,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,hr,"href=""#footnote-2"">&#8224;</linkHtml>",,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,IV,intravenous,,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,Vd,ss,volume of distribution at steady state,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,hr,pg&#183;hr/ml</td>                               </tr>                               <tr>                                  <td>t<sub>&#189;</sub>,,,
clinicalPharmacology,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,SHBG,sex hormone-binding  globulin,,,
clinicalPharmacology,d0da9dd6-c691-4614-99c7-531b0bf34837,6/3/2010,4,IV,intravenous,,,
clinicalPharmacology,5f2cff3a-8862-4c87-90aa-0ca16def7914,3/15/2012,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,MAO,monoamine oxidase,,,
clinicalPharmacology,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,a0d4f0b8-5dcc-4ffe-9590-0203e869622f,2/9/2012,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,a0d4f0b8-5dcc-4ffe-9590-0203e869622f,2/9/2012,3,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,CNS,central nervous system,,,
clinicalPharmacology,56747ded-19ce-4401-a7f2-1cd4714c2f02,8/18/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,56747ded-19ce-4401-a7f2-1cd4714c2f02,8/18/2010,2,IM,intramuscular,,,
clinicalPharmacology,7e29a5ba-57d1-46c5-a93f-ba6b3d6b3327,7/1/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,63dea98d-a7ba-4891-b37c-e5a673073792,2/22/2011,2,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,8b3fe1aa-7268-4fb9-aa5a-a865fcbb4155,6/13/2011,8,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,5F82E53E-D6DB-432F-AF68-9DE88D1B1720,9/19/2006,1,IOP,intraocular pressure,,,
clinicalPharmacology,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DMBA,dimethylbenzanthracene,,,
clinicalPharmacology,A757F9F8-A925-4E47-9B83-131CCCF8E470,4/5/2006,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,238050FD-5221-4B93-BFCD-31793C9088A7,11/15/2007,2,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,238050FD-5221-4B93-BFCD-31793C9088A7,11/15/2007,2,Cyp3A4,cytochrome P450 3A4,,,
clinicalPharmacology,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,bf5cbf1b-af47-419e-bc32-6d6b94a785b5,11/29/2011,1,ECG,electrocardiogram,,,
clinicalPharmacology,f3637209-303e-4232-ae79-07315a990973,1/9/2012,1,ddI,didanosine,,,
clinicalPharmacology,f3637209-303e-4232-ae79-07315a990973,1/9/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,f3637209-303e-4232-ae79-07315a990973,1/9/2012,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,i.e.,improvement,,,
clinicalPharmacology,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,MRS,Manic Rating Scale,,,
clinicalPharmacology,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,CrCl,creatinine clearance,,,
clinicalPharmacology,35312f49-decf-428d-bf5f-4215b762ed3c,6/10/2011,7,NET,norethindrone,,,
clinicalPharmacology,35312f49-decf-428d-bf5f-4215b762ed3c,6/10/2011,7,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,35312f49-decf-428d-bf5f-4215b762ed3c,6/10/2011,7,EE,ethinyl estradiol,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,CYP450,cytochrome P450,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,AV,atrioventricular,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,VT,ventricular tachycardia,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,SCL,sinus cycle length,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,DEA,.N-desethylamiodarone,,,
clinicalPharmacology,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,VF,ventricular fibrillation,,,
clinicalPharmacology,44a07041-456a-4b0b-9a8a-9e1715327d33,1/24/2012,1,min,median,,,
clinicalPharmacology,9a14cb3d-cf49-4d72-ae38-86f847036a58,6/4/2010,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,9d1f630b-e759-4395-9d01-ddc90e4fea75,10/7/2011,12,HTM,Haemophilus Test Media,,,
clinicalPharmacology,bb9fbe40-caa8-4402-a54e-3c2c4ee1df3e,8/19/2010,358,CTZ,chemoreceptor trigger zone,,,
clinicalPharmacology,d583b8b9-e5c7-45d6-8fc1-d51f51a16181,9/24/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,7/17/2008,1,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,7/17/2008,1,Tmax,to maximum concentration,,,
clinicalPharmacology,6350a31e-4299-4ed7-b5b7-aaf4d1fc66b7,2/8/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,TG,triglycerides,,,
clinicalPharmacology,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,RARs,retinoic acid receptors,,,
clinicalPharmacology,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,RXR?,retinoid X                                     receptor subtypes,,,
clinicalPharmacology,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,CTCL,cutaneous T-cell lymphoma,,,
clinicalPharmacology,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,PPARs,peroxisome proliferator activator receptors,,,
clinicalPharmacology,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,Stage IA-IIA,Studies Targretin® gel was evaluated for the                                     treatment of patients with early stage,,,
clinicalPharmacology,8224b9c5-5c4b-4dda-bc58-47b6604c2884,1/16/2012,2,TRNG,tetracycline-resistant Neisseria                             gonorrhoeae,,,
clinicalPharmacology,8224b9c5-5c4b-4dda-bc58-47b6604c2884,1/16/2012,2,MIC’s,minimum inhibitory concentrations,,,
clinicalPharmacology,e3f2f2ff-21f6-47c8-aa76-4dc56b818613,11/10/2010,74,MI,myocardial infarction,,,
clinicalPharmacology,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,i.e.,initial clearance rates,,,
clinicalPharmacology,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,578d747f-c023-4d5a-9e9a-d4a970d8f69f,7/13/2009,2,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,578d747f-c023-4d5a-9e9a-d4a970d8f69f,7/13/2009,2,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,578d747f-c023-4d5a-9e9a-d4a970d8f69f,7/13/2009,2,PVCs,premature ventricular contractions,,,
clinicalPharmacology,0193ddae-c600-4e80-a578-4fe271231991,6/28/2010,1,triazole,Three metabolites of  anastrozole,,,
clinicalPharmacology,0193ddae-c600-4e80-a578-4fe271231991,6/28/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,B242CB72-957A-4701-A2B1-75D5C28C8781,3/29/2007,4,MIC’s,minimum inhibitory concentrations,,,
clinicalPharmacology,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,PBMCs,peripheral blood mononuclear cells,,,
clinicalPharmacology,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,RT,reverse transcriptase,,,
clinicalPharmacology,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,NVP,nevirapine,,,
clinicalPharmacology,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,free,3-fold higher than the non-protein-bound,,,
clinicalPharmacology,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,DLV,delavirdine,,,
clinicalPharmacology,35c69667-b48d-4fda-823b-c4c05a7cc82b,8/11/2009,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,35c69667-b48d-4fda-823b-c4c05a7cc82b,8/11/2009,1,IV,intravenous,,,
clinicalPharmacology,35c69667-b48d-4fda-823b-c4c05a7cc82b,8/11/2009,1,IM,intramuscular,,,
clinicalPharmacology,ea52219d-7f3d-4aea-b733-c35b446312e2,3/12/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,aadf0c91-7e95-46f8-a8f7-a98177831134,6/15/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,aadf0c91-7e95-46f8-a8f7-a98177831134,6/15/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,aadf0c91-7e95-46f8-a8f7-a98177831134,6/15/2011,1,ECL,Enterochromaffin-Like,,,
clinicalPharmacology,aadf0c91-7e95-46f8-a8f7-a98177831134,6/15/2011,1,CYP,cytochrome P450,,,
clinicalPharmacology,cb28abf4-608f-4dcb-b179-9dcf71274dbb,7/21/2010,1,AUC,area under the curve,,,
clinicalPharmacology,f0a6d21d-203f-4fde-b010-a2730b86b491,1/17/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,f5cfb61e-d971-4a9c-b9ef-4f3368fe02f5,6/12/2012,7,TK,thymidine kinase,,,
clinicalPharmacology,1e46fd1c-cb3c-4160-80bb-ed37a5cd7483,9/14/2011,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,21aea811-f47d-4a44-a552-dfc46d2773bf,8/31/2011,4,D/C,discontinuations,,,
clinicalPharmacology,cea5f748-3127-4d36-83af-9ab3cf58503c,1/18/2012,7,NET,norethindrone,,,
clinicalPharmacology,cea5f748-3127-4d36-83af-9ab3cf58503c,1/18/2012,7,HCTZ,hydrochlorothiazide,,,
clinicalPharmacology,cea5f748-3127-4d36-83af-9ab3cf58503c,1/18/2012,7,EE,ethinyl estradiol,,,
clinicalPharmacology,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,PPG,postprandial plasma glucose,,,
clinicalPharmacology,e9f89260-97fb-484a-af52-5d1be77fee76,5/24/2010,1,MAOI,monoamine oxidase inhibitors,,,
clinicalPharmacology,e9f89260-97fb-484a-af52-5d1be77fee76,5/24/2010,1,MAO,monoamine oxidase,,,
clinicalPharmacology,e9f89260-97fb-484a-af52-5d1be77fee76,5/24/2010,1,IAA,indole  acetic acid,,,
clinicalPharmacology,4c6f4f9e-f3f5-4ecf-9f40-887e037e8847,7/8/2011,6,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,1fd2babd-4737-45ad-9464-a7479a3816d9,6/7/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,7e593aec-4ef2-445c-b4e9-13dfc99296f2,12/20/2011,3406,CTZ,chemoreceptor  trigger zone,,,
clinicalPharmacology,52459f70-e1f5-41bb-a9f4-e68ef5f5dcf5,11/3/2011,2,CYP2C19,cytochrome P450 2C19,,,
clinicalPharmacology,52459f70-e1f5-41bb-a9f4-e68ef5f5dcf5,11/3/2011,2,CYP3A,cytochromes P450 3A,,,
clinicalPharmacology,8F6873A2-E579-FCE7-2296-F49F7673FBA5,12/10/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,831f3efb-3b45-94f0-8796-4995e9e81ac9,2/28/2011,4,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,089fc1de-00ae-41b6-7c97-1217f0cecc03,5/30/2012,11,Cl?,Chloride,,,
clinicalPharmacology,089fc1de-00ae-41b6-7c97-1217f0cecc03,5/30/2012,11,Cl?,chloride,,,
clinicalPharmacology,bceaf33f-ddbe-47f6-a5bf-14662b3c58b5,3/31/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,7bb90096-14d3-400e-94d3-048bff6b1292,11/30/2010,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,debf74d1-3250-4858-8a9d-638262f3a7d5,10/12/2011,1,MAO,monoamine oxidase,,,
clinicalPharmacology,debf74d1-3250-4858-8a9d-638262f3a7d5,10/12/2011,1,MHPG,3-methoxy- 4-hydroxyphenyl glycol,,,
clinicalPharmacology,3599277f-1f6e-43f0-9e09-0ec2ec5a0df1,6/28/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,47fdef53-4060-4372-9b48-fdb39a7e3fd3,4/6/2012,2,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,47fdef53-4060-4372-9b48-fdb39a7e3fd3,4/6/2012,2,msec,mseconds,,,
clinicalPharmacology,47fdef53-4060-4372-9b48-fdb39a7e3fd3,4/6/2012,2,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,a806ba79-f8f0-4fe7-b754-59921a93d5ed,5/25/2012,3,Percent,Percentage of Responders at Endpoint                                                                                                                                                                 Difference,,,
clinicalPharmacology,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,triazole,Three metabolites of anastrozole,,,
clinicalPharmacology,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,70a2ac22-7fab-4383-8c34-b6793915a79c,3/29/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,70a2ac22-7fab-4383-8c34-b6793915a79c,3/29/2011,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,70a2ac22-7fab-4383-8c34-b6793915a79c,3/29/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,881eb80b-712e-4aa2-bd23-290a3e5db6cd,11/29/2011,3,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,a6c0e721-2021-4983-a305-49bdf8f135a9,12/8/2008,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,5733e038-7cb5-434b-aa8e-abb25e6252c9,10/16/2009,2,LVEDP,left ventricular end diastolic pressure,,,
clinicalPharmacology,ac549022-4d7f-4c9f-9244-1a2df9a27276,1/20/2011,2,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,ac549022-4d7f-4c9f-9244-1a2df9a27276,1/20/2011,2,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ac549022-4d7f-4c9f-9244-1a2df9a27276,1/20/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,d667ca75-1a17-43fc-9077-f25ce0908f8d,2/15/2011,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,d667ca75-1a17-43fc-9077-f25ce0908f8d,2/15/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,c98eb213-9c80-4698-9710-a9855059b8bb,2/23/2012,8,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,c98eb213-9c80-4698-9710-a9855059b8bb,2/23/2012,8,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,c98eb213-9c80-4698-9710-a9855059b8bb,2/23/2012,8,AUC,area under the concentration-time curve,,,
clinicalPharmacology,9f2fce5a-fee9-4df3-8aef-b1d2cc9a14c4,3/31/2008,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,6686069e-7e43-4963-8a66-961e0b36d84d,4/25/2011,5,AUC,area under the curve,,,
clinicalPharmacology,865228be-5f0b-45fa-88a1-ceb89913ec1b,3/31/2008,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,a588140c-f9ed-4a9b-a9a6-bf3daafd8a5a,12/26/2009,2,PS,PERFORMANCE STATUS,,,
clinicalPharmacology,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,Tmax,to maximum concentration,,,
clinicalPharmacology,27CCB2F4-ABF8-4825-9B05-0BB367B4AC07,3/2/2007,1,MI,myocardial infarction,,,
clinicalPharmacology,27CCB2F4-ABF8-4825-9B05-0BB367B4AC07,3/2/2007,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,1f56e340-dcba-4774-b9d9-8e02dd7c3f69,9/28/2011,13,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,1f56e340-dcba-4774-b9d9-8e02dd7c3f69,9/28/2011,13,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e98886aa-933c-430f-bb56-f1eb3862aae4,6/19/2012,5,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,e98886aa-933c-430f-bb56-f1eb3862aae4,6/19/2012,5,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,MN,mononuclear,,,
clinicalPharmacology,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,cf3d4110-3ae5-46fd-84f4-127fd2998dbb,8/23/2011,1,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,YMRS,Young Mania Rating Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,CPS,complex partial seizures,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,AED,antiepilepsy drug,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,i.e.,improvement,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,TID,three divided doses,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,GAS,Global Assessment Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,BPRS-A,Brief Psychiatric Rating Scale,,,
clinicalPharmacology,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,a9e1d18e-ad45-4183-bd98-53c7e0b36556,7/2/2012,1,TK,thymidine kinase,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,SD,simulated mean,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,Vss,volume of distribution at steady-state,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,INR,International Normalized Ratio,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,MBC/MIC,minimum bactericidal concentration/minimum inhibitory concentration,,,
clinicalPharmacology,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,cSSSI,Complicated Skin and Skin Structure Infection,,,
clinicalPharmacology,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,CNS,central nervous system,,,
clinicalPharmacology,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,S-DDCT,S-didemethylcitalopram,,,
clinicalPharmacology,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,S-DCT,S-demethylcitalopram,,,
clinicalPharmacology,7e3fc83f-e322-44a1-b0c3-30e6292b92d9,4/12/2010,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,e5f8fd45-47c8-41c8-a011-58b27e4fdf21,1/14/2011,2,Percent,Percentage of Responders at Endpoint                                                                                                                                                                 Difference,,,
clinicalPharmacology,50194d47-2761-4bfd-a35b-9c6a186694a5,3/10/2011,3,Vd?,volume of distribution,,,
clinicalPharmacology,264a3dc1-596c-43ab-a20c-65c80ab22f2a,1/18/2012,3,AUC,area under the curve,,,
clinicalPharmacology,6d835181-0454-4edb-b523-940afcd4674f,4/18/2011,6,MAO,monoamine oxidase,,,
clinicalPharmacology,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,CYP2D6,cytochrome  P450 2D6,,,
clinicalPharmacology,ef43ba2d-20ce-4415-b5c2-e486b836812e,11/9/2010,3,B17P,Betamethasone 17-propionate,,,
clinicalPharmacology,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,EM,extensive metabolizers,,,
clinicalPharmacology,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,PM,poor metabolizers,,,
clinicalPharmacology,31e81b55-ddf1-20c0-8d25-b5712435c366,2/1/2009,3,PT,prothrombin time,,,
clinicalPharmacology,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,TURP,transurethral resection of the prostate,,,
clinicalPharmacology,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,CABG,coronary artery bypass graft,,,
clinicalPharmacology,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,ED,erectile dysfunction,,,
clinicalPharmacology,4d97179f-4768-444c-8511-29c527f191f4,4/3/2012,1,Cl-,chloride,,,
clinicalPharmacology,144db6ad-c4cf-45ea-b27c-a76a319dba38,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,144db6ad-c4cf-45ea-b27c-a76a319dba38,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,2cd2a198-36e4-43d7-a7b2-dc40620ad514,2/21/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,2cd2a198-36e4-43d7-a7b2-dc40620ad514,2/21/2012,3,IV,intravenous,,,
clinicalPharmacology,6da33de9-7100-419f-a19f-565701b445ad,2/17/2010,1,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,6da33de9-7100-419f-a19f-565701b445ad,2/17/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6da33de9-7100-419f-a19f-565701b445ad,2/17/2010,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,ODV,O-desmethylvenlafaxine,,,
clinicalPharmacology,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,CGI,Clinical Global Impressions,,,
clinicalPharmacology,4306730b-e894-45ca-b4e9-3fe7f65b7b1d,5/11/2010,1,MIC,minimum  inhibitory concentration,,,
clinicalPharmacology,65daa2aa-cc4a-4eba-b7dc-7a151806865a,1/14/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bf82350e-9a31-47c6-bfd4-3b6a4713a730,2/10/2012,3553,GH,growth  hormone,,,
clinicalPharmacology,bf82350e-9a31-47c6-bfd4-3b6a4713a730,2/10/2012,3553,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,bf82350e-9a31-47c6-bfd4-3b6a4713a730,2/10/2012,3553,LH,luteinizing hormone,,,
clinicalPharmacology,fbe6d514-9d89-48f7-80a0-d1b41983f203,3/10/2006,1,c-AMP,cyclic-3?,5?-adenosine monophosphate,,
clinicalPharmacology,fbe6d514-9d89-48f7-80a0-d1b41983f203,3/10/2006,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,EF56C531-A1CA-B94C-23DE-A0BA617AE2B4,5/29/2007,1,ie,its active metabolites,,,
clinicalPharmacology,EF56C531-A1CA-B94C-23DE-A0BA617AE2B4,5/29/2007,1,BZ,benzodiazepine,,,
clinicalPharmacology,2367340c-d297-4a3f-8253-6d27a0ed39cb,1/20/2012,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,2367340c-d297-4a3f-8253-6d27a0ed39cb,1/20/2012,5,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,2367340c-d297-4a3f-8253-6d27a0ed39cb,1/20/2012,5,broth,be determined using a standardized procedure based on dilution methods,,,
clinicalPharmacology,2367340c-d297-4a3f-8253-6d27a0ed39cb,1/20/2012,5,MICs,minimum inhibitory concentra­tions,,,
clinicalPharmacology,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,FEV1,forced expiratory volume 1 second,,,
clinicalPharmacology,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,GFR,glomerular filtration rate,,,
clinicalPharmacology,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,RPF,renal plasma flow,,,
clinicalPharmacology,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,FVC,forced vital capacity,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,STH,somatotropic hormone,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,ECL,Enterochromaffin-like,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,FSH,follicle stimulating hormone,,,
clinicalPharmacology,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,LH,luteinizing hormone,,,
clinicalPharmacology,6c789378-0ec7-4874-aa42-e3418e859f86,5/23/2012,2,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,6c789378-0ec7-4874-aa42-e3418e859f86,5/23/2012,2,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,d2f4907f-b952-403b-229e-cc5b8327a773,8/15/2011,13,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,d2f4907f-b952-403b-229e-cc5b8327a773,8/15/2011,13,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,d2f4907f-b952-403b-229e-cc5b8327a773,8/15/2011,13,MN,mononuclear,,,
clinicalPharmacology,d2f4907f-b952-403b-229e-cc5b8327a773,8/15/2011,13,PMN,polymorphonuclear,,,
clinicalPharmacology,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,V/F,volume of distribution,,,
clinicalPharmacology,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,AUC,area under the curve,,,
clinicalPharmacology,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,MDG,mean daily glucose,,,
clinicalPharmacology,68e860d7-4adc-418a-ba12-233ccdf85d0a,9/27/2010,35,msec,mseconds,,,
clinicalPharmacology,68e860d7-4adc-418a-ba12-233ccdf85d0a,9/27/2010,35,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,c10af03b-cea2-4929-bcbb-b973bf3c5704,2/29/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c10af03b-cea2-4929-bcbb-b973bf3c5704,2/29/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c10af03b-cea2-4929-bcbb-b973bf3c5704,2/29/2012,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,c10af03b-cea2-4929-bcbb-b973bf3c5704,2/29/2012,1,CYP,cytochrome P450,,,
clinicalPharmacology,97675251-70b8-43bc-93ea-f9ef6bb8cb68,2/9/2010,4,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,97675251-70b8-43bc-93ea-f9ef6bb8cb68,2/9/2010,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,97675251-70b8-43bc-93ea-f9ef6bb8cb68,2/9/2010,4,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,1ecab710-8b7d-4903-80a8-de66562be55a,7/3/2012,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,1ecab710-8b7d-4903-80a8-de66562be55a,7/3/2012,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,CYP,Cytochrome P450,,,
clinicalPharmacology,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,PPAR?,peroxisome  proliferator-activated receptor-gamma,,,
clinicalPharmacology,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,BMI,body mass index,,,
clinicalPharmacology,befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0,5/17/2012,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0,5/17/2012,3,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,709031e4-4c20-4ea7-beff-6c459709a433,1/28/2011,1,CYP3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,709031e4-4c20-4ea7-beff-6c459709a433,1/28/2011,1,SHBG,sex hormone  binding globulin,,,
clinicalPharmacology,b83329ac-a65e-b3af-a3fb-c5a6c740e5e7,7/15/2011,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b83329ac-a65e-b3af-a3fb-c5a6c740e5e7,7/15/2011,5,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,938d167b-bf6d-4c29-8848-fc76aba3cbd0,11/10/2011,2,BPH,Benign Prostatic Hyperplasia,,,
clinicalPharmacology,1c08d30d-7c27-a09a-5240-7050771d5cc7,4/21/1987,1,i.e.,its active metabolites,,,
clinicalPharmacology,48f8aa83-e043-41b8-9a20-dbb098045895,4/19/2012,1,DEXA,Dual Energy X-ray Absorptiometry,,,
clinicalPharmacology,56bf1b0a-463a-4324-957b-585d4cf352ee,4/14/2011,1,I.V.,intravenous,,,
clinicalPharmacology,586651c6-8d9d-4e96-b17b-7bb535eb3153,12/10/2010,1,V/F,volume of distribution,,,
clinicalPharmacology,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,MN,mononuclear,,,
clinicalPharmacology,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,PMN,polymorphonuclear,,,
clinicalPharmacology,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,ITT,intent-to-treat,,,
clinicalPharmacology,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,CLr,clearance,,,
clinicalPharmacology,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,PHN,postherpetic neuralgia,,,
clinicalPharmacology,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,UPDRS,Unified Parkinson’s Disease Rating Scale,,,
clinicalPharmacology,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,COMT,catechol-O-methyltransferase,,,
clinicalPharmacology,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,AUC,area under the curve,,,
clinicalPharmacology,3cdffcf9-b5fa-4622-9e83-ce29ececcc93,5/18/2011,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,d0e05816-ccf8-4008-b5de-4d3fbc3de3c1,2/1/2010,3,PCPZ,prochlorperazine,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,ISH,isolated systolic hypertension,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,DBP,diastolic blood pressure,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,ITT,intention-to-treat,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,CVD,cardiovascular disease,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,SBP,systolic blood pressure,,,
clinicalPharmacology,e5886220-43b7-46e1-9034-5242ba245bd1,2/2/2011,2,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,41e4c31a-cd87-4326-b7f5-bf6bb19ee265,11/7/2011,6,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,CrCl,creatinine clearance,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,CGI-I,Clinical Global Impression-Global Improvement,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,IRLS scale,International RLS Rating Scale,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,L-dopa,levodopa,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,Part I,4-part multi-item rating scale intended to evaluate mentation,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,PET,Positron emission tomographic,,,
clinicalPharmacology,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,MPTP,1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
clinicalPharmacology,4440015d-5a5c-4f2e-8993-13a94035d70a,2/13/2012,2,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,e17b3ec0-7739-4775-b7a2-a262f4f3a836,9/13/2011,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,F9752B21-A8BB-40D5-BCAD-6A55802158C5,10/9/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,WBC,White blood cell,,,
clinicalPharmacology,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,IV,intravenous,,,
clinicalPharmacology,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,IP,intraperitoneal,,,
clinicalPharmacology,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,SC,subcutaneous,,,
clinicalPharmacology,6c77e113-37e3-4c86-834a-6355bb1020e9,10/29/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,6c77e113-37e3-4c86-834a-6355bb1020e9,10/29/2010,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,9a105eaf-ee77-4016-beeb-d425a5565db2,12/12/2011,2,mcg/mL,"underline"">Microorganism</content>                                                 </content>                                              </td>                                              <td align=""center"">                                                 <content styleCode=""bold"">                                                    <content styleCode=""bold underline"">MIC",,,
clinicalPharmacology,9a105eaf-ee77-4016-beeb-d425a5565db2,12/12/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,9a105eaf-ee77-4016-beeb-d425a5565db2,12/12/2011,2,PBP3,penicillin binding protein 3,,,
clinicalPharmacology,a41b9710-a1ec-41be-8417-b03c5d802ae2,4/11/2012,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,546c9817-e41b-4b1d-a1dd-1e9304c97557,9/1/2011,4,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,56ab2ff4-14a6-4297-afd8-56b92e1f64a0,5/31/2012,5,A-V,atrioventricular,,,
clinicalPharmacology,56ab2ff4-14a6-4297-afd8-56b92e1f64a0,5/31/2012,5,IV,intravenous,,,
clinicalPharmacology,56ab2ff4-14a6-4297-afd8-56b92e1f64a0,5/31/2012,5,ISA,in animals with minimal beta1-agonist,,,
clinicalPharmacology,7cf2b373-c8f3-4568-953d-15d70a125182,5/16/2012,2,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,a78a68a4-5425-43c4-81cc-7733b72445b8,12/2/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b4d41487-b8f3-4f36-9144-f0e67a2ea53a,9/6/2011,2,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,c3aeca7e-4b7d-431c-a0c9-f7f5b05ad5a8,8/5/2011,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,3537a73d-2411-498a-8e18-a128f8c5eecb,8/28/2010,379,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,3537a73d-2411-498a-8e18-a128f8c5eecb,8/28/2010,379,HDRS,Hamilton Depression  Rating Scale,,,
clinicalPharmacology,2e34ee28-cfdd-4791-b881-61897c316eb8,5/14/2010,3,HTM,Haemophilus Test Media,,,
clinicalPharmacology,2e34ee28-cfdd-4791-b881-61897c316eb8,5/14/2010,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,2e34ee28-cfdd-4791-b881-61897c316eb8,5/14/2010,3,CLSI,Clinical and Laboratory Standards Institute,,,
clinicalPharmacology,9d42adca-0dd7-4df7-864d-5a7feee52130,7/22/2011,6,AUC,area under the curve,,,
clinicalPharmacology,9d42adca-0dd7-4df7-864d-5a7feee52130,7/22/2011,6,PK,Pharmacokinetic,,,
clinicalPharmacology,9d42adca-0dd7-4df7-864d-5a7feee52130,7/22/2011,6,PI,primary immunodeficiency,,,
clinicalPharmacology,b0442dc3-7f06-4f67-ab14-f338ae5173e7,1/6/2012,9,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,b0442dc3-7f06-4f67-ab14-f338ae5173e7,1/6/2012,9,broth,be determined using a standardized procedure based on dilution methods,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,AEDs,Antiepilepsy Drugs,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,AEDs,antiepilepsy drugs,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,CYP3A4,cytochrome P450 isozyme 3A4,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,SMAP,2–sulfamoylacetyl phenol,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,V/F,volume of distribution,,,
clinicalPharmacology,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,RBC,red blood cells,,,
clinicalPharmacology,623BC6E9-2158-48CC-867E-7AC50F4D892C,8/1/2006,1,Tmax,time to peak exposure,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,CYP 3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,CYP  3A4,cytochrome P-450 3A4,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,SHBG,sex hormone binding  globulin,,,
clinicalPharmacology,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalPharmacology,2709e9fc-2341-4382-af72-c2e3201bd77a,2/10/2012,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,D476C926-4C3D-4C33-B244-3B58E988ECB3,9/2/2008,1,IPPB,intermittent positive-pressure breathing,,,
clinicalPharmacology,D476C926-4C3D-4C33-B244-3B58E988ECB3,9/2/2008,1,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,D476C926-4C3D-4C33-B244-3B58E988ECB3,9/2/2008,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,D476C926-4C3D-4C33-B244-3B58E988ECB3,9/2/2008,1,FEV1,forced expiratory volume in 1 second,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,CUE,cumulative urinary excretion,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,Total-C,total cholesterol,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,Median,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,HDLs,High density lipoproteins,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,"Botrule"">Median",,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,LDL-C,low density lipoprotein cholesterol,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TG,triglycerides,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,PLAC I,Pravastatin Limitation of Atherosclerosis in the Coronary Arteries,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TIA,transient ischemic attack,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,HDL-C,HDL-cholesterol,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,LIPID,Long-term Intervention with Pravastatin in Ischemic Disease,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,VLDLs,very low density lipoproteins,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,IDLs,intermediate density lipoproteins,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,AUC,area under the concentration-time curve,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,CARE,Cholesterol and Recurrent Events,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,CHD,coronary heart disease,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,MI,myocardial infarction,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,LDLs,low density lipoproteins,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TG,Triglycerides,,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,"Botrule"">Median % Change",,,
clinicalPharmacology,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,median,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,ESRD,end-stage renal disease,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,3d6a61cd-77c4-4f52-b826-c030df979270,6/1/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,ETT,exercise tolerance time,,,
clinicalPharmacology,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,PRA,plasma renin activity,,,
clinicalPharmacology,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,4ACDFA96-BD62-4289-8454-276D3886A1A7,12/13/2006,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,CGI,Clinical Global Impression,,,
clinicalPharmacology,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,bdb9e366-7234-422d-a3ab-0765824bb7a7,4/23/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,E1A0DA17-D67C-E44F-BD42-33C4009E4CDD,4/2/2009,2,NMDA,N-methyl d-aspartate,,,
clinicalPharmacology,6c76e98d-b8c3-441f-bac5-a9de6dc8f14f,10/21/2011,11,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,199c7249-4ffa-4889-a53a-ffd58653914f,3/1/2012,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,fd13743d-ec41-4782-8068-4a18d4a6eb4e,6/21/2011,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,fd13743d-ec41-4782-8068-4a18d4a6eb4e,6/21/2011,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,e15a7e9b-8025-49dd-9a6d-bafcccf1959f,2/28/2011,8,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
clinicalPharmacology,e15a7e9b-8025-49dd-9a6d-bafcccf1959f,2/28/2011,8,SD,"styleCode=""bold"">Mean",,,
clinicalPharmacology,8bb91825-b63e-44aa-8edd-4326823f3009,2/27/2008,1,preload,pressure and pulmonary capillary wedge pressure,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,LDL,low density lipoprotein,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,VLDL,very low density lipoprotein,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,HDL,high density lipoprotein,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,TG,triglyceride,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,TG,triglycerides,,,
clinicalPharmacology,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,PPAR?,peroxisome proliferator activated receptor ?,,,
clinicalPharmacology,6fcb75a2-095d-424b-b9ac-f843a8e1d9b1,3/2/2012,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,6fcb75a2-095d-424b-b9ac-f843a8e1d9b1,3/2/2012,1,V/F,volume of distribution,,,
clinicalPharmacology,49421564-d2d3-4f69-93b2-bd9eec7feb8f,1/18/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f15b41bd-ed36-4908-aba5-f0a019b7a26e,4/15/2010,2,GU,gastric ulcer,,,
clinicalPharmacology,f15b41bd-ed36-4908-aba5-f0a019b7a26e,4/15/2010,2,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
clinicalPharmacology,4a38f753-a2bf-40af-b638-00c3e409fb98,2/14/2012,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,3e463126-78a9-4ec5-904c-0424a64d8ae8,5/24/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,885A90B0-7C9F-4BC9-9F22-2C16F15EB108,10/17/2007,2,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,1b5a2dc7-0570-4977-876d-88b4176844a1,8/6/2010,2,PSS,phenotypic susceptibility score,,,
clinicalPharmacology,1b5a2dc7-0570-4977-876d-88b4176844a1,8/6/2010,2,HLMs,human liver microsomes,,,
clinicalPharmacology,b5952252-875f-479c-8864-89f18c974fb1,3/29/2012,14,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4a2f9470-4334-490a-a505-9f4c2081eebf,6/11/2010,2,MUGA,multigated nuclear medicine,,,
clinicalPharmacology,4a2f9470-4334-490a-a505-9f4c2081eebf,6/11/2010,2,LVEF,left ventricular ejection fraction,,,
clinicalPharmacology,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,EEAD,evoked after-discharge,,,
clinicalPharmacology,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,MES,maximum electroshock,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,CGI-I,Clinical Global Impression-Global Improvement,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,RLS,Restless Legs Syndrome,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,IRLS scale,International RLS Rating Scale,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,Part  I,4-part multi-item rating scale intended to evaluate mentation,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,PET,Positron emission  tomographic,,,
clinicalPharmacology,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,MPTP,1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
clinicalPharmacology,7dfb35c5-91a3-4193-94d7-ae2c5d787bc9,8/4/2011,15,HTM,Haemophilus Test Media,,,
clinicalPharmacology,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,OCD,Obsessive Compulsive Disorder,,,
clinicalPharmacology,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,TCA,tricyclic antidepressant,,,
clinicalPharmacology,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,36e02614-9346-483e-8beb-711519b80a9d,2/5/2010,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalPharmacology,36e02614-9346-483e-8beb-711519b80a9d,2/5/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalPharmacology,36e02614-9346-483e-8beb-711519b80a9d,2/5/2010,1,PVCs,premature ventricular contractions,,,
clinicalPharmacology,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,AZA,azathioprine,,,
clinicalPharmacology,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,IMPDH,inosine monophosphate dehydrogenase,,,
clinicalPharmacology,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,IL-2,interleukin-2,,,
clinicalPharmacology,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,GFR,[glomerular filtration rate,,,
clinicalPharmacology,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,IL-1,interleukin-1,,,
clinicalPharmacology,14629e09-a46c-496b-8fe2-1c09ddcd4f71,1/20/2011,1,IV,intravenous,,,
clinicalPharmacology,14629e09-a46c-496b-8fe2-1c09ddcd4f71,1/20/2011,1,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,03BE089C-07E5-4F94-BFCC-C6101B311785,5/10/2006,1,LVEDP,left ventricular end diastolic pressure,,,
clinicalPharmacology,A6120C36-30B8-491E-8555-29A60D6F9F5B,10/2/2006,1,IV,intravenous,,,
clinicalPharmacology,A6120C36-30B8-491E-8555-29A60D6F9F5B,10/2/2006,1,IM,intramuscular,,,
clinicalPharmacology,7b666ef7-871d-403f-865a-4360c5ec61fd,12/13/2011,3375,LH,luteinizing  hormone,,,
clinicalPharmacology,7b666ef7-871d-403f-865a-4360c5ec61fd,12/13/2011,3375,TSH,Thyroid stimulating hormone,,,
clinicalPharmacology,7b666ef7-871d-403f-865a-4360c5ec61fd,12/13/2011,3375,GH,growth hormone,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,HRT,Hormone Replacement Therapy,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,CI,confidence interval,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,LCIS,lobular carcinoma in situ,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,RR,relative risk,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,BCPT,Breast Cancer Prevention Trial,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,BMD,bone mineral density,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,RMT,Royal Marsden Trial,,,
clinicalPharmacology,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,DCIS,ductal carcinoma in situ,,,
clinicalPharmacology,be38b325-3a6f-4569-9ae0-a03feff8535d,10/26/2011,1,ERG,electroretinogram,,,
clinicalPharmacology,be38b325-3a6f-4569-9ae0-a03feff8535d,10/26/2011,1,CAD,Coronary Artery Disease,,,
clinicalPharmacology,8ffe8c3f-9694-4029-fca3-1b19c5cc2f93,9/28/2011,7,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,LH,luteinizing hormone,,,
clinicalPharmacology,f1e576fc-3bce-40e2-bfba-de48e341b722,1/10/2012,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f1e576fc-3bce-40e2-bfba-de48e341b722,1/10/2012,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c62ad12d-a7c1-4846-9dbf-6e11884000bc,12/17/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c62ad12d-a7c1-4846-9dbf-6e11884000bc,12/17/2011,2,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,2d526d15-6014-4389-8dc9-20ea8e512cc2,1/6/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,IV,intravenous,,,
clinicalPharmacology,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,CYP,cytochrome P450,,,
clinicalPharmacology,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,SC,subcutaneous,,,
clinicalPharmacology,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,ng/mL,ng/ml,,,
clinicalPharmacology,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,f09450b6-5e6e-4864-bb61-4e3587ad277b,3/31/2011,4,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,581d1c3d-457a-41f2-8db0-5b6219cdcb09,12/14/2011,3379,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,581d1c3d-457a-41f2-8db0-5b6219cdcb09,12/14/2011,3379,ECL,Enterochromaffin-like,,,
clinicalPharmacology,581d1c3d-457a-41f2-8db0-5b6219cdcb09,12/14/2011,3379,CYP,cytochrome P450,,,
clinicalPharmacology,2d5e70d8-9bf9-212c-63a4-44785f3fd015,11/21/1995,1,ddI,didanosine,,,
clinicalPharmacology,2d5e70d8-9bf9-212c-63a4-44785f3fd015,11/21/1995,1,RT,reverse transcriptase,,,
clinicalPharmacology,2d5e70d8-9bf9-212c-63a4-44785f3fd015,11/21/1995,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,0e996cf8-6975-452a-a84c-ca1033a629b1,5/28/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,93d03943-0655-44f6-b494-57bd1e336a34,4/12/2012,2,AUC,area under the curve,,,
clinicalPharmacology,0d1482d3-4ff6-4e19-b062-57c10bd0d093,4/12/2011,3,CYP450,cytochrome P450,,,
clinicalPharmacology,0d1482d3-4ff6-4e19-b062-57c10bd0d093,4/12/2011,3,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,0d1482d3-4ff6-4e19-b062-57c10bd0d093,4/12/2011,3,PES,programmed electrical stimulation,,,
clinicalPharmacology,bcbdbb65-3d82-42e8-9564-630748549954,1/4/2012,3477,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,8CC23BF2-C306-405B-A9CC-9AE895F8C52E,9/19/2006,1,UGDP,University Group Diabetes Program,,,
clinicalPharmacology,8CC23BF2-C306-405B-A9CC-9AE895F8C52E,9/19/2006,1,V/F,volume of distribution,,,
clinicalPharmacology,8CC23BF2-C306-405B-A9CC-9AE895F8C52E,9/19/2006,1,AUC,area under the curve,,,
clinicalPharmacology,8CC23BF2-C306-405B-A9CC-9AE895F8C52E,9/19/2006,1,MDG,mean daily glucose,,,
clinicalPharmacology,7b03a2d7-f17c-4954-85c9-fb78cfec7d76,5/11/2012,1,SVT,supraventricular tachycardia,,,
clinicalPharmacology,7b03a2d7-f17c-4954-85c9-fb78cfec7d76,5/11/2012,1,DIG,Digitalis Investigation Group,,,
clinicalPharmacology,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,REM,rapid eye movement,,,
clinicalPharmacology,00bf4e02-633e-453b-8c3c-fb8b1d829887,3/21/2012,2,min,median,,,
clinicalPharmacology,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,CPS,complex partial seizures,,,
clinicalPharmacology,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,i.e.,improvement,,,
clinicalPharmacology,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,TID,three divided doses,,,
clinicalPharmacology,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,CYP,cytochrome P450,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,ITT,intention-to-treat,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,CVD,cardiovascular disease,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,SBP,systolic blood pressure,,,
clinicalPharmacology,8574acd5-ad13-424f-bdfe-152c6623b24c,4/12/2012,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,ace67632-4620-49cf-97c4-c105d2b45097,3/30/2010,2,PPG,postprandial plasma glucose,,,
clinicalPharmacology,faaf13ce-5d8d-4c57-a49f-a7a73daa41a5,2/4/2012,2,CYP2D6,cytochrome P450 isoform 2D6,,,
clinicalPharmacology,faaf13ce-5d8d-4c57-a49f-a7a73daa41a5,2/4/2012,2,PM,poor metabolizers,,,
clinicalPharmacology,FBB95791-D582-4FB4-81DF-3084EB069B10,12/26/2006,1,VAS,visual analog scale,,,
clinicalPharmacology,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,SHBG,sex hormone?binding globulin,,,
clinicalPharmacology,7cd5a359-4ebc-4b2a-81d7-3b253069e346,3/16/2012,12,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,04c42f2b-d049-4892-b003-bdf346cb4ab4,5/26/2011,1,GU,gastric ulcer,,,
clinicalPharmacology,04c42f2b-d049-4892-b003-bdf346cb4ab4,5/26/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,1d19a6db-6da5-e7de-f929-2d18bdfa2cf5,1/8/2010,4,AUC,area under the curve,,,
clinicalPharmacology,12e68a18-813e-4645-b513-c64145bde969,8/4/2010,18,TRH,Thyrotropin-releasing hormone,,,
clinicalPharmacology,571fe550-399d-4296-835c-37aa1ab9b409,3/7/2012,3,IOP,intraocular pressure,,,
clinicalPharmacology,6ed50128-78be-467a-8a53-098154705f18,4/6/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,GFR,glomerular filtration rate,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,AUC,area under the curve,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,RPF,renal plasma flow,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,FVC,forced vital capacity,,,
clinicalPharmacology,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,FEV 1,forced expiratory volume 1 second,,,
clinicalPharmacology,f2f20b37-8bd4-4e8a-b596-be80b48ca2f1,9/1/2011,3,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,f2f20b37-8bd4-4e8a-b596-be80b48ca2f1,9/1/2011,3,LV,leucovorin,,,
clinicalPharmacology,f2f20b37-8bd4-4e8a-b596-be80b48ca2f1,9/1/2011,3,5-FU,5-fluorouracil,,,
clinicalPharmacology,f2f20b37-8bd4-4e8a-b596-be80b48ca2f1,9/1/2011,3,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,1292FA83-E2A1-4FDA-B0DD-CCF763265FE1,4/9/2007,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,693aaaaa-f99d-4c23-a712-2cf8b728f104,9/28/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalPharmacology,693aaaaa-f99d-4c23-a712-2cf8b728f104,9/28/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalPharmacology,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,MN,mononuclear,,,
clinicalPharmacology,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalPharmacology,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,432287dc-6d16-4a64-bc5f-ec1327104f7e,9/8/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ea8ce5e2-dad4-4288-a1e1-775ea98a6fb9,8/11/2009,4,CSF,cerebrospinal fluid,,,
clinicalPharmacology,e729d829-4bd0-4074-85ea-e0f9f5d7cdb5,4/16/2012,2,i.v.,intravenous,,,
clinicalPharmacology,E2CAAB63-1E0D-44E8-B9A8-BDFB59CE1288,9/20/2006,1,DNA,deoxyribonucleic acid,,,
clinicalPharmacology,a7e19182-57b5-4783-9c7f-bb83961f1803,6/14/2011,3,SHBG,sex hormone-binding globulin,,,
clinicalPharmacology,253b9eeb-3be5-47d6-a76b-9889bd3c55ed,7/29/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,DCT,demethylcitalopram,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,CT,citalopram,,,
clinicalPharmacology,8d119057-f299-43ea-b516-e84a09cab890,10/5/2011,3,c.i.,"colspan=""5"" align=""left"">",,,
clinicalPharmacology,273e5d83-4890-482c-9b69-972c17e786bb,4/13/2010,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,72fb11b6-b08c-2f02-d82b-f60f52394903,3/16/2012,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,72fb11b6-b08c-2f02-d82b-f60f52394903,3/16/2012,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,a2e051e0-e3fa-ce2a-083b-55bff0505384,12/16/2009,2,IV,intravenous,,,
clinicalPharmacology,d6d7711f-541b-47d1-b937-2c6a021eb6c3,12/2/2010,1,BMD,bone mineral density,,,
clinicalPharmacology,d6a161d9-7e7a-4711-ba0e-c9040c42268d,1/6/2012,4,SAH,subarachnoid hemorrhage,,,
clinicalPharmacology,d6a161d9-7e7a-4711-ba0e-c9040c42268d,1/6/2012,4,III,initial bleed,,,
clinicalPharmacology,6f50bddb-e90d-4a2b-8716-9c1b84f5a22f,6/23/2010,325,NSAID,non-steroidal anti-inflammatory drug,,,
clinicalPharmacology,31d00e75-4fe0-4aec-9cba-c86cb78762c5,2/3/2012,5,HPPH,5-(p-hydroxyphenyl)-5-phenylhydantoin,,,
clinicalPharmacology,6aecd9bf-6cfa-4bc7-be82-d2bc27b80fe9,6/1/2012,2,INR,International Normalized Ratio,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,MN,mononuclear,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,Drugs,Drug Interactions.,,,
clinicalPharmacology,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,PMN,polymorphonuclear,,,
clinicalPharmacology,22457862-0f88-4be8-b507-1c8f264269f2,11/30/2009,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4b546121-ef6b-458c-ae0c-ce5bba3dc9a3,12/14/2010,1,Scores,scores of nasal and non-nasal symptoms,,,
clinicalPharmacology,4b546121-ef6b-458c-ae0c-ce5bba3dc9a3,12/14/2010,1,AUC,area under the concentration-time curve,,,
clinicalPharmacology,4b546121-ef6b-458c-ae0c-ce5bba3dc9a3,12/14/2010,1,Tmax,to maximum plasma  concentrations,,,
clinicalPharmacology,22edd948-d2fe-4df1-b797-1b7d92fc29cf,12/15/2011,8,CGI,Clinical Global Impression,,,
clinicalPharmacology,22edd948-d2fe-4df1-b797-1b7d92fc29cf,12/15/2011,8,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,0b126fcd-2385-409f-9269-5bf886649c1a,3/6/2012,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalPharmacology,0b126fcd-2385-409f-9269-5bf886649c1a,3/6/2012,1,msec,mseconds,,,
clinicalPharmacology,0b126fcd-2385-409f-9269-5bf886649c1a,3/6/2012,1,AAG,alpha-1-acid glycoprotein,,,
clinicalPharmacology,19479eeb-f507-48a8-bca3-c9cc0a0f6021,1/23/2008,1,e.g.,ergotamine and macrolide antibiotics,,,
clinicalPharmacology,6436dfa0-5f27-456a-83b9-c0485a40d9cc,4/10/2012,2,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,83554310-3991-4a9d-92f1-d71ccfd0fb3a,10/15/2009,3,GU,gastric ulcer,,,
clinicalPharmacology,83554310-3991-4a9d-92f1-d71ccfd0fb3a,10/15/2009,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
clinicalPharmacology,e7ea978d-00a1-4c60-97bc-bb1d37d776e9,5/19/2010,1,QTc,QT correction,,,
clinicalPharmacology,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,CHF,.Congestive Heart Failure,,,
clinicalPharmacology,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,i.e.,initial clearance rates,,,
clinicalPharmacology,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,ISH,isolated systolic hypertension,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,DBP,diastolic blood pressure,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,ITT,intention-to-treat,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,ESRD,end-stage renal disease,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,CVD,cardiovascular disease,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,SBP,systolic blood pressure,,,
clinicalPharmacology,46c2cb4b-eb65-45f5-891f-5e574adc962d,6/25/2010,4,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,283636b7-0c65-4572-a552-7a7548fb45b4,10/19/2011,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,51772745-9ea9-42cd-97e6-7266f41ae3ca,2/22/2011,1,DEA,N-desethylamiodarone,,,
clinicalPharmacology,51772745-9ea9-42cd-97e6-7266f41ae3ca,2/22/2011,1,VT,ventricular tachycardia,,,
clinicalPharmacology,51772745-9ea9-42cd-97e6-7266f41ae3ca,2/22/2011,1,VF,ventricular fibrillation,,,
clinicalPharmacology,26fcf4be-4785-4922-a37b-4546570a132c,10/27/2009,1,MICs,minimum  inhibitory concentrations,,,
clinicalPharmacology,26fcf4be-4785-4922-a37b-4546570a132c,10/27/2009,1,MIC,minimum inhibitory  concentration,,,
clinicalPharmacology,aa060190-0e54-447d-e28f-ea11ff471776,7/11/2011,10,LES,lower esophageal sphincter,,,
clinicalPharmacology,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,AAG,alpha1 acid glycoprotein,,,
clinicalPharmacology,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,EM,extensive metabolizers,,,
clinicalPharmacology,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,Tmax,to maximum concentration,,,
clinicalPharmacology,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,PM,poor metabolizers,,,
clinicalPharmacology,610022b7-7dc9-405a-a580-104657f43bdf,4/9/2007,1,placebo,placebo-controlled study in 207 patients,,,
clinicalPharmacology,610022b7-7dc9-405a-a580-104657f43bdf,4/9/2007,1,placebo,placebo-controlled studies in 629 patients,,,
clinicalPharmacology,610022b7-7dc9-405a-a580-104657f43bdf,4/9/2007,1,AUC,Area Under the Curve,,,
clinicalPharmacology,f0d63051-fd8c-41af-92c3-b3be9f95475a,10/3/2011,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f0d63051-fd8c-41af-92c3-b3be9f95475a,10/3/2011,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,f0d63051-fd8c-41af-92c3-b3be9f95475a,10/3/2011,3,ECL,Enterochromaffin-like,,,
clinicalPharmacology,f0d63051-fd8c-41af-92c3-b3be9f95475a,10/3/2011,3,CYP,cytochrome P450,,,
clinicalPharmacology,9b2500f1-eb0d-41e7-b20f-f7e9d6b813f1,3/12/2007,1,CLr,clearance,,,
clinicalPharmacology,9b2500f1-eb0d-41e7-b20f-f7e9d6b813f1,3/12/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,fafe6400-b7c9-485c-b76e-0b85b29db801,1/12/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,6D743386-A8E4-4A3F-AC82-C046896F35AE,8/4/2008,1,i.e.,its active metabolites,,,
clinicalPharmacology,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,EF,ejection  fraction,,,
clinicalPharmacology,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,AUC,area under the  curve,,,
clinicalPharmacology,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,SAM,S-adenosylmethionine,,,
clinicalPharmacology,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,cbl,cofactor metabolism,,,
clinicalPharmacology,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,MTHFR,5,10-methylenetetrahydrofolate reductase,,
clinicalPharmacology,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,CBS,cystathionine beta-synthase,,,
clinicalPharmacology,446c5df3-438a-4b18-a8a7-a23bd1bd86d0,3/19/2012,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,d99b2484-1c4d-4241-b16e-72395f976efb,9/5/2008,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fb66327e-8261-46ae-b39a-4fa79d520844,10/31/2011,3,NYHA,New York Heart Association,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,bone,by examination of additional tissues and fluids,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,MN,mononuclear,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,Drugs,Drug Interactions.,,,
clinicalPharmacology,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,PMN,polymorphonuclear,,,
clinicalPharmacology,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,EM,extensive metabolizers,,,
clinicalPharmacology,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,PM,poor metabolizers,,,
clinicalPharmacology,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,Tmax,time of maximum plasma concentration,,,
clinicalPharmacology,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,CYP450,cytochrome P450,,,
clinicalPharmacology,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,DEA,N-desethylamiodarone,,,
clinicalPharmacology,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,VT,ventricular tachycardia,,,
clinicalPharmacology,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,CYP3A,cytochrome P4503A,,,
clinicalPharmacology,e9108958-b8d7-4fba-87c3-9a32990de551,1/9/2012,2,VF,ventricular fibrillation,,,
clinicalPharmacology,8d2199d5-80bd-497f-8c74-f3e613b9800d,1/3/2011,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,6ab0ca9e-9a79-4cab-9f09-470eda06952e,1/3/2012,2,MBC,minimum bactericidal concentration,,,
clinicalPharmacology,6ab0ca9e-9a79-4cab-9f09-470eda06952e,1/3/2012,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,6ab0ca9e-9a79-4cab-9f09-470eda06952e,1/3/2012,2,PBPs,penicillin binding proteins,,,
clinicalPharmacology,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,V?,volume,,,
clinicalPharmacology,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,Vss,volume of distribution at steady state,,,
clinicalPharmacology,ad98682f-e421-4cf3-85f5-a042a3708262,3/17/2006,1,ISA,in animals with minimal beta1-agonist,,,
clinicalPharmacology,61d3f51b-a8ed-4be5-849c-4bf653538d3e,12/9/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,dc28e719-6fe0-4d9e-a624-adb76b04b299,2/29/2012,1,HTM,Haemophilus Test Media,,,
clinicalPharmacology,dc28e719-6fe0-4d9e-a624-adb76b04b299,2/29/2012,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,d7131853-8850-45bd-9227-c4b1916dd28d,12/13/2011,1,MBC,minimum bactericidal concentrations,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,QCA,quantitative coronary angiography,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,AUC,area under the curve,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,TG,triglycerides,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,CCAIT,Canadian Coronary Atherosclerosis Intervention Trial,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,IMT,intimal-medial thickness,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,RR,risk reductions,,,
clinicalPharmacology,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalPharmacology,0e6364a4-6d66-4151-8197-d45e2a762895,1/11/2012,10,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,YMRS,Young Mania Rating Scale,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,CPS,complex  partial seizures,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,BPRS-A,Brief  Psychiatric Rating Scale,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,TID,three divided doses,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,MRS,Manic  Rating Scale,,,
clinicalPharmacology,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,GAS,Global Assessment Scale,,,
clinicalPharmacology,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,TCA,tricyclic antidepressant,,,
clinicalPharmacology,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalPharmacology,703cc338-c0b6-4a02-b8db-c27aeff181df,1/13/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c96d3986-9d92-4ec4-a319-a50aeb2f4fe7,7/22/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,ECB84B38-ED22-48B0-861C-D09CF8F101C9,10/6/2006,1,Tmax,to maximum concentration,,,
clinicalPharmacology,3700405c-5743-4c82-a3fb-48dae904eed6,10/14/2009,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,DHT,5?-dihydrotestosterone,,,
clinicalPharmacology,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,FSH,follicle-stimulating hormone,,,
clinicalPharmacology,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,IV,intravenous,,,
clinicalPharmacology,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,AUC,area under the curve,,,
clinicalPharmacology,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,LH,luteinizing hormone,,,
clinicalPharmacology,a7b50175-e978-4edd-9d61-593df4806657,6/20/2012,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,PRSP,Penicillin-resistant S. pneumoniae,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,HD,hemodialysis,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,UV,ultraviolet light,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,MED,minimum erythematous dose,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,S-warfarin,single dose of warfarin sodium on the fifth day,,,
clinicalPharmacology,fe9226f8-64f4-4eff-8339-ed3fce0896f2,8/8/2011,2,MIC,more of the following antibiotics: penicillin,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,BIS,Behavior and Ideation Scale,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,CPS,complex partial seizures,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,AED,antiepilepsy drug,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,MSS,Manic Syndrome Scale,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,i.e.,improvement,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,TID,three divided doses,,,
clinicalPharmacology,9b3db659-f64c-4c48-946a-6b4f1d800eba,9/21/2010,1,MRS,Manic Rating Scale,,,
clinicalPharmacology,46b8d7ba-432d-d610-84f2-550bf9d0bae3,10/11/2011,1,TRF,thyroid release factor,,,
clinicalPharmacology,46b8d7ba-432d-d610-84f2-550bf9d0bae3,10/11/2011,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,c6d3c1ff-d873-4903-befa-c0ba47034c6e,12/8/2010,1,MICs,minimal  inhibitory concentrations,,,
clinicalPharmacology,c6d3c1ff-d873-4903-befa-c0ba47034c6e,12/8/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,CL,clearance,,,
clinicalPharmacology,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,CSF,cerebral spinal fluid,,,
clinicalPharmacology,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,PCA,patient-controlled analgesia,,,
clinicalPharmacology,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,VAS,Visual Analog Score,,,
clinicalPharmacology,16b64c7f-b70a-4192-b4b8-b0c941891c1d,3/14/2012,5,Cl-,chloride,,,
clinicalPharmacology,2f3804f1-ce47-4c1c-a012-b7c0c3088105,3/11/2011,1,CNS,central nervous system,,,
clinicalPharmacology,4ab110e4-7b91-42aa-8052-f24cd79293f0,8/30/2011,5,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,9f2aae1f-898d-4955-be31-678e0cf85395,2/3/2012,8,DEXA,Dual Energy X-ray Absorptiometry,,,
clinicalPharmacology,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,GABA,gamma-aminobutyric acid,,,
clinicalPharmacology,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,18e678d8-f1cd-4970-8ae1-f701186180a4,6/6/2008,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,f42c680d-1d80-4091-b794-17e07af10b2e,3/10/2011,1,H+,hydrogen inon,,,
clinicalPharmacology,b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae,6/19/2012,24,IRI,Immunoreactive Insulin,,,
clinicalPharmacology,c00d5f7b-dad7-4479-aae2-fea7c0db40ed,5/25/2012,8,EM,extensive metabolizers,,,
clinicalPharmacology,c00d5f7b-dad7-4479-aae2-fea7c0db40ed,5/25/2012,8,PM,poor metabolizers,,,
clinicalPharmacology,17f8f038-c204-4dab-80d7-6f7ac41ddbec,5/8/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,96ef2f48-d478-478c-95d0-1c0b986493d1,4/18/2012,5,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,A4BE3F71-31F6-4559-82F0-AA11168AF779,5/29/2007,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,A4BE3F71-31F6-4559-82F0-AA11168AF779,5/29/2007,1,IV,intravenous,,,
clinicalPharmacology,f58803b0-f173-4997-b2f8-0f415b94dacf,2/1/2012,5,induction,initial dose of rocuronium bromide injection under sevoflurane,,,
clinicalPharmacology,f58803b0-f173-4997-b2f8-0f415b94dacf,2/1/2012,5,CL,clearance,,,
clinicalPharmacology,f58803b0-f173-4997-b2f8-0f415b94dacf,2/1/2012,5,MAP,mean arterial blood pressure,,,
clinicalPharmacology,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,BOH,beclomethasone,,,
clinicalPharmacology,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,ADP,adenosine diphosphate,,,
clinicalPharmacology,d35db38b-8b0e-4872-ab18-09795c5e07e9,8/25/2010,2,HPLC,high pressure liquid  chromatography,,,
clinicalPharmacology,d35db38b-8b0e-4872-ab18-09795c5e07e9,8/25/2010,2,GLC,gas-liquid chromatography,,,
clinicalPharmacology,ac3dfb81-a4c7-4147-9374-c234153b7c51,12/29/2011,4,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,MMEF,maximum midexpiratory flow rate,,,
clinicalPharmacology,13bd4214-9b7f-425b-af5f-fc1ddc678230,1/21/2012,10,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,18fae555-8c03-4cec-8c65-c7fdaea4b958,1/9/2012,2,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalPharmacology,8b7f7043-5bfb-47a5-80cb-4f3f65358dff,6/23/2010,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,APTTs,activated partial thromboplastin times,,,
clinicalPharmacology,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,Tmax,to maximum concentration,,,
clinicalPharmacology,975581f1-d5af-4709-81f1-be8b46b4d3d2,1/17/2012,1,AUC,area under the curve,,,
clinicalPharmacology,a58fc044-95b2-4443-93b0-2ca7a6f6c159,6/7/2012,4,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,a58fc044-95b2-4443-93b0-2ca7a6f6c159,6/7/2012,4,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,fea44910-400c-4688-bedc-bbb1615cd8f5,4/22/2010,1,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,fea44910-400c-4688-bedc-bbb1615cd8f5,4/22/2010,1,ETEC,enterotoxigenic  strains of Escherichia coli,,,
clinicalPharmacology,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,CSF,cerebrospinal fluid,,,
clinicalPharmacology,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,CSF,cerebrospinal fluid,,,
clinicalPharmacology,246f1e96-0a2f-43c8-aa71-8e885b6c350d,10/19/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9f015e60-1aec-4ae7-b28f-42f6c8f50455,7/23/2012,1,5-HIAA,5-hydroxyindoleacetic acid,,,
clinicalPharmacology,4022e67f-59ce-44bb-7786-2b82831e2cf0,7/17/2012,814,MIC's,minimum inhibitory concentrations,,,
clinicalPharmacology,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,cyclic AMP,cyclic-3’,5’-adenosine monophosphate,,
clinicalPharmacology,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,ATP,adenosine triphosphate,,,
clinicalPharmacology,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,FEV1,forced expiratory volume in 1 second,,,
clinicalPharmacology,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,MMEF,maximum midexpiratory flow rate,,,
clinicalPharmacology,ad65c43d-91c7-4c7c-b16f-5025c764cad6,3/7/2012,5,LVEDP,left ventricular end-diastolic pressure,,,
clinicalPharmacology,ad8193fb-4e3c-42e9-a4a8-49133650b86b,5/31/2010,1,CYP 2D6,cytochrome P450 2D6,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,VLDL,very low-density lipoprotein,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,QCA,quantitative coronary angiography,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,AUC,area under the curve,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,TG,triglycerides,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,CCAIT,Canadian Coronary Atherosclerosis Intervention Trial,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,IMT,intimal-medial thickness,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,EXCEL,Expanded Clinical Evaluation Of Lovastatin,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,RR,risk reductions,,,
clinicalPharmacology,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalPharmacology,e87d7f56-3666-4ba7-89b3-d8e19b78e02c,11/30/2010,1,MIC's,minimal inhibitory concentrations,,,
clinicalPharmacology,3dbab949-6ab7-4040-9c81-314e5bb61d41,3/7/2012,6,Sevo/O2,sevoflurane-O2,,,
clinicalPharmacology,3dbab949-6ab7-4040-9c81-314e5bb61d41,3/7/2012,6,FA,following termination of anesthesia,,,
clinicalPharmacology,99b7f40a-06f9-4b97-8eee-8e61e5106aad,10/9/2009,5,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,60752a58-1d6c-4b4d-98dd-d49c76d2f443,12/27/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,60752a58-1d6c-4b4d-98dd-d49c76d2f443,12/27/2011,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,60752a58-1d6c-4b4d-98dd-d49c76d2f443,12/27/2011,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,60752a58-1d6c-4b4d-98dd-d49c76d2f443,12/27/2011,2,CYP,cytochrome P450,,,
clinicalPharmacology,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,VT,ventricular,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,MI,myocardial infarction,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,WPW,Wolff-Parkinson-White,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,BSA,body surface area,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,AFIB,atrial fibrillation,,,
clinicalPharmacology,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,SVT,supraventricular,,,
clinicalPharmacology,52ee65a7-ca1f-48fd-8fad-d72ea0dad4de,5/7/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,A274E3EA-BF67-4F81-AAA0-10475B20CD69,10/6/2006,1,IBS,irritable bowel syndrome,,,
clinicalPharmacology,A274E3EA-BF67-4F81-AAA0-10475B20CD69,10/6/2006,1,5-HT,5-hydroxytryptamine,,,
clinicalPharmacology,50630775-7f76-413e-9278-ba298dd7f187,12/22/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,946b680e-34e2-4789-8a9f-c00f851ad033,7/1/2009,1,DF,disoproxil fumarate,,,
clinicalPharmacology,f6c30ba1-53d0-4f85-a515-81acfb922e73,5/18/2010,5,ADHD,Attention Deficit  Hyperactivity Disorder,,,
clinicalPharmacology,f6c30ba1-53d0-4f85-a515-81acfb922e73,5/18/2010,5,AUC?,area under the  curve to infinity,,,
clinicalPharmacology,f6c30ba1-53d0-4f85-a515-81acfb922e73,5/18/2010,5,Tmax,to reach maximum plasma concentration,,,
clinicalPharmacology,f6c30ba1-53d0-4f85-a515-81acfb922e73,5/18/2010,5,ADHD-RS,Attention Deficit Hyperactivity Disorder-Rating  Scale,,,
clinicalPharmacology,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,4e0c7ad7-3b44-4db8-b144-a1ad6d152315,7/27/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,4e0c7ad7-3b44-4db8-b144-a1ad6d152315,7/27/2010,2,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4e0c7ad7-3b44-4db8-b144-a1ad6d152315,7/27/2010,2,ECL,Enterochromaffin-like,,,
clinicalPharmacology,4e0c7ad7-3b44-4db8-b144-a1ad6d152315,7/27/2010,2,CYP,cytochrome P450,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,CNS,central nervous system,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,CGI,Clinical Global Impression,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,DCT,demethylcitalopram,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,DDCT,didemethylcitalopram,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,CT,citalopram,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,DA,dopamine,,,
clinicalPharmacology,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,NE,norepinephrine,,,
clinicalPharmacology,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,D2,dopamine Type 2,,,
clinicalPharmacology,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,RA,rheumatoid arthritis,,,
clinicalPharmacology,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,INR,International Normalized  Ratio,,,
clinicalPharmacology,4f1a0b58-f7c8-485e-a317-432e1c374d2f,2/13/2012,9,GERD,Gastroesophageal Reflux Disease,,,
clinicalPharmacology,8e1a3641-25ca-41bd-a940-51ae0ec64ed9,6/29/2012,6,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,8e1a3641-25ca-41bd-a940-51ae0ec64ed9,6/29/2012,6,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,TOPO IV,topoisomerase IV,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,UV,ultraviolet light,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,MED,minimum erythematous dose,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,MBCs,minimum bactericidal concentrations,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,PRSP,penicillin-resistant Streptococcus pneumoniae,,,
clinicalPharmacology,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,i.e.,warfarin-induced anticoagulant activity,,,
clinicalPharmacology,ad81576a-6a25-438e-b39e-d04d7c4b9595,12/14/2009,1,GER,gastroesophageal reflux,,,
clinicalPharmacology,ad81576a-6a25-438e-b39e-d04d7c4b9595,12/14/2009,1,mean age,minutes to 9 pediatric cancer patients receiving chemotherapy,,,
clinicalPharmacology,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalPharmacology,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,CGI,Clinical Global Impression,,,
clinicalPharmacology,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,89dd7e24-85fc-4152-89ea-47ec2b48a1ed,8/1/2011,6,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,CYP1A2,cytochrome P450 1A2,,,
clinicalPharmacology,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,MBC,minimal bactericidal concentration,,,
clinicalPharmacology,E67D21FA-DB5A-4536-FC82-CABFEADB0C6F,2/22/2006,1,ACE,angiotensin converting enzyme,,,
clinicalPharmacology,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,eg,emergency setting,,,
clinicalPharmacology,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalPharmacology,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,ESRD,end-stage renal disease,,,
clinicalPharmacology,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,RAS,renin-angiotensin system,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,ISH,isolated systolic hypertension,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,DBP,diastolic blood pressure,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,ITT,intention-to-treat,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,CVD,cardiovascular disease,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,SBP,systolic blood pressure,,,
clinicalPharmacology,e8979bdc-eae4-4db9-ab70-68e078a9c661,6/1/2011,1,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,e797d0eb-eabb-432a-8053-64eff753f1b0,6/24/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,a3262279-1f9e-401b-9b02-6da3ef374b46,8/23/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,5c133dfe-3cb5-426b-ac30-daf814e12c47,1/9/2012,1,TK,thymidine kinase,,,
clinicalPharmacology,5c133dfe-3cb5-426b-ac30-daf814e12c47,1/9/2012,1,HSV-1,herpes simplex virus types 1,,,
clinicalPharmacology,5c133dfe-3cb5-426b-ac30-daf814e12c47,1/9/2012,1,Vd?,volume of distribution,,,
clinicalPharmacology,ee8787d8-3b83-4a8c-9447-09571aa40964,6/7/2010,3,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,0613b659-2b72-451d-b4a5-30a442364dff,6/22/2010,2,Tmax,to maximum plasma concentration of cefprozil,,,
clinicalPharmacology,0613b659-2b72-451d-b4a5-30a442364dff,6/22/2010,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,adedec4c-e9b0-44ef-9ed9-741adcdc84d7,7/5/2011,1,MAC,Mycobacterium avium complex,,,
clinicalPharmacology,adedec4c-e9b0-44ef-9ed9-741adcdc84d7,7/5/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,adedec4c-e9b0-44ef-9ed9-741adcdc84d7,7/5/2011,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,bcb4364f-7884-4aa3-94db-47607a5ce5fc,10/17/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,H. pylori,Helicobacter pylori,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,SHBG,sex hormone binding globulin,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,STH,somatotropic hormone,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,ECL,Enterochromaffin-like,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,TSH,thyroid stimulating hormone,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,DHEA-S,dehydroepiandrosterone sulfate,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,FSH,follicle stimulating hormone,,,
clinicalPharmacology,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,LH,luteinizing hormone,,,
clinicalPharmacology,907fce46-6f0f-4752-b9d3-838ae113f788,11/3/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,80f3b79c-a399-45b3-b755-8535457719af,6/19/2012,1,APC,aminopentane carboxylic acid,,,
clinicalPharmacology,80f3b79c-a399-45b3-b755-8535457719af,6/19/2012,1,LV,leucovorin,,,
clinicalPharmacology,80f3b79c-a399-45b3-b755-8535457719af,6/19/2012,1,5-FU,5-fluorouracil,,,
clinicalPharmacology,80f3b79c-a399-45b3-b755-8535457719af,6/19/2012,1,UGT1A1,UDP-glucuronosyl transferase 1A1,,,
clinicalPharmacology,5b695ae6-bdb8-43a8-65ab-d8d473aa8ea6,9/28/2011,8,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,b8b4539b-31d1-40cb-b284-86cf8b16522a,1/7/2010,2,NCGS,National Cooperative Gallstone Study,,,
clinicalPharmacology,ac3e3964-90c0-44dd-800c-ec9606629572,11/10/2011,2,Inhibitors,inhibitors,,,
clinicalPharmacology,ac3e3964-90c0-44dd-800c-ec9606629572,11/10/2011,2,NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors,,,
clinicalPharmacology,78f71505-6e1f-4d74-bfb6-faf4e3a4864e,5/5/2010,2,NAPR,nonallergic perennial rhinitis,,,
clinicalPharmacology,78f71505-6e1f-4d74-bfb6-faf4e3a4864e,5/5/2010,2,APR,allergic perennial rhinitis,,,
clinicalPharmacology,13b059c6-0c6c-49a5-b985-a4b05caf9ac9,4/10/2012,1423,msec,milliseconds,,,
clinicalPharmacology,13b059c6-0c6c-49a5-b985-a4b05caf9ac9,4/10/2012,1423,95% CI,95% confidence intervals,,,
clinicalPharmacology,13b059c6-0c6c-49a5-b985-a4b05caf9ac9,4/10/2012,1423,CYP3A,cytochrome P450 3A,,,
clinicalPharmacology,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
clinicalPharmacology,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,PMs,poor metabolizers,,,
clinicalPharmacology,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,EMs,[extensive metabolizers,,,
clinicalPharmacology,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,fe6bfe6c-6350-43e0-aa9e-f2af8d1bf382,1/6/2012,2,PABA,para-aminobenzoic acid,,,
clinicalPharmacology,bba266d2-1d22-49a9-b3db-e4f06802a8a9,2/7/2012,1,i.e.,initial clearance rates,,,
clinicalPharmacology,bba266d2-1d22-49a9-b3db-e4f06802a8a9,2/7/2012,1,COPD,chronic obstructive pulmonary disease,,,
clinicalPharmacology,bba266d2-1d22-49a9-b3db-e4f06802a8a9,2/7/2012,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,bba266d2-1d22-49a9-b3db-e4f06802a8a9,2/7/2012,1,CHF,Congestive Heart Failure,,,
clinicalPharmacology,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,ddU,dideoxyuridine,,,
clinicalPharmacology,365fc265-8e6c-432f-9fda-911f5f7fb451,8/4/2011,15,HTM,Haemophilus Test Media,,,
clinicalPharmacology,86e74b34-0dc1-40fc-9509-d7a63e98ef10,3/23/2011,1,CYP3A4,cytochrome P450 3A4,,,
clinicalPharmacology,86e74b34-0dc1-40fc-9509-d7a63e98ef10,3/23/2011,1,1-PP,1-pyrimidinylpiperazine,,,
clinicalPharmacology,CE61920D-65DF-4423-925D-091E624EA32E,10/14/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,4999bbd9-44ed-4749-9730-be2337bdf490,5/10/2012,9,TRNG,tetracycline-resistant Neisseria gonorrhoeae,,,
clinicalPharmacology,9ac8b9fe-dfb9-0151-30b3-f9da72d74ac2,2/9/2012,10,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,CYP3A4,cytochrome P450 isoform 3A4,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,CNS,central nervous system,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,DCT,demethylcitalopram,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,DDCT,didemethylcitalopram,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,CT,citalopram,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,DA,dopamine,,,
clinicalPharmacology,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,NE,norepinephrine,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,CGI,Clinical Global Impression,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,GAD,Generalized Anxiety Disorder,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,OCD,obsessive compulsive disorder,,,
clinicalPharmacology,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalPharmacology,b23637eb-16ff-4e92-96e5-d6efd5cc4ee8,6/27/2011,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,f63155b9-ea71-4a30-be32-37173f87bcbf,11/1/2010,1,PPAA,?-phenyl-piperidine acetic acid,,,
clinicalPharmacology,f63155b9-ea71-4a30-be32-37173f87bcbf,11/1/2010,1,MPH,methylphenidate,,,
clinicalPharmacology,d3f15563-21af-4e0d-a9f1-1ebc596c848f,4/11/2012,5,SREs,skeletal-related events,,,
clinicalPharmacology,d3f15563-21af-4e0d-a9f1-1ebc596c848f,4/11/2012,5,SAP,serum alkaline phosphatase,,,
clinicalPharmacology,c4c80b87-fc6e-436d-84de-7a0cd9d895eb,10/24/2011,12,i.e.,initial clearance rates,,,
clinicalPharmacology,c4c80b87-fc6e-436d-84de-7a0cd9d895eb,10/24/2011,12,CSF,cerebrospinal fluid,,,
clinicalPharmacology,c4c80b87-fc6e-436d-84de-7a0cd9d895eb,10/24/2011,12,CHF,Congestive Heart Failure,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,ISH,isolated systolic hypertension,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,SiDBP,sitting diastolic blood pressure,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,DBP,diastolic blood pressure,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,ITT,intention-to-treat,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,CVD,cardiovascular disease,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,SBP,systolic blood pressure,,,
clinicalPharmacology,80e8e178-e79a-4c46-91c9-65831e6ad141,12/23/2011,5,LIFE,Losartan Intervention For Endpoint reduction in hypertension,,,
clinicalPharmacology,A833C24B-6DCA-44D7-A0D6-20012FA1EA77,6/30/2008,1,CNS,central nervous system,,,
clinicalPharmacology,8adef75d-3162-4f81-ae25-d63e82f17988,2/2/2010,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,db977f52-2296-4003-9162-c155163d714a,12/8/2010,1,MIC,minimal inhibitory concentration,,,
clinicalPharmacology,888998CC-C7F7-4F2A-8479-DF60F77BC2A1,1/4/2006,1,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,888998CC-C7F7-4F2A-8479-DF60F77BC2A1,1/4/2006,1,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,214a9cfe-a522-4022-81d4-e59f447401fe,12/19/2011,4,MIC,minimum inhibitory concentration,,,
clinicalPharmacology,4f243e45-a1e6-4246-95f8-196f2b491185,1/28/2008,1,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,ef7e6645-e771-4441-8bc4-07547cf30e22,1/19/2009,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,3580641d-64c7-4cca-b5fd-ad0c82ffe8c7,11/16/2011,2,MICs,minimal inhibitory concentrations,,,
clinicalPharmacology,4dd69142-d320-40d9-ad27-680b2fe7fd42,6/19/2006,1,IOP,intraocular pressure,,,
clinicalPharmacology,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,CYP2D6,cytochrome P450 2D6,,,
clinicalPharmacology,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalPharmacology,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,CPS,complex partial seizures,,,
clinicalPharmacology,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,AED,antiepilepsy drug,,,
clinicalPharmacology,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,CSF,cerebrospinal fluid,,,
clinicalPharmacology,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,i.e.,improvement,,,
clinicalPharmacology,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,TID,three divided doses,,,
clinicalPharmacology,fba9cde2-8fbb-562f-f6e6-b18f8c452248,1/17/2011,1,TNSS,total nasal symptom scores,,,
clinicalPharmacology,fba9cde2-8fbb-562f-f6e6-b18f8c452248,1/17/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,fba9cde2-8fbb-562f-f6e6-b18f8c452248,1/17/2011,1,total dose,total daily doses should not exceed 2 sprays in each nostril,,,
clinicalPharmacology,645607af-3ef3-4765-bbff-ba9c483be141,5/21/2012,1,RT,reverse transcriptase,,,
clinicalPharmacology,645607af-3ef3-4765-bbff-ba9c483be141,5/21/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalPharmacology,0d8fd775-950a-465d-8d32-4fe40234bc11,9/12/2011,2,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,7CB92CF2-46F2-4379-937C-168D230E43A4,11/14/2008,1,ACE,angiotensin-converting enzyme,,,
clinicalPharmacology,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,ITT,intent-to-treat,,,
clinicalPharmacology,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,CLr,clearance,,,
clinicalPharmacology,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,PHN,postherpetic neuralgia,,,
clinicalPharmacology,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,0edf333a-776d-45b8-b567-acc863f8599b,8/31/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,CNS,central nervous system,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,CGI,Clinical Global Impression,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,HAMD,Hamilton Depression Rating Scale,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,SSRI,selective serotonin reuptake inhibitor,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,DCT,demethylcitalopram,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,DDCT,didemethylcitalopram,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,GABA,gamma aminobutyric acid,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,DA,dopamine,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,NE,norepinephrine,,,
clinicalPharmacology,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,CT,citalopram ,,,
clinicalPharmacology,2A72A8B8-A77C-49C6-3C8D-43B03672D802,2/6/2007,1,TPN,total parenteral nutrition,,,
clinicalPharmacology,01484f7c-24c9-4c0a-8ae5-c483cb7e6aaa,7/1/2011,2,MICs,minimum inhibitory concentrations,,,
clinicalPharmacology,9832312e-0310-4ab6-8501-afa976fc7eb2,2/29/2012,4,cyclic AMP,cyclic-3',5'-adenosine monophosphate,,
clinicalPharmacology,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,JRA,juvenile rheumatoid arthritis,,,
clinicalPharmacology,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
clinicalPharmacology,91cecd43-afd8-47a0-963e-167a194ef446,3/29/2010,6,IV,intravenous,,,
clinicalPharmacology,91cecd43-afd8-47a0-963e-167a194ef446,3/29/2010,6,VKOR,vitamin K epoxide reductase,,,
clinicalPharmacology,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,NMDA,N-methyl-D-aspartate,,,
clinicalPharmacology,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,EDDP,2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene,
clinicalPharmacology,d9303631-4301-4704-b85f-7547e88c68df,5/31/2011,3,MIC's,minimum inhibitory concentrations,,,
clinicalStudies,fcabfaee-df20-4e7c-b951-8a454f0d355e,4/8/2011,2,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,029e1676-60c5-490a-b176-94f0f41f1077,4/10/2012,2,HoFH,Homozygous Familial Hypercholesterolemia,,,
clinicalStudies,5e814a91-4bb2-4c8d-bdb5-c64ce5babf07,11/9/2011,3108,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,346a77ce-d326-4cda-b7da-0d51c6d11307,2/8/2012,1,ZE,Zollinger-Ellison,,,
clinicalStudies,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PAF,paroxysmal atrial fibrillation/flutter,,,
clinicalStudies,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PSVT,paroxysmal supraventricular tachycardia,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,CGI,Clinical Global Impression,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,OCD,obsessive compulsive disorder,,,
clinicalStudies,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,a2d6beb9-bec4-4623-bcc9-7f1bfddb9f0b,5/16/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,f768e337-a948-420a-9fbe-9be359c7a170,5/3/2010,5,RMR,rifampin monoresistance,,,
clinicalStudies,de381031-cd25-4930-a59a-431acda0e94a,5/6/2011,1,CBZ,carbamazepine,,,
clinicalStudies,f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040,6/30/2011,2,HDD-CKD,Hemodialysis Dependent-Chronic Kidney Disease,,,
clinicalStudies,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,OA,oral agents,,,
clinicalStudies,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,TID,times daily,,,
clinicalStudies,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,80e0016f-e77e-4eec-876e-baff9e640de2,2/22/2012,1,total,the risk of death or hospitalization,,,
clinicalStudies,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,Y-MRS,Young Mania Rating Scale,,,
clinicalStudies,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,CGI,Clinical Global Impression,,,
clinicalStudies,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,PANSS,Positive and Negative Symptoms Scale,,,
clinicalStudies,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,7fd4c66a-1535-4651-b01a-42ba69e0a965,3/15/2012,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,cUTI,complicated urinary tract infections,,,
clinicalStudies,0e15feec-d27e-4861-8152-c5a8b8ccacd4,7/23/2012,5,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,8cbcee12-3eb1-4726-9212-5dddc39a3b0f,3/15/2010,1,LS,least-square,,,
clinicalStudies,b6c4b64a-2f0c-47ce-b423-b74d705b2de8,3/15/2012,3657,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,b6c4b64a-2f0c-47ce-b423-b74d705b2de8,3/15/2012,3657,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,edbff839-779a-431c-b548-1a769577525c,11/19/2009,1,LV,Leucovorin,,,
clinicalStudies,8fb45a78-b2d8-45dd-b844-0de21d1fdde9,12/28/2010,1,VAS,visual analog scale,,,
clinicalStudies,8fb45a78-b2d8-45dd-b844-0de21d1fdde9,12/28/2010,1,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,8fb45a78-b2d8-45dd-b844-0de21d1fdde9,12/28/2010,1,ACR,American College of Rheumatology,,,
clinicalStudies,be2a14b5-8dc0-473e-8672-96297e20e199,4/26/2010,3,TOC,test-of-cure,,,
clinicalStudies,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,d669ff68-ddcf-42f6-913c-d8f1aedbd9c4,6/1/2011,4,SSD,PAH/Scleroderma Spectrum of Diseases,,,
clinicalStudies,d8034b31-fa43-480b-91a5-f4ece35d60eb,5/3/2010,4,TOC,test-of-cure,,,
clinicalStudies,c6c7322b-6a89-4d23-90d1-bf9327bd6d91,4/13/2012,10,TOC,test-of-cure,,,
clinicalStudies,fe9a82be-dbf0-b51e-055e-139c35b00898,7/27/2011,2,MITT,modified Intent-to-Treat,,,
clinicalStudies,fe9a82be-dbf0-b51e-055e-139c35b00898,7/27/2011,2,cure,clinical success rate,,,
clinicalStudies,fe9a82be-dbf0-b51e-055e-139c35b00898,7/27/2011,2,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,QCA,quantitative coronary angiography,,,
clinicalStudies,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,MLD,minimum lumen diameter,,,
clinicalStudies,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,LCAS,Lipoprotein and Coronary Atherosclerosis Study,,,
clinicalStudies,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,PCI,percutaneous coronary intervention,,,
clinicalStudies,911cd48f-01ea-4dec-b30c-95e7e0ea9d2a,6/1/2010,12,MI,myocardial infarction,,,
clinicalStudies,911cd48f-01ea-4dec-b30c-95e7e0ea9d2a,6/1/2010,12,BAT,Bivalirudin Angioplasty Trial,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,BIS,Behavior and Ideation Scale,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,CPS,complex partial seizures,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,AED,antiepilepsy drug,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,MSS,Manic Syndrome Scale,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,TID,three divided doses,,,
clinicalStudies,64797788-fdcb-4d12-a1a4-743ad71bd17b,1/21/2010,3,MRS,Manic Rating Scale,,,
clinicalStudies,f719162f-cb78-487c-b172-ac10d009e6f5,3/1/2012,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,b1ebcf65-f6c3-4267-99aa-1c6b203dffc7,7/21/2012,2,TTP,thrombocytopenic purpura,,,
clinicalStudies,48b2eb14-c9d5-48cb-bfc4-ddfa973db699,3/29/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,69abd0ff-b200-4d1a-b14a-80e980a8e781,4/13/2011,2,HR,[Hazard Ratio,,,
clinicalStudies,140e953d-d180-4097-80da-b3ecb50465d5,5/25/2010,10,ITT,intent-to-treat,,,
clinicalStudies,140e953d-d180-4097-80da-b3ecb50465d5,5/25/2010,10,RFS,relapse-free survival,,,
clinicalStudies,140e953d-d180-4097-80da-b3ecb50465d5,5/25/2010,10,OS,overall survival,,,
clinicalStudies,7e5fb9dd-1672-442b-b5cc-c886c5dda863,3/12/2012,1,CBZ,carbamazepine,,,
clinicalStudies,f548be5b-f479-4ca9-983c-6f5a76281d12,2/1/2011,2,VAS,visual analog scale,,,
clinicalStudies,bfab78e9-ca51-4ae7-87fa-924d6ca5608a,11/30/2011,1,SVR,Sustained Virologic Response,,,
clinicalStudies,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,ebfd2c46-8635-4cb3-8523-852b425feedd,5/26/2010,3,GERD,gastroesophageal reflux disease,,,
clinicalStudies,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,AUA,American Urological Association,,,
clinicalStudies,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,PPG,postprandial plasma glucose,,,
clinicalStudies,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,VAS,visual analog scale,,,
clinicalStudies,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,AEDs,antiepileptic drugs,,,
clinicalStudies,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,ACR,American College of Rheumatology,,,
clinicalStudies,4cde01bb-230b-42d8-a9e1-4c7da1a01b76,8/23/2010,3,OBR,optimized background regimen,,,
clinicalStudies,4cde01bb-230b-42d8-a9e1-4c7da1a01b76,8/23/2010,3,HAART,highly active antiretroviral therapy regimen,,,
clinicalStudies,c0f238ff-2804-4150-9766-22a5111b4e74,10/4/2011,3,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,0a8f3137-0e3a-4a60-a872-cb7d761b30e1,12/22/2011,11,SVR,sustained virologic response,,,
clinicalStudies,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,VAS,visual analog scale,,,
clinicalStudies,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,AEDs,antiepileptic drugs,,,
clinicalStudies,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,ACR,American College of Rheumatology,,,
clinicalStudies,7ef4022c-1176-44a3-9943-04a289331de3,1/1/2011,1,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,7ef4022c-1176-44a3-9943-04a289331de3,1/1/2011,1,total,the risk of death or hospitalization,,,
clinicalStudies,7ef4022c-1176-44a3-9943-04a289331de3,1/1/2011,1,SBP,systolic blood pressure,,,
clinicalStudies,7ef4022c-1176-44a3-9943-04a289331de3,1/1/2011,1,total,the combined end points of all-cause mortality plus hospitalization,,,
clinicalStudies,38be9414-87c4-4a8a-9f17-99be0d0a33fa,5/23/2008,1,STA,soft-tissue anesthesia,,,
clinicalStudies,54de10ef-fe5f-4930-b91d-6bbb04c664bd,1/28/2011,6,i.e.,impairment,,,
clinicalStudies,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,QCA,quantitative coronary angiography,,,
clinicalStudies,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,MLD,minimum lumen diameter,,,
clinicalStudies,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,LCAS,Lipoprotein and Coronary Atherosclerosis Study,,,
clinicalStudies,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,PCI,percutaneous coronary intervention,,,
clinicalStudies,37204b95-bd46-4b12-b5b7-2c4b128b7203,11/17/2010,1,SCLC,small cell lung cancer,,,
clinicalStudies,37204b95-bd46-4b12-b5b7-2c4b128b7203,11/17/2010,1,ECOG,Eastern Cooperative Oncology Group,,,
clinicalStudies,57d62f2d-ccc9-4cdc-a8e8-5b15d5b3c895,3/21/2012,3690,HR,[hazard ratio,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,AZA,azathioprine,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,GFR,glomerular filtration rate,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,CNI,calcineurin inhibitors,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,PRA,panel-reactive antibodies,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,MMF,mycophenolate mofetil,,,
clinicalStudies,3275b824-3f82-4151-2ab2-0036a9ba0acc,6/15/2012,37,GFR,glomerular filtration rates,,,
clinicalStudies,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MAC,MYCOBACTERIUM AVIUM COMPLEX,,,
clinicalStudies,fafa4cf1-99c2-43d5-73ad-51f256de3be0,6/17/2010,8,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalStudies,fafa4cf1-99c2-43d5-73ad-51f256de3be0,6/17/2010,8,AQLQ(S),Asthma Quality of Life Questionnaire,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,CPS,complex partial seizures,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,AED,antiepilepsy drug,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,MSS,Manic Syndrome Scale,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,i.e.,improvement,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,TID,three divided doses,,,
clinicalStudies,ed277cce-453d-4174-b027-17ebf907ce97,5/5/2011,1,MRS,Manic Rating Scale,,,
clinicalStudies,2e806747-b88b-49f6-9a72-5430ca4b31fb,7/23/2010,1,PCPZ,prochlorperazine,,,
clinicalStudies,50c8f400-8704-45bf-a7c7-696b5d54fefc,2/12/2009,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9e58806e-08ba-4813-885a-bde5cf82b26d,1/9/2012,1,min,median,,,
clinicalStudies,91fb6442-1059-4aeb-b562-62ded3932433,11/2/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,19ee9e35-356b-4487-be7a-654fe88d8658,3/9/2011,1,ITT,intention to treat,,,
clinicalStudies,222a28ca-70c3-474c-850e-fae39eaaf40f,11/16/2011,12,GH,growth hormone,,,
clinicalStudies,73f92f9b-3715-4699-ba60-1ffecd677e23,3/22/2012,5,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,SWOG,Southwest Oncology Group,,,
clinicalStudies,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,CHR,complete hematologic response,,,
clinicalStudies,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,NEL,no evidence of leukemia,,,
clinicalStudies,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,MCyR,major cytogenetic response,,,
clinicalStudies,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,MaHR,major hematologic response,,,
clinicalStudies,0e7f054c-7a27-4192-bd1c-6115d8be858f,6/1/2012,1,CCyR,complete cytogenetic response,,,
clinicalStudies,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,MPA,medroxyprogesterone acetate,,,
clinicalStudies,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,WHI,Women’s Health Initiative,,,
clinicalStudies,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,PE,pulmonary embolism,,,
clinicalStudies,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CHD,coronary heart disease,,,
clinicalStudies,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CE,conjugated equine estrogens,,,
clinicalStudies,fa7ddbd9-29e2-4a36-af46-00c96a77ac85,6/20/2011,1,TOC,test-of-cure,,,
clinicalStudies,24fb7339-f5a9-4d02-a492-43617729412b,1/16/2012,2,rTNSS,Reflective Total Nasal Symptom Score,,,
clinicalStudies,24fb7339-f5a9-4d02-a492-43617729412b,1/16/2012,2,rTNSS,reflective total nasal symptom score,,,
clinicalStudies,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,BIS,Behavior and Ideation Scale,,,
clinicalStudies,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,MSS,Manic Syndrome Scale,,,
clinicalStudies,d5625383-dbf0-4716-bcc6-ac1c8b69923b,9/8/2011,1,MRS,Manic Rating Scale,,,
clinicalStudies,dcf45e4f-b46e-6fbb-b67a-2ff619ab1780,1/4/2012,3,min,median,,,
clinicalStudies,cf066b7a-032a-416c-8d40-15ba581423e3,4/12/2011,7,HR,[Hazard Ratio,,,
clinicalStudies,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,ITT,intent-to-treat,,,
clinicalStudies,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,PHN,postherpetic neuralgia,,,
clinicalStudies,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,1b5826d4-5177-42b9-8ac2-d35071b4bccb,7/24/2006,1,VAS,visual analog scores,,,
clinicalStudies,a453647b-16de-4795-a550-4f52eac10a26,8/6/2011,4,min,median,,,
clinicalStudies,ae3defca-06d5-49ac-8a27-be5c4e9304d1,2/13/2007,1,Ointment,ointment,,,
clinicalStudies,03226fdd-8be5-49a7-b63c-62f08e75cd2d,6/25/2012,6,PCPZ,prochlorperazine,,,
clinicalStudies,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,cUTI,complicated urinary tract infections,,,
clinicalStudies,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,4be13bd5-0c39-43c3-9232-b1226ccd4dbc,6/1/2011,2,TOC,test-of-cure,,,
clinicalStudies,295ac292-7b78-437b-9da0-98e02aaed215,11/10/2010,77,HDRS,Hamilton Depression Rating Scale,,,
clinicalStudies,295ac292-7b78-437b-9da0-98e02aaed215,11/10/2010,77,MADRS,Montgomery and  Asberg Depression Rating Scale,,,
clinicalStudies,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,HR,[Hazard Ratio,,,
clinicalStudies,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,Y-MRS,Young Mania Rating Scale,,,
clinicalStudies,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,CGI,Clinical Global Impression,,,
clinicalStudies,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,PANSS,Positive and Negative Symptoms Scale,,,
clinicalStudies,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,636665be-9d7e-443a-8134-e8cc47e6ba24,6/19/2012,2,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,27bee6c9-118a-4609-8949-2eb161b0c5c4,2/28/2012,3593,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,27bee6c9-118a-4609-8949-2eb161b0c5c4,2/28/2012,3593,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,27bee6c9-118a-4609-8949-2eb161b0c5c4,2/28/2012,3593,CV,cardiovascular,,,
clinicalStudies,357e0e6b-cfbd-454c-82d7-cfc460dc0d68,8/23/2010,1,1.0 g/d,1; and 500 mg twice daily,,,
clinicalStudies,357e0e6b-cfbd-454c-82d7-cfc460dc0d68,8/23/2010,1,DAI,Disease Activity Index,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,PFS,progression?free survival,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,CNS,central nervous system,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,NSCLC,Non?Small Cell Lung Cancer,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,CG,cisplatin and gemcitabine,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,ORR,objective response rate,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,IFN??2a,interferon alfa 2a,,,
clinicalStudies,939b5d1f-9fb2-4499-80ef-0607aa6b114e,5/14/2012,10,mRCC,14.4   Metastatic Renal Cell Carcinoma,,,
clinicalStudies,05393315-da87-4679-9ab1-7b3a289e5638,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,05393315-da87-4679-9ab1-7b3a289e5638,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,dffeca56-ca22-4b62-9537-277caf7edbab,10/6/2010,2,AEDs,antiepileptic drugs,,,
clinicalStudies,a262d7c6-2aa9-433c-b801-d8b2dcd68a0f,10/17/2011,4,VAS,visual analog scale,,,
clinicalStudies,a262d7c6-2aa9-433c-b801-d8b2dcd68a0f,10/17/2011,4,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,a262d7c6-2aa9-433c-b801-d8b2dcd68a0f,10/17/2011,4,ACR,American College of Rheumatology,,,
clinicalStudies,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,MITT,modified Intent-to-Treat,,,
clinicalStudies,6307a49b-753a-4232-a51d-bf6d0537b05b,2/16/2012,2,cure,clinical success rate,,,
clinicalStudies,30a70882-b40a-4782-b227-cd0d35e50a26,7/25/2011,1,ITT,intent-to-treat,,,
clinicalStudies,30a70882-b40a-4782-b227-cd0d35e50a26,7/25/2011,1,PHN,postherpetic neuralgia,,,
clinicalStudies,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,SJIA,Systemic Juvenile Idiopathic Arthritis,,,
clinicalStudies,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,HAQ-DI,Health Assessment Questionnaire Disability Index,,,
clinicalStudies,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,CHAQ-DI,Childhood Health Assessment Questionnaire Disability Index,,,
clinicalStudies,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,ESR,erythrocyte sedimentation rate,,,
clinicalStudies,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,4/22/2011,9,ACR,American College of Rheumatology,,,
clinicalStudies,076da359-b3d0-44f7-8c0e-662f5b7a8668,3/12/2010,2,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,076da359-b3d0-44f7-8c0e-662f5b7a8668,3/12/2010,2,SBR,staying on the baseline antiretroviral regimen,,,
clinicalStudies,076da359-b3d0-44f7-8c0e-662f5b7a8668,3/12/2010,2,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalStudies,542c7f49-abdc-4937-bca2-f51c553c5286,9/16/2008,2,HbA1c,hemoglobin A1c,,,
clinicalStudies,542c7f49-abdc-4937-bca2-f51c553c5286,9/16/2008,2,PPG,postprandial plasma glucose,,,
clinicalStudies,3e48217f-8175-4e9b-9fd0-909be4bbba95,11/3/2010,2,MCE,major coronary events,,,
clinicalStudies,3e48217f-8175-4e9b-9fd0-909be4bbba95,11/3/2010,2,MVE,major vascular events,,,
clinicalStudies,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,only,ondansetron was administered intravenously,,,
clinicalStudies,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,57160dd7-1f61-42de-9e87-ded819bb6bdb,11/16/2010,1,cure,clinical success rate,,,
clinicalStudies,582e1593-1e6c-4ce8-8bae-134fbc3a66f0,1/26/2011,1,HoFH,Homozygous Familial Hypercholesterolemia,,,
clinicalStudies,493032ba-3ce8-4788-963a-c7ca17388c05,6/22/2012,2,HR,[hazard ratio,,,
clinicalStudies,493032ba-3ce8-4788-963a-c7ca17388c05,6/22/2012,2,AD,Alzheimer's disease,,,
clinicalStudies,493032ba-3ce8-4788-963a-c7ca17388c05,6/22/2012,2,VaD,vascular dementia,,,
clinicalStudies,10360cf0-1671-3cbe-cd7c-2c8e8753bd1b,1/1/2009,2,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,4906457e-30ad-4da7-b3ac-bb9e6651a670,2/29/2012,2,SPID30,sum of pain intensity difference at 30 minutes,,,
clinicalStudies,13fb5b4c-e9c3-a92d-94bc-a3c6c55812cd,8/26/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,af653650-1825-475d-af3a-fe4d03e552fd,3/8/2012,5,GERD,Gastroesophageal Reflux disease,,,
clinicalStudies,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,MCE,major coronary events,,,
clinicalStudies,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,MVE,major vascular events,,,
clinicalStudies,b4647b22-9a70-4259-a8f6-fac0ce1ac5c5,9/13/2011,1,total,the risk of death or hospitalization,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,BIS,Behavior and Ideation Scale,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,CPS,complex partial seizures,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,AED,antiepilepsy drug,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,MSS,Manic Syndrome Scale,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,i.e.,improvement,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,TID,three divided doses,,,
clinicalStudies,08a65cf4-7749-4ceb-6895-8f4805e2b01f,8/22/2011,1406,MRS,Manic Rating Scale,,,
clinicalStudies,d58c0b66-475f-46b3-949d-cda5343e7239,12/10/2009,1,ZE,Zollinger-Ellison,,,
clinicalStudies,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,7bc7f987-ec1b-4b31-addc-9ff8d2a428ff,11/16/2010,1,cure,clinical success rate,,,
clinicalStudies,c1b5d801-336f-4541-a7d9-a8d4a110a4cc,9/29/2010,3,CI,confidence interval,,,
clinicalStudies,1f841079-8c66-4f93-a244-4c405d01e364,3/20/2012,3677,VLDL,very low density lipoprotein,,,
clinicalStudies,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,CYP,cytochrome P450,,,
clinicalStudies,ec559356-75a3-423b-9e8c-3ff88290a98a,1/1/2012,6,i.e.,improvement,,,
clinicalStudies,7aae16cb-addc-468a-be00-6c5be248da29,1/20/2012,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,7aae16cb-addc-468a-be00-6c5be248da29,1/20/2012,2,BAO,Basal Acid Output,,,
clinicalStudies,e2b3c0b3-02a6-45c3-a8ea-05d210dc9108,11/30/2011,9,DRC,Data Review Committee,,,
clinicalStudies,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,a3b199d0-4ed4-4392-8db6-3ed9fc48db07,4/26/2010,4,TOC,test-of-cure,,,
clinicalStudies,dc5c6650-7ee8-4357-b037-08cd265b985a,5/24/2011,1,i.e.,improvement,,,
clinicalStudies,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,LDL,low density lipoprotein,,,
clinicalStudies,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,VLDL,very low density lipoprotein,,,
clinicalStudies,fa08cf6a-d306-4979-9b23-ac7febf4fd12,5/3/2011,10,TG,triglyceride,,,
clinicalStudies,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,MITT,modified Intent-to-Treat,,,
clinicalStudies,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,cure,clinical success rate,,,
clinicalStudies,f6a52c0b-45db-422e-8c22-e867a11b4439,12/21/2011,3,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,ABS,acute bacterial sinusitis,,,
clinicalStudies,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,EPS,expressed prostatic secretion,,,
clinicalStudies,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,TOC,test-of-cure,,,
clinicalStudies,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,PBPC,peripheral blood progenitor cell,,,
clinicalStudies,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,TBI,total-body irradiation,,,
clinicalStudies,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,Study 1,study of 212 patients,,,
clinicalStudies,1e99efc7-cf3f-4368-7afb-41d8dfaeffcf,1/13/2011,6,i.e.,improvement from baseline,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,ER,estrogen receptor,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,CI,confidence interval,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,RR,relative risk,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,RMT,Royal Marsden Trial,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalStudies,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,EBCTCG,Early Breast Cancer Trialists' Collaborative Group,,,
clinicalStudies,c1a37bf6-6b1c-41be-9396-c7284a49a624,1/19/2012,3,VAS,visual analog scale,,,
clinicalStudies,c1a37bf6-6b1c-41be-9396-c7284a49a624,1/19/2012,3,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,c1a37bf6-6b1c-41be-9396-c7284a49a624,1/19/2012,3,ACR,American College of Rheumatology,,,
clinicalStudies,bd7c11f5-340c-84e1-10d2-3f7100e74048,11/30/2009,1,i.e.,improvement,,,
clinicalStudies,a002b40c-097d-47a5-957f-7a7b1807af7f,12/22/2011,130,PASI,Psoriasis Area and Severity Index,,,
clinicalStudies,cb78606d-683f-456e-bcf3-a64b9855d033,2/1/2012,3,BMD,Bone Mineral Density,,,
clinicalStudies,c33d82ae-7991-443f-8e48-5832c02ea450,10/19/2010,4,AED,antiepileptic drug,,,
clinicalStudies,c33d82ae-7991-443f-8e48-5832c02ea450,10/19/2010,4,AEDs,antiepileptic drugs,,,
clinicalStudies,c33d82ae-7991-443f-8e48-5832c02ea450,10/19/2010,4,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,c33d82ae-7991-443f-8e48-5832c02ea450,10/19/2010,4,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,9af7a792-d38a-4b2a-b5d6-855d2183b029,9/4/2009,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,9af7a792-d38a-4b2a-b5d6-855d2183b029,9/4/2009,1,BAO,Basal Acid Output,,,
clinicalStudies,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,i.e.,improvement,,,
clinicalStudies,77215d87-ad22-4169-bd5f-a453f10b21ef,9/8/2010,1,MED,Minimal Erythema Dose,,,
clinicalStudies,4e4d8017-9c1d-41eb-affb-8046e3548be9,4/5/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,LDL,low density lipoprotein,,,
clinicalStudies,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,VLDL,very low density lipoprotein,,,
clinicalStudies,dc03eb20-7a97-4e82-a060-7b8062474f4f,7/10/2012,3,TG,triglyceride,,,
clinicalStudies,1153e9d4-e621-4c08-914a-69f0f8691824,6/6/2011,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,41aa6cd8-2243-4c7a-aa91-12424c29717b,4/9/2012,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,0a03c798-a652-4895-b29c-3b521a89ba42,7/13/2012,6,ITT,intent-to-treat,,,
clinicalStudies,0a03c798-a652-4895-b29c-3b521a89ba42,7/13/2012,6,RFS,Relapse-free survival,,,
clinicalStudies,0a03c798-a652-4895-b29c-3b521a89ba42,7/13/2012,6,OS,overall survival,,,
clinicalStudies,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,heFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,71d4bca8-0b51-8f0a-ebab-a67c52fff3b7,12/20/1996,1,TOC,test-of-cure,,,
clinicalStudies,ba41b963-ec4a-4421-ac93-26654876a6be,10/26/2011,1,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,99dd96ea-b872-4e99-a1f5-d64ad410f8a6,12/28/2011,5,PASI,Psoriasis Area and Severity Index,,,
clinicalStudies,99dd96ea-b872-4e99-a1f5-d64ad410f8a6,12/28/2011,5,PGA,Physician Global Assessment,,,
clinicalStudies,202b1a2a-11dc-4c3d-aa53-27512a98a042,12/27/2010,1,ITT,intent to treat,,,
clinicalStudies,befdb67d-62e6-4f40-9183-30b6e0718c53,4/30/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,079ed521-3ff0-47fa-86d5-a336732056cc,6/7/2010,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,d4660235-ecaf-450a-8ac6-f3bd8ebf226d,3/1/2012,5,VAS,visual analog scale,,,
clinicalStudies,d4660235-ecaf-450a-8ac6-f3bd8ebf226d,3/1/2012,5,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,d4660235-ecaf-450a-8ac6-f3bd8ebf226d,3/1/2012,5,ACR,American College of Rheumatology,,,
clinicalStudies,27d36fbf-1892-48e1-a9b1-1625607ea516,7/12/2007,1,PGA,Physician’s Global Assessment,,,
clinicalStudies,0b24089f-4c7f-4fee-9a86-89f783b76514,4/17/2012,9,i.e.,improvement,,,
clinicalStudies,e8d9021d-73aa-4c96-8b8a-e90069e78555,2/16/2012,1,i.e.,in FEV1 after exercise,,,
clinicalStudies,e8d9021d-73aa-4c96-8b8a-e90069e78555,2/16/2012,1,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,e8d9021d-73aa-4c96-8b8a-e90069e78555,2/16/2012,1,i.e.,interval,,,
clinicalStudies,e8d9021d-73aa-4c96-8b8a-e90069e78555,2/16/2012,1,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,CGI,Clinical Global Impression,,,
clinicalStudies,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,YMRS,Young Mania Rating Scale,,,
clinicalStudies,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,PANSS,Positive and Negative Syndrome  Scale,,,
clinicalStudies,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,b45ceaaa-1236-493a-98c1-43df2f4a08f5,10/14/2010,3,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,6e6f6c6d-4826-4817-90ff-5c3f4fbe8909,3/1/2012,3607,GERD,GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalStudies,4e81573a-ea76-47f8-897e-0e1d98550e46,6/26/2012,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,CGI,Clinical Global Impressions,,,
clinicalStudies,b501d239-923b-48b2-82ed-6c5c253a67e2,10/27/2010,4,VRS,Verbal Rating Scale,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,IFN ?-2b,Interferon alfa-2b recombinant,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,MIU,million international units,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,RT-PCR,reverse transcriptase polymerase chain reaction,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,HAI,histology activity index,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,ALT,alanine aminotransferase,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,TIW,times per week,,,
clinicalStudies,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,HCV,hepatitis C virus,,,
clinicalStudies,15a80e60-5d8b-4085-ba4c-7616af1ac96b,7/27/2011,5,TOC,test-of-cure,,,
clinicalStudies,e03d1378-6889-43d5-a34c-f96132cffa88,4/1/2012,3,SCCHN,squamous cell carcinoma of the head and neck,,,
clinicalStudies,e03d1378-6889-43d5-a34c-f96132cffa88,4/1/2012,3,RT,radiotherapy,,,
clinicalStudies,e03d1378-6889-43d5-a34c-f96132cffa88,4/1/2012,3,PFS,progression-free survival,,,
clinicalStudies,e03d1378-6889-43d5-a34c-f96132cffa88,4/1/2012,3,DFS,disease-free survival,,,
clinicalStudies,d9a1a7c5-d806-4dbd-a201-5e73790d078b,3/28/2012,8,MCE,major coronary events,,,
clinicalStudies,d9a1a7c5-d806-4dbd-a201-5e73790d078b,3/28/2012,8,MVE,major vascular events,,,
clinicalStudies,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,i.e.,improvement,,,
clinicalStudies,0a997a7b-4735-44c9-9b8c-1aa493c70d43,5/26/2011,1,TOC,test-of-cure,,,
clinicalStudies,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,CI,confidence interval,,,
clinicalStudies,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,DVT,Deep Vein Thrombosis,,,
clinicalStudies,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PE,Pulmonary Embolism,,,
clinicalStudies,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,TE,thromboembolic,,,
clinicalStudies,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,CGI,Clinical Global Impression,,,
clinicalStudies,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,f9e04064-6b9e-4209-8149-8761f29d1cec,10/14/2009,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,cb1ce9ec-4f07-4cc9-85bb-663ee1f2ccc7,6/7/2011,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,b155a027-a5b3-480a-8c07-fa39af3a18fe,10/6/2010,2,AEDs,antiepileptic drugs,,,
clinicalStudies,4654adbd-c107-4846-9ee6-13f314bc2798,6/6/2011,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,ccc8c882-e4d1-4ce6-9817-e212f4c9527f,6/8/2012,12,FEF25-75%,forced expiratory flow over 25-75% of the vital capacity,,,
clinicalStudies,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,MIC,minimal inhibitory concentration,,,
clinicalStudies,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,TOC,test-of-cure,,,
clinicalStudies,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,MCE,major coronary events,,,
clinicalStudies,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HPS,Heart Protection Study,,,
clinicalStudies,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,MVE,major vascular events,,,
clinicalStudies,8c5a4a2a-234e-4702-9ba0-844ea86ec8b9,4/10/2012,2,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalStudies,8c5a4a2a-234e-4702-9ba0-844ea86ec8b9,4/10/2012,2,ESRD,end-stage renal disease,,,
clinicalStudies,1d111239-79a0-4159-965e-f3a644b60360,2/1/2011,2,NTS,nicotine transdermal system,,,
clinicalStudies,1d111239-79a0-4159-965e-f3a644b60360,2/1/2011,2,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalStudies,06d71a33-5578-4012-b11d-764f45bc1e6a,3/20/2012,6,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,608d4639-06d7-4b0d-ad2d-02e556c17f7c,9/8/2011,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,2a97ef74-b338-4655-a60b-923f86720179,10/23/2009,2,FPG,fasting plasma glucose,,,
clinicalStudies,3ff75342-03b6-462f-b6db-80bc1a52fe6c,4/11/2012,1,min,median,,,
clinicalStudies,0224b5a6-25a3-44c9-b94f-90e2e064c164,5/24/2012,13,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,0224b5a6-25a3-44c9-b94f-90e2e064c164,5/24/2012,13,HR,[hazard ratio,,,
clinicalStudies,0224b5a6-25a3-44c9-b94f-90e2e064c164,5/24/2012,13,AD,Alzheimer's disease,,,
clinicalStudies,0224b5a6-25a3-44c9-b94f-90e2e064c164,5/24/2012,13,VaD,vascular dementia,,,
clinicalStudies,6297cf20-830a-11dc-94c8-0002a5d5c51b,1/25/2012,8,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,c94c1206-97cb-4088-b8a1-adf08b938755,5/1/2012,1,SE,Serum Calcium,,,
clinicalStudies,c94c1206-97cb-4088-b8a1-adf08b938755,5/1/2012,1,EOT,End of Titration,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,CGI,Clinical Global Impression,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,OCD,obsessive compulsive disorder,,,
clinicalStudies,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,915e98e2-3c86-4ab4-a253-2aaf2082854e,11/18/2011,3213,i.e.,improvement from baseline,,,
clinicalStudies,a373596c-9fb3-426e-bf92-54cdd6dfc3ec,1/4/2012,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,a373596c-9fb3-426e-bf92-54cdd6dfc3ec,1/4/2012,2,BAO,Basal Acid Output,,,
clinicalStudies,4d19753e-8525-4c67-9657-70ba571f7e74,6/4/2010,1,MCE,major coronary events,,,
clinicalStudies,4d19753e-8525-4c67-9657-70ba571f7e74,6/4/2010,1,MVE,major vascular events,,,
clinicalStudies,45af3eda-caaa-4478-9372-95aa65adc9b3,5/29/2009,2,Ctrough,cyclosporine trough concentrations,,,
clinicalStudies,d579b480-0e49-461c-b784-a51a5272849f,10/16/2009,1,CGI,Clinical Global Impression,,,
clinicalStudies,d579b480-0e49-461c-b784-a51a5272849f,10/16/2009,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,708b7a4d-ba1f-47b5-be4d-a01c2a7017ff,2/8/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,29481887-34eb-460a-bd7f-b8755473065a,2/22/2010,2,ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinical Global  Impression of Change,,,
clinicalStudies,615a4d38-a235-bb1f-a0ef-1909dcfe7b2a,5/6/2011,2,ZE,Zollinger-Ellison,,,
clinicalStudies,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,CTCL,cutaneous T-cell                                     lymphoma,,,
clinicalStudies,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,min,Median % Change,,,
clinicalStudies,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,min,Median,,,
clinicalStudies,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,1f276ab2-a867-4843-8630-19792fb4da52,7/19/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,319a178d-7ffb-4466-85f6-de615d02f223,6/6/2012,2,VLDL,very low density lipoprotein,,,
clinicalStudies,8750bc89-340d-4abf-b0b8-b83012ab7cae,4/23/2012,3,ZE,Zollinger-Ellison,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,HRT,Hormone Replacement Therapy,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,CI,confidence interval,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,LCIS,lobular carcinoma in situ,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,RR,relative risk,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,BMD,bone mineral density,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,RMT,Royal Marsden Trial,,,
clinicalStudies,86dcde0e-347c-49e1-8b38-ad106a25c9af,1/13/2010,2,DCIS,ductal carcinoma in situ,,,
clinicalStudies,3676af6a-198b-4453-b43a-039fb26817dd,2/16/2012,13,i.e.,improvement from baseline,,,
clinicalStudies,ab9f816e-df48-4d90-b8ca-98477659531a,2/1/2012,3,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,ab9f816e-df48-4d90-b8ca-98477659531a,2/1/2012,3,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,ab9f816e-df48-4d90-b8ca-98477659531a,2/1/2012,3,CV,cardiovascular,,,
clinicalStudies,6ade9be7-f10f-40b2-b5c5-39c5aef3a83d,4/4/2011,1,EGSA,Evaluator's Global Severity Assessment,,,
clinicalStudies,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,min,Median % Change,,,
clinicalStudies,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,min,Median,,,
clinicalStudies,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,AUA,American Urological Association,,,
clinicalStudies,0e31b689-9a56-4222-b4ec-055ff44b5ee5,3/13/2012,3,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,97d9d2b7-745b-413e-a7ba-8ebe207a463f,5/26/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,20635579-c92d-4f6c-a332-1096d51002f2,4/1/2011,4,DVT,deep vein thrombosis,,,
clinicalStudies,20635579-c92d-4f6c-a332-1096d51002f2,4/1/2011,4,PE,pulmonary embolism,,,
clinicalStudies,20635579-c92d-4f6c-a332-1096d51002f2,4/1/2011,4,VTE,venous thromboembolic,,,
clinicalStudies,20635579-c92d-4f6c-a332-1096d51002f2,4/1/2011,4,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,AC,and                                             cyclophosphamide,,,
clinicalStudies,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,FACT-L,Functional Assessment of                                             Cancer Therapy-Lung,,,
clinicalStudies,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,NSCLC,Non-Small Cell Lung Carcinoma,,,
clinicalStudies,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,KS,Kaposi’s sarcoma,,,
clinicalStudies,a17e415e-a559-4a8d-a455-699184a01523,2/13/2012,3,ZE,Zollinger-Ellison,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,BIS,Behavior and Ideation Scale,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,CPS,complex partial seizures,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,AED,antiepilepsy drug,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,MSS,Manic Syndrome Scale,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,TID,three divided doses,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,i.e.,improvement,,,
clinicalStudies,1de73260-3bea-43e6-8151-baad8e7092d7,11/1/2011,11,MRS,Manic Rating Scale,,,
clinicalStudies,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,187997be-2dbf-40af-885f-16df6ba9ae46,8/10/2011,3,min,median,,,
clinicalStudies,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,AED,antiepilepsy drug,,,
clinicalStudies,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,CPS,complex partial seizure,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,VTE,venous thromboembolism,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,i.v.,intravenous,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,DVT,deep vein thrombosis,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,PE,pulmonary embolism,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,s.c.,subcutaneously,,,
clinicalStudies,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,MI,myocardial infarction,,,
clinicalStudies,1dc008e7-5b9b-ddcd-c369-9dc080bbd00b,12/8/2008,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,8ceec078-1e2b-470c-9a36-ce32d1e3bc29,6/12/2012,7,HR,[hazard ratio,,,
clinicalStudies,8ceec078-1e2b-470c-9a36-ce32d1e3bc29,6/12/2012,7,VaD,vascular dementia,,,
clinicalStudies,8ceec078-1e2b-470c-9a36-ce32d1e3bc29,6/12/2012,7,AD,Alzheimer disease,,,
clinicalStudies,553de8e9-fa76-4983-84aa-3a6a0df8f165,5/21/2012,1,BSA,body surface area,,,
clinicalStudies,4aa0642b-5de8-5048-a02b-28e4787f7013,10/6/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,4aa0642b-5de8-5048-a02b-28e4787f7013,10/6/2009,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,65d15ea7-ab7e-45f2-b88d-9f51016c5a7a,6/1/2011,1,SIB,Severe Impairment Battery,,,
clinicalStudies,b8fdcb32-b571-43b4-91e9-b4e9f75d86ae,2/28/2011,6,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,0fcdd59a-906b-43df-9c65-97d8a736b4f1,6/9/2011,1,MCE,major coronary events,,,
clinicalStudies,0fcdd59a-906b-43df-9c65-97d8a736b4f1,6/9/2011,1,MVE,major vascular events,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering  Study,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,MCVE,major cardiovascular events,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,TNT,to New Targets Study,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,min,<th>Median,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,CVD,cardiovascular disease,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,FH,familial hypercholesterolemia,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,TNT,to Occurrence of Major Cardiovascular Events,,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,min,"colspan=""2"">Median % Change",,,
clinicalStudies,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,6d2f9c84-a597-4055-8815-8fbcdf4c4876,1/19/2011,5,i.e.,improvement from baseline,,,
clinicalStudies,da030cbb-40f6-4805-9883-0d8945afbcc3,5/27/2010,978,i.e.,improvement,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,CGI,Clinical Global Impression,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,BARS,Behavioural Activity Rating  Scale,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,PANSS,Positive and  Negative Syndrome Scale,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,AUC,area under the curve,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,CGI,Clinical Global  Impression,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,CGI-S,Clinical Global  Impression-Severity of Illness Scale,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,MRS,Mania Rating Scale,,,
clinicalStudies,0f8ff266-c144-4843-9d05-d6276bde2f4d,12/20/2010,161,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,DSMB,Data Safety Monitoring Board,,,
clinicalStudies,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,CMV,cytomegalovirus,,,
clinicalStudies,22de2626-eef5-47a0-a254-10837e5296a3,9/11/2009,7,AEDs,antiepileptic drugs,,,
clinicalStudies,c57982f2-c7da-488a-7ea9-b9609439ac68,7/22/2011,12,total,the risk of death or hospitalization,,,
clinicalStudies,39d936d1-29a7-48b6-9327-94f2028012e7,8/1/2011,8,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,9/30/2011,6,5-HIAA,5-hydroxyindole acetic acid,,,
clinicalStudies,66be8d30-b813-423f-a89b-6945aaf9f796,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,66be8d30-b813-423f-a89b-6945aaf9f796,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,66be8d30-b813-423f-a89b-6945aaf9f796,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,d293d765-e418-4bdf-9955-76a4bdba129b,1/23/2012,9,AEDs,antiepileptic drugs,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,MPA,medroxyprogesterone acetate,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHI,Women’s Health Initiative,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CE/MPA,conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,PE,pulmonary embolism,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CHD,coronary heart disease,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CE,conjugated equine estrogens,,,
clinicalStudies,62b05b4b-11f0-429b-ab92-68a22bceb735,6/29/2012,2,AD,Alzheimer’s disease,,,
clinicalStudies,62b05b4b-11f0-429b-ab92-68a22bceb735,6/29/2012,2,HR,[hazard ratio,,,
clinicalStudies,62b05b4b-11f0-429b-ab92-68a22bceb735,6/29/2012,2,VaD,vascular dementia,,,
clinicalStudies,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,i.e.,improvement from baseline,,,
clinicalStudies,6f650345-0bca-4fe9-96eb-4d7ac80928ec,7/21/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,6f650345-0bca-4fe9-96eb-4d7ac80928ec,7/21/2010,1,BAO,Basal Acid Output,,,
clinicalStudies,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,LDL,low density lipoprotein,,,
clinicalStudies,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,VLDL,very low density lipoprotein,,,
clinicalStudies,806969c4-7702-484a-811d-fe01baa163c6,9/8/2011,4,TG,triglyceride,,,
clinicalStudies,8d442b8c-97a8-40a9-8603-f9cd0542cedc,4/26/2010,2,ERICA,Efficacy of Ranolazine In Chronic Angina,,,
clinicalStudies,2eda833b-1357-4ed4-a093-194524fcb061,3/2/2012,7,TTP,time to progression,,,
clinicalStudies,2eda833b-1357-4ed4-a093-194524fcb061,3/2/2012,7,ENL,14.2.,,,
clinicalStudies,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,i.e.,improvement,,,
clinicalStudies,8953e4d7-699b-4f4a-921c-1ff7c85e71a9,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,8953e4d7-699b-4f4a-921c-1ff7c85e71a9,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,8953e4d7-699b-4f4a-921c-1ff7c85e71a9,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,5ad69fab-7469-419e-9c52-662e07e52c86,2/11/2010,2,HR,[Hazard Ratio,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,CGI,Clinical Global Impression,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,cc52e339-0d3e-43c5-b0d5-be2bbbad931f,2/13/2012,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,c3edb2c8-acff-47f6-aa8a-21a07287cd76,4/6/2012,8,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,MCE,major coronary events,,,
clinicalStudies,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,MVE,major vascular events,,,
clinicalStudies,79637c7b-fe7b-436c-892b-6c36abfdcacc,6/13/2012,8,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,f27ef79a-d212-4752-8300-b88b61d0464d,6/7/2012,8,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,ZE,Zollinger-Ellison,,,
clinicalStudies,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,ITT,intent-to-treat,,,
clinicalStudies,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,RFS,Relapse-free survival,,,
clinicalStudies,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,OS,overall survival,,,
clinicalStudies,9dac97a5-c992-4601-af93-138bfe2302a8,3/15/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,1a252370-5a2d-4558-9c5d-aa591efb089d,11/11/2010,1,cure,clinical success rate,,,
clinicalStudies,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,6a72c1ac-0b15-4933-b1d5-18d2fb064765,3/19/2012,3671,VAS,visual analog scale,,,
clinicalStudies,6a72c1ac-0b15-4933-b1d5-18d2fb064765,3/19/2012,3671,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,6a72c1ac-0b15-4933-b1d5-18d2fb064765,3/19/2012,3671,ACR,American College of Rheumatology,,,
clinicalStudies,7866ec19-dfac-47d4-a53f-511a12643cbf,2/1/2010,6,FCT,fever clearance time,,,
clinicalStudies,7866ec19-dfac-47d4-a53f-511a12643cbf,2/1/2010,6,PCT,parasite clearance time,,,
clinicalStudies,1c845e89-e899-4094-bae6-c14602dbf288,12/17/2010,2,SIB,Severe  Impairment Battery,,,
clinicalStudies,f484218e-4265-7a3f-fda0-07e9c6f24dd5,4/27/2011,1,i.e.,improvement from baseline,,,
clinicalStudies,dbe07049-223d-4e54-b1ab-5b57bb9ad8ae,5/16/2011,9,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,1448e72e-dc7f-4618-9b37-a82c59823839,7/22/2010,2,ER,estrogen receptor,,,
clinicalStudies,1448e72e-dc7f-4618-9b37-a82c59823839,7/22/2010,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,1448e72e-dc7f-4618-9b37-a82c59823839,7/22/2010,2,PgR,progesterone  receptor,,,
clinicalStudies,b3eee508-8bf3-4bd3-9a71-47ee6ea87f95,3/2/2012,2,VAS,visual analog scale,,,
clinicalStudies,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,2a8de5aa-936a-493e-a0e3-813cbc969c6d,12/28/2011,1,min,median,,,
clinicalStudies,b367d81d-4eca-4e28-b490-34be4c003561,4/30/2010,2,i.e.,improvement,,,
clinicalStudies,87b9906a-1e3f-4bd7-9f93-35d20a386315,7/7/2011,3,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,MMEF,maximal midexpiratory flow rate,,,
clinicalStudies,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,9D7666AB-D48A-4507-A120-D7E1229543FD,2/15/2008,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,b13e343b-ff5f-4f1e-ae8f-0868148d58c6,6/17/2010,2,KOOS,Knee Injury and Osteoarthritis Outcome Score,,,
clinicalStudies,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,IR,immediate-release,,,
clinicalStudies,fc0a61a2-78b2-46f7-9933-63fed2c1cebc,10/1/2010,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,fc0a61a2-78b2-46f7-9933-63fed2c1cebc,10/1/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,739d7705-907b-4408-8490-2052514a1a50,3/29/2010,4,ERICA,Efficacy of Ranolazine In Chronic Angina,,,
clinicalStudies,20f8c35b-bf1c-44cf-bdd7-01b56b85bc0c,12/28/2010,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,992d56e6-6a6e-48a2-85f1-f79a7903d8fe,11/1/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,PPG,postprandial plasma glucose,,,
clinicalStudies,1ec7ef4d-8ea8-4189-b1ac-b8ac57d7ebe2,5/9/2012,2,min,median,,,
clinicalStudies,d73a7aa3-5b5f-4532-9936-752366a2430d,7/22/2011,1,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,d73a7aa3-5b5f-4532-9936-752366a2430d,7/22/2011,1,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,d73a7aa3-5b5f-4532-9936-752366a2430d,7/22/2011,1,CV,cardiovascular,,,
clinicalStudies,6056b480-a27f-403f-b92b-b0bc6e5e7b0e,12/13/2011,1,AED,antiepileptic drug,,,
clinicalStudies,6056b480-a27f-403f-b92b-b0bc6e5e7b0e,12/13/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,AUA,American Urological Association,,,
clinicalStudies,79d902bd-c144-4c55-8abc-a07140a62c5e,6/18/2012,8,MCE,major coronary events,,,
clinicalStudies,79d902bd-c144-4c55-8abc-a07140a62c5e,6/18/2012,8,MVE,major vascular events,,,
clinicalStudies,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,ASA,American Society of Anesthesiologists,,,
clinicalStudies,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,PCA,patient-controlled analgesia,,,
clinicalStudies,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,AEDs,antiepileptic drugs,,,
clinicalStudies,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,ITT,intent to treat,,,
clinicalStudies,965c4cb1-f6b8-47ac-bf13-c36639aa908f,11/19/2011,3,HR,[Hazard Ratio,,,
clinicalStudies,9513589d-ef5d-4b8d-a90a-6adb6af2ae11,7/29/2011,1,OA,osteoarthritis,,,
clinicalStudies,e2d6d072-b0fe-5d01-99c5-9fdb8a7ec079,10/22/1997,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,aaf76c17-da55-4117-8796-220cc4bb5e70,4/19/2011,1,SIB,Severe Impairment Battery,,,
clinicalStudies,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,AEDs,antiepileptic drugs,,,
clinicalStudies,01b14603-8f29-4fa3-8d7e-9d523f802e0b,12/31/2011,14,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,e8aae11c-7baa-443c-9db7-fca6694b4988,11/16/2010,1,cure,clinical success rate,,,
clinicalStudies,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,MA,megestrol acetate,,,
clinicalStudies,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,lb.,<br/>&#160;&#160;&#160;&#160;Lean Body Mass,,,
clinicalStudies,4410511e-48ea-4ff4-9535-752863a0ee8f,7/29/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,NSCLC,Non-Small Cell Lung Carcinoma,,,
clinicalStudies,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,AC,and cyclophosphamide,,,
clinicalStudies,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,de70f1fe-b633-4d85-b77d-989d14d922d0,8/15/2011,3,KS,Kaposi's sarcoma,,,
clinicalStudies,26b65fec-9a5d-4b9b-9b87-c3d328c58cd0,7/30/2009,2,i.e.,improvement,,,
clinicalStudies,6c5e836c-2851-4524-b91d-12ffadffd9ba,8/31/2010,1,ITT,intent-to-treat,,,
clinicalStudies,6c5e836c-2851-4524-b91d-12ffadffd9ba,8/31/2010,1,LOCF,last observation carried forward,,,
clinicalStudies,6c5e836c-2851-4524-b91d-12ffadffd9ba,8/31/2010,1,IGA,Investigator's Global Assessment,,,
clinicalStudies,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,ADHDRS,ADHD Rating Scale-IV-Parent Version,,,
clinicalStudies,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,CAARS,Conners Adult ADHD Rating Scale Screening Version,,,
clinicalStudies,2b01a50f-e517-4f6c-bee5-9925ff029e55,9/21/2011,12,MET,Metformin Hydrochloride,,,
clinicalStudies,2b01a50f-e517-4f6c-bee5-9925ff029e55,9/21/2011,12,Comb,Combined Metformin Hydrochloride/Glyburide,,,
clinicalStudies,2b01a50f-e517-4f6c-bee5-9925ff029e55,9/21/2011,12,Glyb,Glyburide,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,YBOCS,Yale Brown Obsessive Compulsive Scale,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PTSD,Posttraumatic Stress Disorder,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CGI,Clinical Global Impression,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,HDRS,Hamilton Depression Rating Scale,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,OCD,obsessive compulsive disorder,,,
clinicalStudies,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,88989ab9-8143-404d-8488-67a289e525b4,6/1/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,CGI,Clinical Global Impression,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MAC,MYCOBACTERIUM AVIUM COMPLEX,,,
clinicalStudies,b32fcb1b-fee4-44b8-a91c-10dfdd3f84ea,3/30/2010,2,BTM,bone turnover markers,,,
clinicalStudies,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,SFR,stenosis flow reserve,,,
clinicalStudies,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,ITT,Intent to Treat,,,
clinicalStudies,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,EOT,end of treatment,,,
clinicalStudies,e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe,5/30/2012,14,DRC,Data Review Committee,,,
clinicalStudies,df07288d-2604-49c6-a6d2-4a18083f2cfd,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,df07288d-2604-49c6-a6d2-4a18083f2cfd,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,df07288d-2604-49c6-a6d2-4a18083f2cfd,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,b18a36bc-1697-4b3c-a1bd-d76d2a543d8c,10/20/2011,14,AED,antiepileptic drug,,,
clinicalStudies,b18a36bc-1697-4b3c-a1bd-d76d2a543d8c,10/20/2011,14,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,b18a36bc-1697-4b3c-a1bd-d76d2a543d8c,10/20/2011,14,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,e2015ac5-0441-43fd-b864-a1b1fe944450,9/30/2010,6,i.e.,improvement,,,
clinicalStudies,efbb228b-7b38-4176-8bae-826103178c35,12/14/2010,1,CSFP,cerebrospinal fluid pressure,,,
clinicalStudies,efbb228b-7b38-4176-8bae-826103178c35,12/14/2010,1,LMA,laryngeal mask airway,,,
clinicalStudies,efbb228b-7b38-4176-8bae-826103178c35,12/14/2010,1,CBF,cerebral blood flow,,,
clinicalStudies,3e1fb774-7460-44d2-bf96-a17c59999676,12/30/2009,2,VAS,visual analog scale,,,
clinicalStudies,3e1fb774-7460-44d2-bf96-a17c59999676,12/30/2009,2,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,3e1fb774-7460-44d2-bf96-a17c59999676,12/30/2009,2,ACR,American College of Rheumatology,,,
clinicalStudies,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,CGI,Clinical Global Impression,,,
clinicalStudies,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,YMRS,Young Mania Rating Scale,,,
clinicalStudies,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,i.e.,improvement,,,
clinicalStudies,d564f2b1-9fc7-4201-8066-d745ac3a671f,7/6/2011,5,UCD,urea cycle disorder,,,
clinicalStudies,89a5ec53-d956-4329-8004-0f40f51c88a3,4/18/2012,29,OBT,optimized background therapy,,,
clinicalStudies,c58c7013-50a0-4734-8a78-38ff20a3e7eb,8/1/2011,2,HR,[Hazard Ratio,,,
clinicalStudies,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,cUTI,complicated urinary tract infections,,,
clinicalStudies,4d5e0add-dc33-4445-0ea0-ca07cd619ee9,1/20/2012,13,OA,osteoarthritis,,,
clinicalStudies,40a96527-f89e-4177-9224-5c79167f3e60,7/27/2011,2,TOC,test-of-cure,,,
clinicalStudies,e196c127-c081-43a7-8f0d-be3e2b434b50,10/6/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,RLQ,right lower quadrant,,,
clinicalStudies,ac0fe5db-e89e-4de7-9bba-15c966776f2a,7/22/2011,5,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,f1d77dba-9dae-4f30-b3e3-b4898993f865,1/12/2012,3,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,BIS,Behavior and Ideation Scale,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,CPS,complex partial seizures,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,AED,antiepilepsy drug,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,MSS,Manic Syndrome Scale,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,i.e.,improvement,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,TID,three divided doses,,,
clinicalStudies,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,MRS,Manic Rating Scale,,,
clinicalStudies,ea4bf1f5-acb3-4da7-9b54-d4c97f31a964,7/20/2011,1,AUA,American Urological Association,,,
clinicalStudies,cb723a07-f9de-414a-b438-27fa3e6337b4,10/4/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,cb723a07-f9de-414a-b438-27fa3e6337b4,10/4/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,46fb9dbc-5345-48a4-a0ec-75039622c76c,5/21/2010,1,BSA,body surface area,,,
clinicalStudies,9483c4be-f0c7-49ea-95d6-d4de6f79ef79,10/10/2011,2,GERD,gastroesophageal reflux disease,,,
clinicalStudies,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,AED,antiepileptic drug,,,
clinicalStudies,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,08e1bfea-7f3f-42d9-823d-f75080e664ff,12/15/2009,2,AEDs,antiepileptic drugs,,,
clinicalStudies,0f079187-1cdf-48c4-a217-9a0e25eb4c92,4/13/2010,1,GERD,Gastroesophageal Reflux disease,,,
clinicalStudies,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,cure,clinical success rate,,,
clinicalStudies,1e505c90-79e4-4267-83c4-2fbb93d75cc6,10/24/2011,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,CGI,Clinical Global Impression,,,
clinicalStudies,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24,4/13/2011,3,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,6ee54fdc-efe6-4411-a711-8154ceee20b6,1/17/2011,2061,TOC,test-of-cure,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,CCyR,complete cytogenetic response rate,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,Ph+ ALL,Philadelphia chromosome positive acute lymphoblastic leukemia,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,HPF,high power fields,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,CHR,Complete hematologic response,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,HES/CEL,Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,PFS,progression-free survival,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,SM,systemic mastocytosis,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,PCyR,partial cytogenetic response,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,GIST,gastrointestinal stromal tumors,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,RFS,Recurrence-free survival,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,OS,overall survival,,,
clinicalStudies,93ddb778-854f-4486-adca-4c5f9071a741,3/1/2012,2,SWOG,Southwestern Oncology Group,,,
clinicalStudies,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,MITT,modified Intent-to-Treat,,,
clinicalStudies,ccf371e5-268c-4a89-a39b-4ca25e5035fc,11/16/2010,3,cure,clinical success rate,,,
clinicalStudies,6ca166e5-8591-4eb1-b6dd-ade7f6f4c1bf,3/21/2008,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,e9d8fb69-a4c7-48cb-a4a9-e5d18eb4fd63,2/9/2012,5,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,CGI,Clinical Global Impressions,,,
clinicalStudies,585d6ac1-c6f5-43d7-a605-135e08accbd7,8/18/2011,1,CBZ,carbamazepine,,,
clinicalStudies,f158fe10-d5dc-4432-b2c9-fc665401291b,11/22/2010,22,PCWP,pulmonary capillary wedge pressure,,,
clinicalStudies,f158fe10-d5dc-4432-b2c9-fc665401291b,11/22/2010,22,mPAP,mean pulmonary artery pressure,,,
clinicalStudies,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,part I,four-part multi-item rating scale intended to evaluate mentation,,,
clinicalStudies,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,ADL,Activities of Daily Living,,,
clinicalStudies,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,UPDRS,Unified Parkinson's Disease Rating Scale,,,
clinicalStudies,3ebcb71e-9a7e-4969-abb9-7c7d3e3aae3c,6/22/2012,3,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,72d36e53-0af8-4008-af73-418934d86567,12/1/2011,2,i.e.,improvement,,,
clinicalStudies,b2a1cfef-4334-458f-b21c-7966f0e1f3bb,10/3/2011,1,DVT,deep vein thrombosis,,,
clinicalStudies,b2a1cfef-4334-458f-b21c-7966f0e1f3bb,10/3/2011,1,PE,pulmonary embolism,,,
clinicalStudies,b2a1cfef-4334-458f-b21c-7966f0e1f3bb,10/3/2011,1,VTE,venous thromboembolic,,,
clinicalStudies,b2a1cfef-4334-458f-b21c-7966f0e1f3bb,10/3/2011,1,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,75e4d917-e5c7-4c21-a782-808353dda907,5/4/2010,1,PCPZ,prochlorperazine,,,
clinicalStudies,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,BIS,Behavior and Ideation Scale,,,
clinicalStudies,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,MSS,Manic Syndrome Scale,,,
clinicalStudies,53c0aa44-940b-489c-90b6-058a6ee3d38d,8/24/2009,3,MRS,Manic Rating Scale,,,
clinicalStudies,d6ff6f94-5cb4-44c3-a9e5-65c1625e6a1f,4/23/2012,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,2e736bd6-01cc-4180-b97c-dd10b2250630,7/30/2010,1,min,median,,,
clinicalStudies,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,HRT,estrogen/hormone replacement therapy,,,
clinicalStudies,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,mean,men between the ages of 38 and 91,,,
clinicalStudies,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,U.S.,United States,,,
clinicalStudies,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,FIT,Fracture Intervention Trial,,,
clinicalStudies,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,mean,men between the ages of 31 and 87,,,
clinicalStudies,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553,4/26/2012,8,Population,Populations,,,
clinicalStudies,f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553,4/26/2012,8,WHO PS,WHO performance status,,,
clinicalStudies,f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553,4/26/2012,8,PFS,Progression-free survival,,,
clinicalStudies,f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553,4/26/2012,8,GIST,gastrointestinal stromal tumors,,,
clinicalStudies,f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553,4/26/2012,8,OS,overall survival,,,
clinicalStudies,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,d466910c-9a76-44e8-8759-4717ec2c591f,12/15/2011,3,MED,Minimal Erythema Dose,,,
clinicalStudies,814301f9-c990-46a5-b481-2879a521a16f,6/8/2012,19,OBR,optimized background regimen,,,
clinicalStudies,814301f9-c990-46a5-b481-2879a521a16f,6/8/2012,19,HAART,highly active antiretroviral therapy regimen,,,
clinicalStudies,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,CGI,Clinical Global Impression,,,
clinicalStudies,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,13871732-3c9f-4cd9-ba5a-3dd53f8de08c,4/11/2011,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,5e7c066c-0950-47ce-899d-76881d80c492,12/11/2009,3,ME,microbiologically evaluable,,,
clinicalStudies,5e7c066c-0950-47ce-899d-76881d80c492,12/11/2009,3,CE,clinically evaluable,,,
clinicalStudies,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,min,Median Percent Change,,,
clinicalStudies,f01e56a9-847e-4a68-93d2-f8741d0ec71c,11/22/2011,4,BIS,Behavior and Ideation Scale,,,
clinicalStudies,f01e56a9-847e-4a68-93d2-f8741d0ec71c,11/22/2011,4,CPS,complex partial seizures,,,
clinicalStudies,f01e56a9-847e-4a68-93d2-f8741d0ec71c,11/22/2011,4,AED,antiepilepsy drug,,,
clinicalStudies,f01e56a9-847e-4a68-93d2-f8741d0ec71c,11/22/2011,4,MSS,Manic Syndrome Scale,,,
clinicalStudies,f01e56a9-847e-4a68-93d2-f8741d0ec71c,11/22/2011,4,MRS,Manic Rating Scale,,,
clinicalStudies,b1b766b1-0327-48cd-ab01-e85038cf365f,1/20/2012,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,5f742224-618e-4f4c-bdec-7693be99c697,5/29/2009,1,Ctrough,cyclosporine trough concentrations,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,IF+,immunofixation,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,nCR,Near complete response,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,CR,Complete response,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,TTP,time to progression,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,IF-,immunofixation test,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,EBMT,European Group for Blood and Marrow Transplantation,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,ISS,international staging system,,,
clinicalStudies,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,PR,Partial response,,,
clinicalStudies,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,08992c51-8fe9-4d37-85cc-42ff337bda00,3/25/2011,8,SVR,Sustained Virologic Response,,,
clinicalStudies,d49fc909-1e02-4e51-b957-45540d678dde,5/18/2012,4,i.e.,improvement,,,
clinicalStudies,ab50f13c-7ec9-44b4-9a9f-ee3ddda6c8ea,11/17/2011,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,f3cb9331-a57d-428c-a13c-7ba5f2eeab14,12/13/2011,3378,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,e2d3f96d-7e36-4b80-8fa5-7a4e606148c3,9/14/2011,1,AED,antiepileptic drug,,,
clinicalStudies,e2d3f96d-7e36-4b80-8fa5-7a4e606148c3,9/14/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,cure,clinical success rate,,,
clinicalStudies,035ce971-cf46-40c0-9b2f-ae52ab4e3468,1/10/2012,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,c4a6a7e6-e49b-4202-b9d3-62c76a13b106,1/31/2012,1,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,8a0a454e-b18e-4d89-bf16-943c4c968fe2,6/3/2011,5,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,8a0a454e-b18e-4d89-bf16-943c4c968fe2,6/3/2011,5,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MTSS,mean total symptom scores,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MNW,mean number of wheals,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MPS,mean pruritus scores,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MTSS,mean total symptom score,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MPS,mean pruritus score,,,
clinicalStudies,a3d17e8d-a8ce-4e1a-9ec2-13736af1d7b5,1/22/2010,2,MNW,mean  number of wheals,,,
clinicalStudies,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,CGI,Clinical Global Impression,,,
clinicalStudies,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,d16d449a-a345-4b7c-8ab5-e18fb37dcb6a,1/17/2012,2,MCE,major coronary events,,,
clinicalStudies,d16d449a-a345-4b7c-8ab5-e18fb37dcb6a,1/17/2012,2,MVE,major vascular events,,,
clinicalStudies,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,d823148f-9c5a-4c4b-962f-633f0b2e1dd8,8/26/2010,1,GERD,gastroesophageal reflux disease,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,CGI,Clinical Global Impression,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,BARS,Behavioural Activity Rating  Scale,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,PANSS,Positive and  Negative Syndrome Scale,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,AUC,area under the curve,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,CGI,Clinical Global  Impression,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,CGI-S,Clinical Global  Impression-Severity of Illness Scale,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,MRS,Mania Rating Scale,,,
clinicalStudies,67696348-8039-4bd2-bbae-d4229c92a4d0,12/20/2010,159,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,ee98f923-8961-4f9f-8fa1-dcd934df89ac,6/9/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,ee98f923-8961-4f9f-8fa1-dcd934df89ac,6/9/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,PPG,postprandial plasma glucose,,,
clinicalStudies,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,17a163ef-b349-4e32-bc8c-b02bac7f65d6,2/29/2012,8,min,median,,,
clinicalStudies,f1c82580-87ae-11e0-bc84-0002a5d5c51b,11/18/2011,3,MFSAF,Myelofibrosis Symptom Assessment Form,,,
clinicalStudies,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,AED,antiepileptic drug,,,
clinicalStudies,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,AEDs,antiepileptic drugs,,,
clinicalStudies,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,PI,primary humoral immunodeficiency,,,
clinicalStudies,30fbaf9e-01cf-492a-b44f-dc81c17d7647,8/9/2011,9,MCE,major coronary events,,,
clinicalStudies,30fbaf9e-01cf-492a-b44f-dc81c17d7647,8/9/2011,9,MVE,major vascular events,,,
clinicalStudies,48bc36db-f3c2-460a-8d11-13e5c576efeb,3/15/2011,1,MCE,major coronary events,,,
clinicalStudies,48bc36db-f3c2-460a-8d11-13e5c576efeb,3/15/2011,1,MVE,major vascular events,,,
clinicalStudies,a96e22b2-eca3-4438-b959-dc5381085d31,9/3/2011,4,HR,[Hazard Ratio,,,
clinicalStudies,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,MITT,modified Intent-to-Treat,,,
clinicalStudies,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,cure,clinical success rate,,,
clinicalStudies,3209b147-11ce-4eeb-8427-5f8e6fb2c83d,12/21/2011,2,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,29c0e001-4855-4903-aa1d-64e4dd155b8a,1/25/2012,9,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,29c0e001-4855-4903-aa1d-64e4dd155b8a,1/25/2012,9,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,29c0e001-4855-4903-aa1d-64e4dd155b8a,1/25/2012,9,CV,cardiovascular,,,
clinicalStudies,c628d376-4b65-4f05-b6fa-eabb1d96a7df,7/30/2009,1,i.e.,improvement,,,
clinicalStudies,11628cdc-4e3c-4063-ee9f-c51e2386a820,4/27/2011,11,HR,[Hazard Ratio,,,
clinicalStudies,02dc4c34-04e8-4f16-8109-b04d600a9c61,4/23/2012,3,PCPZ,prochlorperazine,,,
clinicalStudies,2ac09b93-d769-4f04-af3c-b0f3ce0bd991,5/6/2011,4,AED,antiepilepsy drug,,,
clinicalStudies,2ac09b93-d769-4f04-af3c-b0f3ce0bd991,5/6/2011,4,i.e.,improvement,,,
clinicalStudies,6d2e4c97-0fb1-4ba4-9c58-3de071029e9b,5/30/2012,3,MTPs,minimally treated patients,,,
clinicalStudies,6d2e4c97-0fb1-4ba4-9c58-3de071029e9b,5/30/2012,3,PUPs,previously untreated patients,,,
clinicalStudies,5c4877cc-52bc-4f98-a995-0aa9439da742,2/24/2012,3,AEDs,antiepileptic drugs,,,
clinicalStudies,f4c911f3-484b-44fa-833e-2d970d39be8f,8/1/2011,1,NRS,numerical rating scale,,,
clinicalStudies,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,VAS,visual analog scale,,,
clinicalStudies,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,VAS,Visual Analog Scale,,,
clinicalStudies,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,NFIS,Nine Face Integrated Scale,,,
clinicalStudies,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,OCAS,Ordered Category Anesthesia Scale,,,
clinicalStudies,cf7cf753-b35a-4f04-8dbe-f2cf8e229eec,8/18/2011,1,SVR,Sustained Virologic Response,,,
clinicalStudies,b3e740ad-46d9-48f5-85ab-7c319919ceb1,3/1/2012,1,BSA,body surface area,,,
clinicalStudies,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,MAP,mean airway pressure,,,
clinicalStudies,1ac3b68a-ca60-43c5-a208-f92f10008521,3/23/2012,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,e868925a-676d-469a-a18c-8162bbbb99a8,9/14/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,e5d1f465-e436-b4fd-d351-07a7b2acb440,7/14/2010,2,TSS,TOTAL SYMPTOM SCORE,,,
clinicalStudies,79ad107b-bb20-4ed3-89f0-d7c862f3957c,6/1/2011,1,SIB,Severe Impairment Battery,,,
clinicalStudies,973efa93-7f9d-440a-a09f-521cf331b5e7,11/23/2011,4,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,a0ec4bcc-93ea-4c41-a4b6-95ec19491807,11/9/2011,17,DFS,disease-free survival,,,
clinicalStudies,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,TERIS,Teratogenic effects of drugs: a resource for                 clinicians,,,
clinicalStudies,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,MIC,minimal inhibitory concentration,,,
clinicalStudies,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,cUTI,complicated urinary tract infections,,,
clinicalStudies,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,ENTIS,European                 network of teratology information services,,,
clinicalStudies,78ad1221-f07d-4afc-9ce7-5a0418101ff9,11/3/2009,4,i.e.,improvement from baseline,,,
clinicalStudies,8d767545-1eb9-45a5-bd16-e8a66e628fea,2/24/2012,1,AED,antiepileptic drug,,,
clinicalStudies,8d767545-1eb9-45a5-bd16-e8a66e628fea,2/24/2012,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,8d767545-1eb9-45a5-bd16-e8a66e628fea,2/24/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,1cf82d42-5ad0-4b86-838e-9230c61cf3d4,3/18/2010,3,NOS,not otherwise specified,,,
clinicalStudies,f799137f-9676-42d4-9130-a9685cc9302c,3/29/2011,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,3af8cfe6-1c0d-4b57-ae31-05cffa64132e,12/9/2010,2,DRC,Data Review Committee,,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,TTP,Time to  progression,,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,STA,Sequential Treatments  Analysis,,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,DFS,"styleCode=""bold"">Disease Free  Survival",,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,STA,Sequential Treatments Analysis,,,
clinicalStudies,b73bf908-7979-4955-af20-0414388920da,5/9/2011,1,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,dd966338-c820-4270-b704-09ef75fa3ceb,5/25/2011,1,REA,Restriction Endonuclease Analysis,,,
clinicalStudies,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,AUA,American Urological Association,,,
clinicalStudies,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MAC,MYCOBACTERIUM AVIUM COMPLEX,,,
clinicalStudies,c8d63431-46d0-407b-b350-bb8e57e34f65,6/25/2012,1,REA,Restriction Endonuclease Analysis,,,
clinicalStudies,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,ACT,activated clotting time,,,
clinicalStudies,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,PCI,Percutaneous Coronary Intervention,,,
clinicalStudies,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,CABG,coronary artery bypass graft,,,
clinicalStudies,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,PTCA,percutaneous transluminal coronary angioplasty,,,
clinicalStudies,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,PCIs,percutaneous coronary interventions,,,
clinicalStudies,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,NSCLC,Non-Small Cell Lung Carcinoma,,,
clinicalStudies,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,AC,and cyclophosphamide,,,
clinicalStudies,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,9b424420-cb66-4601-807f-3c229da2b789,11/3/2010,2,KS,Kaposi's sarcoma,,,
clinicalStudies,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,CSFP,cerebrospinal fluid pressure,,,
clinicalStudies,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,CABG,coronary artery bypass graft,,,
clinicalStudies,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,CBF,cerebral blood flow,,,
clinicalStudies,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,CTP,Child-Turcotte-Pugh,,,
clinicalStudies,046e61c9-9298-4b2e-b76e-b26b81fecd20,11/30/2011,22,HBeAg,HBeAg-positive subjects,,,
clinicalStudies,0ae0e103-5250-4745-8ae2-74fa47fbf973,1/3/2011,1,IR,immediate-release,,,
clinicalStudies,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,mean,men between the ages of 38 and 91,,,
clinicalStudies,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,FIT,Fracture Intervention Trial,,,
clinicalStudies,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,HRT,Estrogen/Hormone Replacement Therapy,,,
clinicalStudies,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,mean,men between the ages of 31 and 87,,,
clinicalStudies,4a6953cd-9d64-4443-b7db-5aef2c81324d,3/24/2010,2,SPID48,sum of pain intensity difference over  the first 48 hours,,,
clinicalStudies,4a6953cd-9d64-4443-b7db-5aef2c81324d,3/24/2010,2,SPID,sum of pain intensity  difference,,,
clinicalStudies,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,AED,antiepileptic drug,,,
clinicalStudies,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,AEDs,antiepileptic drugs,,,
clinicalStudies,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,696f9e80-9cae-403b-de9e-078343ce4713,7/6/2012,13,PONV,Postoperative Nausea and Vomiting,,,
clinicalStudies,696f9e80-9cae-403b-de9e-078343ce4713,7/6/2012,13,FLIE,Functional Living Index–Emesis,,,
clinicalStudies,696f9e80-9cae-403b-de9e-078343ce4713,7/6/2012,13,MEC,Moderately Emetogenic Chemotherapy,,,
clinicalStudies,53664f8d-3a93-9f2b-daee-380707e4062c,4/1/2009,3,CGI,Clinical Global Impression,,,
clinicalStudies,53664f8d-3a93-9f2b-daee-380707e4062c,4/1/2009,3,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,02e761f7-24e4-4685-8fb5-0fe9cbbff8f7,6/21/2011,4,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9ab4e06f-2d51-4247-bf43-4636b416e96a,5/31/2011,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,CFU,colony  forming units,,,
clinicalStudies,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,dMAC,disseminated MAC,,,
clinicalStudies,508248c9-fc88-4be0-b509-591001be04e8,10/11/2011,2,HbA1c,hemoglobin A1c,,,
clinicalStudies,508248c9-fc88-4be0-b509-591001be04e8,10/11/2011,2,PPG,postprandial plasma glucose,,,
clinicalStudies,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalStudies,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,ESRD,end-stage renal disease,,,
clinicalStudies,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,AED,antiepileptic drug,,,
clinicalStudies,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,ec2dd06c-0c6f-4e37-b75e-edc4f70646e2,7/13/2011,3049,SPID,sum of pain intensity difference,,,
clinicalStudies,c9b74876-e665-442b-87ad-b7333bc9a67a,9/21/2009,2,TUR,transurethral resection,,,
clinicalStudies,c9b74876-e665-442b-87ad-b7333bc9a67a,9/21/2009,2,MMC,mitomycin C,,,
clinicalStudies,c9b74876-e665-442b-87ad-b7333bc9a67a,9/21/2009,2,SWOG,Southwestern Oncology Group,,,
clinicalStudies,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,a3c08a6d-f986-4efc-9f96-3f0e652704dc,1/3/2011,1,min,median,,,
clinicalStudies,28d1233a-12b6-4b24-9ab6-079b005826ae,11/4/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,e8f94df9-0692-4462-a7f0-fe019a0a3f07,2/22/2012,6,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,e8f94df9-0692-4462-a7f0-fe019a0a3f07,2/22/2012,6,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,CGI,Clinical Global Impression,,,
clinicalStudies,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,ea914046-6cc2-4c7b-b12b-76c31bb18def,11/10/2010,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,b04c23ee-3165-4eb7-86a9-ca457747539e,5/24/2012,1,ZE,Zollinger-Ellison,,,
clinicalStudies,a24e8e53-07b3-49be-87e4-124f7d3aeac1,8/18/2010,1,i.e.,improvement,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,CGI,Clinical Global Impression,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,OCD,obsessive compulsive disorder,,,
clinicalStudies,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,NAPRTCS,North American Pediatric Renal Transplant Cooperative,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,CRI,Chronic Renal Insufficiency,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,BMD,bone mineral,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,VAT,visceral adipose tissue,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,BMD,bone mineral density,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,DEXA,dual energy x?ray,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,CT,computed tomography,,,
clinicalStudies,e6574a25-1ad5-4946-b750-501ce745574f,3/6/2012,3,SD,standard deviation,,,
clinicalStudies,340d2619-4b29-456b-a3ac-0fa329e0b304,9/7/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,4aa6b91f-bc3b-455c-b6d3-9027964d17ed,7/8/2011,1,dMAC,disseminated MAC,,,
clinicalStudies,1fdf16e5-145d-4c19-a318-fc6c10794b50,1/25/2012,1,GERD,GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalStudies,8c166755-7711-4df9-d689-8836a1a70885,3/26/2012,28,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,8c166755-7711-4df9-d689-8836a1a70885,3/26/2012,28,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,7a51d289-2013-4d37-adf2-91ea49df7932,1/20/2010,1,BWSQ,Benzodiazepine Withdrawal Symptom Questionnaire,,,
clinicalStudies,0f026966-e6ed-4b5b-a8e4-1b383b010813,3/13/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,39531d0c-db12-4627-81c9-6563076b637b,6/15/2012,4,SPID30,sum of the pain intensity difference at 30 minutes,,,
clinicalStudies,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,4/5/2012,3,RESTORE,Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis,,,
clinicalStudies,fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,4/5/2012,3,PRISM,Platelet Receptor Inhibition for Ischemic Syndrome Management,,,
clinicalStudies,16966c24-bb2e-4992-b956-9b8593c57449,3/13/2012,4,SAT,subcutaneous adipose tissue,,,
clinicalStudies,16966c24-bb2e-4992-b956-9b8593c57449,3/13/2012,4,T-P,to placebo,,,
clinicalStudies,16966c24-bb2e-4992-b956-9b8593c57449,3/13/2012,4,VAT,visceral adipose tissue,,,
clinicalStudies,16966c24-bb2e-4992-b956-9b8593c57449,3/13/2012,4,P-T,placebo to tesamorelin,,,
clinicalStudies,16966c24-bb2e-4992-b956-9b8593c57449,3/13/2012,4,T-T,to tesamorelin,,,
clinicalStudies,5dd1f9bb-acbf-4deb-9b02-992d52239a6b,6/23/2011,1,TOC,test-of-cure,,,
clinicalStudies,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,b0af5ca1-9189-4c62-bdf1-f1124ec337e7,10/17/2011,17,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,712754fe-4619-4e46-b36e-d72570f80763,11/7/2011,4,CBZ,carbamazepine,,,
clinicalStudies,19a69a72-ac5d-45d5-a94d-a5aaecbe4730,12/7/2011,4,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,LDL,low density lipoprotein,,,
clinicalStudies,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,VLDL,very low density lipoprotine,,,
clinicalStudies,680a6740-8ea8-4a06-b659-41c2e5b1a4fd,7/6/2010,3,TG,triglyceride,,,
clinicalStudies,92e57b8a-47fb-49eb-bbed-cdacdf00f837,3/19/2012,3675,HoFH,Homozygous Familial Hypercholesterolemia,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,HRT,Hormone Replacement Therapy,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,CI,confidence interval,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,RR,relative risk,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,BMD,bone mineral density,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,RMT,Royal Marsden Trial,,,
clinicalStudies,9b8a4211-120f-4981-ad69-928accb97637,8/15/2011,1,DCIS,ductal carcinoma in situ,,,
clinicalStudies,f7cadf45-ffe6-43d1-d5aa-a880506bb782,10/26/2010,10,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,ccf29429-bf8e-4cce-bd12-1de56853fc5b,11/17/2011,4,PFS,progression-free survival,,,
clinicalStudies,ccf29429-bf8e-4cce-bd12-1de56853fc5b,11/17/2011,4,PR,partial,,,
clinicalStudies,aa9d3467-a450-4b06-885a-7d834dcbddff,3/2/2010,1,Dose A,dose of approximately 0.033,,,
clinicalStudies,aa9d3467-a450-4b06-885a-7d834dcbddff,3/2/2010,1,SGA,Small for Gestational Age,,,
clinicalStudies,df502787-46ec-4dd1-a2c0-be90f6d95a5d,6/1/2012,2,SSD,PAH/Scleroderma Spectrum of Diseases,,,
clinicalStudies,b8d95ad1-4725-fec7-e7e2-062cbb46d873,3/1/2012,1,BSA,body surface area,,,
clinicalStudies,e6c2595a-1470-4cf4-93ea-0fedf917cf85,9/28/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,6b4331f5-4475-417a-6a9d-09c2f8334235,10/12/2010,1312,i.e.,improvement,,,
clinicalStudies,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,f60a672d-8d6d-4d67-9a47-5547357e7b5b,12/2/2010,1,min,median,,,
clinicalStudies,38b8c4a5-710f-453c-b7c1-38f19e38e808,8/22/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,MRI,magnetic resonance imaging,,,
clinicalStudies,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalStudies,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalStudies,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalStudies,9084d81c-fdf9-4fcb-899c-55977bdd21c0,3/16/2011,1,IMT,intimal-medial thickness,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,BIS,Behavior and Ideation Scale,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,CPS,complex partial seizures,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,AED,antiepilepsy drug,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,MSS,Manic Syndrome Scale,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,i.e.,improvement,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,TID,three divided doses,,,
clinicalStudies,0f132d75-af5c-4ac1-8e46-afd6ef10a0d5,1/23/2012,1,MRS,Manic Rating Scale,,,
clinicalStudies,261fde67-efb2-4bd7-947e-4f68a56e76ff,9/6/2011,3,EDSS,expanded disability status scale,,,
clinicalStudies,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,PFS,progression free survival,,,
clinicalStudies,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,5-FU,5-Fluorouracil,,,
clinicalStudies,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,MTD,maximum tolerated dose,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,CGI,Clinical Global Impression,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,OCD,obsessive compulsive disorder,,,
clinicalStudies,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,44f634f4-b794-4d55-8ab7-037fdef8ff0f,3/21/2011,14,FLIE,Functional Living Index–Emesis,,,
clinicalStudies,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,ITT,Intent to Treat,,,
clinicalStudies,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,EOT,end of treatment,,,
clinicalStudies,b8de04a0-238d-4e0b-b0d9-7f7878b149d4,8/25/2011,3,DRC,Data Review Committee,,,
clinicalStudies,ddef12df-a0bd-4f58-bd3e-da975581d01b,8/4/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,244DA533-0B72-4015-37B0-A16744490B28,6/12/2008,2,L/min,"align=""left"" valign=""top"">Increase in Morning Peak <br/>Flow Rate",,,
clinicalStudies,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,TURP,transurethral resection of the prostate,,,
clinicalStudies,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,CABG,coronary artery bypass graft,,,
clinicalStudies,b6c0ff30-03f5-4c1b-9077-f0918cf40a91,11/11/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,f3217d4f-d4c0-4289-b5ac-949628f4138e,9/1/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,f3217d4f-d4c0-4289-b5ac-949628f4138e,9/1/2009,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,44260509-a91c-4906-bcc7-4eb5d3465ded,8/18/2011,6,ZE,Zollinger-Ellison,,,
clinicalStudies,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,GI,gastrointestinal,,,
clinicalStudies,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,AUC,and                       bioequivalence,,,
clinicalStudies,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,AD,Alzheimer’s disease,,,
clinicalStudies,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,VaD,vascular dementia,,,
clinicalStudies,880b3ae3-99e5-4d4c-935c-ee232f1f2a45,3/21/2012,4,MCE,major coronary events,,,
clinicalStudies,880b3ae3-99e5-4d4c-935c-ee232f1f2a45,3/21/2012,4,MVE,major vascular events,,,
clinicalStudies,4bec3923-6221-4b8b-9a72-872a63680de1,6/4/2012,2,MCE,major coronary events,,,
clinicalStudies,4bec3923-6221-4b8b-9a72-872a63680de1,6/4/2012,2,MVE,major vascular events,,,
clinicalStudies,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,ITT,intent-to-treat,,,
clinicalStudies,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,PHN,postherpetic neuralgia,,,
clinicalStudies,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,DU,diazolidinyl urea,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,TP,true positive,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,FN,false negative,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,TN,true negative,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,GST,gold sodium thiosulphate,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,MDBGN,methyldibromo glutaronitrile,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,bronopol,2-bromo-2-nitropropane-1,3-diol,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,TIX,tixocortol-21-pivalate,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,PE,phenoxyethanol,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,H-17-B,Hydrocortisone-17-butyrate,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,IMID,imidazolidinyl urea,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,Q-15,Quaternium-15,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,FP,false positive,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,H-17-B,Hydrocortizone-17-butyrate,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,DB106,disperse blue 106,,,
clinicalStudies,2f082b68-dc74-418a-9e6f-b3c285b41d44,3/20/2012,3,BUD,budesonide,,,
clinicalStudies,e5336cf0-04c9-45f2-b364-5d9132726c52,4/9/2012,2,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,bbebb81f-5137-4097-b91f-7ee87bd12bcf,3/1/2012,19,DVT,deep vein thrombosis,,,
clinicalStudies,bbebb81f-5137-4097-b91f-7ee87bd12bcf,3/1/2012,19,PE,pulmonary embolism,,,
clinicalStudies,bbebb81f-5137-4097-b91f-7ee87bd12bcf,3/1/2012,19,VTE,venous thromboembolic,,,
clinicalStudies,bbebb81f-5137-4097-b91f-7ee87bd12bcf,3/1/2012,19,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,BSA,body surface area,,,
clinicalStudies,de61685e-2b8c-4e22-84bb-869e13600440,10/11/2011,17,ULN,upper limit of normal,,,
clinicalStudies,de61685e-2b8c-4e22-84bb-869e13600440,10/11/2011,17,HBV,hepatitis B virus,,,
clinicalStudies,de61685e-2b8c-4e22-84bb-869e13600440,10/11/2011,17,ALT,alanine aminotransferase,,,
clinicalStudies,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,MITT,modified Intent-to-Treat,,,
clinicalStudies,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,cure,clinical success rate,,,
clinicalStudies,db52b91e-79f7-4cc1-9564-f2eee8e31c45,3/11/2011,9,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,e3e96f8d-31a6-4457-8e05-02579b539b8a,3/30/2011,1,lb.,<td>Lean Body Mass,,,
clinicalStudies,cd11b424-cbf7-4029-9fc6-c9397ad1d0e2,5/20/2011,1,CBZ,carbamazepine,,,
clinicalStudies,5ec05500-6333-4bd0-ac83-464fad0d5162,11/16/2011,11,BSA,body surface area,,,
clinicalStudies,c3bd674c-cf21-4957-bbaf-ddd4b0770ff4,8/23/2011,1,AED,antiepileptic drug,,,
clinicalStudies,c3bd674c-cf21-4957-bbaf-ddd4b0770ff4,8/23/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,675d87cb-195c-4d28-8c10-db677e16c656,8/8/2011,3061,MCE,major coronary events,,,
clinicalStudies,675d87cb-195c-4d28-8c10-db677e16c656,8/8/2011,3061,MVE,major vascular events,,,
clinicalStudies,468AF59B-81E9-4876-9903-EACAECD28B3B,11/5/2007,2,HbA1c,hemoglobin A1c,,,
clinicalStudies,468AF59B-81E9-4876-9903-EACAECD28B3B,11/5/2007,2,PPG,postprandial plasma glucose,,,
clinicalStudies,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,ABS,acute bacterial sinusitis,,,
clinicalStudies,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,EPS,expressed prostatic secretion,,,
clinicalStudies,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,MIC,minimal inhibitory concentration,,,
clinicalStudies,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,TOC,test-of-cure,,,
clinicalStudies,2afe7385-2441-4e22-b63e-ab8614b275df,8/24/2009,2,D/C,discontinuations,,,
clinicalStudies,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,AED,antiepileptic drug,,,
clinicalStudies,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,AED,antiepileptic drug,,,
clinicalStudies,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,b40ec321-1181-4e8d-8914-d30772b30cad,7/23/2010,1,i.e.,improvement from baseline,,,
clinicalStudies,d82283c9-57b9-483e-8de4-a92cac6d263f,2/12/2009,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9d4fa3ac-5a6d-460c-bc89-1c83fd436e90,5/12/2010,1,LDL,low density lipoprotein,,,
clinicalStudies,53308478-d3e7-4770-86fd-be9bcc9bc17f,4/23/2012,4,BIS,Behavior and Ideation Scale,,,
clinicalStudies,53308478-d3e7-4770-86fd-be9bcc9bc17f,4/23/2012,4,MSS,Manic Syndrome Scale,,,
clinicalStudies,53308478-d3e7-4770-86fd-be9bcc9bc17f,4/23/2012,4,i.e.,improvement,,,
clinicalStudies,53308478-d3e7-4770-86fd-be9bcc9bc17f,4/23/2012,4,MRS,Manic Rating Scale,,,
clinicalStudies,beb482de-f251-476b-9d38-40577c36f5a3,12/20/2011,1,ERICA,Efficacy of Ranolazine In Chronic Angina,,,
clinicalStudies,5017a927-2a24-4f27-89f9-27c805bf7d59,4/28/2011,12,DVT,deep vein thrombosis,,,
clinicalStudies,5017a927-2a24-4f27-89f9-27c805bf7d59,4/28/2011,12,PE,pulmonary embolism,,,
clinicalStudies,5017a927-2a24-4f27-89f9-27c805bf7d59,4/28/2011,12,VTE,venous thromboembolic,,,
clinicalStudies,5017a927-2a24-4f27-89f9-27c805bf7d59,4/28/2011,12,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,8fbbd6d1-637b-4f67-897d-ab5eaeb5cc0e,9/13/2010,25,HDRS,Hamilton Depression Rating Scale,,,
clinicalStudies,8fbbd6d1-637b-4f67-897d-ab5eaeb5cc0e,9/13/2010,25,MADRS,Montgomery and  Asberg Depression Rating Scale,,,
clinicalStudies,762b51be-1893-4cd1-9511-e645fc420d3a,7/9/2011,7,ARDS,adult respiratory distress syndrome,,,
clinicalStudies,762b51be-1893-4cd1-9511-e645fc420d3a,7/9/2011,7,BPD,Bronchopulmonary Dysplasia,,,
clinicalStudies,762b51be-1893-4cd1-9511-e645fc420d3a,7/9/2011,7,ARDS,Adult Respiratory Distress Syndrome,,,
clinicalStudies,762b51be-1893-4cd1-9511-e645fc420d3a,7/9/2011,7,PMA,postmenstrual age,,,
clinicalStudies,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalStudies,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,DFS,disease-free survival,,,
clinicalStudies,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,OS,overall survival,,,
clinicalStudies,e6c0ee96-5d2a-4725-a460-5ca62f2b6c36,2/13/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,e6c0ee96-5d2a-4725-a460-5ca62f2b6c36,2/13/2012,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,5386fb7c-f4d8-4ee6-b914-780e2da5411b,6/1/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,MCVE,major cardiovascular events,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,TNT,to New Targets Study,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,CVD,cardiovascular disease,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,min,median,,,
clinicalStudies,76a76f8e-d7c6-4621-b0a4-d5db0c24f089,9/4/2009,1,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,MITT,modified Intent-to-Treat,,,
clinicalStudies,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,cure,clinical success rate,,,
clinicalStudies,da7761ce-f58e-64e0-91b4-4eb375829b31,5/12/2011,12,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,AED,antiepileptic drug,,,
clinicalStudies,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,AEDs,antiepileptic drugs,,,
clinicalStudies,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,b124dded-a848-4a7e-b5cd-05797774b6ad,1/12/2012,4,TOC,test-of-cure,,,
clinicalStudies,9fde45b1-b40c-4374-81ad-f2bf1015950b,1/28/2011,1,GERD,gastroesophageal reflux disease,,,
clinicalStudies,83cb43e7-325c-4afc-9bc5-93a1fbbadff4,7/7/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,69049fa6-7dc4-4ae7-99f4-06839af06498,8/26/2010,1,ICU,Intensive Care Unit,,,
clinicalStudies,cf97a72e-951e-a7db-a574-adac12a6b189,6/4/2012,13,i.e.,improvement from baseline,,,
clinicalStudies,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,MCE,major coronary events,,,
clinicalStudies,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HPS,Heart Protection Study,,,
clinicalStudies,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,MVE,major vascular events,,,
clinicalStudies,5bbdc95b-82a1-4ba5-8185-6504ff68cc06,1/31/2012,11,OGTT,oral glucose tolerance test,,,
clinicalStudies,5bbdc95b-82a1-4ba5-8185-6504ff68cc06,1/31/2012,11,BMI,body mass index,,,
clinicalStudies,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,eCLcr,estimated creatinine clearance rates,,,
clinicalStudies,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,MMF,Prograf/mycophenolate mofetil,,,
clinicalStudies,7f667de1-9dfa-4bd6-8ba0-15ee2d78873b,7/5/2012,11,BPAR,biopsy proven acute rejection,,,
clinicalStudies,6ffd38bc-0fa1-4ed5-8391-98487b7823d4,9/21/2011,15,CGI,Clinical Global Impression,,,
clinicalStudies,6ffd38bc-0fa1-4ed5-8391-98487b7823d4,9/21/2011,15,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,d44ae7a1-c7f4-4af5-a250-40083a104e55,3/16/2011,9,ZE,Zollinger-Ellison,,,
clinicalStudies,0f96e04b-436f-477f-98b3-8668c7ee84ee,6/22/2011,3,TTP,thrombocytopenic purpura,,,
clinicalStudies,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,6/17/2011,2,LGD,low-grade dysplasia,,,
clinicalStudies,a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a,1/24/2012,11,HoFH,14.2,,,
clinicalStudies,a0ca0500-8d13-42aa-8c3d-040ea502db75,9/27/2011,1,CBZ,carbamazepine,,,
clinicalStudies,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,9d3b0fc6-c69f-4110-a606-c0b5d690b5e5,6/4/2010,1,i.e.,improvement,,,
clinicalStudies,54c5f945-df7a-4ec6-993e-9633dda6a6ab,5/30/2012,8,MTPs,minimally treated patients,,,
clinicalStudies,54c5f945-df7a-4ec6-993e-9633dda6a6ab,5/30/2012,8,PUPs,previously untreated patients,,,
clinicalStudies,b1f2911f-f8e1-41c0-9979-cb8d683d2f2f,4/17/2012,1,MCE,major coronary events,,,
clinicalStudies,b1f2911f-f8e1-41c0-9979-cb8d683d2f2f,4/17/2012,1,MVE,major vascular events,,,
clinicalStudies,54afe2fd-e628-4655-a3dc-45ae29680f96,6/27/2011,1,dMAC,disseminated MAC,,,
clinicalStudies,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,AED,antiepileptic drug,,,
clinicalStudies,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,AEDs,antiepileptic drugs,,,
clinicalStudies,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,03586c40-eb32-45c5-beb7-6762a6b78790,6/10/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,1893ed5d-eddc-49ea-94d0-b839e0b1bfc9,1/23/2012,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,707127cb-cdcd-81b0-274d-3c11fefa6824,11/3/2011,3,TTP,thrombocytopenic purpura,,,
clinicalStudies,97cc73cc-b5b7-458a-a933-77b00523e193,3/2/2010,102,SCN,Severe chronic neutropenia,,,
clinicalStudies,5562b3f5-8757-11de-8a39-0800200c9a66,3/5/2012,6,SeSBP,seated systolic blood pressure,,,
clinicalStudies,5562b3f5-8757-11de-8a39-0800200c9a66,3/5/2012,6,SeDBP,seated diastolic blood pressure,,,
clinicalStudies,0818c344-2fc5-4cee-ac06-c9cd7fd07680,8/13/2011,1,TOC,test-of-cure,,,
clinicalStudies,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,LDL,low density lipoprotein,,,
clinicalStudies,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,VLDL,very low density lipoprotein,,,
clinicalStudies,c6ed4ecd-ca9c-4e1d-b220-3454e6f1d45d,11/7/2011,2,TG,triglyceride,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,BIS,Behavior and Ideation Scale,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,CPS,complex partial seizures,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,AED,antiepilepsy drug,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,MSS,Manic Syndrome Scale,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,i.e.,improvement,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,TID,three divided doses,,,
clinicalStudies,ea85f517-4773-4688-88b6-5612612330f6,8/20/2010,2,MRS,Manic Rating Scale,,,
clinicalStudies,c49f55c6-e058-49a0-8aed-e3a55d869b83,1/12/2012,3,EGSA,Evaluator's Global Severity Assessment,,,
clinicalStudies,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,AED,antiepileptic drug,,,
clinicalStudies,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,9e5bb949-c9be-48cd-b0a2-6b7fd536e777,9/6/2011,1,cure,clinical success rate,,,
clinicalStudies,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,CGI,Clinical Global Impression,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,YMRS,Young Mania Rating Scale,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,ae879ebe-b620-4829-b6f8-74b58da1c771,4/20/2012,10,PR48,PegIntron + REBETOL for 48 weeks,,,
clinicalStudies,ae879ebe-b620-4829-b6f8-74b58da1c771,4/20/2012,10,SVR,Sustained Virologic Response,,,
clinicalStudies,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,AED,antiepileptic drug,,,
clinicalStudies,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,AEDs,antiepileptic drugs,,,
clinicalStudies,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,PS,performance status,,,
clinicalStudies,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,PFS,progression-free survival,,,
clinicalStudies,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,CLL,14.4,,,
clinicalStudies,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,ZE,Zollinger-Ellison,,,
clinicalStudies,5a09ce48-7139-4fc7-9b6e-439459c8e866,9/7/2011,6,ZE,Zollinger-Ellison,,,
clinicalStudies,cd6cbf0b-34b8-43aa-8037-360480a19cf8,1/27/2012,10,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,1a69848d-95d7-41e8-a3a0-aa5367d4f03b,12/1/2010,1,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,1a69848d-95d7-41e8-a3a0-aa5367d4f03b,12/1/2010,1,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,1a69848d-95d7-41e8-a3a0-aa5367d4f03b,12/1/2010,1,CV,cardiovascular,,,
clinicalStudies,76a36c15-38d3-442e-84a0-b0649a213d13,12/21/2011,4,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,bfbc2cfb-8e96-4cf2-81c7-d63a1b7365c4,12/17/2010,1,i.e.,improvement,,,
clinicalStudies,dac26bcd-7a59-401f-9f66-a0649767cece,7/6/2011,2,ITT,Intent to Treat,,,
clinicalStudies,dac26bcd-7a59-401f-9f66-a0649767cece,7/6/2011,2,EOT,end of treatment,,,
clinicalStudies,dac26bcd-7a59-401f-9f66-a0649767cece,7/6/2011,2,DRC,Data Review Committee,,,
clinicalStudies,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,cUTI,complicated urinary tract infections,,,
clinicalStudies,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,MTSS,mean total symptom scores,,,
clinicalStudies,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,MNW,mean number of wheals,,,
clinicalStudies,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,MPS,mean pruritus scores,,,
clinicalStudies,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,MTSS,mean total symptom score,,,
clinicalStudies,ac0c0247-3b20-445a-84c0-cb7f3939c823,12/15/2008,1,MPS,mean pruritus score,,,
clinicalStudies,d76293c8-2642-4bfc-97bf-59e37251723d,6/7/2011,1,ITT,intent-to-treat,,,
clinicalStudies,d76293c8-2642-4bfc-97bf-59e37251723d,6/7/2011,1,MRSA,methicillin-resistant Staphylococcus aureus,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,AD,Alzheimer’s disease,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,PE,pulmonary embolism,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,VaD,vascular dementia,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,VaD,vascular  dementia,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,BMD,bone mineral density,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,LOCF,last reported day was carried  forward,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,BTM,bone turnover markers,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHI,Women's Health  Initiative,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,MI,myocardial  infarction,,,
clinicalStudies,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,LOCF,LAST OBSERVATION CARRIED FORWARD,,,
clinicalStudies,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,LDL,low density lipoprotein,,,
clinicalStudies,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,VLDL,very low density lipoprotein,,,
clinicalStudies,fbcb5056-910c-42b5-9328-bb5a67b8c5c9,11/14/2011,2,TG,triglyceride,,,
clinicalStudies,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,TURP,transurethral resection of the prostate,,,
clinicalStudies,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,CABG,coronary artery bypass graft,,,
clinicalStudies,7d5cb52e-37dd-4dfa-a6f4-09f9548846c6,7/18/2012,4,i.e.,improvement,,,
clinicalStudies,4e4bc43f-892a-4ca4-ad43-5383c276c61e,5/30/2012,8,MTPs,minimally treated patients,,,
clinicalStudies,4e4bc43f-892a-4ca4-ad43-5383c276c61e,5/30/2012,8,PUPs,previously untreated patients,,,
clinicalStudies,4cfdb571-ec4c-478f-bedc-e0669eeea504,3/25/2012,9,EDSS,expanded disability status scale,,,
clinicalStudies,111ad6f9-170d-4a14-a4e2-ff86f60521cd,5/8/2012,4,TOC,test-of-cure,,,
clinicalStudies,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,ITT,Intent to Treat,,,
clinicalStudies,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,EOT,end of treatment,,,
clinicalStudies,ce3ef5cf-3087-4d92-9d94-9eb8287228db,11/30/2011,18,DRC,Data Review Committee,,,
clinicalStudies,eabc0fb3-da2a-482f-83a7-99b1e823a150,6/3/2009,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,b33520de-f891-43f8-bd04-1b66795d3dd2,1/6/2011,1,HR,[Hazard Ratio,,,
clinicalStudies,0eed7378-67a4-4b08-aeea-32471ce2028e,2/17/2012,3575,GERD,GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalStudies,8bf7c1ce-dfc4-457f-8a8b-365f82aa8512,3/29/2012,3,AED,antiepileptic drug,,,
clinicalStudies,8bf7c1ce-dfc4-457f-8a8b-365f82aa8512,3/29/2012,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,8bf7c1ce-dfc4-457f-8a8b-365f82aa8512,3/29/2012,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,SD,"styleCode=""bold"">Baseline  <br/>Mean",,,
clinicalStudies,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,SD,"styleCode=""bold"">Week 4  <br/>Mean",,,
clinicalStudies,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,SD,"styleCode=""bold"">Week 12  <br/>Mean",,,
clinicalStudies,18b22092-605b-4ae7-8bc8-7f213d7d02eb,6/6/2011,1,ZE,Zollinger-Ellison,,,
clinicalStudies,92201fb1-4570-42db-8da3-3b8c0e291d32,3/1/2012,16,ZE,Zollinger-Ellison,,,
clinicalStudies,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,14191b8c-6048-4c6e-880f-39068a77770d,4/7/2011,1,cure,clinical success rate,,,
clinicalStudies,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,ESVEM,[Electrophysiologic Study Versus Electrocardiographic Monitoring,,,
clinicalStudies,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,PES,programmed electrical stimulation,,,
clinicalStudies,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,NSVT,non-sustained ventricular tachycardia,,,
clinicalStudies,dd818d91-cddf-474f-aa68-43e416da8b8e,6/7/2010,3,total,the risk of death or hospitalization,,,
clinicalStudies,c550dd16-a5e8-44be-87f2-210c15bbb513,3/2/2012,10,PFS,progression free survival,,,
clinicalStudies,c550dd16-a5e8-44be-87f2-210c15bbb513,3/2/2012,10,MTD,maximum tolerated dose,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,ULN,upper limit of normal,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,ANC,absolute neutrophil count,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,NCI,National Cancer Institute,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,DFS,disease-free survival,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,CEA,carcino-embyrogenic antigen,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,NCCTG,North Central Cancer Treatment Group,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,OS,overall survival,,,
clinicalStudies,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,ADHDRS,ADHD Rating Scale-IV-Parent Version,,,
clinicalStudies,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,CAARS,Conners Adult ADHD Rating Scale Screening Version,,,
clinicalStudies,4d0f0f1a-31af-40fa-9c64-e90891fa6ce4,6/15/2012,4,MP,methylprednisolone,,,
clinicalStudies,4b1e7c09-c393-4f1e-be68-8a662ceda185,1/9/2012,1,CGI,Clinical Global Impression,,,
clinicalStudies,4b1e7c09-c393-4f1e-be68-8a662ceda185,1/9/2012,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,8da31eca-51cf-4a01-9159-740f772b0f15,4/29/2011,3,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,MIC,minimal inhibitory concentration,,,
clinicalStudies,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,cUTI,complicated urinary tract infections,,,
clinicalStudies,cffcb7cd-1459-4293-8b22-81b077b0f4df,9/26/2008,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,cffcb7cd-1459-4293-8b22-81b077b0f4df,9/26/2008,1,PPG,postprandial plasma glucose,,,
clinicalStudies,3f35d6e0-3450-4abc-a0da-cc7b277e7c6e,8/17/2011,1,ITT,intent-to-treat,,,
clinicalStudies,3f35d6e0-3450-4abc-a0da-cc7b277e7c6e,8/17/2011,1,CI,confidence interval,,,
clinicalStudies,3f35d6e0-3450-4abc-a0da-cc7b277e7c6e,8/17/2011,1,JRS,Jankovic Rating Scale,,,
clinicalStudies,454f2f4c-5bdd-4aff-b49e-792962dd1a94,7/19/2011,1,ITT,intent-to-treat,,,
clinicalStudies,454f2f4c-5bdd-4aff-b49e-792962dd1a94,7/19/2011,1,PHN,postherpetic neuralgia,,,
clinicalStudies,ea326682-b06d-41e8-b457-85e39ee51034,5/28/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,ea326682-b06d-41e8-b457-85e39ee51034,5/28/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,c07b1c7a-510c-48cd-8eda-42397c41f893,11/29/2011,4,ZE,Zollinger-Ellison,,,
clinicalStudies,893c95d7-d9b6-4064-db97-91dd21ce7e40,12/6/2011,7,T-LBL,T-cell lymphoblastic lymphoma,,,
clinicalStudies,893c95d7-d9b6-4064-db97-91dd21ce7e40,12/6/2011,7,T-ALL,T-cell acute lymphoblastic leukemia,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,BIS,Behavior and Ideation Scale,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,CPS,complex partial seizures,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,AED,antiepilepsy drug,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,MSS,Manic Syndrome Scale,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,TID,three divided doses,,,
clinicalStudies,5be815ed-18ca-4e6d-8a4b-3ea694fc3caf,3/22/2010,1,MRS,Manic Rating Scale,,,
clinicalStudies,a78708cd-04d4-4221-a4e4-53680bbe2912,6/3/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,bb0f3b5e-4bc6-41c9-66b9-6257e2513512,2/28/2012,22,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,bb0f3b5e-4bc6-41c9-66b9-6257e2513512,2/28/2012,22,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,bb0f3b5e-4bc6-41c9-66b9-6257e2513512,2/28/2012,22,CV,cardiovascular,,,
clinicalStudies,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,MIC,minimal inhibitory concentration,,,
clinicalStudies,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,TOC,test-of-cure,,,
clinicalStudies,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,CGI,Clinical Global Impressions,,,
clinicalStudies,44125b2f-10ac-435c-bdb4-a29bf8450dbf,6/10/2011,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,c509f682-d68e-490a-884d-c067e4c23a5b,4/27/2010,5,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,min,Median % Change,,,
clinicalStudies,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,min,Median,,,
clinicalStudies,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,min,median,,,
clinicalStudies,8ebda73d-82a3-4b17-8a81-a1f258003d32,2/17/2012,2,TTP,Time to progression,,,
clinicalStudies,8ebda73d-82a3-4b17-8a81-a1f258003d32,2/17/2012,2,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,MCVE,major cardiovascular events,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,DBP,diastolic blood pressure,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,TNT,to New Targets Study,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,CVD,cardiovascular disease,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,SBP,systolic blood pressure,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,min,median,,,
clinicalStudies,11b56661-6657-4a83-93a3-7cb481d946f7,6/27/2012,3,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,1577bc9c-24d3-450e-b438-d4f1b5db6485,6/7/2010,1,ZE,Zollinger-Ellison,,,
clinicalStudies,c4936878-1643-4e7f-9b0d-e4957935aef2,1/18/2011,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,c4936878-1643-4e7f-9b0d-e4957935aef2,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,4797366a-fb71-4366-a766-79d95c5dcd3c,5/16/2012,3,AEDs,antiepileptic drugs,,,
clinicalStudies,4797366a-fb71-4366-a766-79d95c5dcd3c,5/16/2012,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,4797366a-fb71-4366-a766-79d95c5dcd3c,5/16/2012,3,AED,1 antiepileptic drug,,,
clinicalStudies,4797366a-fb71-4366-a766-79d95c5dcd3c,5/16/2012,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,Y-MRS,Young Mania Rating Scale,,,
clinicalStudies,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,CGI,Clinical Global Impression,,,
clinicalStudies,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,PANSS,Positive and Negative Symptoms Scale,,,
clinicalStudies,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,7f243027-7047-47c4-8b66-288c60ec2008,2/28/2012,2,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,5b6f93c9-43b2-40a9-9f10-054c1145b4cc,3/1/2011,1,ITT,intent-to-treat,,,
clinicalStudies,5b6f93c9-43b2-40a9-9f10-054c1145b4cc,3/1/2011,1,PHN,postherpetic neuralgia,,,
clinicalStudies,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,GAD,Generalized  Anxiety Disorder,,,
clinicalStudies,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,MADRS,Montgomery Asberg Depression Rating Scale,,,
clinicalStudies,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,HAM-A,Hamilton Anxiety Scale,,,
clinicalStudies,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,NSCLC,Non-Small Cell Lung Carcinoma,,,
clinicalStudies,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,AC,and cyclophosphamide,,,
clinicalStudies,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,45e9fa2b-58ed-4308-a1c0-e3b7279dc9ea,3/24/2010,4,KS,Kaposi's sarcoma,,,
clinicalStudies,ae57c8ec-8ea5-4829-a170-a69ddd92c22d,6/12/2012,3,BIS,Behavior and Ideation Scale,,,
clinicalStudies,ae57c8ec-8ea5-4829-a170-a69ddd92c22d,6/12/2012,3,MSS,Manic Syndrome Scale,,,
clinicalStudies,ae57c8ec-8ea5-4829-a170-a69ddd92c22d,6/12/2012,3,TID,three divided doses,,,
clinicalStudies,ae57c8ec-8ea5-4829-a170-a69ddd92c22d,6/12/2012,3,i.e.,improvement,,,
clinicalStudies,ae57c8ec-8ea5-4829-a170-a69ddd92c22d,6/12/2012,3,MRS,Manic Rating Scale,,,
clinicalStudies,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,AED,antiepileptic drug,,,
clinicalStudies,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,f3182470-1965-4e20-dbaf-e3506f893ea5,6/8/2012,7,WHO,World Health Organization,,,
clinicalStudies,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalStudies,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalStudies,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalStudies,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,IMT,intimal-medial thickness,,,
clinicalStudies,44D8F56C-E1ED-4761-A138-CAC1027C1852,3/31/2007,2,HbA1c,hemoglobin A1c,,,
clinicalStudies,44D8F56C-E1ED-4761-A138-CAC1027C1852,3/31/2007,2,PPG,postprandial plasma glucose,,,
clinicalStudies,741c994d-5a25-47e6-865a-33d0d4ccce11,11/24/2010,16,DVT,deep vein thrombosis,,,
clinicalStudies,741c994d-5a25-47e6-865a-33d0d4ccce11,11/24/2010,16,PE,pulmonary embolism,,,
clinicalStudies,741c994d-5a25-47e6-865a-33d0d4ccce11,11/24/2010,16,VTE,venous thromboembolic,,,
clinicalStudies,741c994d-5a25-47e6-865a-33d0d4ccce11,11/24/2010,16,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,CGI,Clinical Global Impression,,,
clinicalStudies,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,HAMD,Hamilton Depression Rating Scale,,,
clinicalStudies,56733651-d331-4e69-a6a3-303756ccc53c,10/9/2009,1,PH/SSD,Pulmonary Hypertension Associated with the Scleroderma Spectrum of Diseases,,,
clinicalStudies,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,AC,and cyclophosphamide,,,
clinicalStudies,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,9/20/2011,8,KS,Kaposi’s sarcoma,,,
clinicalStudies,0a987d59-560f-4650-96ec-31aec81953b5,5/31/2012,5,AED,antiepileptic drug,,,
clinicalStudies,0a987d59-560f-4650-96ec-31aec81953b5,5/31/2012,5,AEDs,antiepileptic drugs,,,
clinicalStudies,0a987d59-560f-4650-96ec-31aec81953b5,5/31/2012,5,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,0a987d59-560f-4650-96ec-31aec81953b5,5/31/2012,5,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,18a413e9-11e0-4a8f-86c0-d33b37b7b771,7/9/2012,7,SPID,Summed Pain Intensity Differences scale,,,
clinicalStudies,18a413e9-11e0-4a8f-86c0-d33b37b7b771,7/9/2012,7,SPID30,sum of the pain intensity difference at 30 minutes,,,
clinicalStudies,e4bf3611-c2b6-4397-a786-ea022f86d7f8,3/11/2011,1,TOC,test-of-cure,,,
clinicalStudies,19ebf09d-cf0d-4744-a874-a3a9f0b624b4,9/4/2009,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,19ebf09d-cf0d-4744-a874-a3a9f0b624b4,9/4/2009,1,PCI,percutaneous coronary intervention,,,
clinicalStudies,4f2f91bb-f119-4e29-8499-f36f436707b3,11/2/2011,1,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,4f2f91bb-f119-4e29-8499-f36f436707b3,11/2/2011,1,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,4f2f91bb-f119-4e29-8499-f36f436707b3,11/2/2011,1,CV,cardiovascular,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,CGI,Clinical Global Impression,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,YMRS,Young Mania Rating Scale,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,ddI,didanosine,,,
clinicalStudies,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,ZDV,zidovudine,,,
clinicalStudies,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,DSMBs,Data and Safety Monitoring Boards,,,
clinicalStudies,7b5c59ae-e4c1-4097-9db1-f6837b7c3688,12/22/2009,1,GERD,Gastroesophageal Reflux disease,,,
clinicalStudies,f7994951-93d4-42cb-88f5-b8ad8e9f5037,6/1/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,MSVS,moderate to severe vasomotor symptoms,,,
clinicalStudies,f7be6506-4d20-401e-a0ff-02ad7c33158a,3/9/2012,3,F/U,follow-up period,,,
clinicalStudies,f7be6506-4d20-401e-a0ff-02ad7c33158a,3/9/2012,3,EOT,end of therapy,,,
clinicalStudies,0005e2a8-3ab9-4173-a46f-9c53881379e2,8/19/2010,2,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,5d7d3cfa-af46-48fd-afee-cddf39d2efde,5/17/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,PCI,percutaneous coronary intervention,,,
clinicalStudies,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,MI,Myocardial Infarction,,,
clinicalStudies,2f078cef-a889-4d8d-b244-37ee13547a67,12/6/2011,2,AEDs,antiepileptic drugs,,,
clinicalStudies,3cae0c4c-faaa-43f5-a186-91b2c8bd0a13,5/10/2007,2,SBIAB,secondary bacterial infections of acute bronchitis,,,
clinicalStudies,3cae0c4c-faaa-43f5-a186-91b2c8bd0a13,5/10/2007,2,ABECB,acute bacterial exacerbations of chronic bronchitis,,,
clinicalStudies,966c8f58-fde1-4af0-964b-c0bddbb05b36,12/23/2009,2,MITT,modified Intent-to-Treat,,,
clinicalStudies,966c8f58-fde1-4af0-964b-c0bddbb05b36,12/23/2009,2,AECB,acute  exacerbation of chronic bronchitis,,,
clinicalStudies,966c8f58-fde1-4af0-964b-c0bddbb05b36,12/23/2009,2,cure,clinical success  rate,,,
clinicalStudies,6ca01de3-a0f9-4cfb-b36a-723c7c42e2a4,4/30/2012,2,min,median,,,
clinicalStudies,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,PCI,percutaneous coronary intervention,,,
clinicalStudies,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,PTCA,percutaneous,,,
clinicalStudies,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,CHF,,,,
clinicalStudies,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,CABG,coronary artery bypass graft,,,
clinicalStudies,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,IABP,intra-aortic,,,
clinicalStudies,dd8d7ec8-79b0-4152-8789-d247c77232ce,7/22/2009,2,ADOPT,A Diabetes Outcome Progression Trial,,,
clinicalStudies,0a238e82-20d5-45ec-8c13-4725d1065230,3/1/2012,3,MCE,major coronary events,,,
clinicalStudies,0a238e82-20d5-45ec-8c13-4725d1065230,3/1/2012,3,MVE,major vascular events,,,
clinicalStudies,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,PSA,Prostate Specific Antigen,,,
clinicalStudies,24ed00e0-25e2-49a8-97fc-66c1b417dc0b,2/9/2011,1,LOCF,last observation carried forward,,,
clinicalStudies,67ddab5a-5443-4ce3-89ac-bf54b795c5a8,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,67ddab5a-5443-4ce3-89ac-bf54b795c5a8,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,67ddab5a-5443-4ce3-89ac-bf54b795c5a8,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,8f0b9785-1b5c-41f0-a6f2-80088aab18b1,9/6/2011,1,cure,clinical success rate,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,MPA,medroxyprogesterone acetate,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,CE,conjugated estrogens,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,CHD,coronary heart disease,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,WHI,Women's Health Initiative,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,PB,pulmonary embolism,,,
clinicalStudies,1e9702c4-f2d7-4ea8-b6e8-7dca31671864,6/3/2009,4,BMD,bone mineral density,,,
clinicalStudies,fdb12700-116b-4203-8d74-9a94b9401fe6,2/19/2010,1,total,the risk of death or hospitalization,,,
clinicalStudies,ed1b74a8-2a9b-4315-b051-673c7941cb13,1/1/2012,2,AED,antiepileptic drug,,,
clinicalStudies,ed1b74a8-2a9b-4315-b051-673c7941cb13,1/1/2012,2,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,ed1b74a8-2a9b-4315-b051-673c7941cb13,1/1/2012,2,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,5cf490d1-edb7-4b3f-9a01-a44ec7e8369c,11/25/2010,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,5cf490d1-edb7-4b3f-9a01-a44ec7e8369c,11/25/2010,1,PPG,postprandial plasma glucose,,,
clinicalStudies,f881ec1a-d330-41d8-b633-143875c06ea4,2/11/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,CGI,Clinical Global Impression,,,
clinicalStudies,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,c6e131fe-e7df-4876-83f7-9156fc4e8228,2/29/2012,8,min,median,,,
clinicalStudies,cc9e1c8c-0e2b-44e2-878b-27057f786be9,5/2/2012,13,IM,intramuscular route,,,
clinicalStudies,20274ff0-f18c-4333-afab-e85ea236dea4,1/16/2012,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,62186279-2814-453e-8256-5592db6aa66f,5/23/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,CVP,central venous pressure,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,SVR,systemic vascular resistance,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,RAP,right atrial pressure,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,PVR,pulmonary vascular resistance,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,PCWP,pulmonary-capillary wedge pressure,,,
clinicalStudies,ab0ae3a1-8c43-40c6-2682-5089ee1c0229,7/10/2012,16,PAP,pulmonary arterial pressure,,,
clinicalStudies,d618a40c-d8c3-488a-9519-fdf11c1ca30d,6/28/2010,2,AED,antiepileptic drug,,,
clinicalStudies,d618a40c-d8c3-488a-9519-fdf11c1ca30d,6/28/2010,2,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,d618a40c-d8c3-488a-9519-fdf11c1ca30d,6/28/2010,2,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,ZDV,zidovudine,,,
clinicalStudies,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,ACT,activated clotting time,,,
clinicalStudies,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,PCI,Percutaneous Coronary Intervention,,,
clinicalStudies,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,CABG,coronary artery bypass graft,,,
clinicalStudies,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,PTCA,percutaneous transluminal coronary angioplasty,,,
clinicalStudies,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,PCIs,percutaneous coronary interventions,,,
clinicalStudies,d544481d-2695-4a89-964b-15e2338670b8,8/1/2011,1,HPS,Heart Protection Study,,,
clinicalStudies,d544481d-2695-4a89-964b-15e2338670b8,8/1/2011,1,95% CI,278.6(51.8)211.9(49)46.9(11.9)90(50.7)186.3(38.1)Simvastatin24 Weeks106% Change from Baseline,,,
clinicalStudies,c16ac648-d5d2-9f7d-8637-e2328572754e,6/15/2011,1,GFR,glomerular filtration rate,,,
clinicalStudies,c16ac648-d5d2-9f7d-8637-e2328572754e,6/15/2011,1,MDRD,Modification of Diet in Renal Disease,,,
clinicalStudies,c16ac648-d5d2-9f7d-8637-e2328572754e,6/15/2011,1,GFR,Glomerular Filtration Rate,,,
clinicalStudies,7c9184c0-7a2e-11df-8c8d-0002a5d5c51b,3/5/2012,2,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,6eeb14df-6fcf-a737-5359-5744eb4accea,5/15/2009,2,CGI,Clinical Global Impression,,,
clinicalStudies,6eeb14df-6fcf-a737-5359-5744eb4accea,5/15/2009,2,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,a1f01e8e-97e9-11de-b91d-553856d89593,10/24/2011,10,TOC,test-of-cure,,,
clinicalStudies,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,LDL,low density lipoprotein,,,
clinicalStudies,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,VLDL,very low density lipoprotein,,,
clinicalStudies,c3afa988-d258-4e83-89ed-d674743109c4,5/25/2010,1,TG,triglyceride,,,
clinicalStudies,4743a48b-d4b5-4054-85e1-9d64cc40de25,10/18/2011,1,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,afd5c7b3-4886-4250-9a12-b61451f65eb5,4/24/2012,2,min,median,,,
clinicalStudies,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,Y-MRS,Young Mania Rating Scale,,,
clinicalStudies,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,CGI,Clinical Global Impression,,,
clinicalStudies,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,PANSS,Positive and Negative Symptoms Scale,,,
clinicalStudies,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,4ef1bc38-4a94-4f45-a6e6-13974bb870a9,4/26/2012,2,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,MCE,major coronary events,,,
clinicalStudies,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,MVE,major vascular events,,,
clinicalStudies,34f6e21e-f6fc-4426-b5fb-1abe97faa7ac,9/20/2011,1,ZE,Zollinger-Ellison,,,
clinicalStudies,662f3e16-bf42-4127-8e56-4eb45780e059,7/20/2012,7,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,LDL,low density lipoprotein,,,
clinicalStudies,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,VLDL,very low density lipoprotein,,,
clinicalStudies,bfc6668c-3f69-4dd3-bc19-0d26c23dd04c,9/27/2010,5,TG,triglyceride,,,
clinicalStudies,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,PGI,patient global impression of change,,,
clinicalStudies,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,MINI,Mini-International Neuropsychiatric  Interview,,,
clinicalStudies,7a8c0140-f34f-4018-956e-1834a9a2abe1,3/13/2012,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,b1ceb35b-25e0-4b7d-bea0-18099464d168,3/29/2012,1,MCE,major coronary events,,,
clinicalStudies,b1ceb35b-25e0-4b7d-bea0-18099464d168,3/29/2012,1,MVE,major vascular events,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,MCVE,major cardiovascular events,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,DBP,diastolic blood pressure,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,TNT,to New Targets Study,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,CVD,cardiovascular disease,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,SBP,systolic blood pressure,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,min,median,,,
clinicalStudies,2f568859-64e6-454f-801b-c0a0a647dc3d,11/10/2011,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,70e52e89-3844-4cd9-a406-b29e9520a12c,4/15/2011,2,AED,antiepileptic drug,,,
clinicalStudies,70e52e89-3844-4cd9-a406-b29e9520a12c,4/15/2011,2,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,70e52e89-3844-4cd9-a406-b29e9520a12c,4/15/2011,2,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,b600c2f8-f252-4f8f-92f5-922ac52bc341,7/23/2012,10,SVR,Sustained Virologic Response,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,CGI,Clinical Global Impression,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,OCD,Obsessive Compulsive Disorder,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,d02af310-d097-4886-86e5-adcf6bca0533,9/26/2007,1,AKs,actinic keratoses,,,
clinicalStudies,e9d6c462-84af-4371-bc05-78cb0bcb589d,10/5/2010,2,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,6fadde9e-dab3-4d01-b3fb-795eef7eff2f,2/1/2010,1,cure,clinical success rate,,,
clinicalStudies,abccfe74-aaf9-4729-a196-2d666f9562b5,10/12/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,ffb158a1-83ba-4100-9221-175aa986dc3e,1/21/2012,3,i.e.,infection,,,
clinicalStudies,b506bc93-f0c9-4483-a7e8-a4e3f6b54282,6/29/2010,1,GERD,gastroesophageal reflux disease,,,
clinicalStudies,06400a4c-42b4-440a-92b4-1f47f98ac7ba,8/16/2011,11,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,06400a4c-42b4-440a-92b4-1f47f98ac7ba,8/16/2011,11,total,the risk of death or hospitalization,,,
clinicalStudies,06400a4c-42b4-440a-92b4-1f47f98ac7ba,8/16/2011,11,SBP,systolic blood pressure,,,
clinicalStudies,06400a4c-42b4-440a-92b4-1f47f98ac7ba,8/16/2011,11,total,the combined end points of all-cause mortality plus hospitalization,,,
clinicalStudies,63319b01-cad6-4d0a-c39b-938fa951a808,3/21/2012,12,ORR,Overall response rate,,,
clinicalStudies,63319b01-cad6-4d0a-c39b-938fa951a808,3/21/2012,12,PFS,progression-free survival,,,
clinicalStudies,63319b01-cad6-4d0a-c39b-938fa951a808,3/21/2012,12,FISH,fluorescence in situ hybridization,,,
clinicalStudies,63319b01-cad6-4d0a-c39b-938fa951a808,3/21/2012,12,OS,overall survival,,,
clinicalStudies,3f09e0ac-80dc-271b-1700-a8d499535a10,12/30/2004,3,VAS,visual analog scale,,,
clinicalStudies,3f09e0ac-80dc-271b-1700-a8d499535a10,12/30/2004,3,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,3f09e0ac-80dc-271b-1700-a8d499535a10,12/30/2004,3,ACR,American College of Rheumatology,,,
clinicalStudies,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,eadf575d-7561-4020-b88f-a280e58d10ba,6/1/2011,1,dMAC,disseminated MAC,,,
clinicalStudies,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,MITT,modified Intent-to-Treat,,,
clinicalStudies,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,cure,clinical success rate,,,
clinicalStudies,d0a35bcc-32c8-476e-94ff-a42c230cc7de,7/24/2012,11,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CGI,Clinical Global Impression,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalStudies,c34e9941-34e8-484f-8f67-829f7cde8642,6/7/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,63b36274-89f0-42d8-9f09-f9e78e179af4,1/11/2012,1,AED,antiepileptic drug,,,
clinicalStudies,63b36274-89f0-42d8-9f09-f9e78e179af4,1/11/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,63b36274-89f0-42d8-9f09-f9e78e179af4,1/11/2012,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,63b36274-89f0-42d8-9f09-f9e78e179af4,1/11/2012,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,910fae46-5eaf-427f-b137-e4e775b065c7,5/31/2012,3831,NOS,not otherwise specified,,,
clinicalStudies,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,cure,clinical success rate,,,
clinicalStudies,51835dc6-68c7-44b0-980c-f9b38b8d7203,6/27/2011,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,90872cf9-e833-47bb-937f-c47594fecdbe,11/3/2011,2,HoFH,14.2,,,
clinicalStudies,00a8921e-46a6-4df1-a744-9e532b6fb06f,7/29/2011,5,SPID,sum of pain intensity difference,,,
clinicalStudies,ac805bbd-26d5-456d-9ce8-cb91ed8703b6,1/3/2011,2,AEDs,antiepileptic drugs,,,
clinicalStudies,cd86ee78-2781-468b-930c-3c4677bcc092,11/14/2011,9,PGA,Physician's Global Assessment,,,
clinicalStudies,57bccb29-1c47-4c64-ab6a-77960a91cc20,4/17/2012,6,ITT,intent-to-treat,,,
clinicalStudies,57bccb29-1c47-4c64-ab6a-77960a91cc20,4/17/2012,6,PS,performance status,,,
clinicalStudies,57bccb29-1c47-4c64-ab6a-77960a91cc20,4/17/2012,6,PFS,progression-free survival,,,
clinicalStudies,57bccb29-1c47-4c64-ab6a-77960a91cc20,4/17/2012,6,OS,overall survival,,,
clinicalStudies,57bccb29-1c47-4c64-ab6a-77960a91cc20,4/17/2012,6,PFS,Progression free survival,,,
clinicalStudies,c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f,5/2/2012,22,MED,Minimal Erythema Dose,,,
clinicalStudies,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,MCE,major coronary events,,,
clinicalStudies,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,MVE,major vascular events,,,
clinicalStudies,6cfd29d7-f519-7b8c-4814-07b39f367f0d,6/3/2011,4,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,6cfd29d7-f519-7b8c-4814-07b39f367f0d,6/3/2011,4,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,d9400bde-4da8-49c8-a61e-15d2be58e73d,11/28/2011,2,DFS,disease-free survival,,,
clinicalStudies,d9400bde-4da8-49c8-a61e-15d2be58e73d,11/28/2011,2,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,9783a5b0-c856-4cbd-8536-53bd805c3a63,8/8/2011,2,MRI,magnetic resonance imaging,,,
clinicalStudies,a3327c31-d987-40ec-b3b5-097bbf2f4f8c,4/26/2012,11,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,HRT,Hormone Replacement Therapy,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,CI,confidence interval,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,LCIS,lobular carcinoma in situ,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,RR,relative risk,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,BMD,bone mineral density,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,RMT,Royal Marsden Trial,,,
clinicalStudies,151ce76c-2d44-4c82-850d-ab213bea4d6b,12/17/2009,1,DCIS,ductal carcinoma in situ,,,
clinicalStudies,1f1490cd-b11b-40cb-96be-865730c989e1,2/11/2008,2,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,1f1490cd-b11b-40cb-96be-865730c989e1,2/11/2008,2,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,CSFP,cerebrospinal fluid pressure,,,
clinicalStudies,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,LMA,laryngeal mask airway,,,
clinicalStudies,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,CBF,cerebral blood flow,,,
clinicalStudies,3b433650-0dca-4714-bb72-341036d3972e,4/15/2009,1,ITT,intent-to-treat,,,
clinicalStudies,3b433650-0dca-4714-bb72-341036d3972e,4/15/2009,1,RFS,relapse-free survival,,,
clinicalStudies,3b433650-0dca-4714-bb72-341036d3972e,4/15/2009,1,OS,overall survival,,,
clinicalStudies,de0b16a5-e886-482b-a0be-ab6161648134,4/10/2012,1,DVT,deep vein thrombosis,,,
clinicalStudies,de0b16a5-e886-482b-a0be-ab6161648134,4/10/2012,1,PE,pulmonary embolism,,,
clinicalStudies,de0b16a5-e886-482b-a0be-ab6161648134,4/10/2012,1,VTE,venous thromboembolic,,,
clinicalStudies,de0b16a5-e886-482b-a0be-ab6161648134,4/10/2012,1,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,45e6dce4-92e2-4ad1-bf11-bbcefb753636,1/5/2012,8,DFS,disease-free survival,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,BIS,Behavior and Ideation Scale,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,CPS,complex partial seizures,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,AED,antiepilepsy drug,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,MSS,Manic Syndrome Scale,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,TID,three divided doses,,,
clinicalStudies,5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8,1/4/2010,4,MRS,Manic Rating Scale,,,
clinicalStudies,68c275e8-992a-4520-8065-ab6d615d89cc,9/13/2011,6,total,the risk of death or hospitalization,,,
clinicalStudies,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,BIS,Behavior and Ideation Scale,,,
clinicalStudies,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,MSS,Manic Syndrome Scale,,,
clinicalStudies,648859e7-659d-4a69-b3f2-ff84747ec200,1/8/2010,2,MRS,Manic Rating Scale,,,
clinicalStudies,d85c5ab8-a3d8-42a3-ac0b-799ea5a6369e,6/20/2011,1,TOC,test-of-cure,,,
clinicalStudies,d69658d9-9471-4896-9593-d3ebf52f2e07,9/19/2011,2,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,d69658d9-9471-4896-9593-d3ebf52f2e07,9/19/2011,2,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,d69658d9-9471-4896-9593-d3ebf52f2e07,9/19/2011,2,CV,cardiovascular,,,
clinicalStudies,053a7300-0bce-11e0-9d16-0002a5d5c51b,4/11/2011,2,SHBG,sex hormone binding globulin,,,
clinicalStudies,32fd146f-7652-877f-cfd1-db9fa367406a,1/30/2012,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,32fd146f-7652-877f-cfd1-db9fa367406a,1/30/2012,2,TTP,Time to progression,,,
clinicalStudies,32fd146f-7652-877f-cfd1-db9fa367406a,1/30/2012,2,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,TURP,transurethral resection of the prostate,,,
clinicalStudies,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,CABG,coronary artery bypass graft,,,
clinicalStudies,96b0cdfb-4893-459a-b787-a788f5e8ed0c,11/16/2011,3996,VAS,visual analog scale,,,
clinicalStudies,96b0cdfb-4893-459a-b787-a788f5e8ed0c,11/16/2011,3996,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,96b0cdfb-4893-459a-b787-a788f5e8ed0c,11/16/2011,3996,ACR,American College of Rheumatology,,,
clinicalStudies,0be2e371-1f05-48d7-8f2e-f2024f3305f3,3/15/2011,1,MCE,major coronary events,,,
clinicalStudies,0be2e371-1f05-48d7-8f2e-f2024f3305f3,3/15/2011,1,MVE,major vascular events,,,
clinicalStudies,18f7f458-9276-4e9d-94b2-99ca8dd4cebf,8/3/2010,3,i.e.,improvement,,,
clinicalStudies,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,YMRS,Young Mania Rating Scale,,,
clinicalStudies,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,1CBEB5ED-32B4-43D7-9A50-7464D11A5CF2,9/11/2007,2,HPA,Hypothalamic-Pituitary-Adrenal,,,
clinicalStudies,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,AEDs,antiepileptic drugs,,,
clinicalStudies,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,5850bfd4-df74-44fb-aef5-ea3fa7c075ee,12/17/2009,1,i.e.,improvement,,,
clinicalStudies,56e4faec-ffe0-43fe-80fd-2258970e63f7,4/27/2011,1,iTNSS,instantaneous scoring,,,
clinicalStudies,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,29785dd0-f94f-48b5-9194-b4a796c464ce,4/12/2012,1,REA,Restriction Endonuclease Analysis,,,
clinicalStudies,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,i.e.,improvement,,,
clinicalStudies,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,BSA,body surface area,,,
clinicalStudies,2835b6f5-93da-4554-9d84-79132fd928ee,4/28/2010,1,CAD,coronary artery disease,,,
clinicalStudies,4165ef14-8dfc-4165-859c-dcf06174d69c,3/2/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,4165ef14-8dfc-4165-859c-dcf06174d69c,3/2/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,04d9fe8b-6d44-f46f-732a-5583a7118b91,6/28/2011,16,ZE,Zollinger-Ellison,,,
clinicalStudies,d567412a-e5ed-4c7f-90f0-ea3039786480,11/22/2010,3,i.e.,infection,,,
clinicalStudies,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,BIS,Behavior  and Ideation Scale,,,
clinicalStudies,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,MSS,Manic Syndrome Scale,,,
clinicalStudies,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,i.e.,improvement,,,
clinicalStudies,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,TID,three divided doses,,,
clinicalStudies,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,MRS,Manic Rating Scale,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,TDM,to distant metastasis,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,SDFS,systemic disease-free survival,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,TTP,Time to progression,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,PCA,Primary Core Analysis,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,STA,Sequential Treatments Analysis,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,DFS,disease-free survival,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,OS,overall survival,,,
clinicalStudies,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,TBR,to breast cancer recurrence,,,
clinicalStudies,0d83cde7-4604-4bdd-a7cd-c31a5830514d,1/12/2010,1,WASO,wake time after sleep onset,,,
clinicalStudies,db1c840d-ab22-4a4c-9ced-ae82c869dd9b,10/13/2011,14,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,AEDs,antiepileptic drugs,,,
clinicalStudies,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,BUN,Blood Urea Nitrogen,,,
clinicalStudies,8290add3-4449-4e58-6c97-8fe1eec972e3,5/30/2012,1416,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,1/31/2012,15,FPG,fasting plasma glucose,,,
clinicalStudies,3391be1e-b57f-4144-8707-f5c6182b2f6e,12/21/2011,3409,i.e.,infection,,,
clinicalStudies,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,only,ondansetron injection was administered intravenously,,,
clinicalStudies,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,min,"valign=""middle""><paragraph>Median time to first</paragraph><paragraph>emetic episode",,,
clinicalStudies,5907ef77-9c4d-4e3f-be7b-6157ebad2173,10/26/2011,1,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4,8/30/2011,8,MTD,maximum tolerated dose,,,
clinicalStudies,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,HDRS,Hamilton Depression Rating Scale,,,
clinicalStudies,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,MADRS,Montgomery and Asberg Depression Rating Scale,,,
clinicalStudies,4fa83401-321d-4fb9-bd7f-8cfa966782e3,10/20/2011,4,CGI,Clinical Global Impression,,,
clinicalStudies,4fa83401-321d-4fb9-bd7f-8cfa966782e3,10/20/2011,4,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,PONV,Postoperative Nausea and Vomiting,,,
clinicalStudies,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,FLIE,Functional Living Index–Emesis,,,
clinicalStudies,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,MEC,Moderately Emetogenic Chemotherapy,,,
clinicalStudies,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,TURP,transurethral resection of the prostate,,,
clinicalStudies,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,CABG,coronary artery bypass graft,,,
clinicalStudies,563c6d6d-56df-43a7-a7aa-709c5ea3cdbe,3/24/2010,10,LOCF,last observation carried forward,,,
clinicalStudies,36d4f6c4-4946-4baa-8f9d-42a03926eeb7,4/11/2012,2,G.I.,gastrointestinal,,,
clinicalStudies,36d4f6c4-4946-4baa-8f9d-42a03926eeb7,4/11/2012,2,AUC,and bioequivalence,,,
clinicalStudies,850a0897-a8c5-4aff-b6db-0ac2cbbab701,12/13/2011,3363,VAS,visual analog scale,,,
clinicalStudies,850a0897-a8c5-4aff-b6db-0ac2cbbab701,12/13/2011,3363,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,850a0897-a8c5-4aff-b6db-0ac2cbbab701,12/13/2011,3363,ACR,American College of Rheumatology,,,
clinicalStudies,cc0c084b-a122-736e-c136-c8cffc92f5f4,6/30/2011,2,HR,[Hazard Ratio,,,
clinicalStudies,82731db6-92fc-483b-9d73-9b2aed79b104,12/13/2011,9,DFS,disease-free survival,,,
clinicalStudies,e2f854cb-7f91-4269-ba67-97065ac8b4a0,3/3/2011,1405,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,749e42fb-2fe0-45dd-9268-b43bb3f4081c,2/23/2011,4,PAP,pulmonary artery pressure,,,
clinicalStudies,749e42fb-2fe0-45dd-9268-b43bb3f4081c,2/23/2011,4,RAP,right atrial pressure,,,
clinicalStudies,749e42fb-2fe0-45dd-9268-b43bb3f4081c,2/23/2011,4,PVR,pulmonary vascular resistance,,,
clinicalStudies,749e42fb-2fe0-45dd-9268-b43bb3f4081c,2/23/2011,4,CI,cardiac index,,,
clinicalStudies,7094279a-281a-4e53-ab2a-23fedb8c778a,1/27/2012,4,PCPZ,prochlorperazine,,,
clinicalStudies,bfd18a45-06cc-4281-b181-40eb5d192a9b,3/20/2012,3,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,a16450f1-77ea-4017-b4ed-a3c5401f9dbf,2/28/2012,18,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,a16450f1-77ea-4017-b4ed-a3c5401f9dbf,2/28/2012,18,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,a16450f1-77ea-4017-b4ed-a3c5401f9dbf,2/28/2012,18,CV,cardiovascular,,,
clinicalStudies,3fb2aa58-3a40-4255-a261-e2db5b9a5dde,2/14/2012,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,AEDs,antiepileptic drugs,,,
clinicalStudies,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,cure,clinical success rate,,,
clinicalStudies,fb5cf9d5-afe9-4d74-a60c-17b38d9b084c,5/13/2011,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,1a56c82e-7ecd-43b0-2899-f89e47adf7db,10/26/2009,5,D/C,discontinuations,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,TDM,to distant metastasis,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,SDFS,systemic disease-free survival,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,TTP,Time to progression,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,PCA,Primary Core Analysis,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,STA,Sequential Treatments Analysis,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,DFS,disease-free survival,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,OS,overall survival,,,
clinicalStudies,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,TBR,to breast cancer recurrence,,,
clinicalStudies,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,cUTI,complicated urinary tract infections,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,HRT,Hormone Replacement Therapy,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,CI,confidence interval,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,RR,relative risk,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,BMD,bone mineral density,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,RMT,Royal Marsden Trial,,,
clinicalStudies,52447e22-c0b9-4657-90ca-9a07889a54d1,7/1/2011,2,DCIS,ductal carcinoma in situ,,,
clinicalStudies,2ef69eb9-ef5b-431f-aeb2-34fc360a7bb5,3/19/2012,3,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,BIS,Behavior and Ideation Scale,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,CPS,complex partial seizures,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,AED,antiepilepsy drug,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,MSS,Manic Syndrome Scale,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,i.e.,improvement,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,TID,three divided doses,,,
clinicalStudies,f23831e9-ef8e-4b4e-b5b3-dd01b76084f2,1/30/2012,2,MRS,Manic Rating Scale,,,
clinicalStudies,d67888ac-5041-4758-88db-845a41f67df4,3/15/2012,2,WHI,Women’s Health Initiative,,,
clinicalStudies,d67888ac-5041-4758-88db-845a41f67df4,3/15/2012,2,PE,pulmonary embolism,,,
clinicalStudies,d67888ac-5041-4758-88db-845a41f67df4,3/15/2012,2,MI,myocardial infarction,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,SDS,Sheehan Disability Scale,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,CGI-BP,Clinical Global Impression - Bipolar,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,CGI-I,Clinical Global Impression-Improvement,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,Y-MRS,Young Mania  Rating Scale,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,CGI-I,Clinical Global Impression of Improvement,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,CGI,Clinical Global  Impression,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,ABC,Aberrant Behavior  Checklist,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,MDD,major  depressive disorder,,,
clinicalStudies,a7f5284b-ff9d-4198-ab0f-bb9fd727662e,10/20/2011,1,AED,antiepileptic drug,,,
clinicalStudies,a7f5284b-ff9d-4198-ab0f-bb9fd727662e,10/20/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,a7f5284b-ff9d-4198-ab0f-bb9fd727662e,10/20/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,95905ef9-1de6-41eb-aa34-ac750e93e292,12/1/2011,3282,HbA1c,hemoglobin A1c,,,
clinicalStudies,95905ef9-1de6-41eb-aa34-ac750e93e292,12/1/2011,3282,PPG,postprandial plasma glucose,,,
clinicalStudies,35fee753-acd7-4da2-bd60-973dc6c0b21f,8/17/2011,9,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,92FE06D1-9AEC-47B4-B7FC-AEA6434CBE10,6/1/2006,1,AUPC,area under the pain curve,,,
clinicalStudies,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,i.e.,improvement from baseline,,,
clinicalStudies,0edf8afb-4af8-4dc9-8d9d-7f233f442736,6/6/2011,2,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,f4853677-1622-4037-688b-fdf533a11d96,1/20/2012,29,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,f4853677-1622-4037-688b-fdf533a11d96,1/20/2012,29,BAO,Basal Acid Output,,,
clinicalStudies,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,AEDs,antiepileptic drugs,,,
clinicalStudies,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,85f11b74-a88d-45a1-9ef1-6007e1bbedf7,11/2/2009,5,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,7b891df0-add4-4f0c-a3ab-d53e864eced7,11/8/2011,2,ZE,Zollinger-Ellison,,,
clinicalStudies,1c0525fc-2d95-4682-a459-7ea4fbe95c72,6/13/2011,8,MCE,major coronary events,,,
clinicalStudies,1c0525fc-2d95-4682-a459-7ea4fbe95c72,6/13/2011,8,MVE,major vascular events,,,
clinicalStudies,3e6bf2b3-9339-4104-bda3-ad86a1949703,9/26/2011,1,DVT,deep vein thrombosis,,,
clinicalStudies,3e6bf2b3-9339-4104-bda3-ad86a1949703,9/26/2011,1,PE,pulmonary embolism,,,
clinicalStudies,3e6bf2b3-9339-4104-bda3-ad86a1949703,9/26/2011,1,VTE,venous thromboembolic,,,
clinicalStudies,3e6bf2b3-9339-4104-bda3-ad86a1949703,9/26/2011,1,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,820839ef-e53d-47e8-a3b9-d911ff92e6a9,3/30/2012,15,NOS,not otherwise specified,,,
clinicalStudies,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,ZE,Zollinger-Ellison,,,
clinicalStudies,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,CGI,Clinical Global Impression,,,
clinicalStudies,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,e63fe922-b35a-406c-8737-f3f5e6d5a30d,1/9/2012,2,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,ITT,intent-to-treat,,,
clinicalStudies,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,PHN,postherpetic neuralgia,,,
clinicalStudies,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,CGI,Clinical Global Impressions,,,
clinicalStudies,5c527c2e-9062-4afe-dbbb-f650db3a340f,4/18/2012,10,BSC,Best Supportive Care,,,
clinicalStudies,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,MITT,modified Intent-to-Treat,,,
clinicalStudies,61c43eb6-c29f-4572-8897-954636a760a1,12/28/2011,3421,cure,clinical success rate,,,
clinicalStudies,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,ITT,intent-to-treat,,,
clinicalStudies,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,PHN,postherpetic neuralgia,,,
clinicalStudies,9bb93e9a-1bac-4a2e-a5fe-16197e129367,7/14/2010,1,total,the risk of death or hospitalization,,,
clinicalStudies,06c0a509-026f-44e0-9975-a94a8de51d43,9/14/2005,3,GERD,gastroesophageal reflux disease,,,
clinicalStudies,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,5/18/2012,22,ITT,intent-to-treat,,,
clinicalStudies,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,5/18/2012,22,MRSA,methicillin-resistant Staphylococcus aureus,,,
clinicalStudies,09120812-5cd3-46b3-ad2f-4712df57f8d0,5/23/2012,3815,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,c3d849eb-7fed-4bac-9fb6-0684094d8dfb,7/25/2011,1,HPS,Heart Protection Study,,,
clinicalStudies,c3d849eb-7fed-4bac-9fb6-0684094d8dfb,7/25/2011,1,95% CI,278.6(51.8)211.9(49)46.9(11.9)90(50.7)186.3(38.1)Simvastatin24 Weeks106% Change from Baseline,,,
clinicalStudies,0fb9f3ab-45d1-405e-a14e-4cb4b1a28c55,10/27/2009,2,IPSS,International Prostate Symptom Score,,,
clinicalStudies,42105671-ad7c-462c-b42f-1cdad94753d2,2/2/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,184d3092-7fc6-4375-816b-1ab06bb99cfd,6/3/2009,3,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,200601d6-2c98-42dd-bece-76fc350c5356,3/5/2012,3617,min,median,,,
clinicalStudies,9a4229fd-fecd-4ac1-9c4f-6d442533457f,3/2/2010,2,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,9a4229fd-fecd-4ac1-9c4f-6d442533457f,3/2/2010,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,ae5682dc-61f0-48ff-9d0d-7ce1aa1c39de,1/18/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,4ac26ddd-b806-4168-aa82-e5a30145276d,11/19/2010,3,PCPZ,prochlorperazine,,,
clinicalStudies,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,CGI,Clinical Global Impression,,,
clinicalStudies,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,CDRS-R,Childhood Depression  Rating Scale-Revised,,,
clinicalStudies,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,8809c12d-06de-4ccb-95d3-5108d2a955fb,8/5/2011,2,ZE,Zollinger-Ellison,,,
clinicalStudies,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,min,Median % Change,,,
clinicalStudies,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,min,Median,,,
clinicalStudies,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,4211fbea-7a8f-4300-b50e-e1aa58bb7c3f,9/8/2011,1,MET,Metformin Hydrochloride,,,
clinicalStudies,4211fbea-7a8f-4300-b50e-e1aa58bb7c3f,9/8/2011,1,Comb,Combined Metformin/Glyburide,,,
clinicalStudies,4211fbea-7a8f-4300-b50e-e1aa58bb7c3f,9/8/2011,1,Glyb,Glyburide,,,
clinicalStudies,4211fbea-7a8f-4300-b50e-e1aa58bb7c3f,9/8/2011,1,mg/dL,mg Once DailyTotal Cholesterol,,,
clinicalStudies,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,ITT,intent-to-treat,,,
clinicalStudies,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,VASPI,Visual Analog Scale of Pain Intensity,,,
clinicalStudies,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,TMA,thrombotic microangiopathy,,,
clinicalStudies,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,min,median,,,
clinicalStudies,99EB1A81-8472-4CFB-BAD8-739636AB5BEC,4/5/2007,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,99EB1A81-8472-4CFB-BAD8-739636AB5BEC,4/5/2007,1,PPG,postprandial plasma glucose,,,
clinicalStudies,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,HDRS,Hamilton  Depression Rating Scale,,,
clinicalStudies,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,CGI,Clinical Global Impressions,,,
clinicalStudies,7fce939e-c38e-497f-ba3f-e7b6ba44bfd9,8/25/2010,1,MCE,major coronary events,,,
clinicalStudies,7fce939e-c38e-497f-ba3f-e7b6ba44bfd9,8/25/2010,1,MVE,major vascular events,,,
clinicalStudies,7c01f541-1c88-400c-41a9-7cbb9dee50c0,4/11/2012,15,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,7c01f541-1c88-400c-41a9-7cbb9dee50c0,4/11/2012,15,MRI,magnetic resonance imaging,,,
clinicalStudies,8e4f7179-81d7-4715-9cc1-babef97fcca0,6/28/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,AC641027-929E-694D-80CD-BF770DC51AA6,1/26/2009,1,NAPR,nonallergic perennial rhinitis,,,
clinicalStudies,AC641027-929E-694D-80CD-BF770DC51AA6,1/26/2009,1,APR,allergic perennial rhinitis,,,
clinicalStudies,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,CFU,colony  forming units,,,
clinicalStudies,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,dMAC,disseminated MAC,,,
clinicalStudies,d44a0b9c-848f-4d69-bf56-1befd40de766,10/11/2011,2,DVT,deep vein thrombosis,,,
clinicalStudies,d44a0b9c-848f-4d69-bf56-1befd40de766,10/11/2011,2,PE,pulmonary embolism,,,
clinicalStudies,d44a0b9c-848f-4d69-bf56-1befd40de766,10/11/2011,2,VTE,venous thromboembolic,,,
clinicalStudies,d44a0b9c-848f-4d69-bf56-1befd40de766,10/11/2011,2,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,98dc2482-ec98-48dc-9449-93ac202e5679,9/13/2011,5,AED,antiepileptic drug,,,
clinicalStudies,98dc2482-ec98-48dc-9449-93ac202e5679,9/13/2011,5,AEDs,antiepileptic drugs,,,
clinicalStudies,98dc2482-ec98-48dc-9449-93ac202e5679,9/13/2011,5,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,98dc2482-ec98-48dc-9449-93ac202e5679,9/13/2011,5,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,a1abf8b8-e74f-4028-83d1-71413901b53f,4/12/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,a1abf8b8-e74f-4028-83d1-71413901b53f,4/12/2011,1,cure,clinical success rate,,,
clinicalStudies,a1abf8b8-e74f-4028-83d1-71413901b53f,4/12/2011,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,bd794164-0cad-4ca3-9f62-ae9118f6e4a2,2/21/2012,5,DVT,deep vein thrombosis,,,
clinicalStudies,bd794164-0cad-4ca3-9f62-ae9118f6e4a2,2/21/2012,5,PE,pulmonary embolism,,,
clinicalStudies,bd794164-0cad-4ca3-9f62-ae9118f6e4a2,2/21/2012,5,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,a9a3c560-2408-4dd0-9f83-ee3e3a549c7b,3/9/2012,2,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,75f6811d-0906-4ed4-8619-eb3eed103d9b,7/1/2011,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,a5d389d2-d0e1-4395-a2a2-b552808e7f98,2/29/2012,6,i.e.,improvement from baseline,,,
clinicalStudies,60185c88-ecfd-46f9-adb9-b97c6b00a553,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,60185c88-ecfd-46f9-adb9-b97c6b00a553,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,60185c88-ecfd-46f9-adb9-b97c6b00a553,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SDS,standard deviation  score,,,
clinicalStudies,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SDS,Standard Deviation  Score,,,
clinicalStudies,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SGA,small  for gestational age,,,
clinicalStudies,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,SDS,Standard Deviation Score,,,
clinicalStudies,f34bb31d-706b-454f-98e9-0b23d45c091f,5/31/2012,3830,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,88820a09-8541-438f-b39c-452b2fa25ec6,6/17/2011,5,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,MTD,maximum tolerated dose,,,
clinicalStudies,cd6d1b85-0ba2-4a10-a5b8-25496ae13fa3,3/26/2012,3703,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,8f549d95-985b-f783-1ebb-ef57bd2ecb05,12/28/2011,9,PID,Pain Intensity Differences,,,
clinicalStudies,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,LDL,low density lipoprotein,,,
clinicalStudies,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,VLDL,very low density lipoprotein,,,
clinicalStudies,e55be390-e4e5-4c45-a21b-7c0198d92d35,5/23/2012,3813,TG,triglyceride,,,
clinicalStudies,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,MHAQ,[Modified Health Assessment Questionnaire,,,
clinicalStudies,151ffcf4-e503-4954-af7c-93d0a4f9f80e,12/15/2010,3,ACR,American College of Rheumatology,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,CGI,Clinical Global Impression,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,BARS,Behavioural Activity Rating  Scale,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,PANSS,Positive and  Negative Syndrome Scale,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,AUC,area under the curve,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,CGI,Clinical Global  Impression,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,CGI-S,Clinical Global  Impression-Severity of Illness Scale,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,MRS,Mania Rating Scale,,,
clinicalStudies,b4001db4-1ccb-42f3-af4a-7276c51f4ad5,12/20/2010,158,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,7f052e0f-8d78-45d8-a6cb-568b201b7e1a,11/21/2011,1,ZE,Zollinger-Ellison,,,
clinicalStudies,423acd42-650c-43fa-98f1-7d0fccceff6b,12/12/2011,3362,VAS,visual analog scale,,,
clinicalStudies,423acd42-650c-43fa-98f1-7d0fccceff6b,12/12/2011,3362,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,423acd42-650c-43fa-98f1-7d0fccceff6b,12/12/2011,3362,ACR,American College of Rheumatology,,,
clinicalStudies,4fee8d4c-bb21-4773-b622-87f9a4ff333a,2/1/2012,2,HR,[Hazard Ratio,,,
clinicalStudies,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,6e030b0f-8ee6-4b23-9345-7193d4280e88,3/12/2012,1,MCE,major coronary events,,,
clinicalStudies,6e030b0f-8ee6-4b23-9345-7193d4280e88,3/12/2012,1,MVE,major vascular events,,,
clinicalStudies,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,dMAC,disseminated MAC,,,
clinicalStudies,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,CFU,colony forming units,,,
clinicalStudies,b07f9eab-44ac-4667-bd46-52d736daa5d6,4/14/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,CGI,Clinical Global Impression,,,
clinicalStudies,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,a75272a5-4af8-4cc8-b718-c4926262c457,11/12/2009,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,1cbda269-2d69-453a-abe3-734a684d835a,5/9/2012,3,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,782af2da-7092-4e55-8f07-9e67c283bf84,2/10/2011,1,min,median,,,
clinicalStudies,01143c04-f5d7-481d-95bb-d384f2413585,5/21/2010,1,LCIS,lobular carcinoma in situ,,,
clinicalStudies,01143c04-f5d7-481d-95bb-d384f2413585,5/21/2010,1,DXA,dual-energy x-ray absorptiometric,,,
clinicalStudies,01143c04-f5d7-481d-95bb-d384f2413585,5/21/2010,1,TVU,transvaginal ultrasonography,,,
clinicalStudies,312e65cb-897f-4c24-b17b-be7e8ce469bb,7/19/2011,2,TOC,test-of-cure,,,
clinicalStudies,4a81b757-0a64-4ed4-86f4-57aeb349105f,1/20/2012,1,MCE,major coronary events,,,
clinicalStudies,4a81b757-0a64-4ed4-86f4-57aeb349105f,1/20/2012,1,MVE,major vascular events,,,
clinicalStudies,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,e480e538-4ea7-47e6-9e5d-dc0f8179e06c,5/16/2012,3,min,median,,,
clinicalStudies,3d263380-4f44-4fd8-aa2a-e69702ab258f,4/10/2012,2,DVT,deep vein thrombosis,,,
clinicalStudies,3d263380-4f44-4fd8-aa2a-e69702ab258f,4/10/2012,2,PE,pulmonary embolism,,,
clinicalStudies,3d263380-4f44-4fd8-aa2a-e69702ab258f,4/10/2012,2,VTE,venous thromboembolic,,,
clinicalStudies,3d263380-4f44-4fd8-aa2a-e69702ab258f,4/10/2012,2,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,F7EC5EC1-FB05-4C78-B821-9AEA638CF144,6/11/2008,1,ITT,intent-to-treat,,,
clinicalStudies,F7EC5EC1-FB05-4C78-B821-9AEA638CF144,6/11/2008,1,RFS,relapse-free survival,,,
clinicalStudies,F7EC5EC1-FB05-4C78-B821-9AEA638CF144,6/11/2008,1,OS,overall survival,,,
clinicalStudies,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,MIC,minimal inhibitory concentration,,,
clinicalStudies,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,TOC,test-of-cure,,,
clinicalStudies,e35e8385-db1f-41a8-8307-20979569ac72,10/27/2009,2,SPID,sum of pain intensity difference,,,
clinicalStudies,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,AC,and cyclophosphamide,,,
clinicalStudies,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,12/7/2011,1,KS,Kaposi’s sarcoma,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,TTP,time to progression,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,CR,Complete Response,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,PR,Partial Response,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,SWOG,Southwest Oncology Group,,,
clinicalStudies,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,g/dL,"<tr><td>&#160;&#160;&#160;&#160;&gt;5.5 mg/L</td><td>30</td><td>31</td></tr> <tr><td><content styleCode=""bold"">Serum M-protein",,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,NAPRTCS,North American Pediatric Renal Transplant Cooperative,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,CRI,Chronic Renal Insufficiency,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,CT,,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,DEXA,dual energy x-ray absorptiometry,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,VAT,visceral adipose tissue,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,BMD,bone mineral density,,,
clinicalStudies,139d2038-e6a9-4ab1-ab00-aa7d8aa8df5f,1/17/2008,2,SD,standard deviation,,,
clinicalStudies,c7fc2d1e-802e-4da1-9763-3355f8aafe3a,4/13/2010,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,c391fe11-fd47-4a35-af6d-c823ab7b8838,3/2/2011,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,c391fe11-fd47-4a35-af6d-c823ab7b8838,3/2/2011,1,TTP,Time to progression,,,
clinicalStudies,c391fe11-fd47-4a35-af6d-c823ab7b8838,3/2/2011,1,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,154af0be-18fb-413e-a702-012bb259962d,2/9/2012,3,PPG,postprandial plasma glucose,,,
clinicalStudies,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,HR,&#160;Hazard ratio,,,
clinicalStudies,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,ITT,intent to treat,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,CGI,Clinical Global Impression,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,a7bf9202-9590-49c8-bde1-78517e60850f,11/16/2010,1,cure,clinical success rate,,,
clinicalStudies,7026f0a7-3f08-4116-aa0b-eb61dc3804ab,2/28/2012,3594,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,7026f0a7-3f08-4116-aa0b-eb61dc3804ab,2/28/2012,3594,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,7026f0a7-3f08-4116-aa0b-eb61dc3804ab,2/28/2012,3594,CV,cardiovascular,,,
clinicalStudies,5783976b-0862-44e5-9b19-0f41d236d5c3,1/5/2012,1,PFS,progression-free survival,,,
clinicalStudies,4bd7e768-2d09-44e6-bacb-7390a5bc5dbc,11/9/2010,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,4bd7e768-2d09-44e6-bacb-7390a5bc5dbc,11/9/2010,2,HR,[Hazard Ratio,,,
clinicalStudies,67c174da-41b8-4738-8a22-dd814b8e96b8,12/22/2011,6,DRC,Data Review Committee,,,
clinicalStudies,d75b0a7e-cb9b-4102-bcac-097403b25129,1/23/2012,1,i.e.,infection,,,
clinicalStudies,9001fa88-7b48-4be7-ba95-000ba1db48b4,10/13/2011,11,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,9001fa88-7b48-4be7-ba95-000ba1db48b4,10/13/2011,11,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,0800d19b-bdd8-47c9-81c3-67a92b81d07a,2/1/2011,5,TTP,Time to progression,,,
clinicalStudies,0800d19b-bdd8-47c9-81c3-67a92b81d07a,2/1/2011,5,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,81ca6361-dbbd-40c2-85df-4535d74c81bc,5/17/2012,2,ITT,intent-to-treat,,,
clinicalStudies,81ca6361-dbbd-40c2-85df-4535d74c81bc,5/17/2012,2,RFS,Relapse-free survival,,,
clinicalStudies,81ca6361-dbbd-40c2-85df-4535d74c81bc,5/17/2012,2,OS,overall survival,,,
clinicalStudies,b32d180f-f8d6-4535-a3b6-45045663a96f,9/30/2011,2,i.e.,improvement,,,
clinicalStudies,13d99b6b-99a5-49e7-8288-f07a087e344c,6/28/2012,4,VLDL,very low density lipoprotein,,,
clinicalStudies,b38489c0-ee7b-11df-b958-0002a5d5c51b,5/13/2011,2,LDL,low density lipoprotein,,,
clinicalStudies,b38489c0-ee7b-11df-b958-0002a5d5c51b,5/13/2011,2,VLDL,very low density lipoprotein,,,
clinicalStudies,b38489c0-ee7b-11df-b958-0002a5d5c51b,5/13/2011,2,TG,triglyceride,,,
clinicalStudies,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,PPB,Per  Protocol Bacteriological Population,,,
clinicalStudies,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,ITTC,intent-to-treat clinical,,,
clinicalStudies,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,ITTB,intent-to-treat bacteriological,,,
clinicalStudies,9fae06b5-bbd5-400a-a7a6-3a4e238361f8,1/13/2010,1,PPC,per protocol,,,
clinicalStudies,4a13b574-ff5e-417e-bef4-279fcc3d5280,12/22/2009,3,AECB,acute  exacerbation of chronic bronchitis,,,
clinicalStudies,c5f32941-3427-4a38-bc3d-38337b41d9d3,1/27/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,c5f32941-3427-4a38-bc3d-38337b41d9d3,1/27/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,6567dfb0-b220-40ea-9c00-551f873ffcf2,5/18/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,1709ae09-e613-4d66-afad-47c0449f62aa,9/25/2009,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,5cb4a1db-f32d-44af-8985-0a94ca506468,9/24/2010,2,AEDs,antiepileptic drugs,,,
clinicalStudies,5cb4a1db-f32d-44af-8985-0a94ca506468,9/24/2010,2,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,23c1160f-be23-4afe-8427-34fd651a62fa,7/12/2011,14,VAS,visual analog scale,,,
clinicalStudies,23c1160f-be23-4afe-8427-34fd651a62fa,7/12/2011,14,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,23c1160f-be23-4afe-8427-34fd651a62fa,7/12/2011,14,ACR,American College of Rheumatology,,,
clinicalStudies,8cc2bf2e-d51f-4abd-bc08-660c5e5f00de,2/2/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,5d7c4d41-2df4-42d4-9a3d-0a567519bf2d,12/20/2010,1,ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinical Global Impression of Change,,,
clinicalStudies,dd0ca36d-1f54-4568-8d19-a7152addcd52,9/9/2011,6,DFS,disease-free survival,,,
clinicalStudies,8e4382de-df78-4821-b11e-c423442a7ff8,4/1/2011,7,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,8e4382de-df78-4821-b11e-c423442a7ff8,4/1/2011,7,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,8e4382de-df78-4821-b11e-c423442a7ff8,4/1/2011,7,CV,cardiovascular,,,
clinicalStudies,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,LDL,low density lipoprotein,,,
clinicalStudies,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,VLDL,very low density lipoprotein,,,
clinicalStudies,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,TG,triglyceride,,,
clinicalStudies,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,4/13/2012,3,BW,body weight,,,
clinicalStudies,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,4/13/2012,3,kJ,kilojoules,,,
clinicalStudies,62b01d29-90f0-45b2-a0c4-3a750ba36c8a,4/13/2012,3,LBM,Lean body mass,,,
clinicalStudies,116464ce-cfd8-4b9f-8b5a-3a114b6ff2b1,5/24/2012,11,AQLQ(S),Asthma Quality of Life Questionnaire,,,
clinicalStudies,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,9FCA10EE-973E-4FE0-AAF5-A0416918A397,12/18/2006,1,EEF,enhancement factor,,,
clinicalStudies,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,ZE,Zollinger-Ellison,,,
clinicalStudies,28fd7158-a617-436a-8f5c-71ffbaafe527,9/14/2005,2,GERD,gastroesophageal reflux disease,,,
clinicalStudies,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,MITT,modified Intent-to-Treat,,,
clinicalStudies,54ba24c0-11dd-4392-8f0f-0160d6373b85,7/8/2011,3042,cure,clinical success rate,,,
clinicalStudies,88e7a888-1464-491a-a439-9a9c127c3702,7/20/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,LDL,low density lipoprotein,,,
clinicalStudies,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,VLDL,very low density lipoprotein,,,
clinicalStudies,a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7,11/28/2011,8,TG,triglyceride,,,
clinicalStudies,4445c26e-ec5c-40f4-956b-93c12fc73c1d,3/6/2012,3,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,0f943869-41a2-4f7e-943d-dd8c17996dd8,1/19/2011,6,BMD,Bone Mineral Density,,,
clinicalStudies,0f943869-41a2-4f7e-943d-dd8c17996dd8,1/19/2011,6,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,0f943869-41a2-4f7e-943d-dd8c17996dd8,1/19/2011,6,PE,pulmonary embolism,,,
clinicalStudies,0f943869-41a2-4f7e-943d-dd8c17996dd8,1/19/2011,6,CHD,coronary heart disease,,,
clinicalStudies,803338bc-9375-11dd-9d53-0ff1e074fd46,10/14/2008,1,SWOG,Southwest Oncology Group,,,
clinicalStudies,50a26e9a-42d5-4d91-a346-57ef3a1e935f,11/11/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,8e9e8cb6-d28a-475a-9584-a1dee4899c4f,9/8/2011,1,AED,antiepileptic drug,,,
clinicalStudies,8e9e8cb6-d28a-475a-9584-a1dee4899c4f,9/8/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,ccdc3aae-6e2d-4cd0-a51c-8375bfee9458,8/17/2010,3,ITT,intent-to-treat,,,
clinicalStudies,ccdc3aae-6e2d-4cd0-a51c-8375bfee9458,8/17/2010,3,CI,confidence interval,,,
clinicalStudies,ccdc3aae-6e2d-4cd0-a51c-8375bfee9458,8/17/2010,3,JRS,Jankovic Rating Scale,,,
clinicalStudies,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,BSA,body surface area,,,
clinicalStudies,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,MIC,minimal inhibitory concentration,,,
clinicalStudies,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,cUTI,complicated urinary tract infections,,,
clinicalStudies,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalStudies,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,ESRD,end-stage renal disease,,,
clinicalStudies,F4216772-6C37-4FF0-A575-F758390656E3,9/23/2008,3,CR,Complete Response,,,
clinicalStudies,F4216772-6C37-4FF0-A575-F758390656E3,9/23/2008,3,none,nauseaSeverity of nausea,,,
clinicalStudies,9ccf0781-4fb3-496e-bd58-54381ea33510,12/29/2011,2,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,6336b9ee-a2f3-44cc-ae6a-43a5f68745f6,3/30/2012,10,MCE,major coronary events,,,
clinicalStudies,6336b9ee-a2f3-44cc-ae6a-43a5f68745f6,3/30/2012,10,MVE,major vascular events,,,
clinicalStudies,690730ea-bd69-4b57-ab9e-2e76309c8d50,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,690730ea-bd69-4b57-ab9e-2e76309c8d50,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,0c0ae87f-c8d8-4332-af8c-58fc3485842c,7/22/2011,5,EGSA,Evaluator's Global Severity Assessment,,,
clinicalStudies,efb1fc6e-2f9e-400a-8069-569d1c0894a5,5/31/2012,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,a23a1cca-bc3e-48c5-abd9-82eddb52e91b,12/28/2010,1,TOC,test-of-cure,,,
clinicalStudies,a92428d1-b8a5-4b3d-965d-50fd333bd743,11/30/2011,8,MCE,major coronary events,,,
clinicalStudies,a92428d1-b8a5-4b3d-965d-50fd333bd743,11/30/2011,8,MVE,major vascular events,,,
clinicalStudies,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,ITT,intent-to-treat,,,
clinicalStudies,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,PHN,postherpetic neuralgia,,,
clinicalStudies,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,PPG,postprandial plasma glucose,,,
clinicalStudies,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,i.e.,improvement from baseline,,,
clinicalStudies,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,J/cm,300 Joules/cm,,,
clinicalStudies,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,HGD,high-grade dysplasia,,,
clinicalStudies,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,BE,Barrett’s Esophagus,,,
clinicalStudies,3814cfed-029f-4231-bba3-89b2b4e01392,2/14/2012,3,HbA1c,hemoglobin A1c,,,
clinicalStudies,3814cfed-029f-4231-bba3-89b2b4e01392,2/14/2012,3,PPG,postprandial plasma glucose,,,
clinicalStudies,d3f7c414-db83-4a7a-a7aa-745c5606cdba,6/7/2011,1,i.e.,improvement,,,
clinicalStudies,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,AUA,American Urological Association,,,
clinicalStudies,dc676bc5-f3f7-4755-92e1-1814498c1f4f,12/31/2010,8,iPTH,intact parathyroid                                             hormone,,,
clinicalStudies,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,TG,triglycerides,,,
clinicalStudies,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,PLAC I,Pravastatin Limitation of Atherosclerosis in the Coronary Arteries,,,
clinicalStudies,762daef1-2ad2-444d-958b-f0a69c8ac259,11/10/2010,1,min,median,,,
clinicalStudies,34eee405-05c1-449a-a06f-ca676056c665,3/21/2012,3686,i.e.,in FEV1 after exercise,,,
clinicalStudies,34eee405-05c1-449a-a06f-ca676056c665,3/21/2012,3686,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,34eee405-05c1-449a-a06f-ca676056c665,3/21/2012,3686,i.e.,interval,,,
clinicalStudies,34eee405-05c1-449a-a06f-ca676056c665,3/21/2012,3686,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,531742d3-613c-44dc-88f0-b526a478aa08,4/8/2011,1,CBZ,carbamazepine,,,
clinicalStudies,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,0569d5d5-70df-46d7-954a-fe00542a7191,8/8/2011,9,HbA1c,hemoglobin A1c,,,
clinicalStudies,0569d5d5-70df-46d7-954a-fe00542a7191,8/8/2011,9,PPG,postprandial plasma glucose,,,
clinicalStudies,d7932a2c-a3b7-46df-a306-1f17716160a0,12/30/2011,5,AEDs,antiepileptic drugs,,,
clinicalStudies,b1918b4e-2238-4cbd-81be-61cae5481c88,5/7/2012,7,AED,antiepileptic drug,,,
clinicalStudies,b1918b4e-2238-4cbd-81be-61cae5481c88,5/7/2012,7,AEDs,antiepileptic drugs,,,
clinicalStudies,b1918b4e-2238-4cbd-81be-61cae5481c88,5/7/2012,7,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,b1918b4e-2238-4cbd-81be-61cae5481c88,5/7/2012,7,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,ace72ca5-277c-4031-85f0-29b0bbe9b504,12/17/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,ace72ca5-277c-4031-85f0-29b0bbe9b504,12/17/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,9869b6dd-03ed-4c6f-9c32-2c324e773b7d,10/26/2011,1,i.e.,improvement,,,
clinicalStudies,4c518892-8a67-493a-8251-7a6dac4345bc,6/21/2011,5,NTS,nicotine transdermal system,,,
clinicalStudies,4c518892-8a67-493a-8251-7a6dac4345bc,6/21/2011,5,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalStudies,a4dd6d6c-c8c7-16a9-aa68-aa46283dfae1,5/11/2012,4,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,a4dd6d6c-c8c7-16a9-aa68-aa46283dfae1,5/11/2012,4,MRI,magnetic resonance imaging,,,
clinicalStudies,e46ed5b8-83c9-4adb-890f-0fc612371eea,8/9/2011,1,HR,[Hazard Ratio,,,
clinicalStudies,bf412e94-ca36-4da9-83d7-fb0f1323cf21,4/23/2012,4,AED,antiepileptic drug,,,
clinicalStudies,bf412e94-ca36-4da9-83d7-fb0f1323cf21,4/23/2012,4,AEDs,antiepileptic drugs,,,
clinicalStudies,bf412e94-ca36-4da9-83d7-fb0f1323cf21,4/23/2012,4,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,bf412e94-ca36-4da9-83d7-fb0f1323cf21,4/23/2012,4,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,fa2d8f3c-84f3-4b94-8ad6-f391045f1cfd,6/14/2012,1,min,"align=""center"">Median",,,
clinicalStudies,fa2d8f3c-84f3-4b94-8ad6-f391045f1cfd,6/14/2012,1,min,Median,,,
clinicalStudies,fa2d8f3c-84f3-4b94-8ad6-f391045f1cfd,6/14/2012,1,min,"align=""center"">Median % Change",,,
clinicalStudies,fa2d8f3c-84f3-4b94-8ad6-f391045f1cfd,6/14/2012,1,min,median,,,
clinicalStudies,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,PGI,patient global impression of change,,,
clinicalStudies,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,MINI,Mini-International Neuropsychiatric  Interview,,,
clinicalStudies,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,CLBP,chronic low back pain,,,
clinicalStudies,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,0fece0aa-2b9c-40a3-975e-1ef2c2ef72f2,6/21/2011,4,AD,Alzheimer’s disease,,,
clinicalStudies,0fece0aa-2b9c-40a3-975e-1ef2c2ef72f2,6/21/2011,4,HR,[hazard ratio,,,
clinicalStudies,0fece0aa-2b9c-40a3-975e-1ef2c2ef72f2,6/21/2011,4,VaD,vascular dementia,,,
clinicalStudies,d91934a0-902e-c26c-23ca-d5accc4151b6,10/4/2011,5,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,MITT,modified Intent-to-Treat,,,
clinicalStudies,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,cure,clinical success rate,,,
clinicalStudies,4d8b1cba-b6ed-4036-8307-28da2322ccd5,7/24/2012,7,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,AZA,azathioprine,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,GFR,glomerular filtration rate,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,CNI,calcineurin inhibitors,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,PRA,panel-reactive antibodies,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,MMF,mycophenolate mofetil,,,
clinicalStudies,0f26220a-f4ab-4ceb-9a98-a13dbdeed81f,4/29/2011,1,GFR,glomerular filtration rates,,,
clinicalStudies,17325a80-fb9c-4a83-b4b4-98e0b999d852,10/9/2009,2,CBZ,carbamazepine,,,
clinicalStudies,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,MTSS,mean total symptom scores,,,
clinicalStudies,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,MNW,mean number of wheals,,,
clinicalStudies,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,MPS,mean pruritus scores,,,
clinicalStudies,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,MTSS,mean total symptom score,,,
clinicalStudies,68178694-31d0-4398-8a01-8ce8ea89574c,5/21/2010,1,MPS,mean pruritus score,,,
clinicalStudies,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,NSCLC,Non-Small Cell Lung Carcinoma,,,
clinicalStudies,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,AC,and cyclophosphamide,,,
clinicalStudies,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,FACT-L,Functional Assessment of Cancer Therapy-Lung,,,
clinicalStudies,566a00ae-47c0-4cd2-b602-79909bdfd9b1,10/18/2011,1,KS,Kaposi’s sarcoma,,,
clinicalStudies,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,TNT,to Occurrence of Major Cardiovascular Events,,,
clinicalStudies,8a201c80-a51d-4c1c-963b-488c071908c0,3/1/2012,4,min,median,,,
clinicalStudies,eb40a594-d58d-4214-b766-9e7a815b2de8,8/8/2011,2,i.e.,improvement,,,
clinicalStudies,63f7ac0f-51d7-4e9e-bc54-aee51183bbaa,8/8/2011,6,Glyb,Glyburide,,,
clinicalStudies,63f7ac0f-51d7-4e9e-bc54-aee51183bbaa,8/8/2011,6,HbA1c,hemoglobin A1c,,,
clinicalStudies,63f7ac0f-51d7-4e9e-bc54-aee51183bbaa,8/8/2011,6,PPG,postprandial plasma glucose,,,
clinicalStudies,63f7ac0f-51d7-4e9e-bc54-aee51183bbaa,8/8/2011,6,mg/dL,<td>Met<br/>Vs Glyb<br/>                            </td>                         </tr>                         <tr>                            <td>Fasting Plasma<br/>Glucose,,,
clinicalStudies,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,ad1b4796-8713-4547-ad35-7e6c63ecc65f,3/12/2010,2,ICSI,intra-cytoplasmic sperm injection,,,
clinicalStudies,ad1b4796-8713-4547-ad35-7e6c63ecc65f,3/12/2010,2,ART,Assisted Reproductive Technologies,,,
clinicalStudies,ad1b4796-8713-4547-ad35-7e6c63ecc65f,3/12/2010,2,IVF,in-vitro fertilization,,,
clinicalStudies,ed710c62-8ba6-4f19-b240-3ee73cd03d67,4/22/2011,2,i.e.,improvement,,,
clinicalStudies,8ad881e0-ca41-42ad-9d7d-eb85b3a30af0,11/17/2011,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,194218c4-3f18-4b6b-a0d9-acc8c862d4b7,3/7/2012,3,min,median,,,
clinicalStudies,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,MCE,major coronary events,,,
clinicalStudies,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,MVE,major vascular events,,,
clinicalStudies,0c3354b5-a1d8-4f98-ad55-2eafe4265c4e,9/29/2010,7,HAV,HIV and markers for viral hepatitis,,,
clinicalStudies,0c3354b5-a1d8-4f98-ad55-2eafe4265c4e,9/29/2010,7,HBsAg,Hepatitis B surface antigen,,,
clinicalStudies,64392954-0d2d-4946-bb5c-05d4b81dc319,1/9/2012,2,BSA,body surface area,,,
clinicalStudies,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,i.e.,improvement,,,
clinicalStudies,c0333e62-bb00-4722-27b6-dca6ab4d1eb1,8/12/2010,1114,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,c0333e62-bb00-4722-27b6-dca6ab4d1eb1,8/12/2010,1114,LOCF,last observation carried forward,,,
clinicalStudies,025fee85-53a8-4161-a806-44fd95d0ca74,12/31/2009,1,FTM,Fumarate and Polysaccharide Iron Complex,,,
clinicalStudies,4f1992ef-d1c8-4219-b3c4-33c608fce28c,10/26/2010,10,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,TURP,transurethral resection of the prostate,,,
clinicalStudies,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,CABG,coronary artery bypass graft,,,
clinicalStudies,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,MITT,modified Intent-to-Treat,,,
clinicalStudies,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,cure,clinical success rate,,,
clinicalStudies,84acc7d8-ae0a-4158-a745-3d380afef64c,1/12/2012,4,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,3fa5b81e-81fd-4017-8e87-a4a4c08119fd,10/14/2009,1,PSA,prostate specific antigen,,,
clinicalStudies,9e51cc79-620c-48d7-b267-78e43c1ef6e4,8/14/2009,2,ULN,upper limit of normal,,,
clinicalStudies,9e51cc79-620c-48d7-b267-78e43c1ef6e4,8/14/2009,2,DFS,disease-free survival,,,
clinicalStudies,9e51cc79-620c-48d7-b267-78e43c1ef6e4,8/14/2009,2,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,9e51cc79-620c-48d7-b267-78e43c1ef6e4,8/14/2009,2,OS,overall survival,,,
clinicalStudies,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,GTC,generalized tonic-clonic,,,
clinicalStudies,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,RR MS,Relapsing-Remitting Multiple Sclerosis,,,
clinicalStudies,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,i.e.,intent-to-treat                                     population,,,
clinicalStudies,45DC1F57-A98A-495C-A5DF-855852A0112F,3/27/2008,1,DSS,Disability Scale Score,,,
clinicalStudies,b2608b36-03d1-46b6-9633-88d21306a317,11/18/2011,3218,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,b2608b36-03d1-46b6-9633-88d21306a317,11/18/2011,3218,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,b2608b36-03d1-46b6-9633-88d21306a317,11/18/2011,3218,CV,cardiovascular,,,
clinicalStudies,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,LDL,low density lipoprotein,,,
clinicalStudies,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,VLDL,very low density lipoprotein,,,
clinicalStudies,2e51aa89-684d-451e-b513-12b00bf9aea0,5/25/2010,2,TG,triglyceride,,,
clinicalStudies,7a0bba98-8f39-4020-b2a5-c487278a057a,4/29/2010,1,NYHA,New York Heart  Association,,,
clinicalStudies,528c67d0-129d-463f-a160-41f370dead6b,11/6/2009,1,AEDs,antiepileptic drugs,,,
clinicalStudies,8206d0ce-030e-4eb0-a1b2-16aeda592112,2/11/2010,5,PCPZ,prochlorperazine,,,
clinicalStudies,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,AUA,American Urological Association,,,
clinicalStudies,19592ac2-e193-47c4-b93e-e1d124d005d6,3/28/2011,3,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,AUA,American Urological Association,,,
clinicalStudies,e1b14939-7262-40dc-a334-2b3b72c88d47,5/24/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,8efb4c07-455b-4c91-b257-6fd43854454c,2/18/2011,2,CEA,carcino-embryogenic antigen,,,
clinicalStudies,8efb4c07-455b-4c91-b257-6fd43854454c,2/18/2011,2,ULN,upper limit of normal,,,
clinicalStudies,8efb4c07-455b-4c91-b257-6fd43854454c,2/18/2011,2,ANC,absolute neutrophil count,,,
clinicalStudies,8efb4c07-455b-4c91-b257-6fd43854454c,2/18/2011,2,DFS,disease-free survival,,,
clinicalStudies,8efb4c07-455b-4c91-b257-6fd43854454c,2/18/2011,2,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,VAS,Visual Analog Scores,,,
clinicalStudies,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,PCA,patient-controlled analgesia,,,
clinicalStudies,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,MTD,maximum tolerated dose,,,
clinicalStudies,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,5dfefed9-5b84-41f7-a8a4-e118f9518d3e,6/13/2011,2,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,5dfefed9-5b84-41f7-a8a4-e118f9518d3e,6/13/2011,2,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,5dfefed9-5b84-41f7-a8a4-e118f9518d3e,6/13/2011,2,CV,cardiovascular,,,
clinicalStudies,da748c7a-d2ae-1cbc-6f1a-8a6fc0402560,6/1/2009,1,SPID,sum of pain intensity difference,,,
clinicalStudies,99e0e848-f8f3-4b42-b880-8fbc42633948,4/29/2012,6,min,median,,,
clinicalStudies,727a5eb4-ac82-444d-8381-44c34ee3b895,5/12/2010,2,CGI,Clinical Global Impression,,,
clinicalStudies,727a5eb4-ac82-444d-8381-44c34ee3b895,5/12/2010,2,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,i.e.,improvement,,,
clinicalStudies,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,cure,clinical success rate,,,
clinicalStudies,ace05c47-3ed1-4b78-8d1c-279d1329fe3a,3/24/2010,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,5d103551-978f-472a-9c62-51e6e4dea068,5/17/2012,6,GERD,GASTROESOPHAGEAL REFLUX DISEASE,,,
clinicalStudies,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,da09f66e-9093-4e07-9820-e7d8ccd594f3,2/29/2012,8,min,median,,,
clinicalStudies,4983a17f-0ea9-4369-9626-6a2ca311210d,8/20/2010,8,EIB,exercise-induced bronchospasm,,,
clinicalStudies,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICP,intracranial pressure,,,
clinicalStudies,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,CSFP,cerebrospinal fluid pressure,,,
clinicalStudies,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,MAC,Monitored Anesthesia Care,,,
clinicalStudies,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,CABG,coronary artery bypass graft,,,
clinicalStudies,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICU,pressure.Intensive Care Unit,,,
clinicalStudies,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,cure,clinical success rate,,,
clinicalStudies,035002de-abec-4da4-8010-c42d186c04a2,6/9/2011,1,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,cbd3e1af-81f3-44f6-8e45-652deab7a508,8/11/2010,3,PCR,polymerase chain reaction,,,
clinicalStudies,cbd3e1af-81f3-44f6-8e45-652deab7a508,8/11/2010,3,min,"valign=""top"">&#160;&#160;&#160;&#160;Median",,,
clinicalStudies,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,dMAC,disseminated MAC,,,
clinicalStudies,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,CFU,colony forming units,,,
clinicalStudies,d0da9dd6-c691-4614-99c7-531b0bf34837,6/3/2010,4,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,94f9e516-6bf6-4e30-8dde-8833c25c2560,1/1/2009,6,CFUs,colony forming units,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,JIA,juvenile idiopathic arthritis,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,MCS,Mental Component Summary,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,JSN,Joint Space Narrowing,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,HAQ-DI,Health Assessment Questionnaire Disability Index,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,TSS,Total Sharp Score,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,IV,intravenous,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,Period B,Period A were randomized into the double-blind phase,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,CRP,C-reactive protein,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,ES,Erosion Score,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,SC,subcutaneous,,,
clinicalStudies,0836c6ac-ee37-5640-2fed-a3185a0b16eb,12/15/2011,9,PCS,Physical Component Summary,,,
clinicalStudies,21628112-0c47-11df-95b3-498d55d89593,1/18/2012,7,ITT,Intent-To-Treat,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,ie,interphalangeal joints,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,JSN,joint space narrowing,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,ASAS,Assessment in Ankylosing Spondylitis,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,VAS,Visual Analog Scale,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,BASFI,Bath Ankylosing Spondylitis Functional Index,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,TSS,Total Sharp Score,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,HAQ-DI,HAQ Disability Index,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,PASI,Psoriasis Area and Severity Index,,,
clinicalStudies,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,HAQ,Health Assessment Questionnaire,,,
clinicalStudies,1058e17c-9261-459c-a3e6-fae38d196c14,5/25/2011,10,Dose A,dose of approximately 0.033,,,
clinicalStudies,1058e17c-9261-459c-a3e6-fae38d196c14,5/25/2011,10,SGA,Small for Gestational Age,,,
clinicalStudies,3edcaae5-81bb-4a18-8bfd-834835187b13,3/18/2010,3,AED,antiepileptic drug,,,
clinicalStudies,3edcaae5-81bb-4a18-8bfd-834835187b13,3/18/2010,3,AEDs,antiepileptic drugs,,,
clinicalStudies,3edcaae5-81bb-4a18-8bfd-834835187b13,3/18/2010,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,3edcaae5-81bb-4a18-8bfd-834835187b13,3/18/2010,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,77f258d9-f380-4815-8140-0b2bfda3099c,3/6/2012,4,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,276c3f70-890e-4afa-af48-8630f9689785,5/28/2010,1,ZE,Zollinger-Ellison,,,
clinicalStudies,8b3fe1aa-7268-4fb9-aa5a-a865fcbb4155,6/13/2011,8,MCE,major coronary events,,,
clinicalStudies,8b3fe1aa-7268-4fb9-aa5a-a865fcbb4155,6/13/2011,8,MVE,major vascular events,,,
clinicalStudies,ff17b6d9-4a76-4cce-af88-aa8316018be6,7/6/2010,2,TOC,Test-of-Cure,,,
clinicalStudies,f31d1e8d-d0f3-4bfd-88b0-b2917365b0ca,12/8/2008,1,ie,improvement,,,
clinicalStudies,f31d1e8d-d0f3-4bfd-88b0-b2917365b0ca,12/8/2008,1,Treatment,treatment and are represented above,,,
clinicalStudies,f31d1e8d-d0f3-4bfd-88b0-b2917365b0ca,12/8/2008,1,CGIC,clinician's global impression of change,,,
clinicalStudies,4b260808-aeed-4223-bfc5-65e11259670e,5/20/2011,1,CBZ,carbamazepine,,,
clinicalStudies,878064ef-6a81-4999-8902-9da151e9c22d,4/3/2012,3739,ZE,Zollinger-Ellison,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,ER,estrogen receptor,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,LCIS,lobular carcinoma in situ,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,CI,confidence interval,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,RR,relative risk,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,BMD,bone mineral density,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,RMT,Royal Marsden Trial,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,HR,[Hazard Ratio,,,
clinicalStudies,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,EBCTCG,Early Breast Cancer Trialists' Collaborative Group,,,
clinicalStudies,508a406f-56cc-4032-99b9-0979fef6467a,8/10/2011,1,Met,Metformin Hydrochloride Tablets,,,
clinicalStudies,508a406f-56cc-4032-99b9-0979fef6467a,8/10/2011,1,mg/dL,mg Twice DailyPlaceboTotal Cholesterol,,,
clinicalStudies,508a406f-56cc-4032-99b9-0979fef6467a,8/10/2011,1,Glyb,Glyburide,,,
clinicalStudies,508a406f-56cc-4032-99b9-0979fef6467a,8/10/2011,1,mg/dL,mg Once DailyTotal Cholesterol,,,
clinicalStudies,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,CDRS-R,Childhood Depression Rating  Scale-Revised,,,
clinicalStudies,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,AED,antiepileptic drug,,,
clinicalStudies,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,AEDs,antiepileptic drugs,,,
clinicalStudies,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,BIS,Behavior and Ideation Scale,,,
clinicalStudies,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,MSS,Manic Syndrome Scale,,,
clinicalStudies,b26359c7-73fb-4397-8d18-5775b763e168,3/23/2011,3,MRS,Manic Rating Scale,,,
clinicalStudies,c9f59aa6-ab0b-47ef-bc98-189965936a27,9/16/2010,2,ICU,Intensive Care Unit,,,
clinicalStudies,0b0f0209-edbd-46f3-9bed-762cbea0d737,9/30/2011,5,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,0b0f0209-edbd-46f3-9bed-762cbea0d737,9/30/2011,5,GTC,generalized tonic-clonic,,,
clinicalStudies,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,TTP,time to progression,,,
clinicalStudies,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,i.e.,independence was first declared,,,
clinicalStudies,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,IWG,International Working Group,,,
clinicalStudies,65b28775-ee59-88cf-e4d8-372c6c79ad14,3/1/2011,2,lb.,<br/>&#160;&#160;&#160;&#160;Lean Body Mass,,,
clinicalStudies,45028573-13c4-4c8b-ae62-6c75bba97c81,8/2/2011,107,SE,Serum Calcium,,,
clinicalStudies,45028573-13c4-4c8b-ae62-6c75bba97c81,8/2/2011,107,EOT,End of Titration,,,
clinicalStudies,44a07041-456a-4b0b-9a8a-9e1715327d33,1/24/2012,1,min,median,,,
clinicalStudies,c17aa1e0-8b69-4c46-8502-9e3e07d461b3,7/7/2010,329,CGI,Clinical Global Impression,,,
clinicalStudies,c17aa1e0-8b69-4c46-8502-9e3e07d461b3,7/7/2010,329,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f,1/14/2010,1,im,intramuscular,,,
clinicalStudies,bc0a3a39-4ac3-47de-a388-9c3672e3e130,11/15/2011,4,ITT,intent-to-treat,,,
clinicalStudies,bc0a3a39-4ac3-47de-a388-9c3672e3e130,11/15/2011,4,RFS,Relapse-free survival,,,
clinicalStudies,bc0a3a39-4ac3-47de-a388-9c3672e3e130,11/15/2011,4,OS,overall survival,,,
clinicalStudies,24b45003-6e3e-4aeb-a091-2da8a9f8d4f8,4/29/2012,6,min,median,,,
clinicalStudies,53fd1302-9e1b-4e04-b06d-1a706547c388,4/30/2011,3,DVT,deep vein thrombosis,,,
clinicalStudies,53fd1302-9e1b-4e04-b06d-1a706547c388,4/30/2011,3,PE,pulmonary embolism,,,
clinicalStudies,53fd1302-9e1b-4e04-b06d-1a706547c388,4/30/2011,3,VTE,venous thromboembolic,,,
clinicalStudies,53fd1302-9e1b-4e04-b06d-1a706547c388,4/30/2011,3,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,5742fd25-09c5-4264-99c1-249ab823d3cd,6/7/2010,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,5742fd25-09c5-4264-99c1-249ab823d3cd,6/7/2010,1,PPG,postprandial plasma glucose,,,
clinicalStudies,accf9569-4b57-4e83-a7db-4e890a75d1ba,6/19/2012,11,MP,methylprednisolone,,,
clinicalStudies,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,139f86a4-75c5-4304-894c-8f8b8a396c78,7/27/2011,2,TOC,test-of-cure,,,
clinicalStudies,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,FATS,Familial Atherosclerosis Treatment Study,,,
clinicalStudies,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,RR,risk reductions,,,
clinicalStudies,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,ACAPS,Asymptomatic Carotid Artery Progression Study,,,
clinicalStudies,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,MARS,Monitored Atherosclerosis Regression Study,,,
clinicalStudies,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,IMT,intimal-medial thickness,,,
clinicalStudies,aac6c6a4-17a3-4643-bc89-db7259aca03a,1/24/2012,1,VAS,visual analog scale,,,
clinicalStudies,aac6c6a4-17a3-4643-bc89-db7259aca03a,1/24/2012,1,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,aac6c6a4-17a3-4643-bc89-db7259aca03a,1/24/2012,1,ACR,American College of Rheumatology,,,
clinicalStudies,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,Stage IA-IIA,Studies Targretin® gel was evaluated for the                                     treatment of patients with early stage,,,
clinicalStudies,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,841bf769-0148-42a8-a4d0-ff062b4734e8,1/1/2011,12,BMD,Bone Mineral Density,,,
clinicalStudies,533260c1-3d9f-4414-a097-068a215876d5,2/10/2012,4,TOC,test-of-cure,,,
clinicalStudies,234076ca-0dca-4670-aa6a-6f7c1f74ff3a,9/13/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,CGI,Clinical Global Impression,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,56788556-2088-4eea-9718-8c369e2efcb1,3/28/2011,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,0193ddae-c600-4e80-a578-4fe271231991,6/28/2010,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,0193ddae-c600-4e80-a578-4fe271231991,6/28/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,NFV,nelfinavir,,,
clinicalStudies,aadf0c91-7e95-46f8-a8f7-a98177831134,6/15/2011,1,ZE,Zollinger-Ellison,,,
clinicalStudies,21aea811-f47d-4a44-a552-dfc46d2773bf,8/31/2011,4,D/C,discontinuations,,,
clinicalStudies,208db529-ae52-462d-8fd2-775b11ce6350,9/18/2008,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,208db529-ae52-462d-8fd2-775b11ce6350,9/18/2008,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,AED,antiepileptic drug,,,
clinicalStudies,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,AEDs,antiepileptic drugs,,,
clinicalStudies,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,cb34c06d-bb42-4b3f-aee8-9c559417ed0a,3/15/2011,1,MCE,major coronary events,,,
clinicalStudies,cb34c06d-bb42-4b3f-aee8-9c559417ed0a,3/15/2011,1,MVE,major vascular events,,,
clinicalStudies,99c5d8c4-92d6-41b3-9caa-777fce558261,4/27/2011,24,i.e.,in FEV1 after exercise,,,
clinicalStudies,99c5d8c4-92d6-41b3-9caa-777fce558261,4/27/2011,24,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,99c5d8c4-92d6-41b3-9caa-777fce558261,4/27/2011,24,i.e.,interval,,,
clinicalStudies,99c5d8c4-92d6-41b3-9caa-777fce558261,4/27/2011,24,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,711f0b6a-b167-46b2-b0c6-dc6dea01737b,11/17/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,cea5f748-3127-4d36-83af-9ab3cf58503c,1/18/2012,7,ITT,Intent-To-Treat,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,CGI,Clinical Global Impression,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,OCD,Obsessive Compulsive Disorder,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,PPG,postprandial plasma glucose,,,
clinicalStudies,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,cUTI,complicated urinary tract infections,,,
clinicalStudies,b95172dd-ff18-4323-a605-ed5ae58a69ed,10/24/2011,10,TOC,test-of-cure,,,
clinicalStudies,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,TTP,time to progression,,,
clinicalStudies,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,DOXIL,doxorubicin HCl liposome injection,,,
clinicalStudies,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,SWOG,Southwest Oncology Group,,,
clinicalStudies,52459f70-e1f5-41bb-a9f4-e68ef5f5dcf5,11/3/2011,2,PP,Per-Protocol,,,
clinicalStudies,52459f70-e1f5-41bb-a9f4-e68ef5f5dcf5,11/3/2011,2,ITT,Intent-to-Treat,,,
clinicalStudies,d7434c6c-5a26-46e0-bade-0c54d71112fc,5/3/2012,2,i.e.,in FEV1 after exercise,,,
clinicalStudies,d7434c6c-5a26-46e0-bade-0c54d71112fc,5/3/2012,2,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,d7434c6c-5a26-46e0-bade-0c54d71112fc,5/3/2012,2,i.e.,interval,,,
clinicalStudies,d7434c6c-5a26-46e0-bade-0c54d71112fc,5/3/2012,2,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,bceaf33f-ddbe-47f6-a5bf-14662b3c58b5,3/31/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,SAH,subarachnoid hemorrhage,,,
clinicalStudies,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,III,initial bleed,,,
clinicalStudies,13671be1-b4b4-44c9-a27d-0727f937bb3c,5/2/2012,1,OBR,optimized background regimen,,,
clinicalStudies,13671be1-b4b4-44c9-a27d-0727f937bb3c,5/2/2012,1,HAART,highly active antiretroviral therapy regimen,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,RA,rheumatoid arthritis,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,OA,osteoarthritis,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,DMARDs,disease-modifying anti-rheumatic drugs,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,BP,blood pressure,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,GI,Gastrointestinal,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,CRP,C-reactive protein,,,
clinicalStudies,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,ACR,American College of Rheumatology,,,
clinicalStudies,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,TMP/SMX,trimethoprim?sulfamethoxazole,,,
clinicalStudies,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,TMTX/LV,trial comparing Neutrexin with concurrent leucovorin protection,,,
clinicalStudies,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,SVR,sustained virologic response,,,
clinicalStudies,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,SVR,Sustained Virologic Response,,,
clinicalStudies,47fdef53-4060-4372-9b48-fdb39a7e3fd3,4/6/2012,2,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,682a1210-b26e-426e-8ffe-d25d91bdd608,2/1/2012,8,CBZ,carbamazepine,,,
clinicalStudies,5aba19da-663f-4901-94e2-f438dba4841f,6/20/2011,2,ZE,Zollinger-Ellison,,,
clinicalStudies,5B555346-57CD-44BB-8A60-BF7124B62C30,5/11/2006,1,NAPR,nonallergic perennial rhinitis,,,
clinicalStudies,5B555346-57CD-44BB-8A60-BF7124B62C30,5/11/2006,1,APR,allergic perennial rhinitis,,,
clinicalStudies,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,TTP,<br/>Time to progression,,,
clinicalStudies,881eb80b-712e-4aa2-bd23-290a3e5db6cd,11/29/2011,3,MCE,major coronary events,,,
clinicalStudies,881eb80b-712e-4aa2-bd23-290a3e5db6cd,11/29/2011,3,MVE,major vascular events,,,
clinicalStudies,a6c0e721-2021-4983-a305-49bdf8f135a9,12/8/2008,1,mITT,modified intent-to-treat,,,
clinicalStudies,37bc2c81-ac05-4a7f-aa8f-cc138dd9b895,6/30/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,ab7226ce-ffda-42fa-abde-7c92ed676686,2/16/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,5ad82e30-50d8-450c-8a2a-b4b507ed1ce2,12/19/2011,6,ACT,activated clotting time,,,
clinicalStudies,5ad82e30-50d8-450c-8a2a-b4b507ed1ce2,12/19/2011,6,PCI,percutaneous coronary intervention,,,
clinicalStudies,ded64147-7a43-4055-accc-2c011828079d,6/8/2010,1,i.e.,improvement,,,
clinicalStudies,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,6f5930b2-ebe9-4b46-b0c2-52ae6626c253,2/24/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,84629614-e14c-47c9-b642-c6aa8b431929,4/7/2011,1,cure,clinical success rate,,,
clinicalStudies,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,NTG,nitroglycerin,,,
clinicalStudies,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,SNP,sodium nitroprusside,,,
clinicalStudies,095081a0-1398-11dc-82e1-0002a5d5c51b,12/31/2011,8,NIC,nicardipine,,,
clinicalStudies,9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00,8/19/2009,2,VAS,visual analog scale,,,
clinicalStudies,9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00,8/19/2009,2,EPT,electric pulp testers,,,
clinicalStudies,cf3d4110-3ae5-46fd-84f4-127fd2998dbb,8/23/2011,1,AED,antiepileptic drug,,,
clinicalStudies,cf3d4110-3ae5-46fd-84f4-127fd2998dbb,8/23/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,0e979fc0-353c-11dc-8dea-0002a5d5c51b,11/24/2010,9,iTNSS,instantaneous total nasal symptom score,,,
clinicalStudies,0e979fc0-353c-11dc-8dea-0002a5d5c51b,11/24/2010,9,rTNSS,reflective total nasal symptom score,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,IWG,International Working Group,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,CR,<br/>Complete <br/>Response,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,CR+PR,"<content styleCode=""bold"">Overall Response Rate",,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,PR,<br/>Partial<br/>Response,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,PR,<br/>Partial Response,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,CR,Complete Response,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,CR,<br/>Complete Response,,,
clinicalStudies,acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2,3/30/2010,3,CR+PR,"<content styleCode=""bold"">Duration of Response</content>                                     <br/>Median time to",,,
clinicalStudies,a83ff94d-956e-48de-bcb2-affff1c6f161,8/24/2009,1,CEA,carcino-embryogenic antigen,,,
clinicalStudies,a83ff94d-956e-48de-bcb2-affff1c6f161,8/24/2009,1,ULN,upper limit of normal,,,
clinicalStudies,a83ff94d-956e-48de-bcb2-affff1c6f161,8/24/2009,1,ANC,absolute neutrophil count,,,
clinicalStudies,a83ff94d-956e-48de-bcb2-affff1c6f161,8/24/2009,1,DFS,disease-free survival,,,
clinicalStudies,a83ff94d-956e-48de-bcb2-affff1c6f161,8/24/2009,1,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,BIS,Behavior and Ideation Scale,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,CPS,complex partial seizures,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,AED,antiepilepsy drug,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,MSS,Manic Syndrome Scale,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,i.e.,improvement,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,TID,three divided doses,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,GAS,Global Assessment Scale,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,MRS,Manic Rating Scale,,,
clinicalStudies,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,BPRS-A,Brief Psychiatric Rating Scale,,,
clinicalStudies,88c9d1ca-f3a8-4078-8de7-21fd9040dd20,2/14/2012,2,ITT,Intent-To-Treat,,,
clinicalStudies,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,CDRS-R,Children’s Depression Rating Scale - Revised,,,
clinicalStudies,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,MADRS,Montgomery Asberg Depression Rating Scale,,,
clinicalStudies,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,HAM-A,Hamilton Anxiety Scale,,,
clinicalStudies,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,ITT,intent-to-treat,,,
clinicalStudies,a7975871-46a6-4e9b-a8b5-38bfcb465f0e,5/30/2012,16,CE,clinically evaluable,,,
clinicalStudies,7e3fc83f-e322-44a1-b0c3-30e6292b92d9,4/12/2010,1,MCE,major coronary events,,,
clinicalStudies,7e3fc83f-e322-44a1-b0c3-30e6292b92d9,4/12/2010,1,MVE,major vascular events,,,
clinicalStudies,a70be430-21fa-49a4-84c1-134621ee2f4f,2/24/2012,2,AEDs,antiepileptic drugs,,,
clinicalStudies,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,CGI,Clinical Global Impression,,,
clinicalStudies,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,Y-BOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,OCD,obsessive compulsive disorder,,,
clinicalStudies,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,CGI,Clinical Global Impressions,,,
clinicalStudies,bc747f6d-f52c-4dcb-bda5-2d0a9f954147,5/17/2012,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,5d86f813-e784-4490-a842-bcb78eb0d9a4,8/1/2011,4,ITT,intent-to-treat,,,
clinicalStudies,5d86f813-e784-4490-a842-bcb78eb0d9a4,8/1/2011,4,PHN,postherpetic neuralgia,,,
clinicalStudies,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,AED,antiepileptic drug,,,
clinicalStudies,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,PGTC,primary generalized tonic-clonic,,,
clinicalStudies,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,OCD,Obsessive Compulsive Disorder,,,
clinicalStudies,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,CDRS-R,Childhood Depression Rating  Scale-Revised,,,
clinicalStudies,e41e7bf5-86b4-4b25-b061-407c88449372,7/1/2011,15,ZE,Zollinger-Ellison,,,
clinicalStudies,aa445f68-1e55-a587-76dc-def068bc9c74,12/11/2011,3,MTD,maximum tolerated dose,,,
clinicalStudies,10db92f9-2300-4a80-836b-673e1ae91610,12/8/2011,4,SD,standard deviation,,,
clinicalStudies,27355e18-e832-4639-93dc-d6995ff193d6,3/8/2012,4,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,27355e18-e832-4639-93dc-d6995ff193d6,3/8/2012,4,TTP,Time to progression,,,
clinicalStudies,27355e18-e832-4639-93dc-d6995ff193d6,3/8/2012,4,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,SDS,Sheehan Disability Scale,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,CGI-BP,Clinical Global Impression - Bipolar,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,CGI-I,Clinical Global Impression-Improvement,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,Y-MRS,Young Mania  Rating Scale,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,CGI-I,Clinical Global Impression of Improvement,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,CGI,Clinical Global  Impression,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,ABC,Aberrant Behavior  Checklist,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,MDD,major  depressive disorder,,,
clinicalStudies,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,TURP,transurethral resection of the prostate,,,
clinicalStudies,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,CABG,coronary artery bypass graft,,,
clinicalStudies,1982fbca-fb5f-4e14-b837-e0c59028dad7,11/3/2010,1,AED,antiepileptic drug,,,
clinicalStudies,1982fbca-fb5f-4e14-b837-e0c59028dad7,11/3/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,1982fbca-fb5f-4e14-b837-e0c59028dad7,11/3/2010,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,1982fbca-fb5f-4e14-b837-e0c59028dad7,11/3/2010,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,dfc41fcd-c5ba-4b25-b647-cf04d3988b3e,2/22/2012,4,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,dfc41fcd-c5ba-4b25-b647-cf04d3988b3e,2/22/2012,4,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,6543c6ba-852e-40fb-b7ec-1331b9c83656,12/1/2010,1,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,144db6ad-c4cf-45ea-b27c-a76a319dba38,12/9/2009,2,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,144db6ad-c4cf-45ea-b27c-a76a319dba38,12/9/2009,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,b50667e4-5ebc-4968-a646-d605058dbef0,6/27/2012,12,MSKCC,Memorial Sloan Kettering Cancer Center,,,
clinicalStudies,b50667e4-5ebc-4968-a646-d605058dbef0,6/27/2012,12,PFS,progression-free survival,,,
clinicalStudies,b50667e4-5ebc-4968-a646-d605058dbef0,6/27/2012,12,RCC,renal cell carcinoma,,,
clinicalStudies,2cd2a198-36e4-43d7-a7b2-dc40620ad514,2/21/2012,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,7494496c-02fc-4509-ae9e-cbd000fa45a1,4/1/2011,7,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,7494496c-02fc-4509-ae9e-cbd000fa45a1,4/1/2011,7,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,7494496c-02fc-4509-ae9e-cbd000fa45a1,4/1/2011,7,CV,cardiovascular,,,
clinicalStudies,4471223e-9023-457e-be2e-8e4e0c2d94d1,12/20/2010,5,PRSP,penicillin-resistant Streptococcus pneumoniae,,,
clinicalStudies,4471223e-9023-457e-be2e-8e4e0c2d94d1,12/20/2010,5,MDRSP*,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,58b66be7-e0ec-42c5-1383-45aadcd6c307,4/18/2012,10,BSC,Best Supportive Care,,,
clinicalStudies,afec67a9-ae16-4f48-bc0b-5331835e8aa2,12/30/2009,1,DVT,deep vein thrombosis,,,
clinicalStudies,afec67a9-ae16-4f48-bc0b-5331835e8aa2,12/30/2009,1,PE,pulmonary embolism,,,
clinicalStudies,afec67a9-ae16-4f48-bc0b-5331835e8aa2,12/30/2009,1,VTE,venous thromboembolic,,,
clinicalStudies,afec67a9-ae16-4f48-bc0b-5331835e8aa2,12/30/2009,1,STEMI,ST-segment elevation myocardial infarction,,,
clinicalStudies,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,SFR,stenosis flow reserve,,,
clinicalStudies,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,99265e39-af23-43eb-a552-305f0a218fdf,8/1/2011,18,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,01a8bfdf-0fac-4e86-a299-daf64a2e885e,5/29/2009,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,01a8bfdf-0fac-4e86-a299-daf64a2e885e,5/29/2009,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,3fc68fa7-3441-478f-a094-5afb7cdecd1f,4/27/2012,1,SVR,Sustained Virologic Response,,,
clinicalStudies,D1915D2E-056B-44BD-4A9C-FC9E41AB10CE,6/23/2008,1,i.e.,infection,,,
clinicalStudies,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,LDL,low density lipoprotein,,,
clinicalStudies,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,VLDL,very low density lipoprotein,,,
clinicalStudies,c850d4e4-2dce-4a03-964f-b9397ec20514,5/9/2011,1,TG,triglyceride,,,
clinicalStudies,1b9dfa57-f295-4038-8aec-8efc54817d07,4/24/2012,12,EGSA,Evaluator's Global Severity Assessment,,,
clinicalStudies,d4550afa-977e-426e-814b-705435d2af81,1/11/2011,5,HR,[Hazard Ratio,,,
clinicalStudies,fa54df87-41d5-96a7-07b6-e700b640bc66,12/1/2010,1,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,fa54df87-41d5-96a7-07b6-e700b640bc66,12/1/2010,1,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,fa54df87-41d5-96a7-07b6-e700b640bc66,12/1/2010,1,CV,cardiovascular,,,
clinicalStudies,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,AML,acute myeloid leukemia,,,
clinicalStudies,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,DNR,daunorubicin,,,
clinicalStudies,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,IDR,idarubicin,,,
clinicalStudies,d31c9625-30c8-4efd-a31f-13930705d573,10/13/2011,14,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,CHR,complete hematologic response,,,
clinicalStudies,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,NEL,no evidence of leukemia,,,
clinicalStudies,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,MCyR,major cytogenetic response,,,
clinicalStudies,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,MaHR,major hematologic response,,,
clinicalStudies,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,10/7/2011,22,CCyR,complete cytogenetic response,,,
clinicalStudies,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,ITT,intent-to-treat,,,
clinicalStudies,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,PHN,postherpetic neuralgia,,,
clinicalStudies,b38e1880-9152-4ca4-93e3-b9f6d14db958,7/7/2011,1,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,MDG,mean daily glucose,,,
clinicalStudies,76c7e13d-37a0-4131-a1f1-fd5af0f60d3e,9/30/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,MCE,major coronary events,,,
clinicalStudies,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,MVE,major vascular events,,,
clinicalStudies,08982e49-d2eb-4b25-b01a-1be52fd669ef,4/11/2012,7,BSA,body surface area,,,
clinicalStudies,6c47a65b-2665-4391-ad69-25c4f5a8b010,2/18/2009,3,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,6c47a65b-2665-4391-ad69-25c4f5a8b010,2/18/2009,3,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,d9d74915-6606-4570-9c52-c4001d3177de,9/30/2011,9,MCS,mental component summary,,,
clinicalStudies,d9d74915-6606-4570-9c52-c4001d3177de,9/30/2011,9,PCS,physical component summary,,,
clinicalStudies,d9d74915-6606-4570-9c52-c4001d3177de,9/30/2011,9,SF-36,Short Form-36,,,
clinicalStudies,d9d74915-6606-4570-9c52-c4001d3177de,9/30/2011,9,HAQ,Health Assessment Questionnaire,,,
clinicalStudies,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,ADOPT,A Diabetes Outcome Progression Trial,,,
clinicalStudies,ea79f802-e9ac-480b-91e6-1e3900b11803,1/3/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,ea79f802-e9ac-480b-91e6-1e3900b11803,1/3/2011,1,BAO,Basal Acid Output,,,
clinicalStudies,e8323922-191d-4bfc-8871-fbe15a8a7b58,2/7/2012,2,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,ea29921d-ae91-4a1b-a8e5-5c00a16be127,8/31/2011,1,TOC,test-of-cure,,,
clinicalStudies,033abda0-1ddc-4da6-99e3-2721db7ea3af,6/29/2010,1,HR,[Hazard Ratio,,,
clinicalStudies,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,MRI,magnetic resonance imaging,,,
clinicalStudies,f1889599-be14-49af-8781-5594e9bd026b,4/9/2012,1,DRC,Data Review Committee,,,
clinicalStudies,c5f46f1b-3594-4ff4-b208-a7b9f830e87e,2/27/2012,3591,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,c5f46f1b-3594-4ff4-b208-a7b9f830e87e,2/27/2012,3591,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,c5f46f1b-3594-4ff4-b208-a7b9f830e87e,2/27/2012,3591,CV,cardiovascular,,,
clinicalStudies,1fd148fb-0fbc-4b6f-b790-23546fb46a71,10/4/2011,8,AC,and cyclophosphamide,,,
clinicalStudies,48f8aa83-e043-41b8-9a20-dbb098045895,4/19/2012,1,DEXA,Dual Energy X-ray Absorptiometry,,,
clinicalStudies,df661166-325d-4071-9bc1-f7bf992996d2,10/6/2010,1,AEDs,antiepileptic drugs,,,
clinicalStudies,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,MCE,major coronary events,,,
clinicalStudies,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,MVE,major vascular events,,,
clinicalStudies,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,MIC,minimal inhibitory concentration,,,
clinicalStudies,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,cUTI,complicated urinary tract infections,,,
clinicalStudies,23452a86-8ae2-4165-aca6-056b3d2c6462,7/29/2011,70,AED,antiepileptic drug,,,
clinicalStudies,23452a86-8ae2-4165-aca6-056b3d2c6462,7/29/2011,70,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,MITT,modified Intent-to-Treat,,,
clinicalStudies,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,cure,clinical success rate,,,
clinicalStudies,f5b6daad-b5a9-462d-8e10-db22a7af1c72,8/24/2010,4,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,3cdffcf9-b5fa-4622-9e83-ce29ececcc93,5/18/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,3cdffcf9-b5fa-4622-9e83-ce29ececcc93,5/18/2011,1,BAO,Basal Acid Output,,,
clinicalStudies,0f55b9ec-2de6-431d-8bc3-1ed418051cd8,3/30/2011,1,AUA,American Urological Association,,,
clinicalStudies,c62e99a1-0612-4c76-9c72-80c6b78e3567,5/10/2011,10,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,8/3/2007,1,sPS,synthetic porcine secretin,,,
clinicalStudies,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,8/3/2007,1,sHS,synthetic human secretin,,,
clinicalStudies,16a686e6-63f4-478f-a673-02dde9474eda,6/22/2010,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,99130b62-7ef7-4ef1-b717-de0798d39aba,9/2/2010,1,ICU,Intensive Care Unit,,,
clinicalStudies,6c77e113-37e3-4c86-834a-6355bb1020e9,10/29/2010,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,6c77e113-37e3-4c86-834a-6355bb1020e9,10/29/2010,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,ULN,upper limit of normal,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,NCI,National Cancer Institute,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,DFS,disease-free survival,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,KPS,"Rrule"">Karnofsky Performance Status",,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,CEA,carcino-embyrogenic antigen,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,NCCTG,North Central Cancer Treatment Group,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,RECIST,Response Evaluation Criteria in Solid Tumors,,,
clinicalStudies,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,OS,overall survival,,,
clinicalStudies,2e97aa6d-09f7-46df-9499-63db7e9bac35,6/22/2012,11,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,2e97aa6d-09f7-46df-9499-63db7e9bac35,6/22/2012,11,SBR,staying on the baseline antiretroviral regimen,,,
clinicalStudies,2e97aa6d-09f7-46df-9499-63db7e9bac35,6/22/2012,11,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalStudies,bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4,9/8/2010,1,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4,9/8/2010,1,total,the risk of death or hospitalization,,,
clinicalStudies,bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4,9/8/2010,1,SBP,systolic blood pressure,,,
clinicalStudies,bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4,9/8/2010,1,total,the combined end points of all-cause mortality plus hospitalization,,,
clinicalStudies,710bede3-2742-4413-8772-63b2a955fab5,4/6/2012,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,CCyR,complete cytogenetic response rate,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,Ph+ ALL,Philadelphia chromosome positive acute lymphoblastic leukemia,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,HPF,high power fields,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,CHR,Complete hematologic response,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,HES/CEL,Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,PFS,progression-free survival,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,SM,systemic mastocytosis,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,PCyR,partial cytogenetic response,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,GIST,gastrointestinal stromal tumors,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,RFS,Recurrence-free survival,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,OS,overall survival,,,
clinicalStudies,211ef2da-2868-4a77-8055-1cb2cd78e24b,1/31/2012,9,SWOG,Southwestern Oncology Group,,,
clinicalStudies,b35e3633-8893-4b0b-af1e-92e342557199,8/22/2011,6,KPS,Karnofsky Performance Status,,,
clinicalStudies,b35e3633-8893-4b0b-af1e-92e342557199,8/22/2011,6,NSCLC,Non-Small Cell Lung Cancer,,,
clinicalStudies,b0f33792-dd96-40cc-a28e-acdcdca2f4b8,4/22/2011,1,i.e.,improvement,,,
clinicalStudies,c5a906d1-b276-48d0-b58e-b45f4c5aa067,8/19/2011,6,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,9d42adca-0dd7-4df7-864d-5a7feee52130,7/22/2011,6,PCR,Polymerase Chain Reaction,,,
clinicalStudies,9d42adca-0dd7-4df7-864d-5a7feee52130,7/22/2011,6,SC,Subcutaneous,,,
clinicalStudies,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,BIS,Behavior and Ideation Scale,,,
clinicalStudies,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,CPS,complex partial seizures,,,
clinicalStudies,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,AED,antiepilepsy drug,,,
clinicalStudies,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,MSS,Manic Syndrome Scale,,,
clinicalStudies,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,MRS,Manic Rating Scale,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,TDM,to distant metastasis,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,TTP,Time to progression,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,PCA,Primary Core Analysis,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,STA,Sequential Treatments Analysis,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,DFS,disease-free survival,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,OS,overall survival,,,
clinicalStudies,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,TBR,to breast cancer recurrence,,,
clinicalStudies,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,MCE,major coronary events,,,
clinicalStudies,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HPS,Heart Protection Study,,,
clinicalStudies,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,MVE,major vascular events,,,
clinicalStudies,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,MCE,major coronary events,,,
clinicalStudies,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,MVE,major vascular events,,,
clinicalStudies,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,min,Median Percent Change,,,
clinicalStudies,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,d385e07a-c16f-4aef-8e55-af95bd1c7526,4/12/2012,5,min,median,,,
clinicalStudies,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,AEDs,antiepileptic drugs,,,
clinicalStudies,b4678d25-f888-84f9-be8e-7f61107a8dc9,1/7/2011,1,AED,antiepileptic drug,,,
clinicalStudies,b4678d25-f888-84f9-be8e-7f61107a8dc9,1/7/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,b4678d25-f888-84f9-be8e-7f61107a8dc9,1/7/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,b4678d25-f888-84f9-be8e-7f61107a8dc9,1/7/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,ef45afc6-6886-485a-aefa-97827ffae024,5/4/2011,1,dMAC,disseminated MAC,,,
clinicalStudies,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,82b77d74-085f-45ac-a7dd-1f5c038bf406,12/25/2011,15,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,82b77d74-085f-45ac-a7dd-1f5c038bf406,12/25/2011,15,TTP,Time to progression,,,
clinicalStudies,82b77d74-085f-45ac-a7dd-1f5c038bf406,12/25/2011,15,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,Median,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,"Botrule"">Median",,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,REGRESS,Regression Growth Evaluation Statin Study,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,KAPS,Kuopio Atherosclerosis Prevention Study,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,LIPID,Long-term Intervention with Pravastatin in Ischemic Disease,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TIA,transient ischemic attack,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,PLAC I,Pravastatin Limitation of Atherosclerosis in the Coronary Arteries,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TG,triglycerides,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,CARE,Cholesterol and Recurrent Events,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,CHD,coronary heart disease,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,MI,myocardial infarction,,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,"Botrule"">Median % Change",,,
clinicalStudies,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,min,median,,,
clinicalStudies,A15D0DF0-3BCA-4FBC-A1D6-34A88C9A9665,3/30/2007,1,IGSS,Investigator’s Global Severity Score,,,
clinicalStudies,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,CGI,Clinical Global Impression,,,
clinicalStudies,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,YMRS,Young Mania Rating Scale,,,
clinicalStudies,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,4ACDFA96-BD62-4289-8454-276D3886A1A7,12/13/2006,3,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,4818abc4-2797-4248-b7d7-5cb4b5cdcf6a,12/14/2010,1,TTP,Time to progression,,,
clinicalStudies,4818abc4-2797-4248-b7d7-5cb4b5cdcf6a,12/14/2010,1,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,MCE,major coronary events,,,
clinicalStudies,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,MVE,major vascular events,,,
clinicalStudies,761834c2-6b61-4583-84c2-f1ca4a97c4f2,2/29/2012,5,AD,Alzheimer’s disease,,,
clinicalStudies,991d2b13-f491-4a25-8ea7-5136d0585874,3/24/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,5ddba454-f3e6-43c2-a7a6-58365d297213,2/29/2012,10,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,5ddba454-f3e6-43c2-a7a6-58365d297213,2/29/2012,10,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,5ddba454-f3e6-43c2-a7a6-58365d297213,2/29/2012,10,CV,cardiovascular,,,
clinicalStudies,47ef5501-1408-41fa-b0e5-f078f18129f5,7/30/2009,1,i.e.,improvement,,,
clinicalStudies,c2ee4728-3388-4ad7-8512-e632b69557d4,2/7/2012,2,OBT,optimized background therapy,,,
clinicalStudies,3e463126-78a9-4ec5-904c-0424a64d8ae8,5/24/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,f0ac27f6-d7e1-42e4-8cf1-95a0db50dcbf,5/25/2011,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,CGI,Clinical Global Impression,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,OCD,obsessive compulsive disorder,,,
clinicalStudies,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CGI,Clinical Global Impression,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalStudies,8725c835-443a-474a-98b9-7d23991a161f,7/31/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,fe64cc25-d490-48b8-afa4-88cd9c3f6ee0,12/21/2011,5,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,10a49211-025b-4d63-b60c-fadfd9b731c0,12/28/2010,1,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,3495a71a-cc04-4776-851f-f185956f32af,1/6/2012,5,CCR,conventional care regimens,,,
clinicalStudies,3495a71a-cc04-4776-851f-f185956f32af,1/6/2012,5,BSC,best supportive care,,,
clinicalStudies,520428f1-2cd5-447f-8782-c8505ce65b72,2/28/2012,10,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,792caee6-6abf-46af-818a-b46a7d85e23c,4/17/2012,1,BSC,Best Supportive Care,,,
clinicalStudies,e90dac00-81f3-4d67-8718-c290136ebd12,3/12/2010,1,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,ZDV,zidovudine,,,
clinicalStudies,4e92bf71-0ba2-4276-af81-5e61b9122044,6/3/2011,1,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,4e92bf71-0ba2-4276-af81-5e61b9122044,6/3/2011,1,TTP,Time to progression,,,
clinicalStudies,4e92bf71-0ba2-4276-af81-5e61b9122044,6/3/2011,1,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,GTC,generalized tonic-clonic,,,
clinicalStudies,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,63773349-0295-4d56-a72e-0d7cade88ddb,10/20/2010,3,ITT,intent-to-treat,,,
clinicalStudies,63773349-0295-4d56-a72e-0d7cade88ddb,10/20/2010,3,LOCF,last observation carried forward,,,
clinicalStudies,5e47c25f-c865-470d-8ea3-b4f9ca2ba5ba,7/20/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,7fcb451e-4834-4905-852b-ec1efe9115f0,2/29/2012,8,min,median,,,
clinicalStudies,580da6bb-b4e8-40a3-bc21-87985d687354,9/9/2011,1,HPS,Heart Protection Study,,,
clinicalStudies,580da6bb-b4e8-40a3-bc21-87985d687354,9/9/2011,1,95% CI,278.6(51.8)211.9(49)46.9(11.9)90(50.7)186.3(38.1)Simvastatin24 Weeks106% Change from Baseline,,,
clinicalStudies,666e8b22-f519-460b-a774-88a621d56139,4/1/2011,1,SVR,Sustained Virologic Response,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,HRT,Hormone Replacement Therapy,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,CI,confidence interval,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,LCIS,lobular carcinoma in situ,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,RR,relative risk,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,BMD,bone mineral density,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,RMT,Royal Marsden Trial,,,
clinicalStudies,7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0,1/9/2007,3,DCIS,ductal carcinoma in situ,,,
clinicalStudies,c674e1bc-5c8e-4c59-8de5-c7fa5306706d,1/26/2011,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,c674e1bc-5c8e-4c59-8de5-c7fa5306706d,1/26/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,a1998c1d-8337-4f00-8dcb-af3b54d39b77,2/16/2011,3,ASQ,Ages & Stages Questionnaire,,,
clinicalStudies,0f85d6e4-35de-4e25-b4aa-af9a0ca24cf8,8/16/2011,7,MTZ,metronidazole,,,
clinicalStudies,0f85d6e4-35de-4e25-b4aa-af9a0ca24cf8,8/16/2011,7,BSS,bismuth subsalicylate,,,
clinicalStudies,0f85d6e4-35de-4e25-b4aa-af9a0ca24cf8,8/16/2011,7,TCN,tetracycline hydrochloride,,,
clinicalStudies,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,MTD,maximum tolerated dose,,,
clinicalStudies,ab115cc4-43cd-4a59-aa01-89e356ce3a08,7/4/2012,1,ITT,intent-to-treat,,,
clinicalStudies,ab115cc4-43cd-4a59-aa01-89e356ce3a08,7/4/2012,1,RFS,Relapse-free survival,,,
clinicalStudies,ab115cc4-43cd-4a59-aa01-89e356ce3a08,7/4/2012,1,OS,overall survival,,,
clinicalStudies,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,ALL,acute lymphoblastic leukemia,,,
clinicalStudies,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,CML,chronic myelogenous leukemia,,,
clinicalStudies,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,AML,acute myelogenous leukemia,,,
clinicalStudies,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,CY/TBI,cyclophosphamide/total body irradiation,,,
clinicalStudies,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,BU/CY,busulfan/cyclophosphamide,,,
clinicalStudies,895c7f90-2c53-43c3-ae4d-31d858e11eff,3/16/2007,1,ACE,angiotensin-converting enzyme,,,
clinicalStudies,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,PE,pulmonary embolism,,,
clinicalStudies,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,ITT,intent-to-treat,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,RAEB,RA with excess blasts,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,RAEB-T,RAEB in transformation,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,RA,refractory anemia,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,AML,acute myelogenous leukemia,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,MDS,myelodysplastic syndromes,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,RARS,RA with ringed sideroblasts,,,
clinicalStudies,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,CMMoL,chronic myelomonocytic leukemia,,,
clinicalStudies,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,MSLT,Multiple Sleep Latency Test,,,
clinicalStudies,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,DSST,Digit Symbol Substitution Test,,,
clinicalStudies,0f799e5c-f782-4f3d-bdb6-52bd413a19cf,10/27/2009,2,VAS,visual analog scale,,,
clinicalStudies,d370635f-5530-4d42-a019-d76b61639787,9/9/2011,14,SVR,Sustained Virologic Response,,,
clinicalStudies,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,MCE,major coronary events,,,
clinicalStudies,2062b3d3-580f-46f8-94b6-4bdecb7b53b1,4/25/2012,6,MVE,major vascular events,,,
clinicalStudies,61b34d13-3b8b-4491-b5a3-e9740b2aaccb,4/27/2010,1,ZE,Zollinger-Ellison,,,
clinicalStudies,3ca9df05-a506-4ec8-a4fe-320f1219ab21,12/19/2011,6,AEDs,antiepileptic drugs,,,
clinicalStudies,42d81ec3-0788-40c3-8eec-e50403f0ab58,4/20/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,ABS,acute bacterial sinusitis,,,
clinicalStudies,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,MDRSP,multi-drug resistant Streptococcus pneumoniae,,,
clinicalStudies,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,EPS,expressed prostatic secretion,,,
clinicalStudies,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,MIC,minimal inhibitory concentration,,,
clinicalStudies,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,TOC,test-of-cure,,,
clinicalStudies,1b51c34d-9631-4520-83af-6f6fb21a58a4,9/1/2008,3,CR,Complete Response,,,
clinicalStudies,e007e7c6-7d5d-4d5c-9a6c-c82d9e9cfaf7,11/19/2010,1,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,e007e7c6-7d5d-4d5c-9a6c-c82d9e9cfaf7,11/19/2010,1,min,median,,,
clinicalStudies,553777EE-8ECA-4A89-89B7-317A3E9084F6,9/16/2007,1,HbA1c,hemoglobin A1c,,,
clinicalStudies,553777EE-8ECA-4A89-89B7-317A3E9084F6,9/16/2007,1,PPG,postprandial plasma glucose,,,
clinicalStudies,00bf4e02-633e-453b-8c3c-fb8b1d829887,3/21/2012,2,min,median,,,
clinicalStudies,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,MCE,major coronary events,,,
clinicalStudies,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,MVE,major vascular events,,,
clinicalStudies,FBB95791-D582-4FB4-81DF-3084EB069B10,12/26/2006,1,VAS,visual analog scale,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,AD,Alzheimer’s disease,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,PE,pulmonary embolism,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,MI,myocardial infarction,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,WHI,Women's Health Initiative,,,
clinicalStudies,fd0c0836-5d23-2183-da81-9dc7f4287052,5/19/2011,15,VaD,vascular dementia,,,
clinicalStudies,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,MPA,medroxyprogesterone acetate,,,
clinicalStudies,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,CHD,coronary heart disease,,,
clinicalStudies,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,PB,pulmonary embolism,,,
clinicalStudies,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,BMD,bone mineral density,,,
clinicalStudies,2e4778d8-8798-4da1-bb33-1aa1414b5809,4/21/2011,1,i.e.,improvement,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,HRT,Hormone Replacement Therapy,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,CI,confidence interval,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,LCIS,lobular carcinoma in situ,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,RR,relative risk,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,BMD,bone mineral density,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,RMT,Royal Marsden Trial,,,
clinicalStudies,407a372d-4448-4d53-afd4-eb0e74bbc336,6/29/2012,7,DCIS,ductal carcinoma in situ,,,
clinicalStudies,9736d9b1-9dca-36a3-5324-3bbeda537aca,2/1/2012,8,min,Median,,,
clinicalStudies,9736d9b1-9dca-36a3-5324-3bbeda537aca,2/1/2012,8,min,"Botrule"">Median",,,
clinicalStudies,9736d9b1-9dca-36a3-5324-3bbeda537aca,2/1/2012,8,min,"Botrule"">Median % Change",,,
clinicalStudies,9736d9b1-9dca-36a3-5324-3bbeda537aca,2/1/2012,8,min,median,,,
clinicalStudies,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,AED,antiepileptic drug,,,
clinicalStudies,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,8609ed02-0b30-4c82-bab1-4d51d92ec224,7/30/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,6393e997-7080-4ce6-8a34-2f80b48f5a3a,6/1/2011,1,rTNSS,Reflective Total Nasal Symptom Score,,,
clinicalStudies,6393e997-7080-4ce6-8a34-2f80b48f5a3a,6/1/2011,1,rTNSS,reflective total nasal symptom score,,,
clinicalStudies,983bd055-d289-4fb1-a69c-5a7f178a07d1,5/4/2011,1,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,HRT,Hormone Replacement Therapy,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,ER,estrogen receptor,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,CI,confidence interval,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,BCPT,Breast Cancer Prevention Trial,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,RR,relative risk,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,EBCTCG,Early Breast Cancer Trialists Collaborative Group,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,BMD,bone mineral density,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,RMT,Royal Marsden Trial,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,ductal carcinoma in situ,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,HR,[Hazard Ratio,,,
clinicalStudies,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,EBCTCG,Early Breast Cancer Trialists’ Collaborative Group,,,
clinicalStudies,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,PCI,percutaneous coronary intervention,,,
clinicalStudies,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,PTCA,percutaneous,,,
clinicalStudies,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,CHF,,,,
clinicalStudies,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,CABG,coronary artery bypass graft,,,
clinicalStudies,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,IABP,intra-aortic,,,
clinicalStudies,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,38bf22b9-59d5-4a05-b517-24e48a61d1cc,5/31/2011,1,cure,clinical success rate,,,
clinicalStudies,e6d22e3b-9343-408f-9a86-59097f6e8983,10/18/2011,2,MCE,major coronary events,,,
clinicalStudies,e6d22e3b-9343-408f-9a86-59097f6e8983,10/18/2011,2,MVE,major vascular events,,,
clinicalStudies,0d7ec602-fd6a-4750-a5bf-d64b614391d5,6/14/2010,5,PCPZ,prochlorperazine,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,rPGA,relative Physician's Global Assessment,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,JSN,joint space narrowing,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,AZA,azathioprine,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,PUVA,plus ultraviolet A treatment,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,sPGA,Static Physician Global Assessment,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,vdH-S,van der Heijde-Sharp,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,BSA,body surface area,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,HAQ-DI,HAQ Disability Index,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,PCDAI,Pediatric Crohn's Disease Activity Index,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,6-MP,6-mercaptopurine,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,PASI,Psoriasis Area and Severity Index,,,
clinicalStudies,a0a046c1-056d-45a9-bfd9-13b47c24f257,10/1/2011,15,IBDQ,inflammatory bowel disease questionnaire,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CGI-I,Clinical Global Impression-Global Improvement Scale,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,PTSD,Posttraumatic Stress Disorder,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CGI,Clinical Global Impression,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,CAPS-2,Clinician-Administered PTSD Scale Part 2,,,
clinicalStudies,32fd11aa-2996-496d-ac3b-76a6afe22e3c,8/11/2010,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,502fac46-67a6-4c4d-a666-65305d50d7a1,8/29/2011,1,AED,antiepileptic drug,,,
clinicalStudies,502fac46-67a6-4c4d-a666-65305d50d7a1,8/29/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,CGI,Clinical Global Impression,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,YMRS,Young Mania Rating Scale,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,f04711a7-652e-427d-a7f5-65d4a1c3cae4,4/10/2012,6,REA,Restriction Endonuclease Analysis,,,
clinicalStudies,4cd8947e-a20e-4d4e-8761-c45bc98899a3,3/12/2012,1,AEDs,antiepileptic drugs,,,
clinicalStudies,253b9eeb-3be5-47d6-a76b-9889bd3c55ed,7/29/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,22367ff1-5edf-429a-955a-728e42695f60,11/4/2011,1,EIB,exercise-induced bronchospasm,,,
clinicalStudies,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,CALGB,Cancer and Leukemia Group B,,,
clinicalStudies,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,SDS,Symptom Distress Scale,,,
clinicalStudies,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,NPCP,National Prostate Cancer Project,,,
clinicalStudies,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,PSA,prostate-specific antigen,,,
clinicalStudies,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,ANLL,acute nonlymphocytic leukemia,,,
clinicalStudies,13c80d46-429e-4007-8f89-eed2ed96eccf,6/17/2010,1,MCE,major coronary events,,,
clinicalStudies,13c80d46-429e-4007-8f89-eed2ed96eccf,6/17/2010,1,MVE,major vascular events,,,
clinicalStudies,a064c4a7-25ec-4a2c-afc2-703491a4a38b,6/30/2011,5,ANC,absolute neutrophil count,,,
clinicalStudies,a064c4a7-25ec-4a2c-afc2-703491a4a38b,6/30/2011,5,dysphagia,defined as complete resolution in clinical symptoms of esophageal candidiasis,,,
clinicalStudies,338fa690-1e15-44ce-b883-d03b2699384d,10/10/2011,3,LVEDP,left ventricular end-diastolic pressure,,,
clinicalStudies,273e5d83-4890-482c-9b69-972c17e786bb,4/13/2010,1,MCE,major coronary events,,,
clinicalStudies,273e5d83-4890-482c-9b69-972c17e786bb,4/13/2010,1,MVE,major vascular events,,,
clinicalStudies,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,SWOG,Southwest Oncology Group,,,
clinicalStudies,3fe3d468-d283-4dd0-a1a7-29291a9b2d0b,2/26/2010,5,CSFP,cerebrospinal fluid pressure,,,
clinicalStudies,3fe3d468-d283-4dd0-a1a7-29291a9b2d0b,2/26/2010,5,LMA,laryngeal mask airway,,,
clinicalStudies,3fe3d468-d283-4dd0-a1a7-29291a9b2d0b,2/26/2010,5,CBF,cerebral blood flow,,,
clinicalStudies,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,LDL,low density lipoprotein,,,
clinicalStudies,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,VLDL,very low density lipoprotein,,,
clinicalStudies,c53c20ed-a944-4b35-b5db-91d9f67240e8,12/20/2010,4,TG,triglyceride,,,
clinicalStudies,dd674424-b151-d7eb-3acf-b1589347f2f7,1/31/2012,2,BMD,Bone Mineral Density,,,
clinicalStudies,e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e,7/11/2012,3,min,median,,,
clinicalStudies,fcca49a1-8009-4375-47b3-543a4f437e02,6/6/2012,11,ITT,intent-to-treat,,,
clinicalStudies,fcca49a1-8009-4375-47b3-543a4f437e02,6/6/2012,11,RFS,relapse-free survival,,,
clinicalStudies,fcca49a1-8009-4375-47b3-543a4f437e02,6/6/2012,11,OS,overall survival,,,
clinicalStudies,481cb8c7-578d-4db0-862e-a010b1af47d7,9/11/2008,1,min,median,,,
clinicalStudies,d6d7711f-541b-47d1-b937-2c6a021eb6c3,12/2/2010,1,BMD,Bone Mineral Density,,,
clinicalStudies,d6a161d9-7e7a-4711-ba0e-c9040c42268d,1/6/2012,4,SAH,subarachnoid hemorrhage,,,
clinicalStudies,d6a161d9-7e7a-4711-ba0e-c9040c42268d,1/6/2012,4,III,initial bleed,,,
clinicalStudies,849e9f62-7414-3c22-9cb1-934f953400fc,3/7/2012,7,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,849e9f62-7414-3c22-9cb1-934f953400fc,3/7/2012,7,HR,[hazard ratio,,,
clinicalStudies,849e9f62-7414-3c22-9cb1-934f953400fc,3/7/2012,7,AD,Alzheimer's disease,,,
clinicalStudies,849e9f62-7414-3c22-9cb1-934f953400fc,3/7/2012,7,VaD,vascular dementia,,,
clinicalStudies,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,MITT,modified Intent-to-Treat,,,
clinicalStudies,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,cure,clinical success rate,,,
clinicalStudies,ae39ebe5-c3c3-45b4-a6c7-7eb9d829e282,11/15/2011,6,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,ae1e0d8a-03fc-419b-9d44-afa68fbd5681,12/27/2010,1,i.e.,impairment,,,
clinicalStudies,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,MCE,major coronary events,,,
clinicalStudies,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,HPS,Heart Protection Study,,,
clinicalStudies,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,hCG,human chorionic gonadotropin,,,
clinicalStudies,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,MVE,major vascular events,,,
clinicalStudies,8489416f-61b4-4711-99d4-d409fab43cfd,10/11/2011,2,ZE,Zollinger-Ellison,,,
clinicalStudies,407e0758-9e2e-4e45-8c1b-10cfd2115b1f,3/15/2012,1,BSC,Best Supportive Care,,,
clinicalStudies,ee80603a-7d4c-4172-aef4-286185b69acd,3/14/2012,1,MCE,major coronary events,,,
clinicalStudies,ee80603a-7d4c-4172-aef4-286185b69acd,3/14/2012,1,MVE,major vascular events,,,
clinicalStudies,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,a49ba8e3-e379-44f1-8ad2-b6dae53bbdf8,5/26/2010,2,GERD,gastroesophageal reflux disease,,,
clinicalStudies,f59f7811-70b7-4c44-99f7-4f4fdce3ed22,6/27/2011,1,DFS,disease-free survival,,,
clinicalStudies,b693e68d-f812-4993-54b6-852e3517c344,9/28/2011,1411,VLDL,very low density lipoprotein,,,
clinicalStudies,e80642ad-bb06-4546-ae33-5bc70cf05cee,1/9/2012,3,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,e80642ad-bb06-4546-ae33-5bc70cf05cee,1/9/2012,3,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,e80642ad-bb06-4546-ae33-5bc70cf05cee,1/9/2012,3,CV,cardiovascular,,,
clinicalStudies,00332c65-edad-a153-9c78-628931daa732,5/31/2012,4,i.e.,improvement,,,
clinicalStudies,d2af616e-673a-4fdd-ace8-db2d0f154604,11/24/2011,6,IPSS,International Prostate Symptom Score,,,
clinicalStudies,0b126fcd-2385-409f-9269-5bf886649c1a,3/6/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,6436dfa0-5f27-456a-83b9-c0485a40d9cc,4/10/2012,2,G.I.,gastrointestinal,,,
clinicalStudies,6436dfa0-5f27-456a-83b9-c0485a40d9cc,4/10/2012,2,AUC,and bioequivalence,,,
clinicalStudies,205bbe94-4869-4abc-9eab-9fd360b40f94,3/22/2012,3692,HR,[hazard ratio,,,
clinicalStudies,ac529edf-5634-49fa-8db5-ba3a39763161,10/6/2011,1,ERICA,Efficacy of Ranolazine In Chronic Angina,,,
clinicalStudies,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,ca16f8de-d9a5-4c6c-957b-ae28497b67ac,11/18/2011,5,HR,[Hazard Ratio,,,
clinicalStudies,1396b8b6-651a-4f2f-a2c1-0165173b2eff,9/8/2009,1,HoFH,14.2,,,
clinicalStudies,d58e820b-bfd2-4e66-9db4-03b526553c93,4/13/2011,11,SVR,Sustained Virologic Response,,,
clinicalStudies,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,PP,Per-Protocol,,,
clinicalStudies,dbfa7ae4-35af-4ed3-bca4-7900cd92047c,11/10/2010,2,ITT,Intent-to-Treat,,,
clinicalStudies,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,28e28cc3-349a-427a-b19c-77503ef43db4,2/20/2012,1,min,median,,,
clinicalStudies,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,4/27/2012,10,ACR,American College of Rheumatology,,,
clinicalStudies,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,4/27/2012,10,mTSS,modified Total Sharp Score,,,
clinicalStudies,369dbfba-9de4-433c-8680-2ec047b8f8d9,7/20/2012,6,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,TURP,transurethral resection of the prostate,,,
clinicalStudies,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,CABG,coronary artery bypass graft,,,
clinicalStudies,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,AUA,American Urological Association,,,
clinicalStudies,4a2b0442-c8f0-4c57-9206-323fbef1a877,5/15/2009,1,i.e.,improvement,,,
clinicalStudies,24f815ef-58e6-42b9-8137-adcd6c382aa6,10/6/2010,3,AEDs,antiepileptic drugs,,,
clinicalStudies,865f4e70-ead8-4480-96a4-6ca7b7d8ed69,3/20/2012,2,min,Median,,,
clinicalStudies,865f4e70-ead8-4480-96a4-6ca7b7d8ed69,3/20/2012,2,min,median,,,
clinicalStudies,61364915-3b0b-427d-9fef-29cdcc427ec5,4/10/2012,4,AD,Alzheimer’s disease,,,
clinicalStudies,61364915-3b0b-427d-9fef-29cdcc427ec5,4/10/2012,4,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,61364915-3b0b-427d-9fef-29cdcc427ec5,4/10/2012,4,VaD,vascular dementia,,,
clinicalStudies,f0d63051-fd8c-41af-92c3-b3be9f95475a,10/3/2011,3,ZE,Zollinger-Ellison,,,
clinicalStudies,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,total,the risk of death or hospitalization,,,
clinicalStudies,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,total,the combined end points of all-cause mortality plus hospitalization,,,
clinicalStudies,4423d70a-b120-4653-bcf3-0c5ea8b97b0e,3/24/2010,2,LOCF,last observation carried forward,,,
clinicalStudies,aca0b44e-598d-490b-87f4-f6701d1aad9e,4/27/2011,2,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,897ad8b7-921d-eb02-a61c-3419e662a2da,2/28/2012,4,min,"align=""center"">Median",,,
clinicalStudies,897ad8b7-921d-eb02-a61c-3419e662a2da,2/28/2012,4,min,Median,,,
clinicalStudies,897ad8b7-921d-eb02-a61c-3419e662a2da,2/28/2012,4,min,"align=""center"">Median % Change",,,
clinicalStudies,897ad8b7-921d-eb02-a61c-3419e662a2da,2/28/2012,4,min,median,,,
clinicalStudies,12084cb5-13db-42ea-b91c-1d361960fba7,6/25/2012,3,LVIDD,left ventricular internal diastolic diameter,,,
clinicalStudies,12084cb5-13db-42ea-b91c-1d361960fba7,6/25/2012,3,VALIANT,VALsartan In Acute myocardial iNfarcTion trial,,,
clinicalStudies,12084cb5-13db-42ea-b91c-1d361960fba7,6/25/2012,3,CV,cardiovascular,,,
clinicalStudies,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,MCE,major coronary events,,,
clinicalStudies,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,MVE,major vascular events,,,
clinicalStudies,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,32ae8f5a-ea78-4e64-a58a-856ed8cf4f78,1/27/2011,1,cure,clinical success rate,,,
clinicalStudies,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,LSAS,Liebowitz Social Anxiety Scale,,,
clinicalStudies,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,CGI,Clinical Global Impression,,,
clinicalStudies,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,GAD,Generalized Anxiety Disorder,,,
clinicalStudies,9eaec71a-3641-4afd-8d92-91c89d9a6edd,7/19/2012,8,HAM-A,Hamilton Rating Scale for Anxiety,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,SDS,Sheehan Disability Scale,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,CGI-I,Clinical  Global Impression of Improvement,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,CGI-BP,Clinical Global Impression - Bipolar,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,CGI-I,Clinical Global Impression-Improvement,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,Y-MRS,Young Mania  Rating Scale,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,CGI,Clinical Global  Impression,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,MADRS,Montgomery-Asberg Depression Rating Scale,,,
clinicalStudies,0dc024ce-efc8-4690-7cb5-639c728fccac,8/23/2011,1406,i.e.,improvement,,,
clinicalStudies,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,part I,four-part multi-item rating scale intended to evaluate mentation,,,
clinicalStudies,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,ADL,Activities of Daily Living,,,
clinicalStudies,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,UPDRS,Unified Parkinson's Disease Rating Scale,,,
clinicalStudies,39d53698-57fa-7c99-fc5b-f52a55684826,6/26/2012,10,IRC,independent review committee,,,
clinicalStudies,39d53698-57fa-7c99-fc5b-f52a55684826,6/26/2012,10,NHL,14.2 Non-Hodgkin Lymphoma,,,
clinicalStudies,39d53698-57fa-7c99-fc5b-f52a55684826,6/26/2012,10,DR,duration of response,,,
clinicalStudies,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,56ecdeb7-89ba-420f-bbaf-65e4dab305d3,6/22/2010,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,3257494f-8f44-4978-b92d-bde87b2444b6,7/2/2012,2,SIB,Severe Impairment Battery,,,
clinicalStudies,90b553fe-4e94-4cce-b5df-ea3e6487930d,10/10/2011,1,AED,antiepileptic drug,,,
clinicalStudies,90b553fe-4e94-4cce-b5df-ea3e6487930d,10/10/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,90b553fe-4e94-4cce-b5df-ea3e6487930d,10/10/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,MMEF,maximal midexpiratory flow rate,,,
clinicalStudies,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,BIS,Behavior and Ideation Scale,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,CPS,complex partial seizures,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,AED,antiepilepsy drug,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,MSS,Manic Syndrome Scale,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,i.e.,improvement,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,TID,three divided doses,,,
clinicalStudies,349cd946-3fd9-4ea3-9140-daf5d7304a65,11/16/2011,3197,MRS,Manic Rating Scale,,,
clinicalStudies,b4c0128b-622c-42db-8e31-48c4ca6b1286,7/21/2011,2,mg/dL,mg  Twice  DailyPlaceboTotal Cholesterol,,,
clinicalStudies,b4c0128b-622c-42db-8e31-48c4ca6b1286,7/21/2011,2,Met,Metformin Hydrochloride Tablets,,,
clinicalStudies,b4c0128b-622c-42db-8e31-48c4ca6b1286,7/21/2011,2,Glyb,Glyburide,,,
clinicalStudies,b4c0128b-622c-42db-8e31-48c4ca6b1286,7/21/2011,2,mg/dL,mg Once DailyTotal Cholesterol,,,
clinicalStudies,f0cdfa57-95e5-416b-bc2f-cde2491c2fd0,3/17/2012,17,SREs,skeletal-related events,,,
clinicalStudies,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,COPD,chronic obstructive pulmonary disease,,,
clinicalStudies,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,AED,antiepileptic drug,,,
clinicalStudies,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,AEDs,antiepileptic drugs,,,
clinicalStudies,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,WHIMS,Women’s Health Initiative Memory Study,,,
clinicalStudies,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,MCE,major coronary events,,,
clinicalStudies,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HPS,Heart Protection Study,,,
clinicalStudies,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HeFH,heterozygous familial hypercholesterolemia,,,
clinicalStudies,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,MVE,major vascular events,,,
clinicalStudies,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,MRI,magnetic resonance imaging,,,
clinicalStudies,83d7a440-e904-4e36-afb5-cb02b1c919f7,12/13/2011,14,ORR,Objective Response Rate,,,
clinicalStudies,83d7a440-e904-4e36-afb5-cb02b1c919f7,12/13/2011,14,TTP,Time to Progression,,,
clinicalStudies,83d7a440-e904-4e36-afb5-cb02b1c919f7,12/13/2011,14,OS,overall survival,,,
clinicalStudies,9CF04DAD-E312-4B8F-A297-1E002D43E151,10/6/2006,1,ACTG,AIDS Clinical Trials Group,,,
clinicalStudies,9CF04DAD-E312-4B8F-A297-1E002D43E151,10/6/2006,1,KS,Kaposi’s sarcoma,,,
clinicalStudies,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,837a3746-7f9a-43a5-a021-e70856df34ee,5/5/2011,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,462dce28-bed1-4885-972b-a6e1028fcead,4/12/2012,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,6cc91855-660f-4df0-9800-4b628cad6f15,8/22/2011,1,CBZ,carbamazepine,,,
clinicalStudies,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,MITT,modified Intent-to-Treat,,,
clinicalStudies,24ea9765-6d74-4681-8110-5a6fc0b04db5,2/18/2010,1,cure,clinical success rate,,,
clinicalStudies,1c747919-7968-40aa-80b2-e2f7d499a801,2/2/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,VAS,Visual Analog Score,,,
clinicalStudies,9b653e01-81f3-49b1-89a2-a56988ad94a3,1/4/2012,3473,GERD,Gastroesophageal Reflux Disease,,,
clinicalStudies,9b653e01-81f3-49b1-89a2-a56988ad94a3,1/4/2012,3473,BAO,Basal Acid Output,,,
clinicalStudies,12f3dec1-4299-4b93-8013-6fa6a963fd81,6/7/2012,4,SVR,Sustained Virologic Response,,,
clinicalStudies,294948d9-3cf2-4c75-85c7-2f14ae04e6e8,6/1/2009,1,NTS,nicotine transdermal system,,,
clinicalStudies,294948d9-3cf2-4c75-85c7-2f14ae04e6e8,6/1/2009,1,COPD,Chronic Obstructive Pulmonary Disease,,,
clinicalStudies,ad627894-4d1e-4dae-8421-9aa1ce9a0208,1/31/2012,7,RMDQ,Roland-Morris Disability Questionnaire,,,
clinicalStudies,9f2aae1f-898d-4955-be31-678e0cf85395,2/3/2012,8,DEXA,Dual Energy X-ray Absorptiometry,,,
clinicalStudies,bd72a7c7-ff12-4b95-8d39-4426231bd5aa,12/28/2011,2,WARIS,Warfarin Re-Infarction Study,,,
clinicalStudies,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,SCLC,small cell lung cancer,,,
clinicalStudies,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,ECOG,Eastern Cooperative Oncology Group,,,
clinicalStudies,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,VAS,visual analog scale,,,
clinicalStudies,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,AEDs,antiepileptic drugs,,,
clinicalStudies,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,FIQ,Fibromyalgia Impact Questionnaire,,,
clinicalStudies,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,ACR,American College of Rheumatology,,,
clinicalStudies,18e678d8-f1cd-4970-8ae1-f701186180a4,6/6/2008,1,EXCEL,Expanded Clinical Evaluation of Lovastatin,,,
clinicalStudies,925d34bb-235a-4655-b5bf-d1c3d93f5daa,1/23/2012,3504,AEDs,antiepileptic drugs,,,
clinicalStudies,ba3db17e-5697-46f0-8fb3-dd19e93e1a08,7/9/2010,1,SPID,sum of pain intensity difference,,,
clinicalStudies,e11b0a54-92bd-4790-8b80-f439f7093c01,1/9/2012,2,UICC,Union Internationale Contre le Cancer,,,
clinicalStudies,e11b0a54-92bd-4790-8b80-f439f7093c01,1/9/2012,2,TTP,Time to progression,,,
clinicalStudies,e11b0a54-92bd-4790-8b80-f439f7093c01,1/9/2012,2,MAA,Monotherapy Arms Analysis,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,CGI,Clinical Global Impression,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,AUC,area under the curve,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,CGI,Clinical Global  Impression,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,CGI-S,Clinical Global  Impression-Severity of Illness Scale,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,BARS,Behavioural Activity Rating Scale,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,MRS,Mania Rating Scale,,,
clinicalStudies,919811b8-c435-44fe-8bb2-827659c3af4e,12/20/2010,158,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,1513b960-d9d1-11de-8a1e-0002a5d5c51b,10/5/2010,5,CI,confidence interval,,,
clinicalStudies,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,CGI,Clinical Global Impression,,,
clinicalStudies,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,CB157743-E18D-F030-3EA3-813FBCD73851,11/4/2008,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,CFU,colony  forming units,,,
clinicalStudies,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,dMAC,disseminated MAC,,,
clinicalStudies,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,FEF25-75%,forced expiratory flow  over 25-75% of the vital capacity,,,
clinicalStudies,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,AM PEF,and morning peak expiratory flow,,,
clinicalStudies,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,FEV1,[forced expiratory volume in 1 second,,,
clinicalStudies,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,db16d6b9-3b89-431d-97f9-9b4a8300e913,3/19/2010,3,PONV,Postoperative Nausea and Vomiting,,,
clinicalStudies,db16d6b9-3b89-431d-97f9-9b4a8300e913,3/19/2010,3,FLIE,Functional Living Index–Emesis,,,
clinicalStudies,db16d6b9-3b89-431d-97f9-9b4a8300e913,3/19/2010,3,MEC,Moderately Emetogenic Chemotherapy,,,
clinicalStudies,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,MRI,magnetic resonance imaging,,,
clinicalStudies,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,MMEF,maximum midexpiratory flow rate,,,
clinicalStudies,96609623-528e-4aba-cabe-7254aed816d5,5/10/2012,17,HR,[hazard ratio,,,
clinicalStudies,96609623-528e-4aba-cabe-7254aed816d5,5/10/2012,17,AD,Alzheimer's disease,,,
clinicalStudies,96609623-528e-4aba-cabe-7254aed816d5,5/10/2012,17,VaD,vascular dementia,,,
clinicalStudies,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,TURP,transurethral resection of the prostate,,,
clinicalStudies,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,CABG,coronary artery bypass graft,,,
clinicalStudies,828C40F4-5969-4254-9008-36AF15CC601B,12/14/2005,1,TTP,thrombocytopenic purpura,,,
clinicalStudies,d4f43676-0746-4765-9689-3f1e3075fa6a,2/29/2012,1,HR,[Hazard Ratio,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,CGI,Clinical Global Impression,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,YMRS,Young Mania Rating Scale,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,caa123c0-462e-463f-a831-671783febfa9,6/22/2011,2,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,78eea56d-15a6-4ceb-b755-d1a3e9707f32,12/1/2010,1,i.e.,in FEV1 after exercise,,,
clinicalStudies,78eea56d-15a6-4ceb-b755-d1a3e9707f32,12/1/2010,1,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,78eea56d-15a6-4ceb-b755-d1a3e9707f32,12/1/2010,1,i.e.,interval,,,
clinicalStudies,78eea56d-15a6-4ceb-b755-d1a3e9707f32,12/1/2010,1,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,f757f066-8288-4d6c-8c5e-2471007c7966,6/10/2011,2,PCWP,pulmonary capillary wedge pressure,,,
clinicalStudies,f757f066-8288-4d6c-8c5e-2471007c7966,6/10/2011,2,mPAP,mean pulmonary artery pressure,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,SF-36,Short Form 36,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,JRA,juvenile rheumatoid arthritis,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,RA,rheumatoid arthritis,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,DOI,Definition of Improvement,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,HAQ DI,HAQ Disability Index,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,MHAQ,[Modified Health Assessment Questionnaire,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,ACR,American College of Rheumatology,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,PCS,Physical Component Summary,,,
clinicalStudies,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,HAQ,Health Assessment Questionnaire,,,
clinicalStudies,7e7517b6-8f9f-4600-881a-9ed8bc1f454a,2/2/2012,1,Part I,posttreatment for success in treating early Lyme disease,,,
clinicalStudies,e5ad3cf6-dd96-4e64-af21-c1eee38d0b88,4/11/2012,7,HR,[hazard ratio,,,
clinicalStudies,e5ad3cf6-dd96-4e64-af21-c1eee38d0b88,4/11/2012,7,AD,Alzheimer's disease,,,
clinicalStudies,e5ad3cf6-dd96-4e64-af21-c1eee38d0b88,4/11/2012,7,VaD,vascular dementia,,,
clinicalStudies,d42eeda8-d810-4481-a403-6a3520b9e69a,3/30/2012,1,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,d42eeda8-d810-4481-a403-6a3520b9e69a,3/30/2012,1,CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate,,,
clinicalStudies,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,cUTI,complicated urinary tract infections,,,
clinicalStudies,1d5bce9c-a788-4c52-a69e-c53174b8d061,7/12/2012,1,min,median,,,
clinicalStudies,5267d7fe-2ad2-5007-7080-cb7cabda6c16,8/5/2010,6,AEDs,antiepileptic drugs,,,
clinicalStudies,334d7b8a-a10d-4312-805d-20ace80baa38,12/6/2011,2,AEDs,antiepileptic drugs,,,
clinicalStudies,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,FEV1,forced expiratory volume in 1 second,,,
clinicalStudies,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,MMEF,maximum midexpiratory flow rate,,,
clinicalStudies,2096a07e-8601-4bdc-ba5a-338a40cd02e9,5/1/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
clinicalStudies,2096a07e-8601-4bdc-ba5a-338a40cd02e9,5/1/2012,1,SBR,staying on the baseline antiretroviral regimen,,,
clinicalStudies,2096a07e-8601-4bdc-ba5a-338a40cd02e9,5/1/2012,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
clinicalStudies,77589cc3-c440-4695-800c-82a0e5128a6c,5/18/2012,6,MTOPS,Medical Therapy of Prostatic Symptoms,,,
clinicalStudies,77589cc3-c440-4695-800c-82a0e5128a6c,5/18/2012,6,MRI,magnetic resonance imaging,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,MCVE,major cardiovascular events,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,DBP,diastolic blood pressure,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,TNT,to New Targets Study,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,CVD,cardiovascular disease,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,SBP,systolic blood pressure,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,min,median,,,
clinicalStudies,d2d28679-a01b-4e63-90e2-d5c23b393c94,11/16/2011,2,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,MI,myocardial infarction,,,
clinicalStudies,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,WPW,Wolff-Parkinson-White,,,
clinicalStudies,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
clinicalStudies,4291b063-0b7d-468e-bae0-bc145e699ded,11/14/2011,1,Comb,Combined Metformin Hydrochloride Tablets/Glyburide,,,
clinicalStudies,4291b063-0b7d-468e-bae0-bc145e699ded,11/14/2011,1,MET,Metformin Hydrochloride Tablets,,,
clinicalStudies,4291b063-0b7d-468e-bae0-bc145e699ded,11/14/2011,1,Glyb,Glyburide,,,
clinicalStudies,A274E3EA-BF67-4F81-AAA0-10475B20CD69,10/6/2006,1,CSBM,Complete Spontaneous Bowel Movement,,,
clinicalStudies,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,AEDs,antiepileptic drugs,,,
clinicalStudies,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,CBZ,carbamazepine,,,
clinicalStudies,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,CGI,Clinical Global Impression,,,
clinicalStudies,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,3bb1b5bf-cd3d-43bd-8543-07426e45df1a,8/30/2010,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,50630775-7f76-413e-9278-ba298dd7f187,12/22/2010,1,ITT,intent-to-treat,,,
clinicalStudies,50630775-7f76-413e-9278-ba298dd7f187,12/22/2010,1,MRSA,methicillin-resistant Staphylococcus aureus,,,
clinicalStudies,739dcf8a-ed73-5eb0-899b-7e51cb73c335,10/23/2011,8,YMRS,Young Mania Rating Scale,,,
clinicalStudies,739dcf8a-ed73-5eb0-899b-7e51cb73c335,10/23/2011,8,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,739dcf8a-ed73-5eb0-899b-7e51cb73c335,10/23/2011,8,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,CGI,Clinical Global Impression,,,
clinicalStudies,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,YMRS,Young Mania Rating Scale,,,
clinicalStudies,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,15BBBE18-9865-40F3-B8A3-05730193BF62,11/5/2008,1,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,CGI,Clinical Global Impression,,,
clinicalStudies,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,HAMD,Hamilton Depression Rating Scale,,,
clinicalStudies,4619aff4-0f80-444f-858d-42e4137aa809,8/26/2011,1407,i.e.,improvement,,,
clinicalStudies,1388D626-36AF-4C4D-8917-A458A38F7176,2/20/2008,2,VAS,visual analog scale,,,
clinicalStudies,4e0c7ad7-3b44-4db8-b144-a1ad6d152315,7/27/2010,2,ZE,Zollinger-Ellison,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,CGI,Clinical Global Impression,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,YMRS,Young Mania Rating Scale,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,PANSS,Positive and Negative Syndrome Scale,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,ABC,Aberrant Behavior Checklist,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,BPRS,Brief Psychiatric Rating Scale,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,CGI-C,Clinical Global Impression - Change,,,
clinicalStudies,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,SANS,Scale for Assessing Negative Symptoms,,,
clinicalStudies,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,LDL,low density lipoprotein,,,
clinicalStudies,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,VLDL,very low density lipoprotein,,,
clinicalStudies,24790a18-0291-4b88-a724-acac43b616ce,10/1/2010,1,TG,triglyceride,,,
clinicalStudies,8e1a3641-25ca-41bd-a940-51ae0ec64ed9,6/29/2012,6,WHIMS,Women's Health Initiative Memory Study,,,
clinicalStudies,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,CAP,Community Acquired Pneumonia,,,
clinicalStudies,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,ABECB,Acute Bacterial Exacerbation of Chronic Bronchitis,,,
clinicalStudies,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,1525056d-c2c2-4956-9ed5-2d925bff459b,9/28/2011,26,i.e.,in FEV1 after exercise,,,
clinicalStudies,1525056d-c2c2-4956-9ed5-2d925bff459b,9/28/2011,26,EIB,Exercise-Induced Bronchoconstriction,,,
clinicalStudies,1525056d-c2c2-4956-9ed5-2d925bff459b,9/28/2011,26,i.e.,interval,,,
clinicalStudies,1525056d-c2c2-4956-9ed5-2d925bff459b,9/28/2011,26,mean dose,mean baseline requirements included beclomethasone dipropionate,,,
clinicalStudies,0d90cadf-d579-47bf-b655-7e9d3bd1cabe,3/15/2010,1,DEXA,Dual Energy X-ray Absorptiometry,,,
clinicalStudies,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,LDL,low density lipoprotein,,,
clinicalStudies,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,VLDL,very low density lipoprotein,,,
clinicalStudies,77e40fef-78a7-4f60-9632-1cc9b66acd71,4/26/2011,3,TG,triglyceride,,,
clinicalStudies,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,IDNT,Irbesartan Diabetic Nephropathy Trial,,,
clinicalStudies,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,ESRD,end-stage renal disease,,,
clinicalStudies,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,MCE,major coronary events,,,
clinicalStudies,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,MVE,major vascular events,,,
clinicalStudies,b7c926f0-8771-41d7-95be-3d4110dc0603,4/19/2011,1,SIB,Severe Impairment Battery,,,
clinicalStudies,398348ed-1b65-4109-9d0f-f9d8a7175d61,4/16/2012,1,TOC,test-of-cure,,,
clinicalStudies,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,LDL,low density lipoprotein,,,
clinicalStudies,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,VLDL,very low density lipoprotein,,,
clinicalStudies,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,TG,triglyceride,,,
clinicalStudies,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,ZES,Zollinger-Ellison syndrome,,,
clinicalStudies,4ac6d01a-af26-44e7-ae2e-3618de0080aa,12/2/2010,5,HbA1c,hemoglobin A1c,,,
clinicalStudies,4ac6d01a-af26-44e7-ae2e-3618de0080aa,12/2/2010,5,PPG,postprandial plasma glucose,,,
clinicalStudies,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,cUTI,complicated urinary tract infections,,,
clinicalStudies,80f3b79c-a399-45b3-b755-8535457719af,6/19/2012,1,BSC,Best Supportive Care,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,CGI,Clinical Global Impression,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,OCD,obsessive-compulsive disorder,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,ac3e3964-90c0-44dd-800c-ec9606629572,11/10/2011,2,ITT,Intent to Treat,,,
clinicalStudies,ac3e3964-90c0-44dd-800c-ec9606629572,11/10/2011,2,EOT,end of treatment,,,
clinicalStudies,ac3e3964-90c0-44dd-800c-ec9606629572,11/10/2011,2,DRC,Data Review Committee,,,
clinicalStudies,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,AED,antiepileptic drug,,,
clinicalStudies,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,JME,Juvenile Myoclonic Epilepsy,,,
clinicalStudies,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,JME,juvenile myoclonic epilepsy,,,
clinicalStudies,8953d343-d137-4ca5-a73f-3ceff1505b55,7/19/2010,1,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,746aa1a9-4605-4991-bb80-62685284bb0b,6/7/2012,3,AEDs,antiepileptic drugs,,,
clinicalStudies,627146d8-fa8e-4c8b-b703-29ee080a6d5b,3/30/2012,20,ABPM,ambulatory blood pressure monitoring,,,
clinicalStudies,0d3e4f7c-0ce1-4631-a801-e3812f7dd456,1/9/2012,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,ADHDRS,ADHD Rating Scale-IV-Parent Version,,,
clinicalStudies,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,CAARS,Conners Adult ADHD Rating Scale Screening Version,,,
clinicalStudies,b2eb10c8-9d8c-41e6-a045-01e425c3f8a7,11/14/2011,3154,AEDs,antiepileptic drugs,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,CGI,Clinical Global Impression,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,YBOCS,Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,OCD,Obsessive Compulsive Disorder,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,HAM-D,Hamilton Depression Rating Scale,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale,,,
clinicalStudies,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,CDRS-R,Childhood Depression Rating Scale-Revised,,,
clinicalStudies,3b1e1cf1-ebd2-4aba-a219-9f9939fdb03b,2/2/2012,2,EGSA,Evaluator's Global Severity Assessment,,,
clinicalStudies,da242926-93db-4a2b-b68c-23af13ea747e,8/9/2011,1,EPT,electric pulp testers,,,
clinicalStudies,3071978c-a77f-43ff-b68b-a951f1fd0816,4/1/2010,3,PPG,postprandial plasma glucose,,,
clinicalStudies,594e76e5-2833-4386-991d-234d4f937e1b,10/10/2011,8,Gel,mcg/g once daily for 16 weeks,,,
clinicalStudies,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,i.e.,improvement from baseline,,,
clinicalStudies,d1697161-ebe8-42b0-83e7-c9de4412546c,2/9/2011,1,ADCS-ADL,Alzheimer’s Disease Cooperative Study-Activities of Daily Living,,,
clinicalStudies,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,MCE,major coronary events,,,
clinicalStudies,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,MVE,major vascular events,,,
clinicalStudies,d068b6a4-63c0-40fc-b3a3-7145bde7ed72,11/21/2011,3236,total,the risk of death or hospitalization,,,
clinicalStudies,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,TNT,to Occurrence of Major Cardiovascular Events,,,
clinicalStudies,808c5c03-9fd7-4d8b-b4d0-57c7527b42df,5/11/2012,1,min,median,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,MCVE,major cardiovascular events,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,DBP,diastolic blood pressure,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,TNT,to New Targets Study,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,CVD,cardiovascular disease,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,SBP,systolic blood pressure,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,min,median,,,
clinicalStudies,6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6,8/11/2011,10,CARDS,Collaborative Atorvastatin Diabetes Study,,,
clinicalStudies,c22dfa61-ca2e-419c-9ff6-484023793699,7/1/2011,4,ZE,Zollinger-Ellison,,,
clinicalStudies,34704c52-b71c-4a6d-9335-00cce4ec7302,8/13/2011,1,TOC,test-of-cure,,,
clinicalStudies,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
clinicalStudies,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,INCAT,Inflammatory Neuropathy Cause and Treatment,,,
clinicalStudies,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,AUA,American Urological Association,,,
clinicalStudies,04d2b6f4-bd9b-4871-9527-92c81aa2d4d0,10/27/2011,9,SVR,sustained virologic response,,,
clinicalStudies,04d2b6f4-bd9b-4871-9527-92c81aa2d4d0,10/27/2011,9,SVR,Sustained Virologic Response,,,
clinicalStudies,d7b4d497-0b70-49e8-b17b-643fa82a0d8c,6/28/2010,3,GERD,gastroesophageal reflux disease,,,
clinicalStudies,645607af-3ef3-4765-bbff-ba9c483be141,5/21/2012,1,BSA,body surface area,,,
clinicalStudies,27e63200-c82c-47cd-a212-a2b5edc343bf,1/3/2011,1,IR,immediate-release,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,JSN,Joint Space Narrowing,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,TSS,Total Sharp Score,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,BSA,body surface area,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,i.e.,interphalangeal joints,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,ASQoL,Ankylosing Spondylitis Quality of Life Questionnaire,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,EOW,every other week,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,PASI,Psoriasis Area and Severity Index,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,PGA,Physician’s Global Assessment,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,PCS,Physical Component Summary,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,PASI 75,PASI score of at least 75%,,,
clinicalStudies,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,mTSS,modified Total Sharp Score,,,
clinicalStudies,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,ITT,intent-to-treat,,,
clinicalStudies,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,PHN,postherpetic neuralgia,,,
clinicalStudies,19fc5f11-e83f-4ff2-b92f-33e9c3f6a7cb,5/12/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,9aa8023c-4905-4d63-86b5-259d20cba579,7/1/2011,1,AEDs,antiepileptic drugs,,,
clinicalStudies,a1b077e6-b070-43f2-a98e-380cc635419d,1/20/2012,19,ZE,Zollinger-Ellison,,,
clinicalStudies,a40d0e73-3f9f-4b01-979d-402c9cdaeb60,2/3/2012,6,ADL,activities of daily living,,,
clinicalStudies,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,MITT,modified Intent-to-Treat,,,
clinicalStudies,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,cure,clinical success rate,,,
clinicalStudies,c9bb38a9-b637-4146-b66e-54b5a0862316,3/11/2011,9,AECB,acute exacerbation of chronic bronchitis,,,
clinicalStudies,778b1225-3c5d-4683-9888-8b3306a6e49d,2/28/2012,18,cIMT,carotid intimal-medial thickness,,,
clinicalStudies,778b1225-3c5d-4683-9888-8b3306a6e49d,2/28/2012,18,METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg,,,
clinicalStudies,778b1225-3c5d-4683-9888-8b3306a6e49d,2/28/2012,18,CV,cardiovascular,,,
clinicalStudies,1086a7b4-b89b-4bee-8120-5f752626c046,12/28/2010,1,GPIIb/IIIa,glycoprotein IIb/IIIa,,,
clinicalStudies,e4ce209d-3f8c-4ac4-bec1-2525a93708bc,9/6/2011,1,PR,2. Pain Relief,,,
clinicalStudies,258e1602-a3cf-4ccc-ca80-73dbbfb812ff,5/21/2012,17,HR,[hazard ratio,,,
contraindication,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,MAOIs,monoamine oxidase inhibitors,,,
contraindication,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,CABG,coronary artery bypass graft,,,
contraindication,d471d6b5-2a16-41a0-9058-cbe5dfa3011f,5/27/2008,3,CABG,coronary artery bypass graft,,,
contraindication,e110f879-98e6-49cb-a3b0-68805cdf602a,4/13/2012,3,CABG,coronary artery bypass graft,,,
contraindication,4979723b-f283-4156-bb0b-dc3a60a76065,3/12/2007,1,MAO,monoamine oxidase,,,
contraindication,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,7c065a08-bd12-4d43-ad9a-13228d99d106,8/13/2007,1,MAO,monoamine oxidase,,,
contraindication,9c9541af-3221-4e6c-a1eb-fae64925a488,10/24/2011,3,CABG,coronary artery bypass graft,,,
contraindication,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,DHT,5?-dihydrotestosterone,,,
contraindication,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,MAO,monoamine oxidase,,,
contraindication,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,d77f1654-4423-464f-a846-6767a2377ce1,1/14/2011,1,CABG,coronary artery bypass graft,,,
contraindication,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,MAO,monoamine oxidase,,,
contraindication,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,MAO,monoamine oxidase,,,
contraindication,1ec26930-abe6-4db3-9315-aa896f7d5232,5/18/2009,3,CABG,coronary artery bypass graft,,,
contraindication,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,206ea94a-8386-4d65-a74e-8abd52e1bfc3,3/5/2012,1,MAO,monoamine oxidase,,,
contraindication,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,CABG,coronary artery bypass graft,,,
contraindication,a1dc5b3f-0bca-461e-9018-32efcf335653,12/22/2011,2,MAO,monoamine oxidase,,,
contraindication,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,CABG,coronary artery bypass graft,,,
contraindication,40caec0c-902c-424c-8c87-63878134641e,4/21/2011,2,CYP 3A,cytochrome P450 3A,,,
contraindication,ac387aa0-3f04-4865-a913-db6ed6f4fdc5,3/8/2012,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
contraindication,0396bfec-afe1-460c-8141-e8ad877b4bc0,4/1/2010,1,CABG,coronary artery bypass graft,,,
contraindication,171c535c-1ed3-47bc-a0d5-c6f0e6986292,8/18/2011,1,MAO,monoamine oxidase,,,
contraindication,003aee15-e811-4dae-aa8c-4381ae5a17e3,3/5/2012,1,MAO,monoamine oxidase,,,
contraindication,e61ae711-e6d2-44e4-b7d7-943a9d06f985,3/17/2011,1,CABG,coronary artery bypass graft,,,
contraindication,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,MAO,monoamine oxidase,,,
contraindication,a41b9710-a1ec-41be-8417-b03c5d802ae2,4/11/2012,1,CABG,coronary artery bypass graft,,,
contraindication,334fa37b-f73a-459a-9f67-281022273fed,8/1/2011,12,CABG,coronary artery bypass graft,,,
contraindication,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,CABG,coronary artery bypass graft,,,
contraindication,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,PCOS,polycystic ovary syndrome,,,
contraindication,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,704A5E3E-6ADF-4D38-A793-80978AB6E3BB,1/16/2007,1,MAOI,monoamine oxidase,,,
contraindication,14496afb-a541-4b01-a672-fcd411292b8d,4/2/2007,1,CABG,coronary artery bypass graft,,,
contraindication,1154688c-1383-442b-a3a5-ec01e038795c,10/12/2010,5,MAO,monoamine oxidase,,,
contraindication,1b368b80-f054-4c47-bd62-0d77ca03ac53,3/11/2011,1,CABG,coronary artery bypass graft,,,
contraindication,e78781c4-ac46-43b6-af8c-331233a3bb6b,5/12/2011,39,CABG,coronary artery bypass graft,,,
contraindication,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,MAO,monoamine oxidase,,,
contraindication,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,MAO,monoamine oxidase,,,
contraindication,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,4b4b0091-bcf9-499e-a23e-efcee252f2f6,8/26/2011,1,CABG,coronary artery bypass graft,,,
contraindication,c3bb55bc-5465-4c28-a763-ffd252758b96,7/12/2011,1,CABG,coronary artery bypass graft,,,
contraindication,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,MAOIs,monoamine oxidase inhibitors,,,
contraindication,C1DFE613-D8AC-4F18-9AAF-5F11044DE2B1,11/4/2008,1,MAO,monoamine oxidase,,,
contraindication,4a6953cd-9d64-4443-b7db-5aef2c81324d,3/24/2010,2,MAO,monoamine oxidase,,,
contraindication,ced93eb0-e8b6-44b8-9d2c-e2afa92500f7,1/4/2008,1,MAO,monoamine oxidase,,,
contraindication,14710a71-e2e9-4e4e-bd65-1c296f70c166,12/8/2009,5,MAO,monoamine oxidase,,,
contraindication,42fcf2b5-3466-4493-8a47-c4675538ece3,1/14/2011,1,CABG,coronary artery bypass graft,,,
contraindication,d207da6e-d074-4dab-95f1-265b1df41aea,10/27/2009,2,CABG,coronary artery bypass graft,,,
contraindication,81f1e36a-6367-4334-b007-1426612f292b,4/26/2011,1,CABG,coronary artery bypass graft,,,
contraindication,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,MAOI,monoamine oxidase inhibitor,,,
contraindication,6fcb75a2-095d-424b-b9ac-f843a8e1d9b1,3/2/2012,1,CABG,coronary artery bypass graft,,,
contraindication,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,MAO,monoamine oxidase,,,
contraindication,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,CABG,coronary artery bypass graft,,,
contraindication,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,830a28fb-9b80-4fbb-99dc-56ec80e4e581,8/14/2007,1,E®,emollient cream,,,
contraindication,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,MAOIs,monoamine oxidase inhibitors,,,
contraindication,9514418a-0020-442d-9227-0241a989d6e4,6/27/2011,2,CABG,coronary artery bypass graft,,,
contraindication,4e655dc5-ada6-446f-ab12-5e7b5f2039b2,4/18/2011,1,CABG,coronary artery bypass graft,,,
contraindication,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,885A90B0-7C9F-4BC9-9F22-2C16F15EB108,10/17/2007,2,CABG,coronary artery bypass graft,,,
contraindication,751887d9-71da-4226-8ae1-d7ca59259cbe,3/4/2009,1,CABG,coronary artery bypass graft,,,
contraindication,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,4021a77c-36ad-4f3a-bb4b-b44de96173b2,12/8/2009,1,MAO,monoamine oxidase,,,
contraindication,47129a3e-fe0d-4e24-9c27-b5a8e7250106,11/18/2011,3217,CYP3A,cytochrome P450 3A,,,
contraindication,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,MAO,monoamine oxidase,,,
contraindication,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,e5808712-4487-43b2-891f-e1ef47a9e28d,10/24/2011,1,MAOI,monoamine oxidase inhibitors,,,
contraindication,35f9e465-76c0-435c-9e81-8fd9bb16cedf,8/30/2011,1,CABG,coronary artery bypass graft,,,
contraindication,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,CABG,coronary artery bypass graft,,,
contraindication,9b711ce9-f8cb-4ef0-b0c8-9477b1b30230,10/11/2010,50,UGDP,University Group Diabetes Program,,,
contraindication,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox,ceftizoxime for injection,,,
contraindication,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,MAO,monoamine oxidase,,,
contraindication,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,MAOIs,monoamine oxidase inhibitors,,,
contraindication,33694be4-87ce-4d25-92f6-6ae517bdf5ff,11/2/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,DHT,5?-dihydrotestosterone,,,
contraindication,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,MAO,monoamine oxidase,,,
contraindication,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,MAOI,monoamine oxidase inhibitor,,,
contraindication,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,MAOI,monoamine oxidase inhibitor,,,
contraindication,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,cGMP,cyclic guanosine                                         monophosphate,,,
contraindication,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,PDE5,phosphodiesterase type 5,,,
contraindication,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,cGMP,cyclic guanosine                                     monophosphate,,,
contraindication,23dc7eeb-0b0a-4a11-9783-fdba769309cd,4/18/2011,1,CABG,coronary artery bypass graft,,,
contraindication,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,NSAIDs,nonsteroidal                                 anti-inflammatory drugs,,,
contraindication,d4aa609c-1e1d-4970-958a-ba4b13611d00,12/6/2011,3324,CABG,coronary artery bypass graft,,,
contraindication,3ad7567d-b11c-407b-9c0b-a198406b7102,10/27/2009,1,CABG,coronary artery bypass graft,,,
contraindication,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,CABG,coronary artery bypass graft,,,
contraindication,4d32f781-f72f-41f4-a349-d0ee04b4d912,4/21/2011,2,MAO,monoamine oxidase,,,
contraindication,f82dcff5-4afa-45d8-bc8c-f0f7c0c96272,12/28/2006,1,UGDP,University Group Diabetes Program,,,
contraindication,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
contraindication,3202b686-e944-4b52-a226-9297fe899606,6/28/2011,1,MAO,monoamine oxidase,,,
contraindication,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,MAO,monoamine oxidase,,,
contraindication,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,MAOI,monoamine oxidase inhibitor,,,
contraindication,18c897d3-47c2-461a-a0e7-0926453d45e3,12/30/2009,1,CABG,coronary artery bypass graft,,,
contraindication,51500008-2034-452c-8e9b-bb112d1b9039,5/27/2008,1,MAO,monoamine oxidase,,,
contraindication,91356085-a6d8-4a41-8197-785fc21fb9de,8/1/2011,7,MAO,monoamine oxidase,,,
contraindication,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,PEP,post-exposure prophylaxis,,,
contraindication,8E6E1AEA-D1C9-F6BF-2A8C-0504437BE95C,2/12/2009,1,CABG,coronary artery bypass graft,,,
contraindication,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,3187a670-e0de-47b0-9c68-fdf7d2d162d6,10/12/2006,1,MAO,monoamine oxidase,,,
contraindication,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,CABG,coronary artery bypass graft,,,
contraindication,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,CABG,coronary artery bypass graft,,,
contraindication,93d73c30-f90d-435b-a31b-036884caa7b4,10/12/2007,1,GI,4)Gastrointestinal,,,
contraindication,197c0496-3910-44ed-b8fb-df01b0f925a8,5/12/2011,125,CABG,coronary artery bypass graft,,,
contraindication,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,CABG,coronary artery bypass graft,,,
contraindication,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,0d02b3a0-4de3-473b-8ed9-a1974747970f,6/13/2006,1,Amino Acid,amino acids present in the solution.®,,,
contraindication,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,a156e748-72c2-437a-a778-1e665157baba,11/22/2011,3239,CABG,coronary artery bypass graft,,,
contraindication,434f601e-cc7f-4b1e-a9df-429d61f32350,12/6/2011,3330,CABG,coronary artery bypass graft,,,
contraindication,ABE1900F-615A-49E9-94FB-B44261F57D2D,12/14/2005,1,prolonged,age;Prophylactic use of Fansidar in pregnancy at term and during the nursing period.Repeated prophylactic,,,
contraindication,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,NMS,neuroleptic malignant syndrome,,,
contraindication,111F628A-7E1E-4D47-8AC1-F898CBFC9B74,8/3/2007,2,e.g.,each other.1 agonists,,,
contraindication,08570dbd-45f7-47d2-8b63-b4e63995e966,8/1/2011,7,CABG,coronary artery bypass graft,,,
contraindication,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,MAO,monoamine oxidase,,,
contraindication,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,4710e965-7e92-4fef-b7fa-d4ecece6a606,7/18/2011,1,CABG,coronary artery bypass graft,,,
contraindication,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
contraindication,4b52487b-dfed-402e-ba8b-766f96313b67,4/21/2011,1,CABG,coronary artery bypass graft,,,
contraindication,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,CABG,coronary artery bypass graft,,,
contraindication,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,CABG,coronary artery bypass graft,,,
contraindication,b720c99f-feaa-4453-ba4a-c3377501f7b8,8/1/2011,4,CABG,coronary artery bypass graft,,,
contraindication,2238E083-08F2-0AA8-59B7-16B6D68DBD48,12/3/2008,1,CYP 3A,cytochrome P450 3A,,,
contraindication,ea8ce5e2-dad4-4288-a1e1-775ea98a6fb9,8/11/2009,4,CABG,coronary artery bypass graft,,,
contraindication,07506e83-e681-4225-8c65-3e8d21d69064,6/21/2012,9,CABG,coronary artery bypass graft,,,
contraindication,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,CABG,coronary artery bypass graft,,,
contraindication,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,MAO,monoamine oxidase,,,
contraindication,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,MAO,monoamine oxidase,,,
contraindication,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,PEP,post-exposure prophylaxis,,,
contraindication,4077592a-8790-4d45-8cb6-2c95a0a929de,7/25/2011,1,CABG,coronary artery bypass graft,,,
contraindication,967ef131-3dce-4c05-8f17-a5c9e01ca9a0,6/9/2011,1,CABG,coronary artery bypass graft,,,
contraindication,31eaf8b6-5e2a-424c-8830-2c561044cdf8,3/30/2012,1,CABG,coronary artery bypass graft,,,
contraindication,326fa31a-5420-429b-9f7f-170cb38f64bd,7/22/2011,4,CYP3A,cytochrome P450 3A,,,
contraindication,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,5e46b7e9-e640-4db5-882f-73a5dd2482d2,6/2/2010,1,CABG,coronary artery bypass graft,,,
contraindication,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,CABG,coronary artery bypass graft,,,
contraindication,026da3c7-c865-4eff-a6e5-381f9645f717,12/6/2010,121,CABG,coronary artery bypass graft,,,
contraindication,039c413c-acd2-4e8c-a619-2f48c58ae3c2,6/18/2010,1,CYP 3A,cytochrome P450 3A,,,
contraindication,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,MAO,monoamine oxidase,,,
contraindication,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,c4b45105-6b8a-45f7-bf50-9fc83b84d048,6/28/2011,1,CABG,coronary artery bypass graft,,,
contraindication,1b8aeeb9-5f5c-4591-b4a5-78a2e84dff3f,5/10/2011,1,CABG,coronary artery bypass graft,,,
contraindication,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,041ae7f6-7e42-4803-a015-f3bfcce277ba,6/9/2011,4,CYP3A,cytochrome P450 3A,,,
contraindication,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,CABG,coronary artery bypass graft,,,
contraindication,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,MAO,monoamine oxidase,,,
contraindication,cf6676ff-1122-4495-b64d-f70771a09633,1/22/2010,1,MAO,monoamine oxidase,,,
contraindication,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,CABG,coronary artery bypass graft,,,
contraindication,f56be63c-88e4-4b78-b12d-d80e3e8b3893,8/9/2007,1,CABG,coronary artery bypass graft,,,
contraindication,8f424c9c-8d19-4619-9607-abb1eea55dcb,11/9/2009,2,CABG,coronary artery bypass graft,,,
contraindication,7b71e4c3-86f2-464a-b0a9-4f98adfef9c5,11/9/2009,2,CABG,coronary artery bypass graft,,,
contraindication,676b8fd6-b611-4df1-a52c-2f08b0f4d031,6/14/2012,3866,CYP 3A,cytochrome P450 3A,,,
contraindication,b2fbd294-5fb9-45bc-baf0-8c5b72bddb74,10/22/2010,1,hCG,human chorionic  gonadotropin,,,
contraindication,07c33315-90c9-4a73-bf1d-bca70c7e0ff5,9/29/2010,405,MAO,monoamine oxidase,,,
contraindication,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,MAOI,monoamine oxidase inhibitor,,,
contraindication,9ce60fd6-b58b-4b7c-835d-305107552f44,5/15/2009,1,CABG,coronary artery bypass graft,,,
contraindication,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,e58f5696-806d-42ad-9357-a30cb7b3652b,12/19/2011,3394,CABG,coronary artery bypass graft,,,
contraindication,6D743386-A8E4-4A3F-AC82-C046896F35AE,8/4/2008,1,CYP 3A,cytochrome P450 3A,,,
contraindication,A8207FBD-F307-4120-95F7-4276A63BD4A1,5/3/2007,2,CABG,coronary artery bypass graft,,,
contraindication,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,MAOIs,monoamine oxidase inhibitors,,,
contraindication,30d013bd-1038-4f4e-a5ed-433dca2bdbdb,11/23/2010,105,CABG,coronary artery bypass graft,,,
contraindication,3b2c237c-f551-4cfc-8338-ee33e52929a8,4/25/2011,3,CABG,coronary artery bypass graft,,,
contraindication,a5cb1c8d-dc64-4e38-ab17-1682c76a0bad,4/12/2011,1,CABG,coronary artery bypass graft,,,
contraindication,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,MAOIs,monoamine oxidase inhibitors,,,
contraindication,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,86530199-999b-9f92-b1bc-b8515ec829f3,9/26/2011,2,MAO,monoamine oxidase,,,
contraindication,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,CABG,coronary artery bypass graft,,,
contraindication,1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5,6/24/2011,102,PRCA,Pure red cell aplasia,,,
contraindication,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,MAOI,Monoamine Oxidase Inhibitors,,,
contraindication,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,CABG,coronary artery bypass graft,,,
contraindication,a28547a9-0831-488b-bfdf-7ae8bed82da9,11/17/2010,466,CABG,coronary artery bypass graft,,,
contraindication,18f94362-34c5-4271-9177-d81c92fa2d41,3/2/2012,1,PDE-5,phosphodiesterase-5,,,
contraindication,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox,ceftizoxime for injection,,,
contraindication,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,CABG,coronary artery bypass graft,,,
contraindication,e612049e-fff7-4218-8663-b92d12f83fbd,11/23/2010,461,CABG,coronary artery bypass graft,,,
contraindication,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,MAO,monoamine oxidase,,,
contraindication,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,CABG,coronary artery bypass graft,,,
contraindication,71359f14-0f8f-4e90-af1d-426e8c21bd61,8/1/2011,12,MAO,monoamine oxidase,,,
contraindication,82207a72-07a0-4501-aff4-8a6f6e2bccb3,8/23/2011,1,CABG,coronary artery bypass graft,,,
contraindication,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,DHT,5?-dihydrotestosterone,,,
contraindication,4b5513c3-b57f-46f1-9855-dad1063aa4c9,4/7/2010,2,CABG,coronary artery bypass graft,,,
contraindication,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,a43c1fa5-1c00-413b-8709-27894367ddab,7/8/2011,1,CABG,coronary artery bypass graft,,,
contraindication,2f3804f1-ce47-4c1c-a012-b7c0c3088105,3/11/2011,1,MAO,monoamine oxidase,,,
contraindication,dfd184f0-2e52-454c-8ef2-3153be7dd4c9,9/8/2011,1,CABG,coronary artery bypass graft,,,
contraindication,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,MAO,monoamine oxidase,,,
contraindication,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,MAOI,monoamine oxidase inhibitor,,,
contraindication,c149ba5c-4c25-426a-a172-6ac3b899cbe3,10/25/2011,1,CABG,coronary artery bypass graft,,,
contraindication,082A3791-20C6-4FFA-A113-B60128344381,10/28/2008,1,CYP3A,cytochrome P450 3A,,,
contraindication,61ba7f4a-08e9-48c0-b2ff-509e79cfecda,8/11/2011,2,CABG,coronary artery bypass graft,,,
contraindication,ad436213-ad9b-42cd-8836-ade94ad990d8,6/5/2012,1,CABG,coronary artery bypass graft,,,
contraindication,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAOI,monoamine oxidase inhibitor,,,
contraindication,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,MAO,monoamine oxidase,,,
contraindication,87e10b06-773c-4d7b-97a7-34b2437c2b53,12/15/2010,2,MAOI,monoamine oxidase inhibitor,,,
contraindication,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,MAO,monoamine oxidase,,,
contraindication,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,MAOI's,monoamine oxidase inhibitors,,,
contraindication,AF5B3E8B-D6DC-4664-89A7-F347D1853ACE,3/30/2007,1,MAO,monoamine oxidase,,,
contraindication,a697e731-8d19-4845-8f31-16c4b19bb338,10/27/2009,2,CABG,coronary artery bypass graft,,,
contraindication,bae70c53-6ef4-4d0e-afd5-7d6c20a952ef,5/10/2011,3,MAO,monoamine oxidase,,,
contraindication,2e419114-8733-409c-ac5d-3c5ebbd2cb33,9/8/2011,1,CABG,coronary artery bypass graft,,,
contraindication,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,MAO,monoamine oxidase,,,
contraindication,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,953CEE06-5C26-4F30-870A-46B9FBB66E79,3/8/2007,1,CABG,coronary artery bypass graft,,,
contraindication,92ae1de4-6b27-4f03-acb5-7170664f67cb,9/11/2006,1,Plus,prednisolone acetate ophthalmic suspension,,,
contraindication,238050FD-5221-4B93-BFCD-31793C9088A7,11/15/2007,2,CYP3A,cytochrome P450 3A,,,
contraindication,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,b498d45e-c832-420a-b975-18800a14c029,8/3/2007,1,MAO,monoamine oxidase,,,
contraindication,987a91b8-dd9e-47ce-bd43-f8189a54838e,3/7/2008,1,MAO,monoamine oxidase,,,
contraindication,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,MAO,monoamine oxidase,,,
contraindication,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,CABG,coronary artery bypass graft,,,
contraindication,705f45f0-0be4-45f6-8268-3db0c8e8950a,1/12/2012,1,CABG,coronary artery bypass graft,,,
contraindication,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,CABG,coronary artery bypass graft,,,
contraindication,e18b3b92-2b7f-453a-ab43-7790a4e3020d,5/22/2011,3,CABG,coronary artery bypass graft,,,
contraindication,a585baa1-78b4-4d13-8b15-03144d402f98,1/12/2011,2,LEVONEST™,levonorgestrel and ethinyl estradiol tablets–triphasic regimen,,,
contraindication,62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,7/17/2008,1,CABG,coronary artery bypass graft,,,
contraindication,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,MAO,monoamine oxidase,,,
contraindication,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,NMS,neuroleptic malignant syndrome,,,
contraindication,9f5a14c2-b460-402e-acb4-04402278e64b,11/2/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,f674ad5c-b022-463a-af41-05bb03ee171b,6/2/2011,1,CABG,coronary artery bypass graft,,,
contraindication,60aa95a1-5f7d-4438-bf78-fba6127a022b,8/24/2011,1,CABG,coronary artery bypass graft,,,
contraindication,315a70bc-bfd8-471d-9379-d2746823537d,12/2/2009,1,MAO,monoamine oxidase,,,
contraindication,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,MAO,monoamine oxidase,,,
contraindication,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,6569dfd1-0164-4241-b508-ccd540d1e858,4/16/2010,2,CABG,coronary artery bypass graft,,,
contraindication,91571ecc-172d-458e-872d-89d71cb9c4b6,12/13/2011,3373,CABG,coronary artery bypass graft,,,
contraindication,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,NNRTI,non-nucleoside reverse transcriptase inhibitors,,,
contraindication,5beea615-1892-41fb-8c39-3f70aa6ab63d,3/27/2012,2,CABG,coronary artery bypass graft,,,
contraindication,e821dc08-e355-4a29-b053-8375bcb047cf,4/18/2011,1,CABG,coronary artery bypass graft,,,
contraindication,bd27460e-46ff-4450-a4f2-a41420c1f93d,1/14/2011,2,CABG,coronary artery bypass graft,,,
contraindication,AA447BAC-DFBD-44AE-B1D1-3E1BE6D7EF9E,2/21/2008,2,CABG,coronary artery bypass graft,,,
contraindication,fe580e12-03fa-4678-9887-458297007441,10/27/2009,2,CABG,coronary artery bypass graft,,,
contraindication,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,CABG,coronary artery bypass graft,,,
contraindication,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,MAO,monoamine oxidase,,,
contraindication,d0a209f9-0406-4868-89f6-fe864ccc5d7d,8/25/2011,2,MAO,monoamine oxidase,,,
contraindication,c3f47985-0027-4fa7-aab2-5bc6ca79a6e8,8/1/2011,7,CABG,coronary artery bypass graft,,,
contraindication,14000fc7-add4-4da3-bdb0-d7df75b3bde1,3/14/2012,1,CABG,coronary artery bypass graft,,,
contraindication,ee10e027-5953-4d10-8c58-5f2412978a49,4/7/2010,1,CABG,coronary artery bypass graft,,,
contraindication,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,MAOI,Monoamine Oxidase Inhibitors,,,
contraindication,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,6f49de96-1090-46bc-b7bf-0dc70f7d9530,8/1/2011,9,MAO,monoamine oxidase,,,
contraindication,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,MAOIs,monoamine oxidase inhibitors,,,
contraindication,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,CABG,coronary artery bypass graft,,,
contraindication,9244e41c-94c9-428b-a254-703b71f9460b,7/30/2009,1001,CABG,coronary artery bypass graft,,,
contraindication,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,MAO,monoamine oxidase,,,
contraindication,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,MAOI,monoamine oxidase inhibitor,,,
contraindication,110aada7-dfe8-4ecf-80c7-4dac8907ad29,5/4/2011,1,CABG,coronary artery bypass graft,,,
contraindication,907fce46-6f0f-4752-b9d3-838ae113f788,11/3/2011,1,CABG,coronary artery bypass graft,,,
contraindication,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,MAOI,monoamine oxidase inhibitor,,,
contraindication,e6d137df-c681-4cf1-8475-19731aaeb929,11/4/2011,1,CABG,coronary artery bypass graft,,,
contraindication,59e94a55-08b6-4d04-bc10-9911e5a585e0,11/11/2011,3142,CABG,coronary artery bypass graft,,,
contraindication,CA26071D-1FF4-4000-8104-17F211CC6B71,5/11/2006,1,UGDP,University Group Diabetes Program,,,
contraindication,403af9f8-63bf-41a2-bf3b-20e5b92c389a,8/1/2011,8,CABG,coronary artery bypass graft,,,
contraindication,E1FF4C1F-5D6F-44A6-A0F6-D7CA2A94ADB9,11/5/2007,2,MAO,monoamine oxidase,,,
contraindication,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,CABG,coronary artery bypass graft,,,
contraindication,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,MAO,monoamine oxidase,,,
contraindication,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,SR®*,(SR),,,
contraindication,c957df9a-eb66-432f-a280-9cd74389d667,8/1/2011,13,CABG,coronary artery bypass graft,,,
contraindication,397979cb-f605-4211-b810-0a4572d4b973,6/22/2012,1,CABG,coronary artery bypass graft,,,
contraindication,A69EC903-874E-4FEF-9E71-81E608DEB6A7,12/11/2008,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,MAOI,monoamine oxidase inhibitor,,,
contraindication,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,CABG,coronary artery bypass graft,,,
contraindication,635f8a00-0048-4421-9f5f-f8e38034f230,8/17/2011,1,CABG,coronary artery bypass graft,,,
contraindication,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,MAOIs,monoamine oxidase inhibitors,,,
contraindication,b695b4cc-f3b0-4704-910c-bd840efaf443,5/13/2011,2,CABG,coronary artery bypass graft,,,
contraindication,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,NMS,Neuroleptic Malignant  Syndrome,,,
contraindication,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,NMS,neuroleptic malignant syndrome,,,
contraindication,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,OCD,Obsessive Compulsive Disorder,,,
contraindication,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,triptan,treatment of fluoxetine with a 5-hydroxytryptamine receptor  agonist,,,
contraindication,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
contraindication,c7a79060-0369-4f9e-8fdd-f5351d23eeca,8/30/2011,1,CABG,coronary artery bypass graft,,,
contraindication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,d7a65845-41d3-4859-b29d-513cffc6d0be,3/28/2012,2,CABG,coronary artery bypass graft,,,
contraindication,a8ed14ef-cd4b-3be7-0b5f-b677c72d2e88,7/12/2011,1,CABG,coronary artery bypass graft,,,
contraindication,e077756b-af95-40e9-a65c-1b03012c855b,10/26/2011,1,MAOI,monoamine oxidase inhibitors,,,
contraindication,41f58ecc-abce-46cc-b18d-1acea74cfa39,3/1/2012,1,CABG,coronary artier bypass graft,,,
contraindication,70e73a11-5951-43db-9cd2-dc851cd5fa7b,11/11/2009,1005,CABG,coronary artery bypass graft,,,
contraindication,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,MAOIs,monoamine oxidase inhibitors,,,
contraindication,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,MAO,monoamine oxidase,,,
contraindication,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,CABG,coronary artery bypass graft,,,
contraindication,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,CABG,coronary artery bypass graft,,,
contraindication,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,CABG,coronary artery bypass graft,,,
contraindication,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,monoamine oxidase,,,
contraindication,baa6d111-4222-4fa8-b7d2-295310177d96,4/26/2011,1,MAO,monoamine oxidase,,,
contraindication,21f82a95-c283-4c18-b47d-f6ba26e34299,6/9/2011,1,CABG,coronary artery bypass graft,,,
contraindication,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,CABG,coronary artery bypass graft,,,
contraindication,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,MAOIs,monoamine oxidase inhibitors,,,
contraindication,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAOI,monoamine oxidase inhibitor,,,
contraindication,763213c9-3e4b-4ea1-a544-f7d3720568ad,12/28/2011,3,CABG,coronary artery bypass graft,,,
contraindication,07800675-f689-47d7-8203-073c797f7e21,10/18/2011,1,MAOI,monoamine oxidase inhibitors,,,
contraindication,3364cee6-0a88-47bb-9af8-8e90843de236,8/1/2011,9,CYP 3A,cytochrome P450 3A,,,
contraindication,f2432095-d84f-4c1f-a2d7-c318f28b5a36,12/29/2009,3,CABG,coronary artery bypass graft,,,
contraindication,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,CABG,coronary artery bypass graft,,,
contraindication,a5a77f2d-2833-4dd9-8839-95f0e63b1606,3/8/2011,1,CABG,coronary artery bypass graft,,,
contraindication,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,PEP,post-exposure prophylaxis,,,
contraindication,2c6fb487-5574-44e0-a3e7-fc6e666dbc11,4/21/2011,1,CABG,coronary artery bypass graft,,,
contraindication,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,MAOIs,monoamine oxidase inhibitors,,,
description,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,C0938808-FE14-4B8D-98C4-D04DCC5C9642,8/7/2008,3,logP,log partition coefficient,,,
description,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,HUMAN,human plasma used in the manufacture of ALBUMIN,,,
description,f6dd9b86-0d18-95d4-2bc7-05591bfdd597,1/31/2012,15,DPP-4,dipeptidyl peptidase-4,,,
description,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,I.V.,Intravenous,,,
description,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,HCl,hydrochloride,,,
description,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,I.M.,Intramuscular,,,
description,caaa9ab5-e3f4-489d-9f4c-0ecbee6fca83,12/25/2011,11,HVL,half-value layer,,,
description,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
description,11baee9b-f5ff-4671-9d38-483df70a19d2,1/18/2011,2,mL,milliliter,,,
description,376093e7-e09e-4a57-3199-195e45251866,8/22/2011,10,mL,milliliter,,,
description,23c49912-42da-442b-9c17-54d1a53ce43d,7/13/2011,1,TK,thymidine kinase,,,
description,966d728e-87ca-4491-9411-2ec253eca632,8/12/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
description,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,IUPAC,International Union of Pure and Applied Chemistry,,,
description,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,HCl,hydrochloride,,,
description,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,IV,intravenous,,,
description,01c5574c-1056-49c6-af20-e950db3f4139,9/24/2010,1,HIV,human immunodeficiency virus,,,
description,1ec26930-abe6-4db3-9315-aa896f7d5232,5/18/2009,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,75a54819-053b-4347-8b14-7b9ccc575042,4/9/2009,1,COX-2,cyclooxygenase-2,,,
description,75a54819-053b-4347-8b14-7b9ccc575042,4/9/2009,1,NSAIDS,Non-steroidal anti-inflammatory drugs,,,
description,75a54819-053b-4347-8b14-7b9ccc575042,4/9/2009,1,ACE,angiotensin converting  enzyme,,,
description,b2f0ca0d-76e9-45f0-bf60-e9781c227676,5/1/2012,5,Iron,iron complex,,,
description,6281ca7c-2aec-4f14-b7e4-82401a701c96,9/19/2006,3,CNS,central nervous system,,,
description,f0e13ed2-910d-463c-b023-0e427cf3819e,12/14/2010,141,7.5 mg/mL,9.75 mg/1.3 mL,,,
description,380436f7-7a26-462b-a098-315b48d9ba68,9/12/2006,1,logP,log partition coefficient,,,
description,21bfd9fb-6963-4149-ba3d-e2c79f8b05d8,3/27/2012,2,mL,milliliter,,,
description,f548be5b-f479-4ca9-983c-6f5a76281d12,2/1/2011,2,logP,log partition coefficient,,,
description,f548be5b-f479-4ca9-983c-6f5a76281d12,2/1/2011,2,ER,Extended-Release,,,
description,92FE06D1-9AEC-47B4-B7FC-AEA6434CBE10,6/1/2006,1,EDTMP,ethylenediaminetetramethylenephosphonic acid,,,
description,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,5-ASA,5-aminosalicylic acid,,,
description,cbd3396e-6b85-41bf-82d2-940beba86686,5/1/2012,2,TNAs,total nutrient admixtures,,,
description,22e92e0a-77ad-4128-8ea9-28766297026a,12/22/2010,1,PET,polyethylene terephthalate,,,
description,DC293A1C-995D-40FA-AC99-68DF12EB6D9E,10/23/2006,1,BHT,butylated hydroxytoluene,,,
description,DC293A1C-995D-40FA-AC99-68DF12EB6D9E,10/23/2006,1,BHA,butylated hydroxyanisole,,,
description,3adddbd4-0b17-4312-83a2-a8420caf045e,3/28/2012,2,IM,Intramuscular,,,
description,3adddbd4-0b17-4312-83a2-a8420caf045e,3/28/2012,2,IV,Intravenous,,,
description,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,hFSH,human               follicle-stimulating hormone,,,
description,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,rDNA,recombinant DNA,,,
description,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,hFSH,human follicle-stimulating hormone,,,
description,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,CHO,Chinese hamster ovary,,,
description,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,LH,luteinizing hormone,,,
description,14496afb-a541-4b01-a672-fcd411292b8d,4/2/2007,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,11e4ff36-9925-49db-a2ef-7fa230f52317,8/24/2010,1,mL,milliliter,,,
description,A699614A-8E5B-4BEC-81C9-49305129EB39,12/18/2006,2,HCl,hydrochloride,,,
description,A754EAD7-1B6E-42C5-33A1-353EDB465F8E,1/12/2006,1,acetate,"align=""center"" valign=""top""><paragraph>425</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine",,,
description,A754EAD7-1B6E-42C5-33A1-353EDB465F8E,1/12/2006,1,acetate,"align=""center"" valign=""top""><paragraph>850</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine",,,
description,1b368b80-f054-4c47-bd62-0d77ca03ac53,3/11/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,3832ede8-d3fc-455d-ecab-3b77be5869f5,5/17/2011,11,IV,intravenous,,,
description,3832ede8-d3fc-455d-ecab-3b77be5869f5,5/17/2011,11,SC,subcutaneous,,,
description,3832ede8-d3fc-455d-ecab-3b77be5869f5,5/17/2011,11,IM,intramuscular,,,
description,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,CEFOTAN,cefotetan disodium for injection,,,
description,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,CEFOTAN,cefotetan injection,,,
description,476e704c-95ae-4591-94f7-ee4ab827ff13,2/23/2007,1,HCl,hydrochloride,,,
description,9a2b64bb-011a-4b23-b097-7dce576c57f8,10/12/2011,1,AEDs,antiepileptic drugs,,,
description,36a95013-bc64-415b-b429-d5318912df89,8/31/2009,2,NLT,not less than,,,
description,36a95013-bc64-415b-b429-d5318912df89,8/31/2009,2,USP,United States Pharmacopeia,,,
description,36a95013-bc64-415b-b429-d5318912df89,8/31/2009,2,NMT,not more than,,,
description,AD674645-D468-4720-B2FF-D47E96C061B3,4/7/2006,1,C15H25NO3,1-(isopropylamino)-3-[(C15H25NO3)2 -C4H6O6,,,
description,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,ALFENTA,alfentanil hydrochloride,,,
description,A2DE6991-EEB8-45A8-E0A7-B635C90A384A,12/4/2006,1,mL,milliliter,,,
description,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,IV,intravenous,,,
description,54662ff4-10d8-425f-a2ae-978715093da1,5/13/2010,5,logP,log partition coefficient,,,
description,1cf306eb-367b-4ccc-a15f-bea996015332,4/18/2007,1,ACE,angiotensin converting enzyme,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,AI,Adequate Intake,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,RFD,reference dose,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,GTF,glucose tolerance factor,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,T2DM,type 2 diabetes mellitus,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,IOM,Institute of Medicine,,,
description,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,DV,Daily Value,,,
description,EE91667E-B636-43CE-5796-3A9E738557A3,3/14/2007,2,IV,intravenous,,,
description,EE91667E-B636-43CE-5796-3A9E738557A3,3/14/2007,2,SC,subcutaneous,,,
description,EE91667E-B636-43CE-5796-3A9E738557A3,3/14/2007,2,IM,intramuscular,,,
description,de6a969a-7e0f-4e5f-8d12-de5c7129d39c,8/26/2010,1,mL,milliliter,,,
description,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,AEDs,antiepileptic drugs,,,
description,8baab7a7-5d20-46ad-9c4a-762992ef6b51,9/13/2011,1,Baseline,baseline and the post-ingestion measurements,,,
description,38f88829-a226-4810-866c-1b62c47e8aee,2/7/2012,2,IM,Intramuscular,,,
description,38f88829-a226-4810-866c-1b62c47e8aee,2/7/2012,2,IV,Intravenous,,,
description,961C81A1-4DFC-4CFC-D8AA-94FE79F8B2D2,7/5/2006,1,MPF,Methyl Paraben Free,,,
description,AE7C54B1-B440-4CCA-97E8-E5B825413D32,3/30/2007,1,logP,log partition coefficient,,,
description,df60f030-866b-4374-a31f-8ae3f6b45c38,7/11/2011,6,pNP-Glc,para-nitrophenyl-?-D-glucopyranoside,,,
description,8accbb78-fc64-45d5-69b0-35c23a1d2a2e,7/28/2011,11,IV,intravenous,,,
description,8accbb78-fc64-45d5-69b0-35c23a1d2a2e,7/28/2011,11,IM,intramuscular,,,
description,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
description,830a28fb-9b80-4fbb-99dc-56ec80e4e581,8/14/2007,1,E®,emollient cream,,,
description,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,IT,intrathecal,,,
description,84f74103-3e89-4b8b-a2fb-d7ed13e03521,5/9/2011,1,TK,thymidine kinase,,,
description,9647db9a-065f-46a7-acfe-b74aeb532789,12/17/2009,4,mg/mL,mg/5 mL,,,
description,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,ara-A,9-?-D-arabinofuranosyladenine,,,
description,1acbe215-8cbb-491b-a5f5-34bab337aa99,6/12/2012,4,HVL,half-value layer,,,
description,1ab87313-f82a-4819-9e32-f1320a747fef,1/28/2011,2,HVL,half-value layer,,,
description,912c536b-0d0c-4a9f-8778-c1534ceca658,11/1/2010,7,NSAID,nonsteroidal anti-inflammatory drug,,,
description,a41b3e0c-8f43-49a5-90ea-0509e5fc18e2,8/10/2010,1,mL,milliliter,,,
description,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,AEDs,antiepileptic drugs,,,
description,8e80c83e-a03c-4dc8-a0d8-2f07532c01aa,9/8/2010,1,mL,milliliter,,,
description,2028be0c-333c-4e0c-be57-099276c725d7,12/12/2011,2,HVL,half-value layer,,,
description,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SSRI,selective serotonin reuptake inhibitor,,,
description,7ef9e3a5-fc39-4ae1-0dad-6b47a1684635,2/22/2012,2,mL,mg phospholipids,,,
description,b630824c-bee7-4a78-9349-d995c1eb0f16,3/12/2009,1,ACE,angiotensin-converting enzyme,,,
description,dad7735c-709b-40ea-ab7a-15577e24a966,11/18/2011,2,DEHP,di-2-ethylhexyl phthalate,,,
description,8189025b-d21d-405b-96d4-50a3428e9037,9/25/2009,1,Calcium,calcium phosphate,,,
description,cc430bfd-6940-41ca-bda4-6d29eb4dc1f2,1/1/2011,2,HVL,half-value layer,,,
description,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,MPEG-DSPE,N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt,,
description,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,HCl,hydrochloride,,,
description,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
description,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,HSPC,hydrogenated soy phosphatidylcholine,,,
description,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,HCl,hydrochloride,,,
description,3cdbb3b0-6a82-4e53-9252-140d9d313ab0,11/18/2009,1,Calcium,calcium phosphate,,,
description,5bb99cd0-a9e6-4df6-a694-a27430c8f996,11/18/2011,2,MPF,Methyl Paraben Free,,,
description,49E5A402-A084-4B48-9ADE-1E123F49391E,1/23/2008,1,ISDN,Isosorbide dinitrate,,,
description,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,ara-A,#NAME?,,,
description,e58e52c4-50f9-4727-9950-bfefadabb2d0,12/31/2009,2,CNS,central nervous system,,,
description,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,3/6/2012,6,PMFE,pentafluoromethoxy isopropyl fluoromethyl ether,,,
description,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,3/6/2012,6,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,3/6/2012,6,PIFE,pentafluoroisopropenyl fluoromethyl ether,,,
description,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,ADP,adenosine diphosphate,,,
description,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,HUMAN,human plasma used in the manufacture of ALBUMIN,,,
description,1d5beebf-77f3-47ca-a9a1-5f64f42fed07,5/22/2012,3,AUC,area under the curve,,,
description,c85e6c03-ca15-4c61-b023-22b0f50cbe9a,1/11/2012,2,MPF,Methyl Paraben Free,,,
description,08290748-39dc-4f89-b582-b7eb8b482a2e,4/25/2011,2,mL,milliliter,,,
description,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,IV,intravenous infusion,,,
description,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,SC,subcutaneous injection,,,
description,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,rhu GM-CSF,recombinant human granulocyte-macrophage colony stimulating factor,,,
description,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
description,AD74FBC0-3EE4-401A-A0C2-4DF5CD151D38,12/18/2007,3,1 mCi,1 mL and each milliliter contains 37 MBq,,,
description,AC7A6838-AA9F-4855-B410-351649A272C3,8/20/2008,1,logP,log partition coefficient,,,
description,37ab59db-4cf2-49bf-9379-498c47d01287,2/9/2012,1,HVL,half-value layer,,,
description,7d5fbee5-a8e7-4f5d-954a-ed6623ba2f19,9/28/2011,1,logP,log partition coefficient,,,
description,A48B7542-EF46-4FF9-9496-468D3B4046EE,9/11/2008,1,tizanidine,Tizanidine HCl,,,
description,A2C1F1B7-70B0-416B-8BDF-9EAED156E34B,4/12/2006,1,C17H19NO3,formula:(C17H19NO3)2•H2SO4????????????Molecular Weight: 668.77,,,
description,f78387c2-e64e-404c-a6e1-03328df2515e,11/19/2010,1,SODAS®,Spheroidal Oral  Drug Absorption System,,,
description,08570dbd-45f7-47d2-8b63-b4e63995e966,8/1/2011,7,NSAID,nonsteroidal anti-inflammatory drug,,,
description,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,E coli,Escherichia coli,,,
description,007B604F-9776-4F64-95DB-C0AAC776FA5D,10/15/2008,1,KGF,keratinocyte growth factor,,,
description,9CDAF357-6EA9-4B6A-860F-C28EDC653FFD,1/12/2006,1,logP,log partition coefficient,,,
description,9822CA3F-AEE2-46E5-8A96-495400E65D10,10/6/2006,1,mL,milliliter,,,
description,d6c156b2-99f6-4f26-9430-908cd966213c,5/3/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,b14ef252-fe31-4dfd-840d-2588f591cb7c,2/27/2009,4,GI,gastrointestinal,,,
description,b720c99f-feaa-4453-ba4a-c3377501f7b8,8/1/2011,4,NSAID,nonsteroidal anti-inflammatory drug,,,
description,aea0b5a1-444b-4330-a3ce-26485dbbfe75,8/4/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
description,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,PIF,peak inspiratory flow,,,
description,61767a0d-c94c-44d8-b35c-316a5731a275,2/9/2012,3,IM,Intramuscular,,,
description,61767a0d-c94c-44d8-b35c-316a5731a275,2/9/2012,3,IV,Intravenous,,,
description,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
description,61409678-d2f6-42cd-b03d-b26b11b39641,3/19/2012,1,HIV-1,Human Immunodeficiency Virus Type 1,,,
description,d17d767b-08c4-4a25-ad73-03a36d56902a,8/16/2011,6,SSRI,selective serotonin reuptake inhibitor,,,
description,27d36fbf-1892-48e1-a9b1-1625607ea516,7/12/2007,1,BHT,butylated hydroxytoluene,,,
description,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,MAOI,monoamine oxidase inhibitors,,,
description,7f675fee-8940-4ece-bb0c-75ac79d8708c,12/23/2010,7,DEHP,di 2-ethylhexyl phthalate,,,
description,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
description,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,E. coli,Escherichia coli,,,
description,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,SC,subcutaneous,,,
description,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,PDT,photodynamic therapy,,,
description,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,HGD,high-grade dysplasia,,,
description,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,BE,Barrett’s esophagus,,,
description,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
description,94c12711-d672-450d-baae-06e24a72aace,9/19/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,1b8aeeb9-5f5c-4591-b4a5-78a2e84dff3f,5/10/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,anti-Xa,anti-Factor Xa IU,,,
description,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,anti-Xa,anti-factor Xa,,,
description,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,4A18ECF0-8FD6-4A60-B88E-AE5AC73E958A,6/6/2006,1,tizanidine,Tizanidine HCl,,,
description,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,8fbd0773-6645-4235-9ef2-56edf9c7fb83,1/10/2008,1,ADH,avoid possible contamination with vasopressin,,,
description,6f25ed16-e5e9-4170-b4b4-3b460887779e,12/16/2011,9,ACE,angiotensin converting enzyme,,,
description,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,149b6307-91f4-4e0d-8741-0a7211e1aaff,10/25/2011,1,MPF,Methyl Paraben Free,,,
description,5fa6a683-9685-4591-bd00-19f15c9bcf12,1/23/2008,1,Solution,solution,,,
description,9b15b867-36a9-4896-9ecf-94de607bf50d,12/31/2009,2,DHA,Docosahexaenoic Acid,,,
description,9b15b867-36a9-4896-9ecf-94de607bf50d,12/31/2009,2,EPA,Eicosapentaenoic Acid,,,
description,d19c57bd-56f8-4640-b891-18f9c365e372,4/23/2012,6,HIV-1,human immunodeficiency virus type 1,,,
description,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,CEFOTAN,cefotetan disodium for injection,,,
description,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,CEFOTAN,cefotetan injection,,,
description,37992a25-68bd-4050-b936-596ddedc25a3,1/31/2009,1,NTD's,Neural tube defects,,,
description,37992a25-68bd-4050-b936-596ddedc25a3,1/31/2009,1,PIC,Polysaccharide iron complex,,,
description,f8fd8297-4d47-4781-93ef-d0e6946fc55c,6/14/2010,2,WNV,West Nile virus,,,
description,f8fd8297-4d47-4781-93ef-d0e6946fc55c,6/14/2010,2,HCV,hepatitis C virus,,,
description,d834721b-b624-4b27-9009-95e09827122e,11/15/2010,2,HVL,half-value layer,,,
description,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,AEDs,antiepileptic drugs,,,
description,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,RARs,retinoic acid receptors,,,
description,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,bexarotene,bexarotene.®,,,
description,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,RXRs,retinoid X receptors,,,
description,A8207FBD-F307-4120-95F7-4276A63BD4A1,5/3/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
description,30d013bd-1038-4f4e-a5ed-433dca2bdbdb,11/23/2010,105,NSAID,nonsteroidal anti-inflammatory drug,,,
description,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,SSRI,selective serotonin reuptake inhibitor,,,
description,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
description,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,DEHP,di-(2- ethylhexyl)phthalate,,,
description,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,PVC,polyvinylchloride,,,
description,025fee85-53a8-4161-a806-44fd95d0ca74,12/31/2009,1,PIC,Polysaccharide iron complex,,,
description,025fee85-53a8-4161-a806-44fd95d0ca74,12/31/2009,1,PIC,Polysaccharide Iron Complex,,,
description,025fee85-53a8-4161-a806-44fd95d0ca74,12/31/2009,1,FTM,Fumarate and Polysaccharide Iron Complex,,,
description,1bf429e3-6e0c-4244-ba1a-af1a3a153c24,8/3/2010,1,mL,milliliter,,,
description,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox®,ceftizoxime for injection,,,
description,22700993-851a-48aa-941e-1d2b6b04081f,5/30/2012,1,HFIP,hexafluoroisopropanol,,,
description,22700993-851a-48aa-941e-1d2b6b04081f,5/30/2012,1,PMFE,pentafluromethoxy isopropyl fluoromethyl ether,,,
description,22700993-851a-48aa-941e-1d2b6b04081f,5/30/2012,1,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,delta-9-THC,delta-9-tetrahydrocannabinol,,,
description,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,mL,mg dalteparin sodium,,,
description,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,Injection,injection,,,
description,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,IU,international units,,,
description,75e6a13c-39a7-4df0-b39a-b65b8bd7f618,11/5/2010,450,SBECD,sulfobutylether ?-cyclodextrin sodium,,,
description,becc7410-0a25-49f5-b0c3-240078479dc8,12/11/2009,3,DEHP,di-2-ethylhexyl phthalate,,,
description,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
description,d77846ab-bce6-4646-8c09-ddfcf09898a3,5/23/2011,1,DHA,Docosahexaenoic Acid,,,
description,d77846ab-bce6-4646-8c09-ddfcf09898a3,5/23/2011,1,EPA,Eicosapentaenoic Acid,,,
description,6982a931-15b8-482a-bfe0-05d61f37b462,6/17/2011,1,BHA,Butylated hydroxyanisole,,,
description,5d05df4a-463e-4e66-9387-f3a842e20cd0,1/28/2011,2,HVL,half-value layer,,,
description,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,DPPG,1,2-dipalmitoyl-sn-glycero-3?phospho-rac-(1-glycerol),,
description,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,DOPC,1,2-dioleoyl-sn-glycero-3?phosphocholine,,
description,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,DEHP,di-(2-ethylhexyl)phthalate,,,
description,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,PVC,polyvinylchloride,,,
description,926914a9-78b2-40ea-b37d-2a55c09bf275,8/9/2010,3,WHO,World Health Organization,,,
description,926914a9-78b2-40ea-b37d-2a55c09bf275,8/9/2010,3,IU,International Unit,,,
description,89967042-5a78-451a-af91-bab38afa7a4d,8/2/2010,5,HCl,hydrochloride,,,
description,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
description,7E971C99-1F3F-4A9F-5084-FBE5B9F1A9E1,10/3/2006,1,OINTMENT,ointment,,,
description,b0172db6-fd8d-4ef3-873d-6c4de6538454,12/2/2011,7,DEHP,di-2-ethylhexylphthalate,,,
description,aee04f17-8ee9-42f5-861f-b6ba17220ca4,3/31/2011,3,ACE,angiotensin-converting enzyme,,,
description,9b8ea543-1de8-472f-9666-34f99ca2f183,2/27/2006,1,IV,intravenous,,,
description,01ab131c-7b06-4982-8cf0-4e60879e0c8c,8/25/2010,1,mL,milliliter,,,
description,508a406f-56cc-4032-99b9-0979fef6467a,8/10/2011,1,GI tract,Gastro Intestinal tract,,,
description,71c0cfcf-e6b9-47ae-8039-391702a0ab68,5/1/2012,1,Iron,iron complex,,,
description,ea1b0dc1-bd3d-4762-9f27-4300e4606d3d,6/22/2012,3,PPA,Phenylpropanolamine hydrochloride,,,
description,7ac7db49-16ff-4c29-9327-54323ba415c9,4/21/2010,4,cGMP,current good manufacturing practices,,,
description,7ac7db49-16ff-4c29-9327-54323ba415c9,4/21/2010,4,EPA,Eicosapentaenoic Acid,,,
description,11fa7725-cb19-46f6-9468-01a0a430492c,10/8/2006,1,ISDN,Isosorbide dinitrate,,,
description,545776FE-63DF-44AB-ACE3-F3D73D2E0092,5/11/2006,1,FLUOR-OP,fluorometholone ophthalmic suspension,,,
description,3f30e6a5-f3c0-4c20-b1a2-142575eb0e24,9/13/2011,1,5-HT1B/1D,5-hydroxytryptamine1B/1D,,,
description,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,AEDs,antiepileptic drugs,,,
description,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,EDDP,2-ethylidene1,5-dimethyl-3,3-diphenylpyrrolidene,
description,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,NMDA,N-methyl-D-aspartate,,,
description,aa88f583-4f5f-433b-80b4-1f4c9fb28357,9/21/2011,5,EAE,encephalomyelitis,,,
description,62bd8d9d-0806-4e8d-a6e1-e7dddc2b5404,7/17/2008,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,BHA,Butylated hydroxyanisole,,,
description,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,RARs,retinoic acid receptors,,,
description,E415C4C8-3144-4172-94A0-F4F3243130AE,3/28/2006,1,RXRs,retinoid X                             receptors,,,
description,9f5a14c2-b460-402e-acb4-04402278e64b,11/2/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
description,01655AF6-E754-49B5-B130-DD2416A7CF1C,3/28/2008,1,ACE,angiotensin-converting enzyme,,,
description,C0715FAA-E6E5-4556-FC9B-3E6478578435,1/25/2007,1,MPF,Methyl Paraben Free,,,
description,a912d27c-00cb-2ed0-effe-2d88d1f2ca67,8/1/2008,4,HUMAN,human plasma used in the manufacture of ALBUMIN,,,
description,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,IONSYS™,iontophoretic transdermal system,,,
description,e821dc08-e355-4a29-b053-8375bcb047cf,4/18/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,f5cfb61e-d971-4a9c-b9ef-4f3368fe02f5,6/12/2012,7,hydrous,hydrochloride USP,,,
description,29F674BB-701C-49D5-B77C-456EB2464FF2,8/3/2007,2,logP,log partition coefficient,,,
description,4A423BBA-3BC1-4323-ABBB-EF6C5C315784,11/17/2006,1,IUPAC,International Union of Pure and Applied Chemistry,,,
description,ee10e027-5953-4d10-8c58-5f2412978a49,4/7/2010,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,C33601EC-EF89-4BD4-8485-F81871AFAD94,8/23/2006,1,logP,log partition coefficient,,,
description,dcb80f61-817a-496e-8fbe-c2d8b08efa13,4/20/2011,3,EFA,essential fatty acid,,,
description,dcb80f61-817a-496e-8fbe-c2d8b08efa13,4/20/2011,3,DHA,docosahexaenoic acid,,,
description,dcb80f61-817a-496e-8fbe-c2d8b08efa13,4/20/2011,3,i.e.,in the United States,,,
description,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,PET,positron emission tomography,,,
description,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,EOS,end of synthesis,,,
description,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,HVL,half-value layer,,,
description,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,PEG 400,polyethylene glycol 400,,,
description,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,DHFR,dihydrofolate reductase,,,
description,71b33cc6-2801-4cd7-857d-9398cea3d5d2,9/20/2011,1,TK,thymidine kinase,,,
description,e196c127-c081-43a7-8f0d-be3e2b434b50,10/6/2010,1,AEDs,antiepileptic drugs,,,
description,e6d137df-c681-4cf1-8475-19731aaeb929,11/4/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,403af9f8-63bf-41a2-bf3b-20e5b92c389a,8/1/2011,8,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,e93460a9-8c68-4679-aa86-73f47884fd8c,6/7/2012,2,HVL,half-value layer,,,
description,711fa83c-c283-4b26-aa22-fc6ec215ce42,4/24/2007,1,IM,Intramuscular,,,
description,711fa83c-c283-4b26-aa22-fc6ec215ce42,4/24/2007,1,IV,Intravenous,,,
description,fa3cbd5d-677c-4b19-9032-d9182cb69a83,5/1/2012,4,pNP-Glc,para-nitrophenyl-?-D-glucopyranoside,,,
description,8A44F966-7F5A-4245-88B6-581F71F7B038,3/31/2007,1,HM-PAO,hexamethylpropylene amine oxime,,,
description,93bbb992-f6b1-44a2-9de8-46208f3abdf5,7/25/2011,1,EPA,Eicosapentaenoic Acid,,,
description,93bbb992-f6b1-44a2-9de8-46208f3abdf5,7/25/2011,1,cGMP,current good manufacturing practice,,,
description,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
description,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,DMSO,dimethyl sulfoxide,,,
description,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,IV,intravenous,,,
description,cff1fed3-1f30-4da9-93b4-8eebd0fd88b3,10/18/2011,2,IM,intramuscular,,,
description,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,AEDs,antiepileptic drugs,,,
description,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,7.5 mg/mL,9.75 mg/1.3 mL,,,
description,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
description,6e76d0ef-93ca-4be9-8384-65656fe8bd47,12/5/2009,1,I.V.,Intravenous,,,
description,6e76d0ef-93ca-4be9-8384-65656fe8bd47,12/5/2009,1,HCl,hydrochloride,,,
description,6e76d0ef-93ca-4be9-8384-65656fe8bd47,12/5/2009,1,I.M.,Intramuscular,,,
description,edb15e3c-848d-433d-9f1c-c73a3c72861b,12/1/2011,1,HVL,half-value layer,,,
description,d5f0457f-b722-48b7-8901-61da7fbb4090,8/1/2011,11,MDD,major depressive disorder,,,
description,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,DHT,5?-dihydrotestosterone,,,
description,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,PET,positron emission tomography,,,
description,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,EOS,end of synthesis,,,
description,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,HVL,half-value layer,,,
description,15ca19c2-f28b-4703-aa23-5af265af9e8b,10/27/2011,2,TIMOPTIC,timolol maleate ophthalmic solution,,,
description,6f25ed16-e5e9-4170-b4b4-3b460887779d,1/1/2011,1,ACE,angiotensin converting enzyme,,,
description,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,AEDs,antiepileptic drugs,,,
description,cfd96e4b-fcf1-4959-aaf4-7aabe0d80ab5,11/13/2008,2,ACE,angiotensin converting enzyme,,,
description,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,82CEB312-3AAA-4A5C-9849-7F246CC06DED,3/10/2008,1,i.v.,intravenous,,,
description,ECA8BCBB-33E4-4EF9-9BA5-2D8C91E2DAEA,4/7/2006,1,HIV,human immunodeficiency virus,,,
description,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,DHT,5?-dihydrotestosterone,,,
description,52146dd3-bbf8-4486-803f-69a779adbcad,9/28/2011,1,MPF,Methyl Paraben Free,,,
description,13DDBD97-DA1A-D20D-FEEF-8F8B737126F0,1/12/2007,1,ACE,angiotensin-converting enzyme,,,
description,043F8DEA-E33C-455D-2EB6-D7EB1506B4DD,5/20/2009,2,DEHP,di-2-ethylhexyl phthlate,,,
description,c20e9333-aab2-4781-a755-5cee11b043d8,7/14/2011,1,TK,thymidine kinase,,,
description,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,SSRI,selective serotonin reuptake inhibitor,,,
description,5ceed28f-2cb1-4eef-b1ce-3cc83b8f49aa,2/3/2010,1,HIV,human immunodeficiency virus,,,
description,dd4944b6-9d6e-4180-bb68-c0516a27a379,8/31/2010,1,mL,milliliter,,,
description,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
description,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,DHT,5?-dihydrotestosterone,,,
description,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,S/D,solvent/detergent,,,
description,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,NAT,Nucleic Acid Test,,,
description,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,TNBP,tri-n-butyl phosphate,,,
description,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,IgG,immunoglobulin G,,,
description,cd989627-71ff-479d-a103-c1a22aa9e5e2,5/26/2010,1,mg/mL,mg/5 mL,,,
description,47c63700-d5ae-4010-b6c4-de1478d5128f,5/16/2009,1,CBER,Center for Biologics Evaluation and Research,,,
description,47c63700-d5ae-4010-b6c4-de1478d5128f,5/16/2009,1,IEF,Isoelectric focusing,,,
description,6b17b98b-e06d-42ed-925f-69aa2699dead,2/9/2007,3,DEHP,di-2-ethylhexyl phthalate,,,
description,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,COMT,catechol-O-methyltransferase,,,
description,4C52C904-8137-4B10-8A85-D9B96C2D8A00,5/10/2006,1,HEPES,N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid,,,
description,4C52C904-8137-4B10-8A85-D9B96C2D8A00,5/10/2006,1,oxine,oxyquinoline,,,
description,6d2e4c97-0fb1-4ba4-9c58-3de071029e9b,5/30/2012,3,IU,international units,,,
description,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,NSAIDs,nonsteroidal antiinflammatory drugs,,,
description,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,PVP,polyvinylpyrrolidone,,,
description,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,17.7 mA-min,1.77 mA for 10 minutes,,,
description,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,mA-min,milliampere-minutes,,,
description,7c087473-393f-4c18-a958-c08c18bf9584,11/8/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,9222a610-a6d9-4b06-8ea0-c23a9ba8e281,3/6/2012,1,BHT,butylated hydroxytoluene,,,
description,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,IU,International Units,,,
description,334fa37b-f73a-459a-9f67-281022273fed,8/1/2011,12,NSAID,nonsteroidal anti-inflammatory drug,,,
description,56ab2ff4-14a6-4297-afd8-56b92e1f64a0,5/31/2012,5,HCl,hydrochloride,,,
description,c18058a0-9c69-49cf-8454-db3b98427808,11/17/2010,1,HCl,hydrochloride,,,
description,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,I.V.,Intravenous,,,
description,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,HCl,hydrochloride,,,
description,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,I.M.,Intramuscular,,,
description,1cf82d42-5ad0-4b86-838e-9230c61cf3d4,3/18/2010,3,PIF,peak inspiratory flow,,,
description,fb77dffc-b38d-461c-8926-bc57bef1f321,1/12/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,BHAT,Beta-Blocker Heart Attack Trial,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,p-gp,p-glycoprotein,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,SLE,Systemic lupus erythematosus,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,PMs,poor metabolizers,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,EMs,extensive  metabolizers,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,MRHD,maximum recommended human oral daily dose,,,
description,60c0a5e1-9298-4a00-92b7-3a1ef7ad17cc,4/9/2009,1,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
description,4a0166c7-7097-4e4a-9036-6c9a60d08fc6,11/11/2011,5,GI,gastrointestinal,,,
description,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,IV,intravenous,,,
description,63b51e87-a223-4d62-b94e-60adf4872376,12/29/2011,2,IM,intramuscular,,,
description,8d8aaac5-3203-4ade-ae74-e2ea469dae18,4/20/2011,1,BHT,butylated hydroxytoluene,,,
description,e174c804-fe33-4cd8-809a-d107b5200064,12/29/2009,2,PIC,Polysaccharide iron complex,,,
description,e174c804-fe33-4cd8-809a-d107b5200064,12/29/2009,2,PIC,Polysaccharide Iron Complex,,,
description,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,DMSO,dimethyl sulfoxide,,,
description,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,623BC6E9-2158-48CC-867E-7AC50F4D892C,8/1/2006,1,logP,log partition coefficient,,,
description,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,ACE,angiotensin I-converting enzyme,,,
description,05f326e6-10e4-4ceb-8a23-f53c592f00b8,11/18/2011,3,DEHP,di-2-ethylhexyl phthalate,,,
description,9899985f-649f-4bcc-890f-0f4800227929,3/1/2012,2,logP,log partition coefficient,,,
description,14610ffa-899e-4c67-9f19-bee92d8951ca,7/28/2011,1,TK,thymidine kinase,,,
description,14610ffa-899e-4c67-9f19-bee92d8951ca,7/28/2011,1,HSV-1,herpes simplex virus types 1,,,
description,14610ffa-899e-4c67-9f19-bee92d8951ca,7/28/2011,1,VZV,varicella-zoster virus,,,
description,fc55530f-f7d5-4835-96aa-609314b0c6fc,7/10/2006,1,IV,intravenous,,,
description,fc55530f-f7d5-4835-96aa-609314b0c6fc,7/10/2006,1,SC,subcutaneous,,,
description,fc55530f-f7d5-4835-96aa-609314b0c6fc,7/10/2006,1,IM,intramuscular,,,
description,c3bb55bc-5465-4c28-a763-ffd252758b96,7/12/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,a2360c52-f2b3-43c6-8485-292d828a7488,6/9/2006,1,DEHP,di-2-ethylhexylphthalate,,,
description,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,ACE,angiotensin I-converting enzyme,,,
description,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,CAPOZIDE®,captopril and hydrochlorothiazide tablets,,,
description,61c5f011-e393-4f9c-b65b-3c06d93baebd,12/31/2011,4,AU/mL,Allergy Units/mL,,,
description,88218156-081a-4809-8143-f97bdab194ba,10/11/2010,2,IU,International Unit,,,
description,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,Hydroxide,hydroxide,,,
description,81f1e36a-6367-4334-b007-1426612f292b,4/26/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,a360d43c-bed8-4f41-ab36-e2aa77dfbff2,8/15/2011,1,I.V.,Intravenous,,,
description,a360d43c-bed8-4f41-ab36-e2aa77dfbff2,8/15/2011,1,I.M.,Intramuscular,,,
description,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,AEDs,antiepileptic drugs,,,
description,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,Estradiol,17?-estradiol,,,
description,8bb91825-b63e-44aa-8edd-4326823f3009,2/27/2008,1,ISDN,Isosorbide dinitrate,,,
description,c1ac4f63-695c-6bd6-4a7f-ecb97e03569e,3/7/2012,4,PEG 400,polyethylene glycol 400,,,
description,702727cb-3eff-425b-9573-031332849430,8/18/2010,3,HIV,human immunodeficiency virus,,,
description,c1114779-3e11-47ab-8889-f534406f4041,3/11/2011,5,RID,radial immunodiffusion,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,Oil,oil,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,Magnesium,magnesium oxide,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,Zinc,zinc oxide,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,cGMP,current Good Manufacturing Practices,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,DHA,Docosahexaenoic Acid,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,EPA,Eicosapentaenoic Acid,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,Calcium,calcium carbonate,,,
description,cf5a8d87-aeaa-470f-8697-4146c49e22fa,4/20/2011,8,Iron,iron protein succinylate,,,
description,fb6dbbf8-45fd-4956-9b12-9125474c825d,8/31/2009,2,NLT,not less than,,,
description,fb6dbbf8-45fd-4956-9b12-9125474c825d,8/31/2009,2,USP,United States Pharmacopeia,,,
description,fb6dbbf8-45fd-4956-9b12-9125474c825d,8/31/2009,2,NMT,not more than,,,
description,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,PEG 400,polyethylene glycol 400,,,
description,4e655dc5-ada6-446f-ab12-5e7b5f2039b2,4/18/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,febcda43-7c1f-459d-a7bf-b91efd064017,10/25/2010,1,GI,gastrointestinal,,,
description,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
description,751887d9-71da-4226-8ae1-d7ca59259cbe,3/4/2009,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,58e42210-291a-4f12-b6d3-5fbad7c5268b,8/9/2006,1,Estradiol,17?-estradiol,,,
description,ea8bf997-2c71-4014-b18d-4f7ab45dfa19,12/14/2011,4,HFIP,hexafluoroisopropanol,,,
description,ea8bf997-2c71-4014-b18d-4f7ab45dfa19,12/14/2011,4,PMFE,pentafluromethoxy isopropyl fluoromethyl ether,,,
description,ea8bf997-2c71-4014-b18d-4f7ab45dfa19,12/14/2011,4,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,520428f1-2cd5-447f-8782-c8505ce65b72,2/28/2012,10,BHA,Butylated hydroxyanisole,,,
description,520428f1-2cd5-447f-8782-c8505ce65b72,2/28/2012,10,HMG?CoA,3?hydroxy-3?methylglutaryl-coenzyme A,,,
description,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
description,42097235-FA5F-4052-A558-763116AFD58D,4/5/2007,1,tizanidine,Tizanidine hydrochloride,,,
description,6255ce29-25db-4964-309d-10939a436ff4,4/12/2010,3,clear,CARBOCAINE is a local anesthetic available as sterile isotonic solutions,,,
description,e5808712-4487-43b2-891f-e1ef47a9e28d,10/24/2011,1,MPF,Methyl Paraben Free,,,
description,c9aa6489-5a36-44ed-9512-b996833d82f7,5/4/2011,1405,HFIP,hexafluoroisopropanol,,,
description,c9aa6489-5a36-44ed-9512-b996833d82f7,5/4/2011,1405,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,ba29b053-3eb6-4dc8-b8a9-fffce9cca121,11/17/2010,90,logP,log partition coefficient,,,
description,8d60148f-779c-453a-bd37-51b875ec1656,2/8/2010,1,EDE,effective dose equivalent,,,
description,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox®,ceftizoxime for injection,,,
description,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,IMPDH,inosine monophosphate dehydrogenase,,,
description,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MMF,mycophenolate mofetil,,,
description,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MPA,mycophenolic acid,,,
description,33694be4-87ce-4d25-92f6-6ae517bdf5ff,11/2/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
description,03BE089C-07E5-4F94-BFCC-C6101B311785,5/10/2006,1,GITS,Gastrointestinal Therapeutic System,,,
description,81E856DC-9B73-4E77-1EB9-415F33935C9E,1/9/2007,2,acetate,"align=""center"" valign=""top""><paragraph>425</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine",,,
description,81E856DC-9B73-4E77-1EB9-415F33935C9E,1/9/2007,2,acetate,"align=""center"" valign=""top""><paragraph>850</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine",,,
description,81E856DC-9B73-4E77-1EB9-415F33935C9E,1/9/2007,2,DEHP,di-2-ethylhexyl phthalate,,,
description,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,DHT,5?-dihydrotestosterone,,,
description,22991030-8116-4CBA-8A99-BDC708F0F524,12/4/2006,1,mL,milliliter,,,
description,cf10d256-dd89-4a91-a3ed-81db505a79c2,10/31/2011,6,HCl,hydrochloride,,,
description,30bac07f-86bd-4a03-8ea1-7ab2d42d3ea3,7/30/2009,1,ara-A,#NAME?,,,
description,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,IUPAC,International Union of Pure and Applied Chemistry,,,
description,23dc7eeb-0b0a-4a11-9783-fdba769309cd,4/18/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,290C3E9C-C0C6-440A-1A9C-46E3E2B07A77,5/11/2006,1,EDTA,ethylenediamine tetraacetic acid,,,
description,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,NSAIDs,nonsteroidal                             anti-inflammatory drugs,,,
description,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,IV,intravenous,,,
description,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,IM,intramuscular,,,
description,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,DMA,N,N-dimethylacetamide,,
description,f9bf6322-75b4-4ccf-9a4b-4724203f5eef,7/4/2010,3,TSE,transmissible spongiform encephalopathy,,,
description,e437efe0-9c6a-4f87-b3b4-de90443b095f,12/22/2006,2,DMSO,dimethylsulfoxide,,,
description,0f799e5c-f782-4f3d-bdb6-52bd413a19cf,10/27/2009,2,logP,log partition coefficient,,,
description,0f799e5c-f782-4f3d-bdb6-52bd413a19cf,10/27/2009,2,ER,Extended-Release,,,
description,0e996cf8-6975-452a-a84c-ca1033a629b1,5/28/2007,1,CFC,chlorofluorocarbon,,,
description,67c46f2e-59fe-4c20-a07d-79935d496d1f,1/5/2012,3486,HCl,hydrochloride,,,
description,f0a096a0-bde2-494f-a1af-2f778bb7c5c1,8/1/2011,17,HCl,hydrochloride,,,
description,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
description,5f6c3eed-2a5d-46ed-9a7c-59715f338a15,5/22/2012,1,HIV-1,Human Immunodeficiency Virus Type 1,,,
description,a33b5ede-e5d0-4c72-ba38-419c33bc3e91,8/12/2010,3,WHO,World Health Organization,,,
description,a33b5ede-e5d0-4c72-ba38-419c33bc3e91,8/12/2010,3,IU,International Unit,,,
description,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,CNS,central nervous system,,,
description,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,Sodium®,Sodium Capsules,,,
description,3ccb9150-4b3c-47c7-b1a6-e80b68d5e21d,5/9/2011,1,TK,thymidine kinase,,,
description,93d73c30-f90d-435b-a31b-036884caa7b4,10/12/2007,1,PEG,[Polyethylene glycol,,,
description,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,AEDs,antiepileptic drugs,,,
description,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,NLT,not less than,,,
description,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,DIT,diiodotyrosine,,,
description,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,MIT,monoiodotyrosine,,,
description,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,USP,United States Pharmacopeia,,,
description,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,NMT,not more than,,,
description,58896863-63AC-4B99-9D3C-97CA472357C7,4/21/2008,1,IUPAC,International Union of Pure and Applied Chemistry,,,
description,0d02b3a0-4de3-473b-8ed9-a1974747970f,6/13/2006,1,mL,mEq/L,,,
description,0d02b3a0-4de3-473b-8ed9-a1974747970f,6/13/2006,1,Amino Acid,amino acids.®,,,
description,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,IUPAC,International Union of Pure and Applied Chemistry,,,
description,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,AEDs,antiepileptic drugs,,,
description,4b52487b-dfed-402e-ba8b-766f96313b67,4/21/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
description,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,2bbd8f48-fdf9-45cb-8305-124a03f7a52c,12/12/2011,2,HVL,half-value layer,,,
description,b3337f3e-fe90-4969-8fd1-4de8de6ef76c,6/14/2010,2,WNV,West Nile virus,,,
description,b3337f3e-fe90-4969-8fd1-4de8de6ef76c,6/14/2010,2,HCV,hepatitis C virus,,,
description,bd2051f7-b887-46f6-8d4a-b099fcd08629,12/30/2009,1,INR,international normalized ratio,,,
description,bd2051f7-b887-46f6-8d4a-b099fcd08629,12/30/2009,1,DHA,Docosahexaenoic Acid,,,
description,bd2051f7-b887-46f6-8d4a-b099fcd08629,12/30/2009,1,EPA,Eicosapentaenoic Acid,,,
description,50a58159-9572-4445-9859-b392632597da,12/8/2011,6,ACE,angiotensin-converting enzyme,,,
description,57578387-1918-4e56-a564-f14fb22340bf,11/7/2011,4,HCl,hydrochloride,,,
description,54c5f945-df7a-4ec6-993e-9633dda6a6ab,5/30/2012,8,IU,international units,,,
description,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,92123CFA-5BD5-4554-8D5D-B877D5CB9C02,6/19/2007,1,CNS,central nervous system,,,
description,96398ed5-ffb9-4ed4-92c1-6a9535864475,1/18/2012,2,HVL,half-value layer,,,
description,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,AEDs,antiepileptic drugs,,,
description,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,ara-A,9-?-D-arabinofuranosyladenine,,,
description,d356b7bb-929e-4cc0-98f7-bcf081c9c3b6,1/12/2012,7,HIV-1,human immunodeficiency virus type 1,,,
description,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,379f8193-c371-4ae9-a272-43c5b9b18349,8/1/2011,3,logP,log partition coefficient,,,
description,31f8110b-fc54-4d57-a07c-8528ca5e6074,12/20/2011,1,GI,gastrointestinal,,,
description,0525e04f-91b7-4d75-8ff9-a6fb5705d993,2/6/2012,1,IU,International Unit,,,
description,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,AEDs,antiepileptic drugs,,,
description,22edd948-d2fe-4df1-b797-1b7d92fc29cf,12/15/2011,8,SSRI,selective serotonin reuptake inhibitor,,,
description,3e4221f1-dade-4482-b5e5-2d75a96154d6,6/10/2009,3,DEHP,di-2-ethylhexyl phthalate,,,
description,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,delta-9-THC,delta-9-tetrahydrocannabinol,,,
description,cb4f1002-9372-4fac-aea3-99142f93dd37,10/30/2009,1,CFCs,chlorofluorocarbons,,,
description,7c72520e-de3c-493d-8aea-11933376d968,7/25/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,ACE,angiotensin I-converting enzyme,,,
description,4e4bc43f-892a-4ca4-ad43-5383c276c61e,5/30/2012,8,IU,international units,,,
description,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
description,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,NLT,not less than,,,
description,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,DIT,diiodotyrosine,,,
description,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,MIT,monoiodotyrosine,,,
description,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,USP,United States Pharmacopeia,,,
description,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,NMT,not more than,,,
description,d267425d-4e5f-4e7a-a27e-fe8814f0e225,8/1/2011,9,HCl,hydrochloride,,,
description,d356f9f6-d094-478d-bf79-7781490588cc,5/22/2009,1,CHO,Chinese Hamster Ovary,,,
description,d356f9f6-d094-478d-bf79-7781490588cc,5/22/2009,1,NMS,neuroleptic malignant syndrome,,,
description,d356f9f6-d094-478d-bf79-7781490588cc,5/22/2009,1,MRHD,maximum recommended human dose,,,
description,d356f9f6-d094-478d-bf79-7781490588cc,5/22/2009,1,ADHD,Attention-Deficit Hyperactivity Disorder,,,
description,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SSRI,selective serotonin reuptake inhibitor,,,
description,d99b2484-1c4d-4241-b16e-72395f976efb,9/5/2008,1,IV,intravenous,,,
description,c794add2-925e-492c-9832-a603e3cc23fd,12/14/2010,142,7.5 mg/mL,9.75 mg/1.3 mL,,,
description,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,SSRI,selective serotonin reuptake inhibitor,,,
description,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,betadex,betacyclodextrin,,,
description,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,DEHP,di-(2-ethylhexyl)phthalate,,,
description,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,PVC,polyvinylchloride,,,
description,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,IV,intravenous,,,
description,b4b2ee9a-f59d-4c2f-878c-04a870e2a369,10/21/2011,1,IM,intramuscular,,,
description,cffcb7cd-1459-4293-8b22-81b077b0f4df,9/26/2008,1,GI,gastrointestinal,,,
description,87768fbf-7c63-47da-8925-0316f343d6ef,10/29/2011,5,ACE,angiotensin-converting enzyme,,,
description,FAE013FC-E199-43F3-86EF-66D34017C534,5/11/2006,1,PGE2,prostaglandin E2,,,
description,91edab72-c889-470e-8315-1798b5548dca,10/31/2009,3,CJD,Creutzfeldt-Jakob disease,,,
description,91edab72-c889-470e-8315-1798b5548dca,10/31/2009,3,TSE,transmissible spongiform encephalopathy,,,
description,91edab72-c889-470e-8315-1798b5548dca,10/31/2009,3,vCJD,variant Creutzfeldt-Jakob disease,,,
description,b4c0128b-622c-42db-8e31-48c4ca6b1286,7/21/2011,2,GI tract,Gastro Intestinal tract,,,
description,e17d7cc3-e193-4f41-a457-4b6b32a9201d,3/23/2007,1,GI,gastrointestinal,,,
description,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A,,,
description,1f32c7ce-8ec1-43d1-8e24-e7d486194938,5/10/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,ECB84B38-ED22-48B0-861C-D09CF8F101C9,10/6/2006,1,mg/mL,mg/5 mL,,,
description,d5b85158-b0d6-4855-9d07-8d1b3ad9ab71,10/18/2010,7,DEHP,di-2-ethylhexyl phthalate,,,
description,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,PE,phenytoin sodium equivalents,,,
description,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,PE,phenytoin sodium                                                   equivalent units,,,
description,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,DHT,5?-dihydrotestosterone,,,
description,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,dapsone,diaminodiphenylsulfone and its structural formula is:12HEach gram of ACZONE™,,,
description,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
description,91ca765f-fe58-4dee-a7eb-c8d3de9f115a,7/12/2012,9,IU,International Units,,,
description,a43c1fa5-1c00-413b-8709-27894367ddab,7/8/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,AB044C63-96B6-4B02-86CB-E1B93C59EB63,11/1/2007,1,TK,thymidine kinase,,,
description,AB044C63-96B6-4B02-86CB-E1B93C59EB63,11/1/2007,1,HSV-1,herpes simplex virus types 1,,,
description,AB044C63-96B6-4B02-86CB-E1B93C59EB63,11/1/2007,1,VZV,varicella-zoster virus,,,
description,61ba7f4a-08e9-48c0-b2ff-509e79cfecda,8/11/2011,2,NSAID,nonsteroidal anti-inflammatory drug,,,
description,d5ab4f08-1d12-4c64-b3bf-e72c705aeca8,12/5/2011,2,logP,log partition coefficient,,,
description,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,BHA,Butylated hydroxyanisole,,,
description,702c3291-ecdc-4bf2-9caf-09f307fd3d6f,10/24/2011,1,HVL,half-value layer,,,
description,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
description,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,KIU,Kallikrein Inhibitor Units,,,
description,d8c6943d-2d9c-4e32-a14b-27de9adc4c8d,1/1/2007,1,DEHP,di-2-ethylhexyl phthalate,,,
description,A4BE3F71-31F6-4559-82F0-AA11168AF779,5/29/2007,1,HCl,hydrochloride,,,
description,953CEE06-5C26-4F30-870A-46B9FBB66E79,3/8/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,92ae1de4-6b27-4f03-acb5-7170664f67cb,9/11/2006,1,Plus,prednisolone acetate ophthalmic suspension,,,
description,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,CFCs,chlorofluorocarbons,,,
description,0b2249cb-ecf4-4be9-a6b2-0fe6ca2a7a36,6/22/2012,3,PPA,Phenylpropanolamine hydrochloride,,,
description,1deaaa92-1c98-4295-8aa6-7a70bc29f55d,12/7/2011,1,HVL,half-value layer,,,
description,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,HIV-1,human immunodeficiency virus type 1,,,
description,333d672c-44bf-4544-bf8c-f6f72f3dfefe,8/31/2006,1,DEHP,di-2-ethylhexyl phthalate,,,
description,9f9e4491-9c18-487c-8a88-9738dfbad16e,12/12/2010,2,IU,International Unit,,,
description,a684789b-3174-2585-1056-a9152a97675d,6/5/2012,2,IU,International Unit,,,
description,57235471-b8d6-4822-9d87-da32471e3fb0,5/16/2011,1,TK,thymidine kinase,,,
description,ac3dfb81-a4c7-4147-9374-c234153b7c51,12/29/2011,4,HCl,hydrochloride,,,
description,979f320d-f91a-47b4-a4d1-958446a3b5ad,4/19/2012,1,mL,milliliter,,,
description,089bde88-521a-401e-8f03-1320e7e6ae03,6/22/2012,3,PPA,Phenylpropanolamine hydrochloride,,,
description,bcf72938-7043-4d66-9edc-29a4599021a1,3/20/2007,1,ACE,angiotensin-converting enzyme,,,
description,e35aa027-aef2-485d-927c-ab350f51f977,2/16/2006,1,MEXITIL®,mexiletine hydrochloride,,,
description,7c040a9d-c19f-4ca2-a095-4f8b60e03a76,1/25/2012,3,IU,International Unit,,,
description,71107f70-1eb5-4f9c-b740-9631ca222357,11/8/2010,74,AEDs,antiepileptic drugs,,,
description,3e65b958-03cd-4f8c-a6a0-990b53ae7ab4,12/31/2011,3,IEF,Isoelectric focusing,,,
description,3e65b958-03cd-4f8c-a6a0-990b53ae7ab4,12/31/2011,3,CBER,Center for Biologics Evaluation and Research,,,
description,2f078cef-a889-4d8d-b244-37ee13547a67,12/6/2011,2,AEDs,antiepileptic drugs,,,
description,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,b8ca1d80-6ea9-4a3f-ab06-beedf845de8f,2/18/2011,1,HCl,hydrochloride,,,
description,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,ec7a340e-b4e2-483a-ab04-7baffbf58a00,12/1/2011,1,HVL,half-value layer,,,
description,0d929726-76c3-48fc-b4e7-fd06409f9fb3,7/21/2010,2,DEHP,di-2-ethylhexyl phthalate,,,
description,967bd870-7517-43bc-90eb-05e831d688ae,2/17/2012,1,COMT,catechol-O-methyltransferase,,,
description,4d4f77d5-cc55-46bd-8963-b125842543be,4/29/2011,1,GI tract,Gastro Intestinal tract,,,
description,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,IV,intravenous,,,
description,9f015e60-1aec-4ae7-b28f-42f6c8f50455,7/23/2012,1,HCl,hydrochloride,,,
description,f2357c3c-7c64-4dba-9f85-c79a1d45746f,1/7/2012,1,SS,sulfur USP 5%,,,
description,7e5649da-75be-4a42-8eeb-4aeba562c401,5/9/2012,12,TSE,transmissible spongiform encephalopathy,,,
description,25418092-48c3-4ac0-92b0-72a6289d423f,10/24/2011,1,HVL,half-value layer,,,
description,bb934a63-ed66-433a-a9a7-b9c5e9963f73,10/25/2010,38,HCl,hydrochloride,,,
description,3dbab949-6ab7-4040-9c81-314e5bb61d41,3/7/2012,6,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,3dbab949-6ab7-4040-9c81-314e5bb61d41,3/7/2012,6,PIFE,pentafluoroisopropenyl fluoromethyl ether,,,
description,AA447BAC-DFBD-44AE-B1D1-3E1BE6D7EF9E,2/21/2008,2,NSAIDs,non-steroidal anti-inflammatory drugs,,,
description,1388D626-36AF-4C4D-8917-A458A38F7176,2/20/2008,2,logP,log partition coefficient,,,
description,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,SSRI,selective serotonin reuptake inhibitor,,,
description,3C1ECA7E-57A0-4876-8ED6-CD655EF5E296,3/9/2007,2,HM-PAO,hexamethylpropylene amine oxime,,,
description,9e5b9309-e835-4863-ab6f-e3018e38fc64,12/31/2009,1,PIC,Polysaccharide iron complex,,,
description,9e5b9309-e835-4863-ab6f-e3018e38fc64,12/31/2009,1,PIC,Polysaccharide Iron Complex,,,
description,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,GdDTPA,gadolinium diethylenetriaminepentaacetic acid,,,
description,A63BD1BB-6487-4B0D-AA8C-C4313F5B36A8,1/17/2008,1,SUSPENSION,suspension,,,
description,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,PE,phenytoin sodium equivalents,,,
description,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,PE,phenytoin sodium equivalent units,,,
description,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
description,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,SSRI,selective serotonin reuptake inhibitor,,,
description,bbefaa05-1dc0-3ae7-7264-ce1eddf0da2b,10/10/2011,1,HBsAg,Hepatitis-B Surface Antigen,,,
description,bbefaa05-1dc0-3ae7-7264-ce1eddf0da2b,10/10/2011,1,anti-HCV,antibody to Hepatitis C Virus,,,
description,L7dfd3fdd-efa4-4239-8cd7-ddf2de682328,1/16/2008,1,HCV,hepatitis C virus,,,
description,324a8674-c4a6-4afb-b504-aa2f67f5793e,11/18/2011,2,DEHP,di-2-ethylhexyl phthalate,,,
description,8f91e243-7395-4ec9-adf5-37520983daf2,8/18/2006,1,CNS,central nervous system,,,
description,4c6e76bc-c964-4955-e0a3-511d3386a9cc,5/2/2011,1409,HFIP,hexafluoroisopropanol,,,
description,4c6e76bc-c964-4955-e0a3-511d3386a9cc,5/2/2011,1409,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,ddC,2',3'-dideoxycytidine,,
description,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,HIV,human immunodeficiency virus,,,
description,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,SODAS®,Spheroidal Oral Drug Absorption System,,,
description,397979cb-f605-4211-b810-0a4572d4b973,6/22/2012,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,29ff5c13-7291-4788-811e-946c8f530b75,12/6/2011,1,TK,thymidine kinase,,,
description,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,SSRI,selective serotonin reuptake inhibitor,,,
description,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,BHA,Butylated hydroxyanisole,,,
description,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,HMG-CoA,3-hydroxy-3-methylglutarylcoenzyme A,,,
description,d87e4d0b-2442-4135-b3f9-5c4f74845b87,12/16/2009,2,HSA,human serum albumin,,,
description,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
description,c63c2921-fc55-4ad8-a5e5-0d7258ab1f4e,11/22/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,e077756b-af95-40e9-a65c-1b03012c855b,10/26/2011,1,MPF,Methyl Paraben Free,,,
description,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,TSE,transmissible spongiform encephalopathy,,,
description,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,ALA,aminolevulinic acid,,,
description,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,ALA HCl,aminoketone.Aminolevulinic acid HCl,,,
description,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,HCl,hydrochloride,,,
description,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,IV,intravenous,,,
description,A4C1305C-F18C-4FB0-83D8-2822341F2DFA,8/3/2007,1,TK,thymidine kinase,,,
description,A4C1305C-F18C-4FB0-83D8-2822341F2DFA,8/3/2007,1,HSV-1,herpes simplex virus types 1,,,
description,A4C1305C-F18C-4FB0-83D8-2822341F2DFA,8/3/2007,1,VZV,varicella-zoster virus,,,
description,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,HFIP,hexafluoroisopropanol,,,
description,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,BCDFE,2-bromo-2-chloro-1,1-difluoro ethylene,,
description,7eb2efae-d41d-42d0-bd7a-0b354b97cdde,11/3/2011,1,MPF,Methyl Paraben Free,,,
description,08d06e6f-a1d8-4bd9-b851-d63858d55f91,8/22/2011,2,5-HT1B/1D,5-hydroxytryptamine1B/1D,,,
description,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
description,23d3765c-8f10-4bfc-9489-e1ed064ad813,4/3/2012,1,mL,milliliter,,,
description,2A4CD065-A1DD-4B88-9F7A-7BA93502F972,10/26/2006,1,ISDN,Isosorbide dinitrate,,,
description,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,AEDs,antiepileptic drugs,,,
description,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,SSRI,selective serotonin reuptake inhibitor,,,
description,2A72A8B8-A77C-49C6-3C8D-43B03672D802,2/6/2007,1,acetate,"align=""center"" valign=""top""><paragraph>940</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine",,,
description,7F2F057B-9AFC-42AE-9D1D-1B1041D1360B,9/14/2006,1,IPPB,intermittent positive pressure breathing apparatus,,,
description,07800675-f689-47d7-8203-073c797f7e21,10/18/2011,1,MPF,Methyl Paraben Free,,,
description,181705c7-40e4-4d7d-b9ea-ada99380e7a9,6/11/2009,2,DEHP,di-2-ethylhexyl                             phthalate,,,
description,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,NNRTI,non-nucleoside reverse transcriptase inhibitor,,,
description,8dfe86aa-ea5d-48d2-94a8-1a5506055d70,5/23/2012,1,HIV-1,Human Immunodeficiency Virus Type 1,,,
description,2c6fb487-5574-44e0-a3e7-fc6e666dbc11,4/21/2011,1,NSAID,nonsteroidal anti-inflammatory drug,,,
description,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
dosage,d99348b1-edad-41de-aed9-903a6f9f279f,10/1/2010,8,IV,intravenous,,,
dosage,c08ed05f-89ff-4620-8bc6-60419fa02131,2/8/2011,1,BSA,body surface area,,,
dosage,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,AED,antiepilepsy drug,,,
dosage,42DBD449-BF4C-417C-B26B-0A9D7534C8BB,9/18/2007,1,Tablets,tablets,,,
dosage,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,HUMAN,Hemodilution may follow administration of ALBUMIN,,,
dosage,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,ARDS,Adult Respiratory Distress Syndrome,,,
dosage,eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4,8/30/2011,8,AGC,absolute granulocyte count,,,
dosage,eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4,8/30/2011,8,CBC,complete blood count,,,
dosage,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,TCA,Tricyclic Antidepressant,,,
dosage,22734527-78ad-4075-bcd5-3e6d535c61e9,2/1/2008,1,CPR,cardiopulmonary resuscitation,,,
dosage,50ed7e31-b9b7-4f0a-8e36-91ed5af86b81,3/13/2012,6,IUS,intrauterine system,,,
dosage,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,CBC,COMPLETE BLOOD COUNT,,,
dosage,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,Suspension,suspension,,,
dosage,1e9675c8-bcff-4621-90f7-b80489e1b840,3/6/2012,1,ie,in 2 divided doses,,,
dosage,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,i.e.,insufficiency,,,
dosage,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,i.e.,initial route of therapy,,,
dosage,1c12b44c-f074-4a14-efad-4a6c743613cf,7/9/2012,11,II,Intravenous Fat Emulsion,,,
dosage,1c12b44c-f074-4a14-efad-4a6c743613cf,7/9/2012,11,PVC,polyvinyl chloride,,,
dosage,1c12b44c-f074-4a14-efad-4a6c743613cf,7/9/2012,11,EVA,ethylene vinyl acetate,,,
dosage,1c12b44c-f074-4a14-efad-4a6c743613cf,7/9/2012,11,PVC,polyvinylchloride,,,
dosage,9d73278f-c9c0-4e02-9879-8952a024421c,5/24/2011,4,BHAT,Beta-Blocker Heart Attack Trial,,,
dosage,88f78780-399f-4780-be19-205739db1682,5/18/2011,4,mL,milliliters,,,
dosage,88f78780-399f-4780-be19-205739db1682,5/18/2011,4,mL,Maintenance Dose for diluents,,,
dosage,49be5b16-dab5-4a95-b202-bfb13d730d83,4/30/2011,6,5-FU,5-Fluorouracil,,,
dosage,47137273-b9c1-4cb4-99ca-2dab9690b560,10/14/2010,4,PMs,poor metabolizers,,,
dosage,47137273-b9c1-4cb4-99ca-2dab9690b560,10/14/2010,4,HI,hepatic insufficiency,,,
dosage,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,i.e.,In the controlled adjunctive,,,
dosage,669e5dc4-21ef-7a2d-d232-edc47c5716c5,6/2/2010,1,i.e.,in 2 divided doses,,,
dosage,3a2e370b-f585-4489-a957-f5134019ef79,10/11/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,79f3b5ee-fc95-47c3-96a4-55dd91121e55,11/25/2010,5,G-CSF,granulocyte-colony stimulating factor,,,
dosage,13705c4d-f47e-4158-88d9-4494324142d4,1/17/2008,2,mL,milliliters,,,
dosage,13705c4d-f47e-4158-88d9-4494324142d4,1/17/2008,2,mL,Maintenance Dose for diluents,,,
dosage,1a56c82e-7ecd-43b0-2899-f89e47adf7db,10/26/2009,5,i.e.,in labeling,,,
dosage,1a56c82e-7ecd-43b0-2899-f89e47adf7db,10/26/2009,5,Clcr,Calculate Creatine Clearance,,,
dosage,1a56c82e-7ecd-43b0-2899-f89e47adf7db,10/26/2009,5,i.e.,interval prolongation,,,
dosage,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,i.e.,insufficiency,,,
dosage,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,i.e.,initial route of therapy,,,
dosage,7603f1ba-cfbd-4ec5-881a-13f4832c9893,5/6/2011,2,MAC,Monitored Anesthesia Care,,,
dosage,63328937-ec82-445b-8bf8-f528f7803326,6/1/2012,4,BSA,body surface area,,,
dosage,ad369f69-12d5-400b-8b67-5fa73adf8412,2/9/2012,8,MBq,megabecquerel,,,
dosage,ad369f69-12d5-400b-8b67-5fa73adf8412,2/9/2012,8,mGy,milligray,,,
dosage,ad369f69-12d5-400b-8b67-5fa73adf8412,2/9/2012,8,mCi,millicurie,,,
dosage,d461c90b-9411-44df-a7ea-f3db1f17c695,10/27/2009,2,PET,polyethylene  terephthalate,,,
dosage,d461c90b-9411-44df-a7ea-f3db1f17c695,10/27/2009,2,Suspension,suspension,,,
dosage,c960d736-2657-4b79-967f-d2c9bb4076cd,6/22/2011,2,ADT®,Alternate Day  Therapy,,,
dosage,c960d736-2657-4b79-967f-d2c9bb4076cd,6/22/2011,2,HPA,hypothalamic-pituitary-adrenal,,,
dosage,140e953d-d180-4097-80da-b3ecb50465d5,5/25/2010,10,ANC,absolute neutrophil counts,,,
dosage,dd6dcaed-3e37-4aba-b1cf-e949184f78eb,1/25/2011,2,ie,in 2 divided doses,,,
dosage,f548be5b-f479-4ca9-983c-6f5a76281d12,2/1/2011,2,IR,immediate-release,,,
dosage,dee07488-7a2b-4d45-89e1-d65ab895fd52,12/2/2011,3306,CCr,creatinine clearance,,,
dosage,92FE06D1-9AEC-47B4-B7FC-AEA6434CBE10,6/1/2006,1,MIRD,Medical Internal Radiation Dose,,,
dosage,cbd3396e-6b85-41bf-82d2-940beba86686,5/1/2012,2,PVC,polyvinyl chloride,,,
dosage,cbd3396e-6b85-41bf-82d2-940beba86686,5/1/2012,2,TPN,Total Parenteral     Nutrition,,,
dosage,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,TCA,Tricyclic Antidepressant,,,
dosage,19b19a55-972c-47c1-b031-cad69c624fa1,4/29/2010,1,NGU,Nongonococcal urethritis,,,
dosage,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,PAF,paroxysmal AF,,,
dosage,b95b7647-d6c0-4470-fba0-680256661dd2,10/27/2011,10,TPN,Total parenteral nutrition,,,
dosage,33770d80-754f-11de-8dba-0002a5d5c51b,4/25/2012,7,PET,polyethylene terephthalate,,,
dosage,a671ec20-1d70-45e1-9893-025f832444c5,12/20/2011,4,PMs,poor metabolizers,,,
dosage,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,ART,Assisted Reproductive                 Technologies,,,
dosage,1979fd2a-7e2b-4d9a-9286-1066a0da944c,8/19/2010,3,PET,polyethylene terephthalate,,,
dosage,A7774E5C-98F0-4F2D-9992-113BCB5324B8,3/30/2007,1,water,water.Prepare an aqueous,,,
dosage,A754EAD7-1B6E-42C5-33A1-353EDB465F8E,1/12/2006,1,EFAD,essential fatty acid deficiency,,,
dosage,8c2ead65-6489-4841-9bd8-97165b94aab3,8/2/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,2/27/2012,2,E.O.E.,end of elution,,,
dosage,ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,2/27/2012,2,ALARA,as low as reasonably achievable,,,
dosage,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,CEFOTAN,cefotetan disodium for injection,,,
dosage,b60a9829-f356-4e43-97d5-7666fe11588c,9/28/2010,42,i.e.,Inpatients,,,
dosage,9a2b64bb-011a-4b23-b097-7dce576c57f8,10/12/2011,1,mg/kg/day,mg/kg/day: Daily dose,,,
dosage,4c2f052b-7ba2-4122-a50b-37ef2a834d61,1/19/2011,1,mL,Maintenance Dose                             for diluents,,,
dosage,78E738D9-9C13-4FBD-BFFA-77B003CDADAC,8/7/2006,1,MDRTB,Multi-Drug Resistant Tuberculosis,,,
dosage,78E738D9-9C13-4FBD-BFFA-77B003CDADAC,8/7/2006,1,DOT,Directly Observed Therapy,,,
dosage,78E738D9-9C13-4FBD-BFFA-77B003CDADAC,8/7/2006,1,DOT,.Directly Observed Therapy,,,
dosage,ade2c3d1-f568-4f6c-a583-48edfa199385,12/22/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,MAC,monitored anesthesia care,,,
dosage,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,CCr,creatinine clearance,,,
dosage,c4877476-24ca-31d3-9392-ea14e2f929b8,2/4/2009,2,NMS,Neuroleptic Malignant Syndrome,,,
dosage,73aea9e0-ff14-4eac-97bd-3d3b6b7ed524,1/18/2012,6,i.e.,insufficiency,,,
dosage,73aea9e0-ff14-4eac-97bd-3d3b6b7ed524,1/18/2012,6,i.e.,initial route of therapy,,,
dosage,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,CCr,creatinine clearance,,,
dosage,EE91667E-B636-43CE-5796-3A9E738557A3,3/14/2007,2,Trade,"<tr><td valign=""bottom""><content styleCode=""bold"">Nonproprietary",,,
dosage,f1a60c72-a4e3-437d-b472-8d5bffc91273,3/24/2011,2,CAD,coronary artery disease,,,
dosage,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,CCr,creatinine clearance,,,
dosage,304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e,3/8/2012,1,PVC,polyvinyl chloride,,,
dosage,A3DB901C-191C-472B-8BBC-5F12472C6D02,6/25/2007,1,mg/mL,mg in 100 mL,,,
dosage,a8010e10-68fd-455f-968f-d62a1c3e0ffd,5/26/2010,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,mg/kg/day,mg/kg/day:                                                Daily dose,,,
dosage,d970b074-957a-4036-92d3-1712386f3858,2/19/2010,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,a34ae37c-f8a3-4817-b7f3-babe474255f4,6/14/2011,1,i.e.,insufficiency,,,
dosage,a34ae37c-f8a3-4817-b7f3-babe474255f4,6/14/2011,1,i.e.,initial route of therapy,,,
dosage,c3d849eb-7fed-4bac-9fb6-0684094d8dfb,7/25/2011,1,i.e.,in special populations,,,
dosage,51f4c57b-8aec-4916-bafe-db93818e1c62,8/30/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,51f4c57b-8aec-4916-bafe-db93818e1c62,8/30/2011,1,PAF,paroxysmal AF,,,
dosage,f775d030-4a1a-4639-8de2-a4191c727900,2/10/2012,2,LD,loading dose,,,
dosage,fa5cce05-9850-48ef-8a8b-14a11ccc385a,6/2/2011,1,i.e.,in 2 divided doses,,,
dosage,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MAC,Mycobacterium avium complex,,,
dosage,99a0571d-2db3-4bc5-9c85-e70f48f15997,6/20/2012,6,mL,milliliters,,,
dosage,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,TCA,Tricyclic Antidepressant,,,
dosage,1ab0efd3-d23c-47ac-8708-d8ad164bd3ba,1/12/2012,1,NGU,Nongonococcal urethritis,,,
dosage,d539c8b2-13fe-4ba2-994e-b4d0ee1ef490,2/15/2012,2,CNS,Central Nervous System,,,
dosage,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,PDE-5,phosphodiesterase-5,,,
dosage,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,IT,intrathecally,,,
dosage,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,CCr,creatinine clearance,,,
dosage,711267c9-fc78-45b6-b219-bdb9e90fac35,10/27/2011,2,BSA,body surface area,,,
dosage,aa8e14c1-fbfd-4e4d-b59e-2d4ae1ca815f,1/10/2012,1,i.e.,intended dosing schedule,,,
dosage,28c0e61e-1af9-410a-9fa9-b71bf99a776b,2/10/2012,1,mL/day,mg/kg/day:                         Total daily dose,,,
dosage,0a47114c-569c-40be-afd8-a22d2e99bb5d,12/25/2009,4,PVC,polyvinylchloride,,,
dosage,f4d851f6-6bf5-4ed5-8d3a-1646773c4d40,5/22/2012,11,TSH,Thyrotropin-Stimulating Hormone,,,
dosage,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,SR,(SR),,,
dosage,eb636dad-0446-4299-b12d-867d4320a522,11/16/2006,1,one tablet,of ketoconazole tablets is a single daily administration of 200 mg,,,
dosage,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,i.e.,insufficiency,,,
dosage,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,i.e.,initial route of therapy,,,
dosage,177f0371-46e7-4527-8381-0067cad57025,7/18/2011,4,i.e.,in 2 divided doses,,,
dosage,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,AED,antiepilepsy drug,,,
dosage,06e33e48-0c96-4f34-bbfb-39d29ea97dde,6/13/2011,3,TIBC,total iron binding capacity,,,
dosage,06e33e48-0c96-4f34-bbfb-39d29ea97dde,6/13/2011,3,mL,may be calculated: Dose,,,
dosage,d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2,11/28/2011,1,i.e.,interval,,,
dosage,bd794164-0cad-4ca3-9f62-ae9118f6e4a2,2/21/2012,5,PCI,percutaneous coronary intervention,,,
dosage,d73713c3-3c48-4cce-8437-1723ca54d077,2/2/2010,2,PET,polyethylene terephthalate,,,
dosage,d73713c3-3c48-4cce-8437-1723ca54d077,2/2/2010,2,Suspension,suspension,,,
dosage,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,mg/kg/day,mg/kg/day: Daily dose,,,
dosage,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,140-age,(140-age)(weight)/[(72)(Sfor males C cr =,,,
dosage,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,C Cr,creatinine clearance,,,
dosage,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,IGF-I,insulin-like growth factor I,,,
dosage,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,GHD,Growth Hormone Deficiency,,,
dosage,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,rhGH,recombinant human GH,,,
dosage,54480d98-5ad3-492b-a63c-d3a39187e82c,7/17/2006,1,IPPB,intermittent positive pressure breathing,,,
dosage,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,AGC,absolute granulocyte count,,,
dosage,529d1155-e911-45bd-baf4-9a2aeebc8e4f,7/14/2011,1,CBC,complete blood count,,,
dosage,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,i.e.,insufficiency,,,
dosage,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,i.e.,initial route of therapy,,,
dosage,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,TCA,Tricyclic Antidepressant,,,
dosage,6c8d1720-4129-4d96-b037-b0b82b2d1f2e,7/5/2010,2,PET,polyethylene terephthalate,,,
dosage,595cc3d5-1306-4828-aefa-5595219ffd62,2/4/2011,3,CAD,coronary artery disease,,,
dosage,DE99A659-DD2D-BE44-1EDC-E531D7A9FA2A,2/9/2007,1,one tablet,of Ketoconazole Tablets is a single daily administration of 200 mg,,,
dosage,27bee6c9-118a-4609-8949-2eb161b0c5c4,2/28/2012,3593,Suspension,suspension,,,
dosage,930a8a8c-a81a-4110-bb2e-c87e531cbd83,2/17/2012,6,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,930a8a8c-a81a-4110-bb2e-c87e531cbd83,2/17/2012,6,TCA,Tricyclic Antidepressant,,,
dosage,7c50bb9c-7c49-4ba7-a3e5-c28ff0719ce5,5/19/2011,1,CCr,creatinine clearance,,,
dosage,64d0b20a-cecd-474e-a0a1-8f8853500def,4/2/2012,4,i.e.,insufficiency,,,
dosage,64d0b20a-cecd-474e-a0a1-8f8853500def,4/2/2012,4,i.e.,initial route of therapy,,,
dosage,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,i.e.,in special populations,,,
dosage,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,SR®,(SR),,,
dosage,3b3d22dc-df09-4910-8c9b-1204eeedbd68,1/18/2012,6,i.e.,insufficiency,,,
dosage,3b3d22dc-df09-4910-8c9b-1204eeedbd68,1/18/2012,6,i.e.,initial route of therapy,,,
dosage,dfecf849-5261-438a-bd1c-68a7a72c6e3a,4/6/2012,3,BSA,Body surface area,,,
dosage,34bc6919-b7bb-4b2e-962a-2ad695788f5b,12/15/2011,5,i.e.,insufficiency,,,
dosage,34bc6919-b7bb-4b2e-962a-2ad695788f5b,12/15/2011,5,i.e.,initial route of therapy,,,
dosage,dffeca56-ca22-4b62-9537-277caf7edbab,10/6/2010,2,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,6f6de376-2916-4a59-9bfd-217617195350,5/5/2010,1,mg/mL,mg in 100 mL,,,
dosage,6f6de376-2916-4a59-9bfd-217617195350,5/5/2010,1,Use:,USE IN NEWBORNS.,,,
dosage,a5757b1a-62c9-4421-9794-6fb121ce9b7e,2/2/2010,3,i.e.,in 2 divided doses,,,
dosage,15b91de7-1954-4055-aef6-fb57d8568a80,7/12/2012,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,ie,in 2 divided doses,,,
dosage,30a70882-b40a-4782-b227-cd0d35e50a26,7/25/2011,1,CCr,creatinine clearance,,,
dosage,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,AEDs,antiepilepsy drugs,,,
dosage,F7EC5EC1-FB05-4C78-B821-9AEA638CF144,6/11/2008,1,ANC,absolute neutrophil counts,,,
dosage,A8A9D867-1AF3-4749-B740-39F3AD15B09C,9/16/2008,1,e.g.,existing treatment regimen,,,
dosage,A8A9D867-1AF3-4749-B740-39F3AD15B09C,9/16/2008,1,e.g.,environmental agents,,,
dosage,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,PPI,Pump Inhibitors,,,
dosage,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
dosage,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl  liposome injection,,,
dosage,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,HFS,hand-foot syndrome,,,
dosage,822ad5ca-be57-4477-9dfe-b019b5da00fe,4/19/2010,1,mL,milliliters,,,
dosage,822ad5ca-be57-4477-9dfe-b019b5da00fe,4/19/2010,1,mL,Maintenance Dose for diluents,,,
dosage,10b6e166-58ea-4b78-9ca2-471f19737101,9/6/2011,3,mg/mL,mg in 100 mL,,,
dosage,5bb99cd0-a9e6-4df6-a694-a27430c8f996,11/18/2011,2,MPF,Methyl Paraben Free,,,
dosage,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,CLL,dose.Chronic Lymphocytic Leukemia,,,
dosage,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,Impairment,impairment (creatinine clearance 30 to 70 mL/min/1.73 m2).2,,,
dosage,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,BSA,body surface area,,,
dosage,42c535b9-c55e-4fe4-be69-0fc76831bc92,11/8/2010,71,BHAT,Beta-Blocker Heart Attack Trial,,,
dosage,11f1e618-c6ec-42a1-a6ac-5d9a648a21d6,10/3/2011,4,aPTT,activated partial thromboplastin time,,,
dosage,11f1e618-c6ec-42a1-a6ac-5d9a648a21d6,10/3/2011,4,PAF,paroxysmal AF,,,
dosage,f5a860f3-37ec-429c-ae04-9c88d7c55c08,7/23/2012,34,PVC,polyvinyl chloride,,,
dosage,457d7810-23f1-4318-9561-2cd58a9cf973,11/15/2011,4,i.e.,insufficiency,,,
dosage,457d7810-23f1-4318-9561-2cd58a9cf973,11/15/2011,4,i.e.,initial route of therapy,,,
dosage,7026f0a7-3f08-4116-aa0b-eb61dc3804ab,2/28/2012,3594,Suspension,suspension,,,
dosage,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,PAF,paroxysmal AF,,,
dosage,631dc216-df9e-4126-b59e-c8079ba6e287,8/12/2010,1,APTT,activated partial  thromboplastin time,,,
dosage,5783976b-0862-44e5-9b19-0f41d236d5c3,1/5/2012,1,ILD,Interstitial Lung Disease,,,
dosage,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,HUMAN,Hemodilution may follow administration of ALBUMIN,,,
dosage,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,ARDS,Adult Respiratory Distress Syndrome,,,
dosage,3e4402d4-e0d3-9846-3e81-ed46f34137fe,2/1/2012,9,i.e.,insufficiency,,,
dosage,3e4402d4-e0d3-9846-3e81-ed46f34137fe,2/1/2012,9,i.e.,initial route of therapy,,,
dosage,1d4392ca-6765-494c-bf1f-df6e89964efe,3/12/2012,1,i.e.,insufficiency,,,
dosage,1d4392ca-6765-494c-bf1f-df6e89964efe,3/12/2012,1,i.e.,initial route of therapy,,,
dosage,7a466a45-182a-4178-8648-61d202e794be,1/9/2012,1,i.e.,insufficiency,,,
dosage,7a466a45-182a-4178-8648-61d202e794be,1/9/2012,1,i.e.,initial route of therapy,,,
dosage,fa04ba45-0439-4c97-ecba-2db7f27314ce,6/7/2011,4,overwrap,of Abbott ADD-Vantage containers following removal of the outer packaging,,,
dosage,b32d180f-f8d6-4535-a3b6-45045663a96f,9/30/2011,2,AED,antiepilepsy drug,,,
dosage,8c353bf4-f26b-4ab8-9694-aa9f10dfe965,2/12/2010,1,i.e.,insufficiency,,,
dosage,8c353bf4-f26b-4ab8-9694-aa9f10dfe965,2/12/2010,1,i.e.,initial route of therapy,,,
dosage,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,PAF,paroxysmal AF,,,
dosage,37527eca-115e-4582-88cd-bba851ac6069,4/10/2012,4,i.e.,insufficiency,,,
dosage,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,i.e.,Inpatients,,,
dosage,61dee012-43af-0e9a-3843-9b9b91e022c4,3/21/2012,3,EDTA,ethylene diamine tetraacetic acid,,,
dosage,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,PET,polyethylene terephthalate,,,
dosage,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,Suspension,suspension,,,
dosage,159B5FAC-255C-4A22-98AD-891ABA73EAE1,11/24/2006,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,159B5FAC-255C-4A22-98AD-891ABA73EAE1,11/24/2006,1,GERD,age:GASTROESOPHAGEAL REFLUX DISEASE,,,
dosage,fcc8658c-761a-443f-8c32-1499d86028ec,5/11/2010,3,PVC,polyvinyl chloride,,,
dosage,fd191c06-9d3b-4e46-9f79-90f6af614947,11/3/2011,4,E.G.,EQUIPMENT CONTAINING ALUMINUM,,,
dosage,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,TCA,Tricyclic Antidepressant,,,
dosage,B1F1EF14-E197-42D3-A7B7-7FDCCA8771D0,10/11/2006,1,EFAD,essential fatty acid deficiency,,,
dosage,805cecd0-fd1f-11dd-87af-0800200c9a66,2/29/2012,4,DIP,distal interphalangeal,,,
dosage,2C07CE91-CC83-45e3-BD2B-F923A9C8286C,6/23/2007,1,GFR,glomerular filtration rate,,,
dosage,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,Ductal Carcinoma in Situ,,,
dosage,a002b40c-097d-47a5-957f-7a7b1807af7f,12/22/2011,130,MTX,methotrexate,,,
dosage,a002b40c-097d-47a5-957f-7a7b1807af7f,12/22/2011,130,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
dosage,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,i.e.,initial route of therapy,,,
dosage,546eeb4d-bd1c-4ec4-b7a9-e8344593940f,3/1/2012,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,f6095ec0-c17c-4ea1-847c-88c3e572d93c,4/20/2010,1,i.e.,insufficiency,,,
dosage,f6095ec0-c17c-4ea1-847c-88c3e572d93c,4/20/2010,1,i.e.,initial route of therapy,,,
dosage,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,GLD,greatest linear dimension,,,
dosage,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,aPTT,activated partial thromboplastin time,,,
dosage,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,PAF,paroxysmal AF,,,
dosage,0a03c798-a652-4895-b29c-3b521a89ba42,7/13/2012,6,ANC,absolute neutrophil counts,,,
dosage,05c12da2-8814-4afd-bec0-30cf4cdd2b33,5/1/2012,9,PET,polyethylene terephthalate,,,
dosage,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,i.e.,in 2 divided doses,,,
dosage,e2c1bea3-3c6d-4fe9-9bfd-09dbbce0fd7c,3/7/2012,1,CCr,creatinine clearance,,,
dosage,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,CNS,central nervous system,,,
dosage,a3c2532a-5880-4d52-b2a1-2e6d4dbd6021,4/1/2012,1,BSA,body surface area,,,
dosage,a36705c4-867f-41f1-94c9-78b8b31836ce,4/20/2012,1,i.e.,intended dosing schedule,,,
dosage,A4CCFE5C-72F5-4B0E-A576-8F6DE957E879,6/1/2006,1,e.g.,existing treatment regimen,,,
dosage,A4CCFE5C-72F5-4B0E-A576-8F6DE957E879,6/1/2006,1,e.g.,environmental agents,,,
dosage,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,i.e.,insufficiency,,,
dosage,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,i.e.,initial route of therapy,,,
dosage,202b1a2a-11dc-4c3d-aa53-27512a98a042,12/27/2010,1,teaspoon,the capsule and sprinkling the entire contents on a small amount,,,
dosage,377EEFB1-E588-4D23-BBFC-F9ED877124B0,11/12/2008,3,see,should be considered,,,
dosage,9fd7a181-ab26-4e68-8404-20ce339b0844,9/30/2010,2,PVC,polyvinyl chloride,,,
dosage,8f0ff905-5eb3-4ad0-ad31-fe35b924211f,10/27/2009,1,PPHN,pulmonary hypertension of the newborn,,,
dosage,d771185e-fee2-436c-aa96-36da8de3f611,6/7/2010,1,ie,in 2 divided doses,,,
dosage,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,CCr,creatinine clearance,,,
dosage,f27afd42-f81e-483a-ad1a-e0ea03c4f63e,10/26/2009,2,HPA,hypothalamic-pituitary-adrenal,,,
dosage,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,HGD,diffuser.High-Grade Dysplasia,,,
dosage,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,PDT,Photodynamic Therapy,,,
dosage,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,HGD,High-Grade Dysplasia,,,
dosage,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,BE,Barrett’s Esophagus,,,
dosage,44146b18-78ee-406e-be8d-89a6afa15454,4/19/2011,3,BHAT,Beta-Blocker Heart Attack Trial,,,
dosage,10124262-e443-49a5-a1cc-8cc34c74d953,11/29/2010,1,i.e.,Inpatients,,,
dosage,20b33290-a1fb-499a-86c8-bdf82f1f6ad7,8/7/2006,1,mL,milliliters,,,
dosage,20b33290-a1fb-499a-86c8-bdf82f1f6ad7,8/7/2006,1,mL,Maintenance Dose for diluents,,,
dosage,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,TCA,Tricyclic Antidepressant,,,
dosage,20127592-3a20-e280-2c70-f3d4e1ce009f,5/19/2009,4,i.e.,intended dosing schedule,,,
dosage,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,supine,Subcutaneous Injection Technique: Patients should be lying down,,,
dosage,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,supine,injection.Subcutaneous Injection Technique: Patients should be lying down,,,
dosage,b155a027-a5b3-480a-8c07-fa39af3a18fe,10/6/2010,2,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,0a9891a2-fd39-47b0-adb2-2ed8392b6aff,6/27/2011,3,i.e.,insufficiency,,,
dosage,0a9891a2-fd39-47b0-adb2-2ed8392b6aff,6/27/2011,3,i.e.,initial route of therapy,,,
dosage,4c6a405d-d853-4ec4-94c4-3db5f2e99b08,10/11/2011,1,PET,polyethylene terephthalate,,,
dosage,4c6a405d-d853-4ec4-94c4-3db5f2e99b08,10/11/2011,1,Suspension,suspension,,,
dosage,f1ec6ac1-6b94-40bb-a329-9056f201090c,1/20/2012,1,PET,polyethylene terephthalate,,,
dosage,8fbd0773-6645-4235-9ef2-56edf9c7fb83,1/10/2008,1,mU,milliunits,,,
dosage,27c971a9-5c54-4085-be89-c85e84317294,5/17/2010,2,PET,polyethylene  terephthalate,,,
dosage,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,i.e.,insufficiency,,,
dosage,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,i.e.,initial route of therapy,,,
dosage,ef7804d7-c691-495b-8aaf-5bc54fd5d9f6,4/25/2011,7,AC-PC,anterior commissure-posterior commissure,,,
dosage,149b6307-91f4-4e0d-8741-0a7211e1aaff,10/25/2011,1,MPF,Methyl Paraben Free,,,
dosage,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,CCr,creatinine clearance,,,
dosage,3c11c1c2-8e62-4f63-8293-2f8b8d845f7e,6/11/2008,1,i.e.,in tolerance,,,
dosage,bf412e94-ca36-4da9-83d7-fb0f1323cf21,4/23/2012,4,BSA,body surface area,,,
dosage,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,i.e.,insufficiency,,,
dosage,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,i.e.,initial route of therapy,,,
dosage,db1b94a8-6635-4faa-a361-71706ead1ee7,6/30/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,db1b94a8-6635-4faa-a361-71706ead1ee7,6/30/2011,1,PAF,paroxysmal AF,,,
dosage,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,CEFOTAN,cefotetan disodium for injection,,,
dosage,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,TCA,Tricyclic Antidepressant,,,
dosage,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,Suspension,suspension,,,
dosage,eb40a594-d58d-4214-b766-9e7a815b2de8,8/8/2011,2,AED,antiepilepsy drug,,,
dosage,9d9f5a4d-e3d2-4adb-bce0-ed2aab9a368e,2/24/2011,18,NGU,Nongonococcal urethritis,,,
dosage,7a4840d6-98e3-4523-81a0-ef0b3a47d0c2,7/9/2012,5,i.e.,intended dosing schedule,,,
dosage,e7bfb636-4b0a-440c-a4d3-d26393a14ac5,2/7/2011,1,SWD,Shift Work Sleep Disorder,,,
dosage,b91de288-ed7b-4b8d-b4d8-b84055bd501a,5/20/2010,1,PET,polyethylene terephthalate,,,
dosage,b0df082a-838f-4556-8399-dd8229c5974a,6/13/2012,1,CAD,coronary artery disease,,,
dosage,5a124f61-c716-4867-99da-7fda1852b6f1,4/9/2010,1,mg/mL,mg in 100 mL,,,
dosage,5a124f61-c716-4867-99da-7fda1852b6f1,4/9/2010,1,Use,USE IN NEWBORNS.,,,
dosage,6044028a-26d0-4e48-9cfa-8d045c36661a,4/8/2011,1,PET,polyethylene terephthalate,,,
dosage,6044028a-26d0-4e48-9cfa-8d045c36661a,4/8/2011,1,Suspension,suspension,,,
dosage,aec1c528-a32b-4f23-b897-87e96d73aca7,5/31/2006,1,TPN,total parenteral nutrition,,,
dosage,aec1c528-a32b-4f23-b897-87e96d73aca7,5/31/2006,1,Amino Acid,amino acids.Adequate                                     calories should be administered simultaneously.Patients                                     receiving RenAmin®,,,
dosage,aec1c528-a32b-4f23-b897-87e96d73aca7,5/31/2006,1,Amino Acid,amino acids.®,,,
dosage,aec1c528-a32b-4f23-b897-87e96d73aca7,5/31/2006,1,EFAD,essential fatty                             acid deficiency,,,
dosage,2849298e-de6e-47bb-8194-56e075b33fc3,3/1/2012,1406,BSA,Body surface area,,,
dosage,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,AED,antiepilepsy drug,,,
dosage,f446e1b0-2c46-4763-8eb0-b3a6be956f69,3/7/2012,3,15 mg/min,150 mg over the FIRST 10 minutes,,,
dosage,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,PAF,paroxysmal AF,,,
dosage,abff005f-23fc-4d1e-b469-88aa07589a43,6/8/2010,3,NMS,Neuroleptic  Malignant Syndrome,,,
dosage,cb8aed34-2f3b-48b1-86ea-84b0d9e2b618,12/30/2011,6,BSA,body surface area,,,
dosage,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox,ceftizoxime for injection,,,
dosage,4c0dd824-b099-47c3-aaf5-f6ddb873b3ee,4/1/2010,2,ADT®,Alternate Day  Therapy,,,
dosage,4c0dd824-b099-47c3-aaf5-f6ddb873b3ee,4/1/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
dosage,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,mL,mg tablet,,,
dosage,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,chewable,conversion to monotherapy with lamotrigine tablets,,,
dosage,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,chewable,chronic treatment with lamotrigine tablets,,,
dosage,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,b.i.d.,be administered orally twice daily,,,
dosage,ae97eb2b-587a-4705-8c55-de0f97ee1f1f,9/14/2011,5,BSA,body surface area,,,
dosage,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,AEDs,antiepilepsy drugs,,,
dosage,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,i.e.,in 2 divided doses,,,
dosage,21a09954-398a-4514-93c3-7bce55384fa5,3/20/2012,3676,SSV,Suspension Structured Vehicle USP-NF,,,
dosage,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,s.c.,subcutaneously,,,
dosage,528c67d0-129d-463f-a160-41f370dead6b,11/6/2009,1,mg/kg/day,mg/kg/day:                                                                                                    Daily dose,,,
dosage,eddf7077-02fb-4771-9823-31984f4ff2bb,5/21/2009,3,i.e.,intended dosing schedule,,,
dosage,29489c0e-e981-4bc0-beaf-05c9a9c55c1f,9/8/2011,2,BSA,body surface area,,,
dosage,6f9e5a38-738c-470f-b9cf-4fcef6bc7f01,12/31/2011,3,IET,Intradermal endpoint titration,,,
dosage,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,AtroPen®,atropine which could result in temporary incapacitation (inability to walk properly,,,
dosage,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,AtroPen®,and Caregiver Directions for Use at the end of this package insert,,,
dosage,b8fadaec-9985-4f17-9b2f-b2f6a28cae1c,10/24/2011,1,HPA,HYPOTHALAMIC-PITUTARY-ADRENAL,,,
dosage,afebcc90-e2b5-416d-a041-db2dd593a648,1/17/2011,1,i.e.,in 2 divided doses,,,
dosage,9f9b2391-90eb-4773-bb6b-897c49d82ba5,8/7/2009,4,i.e.,insufficiency,,,
dosage,98c85037-a907-4a3a-8864-c3a5298b4759,3/30/2012,3,EDE,Effective dose equivalents,,,
dosage,22de2626-eef5-47a0-a254-10837e5296a3,9/11/2009,7,mg/kg/day,mg/kg/day:                                                                            Daily dose,,,
dosage,cdd50dc7-f712-4248-b0e3-ba247cf08cee,8/22/2011,10,PVC,polyvinyl chloride,,,
dosage,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,IU,International Units,,,
dosage,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,IV,intravenous,,,
dosage,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,IU,International Unit,,,
dosage,b8fc7086-c034-41c2-aa24-ca30c45753f5,4/21/2011,1,ECG's,electrocardiograms,,,
dosage,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,AGC,absolute granulocyte count,,,
dosage,632a8105-9cb2-44ba-8c10-2a1efd6ac960,7/13/2011,1,CBC,complete blood count,,,
dosage,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,i.e.,In the controlled adjunctive,,,
dosage,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
dosage,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICU,Intensive Care Unit,,,
dosage,cd3f2a72-3f01-49ba-9efe-9f2e6fedbd01,2/1/2012,3,BSA,body surface area,,,
dosage,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,COCs,contraceptives,,,
dosage,21628112-0c47-11df-95b3-498d55d89593,1/18/2012,7,teaspoon,the capsule and sprinkling the entire contents on a small amount,,,
dosage,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,AED,antiepilepsy drug,,,
dosage,60ED4629-A0E6-45E2-B8A5-4323D8A693F4,5/11/2006,2,mL,mg of lidocaine HCl,,,
dosage,A0EEEC15-C76D-41DF-80F3-5572C9857DA6,3/31/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,829c35f9-ace0-11dd-8800-f3e252b43544,5/15/2010,4,NMS,Neuroleptic Malignant Syndrome,,,
dosage,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,MTX,methotrexate,,,
dosage,cae040bf-f379-49d5-b175-1da409832aff,2/16/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
dosage,012a7f03-269d-402c-923d-e5c317a795d2,6/9/2011,1,PDE-5,phosphodiesterase-5,,,
dosage,3edcaae5-81bb-4a18-8bfd-834835187b13,3/18/2010,3,mg/kg/day,mg/kg/day:                                                                                       Daily dose,,,
dosage,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,AED,antiepilepsy drug,,,
dosage,017021a4-25a4-4914-aab3-c21daf97ea50,3/15/2012,3,i.e.,insufficiency should be conservative,,,
dosage,9bb51256-bd5a-4745-aab1-5a025b617552,3/29/2012,1,NGU,Nongonococcal urethritis,,,
dosage,c14a40f7-6cd7-49c2-9e66-27cbff612257,8/25/2010,1,i.e.,insufficiency,,,
dosage,c14a40f7-6cd7-49c2-9e66-27cbff612257,8/25/2010,1,i.e.,initial route of therapy,,,
dosage,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DCIS,Ductal Carcinoma in Situ,,,
dosage,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,TCA,Tricyclic Antidepressant,,,
dosage,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,MAOI,Monoamine Oxidase  Inhibitor,,,
dosage,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,mg/kg/day,mg/kg/day:                                                                      Daily dose,,,
dosage,9dac97a5-c992-4601-af93-138bfe2302a8,3/15/2011,1,i.e.,insufficiency,,,
dosage,9dac97a5-c992-4601-af93-138bfe2302a8,3/15/2011,1,i.e.,initial route of therapy,,,
dosage,f91fc962-7c70-46a9-81fe-b98e93a2028a,1/16/2012,4,ANC,absolute neutrophil counts,,,
dosage,16a1566c-b4d9-46a7-9dce-050b1d1cd5d2,1/17/2011,2091,i.e.,in 2 divided doses,,,
dosage,8f7cba0f-cfcc-cb98-8657-20bd604165d5,1/1/2009,4,NMS,Neuroleptic Malignant Syndrome,,,
dosage,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,ANC,Absolute Neutrophil counts,,,
dosage,5fa97bf5-28a2-48f1-8955-f56012d296be,3/21/2012,12,MDS,myelodysplastic syndromes,,,
dosage,83a2a183-7354-4ba8-bd8d-9b6fd1d1a351,1/11/2010,1,TDD,total daily  dose,,,
dosage,75bcbcb2-5666-47d5-93fe-0ae9eab40cf5,7/20/2011,47,Scr,serum creatinine concentrations,,,
dosage,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,ICU,Intensive Care Unit,,,
dosage,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,MAC,Monitored Anesthesia Care,,,
dosage,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,Sedation:,See WARNINGS and DOSAGE AND ADMINISTRATION - Handling Procedures.,,,
dosage,b367d81d-4eca-4e28-b490-34be4c003561,4/30/2010,2,AED,antiepilepsy drug,,,
dosage,bc0a3a39-4ac3-47de-a388-9c3672e3e130,11/15/2011,4,ANC,absolute neutrophil counts,,,
dosage,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,mg/kg/day,mg/kg/day:                                        Daily dose,,,
dosage,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,mg/mL,mg in 100 mL,,,
dosage,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,ICU,Intensive Care Unit,,,
dosage,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,OR,Operating Room,,,
dosage,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,CNS,central nervous system,,,
dosage,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,i.e.,insufficiency,,,
dosage,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,i.e.,initial route of therapy,,,
dosage,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,d8028584-4186-41d6-b74b-2535971aa216,12/16/2011,8,SSV,Suspension Structured Vehicle USP-NF,,,
dosage,42602989-2a6d-4df6-ac41-780c1aa724ae,8/25/2011,1,DOT,Directly Observed Therapy,,,
dosage,42602989-2a6d-4df6-ac41-780c1aa724ae,8/25/2011,1,MDRTB,Multi-Drug Resistant  Tuberculosis,,,
dosage,7a83e68b-0c37-4e1a-9648-ce21fb4aff00,8/8/2006,1,mL,mg prednisolone base,,,
dosage,8f89bc0b-0921-4b7b-d5b8-c3cecfe3b049,10/13/2011,1431,PDS,prefilled dual chamber syringe,,,
dosage,db56d1ba-eb56-4c34-8283-fa163da9621c,5/24/2010,2,CAD,coronary artery disease,,,
dosage,a912d27c-00cb-2ed0-effe-2d88d1f2ca67,8/1/2008,4,HUMAN,Hemodilution may follow administration of ALBUMIN,,,
dosage,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,RN,registered Nurse,,,
dosage,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,RN,registered nurse,,,
dosage,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,teaspoon,the capsule and sprinkling the entire contents on a small amount,,,
dosage,76635b0d-0a20-44b7-a076-b8f3c689c2ce,4/19/2011,1,CCr,creatinine clearance,,,
dosage,21aea811-f47d-4a44-a552-dfc46d2773bf,8/31/2011,4,i.e.,in labeling,,,
dosage,21aea811-f47d-4a44-a552-dfc46d2773bf,8/31/2011,4,Clcr,Calculate Creatine Clearance,,,
dosage,21aea811-f47d-4a44-a552-dfc46d2773bf,8/31/2011,4,i.e.,interval prolongation,,,
dosage,0879f244-ec2f-4091-b0e3-ca9c1475ab21,12/1/2011,3284,ie,in 2 divided doses,,,
dosage,309de576-c318-404a-bc15-660c2b1876fb,7/5/2012,37,PMs,poor metabolizers,,,
dosage,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,mg/kg/day,mg/kg/day:                                                                  Daily dose,,,
dosage,c45f9a58-37c1-4f76-8e36-97d38c577037,12/19/2011,106,mcg,micrograms,,,
dosage,c45f9a58-37c1-4f76-8e36-97d38c577037,12/19/2011,106,IVIG,intravenous immunoglobulin,,,
dosage,cea5f748-3127-4d36-83af-9ab3cf58503c,1/18/2012,7,teaspoon,the capsule and sprinkling the entire contents on a small amount,,,
dosage,26b65fec-9a5d-4b9b-9b87-c3d328c58cd0,7/30/2009,2,AED,antiepilepsy drug,,,
dosage,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,TCA,Tricyclic Antidepressant,,,
dosage,795AA202-2825-43FC-B4BE-E92AC4FD0B3E,2/6/2007,1,EFAD,essential fatty acid deficiency,,,
dosage,fec93dc7-aba2-4aad-a529-8b6fc06f2562,5/23/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,fec93dc7-aba2-4aad-a529-8b6fc06f2562,5/23/2011,1,PAF,paroxysmal AF,,,
dosage,d74e59ba-bfeb-4c48-9596-da44328561a9,5/26/2010,7,IV,intravenous,,,
dosage,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,PMs,poor metabolizers,,,
dosage,a9a60b57-445d-4c27-bdca-5a0cbfb90502,11/17/2011,6,i.e.,insufficiency,,,
dosage,a9a60b57-445d-4c27-bdca-5a0cbfb90502,11/17/2011,6,i.e.,initial route of therapy,,,
dosage,1b6a2ecf-51b5-4591-8723-6c604992f2e1,12/7/2011,3,i.e.,initial route of therapy,,,
dosage,7e593aec-4ef2-445c-b4e9-13dfc99296f2,12/20/2011,3406,TDD,total daily  dose,,,
dosage,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MAC,Mycobacterium avium complex,,,
dosage,6b35138f-491b-46cf-97d3-55f43e651d63,2/2/2010,2,e.g.,EQUIPMENT CONTAINING ALUMINUM,,,
dosage,e2015ac5-0441-43fd-b864-a1b1fe944450,9/30/2010,6,AED,antiepilepsy drug,,,
dosage,c7bc930b-05c1-4d3c-acfd-93edf0ba6cac,3/1/2012,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,debf74d1-3250-4858-8a9d-638262f3a7d5,10/12/2011,1,ECGs,electrocardiograms,,,
dosage,9244e41c-94c9-428b-a254-703b71f9460b,7/30/2009,1001,ie,in 2 divided doses,,,
dosage,ddcfb616-78c1-42eb-9dcb-2cc41291a2ac,6/1/2009,2,TDD,total daily  dose,,,
dosage,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,i.e.,intended dosing schedule,,,
dosage,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,ESRD,end-stage renal disease,,,
dosage,d45fc842-2563-4421-86af-a55b3191e19b,1/9/2012,3,CYP3A4/5,cytochrome P450 3A4/5,,,
dosage,384848CD-55EA-4107-89D3-CE0B819F4DD2,8/28/2008,1,CCa,Albumin-corrected serum calcium,,,
dosage,384848CD-55EA-4107-89D3-CE0B819F4DD2,8/28/2008,1,i.e.,insufficiency.Longer infusions,,,
dosage,322513fd-6be0-4cd9-a0ea-7e4b5b578336,3/19/2010,2,IR,immediate-release,,,
dosage,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,i.e.,insufficiency,,,
dosage,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,i.e.,initial route of therapy,,,
dosage,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,i.e.,insufficiency,,,
dosage,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,i.e.,initial route of therapy,,,
dosage,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,PDE-5,phosphodiesterase-5,,,
dosage,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,i.e.,intended dosing schedule,,,
dosage,e196c127-c081-43a7-8f0d-be3e2b434b50,10/6/2010,1,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,IV,intravenous,,,
dosage,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,i.e.,initial route of therapy,,,
dosage,E1FF4C1F-5D6F-44A6-A0F6-D7CA2A94ADB9,11/5/2007,2,NMS,Neuroleptic Malignant Syndrome,,,
dosage,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,AGC,absolute granulocyte count,,,
dosage,b9347b14-7ca2-43f5-9ee8-7ba709ae6b52,9/12/2011,3,CBC,complete blood count,,,
dosage,2d38cbdb-4e4d-4174-461d-7a3b6475e6a5,9/22/2010,7,CAPD,chronic ambulatory peritoneal dialysis,,,
dosage,2d38cbdb-4e4d-4174-461d-7a3b6475e6a5,9/22/2010,7,ESRD,end-stage renal disease,,,
dosage,2d38cbdb-4e4d-4174-461d-7a3b6475e6a5,9/22/2010,7,CAVHD,continuous arteriovenous hemofiltration/dialysis,,,
dosage,d4b8a490-d96f-414e-b020-9460625c40ef,8/17/2011,1,PET,polyethylene terephthalate,,,
dosage,cce0199c-40e9-4c8c-b04c-c2b969e9a5ba,10/12/2011,1,i.e.,in 2 divided doses,,,
dosage,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,AED,antiepilepsy drug,,,
dosage,88c9d1ca-f3a8-4078-8de7-21fd9040dd20,2/14/2012,2,teaspoon,the capsule and sprinkling the entire contents on a small amount,,,
dosage,6f41228b-974a-443b-a313-2fbb3d845915,2/16/2010,1,i.e.,insufficiency,,,
dosage,6f41228b-974a-443b-a313-2fbb3d845915,2/16/2010,1,i.e.,initial route of therapy,,,
dosage,6df09f15-b102-431c-adde-d7aeef6f5d84,5/31/2012,6,BSA,body surface area,,,
dosage,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,TCA,Tricyclic Antidepressant,,,
dosage,a70be430-21fa-49a4-84c1-134621ee2f4f,2/24/2012,2,mg/kg/day,mg/kg/day:                   Daily dose,,,
dosage,90f90650-709f-4d2a-bf94-26aad80e0805,2/21/2012,1,mg/kg/day,mg/kg/day:                                                                      Daily dose,,,
dosage,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,PPHN,pulmonary hypertension of the newborn,,,
dosage,6d835181-0454-4edb-b523-940afcd4674f,4/18/2011,6,ECG's,electrocardiograms,,,
dosage,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,TCA,Tricyclic Antidepressant,,,
dosage,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,MAOI,Monoamine Oxidase  Inhibitor,,,
dosage,5d86f813-e784-4490-a842-bcb78eb0d9a4,8/1/2011,4,CCr,creatinine clearance,,,
dosage,decda177-7c1a-4d28-84fc-c6d7aa251561,3/15/2010,1,PET,polyethylene  terephthalate,,,
dosage,decda177-7c1a-4d28-84fc-c6d7aa251561,3/15/2010,1,Suspension,suspension,,,
dosage,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,mg/kg/day,mg/kg/day: Daily dose,,,
dosage,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,CCr,creatinine clearance,,,
dosage,6ca166e5-8591-4eb1-b6dd-ade7f6f4c1bf,3/21/2008,3,GERD,Gastroesophageal Reflux                                 Disease,,,
dosage,aa445f68-1e55-a587-76dc-def068bc9c74,12/11/2011,3,AGC,absolute granulocyte count,,,
dosage,aa445f68-1e55-a587-76dc-def068bc9c74,12/11/2011,3,CBC,complete blood count,,,
dosage,d26b56fa-d521-461b-a619-40b65862b644,8/1/2009,1,NMS,Neuroleptic Malignant Syndrome,,,
dosage,6c5bb008-e66f-4ef0-bf84-aca7eb5983e9,1/25/2011,2,ie,in 2 divided doses,,,
dosage,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,OHSS,ovarian hyperstimulation syndrome,,,
dosage,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,IVF,In Vitro Fertilization,,,
dosage,96f11b5d-cc7b-48aa-830a-a28e1962d871,8/1/2011,8,ICSI,Intracytoplasmic Sperm Injection,,,
dosage,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,TCA,Tricyclic Antidepressant,,,
dosage,70e73a11-5951-43db-9cd2-dc851cd5fa7b,11/11/2009,1005,ie,in 2 divided doses,,,
dosage,26b11116-95f5-488f-a9c0-3b07d4db6678,11/3/2011,4,mL,milliliters,,,
dosage,26b11116-95f5-488f-a9c0-3b07d4db6678,11/3/2011,4,mL,Maintenance Dose for diluents,,,
dosage,a61cf5cb-351d-4b31-b731-6154a27aeb56,1/13/2012,3,CAPD,Continuous Ambulatory Peritoneal Dialysis,,,
dosage,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,LD,loading dose,,,
dosage,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,mg/kg/day,mg/kg/day: Daily dose,,,
dosage,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,PAF,paroxysmal AF,,,
dosage,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,ie,in 2 divided doses,,,
dosage,e38987d4-31de-429b-a81d-1ed23c1b0a55,5/21/2010,1,i.e.,insufficiency,,,
dosage,e38987d4-31de-429b-a81d-1ed23c1b0a55,5/21/2010,1,i.e.,initial route of therapy,,,
dosage,8e2772cb-7dea-42d1-ba31-d479ba7cb09a,9/30/2011,4,i.e.,in labeling,,,
dosage,abacb7fa-2fc2-471e-9200-944eeac8ca2a,12/16/2009,3,mL,may be calculated: Dose,,,
dosage,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,i.e.,in 2 divided doses,,,
dosage,1feab7cb-aa81-4c49-8db4-7e3f1ac3a5e9,10/21/2011,11,i.e.,in 2 divided doses,,,
dosage,1521d321-e724-4ffc-adad-34bf4f44fac7,1/16/2012,16,BSA,body surface area,,,
dosage,e62ae0e4-0689-431a-a552-f0711ca68844,9/16/2011,3,BSA,body surface area,,,
dosage,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,i.e.,insufficiency,,,
dosage,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,i.e.,initial route of therapy,,,
dosage,62192e4e-5bf6-4a90-965b-bab9e0366020,11/30/2009,1,ie,in 2 divided doses,,,
dosage,043F8DEA-E33C-455D-2EB6-D7EB1506B4DD,5/20/2009,2,EFAD,essential fatty acid deficiency,,,
dosage,A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A,1/17/2007,1,CCr,creatinine clearance,,,
dosage,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,LD,loading dose,,,
dosage,E49D032C-2805-4C9B-887C-66D1852DB3EB,5/11/2006,1,mL,mg lidocaine HCl,,,
dosage,c77ababd-a449-4e89-a9c6-b7e401120ba1,12/28/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
dosage,76c7e13d-37a0-4131-a1f1-fd5af0f60d3e,9/30/2010,1,mg/kg/day,mg/kg/day:                                                                      Daily dose,,,
dosage,e1685937-3980-40e3-8f04-998174fef3a2,2/23/2012,5,NSAIDs,non-steroidal anti-inflammatory drugs,,,
dosage,6467d400-d373-4137-af06-568b98813c8e,8/13/2010,1,APTT,activated partial  thromboplastin time,,,
dosage,ec694185-fcb9-49d9-aaf5-e88861346c7c,11/30/2009,1,i.e.,intended dosing schedule,,,
dosage,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,i.e.,insufficiency,,,
dosage,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,i.e.,initial route of therapy,,,
dosage,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,FPG,fasting  plasma glucose,,,
dosage,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,HbA1c,hemoglobin A1c,,,
dosage,b83329ac-a65e-b3af-a3fb-c5a6c740e5e7,7/15/2011,5,GERD,Gastroesophageal Reflux Disease,,,
dosage,dd7f12a7-7fe5-470b-b151-6ccf19945638,8/3/2010,1,PET,polyethylene terephthalate,,,
dosage,938d167b-bf6d-4c29-8848-fc76aba3cbd0,11/10/2011,2,PDE-5,phosphodiesterase-5,,,
dosage,bdab7205-d0ff-41c3-8430-2d399dfaa759,10/1/2011,3,PMs,poor metabolizers,,,
dosage,bdab7205-d0ff-41c3-8430-2d399dfaa759,10/1/2011,3,HI,hepatic insufficiency,,,
dosage,28972d09-9ee7-4027-a9cd-433b5b16b978,9/30/2010,6,mL/day,mg/kg/day:                               Total daily dose,,,
dosage,f7214f89-5215-49b4-5491-6462a71b1f5c,7/13/2011,10,BSA,body surface area,,,
dosage,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,IGIV,immune globulin intravenous,,,
dosage,29c0e001-4855-4903-aa1d-64e4dd155b8a,1/25/2012,9,Suspension,suspension,,,
dosage,df661166-325d-4071-9bc1-f7bf992996d2,10/6/2010,1,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,i.e.,insufficiency,,,
dosage,1e2fb42a-5dc9-49c0-8575-116173cd4ccb,3/2/2012,3,i.e.,insufficiency,,,
dosage,1e2fb42a-5dc9-49c0-8575-116173cd4ccb,3/2/2012,3,i.e.,initial route of therapy,,,
dosage,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,CCr,creatinine clearance,,,
dosage,c628d376-4b65-4f05-b6fa-eabb1d96a7df,7/30/2009,1,AED,antiepilepsy drug,,,
dosage,b40bfd2b-9ff1-45bf-a40f-e9812f1df228,6/3/2010,323,7.5 mg/mL,9.75 mg/1.3 mL,,,
dosage,f322ff90-e08d-4d99-9348-94cc6a56afcd,11/30/2009,1,i.e.,insufficiency should be conservative,,,
dosage,6059a68d-5434-4a0e-9f53-b793c3dc8630,7/24/2012,10,i.e.,intended dosing schedule,,,
dosage,5c4877cc-52bc-4f98-a995-0aa9439da742,2/24/2012,3,mg/kg/day,mg/kg/day:                   Daily dose,,,
dosage,c4caf469-f684-4f6d-98e8-b6a2fff1de98,8/31/2011,5,i.e.,in labeling,,,
dosage,c8d2e135-ec31-4eee-bce2-c85e7858c5e1,3/9/2012,2,CAD,coronary artery disease,,,
dosage,a671b0fb-6b6b-43e7-994b-5de54582c4a7,2/24/2012,3,ie,in 2 divided doses,,,
dosage,7c087473-393f-4c18-a958-c08c18bf9584,11/8/2006,1,TPN,total parenteral nutrition,,,
dosage,7c087473-393f-4c18-a958-c08c18bf9584,11/8/2006,1,EFAD,essential                             fatty acid deficiency,,,
dosage,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,ANC,absolute neutrophil counts,,,
dosage,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,8/3/2007,1,ERCP,endoscopic retrograde cholangiopancreatography,,,
dosage,46ac55cf-d85e-4c34-bb33-f49e078c4a03,3/14/2012,5,EDTA,ethylene diamine tetraacetic acid,,,
dosage,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,IV,intravenously,,,
dosage,D046EC54-9AC8-4C9F-87A7-69E9900D8016,7/24/2006,1,IM,intramuscularly,,,
dosage,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,mL,mg vial,,,
dosage,8f6e4a86-5fc1-45b1-adab-25a81f93cb05,6/21/2011,1,i.e.,insufficiency,,,
dosage,8f6e4a86-5fc1-45b1-adab-25a81f93cb05,6/21/2011,1,i.e.,initial route of therapy,,,
dosage,99a81fda-81dc-40b3-b55a-165b6e4ca4ee,11/30/2011,2,i.e.,insufficiency,,,
dosage,99a81fda-81dc-40b3-b55a-165b6e4ca4ee,11/30/2011,2,i.e.,initial route of therapy,,,
dosage,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,i.e.,insufficiency,,,
dosage,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,i.e.,initial route of therapy,,,
dosage,b4332b67-833d-4838-9594-b2b76f98d1ab,7/21/2010,1,ADT®,Alternate Day Therapy,,,
dosage,b4332b67-833d-4838-9594-b2b76f98d1ab,7/21/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,OND,ondansetron,,,
dosage,c7156e83-f344-4e9f-a42d-6dc8ce90a0b9,3/31/2011,1,METROGEL®,metronidazole topical gel,,,
dosage,19977c31-02d3-40fa-bcad-9c3c88768e11,6/9/2011,3,LADs,Luer-Activated Devices,,,
dosage,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,PAF,paroxysmal AF,,,
dosage,ee501e38-3223-41bf-8211-3248e76c6eff,1/21/2011,2,mL,milliliters,,,
dosage,ee501e38-3223-41bf-8211-3248e76c6eff,1/21/2011,2,mL,Maintenance Dose for diluents,,,
dosage,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MAC,Mycobacterium avium complex,,,
dosage,9899985f-649f-4bcc-890f-0f4800227929,3/1/2012,2,IR,immediate-release,,,
dosage,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,INRW,INR value on warfarin alone,,,
dosage,cea3f6aa-cd1c-4152-98bb-bbb7b977497a,9/27/2011,14,INR,International Normalized Ratio,,,
dosage,e82f52f2-ecf8-4c04-a206-f3253b265903,12/22/2011,3,i.e.,insufficiency,,,
dosage,e82f52f2-ecf8-4c04-a206-f3253b265903,12/22/2011,3,i.e.,initial route of therapy,,,
dosage,e82f52f2-ecf8-4c04-a206-f3253b265903,12/22/2011,3,mL/min,may be used to estimate creatinine clearance:                         Men: Creatinine clearance,,,
dosage,0b72a120-ca4e-4b90-7d89-52967a39adb3,5/19/2009,1,i.e.,intended dosing schedule,,,
dosage,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,PAF,paroxysmal AF,,,
dosage,8d3cb614-20c1-4a6d-9e89-22785f78c56e,12/1/2011,3284,HPA,hypothalamic-pituitary-adrenal,,,
dosage,d6fc590a-7ff9-488c-9898-eec926303b76,4/4/2011,1,ECGs,electrocardiograms,,,
dosage,2A0A2D3A-1900-4C73-89C5-C4BDE1B61553,2/29/2008,6,mL,milliliters,,,
dosage,30f6b141-b825-4f1f-8d6c-2136de1b1155,5/5/2010,6,mg/mL,mg in 100 mL,,,
dosage,30f6b141-b825-4f1f-8d6c-2136de1b1155,5/5/2010,6,Use:,USE IN NEWBORNS.,,,
dosage,cb3897b7-d4f1-4081-bb3c-e5e270a84930,2/1/2012,1,ie,in 2 divided doses,,,
dosage,e231b3d8-d665-41f1-b8af-d9a71bda09f2,11/9/2011,2,i.e.,in 2 divided doses,,,
dosage,33C9CD03-A005-476A-9A57-50BFE913674A,8/2/2007,1,NGU,days.Nongonococcal urethritis,,,
dosage,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,mg/mL,mg in 100 mL,,,
dosage,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,ICU,Intensive Care Unit,,,
dosage,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,OR,Operating Room,,,
dosage,86f44ab3-81c4-4d3e-a70e-5985c172af0b,11/3/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,4ACDFA96-BD62-4289-8454-276D3886A1A7,12/13/2006,3,GERD,Gastroesophageal Reflux Disease,,,
dosage,165703a0-16d0-b7ff-5b66-88f1f7fa0600,12/11/2009,2,PET,polyethylene terephthalate,,,
dosage,b932df7e-04a5-4e54-a4ee-d553934b812e,8/2/2006,1,mL,milliliters,,,
dosage,b932df7e-04a5-4e54-a4ee-d553934b812e,8/2/2006,1,mL,MAINTENANCE DOSE for                             diluents,,,
dosage,42CD4847-B706-4D51-97E3-B736839C2D24,10/11/2006,1,CVP,central venous pressure,,,
dosage,d59a23ba-9e28-42a3-8bfe-a3742fdfdebe,1/1/2011,1,PET,polyethylene terephthalate,,,
dosage,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,Hydroxide,hydroxide,,,
dosage,11939A69-D373-42DF-BABB-9FB7B9C8F6CB,3/7/2007,1,mL,mg prednisolone base,,,
dosage,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,BSA,body surface area,,,
dosage,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,CNS,central nervous system,,,
dosage,787c1115-61fa-41d1-a0b2-32318f1e20f5,8/1/2011,8,PET,polyethylene terephthalate,,,
dosage,787c1115-61fa-41d1-a0b2-32318f1e20f5,8/1/2011,8,Suspension,suspension,,,
dosage,eaa404d1-68a9-4fac-b3f3-b444a20df120,1/10/2012,3,mg/mL,mg in 100 mL,,,
dosage,e0d66bf0-04d0-4168-ac72-3fd0116d5e64,5/6/2010,3,HPA,hypothalamic-pituitary-adrenal,,,
dosage,a24e8e53-07b3-49be-87e4-124f7d3aeac1,8/18/2010,1,AED,antiepilepsy drug,,,
dosage,a70baf53-e38a-4b23-8905-ee284170236d,3/6/2007,1,CAD,coronary artery disease,,,
dosage,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,TCA,Tricyclic Antidepressant,,,
dosage,4aa6b91f-bc3b-455c-b6d3-9027964d17ed,7/8/2011,1,q12h,q12hWeightDose,,,
dosage,676e73fb-51d2-449a-8749-1a7bcc257b11,3/15/2012,9,JRA,2.4??Juvenile Rheumatoid Arthritis,,,
dosage,1fdf16e5-145d-4c19-a318-fc6c10794b50,1/25/2012,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,807273be-f765-48f0-bd2e-94f9f70152bd,3/31/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,5ddba454-f3e6-43c2-a7a6-58365d297213,2/29/2012,10,Suspension,suspension,,,
dosage,d6504eb1-f8ee-4cc1-9689-adb9e06b6fd1,11/9/2010,74,ADT®,Alternate Day Therapy,,,
dosage,d6504eb1-f8ee-4cc1-9689-adb9e06b6fd1,11/9/2010,74,HPA,hypothalamic-pituitary-adrenal,,,
dosage,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,ESRD,end-stage renal disease,,,
dosage,ba48ac4b-9503-4006-f6e2-3b8a83059c03,12/16/2011,6,CYP3A4/5,cytochrome P450 3A4/5,,,
dosage,2a569ec5-08d7-44ab-b649-384a496e173c,5/26/2010,9,IV,intravenous,,,
dosage,47ef5501-1408-41fa-b0e5-f078f18129f5,7/30/2009,1,AED,antiepilepsy drug,,,
dosage,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,PAF,paroxysmal AF,,,
dosage,3e463126-78a9-4ec5-904c-0424a64d8ae8,5/24/2011,1,i.e.,initial route of therapy,,,
dosage,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,TCA,Tricyclic Antidepressant,,,
dosage,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,TCA,Tricyclic Antidepressant,,,
dosage,9b993fc7-e026-4749-b785-cbd3b9c29003,3/31/2011,3,NMS,Neuroleptic  Malignant Syndrome,,,
dosage,A4990248-0611-426F-9AAA-181CC2561832,6/30/2008,2,one tablet,of ketoconazole tablets is a single daily administration of 200 mg,,,
dosage,d8d04647-8e25-4127-8ecf-360ce1991c2f,1/25/2012,1,PVC,polyvinyl chloride,,,
dosage,e96e6f6b-d7e6-48f4-bae8-2d878a5b7694,11/10/2010,77,PDE-5,phosphodiesterase-5,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,MI,myocardial infarction,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,aPTT,activated  partial thromboplastin time,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,aPTT,activated partial thromboplastin time,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,PAF,paroxysmal AF,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,INR,International Normalized Ratio,,,
dosage,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,VKA,vitamin-K  antagonist,,,
dosage,4255bf9a-b114-474b-b310-f22ff048b2a6,4/1/2012,1,BSA,body surface area,,,
dosage,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,i.e.,insufficiency,,,
dosage,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,i.e.,initial route of therapy,,,
dosage,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,TCA,Tricyclic Antidepressant,,,
dosage,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox,ceftizoxime for injection,,,
dosage,2150f73a-179b-4afc-b8ce-67c85cc72f04,4/30/2012,24,TDM,therapeutic drug monitoring,,,
dosage,580da6bb-b4e8-40a3-bc21-87985d687354,9/9/2011,1,i.e.,in special populations,,,
dosage,25c2a91c-dfc2-4596-8a24-63acf04a2568,7/9/2010,1,TDD,total daily  dose,,,
dosage,81E856DC-9B73-4E77-1EB9-415F33935C9E,1/9/2007,2,EFAD,essential fatty acid deficiency,,,
dosage,7e2462b2-bfed-4da4-8c47-46838d6153f8,11/28/2011,1,i.e.,interval,,,
dosage,7217ffdd-bcd2-48b7-a397-da966ea533bd,9/17/2009,2,i.e.,insufficiency,,,
dosage,7217ffdd-bcd2-48b7-a397-da966ea533bd,9/17/2009,2,i.e.,initial route of therapy,,,
dosage,7217ffdd-bcd2-48b7-a397-da966ea533bd,9/17/2009,2,mL/min,may be used to estimate creatinine clearance:                         Men: Creatinine clearance,,,
dosage,efe8ac26-e80c-4dc4-89ce-70bd307e3826,7/22/2010,4,TURB,transurethral resection of the bladder,,,
dosage,efe8ac26-e80c-4dc4-89ce-70bd307e3826,7/22/2010,4,PDD,Photodynamic Diagnostic,,,
dosage,efe8ac26-e80c-4dc4-89ce-70bd307e3826,7/22/2010,4,PDD,Photodynamic Diagnosis,,,
dosage,51d70f1a-85d5-4328-9e9c-6111bab0ba25,9/26/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,AGC,absolute granulocyte count,,,
dosage,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,CBC,complete blood count,,,
dosage,598b880e-e887-4e40-8b0a-cbb6cbaa2fa8,6/7/2010,1,i.e.,in 2 divided doses,,,
dosage,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,TCA,Tricyclic Antidepressant,,,
dosage,a439bf07-53db-0352-846a-99d9da772f9b,5/10/2010,2,G-CSF,granulocyte-colony stimulating factor,,,
dosage,ddef12df-a0bd-4f58-bd3e-da975581d01b,8/4/2011,1,i.e.,insufficiency,,,
dosage,ddef12df-a0bd-4f58-bd3e-da975581d01b,8/4/2011,1,i.e.,initial route of therapy,,,
dosage,db42eca3-274a-43d3-a0be-e5209747bedc,1/18/2011,1,PVC,polyvinylchloride,,,
dosage,f1e576fc-3bce-40e2-bfba-de48e341b722,1/10/2012,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,536735fc-566c-4ad4-b83e-602199ff82b4,12/21/2011,4,BSA,body surface area,,,
dosage,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,years.Ductal Carcinoma in Situ,,,
dosage,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,Ductal Carcinoma in Situ,,,
dosage,290C3E9C-C0C6-440A-1A9C-46E3E2B07A77,5/11/2006,1,diluted,PRECAUTIONS.Drug InteractionsDrug InteractionsAdditives may be incompatible with the reconstituted,,,
dosage,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,AGC,absolute granulocyte count,,,
dosage,d16907e7-a8c8-4039-ace4-cf4e24ba68c0,10/7/2011,14,CBC,complete blood count,,,
dosage,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,AIBW,Adjusted ideal body weight,,,
dosage,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,IBW,Ideal body weight,,,
dosage,2c4f826c-e71b-4462-a025-19730701a9de,3/19/2010,1,ie,in 2 divided doses,,,
dosage,f16f9ae6-d29f-4b31-a240-c7ebb0d7d36a,4/27/2012,1,i.e.,in labeling,,,
dosage,5498f6aa-f4c1-49a3-b969-0711077dde81,8/23/2010,1,Injection,injection,,,
dosage,fd2fa2af-5929-4152-afd3-55e4e162f765,6/13/2011,1,overwrap,of Abbott ADD-Vantage containers following removal of the outer packaging,,,
dosage,68848217-03c9-4377-9be6-6f567e629129,12/16/2010,16,ie,in 2 divided doses,,,
dosage,0f799e5c-f782-4f3d-bdb6-52bd413a19cf,10/27/2009,2,IR,immediate-release,,,
dosage,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,CCr,creatinine clearance,,,
dosage,d41d6d19-086c-4e17-814c-6fd6f3e81e24,7/5/2010,2,PET,polyethylene terephthalate,,,
dosage,93d03943-0655-44f6-b494-57bd1e336a34,4/12/2012,2,EDTA,ethylene diamine tetraacetic acid,,,
dosage,7c6e428b-305f-477e-a758-753d2ea5a060,6/28/2011,1,i.e.,insufficiency,,,
dosage,7c6e428b-305f-477e-a758-753d2ea5a060,6/28/2011,1,i.e.,initial route of therapy,,,
dosage,87a90438-84b6-4485-b43a-d9b9a58b933a,5/8/2012,1,ie,in 2 divided doses,,,
dosage,09e383a8-e912-4cf7-8fb3-05545af80dd0,9/30/2011,8,PET,polyethylene terephthalate,,,
dosage,09e383a8-e912-4cf7-8fb3-05545af80dd0,9/30/2011,8,Suspension,suspension,,,
dosage,141bddee-8e4d-4c68-89bf-03f2270c766d,1/15/2010,2,i.e.,insufficiency,,,
dosage,141bddee-8e4d-4c68-89bf-03f2270c766d,1/15/2010,2,i.e.,initial route of therapy,,,
dosage,d3b851af-f8e9-4375-bbbe-7132e66ee0d0,7/21/2011,2,mg/mL,mg in 100 mL,,,
dosage,42d81ec3-0788-40c3-8eec-e50403f0ab58,4/20/2011,1,i.e.,insufficiency,,,
dosage,42d81ec3-0788-40c3-8eec-e50403f0ab58,4/20/2011,1,i.e.,initial route of therapy,,,
dosage,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,i.e.,in 2 divided doses,,,
dosage,d460371b-545c-4a16-b5a8-ef8d748cecb9,7/15/2011,1,i.e.,in special populations,,,
dosage,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,ie,in 2 divided doses,,,
dosage,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,AED,antiepilepsy drug,,,
dosage,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,GERD,Gastroesophageal Reflux Disease,,,
dosage,ca9f0c57-fc8b-4da4-a987-0fc52b7fd4f4,8/11/2011,1,BSA,body surface area,,,
dosage,2a6f5fe2-add6-4c6d-b07c-ce707bf49203,7/9/2012,5,PET,polyethylene terephthalate,,,
dosage,158d03d1-5c7c-460a-acb0-624069e231ee,2/15/2011,1,mg/kg/day,mg/kg/day:                                                                                       Daily dose,,,
dosage,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,BSA,body surface area,,,
dosage,ecf64245-20b1-4bff-9fcc-b8a16905e27b,12/22/2011,5,e.g.,EQUIPMENT CONTAINING ALUMINUM,,,
dosage,1F7D5370-94D6-4BE4-9FB5-990DC924C815,7/18/2006,1,oxytocin,or 5% dextrose in physiologic saline solution to which 10 units of Syntocinon®,,,
dosage,b3ad0449-fd60-482a-9ba7-afd8f5555b83,1/13/2012,8,CAPD,Continuous Ambulatory Peritoneal Dialysis,,,
dosage,ADB54FE50FCC4A01AFC64AA3D3DB45BB,11/7/2006,2,GERD,Gastroesophageal Reflux Disease,,,
dosage,7967f8f4-eba8-4849-a176-944fffa2ee53,6/27/2011,1,mg/kg/day,mg/kg/day:                                                                       Daily dose,,,
dosage,0d02b3a0-4de3-473b-8ed9-a1974747970f,6/13/2006,1,E.F.A.D.,essential fatty acid deficiency,,,
dosage,61ea67c2-8c0e-486f-8c0c-6167a1d3d95a,5/2/2011,1,SSV,Suspension Structured Vehicle USP-NF,,,
dosage,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,ANC,absolute neutrophil count,,,
dosage,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,AC,and cyclophosphamide 600 mg/m2,,,
dosage,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,Ductal Carcinoma in Situ,,,
dosage,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,i.e.,intended dosing schedule,,,
dosage,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,mL,mg tablet,,,
dosage,fdebf4d8-8171-4e56-9aac-89d9c61f0929,12/2/2011,1,CCr,creatinine clearance,,,
dosage,1292FA83-E2A1-4FDA-B0DD-CCF763265FE1,4/9/2007,2,NGU,days.Nongonococcal urethritis,,,
dosage,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,BSA,body surface area,,,
dosage,66a1e273-ab59-4e7a-a223-a96b86501f51,8/17/2011,1,SWFI,,,,
dosage,9fde45b1-b40c-4374-81ad-f2bf1015950b,1/28/2011,1,GERD,Gastroesophageal Reflux Disease,,,
dosage,49a3fccf-6592-48c6-9b69-33230182457c,1/25/2011,2,ie,in 2 divided doses,,,
dosage,50954ade-19ad-40dd-8e06-0b33394895f7,4/21/2010,2,ie,in 2 divided doses,,,
dosage,a767e888-f825-4429-b3a4-05580ea6d157,9/19/2011,1,ECGs,electrocardiograms,,,
dosage,994dfdaa-6cf7-4177-8cea-b20b56f1512a,1/11/2010,3,TDD,total daily  dose,,,
dosage,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
dosage,C3F7CD94-D842-4F6B-A582-A38C751A790A,6/26/2008,2,MICs,minimal inhibitory concentrations,,,
dosage,88ee9c0e-aa2a-47ce-b649-25bfa6fc8a7b,3/12/2012,1,i.e.,insufficiency,,,
dosage,88ee9c0e-aa2a-47ce-b649-25bfa6fc8a7b,3/12/2012,1,i.e.,initial route of therapy,,,
dosage,42836232-a71f-4e4b-8060-2bdbd853398a,10/26/2010,65,i.e.,Inpatients,,,
dosage,253b9eeb-3be5-47d6-a76b-9889bd3c55ed,7/29/2011,1,i.e.,initial route of therapy,,,
dosage,370faf80-e054-4b14-b4b3-a7b32d61a4ac,2/22/2012,3581,PET,polyethylene terephthalate,,,
dosage,c5cd4a8e-14c0-440b-b453-9f3d3250c951,10/31/2010,8,lb,"Lrule Rrule""> Patient<br/>weight",,,
dosage,18f1a4fc-dfca-4dde-8a11-f7e6d9e5656d,3/23/2012,6,PET,polyethylene terephthalate,,,
dosage,63bb3dc4-3bdd-4a7e-a3a3-bf6a0c8c0598,2/25/2011,11,i.e.,insufficiency,,,
dosage,63bb3dc4-3bdd-4a7e-a3a3-bf6a0c8c0598,2/25/2011,11,i.e.,initial route of therapy,,,
dosage,96398ed5-ffb9-4ed4-92c1-6a9535864475,1/18/2012,2,EOS,end of synthesis,,,
dosage,54afe2fd-e628-4655-a3dc-45ae29680f96,6/27/2011,1,q12h,q12hWeightDose,,,
dosage,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,mg/kg/day,mg/kg/day: Daily dose,,,
dosage,e9385674-c074-4854-9b5c-655846cd8e09,6/14/2012,8,PET,polyethylene terephthalate,,,
dosage,e9385674-c074-4854-9b5c-655846cd8e09,6/14/2012,8,Suspension,suspension,,,
dosage,e607b0e3-e22e-429f-b40a-0567ded993a7,4/27/2011,7,GERD,Gastroesophageal Reflux Disease,,,
dosage,fa613fa5-8848-4a34-a405-87d6f3f5f2a9,4/27/2009,2,i.e.,insufficiency,,,
dosage,fa613fa5-8848-4a34-a405-87d6f3f5f2a9,4/27/2009,2,i.e.,initial route of therapy,,,
dosage,f685b4d6-0e5b-4ca1-87b5-c177db52e320,8/30/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,9a2c643d-5c5f-4427-804d-8b0eb9797157,4/13/2010,1,BSA,body surface area,,,
dosage,4a3b2bc3-d837-4ca9-aee1-452633b6a06b,9/29/2009,7,i.e.,intended dosing schedule,,,
dosage,96D1CD4E-9A27-4504-AC3B-749C0DF7076E,6/25/2008,1,water,water.Prepare an aqueous,,,
dosage,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,AF,atrial fibrillation,,,
dosage,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,MI,myocardial infarction,,,
dosage,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,VKA,vitamin-K antagonist,,,
dosage,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,aPTT,activated partial thromboplastin time,,,
dosage,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,PAF,paroxysmal AF,,,
dosage,9186036e-589d-48a8-a1a8-2386bf553374,10/5/2011,1,PET,polyethylene terephthalate,,,
dosage,9186036e-589d-48a8-a1a8-2386bf553374,10/5/2011,1,Suspension,suspension,,,
dosage,c81ec366-538d-4341-a4f4-163910e55202,10/17/2011,1,mg/mL,mg in 100 mL,,,
dosage,c81ec366-538d-4341-a4f4-163910e55202,10/17/2011,1,Use:,USE IN NEWBORNS.,,,
dosage,E049B79D-D174-440E-88FA-A602CE666900,10/29/2007,1,mL,milliliters,,,
dosage,E049B79D-D174-440E-88FA-A602CE666900,10/29/2007,1,mL,Maintenance Dose for diluents,,,
dosage,3400D26A-41CB-40E4-99B4-780E1E0EC561,3/30/2007,1,ADT®,Alternate Day Therapy,,,
dosage,3400D26A-41CB-40E4-99B4-780E1E0EC561,3/30/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,mL/day,mg/kg/day:                         Total daily dose,,,
dosage,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,i.e.,in special populations,,,
dosage,a086ead1-b906-4198-af19-5423957c9e2a,2/7/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,i.e.,insufficiency,,,
dosage,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,i.e.,initial route of therapy,,,
dosage,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,i.e.,insufficiency,,,
dosage,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,i.e.,initial route of therapy,,,
dosage,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,BSA,body surface area,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,RA,Rheumatoid Arthritis,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,Y-90-,Yttrium-90-,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,MPA,Microscopic Polyangiitis,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,PCP,Pneumocystis jiroveci pneumonia,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,CLL,Chronic Lymphocytic Leukemia,,,
dosage,b172773b-3905-4a1c-ad95-bab4b6126563,2/27/2012,7,WG,Wegener's Granulomatosis,,,
dosage,f501c511-2aa2-4c12-94ad-1cc42b18ef3e,8/1/2011,12,CCr,creatinine clearance,,,
dosage,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,GERD,Gastroesophageal Reflux Disease,,,
dosage,e80642ad-bb06-4546-ae33-5bc70cf05cee,1/9/2012,3,Suspension,suspension,,,
dosage,cf856e2f-eaf7-4898-994c-91ae310a82b0,2/25/2011,6,i.e.,insufficiency,,,
dosage,cf856e2f-eaf7-4898-994c-91ae310a82b0,2/25/2011,6,i.e.,initial route of therapy,,,
dosage,00332c65-edad-a153-9c78-628931daa732,5/31/2012,4,AED,antiepilepsy drug,,,
dosage,AF98223E-BAA3-4B94-60B0-20AF2CD5516C,12/30/2008,1,EFAD,essential fatty acid deficiency,,,
dosage,775d260f-cf89-4040-a76d-d8b7e262b7e4,10/5/2006,1,mL,mL/kg,,,
dosage,775d260f-cf89-4040-a76d-d8b7e262b7e4,10/5/2006,1,DSA,Digital Subtraction Angiography,,,
dosage,a341d31b-a011-457a-76a1-a96146d2924e,3/14/2012,9,i.e.,insufficiency,,,
dosage,a341d31b-a011-457a-76a1-a96146d2924e,3/14/2012,9,i.e.,initial route of therapy,,,
dosage,3c926b78-999e-4d26-9498-7f1bcaf0b992,12/8/2011,3,i.e.,intended dosing schedule,,,
dosage,08ee2a98-627f-4f95-83bd-2cbeb254bf70,1/6/2012,10,i.e.,initial route of therapy,,,
dosage,d0e6a966-179a-45e0-8444-4c1b8523f8d2,7/9/2012,1,i.e.,intended dosing schedule,,,
dosage,42c00a53-66db-4c8b-b5db-ccb9d02e5344,1/3/2012,1,i.e.,insufficiency,,,
dosage,42c00a53-66db-4c8b-b5db-ccb9d02e5344,1/3/2012,1,i.e.,initial route of therapy,,,
dosage,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,i.e.,insufficiency,,,
dosage,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,i.e.,initial route of therapy,,,
dosage,5cc4f6f0-8925-81e1-b210-b5a4509a25a9,12/11/2009,1,PET,polyethylene terephthalate,,,
dosage,779277af-dcd9-45b5-adeb-2cfdf3c001de,9/23/2010,4,i.e.,in 2 divided doses,,,
dosage,46942e6e-73bb-4687-853a-e3ec2734cc70,10/13/2011,1,BHAT,Beta-Blocker Heart Attack Trial,,,
dosage,2215dc1d-0b5a-469e-9b51-4d7480a51078,11/16/2007,1,mEq/day,mEq three times/day with meals,,,
dosage,2215dc1d-0b5a-469e-9b51-4d7480a51078,11/16/2007,1,sodium,should be avoided.Serum electrolytes,,,
dosage,51772745-9ea9-42cd-97e6-7266f41ae3ca,2/22/2011,1,PVC,polyvinyl chloride,,,
dosage,6dfef8f0-69cf-4a65-8f9b-bc9359926d1c,4/20/2011,2,CNS,central nervous system,,,
dosage,30c46443-aaff-4681-91a9-8293c11dd95c,4/19/2010,3,mL,milliliters,,,
dosage,30c46443-aaff-4681-91a9-8293c11dd95c,4/19/2010,3,mL,Maintenance Dose for diluents,,,
dosage,2e4adfff-e6d5-4031-903d-16eaf4bf74d7,5/15/2012,3,i.e.,insufficiency,,,
dosage,2e4adfff-e6d5-4031-903d-16eaf4bf74d7,5/15/2012,3,i.e.,initial route of therapy,,,
dosage,db142333-5880-44ed-9fc7-db21bff3c66e,1/25/2011,1,ie,in 2 divided doses,,,
dosage,802ab399-479b-4271-a2a7-07aadde91cff,5/2/2011,1,i.e.,intended dosing schedule,,,
dosage,4cd49351-6dde-4c85-be33-9a20bde785db,11/14/2009,1,PVC,polyvinylchloride,,,
dosage,18b64187-b9c6-41bd-b565-8e8459de8d76,2/8/2011,2,TPN,Total Parenteral Nutrition,,,
dosage,b40932cc-7867-4c87-8a82-402e95b3a1fc,3/27/2007,1,i.e.,infections,,,
dosage,24f815ef-58e6-42b9-8137-adcd6c382aa6,10/6/2010,3,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,18f335df-d664-4850-9efc-8b26adea9d69,1/1/2009,3,PVC,polyvinylchloride,,,
dosage,9b2500f1-eb0d-41e7-b20f-f7e9d6b813f1,3/12/2007,1,CCr,creatinine clearance,,,
dosage,9b2500f1-eb0d-41e7-b20f-f7e9d6b813f1,3/12/2007,1,140-age,(140-age)(weight)/[(72)(Sfor males Ccr =,,,
dosage,5d85fd0c-c544-4026-b797-93445ce6ba7e,6/7/2010,1,i.e.,in 2 divided doses,,,
dosage,2f3b8f28-b3da-4658-bdc4-fe86dec62d32,8/15/2007,1,NMS,Neuroleptic Malignant Syndrome,,,
dosage,38e8f819-985c-4d20-aafd-3ba953af26ca,8/3/2010,6,PVC,polyvinyl chloride,,,
dosage,c550dd16-a5e8-44be-87f2-210c15bbb513,3/2/2012,10,AGC,absolute granulocyte count,,,
dosage,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,PVC,polyvinyl chloride,,,
dosage,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,i.e.,insufficiency,,,
dosage,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,i.e.,initial route of therapy,,,
dosage,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,i.e.,insufficiency,,,
dosage,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,i.e.,initial route of therapy,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,AF,atrial fibrillation,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,MI,myocardial infarction,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,VKA,vitamin-K antagonist,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,aPTT,activated partial thromboplastin time,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,PAF,paroxysmal AF,,,
dosage,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,INR,International Normalized Ratio,,,
dosage,294819e9-aa55-49a3-b1d9-050a4285d3ed,7/23/2009,1,mg/mL,mg in 100 mL,,,
dosage,bd49ff83-5c84-436b-35bb-08cfd3182975,6/18/2012,11,mg/mL,mg in 100 mL,,,
dosage,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,TCA,Tricyclic Antidepressant,,,
dosage,454f2f4c-5bdd-4aff-b49e-792962dd1a94,7/19/2011,1,CCr,creatinine clearance,,,
dosage,084020fe-6571-4fb3-a13e-937615432fe8,2/1/2012,1,i.e.,insufficiency,,,
dosage,084020fe-6571-4fb3-a13e-937615432fe8,2/1/2012,1,i.e.,initial route of therapy,,,
dosage,5e36488b-8f2d-4dc9-b803-af1829e6fdd0,8/1/2011,1,PVC,polyvinylchloride,,,
dosage,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,60f0fb82-d870-4f07-82af-e4aeb79ed023,3/28/2007,1,PET,polyethylene terephthalate,,,
dosage,0e6364a4-6d66-4151-8197-d45e2a762895,1/11/2012,10,PET,polyethylene terephthalate,,,
dosage,0e6364a4-6d66-4151-8197-d45e2a762895,1/11/2012,10,Suspension,suspension,,,
dosage,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,AED,antiepilepsy drug,,,
dosage,8d24d1ab-8701-42c1-9537-81526b7adf7a,11/24/2010,107,GERD,Gastroesophageal Reflux Disease,,,
dosage,7049f870-6741-4a67-8033-398c36126a06,1/17/2012,9,i.e.,insufficiency,,,
dosage,26891c3e-bc45-4f29-baed-f0efc08c6c1e,1/27/2011,1,mL,Maintenance Dose                             for diluents,,,
dosage,f3e0fe88-f63e-4ee1-b96c-84161b9c17df,3/29/2012,3,i.e.,insufficiency,,,
dosage,f3e0fe88-f63e-4ee1-b96c-84161b9c17df,3/29/2012,3,i.e.,initial route of therapy,,,
dosage,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,PE,phenytoin sodium equivalents,,,
dosage,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,PE,phenytoin sodium equivalent units,,,
dosage,3b0fd893-75f6-44e6-9a8b-ec5c2f0a2828,3/1/2012,7,HPA,hypothalamic-pituitary-adrenal,,,
dosage,54c4b48b-cad7-4889-808f-f741352a2c97,11/1/2011,13,CAPD,continuous ambulatory peritoneal dialysis,,,
dosage,94f069f9-dd52-4a69-a103-ebdb4294f088,5/6/2008,1,CAD,coronary artery disease,,,
dosage,cda35690-672f-46cd-8520-e37f4d66a8d7,10/27/2010,2,IM,intramuscularly,,,
dosage,4bbe6e74-b13e-4609-b4cc-aa0b00d66df8,4/27/2010,1,ie,in 2 divided doses,,,
dosage,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,PAF,paroxysmal AF,,,
dosage,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,aPTT,activated partial thromboplastin time,,,
dosage,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,PAF,paroxysmal AF,,,
dosage,b5331161-8f50-4598-b87d-1bee1e890873,10/27/2011,1,ie,in 2 divided doses,,,
dosage,5b6f93c9-43b2-40a9-9f10-054c1145b4cc,3/1/2011,1,CCr,creatinine clearance,,,
dosage,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,i.e.,intended dosing schedule,,,
dosage,fd0b42d6-6733-4525-6283-715ee5a466a9,11/22/2011,10,kcal,kilocalories,,,
dosage,fd0b42d6-6733-4525-6283-715ee5a466a9,11/22/2011,10,EFAD,essential fatty acid deficiency,,,
dosage,bf5e6bcd-e935-40c2-870a-b097e7a2ef7f,1/19/2012,9,i.e.,initial route of therapy,,,
dosage,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,AGC,absolute granulocyte count,,,
dosage,c90cdf38-2b2a-4d8c-a7b5-373787173193,4/10/2012,2,CBC,complete blood count,,,
dosage,bc6a65ea-9fdf-42a4-972d-5a602d9a0a61,9/23/2010,4,i.e.,in 2 divided doses,,,
dosage,925d34bb-235a-4655-b5bf-d1c3d93f5daa,1/23/2012,3504,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,eb02779c-acdc-48ed-9d23-ca39ba152d0d,1/17/2012,1,mg/kg/day,mg/kg/day:                                                                       Daily dose,,,
dosage,a974ef05-1cc3-4cbc-a0b4-36b46ed107c9,9/19/2011,1,i.e.,insufficiency,,,
dosage,a974ef05-1cc3-4cbc-a0b4-36b46ed107c9,9/19/2011,1,i.e.,initial route of therapy,,,
dosage,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,b57529e5-c106-464e-8637-dc02871031f7,12/15/2009,1,i.e.,insufficiency,,,
dosage,b57529e5-c106-464e-8637-dc02871031f7,12/15/2009,1,i.e.,initial route of therapy,,,
dosage,5f907502-fb9d-4d6d-a8cb-369a832736ed,7/16/2009,2,ANC,absolute neutrophil counts,,,
dosage,f9fd4805-cbc1-4bc7-955f-e5cd4e1b03bb,3/10/2011,5,CNS,Central Nervous System,,,
dosage,96ef2f48-d478-478c-95d0-1c0b986493d1,4/18/2012,5,ie,in 2 divided doses,,,
dosage,31ce4750-ded5-4a0b-95e9-f229fa6bc822,2/28/2012,3,NCI,National Cancer Institute,,,
dosage,31ce4750-ded5-4a0b-95e9-f229fa6bc822,2/28/2012,3,CTCAE,Common Terminology Criteria for Adverse Events,,,
dosage,28a7b3ee-d0b9-499e-b5f1-7f69a552c4ee,1/7/2011,2,PDS,prefilled dual chamber syringe,,,
dosage,b1a9ef34-092b-409b-a6b0-59cb079bad0a,3/31/2011,1,CCr,creatinine clearance,,,
dosage,176A1E12-A9A1-4901-8900-A530F7937F03,11/14/2008,1,CCa,insufficiency.*Albumin-corrected serum calcium,,,
dosage,0936353b-88ab-4746-c881-cb0a4c7e6e2b,7/11/2012,12,TPN,Total parenteral nutrition,,,
dosage,0936353b-88ab-4746-c881-cb0a4c7e6e2b,7/11/2012,12,E.F.A.D.,essential fatty acid deficiency,,,
dosage,69c31552-4568-4880-927c-0399494f6fa1,10/13/2009,3,i.e.,in 2 divided doses,,,
dosage,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,PPI,Pump Inhibitors,,,
dosage,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,i.e.,insufficiency,,,
dosage,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,i.e.,initial route of therapy,,,
dosage,4AD759F3-72DD-412E-9500-055335CDA6CF,5/3/2007,1,i.e.,infections,,,
dosage,77104557-087c-4bc5-9bea-521843b83e07,12/31/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,b5806c40-12ce-48e3-8abd-9f8997ef4428,7/6/2011,2,Scr,serum creatinine,,,
dosage,5fc4f89c-cf94-4e7a-bf31-d3d86a242efa,3/19/2007,1,i.e.,infections,,,
dosage,33fbe430-b429-43c0-a3f1-9cf016ff23af,3/28/2011,1,NMS,Neuroleptic Malignant Syndrome,,,
dosage,3e65b958-03cd-4f8c-a6a0-990b53ae7ab4,12/31/2011,3,IET,Intradermal endpoint titration,,,
dosage,A784F545-F209-46D4-9350-AE64FAD9E07C,1/12/2009,4,HPA,hypothalamic-pituitary-adrenal,,,
dosage,2f078cef-a889-4d8d-b244-37ee13547a67,12/6/2011,2,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,CCr,creatinine clearance,,,
dosage,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,140-age,(140-age)(weight)/[(72)(Sfor males CCr =,,,
dosage,d908e334-b74b-4b4d-b159-c592c2ecc7f9,2/14/2012,3560,TDD,total daily  dose,,,
dosage,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,APTT,activated partial thromboplastin time,,,
dosage,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,TCA,Tricyclic Antidepressant,,,
dosage,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,50 mg,"valign=""top""><paragraph>500 mL</paragraph></td><td valign=""top""><paragraph>10 mL",,,
dosage,E4A44835-5307-4519-06B6-3E2DCFA61C62,2/6/2006,1,25 mg,"valign=""top""><paragraph>250 mL</paragraph></td><td valign=""top""><paragraph>5 mL",,,
dosage,69e391bf-1250-4083-aa60-6aa41c33657f,8/17/2011,2,SWFI,,,,
dosage,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,i.e.,initial route of therapy,,,
dosage,d2112f37-5080-4a19-bcc3-6386b49abe1d,8/5/2011,3,e.g.,EQUIPMENT CONTAINING ALUMINUM,,,
dosage,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,mL/min,may be used to estimate creatinine clearance:Men: Creatinine clearance,,,
dosage,ad114052-9af5-c940-1ca2-0f0904c55eb6,6/9/2004,1,i.e.,insufficiency,,,
dosage,ad114052-9af5-c940-1ca2-0f0904c55eb6,6/9/2004,1,i.e.,initial route of therapy,,,
dosage,5267d7fe-2ad2-5007-7080-cb7cabda6c16,8/5/2010,6,mg/kg/day,mg/kg/day:                                                                                                    Daily dose,,,
dosage,334d7b8a-a10d-4312-805d-20ace80baa38,12/6/2011,2,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,c9b4d3f9-72f3-403b-9399-9426d3555350,6/26/2012,805,STEARATE,stearate,,,
dosage,56bac591-9f78-4958-8a3b-878d36d3ceca,6/30/2010,5,OHSS,ovarian hyperstimulation syndrome,,,
dosage,A3C3048F-81A7-4A86-8A06-F1F00909F6D1,12/21/2006,2,HPA,hypothalamic-pituitary-adrenal,,,
dosage,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,NCEP,National Cholesterol Education Program,,,
dosage,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
dosage,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,i.e.,in labeling,,,
dosage,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,ECG,electrocardiographic,,,
dosage,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,TCA,Tricyclic Antidepressant,,,
dosage,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MAOI,Monoamine Oxidase  Inhibitor,,,
dosage,ff7bf21e-6ea9-4c1d-8448-3dda03f772e9,1/15/2010,1002,i.e.,insufficiency,,,
dosage,ff7bf21e-6ea9-4c1d-8448-3dda03f772e9,1/15/2010,1002,i.e.,initial route of therapy,,,
dosage,62186279-2814-453e-8256-5592db6aa66f,5/23/2011,1,i.e.,insufficiency,,,
dosage,62186279-2814-453e-8256-5592db6aa66f,5/23/2011,1,i.e.,initial route of therapy,,,
dosage,65fff92f-b51b-4f5e-20bd-b651e613578d,3/26/2012,5,i.e.,insufficiency,,,
dosage,65fff92f-b51b-4f5e-20bd-b651e613578d,3/26/2012,5,i.e.,initial route of therapy,,,
dosage,1388D626-36AF-4C4D-8917-A458A38F7176,2/20/2008,2,IR,immediate-release,,,
dosage,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,INRW,INR value on warfarin alone,,,
dosage,0cdf3f67-5bf3-4d58-b330-03febdc652bf,3/8/2012,3,INR,International Normalized Ratio,,,
dosage,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,tiw,times a week,,,
dosage,d544481d-2695-4a89-964b-15e2338670b8,8/1/2011,1,i.e.,in special populations,,,
dosage,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,CAPD,continuous ambulatory peritoneal dialysis,,,
dosage,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,AF,atrial fibrillation,,,
dosage,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,MI,myocardial infarction,,,
dosage,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,VKA,vitamin-K antagonist,,,
dosage,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,PAF,paroxysmal AF,,,
dosage,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,INR,International Normalized Ratio,,,
dosage,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,i.e.,insufficiency,,,
dosage,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,i.e.,initial route of therapy,,,
dosage,48850874-2b01-404a-bbd9-eb83b15c69fb,11/19/2010,3,IR,immediate release,,,
dosage,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,PMs,poor metabolizers,,,
dosage,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,HI,hepatic insufficiency,,,
dosage,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,i.e.,insufficiency,,,
dosage,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,i.e.,initial route of therapy,,,
dosage,d895f039-acf5-4fac-9698-11b8bac45159,5/18/2011,1,i.e.,in 2 divided doses,,,
dosage,23c702e2-3abc-4d7d-b88f-a089e2179f42,8/9/2011,2,PMs,poor metabolizers,,,
dosage,23c702e2-3abc-4d7d-b88f-a089e2179f42,8/9/2011,2,HI,hepatic insufficiency,,,
dosage,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,PE,phenytoin sodium equivalents,,,
dosage,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,PE,phenytoin sodium equivalent units,,,
dosage,A63BD1BB-6487-4B0D-AA8C-C4313F5B36A8,1/17/2008,1,SUSPENSION,suspension,,,
dosage,237b3a0c-8389-40e1-8fb0-1f6f4ed5bfb4,11/1/2009,1,140-age,(140-age)(weight)/[(72)(SCr)]                   for males CCr =,,,
dosage,d52486b3-623d-4e9c-b551-943e53be2783,4/18/2012,1,1&#160;unit,"valign=""top"">9-17&#160;minutes</td>                               </tr>                               <tr>                                  <td align=""left"" valign=""top"">1-mg",,,
dosage,f3fa566a-d2d8-4d73-b8bf-33ad0f4ca746,9/24/2010,1,LADs,Luer-Activated Devices,,,
dosage,9db2ddc3-8193-4efc-bd39-f532ccec47c5,1/27/2010,1,e.g.,EQUIPMENT CONTAINING ALUMINUM,,,
dosage,f8e0d8f8-cb73-4206-a484-88f5c4fbd719,12/16/2011,8,SSV,Suspension Structured Vehicle USP-NF,,,
dosage,f2057290-4286-4581-9711-50a0a834e228,9/29/2009,7,i.e.,intended dosing schedule,,,
dosage,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,Suspension,suspension,,,
dosage,41D549E0-23AE-4D86-B92C-2ACBDEEACA66,4/6/2007,2,MICs,minimal inhibitory concentrations,,,
dosage,a625c92b-c569-4b98-8d2e-2b3f5e12b34f,4/1/2011,14,AGC,absolute granulocyte count,,,
dosage,a625c92b-c569-4b98-8d2e-2b3f5e12b34f,4/1/2011,14,CBC,complete blood count,,,
dosage,35460df2-18d3-4132-85e6-5289bad4c670,4/26/2011,2,CAD,coronary artery disease,,,
dosage,F103B9F9-E081-419D-A2D8-B86ACDA834DD,6/30/2008,1,PET,polyethylene terephthalate,,,
dosage,F103B9F9-E081-419D-A2D8-B86ACDA834DD,6/30/2008,1,Suspension,suspension,,,
dosage,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,MAOI,Monoamine Oxidase Inhibitor,,,
dosage,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,TCA,Tricyclic Antidepressant,,,
dosage,332c4d37-04d0-ed7a-949f-df7cf4efb12e,7/1/2007,1,ie,in 2 divided doses,,,
dosage,907fce46-6f0f-4752-b9d3-838ae113f788,11/3/2011,1,i.e.,in 2 divided doses,,,
dosage,5f655f62-6621-4113-ae8e-581a71cb28fc,5/26/2011,1,BSA,body surface area,,,
dosage,2ffbec78-5bd4-4647-b282-d6edf8e22ccc,7/15/2011,4,GERD,Gastroesophageal Reflux Disease,,,
dosage,fe7e0c86-8007-4af5-965c-184c6dbce17d,7/1/2011,1,mg/kg/day,mg/kg/day:                                                                                                                    Daily dose,,,
dosage,a651e06c-6295-4ed2-8d67-334645f05b30,6/22/2011,1,ADT®,Alternate Day  Therapy,,,
dosage,a651e06c-6295-4ed2-8d67-334645f05b30,6/22/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
dosage,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,mL,mg tablet,,,
dosage,4ce6888c-e639-4a0c-8490-2a78bcaa41e9,9/10/2010,1,i.e.,insufficiency,,,
dosage,4ce6888c-e639-4a0c-8490-2a78bcaa41e9,9/10/2010,1,i.e.,initial route of therapy,,,
dosage,38d9dd05-fbdc-4d2d-a8fc-a1fda2dc4056,10/22/2009,2,Scr,serum creatinine,,,
dosage,b2eb10c8-9d8c-41e6-a045-01e425c3f8a7,11/14/2011,3154,mg/kg/day,mg/kg/day:                                                                          Daily dose,,,
dosage,8198f921-5dea-4077-938e-010269fb7abe,5/26/2010,9,IV,intravenous,,,
dosage,3172560a-e692-41f0-9ac3-bf6bfb90c4d6,7/25/2012,5,SSV,Suspension Structured Vehicle USP-NF,,,
dosage,9d04904f-872b-4e1c-9bc7-e012f42ce584,8/25/2010,1,i.e.,insufficiency,,,
dosage,9d04904f-872b-4e1c-9bc7-e012f42ce584,8/25/2010,1,i.e.,initial route of therapy,,,
dosage,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,SR®*,(SR),,,
dosage,8c9cdf80-3a83-4336-850a-1a684a6841a5,11/17/2010,1,5 g,500 mg  Tablets,,,
dosage,8c07a4af-dd56-40e4-bd27-dcc0112f6f99,2/22/2012,3582,PET,polyethylene terephthalate,,,
dosage,db0a1e4b-90b1-4754-9a6d-17042e54ce05,8/9/2010,1,mg/kg/day,mg/kg/day:                                                                                  Daily dose,,,
dosage,6ee6e904-a8e2-41d4-8261-67103ecfa605,3/12/2012,4,i.e.,in labeling,,,
dosage,62045862-c90d-4545-9494-af32a65cf689,11/1/2010,3,i.e.,in 2 divided doses,,,
dosage,635f8a00-0048-4421-9f5f-f8e38034f230,8/17/2011,1,ie,in 2 divided doses,,,
dosage,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,i.e.,intended dosing schedule,,,
dosage,b695b4cc-f3b0-4704-910c-bd840efaf443,5/13/2011,2,i.e.,in 2 divided doses,,,
dosage,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,Suspension,suspension,,,
dosage,c80a98e4-ded4-487d-9281-55865dd5c25c,11/18/2010,91,ENL,Erythema nodosum leprosum,,,
dosage,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,NCEP,National Cholesterol Education Program,,,
dosage,6ec4db1a-33d2-4ede-be1c-dae2f5c23c07,2/22/2010,1,BSA,body surface area,,,
dosage,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,chewable,conversion to monotherapy with lamotrigine tablets,,,
dosage,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,CSFP,cerebrospinal fluid pressure,,,
dosage,7f977eb6-c7c4-4dc5-ab3b-07414dbe5da5,12/9/2010,1,PACU,post anesthesia care unit,,,
dosage,3b433650-0dca-4714-bb72-341036d3972e,4/15/2009,1,ANC,absolute neutrophil counts,,,
dosage,C89D3ECC-4F4C-4566-8808-79152344194D,10/2/2008,1,SPECT,Single photon emission computed tomography,,,
dosage,8adef75d-3162-4f81-ae25-d63e82f17988,2/2/2010,1,NGU,Nongonococcal urethritis,,,
dosage,888998CC-C7F7-4F2A-8479-DF60F77BC2A1,1/4/2006,1,Cefizox®,ceftizoxime injection,,,
dosage,8a2d541e-dfa2-4b37-9b18-ed72c7e4aafb,5/8/2012,2,i.e.,in 2 divided doses,,,
dosage,d851ebb0-2370-4363-925c-628ba7fbc221,4/22/2011,6,BSA,body surface area,,,
dosage,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,D5/W,diluted with 5% dextrose in water,,,
dosage,ade6b84a-e95b-0a49-3296-f56208fdf35b,10/25/2010,2,IGSC,Immune Globulin Subcutaneous,,,
dosage,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,adults,accordance with the dosing guidelines in Tables 10,,,
dosage,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,IBW,ideal body weight,,,
dosage,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,mcg/kg,"styleCode=""bold"">(mcg/kg/min)  </content></td><td align=""center""><content styleCode=""bold"">Supplemental IV Bolus Dose of</content><br/><content styleCode=""bold"">ULTIVA",,,
dosage,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,mcg/kg,"<br/>(mcg/kg/min)</content></td><td align=""center""><content styleCode=""bold"">Supplemental IV             <br/>Bolus Dose of             <br/>ULTIVA",,,
dosage,f143db10-e889-41c3-84ed-603a0ab02f61,9/12/2011,6,1&#160;unit,"valign=""top"">9-17&#160;minutes</td>                               </tr>                               <tr>                                  <td align=""left"" valign=""top"">1-mg",,,
dosage,7eb2efae-d41d-42d0-bd7a-0b354b97cdde,11/3/2011,1,MPF,Methyl Paraben Free,,,
dosage,6d122068-ecf8-4307-8ac2-beb25e4e0f95,5/24/2010,1,CAD,coronary artery disease,,,
dosage,8dd7fade-d750-49ce-b798-a1d3615e57b7,1/31/2012,1,i.e.,in 2 divided doses,,,
dosage,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,TCA,Tricyclic Antidepressant,,,
dosage,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,MAOI,Monoamine Oxidase  Inhibitor,,,
dosage,608d4f0d-b19f-46d3-749a-7159aa5f933d,6/11/2012,1451,6-MP,6-mercaptopurine,,,
dosage,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,AED,antiepilepsy drug,,,
dosage,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,CCr,creatinine clearance,,,
dosage,4ce97d53-e852-49ad-92e3-24031a115e26,3/10/2011,1,BSA,body surface area,,,
dosage,E658CC4B-DA3D-4A5E-EAB3-0E60A03657CD,11/27/2007,1,mL,mg of lidocaine HCl,,,
dosage,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,mg/kg/day,mg/kg/day:                                                Daily dose,,,
dosage,2A72A8B8-A77C-49C6-3C8D-43B03672D802,2/6/2007,1,TPN,desired.Total parenteral nutrition,,,
dosage,2A72A8B8-A77C-49C6-3C8D-43B03672D802,2/6/2007,1,E.F.A.D.,essential fatty acid deficiency,,,
dosage,7F2F057B-9AFC-42AE-9D1D-1B1041D1360B,9/14/2006,1,IPPB,intermittent positive pressure breathing apparatus,,,
dosage,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,AED,antiepilepsy drug,,,
dosage,1eee14d3-acfc-4002-b457-6bd69afbd2c7,8/4/2011,1,BHAT,Beta-Blocker Heart Attack Trial,,,
dosage,5be97a06-1a2b-460c-845e-e9ed18016df9,12/13/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
drugInteractions,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,CBZ,carbamazepine,,,
drugInteractions,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,SCE,sister chromatid exchange,,,
drugInteractions,5500a729-9066-4692-b544-a6cfe935a063,11/16/2010,86,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,9c7bb7e7-a775-4f93-bd77-d08c48a86f7c,7/10/2007,2,LAIV,aspirin.Live Attenuated Influenza Vaccine,,,
drugInteractions,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,i.e.,inducers of CYP3A4,,,
drugInteractions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,ECT,electroconvulsive therapy,,,
drugInteractions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,CA8A0862-1956-43AD-844D-77153AA09DFB,12/6/2006,1,MAO,monoamine oxidase,,,
drugInteractions,de381031-cd25-4930-a59a-431acda0e94a,5/6/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,TCAs,tricyclic antidepressants,,,
drugInteractions,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,AUC,Area Under the Curve,,,
drugInteractions,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,PT,prothrombin time,,,
drugInteractions,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,INR,international normalized ratio,,,
drugInteractions,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,INR,international normalized ratio,,,
drugInteractions,d4d296c1-aca8-44a2-86dd-4b3fa7d80faf,8/27/2010,369,INR,International  Normalized Ratio,,,
drugInteractions,7d8e9ae0-2299-4d96-b925-bbceecf2c5d9,7/15/2011,1,PTU,Propylthiouracil,,,
drugInteractions,7d8e9ae0-2299-4d96-b925-bbceecf2c5d9,7/15/2011,1,FT4I,free-T4 index,,,
drugInteractions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,NET,norethindrone,,,
drugInteractions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,EE,ethinyl estradiol,,,
drugInteractions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,INR,International Normalized Ratio,,,
drugInteractions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,AUC,Area Under the Curve,,,
drugInteractions,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,DSST,digit symbol substitution test,,,
drugInteractions,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,NET,norethindrone,,,
drugInteractions,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,AED,antiepileptic drug,,,
drugInteractions,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,EE,ethinyl estradiol,,,
drugInteractions,b00b296d-6c34-48c8-9cfb-71ccc5c9a908,6/10/2011,1,MAOI,monoamine oxidase inhibitors,,,
drugInteractions,40caec0c-902c-424c-8c87-63878134641e,4/21/2011,2,CYP 3A,cytochrome P450 3A,,,
drugInteractions,c6c7322b-6a89-4d23-90d1-bf9327bd6d91,4/13/2012,10,INR,International Normalized Ratio,,,
drugInteractions,6faf465b-c3a3-4ae7-9e16-1ba758f6962a,4/26/2012,3,THC,tetrahydrocannabinol,,,
drugInteractions,7e5fb9dd-1672-442b-b5cc-c886c5dda863,3/12/2012,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,ad682e7f-e0f5-4f11-8e05-dd308cbf6a05,6/9/2010,1,MRHDD,maximum recommended human daily dose,,,
drugInteractions,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,i.e.,increased risk of bleeding,,,
drugInteractions,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,8f935afa-f845-46cd-b61a-db7a48e559c0,4/22/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,EM,extensive metabolizers,,,
drugInteractions,b07f23d8-97ec-4a50-984a-b7dea69f9705,10/7/2010,1,PM,poor metabolizers,,,
drugInteractions,4cde01bb-230b-42d8-a9e1-4c7da1a01b76,8/23/2010,3,NRTIs,nucleoside reverse transcriptase inhibitors,,,
drugInteractions,32ca90a7-f95b-4716-8f0f-d4f9a34bfbf4,7/20/2011,3,CBZ,carbamazepine,,,
drugInteractions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,ODV,O–desvenlafaxine,,,
drugInteractions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,ODV,O-desmethylvenlafaxine,,,
drugInteractions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,EM,extensive metabolizers,,,
drugInteractions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,PM,poor metabolizers,,,
drugInteractions,b60a9829-f356-4e43-97d5-7666fe11588c,9/28/2010,42,MAO,monoamine oxidase,,,
drugInteractions,476e704c-95ae-4591-94f7-ee4ab827ff13,2/23/2007,1,i.e.,inducers of CYP3A4,,,
drugInteractions,4f6c075f-e2b7-41fa-82c7-eba85cbe27a3,12/13/2011,2,CYP3A,cytochrome P450 3A,,,
drugInteractions,330cc74e-0f50-477d-85b1-fec1438c81f6,9/14/2010,2,i.e.,inducers of CYP3A4,,,
drugInteractions,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,DSST,digit symbol substitution test,,,
drugInteractions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,PM,PMs - 38% to 105%,,,
drugInteractions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,ODV,O-desmethylvenlafaxine,,,
drugInteractions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,EM,extensive metabolizers,,,
drugInteractions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,PM,poor metabolizers,,,
drugInteractions,06c485cd-ee30-44f2-be63-bb98f8d1a907,1/15/2010,2,DV,Daily Value,,,
drugInteractions,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,THC,tetrahydrocannabinol,,,
drugInteractions,4e66ad5c-572c-4819-8b6e-6930c33cc210,10/27/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,AEDs,Antiepileptic Drugs,,,
drugInteractions,34c30372-08b0-4060-8aba-779b5bc1e5dd,10/26/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,c3d849eb-7fed-4bac-9fb6-0684094d8dfb,7/25/2011,1,INR,International Normalized Ratio,,,
drugInteractions,6ec3eda9-d415-4796-8cfd-9225052f6b1b,11/16/2010,91,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,6ec3eda9-d415-4796-8cfd-9225052f6b1b,11/16/2010,91,TCAs,tricyclic antidepressants,,,
drugInteractions,8bea42cb-5e06-4be7-983d-cae573ceaba6,6/27/2011,1,PTU,Propylthiouracil,,,
drugInteractions,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,TCAs,Tricyclic Antidepressants,,,
drugInteractions,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,ECT,Electroconvulsive Therapy,,,
drugInteractions,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,5bffe9a4-9b4b-4c74-b7ed-ebca90c9c9a1,1/30/2012,1,CYP3A,cytochrome P450 3A,,,
drugInteractions,6a9cbc29-9f15-4b24-8d86-206b82887f3d,3/30/2012,8,ENF,enfuvirtide,,,
drugInteractions,c4de72a8-2a75-4984-ce90-e4870226dc12,6/21/2012,10,MAOI,monoamine oxidase inhibitors,,,
drugInteractions,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,i.e.,interaction,,,
drugInteractions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,TCAs,Tricyclic Antidepressants,,,
drugInteractions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,TCAs,tricyclic antidepressants,,,
drugInteractions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,ECT,Electroconvulsive Therapy,,,
drugInteractions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
drugInteractions,d804fd47-a37b-41c6-ab34-c311abf14d71,7/14/2011,1,PTU,Propylthiouracil,,,
drugInteractions,d804fd47-a37b-41c6-ab34-c311abf14d71,7/14/2011,1,FT4I,free-T4 index,,,
drugInteractions,abbf31eb-9966-411a-9c5d-91025ff7a782,9/9/2010,4,CYP,cytochrome P450,,,
drugInteractions,7fce939e-c38e-497f-ba3f-e7b6ba44bfd9,8/25/2010,1,INR,International Normalized Ratio,,,
drugInteractions,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,CYP3A4,cytochrome P450 3A4,,,
drugInteractions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CBZ,carbamazepine,,,
drugInteractions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,PTU,Propylthiouracil,,,
drugInteractions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,PTU,<paragraph>Propylthiouracil,,,
drugInteractions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,17209c32-56eb-4f84-954d-aed7b7a1b18d,10/18/2011,13,DX/DM,dextrorphan/dextromethorphan,,,
drugInteractions,56ad5b97-8e5f-48a5-b2ba-a5484b43d018,1/1/2012,3,THC,tetrahydrocannabinol,,,
drugInteractions,477a318a-d594-4374-81d7-abd28a98bdd1,3/4/2009,1001,NTP,National Toxicology Program,,,
drugInteractions,cf73c2e3-f43b-403f-a461-47438a7270ad,6/10/2011,4,MAOI,monoamine oxidase inhibitors,,,
drugInteractions,7bd4b144-cada-4732-a1e1-eac502600b84,4/8/2011,2,CYP450,cytochrome P450,,,
drugInteractions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,ECT,electroconvulsive therapy,,,
drugInteractions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,ECT,electroconvulsive therapy,,,
drugInteractions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,6e030b0f-8ee6-4b23-9345-7193d4280e88,3/12/2012,1,INR,International Normalized Ratio,,,
drugInteractions,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,Pgp,P-glycoprotein,,,
drugInteractions,ab0863e8-cecd-4d66-85f4-72ceb684e97b,4/22/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,INR,International Normalized Ratio,,,
drugInteractions,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,AUC,area  under the curve,,,
drugInteractions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,INR,International Normalized Ratio,,,
drugInteractions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,AUC,Area Under the Curve,,,
drugInteractions,521c0ce2-8bf9-432a-bb9b-b281b55f0320,7/21/2011,1,CBZ,carbamazepine,,,
drugInteractions,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,INR,International Normalized Ratio,,,
drugInteractions,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,PDE5,phosphodiesterase type 5,,,
drugInteractions,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,cGMP,cyclic guanosine                                     monophosphate,,,
drugInteractions,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,APTT,Activated partial thromboplastin times,,,
drugInteractions,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,t-PA,7.3)Tissue-type plasminogen activator,,,
drugInteractions,F9EB07A2-5EBC-40EA-9890-1A0B03E859FF,3/30/2007,1,t-PA,tissue-type plasminogen activator,,,
drugInteractions,4a81b757-0a64-4ed4-86f4-57aeb349105f,1/20/2012,1,INR,International Normalized Ratio,,,
drugInteractions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,CYP450,cytochrome P450,,,
drugInteractions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,CYP3A4,cytochromes P450 3A4,,,
drugInteractions,92919b7e-b499-4afb-8f78-1b1fff099bae,12/14/2011,5,LNG,levonorgestrel,,,
drugInteractions,92919b7e-b499-4afb-8f78-1b1fff099bae,12/14/2011,5,EE,ethinylestradiol,,,
drugInteractions,7a9ecaf3-0a05-4233-a402-ecfc512c693f,12/28/2011,2,PTU,Propylthiouracil,,,
drugInteractions,7a9ecaf3-0a05-4233-a402-ecfc512c693f,12/28/2011,2,FT4I,free-T4 index,,,
drugInteractions,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,5HIAA,5-hydroxy indoleacetic acid,,,
drugInteractions,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,ec61dd9d-a016-4740-b9b8-20754e50be98,12/12/2011,2,INR,International Normalized Ratio,,,
drugInteractions,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,PPI,Pump Inhibitors,,,
drugInteractions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,AUC,Area Under the Curve,,,
drugInteractions,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,i.e.,inducers of CYP3A4,,,
drugInteractions,07315965-0be6-4c18-a8b9-25821a3732e2,10/26/2006,1,MAO,monoamine oxidase,,,
drugInteractions,c0031057-b10b-49d8-a156-df88ed34a943,5/12/2011,2,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
drugInteractions,cd6868b9-5824-442b-8d65-4db29ecb70a4,4/1/2012,21,ADP,adenosine diphosphate,,,
drugInteractions,03c696e9-0e6b-4e5c-be0a-41416f8019be,2/16/2011,1,DX/DM,dextrorphan/dextromethorphan,,,
drugInteractions,42abbb51-a476-4837-bdf9-01eb288ceec2,7/13/2011,4,LNG,levonorgestrel,,,
drugInteractions,42abbb51-a476-4837-bdf9-01eb288ceec2,7/13/2011,4,EE,ethinylestradiol,,,
drugInteractions,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
drugInteractions,2E0570E7-D28F-4936-CBA8-81EE0C4C3547,9/11/2006,1,MAOI,monoamine oxidase inhibitors,,,
drugInteractions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,PM,PMs - 38% to 105%,,,
drugInteractions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,ODV,O-desmethylvenlafaxine,,,
drugInteractions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,ODV,O-desvenlafaxine,,,
drugInteractions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,EM,extensive metabolizers,,,
drugInteractions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,PM,poor metabolizers,,,
drugInteractions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,TCAs,Tricyclic Antidepressants,,,
drugInteractions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,TCAs,tricyclic antidepressants,,,
drugInteractions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,ECT,Electroconvulsive Therapy,,,
drugInteractions,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,HO-NEF,hydroxynefazodone,,,
drugInteractions,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,CYP3A4,Cytochrome P450 3A4,,,
drugInteractions,197c0496-3910-44ed-b8fb-df01b0f925a8,5/12/2011,125,DST,dexamethasone suppression test,,,
drugInteractions,197c0496-3910-44ed-b8fb-df01b0f925a8,5/12/2011,125,PRA,plasma renin activity,,,
drugInteractions,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,96a9f4c5-de60-49ca-aa93-abf3258c2662,12/23/2010,167,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,96a9f4c5-de60-49ca-aa93-abf3258c2662,12/23/2010,167,TCAs,tricyclic  antidepressants,,,
drugInteractions,1e190303-00f3-4a23-bed0-39fea1d15ae0,1/26/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
drugInteractions,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,MAO,monoamine oxidase,,,
drugInteractions,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,TCAs,Tricyclic Antidepressants,,,
drugInteractions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,TCAs,tricyclic antidepressants,,,
drugInteractions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,ECT,Electroconvulsive Therapy,,,
drugInteractions,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,INR,International Normalized Ratio,,,
drugInteractions,A0D01539-8413-4703-94CC-D221918630A1,7/23/2007,1,LDH,lactate dehydrogenase,,,
drugInteractions,A0D01539-8413-4703-94CC-D221918630A1,7/23/2007,1,ALT,alanine aminotransferase,,,
drugInteractions,A0D01539-8413-4703-94CC-D221918630A1,7/23/2007,1,AST,aspartate aminotransferase,,,
drugInteractions,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,CBZ,carbamazepine,,,
drugInteractions,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,PM,PMs - 38% to 105%,,,
drugInteractions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,ODV,O-desmethylvenlafaxine,,,
drugInteractions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,EM,extensive metabolizers,,,
drugInteractions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,PM,poor metabolizers,,,
drugInteractions,0dc9682c-a4ae-4786-8dd9-31e33ce9861b,11/12/2009,1,CYP,cytochrome P450,,,
drugInteractions,2238E083-08F2-0AA8-59B7-16B6D68DBD48,12/3/2008,1,CYP 3A,cytochrome P450 3A,,,
drugInteractions,33136f77-ac1b-4ebe-8b29-e5509dad3902,9/1/2011,2,i.e.,inducers of CYP3A4,,,
drugInteractions,88e7a888-1464-491a-a439-9a9c127c3702,7/20/2011,1,CBZ,ConcentrationPhenytoinNC or 25% increasea48% decreaseCarbamazepine,,,
drugInteractions,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,CYP,cytochrome P450,,,
drugInteractions,0f11c856-af9a-409a-9c0f-e7a10bbfe5a6,10/31/2011,1,PTU,Propylthiouracil,,,
drugInteractions,0f11c856-af9a-409a-9c0f-e7a10bbfe5a6,10/31/2011,1,Iodide,iodine- containing Radiographic contrast agents,,,
drugInteractions,0f11c856-af9a-409a-9c0f-e7a10bbfe5a6,10/31/2011,1,oral,oralAsparaginasecontraceptivesGlucocorticoidsEstrogens,,,
drugInteractions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,patients.Dexamethasone suppression test,,,
drugInteractions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,dexamethasone suppression test,,,
drugInteractions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,CYP 3A4,cytochrome P450 3A4,,,
drugInteractions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,use.Dexamethasone suppression test,,,
drugInteractions,05c41447-f0d7-4a7c-8d44-a749ff55fc9d,4/20/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,Mice,Micronucleus Test,,,
drugInteractions,5d344c39-175b-4819-b9da-8ba630530ad7,4/7/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,fefc2713-f410-49ad-bc06-3c4f9c20a031,3/7/2012,1,ACE,angiotensin-converting enzyme,,,
drugInteractions,08f23f6e-150d-45ea-098e-f2edf64c21a1,7/10/2012,11,MAO,monoamine oxidase,,,
drugInteractions,326fa31a-5420-429b-9f7f-170cb38f64bd,7/22/2011,4,CYP3A,cytochrome P450 3A,,,
drugInteractions,a92428d1-b8a5-4b3d-965d-50fd333bd743,11/30/2011,8,INR,International Normalized Ratio,,,
drugInteractions,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,PM,PMs - 38% to 105%,,,
drugInteractions,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,47a00976-3625-4d19-8418-b88b8693f968,4/21/2011,1,PDE-5,phosphodiesterase-5,,,
drugInteractions,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,PM,PM's -38% to 105%,,,
drugInteractions,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,ODV,O-desmethylvenlafaxine,,,
drugInteractions,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,EM,extensive metabolizers,,,
drugInteractions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,ECT,electroconvulsive therapy,,,
drugInteractions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,AEDs,antiepilepsy drugs,,,
drugInteractions,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,EM,extensive metabolizers,,,
drugInteractions,ba30cac2-62d9-4964-97ea-10ad751985e4,7/28/2010,1,PM,poor metabolizers,,,
drugInteractions,10124262-e443-49a5-a1cc-8cc34c74d953,11/29/2010,1,MAO,monoamine oxidase,,,
drugInteractions,44146b18-78ee-406e-be8d-89a6afa15454,4/19/2011,3,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
drugInteractions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,ECT,electroconvulsive therapy,,,
drugInteractions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,MRHD,maximum recommended human dose,,,
drugInteractions,531742d3-613c-44dc-88f0-b526a478aa08,4/8/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,i.e.,interaction,,,
drugInteractions,8920d813-dc88-456d-8607-47a0156a4b4b,9/6/2011,2,e.g.,exaggerated response,,,
drugInteractions,a1575590-4bdd-4f66-91fb-337e5f681747,9/27/2010,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,CBZ,carbamazepine,,,
drugInteractions,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,PBI,protein-bound iodine,,,
drugInteractions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,TBG,thyroid-binding globulin,,,
drugInteractions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,CBG,corticosteroid binding globulin,,,
drugInteractions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,SHBG,sex hormone-binding globulin,,,
drugInteractions,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,HO-NEF,hydroxynefazodone,,,
drugInteractions,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,CYP3A4,Cytochrome P450 3A4,,,
drugInteractions,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,GI,gastrointestinal,,,
drugInteractions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,ECT,electroconvulsive therapy,,,
drugInteractions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,PMs,PMs4% to 134%,,,
drugInteractions,d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b,12/12/2011,2,INR,International Normalized Ratio,,,
drugInteractions,009575f9-74e8-4a6d-9fa6-3cae72fd01c3,4/14/2010,1,HRT,hormone replacement therapy,,,
drugInteractions,009575f9-74e8-4a6d-9fa6-3cae72fd01c3,4/14/2010,1,INR,international normalized ratio,,,
drugInteractions,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,INR,International Normalized Ratio,,,
drugInteractions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,NMS,Neuroleptic Malignant Syndrome,,,
drugInteractions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,ECT,Electroconvulsive Therapy,,,
drugInteractions,442AED6E-6242-4A96-90AA-D988B62D55E8,2/25/2008,3,MAO,monoamine oxidase,,,
drugInteractions,4d19753e-8525-4c67-9657-70ba571f7e74,6/4/2010,1,INR,International Normalized Ratio,,,
drugInteractions,f302ddf5-0213-43b3-b6c1-b3edf2bafbcd,6/17/2010,3,MAOI,Monoamine oxidase inhibitors,,,
drugInteractions,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,AEDs,Antiepileptic Drugs,,,
drugInteractions,624a18c4-f07a-4f8a-9a14-bbfd9c6c7c68,10/28/2009,1,CNS,central nervous system,,,
drugInteractions,624a18c4-f07a-4f8a-9a14-bbfd9c6c7c68,10/28/2009,1,Pgp,P-glycoprotein,,,
drugInteractions,93B19AE0-C0A1-4400-9A56-6827939B7E7A,10/6/2006,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,53ee103c-52d2-4f8a-8e24-54d1f1551b8e,10/21/2011,1,PTU,Propylthiouracil,,,
drugInteractions,53ee103c-52d2-4f8a-8e24-54d1f1551b8e,10/21/2011,1,FT4I,free-T4 index,,,
drugInteractions,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,CBZ,carbamazepine,,,
drugInteractions,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,199cf13e-0859-4a73-9b45-e700d0cd1049,6/26/2012,8,LDL,low-density lipoprotein,,,
drugInteractions,199cf13e-0859-4a73-9b45-e700d0cd1049,6/26/2012,8,HDL,high-density lipoprotein,,,
drugInteractions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,ECT,electroconvulsive therapy,,,
drugInteractions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,MRHD,maximum recommended human dose,,,
drugInteractions,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,EM,extensive metabolizers,,,
drugInteractions,6fb8a408-8e63-41f0-adc3-ddac62b64503,5/12/2011,1,PM,poor metabolizers,,,
drugInteractions,818a4d9a-c8a2-476c-b70c-0840b6d603a1,8/24/2009,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,52b448ca-30fa-464c-b79d-2835779357cb,11/1/2011,1,PTU,Propylthiouracil,,,
drugInteractions,52b448ca-30fa-464c-b79d-2835779357cb,11/1/2011,1,Iodide,iodine- containing Radiographic contrast agents,,,
drugInteractions,52b448ca-30fa-464c-b79d-2835779357cb,11/1/2011,1,oral,oralAsparaginasecontraceptivesGlucocorticoidsEstrogens,,,
drugInteractions,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,INR,International Normalized Ratio,,,
drugInteractions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,NSAIDs,function.Nonsteroidal Anti-Inflammatory Drugs,,,
drugInteractions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,ACE,Angiotensin Converting Enzyme,,,
drugInteractions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
drugInteractions,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,TCAs,tricyclic antidepressants,,,
drugInteractions,09325220-e4c5-4fac-aefd-ee3e42602198,9/14/2011,5,i.e.,interaction,,,
drugInteractions,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,AEDs,antiepilepsy drugs,,,
drugInteractions,7589f8f3-e82a-43b0-868a-cbb991e2183f,12/12/2011,1,Sodium,sodium,,,
drugInteractions,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,EM,extensive metabolizers,,,
drugInteractions,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,PM,poor metabolizers,,,
drugInteractions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,ECT,electroconvulsive therapy,,,
drugInteractions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,0fcdd59a-906b-43df-9c65-97d8a736b4f1,6/9/2011,1,INR,International Normalized Ratio,,,
drugInteractions,1950F4D6-7FC2-44CD-9F7D-1359315353FC,5/23/2006,1,drying,Drug Interaction MAO inhibitors prolong and intensify the anticholinergic,,,
drugInteractions,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,EM,extensive metabolizers,,,
drugInteractions,aecd6c1b-d3e3-4568-b8cb-89954f0aee5d,6/23/2010,1,PM,poor metabolizers,,,
drugInteractions,88c45123-f475-4dd0-bbac-c261868924ef,7/19/2011,7,CNS,Central Nervous System,,,
drugInteractions,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,CNS,central nervous system,,,
drugInteractions,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,39d936d1-29a7-48b6-9327-94f2028012e7,8/1/2011,8,i.e.,interaction,,,
drugInteractions,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,CYP450,cytochrome P450,,,
drugInteractions,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,CYP3A4,cytochrome P450 3A4,,,
drugInteractions,2dc814a4-1bb2-497b-987d-c3ebe444994e,11/16/2011,2,PDE-5,phosphodiesterase-5,,,
drugInteractions,47499f96-d382-4ed5-a658-525196c49538,9/21/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,NET,norethindrone,,,
drugInteractions,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,AED,antiepileptic drug,,,
drugInteractions,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,EE,ethinyl estradiol,,,
drugInteractions,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,CYP3A4,cytochrome P450 3A4,,,
drugInteractions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,BPH,benign prostatic hyperplasia,,,
drugInteractions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,SBP,systolic blood pressure,,,
drugInteractions,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,CBZ,carbamazepine,,,
drugInteractions,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,1c713b59-a628-42e6-b166-ae71c3913284,4/30/2011,4,LNG,levonorgestrel,,,
drugInteractions,1c713b59-a628-42e6-b166-ae71c3913284,4/30/2011,4,EE,ethinylestradiol,,,
drugInteractions,c149ba5c-4c25-426a-a172-6ac3b899cbe3,10/25/2011,1,PRA,plasma renin activity,,,
drugInteractions,5ce42a9d-cdce-4889-9def-cb7be2cb8d7b,3/10/2010,1002,Pgp,P-glycoprotein,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,CYP450,cytochrome P450,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,NMS,Neuroleptic Malignant Syndrome,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,PM,poor metabolizers,,,
drugInteractions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,EM,extensive metabolizers,,,
drugInteractions,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,Pgp,P-glycoprotein,,,
drugInteractions,3F0F6064-CC9F-491C-A940-3F087ABBC774,1/9/2008,1,MAO,monoamine oxidase,,,
drugInteractions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,ECT,electroconvulsive therapy,,,
drugInteractions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,TCAs,Tricyclic Antidepressants,,,
drugInteractions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,ECT,Electroconvulsive Therapy,,,
drugInteractions,5680bf94-524d-45ee-b1dd-d2e81e48a312,8/10/2011,1,PTU,Propylthiouracil,,,
drugInteractions,5680bf94-524d-45ee-b1dd-d2e81e48a312,8/10/2011,1,FT4I,free-T4 index,,,
drugInteractions,3fbcd7d8-cc53-4dbb-8edc-451acadc472c,10/5/2010,1,CYP,cytochrome P450,,,
drugInteractions,2eabc9b4-2d5c-44b2-bf05-eb6c3260c1bd,1/16/2011,2,TBg,thyroxine-binding globulin,,,
drugInteractions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAO,monoamine oxidase,,,
drugInteractions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAOI,caution.Monoamine oxidase inhibitors,,,
drugInteractions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAOI,concomitantly.Monoamine oxidase inhibitors,,,
drugInteractions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,PM,PMs - 38% to 105%,,,
drugInteractions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,ODV,O-desmethylvenlafaxine,,,
drugInteractions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,ODV,O-desvenlafaxine,,,
drugInteractions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,EM,extensive metabolizers,,,
drugInteractions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,PM,poor metabolizers,,,
drugInteractions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,TdP,torsades de pointes,,,
drugInteractions,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,MAO,depression.Monoamine oxidase,,,
drugInteractions,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,MAO,of:Monoamine oxidase,,,
drugInteractions,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,CBZ,carbamazepine,,,
drugInteractions,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,db1291e9-ba65-4b6b-83fa-6b6187b17f41,3/25/2010,1,CYP3A,cytochrome P450 3A,,,
drugInteractions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,PTU,Propylthiouracil,,,
drugInteractions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,PTU,<paragraph>Propylthiouracil,,,
drugInteractions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,d6851c71-0c2f-43f6-883c-a43fe894985d,10/13/2011,6,MAC,minimum alveolar concentration,,,
drugInteractions,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,MAO,monoamine oxidase,,,
drugInteractions,2e419114-8733-409c-ac5d-3c5ebbd2cb33,9/8/2011,1,RA,rheumatoid arthritis,,,
drugInteractions,2e419114-8733-409c-ac5d-3c5ebbd2cb33,9/8/2011,1,INR,International Normalized Ratio,,,
drugInteractions,a57b8c7c-b8a9-45e4-b6fa-b83ebfbacae2,5/2/2011,1,PMs,PMs4% to 134%,,,
drugInteractions,4b260808-aeed-4223-bfc5-65e11259670e,5/20/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,INR,International Normalized Ratio,,,
drugInteractions,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,AUC,Area Under the Curve,,,
drugInteractions,238050FD-5221-4B93-BFCD-31793C9088A7,11/15/2007,2,CYP3A,cytochrome P450 3A,,,
drugInteractions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,ECT,electroconvulsive therapy,,,
drugInteractions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,ab5f9512-335f-4490-a6a9-12f611646991,3/9/2010,1,CYP,cytochrome P450,,,
drugInteractions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,ECT,electroconvulsive therapy,,,
drugInteractions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,ECT,electroconvulsive therapy,,,
drugInteractions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,JRA,juvenile rheumatoid arthritis,,,
drugInteractions,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,GI,gastrointestinal,,,
drugInteractions,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,CHO,Chinese hamster ovary,,,
drugInteractions,35312f49-decf-428d-bf5f-4215b762ed3c,6/10/2011,7,NET,norethindrone,,,
drugInteractions,35312f49-decf-428d-bf5f-4215b762ed3c,6/10/2011,7,EE,ethinyl estradiol,,,
drugInteractions,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,DSST,digit symbol substitution test,,,
drugInteractions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,CYP450,cytochrome P450,,,
drugInteractions,d37db064-3a5a-4a0c-a60b-b4b417fe742a,5/18/2012,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
drugInteractions,2f522701-397a-11de-8a39-0800200c9a66,11/14/2011,5,AEDs,antiepileptic drugs,,,
drugInteractions,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,DSST,digit symbol substitution test,,,
drugInteractions,67cb9ea4-5adb-4a3a-9568-266b6f472078,9/7/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
drugInteractions,60aa95a1-5f7d-4438-bf78-fba6127a022b,8/24/2011,1,RA,rheumatoid arthritis,,,
drugInteractions,60aa95a1-5f7d-4438-bf78-fba6127a022b,8/24/2011,1,INR,International Normalized Ratio,,,
drugInteractions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,PB,"valign=""top""><td>Phenobarbital",,,
drugInteractions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,MTX,"valign=""top""><td>Methotrexate",,,
drugInteractions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,i.e.,interaction,,,
drugInteractions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,IV,"increase</td></tr> <tr valign=""top""><td>Isoproterenol",,,
drugInteractions,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,INR,International Normalized Ratio,,,
drugInteractions,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,AUC,Area Under the Curve,,,
drugInteractions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,MAO,observation.Monoamine Oxidase,,,
drugInteractions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,MAO,Monoamine Oxidase,,,
drugInteractions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,SSRI's,selective serotonin reuptake inhibitors,,,
drugInteractions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,AUC,area under the concentration-time curve,,,
drugInteractions,234076ca-0dca-4670-aa6a-6f7c1f74ff3a,9/13/2011,1,NET,norethindrone,,,
drugInteractions,234076ca-0dca-4670-aa6a-6f7c1f74ff3a,9/13/2011,1,HCTZ,Hydrochlorothiazide,,,
drugInteractions,234076ca-0dca-4670-aa6a-6f7c1f74ff3a,9/13/2011,1,EE,ethinyl estradiol,,,
drugInteractions,35f99f76-f2ef-4a81-91ff-285419664be3,12/6/2011,6,NRTIs,nucleoside reverse transcriptase inhibitors,,,
drugInteractions,35f99f76-f2ef-4a81-91ff-285419664be3,12/6/2011,6,IMDH,Inosine monophosphate dehydrogenase,,,
drugInteractions,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,EM,extensive metabolizers,,,
drugInteractions,f2bb56f9-0e60-4462-b17b-46b49638a841,7/11/2011,1,PM,poor metabolizers,,,
drugInteractions,99400099-eae2-4061-a2c7-f56314973dc0,3/7/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,CYP3A4,cytochrome P450 3A4 enzyme,,,
drugInteractions,82549679-2e3b-48e8-95d7-7fdb902f9215,7/13/2011,1,PTU,Propylthiouracil,,,
drugInteractions,82549679-2e3b-48e8-95d7-7fdb902f9215,7/13/2011,1,FT4I,free-T4 index,,,
drugInteractions,870089d6-87e4-46b9-bcfb-c5b82cf06c3f,8/1/2011,8,LAIV,Live Attenuated Influenza Vaccine,,,
drugInteractions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,ODV,O–desvenlafaxine,,,
drugInteractions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,ODV,O-desmethylvenlafaxine,,,
drugInteractions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,EM,extensive metabolizers,,,
drugInteractions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,PM,poor metabolizers,,,
drugInteractions,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,INR,International Normalized Ratio,,,
drugInteractions,32723719-5d99-4ef1-a991-b65767327c1d,12/8/2011,1,PTU,Propylthiouracil,,,
drugInteractions,32723719-5d99-4ef1-a991-b65767327c1d,12/8/2011,1,Iodide,iodine- containing Radiographic contrast agents,,,
drugInteractions,32723719-5d99-4ef1-a991-b65767327c1d,12/8/2011,1,oral,oralAsparaginasecontraceptivesGlucocorticoidsEstrogens,,,
drugInteractions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,CYP450,cytochrome P450,,,
drugInteractions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,CYP3A4,cytochrome P450 3A4,,,
drugInteractions,5664d192-10d8-4766-b0ba-6095d14c927d,6/21/2010,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,5664d192-10d8-4766-b0ba-6095d14c927d,6/21/2010,1,TCAs,tricyclic  antidepressants,,,
drugInteractions,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,PMs,poor metabolizers,,,
drugInteractions,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,EMs,extensive metabolizers,,,
drugInteractions,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,MRP-2,multidrug-resistance-associated protein 2,,,
drugInteractions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,TCAs,tricyclic antidepressants,,,
drugInteractions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,ba1a46f0-61b0-4204-a2a0-c94f861fccc6,12/6/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,e.g.,e.g.:macrolide antibiotics,,,
drugInteractions,b93d1bcd-91b6-42fe-a668-2e0dcfc78bfe,8/10/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,debf74d1-3250-4858-8a9d-638262f3a7d5,10/12/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,ECT,electroconvulsive therapy,,,
drugInteractions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,9244e41c-94c9-428b-a254-703b71f9460b,7/30/2009,1001,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,9244e41c-94c9-428b-a254-703b71f9460b,7/30/2009,1001,5HIAA,5-hydroxy indoleacetic  acid,,,
drugInteractions,9244e41c-94c9-428b-a254-703b71f9460b,7/30/2009,1001,SSRIs,Selective  Serotonin Reuptake Inhibitors,,,
drugInteractions,3154c861-62fd-487a-aac0-f5e79ae3b284,3/26/2012,2,INR,International Normalized Ratio,,,
drugInteractions,3154c861-62fd-487a-aac0-f5e79ae3b284,3/26/2012,2,AUC,Area Under the Curve,,,
drugInteractions,13671be1-b4b4-44c9-a27d-0727f937bb3c,5/2/2012,1,NRTIs,nucleoside reverse transcriptase inhibitors,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,TERIS,Teratogen Information System,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,NSTs,nonstress tests,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,MAO,observation.Monoamine Oxidase,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,TERIS,there is no risk,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,AUC,area under the concentration-time curve,,,
drugInteractions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,MAO,may be needed.OthersOthersMonoamine Oxidase,,,
drugInteractions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,ZE,Zollinger-Ellison,,,
drugInteractions,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,TCAs,tricyclic antidepressants,,,
drugInteractions,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,NRTIs,Nucleoside Reverse Transcriptase Inhibitors,,,
drugInteractions,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,IMDH,Inosine monophosphate dehydrogenase,,,
drugInteractions,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,CBZ,carbamazepine,,,
drugInteractions,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,682a1210-b26e-426e-8ffe-d25d91bdd608,2/1/2012,8,LNG,levonorgestrel,,,
drugInteractions,682a1210-b26e-426e-8ffe-d25d91bdd608,2/1/2012,8,EE,ethinylestradiol,,,
drugInteractions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,AUC,Area Under the Curve,,,
drugInteractions,ffc1748b-5462-4d4d-8386-0b51fabe12bd,11/30/2010,109,NTP,National Toxicology Program,,,
drugInteractions,ffc1748b-5462-4d4d-8386-0b51fabe12bd,11/30/2010,109,CHO,Chinese  Hamster Ovary,,,
drugInteractions,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,INR,international normalized ratio,,,
drugInteractions,856d0894-e840-4b87-95aa-3085d5aed5be,8/7/2008,1,MAO,monoamine oxidase,,,
drugInteractions,bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb,8/30/2010,1,LDH,lactate dehydrogenase,,,
drugInteractions,bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb,8/30/2010,1,ALT,alanine aminotransferase,,,
drugInteractions,bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb,8/30/2010,1,AST,aspartate aminotransferase,,,
drugInteractions,74f813ac-3d04-44db-b5e0-99dbbfb5aea3,5/12/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,CBZ,carbamazepine,,,
drugInteractions,4f43644d-9b04-6911-9be5-81b6e25557cc,3/14/2011,4,LNG,levonorgestrel,,,
drugInteractions,4f43644d-9b04-6911-9be5-81b6e25557cc,3/14/2011,4,EE,ethinylestradiol,,,
drugInteractions,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,4c9ae54a-97a0-4613-a092-31e86d9bfc91,1/17/2008,1,CYP,cytochrome P450,,,
drugInteractions,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,PM,poor metabolizers,,,
drugInteractions,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,EM,extensive metabolizers,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,ECT,electroconvulsive therapy,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,TCAs,Tricyclic Antidepressants,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,MRHD,maximum  recommended human daily dose,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,UDS,unscheduled DNA synthesis,,,
drugInteractions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,ECT,Electroconvulsive Therapy,,,
drugInteractions,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,TCAs,reduced.Tricyclic Antidepressants,,,
drugInteractions,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,EM,extensive metabolizers,,,
drugInteractions,e44f82cc-4a34-40fc-bc31-42e06ca5e8b8,7/14/2011,1,PTU,Propylthiouracil,,,
drugInteractions,e44f82cc-4a34-40fc-bc31-42e06ca5e8b8,7/14/2011,1,FT4I,free-T4 index,,,
drugInteractions,b91d1729-2e8e-4398-9a0d-02763bcfe284,2/19/2010,1,e.g.,ergot alkaloid drugs,,,
drugInteractions,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,TCAs,Tricyclic Antidepressants,,,
drugInteractions,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,ECT,Electroconvulsive Therapy,,,
drugInteractions,cab63f24-8728-4927-aba5-53e8d2e44cdb,2/29/2012,5,i.e.,inducers of CYP3A4,,,
drugInteractions,5becda16-dd41-4ae0-ac40-013c5e07138e,12/7/2011,1,AEDs,Antiepileptic Drugs,,,
drugInteractions,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,HO-NEF,hydroxynefazodone,,,
drugInteractions,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,CYP3A4,Cytochrome P450 3A4,,,
drugInteractions,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,PM,PM's -38% to 105%,,,
drugInteractions,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,ODV,O-desmethylvenlafaxine,,,
drugInteractions,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,EM,extensive metabolizers,,,
drugInteractions,585d6ac1-c6f5-43d7-a605-135e08accbd7,8/18/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,f347f490-7199-4de6-bca2-0d44a74979af,1/19/2011,1,TBg,thyroxine-binding globulin,,,
drugInteractions,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,DSST,digit symbol substitution test,,,
drugInteractions,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,TCAs,Tricyclic Antidepressants,,,
drugInteractions,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,ECT,Electroconvulsive Therapy,,,
drugInteractions,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,i.e.,interaction,,,
drugInteractions,061cf52b-4432-422d-a97b-c3e1f8c4bab6,11/18/2010,3,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
drugInteractions,814301f9-c990-46a5-b481-2879a521a16f,6/8/2012,19,NRTIs,nucleoside reverse transcriptase inhibitors,,,
drugInteractions,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,INR,International Normalized Ratio,,,
drugInteractions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,depression.Monoamine oxidase,,,
drugInteractions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,of:Monoamine oxidase,,,
drugInteractions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,inhibitors;Monoamine oxidase,,,
drugInteractions,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,INR,International Normalized Ratio,,,
drugInteractions,ECA8BCBB-33E4-4EF9-9BA5-2D8C91E2DAEA,4/7/2006,1,Pgp,P-Glycoprotein,,,
drugInteractions,16eb7d1c-77c4-4709-970a-1e1bdb29eb76,8/10/2011,1,PTU,Propylthiouracil,,,
drugInteractions,16eb7d1c-77c4-4709-970a-1e1bdb29eb76,8/10/2011,1,FT4I,free-T4 index,,,
drugInteractions,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,ACE,angiotensin-converting enzyme,,,
drugInteractions,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
drugInteractions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAOI,Solution.Monoamine Oxidase Inhibitors,,,
drugInteractions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAOI,caution.Monoamine Oxidase Inhibitors,,,
drugInteractions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAO,monoamine oxidase,,,
drugInteractions,3364cee6-0a88-47bb-9af8-8e90843de236,8/1/2011,9,CYP 3A,cytochrome P450 3A,,,
drugInteractions,c68734cc-d998-4909-922d-8e55cdd780e2,10/19/2011,1,MICs,minimum inhibitory concentrations,,,
drugInteractions,d49fc909-1e02-4e51-b957-45540d678dde,5/18/2012,4,CBZ,carbamazepine,,,
drugInteractions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,ECT,electroconvulsive therapy,,,
drugInteractions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,TCAs,Tricyclic Antidepressants,,,
drugInteractions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,ECT,Electroconvulsive Therapy,,,
drugInteractions,5ceed28f-2cb1-4eef-b1ce-3cc83b8f49aa,2/3/2010,1,CI,confidence interval,,,
drugInteractions,a8f589fc-f646-4f94-85a4-12faff014b63,7/20/2011,1,CBZ,carbamazepine,,,
drugInteractions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,ECT,electroconvulsive therapy,,,
drugInteractions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,a9b0d279-118b-4372-bd51-d4bad9c1cfca,12/15/2010,1,THC,tetrahydrocannabinol,,,
drugInteractions,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,ACE,angiotensin-converting enzyme,,,
drugInteractions,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
drugInteractions,41999580-5495-4b5d-9a41-9b4466c65eda,9/20/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,INR,International Normalized Ratio,,,
drugInteractions,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,GI,gastrointestinal,,,
drugInteractions,ad380dae-0ccb-4efa-9c0c-752f31a50b65,11/17/2010,88,CHO,Chinese Hamster Ovary,,,
drugInteractions,ad380dae-0ccb-4efa-9c0c-752f31a50b65,11/17/2010,88,MRHD,Maximum Recommended Human Dose,,,
drugInteractions,ad380dae-0ccb-4efa-9c0c-752f31a50b65,11/17/2010,88,NTP,National Toxicology Program,,,
drugInteractions,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,e.g.,estrogens,,,
drugInteractions,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,TMP/SMX,Trimethoprim/Sulfamethoxazole,,,
drugInteractions,8893395a-6bfa-4b3c-84c2-d1d0c923304f,7/12/2012,16,DTPA,99mTc-diethylenetriaminepentaacetic acid,,,
drugInteractions,8893395a-6bfa-4b3c-84c2-d1d0c923304f,7/12/2012,16,NSAID,Nonsteroidal Anti-inflammatory Drug,,,
drugInteractions,6eebe6be-34a5-41c5-a63f-53fddc8bd0c0,12/7/2010,126,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,6eebe6be-34a5-41c5-a63f-53fddc8bd0c0,12/7/2010,126,TCAs,tricyclic  antidepressants,,,
drugInteractions,d1f29fda-6ea3-4c53-bf2e-1128cc19d3e2,4/14/2008,2,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
drugInteractions,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,EM,extensive metabolizers,,,
drugInteractions,bcd86877-5868-49dd-840b-7860b405fac7,3/27/2010,1,PM,poor metabolizers,,,
drugInteractions,704A5E3E-6ADF-4D38-A793-80978AB6E3BB,1/16/2007,1,MAO,Monoamine oxidase,,,
drugInteractions,704A5E3E-6ADF-4D38-A793-80978AB6E3BB,1/16/2007,1,CNS,Central nervous system,,,
drugInteractions,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,CBZ,carbamazepine,,,
drugInteractions,95a4ddd8-b76a-4128-b2ed-8a36cd5738f9,9/8/2010,7,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,b602edb3-45eb-42f4-8e75-1530c1f4355c,9/21/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,AEDs,antiepilepsy drugs,,,
drugInteractions,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,INR,International Normalized Ratio,,,
drugInteractions,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,INR,International Normalized Ratio,,,
drugInteractions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,INR,International Normalized Ratio,,,
drugInteractions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,AUC,Area Under the Curve,,,
drugInteractions,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,i.e.,interaction,,,
drugInteractions,ef45afc6-6886-485a-aefa-97827ffae024,5/4/2011,1,CNS,central nervous system,,,
drugInteractions,ef45afc6-6886-485a-aefa-97827ffae024,5/4/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
drugInteractions,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,TCAs,tricyclic antidepressants,,,
drugInteractions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,TCAs,Tricyclic Antidepressants,,,
drugInteractions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,TCAs,tricyclic antidepressants,,,
drugInteractions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,ECT,Electroconvulsive Therapy,,,
drugInteractions,1beeea2f-a922-43df-aa9e-2231ef404ba4,7/31/2008,1,COX-2,cyclooxgenase-2,,,
drugInteractions,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,INR,International Normalized Ratio,,,
drugInteractions,e15a7e9b-8025-49dd-9a6d-bafcccf1959f,2/28/2011,8,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
drugInteractions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,ECT,Electroconvulsive therapy,,,
drugInteractions,097d95e4-707e-47aa-b18e-aad18fecd42a,3/28/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,340d2619-4b29-456b-a3ac-0fa329e0b304,9/7/2011,1,NET,norethindrone,,,
drugInteractions,340d2619-4b29-456b-a3ac-0fa329e0b304,9/7/2011,1,HCTZ,Hydrochlorothiazide,,,
drugInteractions,340d2619-4b29-456b-a3ac-0fa329e0b304,9/7/2011,1,EE,ethinyl estradiol,,,
drugInteractions,4aa6b91f-bc3b-455c-b6d3-9027964d17ed,7/8/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,INR,International Normalized Ratio,,,
drugInteractions,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,AUC,Area Under the Curve,,,
drugInteractions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,NMS,Neuroleptic Malignant Syndrome,,,
drugInteractions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,EM,extensive metabolizers,,,
drugInteractions,ac7b43d5-3d14-4109-b6b4-e6f290d144d7,4/27/2011,1,i.e.,interaction,,,
drugInteractions,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,PT,prothrombin time,,,
drugInteractions,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,CPK,creatine phosphokinase,,,
drugInteractions,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,INR,international normalization ratio,,,
drugInteractions,0b5bbefd-5b56-46f9-84f5-1456371577fd,6/29/2012,1,PTT,partial thromboplastin time,,,
drugInteractions,6FAF0958-76A3-49F1-A385-514298CB7992,3/3/2006,2,MAO,Monoamine oxidase,,,
drugInteractions,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,ECT,Electroconvulsive therapy,,,
drugInteractions,9778AFDE-01AE-49DF-E7AB-D25D89711602,5/10/2006,2,e.g.,effects of digitalis,,,
drugInteractions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,ECT,electroconvulsive therapy,,,
drugInteractions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,ECT,electroconvulsive therapy,,,
drugInteractions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,MRHD,maximum recommended human dose,,,
drugInteractions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,PPHN,pulmonary hypertension of the newborn,,,
drugInteractions,585577b5-44f4-4c04-9e3a-d74f68d442cf,11/1/2010,400,INR,International  Normalized Ratio,,,
drugInteractions,712754fe-4619-4e46-b36e-d72570f80763,11/7/2011,4,MHD,10-monohydroxy metabolite,,,
drugInteractions,3E28CF99-2B70-4FD7-7988-A808DFAC54C4,8/28/2007,2,MAC,minimum alveolar concentration,,,
drugInteractions,1b5a2dc7-0570-4977-876d-88b4176844a1,8/6/2010,2,ENF,enfuvirtide,,,
drugInteractions,408eda31-0188-4f1d-96b9-8224dfe1bbc7,8/17/2009,1001,PGP,P-Glycoprotein,,,
drugInteractions,a5215931-3385-4d8e-b121-47aa1c20420c,2/7/2008,1,MAOI,Monoamine oxidase inhibitors,,,
drugInteractions,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,PAH,pulmonary arterial hypertension,,,
drugInteractions,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,INR,International Normalized Ratio,,,
drugInteractions,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,FMF,familial Mediterranean fever,,,
drugInteractions,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,NNRTIs,"styleCode=""italics"">Non-nucleoside Reverse Transcriptase Inhibitors",,,
drugInteractions,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,3/14/2012,12,PAH,pulmonary hypertension,,,
drugInteractions,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,INR,International Normalized Ratio,,,
drugInteractions,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,AUC,Area Under the Curve,,,
drugInteractions,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,TCAs,Tricyclic Antidepressants,,,
drugInteractions,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,ECT,Electroconvulsive Therapy,,,
drugInteractions,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,580da6bb-b4e8-40a3-bc21-87985d687354,9/9/2011,1,INR,International Normalized Ratio,,,
drugInteractions,58DDDE62-2BA2-4F39-8E32-5130D3963144,7/25/2006,1,CNS,Central Nervous System,,,
drugInteractions,25c2a91c-dfc2-4596-8a24-63acf04a2568,7/9/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,38b8c4a5-710f-453c-b7c1-38f19e38e808,8/22/2011,1,NET,norethindrone,,,
drugInteractions,38b8c4a5-710f-453c-b7c1-38f19e38e808,8/22/2011,1,HCTZ,Hydrochlorothiazide,,,
drugInteractions,38b8c4a5-710f-453c-b7c1-38f19e38e808,8/22/2011,1,EE,ethinyl estradiol,,,
drugInteractions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MPA,mycophenolic acid,,,
drugInteractions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MRP-2,multidrug-resistance-associated protein 2,,,
drugInteractions,ca5598e4-4226-45ab-abd1-e961707ae457,12/7/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,ACE,angiotensin-converting enzyme,,,
drugInteractions,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
drugInteractions,cf10d256-dd89-4a91-a3ed-81db505a79c2,10/31/2011,6,i.e.,inducers of CYP3A4,,,
drugInteractions,44f634f4-b794-4d55-8ab7-037fdef8ff0f,3/21/2011,14,SD,systolic blood pressure [mean,,,
drugInteractions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,ECT,treatment.Electroconvulsive therapy,,,
drugInteractions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,ECT,stopped.Electroconvulsive therapy,,,
drugInteractions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,PM,PMs -38% to 105%,,,
drugInteractions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,ODV,O-desmethylvenlafaxine,,,
drugInteractions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,EM,extensive metabolizers,,,
drugInteractions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,PM,poor metabolizers,,,
drugInteractions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,NET,norethindrone,,,
drugInteractions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,HCTZ,Hydrochlorothiazide,,,
drugInteractions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,EE,ethinyl estradiol,,,
drugInteractions,be38b325-3a6f-4569-9ae0-a03feff8535d,10/26/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,PT,prothrombin time,,,
drugInteractions,8634a53f-fba5-4433-87bf-e6cf72acf869,5/19/2011,6,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,b3bbc16e-8305-469a-9dc3-8e698339a98b,7/8/2010,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,B6D9F638-71C4-4701-8CA0-AC83AFD08266,12/6/2006,1,MAO,monoamine oxidase,,,
drugInteractions,f72a1419-0df4-4aaa-84cf-606a17cac493,8/1/2011,3,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,f72a1419-0df4-4aaa-84cf-606a17cac493,8/1/2011,3,TCAs,tricyclic antidepressants,,,
drugInteractions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,PBI,protein bound iodine,,,
drugInteractions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,GC/MS,gas chromatography/mass  spectrometry,,,
drugInteractions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,ACE,Angiotensin Converting Enzyme,,,
drugInteractions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,NSAID's,Nonsteroidal Anti-inflammatory Drugs,,,
drugInteractions,529ac72c-c4a0-4001-8cf9-b94f5bf7265c,2/1/2012,3,INR,International Normalized Ratio,,,
drugInteractions,9e888ce6-8efe-4a36-98f4-a272286252cd,11/15/2011,2,i.e.,inducers of CYP3A4,,,
drugInteractions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,TCAs,tricyclic antidepressants,,,
drugInteractions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
drugInteractions,d460371b-545c-4a16-b5a8-ef8d748cecb9,7/15/2011,1,INR,International Normalized Ratio,,,
drugInteractions,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
drugInteractions,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,MAOIs,inhibited.Monoamine Oxidase Inhibitors,,,
drugInteractions,cd11b424-cbf7-4029-9fc6-c9397ad1d0e2,5/20/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,INR,International Normalized Ratio,,,
drugInteractions,9f852453-5d49-4a83-bba9-54aa454d0c2b,2/13/2012,4,INR,International Normalized Ratio,,,
drugInteractions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,PBI,protein-bound iodine,,,
drugInteractions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,TBG,thyroid-binding globulin,,,
drugInteractions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,i.e.,in serum,,,
drugInteractions,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,DSST,digit symbol substitution test,,,
drugInteractions,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,CNS,central nervous system,,,
drugInteractions,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,PIs,protease inhibitors,,,
drugInteractions,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,AUC,area under the curve,,,
drugInteractions,1ef407ee-6487-428e-8d4e-1a896aa15e43,6/6/2011,1,PDE-5,phosphodiesterase-5,,,
drugInteractions,cea90a32-b896-4776-8236-a3ba6bc51df1,12/17/2010,155,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,cea90a32-b896-4776-8236-a3ba6bc51df1,12/17/2010,155,TCAs,tricyclic  antidepressants,,,
drugInteractions,91e9be98-8d98-43c3-a1c0-0249b65d2744,9/15/2010,26,eg,exaggerated response,,,
drugInteractions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,AUC,Area Under the Curve,,,
drugInteractions,0bf2cfc3-b564-44ed-9268-1a5409a89eeb,7/28/2011,1,PTU,Propylthiouracil,,,
drugInteractions,0bf2cfc3-b564-44ed-9268-1a5409a89eeb,7/28/2011,1,FT4I,free-T4 index,,,
drugInteractions,a767e888-f825-4429-b3a4-05580ea6d157,9/19/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,e.g.,estrogens,,,
drugInteractions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,CYP 2C9,cytochrome P450 2C9 enzyme,,,
drugInteractions,4710e965-7e92-4fef-b7fa-d4ecece6a606,7/18/2011,1,RA,rheumatoid arthritis,,,
drugInteractions,4710e965-7e92-4fef-b7fa-d4ecece6a606,7/18/2011,1,INR,International Normalized Ratio,,,
drugInteractions,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,INR,International Normalized Ratio,,,
drugInteractions,AAAF4D12-4E68-45F9-AC10-2238480A0160,4/5/2006,1,MAOI,caution.Monoamine Oxidase Inhibitors,,,
drugInteractions,f21494ed-c5e8-4ddf-b140-ecd68c5c312b,8/8/2008,1,Pgp,Pglycoprotein,,,
drugInteractions,3292a8ff-0664-c0a4-42a6-9827ddb93665,3/28/2007,1,CYP3A,cytochrome P450 3A,,,
drugInteractions,42836232-a71f-4e4b-8060-2bdbd853398a,10/26/2010,65,MAO,monoamine oxidase,,,
drugInteractions,a0ca0500-8d13-42aa-8c3d-040ea502db75,9/27/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,57578387-1918-4e56-a564-f14fb22340bf,11/7/2011,4,i.e.,inducers of CYP3A4,,,
drugInteractions,12016940-1156-44ce-b18d-eee811267eea,3/14/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,83a005d5-e054-4ff0-afa7-de57811f8de7,4/25/2011,2,PMs,PMs4% to 134%,,,
drugInteractions,cf355b07-134e-48bb-b5b8-1859ec8800bd,10/27/2010,1,LDL,low-density lipoprotein,,,
drugInteractions,cf355b07-134e-48bb-b5b8-1859ec8800bd,10/27/2010,1,HDL,high-density lipoprotein,,,
drugInteractions,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,INR,International Normalized Ratio,,,
drugInteractions,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,AUC,Area Under the Curve,,,
drugInteractions,13c80d46-429e-4007-8f89-eed2ed96eccf,6/17/2010,1,INR,International Normalized Ratio,,,
drugInteractions,cf3630b8-7deb-48ee-9c99-b51b38934d7e,1/17/2012,3,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,54afe2fd-e628-4655-a3dc-45ae29680f96,6/27/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,4077592a-8790-4d45-8cb6-2c95a0a929de,7/25/2011,1,PRA,plasma renin activity,,,
drugInteractions,2a1f280e-4edb-4726-844d-18ec19789152,11/7/2011,3,AEDs,Antiepileptic Drugs,,,
drugInteractions,d4dee7ff-6f1a-45e0-9ade-cda3ff418ad1,7/7/2011,32,i.e.,interaction,,,
drugInteractions,d6d7711f-541b-47d1-b937-2c6a021eb6c3,12/2/2010,1,NSAIDs,Aspirin/Nonsteroidal Anti-Inflammatory Drugs,,,
drugInteractions,b92afca2-4526-474d-a023-858f1d1f166f,5/1/2012,1,ADP,adenosine diphosphate,,,
drugInteractions,d3284649-ed4c-4096-987b-4ac16b8278f2,7/6/2010,1,ACE,angiotensin converting enzyme,,,
drugInteractions,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,INR,International Normalized Ratio,,,
drugInteractions,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,INR,International Normalized Ratio,,,
drugInteractions,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,AUC,Area Under the Curve,,,
drugInteractions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,ECT,electroconvulsive therapy,,,
drugInteractions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,ea350660-9be8-40b2-98f9-af759a8f7864,2/24/2010,4,CYP3A,cytochrome P450 3A,,,
drugInteractions,c202834e-0aba-4a06-838c-cf076681e6e4,5/23/2011,1,PTU,Propylthiouracil,,,
drugInteractions,6869fec9-1837-4221-afd8-5cc6fadd025d,11/18/2010,4,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,i.e.,interaction,,,
drugInteractions,46942e6e-73bb-4687-853a-e3ec2734cc70,10/13/2011,1,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
drugInteractions,6dfef8f0-69cf-4a65-8f9b-bc9359926d1c,4/20/2011,2,LAIV,live attenuated influenza vaccine,,,
drugInteractions,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,EM,extensive metabolizers,,,
drugInteractions,c32e14cb-8c76-450d-9b86-993fa7a826b2,5/18/2011,2,PM,poor metabolizers,,,
drugInteractions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,ECT,electroconvulsive therapy,,,
drugInteractions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,06de3c9d-63bf-47c1-f78c-4fbdd482928a,9/20/2011,8,PRA,plasma renin activity,,,
drugInteractions,886c13fa-4547-4411-88aa-8e23a7a698f6,3/23/2010,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,886c13fa-4547-4411-88aa-8e23a7a698f6,3/23/2010,1,SNRIs,serotonin norepinephrine reuptake inhibitors,,,
drugInteractions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,ECT,electroconvulsive therapy,,,
drugInteractions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,MRHD,maximum recommended human dose,,,
drugInteractions,2f3b8f28-b3da-4658-bdc4-fe86dec62d32,8/15/2007,1,MAO,monoamine oxidase,,,
drugInteractions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,ECT,electroconvulsive therapy,,,
drugInteractions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,TCAs,Tricyclic Antidepressants,,,
drugInteractions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,ECT,Electroconvulsive Therapy,,,
drugInteractions,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,INR,International Normalized Ratio,,,
drugInteractions,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,PMs,poor metabolizers,,,
drugInteractions,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,EMs,extensive metabolizers,,,
drugInteractions,18f94362-34c5-4271-9177-d81c92fa2d41,3/2/2012,1,APTT,activated partial thromboplastin times,,,
drugInteractions,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,TCAs,Tricyclic Antidepressants,,,
drugInteractions,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,ECT,Electroconvulsive Therapy,,,
drugInteractions,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,i.e.,interaction,,,
drugInteractions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,ECT,electroconvulsive therapy,,,
drugInteractions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,BDD0658E-38FB-4726-9720-09C502138AB0,4/7/2006,1,e.g.,effects of digitalis,,,
drugInteractions,B151E4EB-BB9A-41B9-98A4-2E12BB4E2E5F,5/11/2006,1,MAO,monoamine oxidase,,,
drugInteractions,5bb0d56c-d58e-4f9f-9848-d241cac5b3db,9/30/2011,2,MAO,monoamine oxidase,,,
drugInteractions,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,INR,International Normalized Ratio,,,
drugInteractions,82207a72-07a0-4501-aff4-8a6f6e2bccb3,8/23/2011,1,RA,rheumatoid arthritis,,,
drugInteractions,82207a72-07a0-4501-aff4-8a6f6e2bccb3,8/23/2011,1,INR,International Normalized Ratio,,,
drugInteractions,27d801ea-b342-4a8a-aeda-301a0175fe84,8/3/2007,1,ACE,angiotensin-converting enzyme,,,
drugInteractions,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,ACE,angiotensin-converting enzyme,,,
drugInteractions,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
drugInteractions,fe8480c4-b176-45ae-b4d6-fa59912fe286,7/22/2010,4,RA,rheumatoid arthritis,,,
drugInteractions,fe8480c4-b176-45ae-b4d6-fa59912fe286,7/22/2010,4,INR,International Normalized Ratio,,,
drugInteractions,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,PM,PMs - 38% to 105%,,,
drugInteractions,449ddc89-6dff-4e3e-a480-66b68389c73d,7/14/2011,1,INR,International Normalized Ratio,,,
drugInteractions,f8eaf67a-72e6-4ecd-bbf6-7ec8d34df2a2,6/22/2011,1,PTU,Propylthiouracil,,,
drugInteractions,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,PM,PM's -38% to 105%,,,
drugInteractions,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,ODV,O-desmethylvenlafaxine,,,
drugInteractions,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,EM,extensive metabolizers,,,
drugInteractions,6cc91855-660f-4df0-9800-4b628cad6f15,8/22/2011,1,MHD,10-monohydroxy metabolite,,,
drugInteractions,428481bb-b7cf-4d76-b57d-0d6bfa2b6ac3,9/1/2011,8,LDL,low-density lipoprotein,,,
drugInteractions,428481bb-b7cf-4d76-b57d-0d6bfa2b6ac3,9/1/2011,8,HDL,high-density lipoprotein,,,
drugInteractions,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,DSST,digit symbol substitution test,,,
drugInteractions,1f5f940c-d5b9-4d09-958d-246931e167af,11/7/2011,5,NET,norethindrone,,,
drugInteractions,1f5f940c-d5b9-4d09-958d-246931e167af,11/7/2011,5,EE,ethinyl estradiol,,,
drugInteractions,dfd184f0-2e52-454c-8ef2-3153be7dd4c9,9/8/2011,1,PRA,plasma renin activity,,,
drugInteractions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,NET,norethindrone,,,
drugInteractions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,HCTZ,Hydrochlorothiazide,,,
drugInteractions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,EE,ethinyl estradiol,,,
drugInteractions,e29485f8-df97-47b2-b5f9-62e99adcf4af,11/11/2010,80,CI,confidence interval,,,
drugInteractions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,INR,International Normalized Ratio,,,
drugInteractions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,AUC,Area Under the Curve,,,
drugInteractions,df441cd9-fc5f-4f25-998d-f7f274cff691,5/17/2011,1,COX-2,cyclooxygenase-2,,,
drugInteractions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,DST,Dexamethasone Suppression Test,,,
drugInteractions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,DST,dexamethasone suppression test,,,
drugInteractions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,CYP 3A4,cytochrome P450 3A4,,,
drugInteractions,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,CYP,Cytochrome P450,,,
drugInteractions,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,CYP3A,Cytochrome P450 3A,,,
drugInteractions,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,517fbb02-8793-4647-83c7-25a91be49622,7/8/2010,8,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,TCAs,tricyclic antidepressants,,,
drugInteractions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,ECT,electroconvulsive therapy,,,
drugInteractions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,ACT,activated clotting time,,,
drugInteractions,63bea240-a32d-4c12-85d1-b7edeca76b67,9/27/2011,1,PTU,Propylthiouracil,,,
drugInteractions,63bea240-a32d-4c12-85d1-b7edeca76b67,9/27/2011,1,Iodide,iodine- containing Radiographic contrast agents,,,
drugInteractions,63bea240-a32d-4c12-85d1-b7edeca76b67,9/27/2011,1,oral,oralAsparaginasecontraceptivesGlucocorticoidsEstrogens,,,
drugInteractions,01e537e6-f19c-4259-952d-22224c10c74c,12/23/2010,166,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,01e537e6-f19c-4259-952d-22224c10c74c,12/23/2010,166,TCAs,tricyclic  antidepressants,,,
drugInteractions,dac99035-9098-4710-bf55-c46889ffc282,1/19/2011,1,TBg,thyroxine-binding globulin,,,
drugInteractions,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,PPI,Pump Inhibitors,,,
drugInteractions,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,HO-NEF,hydroxynefazodone,,,
drugInteractions,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,CYP3A4,Cytrochrome P450 3A4,,,
drugInteractions,707fb53f-f27d-4169-86ff-62d02014e9c4,12/1/2011,1,PTU,Propylthiouracil,,,
drugInteractions,707fb53f-f27d-4169-86ff-62d02014e9c4,12/1/2011,1,FT4I,free-T4 index,,,
drugInteractions,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,COX-2,cyclooxygenase-2,,,
drugInteractions,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,ACE,angiotensin converting enzyme,,,
drugInteractions,b498d45e-c832-420a-b975-18800a14c029,8/3/2007,1,MAO,recommended.Monoamine oxidase,,,
drugInteractions,ac3dfb81-a4c7-4147-9374-c234153b7c51,12/29/2011,4,i.e.,inducers of CYP3A4,,,
drugInteractions,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,PTU,<br/>Propylthiouracil,,,
drugInteractions,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,SSRIs,Selective  Serotonin Reuptake Inhibitors<br/>&#160;,,,
drugInteractions,bc695a1b-b510-4376-a9a0-bcbd7c63906f,12/8/2010,132,FT4I,free-T4 index,,,
drugInteractions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,ECT,electroconvulsive therapy,,,
drugInteractions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,2F44755A-2661-475D-83C5-8923101EB7A3,6/13/2007,1,MAO,monoamine oxidase,,,
drugInteractions,64e8907b-a0c7-4d7a-a8a7-cbfacab24a4a,3/30/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,INR,International Normalized Ratio,,,
drugInteractions,14a764d2-6142-443e-9598-414f11cbb627,11/30/2011,2,PDE-5,phosphodiesterase-5,,,
drugInteractions,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,human,heparin is enhanced by concurrent treatment with antithrombin III,,,
drugInteractions,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,human,heparin is recommended during treatment with antithrombin III,,,
drugInteractions,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,RA,rheumatoid arthritis,,,
drugInteractions,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,INR,International Normalized Ratio,,,
drugInteractions,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,INR,International Normalized Ratio,,,
drugInteractions,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,CYP,cytochrome P450,,,
drugInteractions,246f1e96-0a2f-43c8-aa71-8e885b6c350d,10/19/2011,1,MICs,minimum inhibitory concentrations,,,
drugInteractions,9f015e60-1aec-4ae7-b28f-42f6c8f50455,7/23/2012,1,i.e.,inducers of CYP3A4,,,
drugInteractions,947D5617-4E91-4507-AC80-977824D2B50B,2/23/2006,1,MAO,monoamine oxidase,,,
drugInteractions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,TCAs,tricyclic antidepressants,,,
drugInteractions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
drugInteractions,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,AF,after sotalol hydrochloride tablets,,,
drugInteractions,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MAOI,monoamine oxidase inhibitor,,,
drugInteractions,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,73667241-b95a-49b0-9c51-a4289f20d5c2,7/28/2010,1,ENF,enfuvirtide,,,
drugInteractions,a7c456e6-403b-4aae-a576-60b106bf66a7,10/4/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
drugInteractions,58159bbc-d862-4a2a-8486-874e0007487b,12/22/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,MRHD,maximum recommended human dose,,,
drugInteractions,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,LNG,levonorgestrel,,,
drugInteractions,b9e7c593-9499-49c7-8775-1e7761176857,11/20/2010,96,EE,ethinylestradiol,,,
drugInteractions,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,INR,International Normalized Ratio,,,
drugInteractions,424c69ef-b5a4-4480-98f1-6c8bed9cbcf2,12/15/2010,147,HO-NEF,hydroxynefazodone,,,
drugInteractions,424c69ef-b5a4-4480-98f1-6c8bed9cbcf2,12/15/2010,147,CYP3A4,Cytochrome P450 3A4,,,
drugInteractions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,ECT,electroconvulsive therapy,,,
drugInteractions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,ECT,Electroconvulsive Therapy,,,
drugInteractions,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,PAH,pulmonary arterial hypertension,,,
drugInteractions,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,INR,International Normalized Ratio,,,
drugInteractions,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,FMF,familial Mediterranean fever,,,
drugInteractions,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,NNRTIs,"styleCode=""italics"">Non-nucleoside Reverse Transcriptase Inhibitors",,,
drugInteractions,025876b6-f031-43ea-967a-b1d95b4685a6,2/17/2012,2,PAH,pulmonary hypertension,,,
drugInteractions,d544481d-2695-4a89-964b-15e2338670b8,8/1/2011,1,INR,International Normalized Ratio,,,
drugInteractions,aa756b80-11eb-4f67-abb8-8babcee728b2,7/8/2010,4,MPA,mycophenolic acid,,,
drugInteractions,bd55dd57-348c-4d78-b322-d1ae10279298,4/20/2012,2,TMP/SMX,Trimethoprim/Sulfamethoxazole,,,
drugInteractions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,ECT,electroconvulsive therapy,,,
drugInteractions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,COX-2,cyclooxygenase-2,,,
drugInteractions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,NSAIDS,Non-steroidal anti-inflammatory drugs,,,
drugInteractions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,ACE,angiotensin converting enzyme,,,
drugInteractions,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,PMs,poor metabolizers,,,
drugInteractions,28eefc95-d92e-4555-b6c5-2933860b0610,7/2/2012,1,ACE,angiotensin converting enzyme,,,
drugInteractions,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,INR,International Normalized Ratio,,,
drugInteractions,E67D21FA-DB5A-4536-FC82-CABFEADB0C6F,2/22/2006,1,PLENDIL,prolongation in the half-life of felodipine.Erythromycin—Co-administration of felodipine,,,
drugInteractions,c0c15d60-1171-11e1-9be0-0002a5d5c51b,11/23/2011,2,AEDs,antiepileptic drugs,,,
drugInteractions,6ed06682-7507-4c11-a782-42e694c21b53,2/21/2012,1,RA,rheumatoid arthritis,,,
drugInteractions,6ed06682-7507-4c11-a782-42e694c21b53,2/21/2012,1,INR,International Normalized Ratio,,,
drugInteractions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,ECT,electroconvulsive therapy,,,
drugInteractions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,MRHD,maximum recommended human dose,,,
drugInteractions,0306cdb2-f143-4f55-9d63-f0508c842609,12/2/2010,145,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,0306cdb2-f143-4f55-9d63-f0508c842609,12/2/2010,145,TCAs,tricyclic  antidepressants,,,
drugInteractions,a203a396-f64b-4e2d-a57e-47ea7e83c3bf,12/12/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,Statins,STABILIZED.HMG-CoA Reductase Inhibitors,,,
drugInteractions,110aada7-dfe8-4ecf-80c7-4dac8907ad29,5/4/2011,1,PRA,plasma renin activity,,,
drugInteractions,bcb4364f-7884-4aa3-94db-47607a5ce5fc,10/17/2011,2,MICs,minimum inhibitory concentrations,,,
drugInteractions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,ECT,treatment.Electroconvulsive Therapy,,,
drugInteractions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,ECT,Electroconvulsive Therapy,,,
drugInteractions,e9060459-ec1b-4eb5-a34a-d777f1544f3d,12/7/2011,1,PTU,Propylthiouracil,,,
drugInteractions,e9060459-ec1b-4eb5-a34a-d777f1544f3d,12/7/2011,1,FT4I,free-T4 index,,,
drugInteractions,1636fbd8-ac5f-4395-974b-561d0d523aee,10/24/2011,1,ACE,Angiotensin-converting enzyme,,,
drugInteractions,eadf575d-7561-4020-b88f-a280e58d10ba,6/1/2011,1,Pgp,P-glycoprotein,,,
drugInteractions,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,PMs,poor metabolizers,,,
drugInteractions,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,EMs,extensive metabolizers,,,
drugInteractions,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,i.e.,interaction,,,
drugInteractions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,ECT,electroconvulsive therapy,,,
drugInteractions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,TCAs,Tricyclic Antidepressants,,,
drugInteractions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,TCAs,tricyclic antidepressants,,,
drugInteractions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,c957df9a-eb66-432f-a280-9cd74389d667,8/1/2011,13,5HIAA,5-hydroxy indoleacetic acid,,,
drugInteractions,6f31e729-e36b-4b6e-98de-88077b29bf2b,9/28/2011,2,MAO,monoamine oxidase,,,
drugInteractions,80971965-5c77-4950-b65d-7996b802d2cd,7/8/2010,8,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
drugInteractions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,CNS,central nervous system,,,
drugInteractions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,MAOIs,Monoamine Oxidase Inhibitors,,,
drugInteractions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,MAOIs,treatment.Monoamine Oxidase Inhibitors,,,
drugInteractions,ac805bbd-26d5-456d-9ce8-cb91ed8703b6,1/3/2011,2,AED,antiepileptic drug,,,
drugInteractions,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,INR,International Normalized Ratio,,,
drugInteractions,3f3a870e-f325-475b-8453-fe3d1bb8f54a,3/19/2010,1,PGP,P-Glycoprotein,,,
drugInteractions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desmethylvenlafaxine,,,
drugInteractions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desvenlafaxine,,,
drugInteractions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,EM,extensive metabolizers,,,
drugInteractions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,PM,poor metabolizers,,,
drugInteractions,AA69C63C-CED6-4676-A16B-554F1AF7D210,10/25/2007,13,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,AA69C63C-CED6-4676-A16B-554F1AF7D210,10/25/2007,13,TCAs,tricyclic antidepressants,,,
drugInteractions,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
drugInteractions,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,TCAs,tricyclic antidepressants,,,
drugInteractions,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,ECT,Electroconvulsive Therapy,,,
drugInteractions,c7a79060-0369-4f9e-8fdd-f5351d23eeca,8/30/2011,1,RA,rheumatoid arthritis,,,
drugInteractions,c7a79060-0369-4f9e-8fdd-f5351d23eeca,8/30/2011,1,INR,International Normalized Ratio,,,
drugInteractions,a61138f0-b7e0-4b8f-923f-649c1845be46,11/2/2011,1,ACE,Angiotensin-converting enzyme,,,
drugInteractions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,ECT,electroconvulsive therapy,,,
drugInteractions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,CYP,Cytochrome P450,,,
drugInteractions,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,CYP3A,Cytochrome P450 3A,,,
drugInteractions,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,CYP,cytochrome P450 isoenzymes,,,
drugInteractions,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
drugInteractions,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,INR,International Normalized Ratio,,,
drugInteractions,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,PT,prothrombin time,,,
drugInteractions,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,CPK,creatine phosphokinase,,,
drugInteractions,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,INR,international normalization ratio,,,
drugInteractions,1f66fba7-4026-4504-918d-4c88f2835cc0,4/26/2011,11,PTT,partial thromboplastin time,,,
drugInteractions,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,EM,extensive metabolizers,,,
drugInteractions,af558603-15f3-43e4-9ee5-9d38d59ef1c1,1/19/2012,3,PM,poor metabolizers,,,
drugInteractions,3185D299-AB4C-4BF1-86A4-3C126144B245,9/17/2008,1,MAOI,Monoamine Oxidase Inhibitors,,,
drugInteractions,47c21109-6e7e-4647-9963-d2151f5ef820,10/13/2011,1,HO-NEF,hydroxynefazodone,,,
drugInteractions,47c21109-6e7e-4647-9963-d2151f5ef820,10/13/2011,1,CYP3A4,Cytochrome P450 3A4,,,
drugInteractions,e29d7f37-212b-4caa-a1da-171c828e2d52,7/22/2011,1,PTU,Propylthiouracil,,,
drugInteractions,e29d7f37-212b-4caa-a1da-171c828e2d52,7/22/2011,1,FT4I,free-T4 index,,,
drugInteractions,234bb0f5-8a33-440b-8d74-d05185e75222,6/20/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
drugInteractions,4a4c577d-9267-40eb-9ed9-09ceb6377026,11/30/2010,112,GGT,gamma glutamyl transpeptidase,,,
drugInteractions,8887de7e-eba5-4f00-97ca-5077cfaa361b,7/19/2012,5,NET,norethindrone,,,
drugInteractions,8887de7e-eba5-4f00-97ca-5077cfaa361b,7/19/2012,5,EE,ethinyl estradiol,,,
drugInteractions,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,AEDs,Antiepileptic Drugs,,,
drugInteractions,8d9a17e9-fd2d-4976-9704-42c6e1760db4,5/14/2010,401,EM,extensive metabolizers,,,
drugInteractions,8d9a17e9-fd2d-4976-9704-42c6e1760db4,5/14/2010,401,PM,poor metabolizers,,,
drugInteractions,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,CBZ,carbamazepine,,,
drugInteractions,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
drugInteractions,9832312e-0310-4ab6-8501-afa976fc7eb2,2/29/2012,4,MAOs,Monoamine oxidase inhibitors,,,
drugInteractions,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,GI,gastrointestinal,,,
drugInteractions,1eee14d3-acfc-4002-b457-6bd69afbd2c7,8/4/2011,1,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
drugInteractions,7F56F5C9-32FE-40FE-8151-F7EA9DA1A0C1,7/7/2006,1,MAO,monoamine oxidase,,,
drugInteractions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,ECT,hydrobromide.Electroconvulsive Therapy,,,
drugInteractions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,ECT,electroconvulsive therapy,,,
drugInteractions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
drugInteractions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,TCAs,Tricyclic Antidepressants,,,
drugInteractions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,MAOIs,recommended.Monoamine Oxidase Inhibitors,,,
supply,42DBD449-BF4C-417C-B26B-0A9D7534C8BB,9/18/2007,1,Tablets,tablets,,,
supply,39DC3695-DBF2-4783-B1BF-97237593F1C0,7/2/2008,1,SUFENTA,Sufentanil Citrate Injection,,,
supply,82da3098-03b8-4d43-9271-1e96f9d75e4b,5/30/2006,1,HIPS,high impact polystyrene,,,
supply,a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667,3/6/2012,16,MAOI,monoamine oxidase inhibitor,,,
supply,a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667,3/6/2012,16,SR®,(SR),,,
supply,549d38db-d4ed-4708-8f76-7cdaa157063f,3/15/2012,19,RFID,Radio Frequency Identification,,,
supply,5fa6a683-9685-4591-bd00-19f15c9bcf12,1/23/2008,1,Solution,solution,,,
supply,cb4f1002-9372-4fac-aea3-99142f93dd37,10/30/2009,1,CFCs,chlorfluorocarbons,,,
supply,145a1b4a-16ef-4f29-b47e-f52c47514c9a,10/28/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,2.5 mg/mL,25 mg/10 mL,,,
supply,1612d931-d86e-4dba-bbd7-0aac3eaee131,2/28/2006,1,HIPS,high impact polystyrene,,,
supply,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,CEFOTAN,cefotetan disodium for injection,,,
supply,A71FBAB2-1D12-4392-F78B-E8B94212B413,9/19/2006,1,CEFOTAN,cefotetan injection,,,
supply,4E25A881-DFC3-44A2-9EDE-49F7443776D8,4/8/2008,1,PET,packaged in a clear plastic,,,
supply,d834721b-b624-4b27-9009-95e09827122e,11/15/2010,2,EOS,end of synthesis,,,
supply,C7C7FEF7-AD39-420B-8766-69514C23A243,5/11/2006,1,HDPE,high density polyethylene,,,
supply,c1888b7a-0a14-4e24-9ba7-1458154d07d9,6/4/2012,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,FAC0C875-111E-4AF2-D186-ED4D4EE9DE59,4/24/2007,2,PIPRACIL®,piperacillin for injection,,,
supply,e0fa4bca-f245-4d92-ae29-b0c630a315c2,12/13/2011,107,20 mg/mL,200 mg of panitumumab in 10 mL,,,
supply,8878F134-42B9-4C30-B240-2761B6B3AA5F,5/11/2006,1,Steri-Dose,solution containing 50 mg diphenhydramine hydrochloride in a 1-mL disposable syringe,,,
supply,209a4cc3-8453-4e4c-8af5-ad059bebf046,1/14/2011,1,Flat,FL 33637                         ©Bausch & Lomb Incorporated                         9105000,,,
supply,1cec7a02-b7a5-49e1-ab64-3a4dab4149d2,4/30/2012,2,CCB,calcium channel blocker,,,
supply,b972af81-3a37-40be-9fe1-3ddf59852528,6/15/2011,6,top/bottom,"<td styleCode=""Botrule Lrule Rrule""> Caplet </td>                         </tr>                         <tr>                            <td styleCode=""Botrule Lrule Rrule"">                               <content styleCode=""bold"">Debossment",,,
supply,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,CABG,“coronary artery bypass graft,,,
supply,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,AACEE94D-15AF-4CCC-9CC9-6CD52905EC4E,11/28/2007,1,2 mg/mL,10139-061-25200 mg/100 mL,,,
supply,97532b47-41c4-41e5-a89b-fc788528204b,9/8/2011,5,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,c7ef31c4-e3d9-4a9b-98bd-46b609f7f3aa,2/21/2006,1,EPA's,Environmental Protection Agency's,,,
supply,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,EPA's,Environmental Protection Agency's,,,
supply,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,CFCs,chlorofluorocarbons,,,
supply,ad98682f-e421-4cf3-85f5-a042a3708262,3/17/2006,1,PR,Pharma,,,
supply,638e4f36-1a27-4220-8ec9-3fa9d9b36c11,6/1/2012,1,GREPCO,Group for Epidemiology and Prevention of Cholelithiasis,,,
supply,5e2ea873-f8a4-4b19-b79f-93f957114352,1/14/2011,2,PSA,Prostate-Specific Antigen,,,
supply,8c7b265e-7500-464a-854e-9c4a22c8d211,2/18/2010,3,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox®,ceftizoxime for injection,,,
supply,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,bottle,bottles of 100 and 500.100's,,,
supply,c89eb8fd-6c31-4f8b-8103-1f559424eda1,10/9/2006,1,CFCs,chlorofluorocarbons,,,
supply,9448e8ba-b73a-4d2a-b58c-afdcd19f8e12,8/4/2010,18,PEG,polyethylene glycol,,,
supply,bfadc9b6-1dd6-4bf3-af5f-b50fbdae55d3,6/1/2012,1,GREPCO,Group for Epidemiology and Prevention of Cholelithiasis,,,
supply,e2d4307d-da8f-49f5-aac0-02355dd9ffb7,7/21/2007,1,atropine,Atropine Injection,,,
supply,a8984705-a43a-4977-808a-44df42930de1,4/27/2011,3,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,A1A68BE1-F5D2-485B-B6A4-C8D8B906172B,8/18/2006,1,Vial,"valign=""top""/></tr> <tr><td valign=""top""><paragraph>Temperature Probe",,,
supply,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,PE,phenytoin sodium                                                   equivalent units,,,
supply,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,CEFOTAN,cefotetan disodium for injection,,,
supply,56912A83-4CBA-4461-D983-3A0656515458,4/7/2006,1,CEFOTAN,cefotetan injection,,,
supply,2dc814a4-1bb2-497b-987d-c3ebe444994e,11/16/2011,2,N/593,N over bisect 593,,,
supply,2dc814a4-1bb2-497b-987d-c3ebe444994e,11/16/2011,2,N/596,N over bisect 596,,,
supply,2dc814a4-1bb2-497b-987d-c3ebe444994e,11/16/2011,2,N/598,N over bisect 598,,,
supply,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,NIOSH,National Institute for Occupational Safety and Health Administration,,,
supply,A8C96721-FC32-41A1-AC15-05C984210784,5/1/2009,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,ALFENTA,alfentanil hydrochloride,,,
supply,d3f12dab-1802-4d6a-9f90-6359e6b24565,7/30/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,d3f12dab-1802-4d6a-9f90-6359e6b24565,7/30/2010,1,CABG,“coronary artery bypass graft,,,
supply,d3f12dab-1802-4d6a-9f90-6359e6b24565,7/30/2010,1,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,d3f12dab-1802-4d6a-9f90-6359e6b24565,7/30/2010,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
supply,A83D7327-ABA2-43E0-A510-9EEABF1BC560,6/17/2008,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,A83D7327-ABA2-43E0-A510-9EEABF1BC560,6/17/2008,1,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,3cb9494c-4d70-4ebd-98ec-0e28021c1fee,7/29/2011,1,i.e.,is approximately 1%,,,
supply,4babe1c2-15f2-40af-b326-b256507a921c,7/30/2010,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,4babe1c2-15f2-40af-b326-b256507a921c,7/30/2010,2,CABG,“coronary artery bypass graft,,,
supply,4babe1c2-15f2-40af-b326-b256507a921c,7/30/2010,2,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,4babe1c2-15f2-40af-b326-b256507a921c,7/30/2010,2,NSAIDs,non-steroidal anti-inflammatory drugs,,,
supply,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,Vial,vial,,,
supply,a2360c52-f2b3-43c6-8485-292d828a7488,6/9/2006,1,2 mg/mL,follows:200 mg/100 mL,,,
supply,14710a71-e2e9-4e4e-bd65-1c296f70c166,12/8/2009,5,HDPE,high-density polyethylene,,,
supply,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,CAPOZIDE®,captopril and hydrochlorothiazide tablets,,,
supply,86719bea-90f8-4696-ad0c-10a31967c850,6/30/2009,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,94f9e516-6bf6-4e30-8dde-8833c25c2560,1/1/2009,6,CFUs,colony forming units,,,
supply,942c2438-9fe9-4f31-9617-3c6d029154d3,10/6/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,DE3C370C-7247-4260-8C6B-C0C35EB6F9BA,10/12/2007,2,Codeine,codeine phosphate,,,
supply,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,NCEP,National Cholesterol Education Program,,,
supply,b60c9c82-e5c7-4e05-98c7-5bbba4af04b2,7/21/2010,2,PE,phenytoin sodium                                             equivalent units,,,
supply,58860ee1-5a9d-4422-b9bc-78e8b7958b53,3/2/2010,1,CFCs,chlorofluorocarbons,,,
supply,596c7a8f-27cd-4de2-9491-476f43570b8b,5/17/2007,1,atropine,Atropine Injection,,,
supply,9b8ea543-1de8-472f-9666-34f99ca2f183,2/27/2006,1,AMPHOTEC®,Amphotericin B,,,
supply,830a28fb-9b80-4fbb-99dc-56ec80e4e581,8/14/2007,1,E®,emollient cream,,,
supply,87d5a720-f154-4c4b-b2d4-0ae58455dda0,3/31/2011,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,87d5a720-f154-4c4b-b2d4-0ae58455dda0,3/31/2011,2,NSAIDs,Non- Steroidal Anti-Inflammatory Drugs,,,
supply,87d5a720-f154-4c4b-b2d4-0ae58455dda0,3/31/2011,2,CABG,“coronary artery bypass graft,,,
supply,87d5a720-f154-4c4b-b2d4-0ae58455dda0,3/31/2011,2,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,thiamine,Thiamine Mononitrate,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,niacin,Niacinaminde,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,folic acid,Folic Acid,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,magnesium,Magnesium Sulfate,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,pyridoxine,Pyridoxine Hydrochloride,,,
supply,bae7d458-01ce-423a-acae-40a834057103,6/1/2012,2,riboflavin,Riboflavin,,,
supply,77104557-087c-4bc5-9bea-521843b83e07,12/31/2006,1,CFC's,chlorofluorocarbons,,,
supply,2DA604EA-01C4-44F3-852F-E6E55F140360,3/30/2007,1,5 mL,0.5 gm sulfisoxazole per teaspoonful,,,
supply,a22565c1-fe03-4cd4-bb9c-f65b5fe3c194,3/14/2011,2,LDPE,low density polyethylene,,,
supply,1ab87313-f82a-4819-9e32-f1320a747fef,1/28/2011,2,EOS,end of synthesis,,,
supply,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,EPA,Environmental Protection Agency,,,
supply,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,CFC's,chlorofluorocarbons,,,
supply,6b10c3ff-7cd9-4a59-9436-d2c6a64e4a69,6/7/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,9720518e-9f70-4811-84ca-69a526d8a904,1/9/2012,1,MAOI,monoamine oxidase inhibitor,,,
supply,3E28CF99-2B70-4FD7-7988-A808DFAC54C4,8/28/2007,2,NIOSH,National Institute for Occupational Safety and Health Administration,,,
supply,e35aa027-aef2-485d-927c-ab350f51f977,2/16/2006,1,MEXITIL,mexiletine hydrochloride,,,
supply,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,5bc7eccb-f0f7-4242-9c32-574182804e44,11/8/2011,3105,CABG,“coronary artery bypass graft,,,
supply,0fcdbdb5-4b27-4ef8-aa1c-b72d355def41,2/1/2010,1,ADHD,Attention-Deficit Hyperactivity Disorder,,,
supply,545776FE-63DF-44AB-ACE3-F3D73D2E0092,5/11/2006,1,FLUOR-OP,fluorometholone ophthalmic suspension,,,
supply,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,EPA's,Environmental Protection Agency's,,,
supply,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,CFCs,chlorofluorocarbons,,,
supply,f35e3310-0246-446a-aabe-c17f9000ce26,10/6/2006,1,EPA’s,Environmental Protection Agency’s,,,
supply,f35e3310-0246-446a-aabe-c17f9000ce26,10/6/2006,1,CFCs,chlorofluorocarbons,,,
supply,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,Vial,vial,,,
supply,4021a77c-36ad-4f3a-bb4b-b44de96173b2,12/8/2009,1,HDPE,high-density polyethylene,,,
supply,1cfbda56-d700-4049-8a51-e24af8a622c4,9/8/2011,1,PSA,Prostate-Specific Antigen,,,
supply,312042cf-df60-4dc5-90dd-4e77ebd4a781,10/17/2006,1,ENLON,edrophonium chloride injection,,,
supply,a585baa1-78b4-4d13-8b15-03144d402f98,1/12/2011,2,LEVONEST™,levonorgestrel and ethinyl estradiol tablets—triphasic regimen,,,
supply,4dec1dbd-c63b-4a1b-81cb-c8d29696cc40,8/25/2009,2,Injection,injection] aqueous,,,
supply,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox®,ceftizoxime for injection,,,
supply,9bca4410-32a6-4e1e-af7a-23f372e778c2,3/12/2007,1,EPA,Environmental Protection Agency,,,
supply,5e2dbda9-aceb-4bfb-9c3f-e7b6118f580c,10/27/2009,1,OND,ondansetron,,,
supply,244DA533-0B72-4015-37B0-A16744490B28,6/12/2008,2,EPA's,Environmental Protection Agency's,,,
supply,244DA533-0B72-4015-37B0-A16744490B28,6/12/2008,2,CFCs,chlorofluorocarbons,,,
supply,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,2.5 mg/mL,25 mg/10 mL,,,
supply,0527eaca-7774-42de-aeca-bb23f05fbe02,3/1/2007,1,HIPS,high impact polystyrene,,,
supply,0fab6e05-729f-4675-b74b-58964c27a84d,4/14/2006,1,HIPS,high impact polystyrene,,,
supply,Lf69f100f-c766-490f-9143-5e8e0c8cb7c9,9/14/2007,1,LDPE,low density polyethylene,,,
supply,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,6mg/mL,6 mg/mL for intravenous use.NDC 67286-0054-2            10mL,,,
supply,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,TROVAN,trovafloxacin mesylate,,,
supply,895c7f90-2c53-43c3-ae4d-31d858e11eff,3/16/2007,1,PR,Pharma,,,
supply,701b69d8-cce8-42de-a770-96020c1a870a,8/1/2011,8,bottle,bottles of 100 and 500 100’s,,,
supply,a1566fe7-4ffb-49c9-a24b-c70b39fe7eaf,10/9/2009,1,PE,phenytoin sodium equivalent units,,,
supply,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,CRC,Child Resistant Control,,,
supply,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl liposome injection,,,
supply,688fa1d0-6e17-4191-8618-8f62bc7765d3,6/1/2009,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,da52e74a-1baf-4a33-a068-b49176700320,6/1/2012,1,GREPCO,Group for Epidemiology and Prevention of Cholelithiasis,,,
supply,ab1cbed4-50c4-4769-9947-1927333f278c,10/16/2009,1,EXP,expiration,,,
supply,07315965-0be6-4c18-a8b9-25821a3732e2,10/26/2006,1,CFC's,chlorofluorocarbons,,,
supply,0e996cf8-6975-452a-a84c-ca1033a629b1,5/28/2007,1,CFCs,chlorofluorocarbons,,,
supply,EC09AB1C-52FA-4F41-BF65-A632DCE8F097,3/31/2007,1,Ismo®,isosorbide mononitrate,,,
supply,5f411d45-7836-43b2-bf0e-a524b0b626f1,4/15/2009,2,LDPE,low density polyethylene,,,
supply,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,PE,phenytoin sodium equivalent units,,,
supply,1a10952e-0662-4f2c-bd02-28dd4eee138f,10/4/2010,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,EOS,end of synthesis,,,
supply,93d73c30-f90d-435b-a31b-036884caa7b4,10/12/2007,1,PEG,polyethylene glycol,,,
supply,e58641de-b6fd-484c-8902-b9262d7ce251,9/27/2010,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,e11652b8-6ce6-4366-9519-a43a0d36f235,1/13/2011,1,SLE,systemic lupus erythematosus,,,
supply,68d4eeed-2501-494b-b979-502720de86c0,7/12/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,5B555346-57CD-44BB-8A60-BF7124B62C30,5/11/2006,1,HDPE,high density polyethylene,,,
supply,23688476-d9ee-4df6-a2cc-73594ab22066,2/28/2007,3,Ethiodol,ethiodized oil for injection,,,
supply,0d02b3a0-4de3-473b-8ed9-a1974747970f,6/13/2006,1,USA,use.Caution: Federal,,,
supply,23b73332-cbb3-4155-8ad8-b24619cdea85,4/4/2012,1,mg/mL,mg of anhydrous tacrolimus per mL,,,
supply,7179a2e5-f2e5-4b68-9ea6-92d0f680f1a7,5/14/2010,2,LDPE,low density polyethylene,,,
supply,ADD7FCAF-46CA-48CB-AC8D-0D9CF10CE1CD,5/22/2009,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,97b051b0-65e1-4797-b72d-96f7ac623d1d,10/13/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,c84cda13-e2fb-46d6-a9a2-5a3311387ff8,7/13/2011,4,2.5 mg/mL,25 mg/10 mL,,,
supply,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,ARB,angiotensin receptor blocker,,,
supply,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,Lupus,lupus erythematosus,,,
supply,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
supply,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,LVH,left ventricular hypertrophy,,,
supply,5ad9b285-4963-47fc-9b48-7e46b83aaa84,2/20/2012,1,LVH,Left Ventricular Hypertrophy,,,
supply,1e99efc7-cf3f-4368-7afb-41d8dfaeffcf,1/13/2011,6,MRHD,maximum recommended human dose,,,
supply,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
supply,f15b043d-fcfa-4ade-a3da-76700c0c5c2a,12/28/2010,1,mg/mL,mg of anhydrous tacrolimus per mL,,,
supply,53EDA85C-65CD-4D6C-B4B7-EB3AE2942ED0,3/30/2007,2,Injection;,Injection USP 3%,,,
supply,ea3eb74a-63b0-40cc-9d32-f37d881a2b88,7/1/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,d8b9d517-5dd4-4c6b-8aa0-736bce87e7b4,7/12/2010,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,MITT,modified Intent-to-Treat,,,
supply,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,cure,clinical success rate,,,
supply,5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d,1/27/2012,16,AECB,acute exacerbation of chronic bronchitis,,,
supply,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,EOS,end of synthesis,,,
supply,b4219281-d79f-45ac-86dd-82c399415032,1/9/2012,1,MAOI,monoamine oxidase inhibitor,,,
supply,394d3238-f763-4f67-bb9d-08751ec6ed31,1/4/2006,1,CFC's,chlorofluorocarbons,,,
supply,6f50bddb-e90d-4a2b-8716-9c1b84f5a22f,6/23/2010,325,NSAIDs,Non-Steroidal  Anti-Inflammatory Drugs,,,
supply,fbe6d514-9d89-48f7-80a0-d1b41983f203,3/10/2006,1,EPA's,Environmental Protection Agency's,,,
supply,fbe6d514-9d89-48f7-80a0-d1b41983f203,3/10/2006,1,CFC's,chlorofluorocarbons,,,
supply,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,1 mg/mL,10 mg/10 mL vial,,,
supply,2B1B7B5F-2F20-418C-B1AC-794C2EF1CE5E,5/24/2007,1,1 mg/mL,1 mg of donepezil hydrochloride in each mL,,,
supply,20b33290-a1fb-499a-86c8-bdf82f1f6ad7,8/7/2006,1,PR,Pharma,,,
supply,a57b897e-0cbe-4ac3-969f-b00357a0cfa8,3/31/2011,2,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
supply,a57b897e-0cbe-4ac3-969f-b00357a0cfa8,3/31/2011,2,NSAIDs,Non- Steroidal Anti-Inflammatory Drugs,,,
supply,a57b897e-0cbe-4ac3-969f-b00357a0cfa8,3/31/2011,2,CABG,“coronary artery bypass graft,,,
supply,a57b897e-0cbe-4ac3-969f-b00357a0cfa8,3/31/2011,2,NSAID,Non-Steroidal Anti-Inflammatory Drug,,,
supply,a4d91839-eefa-44dc-8162-eb4f8bd426a2,3/6/2012,6,MAOI,monoamine oxidase inhibitor,,,
supply,9d71d7fd-2b25-4163-922f-018ed8c5171f,2/20/2007,1,FML-S®,fluorometholone and sulfacetamide sodium  ophthalmic suspension,,,
supply,9d71d7fd-2b25-4163-922f-018ed8c5171f,2/20/2007,1,HIPS,high impact polystyrene,,,
supply,cf6676ff-1122-4495-b64d-f70771a09633,1/22/2010,1,HDPE,high-density polyethylene,,,
supply,6f4af312-ad59-412b-ba67-c5e3e91f90a3,5/15/2006,1,PR,Pharma,,,
supply,5542fe40-8ae1-421a-b861-6f66f8b7f675,8/21/2006,1,Codeprex,codeine polistirex and chlorpheniramine polistirex,,,
inactiveIngredients,70eda21e-e566-42f4-9a49-b0d3ad000652,4/12/2012,17,camphor,Camphora,,,
inactiveIngredients,3b75b7fb-62aa-4210-941f-b15589037141,5/9/2012,1,Basil,Basilicum,,,
inactiveIngredients,87062265-a8a3-4f33-b915-940f7cc453c7,6/11/2012,1,Jasmine,Jasminum Officinale,,,
inactiveIngredients,447d4945-4edf-44ce-8ee7-0edd750986dc,6/7/2012,1,JASMINE,JASMINUM OFFICINALE,,,
inactiveIngredients,51976520-5011-46cc-95b4-364fcba62493,6/7/2012,1,Jasmine,Jasminum Officinale,,,
indication,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,OHSS,Ovarian Hyperstimulation Syndrome,,,
indication,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,ARDS,Adult Respiratory Distress Syndrome,,,
indication,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,OHSS,ovarian hyperstimulation syndrome,,,
indication,4ddaae99-05e1-e05c-e63c-0c58965d157d,8/1/2008,4,HDN,Hemolytic Disease of the Newborn,,,
indication,ABF83FA7-E6E4-421E-940E-F6FEC0F1BDF5,1/21/2009,1,kg,kilograms,,,
indication,ABF83FA7-E6E4-421E-940E-F6FEC0F1BDF5,1/21/2009,1,BMI,Body Mass Index,,,
indication,b5349a88-9275-489e-8c71-2bd22eb9e520,11/4/2010,69,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PAF,paroxysmal atrial fibrillation/flutter,,,
indication,b764c8b8-7e23-4016-830f-68312d84f3d3,1/12/2006,1,PSVT,paroxysmal supraventricular tachycardias,,,
indication,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,OCD,obsessive-compulsive disorder,,,
indication,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,HEC,highly emetogenic cancer chemotherapy,,,
indication,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,PONV,Postoperative Nausea and Vomiting,,,
indication,ec44482e-6194-4829-a3f7-ebe8d48a41a5,2/23/2012,1,MEC,moderately emetogenic cancer chemotherapy,,,
indication,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,RA,rheumatoid arthritis,,,
indication,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,DMARDs,disease modifying anti-rheumatic drugs,,,
indication,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,OCD,obsessive compulsive disorder,,,
indication,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders - 3rd edition,,,
indication,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,Total-C,total cholesterol,,,
indication,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,NCEP,National Cholesterol Education Program,,,
indication,b1a6939e-8d77-449d-b55f-0fd9a500352a,10/15/2010,1,MINOCIN®,minocycline hydrochloride,,,
indication,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,DSM,Diagnostic and Statistical Manual,,,
indication,8e8612cd-9f21-4348-a06c-ca7ea151f848,8/23/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,3fe3b576-567d-4589-9d4c-620b834b8746,2/4/2011,2126,CAD,Coronary Artery Disease,,,
indication,f8bb3384-355a-45fa-ad59-b7402a9f5533,3/22/2007,1,BPH,Benign Prostatic Hyperplasia,,,
indication,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,OCD,Obsessive Compulsive Disorder,,,
indication,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,DPN,diabetic peripheral neuropathy,,,
indication,0a9d7dab-527d-429f-8590-16a32737fd58,12/31/2010,2,PHN,Post herpetic neuralgia,,,
indication,caf7c3af-8256-4557-af40-e8143e9af9f1,3/12/2012,4,NCEP,National Cholesterol Education Program,,,
indication,4e07acff-27c2-4f5a-9d12-c9598496e9a0,11/19/2008,2,ART,Assisted Reproductive Technology,,,
indication,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,DPN,diabetic peripheral neuropathy,,,
indication,ba5d931f-5341-44cf-979c-a3df4f3cae3a,2/6/2012,3535,PHN,Post herpetic neuralgia,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,Apo B,apolipoprotein B,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,HDL-C,high-density lipoprotein cholesterol,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,CVD,cardiovascular disease,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,LDL-C,low-density lipoprotein                 cholesterol,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,i.e.,is elevation of chylomicrons,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,total-C,total cholesterol,,,
indication,a893d609-a538-4922-98c0-f6089da66149,9/21/2010,41,TG,triglycerides,,,
indication,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,DSM,Diagnostic and Statistical Manual,,,
indication,ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,2/27/2012,2,PET,Positron Emission Tomography,,,
indication,78E738D9-9C13-4FBD-BFFA-77B003CDADAC,8/7/2006,1,HIV,human immunodeficiency virus,,,
indication,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,MAC,monitored anesthesia care,,,
indication,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,GERD,Gastroesophageal Reflux Disease,,,
indication,83a0bb34-405b-4aea-9557-4f8b8fd811d7,6/7/2010,1,e.g.,esophagitis or GERD symptoms,,,
indication,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,Total-C,total cholesterol,,,
indication,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,NCEP,National Cholesterol Education Program,,,
indication,1109ac28-47eb-4dc7-8abc-8bc1f19b25eb,6/8/2011,1,i.e.,in the study cited,,,
indication,9f4b181e-2675-40c6-a3d7-a8fe671230c1,1/31/2012,2,COPD,chronic obstructive pulmonary disease,,,
indication,9f4b181e-2675-40c6-a3d7-a8fe671230c1,1/31/2012,2,PCP,Pneumocystis carinii pneumonia,,,
indication,eda64039-771b-41d7-b9c4-970cfbf5fbb9,1/3/2012,2,GERD,Gastroesophageal Reflux Disease,,,
indication,d970b074-957a-4036-92d3-1712386f3858,2/19/2010,1,eg,esophagitis or GERD symptoms,,,
indication,c3d849eb-7fed-4bac-9fb6-0684094d8dfb,7/25/2011,1,i.e.,is elevation of chylomicrons,,,
indication,ac66be47-babc-41eb-b259-03a7020cec23,5/16/2012,1,MAC,Mycobacterium avium complex,,,
indication,fc19a22c-2c39-4174-ba9a-c95ff4388d89,12/7/2011,1,HIV,human immunodeficiency virus,,,
indication,53522b35-6215-4e9c-b51d-8b81728e0817,11/1/2010,1,Injection,injectable suspension,,,
indication,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,OCD,Obsessive Compulsive Disorder,,,
indication,058b94d0-9811-4dd2-a28d-377a26e5e6f8,12/21/2011,6,NCEP,National Cholesterol Education Program,,,
indication,69b514f7-7f0c-4954-ba67-64770959d984,9/20/2011,1,TG,triglycerides,,,
indication,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,BPH,benign prostatic hyperplasia,,,
indication,830a28fb-9b80-4fbb-99dc-56ec80e4e581,8/14/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
indication,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,IT,intrathecal,,,
indication,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,GAD,Generalized Anxiety Disorder,,,
indication,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,OCD,obsessive compulsive disorder,,,
indication,4E9A1841-B44D-413E-6B98-C33C25095BA1,12/22/2006,1,i.e.,INFECTIONS,,,
indication,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,PNH,Paroxysmal Nocturnal Hemoglobinuria,,,
indication,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,TMA,thrombotic microangiopathy,,,
indication,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,5/29/2012,4,STEC-HUS,Shiga toxin E. coli related hemolytic uremic syndrome,,,
indication,d3620ebe-87e1-4a93-96cc-ff20ddbb30b2,12/13/2011,1,NCEP,National Cholesterol Education Program,,,
indication,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,CLL,chronic lymphocytic leukemia,,,
indication,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,DSM,Diagnostic and Statistical Manual,,,
indication,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,CNS,CENTRAL N E RVOUS SYSTEM,,,
indication,bd48e816-d63f-4855-baad-c02f529bdf2a,4/25/2011,2,i.e.,Infections:,,,
indication,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,IGF-1,insulin growth factor-1,,,
indication,f11b1d88-74ca-4a6d-89fb-40d0f51bca95,10/12/2007,1,GH,growth hormone,,,
indication,b961e6cc-4956-405f-9e53-b55604be23f6,10/31/2011,8,BMI,BODY MASS INDEX,,,
indication,65314bad-fcc2-4e6d-b4ea-2684b7e212c5,6/30/2011,1,CDC,Center for Disease Control,,,
indication,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,MAC,Mycobacterium avium complex,,,
indication,37A18BD1-034F-4366-8323-EC4E1C52AC1E,7/21/2007,1,NIDDM,non-insulin-dependent diabetes mellitus,,,
indication,57ecf637-0e47-4364-b5aa-5b22f865003d,5/12/2011,2,GAD,Generalized Anxiety Disorder,,,
indication,7e7a04d3-c010-4416-932a-0a7857f6b00c,7/23/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
indication,4bc249f2-7e8b-05cb-38ad-3085e947e0f1,11/18/2011,9,HIV,human immunodeficiency virus,,,
indication,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,OCD,Obsessive Compulsive Disorder,,,
indication,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,DSM,Diagnostic and Statistical Manual,,,
indication,295ac292-7b78-437b-9da0-98e02aaed215,11/10/2010,77,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,3fd6b3a8-b17b-4b98-ad03-a8af7b6f3368,3/7/2012,5,kg,kilograms,,,
indication,3fd6b3a8-b17b-4b98-ad03-a8af7b6f3368,3/7/2012,5,BMI,BODY MASS INDEX,,,
indication,3fd6b3a8-b17b-4b98-ad03-a8af7b6f3368,3/7/2012,5,BMI,Body Mass Index,,,
indication,3fd6b3a8-b17b-4b98-ad03-a8af7b6f3368,3/7/2012,5,BMI,body mass index,,,
indication,4e936802-5b5d-4772-8b1d-4f30867ffa59,4/24/2012,2,FMF,Familial Mediterranean fever,,,
indication,4e936802-5b5d-4772-8b1d-4f30867ffa59,4/24/2012,2,FMF,familial Mediterranean fever,,,
indication,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,Children,clarithromycin immediate-release tablets and clarithromycin for oral suspension,,,
indication,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,Mycobacterium avium complex,,,
indication,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,MAC,infection.Mycobacterium avium complex,,,
indication,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,non-HDL-C,non-high-density lipoprotein cholesterol,,,
indication,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme  A,,,
indication,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,HoFH,homozygous familial  hypercholesterolemia,,,
indication,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,HoFH,Homozygous Familial Hypercholesterolemia,,,
indication,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,8743e5fd-babe-404b-b072-517723e77700,12/8/2011,1,i.e.,is elevation of chylomicrons,,,
indication,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,DSM,Diagnostic and Statistical Manual,,,
indication,15b91de7-1954-4055-aef6-fb57d8568a80,7/12/2012,1,e.g.,esophagitis or GERD symptoms,,,
indication,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,MI,myocardial infarction,,,
indication,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,UA,[unstable angina,,,
indication,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,NSTEMI,/non-ST-elevation myocardial infarction,,,
indication,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,ACS,Acute Coronary Syndrome,,,
indication,3d021d9b-c0b8-41a3-a99b-37f50d2a20ae,5/3/2012,1,STEMI,ST-elevation myocardial infarction,,,
indication,F764D619-D2DD-4081-8467-DD2EC2AC68C3,1/24/2008,4,DOXIL,doxorubicin HCl  liposome injection,,,
indication,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,BPH,Benign Prostatic Hyperplasia,,,
indication,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,CLL,chronic lymphocytic leukemia,,,
indication,ec04ecbb-2896-3feb-85fd-a64aba93b289,8/1/2011,8,Injection,injectable suspension,,,
indication,58af2ab3-fc28-4cec-b2ff-06c30b3c1da0,6/21/2012,1,JASMINE,JASMINUM OFFICINALE,,,
indication,704dcc0f-a20d-4d92-b338-cc478d5ae895,10/14/2009,2,HPA,hypothalamic-pituitary-adrenal,,,
indication,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,MI,myocardial infarction,,,
indication,3b1f8ee3-d582-4faa-a7f2-0fbc45721298,7/13/2011,1,HAI,Histologic Activity Index,,,
indication,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,OHSS,Ovarian Hyperstimulation Syndrome,,,
indication,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,ARDS,Adult Respiratory Distress Syndrome,,,
indication,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,OHSS,ovarian hyperstimulation syndrome,,,
indication,90f0c351-3977-2b84-0a6a-e9cb091430ca,8/1/2008,5,HDN,Hemolytic Disease of the Newborn,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,LDL-C,low-density lipoprotein cholesterol,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,Apo B,apolipoprotein B,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,HDL-C,high-density lipoprotein cholesterol,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,CVD,cardiovascular disease,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,i.e.,is elevation of chylomicrons,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,total-C,total cholesterol,,,
indication,fdbfe194-b845-42c5-bb87-a48118bc72e7,6/11/2012,18,TG,triglycerides,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,BMT,bone marrow transplantation,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,ALL,acute lymphoblastic leukemia,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,ANLL,acute non-lymphocytic leukemia,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,AML,acute myelogenous leukemia,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,NHL,non-Hodgkin's lymphoma,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,CBC,complete blood count,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,MOF,multiple organ failure,,,
indication,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,FAB,French-American-British,,,
indication,3451ced4-f2a3-476e-a279-b96c8c3f0acf,12/15/2010,145,GAD,Generalized Anxiety  Disorder,,,
indication,ff4941b3-9901-4aab-adcf-c5327bede34e,1/26/2011,1,mmol/L,monoxide associated with smoke inhalation also contributes to lactic acidemia,,,
indication,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,VLDL,very low-density lipoprotein,,,
indication,E177C228-33E1-4074-3E98-7D484C370E58,10/31/2007,4,AIDS,acquired immunodeficiency syndrome,,,
indication,159B5FAC-255C-4A22-98AD-891ABA73EAE1,11/24/2006,1,GERD,gastroesophageal reflux disease,,,
indication,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,GAD,Generalized Anxiety Disorder,,,
indication,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,OCD,obsessive compulsive disorder,,,
indication,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,OTPs,Opioid Treatment Programs,,,
indication,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,DEA,Drug Enforcement Administration,,,
indication,ad94cde9-4f4d-438a-bb95-d4350be8653b,4/13/2011,1,VLDL,very low density lipoprotein,,,
indication,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,OCD,Obsessive Compulsive Disorder,,,
indication,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,GAD,Generalized Anxiety Disorder,,,
indication,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,OCD,obsessive compulsive disorder,,,
indication,cf4d2e56-eb0d-43c9-b44b-764381a23326,7/16/2008,1,autoimmune,adults Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Secondary thrombocytopenia in adults Acquired,,,
indication,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,VLDL,very low density lipoprotein,,,
indication,6FE11357-7165-4C8B-BE0A-42C277A12BF9,1/29/2009,2,PPAR?,peroxisome proliferator receptor alpha,,,
indication,8E4710A7-8757-49BE-8BEC-A1DC39E6C695,1/22/2007,1,DCIS,Ductal Carcinoma in Situ,,,
indication,93f5f759-1487-42c5-82e9-aeed03e4014a,10/25/2007,1,DCCT,Diabetes Control and Complications Trial,,,
indication,2BD8C04F-491C-4269-9281-642EFA05A7C8,4/16/2008,1,AIDS,acquired immunodeficiency syndrome,,,
indication,19a44450-d690-4ec9-9052-59096ff3e803,7/19/2006,1,kg,kilograms,,,
indication,19a44450-d690-4ec9-9052-59096ff3e803,7/19/2006,1,BMI,Body Mass Index,,,
indication,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,OCD,Obsessive Compulsive Disorder,,,
indication,33eb5ae0-2867-4bf4-af34-f4bf7946423b,9/23/2011,1,NCEP,National Cholesterol Education Program,,,
indication,220cd180-8a71-4530-b8ca-8864bee9caa0,1/27/2012,3,TURP,transurethral resection of the prostate,,,
indication,F4216772-6C37-4FF0-A575-F758390656E3,9/23/2008,3,PONV,postoperative nausea and vomiting,,,
indication,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,i.e.,in the study cited,,,
indication,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
indication,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,MDD,major depressive disorder,,,
indication,F5FDDA24-DA7D-4E61-936E-9D1A55056B82,9/11/2006,1,NSCLC,non-small-cell lung cancer,,,
indication,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PMDD,Premenstrual Dysphoric Disorder,,,
indication,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PTSD,Posttraumatic Stress Disorder,,,
indication,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,OCD,obsessive-compulsive disorder,,,
indication,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PMDD,premenstrual dysphoric disorder,,,
indication,8920d813-dc88-456d-8607-47a0156a4b4b,9/6/2011,2,HIV,human immunodeficiency virus,,,
indication,ad14d292-6b01-4d5c-bb90-a5dde44ccb1c,12/15/2010,147,GAD,Generalized Anxiety  Disorder,,,
indication,A719EC72-771F-49C9-B93D-9D5F585176A4,8/7/2006,1,CDC,Center for Disease Control,,,
indication,8fe7a7f5-289d-4546-8d08-33dd0664c5f6,10/1/2009,1,MAC,Mycobacterium avium complex,,,
indication,8fe7a7f5-289d-4546-8d08-33dd0664c5f6,10/1/2009,1,MAC,Mycobacterium  avium complex,,,
indication,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,RLS,Restless Legs Syndrome,,,
indication,b6f298ba-2d7e-4a3c-9edb-8b60aba716d6,1/19/2012,7,CAD,Coronary Artery Disease,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,LDL-C,low-density lipoprotein cholesterol,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,HDL-C,high-density lipoprotein cholesterol,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,CHD,coronary heart disease,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,CVD,cardiovascular disease,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,Apo B,apolipoprotein B,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,i.e.,is elevation of chylomicrons,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,total-C,total cholesterol,,,
indication,0376351b-f1a0-43e5-a0b4-533072c49f39,6/22/2012,4,TG,triglycerides,,,
indication,5fa6a683-9685-4591-bd00-19f15c9bcf12,1/23/2008,1,Solution,solution,,,
indication,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,FM,fibromyalgia,,,
indication,d19c57bd-56f8-4640-b891-18f9c365e372,4/23/2012,6,HIV,human immunodeficiency virus,,,
indication,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,OCD,obsessive compulsive disorder,,,
indication,97a9dfe0-4c36-4733-aa06-c2cd2a1f1ca6,9/13/2011,1,HAI,Histologic Activity Index,,,
indication,b72c98da-f1b3-44d4-b8a6-b9324b3e2e10,11/30/2011,1,TG,triglycerides,,,
indication,af1fef85-fb8e-478d-999a-5a8adc42baa3,2/1/2011,4,HSV,herpes simplex virus,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,Apo B,apolipoprotein B,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,CVD,cardiovascular disease,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,i.e.,is elevation of chylomicrons,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,total-C,total cholesterol,,,
indication,330e35ed-fd6b-4123-864a-a5aa339c24d6,12/27/2011,1,TG,triglycerides,,,
indication,bcac6719-ad8c-e4a5-c32a-af1c0511c591,3/19/2012,2,BMD,bone mineral density,,,
indication,1c1b1efe-735d-4ddb-aafe-ff1ece78ecc4,4/13/2011,7,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,8c1d8b73-299f-4a17-8511-00865b61d201,11/17/2011,1,TG,triglycerides,,,
indication,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,DCCT,Diabetes Control and Complications Trial,,,
indication,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox,ceftizoxime for injection,,,
indication,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,AED,antiepileptic drug,,,
indication,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,VTE,venous thromboembolism,,,
indication,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,DVT,deep vein thrombosis,,,
indication,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,PE,pulmonary embolism,,,
indication,AC196FF5-9215-402B-BC57-69AA87F8BADE,10/2/2008,1,e.g.,emptying,,,
indication,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,d742707b-4c17-4b08-a9d0-491ba2bf6415,12/15/2010,3,BPH,benign prostatic hyperplasia,,,
indication,b989cb92-dbe5-4325-bcd3-43fe8a5f13b7,10/10/2010,46,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,10a7ba02-42d6-4cae-8904-b256e2da5496,8/6/2009,5,HoFH,homozygous familial  hypercholesterolemia,,,
indication,2caaf94b-b382-4573-8614-57815776b659,2/17/2010,4,GERD,Gastroesophageal Reflux Disease,,,
indication,6982a931-15b8-482a-bfe0-05d61f37b462,6/17/2011,1,NCEP,National Cholesterol Education Program,,,
indication,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,VWD,von Willebrand disease,,,
indication,c5f4b63b-8d8b-45b3-b530-2f1c32a1b852,1/14/2010,4,VWD,1.2,,,
indication,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,LGS,Lennox-Gastaut syndrome,,,
indication,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
indication,7f731d62-736d-4df6-9592-98caed4fe5b4,10/12/2007,1,CT,computed tomography,,,
indication,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,ICU,Intensive Care Unit,,,
indication,C0403897-79F5-4086-94B7-56C0CB7EE65C,8/4/2007,3,MAC,monitored anesthesia care,,,
indication,56c130d1-7581-4152-99a2-0014ee9366c0,6/30/2012,1,FMF,Familial Mediterranean fever,,,
indication,56c130d1-7581-4152-99a2-0014ee9366c0,6/30/2012,1,FMF,familial Mediterranean fever,,,
indication,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,MAC,Mycobacterium avium complex,,,
indication,50972F39-A15B-4C90-B9E6-CF7F76CD6E99,10/9/2006,1,plague,potentially toxic agents.a.Pasteurella pestis,,,
indication,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,OCD,Obsessive Compulsive Disorder,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,LDL-C,low-density lipoprotein cholesterol,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,Apo B,apolipoprotein B,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,HDL-C,high-density lipoprotein cholesterol,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,CVD,cardiovascular disease,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,i.e.,is elevation of chylomicrons,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,total-C,total cholesterol,,,
indication,9f89e53e-a8fb-4ba7-a26d-21a962abcb1b,2/14/2012,6,TG,triglycerides,,,
indication,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,TG,triglycerides,,,
indication,F1569CD1-A0E9-409E-911A-5CB8739C7410,4/5/2007,1,DCIS,Ductal Carcinoma in Situ,,,
indication,3636a53b-caaf-4af9-8105-9a27ec7473c4,8/16/2010,1,MINOCIN®,minocycline,,,
indication,A188664A-8FA1-479F-9493-0DA4A6C592F7,10/3/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
indication,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,OCD,obsessive-compulsive disorder,,,
indication,ab2edabd-e57d-4754-9822-93bd17af9e88,6/14/2007,2,PSVT,paroxysmal supraventricular tachycardia,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,DPNP,Diabetic Peripheral Neuropathic Pain,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,FM,Fibromyalgia,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,FM,fibromyalgia,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,MDD,major depressive disorder,,,
indication,7db112de-473a-4407-bc1c-35d0ab748700,7/22/2011,1,CLBP,chronic low back pain,,,
indication,A1CD682A-FA73-491D-B276-8C96D801B083,12/31/2006,1,moniliasis,MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis,,,
indication,e185959e-d360-4ecc-8690-e62256f696cd,5/1/2012,1,HIV,human immunodeficiency virus,,,
indication,e496494b-f70c-4a82-b661-ddfca28be580,10/24/2011,1,NCEP,National Cholesterol Education Program,,,
indication,72ddd1c9-ddbd-4c95-acd9-003189a353a3,10/23/2006,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
indication,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,OCD,Obsessive Compulsive Disorder,,,
indication,4f4a726a-8ac1-4a37-89ec-da1406784195,2/1/2010,1,kg,kilograms,,,
indication,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,OTPs,opioid treatment programs,,,
indication,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,DEA,Drug Enforcement Administration,,,
indication,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,7a83e68b-0c37-4e1a-9648-ce21fb4aff00,8/8/2006,1,COPD,chronic obstructive pulmonary disease,,,
indication,7a83e68b-0c37-4e1a-9648-ce21fb4aff00,8/8/2006,1,PCP,Pneumocystis carinii pneumonia,,,
indication,4216e0ce-e3c4-4cd7-9321-34e1a9e3d867,9/28/2011,1,HIV,human immunodeficiency virus,,,
indication,35f99f76-f2ef-4a81-91ff-285419664be3,12/6/2011,6,CHC,Chronic Hepatitis C,,,
indication,35f99f76-f2ef-4a81-91ff-285419664be3,12/6/2011,6,CHC,,,,
indication,B242CB72-957A-4701-A2B1-75D5C28C8781,3/29/2007,4,ampicillin,anaerobic bacteria resistant to some penicillin antibiotics,,,
indication,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,topiramate,TOPAMAX® in the acute treatment of migraine headache has not been studied.®,,,
indication,f5cfb61e-d971-4a9c-b9ef-4f3368fe02f5,6/12/2012,7,HSV,herpes simplex virus,,,
indication,B7E8C9FB-75BC-0A1A-4523-4C0AB400E078,9/22/2008,1,AIDS,acquired immunodeficiency syndrome,,,
indication,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,RA,rheumatoid arthritis,,,
indication,3494332D-3E3F-4EC5-82E9-38FD6107F32A,10/25/2007,1,i.e.,Infections,,,
indication,3ca226a5-b121-47d4-967f-bc2b40687dac,9/19/2011,2,CAD,1.2,,,
indication,0971fa2e-d660-48b0-9fbb-96a2db167b92,4/30/2010,1,kg,kilograms,,,
indication,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,OCD,Obsessive Compulsive Disorder,,,
indication,59de2889-c3d3-4ebf-8826-13f30a3fa439,11/18/2010,1,MDD,Major Depressive Disorder,,,
indication,28d7ba00-f824-4e55-139a-03f509c099db,1/5/2010,4,ICU,Intensive Care Unit,,,
indication,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
indication,6a6964c3-e022-43e3-a88e-45806c5faba8,5/16/2011,1,ADHD,Attention-Deficit/ Hyperactivity Disorder,,,
indication,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PTSD,Posttraumatic Stress Disorder,,,
indication,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,GAD,Generalized Anxiety Disorder,,,
indication,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,OCD,obsessive compulsive disorder,,,
indication,21d9c619-7e94-49e2-ac41-31e9ea96554a,3/14/2012,6,DOXIL,doxorubicin HCl liposome injection,,,
indication,de7f60ec-40ff-4f5f-8f72-5ff9711cc574,11/22/2010,1,MAC,Mycobacterium avium complex,,,
indication,5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7,3/15/2012,14,FMF,Familial Mediterranean fever,,,
indication,5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7,3/15/2012,14,FMF,familial Mediterranean fever,,,
indication,d7434c6c-5a26-46e0-bade-0c54d71112fc,5/3/2012,2,EIB,exercise-induced bronchoconstriction,,,
indication,23595590-cd10-4850-9d6f-d13b76726237,12/22/2011,3,PET,Positron Emission Tomography,,,
indication,665ABE12-209D-4B80-8020-EF9E3F9BDADE,5/28/2009,3,CLORPRES®,clonidine hydrochloride USP/chlorthalidone USP,,,
indication,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,i.e.,post-ictus neurological condition,,,
indication,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,BPH,Benign Prostatic Hyperplasia,,,
indication,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,OTPs,Opioid Treatment Programs,,,
indication,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,DEA,Drug Enforcement Administration,,,
indication,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,OTPs,Opioid Treatment Programs,,,
indication,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,DEA,Drug Enforcement Administration,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,AIDS,acquired immunodeficiency syndrome,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,ACTG,AIDS Clinical Trials Group,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,TMP/SMX,trimethoprim?sulfamethoxazole,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,TMTX/LV,trial comparing Neutrexin with concurrent leucovorin protection,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,PCP,contraindicated.Pneumocystis carinii pneumonia,,,
indication,AD0F8925-F817-4460-AA6B-172A043A440B,5/11/2006,1,PCP,Pneumocystis carinii pneumonia,,,
indication,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,SVR,Sustained Virologic Response,,,
indication,eee304d0-c2ea-44f4-97d9-92a414d31b6c,4/5/2011,6,CHC,chronic hepatitis C,,,
indication,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,SAMHSA,Substance Abuse and Mental Health  Services Administration,,,
indication,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,DEA,Drug Enforcement  Administration,,,
indication,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,BPH,benign prostatic hyperplasia,,,
indication,a6c0e721-2021-4983-a305-49bdf8f135a9,12/8/2008,1,S. pyogenes,Streptococcus pyogenes,,,
indication,a6c0e721-2021-4983-a305-49bdf8f135a9,12/8/2008,1,S. pyogenes,older.Streptococcus pyogenes,,,
indication,F0FC4960-8262-48E1-805C-DAE63FD045B0,3/27/2007,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
indication,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,PAF,paroxysmal atrial fibrillation/flutter,,,
indication,352d26ca-9f68-42bd-ad8c-ed647aca7009,3/28/2007,1,PSVT,paroxysmal supraventricular tachycardia,,,
indication,AE6C88E4-C6E6-4C5F-8248-F1D01D73DAB2,12/18/2008,2,BPH,Benign Prostatic Hyperplasia,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,DPNP,Diabetic Peripheral Neuropathic Pain,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,FM,Fibromyalgia,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,GAD,Generalized Anxiety Disorder,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,GAD,generalized anxiety disorder,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,FM,fibromyalgia,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,MDD,major depressive disorder,,,
indication,604b9f2f-fee6-48ef-a6c2-289bf98692b1,6/20/2012,2,CLBP,chronic low back pain,,,
indication,93285568-950e-4cdd-973e-0b714a536223,11/10/2011,3133,GAD,Generalized Anxiety Disorder,,,
indication,614401aa-cda6-4cea-88e8-11967fbdde6b,8/11/2010,2,MINOCIN®,minocycline hydrochloride,,,
indication,e498b80d-7177-4f9d-8471-2e8f913196af,11/9/2010,453,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,e498b80d-7177-4f9d-8471-2e8f913196af,11/9/2010,453,CVD,cardiovascular disease,,,
indication,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,GAD,Generalized Anxiety Disorder,,,
indication,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
indication,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,MDD,Major Depressive Disorder,,,
indication,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,OCD,obsessive compulsive disorder,,,
indication,e4a1887d-c0a8-4d18-9233-0d9c9d366807,12/7/2010,127,GAD,Generalized Anxiety Disorder,,,
indication,6d50ff09-5394-46d6-b306-f554ab8d7434,12/13/2010,140,MDD,major depressive disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,DSM-IV,DSM-IV.Social Anxiety Disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SAD,Social Anxiety Disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SAD,1.1)Social Anxiety Disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MDD,Major Depressive Disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MDD,1.2)Major Depressive Disorder,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
indication,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,MDD,major depressive disorder,,,
indication,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,GAD,Generalized Anxiety  Disorder,,,
indication,da057d69-00a3-4f65-8cc8-9f08042a95a2,12/15/2011,1,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,c857724f-b172-4844-ad42-6fa4c42b0405,1/22/2011,1,PET,Positron Emission Tomography,,,
indication,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,OCD,Obsessive Compulsive Disorder,,,
indication,a61cf5cb-351d-4b31-b731-6154a27aeb56,1/13/2012,3,HIV,human immunodeficiency virus,,,
indication,44ff9ecb-4c2b-4ac5-b2dc-5f6e83dbb2fd,7/8/2011,1,i.e.,is elevation of chylomicrons,,,
indication,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,AML,acute myeloid leukemia,,,
indication,732834F2-E21F-4630-BEA8-AC5B41C8E1DA,8/31/2007,1,FAB,French-American-British,,,
indication,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,DSM-III,Diagnostic and Statistical Manual of Mental Disorders - 3rd edition,,,
indication,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,TURP,transurethral resection of the prostate,,,
indication,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,BPH,benign prostatic hyperplasia,,,
indication,ef14e332-51ac-ea97-3542-9bc92557dbed,8/20/2010,3,ICU,Intensive Care Unit,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,LDL-C,low-density lipoprotein cholesterol,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,Apo B,apolipoprotein B,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,HDL-C,high-density lipoprotein cholesterol,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,CVD,cardiovascular disease,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,i.e.,is elevation of chylomicrons,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,total-C,total cholesterol,,,
indication,6fcd7ba3-02cd-41e9-85d5-494961155d3e,12/14/2011,2,TG,triglycerides,,,
indication,6c47a65b-2665-4391-ad69-25c4f5a8b010,2/18/2009,3,GAD,Generalized Anxiety Disorder,,,
indication,b83329ac-a65e-b3af-a3fb-c5a6c740e5e7,7/15/2011,5,e.g.,esophagitis or GERD symptoms,,,
indication,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,TURP,transurethral resection of the prostate,,,
indication,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,BPH,benign prostatic hyperplasia,,,
indication,810c8752-a7cb-0bce-777d-8539429773c2,9/9/2009,4,PI,primary humoral immunodeficiency,,,
indication,7fccca4e-fb8f-42b8-9555-8f78a5804ed3,4/10/2007,2,sBCC,superficial basal cell carcinoma,,,
indication,7fccca4e-fb8f-42b8-9555-8f78a5804ed3,4/10/2007,2,AK,actinic keratoses,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,LDL-C,low-density lipoprotein cholesterol,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,Apo B,apolipoprotein B,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,HDL-C,high-density lipoprotein cholesterol,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,CVD,cardiovascular disease,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,i.e.,is elevation of chylomicrons,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,total-C,total cholesterol,,,
indication,b3022011-4c11-7516-1f6e-ef606f5954a4,2/2/2010,6,TG,triglycerides,,,
indication,0a5ce8f7-2f8e-4944-7692-5a1c549f451a,10/12/2010,6,BMI,body mass index,,,
indication,d76a0419-05ee-437e-884c-65807aea9569,2/22/2012,11,HCTZ,hydrochlorothiazide,,,
indication,d76a0419-05ee-437e-884c-65807aea9569,2/22/2012,11,ARB,angiotensin II receptor blocker,,,
indication,d76a0419-05ee-437e-884c-65807aea9569,2/22/2012,11,Diovan,Diovan HCT is the combination tablet of valsartan,,,
indication,a1dc5b3f-0bca-461e-9018-32efcf335653,12/22/2011,2,DSM,Diagnostic and Statistical Manual,,,
indication,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,RLS,Restless Legs Syndrome,,,
indication,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,RDS,radiologic findings,,,
indication,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,RDS,Respiratory Distress Syndrome,,,
indication,b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,8/3/2007,1,ERCP,endoscopic retrograde cholangiopancreatography,,,
indication,003aee15-e811-4dae-aa8c-4381ae5a17e3,3/5/2012,1,DSM,Diagnostic and Statistical Manual,,,
indication,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,CBC,complete blood count,,,
indication,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,DSM-III,Diagnostic and Statistical Manual of Mental Disorders - 3rd edition,,,
indication,58172053-c4ea-439f-877d-926ab14eb172,10/20/2011,1,NCEP,National Cholesterol Education Program,,,
indication,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,SSRI,selective serotonin reuptake inhibitor,,,
indication,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,MDD,Major Depressive Disorder,,,
indication,fb0ff563-b87b-439b-885d-49572d3c0c12,11/22/2010,1,MAC,Mycobacterium avium complex,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,LDL-C,low-density lipoprotein cholesterol,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,HDL-C,high-density lipoprotein cholesterol,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,CHD,coronary heart disease,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,CVD,cardiovascular disease,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,Apo B,apolipoprotein B,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,i.e.,is elevation of chylomicrons,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,total-C,total cholesterol,,,
indication,324a3791-d53e-4716-89cc-9516917407cf,6/21/2012,4,TG,triglycerides,,,
indication,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,CHD,coronary heart disease,,,
indication,a9415031-0643-42f6-a162-662433fc1071,5/29/2012,6,i.e.,is elevation of chylomicrons,,,
indication,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,CNS,CENTRAL N E RVOUS SYSTEM,,,
indication,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TIA,stroke/transient ischemic attack,,,
indication,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,TG,triglycerides,,,
indication,A15D0DF0-3BCA-4FBC-A1D6-34A88C9A9665,3/30/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
indication,4ACDFA96-BD62-4289-8454-276D3886A1A7,12/13/2006,3,GERD,gastroesophageal reflux disease,,,
indication,c28c5e33-5de2-4e92-a75a-4afc7a873554,12/9/2011,3349,MAC,Mycobacterium avium complex,,,
indication,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,GERD,Gastroesophageal Reflux Disease,,,
indication,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,eg,esophagitis or GERD symptoms,,,
indication,11939A69-D373-42DF-BABB-9FB7B9C8F6CB,3/7/2007,1,COPD,chronic obstructive pulmonary disease,,,
indication,11939A69-D373-42DF-BABB-9FB7B9C8F6CB,3/7/2007,1,PCP,Pneumocystis carinii pneumonia,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,Apo B,apolipoprotein B,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,CVD,cardiovascular disease,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,i.e.,is elevation of chylomicrons,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,total-C,total cholesterol,,,
indication,ce3ac5e8-bdef-d195-e0a0-e1a982008efe,2/26/2008,1,TG,triglycerides,,,
indication,DE3C370C-7247-4260-8C6B-C0C35EB6F9BA,10/12/2007,2,Codeine,codeine phosphate,,,
indication,c83616c9-c222-4e3e-91bd-c7839406bb2a,1/11/2010,1,GERD,gastroesophageal reflux disease,,,
indication,976916CA-85FA-4099-9607-FD377E9CF319,10/25/2007,1,i.e.,Infections,,,
indication,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,VLDL,very low density lipoprotein,,,
indication,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,OCD,obsessive compulsive disorder,,,
indication,5991738a-da62-4814-b1ae-3007f62e3d01,5/14/2012,1,selenium,Selenium metallicum,,,
indication,5991738a-da62-4814-b1ae-3007f62e3d01,5/14/2012,1,formic acid,Formicum acidum,,,
indication,5991738a-da62-4814-b1ae-3007f62e3d01,5/14/2012,1,cortisone,Cortisone aceticum,,,
indication,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,e18ac1f5-4815-4123-b4c2-edfc2f73763b,7/13/2010,340,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
indication,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,OCD,obsessive compulsive disorder,,,
indication,bc62b38c-4cc9-4e64-8852-1a0be6d36d8e,8/30/2011,1,HAI,Histologic Activity Index,,,
indication,67927928-c20f-4e12-a327-d26561d7810a,3/31/2010,1,DPNP,Diabetic Peripheral Neuropathic Pain,,,
indication,67927928-c20f-4e12-a327-d26561d7810a,3/31/2010,1,FM,Fibromyalgia,,,
indication,67927928-c20f-4e12-a327-d26561d7810a,3/31/2010,1,GAD,Generalized Anxiety Disorder,,,
indication,67927928-c20f-4e12-a327-d26561d7810a,3/31/2010,1,FM,fibromyalgia,,,
indication,67927928-c20f-4e12-a327-d26561d7810a,3/31/2010,1,MDD,major depressive disorder,,,
indication,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,OCD,Obsessive Compulsive Disorder,,,
indication,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,OCD,obsessive compulsive disorder,,,
indication,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,OTPs,Opioid Treatment Programs,,,
indication,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,DEA,Drug Enforcement Administration,,,
indication,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,RLS,Restless Legs Syndrome,,,
indication,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,AED,antiepileptic drug,,,
indication,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,OCD,Obsessive Compulsive Disorder,,,
indication,f95f01c5-22f8-43c2-aaf4-0840aa256486,4/13/2011,3,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox,ceftizoxime for injection,,,
indication,564d76e0-77e9-4c87-85d7-43cbeb473485,3/22/2007,1,i.e.,in mental capacity,,,
indication,564d76e0-77e9-4c87-85d7-43cbeb473485,3/22/2007,1,SCAG,Sandoz-Clinical Assessment Geriatric,,,
indication,580da6bb-b4e8-40a3-bc21-87985d687354,9/9/2011,1,i.e.,is elevation of chylomicrons,,,
indication,3f4703c0-0b9e-41a0-8b70-da26683d9ed2,1/4/2012,4,CAD,Coronary Artery Disease,,,
indication,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,SAMHSA,Substance Abuse and Mental Health  Services Administration,,,
indication,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,DEA,Drug Enforcement  Administration,,,
indication,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,TURP,transurethral resection of the prostate,,,
indication,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,BPH,benign prostatic hyperplasia,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,HeFH, heterozygous  familial hypercholesterolemia,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,Total-C,total cholesterol,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,ApoB,apolipoprotein B,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,MI,myocardial infarction,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,CVD,cardiovascular disease,,,
indication,99cc0546-bb2d-751e-edfd-1c15a1182e0c,4/2/2012,1,TG,triglyceride,,,
indication,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,OCD,obsessive compulsive disorder,,,
indication,f1e576fc-3bce-40e2-bfba-de48e341b722,1/10/2012,1,e.g.,esophagitis or GERD symptoms,,,
indication,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,therapy.Ductal Carcinoma in Situ,,,
indication,8f642753-9e12-433c-a0bc-ab33dac41ddf,4/20/2007,1,DCIS,Ductal Carcinoma in Situ,,,
indication,ca4520ad-7f42-4632-8065-5b88a0ca7f2f,10/24/2009,1,PSVT,paroxysmal supraventricular tachycardia,,,
indication,A1DA5A84-7529-4F62-867F-808A6CAB40B8,1/1/2007,1,VLDL,very low density lipoprotein,,,
indication,d460371b-545c-4a16-b5a8-ef8d748cecb9,7/15/2011,1,i.e.,is elevation of chylomicrons,,,
indication,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,OCD,obsessive compulsive disorder,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,LDL-C,low-density lipoprotein cholesterol,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,HDL-C,high-density lipoprotein cholesterol,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,CVD,cardiovascular disease,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,Apo B,apolipoprotein B,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,i.e.,is elevation of chylomicrons,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,total-C,total cholesterol,,,
indication,c9e01766-a758-40dd-aa66-8cb24d77cd63,4/14/2011,4,TG,triglycerides,,,
indication,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,GERD,Gastroesophageal Reflux Disease,,,
indication,3660ed71-6268-4491-a4a3-4d5aeabbb489,11/4/2009,3,eg,esophagitis or GERD symptoms,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,LDL-C,low-density lipoprotein cholesterol,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,Apo B,apolipoprotein B,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,HDL-C,high-density lipoprotein cholesterol,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,CVD,cardiovascular disease,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,i.e.,is elevation of chylomicrons,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,total-C,total cholesterol,,,
indication,a0714ce3-bd46-4536-9b1e-83489c368f40,9/8/2011,4,TG,triglycerides,,,
indication,9d4fa3ac-5a6d-460c-bc89-1c83fd436e90,5/12/2010,1,VLDL,very low  density lipoprotein,,,
indication,ADB54FE50FCC4A01AFC64AA3D3DB45BB,11/7/2006,2,GERD,gastroesophageal reflux disease,,,
indication,b3ad0449-fd60-482a-9ba7-afd8f5555b83,1/13/2012,8,HIV,human immunodeficiency virus,,,
indication,8fbbd6d1-637b-4f67-897d-ab5eaeb5cc0e,9/13/2010,25,DSM-III,Diagnostic and Statistical  Manual of Mental Disorders-3rd edition,,,
indication,552ba162-76ed-4bc9-8c2c-fac7a1804da0,2/23/2012,11,TIRF,Transmucosal Immediate Release Fentanyl,,,
indication,063FA789-4570-4715-C3BD-1BAD0449FB26,1/12/2007,1,DCIS,Ductal Carcinoma in Situ,,,
indication,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,SAMHSA,Substance Abuse and Mental Health  Services Administration,,,
indication,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,DEA,Drug Enforcement  Administration,,,
indication,f341e909-6fa7-4e86-b585-182f1fffca97,12/13/2006,1,CT,computed tomography,,,
indication,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,LDL-C,low-density lipoprotein cholesterol,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,HDL-C,high-density lipoprotein cholesterol,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,CHD,coronary heart disease,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,CVD,cardiovascular disease,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,Apo B,apolipoprotein B,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,i.e.,is elevation of chylomicrons,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,total-C,total cholesterol,,,
indication,012be6a1-42eb-478c-94c2-3326c40fbe72,11/23/2011,3252,TG,triglycerides,,,
indication,AF8317D7-B280-4F40-AD88-802F99D33D78,10/29/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
indication,a7e19182-57b5-4783-9c7f-bb83961f1803,6/14/2011,3,BMI,body mass index,,,
indication,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,NCEP,National Cholesterol Education Program,,,
indication,7401068e-7e38-4c8c-8590-1eb81f0e9a1d,4/27/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
indication,79D6DEE4-5927-458D-A8AF-228328A37DB3,8/3/2007,1,ANLL,acute nonlymphocytic leukemia,,,
indication,96398ed5-ffb9-4ed4-92c1-6a9535864475,1/18/2012,2,PET,positron emission tomography,,,
indication,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,CLL,chronic lymphocytic leukemia,,,
indication,e607b0e3-e22e-429f-b40a-0567ded993a7,4/27/2011,7,GERD,gastroesophageal reflux disease,,,
indication,5a33d7f7-6a79-62df-baaa-57950e256842,2/25/2011,3,NCEP,National Cholesterol Education Program,,,
indication,909fad96-a941-443a-a39f-4f93607410fb,11/30/2009,1,CAD,Coronary Artery Disease,,,
indication,4fc5df6d-9253-409c-9c4f-26159aa651bd,2/28/2012,1,NCEP,National Cholesterol Education Program,,,
indication,d356b7bb-929e-4cc0-98f7-bcf081c9c3b6,1/12/2012,7,HIV,human immunodeficiency virus,,,
indication,4384953c-de3e-46e3-bf76-1f72aa7b1281,6/25/2012,2,TSH,thyroid stimulating hormone,,,
indication,0121363e-dcd9-4c24-940b-ea890ab762e7,7/13/2010,2037,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
indication,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,CVD,cardiovascular disease,,,
indication,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,i.e.,is elevation of chylomicrons,,,
indication,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,GERD,Gastroesophageal Reflux Disease,,,
indication,80cbc57e-d864-4c17-bd64-b5206ee55aab,2/24/2012,3,e.g.,esophagitis or GERD symptoms,,,
indication,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,8ce0eca5-c5a5-444a-b06a-5763be139949,3/30/2011,1,DSM-III,Diagnostic and Statistical Manual of Mental Disorders3rd edition,,,
indication,46e90ef7-7720-4554-9ca7-e96cac5fa529,6/21/2011,1,HIV,human immunodeficiency virus,,,
indication,08BB4884-403B-4163-BEE7-5AA40992AC4E,6/7/2006,1,HYCODAN,hydrocodone bitartrate and homatropine methylbromide,,,
indication,775d260f-cf89-4040-a76d-d8b7e262b7e4,10/5/2006,1,DSA,digital subtraction angiography,,,
indication,775d260f-cf89-4040-a76d-d8b7e262b7e4,10/5/2006,1,CT,computed tomography,,,
indication,686cd696-0011-47b2-b342-142c20169ac6,11/7/2008,1,i.e.,Infections:,,,
indication,47F221E7-A340-4FAB-F2BD-3717994C816D,5/10/2006,2,ADHD,Attention Deficit Hyperactivity Disorder,,,
indication,2215dc1d-0b5a-469e-9b51-4d7480a51078,11/16/2007,1,RTA,renal tubular acidosis,,,
indication,f3bc8ede-13a3-4119-a47a-8234c80bbc05,3/29/2010,1,GAD,Generalized Anxiety Disorder,,,
indication,62A71C8C-D92D-4122-848F-9AE35F8BBE2B,12/1/2006,1,AFIB/AFL,atrial fibrillation/atrial flutter,,,
indication,1cec7a02-b7a5-49e1-ab64-3a4dab4149d2,4/30/2012,2,CAD,Coronary Artery Disease,,,
indication,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,CBS,in:cystathionine beta-synthase,,,
indication,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,CBS,.cbl).cystathionine beta-synthase,,,
indication,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,cbl,cofactor metabolism,,,
indication,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,MTHFR,,5,10-methylenetetrahydrofolate reductase,
indication,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,OCD,obsessive-compulsive disorder,,,
indication,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,PMDD,premenstrual dysphoric disorder,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,LDL-C,low-density lipoprotein cholesterol,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,Apo B,apolipoprotein B,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,HDL-C,high-density lipoprotein cholesterol,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,CVD,cardiovascular disease,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,i.e.,is elevation of chylomicrons,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,total-C,total cholesterol,,,
indication,ff4a8eab-17d5-caf4-efba-7e7688202bf5,12/4/2009,2,TG,triglycerides,,,
indication,173018F5-FD76-4480-90F8-4B7EFE328444,5/11/2006,1,UTIs,urinary tract infections,,,
indication,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,VT,ventricular tachycardia,,,
indication,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,VF,ventricular fibrillation,,,
indication,6f6bea0c-297b-43ff-8960-ecc11243e06e,5/17/2011,4,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
indication,93339B03-114C-837D-32A8-40B6F1EB71D7,11/20/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
indication,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,OCD,Obsessive Compulsive Disorder,,,
indication,0e2b79ca-9d94-4bbf-8b59-d06c0f91b2d6,3/9/2011,1,NCEP,National Cholesterol Education Program,,,
indication,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,DCCT,Diabetes Control and Complications Trial,,,
indication,d677acab-c2bd-4be5-82e8-293e310bba85,10/1/2009,5,i.e.,Infections:,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,LDL-C,low-density lipoprotein cholesterol,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,HDL-C,high-density lipoprotein cholesterol,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,CHD,coronary heart disease,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,CVD,cardiovascular disease,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,Apo B,apolipoprotein B,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,i.e.,is elevation of chylomicrons,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,total-C,total cholesterol,,,
indication,4724dbb4-3613-4e6a-948f-a43d34f97f06,2/6/2012,9,TG,triglycerides,,,
indication,67044E85-DD05-4AB4-BB85-D56679372599,10/18/2006,1,GERD,gastroesophageal reflux disease,,,
indication,8d24d1ab-8701-42c1-9537-81526b7adf7a,11/24/2010,107,GERD,gastroesophageal reflux disease,,,
indication,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,TURP,transurethral resection of the prostate,,,
indication,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,BPH,benign prostatic hyperplasia,,,
indication,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,G6PD,vulgaris.Glucose 6-phosphate dehydrogenase,,,
indication,13D85420-75E2-46E7-93EB-DCD10675CD03,10/10/2008,1,TTP,thrombocytopenic purpura,,,
indication,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,AED,antiepileptic drug,,,
indication,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,SNRI,serotonin and norepinephrine reuptake inhibitor,,,
indication,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,MDD,major depressive disorder,,,
indication,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,GAD,Generalized Anxiety  Disorder,,,
indication,39f30f39-a52c-4034-bc41-1ec312b52c99,6/8/2011,1,TG,triglycerides,,,
indication,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition,,,
indication,4dee18e8-93fc-43c3-8655-d99eba8d0de8,10/3/2007,2,CT,computed tomography,,,
indication,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,OTPs,Opioid Treatment Programs,,,
indication,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,DEA,Drug Enforcement Administration,,,
indication,0fd36cb9-c4f6-4167-93c9-8530865db3f9,6/24/2011,105,CKD,chronic kidney disease,,,
indication,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,DPN,diabetic peripheral neuropathy,,,
indication,1dc1ceb2-c0cc-4118-bd02-07145ccc7b09,2/8/2012,3544,PHN,Post herpetic neuralgia,,,
indication,00cffa69-982f-4067-aa73-bcc3debe8154,7/19/2011,1,HIV,human immunodeficiency virus,,,
indication,92bad7f3-c4e8-458c-8349-d2714e7d4f1f,12/2/2011,1,NCEP,National Cholesterol Education Program,,,
indication,3F7F39A5-D5F9-40B3-B20B-55E2C2D4EF3E,5/11/2006,1,ADHD,Attention Deficit Hyperactivity Disorder,,,
indication,19ebf09d-cf0d-4744-a874-a3a9f0b624b4,9/4/2009,1,MI,myocardial infarction,,,
indication,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,MAC,Mycobacterium avium  complex,,,
indication,3895e5cb-14d0-4676-9e57-3c224806bf3e,3/21/2012,17,NCEP,National Cholesterol Education Program,,,
indication,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,MI,myocardial infarction,,,
indication,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,UA,[unstable angina,,,
indication,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,NSTEMI,/non-ST-elevation myocardial infarction,,,
indication,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,ACS,Acute Coronary Syndrome,,,
indication,0078fb3d-3595-4ae1-a059-1d5e81c879cf,5/17/2012,1,STEMI,ST-elevation myocardial infarction,,,
indication,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,GAD,Generalized Anxiety Disorder,,,
indication,2d58c096-d6f5-41c5-bdaa-481cfb5f2e1b,5/3/2011,1,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,48e43995-4551-40c1-9d05-46a3956aabaa,1/24/2008,1,SPECT,Single Photon Emission Computed Tomography,,,
indication,18fae555-8c03-4cec-8c65-c7fdaea4b958,1/9/2012,2,NCEP,National Cholesterol Education Program,,,
indication,fd653d74-48ab-49e4-a42d-ec1cbc59badb,6/4/2012,9,TSH,thyroid-stimulating hormone,,,
indication,5a90ba32-8479-468d-b0c5-fda9a5f7d2db,11/24/2009,1,MI,myocardial infarction,,,
indication,A784F545-F209-46D4-9350-AE64FAD9E07C,1/12/2009,4,autoimmune,antituberculous chemotherapy; aspiration pneumonitis.Hematologic disorders: idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired,,,
indication,78eea56d-15a6-4ceb-b755-d1a3e9707f32,12/1/2010,1,EIB,exercise-induced bronchoconstriction,,,
indication,02010995-9826-4A67-945B-F3022E6081DF,8/20/2007,2,S. faecalis,strains of the following organisms:  Escherichia coli     Enterococcus,,,
indication,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,RA,rheumatoid arthritis,,,
indication,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,SAMHSA,Substance Abuse and Mental Health  Services Administration,,,
indication,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,DEA,Drug Enforcement  Administration,,,
indication,07c99997-31c7-4c03-ae35-49788213b43e,4/13/2010,1,i.e.,is elevation of chylomicrons,,,
indication,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,GAD,Generalized Anxiety Disorder,,,
indication,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,OCD,obsessive compulsive disorder,,,
indication,A3C3048F-81A7-4A86-8A06-F1F00909F6D1,12/21/2006,2,autoimmune,antituberculous chemotherapyAspiration pneumonitisHematologic DisordersHematologic DisordersIdiopathic thrombocytopenic purpura in adultsSecondary thrombocytopenia in adultsAcquired,,,
indication,e2a38bbb-7505-407f-ba38-469500347697,4/13/2011,3,CNS,CENTRAL NERVOUS SYSTEM,,,
indication,e360bc09-c9b4-4dcc-974f-c26e3194bd40,12/12/2011,1,NCEP,National Cholesterol Education Program,,,
indication,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,AFIB/AFL,atrial fibrillation/atrial flutter,,,
indication,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
indication,2E129105-0F1F-4E64-8D93-81399D744619,3/31/2007,2,ampicillin,anaerobic bacteria resistant to some penicillin antibiotics,,,
indication,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,OCD,obsessive compulsive disorder,,,
indication,A274E3EA-BF67-4F81-AAA0-10475B20CD69,10/6/2006,1,IBS,irritable bowel syndrome,,,
indication,5683ec23-d01d-493c-b5a9-00a3e240bb07,3/29/2012,1,GAD,Generalized Anxiety Disorder,,,
indication,f6c30ba1-53d0-4f85-a515-81acfb922e73,5/18/2010,5,ADHD,Attention Deficit Hyperactivity Disorder,,,
indication,424c69ef-b5a4-4480-98f1-6c8bed9cbcf2,12/15/2010,147,GAD,Generalized Anxiety Disorder,,,
indication,f8035130-1a60-4ba3-a9be-b1a739c946db,8/18/2011,1,RA,Rheumatoid Arthritis,,,
indication,d0a209f9-0406-4868-89f6-fe864ccc5d7d,8/25/2011,2,DSM,Diagnostic and Statistical Manual,,,
indication,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,CML,chronic myelogenous leukemia,,,
indication,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,Ph,Philadelphia chromosome,,,
indication,d544481d-2695-4a89-964b-15e2338670b8,8/1/2011,1,i.e.,is elevation of chylomicrons,,,
indication,187cee88-8cdb-48b9-bd2d-5144ad322f1c,8/12/2011,13,CAD,Coronary Artery Disease,,,
indication,a240bf74-5dee-ab9f-65fc-09565dc32f44,12/10/2009,3,ICU,Intensive Care Unit,,,
indication,ad81576a-6a25-438e-b39e-d04d7c4b9595,12/14/2009,1,e.g.,emptying,,,
indication,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,PRSP,penicillin-resistant Streptococcus pneumoniae,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,Apo B,apolipoprotein B,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,CVD,cardiovascular disease,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,i.e.,is elevation of chylomicrons,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,total-C,total cholesterol,,,
indication,871251c0-36a1-4a32-9eab-ff6c1e925ca9,3/15/2011,1,TG,triglycerides,,,
indication,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,AIOD,aortoiliac occlusive disease,,,
indication,B6C35A62-A7EA-4C1D-A00A-24D82CDC65BE,1/2/2009,1,MRA,magnetic resonance angiography,,,
indication,A63BD1BB-6487-4B0D-AA8C-C4313F5B36A8,1/17/2008,1,SUSPENSION,suspension,,,
indication,f3fa566a-d2d8-4d73-b8bf-33ad0f4ca746,9/24/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
indication,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,DPNP,Diabetic Peripheral Neuropathic Pain,,,
indication,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,FM,Fibromyalgia,,,
indication,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,GAD,Generalized Anxiety Disorder,,,
indication,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,MDD,Major Depressive Disorder,,,
indication,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,FM,fibromyalgia,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,Apo B,apolipoprotein B,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,CVD,cardiovascular disease,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,i.e.,is elevation of chylomicrons,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,total-C,total cholesterol,,,
indication,7442f35f-74e8-4c35-9666-190a3baad549,2/28/2012,1,TG,triglycerides,,,
indication,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,OCD,Obsessive Compulsive Disorder,,,
indication,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,MDD,Major Depressive Disorder,,,
indication,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,VLDL,very low-density lipoprotein,,,
indication,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,OCD,obsessive-compulsive disorder,,,
indication,2ffbec78-5bd4-4647-b282-d6edf8e22ccc,7/15/2011,4,e.g.,esophagitis or GERD symptoms,,,
indication,eadf575d-7561-4020-b88f-a280e58d10ba,6/1/2011,1,Children,clarithromycin immediate-release tablets and clarithromycin for oral suspension,,,
indication,76b8f7da-7e69-4953-be59-e38397e0fd36,10/4/2010,1,ADHD,Attention-Deficit/Hyperactivity Disorder,,,
indication,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,DSM,Diagnostic and Statistical Manual,,,
indication,abfeded8-9da9-4884-8429-bed89763d873,2/22/2012,11,HCTZ,hydrochlorothiazide,,,
indication,abfeded8-9da9-4884-8429-bed89763d873,2/22/2012,11,ARB,angiotensin II receptor blocker,,,
indication,abfeded8-9da9-4884-8429-bed89763d873,2/22/2012,11,Diovan,Diovan HCT is the combination tablet of valsartan,,,
indication,86e74b34-0dc1-40fc-9509-d7a63e98ef10,3/23/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,ac805bbd-26d5-456d-9ce8-cb91ed8703b6,1/3/2011,2,LGS,Lennox-Gastaut syndrome,,,
indication,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,OCD,Obsessive Compulsive Disorder,,,
indication,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,MDD,Major Depressive Disorder,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,LDL-C,low-density lipoprotein cholesterol,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,Apo B,apolipoprotein B,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,HDL-C,high-density lipoprotein cholesterol,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,CVD,cardiovascular disease,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,i.e.,is elevation of chylomicrons,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,total-C,total cholesterol,,,
indication,b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5,2/26/2008,1,TG,triglycerides,,,
indication,4acf51de-26f7-42b2-8acc-61b800627ef3,12/13/2010,2,HSV,herpes simplex virus,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,LDL-C,low-density lipoprotein cholesterol,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,HeFH,Heterozygous Familial Hypercholesterolemia,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,HDL-C,high-density lipoprotein cholesterol,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,CVD,cardiovascular disease,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,Apo B,apolipoprotein B,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,i.e.,is elevation of chylomicrons,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,total-C,total cholesterol,,,
indication,e9e50cdb-4cef-4d03-9fb6-973d0c2bf293,12/13/2011,8,TG,triglycerides,,,
indication,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,SAMHSA,Substance Abuse and Mental Health  Services Administration,,,
indication,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,DEA,Drug Enforcement  Administration,,,
indication,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,GAD,Generalized Anxiety Disorder,,,
indication,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,OCD,obsessive compulsive disorder,,,
indication,930C6836-88DC-483F-A95E-481522D2DD68,3/31/2007,1,NCEP,National Cholesterol Education Program,,,
indication,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,AED,antiepileptic drug,,,
indication,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,VLDL,very low density lipoprotein,,,
indication,db977f52-2296-4003-9162-c155163d714a,12/8/2010,1,i.e.,INFECTIONS,,,
indication,b5d286ce-e23f-4dde-b400-cb4832172ece,1/4/2012,3472,DSM,Diagnostic and Statistical Manual,,,
indication,47c21109-6e7e-4647-9963-d2151f5ef820,10/13/2011,1,GAD,Generalized Anxiety Disorder,,,
indication,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,OCD,obsessive compulsive  disorder,,,
indication,9abf41f1-66f9-4be4-a6d7-6c9aa0d5d387,11/4/2010,448,CAD,Coronary Artery Disease,,,
indication,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,RA,Rheumatoid Arthritis,,,
indication,d5e12448-1ca1-46a4-8de4-e8b94567e5a8,11/11/2011,9,OA,Osteoarthritis,,,
indication,ef4d3d9f-4976-4eae-92b1-77749de3c63c,2/6/2006,2,i.e.,is recognized,,,
indication,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,CNS,CENTRAL N E RVOUS SYSTEM,,,
indication,7F2F057B-9AFC-42AE-9D1D-1B1041D1360B,9/14/2006,1,IPPB,intermittent positive pressure breathing apparatus,,,
indication,ac323b5b-132a-4513-927e-2c38b6d33d71,4/12/2012,2,i.e.,Infections:,,,
indication,2835b6f5-93da-4554-9d84-79132fd928ee,4/28/2010,1,TG,triglycerides,,,
indication,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,SAMHSA,Substance Abuse and Mental Health Services Administration,,,
indication,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,DEA,Drug Enforcement Administration,,,
indication,ea7567c4-4bf9-58f1-1ccb-65d1a1a8c620,10/26/2009,2,ICU,Intensive Care Unit,,,
overdosage,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,PDR®,Physicians’ Desk Reference®,,,
overdosage,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,PDR,.Physicians' Desk Reference,,,
overdosage,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,PDR,Physicians' Desk Reference,,,
overdosage,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,PDR,.Physicians’ Desk Reference,,,
overdosage,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,66a8531a-2507-402c-8919-c666ec3024c1,9/20/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,AEC0308F-F583-4E27-9BB8-21800BDE7FAA,11/16/2007,1,PDR,Physician’s Desk Reference®,,,
overdosage,d94dc983-98a9-47e1-9336-95c9142ca497,11/29/2011,3268,NAC,N-acetylcysteine,,,
overdosage,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,d7f92280-7a55-4a12-a42b-2ea21a29230c,12/6/2011,3323,NAC,N-acetylcysteine,,,
overdosage,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,783be2dd-5648-4549-8ebf-5067f1b1e5f1,2/2/2012,3522,NAC,N-acetylcysteine,,,
overdosage,6b17b98b-e06d-42ed-925f-69aa2699dead,2/9/2007,3,PDR,Physicians’ Desk Reference,,,
overdosage,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,PDR,Physicians’ Desk Reference,,,
overdosage,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,PDR,Physicians' Desk Reference®,,,
overdosage,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,eg,Electrocardiogram changes,,,
overdosage,a1dc5b3f-0bca-461e-9018-32efcf335653,12/22/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470,9/10/2007,2,CNS,central nervous system,,,
overdosage,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,i.e.,in transaminase values,,,
overdosage,d79db1b1-e04b-46f4-ba7c-ed5bde835463,3/15/2012,2,PDR,Physicians’ Desk Reference,,,
overdosage,171c535c-1ed3-47bc-a0d5-c6f0e6986292,8/18/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,003aee15-e811-4dae-aa8c-4381ae5a17e3,3/5/2012,1,PDR,Physicians'Desk Reference,,,
overdosage,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,9A148542-E478-422A-B8FB-88047C30534B,11/29/2007,2,PDR,Physicians’ Desk Reference,,,
overdosage,9A148542-E478-422A-B8FB-88047C30534B,11/29/2007,2,PDR,patient.Physicians’ Desk Reference,,,
overdosage,60f43308-1deb-4f05-8f17-aa49ebdcf498,8/5/2011,1,NAC,N-acetylcysteine,,,
overdosage,7d2d79e4-33ae-4436-98e3-14e91753886c,8/6/2009,1003,NAC,N-acetylcysteine,,,
overdosage,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,3537a73d-2411-498a-8e18-a128f8c5eecb,8/28/2010,379,PDR,Physicians’ Desk Reference,,,
overdosage,6e9edbfc-1950-4893-9d38-e82b119ddb9a,4/4/2007,1,Injection,injection,,,
overdosage,6e9edbfc-1950-4893-9d38-e82b119ddb9a,4/4/2007,1,Bitartrate,bitartrate injection,,,
overdosage,09e1e32d-1874-40d7-8829-52b3a489d9fd,6/20/2011,1,CPR,cardiopulmonary resuscitation,,,
overdosage,dc537761-d5f4-488d-24ab-b2bcd2b17b7a,8/8/2011,2,PDR,Physicians' Desk Reference,,,
overdosage,13831529-e814-4b95-9287-c5ba6678bf52,2/22/2010,2,PDR,Physicians' Desk Reference,,,
overdosage,d9a049bd-2161-4a9b-8f6d-0c7d2bfdb0ed,3/10/2010,1,PDR,Physicians’ Desk Reference,,,
overdosage,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,e.g.,Electrocardiogram changes,,,
overdosage,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,PDR,Physicians’ Desk Reference,,,
overdosage,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,PDR,Physicians’ Desk Reference,,,
overdosage,04c8ab3f-b026-4009-bf0f-d6eb71517d23,4/1/2010,1,NAC,N-acetylcysteine,,,
overdosage,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,18ecff0f-15f7-4a40-bec7-d0ea734d6ef6,3/22/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,18ecff0f-15f7-4a40-bec7-d0ea734d6ef6,3/22/2007,1,PDR,patient.Physicians’ Desk Reference,,,
overdosage,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,i.e.,induce seizures,,,
overdosage,1109ac28-47eb-4dc7-8abc-8bc1f19b25eb,6/8/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,i.e.,in transaminase values,,,
overdosage,2564646d-183c-4759-8726-155a4c22aa2b,1/11/2012,5,i.e.,Initiate conventional therapy,,,
overdosage,11d14362-8f69-4c30-b487-5d05f6462bd7,5/7/2012,4,PDR,Physicians' Desk Reference,,,
overdosage,D476C926-4C3D-4C33-B244-3B58E988ECB3,9/2/2008,1,sc,subcutaneous,,,
overdosage,7F11BE5C-6112-C93E-4D0F-D3A085AC698A,4/2/2009,1,PDR,Physicians' Desk Reference,,,
overdosage,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,e.g.,Electrocardiogram changes,,,
overdosage,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,PDR,Physicians' Desk Reference®,,,
overdosage,10898a71-a778-4e39-aadb-8f936c92aba2,7/12/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,d980eddb-f7e1-4a40-93e3-adc8df04d77c,1/17/2012,2,PDR,Physicians’ Desk Reference,,,
overdosage,0FB7864F-BE1C-4992-A996-556AEF29981F,6/25/2008,2,CNS,central nervous system,,,
overdosage,4cf33260-5a78-4207-b113-a9d6771811a3,8/1/2008,1,CPR,cardiopulmonary resuscitation,,,
overdosage,cc8ef530-dd8c-40f5-af7e-4622c9e01d52,6/8/2006,1,PDR,Physicians' Desk Reference,,,
overdosage,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,CAPD,chronic ambulatory peritoneal dialysis,,,
overdosage,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,PDR,Physicians’ Desk  Reference,,,
overdosage,35b99e65-32d3-43bc-89d9-2e7c7838aa14,4/20/2011,1,NAC,N-acetylcysteine,,,
overdosage,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,PDR,Physicians’ Desk Reference,,,
overdosage,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,748977db-fd10-46b8-a219-381ba34e55cd,5/28/2007,1,RDA,Recommended Dietary Allowance,,,
overdosage,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,PDR,.Physicians’ Desk Reference,,,
overdosage,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,PDR,Physicians’ Desk Reference,,,
overdosage,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,PDR®,Physicians’ Desk Reference ®,,,
overdosage,ac7b43d5-3d14-4109-b6b4-e6f290d144d7,4/27/2011,1,i.e.,induce seizures,,,
overdosage,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,i.e.,induce seizures,,,
overdosage,db671a67-346d-4d55-bfe3-eeecf60da01f,2/29/2008,2,e.g.,exaggerated pharmacological effects,,,
overdosage,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,PDR,Physicians' Desk Reference,,,
overdosage,9cd06d37-5515-444e-b561-64e5cc6e9539,4/20/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,469779cc-9a1b-470b-b54e-cf30191b97a4,11/10/2011,1,NAC,N-acetylcysteine,,,
overdosage,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,PDR,.Physicians' Desk Reference,,,
overdosage,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,PDR,Physicians' Desk Reference,,,
overdosage,C07DF5A8-A4ED-4A2F-AC97-BF5F4E55D80D,4/4/2008,1,sc,subcutaneous,,,
overdosage,a0882db1-2532-4b80-b753-68f013fe79e7,1/25/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,PDR®,Physicians’ Desk Reference®,,,
overdosage,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,6f8cced0-4749-4a11-8f00-96d8c23c1cfd,7/11/2011,6,NAC,N-acetylcysteine,,,
overdosage,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,PDR,Physicians’ Desk Reference,,,
overdosage,45d5d3f1-43e6-41e4-b2b4-51ba9085a526,6/23/2010,1,PDR,Physicians' Desk Reference,,,
overdosage,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,295ac292-7b78-437b-9da0-98e02aaed215,11/10/2010,77,PDR,Physicians’ Desk Reference,,,
overdosage,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,PDR,Physicians’ Desk Reference,,,
overdosage,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,PDR,.Physicians’ Desk Reference,,,
overdosage,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,PDR,Physicians’ Desk Reference,,,
overdosage,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,sc,subcutaneous,,,
overdosage,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,PDR,Physicians' Desk Reference,,,
overdosage,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,eg,Electrocardiogram changes,,,
overdosage,78794e3d-f293-4eeb-22ac-8f536d5947eb,5/2/2012,11,CNS,central nervous system,,,
overdosage,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,PDR,Physicians’ Desk Reference,,,
overdosage,A551FAC0-8738-40B3-9B03-602F794A4B66,6/12/2008,1,CNS,central nervous system,,,
overdosage,77e4446e-78a0-4596-9679-15938eb0f892,7/24/2012,1,NAC,N-acetylcysteine,,,
overdosage,2cb9090d-76dd-44a2-9590-37c6e7ed495b,11/10/2009,4,NAC,N-acetylcysteine,,,
overdosage,6698016a-d9a5-4004-9302-5d202c626b2a,3/31/2011,1,PD R,Physicians'Desk Reference,,,
overdosage,3202b686-e944-4b52-a226-9297fe899606,6/28/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,PDR,Physicians’ Desk Reference,,,
overdosage,eda68f78-442e-4062-a799-600fafbd389b,7/2/2012,3895,NAC,N-acetylcysteine,,,
overdosage,a3185171-0581-4e49-9be0-ec2dce877aa4,6/5/2009,1003,NAC,N-acetylcysteine,,,
overdosage,f6a79b4e-d7b3-4849-a552-7a37017e0a7a,12/28/2009,1,MRHD,maximum recommended human dose,,,
overdosage,c9202158-e3e4-4efc-9cc7-58e92d7fde8d,6/27/2012,4,PDR,Physicians' Desk Reference,,,
overdosage,10727aa8-a03e-4b61-9a80-a024cb4a2d28,10/5/2011,2,PDR,Physicians’ Desk Reference,,,
overdosage,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,PDR,Physicians' Desk Reference,,,
overdosage,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,eg,Electrocardiogram changes,,,
overdosage,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,PDR,Physicians’ Desk Reference,,,
overdosage,fbed0f64-1143-4439-8f03-88f393d20390,5/10/2011,1,NAC,N-acetylcysteine,,,
overdosage,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,PDR®,Physicians' Desk Reference®,,,
overdosage,5681d4d2-9b67-4cac-9b94-8368f9978231,3/9/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,c6d56d5e-856e-4e48-85f7-fce2beade4d1,4/29/2011,2,PDR,Physicians' Desk Reference,,,
overdosage,8fbbd6d1-637b-4f67-897d-ab5eaeb5cc0e,9/13/2010,25,PDR,Physicians’ Desk  Reference,,,
overdosage,DC92F45F-8D27-4dcb-B72D-6B8B04C6F0CE,8/4/2007,3,PDR,“Physicians' Desk Reference,,,
overdosage,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,PDR,Physicians' Desk Reference,,,
overdosage,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,PDR,Physicians' Desk Reference,,,
overdosage,111F628A-7E1E-4D47-8AC1-F898CBFC9B74,8/3/2007,2,PDR,Physician's Desk Reference®,,,
overdosage,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,59C9BF80-B46E-E302-4EB7-4F751ECD1FEE,4/3/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,036ad971-9946-4950-8530-2a1a90bdcb1d,3/8/2012,1,PDR,“Physicians’ Desk Reference,,,
overdosage,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,PDR,Physicians' Desk Reference®,,,
overdosage,53b3ed76-db40-4aa8-8c55-21991d557b42,4/29/2012,3,NAC,N-acetylcysteine,,,
overdosage,42ae28da-a613-4db4-b471-efa4e2638dc8,1/28/2009,2,PDR,patient.Physicians' Desk Reference,,,
overdosage,42ae28da-a613-4db4-b471-efa4e2638dc8,1/28/2009,2,PDR,Physicians' Desk Reference,,,
overdosage,E2CAAB63-1E0D-44E8-B9A8-BDFB59CE1288,9/20/2006,1,RDA,Recommended Dietary Allowance,,,
overdosage,83a005d5-e054-4ff0-afa7-de57811f8de7,4/25/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,83a005d5-e054-4ff0-afa7-de57811f8de7,4/25/2011,2,e.g.,Electrocardiogram changes,,,
overdosage,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,e0f4ad87-07c0-41b7-85d2-ddf66e0840ad,7/11/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,fe8b7729-d870-4e61-a5a4-91e28bdd5a94,12/8/2010,1,PDR,Physicians’ Desk Reference,,,
overdosage,4799261f-9fac-4b0a-a470-daa709569405,9/10/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,386b8c18-5be1-4cef-90a8-28096293bffb,6/16/2011,4,PDR,Physicians'Desk Reference,,,
overdosage,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,e.g.,Electrocardiogram changes,,,
overdosage,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,PDR,.Physicians’ Desk Reference,,,
overdosage,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,aaccfdf4-ce07-4799-9a7c-14dc0588a2a3,6/20/2011,1,CPR,cardiopulmonary resuscitation,,,
overdosage,5efa48e3-1f8e-4a69-b41f-bf1adc754f94,12/8/2006,1,PDR,Physicians’ Desk Reference,,,
overdosage,5efa48e3-1f8e-4a69-b41f-bf1adc754f94,12/8/2006,1,PDR,patient.Physicians’ Desk Reference,,,
overdosage,8f0ff905-5eb3-4ad0-ad31-fe35b924211f,10/27/2009,1,PDR,Physicians’ Desk Reference,,,
overdosage,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,e.g.,Electrocardiogram changes,,,
overdosage,c0dd68b3-20af-464d-b3ba-34eb886df6ae,1/25/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,LDH,lactic dehydrogenase,,,
overdosage,A7248ECA-45D6-472D-8C2A-D8887C2594D5,12/6/2007,1,AST,aspartate transaminase,,,
overdosage,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PDR®,Physicians’ Desk Reference®,,,
overdosage,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,0525e04f-91b7-4d75-8ff9-a6fb5705d993,2/6/2012,1,EDTA,ethylenediaminetetraacetic acid,,,
overdosage,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,i.e.,induce seizures,,,
overdosage,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,PDR,Physicians' Desk Reference®,,,
overdosage,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,eg,Electrocardiogram changes,,,
overdosage,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,PDR,Physicians’ Desk Reference,,,
overdosage,8ce0eca5-c5a5-444a-b06a-5763be139949,3/30/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,3e4221f1-dade-4482-b5e5-2d75a96154d6,6/10/2009,3,i.e.,induce seizures,,,
overdosage,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,PDR,Physicians' Desk  Reference,,,
overdosage,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,5C952479-FF16-4520-0FB2-BFDFB285300A,11/8/2006,1,PDR,Physicians’ Desk Reference,,,
overdosage,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,e.g.,Electrocardiogram changes,,,
overdosage,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,i.e.,induce seizures,,,
overdosage,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,PDR,Physicians' Desk Reference,,,
overdosage,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,PDR,Physicians' Desk Reference,,,
overdosage,944d3e60-7eee-11de-a413-0002a5d5c51b,11/22/2011,9,NAC,N-acetylcysteine,,,
overdosage,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,PDR,.Physicians' Desk Reference,,,
overdosage,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,PDR,Physicians' Desk Reference,,,
overdosage,527180e9-7172-4811-87bb-bb47439b5542,10/6/2006,1,MLD,minimum lethal dose,,,
overdosage,7f888a0c-189e-4c76-86d8-7bc6f21e3b16,2/21/2012,1,i.e.,Initiate conventional therapy,,,
overdosage,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,PDR®,Physicians’ Desk Reference®,,,
overdosage,d99b2484-1c4d-4241-b16e-72395f976efb,9/5/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,PDR®,Physicians’ Desk Reference®,,,
overdosage,8e28f049-6110-4473-830f-c494191a7197,12/28/2010,3,PDR,Physicians' Desk Reference,,,
overdosage,86530199-999b-9f92-b1bc-b8515ec829f3,9/26/2011,2,PDR,Physicians’ Desk Reference,,,
overdosage,7F60424F-B90C-459C-AE53-B732EE3D67B5,11/27/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,7F60424F-B90C-459C-AE53-B732EE3D67B5,11/27/2007,1,PDR,patient.Physicians’ Desk Reference,,,
overdosage,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,PDR,Physicians’ Desk Reference,,,
overdosage,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,i.e.,induce seizures,,,
overdosage,A37E08C3-92CB-4BFB-901F-219C6CDCFFE2,4/7/2006,1,RDA,Recommended Dietary Allowance,,,
overdosage,215f46ea-6633-48bc-b7df-2fdb012429b7,7/21/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,25b87a16-3e28-45b5-9ae8-98053f1f387a,8/25/2009,1,PDR,Physicians' Desk Reference,,,
overdosage,c8be6c8d-7c55-459b-bc16-7651c2fd6e27,1/31/2012,5,NAC,N-acetylcysteine,,,
overdosage,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,PDR,.Physicians' Desk Reference,,,
overdosage,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,PDR,Physicians' Desk Reference,,,
overdosage,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,e.g.,Electrocardiogram changes,,,
overdosage,f5c2fe10-c61f-4cbe-bc45-7ab14baa691c,12/31/2008,1,sc,subcutaneous,,,
overdosage,68fba58a-7748-4581-8432-f5286c46d90a,3/16/2007,1,PDR,Physicians' Desk Reference,,,
overdosage,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,e.g.,Electrocardiogram changes,,,
overdosage,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,eg,Electrocardiogram changes,,,
overdosage,2f3804f1-ce47-4c1c-a012-b7c0c3088105,3/11/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,PDR,Physicians’ Desk Reference,,,
overdosage,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,TCAs,.Tricyclic Antidepressants,,,
overdosage,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,PDR,.Physicians' Desk Reference,,,
overdosage,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,PDR,Physicians' Desk Reference,,,
overdosage,79b15110-e484-4b84-8947-15653746773c,7/26/2006,1,Regitine®,regard: Intravenous phentolamine,,,
overdosage,7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4,11/18/2008,1,CPR,cardiopulmonary resuscitation,,,
overdosage,569f3007-0faf-41c2-991c-66ff0779810b,11/18/2010,98,Injection,injection,,,
overdosage,569f3007-0faf-41c2-991c-66ff0779810b,11/18/2010,98,Bitartrate,bitartrate  injection,,,
overdosage,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,PDR,Physicians' Desk  Reference,,,
overdosage,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,CNS,Central Nervous System,,,
overdosage,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,adult,and Lethal Doses Butalbital: toxic dose 1 g,,,
overdosage,6e88b4d2-223e-44ac-8b9c-3eecf4d573a5,1/15/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,63841f53-a567-4102-80b5-3565d9b52373,7/1/2011,2,NAC,N-acetylcysteine,,,
overdosage,bae70c53-6ef4-4d0e-afd5-7d6c20a952ef,5/10/2011,3,ARCI,Addiction Research Center Inventories,,,
overdosage,a57b8c7c-b8a9-45e4-b6fa-b83ebfbacae2,5/2/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,a57b8c7c-b8a9-45e4-b6fa-b83ebfbacae2,5/2/2011,1,e.g.,Electrocardiogram changes,,,
overdosage,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,d4f97887-3353-441e-b1e3-c32bde2a9016,4/26/2012,1,NAC,N-acetylcysteine,,,
overdosage,A3A62C66-BBA9-4A96-B409-90687CA4A76A,2/17/2009,1,PDR,“Physicians’ Desk Reference,,,
overdosage,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,ie,Initiate conventional therapy,,,
overdosage,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,PDR,Physicians' Desk Reference,,,
overdosage,73c1059b-0c7d-42ef-9827-f018858fc447,7/6/2011,12,NAC,N-acetylcysteine,,,
overdosage,A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC,2/17/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,e.g.,Electrocardiogram changes,,,
overdosage,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,PDR,Physicians’ Desk Reference,,,
overdosage,c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1,7/6/2011,10,PDR,Physicians’ Desk Reference,,,
overdosage,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,CAPD,chronic ambulatory peritoneal dialysis,,,
overdosage,35019655-9a30-4305-a262-936ad0e73071,7/22/2010,4,PDR,Physicians’ Desk Reference,,,
overdosage,079fdde2-8b69-42c4-88f5-830ed7d2ba5f,6/7/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,PDR,Physicians' Desk Reference,,,
overdosage,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,PDR,Physicians’ Desk Reference,,,
overdosage,d1b9dd40-8140-40df-8083-7255f1035cbc,6/17/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,PDR,Physicians' Desk Reference,,,
overdosage,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,PDR,Physicians’ Desk Reference,,,
overdosage,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,i.e.,induce seizures,,,
overdosage,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
overdosage,52ee65a7-ca1f-48fd-8fad-d72ea0dad4de,5/7/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,52ee65a7-ca1f-48fd-8fad-d72ea0dad4de,5/7/2007,1,PDR,patient.Physicians’ Desk Reference,,,
overdosage,69760d70-a6d5-4a00-9437-dce466e103a2,11/9/2011,3112,NAC,N-acetylcysteine,,,
overdosage,4fec8daf-6e09-4153-926f-64709dbdd26c,12/21/2011,8,PDR,Physicians’ Desk Reference,,,
overdosage,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,e.g.,Electrocardiogram changes,,,
overdosage,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,PDR,Physicians’ Desk Reference,,,
overdosage,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,CAPD,chronic ambulatory peritoneal dialysis,,,
overdosage,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,PDR,Physicians’ Desk Reference,,,
overdosage,d0a209f9-0406-4868-89f6-fe864ccc5d7d,8/25/2011,2,PDR,Physicians'Desk Reference,,,
overdosage,E67D21FA-DB5A-4536-FC82-CABFEADB0C6F,2/22/2006,1,PDR,Physicians’ Desk Reference,,,
overdosage,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,PDR,Physicians’ Desk Reference,,,
overdosage,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,PDR,Physicians' Desk Reference,,,
overdosage,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,PDR®,Physicians’ Desk Reference®,,,
overdosage,665ABE12-209D-4B80-8020-EF9E3F9BDADE,5/28/2009,3,MLD,minimum lethal dose,,,
overdosage,83df297b-6467-451e-af4d-2c1f996cd009,8/1/2011,9,PDR,Physicians’ Desk Reference,,,
overdosage,3154c861-62fd-487a-aac0-f5e79ae3b284,3/26/2012,2,PDR,Physicians'Desk Reference,,,
overdosage,A26390E8-EB86-4623-8CDD-45B24B14DF74,3/30/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,PDR,Physicians’ Desk Reference,,,
overdosage,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,PDR,Physicians' Desk Reference,,,
overdosage,70a2ac22-7fab-4383-8c34-b6793915a79c,3/29/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,0ae5f19b-e8d5-4ec7-bcf1-697e88c0e66c,4/18/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,453f8966-f89c-4ab2-b91e-c7bb50304028,3/22/2012,1,NAC,N-acetylcysteine,,,
overdosage,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,i.e.,induce seizures,,,
overdosage,A1A85756-9773-4FBF-AB52-F29EB2A92413,2/16/2007,3,CPR,cardiopulmonary resuscitation,,,
overdosage,52057058-abdb-44ed-b60d-a718c97fbfda,8/1/2011,8,PDR,Physicians’ Desk Reference,,,
overdosage,61c36d81-8f1a-446d-8db5-72c3635589fc,4/3/2012,3725,NAC,N-acetylcysteine,,,
overdosage,9ac8b9fe-dfb9-0151-30b3-f9da72d74ac2,2/9/2012,10,PDR,Physicians’ Desk Reference,,,
overdosage,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,PDR,Physicians’ Desk Reference,,,
overdosage,4d80812c-dfc1-456c-9368-697267630c2c,11/30/2011,1,PDR,Physicians' Desk Reference,,,
overdosage,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,PDR,.Physicians’ Desk Reference,,,
overdosage,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,PDR,Physicians’ Desk Reference,,,
overdosage,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,PDR,Physicians’ Desk Reference,,,
overdosage,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,PDR,Physicians' Desk Reference,,,
overdosage,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,eg,Electrocardiogram changes,,,
overdosage,2298ed2a-e01b-4f7c-9902-7c58a6e06b7a,4/13/2011,3,i.p.,intraperitoneally,,,
overdosage,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,PDR,Physicians' Desk Reference,,,
overdosage,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,e.g.,Electrocardiogram changes,,,
overdosage,4dd36cf5-8f73-404a-8b1d-3bd53bd90c25,2/13/2012,17,NAC,N-acetylcysteine,,,
overdosage,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,eg,Electrocardiogram changes,,,
overdosage,b5d286ce-e23f-4dde-b400-cb4832172ece,1/4/2012,3472,PDR,Physicians’ Desk Reference,,,
overdosage,0644a3a3-1f7e-4e77-b469-7f4b41625baf,6/12/2012,5,ECG,ELECTROCARDIOGRAPHIC,,,
overdosage,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,PDR,Physicians’ Desk Reference,,,
overdosage,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,PDR,Physicians' Desk Reference®,,,
overdosage,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,eg,Electrocardiogram changes,,,
overdosage,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,i.e.,induce seizures,,,
overdosage,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,PDR,Physicians'Desk Reference,,,
overdosage,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,CNS,Central Nervous System,,,
overdosage,9943a961-3b50-4847-8a84-d8414ce38daa,11/16/2011,10,PDR,Physicians’ Desk Reference,,,
overdosage,0e4ff499-980a-4c3d-b921-abcea52654fe,2/7/2012,3,NAC,N-acetylcysteine,,,
precautions,ea4ece7f-e81f-48de-b262-577db5b6fe6c,2/16/2012,6,COX-2,cyclooxygenase-2,,,
precautions,ea4ece7f-e81f-48de-b262-577db5b6fe6c,2/16/2012,6,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,ea4ece7f-e81f-48de-b262-577db5b6fe6c,2/16/2012,6,ACE,angiotensin converting enzyme,,,
precautions,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,C0336606-7366-41CE-9CEF-AA6524B92B11,1/27/2009,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,42DBD449-BF4C-417C-B26B-0A9D7534C8BB,9/18/2007,1,PBI,protein-bound iodine,,,
precautions,42DBD449-BF4C-417C-B26B-0A9D7534C8BB,9/18/2007,1,TBG,thyroid-binding globulin,,,
precautions,9c7bb7e7-a775-4f93-bd77-d08c48a86f7c,7/10/2007,2,LAIV,aspirin.Live Attenuated Influenza Vaccine,,,
precautions,fdd1fa5e-9dbf-4951-a8e9-33d06e05bdba,12/1/2010,1,CHF,congestive heart failure,,,
precautions,fdd1fa5e-9dbf-4951-a8e9-33d06e05bdba,12/1/2010,1,MRHD,maximum recommended human dose,,,
precautions,fdd1fa5e-9dbf-4951-a8e9-33d06e05bdba,12/1/2010,1,NTS,nicotine transdermal system,,,
precautions,5626e08c-de45-48ff-b85f-21abdfae6574,7/18/2012,2,MRHD,maximum recommended human dose,,,
precautions,5626e08c-de45-48ff-b85f-21abdfae6574,7/18/2012,2,AEDs,antiepilepsy drugs,,,
precautions,5626e08c-de45-48ff-b85f-21abdfae6574,7/18/2012,2,NAAED,North American Antiepileptic Drug,,,
precautions,5626e08c-de45-48ff-b85f-21abdfae6574,7/18/2012,2,BUN,blood urea nitrogen,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,MRHD,maximum recommended human dose,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,MRD,maximum recommended dose,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,ECT,Electroconvulsive Therapy,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,11544DEA-2F5E-1536-584A-5D1F37A99770,3/27/2009,1,PPHN,pulmonary  hypertension of the newborn,,,
precautions,95a33c9b-79a6-47c7-8433-fc217950b88f,3/30/2010,1,MAO,monoamine  oxidase,,,
precautions,7E20C7B5-8A7D-4AE6-BA73-0E6EEEB2016E,8/3/2007,1,PBI,Protein-bound iodine,,,
precautions,7E20C7B5-8A7D-4AE6-BA73-0E6EEEB2016E,8/3/2007,1,PBI,affected.Protein-bound iodine,,,
precautions,52e42bf6-34a3-4b95-9907-5e8d19108d47,12/4/2009,3,TSH,thyroid stimulating hormone,,,
precautions,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,CBC,COMPLETE BLOOD COUNT,,,
precautions,6163F0B3-031B-4552-9299-B3F735762D24,11/17/2006,1,CBC,Complete Blood Count,,,
precautions,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,PBI,protein-bound iodine,,,
precautions,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,TBG,thyroid-binding globulin,,,
precautions,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,WHI,Women’s Health Initiative,,,
precautions,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,437edd12-2c08-4df4-8cf7-64c47e4779ac,1/18/2011,2,i.e.,in serum,,,
precautions,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,SNRIs,serotonin and  norepinephrine reuptake inhibitors,,,
precautions,26683db8-b319-4d67-8cd8-3c9803daa628,6/29/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,c55cf30f-6d98-4212-86bd-f7f9f08bbce3,7/21/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,d77f1654-4423-464f-a846-6767a2377ce1,1/14/2011,1,see,seek immediate medical therapy,,,
precautions,d77f1654-4423-464f-a846-6767a2377ce1,1/14/2011,1,see,signs of renal failure,,,
precautions,d77f1654-4423-464f-a846-6767a2377ce1,1/14/2011,1,see,seek immediate emergency help,,,
precautions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,MRHD,maximum recommended human dose,,,
precautions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,MRHD,maximum recommended human dose ,,,
precautions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,GFR,[glomerular filtration rate,,,
precautions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,INR,International Normalized Ratio,,,
precautions,d8d5631c-7390-9500-b1b0-9544b378f2e9,8/17/2009,1,AUC,Area Under the Curve,,,
precautions,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,Mice,Micronucleus Test,,,
precautions,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,CNS,central nervous system,,,
precautions,2b3b6a9f-259c-4736-b88f-f49d1eb64286,3/13/2012,9,INR,international normalized ratio,,,
precautions,9d73278f-c9c0-4e02-9879-8952a024421c,5/24/2011,4,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
precautions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,MRHD,maximum recommended human dose,,,
precautions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,GFR,[glomerular filtration rate,,,
precautions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,INR,International Normalized Ratio,,,
precautions,1501000f-664d-42ef-bff0-f85a7996b11c,2/8/2012,1,AUC,Area Under the Curve,,,
precautions,55e88727-864e-4313-860c-31a6ca45168f,10/11/2011,8,BUN,Blood Urea Nitrogen,,,
precautions,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,MRHD,maximum recommended human dose,,,
precautions,9f581c98-0631-414e-9676-0865a66dbc44,6/10/2008,1,DSST,digit symbol substitution test,,,
precautions,0bbc6889-0fd5-4763-97f4-061f5a50c7b1,4/15/2009,1,CHO,Chinese Hamster Ovary,,,
precautions,0bbc6889-0fd5-4763-97f4-061f5a50c7b1,4/15/2009,1,NTP,National Toxicology Program,,,
precautions,0bbc6889-0fd5-4763-97f4-061f5a50c7b1,4/15/2009,1,ACTH,adrenocorticotropic hormone,,,
precautions,b00b296d-6c34-48c8-9cfb-71ccc5c9a908,6/10/2011,1,MAOI,monoamine oxidase inhibitors,,,
precautions,265665e6-f527-4746-af8d-38ba25110b19,6/21/2012,1,MAO,monoamine  oxidase,,,
precautions,7B5F7DD0-0BFC-4DA4-9619-4FD0AFEB98A7,1/8/2007,1,IOP,intraocular pressure,,,
precautions,7B5F7DD0-0BFC-4DA4-9619-4FD0AFEB98A7,1/8/2007,1,CHO,Chinese hamster ovary,,,
precautions,8B84D814-9BB3-4677-AA3E-A04DE9302286,1/17/2008,1,GI,Gastrointestinal,,,
precautions,0d466214-78a8-44cd-923c-c286a0f74f66,3/23/2011,1,CYP,Cytochrome P450,,,
precautions,171c535c-1ed3-47bc-a0d5-c6f0e6986292,8/18/2011,1,CHF,congestive heart failure,,,
precautions,171c535c-1ed3-47bc-a0d5-c6f0e6986292,8/18/2011,1,NTS,nicotine transdermal system,,,
precautions,6281ca7c-2aec-4f14-b7e4-82401a701c96,9/19/2006,3,CHO,Chinese Hamster Ovary,,,
precautions,6281ca7c-2aec-4f14-b7e4-82401a701c96,9/19/2006,3,MRHD,maximum recommended human dose,,,
precautions,1e1ede8b-30a8-4892-bf7b-a4e1ed1e59f3,4/4/2012,1,MAO,monoamine  oxidase,,,
precautions,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,CHF,congestive heart failure,,,
precautions,c5c7ae0a-f7b5-4e0d-9e42-dfe76e3e5a00,3/1/2011,1,NTS,nicotine transdermal system,,,
precautions,c9080cf5-4fc3-4cf9-a241-6e40a6fddc75,10/11/2011,4,SCLC,small cell lung cancer,,,
precautions,ce081f5d-4db0-4b21-95e5-d7869e0b244c,4/11/2011,1,WBC,white blood cell count,,,
precautions,ce081f5d-4db0-4b21-95e5-d7869e0b244c,4/11/2011,1,PKU,phenylketonuria,,,
precautions,ce081f5d-4db0-4b21-95e5-d7869e0b244c,4/11/2011,1,CBC,complete blood count,,,
precautions,e8f5aad8-8984-4f1e-8ab0-72f7af5e42ea,10/5/2010,413,MRHD,Maximum Recommended Human Dose,,,
precautions,e8f5aad8-8984-4f1e-8ab0-72f7af5e42ea,10/5/2010,413,i.e.,in  vertebrates,,,
precautions,75a96561-6f52-4c11-a105-391fbbfe4827,10/3/2007,2,i.e.,increased risk of bleeding,,,
precautions,d5574dfc-203f-4540-bce2-c5f83aefc6bd,2/5/2009,3,Use,USAGE andDOSAGE AND ADMINISTRATION.,,,
precautions,A5420636-BB42-467C-9236-5AC8B9EE735C,7/28/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,I.M.,Intramuscular,,,
precautions,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,topical,acidsulindaccisapridemethimazole*tamoxifenclarithromycinmethyldopatetracyclineclofibratemethylphenidatethyroidwarfarin sodium overdosemethylsalicylate ointment,,,
precautions,10f74ba2-62f8-4c09-87a3-2598e870ddcf,4/7/2011,1,high dose,have been reported.alcohol*warfarin sodium underdosagephenytoin*aminoglutethimidecyclophosphamide*Pravastatin*amobarbitaldicloxacillinPrednisone*atorvastatin*ethchlorvynolprimidoneazathioprineglutethimidePropylthiouracil*butabarbitalgriseofulvinraloxifenebutalbitalhaloperidolranitidine*carbamazepinemeprobamaterifampinchloral hydrate*6-mercaptopurinesecobarbitalchlordiazepoxidemethimazole*spironolactonechlorthalidonemoricizine hydrochloride*sucralfatecholestyramine*nafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,64d4bbee-1cc4-409e-b65a-1f2e927cf0d1,2/21/2011,1,CHF,congestive heart failure,,,
precautions,64d4bbee-1cc4-409e-b65a-1f2e927cf0d1,2/21/2011,1,MRHD,maximum recommended human dose,,,
precautions,64d4bbee-1cc4-409e-b65a-1f2e927cf0d1,2/21/2011,1,NTS,nicotine transdermal system,,,
precautions,e7a74ffc-83a4-45bf-9da7-359ef5e11679,8/19/2011,1,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,e222620f-0dc7-4d2d-8ea1-246189d8af9b,5/1/2010,9,FBG,fasting blood glucose,,,
precautions,628efd34-8121-4f8d-8006-f8f659b5dd29,4/25/2011,2,AUC,area under the curve,,,
precautions,3c85be0f-2731-44f1-a18e-d3852d54846f,10/17/2011,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,f2bc3c76-fd41-4a79-aa5d-3eb45133c1ee,3/11/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,f2bc3c76-fd41-4a79-aa5d-3eb45133c1ee,3/11/2010,1,HED,human equivalent dose,,,
precautions,6ebf24fd-41cd-4b3c-8176-a1436253ba2d,2/9/2012,6,CYP,cytochrome P450,,,
precautions,aae18c5d-5d4b-4fe2-930b-dbc58dc59665,4/25/2012,4,MRHD,maximum recommended human dose,,,
precautions,aae18c5d-5d4b-4fe2-930b-dbc58dc59665,4/25/2012,4,DSST,digit symbol substitution test,,,
precautions,E29270D6-0A99-4161-918F-26B3FCAD548D,2/6/2006,1,UDS,unscheduled DNA synthesis,,,
precautions,E29270D6-0A99-4161-918F-26B3FCAD548D,2/6/2006,1,Ames,assay using human lymphocytes was negative.Salmonella,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,ODV,O–desvenlafaxine,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,GAD,generalized anxiety disorder,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,ODV,O-desmethylvenlafaxine,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,EM,extensive metabolizers,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,MDD,major depressive disorder,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,PM,poor metabolizers,,,
precautions,3942d30d-827b-46c7-8454-3020d5d7865d,7/9/2010,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,476e704c-95ae-4591-94f7-ee4ab827ff13,2/23/2007,1,i.e.,inducers of CYP3A4,,,
precautions,18ecff0f-15f7-4a40-bec7-d0ea734d6ef6,3/22/2007,1,APCs,atrial premature contractions,,,
precautions,b35a72bb-c06b-4671-8dc2-ce0ccdf45ce9,5/14/2010,5,MRHD,*Maximum recommended human dose,,,
precautions,250d998f-7100-495c-81ff-10fcfd5ba61d,8/4/2010,2,ECT,electroconvulsive therapy,,,
precautions,250d998f-7100-495c-81ff-10fcfd5ba61d,8/4/2010,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,250d998f-7100-495c-81ff-10fcfd5ba61d,8/4/2010,2,MRHD,maximum recommended human dose,,,
precautions,250d998f-7100-495c-81ff-10fcfd5ba61d,8/4/2010,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,6c2db888-775c-4baf-a1b4-1cfa63b83357,6/18/2012,5,AUC,area under the curve,,,
precautions,e38126a5-9d6a-422f-812c-a01610108162,3/23/2011,1,CYP,Cytochrome P450,,,
precautions,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,ICU,Intensive Care Unit,,,
precautions,98ca2c17-43e2-49af-abbc-f870877e5786,5/14/2009,1,MH,Malignant Hyperthermia,,,
precautions,ab047628-67d0-4a64-8d77-36b054969b44,6/6/2011,1,botanicals,botanical medicines,,,
precautions,10898a71-a778-4e39-aadb-8f936c92aba2,7/12/2011,1,GFR,[glomerular filtration rate,,,
precautions,73aea9e0-ff14-4eac-97bd-3d3b6b7ed524,1/18/2012,6,Mice,Micronucleus Test,,,
precautions,73aea9e0-ff14-4eac-97bd-3d3b6b7ed524,1/18/2012,6,CNS,central nervous system,,,
precautions,4e66ad5c-572c-4819-8b6e-6930c33cc210,10/27/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,LFT,liver function tests,,,
precautions,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,AEDs,Antiepileptic Drugs,,,
precautions,9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A,1/30/2009,1,MRHD,maximum recommended daily human dose,,,
precautions,a34ae37c-f8a3-4817-b7f3-babe474255f4,6/14/2011,1,Mice,Micronucleus Test,,,
precautions,ac114cc0-70d3-4593-af05-55d6687fd01d,6/6/2011,2,e.g.,effects of digitalis,,,
precautions,51f4c57b-8aec-4916-bafe-db93818e1c62,8/30/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,51f4c57b-8aec-4916-bafe-db93818e1c62,8/30/2011,1,I.M.,Intramuscular,,,
precautions,3231dc15-5ce2-cf61-7d1f-bd86704269ae,10/20/2011,6,ANLL,acute nonlymphocytic leukemia,,,
precautions,f775d030-4a1a-4639-8de2-a4191c727900,2/10/2012,2,i.e.,indicated,,,
precautions,53522b35-6215-4e9c-b51d-8b81728e0817,11/1/2010,1,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,53522b35-6215-4e9c-b51d-8b81728e0817,11/1/2010,1,ie,increased risk of osteoporosis,,,
precautions,e235e2ea-9d09-426f-8849-468302aee1ae,7/11/2011,1,BUN,blood urea nitrogen,,,
precautions,9e8874f0-ad2e-41ce-8a35-bed819615a5d,5/26/2010,1,rat,rabbits when given in doses 13,,,
precautions,f0b60ec1-3fbc-4130-9235-22dcc96f8219,5/8/2012,1,MAO,monoamine  oxidase,,,
precautions,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,GFR,glomerular filtration rate,,,
precautions,4696e856-69c4-4e7e-b76d-d70d85c4b561,10/26/2011,1,BUN,blood urea nitrogen,,,
precautions,cd57e895-6816-4ef8-8bc6-4696d8c2f92f,9/14/2011,3,e.g.,effects of digitalis,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,OTC,over-the-counter,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,ECT,electroconvulsive therapy,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,MRHD,maximum recommended human dose,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,1292A04E-7220-4B2D-AE6F-334E1277000C,4/9/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,abbf31eb-9966-411a-9c5d-91025ff7a782,9/9/2010,4,CYP,cytochrome P450,,,
precautions,A4A44EB4-E84D-47BE-BFA4-9B1B193DD3F9,2/26/2009,1,ALL,acute lymphocytic leukemia,,,
precautions,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,LDH,lactate dehydrogenase,,,
precautions,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,ALT,alanine aminotransferase,,,
precautions,A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78,11/27/2006,3,AST,aspartate aminotransferase,,,
precautions,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,CNS,central nervous system,,,
precautions,c470ff87-657d-4051-8422-19931f822cd4,12/12/2011,2,e.g.,exaggerated sunburn reactions,,,
precautions,d9db2fd3-a668-4d37-9082-18f6ceb8c3cb,2/2/2012,1,Pgp,P-glycoprotein,,,
precautions,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,PBI,protein-bound iodine,,,
precautions,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,TBG,thyroid-binding globulin,,,
precautions,DCC019EB-42F1-4A25-AF2A-6328B0FDB7D4,12/13/2006,1,i.e.,in serum,,,
precautions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CBZ,carbamazepine,,,
precautions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,NAAED,North American Antiepileptic Drug,,,
precautions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,SCE,sister chromatid exchange,,,
precautions,dbba2df7-6cb5-438f-bcde-6316f3fe10c8,2/23/2012,3,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,4b9f0bba-1bdf-4be0-846e-e25761946f71,12/8/2010,129,CBC,complete blood count,,,
precautions,bf7d0367-df73-47d2-b4a0-66bbf5e119a2,4/25/2011,2,AUC,area under the curve,,,
precautions,ee6e2161-789b-4ba0-b234-d4b36fe41c94,1/5/2011,1,MROHD,maximum recommended ocular human dose,,,
precautions,98C0C097-C253-4CC2-939E-6C172752D394,6/7/2006,1,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,477a318a-d594-4374-81d7-abd28a98bdd1,3/4/2009,1001,MAO,monoamine oxidase,,,
precautions,5abfea02-c3e4-4c09-8b4b-9159309ea6bf,10/17/2011,1,LFT,liver function tests,,,
precautions,22009d23-999c-4fa6-bfe7-21395f577236,9/17/2010,1,CHF,congestive heart failure,,,
precautions,22009d23-999c-4fa6-bfe7-21395f577236,9/17/2010,1,MRHD,maximum recommended human dose,,,
precautions,22009d23-999c-4fa6-bfe7-21395f577236,9/17/2010,1,NTS,nicotine transdermal system,,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,NET,norethindrone,,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,CBZ,"valign=""top"">Carbamazepine",,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,RHD,recommended human dose,,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,NAAED,North American Antiepileptic Drug,,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,HCTZ,Hydrochlorothiazide,,,
precautions,40c158ae-07b0-fae9-eecc-5acf8273c526,3/27/2009,1,EE,ethinyl estradiol,,,
precautions,cb97d4a0-89ed-407c-a763-209386b6f75c,1/23/2012,3,MAO,monoamine oxidase,,,
precautions,4021a77c-36ad-4f3a-bb4b-b44de96173b2,12/8/2009,1,MAO,monoamine oxidase,,,
precautions,4021a77c-36ad-4f3a-bb4b-b44de96173b2,12/8/2009,1,NTP,National Toxicology Program,,,
precautions,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,or delegate,of wholesaler records for verification of compliance with the iPLEDGE program by the isotretinoin manufacturer,,,
precautions,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,flare,full glass of liquid.Patients should be informed that transient exacerbation,,,
precautions,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,RMA,Risk Management Authorization,,,
precautions,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,LH,luteinizing hormone,,,
precautions,d5a26c5e-9c3e-4781-8c08-62b91d21a68d,11/7/2006,1,FSH,follicle stimulating hormone,,,
precautions,fe15e56e-8b86-4a65-825c-31d37dd81612,7/1/2012,6,MRHD,maximum recommended human dose,,,
precautions,fe15e56e-8b86-4a65-825c-31d37dd81612,7/1/2012,6,AEDs,antiepilepsy drugs,,,
precautions,fe15e56e-8b86-4a65-825c-31d37dd81612,7/1/2012,6,NAAED,North American Antiepileptic Drug,,,
precautions,fe15e56e-8b86-4a65-825c-31d37dd81612,7/1/2012,6,BUN,blood urea nitrogen,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,PM,PMs -38% to 105%,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,GAD,generalized anxiety disorder,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,ODV,O-desmethylvenlafaxine,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,EM,extensive metabolizers,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,MDD,major depressive disorder,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,eb28f976-ce74-47e1-7757-c0832c28be75,6/14/2012,10,PM,poor metabolizers,,,
precautions,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,F9A4752B-FDB0-4E26-A024-0C98D55F9DCA,8/12/2008,1,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,Mice,Micronucleus Test,,,
precautions,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,CNS,central nervous system,,,
precautions,7acb5b4b-5330-46b0-a400-90095826be43,6/7/2011,3,e.g.,exaggerated sunburn reactions,,,
precautions,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,CHF,congestive heart failure,,,
precautions,360a3cca-d823-468e-8cd0-d49f482e3d5e,5/12/2011,2,NTS,nicotine transdermal system,,,
precautions,e883e5ac-4ee4-466e-bb6c-bff0a5ea8479,9/1/2011,2,NET,norethindrone,,,
precautions,e883e5ac-4ee4-466e-bb6c-bff0a5ea8479,9/1/2011,2,see,systematically investigated,,,
precautions,e883e5ac-4ee4-466e-bb6c-bff0a5ea8479,9/1/2011,2,RHD,recommended human dose,,,
precautions,e883e5ac-4ee4-466e-bb6c-bff0a5ea8479,9/1/2011,2,HCTZ,Hydrochlorothiazide,,,
precautions,e883e5ac-4ee4-466e-bb6c-bff0a5ea8479,9/1/2011,2,EE,ethinyl estradiol,,,
precautions,ef345c23-20a8-40d4-bf3c-5650ed81e2f1,6/14/2012,1,ESR,Erythrocyte sedimentation rate,,,
precautions,295ac292-7b78-437b-9da0-98e02aaed215,11/10/2010,77,GFR,[glomerular filtration rate,,,
precautions,563e576e-6966-4f8d-91bb-0a1a951de324,4/30/2007,1,CNS,central nervous system,,,
precautions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,MRHD,maximum recommended human dose,,,
precautions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,MRHD,maximum recommended human dose ,,,
precautions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,GFR,[glomerular filtration rate,,,
precautions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,INR,International Normalized Ratio,,,
precautions,a4c012f0-50b6-42fb-9f06-a14632f23f2e,1/14/2011,5,AUC,Area Under the Curve,,,
precautions,7c50bb9c-7c49-4ba7-a3e5-c28ff0719ce5,5/19/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,A78ED96A-BE70-497D-BD65-CB0D797969A3,11/12/2008,2,sc,subcutaneous,,,
precautions,64d0b20a-cecd-474e-a0a1-8f8853500def,4/2/2012,4,Mice, Micronucleus Test,,,
precautions,b630824c-bee7-4a78-9349-d995c1eb0f16,3/12/2009,1,CHO,Chinese hamster ovary,,,
precautions,79c09ef1-9a3d-4566-b85e-a3b9d55d24d5,5/21/2012,1,MAO,monoamine  oxidase,,,
precautions,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,CHF,congestive heart failure,,,
precautions,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,MRHD,maximum recommended human dose,,,
precautions,82f5292b-b113-4f10-9469-04386fa8e9d4,10/22/2009,5,NTS,nicotine  transdermal system,,,
precautions,ab907b70-5cdc-49b4-a702-1b14e1351a96,8/8/2011,1,MAO,monoamine oxidase,,,
precautions,f75c59e5-c760-4c96-b902-8e9d69253c65,6/18/2012,1,MAO,monoamine  oxidase,,,
precautions,3b3d22dc-df09-4910-8c9b-1204eeedbd68,1/18/2012,6,Mice,Micronucleus Test,,,
precautions,3b3d22dc-df09-4910-8c9b-1204eeedbd68,1/18/2012,6,CNS,central nervous system,,,
precautions,34bc6919-b7bb-4b2e-962a-2ad695788f5b,12/15/2011,5,Mice,Micronucleus Test,,,
precautions,9661f969-f2f5-4bea-b757-2db5b404f288,12/13/2010,138,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,9661f969-f2f5-4bea-b757-2db5b404f288,12/13/2010,138,TCAs,tricyclic  antidepressants,,,
precautions,c095ffa5-3786-44ef-9a66-e8441e39dee1,9/8/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,ca6ae964-3b4b-4c24-a939-0100791ce1fe,4/16/2012,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,ca6ae964-3b4b-4c24-a939-0100791ce1fe,4/16/2012,2,CYP,cytochrome P450,,,
precautions,30a70882-b40a-4782-b227-cd0d35e50a26,7/25/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,bcd26183-313e-e4e1-092b-49b35b12863f,8/31/2009,10,MRHD,maximum recommended human dose,,,
precautions,6698016a-d9a5-4004-9302-5d202c626b2a,3/31/2011,1,GFR,[glomerular filtration rate,,,
precautions,243d736d-d7fc-493b-a98b-5c0224f55d84,10/29/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,90d1bade-5fc7-4a3e-8d73-99c99906f2e0,4/15/2011,3,CHF,congestive heart failure,,,
precautions,90d1bade-5fc7-4a3e-8d73-99c99906f2e0,4/15/2011,3,MRHD,maximum recommended human dose,,,
precautions,90d1bade-5fc7-4a3e-8d73-99c99906f2e0,4/15/2011,3,NTS,nicotine transdermal system,,,
precautions,1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA,9/19/2008,1,i.e.,inducers of CYP3A4,,,
precautions,c0031057-b10b-49d8-a156-df88ed34a943,5/12/2011,2,NSAIDs,non-steroidal anti-inflammatory drugs,,,
precautions,c0031057-b10b-49d8-a156-df88ed34a943,5/12/2011,2,ECG,electrocardiogram,,,
precautions,49E5A402-A084-4B48-9ADE-1E123F49391E,1/23/2008,1,MRHD,Maximum Recommended Human Dose,,,
precautions,27dd39ca-207e-44db-8da1-a0689f0d6b6f,10/23/2009,1,ie,in children and adolescents,,,
precautions,ec04ecbb-2896-3feb-85fd-a64aba93b289,8/1/2011,8,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,ec04ecbb-2896-3feb-85fd-a64aba93b289,8/1/2011,8,ie,increased risk of osteoporosis,,,
precautions,42abbb51-a476-4837-bdf9-01eb288ceec2,7/13/2011,4,MRHD,maximum recommended human dose,,,
precautions,42abbb51-a476-4837-bdf9-01eb288ceec2,7/13/2011,4,LNG,levonorgestrel,,,
precautions,42abbb51-a476-4837-bdf9-01eb288ceec2,7/13/2011,4,EE,ethinylestradiol,,,
precautions,ADA307F1-B6B1-4B64-A060-5C254B1948F2,3/28/2006,1,MRHD,maximum recommended human dose,,,
precautions,4f850eb2-3542-43a0-90e8-bb37fa05cf15,2/2/2011,1,SCLC,small cell lung cancer,,,
precautions,ac5d715d-6b6e-40d5-a5df-e3b884c3ef84,6/1/2012,2,botanicals,botanical medicines,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,PM,PMs - 38% to 105%,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,GAD,generalized anxiety disorder,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,ODV,O-desmethylvenlafaxine,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,ODV,O-desvenlafaxine,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,EM,extensive metabolizers,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,MDD,major depressive disorder,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,PM,poor metabolizers,,,
precautions,55889b3d-74c9-4638-9a14-6a4ca3a99f7f,3/2/2009,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,3e4402d4-e0d3-9846-3e81-ed46f34137fe,2/1/2012,9,Mice, Micronucleus Test,,,
precautions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,TCAs,Tricyclic Antidepressants,,,
precautions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,TCAs,tricyclic antidepressants,,,
precautions,08320ea3-8f93-6f04-5d1c-f69af3eb5a81,2/9/2012,6,ECT,Electroconvulsive Therapy,,,
precautions,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,37b264f9-b46d-4635-8fab-246b1e08b653,11/2/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,MRHD,maximum recommended human dose,,,
precautions,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,DVT,deep vein thrombosis,,,
precautions,94a4a99b-24df-4e81-b409-5325d36647d2,9/24/2008,1,PE,pulmonary embolus,,,
precautions,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,high dose,have been reported.Specific Drugs ReportedalcoholcyclophosphamidephenytoinaminoglutethimidedicloxacillinpravastatinamobarbitalethchlorvynolprednisoneatorvastatinglutethimideprimidoneazathioprinegriseofulvinpropylthiouracilbutabarbitalhaloperidolraloxifenebutalbitalJantovenTablets  underdosageranitidinecarbamazepinemeprobamaterifampinchloral hydrate6-mercaptopurinesecobarbitalchlordiazepoxidemethimazolespironolactonechlorthalidonemoricizine hydrochloridesucralfatecholestyraminenafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,IM,Intramuscular,,,
precautions,7f5b87ca-38c1-4f79-b130-a0498732a2e7,9/28/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,c709aa98-4999-4dda-81a5-cc3bbed74bba,5/21/2007,1,MRHD,Maximum Recommended Human Dose,,,
precautions,c709aa98-4999-4dda-81a5-cc3bbed74bba,5/21/2007,1,BSA,body surface area,,,
precautions,c709aa98-4999-4dda-81a5-cc3bbed74bba,5/21/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,OTC,over-the-counter,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,ECT,electroconvulsive therapy,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,MRHD,maximum recommended human dose,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,74d9e09f-b9aa-42ee-b1b8-293dca821dcf,3/17/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,17471bd6-4f48-40e0-952e-6a69bd0eeec9,9/1/2011,2,NET,norethindrone,,,
precautions,17471bd6-4f48-40e0-952e-6a69bd0eeec9,9/1/2011,2,see,systematically investigated,,,
precautions,17471bd6-4f48-40e0-952e-6a69bd0eeec9,9/1/2011,2,RHD,recommended human dose,,,
precautions,17471bd6-4f48-40e0-952e-6a69bd0eeec9,9/1/2011,2,HCTZ,Hydrochlorothiazide,,,
precautions,17471bd6-4f48-40e0-952e-6a69bd0eeec9,9/1/2011,2,EE,ethinyl estradiol,,,
precautions,A699724B-7412-479E-9894-4CF6EC454D8B,10/25/2007,6,MAO,monoamine oxidase,,,
precautions,c6613708-c1f7-4f5c-91a3-ebbc1d7905c6,9/16/2009,1,MH,malignant hyperthermia,,,
precautions,c6613708-c1f7-4f5c-91a3-ebbc1d7905c6,9/16/2009,1,MAP,mean arterial                                     pressure,,,
precautions,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,CVC,central venous catheter,,,
precautions,5cb9d285-1803-4a99-946a-d0b239b32df6,9/16/2010,6,i.e.,in a frozen state,,,
precautions,E177C228-33E1-4074-3E98-7D484C370E58,10/31/2007,4,AUC,area-under-the-time/concentration curve,,,
precautions,E177C228-33E1-4074-3E98-7D484C370E58,10/31/2007,4,rat,rabbits were approximately one-eighth,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,TERIS,Teratogen Information System,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,NSTs,nonstress tests,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,TERIS,there is no risk,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,MAO,Monoamine Oxidase,,,
precautions,DA0A54C6-8B53-4774-8C40-E615AC8D804D,9/16/2007,1,AUC,area under the concentration-time curve,,,
precautions,f78387c2-e64e-404c-a6e1-03328df2515e,11/19/2010,1,CNS,central nervous system,,,
precautions,f78387c2-e64e-404c-a6e1-03328df2515e,11/19/2010,1,NWS,neonatal withdrawal syndrome,,,
precautions,f78387c2-e64e-404c-a6e1-03328df2515e,11/19/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,f78387c2-e64e-404c-a6e1-03328df2515e,11/19/2010,1,MRHDD,maximum recommended human daily dose,,,
precautions,0ad893bd-5e2e-4ea4-b11c-80ed34a85b35,3/2/2012,3610,MO-TMS,methoxime-trimethylsilyl,,,
precautions,0ad893bd-5e2e-4ea4-b11c-80ed34a85b35,3/2/2012,3610,GC/MS,gas chromatography/mass spectrometry,,,
precautions,0ad893bd-5e2e-4ea4-b11c-80ed34a85b35,3/2/2012,3610,TLC,thin-layer chromatography,,,
precautions,0ad893bd-5e2e-4ea4-b11c-80ed34a85b35,3/2/2012,3610,GC/MS,Gas chromatography/mass spectrometry,,,
precautions,4a50cc68-af58-44e7-a278-728e781f0d4e,5/13/2011,1,ACTH,adrenocorticotropic hormone,,,
precautions,e962fb9a-d9fb-49c5-a8b4-0b355b8f829b,8/26/2010,2,CHF,congestive heart failure,,,
precautions,e962fb9a-d9fb-49c5-a8b4-0b355b8f829b,8/26/2010,2,MRHD,maximum recommended human dose,,,
precautions,e962fb9a-d9fb-49c5-a8b4-0b355b8f829b,8/26/2010,2,NTS,nicotine transdermal system,,,
precautions,f6095ec0-c17c-4ea1-847c-88c3e572d93c,4/20/2010,1,Mice, Micronucleus Test,,,
precautions,a5fcb10d-31f6-40bd-8e0e-f01e2eb8ef7f,9/2/2010,1,UDS,unscheduled  DNA synthesis,,,
precautions,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,SCE,sister chromatid exchanges,,,
precautions,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,IV,intravenous,,,
precautions,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,NOAEL,no observed adverse effect level,,,
precautions,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,PDT,verteporfin.Photodynamic therapy,,,
precautions,AC57F330-244D-48F8-A224-459C2BD2A970,4/23/2007,1,CHO,Chinese hamster ovary,,,
precautions,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,CBZ,carbamazepine,,,
precautions,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,SCE,sister chromatid exchange,,,
precautions,bcf57b31-4811-4104-82b3-46fb91a53ee0,1/10/2011,2,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,a22f30e6-e97f-458e-892f-6addefe3fecf,5/21/2012,1,MAO,monoamine  oxidase,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,ODV,O?desmethylvenlafaxine,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,PM,PMs - 38% to 105%,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,ODV,O-desmethylvenlafaxine,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,EM,extensive metabolizers,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,MDD,major depressive disorder,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,PM,poor metabolizers,,,
precautions,7027be98-61d6-a986-c9df-60ceef5f7ff0,10/29/2010,5,rat,rabbits given doses up to 2.5 times,,,
precautions,42ae28da-a613-4db4-b471-efa4e2638dc8,1/28/2009,2,CHO,Chinese Hamster Ovary,,,
precautions,8bcc115b-88da-4ff0-b4e1-ef10d5287e54,11/5/2010,1,ECG,electrocardiogram,,,
precautions,2238E083-08F2-0AA8-59B7-16B6D68DBD48,12/3/2008,1,CYP 3A,cytochrome P450 3A,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,CYP450,cytochrome P450,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,9C16F853-1A0B-4CE3-8E17-E2BF666C4292,10/9/2007,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,AF3CA49D-65E0-47BC-A2E6-A38277DB9408,2/6/2007,1,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,3F994C51-D9E5-450A-E4BE-EEB12D70D2A7,2/21/2007,2,CYP,cytochrome P450,,,
precautions,e2c1bea3-3c6d-4fe9-9bfd-09dbbce0fd7c,3/7/2012,1,NAAED,North American Antiepileptic Drug,,,
precautions,f7dcea2d-0dd4-48e6-9c7f-762331088298,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,patients.Dexamethasone suppression test,,,
precautions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,dexamethasone suppression test,,,
precautions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,CYP 3A4,cytochrome P450 3A4,,,
precautions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,HPA,hypothalamic-pituitary-adrenal,,,
precautions,1495284D-750F-437E-8525-6834CCCB78EB,1/9/2007,3,DST,use.Dexamethasone suppression test,,,
precautions,38f42bad-6b2a-423d-af66-0e526ba03da1,4/28/2010,1,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,38f42bad-6b2a-423d-af66-0e526ba03da1,4/28/2010,1,RIA,radioimmunoassay,,,
precautions,d17d767b-08c4-4a25-ad73-03a36d56902a,8/16/2011,6,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,FF96762D-A841-4558-BEFD-D14761BBE6FC,9/4/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,B5C93AB1-317E-4F99-9EC5-E47B30FAF650,4/9/2009,1,FT4I,free-T4 index,,,
precautions,f6c60617-2a61-448e-a79e-9003bca17e9d,9/29/2010,1,MRHD,*Maximum recommended human dose,,,
precautions,e4020ca3-82d0-4668-b4bc-92e4a53c1f4e,4/13/2011,1,NTP,National Toxicology Program,,,
precautions,01f1f478-5493-439f-9b99-f4f82023781c,2/3/2012,4,CHO,Chinese Hamster Ovary,,,
precautions,01f1f478-5493-439f-9b99-f4f82023781c,2/3/2012,4,NTP,National Toxicology Program,,,
precautions,01f1f478-5493-439f-9b99-f4f82023781c,2/3/2012,4,e.g.,effects of digitalis,,,
precautions,ae770b46-173e-42f8-b83e-efeb11b0fb11,8/26/2010,2,DST,dexamethasone suppression test,,,
precautions,10124262-e443-49a5-a1cc-8cc34c74d953,11/29/2010,1,MAO,monoamine oxidase,,,
precautions,A08B5877-E83E-449F-865E-30FCFBDE665F,1/24/2008,1,HPA,ratio.Hypothalamic-pituitary-adrenal,,,
precautions,A08B5877-E83E-449F-865E-30FCFBDE665F,1/24/2008,1,HPA,hypothalamic pituitary-adrenal,,,
precautions,56145d1a-1c0c-4c39-951e-45b9f324abcb,12/1/2010,1,NET,norethindrone,,,
precautions,56145d1a-1c0c-4c39-951e-45b9f324abcb,12/1/2010,1,RHD,recommended human dose,,,
precautions,56145d1a-1c0c-4c39-951e-45b9f324abcb,12/1/2010,1,HCTZ,Hydrochlorothiazide,,,
precautions,56145d1a-1c0c-4c39-951e-45b9f324abcb,12/1/2010,1,EE,ethinyl estradiol,,,
precautions,1c5bc1dd-e9ec-44c1-9281-67ad482315d9,8/16/2011,10,SAH,subarachnoid hemorrhage,,,
precautions,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,CBZ,carbamazepine,,,
precautions,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,SCE,sister chromatid exchange,,,
precautions,7386b72a-de47-48e3-b070-8bd9437c2230,4/13/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PT,prothrombin time,,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,DVT,deep vein thrombosis,,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,PE,pulmonary embolism,,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,aPTT,activated partial thromboplastin time,,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,IRIS study,interim analysis of an ongoing study,,,
precautions,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,4/14/2008,1,UFH,unfractionated heparin,,,
precautions,0a9891a2-fd39-47b0-adb2-2ed8392b6aff,6/27/2011,3,Mice, Micronucleus Test,,,
precautions,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,PBI,protein-bound iodine,,,
precautions,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,TBG,thyroid-binding globulin,,,
precautions,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,WHI,Women’s Health Initiative,,,
precautions,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,e5f5c46c-b8b7-4502-9d2b-8f12284d1a63,10/4/2010,2,i.e.,in serum,,,
precautions,4A18ECF0-8FD6-4A60-B88E-AE5AC73E958A,6/6/2006,1,UDS,unscheduled DNA synthesis,,,
precautions,cf6676ff-1122-4495-b64d-f70771a09633,1/22/2010,1,MAO,monoamine oxidase,,,
precautions,cf6676ff-1122-4495-b64d-f70771a09633,1/22/2010,1,NTP,National Toxicology Program,,,
precautions,5542fe40-8ae1-421a-b861-6f66f8b7f675,8/21/2006,1,CHO,Chinese hamster ovary,,,
precautions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,3b39a91e-f83c-45e3-bebc-a96078adc7f6,4/26/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,GAD,generalized anxiety disorder,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,ODV,O-desmethylvenlafaxine,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,EM,extensive metabolizers,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,MDD,major depressive disorder,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,04c95282-2e10-4ab5-baf2-62d44dd8f22f,11/30/2011,4,PM,poor metabolizers,,,
precautions,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,Mice,Micronucleus Test,,,
precautions,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,CNS,central nervous system,,,
precautions,a57066d7-dc2c-d2d0-b003-d9143fcca1c5,6/9/2004,1,e.g.,exaggerated sunburn reactions,,,
precautions,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,CYP3A4,cytochrome P450 3A4,,,
precautions,32c68820-1c9a-430c-9b4b-122c1ee15098,3/23/2011,1,e.g.,estradiol-containing drug products,,,
precautions,A7C486DA-1104-4566-A0BB-B8FFE5B964C4,11/17/2008,1,MRHTD,maximum recommended human topical dose,,,
precautions,1D7E21F7-00C1-4737-B663-C240BADCC206,6/20/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,e133d726-2a1f-4f9a-96b3-320f5cd9f7b0,1/14/2010,1,ECL,enterochromaffin-like,,,
precautions,c103da18-a822-4944-1bd7-8ecdb5205d69,2/13/2012,3,Mice, Micronucleus Test,,,
precautions,944d3e60-7eee-11de-a413-0002a5d5c51b,11/22/2011,9,MO-TMS,methoxime-trimethylsilyl,,,
precautions,944d3e60-7eee-11de-a413-0002a5d5c51b,11/22/2011,9,GC/MS,gas chromatography/mass spectrometry,,,
precautions,944d3e60-7eee-11de-a413-0002a5d5c51b,11/22/2011,9,TLC,thin-layer chromatography,,,
precautions,944d3e60-7eee-11de-a413-0002a5d5c51b,11/22/2011,9,GC/MS,Gas chromatography/mass spectrometry,,,
precautions,442AED6E-6242-4A96-90AA-D988B62D55E8,2/25/2008,3,MAO,monoamine oxidase,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,MRHD,maximum recommended human dose,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,NMS,Neuroleptic Malignant Syndrome,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,MRD,maximum recommended dose,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,ECT,Electroconvulsive Therapy,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,142F9B27-65A7-4ADD-BDCC-2468695FEDFF,3/17/2009,4,PPHN,pulmonary hypertension of the newborn,,,
precautions,d35a9f96-a0db-4060-9f9d-ba2117288fd0,7/9/2012,1,MAO,monoamine  oxidase,,,
precautions,0593fa48-8a47-4a0e-a9c6-2ef244470b4e,7/17/2012,1,MCI,mild cognitive impairment,,,
precautions,ad4cd608-ee26-4467-9957-a95b33101f9a,5/10/2006,1,MTD,maximally tolerated dose,,,
precautions,e3dffeff-e499-4b88-88ec-a968a35e1e18,4/13/2011,6,BUN,blood urea nitrogen,,,
precautions,45af3eda-caaa-4478-9372-95aa65adc9b3,5/29/2009,2,MPA,mycophenolic acid,,,
precautions,93c8fc6b-4a19-4f55-b7cf-8b0e1255cdf9,8/11/2010,347,e.g.,effects of digitalis,,,
precautions,f9a15b63-f48e-4802-bd4d-53fdb65ca6a2,12/11/2009,5,NTP,National Toxicology Program,,,
precautions,e7bfb636-4b0a-440c-a4d3-d26393a14ac5,2/7/2011,1,CPAP,continuous positive airway pressure,,,
precautions,e7bfb636-4b0a-440c-a4d3-d26393a14ac5,2/7/2011,1,MAO,Monoamine Oxidase,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,GAD,generalized anxiety disorder,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,ODV,O-desmethylvenlafaxine,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,ODV,O-desvenlafaxine,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,EM,extensive metabolizers,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,MDD,major depressive disorder,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2,1/22/2010,11,PM,poor metabolizers,,,
precautions,18705002-da4b-4562-b0d9-df3d56a16c84,12/9/2009,2,ie,in children and adolescents,,,
precautions,63656F64-E240-4855-8DF9-CA1655863735,3/28/2006,1,e.g.,enhancing                                             insulin secretion,,,
precautions,93B19AE0-C0A1-4400-9A56-6827939B7E7A,10/6/2006,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,93A0696B-B261-4262-9E06-F3180B419F8F,5/4/2007,1,p.p.,post-partum,,,
precautions,93A0696B-B261-4262-9E06-F3180B419F8F,5/4/2007,1,p.c.,post coitum,,,
precautions,10161af7-527c-426e-ac8e-c43e4736f2c1,6/25/2012,1,MAO,monoamine  oxidase,,,
precautions,7b466e08-a51f-414c-bf87-eafed577ff2d,10/29/2010,1,BSA,body surface area,,,
precautions,7b466e08-a51f-414c-bf87-eafed577ff2d,10/29/2010,1,MRHD,Maximum  Recommended Human Dose,,,
precautions,11882E93-AA62-4D24-895C-6F01D97FC730,5/13/2008,1,AUC,area under the curve,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,GAD,generalized anxiety disorder,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,ODV,O-desmethylvenlafaxine,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,EM,extensive metabolizers,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,MDD,major depressive disorder,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,72efad5f-0909-46a5-aa13-ac24fe015fe6,5/4/2011,3,PM,poor metabolizers,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,ECT,electroconvulsive therapy,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,TCAs,Tricyclic Antidepressants,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,MRHD,maximum recommended human daily dose,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,ECT,Electroconvulsive Therapy,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,613768da-6140-4c11-affc-85ba8fe92018,5/21/2010,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,OTC,over-the-counter,,,
precautions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,ECT,electroconvulsive therapy,,,
precautions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,MRHD,maximum recommended human dose,,,
precautions,Lb6cc6969-daa0-4211-872a-05453cb33c70,3/5/2007,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,cec41945-8d64-4793-8784-4c2b8ec37b0f,12/2/2010,8,CHF,congestive heart failure,,,
precautions,cec41945-8d64-4793-8784-4c2b8ec37b0f,12/2/2010,8,MRHD,maximum recommended human dose,,,
precautions,cec41945-8d64-4793-8784-4c2b8ec37b0f,12/2/2010,8,NTS,nicotine transdermal system,,,
precautions,ED73F7F4-0A3B-44DE-805A-3E26E20FB0B2,11/26/2008,5,HPA,hypothalamic-pituitary-adrenal,,,
precautions,ED73F7F4-0A3B-44DE-805A-3E26E20FB0B2,11/26/2008,5,HPA,ratio.Hypothalamic-pituitary-adrenal,,,
precautions,18f94d60-1385-483d-abed-b6ef38452225,2/1/2007,1,Ames test,area.Glimepiride was non-mutagenic in a battery ofin vitroandin vivomutagenicity studies,,,
precautions,a6c24189-293f-42ca-b969-75870bb55af0,1/21/2011,6,CNS,central nervous system,,,
precautions,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,Cefizox,ceftizoxime for injection,,,
precautions,0013824B-6AEE-4DA4-AFFD-35BC6BF19D91,6/8/2006,1,CPK,creatine phosphokinase,,,
precautions,5fa1e0b6-3836-4d56-99ee-0545908ee405,5/19/2010,1,MRHTD,maximum recommended human topical dose,,,
precautions,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,GI,Gastrointestinal,,,
precautions,86D83310-3668-44FA-A445-077FAEEC2FA9,10/30/2006,1,INR,International Normalized Ratio,,,
precautions,edd4dbbc-04ed-4741-9cd9-42e9b744f99e,5/25/2010,1,MRHD,maximum recommended human daily dose,,,
precautions,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,MRHD,maximum recommended  human dose,,,
precautions,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,MRHD,maximum recommended human dose,,,
precautions,fffb4e00-c921-4958-aeab-18deae4a2e38,3/29/2011,1,NTP,National Toxicology Program,,,
precautions,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,MRHD,maximum recommended human dose,,,
precautions,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,AEDs,antiepilepsy drugs,,,
precautions,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,11/4/2011,2,NAAED,North American Antiepileptic Drug,,,
precautions,88ac83d9-798a-4610-b242-c443b43bdc88,8/3/2010,2,MPA,mycophenolic acid,,,
precautions,479E8F92-21C0-4A8F-8298-76AF6B907D00,8/3/2007,2,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,APTT,Activated Partial Thromboplastin Time,,,
precautions,529711C6-6029-4E50-8ECE-C0E59B06FF38,3/4/2009,1,PT,Prothrombin Time,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,SNRIs,Serotonin and Norepinephrine Reuptake  Inhibitors,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,ODV,O-desmethylvenlafaxine,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,EM,extensive metabolizers,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,MDD,major depressive disorder,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,d87fba09-06b6-41a8-867c-a8428fce240e,5/13/2011,4,PM,poor metabolizers,,,
precautions,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,LDH,lactate dehydrogenase,,,
precautions,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,ALT,alanine aminotransferase,,,
precautions,1b3ee0b2-0bf7-49e2-a18e-d89421660a7b,8/2/2007,1,AST,aspartate aminotransferase,,,
precautions,7f9eb38f-0dfa-4798-b3c1-32381d33affa,12/5/2011,6,NET,norethindrone,,,
precautions,7f9eb38f-0dfa-4798-b3c1-32381d33affa,12/5/2011,6,RHD,recommended human dose,,,
precautions,7f9eb38f-0dfa-4798-b3c1-32381d33affa,12/5/2011,6,HCTZ,Hydrochlorothiazide,,,
precautions,7f9eb38f-0dfa-4798-b3c1-32381d33affa,12/5/2011,6,EE,ethinyl estradiol,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,OTC,over-the-counter,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,ECT,electroconvulsive therapy,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,MRHD,maximum recommended human dose,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2,8/2/2007,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,3b7f0fed-9046-4094-a131-29d560733e47,5/24/2010,1,MRHD,Maximum  Recommended Human Dose,,,
precautions,de5b78ab-ff79-3e0f-cad4-ecab11ebbdcd,9/2/2011,3,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,PM,PMs - 38% to 105%,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,GAD,generalized anxiety disorder,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,ODV,O-desmethylvenlafaxine,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,EM,extensive metabolizers,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,MDD,major depressive disorder,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,106d0d7b-925b-74e7-83cb-562144ce1f92,11/27/2009,3,PM,poor metabolizers,,,
precautions,1950F4D6-7FC2-44CD-9F7D-1359315353FC,5/23/2006,1,drying,Drug Interaction MAO inhibitors prolong and intensify the anticholinergic,,,
precautions,0ea81a95-cb4f-42af-be32-1cd6c9ab87ae,12/15/2010,1,i.e.,in the elderly,,,
precautions,0ea81a95-cb4f-42af-be32-1cd6c9ab87ae,12/15/2010,1,CHO,Chinese Hamster Ovary,,,
precautions,0ea81a95-cb4f-42af-be32-1cd6c9ab87ae,12/15/2010,1,NTP,National Toxicology Program,,,
precautions,f5c2fe10-c61f-4cbe-bc45-7ab14baa691c,12/31/2008,1,sc,subcutaneous,,,
precautions,1EFECA40-3DF8-4B89-950C-EC8CAC6B7780,1/30/2009,1,rT3,reverse T3,,,
precautions,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,MRHD,maximum recommended human dose,,,
precautions,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,GFR,glomerular filtration rate,,,
precautions,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,AEDs,antiepilepsy drugs,,,
precautions,d049bfcf-0634-4649-a782-12976ee4c49e,3/1/2011,1,BUN,blood urea nitrogen,,,
precautions,23f20b4e-e90a-4634-ab69-168151b4e90b,1/10/2011,1,MRDHD,maximum recommended daily human dose,,,
precautions,abf2fe45-8b69-4d3c-981e-289c0aa3e98b,4/30/2012,9,ACE,angiotensin-converting enzyme,,,
precautions,abf2fe45-8b69-4d3c-981e-289c0aa3e98b,4/30/2012,9,MRHD,Maximum Recommended Human Dose,,,
precautions,abf2fe45-8b69-4d3c-981e-289c0aa3e98b,4/30/2012,9,NTP,National Toxicology Program,,,
precautions,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,PBI,protein-bound iodine,,,
precautions,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,TBG,thyroid-binding globulin,,,
precautions,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,i.e.,in serum,,,
precautions,83B78F99-DF2E-46C5-B308-03BAC56A8C8F,3/30/2007,3,Estraderm®,estradiol transdermal system,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,GAD,generalized anxiety disorder,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,ODV,O-desmethylvenlafaxine,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,ODV,O-desvenlafaxine,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,EM,extensive metabolizers,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,MDD,major depressive disorder,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,04b9b820-228c-d7f8-519d-d65feb897199,5/7/2012,2,PM,poor metabolizers,,,
precautions,cc79e200-ce69-4ffd-be5b-8c1a6bb88c5c,4/24/2012,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,80E736D3-2017-4D68-94B4-38255C3C59C6,8/1/2008,1,ANA,antinuclear antibody,,,
precautions,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,MRHD,maximum recommended human dose,,,
precautions,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,AEDs,antiepilepsy drugs,,,
precautions,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,NAAED,North American Antiepileptic Drug,,,
precautions,f89aba5c-bd19-4476-925c-bd7bd34723bb,11/17/2010,2,BUN,blood urea nitrogen,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,CYP450,cytochrome P450,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,TCAs,Tricyclic Antidepressants,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,NMS,Neuroleptic Malignant Syndrome,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,ECT,Electroconvulsive Therapy,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,PM,poor metabolizers,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,EM,extensive metabolizers,,,
precautions,85B61F83-AB47-470D-8673-02FEA29247BE,9/20/2007,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,59702986-5a93-4a45-851f-c52dc5fdb3f6,7/28/2011,5,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,d197466a-c6c9-4d47-91f3-5f26b07bb943,2/22/2011,1,NSAIDS,Non-Steroidal Anti-Inflammatory DrugsNonsteroidal anti-inflammatory drugs,,,
precautions,d197466a-c6c9-4d47-91f3-5f26b07bb943,2/22/2011,1,MRHD,maximum recommended human oral daily dose,,,
precautions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,ARDS,adult respiratory distress syndrome,,,
precautions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,TdP,torsades de pointes,,,
precautions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,ALT,values-alanine aminotransferase,,,
precautions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,GGT,gamma-glutamyl transferase,,,
precautions,990C1CB3-3370-75E0-FF2A-BB51379F5DAB,1/22/2008,1,AST,aspartate aminotransferase,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,PM,PMs - 38% to 105%,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,ODV,O-desmethylvenlafaxine,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,EM,extensive metabolizers,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,84034bf7-0ba3-060d-73f5-275de6aff417,6/28/2010,1,PM,poor metabolizers,,,
precautions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,PTU,Propylthiouracil,,,
precautions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,PTU,<paragraph>Propylthiouracil,,,
precautions,951c6e16-7251-42ed-ac19-d8367a6aee4f,1/22/2010,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,012a7f03-269d-402c-923d-e5c317a795d2,6/9/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,SGOT,serum glutamic-oxalacetic transaminase,,,
precautions,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,MAO,monoamine oxidase,,,
precautions,c8b93fc1-472c-4890-8d02-2ee4f7175c22,10/25/2007,1,VMA,vanillylmandelic acid,,,
precautions,017021a4-25a4-4914-aab3-c21daf97ea50,3/15/2012,3,e.g.,effects of other drugs,,,
precautions,a4985462-793f-45ab-bbee-43bc9d1135ce,1/30/2012,10,CHO,Chinese hamster ovary,,,
precautions,486bad46-d856-4f02-8738-fbe4d5d3bff7,6/29/2012,3891,e.g.,effects of digitalis,,,
precautions,a57b8c7c-b8a9-45e4-b6fa-b83ebfbacae2,5/2/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,a57b8c7c-b8a9-45e4-b6fa-b83ebfbacae2,5/2/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9f6cbd82-7c2c-4810-aae0-e6d3ae55917d,8/17/2011,5,WBC,white blood cell count,,,
precautions,9f6cbd82-7c2c-4810-aae0-e6d3ae55917d,8/17/2011,5,CBC,complete blood count,,,
precautions,596c7a8f-27cd-4de2-9491-476f43570b8b,5/17/2007,1,ATNAA,ADMINISTRATION and Patient Instruction Sheet,,,
precautions,c14a40f7-6cd7-49c2-9e66-27cbff612257,8/25/2010,1,Mice,Micronucleus Test,,,
precautions,96549128-b031-4abd-a410-c7b1a877ce65,2/23/2011,1,HPA,Hypothalamic- pituitary-adrenal,,,
precautions,d36b7894-2152-452d-9bba-38067c52c79e,12/31/2006,1,LDH,lactate dehydrogenase,,,
precautions,d36b7894-2152-452d-9bba-38067c52c79e,12/31/2006,1,ALT,alanine aminotransferase,,,
precautions,d36b7894-2152-452d-9bba-38067c52c79e,12/31/2006,1,AST,aspartate aminotransferase,,,
precautions,d36b7894-2152-452d-9bba-38067c52c79e,12/31/2006,1,AUCs,affords minimal peak serum levels and systemic exposure,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,ECT,electroconvulsive therapy,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,TCAs,Tricyclic Antidepressants,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,UDS,unscheduled DNA synthesis,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,MRHD,maximum recommended human daily dose,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,ECT,Electroconvulsive Therapy,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,0979fb90-9c22-4b74-8648-1174b905654d,3/19/2010,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,ab2edabd-e57d-4754-9822-93bd17af9e88,6/14/2007,2,PSVT,paroxysmal supraventricular tachycardia,,,
precautions,BBDAF2F2-14E6-45C4-B807-5B22955444B0,9/9/2008,1,MCI,Mild Cognitive Impairment,,,
precautions,BBDAF2F2-14E6-45C4-B807-5B22955444B0,9/9/2008,1,MCI,mild cognitive impairment,,,
precautions,8944EA18-016E-4971-876D-2365FAC190EA,4/21/2008,1,MAOI's,monoamine oxidase inhibitors,,,
precautions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,ECT,electroconvulsive therapy,,,
precautions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,SSRI,selective serotonin reuptake inhibitor,,,
precautions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,MRHD,maximum recommended human dose,,,
precautions,a793ccd0-f47c-43f7-a085-62eb74ec6c35,9/28/2009,3,PPHN,pulmonary hypertension of the newborn,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,GAD,generalized anxiety disorder,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,EM,extensive metabolizers,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,MDD,major depressive disorder,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,83cb4d74-d75e-4aad-9bae-a09a5a789806,6/20/2011,1,PM,poor metabolizers,,,
precautions,0146650F-D6E6-4A9C-8925-415B3C92B0E7,2/22/2007,2,MRHD,maximum recommended daily human oral dose,,,
precautions,e8920d77-5d6e-4dc3-ad80-8b54861d93f8,9/15/2011,6,WBC,white blood cell count,,,
precautions,e8920d77-5d6e-4dc3-ad80-8b54861d93f8,9/15/2011,6,CBC,complete blood count,,,
precautions,01735685-40e0-4323-af5a-91db399f6451,4/2/2012,3,MRHD,maximum  recommended human dose,,,
precautions,01735685-40e0-4323-af5a-91db399f6451,4/2/2012,3,VMA,vanillylmandelic acid,,,
precautions,686B528E-5480-4CAA-8FF4-B1BAAF5983EC,12/7/2006,1,HPA,ratio.Hypothalamic-pituitary-adrenal,,,
precautions,83a2a183-7354-4ba8-bd8d-9b6fd1d1a351,1/11/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,3FDC757C-DFE5-4EB6-8753-9813B3F23B23,1/25/2008,1,Ames test,administration did not produce chromosome aberrations.in vitro bacterial reverse mutation assay,,,
precautions,70dbd2d1-f9d3-4bc7-936e-0768e84e8af7,4/12/2012,1,MAO,monoamine  oxidase,,,
precautions,2f522701-397a-11de-8a39-0800200c9a66,11/14/2011,5,AEDs,antiepileptic drugs,,,
precautions,5F06A992-93AE-461D-B605-9962249DAEBA,12/7/2006,1,sc,subcutaneous,,,
precautions,c77f3c7e-e8ef-4169-9672-04599a63638a,1/3/2012,3,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,LFT,liver function tests,,,
precautions,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,AEDs,Antiepileptic Drugs,,,
precautions,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,phenytoin,protein binding sites are therefore unlikely.Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies,,,
precautions,7d060be3-1429-46c7-b312-d5727064eaaa,1/21/2009,1,MRHD,maximum recommended daily human dose,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,TERIS,Teratogen Information System,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,NSTs,nonstress tests,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,TERIS,there is no risk,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,MAO,Monoamine Oxidase,,,
precautions,552751F7-42FF-40C7-8495-A6AA306D5C23,5/8/2008,2,AUC,area under the concentration-time curve,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,CNS,central nervous system,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,EPS,extrapyramidal signs and symptoms,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,LAIV,live attenuated influenza vaccine,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,IVF,in  vitro fertilization,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,NMS,Neuroleptic Malignant Syndrome,,,
precautions,14452da8-3b48-497d-9017-bdfb967b7f56,11/17/2010,1,GLP,Good Laboratory Practice,,,
precautions,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,MRHD,maximum recommended human dose,,,
precautions,bc7639e9-c2cb-47bb-a295-efb0f656ccd1,10/10/2009,1,DSST,digit symbol substitution test,,,
precautions,ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9,3/8/2010,1,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9,3/8/2010,1,RIA,radioimmunoassay,,,
precautions,4f4a52b2-a43f-4c72-bb0d-ead2cceb9feb,2/15/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,GAD,generalized anxiety disorder,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,EM,extensive metabolizers,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,MDD,major depressive disorder,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,51334651-7a7f-4653-bf9d-d5be04fd902d,5/4/2011,1,PM,poor metabolizers,,,
precautions,5ca97412-1594-4a4e-b5e4-8593ffa1b242,7/15/2011,2,GLP,Good Laboratory Practices,,,
precautions,67cb9ea4-5adb-4a3a-9568-266b6f472078,9/7/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,PM,PMs - 38% to 105%,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,ODV,O-desmethylvenlafaxine,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,EM,extensive metabolizers,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9a30e1b5-272b-4109-ad6c-a3c9a895822f,7/9/2012,5,PM,poor metabolizers,,,
precautions,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,ff281ebd-29c2-4852-a8ab-c4f21abe8b7c,4/23/2012,1,FBG,fasting blood glucose,,,
precautions,581623fe-14d9-44b3-b569-e5b5dc7cefb4,9/15/2011,1,WBC,white blood cell count,,,
precautions,581623fe-14d9-44b3-b569-e5b5dc7cefb4,9/15/2011,1,CBC,complete blood count,,,
precautions,7a83e68b-0c37-4e1a-9648-ce21fb4aff00,8/8/2006,1,i.e.,increased risk of osteoporosis,,,
precautions,91f37277-4aa2-44e0-a1ea-f47e9144c567,8/27/2010,1,CHF,congestive heart failure,,,
precautions,91f37277-4aa2-44e0-a1ea-f47e9144c567,8/27/2010,1,MRHD,maximum recommended human dose,,,
precautions,91f37277-4aa2-44e0-a1ea-f47e9144c567,8/27/2010,1,NTS,nicotine transdermal system,,,
precautions,6056b480-a27f-403f-b92b-b0bc6e5e7b0e,12/13/2011,1,Patients,patients,,,
precautions,6056b480-a27f-403f-b92b-b0bc6e5e7b0e,12/13/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,NET,norethindrone,,,
precautions,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,RHD,recommended human dose,,,
precautions,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,HCTZ,combination.Hydrochlorothiazide,,,
precautions,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,HCTZ,bleeding.Hydrochlorothiazide,,,
precautions,7f3d81cc-caec-47a0-b703-fdff6fbc3f6f,4/3/2009,1,EE,ethinyl estradiol,,,
precautions,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,PBI,protein-bound iodine,,,
precautions,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,TBG,thyroid-binding globulin,,,
precautions,410f9433-98ed-4c3f-abb1-2386296d2f72,9/1/2004,2,i.e.,in serum,,,
precautions,fb2f0e77-d674-4ac0-8b84-1454c113ed17,3/31/2011,3,TCAs,tricyclic antidepressants,,,
precautions,fb2f0e77-d674-4ac0-8b84-1454c113ed17,3/31/2011,3,SSRIs,selective serotonin reuptake  inhibitors,,,
precautions,c08efb51-2f14-4e11-a5b9-f4ff9d5dafb9,7/25/2007,2,CYP3A4,cytochrome P450 3A4 enzyme,,,
precautions,91571ecc-172d-458e-872d-89d71cb9c4b6,12/13/2011,3373,U.V.,ultraviolet,,,
precautions,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,NET,norethindrone,,,
precautions,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,CBZ,"valign=""top"">Carbamazepine",,,
precautions,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,RHD,recommended human dose,,,
precautions,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,HCTZ,Hydrochlorothiazide,,,
precautions,dede8847-972b-41df-9f68-2e069f269af8,4/18/2008,6,EE,ethinyl estradiol,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,CYP450,cytochrome P450,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,DEA,desethylamiodarone,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,CYP3A4,cytochrome P450 3A4,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,ARDS,unknown.Adult Respiratory Distress Syndrome,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,ARDS,amiodarone.Adult Respiratory Distress Syndrome,,,
precautions,99991CC3-7271-44FC-91C3-3CAB0BBE7645,9/12/2006,1,rT3,reverse T3,,,
precautions,ce3259a1-89f8-dd38-3e9f-296063af3e5e,9/1/2010,6,i.e.,inducers of CYP3A4,,,
precautions,CB06C97D-3B98-4C29-BCB2-5B04F41DB481,10/14/2008,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,SNRIs,serotonin norepinephrine reuptake  inhibitors,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,SSRIs,selective  serotonin reuptake inhibitors,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,SNRIs,serotonin norepinephrine  reuptake inhibitors,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,MTD,maximum tolerated dose,,,
precautions,294d60f3-005b-40d9-a404-cdd77f62b820,8/18/2010,354,MRHD,maximum recommended daily human dose,,,
precautions,f541cdc9-9f95-425d-bf5e-7f52baa0b6c5,7/22/2011,1,WBC,white blood cell count,,,
precautions,f541cdc9-9f95-425d-bf5e-7f52baa0b6c5,7/22/2011,1,CBC,complete blood count,,,
precautions,e608d164-5f77-40f5-a72b-26dd20ad7a8a,5/21/2010,1,NET,norethindrone,,,
precautions,e608d164-5f77-40f5-a72b-26dd20ad7a8a,5/21/2010,1,RHD,recommended human dose,,,
precautions,e608d164-5f77-40f5-a72b-26dd20ad7a8a,5/21/2010,1,HCTZ,Hydrochlorothiazide,,,
precautions,e608d164-5f77-40f5-a72b-26dd20ad7a8a,5/21/2010,1,EE,ethinyl estradiol,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,ODV,O–desvenlafaxine,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,GAD,generalized anxiety disorder,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,ODV,O-desmethylvenlafaxine,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,EM,extensive metabolizers,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,MDD,major depressive disorder,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,PM,poor metabolizers,,,
precautions,b23637e5-d37f-41b5-ba76-fc053e903bc2,5/6/2011,6,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,6e98e79a-7de2-4152-8077-ea2c7d342aef,3/28/2011,2,e.g.,effects of digitalis,,,
precautions,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,TFMA,4-trifluoromethylaniline,,,
precautions,68d04ab4-19c6-4d74-b346-2fe96452b4ad,1/29/2007,1,INR,International Normalized Ratio,,,
precautions,4A423BBA-3BC1-4323-ABBB-EF6C5C315784,11/17/2006,1,TSH,thyroid stimulating hormone,,,
precautions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,CYP450,cytochrome P450,,,
precautions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,DEA,desethylamiodarone,,,
precautions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,CYP3A4,cytochrome P450 3A4,,,
precautions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,rT3,reverse T3,,,
precautions,E542EE34-6519-4934-ABBD-58FD8A7440AF,2/12/2008,3,ARDS,Adult Respiratory Distress Syndrome,,,
precautions,85b7911b-061c-4646-bdd7-f1f8002cb4b9,8/24/2011,1,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,0971fa2e-d660-48b0-9fbb-96a2db167b92,4/30/2010,1,MAO,monoamine oxidase,,,
precautions,0971fa2e-d660-48b0-9fbb-96a2db167b92,4/30/2010,1,i.e.,interfere with antihypertensive  drugs,,,
precautions,c7961b19-3f23-4372-b071-34423124d801,3/24/2011,2,PKU,phenylketonuria,,,
precautions,fec93dc7-aba2-4aad-a529-8b6fc06f2562,5/23/2011,1,t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator,,,
precautions,fec93dc7-aba2-4aad-a529-8b6fc06f2562,5/23/2011,1,IM,Intramuscular,,,
precautions,fec93dc7-aba2-4aad-a529-8b6fc06f2562,5/23/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,BSA,body surface area,,,
precautions,75e05dc4-a378-4437-e399-6f890232206b,7/26/2011,1,MRP-2,multidrug-resistance-associated protein 2,,,
precautions,b4509afc-539b-4d7f-97d4-5e9c98c2f65a,7/1/2011,1,MRHD,maximum recommended human dose,,,
precautions,a9a60b57-445d-4c27-bdca-5a0cbfb90502,11/17/2011,6,Mice,Micronucleus Test,,,
precautions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,MRHD,maximum recommended human dose,,,
precautions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,TCAs,Tricyclic Antidepressants,,,
precautions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,TCAs,tricyclic antidepressants,,,
precautions,590CD4BB-C1BD-4CF1-893A-1E418621EED4,8/2/2007,2,ECT,Electroconvulsive Therapy,,,
precautions,b32fcb1b-fee4-44b8-a91c-10dfdd3f84ea,3/30/2010,2,WHIMS,Women's Health Initiative Memory Study,,,
precautions,b32fcb1b-fee4-44b8-a91c-10dfdd3f84ea,3/30/2010,2,WHI,Women's Health Initiative,,,
precautions,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,GFR,glomerular filtration rate,,,
precautions,fe9efeaf-09e3-4836-9ade-995cd3e59e45,2/14/2012,3563,BUN,blood urea nitrogen,,,
precautions,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,Patients,Patient Package Insert,,,
precautions,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,345478A6-8389-4229-92B3-6E40DA7B06FD,6/4/2007,2,AUCs,a measure of systemic exposure,,,
precautions,3154c861-62fd-487a-aac0-f5e79ae3b284,3/26/2012,2,GFR,[glomerular filtration rate,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,TERIS,Teratogen Information System,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,NSTs,nonstress tests,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,MAO,observation.Monoamine Oxidase,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,TERIS,there is no risk,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,AUC,area under the concentration-time curve,,,
precautions,D3B7A707-78AF-4FD5-9B66-B63050BBD6F6,3/30/2007,1,MAO,may be needed.OthersOthersMonoamine Oxidase,,,
precautions,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,CBZ,carbamazepine,,,
precautions,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,SCE,sister chromatid exchange,,,
precautions,6541ab19-3cfc-4786-9cfe-0455f428edb5,4/5/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,384848CD-55EA-4107-89D3-CE0B819F4DD2,8/28/2008,1,ONJ,Osteonecrosis of the jaw,,,
precautions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,MRHD,maximum recommended human dose,,,
precautions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,MRHD,maximum recommended human dose ,,,
precautions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,GFR,[glomerular filtration rate,,,
precautions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,INR,International Normalized Ratio,,,
precautions,18a9c172-7081-484a-8c3b-bde9b2e54e95,12/20/2011,2,AUC,Area Under the Curve,,,
precautions,7cf101d0-6515-4474-b451-c58e119ad72c,7/10/2011,1,CHO,Chinese Hamster Ovary,,,
precautions,7cf101d0-6515-4474-b451-c58e119ad72c,7/10/2011,1,NTP,National Toxicology Program,,,
precautions,7cf101d0-6515-4474-b451-c58e119ad72c,7/10/2011,1,e.g.,effects of digitalis,,,
precautions,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,Mice,Micronucleus Test,,,
precautions,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,CNS,central nervous system,,,
precautions,be48d02c-5c26-471c-8cd0-6bbbc04fd441,3/12/2012,3,INR,international normalized ratio,,,
precautions,6cef2a80-c7e5-44a2-92db-06082092bb35,12/10/2010,1,UV,ultraviolet,,,
precautions,6cef2a80-c7e5-44a2-92db-06082092bb35,12/10/2010,1,MPA,mycophenolic acid,,,
precautions,856d0894-e840-4b87-95aa-3085d5aed5be,8/7/2008,1,MAO,monoamine oxidase,,,
precautions,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,Mice,Micronucleus Test,,,
precautions,6ca65e3e-75ed-46b2-8cca-60bc9dbbe8f7,3/5/2012,5,CNS,central nervous system,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,TERIS,Teratogen Information System,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,NSTs,nonstress tests,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,AUC,area under the concentration-time  curve,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,TERIS,there is no risk,,,
precautions,cf10ec82-1f41-45c0-b438-5ade38b5625a,6/14/2010,1,MAO,Monoamine Oxidase,,,
precautions,af67a2f3-65b7-4a6e-9a51-315a280f976b,10/1/2007,1,HAMA,human anti-mouse antibodies,,,
precautions,AE6C88E4-C6E6-4C5F-8248-F1D01D73DAB2,12/18/2008,2,AUCs,a measure of systemic exposure,,,
precautions,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,Mice,Micronucleus Test,,,
precautions,d54a97d5-3664-4ca5-bffd-8366c7255b73,5/23/2012,8,CNS,central nervous system,,,
precautions,c446aed2-1add-4b09-9cc2-69ab95ae12d2,7/26/2011,3,IVF,in vitro fertilization,,,
precautions,c446aed2-1add-4b09-9cc2-69ab95ae12d2,7/26/2011,3,LAIV,live attenuated influenza vaccine,,,
precautions,c446aed2-1add-4b09-9cc2-69ab95ae12d2,7/26/2011,3,GLP,Good Laboratory Practice,,,
precautions,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,UCD,WARNINGS-Urea Cycle Disorders,,,
precautions,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,CBZ,carbamazepine,,,
precautions,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,NAAED,North American Antiepileptic Drug,,,
precautions,ab6f3285-69d5-4889-ae56-84afc6f042bd,1/5/2010,4,SCE,sister chromatid exchange,,,
precautions,74ae4775-8190-4bab-93d0-0f209023f973,5/10/2010,1,NSAIDs,nonsteroidal  anti-inflammatory drugs,,,
precautions,03c66d8c-186a-4923-9a32-07ab07d472ad,1/10/2012,1,ie,in children and adolescents,,,
precautions,5C3C2527-0FC0-4C13-A551-3B80E527BFE5,8/4/2007,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,543f84b1-a040-48aa-8628-0809e114448d,3/28/2011,1,eg,effects of digitalis,,,
precautions,bd3b62b6-4a80-495b-a1d3-d54eb15baf79,3/31/2011,1,LDH,lactate dehydrogenase,,,
precautions,bd3b62b6-4a80-495b-a1d3-d54eb15baf79,3/31/2011,1,ALT,alanine aminotransferase,,,
precautions,bd3b62b6-4a80-495b-a1d3-d54eb15baf79,3/31/2011,1,AST,aspartate aminotransferase,,,
precautions,331f6960-a09d-4513-9e6b-a03527d9131e,4/25/2012,2,MAO,monoamine  oxidase,,,
precautions,09f988b2-e313-4568-964e-fe1f23ab2b59,8/31/2010,1,MAOI,monoamine oxidase inhibitors,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,ECT,Electroconvulsive therapy,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,MRHD,maximum recommended human dose,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,MRD,maximum recommended dose,,,
precautions,F63868AF-7C5B-430A-81E7-2483286936F1,9/16/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,49f8ca7e-bedd-40b4-a31a-b1493b32c58b,12/16/2010,148,SIADH,syndrome of inappropriate  antidiuretic hormone secretion,,,
precautions,cab63f24-8728-4927-aba5-53e8d2e44cdb,2/29/2012,5,i.e.,inducers of CYP3A4,,,
precautions,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,Patients,Patient Package  Insert,,,
precautions,2cfedf7a-8ec2-4060-a4cf-305c06e03192,1/3/2012,7,i.e.,in  vertebrates,,,
precautions,151d1497-7655-44ce-8e97-dd1cd91f686a,11/15/2010,2,MRHD,maximum recommended human dose,,,
precautions,DF687429-C3D0-4987-9CF0-B958B8EE6290,1/4/2006,1,Patients,patient is incompetent,,,
precautions,c90be37c-0ad0-4ccd-8fe7-b9a3427f0d80,10/26/2011,1,botanicals,botanical medicines,,,
precautions,45d52221-5644-4f07-91eb-40faf3f899e6,12/21/2011,3412,NWS,neonatal withdrawal  syndrome,,,
precautions,45d52221-5644-4f07-91eb-40faf3f899e6,12/21/2011,3412,CNS,central  nervous system,,,
precautions,45d52221-5644-4f07-91eb-40faf3f899e6,12/21/2011,3412,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,45d52221-5644-4f07-91eb-40faf3f899e6,12/21/2011,3412,MRHD,maximum recommended human dose,,,
precautions,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,CHO,Chinese Hamster Ovary,,,
precautions,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,NTP,National Toxicology Program,,,
precautions,d188b06d-1d45-4a1d-85f8-cd485c53d527,11/19/2010,5,e.g.,effects of digitalis,,,
precautions,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,PTU,<br/>Propylthiouracil,,,
precautions,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,PTU,<br/>Lithium<br/>Methimazole<br/>Propylthiouracil,,,
precautions,abe005b2-d962-4ba7-9cb6-a09d35e68ae7,10/1/2009,2,FT4I,free T4 index,,,
precautions,A0067DCB-4FEA-4A88-A0B1-315A2C21966C,2/6/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,MRHD,maximum recommended human dose,,,
precautions,8fef39a1-b4bf-4583-b6f2-5b89990c6c86,5/23/2012,1,DSST,digit symbol substitution test,,,
precautions,8362b919-efa6-4451-8c44-49380f81b5db,7/8/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,6f25ed16-e5e9-4170-b4b4-3b460887779d,1/1/2011,1,MRHDD,maximum recommended human daily dose,,,
precautions,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,FIT,Fracture Intervention Trial,,,
precautions,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,HRT,Estrogen/hormone replacement therapy,,,
precautions,4323d3aa-cbb0-41e2-aba7-7a94a0516993,6/6/2011,2,ONJ,Osteonecrosis of the jaw,,,
precautions,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,i.e.,indicated,,,
precautions,754e8580-c710-4a60-8c4e-184be3cf1f41,11/24/2006,1,i.e.,interaction,,,
precautions,a204c899-a892-41db-a96b-45478e5588f2,6/14/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,235952e6-f748-4408-a8e7-7d980da0e5e6,7/1/2009,2,CHF,congestive heart failure,,,
precautions,235952e6-f748-4408-a8e7-7d980da0e5e6,7/1/2009,2,MRHD,maximum recommended human dose,,,
precautions,235952e6-f748-4408-a8e7-7d980da0e5e6,7/1/2009,2,NTS,nicotine transdermal system,,,
precautions,099c0df0-098d-40d4-854e-3fb9b33e13d3,9/21/2011,1,LFT,liver function tests,,,
precautions,5f36e697-5a4c-419f-882e-d2d35e829635,2/10/2012,1,CHF,congestive heart failure,,,
precautions,5f36e697-5a4c-419f-882e-d2d35e829635,2/10/2012,1,NTS,nicotine transdermal system,,,
precautions,6c826b0a-ac87-48cc-a780-9a4a2118e8a8,6/11/2010,1,NWS,neonatal withdrawal  syndrome,,,
precautions,6c826b0a-ac87-48cc-a780-9a4a2118e8a8,6/11/2010,1,CNS,central  nervous system,,,
precautions,6c826b0a-ac87-48cc-a780-9a4a2118e8a8,6/11/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,6c826b0a-ac87-48cc-a780-9a4a2118e8a8,6/11/2010,1,MRHD,maximum recommended human dose,,,
precautions,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,GI,Gastrointestinal,,,
precautions,4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B,1/1/2007,1,INR,International Normalized Ratio,,,
precautions,9d222859-6697-47bf-98ec-91984002e0d9,6/1/2010,2,UDS,unscheduled DNA synthesis,,,
precautions,36F623DF-2AE3-4858-9783-C058097951F4,2/27/2007,2,i.e.,increased risk of osteoporosis,,,
precautions,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,5HIAA,5-hydroxy indoleacetic  acid,,,
precautions,577b9f26-ab59-4b15-a26a-465f0d255bad,8/13/2010,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,801e4da1-5459-47d2-b67b-009f0a3247cc,6/3/2010,1,botanicals,botanical medicines,,,
precautions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,depression.Monoamine oxidase,,,
precautions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,of:Monoamine oxidase,,,
precautions,A5183AE7-81F9-4771-9609-5544A2712672,4/19/2007,1,MAO,inhibitors;Monoamine oxidase,,,
precautions,7789ec40-7c8d-4f44-bc04-784d3d686d03,6/19/2012,1,MAO,monoamine  oxidase,,,
precautions,ECA8BCBB-33E4-4EF9-9BA5-2D8C91E2DAEA,4/7/2006,1,AUC values,and reproductive performance were not affected in rats at plasma exposures,,,
precautions,ECA8BCBB-33E4-4EF9-9BA5-2D8C91E2DAEA,4/7/2006,1,Pgp,P-Glycoprotein,,,
precautions,ECA8BCBB-33E4-4EF9-9BA5-2D8C91E2DAEA,4/7/2006,1,PPI,Patient Package Insert,,,
precautions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAOI,Solution.Monoamine Oxidase Inhibitors,,,
precautions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAOI,caution.Monoamine Oxidase Inhibitors,,,
precautions,AB79AE6F-A8DC-4F6F-9093-D46902724669,10/10/2008,2,MAO,monoamine oxidase,,,
precautions,5f742224-618e-4f4c-bdec-7693be99c697,5/29/2009,1,MPA,mycophenolic acid,,,
precautions,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,Mice,Micronucleus Test,,,
precautions,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,CNS,central nervous system,,,
precautions,b08afc40-cfb0-4808-aa0b-b8a2b6008dd8,2/6/2012,1,e.g.,exaggerated sunburn reactions,,,
precautions,1b0bcd3d-de49-4a1a-b94c-8a3853175580,9/15/2011,2,WBC,white blood cell count,,,
precautions,1b0bcd3d-de49-4a1a-b94c-8a3853175580,9/15/2011,2,CBC,complete blood count,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,ECT,electroconvulsive therapy,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,TCAs,Tricyclic Antidepressants,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,UDS,unscheduled DNA synthesis,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,MRHD,maximum recommended human daily dose,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,ECT,Electroconvulsive Therapy,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,e7a2cbdd-1bdb-4e59-a3dd-298a189753ae,6/13/2012,7,PPHN,pulmonary hypertension of the newborn,,,
precautions,e2857ea0-df36-4d91-a705-a574fa323b2e,8/26/2010,1,SC,subcutaneous,,,
precautions,4734213a-034e-4d52-a4df-4f39ca93c228,5/9/2012,1,MAO,monoamine  oxidase,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,PM,PMs -38% to 105%,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,GAD,generalized anxiety disorder,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,ODV,O-desmethylvenlafaxine,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,EM,extensive metabolizers,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,MDD,major depressive disorder,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,53c3e7ac-1852-4d70-d2b6-4fca819acf26,11/29/2011,14,PM,poor metabolizers,,,
precautions,c77ababd-a449-4e89-a9c6-b7e401120ba1,12/28/2010,2,NOEL,no-observed-effect-level,,,
precautions,c77ababd-a449-4e89-a9c6-b7e401120ba1,12/28/2010,2,NOAEL,no-observed-adverse-effect-level,,,
precautions,c77ababd-a449-4e89-a9c6-b7e401120ba1,12/28/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,e2d3f96d-7e36-4b80-8fa5-7a4e606148c3,9/14/2011,1,Patients,patients,,,
precautions,e2d3f96d-7e36-4b80-8fa5-7a4e606148c3,9/14/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,6467d400-d373-4137-af06-568b98813c8e,8/13/2010,1,HIT,Heparin-induced Thrombocytopenia,,,
precautions,6467d400-d373-4137-af06-568b98813c8e,8/13/2010,1,HITT,Heparin-induced Thromocytopenia and Thrombosis,,,
precautions,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,Mice,Micronucleus Test,,,
precautions,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,CNS,central nervous system,,,
precautions,ef468722-68cd-440b-afd7-2285029db41f,1/11/2011,2,e.g.,exaggerated sunburn reactions,,,
precautions,dcae7a8a-9d9e-4f7f-954c-39e371f30f75,6/21/2011,2,INR,international normalized ratio,,,
precautions,dcae7a8a-9d9e-4f7f-954c-39e371f30f75,6/21/2011,2,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,dcae7a8a-9d9e-4f7f-954c-39e371f30f75,6/21/2011,2,ARBs,angiotensin receptor blockers,,,
precautions,dcae7a8a-9d9e-4f7f-954c-39e371f30f75,6/21/2011,2,ACE,angiotensin converting enzyme,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,ECT,electroconvulsive therapy,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,TCAs,Tricyclic Antidepressants,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,UDS,unscheduled DNA synthesis,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,MRHD,maximum recommended human daily dose,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,ECT,Electroconvulsive Therapy,,,
precautions,08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0,9/16/2007,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,7010b662-8b34-49ce-8e5b-73dee0821a60,5/13/2010,5,FBG,fasting blood glucose,,,
precautions,dd7f12a7-7fe5-470b-b151-6ccf19945638,8/3/2010,1,MRHDD,maximum recommended human daily dose,,,
precautions,feaa5f6f-9753-4f37-ab81-04c9c6b45e6a,6/6/2011,1,botanicals,botanical medicines,,,
precautions,ff54560e-c905-4df4-b101-1f19a87af562,11/24/2010,463,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,CHF,congestive heart failure,,,
precautions,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,MRHD,maximum recommended human dose,,,
precautions,0d1715b2-4193-43d6-9a23-0469d6338ea4,7/18/2011,1,NTS,nicotine  transdermal system,,,
precautions,e6dbc897-3ced-4bec-a02d-6def2cef3551,6/21/2012,1,MAO,monoamine  oxidase,,,
precautions,b32d82ee-7727-4501-a858-a8304135b11b,1/12/2011,1,APTT,activated partial thromboplastin times,,,
precautions,7ef6e753-7e8a-4ded-84a9-d7aae9f6f2db,5/19/2010,311,MRDHD,maximum recommended daily human dose,,,
precautions,7cee4c3b-1ee0-42c6-9b3a-cf9d0dd7957b,1/9/2012,2,CYP3A,cytochrome P450 33A,,,
precautions,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,MI,myocardial infarction,,,
precautions,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,GI,Gastrointestinal,,,
precautions,8FAD5C7C-15F1-4979-99A6-BAD75D45C393,9/13/2007,2,INR,International Normalized Ratio,,,
precautions,5b3201f8-fa99-41bf-84c1-4e9355a58ce6,5/16/2012,4,i.e.,increased risk of osteoporosis,,,
precautions,a1dc5b3f-0bca-461e-9018-32efcf335653,12/22/2011,2,CHF,congestive heart failure,,,
precautions,a1dc5b3f-0bca-461e-9018-32efcf335653,12/22/2011,2,NTS,nicotine transdermal system,,,
precautions,c8d2e135-ec31-4eee-bce2-c85e7858c5e1,3/9/2012,2,1 mg/kg/min,1000 mcg/kg/min,,,
precautions,c8d2e135-ec31-4eee-bce2-c85e7858c5e1,3/9/2012,2,10 mg/kg/min,10,000 mcg/kg/min,,
precautions,c8d2e135-ec31-4eee-bce2-c85e7858c5e1,3/9/2012,2,3 mg/kg/min,3000 mcg/kg/min,,,
precautions,c8d2e135-ec31-4eee-bce2-c85e7858c5e1,3/9/2012,2,2.5 mg/kg/min,2500 mcg/kg/min,,,
precautions,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,IVH,intraventricular hemorrhage,,,
precautions,315c128a-272d-4c57-bfbe-1a8b3402af08,7/21/2011,1,PVL,periventricular leukomalacia,,,
precautions,cb8b926d-cf66-bc7e-c940-e820fd4e877c,9/15/2009,1,MH,malignant hyperthermia,,,
precautions,cb8b926d-cf66-bc7e-c940-e820fd4e877c,9/15/2009,1,MAP,mean arterial                                     pressure,,,
precautions,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,CHO,Chinese Hamster Ovary,,,
precautions,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,NSAIDs,     Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,4b37f277-4319-4557-b613-657846993960,7/28/2011,1,NTP,National Toxicology Program,,,
precautions,92a6f533-1a3d-4734-b413-d245592454e3,1/11/2012,9,SGOT,Significant elevations of aminotransferase AST,,,
precautions,4e9b122b-eddf-42d3-aeae-bee38badb2d5,11/2/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,4e9b122b-eddf-42d3-aeae-bee38badb2d5,11/2/2011,2,TCAs,tricyclic  antidepressants,,,
precautions,ad556626-b390-4f8a-a431-9afcb4dd2a44,1/25/2010,1,MO-TMS,methoxime-trimethylsilyl,,,
precautions,ad556626-b390-4f8a-a431-9afcb4dd2a44,1/25/2010,1,GC/MS,gas chromatography/mass spectrometry,,,
precautions,ad556626-b390-4f8a-a431-9afcb4dd2a44,1/25/2010,1,TLC,thin-layer chromatography,,,
precautions,ad556626-b390-4f8a-a431-9afcb4dd2a44,1/25/2010,1,GC/MS,Gas chromatography/mass spectrometry,,,
precautions,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,NTP,National Toxicology Program,,,
precautions,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,CHO,Chinese  Hamster Ovary,,,
precautions,67a67718-e59f-4988-8bfc-9b4ac103e370,3/31/2011,1,e.g.,effects of digitalis,,,
precautions,8f6e4a86-5fc1-45b1-adab-25a81f93cb05,6/21/2011,1,Mice,Micronucleus Test,,,
precautions,c98d2f36-51b6-4b20-a278-27311303973f,5/5/2009,1,MAO,monoamine oxidase,,,
precautions,9A148542-E478-422A-B8FB-88047C30534B,11/29/2007,2,ECL,enterochromaffin-like,,,
precautions,99a81fda-81dc-40b3-b55a-165b6e4ca4ee,11/30/2011,2,Mice, Micronucleus Test,,,
precautions,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,CNS,central nervous             system,,,
precautions,d639081b-8b55-4f42-bdee-419e5ff5c04c,10/11/2010,49,e.g.,exaggerated sunburn reactions,,,
precautions,02500709-7f2c-4251-bd8c-94ab6cdadd4c,8/26/2010,1,CHF,congestive heart failure,,,
precautions,02500709-7f2c-4251-bd8c-94ab6cdadd4c,8/26/2010,1,MRHD,maximum recommended human dose,,,
precautions,02500709-7f2c-4251-bd8c-94ab6cdadd4c,8/26/2010,1,NTS,nicotine transdermal system,,,
precautions,8893395a-6bfa-4b3c-84c2-d1d0c923304f,7/12/2012,16,DTPA,99mTc-diethylenetriaminepentaacetic acid,,,
precautions,8893395a-6bfa-4b3c-84c2-d1d0c923304f,7/12/2012,16,NSAID,Nonsteroidal Anti-inflammatory Drug,,,
precautions,8893395a-6bfa-4b3c-84c2-d1d0c923304f,7/12/2012,16,SCE,sister chromatid exchange,,,
precautions,d76ebb82-bc6b-47fc-9a32-58357a43e783,1/24/2012,2,MAO,monoamine oxidase,,,
precautions,5747157d-7bcd-4021-83f1-289f348e9c3f,3/4/2010,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,a0e8f7d7-9316-4b78-acc8-17519b9b3165,6/27/2012,9,MAO,monoamine oxidase,,,
precautions,c7156e83-f344-4e9f-a42d-6dc8ce90a0b9,3/31/2011,1,METROGEL®,metronidazole topical gel,,,
precautions,4a246ce7-c04e-4119-9201-23e5f90152a8,6/30/2010,4,i.e.,in children and  adolescents,,,
precautions,d1f29fda-6ea3-4c53-bf2e-1128cc19d3e2,4/14/2008,2,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,4cafa90a-9903-40d0-b8be-6ad78018b4b6,2/9/2010,1,e.g.,estrogens,,,
precautions,89245260-c470-4a4c-8ef6-12598dc28e4c,6/23/2009,2,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,1395f5f3-f3dd-4223-81c1-f2b6da1b303b,1/20/2010,1,ECG,Electrocardiogram,,,
precautions,c7136fad-0fba-41e9-bc0a-36c275f18d27,5/9/2012,1,MAO,monoamine  oxidase,,,
precautions,0cbedaf8-da10-4a1c-8ca7-abf93723ca92,4/26/2011,1,WBC,white blood cell count,,,
precautions,0cbedaf8-da10-4a1c-8ca7-abf93723ca92,4/26/2011,1,CBC,complete blood count,,,
precautions,4A8AE85C-66A0-48BE-4099-B3C72C838176,5/11/2009,2,ALL,acute lymphocytic leukemia,,,
precautions,bf4d8d29-852d-4281-b732-4af0eca019e1,4/26/2011,2,LMA,laryngeal mask airway,,,
precautions,9940057a-831f-4bdb-8741-d10c0ca24925,10/8/2006,1,i.e.,interaction,,,
precautions,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator,,,
precautions,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,IM,Intramuscular,,,
precautions,896e6692-be60-4565-982d-0d1e1e0d6d54,11/30/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,d2e353a9-ac30-4378-af05-189b54b63e53,2/7/2012,1,WBC,white blood cell count,,,
precautions,d2e353a9-ac30-4378-af05-189b54b63e53,2/7/2012,1,PKU,phenylketonuria,,,
precautions,d2e353a9-ac30-4378-af05-189b54b63e53,2/7/2012,1,CBC,complete blood count,,,
precautions,d6de628c-bbe5-437e-9338-6f54cd661be1,4/6/2012,3,MAC,minimum alveolar concentration,,,
precautions,79e401a6-30ae-47b6-8faf-85a54f1090ad,12/28/2011,3431,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,FIT,Fracture Intervention Trial,,,
precautions,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,HRT,Estrogen/hormone replacement therapy,,,
precautions,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,ONJ,Osteonecrosis of the jaw,,,
precautions,2564646d-183c-4759-8726-155a4c22aa2b,1/11/2012,5,MRHD,maximum recommended human dose,,,
precautions,9953df12-a2b4-4d22-b204-746fc29f7a5f,5/31/2011,5,HPA,hypothalamic-pituitary-adrenal,,,
precautions,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,LFT,liver function tests,,,
precautions,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,NAAED,North American Antiepileptic Drug,,,
precautions,dd713e60-478c-43cd-b680-ff594a0b3864,10/16/2010,5,MRHD,maximum recommended daily human dose,,,
precautions,4536ad0b-42f4-4bd1-83d4-467762291664,12/20/2011,2,MRD,maximum recommended dose,,,
precautions,11939A69-D373-42DF-BABB-9FB7B9C8F6CB,3/7/2007,1,i.e.,increased risk of osteoporosis,,,
precautions,DE3C370C-7247-4260-8C6B-C0C35EB6F9BA,10/12/2007,2,Codeine,codeine phosphate,,,
precautions,B48476E0-9F63-483E-89FE-1AF123665951,12/12/2008,4,G-6-PD,glucose-6 phosphate dehydrogenase,,,
precautions,a0949773-c75f-4ef0-a69c-1abd978340d0,12/22/2010,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,ECT,Electroconvulsive therapy,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,MRHD,maximum recommended human dose,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,MRD,maximum recommended dose,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,3195db14-0cae-4b49-9fba-49b869fe92a8,3/23/2010,4,PPHN,pulmonary hypertension of the newborn,,,
precautions,a70baf53-e38a-4b23-8905-ee284170236d,3/6/2007,1,1 mg/kg/min,1000 mcg/kg/min,,,
precautions,a70baf53-e38a-4b23-8905-ee284170236d,3/6/2007,1,3 mg/kg/min,3000 mcg/kg/min,,,
precautions,475eeaf4-d675-49fb-b1be-657515968446,4/7/2011,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,5ed5bfc4-9c83-4921-a541-a401cf05f59f,6/20/2012,1,MAO,monoamine  oxidase,,,
precautions,1fdf16e5-145d-4c19-a318-fc6c10794b50,1/25/2012,1,AUC,area under the curve,,,
precautions,1109d178-d4f5-432b-ad50-0d446bb53584,9/21/2011,1,GFR,[glomerular filtration rate,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,TCAs,Tricyclic Antidepressants,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,NMS,Neuroleptic Malignant Syndrome,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,ECT,Electroconvulsive Therapy,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,EM,extensive metabolizers,,,
precautions,3fd2d938-38dc-4c40-94de-c9192a668048,3/10/2008,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9321c20d-04f4-2bcd-a080-43c9e45025b2,6/19/2006,2,botanicals,botanical medicines,,,
precautions,7cd48453-9303-4d63-825a-274ad54ba695,12/8/2011,2,PKU,phenylketonuria,,,
precautions,6FAF0958-76A3-49F1-A385-514298CB7992,3/3/2006,2,CHO,Chinese Hamster Ovary,,,
precautions,6FAF0958-76A3-49F1-A385-514298CB7992,3/3/2006,2,MAO,Monoamine oxidase,,,
precautions,6FAF0958-76A3-49F1-A385-514298CB7992,3/3/2006,2,NTP,National Toxicology Program,,,
precautions,6FAF0958-76A3-49F1-A385-514298CB7992,3/3/2006,2,e.g.,effects of digitalis,,,
precautions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,b7fe7a71-a1bc-47a6-9377-3e515090d7f7,5/16/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,PBI,protein-bound iodine,,,
precautions,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,TBG,thyroid-binding globulin,,,
precautions,1cd07b54-f66f-4040-9058-462324267196,9/1/2004,1,i.e.,in serum,,,
precautions,ea2a9cd6-1b03-4d96-9081-5cbc45473020,1/6/2012,14,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,ea2a9cd6-1b03-4d96-9081-5cbc45473020,1/6/2012,14,Patients,patient package insert,,,
precautions,ea2a9cd6-1b03-4d96-9081-5cbc45473020,1/6/2012,14,AUCs,a measure of systemic exposure,,,
precautions,3E28CF99-2B70-4FD7-7988-A808DFAC54C4,8/28/2007,2,MAC,minimum alveolar concentration,,,
precautions,1dc5c813-501a-43fe-ac86-ce5257f51410,4/26/2011,3,PBI,protein-bound  iodine,,,
precautions,1dc5c813-501a-43fe-ac86-ce5257f51410,4/26/2011,3,GGT,gamma glutamyl transpeptidase,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,OTC,over-the-counter,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,ECT,electroconvulsive therapy,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,MRHD,maximum recommended human dose,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,NSAID,NSAIDs that inhibit both cyclooxygenase isoenzymes,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,4A0AFC61-F83D-4871-86EB-929C9428A1E3,4/10/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a5215931-3385-4d8e-b121-47aa1c20420c,2/7/2008,1,MAOI,Monoamine oxidase inhibitors,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,TERIS,Teratogen Information System,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,NSTs,nonstress tests,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,MAO,observation.Monoamine Oxidase,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,TERIS,there is no risk,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,AUC,area under the concentration-time curve,,,
precautions,C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F,12/5/2007,2,MAO,may be needed.OthersOthersMonoamine Oxidase,,,
precautions,bac9ca81-db70-41aa-82af-6c5bb8496846,6/28/2010,2,UDS,unscheduled DNA synthesis,,,
precautions,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,botanicals,botanical medicines,,,
precautions,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,91fa852c-b43d-4a55-983b-74aa6827125d,9/25/2009,3,I.M.,Intramuscular,,,
precautions,dd6dda39-0e75-4a7a-bd6b-3fad3c462337,7/7/2011,1,GFR,[glomerular filtration rate,,,
precautions,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,Mice,Micronucleus Test,,,
precautions,739f14fe-1aa6-4880-ab68-4ab5c839eab8,3/9/2012,1,CNS,central nervous system,,,
precautions,d7214539-6c3d-466a-a474-6fde096fa182,2/3/2011,3,CHO,Chinese Hamster Ovary,,,
precautions,d7214539-6c3d-466a-a474-6fde096fa182,2/3/2011,3,NTP,National Toxicology Program,,,
precautions,d7214539-6c3d-466a-a474-6fde096fa182,2/3/2011,3,e.g.,effects of digitalis,,,
precautions,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,Cefizox,ceftizoxime for injection,,,
precautions,3574DF06-FEC5-4888-8080-3B817ADDFB02,8/4/2007,2,CPK,creatine phosphokinase,,,
precautions,f242cdf5-6921-431f-8add-4d17887ebc93,9/14/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,A8DF90D8-78B3-48C3-B42E-1E651D81454B,3/4/2009,2,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,A8DF90D8-78B3-48C3-B42E-1E651D81454B,3/4/2009,2,RIA,radioimmunoassay,,,
precautions,25c2a91c-dfc2-4596-8a24-63acf04a2568,7/9/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,58DDDE62-2BA2-4F39-8E32-5130D3963144,7/25/2006,1,CNS,Central Nervous System,,,
precautions,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,AUC,area under the concentration-time  curve,,,
precautions,052cc172-e3f8-436a-ad92-234c3b7b4e38,9/15/2010,387,MAO,Monoamine Oxidase,,,
precautions,33f3a036-780c-4f8c-8973-a44a6c49f9fe,6/15/2012,1,MAO,monoamine  oxidase,,,
precautions,5c5210b3-95c6-41f0-945a-3c3567b19b05,7/18/2012,2,CHF,congestive heart failure,,,
precautions,5c5210b3-95c6-41f0-945a-3c3567b19b05,7/18/2012,2,MRHD,maximum recommended human dose,,,
precautions,5c5210b3-95c6-41f0-945a-3c3567b19b05,7/18/2012,2,NTS,nicotine transdermal system,,,
precautions,5c5210b3-95c6-41f0-945a-3c3567b19b05,7/18/2012,2,SR®,(SR),,,
precautions,d6d6c0df-adbf-46a4-a709-091183a56ec2,10/10/2020,429,rats,rabbits at doses 40  times,,,
precautions,cf10d256-dd89-4a91-a3ed-81db505a79c2,10/31/2011,6,i.e.,inducers of CYP3A4,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,MRHD,maximum recommended human dose,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,MRD,maximum recommended dose,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,ECT,treatment.Electroconvulsive therapy,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,ECT,stopped.Electroconvulsive therapy,,,
precautions,cb8c497a-4c4e-4af7-84d0-04c8c4636630,8/27/2007,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,6025e8d4-5083-4c3a-58a0-050e7b0b6150,9/2/2011,10,MRHD,maximum recommend human dose,,,
precautions,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,MRHD,maximum recommended human dose,,,
precautions,d2f0b90f-9495-48c5-b21f-86e487a04854,5/17/2011,2,TSH,thyroid stimulating hormone,,,
precautions,78794e3d-f293-4eeb-22ac-8f536d5947eb,5/2/2012,11,i.e.,in children and adolescents,,,
precautions,78bdb7ca-acb0-491c-bed9-4ebbf2a07918,7/1/2012,6,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,MRHD,Maximum Recommended Human Dose,,,
precautions,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,03bdf36c-0cae-4d4f-b85d-99078bc12d11,6/27/2011,9,MTD,Maximum Tolerated Dose,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,PBI,protein-bound iodine,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,TBG,thyroid-binding globulin,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,WHI,Women's Health Initiative,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,SHBG,sex hormone binding globulin,,,
precautions,86b90d68-bfb6-47f6-aa5b-a6642391ff13,6/3/2010,1,CBG,corticosteroid  binding globulin,,,
precautions,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,PTT,partial thromboplastin time,,,
precautions,16399285-31cf-4ae2-b28e-76abf961e6e1,1/26/2006,1,PT,prothrombin                                             time,,,
precautions,fbf57c5a-7e0d-4537-9331-739375620ec7,5/9/2011,1,e.g.,effects of digitalis,,,
precautions,2cb9090d-76dd-44a2-9590-37c6e7ed495b,11/10/2009,4,GC/MS,gas  chromatography/mass spectrometry,,,
precautions,Leae41728-12e3-4bde-a6bb-b384a5cbae41,11/20/2007,1,MROHD,maximum recommended ocular human dose,,,
precautions,2cc75d23-408a-407a-93dd-640d49453292,12/21/2010,161,WBC,white blood cell count,,,
precautions,2cc75d23-408a-407a-93dd-640d49453292,12/21/2010,161,CBC,complete blood count,,,
precautions,8b245b30-1ee2-4d4b-8e8e-45d084bb7b6f,7/1/2009,2,CHF,congestive heart failure,,,
precautions,8b245b30-1ee2-4d4b-8e8e-45d084bb7b6f,7/1/2009,2,MRHD,maximum recommended human dose,,,
precautions,8b245b30-1ee2-4d4b-8e8e-45d084bb7b6f,7/1/2009,2,NTS,nicotine transdermal system,,,
precautions,5498f6aa-f4c1-49a3-b969-0711077dde81,8/23/2010,1,SC,subcutaneous,,,
precautions,d514ac98-2895-40f1-b1d2-00f3701434b5,9/22/2010,43,NAAED,North American Antiepileptic Drug,,,
precautions,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,MRHD,maximum recommended human dose,,,
precautions,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,BUN,blood urea nitrogen,,,
precautions,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,NTP,National Toxicology Program,,,
precautions,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,CHO,Chinese  Hamster Ovary,,,
precautions,f0266d1a-2af2-415b-9433-69b5a690f9bb,12/2/2010,1,e.g.,effects of digitalis,,,
precautions,7e351770-8975-4417-a599-feaa3cba7514,10/13/2010,1,NAAED,North American Antiepileptic Drug,,,
precautions,538D6550-D873-4236-B9B3-FFE33D34571D,10/16/2006,1,mouse,maleate was devoid of mutagenic potential when tested invivo,,,
precautions,b3bbc16e-8305-469a-9dc3-8e698339a98b,7/8/2010,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,141bddee-8e4d-4c68-89bf-03f2270c766d,1/15/2010,2,Mice,Micronucleus Test,,,
precautions,f7036088-40c5-444a-80d4-cead603d2f2e,12/11/2009,1,NTP,National Toxicology Program,,,
precautions,64cc3f79-7a39-44a4-8335-4bad29f3f277,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,91bd0351-f33c-43ca-bd77-7da97969985b,12/13/2010,1,Mice,   Micronucleus Test,,,
precautions,A0B58C0C-D67A-4BA6-8D84-CCDC78F24634,8/3/2007,1,PBI,Protein-bound iodine,,,
precautions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,TCAs,Tricyclic Antidepressants,,,
precautions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,TCAs,tricyclic antidepressants,,,
precautions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,ECT,Electroconvulsive Therapy,,,
precautions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,4a765347-d687-4af1-a33f-fbff972c6252,3/30/2011,1,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
precautions,17367E1C-A4AD-451B-92C4-95565312E51A,10/5/2006,1,RENESE,recommended human dose,,,
precautions,c3bd674c-cf21-4957-bbaf-ddd4b0770ff4,8/23/2011,1,Patients,patients,,,
precautions,c3bd674c-cf21-4957-bbaf-ddd4b0770ff4,8/23/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,4789c1dd-ae52-4962-be54-6ae7e08ac0e4,5/1/2007,1,CBC,complete blood count,,,
precautions,ADB54FE50FCC4A01AFC64AA3D3DB45BB,11/7/2006,2,AUC,area under the curve,,,
precautions,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,MRHD,maximum recommended human dose,,,
precautions,5f114994-7987-4cb6-be4a-f0fc37a54ddf,7/27/2011,1,DSST,digit symbol substitution test,,,
precautions,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,TBPA,thyroxine-binding  prealbumin,,,
precautions,a42269e2-227b-4009-a19b-dc3f7aec8374,10/27/2009,1,TBg,thyroxine-binding globulin,,,
precautions,58896863-63AC-4B99-9D3C-97CA472357C7,4/21/2008,1,TSH,thyroid stimulating hormone,,,
precautions,8fbbd6d1-637b-4f67-897d-ab5eaeb5cc0e,9/13/2010,25,GFR,[glomerular filtration rate,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,MRHD,maximum recommended human dose,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,UDS,unscheduled DNA synthesis,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,MRHD,maximum recommended human daily dose,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,a6ad0d10-3d6b-454c-a5a1-d95079befc48,6/14/2011,7,PPHN,pulmonary hypertension of the newborn,,,
precautions,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,AML,acute myelogenous leukemia,,,
precautions,6bcde92b-e584-4919-866a-68847ea201ba,2/20/2012,2,MDS,myelodysplastic syndrome,,,
precautions,3e64e493-ef35-43b9-b08c-3c30fe4a7164,12/13/2010,1,Mice,Micronucleus Test,,,
precautions,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,TERIS,Teratogen Information System,,,
precautions,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,AUC,area under the concentration-time  curve,,,
precautions,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,TERIS,there is no risk,,,
precautions,1deb3865-48b5-4860-880f-625f912d7ed4,2/6/2012,3539,MAO,Monoamine Oxidase,,,
precautions,fdebf4d8-8171-4e56-9aac-89d9c61f0929,12/2/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,7830fe02-a2ec-48cf-85ce-3e3f6dadab4e,10/9/2009,1001,UDS,unscheduled DNA synthesis,,,
precautions,7830fe02-a2ec-48cf-85ce-3e3f6dadab4e,10/9/2009,1001,DSI,DNA synthesis inhibition,,,
precautions,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,LFT,liver function tests,,,
precautions,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,AEDs,Antiepileptic Drugs,,,
precautions,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,NAAED,North American Antiepileptic Drug,,,
precautions,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,MRHD,maximum recommended daily human dose,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,PM,PMs -38% to 105%,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,see,serotonin syndrome,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,see,supplements is not recommended,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,GAD,generalized anxiety disorder,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,see and,Safety and effectiveness in the pediatric population have not been established,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,ODV,O-desmethylvenlafaxine,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,EM,extensive metabolizers,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,see,substantially altered in the elderly,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,MDD,major depressive disorder,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,PM,poor metabolizers,,,
precautions,db64c361-7960-4e86-8c71-5d96a381ae23,8/10/2011,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a6b1858a-e796-4cb0-8a4d-d5c521874e84,6/15/2011,1,NWS,neonatal withdrawal  syndrome,,,
precautions,a6b1858a-e796-4cb0-8a4d-d5c521874e84,6/15/2011,1,CNS,central  nervous system,,,
precautions,a6b1858a-e796-4cb0-8a4d-d5c521874e84,6/15/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,a6b1858a-e796-4cb0-8a4d-d5c521874e84,6/15/2011,1,MRHD,maximum recommended human dose,,,
precautions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,MRHD,maximum recommended human dose,,,
precautions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,MRHD,maximum recommended human dose ,,,
precautions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,GFR,[glomerular filtration rate,,,
precautions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,INR,International Normalized Ratio,,,
precautions,d0cda063-00c5-0921-ee39-d4de1381f91a,8/17/2009,1,AUC,Area Under the Curve,,,
precautions,A9ED59B9-B01C-4B39-80F6-A73053EC1AB6,10/20/2008,1,CHO,Chinese Hamster Ovary,,,
precautions,A9ED59B9-B01C-4B39-80F6-A73053EC1AB6,10/20/2008,1,NTP,National Toxicology Program,,,
precautions,A9ED59B9-B01C-4B39-80F6-A73053EC1AB6,10/20/2008,1,e.g.,effects of digitalis,,,
precautions,69049fa6-7dc4-4ae7-99f4-06839af06498,8/26/2010,1,AUC,area under the curve,,,
precautions,69049fa6-7dc4-4ae7-99f4-06839af06498,8/26/2010,1,AUC,area under the plasma concentrationtime curve,,,
precautions,88ee9c0e-aa2a-47ce-b649-25bfa6fc8a7b,3/12/2012,1,Mice,Micronucleus Test,,,
precautions,f15b043d-fcfa-4ade-a3da-76700c0c5c2a,12/28/2010,1,MPA,mycophenolic acid,,,
precautions,AF8317D7-B280-4F40-AD88-802F99D33D78,10/29/2008,1,HPA,ratio.Hypothalamic-pituitary-adrenal,,,
precautions,AAAF4D12-4E68-45F9-AC10-2238480A0160,4/5/2006,1,MAOI,caution.Monoamine Oxidase Inhibitors,,,
precautions,f21494ed-c5e8-4ddf-b140-ecd68c5c312b,8/8/2008,1,Pgp,Pglycoprotein,,,
precautions,8d27e3a8-292f-4afb-9277-03bce380364c,6/21/2012,1,MAO,monoamine  oxidase,,,
precautions,50a58159-9572-4445-9859-b392632597da,12/8/2011,6,CHO,Chinese hamster ovary,,,
precautions,bd637448-fc45-466d-af90-20e1560bc293,10/27/2009,2,AUCs,a measure of  systemic exposure,,,
precautions,BCC2D379-83D6-4B10-BA7F-729AE87FE57E,2/7/2007,1,HAPE,high altitude pulmonary edema,,,
precautions,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,PTU,<br/>Propylthiouracil,,,
precautions,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,PTU,<br/>Lithium<br/>Methimazole<br/>Propylthiouracil,,,
precautions,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,FT4I,free T4 index,,,
precautions,71139e30-10c8-4474-b7a3-b575c3fd32f9,3/23/2011,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,86e4b89d-42df-463d-a740-8d0d06b75daa,7/22/2011,1,GFR,[glomerular filtration rate,,,
precautions,92123CFA-5BD5-4554-8D5D-B877D5CB9C02,6/19/2007,1,5-HIAA,5-hydroxyindoleacetic acid,,,
precautions,92123CFA-5BD5-4554-8D5D-B877D5CB9C02,6/19/2007,1,VMA,vanillylmandelic acid,,,
precautions,07833fa7-ff72-44f0-b9e0-ed9f879f3289,4/12/2012,1,MAO,monoamine  oxidase,,,
precautions,b8e0d977-6eb7-4b14-9176-64e5738d14da,1/23/2012,3,MRHD,*Maximum recommended human dose,,,
precautions,e607b0e3-e22e-429f-b40a-0567ded993a7,4/27/2011,7,AUC,area under the curve,,,
precautions,b4219281-d79f-45ac-86dd-82c399415032,1/9/2012,1,CHF,congestive heart failure,,,
precautions,b4219281-d79f-45ac-86dd-82c399415032,1/9/2012,1,MRHD,maximum recommended human dose,,,
precautions,b4219281-d79f-45ac-86dd-82c399415032,1/9/2012,1,NTS,nicotine transdermal system,,,
precautions,a7791982-48e3-4a8a-afd2-f6977048c17c,8/23/2011,1,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,d63c6e0a-48c1-49f4-b07b-bc646bd90d8e,10/7/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,d63c6e0a-48c1-49f4-b07b-bc646bd90d8e,10/7/2011,1,ECG,electrocardiogram,,,
precautions,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,HRT,Estrogen/hormone replacement therapy,,,
precautions,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,FIT,Fracture Intervention  Trial,,,
precautions,e6ffadda-2ace-4e99-8bb4-75631c54f39b,3/5/2010,1,ONJ,osteonecrosis of the jaw,,,
precautions,A1A8067E-2C0A-4161-A299-1DF7C9C8D84C,11/29/2007,2,CHO,Chinese Hamster Ovary,,,
precautions,1d27873f-b29b-4873-954b-bf50544981e7,12/14/2011,6,MRHD,maximum  recommended daily human oral dose,,,
precautions,19ef0b2d-15e7-4985-b3a7-a980105638d1,8/2/2011,7,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,6557d0f0-c276-442b-a81c-57cd8fa669c3,1/9/2012,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,A04AEF42-3925-44A6-8309-1AB6FE6466EA,7/21/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,A04AEF42-3925-44A6-8309-1AB6FE6466EA,7/21/2007,1,NTP,National Toxicology Program,,,
precautions,A04AEF42-3925-44A6-8309-1AB6FE6466EA,7/21/2007,1,e.g.,effects of digitalis,,,
precautions,d926172a-b879-48c3-9b32-1e6d92816773,9/15/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,0263d4bf-7f74-414a-b661-e84a84e14c73,9/27/2011,1,e.g.,effects of digitalis,,,
precautions,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,NAAED,NorthAmerican Antiepileptic Drug,,,
precautions,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,b9acd365-1b80-4428-bd33-3a5eac814677,1/5/2011,1,LFT,liver functiontests,,,
precautions,d5c837a4-d1c6-4615-b7ad-27f3162a03aa,1/4/2012,5,MRHD,maximum recommended human dose,,,
precautions,255d0d9b-1253-4a33-8c9d-f4f168788d87,7/18/2011,1,GFR,[glomerular filtration rate,,,
precautions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,2ecc1f28-5673-4ba6-884d-b59d3167fe3b,7/22/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,a086ead1-b906-4198-af19-5423957c9e2a,2/7/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,CNS,central nervous system,,,
precautions,5d0b334f-6bd7-48b7-989a-c1ec8696026d,6/8/2011,1,e.g.,exaggerated sunburn reactions,,,
precautions,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,LFT,liver function tests,,,
precautions,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,AEDs,Antiepileptic Drugs,,,
precautions,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,NAAED,North American Antiepileptic Drug,,,
precautions,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,MRHD,maximum recommended daily human dose,,,
precautions,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,MRHD,maximum recommended human dose,,,
precautions,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,MRHD,maximum recommended human dose ,,,
precautions,34c0b734-98ca-4aec-965f-e55edd3317f3,8/6/2010,2,GFR,[glomerular filtration rate,,,
precautions,08BB4884-403B-4163-BEE7-5AA40992AC4E,6/7/2006,1,HYCODAN,hydrocodone bitartrate and homatropine                                     methylbromide,,,
precautions,a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667,3/6/2012,16,CHF,congestive heart failure,,,
precautions,a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667,3/6/2012,16,NTS,nicotine transdermal system,,,
precautions,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,Mice,Micronucleus Test,,,
precautions,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,CNS,central nervous system,,,
precautions,ba0f2532-b1ab-48c1-8476-aaae04ee98aa,6/7/2011,3,e.g.,exaggerated sunburn reactions,,,
precautions,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,UDS,unscheduled DNA synthesis,,,
precautions,A7A2A4E1-9ECD-4E59-82B5-2068B5E50164,6/12/2007,2,SCE,sister chromatid exchange,,,
precautions,ceccf36f-d165-4c2f-bed6-07ff1f5a70bc,2/22/2011,2,AUC,area-under-the-curve,,,
precautions,908bdfc3-ac28-44c9-aa59-39e7b9b28903,10/22/2009,3,MAO,monoamine  oxidase,,,
precautions,ADF16E64-345F-469A-B987-3FBDD17E0AC2,3/31/2007,1,NOTEL,“No Observable Teratogenic Effects Level”,,,
precautions,ADF16E64-345F-469A-B987-3FBDD17E0AC2,3/31/2007,1,NIOSH,National Institute of Occupational Safety and Health,,,
precautions,bd41a994-755a-40eb-983e-4a9633562178,3/28/2012,3714,CHO,Chinese Hamster Ovary,,,
precautions,bd41a994-755a-40eb-983e-4a9633562178,3/28/2012,3714,NTP,National Toxicology Program,,,
precautions,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,MRHD,Maximum Recommended Human Dose,,,
precautions,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,a2a9f459-e692-4e85-83b0-a35fbf35e91b,7/20/2009,1,MTD,Maximum Tolerated Dose,,,
precautions,6dfef8f0-69cf-4a65-8f9b-bc9359926d1c,4/20/2011,2,CNS,central nervous system,,,
precautions,6dfef8f0-69cf-4a65-8f9b-bc9359926d1c,4/20/2011,2,EPS,extrapyramidal signs and symptoms,,,
precautions,9917bb41-6723-42a2-852b-f00b7c36cb50,4/12/2012,1,MAO,monoamine  oxidase,,,
precautions,FF2EFEA5-4A51-0999-5179-56C51DF0B2D3,11/12/2008,1,mouse,maleate was devoid of mutagenic potential when tested in vivo,,,
precautions,1f1af798-17d5-47d0-b129-21d4aa1eb125,7/9/2012,1,MRHD,maximum recommended human dose,,,
precautions,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,TBPA,thyroxine-binding  prealbumin,,,
precautions,d4e23cbd-2e01-46c2-a690-0b87158d7003,12/30/2010,1,TBg,thyroxine-binding globulin,,,
precautions,7f888a0c-189e-4c76-86d8-7bc6f21e3b16,2/21/2012,1,MRHD,maximum recommended human dose,,,
precautions,286af67c-b47f-4265-baab-d10a793e974c,4/17/2012,1,MAO,monoamine  oxidase,,,
precautions,c0625060-29c7-4cda-b6f9-cfa15e59775e,3/1/2010,1,PBI,protein-bound iodine,,,
precautions,c0625060-29c7-4cda-b6f9-cfa15e59775e,3/1/2010,1,TBG,thyroid-binding globulin,,,
precautions,c0625060-29c7-4cda-b6f9-cfa15e59775e,3/1/2010,1,SHBG,sex hormone binding globulin,,,
precautions,2f3b8f28-b3da-4658-bdc4-fe86dec62d32,8/15/2007,1,MAO,monoamine oxidase,,,
precautions,38f12473-08e0-4970-a6ef-a825cc7de8d8,6/27/2012,8,MAO,monoamine oxidase,,,
precautions,06fbdb63-d32f-4212-9962-f1de15597dda,12/16/2009,4,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,8ea7230b-f228-46c6-a486-bb0394126c7f,3/27/2012,1,MAO,monoamine  oxidase,,,
precautions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,b0e39608-a7ed-464a-91c9-867ad7cd293c,8/1/2011,9,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,1873bce1-172f-4eb0-b5bc-cb7d444a8d8e,4/25/2012,14,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,5545797a-e276-4d45-8785-5e5d51f77fa7,6/18/2012,1,MAO,monoamine  oxidase,,,
precautions,86530199-999b-9f92-b1bc-b8515ec829f3,9/26/2011,2,CHF,congestive heart failure,,,
precautions,86530199-999b-9f92-b1bc-b8515ec829f3,9/26/2011,2,NTS,nicotine transdermal system,,,
precautions,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,GI,Gastrointestinal,,,
precautions,cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0,5/23/2007,1,INR,International Normalized Ratio,,,
precautions,786afae4-5d36-4169-acf8-e2d7c9a7e857,8/30/2010,3,CHO,Chinese Hamster Ovary,,,
precautions,786afae4-5d36-4169-acf8-e2d7c9a7e857,8/30/2010,3,NTP,National Toxicology Program,,,
precautions,786afae4-5d36-4169-acf8-e2d7c9a7e857,8/30/2010,3,e.g.,effects of digitalis,,,
precautions,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,CNS,central  nervous system,,,
precautions,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,Mice,Assay Micronucleus Test,,,
precautions,cd386aaf-6a18-42f6-85e9-51e2c257f3a8,2/29/2012,3601,e.g.,exaggerated sunburn reactions,,,
precautions,93339B03-114C-837D-32A8-40B6F1EB71D7,11/20/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,a945af86-e4d6-46ff-bb65-971df3bf8415,6/6/2011,2,mL,mEq/liter,,,
precautions,e612049e-fff7-4218-8663-b92d12f83fbd,11/23/2010,461,U.V.,ultraviolet,,,
precautions,454f2f4c-5bdd-4aff-b49e-792962dd1a94,7/19/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,9FC0BDC2-5BA2-48DD-AA87-7B0050A2D6CE,3/30/2007,1,ADHD,attention-deficit hyperactivity disorder,,,
precautions,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,Ames test,area.Glimepiride was non-mutagenic in a battery ofin vitroandin vivomutagenicity studies,,,
precautions,DBAE4496-6D22-48B0-A100-70F686D7C0BD,1/28/2009,3,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,1700a5b8-4029-424a-bfed-15f6737dd210,12/1/2009,1,LDPE,low-density polyethylene,,,
precautions,0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A,5/11/2006,1,Ames,a rat micronucleus test.Salmonella,,,
precautions,0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A,5/11/2006,1,Ames,assays included bacterial mutagenicity tests with Salmonella,,,
precautions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,ECT,electroconvulsive therapy,,,
precautions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,MRHD,maximum recommended human dose,,,
precautions,0aee46a9-7c7e-4363-a05d-bf2595930f03,10/7/2011,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,67044E85-DD05-4AB4-BB85-D56679372599,10/18/2006,1,AUC,area under the curve,,,
precautions,7049f870-6741-4a67-8033-398c36126a06,1/17/2012,9,Mice,Micronucleus Test,,,
precautions,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,MRHD,maximum recommended human dose,,,
precautions,15A945E1-6B94-4D11-858F-604E7A2EB109,10/3/2007,5,GFR,[glomerular filtration rate,,,
precautions,232a00a4-761e-422f-b62a-1a16de631eb6,12/1/2010,1,ECT,electroconvulsive therapy,,,
precautions,232a00a4-761e-422f-b62a-1a16de631eb6,12/1/2010,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,232a00a4-761e-422f-b62a-1a16de631eb6,12/1/2010,1,MRHD,maximum recommended human dose,,,
precautions,232a00a4-761e-422f-b62a-1a16de631eb6,12/1/2010,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,5837e9d4-54fa-4bae-a0ff-75f45def36f8,8/3/2007,1,GGT,gamma glutamyl                                                   transpeptidase,,,
precautions,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,TMP/SMX,trimethoprim/sulfamethoxazole,,,
precautions,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,NAD,N-acetyl-dapsone,,,
precautions,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,DHA,dapsone hydroxylamine,,,
precautions,AA249ECD-AFD3-4800-B196-D4F7B8C8FC6E,9/4/2007,1,CHO,Chinese hamster ovary,,,
precautions,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,af43f958-c8da-47c1-9227-443b6bfb281d,8/5/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,f9609aa3-cba3-4478-bf77-22d594ecd728,4/4/2012,1,MAO,monoamine  oxidase,,,
precautions,ea6fc6e7-814d-4d42-a59a-6c0c75971744,2/23/2011,1,HPA,Hypothalamic- pituitary-adrenal,,,
precautions,e61159ba-ff6b-4696-a642-4f64c79c4708,11/2/2009,1,TSH,thyroid stimulating hormone,,,
precautions,54c4b48b-cad7-4889-808f-f741352a2c97,11/1/2011,13,e.g.,exaggerated sunburn reactions,,,
precautions,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,I.M.,Intramuscular,,,
precautions,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,topical,acidsulindaccisapridemethimazole*tamoxifenclarithromycinmethyldopatetracyclineclofibratemethylphenidatethyroidwarfarin sodium overdosemethylsalicylate ointment,,,
precautions,3d35df36-1a19-4559-91fe-252b7082295b,8/30/2011,1,high dose,have been reported.alcohol*warfarin sodium underdosagephenytoin*aminoglutethimidecyclophosphamide*Pravastatin*amobarbitaldicloxacillinPrednisone*atorvastatin*ethchlorvynolprimidoneazathioprineglutethimidePropylthiouracil*butabarbitalgriseofulvinraloxifenebutalbitalhaloperidolranitidine*carbamazepinemeprobamaterifampinchloral hydrate*6-mercaptopurinesecobarbitalchlordiazepoxidemethimazole*spironolactonechlorthalidonemoricizine hydrochloride*sucralfatecholestyramine*nafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,high dose,have been reported.Specific Drugs ReportedalcoholcyclophosphamidephenytoinaminoglutethimidedicloxacillinpravastatinamobarbitalethchlorvynolprednisoneatorvastatinglutethimideprimidoneazathioprinegriseofulvinpropylthiouracilbutabarbitalhaloperidolraloxifenebutalbitalJantovenTablets  underdosageranitidinecarbamazepinemeprobamaterifampinchloral hydrate6-mercaptopurinesecobarbitalchlordiazepoxidemethimazolespironolactonechlorthalidonemoricizine hydrochloridesucralfatecholestyraminenafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,IM,Intramuscular,,,
precautions,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,8a6a5b4b-3d0c-4443-8079-bbe1fd42cd20,12/7/2011,1,t-PA,tissue plasminogendiclofenacmoricizine hydrochlorideactivator,,,
precautions,dcf946ba-1ca6-4a6a-b1c0-d172b19fbf57,3/15/2012,1,e.g.,effects of digitalis,,,
precautions,7c0657e3-ca2f-4687-bc93-877bc27011fe,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,MRHD,maximum recommended human dose,,,
precautions,e092f3ca-bf44-4568-a72c-3fb2cf5b192b,7/2/2012,5,DSST,digit symbol substitution test,,,
precautions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,NET,norethindrone,,,
precautions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,HCTZ,Hydrochlorothiazide,,,
precautions,4a2ef860-4349-f2a0-0815-6d47ba08e311,3/27/2009,2,EE,ethinyl estradiol,,,
precautions,5c44de38-a291-471d-8335-abc65e04387d,5/19/2011,4,NET,norethindrone,,,
precautions,5c44de38-a291-471d-8335-abc65e04387d,5/19/2011,4,RHD,recommended human dose,,,
precautions,5c44de38-a291-471d-8335-abc65e04387d,5/19/2011,4,HCTZ,Hydrochlorothiazide,,,
precautions,5c44de38-a291-471d-8335-abc65e04387d,5/19/2011,4,EE,ethinyl estradiol,,,
precautions,082A3791-20C6-4FFA-A113-B60128344381,10/28/2008,1,CYP3A,cytochrome P450 3A,,,
precautions,29c44184-6d77-4d84-97f4-fbaa4f40fc3e,4/27/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,f916dfb5-15fc-408f-b874-5656aeb80743,4/4/2011,1,WBC,white blood cell count,,,
precautions,f916dfb5-15fc-408f-b874-5656aeb80743,4/4/2011,1,CBC,complete blood count,,,
precautions,5b6f93c9-43b2-40a9-9f10-054c1145b4cc,3/1/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,8abdd127-0fe1-4d7a-9feb-171a1793e400,12/13/2010,140,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,8abdd127-0fe1-4d7a-9feb-171a1793e400,12/13/2010,140,TCAs,tricyclic  antidepressants,,,
precautions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,DST,Dexamethasone Suppression Test,,,
precautions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,DST,dexamethasone suppression test,,,
precautions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,CYP 3A4,cytochrome P450 3A4,,,
precautions,537B424A-3E07-4C81-978C-1AD99014032A,10/25/2007,8,HPA,hypothalamic-pituitary-adrenal,,,
precautions,9f703e6a-1636-492f-8b4f-e12abe969a99,2/5/2008,4,PBI,protein bound iodine,,,
precautions,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28,11/6/2008,1,TCAs,tricyclic antidepressants,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,MRHD,maximum recommended human daily  dose,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,ECT,electroconvulsive therapy,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,TCAs,Tricyclic Antidepressants,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,UDS,unscheduled DNA synthesis,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,ECT,Electroconvulsive Therapy,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,774D9D1F-523B-4061-850A-00607DA15787,3/3/2008,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,b57529e5-c106-464e-8637-dc02871031f7,12/15/2009,1,Mice, Micronucleus Test,,,
precautions,3F82E6B5-C6B6-4D96-8295-948FEC7E7FDB,2/12/2009,4,MRHTD,maximum recommended human topical dose,,,
precautions,18250b3f-8c5f-4623-9617-62c298458871,9/8/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,PBI,protein-bound iodine,,,
precautions,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,TBG,thyroid-binding globulin,,,
precautions,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,SHBG,sex hormone-binding globulin,,,
precautions,0c9bcd9a-8e35-4b81-b088-630c124a51e9,5/17/2010,2,CBG,corticosteroid  binding globulin,,,
precautions,c8e2a37e-fdb2-4dd3-a728-60d2744d861a,11/29/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,AChE,Acetylcholinesterase,,,
precautions,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,HCTZ,hydrochlorothiazide,,,
precautions,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,TA,triamterene,,,
precautions,652215b5-f950-4bc9-9de4-d66a5b70019b,12/22/2009,2,NMDA,N-methyl-D-aspartate,,,
precautions,b1a9ef34-092b-409b-a6b0-59cb079bad0a,3/31/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,176A1E12-A9A1-4901-8900-A530F7937F03,11/14/2008,1,ONJ,Osteonecrosis of the jaw,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,CHO,Chinese Hamster Ovary,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,MRHD,maximum recommended human dose,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,NTP,National Toxicology Program,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,mice,maximum recommended human doses are 400,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,B/H,bisoprolol/hydrochlorothiazide,,,
precautions,A9630311-A5DB-4FBA-B95E-5E13AD286BC8,11/27/2006,2,ACTH,adrenocorticotropic hormone,,,
precautions,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,HO-NEF,hydroxynefazodone,,,
precautions,239dcefe-45a9-48f5-a6f1-1ac6546e0da2,4/18/2007,1,CYP3A4,Cytrochrome P450 3A4,,,
precautions,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,CNS,central nervous system,,,
precautions,d3a87562-dac4-4ccd-b396-d206e3e26257,5/5/2011,2,e.g.,exaggerated sunburn reactions,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,PMs,PMs - 4% to 134%,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,GAD,generalized anxiety disorder,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,ODV,O-desmethylvenlafaxine,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,ODV,O-desvenlafaxine,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,EM,extensive metabolizers,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,MDD,major depressive disorder,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,6be70efb-322e-4e65-9851-a7d167065dd8,12/3/2010,2,PM,poor metabolizers,,,
precautions,c337bce8-27e9-48fd-85fa-381d0242a36a,8/31/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,2D16F118-C185-4956-8A55-F0DBD5182B50,11/10/2008,3,PPI,patient package insert,,,
precautions,0abb4c22-c663-4833-af96-8b8195d0b118,2/14/2012,3,BUN,Blood Urea Nitrogen,,,
precautions,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,CHF,congestive heart failure,,,
precautions,b4743414-6bd6-468a-98ce-099f032a29a0,9/8/2011,1,NTS,nicotine transdermal system,,,
precautions,82c7da04-771f-4a9d-b8c9-159307a83328,3/14/2012,3,MRDHD,maximum recommended daily human dose,,,
precautions,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,PBI,protein-bound iodine,,,
precautions,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,TBG,thyroid-binding globulin,,,
precautions,70d00600-b8d3-4820-8db6-40d4536a6f9e,9/1/2010,4,i.e.,in serum,,,
precautions,23b776e0-7a03-4946-0110-6f70e70031e8,3/29/2010,1,IM,Intramuscular,,,
precautions,23b776e0-7a03-4946-0110-6f70e70031e8,3/29/2010,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,23b776e0-7a03-4946-0110-6f70e70031e8,3/29/2010,1,see,sodium are recommended for elderly patients,,,
precautions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,41d98a07-65ac-4f00-b621-f580aa52ef03,6/8/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,d908e334-b74b-4b4d-b159-c592c2ecc7f9,2/14/2012,3560,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,7a1e523a-b377-43dc-b231-7591c4c888ea,12/15/2011,4,CYP,cytochrome P450,,,
precautions,93983865-362f-40a8-ba41-a8bcb99e35cb,4/26/2011,1,MPA,mycophenolic acid,,,
precautions,a4fd82b1-30e9-4480-a361-a84af05b7e77,6/6/2012,8,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,35019655-9a30-4305-a262-936ad0e73071,7/22/2010,4,CHO,Chinese Hamster Ovary,,,
precautions,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,AUC,area under the concentration-time  curve,,,
precautions,cf106b94-9c17-4a22-a1ba-ad45d32b41ce,10/4/2010,409,MAO,Monoamine Oxidase,,,
precautions,82c5998f-2253-4880-9be5-feaba553d5d1,5/10/2006,1,MRI,magnetic resonance imaging,,,
precautions,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,NTP,National Toxicology Program,,,
precautions,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,CHO,Chinese  Hamster Ovary,,,
precautions,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
precautions,45745495-d53f-4c52-909e-ef12ac437733,6/1/2010,1,ECG,electrocardiogram,,,
precautions,c9b4d3f9-72f3-403b-9399-9426d3555350,6/26/2012,805,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,cafe4650-6aa4-4466-9beb-064ee5a0e401,11/1/2011,1,MROHD,maximum recommended ocular human dose of 0.0014 mg/kg/day,,,
precautions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,TCAs,Tricyclic Antidepressants,,,
precautions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,TCAs,tricyclic antidepressants,,,
precautions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,ECT,Electroconvulsive Therapy,,,
precautions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,555c3588-1fc0-490b-8ccf-bee553b0496a,3/12/2012,1,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
precautions,5e2dbda9-aceb-4bfb-9c3f-e7b6118f580c,10/27/2009,1,i.e.,inducers of CYP3A4,,,
precautions,63ab97a3-5f44-4881-f38b-960b4f474790,7/2/2012,1315,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,d53c1531-3864-4d07-8af2-31f7b5529d5c,11/1/2010,2,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,d53c1531-3864-4d07-8af2-31f7b5529d5c,11/1/2010,2,ie,increased risk of osteoporosis,,,
precautions,707a3bc2-4e33-4307-9755-947e7c8dfaf9,4/22/2011,1,e.g.,effects of digitalis,,,
precautions,57d438aa-eee7-4403-9ecf-04730fa32f2f,7/11/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,a7c456e6-403b-4aae-a576-60b106bf66a7,10/4/2011,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,DA9B26BB-D2D7-4113-A0F9-C6C2280F4875,2/6/2006,1,INR,International Normalized Ratio,,,
precautions,Lf69f100f-c766-490f-9143-5e8e0c8cb7c9,9/14/2007,1,Ames test,at dietary doses up to 6 mg/kg/day of ipratropium bromide.Results of various mutagenicity studies,,,
precautions,15458a74-ed2a-467c-a427-5c0e77b322e5,4/26/2012,1,MAO,monoamine  oxidase,,,
precautions,ff7bf21e-6ea9-4c1d-8448-3dda03f772e9,1/15/2010,1002,Mice,Micronucleus Test,,,
precautions,6a3c0df3-7ed1-4c69-b963-374f9baccff3,3/1/2012,2,CHF,congestive heart failure,,,
precautions,6a3c0df3-7ed1-4c69-b963-374f9baccff3,3/1/2012,2,MRHD,maximum recommended human dose,,,
precautions,6a3c0df3-7ed1-4c69-b963-374f9baccff3,3/1/2012,2,NTS,nicotine transdermal system,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,EM,extensive metabolizers,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,MDD,major depressive disorder,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,5351fe67-17d9-42ec-9e8b-6585fdb9e29e,4/12/2011,1,PM,poor metabolizers,,,
precautions,d9243be5-bd27-4f37-ba8b-9f6f55f8b3e4,12/16/2009,1,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,e.g.,elevated triglycerides,,,
precautions,4C918B02-F158-4F7C-8ECC-FD49574EC228,7/14/2008,2,TSH,thyroid stimulating hormone,,,
precautions,db15690c-6f65-4ad1-845c-d337b8ab5f54,3/23/2012,3697,MRHD,maximum recommended human oral daily dose,,,
precautions,db15690c-6f65-4ad1-845c-d337b8ab5f54,3/23/2012,3697,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
precautions,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,D174F2B8-FEE2-4817-AD6C-364A1880E24B,1/8/2007,1,I.M.,present.Intramuscular,,,
precautions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,COX-2,cyclooxygenase-2,,,
precautions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,NSAIDS,Non-steroidal anti-inflammatory drugs,,,
precautions,083ca85f-a450-4fe9-973e-47a13cd18dd1,1/27/2009,1,ACE,angiotensin converting enzyme,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,OTC,over-the-counter,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,ECT,electroconvulsive therapy,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,MRHD,maximum recommended human dose,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,A8B2AD71-CFDC-4A29-8194-DEEFEA138B16,5/16/2008,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,OTC,over-the-counter,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,ECT,electroconvulsive therapy,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,MRHD,maximum recommended human dose,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,PPHN,pulmonary hypertension of the newborn,,,
precautions,9ECC70DE-F89E-436C-9E7D-1B303C413E47,4/7/2008,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,d02af310-d097-4886-86e5-adcf6bca0533,9/26/2007,1,ALA,aminolevulinate,,,
precautions,7d359680-2a9e-426a-a033-6906f51af1b5,9/13/2011,1,CHF,congestive heart failure,,,
precautions,7d359680-2a9e-426a-a033-6906f51af1b5,9/13/2011,1,MRHD,maximum recommended human dose,,,
precautions,7d359680-2a9e-426a-a033-6906f51af1b5,9/13/2011,1,NTS,nicotine transdermal system,,,
precautions,6e04f24a-a4ca-4e84-b3b3-7deba0b9cad0,5/29/2012,1,MAO,monoamine  oxidase,,,
precautions,b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882,1/4/2012,1,BUN,blood urea nitrogen,,,
precautions,251e7648-292b-466e-aea0-da484dd7f781,5/21/2012,1,MAO,monoamine  oxidase,,,
precautions,55267322-113A-4FF2-24AF-C4828DE06836,2/7/2007,2,mouse,maleate was devoid of mutagenic potential when tested in vivo,,,
precautions,110aada7-dfe8-4ecf-80c7-4dac8907ad29,5/4/2011,1,DST,dexamethasone suppression test,,,
precautions,110aada7-dfe8-4ecf-80c7-4dac8907ad29,5/4/2011,1,PRA,plasma renin activity,,,
precautions,bc1785c5-1448-4791-9868-2fbbc8703b3b,1/12/2010,1,CHO,Chinese hamster ovary,,,
precautions,c7b80939-0b2d-4dbc-b921-2081cfd5ae3e,6/2/2010,1,CHF,congestive heart failure,,,
precautions,c7b80939-0b2d-4dbc-b921-2081cfd5ae3e,6/2/2010,1,MRHD,maximum recommended human dose,,,
precautions,c7b80939-0b2d-4dbc-b921-2081cfd5ae3e,6/2/2010,1,NTS,nicotine transdermal system,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,PM,PMs -38% to 105%,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,GAD,generalized anxiety disorder,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,ODV,O-desmethylvenlafaxine,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,EM,extensive metabolizers,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,MDD,major depressive disorder,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,8a2302ca-5c25-4d2d-9ffe-320080934aab,9/24/2010,1,PM,poor metabolizers,,,
precautions,fead084a-a376-4d57-bdf0-aa7ed3655505,6/9/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,1c636622-85e2-4455-a20f-ce0102e806a6,6/18/2012,2,MAO,monoamine  oxidase,,,
precautions,23b73332-cbb3-4155-8ad8-b24619cdea85,4/4/2012,1,MPA,mycophenolic acid,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,MO-TMS,methoxime-trimethylsilyl,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,GC/MS,Gas  chromatography/mass spectrometry,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,TLC,thin-layer chromatography,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,PBI,protein bound iodine,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,NSAID's,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,GC/MS,gas  chromatography/mass spectrometry,,,
precautions,946b4df5-f1dc-42a7-acb9-1d2543c9bb44,8/29/2011,1,ACE,AspirinAngiotensin Converting Enzyme,,,
precautions,5bb45257-cf4e-4760-a1eb-37f27862e806,3/14/2011,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,A7C01224-B32B-40EF-935B-164893A93B22,5/21/2007,1,i.e.,interaction,,,
precautions,A5FC8F9E-7813-45BC-A9D8-71D10F61D97B,1/16/2009,4,HPA,hypothalamic-pituitary-adrenal,,,
precautions,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,CHF,congestive heart failure,,,
precautions,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,MRHD,maximum recommended human dose,,,
precautions,7783a1ca-d686-4693-84e1-41933130a6c4,12/5/2011,3309,NTS,nicotine  transdermal system,,,
precautions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,TCAs,Tricyclic Antidepressants,,,
precautions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,TCAs,tricyclic antidepressants,,,
precautions,84b1b1f0-d375-4fda-99af-9487f8ef50c7,7/10/2012,2,ECT,Electroconvulsive Therapy,,,
precautions,6f31e729-e36b-4b6e-98de-88077b29bf2b,9/28/2011,2,MAO,monoamine oxidase,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,EM,extensive metabolizers,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,MDD,major depressive disorder,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,1be1be3a-304b-4e31-8732-335247029191,4/18/2011,1,PM,poor metabolizers,,,
precautions,1f066b90-a35d-4e4a-836e-e0f9b44fba02,1/10/2012,4,CHO,Chinese Hamster Ovary,,,
precautions,1f066b90-a35d-4e4a-836e-e0f9b44fba02,1/10/2012,4,NTP,National Toxicology Program,,,
precautions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,CNS,central nervous system,,,
precautions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,NWS,neonatal withdrawal syndrome,,,
precautions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,MAOIs,treatment.Monoamine Oxidase Inhibitors,,,
precautions,D06642A8-A26A-4007-9ED6-812C4B87F1E8,8/8/2006,1,MRHDD,maximum recommended human daily dose,,,
precautions,635f8a00-0048-4421-9f5f-f8e38034f230,8/17/2011,1,5HIAA,5-hydroxy indoleacetic  acid,,,
precautions,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,TERIS,Teratogen Information System,,,
precautions,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,AUC,area under the concentration-time  curve,,,
precautions,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,TERIS,there is no risk,,,
precautions,04d04496-36bb-46df-a6e9-5c8aa8578222,10/11/2010,424,MAO,Monoamine Oxidase,,,
precautions,AA69C63C-CED6-4676-A16B-554F1AF7D210,10/25/2007,13,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,AA69C63C-CED6-4676-A16B-554F1AF7D210,10/25/2007,13,TCAs,tricyclic antidepressants,,,
precautions,78f39126-3e3b-4633-a4e0-c1f09a794eec,11/15/2011,6,mouse,maleate was devoid of mutagenic potential when tested in vivo,,,
precautions,883ccd45-6d10-458e-b850-fa574d91da06,9/2/2011,5,NTP,National Toxicology Program,,,
precautions,319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8,2/29/2008,1,PSA,prostate-specific antigen,,,
precautions,a61138f0-b7e0-4b8f-923f-649c1845be46,11/2/2011,1,BUN,blood urea nitrogen level,,,
precautions,a61138f0-b7e0-4b8f-923f-649c1845be46,11/2/2011,1,e.g,effects of digitalis,,,
precautions,ACCA05AB-185B-41A6-9CE2-783FC3C3CF96,1/30/2008,2,CPK,creatine phosphokinase,,,
precautions,76de65bb-1d49-444a-9419-570e7f2e8b9a,2/25/2011,1,HI,hyperinsulinism,,,
precautions,76de65bb-1d49-444a-9419-570e7f2e8b9a,2/25/2011,1,PHHI,persistent hyperinsulinemic hypoglycemia of infancy,,,
precautions,3CC53DA3-1F12-4051-05A1-8A5D345F2C8C,9/11/2007,3,MRHD,maximum recommended human dose,,,
precautions,L51b031a0-bc40-4159-a434-d48c3eadd2ca,10/8/2006,1,PDT,photodynamic therapy,,,
precautions,acd53964-52dc-4534-b20f-14a7561b8a6c,10/23/2009,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,acd53964-52dc-4534-b20f-14a7561b8a6c,10/23/2009,1,TCAs,tricyclic  antidepressants,,,
precautions,99d9e8a9-e299-4ee4-9f04-a82a83845594,8/9/2010,1,PKU,phenyketonuria,,,
precautions,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,MRHD,Maximum Recommended Human Dose,,,
precautions,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,0b0be196-0c62-461c-94f4-9a35339b4501,6/27/2011,9,MTD,Maximum Tolerated Dose,,,
precautions,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,CHF,congestive heart failure,,,
precautions,c35b18c6-68fa-459a-a88a-7e30bb33727c,3/14/2011,1,NTS,nicotine transdermal system,,,
precautions,5666ece8-9a10-4dcc-a7dc-3cd29df10e28,8/24/2011,1,5-HIAA,5-hydroxyindoleacetic acid,,,
precautions,5666ece8-9a10-4dcc-a7dc-3cd29df10e28,8/24/2011,1,VMA,vanillylmandelic acid,,,
precautions,2A4CD065-A1DD-4B88-9F7A-7BA93502F972,10/26/2006,1,MRHD,Maximum Recommended Human Dose,,,
precautions,4a4c577d-9267-40eb-9ed9-09ceb6377026,11/30/2010,112,NAAED,North American Antiepileptic  Drug,,,
precautions,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,CHO,Chinese Hamster Ovary,,,
precautions,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,NTP,National Toxicology Program,,,
precautions,dc177d6c-c754-4379-8c2f-1cf6f52f950a,11/18/2010,8,e.g.,effects of digitalis,,,
precautions,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,NET,norethindrone,,,
precautions,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,RHD,recommended human dose,,,
precautions,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,HCTZ,Hydrochlorothiazide,,,
precautions,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,EE,ethinyl estradiol,,,
precautions,011eedbd-efb1-4d4e-99f0-b6bca81fb5ad,5/25/2012,3,NAAED,North American Antiepileptic  Drug,,,
precautions,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,LFT,liver function tests,,,
precautions,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,AEDs,Antiepileptic Drugs,,,
precautions,FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213,1/30/2009,1,MRHD,maximum recommended daily human dose,,,
precautions,74df795f-0a99-42f9-a604-e0fed5ae2b71,4/3/2012,1,MAO,monoamine  oxidase,,,
precautions,eea7b068-06d4-4a04-8a8a-20b3812561c8,6/25/2012,1,MAO,monoamine  oxidase,,,
precautions,db109e3c-47aa-419f-a021-2fe63545ebb2,7/19/2011,1,WBC,white blood cell count,,,
precautions,db109e3c-47aa-419f-a021-2fe63545ebb2,7/19/2011,1,CBC,complete blood count,,,
precautions,4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681,6/24/2008,2,MRHD,maximum recommended human dose,,,
precautions,D8CF50D4-0448-4527-A498-CDDD511213F0,10/2/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,NET,norethindrone,,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,CBZ,"valign=""top"">Carbamazepine",,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,RHD,recommended human dose,,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,NAAED,North American Antiepileptic Drug,,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,HCTZ,Hydrochlorothiazide,,,
precautions,a703595c-1215-453e-b63e-9f0cdcdd1eaa,11/29/2011,3266,EE,ethinyl estradiol,,,
precautions,fae5cc34-5917-4445-9516-25f97ffca8db,5/10/2011,5,sleep aids,should not combine meperidine hydrochloride tablets with alcohol or other central nervous system depressants,,,
precautions,0750d877-b6f0-46bb-8c1a-46a7c27ebefb,4/28/2011,1,botanicals,botanical medicines,,,
precautions,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,i.e.,inducers of CYP3A4,,,
precautions,BE758639-894F-430F-1191-30181991FBFD,3/19/2008,1,Vomiting,Vomiting.,,,
precautions,4979723b-f283-4156-bb0b-dc3a60a76065,3/12/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,OTC,over-the-counter,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,ECT,electroconvulsive therapy,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,MRHD,maximum recommended human dose,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,MDD,Major Depressive Disorder,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,7f144b68-ae90-483c-b030-f6824662a734,1/12/2012,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,MRHD,maximum recommended human dose,,,
precautions,f23631be-c7ae-46e9-b771-a70be17bc9f0,1/17/2008,3,GFR,[glomerular filtration rate,,,
precautions,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,MRHD,Maximum Recommended Human Dose,,,
precautions,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,442a09ee-e7de-4d53-a32e-07c7530cdede,4/10/2012,3,MTD,Maximum Tolerated Dose,,,
precautions,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,31366b4b-dfd6-4fda-babe-2cb3d2c14a2b,11/6/2010,6,BUN,blood urea nitrogen,,,
precautions,CA8A0862-1956-43AD-844D-77153AA09DFB,12/6/2006,1,MAO,monoamine oxidase,,,
precautions,cadb8d68-5fe6-471d-9d14-5bda6034b802,3/1/2011,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,719ef928-c061-49d3-83d3-6e7482462679,6/28/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,f94b2ba4-024f-4068-8759-da6c8d31c546,1/30/2012,8,NAAED,North American Antiepileptic Drug,,,
precautions,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,PT,prothrombin time,,,
precautions,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,INR,international normalized ratio,,,
precautions,4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212,3/18/2009,3,NTP,National Toxicology Program,,,
precautions,fbf22eeb-27f5-46aa-be39-5aef43101369,10/25/2010,1,ADHD,attention-deficit hyperactivity disorder,,,
precautions,117a86c1-50f1-4bd5-b5be-6494507cc245,10/25/2011,6,e.g.,effects of digitalis,,,
precautions,13ac45e5-59b1-456a-87fc-8e60107818a1,4/3/2012,3,CHO,Chinese Hamster Ovary,,,
precautions,13ac45e5-59b1-456a-87fc-8e60107818a1,4/3/2012,3,NTP,National Toxicology Program,,,
precautions,13ac45e5-59b1-456a-87fc-8e60107818a1,4/3/2012,3,MRHDD,maximum recommended human daily dose,,,
precautions,13ac45e5-59b1-456a-87fc-8e60107818a1,4/3/2012,3,e.g.,effects of digitalis,,,
precautions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,NET,norethindrone,,,
precautions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,RHD,recommended human dose,,,
precautions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,HCTZ,Hydrochlorothiazide,,,
precautions,1af94c80-2b17-409a-98f6-ce00f942351d,7/20/2012,5,EE,ethinyl estradiol,,,
precautions,48caf986-3126-48e1-afcd-16d65c9cfe00,4/19/2012,3,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,adea2968-68fa-435e-9c8c-dfa0f9903b00,6/19/2012,1035,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,PM,PMs - 38% to 105%,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,EM,extensive metabolizers,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,MDD,major depressive disorder,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,PM,poor metabolizers,,,
precautions,c32ccd4d-77b4-4451-8c03-ffc6484bc1f3,4/15/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,d5a99052-a939-4d9e-a401-0f106d8b5893,4/13/2007,1,BUN,blood urea nitrogen,,,
precautions,c4572a72-e49a-4c29-b121-a530a6b5fd4f,4/5/2011,2,MCI,Mild Cognitive Impairment,,,
precautions,c4572a72-e49a-4c29-b121-a530a6b5fd4f,4/5/2011,2,MCI,mild cognitive impairment,,,
precautions,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,Mice,Micronucleus Test,,,
precautions,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,CNS,central nervous system,,,
precautions,f41770ce-c016-4da7-8b76-93bca8e0ae5f,6/7/2011,3,e.g.,exaggerated sunburn reactions,,,
precautions,ee15d911-73c7-4bc6-96f2-089a8aa64e18,5/20/2011,1,CYP,cytochrome P450,,,
precautions,6d46258b-31d0-4e43-9acd-4c821f09ec0f,1/28/2010,1,NET,norethindrone,,,
precautions,6d46258b-31d0-4e43-9acd-4c821f09ec0f,1/28/2010,1,RHD,recommended human dose,,,
precautions,6d46258b-31d0-4e43-9acd-4c821f09ec0f,1/28/2010,1,NAAED,North American Antiepileptic Drug,,,
precautions,6d46258b-31d0-4e43-9acd-4c821f09ec0f,1/28/2010,1,HCTZ,Hydrochlorothiazide,,,
precautions,6d46258b-31d0-4e43-9acd-4c821f09ec0f,1/28/2010,1,EE,ethinyl estradiol,,,
precautions,4700340f-4f77-48f2-bef2-bf6391bc25da,9/22/2009,5,MRHDD,maximum recommended  human daily dose,,,
precautions,4700340f-4f77-48f2-bef2-bf6391bc25da,9/22/2009,5,eg,effects of digitalis,,,
precautions,4700340f-4f77-48f2-bef2-bf6391bc25da,9/22/2009,5,CHO,Chinese Hamster  Ovary,,,
precautions,4700340f-4f77-48f2-bef2-bf6391bc25da,9/22/2009,5,NTP,National Toxicology Program,,,
precautions,a6182855-6287-45e9-b6b4-7b57efc9c76e,4/6/2012,4,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,a6182855-6287-45e9-b6b4-7b57efc9c76e,4/6/2012,4,RIA,radioimmunoassay,,,
precautions,4bacbdc0-1da8-4d6f-922c-c53868ecf6b4,4/19/2012,1,MAO,monoamine  oxidase,,,
precautions,1C3A94FF-91F0-4BC1-8BC8-1B6AA87E8026,4/5/2007,1,ALA,delta-aminolevulinic acid,,,
precautions,B1E6C7AB-EEFE-4089-B403-EDEAAB4F6E36,1/3/2007,1,MRHD,maximum recommended human dose,,,
precautions,B1E6C7AB-EEFE-4089-B403-EDEAAB4F6E36,1/3/2007,1,A®,assay,,,
precautions,B1E6C7AB-EEFE-4089-B403-EDEAAB4F6E36,1/3/2007,1,VMA,vanillylmandelic acid,,,
precautions,f8bb3384-355a-45fa-ad59-b7402a9f5533,3/22/2007,1,Patients,patient package insert,,,
precautions,f8bb3384-355a-45fa-ad59-b7402a9f5533,3/22/2007,1,AUCs,a measure of systemic exposure,,,
precautions,dee07488-7a2b-4d45-89e1-d65ab895fd52,12/2/2011,3306,NAAED,North American Antiepileptic Drug,,,
precautions,4695e0ea-7742-49a9-ba4d-3280f1bfa4db,4/11/2012,1,MAO,monoamine  oxidase,,,
precautions,92FE06D1-9AEC-47B4-B7FC-AEA6434CBE10,6/1/2006,1,ECG,electrocardiographic,,,
precautions,c89eb8fd-6c31-4f8b-8103-1f559424eda1,10/9/2006,1,UDS,unscheduled DNA syntheses,,,
precautions,c89eb8fd-6c31-4f8b-8103-1f559424eda1,10/9/2006,1,SCEs,sister chromatid exchanges,,,
precautions,c89eb8fd-6c31-4f8b-8103-1f559424eda1,10/9/2006,1,RPMC,rat pleural mesothelial cells,,,
precautions,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,MRHD,maximum recommended human dose,,,
precautions,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,AEDs,antiepilepsy drugs,,,
precautions,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,NAAED,North American Antiepileptic Drug,,,
precautions,6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d,3/17/2006,1,BUN,blood urea nitrogen,,,
precautions,8f935afa-f845-46cd-b61a-db7a48e559c0,4/22/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,df26edb0-9bd6-449c-a187-0be0c9e2600c,12/2/2010,7,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,e109ba4b-f8c8-418e-a2bb-1d6ee8b303d4,3/20/2012,3,MAO,monoamine  oxidase,,,
precautions,DC293A1C-995D-40FA-AC99-68DF12EB6D9E,10/23/2006,1,iPTH,intact PTH,,,
precautions,DC293A1C-995D-40FA-AC99-68DF12EB6D9E,10/23/2006,1,iPTH,Intact PTH,,,
precautions,2f36d6b4-1175-4127-b3e5-2be95b710014,2/28/2012,7,CHO,Chinese Hamster Ovary,,,
precautions,2f36d6b4-1175-4127-b3e5-2be95b710014,2/28/2012,7,NTP,National Toxicology Program,,,
precautions,2f36d6b4-1175-4127-b3e5-2be95b710014,2/28/2012,7,e.g.,effects of digitalis,,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,NET,norethindrone,,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,CBZ,"valign=""top"">Carbamazepine",,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,RHD,recommended human dose,,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,NAAED,North American Antiepileptic Drug,,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,HCTZ,Hydrochlorothiazide,,,
precautions,8fefc750-b4a6-42a5-ae69-368b25c76365,12/5/2011,3312,EE,ethinyl estradiol,,,
precautions,14496afb-a541-4b01-a672-fcd411292b8d,4/2/2007,1,5HIAA,5-hydroxyindoleacetic acid,,,
precautions,8a2b58d6-ca8e-41e1-837f-928fa46e2097,3/20/2012,3682,CHF,congestive heart failure,,,
precautions,8a2b58d6-ca8e-41e1-837f-928fa46e2097,3/20/2012,3682,MRHD,maximum recommended human dose,,,
precautions,8a2b58d6-ca8e-41e1-837f-928fa46e2097,3/20/2012,3682,NTS,nicotine transdermal system,,,
precautions,A7774E5C-98F0-4F2D-9992-113BCB5324B8,3/30/2007,1,water,water.Prepare an aqueous,,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,NET,norethindrone,,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,CBZ,"valign=""top"">Carbamazepine",,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,RHD,recommended human dose,,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,NAAED,North American Antiepileptic Drug,,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,HCTZ,Hydrochlorothiazide,,,
precautions,2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef,11/1/2009,1,EE,ethinyl estradiol,,,
precautions,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,CHF,congestive heart failure,,,
precautions,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,MRHD,maximum recommended human dose,,,
precautions,29848192-7de3-4c0d-a822-1268dcf128b0,4/8/2010,1,NTS,nicotine transdermal system,,,
precautions,10644068-fa47-4e3b-9e93-f57ebac3dd17,4/1/2010,1,NSAIDs,nonsteroidal  anti-inflammatory drugs,,,
precautions,330cc74e-0f50-477d-85b1-fec1438c81f6,9/14/2010,2,i.e.,inducers of CYP3A4,,,
precautions,BB56DF52-5ABF-47DC-AB8D-902CFE19CCB2,2/25/2008,1,MAC,Monitored Anesthesia Care,,,
precautions,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,MRHD,maximum recommended human dose,,,
precautions,635e080f-352b-4d5c-852e-bac808e8b66a,12/5/2011,3316,DSST,digit symbol substitution test,,,
precautions,f7c1fd34-d615-43a2-8989-898fe11f90df,5/2/2012,3,NAAED,North American Antiepileptic Drug,,,
precautions,fbf67fc8-8d29-4ae2-a533-75461754c5b1,3/14/2012,4,CYP,cytochrome P450,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,PM,PMs - 38% to 105%,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,ODV,O-desmethylvenlafaxine,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,EM,extensive metabolizers,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,MDD,major depressive disorder,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,PM,poor metabolizers,,,
precautions,85d3ce8b-8966-45d9-bdaf-f6f0475096e1,11/23/2011,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,7efb04ae-3d39-4853-9741-466c8973e8b2,8/30/2011,1,ACTH,adrenocorticotropic hormone,,,
precautions,4f4e77f5-5421-4482-82b6-c84b49dcdbea,3/22/2012,1,NAAED,North American Antiepileptic Drug,,,
precautions,dc8ceafe-9597-4de6-968d-43c87a261162,5/24/2012,1303,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,14710a71-e2e9-4e4e-bd65-1c296f70c166,12/8/2009,5,MAO,monoamine oxidase,,,
precautions,14710a71-e2e9-4e4e-bd65-1c296f70c166,12/8/2009,5,NTP,National Toxicology Program,,,
precautions,f1a60c72-a4e3-437d-b472-8d5bffc91273,3/24/2011,2,1 mg/kg/min,1000 mcg/kg/min,,,
precautions,f1a60c72-a4e3-437d-b472-8d5bffc91273,3/24/2011,2,10 mg/kg/min,10,000 mcg/kg/min,,
precautions,f1a60c72-a4e3-437d-b472-8d5bffc91273,3/24/2011,2,3 mg/kg/min,3000 mcg/kg/min,,,
precautions,f1a60c72-a4e3-437d-b472-8d5bffc91273,3/24/2011,2,2.5 mg/kg/min,2500 mcg/kg/min,,,
precautions,5ac5271e-316c-4802-a172-aa602d22571f,8/12/2010,1,NAAED,North American Antiepileptic Drug,,,
precautions,a8010e10-68fd-455f-968f-d62a1c3e0ffd,5/26/2010,1,AUC,area under the curve,,,
precautions,f0456563-acf1-4643-823a-2517e87adf49,6/12/2012,1,MAO,monoamine  oxidase,,,
precautions,06d55c37-5b80-45b6-bfea-6b00fd960ed4,1/18/2012,1,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,34c30372-08b0-4060-8aba-779b5bc1e5dd,10/26/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,43b169ad-58a2-4fda-8cf5-580cf3466c7e,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,7d028b83-5166-4b2e-b442-ba6cbfefbfd6,1/31/2008,2,TBg,thyroxine-binding globulin,,,
precautions,f60e8f65-a12b-4073-ac0f-81e1186617d7,10/27/2009,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,f60e8f65-a12b-4073-ac0f-81e1186617d7,10/27/2009,1,HED,human equivalent dose,,,
precautions,4fecb867-7213-49ce-9d8f-433f157635d1,4/25/2011,2,PBI,protein-bound iodine,,,
precautions,4fecb867-7213-49ce-9d8f-433f157635d1,4/25/2011,2,GGT,gamma glutamyl transpeptidase,,,
precautions,ed67fdb9-db87-4b9a-a588-7c26f538efab,4/13/2011,1,ACE,angiotensin converting enzyme,,,
precautions,38239661-eae1-48ae-ae99-9e0c1fe05f56,7/12/2012,1,MAO,monoamine  oxidase,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,PM,PMs -38% to 105%,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,GAD,generalized anxiety disorder,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,ODV,O-desmethylvenlafaxine,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,EM,extensive metabolizers,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,MDD,major depressive disorder,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a821ed7b-53cf-438d-b8ab-6d7ac1c08912,11/18/2011,3219,PM,poor metabolizers,,,
precautions,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,MRHD,maximum recommended human dose,,,
precautions,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,GFR,glomerular filtration rate,,,
precautions,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,AEDs,antiepilepsy drugs,,,
precautions,0ab183cf-51aa-402a-9351-53a4f112d1f9,4/25/2011,1,BUN,blood urea nitrogen,,,
precautions,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,Patients,Patient Package Insert,,,
precautions,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,PSA,prostate specific antigen,,,
precautions,EE7A527D-290E-437D-BB9D-1617AFE1C1AF,12/15/2006,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,1483b1e1-81ae-4497-be9e-1f2aee140030,7/20/2011,1,e.g.,effects of digitalis,,,
precautions,b6a476e8-9ceb-4320-873d-946df820b502,10/16/2006,1,i.e.,interaction,,,
precautions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,TCAs,Tricyclic Antidepressants,,,
precautions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,TCAs,tricyclic antidepressants,,,
precautions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,ECT,Electroconvulsive Therapy,,,
precautions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,326e8ab0-6886-4749-9544-885b37070051,3/30/2011,9,Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS,,,
precautions,25cf6c40-a239-4dd0-9cad-28da84d285db,10/11/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,aa8e14c1-fbfd-4e4d-b59e-2d4ae1ca815f,1/10/2012,1,NSTs,nonstress tests,,,
precautions,aa8e14c1-fbfd-4e4d-b59e-2d4ae1ca815f,1/10/2012,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,aa8e14c1-fbfd-4e4d-b59e-2d4ae1ca815f,1/10/2012,1,AUC,area under the concentration-time curve,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,GAD,generalized anxiety disorder,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,EM,extensive metabolizers,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,MDD,major depressive disorder,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a4e1d3bc-4e97-4ff0-9e30-22a699c96072,12/13/2011,1,PM,poor metabolizers,,,
precautions,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,CHF,congestive heart failure,,,
precautions,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,NTS,nicotine transdermal system,,,
precautions,65261557-1a71-43a6-a549-d2a391e7dc32,3/25/2010,1,SR,(SR),,,
precautions,B4C6A2B1-427F-4499-AE6C-1886ADE59E37,9/26/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,B4C6A2B1-427F-4499-AE6C-1886ADE59E37,9/26/2008,1,HPA,ratio.Hypothalamic-pituitary-adrenal,,,
precautions,5e2f3987-624f-4cbf-9cf1-fad4f181a78f,6/18/2012,1,MAO,monoamine  oxidase,,,
precautions,d4eda27a-0c99-48a2-a973-03c5267634da,6/8/2012,3,UDS,unscheduled DNA synthesis,,,
precautions,c14051fd-deeb-4340-b9a9-9482ef6c198c,2/7/2012,1,Pgp,P-glycoprotein,,,
precautions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,PTU,Propylthiouracil,,,
precautions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,PTU,<paragraph>Propylthiouracil,,,
precautions,d2a08338-1dfc-4058-b139-b1070f21b27a,1/22/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,15f8a5be-e269-2e07-60d9-1dd7bf5f5281,5/20/2009,1,CBZ,carbamazepine,,,
precautions,15f8a5be-e269-2e07-60d9-1dd7bf5f5281,5/20/2009,1,NAAED,North American Antiepileptic Drug,,,
precautions,15f8a5be-e269-2e07-60d9-1dd7bf5f5281,5/20/2009,1,SCE,sister chromatid exchange,,,
precautions,15f8a5be-e269-2e07-60d9-1dd7bf5f5281,5/20/2009,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,e8240633-04c4-4789-9b64-f11b319c6a8a,6/22/2012,1,MAO,monoamine  oxidase,,,
precautions,250644e0-94b7-4da2-821a-50f66b54eb35,6/21/2012,1,MAO,monoamine  oxidase,,,
precautions,86d1eec6-fb4d-42da-86f4-16ecd9f6a0df,9/25/2009,5,CYP3A,cytochrome P450 3A,,,
precautions,A72329C8-A565-42F7-9640-05E712703D42,1/20/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,A72329C8-A565-42F7-9640-05E712703D42,1/20/2007,1,TCAs,tricyclic antidepressants,,,
precautions,cf73c2e3-f43b-403f-a461-47438a7270ad,6/10/2011,4,MAOI,monoamine oxidase inhibitors,,,
precautions,CE8A0EC5-9323-4216-B6B2-52E84177E67D,10/10/2006,1,ANA,antinuclear antibody,,,
precautions,7e7a04d3-c010-4416-932a-0a7857f6b00c,7/23/2010,1,PSVT,paroxysmal supraventricular tachycardia,,,
precautions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,dd47be37-dd40-49d6-9f46-24fae5d02be0,8/8/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,f960dbfa-b00c-4f3e-ad32-ed6a5deea831,9/19/2007,2,ALA,aminolevulinic acid,,,
precautions,cf73c385-5173-4b54-af23-069581c5d560,8/24/2010,1,cyclical,"<content styleCode=""bold"">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg",,,
precautions,9b711ce9-f8cb-4ef0-b0c8-9477b1b30230,10/11/2010,50,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,OTC,over-the-counter,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,ECT,electroconvulsive therapy,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SSRI,selective serotonin reuptake inhibitor,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,MRHD,maximum recommended human dose,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,MDD,Major Depressive Disorder,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,PPHN,pulmonary hypertension of the newborn,,,
precautions,01800452-c353-4235-a66a-214048752e74,11/12/2009,6,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,AC0289A6-9533-4F8C-B46C-506DCE1B90B5,3/10/2008,2,MRHDD,maximum recommended human daily dose,,,
precautions,29eb29a8-0a20-4e4a-beb8-edab431acdb4,8/15/2011,1,WBC,white blood cell count,,,
precautions,29eb29a8-0a20-4e4a-beb8-edab431acdb4,8/15/2011,1,CBC,complete blood count,,,
precautions,27a82cef-a75a-4f41-97a1-023f7ba04fc0,4/9/2012,1,MAO,monoamine  oxidase,,,
precautions,f931d3af-c32a-4406-8799-9b097f41594b,6/16/2010,2,CHO,Chinese Hamster Ovary,,,
precautions,f931d3af-c32a-4406-8799-9b097f41594b,6/16/2010,2,MRHD,maximum recommended human dose,,,
precautions,01b388a0-7dfb-11de-bc4e-0002a5d5c51b,2/12/2010,2,BUN,Blood Urea Nitrogen,,,
precautions,94c182ed-f2d6-4f7f-bdd9-69b136c54623,8/26/2008,1,Pgp,P-glycoprotein,,,
precautions,25b2fdbe-2f18-4153-835a-7a67bff83ef8,6/25/2012,5,i.e.,interaction,,,
precautions,88d32118-a2a2-4bb3-a609-b44d46a3c295,4/4/2011,1,CHO,Chinese Hamster Ovary,,,
precautions,88d32118-a2a2-4bb3-a609-b44d46a3c295,4/4/2011,1,COX-2,Cyclooxygenase-2,,,
precautions,88d32118-a2a2-4bb3-a609-b44d46a3c295,4/4/2011,1,e.g.,effects of digitalis,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,CYP450,cytochrome P450,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,DEA,desethylamiodarone,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,ARDS,adult respiratory distress syndrome,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,CYP3A4,cytochromes P450 3A4,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,AST,aspartate amino – transferase,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,TdP,torsades de pointes,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,ALT,values-alanine aminotransferase,,,
precautions,01C3122F-E791-40A5-B52E-963CB6685F71,3/9/2007,2,GGT,gamma-glutamyl transferase,,,
precautions,b9bbf9ed-4781-42a9-bc3e-deda9f05e810,9/25/2009,2,MRHD,maximum recommended human dose,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,PM,PMs - 38% to 105%,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,EM,extensive metabolizers,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,28f12fa3-b5ef-41c7-a750-32c80d8881cf,8/29/2011,1,PM,poor metabolizers,,,
precautions,4db011bd-5e43-45d4-b510-e3135d356a83,5/10/2012,1,MAO,monoamine  oxidase,,,
precautions,e83c5fef-74e9-46ed-8277-063df09a1e3d,5/10/2010,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,e83c5fef-74e9-46ed-8277-063df09a1e3d,5/10/2010,1,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,e83c5fef-74e9-46ed-8277-063df09a1e3d,5/10/2010,1,HED,human equivalent dose,,,
precautions,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,AEDs,Antiepilepsy Drugs,,,
precautions,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,MRHD,maximum  recommended human dose,,,
precautions,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,AED,antiepilepsy drug,,,
precautions,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,AEDs,antiepilepsy drugs,,,
precautions,175f2d9f-449b-4d95-a4b9-94f891f8e3ae,8/18/2011,2,NAAED,North American Antiepileptic  Drug,,,
precautions,80e9d61d-9674-4ac4-b84c-79a875d408dd,6/14/2012,10,CHO,Chinese hamster ovary,,,
precautions,e77a5be9-6b79-4deb-9fb7-9158fc670b73,6/22/2012,1,MAO,monoamine  oxidase,,,
precautions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,MRHD,maximum recommended human dose,,,
precautions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,MRHD,maximum recommended human dose ,,,
precautions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,GFR,[glomerular filtration rate,,,
precautions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,INR,International Normalized Ratio,,,
precautions,aa05d606-29fd-443e-802b-1d65584d6bb1,5/26/2011,4,AUC,Area Under the Curve,,,
precautions,3202b686-e944-4b52-a226-9297fe899606,6/28/2011,1,CHF,congestive heart failure,,,
precautions,3202b686-e944-4b52-a226-9297fe899606,6/28/2011,1,NTS,nicotine transdermal system,,,
precautions,17dd7e74-a965-497d-81cb-f73041aa392a,4/7/2009,1,AUC,area under the curve,,,
precautions,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,AUCs,a measure of systemic exposure,,,
precautions,17d13f2e-6b0e-4b66-8351-6c590f79536b,12/15/2006,1,Patients,package insertpatient package insert),,,
precautions,BFE5CFB9-591D-4DF8-12A3-6555CDE3185D,6/8/2007,1,aPTT,activated partial thromboplastin time,,,
precautions,c6785b89-6058-0807-1761-66b59416a850,12/3/2004,1,CHF,congestive heart failure,,,
precautions,c6785b89-6058-0807-1761-66b59416a850,12/3/2004,1,MRHD,maximum recommended human dose,,,
precautions,c6785b89-6058-0807-1761-66b59416a850,12/3/2004,1,NTS,nicotine transdermal system,,,
precautions,07315965-0be6-4c18-a8b9-25821a3732e2,10/26/2006,1,MAO,monoamine oxidase,,,
precautions,18c897d3-47c2-461a-a0e7-0926453d45e3,12/30/2009,1,JRA,juvenile rheumatoid arthritis,,,
precautions,18c897d3-47c2-461a-a0e7-0926453d45e3,12/30/2009,1,GI,gastrointestinal,,,
precautions,18c897d3-47c2-461a-a0e7-0926453d45e3,12/30/2009,1,CHO,Chinese hamster ovary,,,
precautions,cd6bb11b-3b9d-4d73-a093-d198913c4bff,12/13/2010,1,Mice,Assay Micronucleus Test,,,
precautions,214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8,3/31/2011,3,HPA,hypothalamic-pituitary-adrenal,,,
precautions,214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8,3/31/2011,3,CYP,cytochrome P450,,,
precautions,11f1e618-c6ec-42a1-a6ac-5d9a648a21d6,10/3/2011,4,t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator,,,
precautions,11f1e618-c6ec-42a1-a6ac-5d9a648a21d6,10/3/2011,4,IM,Intramuscular,,,
precautions,11f1e618-c6ec-42a1-a6ac-5d9a648a21d6,10/3/2011,4,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7,2/7/2007,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
precautions,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,d48526eb-c40a-4f30-9d5c-c8cf88f52e64,11/15/2011,1,I.M.,Intramuscular,,,
precautions,631dc216-df9e-4126-b59e-c8079ba6e287,8/12/2010,1,HITT,Heparin-induced Thrombocytopenia and Thrombosis,,,
precautions,2E0570E7-D28F-4936-CBA8-81EE0C4C3547,9/11/2006,1,MAOI,monoamine oxidase inhibitors,,,
precautions,b4df0c0d-c207-497e-85ce-80e2fe10e824,12/22/2010,1,HPA,Hypothalamic- pituitary-adrenal,,,
precautions,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,WBC,white blood cell,,,
precautions,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,AML,acute myelogenous leukemia,,,
precautions,723782D7-A2AB-4CC6-A767-387975CCEC80,5/14/2008,3,MDS,myelodysplastic syndromes,,,
precautions,fbed0f64-1143-4439-8f03-88f393d20390,5/10/2011,1,MO-TMS,methoxime-trimethylsilyl,,,
precautions,fbed0f64-1143-4439-8f03-88f393d20390,5/10/2011,1,GC/MS,Gas  chromatography/mass spectrometry,,,
precautions,fbed0f64-1143-4439-8f03-88f393d20390,5/10/2011,1,GC/MS,gas chromatography/mass spectrometry,,,
precautions,fbed0f64-1143-4439-8f03-88f393d20390,5/10/2011,1,TLC,thin-layer chromatography,,,
precautions,f05b2042-3183-486f-bf69-409acf87e6ab,7/9/2012,2,MAO,monoamine  oxidase,,,
precautions,e435ee3d-20b1-449b-8704-b2bf2a579af8,11/20/2009,1,CHO,Chinese Hamster  Ovary,,,
precautions,e435ee3d-20b1-449b-8704-b2bf2a579af8,11/20/2009,1,NTP,National Toxicology Program,,,
precautions,e435ee3d-20b1-449b-8704-b2bf2a579af8,11/20/2009,1,MRHDD,maximum recommended human daily dose,,,
precautions,e435ee3d-20b1-449b-8704-b2bf2a579af8,11/20/2009,1,e.g.,effects of digitalis,,,
precautions,b6d3c9af-53f7-4c14-8608-f41a3ef9894d,4/26/2011,3,MAOI,monoamine oxidase inhibitors,,,
precautions,A48B7542-EF46-4FF9-9496-468D3B4046EE,9/11/2008,1,UDS,unscheduled DNA synthesis,,,
precautions,e5c28db5-efce-49a7-9e5f-12338d1f216b,1/21/2010,1,DST,Dexamethasone Suppression Test,,,
precautions,e5c28db5-efce-49a7-9e5f-12338d1f216b,1/21/2010,1,DST,dexamethasone suppression test,,,
precautions,e5c28db5-efce-49a7-9e5f-12338d1f216b,1/21/2010,1,CYP 3A4,cytochrome P450 3A4,,,
precautions,e5c28db5-efce-49a7-9e5f-12338d1f216b,1/21/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,1399ff8e-378e-4624-96e4-867402bdbe05,1/13/2011,2,DST,dexamethasone suppression test,,,
precautions,13d36ab1-98c8-4672-8632-c6eb4922de40,12/7/2011,1,BUN,blood urea nitrogen,,,
precautions,159B5FAC-255C-4A22-98AD-891ABA73EAE1,11/24/2006,1,AUC,area under the curve,,,
precautions,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,TCAs,tricyclic antidepressants,,,
precautions,0a580de2-95d2-49b6-a1e2-6daf70f1f8c8,5/29/2010,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,03a90b9f-e4d9-48c7-8bb2-745f86cf0634,9/4/2009,1002,GC/MS,Gas  chromatography/mass spectrometry,,,
precautions,03a90b9f-e4d9-48c7-8bb2-745f86cf0634,9/4/2009,1002,TLC,thin-layer chromatography,,,
precautions,03a90b9f-e4d9-48c7-8bb2-745f86cf0634,9/4/2009,1002,MO-TMS,methoximetrimethylsilyl,,,
precautions,03a90b9f-e4d9-48c7-8bb2-745f86cf0634,9/4/2009,1002,GC/MS,gas  chromatography/mass spectrometry,,,
precautions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,TCAs,Tricyclic Antidepressants,,,
precautions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,TCAs,tricyclic antidepressants,,,
precautions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,ECT,Electroconvulsive Therapy,,,
precautions,e1ea4019-bb66-403c-a3d5-6ae056a59116,6/1/2012,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,8de2c303-5d99-46b6-ad6d-a4caadea3604,2/23/2006,1,Ames,a battery of mutagenicity tests,,,
precautions,A4E9183F-D0EB-4BA7-9204-760B1FD62010,1/1/2007,1,RIA,radioimmunoassay,,,
precautions,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,Mice,Micronucleus Test,,,
precautions,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,CNS,central nervous system,,,
precautions,6d8d72fe-e89c-4e08-9ca1-ec64c4890205,6/27/2011,1,e.g.,exaggerated sunburn reactions,,,
precautions,BB96F3CF-FD80-40C9-A6AA-C7464AB3226F,12/29/2008,10,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,627031fc-9b91-4854-b08f-f9fc0c73f1de,11/29/2010,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,NOAEL,no adverse effect level,,,
precautions,d7c2edeb-ced4-4444-b519-d6b0299501c3,2/21/2007,2,death,dose was associated with maternal toxicity,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,PM,PMs -38% to 105%,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,GAD,generalized anxiety disorder,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,ODV,O-desmethylvenlafaxine,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,EM,extensive metabolizers,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,MDD,major depressive disorder,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,35f4790c-1235-49fe-bb9b-842f9e8c09f7,11/16/2011,3196,PM,poor metabolizers,,,
precautions,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator,,,
precautions,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,IM,Intramuscular,,,
precautions,ed467a7f-748b-4744-b8e3-c2a3e0cb0293,10/19/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,9FCA10EE-973E-4FE0-AAF5-A0416918A397,12/18/2006,1,e.g.,endogenous metals,,,
precautions,FFA52DFA-8ADF-4F70-39A7-461757F226E9,9/28/2007,2,SC,subcutaneous,,,
precautions,1b11750e-4db4-4dd3-8b21-c9917b00aeaa,4/15/2010,4,MRHD,maximum recommended human dose,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,ECT,electroconvulsive therapy,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,TCAs,Tricyclic Antidepressants,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,UDS,unscheduled DNA synthesis,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,MRHD,maximum recommended human daily dose,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,ECT,Electroconvulsive Therapy,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,793c9089-8139-4d21-9e8c-64eb0d554063,8/17/2011,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,8c0c49c9-aa28-4587-869e-b40368152540,12/28/2010,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,8e9e8cb6-d28a-475a-9584-a1dee4899c4f,9/8/2011,1,Patients,patients,,,
precautions,8e9e8cb6-d28a-475a-9584-a1dee4899c4f,9/8/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,9da64837-eafa-4410-90ce-1bddfd226cd9,6/30/2011,1,CHO,Chinese Hamster Ovary,,,
precautions,9da64837-eafa-4410-90ce-1bddfd226cd9,6/30/2011,1,NTP,National Toxicology Program,,,
precautions,9da64837-eafa-4410-90ce-1bddfd226cd9,6/30/2011,1,e.g.,effects of digitalis,,,
precautions,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,CHF,congestive heart failure,,,
precautions,8d6959cc-479c-4b26-a8bb-fc6388743906,12/13/2011,2,NTS,nicotine transdermal system,,,
precautions,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,CNS,central nervous             system,,,
precautions,02a9c070-77ab-445b-9bf0-78dcb47bf4da,10/18/2010,50,e.g.,exaggerated sunburn reactions,,,
precautions,177552ba-bd25-4111-9c2a-d424c9a9e63e,6/26/2012,1,MAO,monoamine  oxidase,,,
precautions,5d344c39-175b-4819-b9da-8ba630530ad7,4/7/2011,1,BUN,blood urea nitrogen,,,
precautions,b7f1a9ef-c7bb-465c-e4d7-a41395205cad,1/18/2012,7,MRD,maximum recommended dose,,,
precautions,967ef131-3dce-4c05-8f17-a5c9e01ca9a0,6/9/2011,1,U.V.,ultraviolet,,,
precautions,fefc2713-f410-49ad-bc06-3c4f9c20a031,3/7/2012,1,BUN,blood urea nitrogen level,,,
precautions,fefc2713-f410-49ad-bc06-3c4f9c20a031,3/7/2012,1,e.g.,effects of digitalis,,,
precautions,64ae46f5-889c-4c13-ab07-92bebe8d5ef2,10/27/2009,2,TBG,thyroid-binding globulin,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,NAAED,North American  Antiepileptic Drug,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,MRHD,maximum recommended human dose,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,GFR,glomerular filtration rate,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,MRHD,maximum  recommended human dose,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,AEDs,antiepilepsy drugs,,,
precautions,902a17d4-ce4f-476a-81d8-bb518041c814,1/6/2011,2,BUN,blood urea nitrogen,,,
precautions,a4a380d5-6c22-4d1f-9c49-cdc5bef308cf,5/4/2011,2,e.g.,effects of digitalis,,,
precautions,14e43813-665c-4cef-b3b1-60eafc880f41,9/13/2011,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,7bc5effe-c9ed-4f20-896b-83c5bfb2c621,2/1/2011,6,CHO,Chinese Hamster Ovary,,,
precautions,7bc5effe-c9ed-4f20-896b-83c5bfb2c621,2/1/2011,6,NTP,National Toxicology Program,,,
precautions,7bc5effe-c9ed-4f20-896b-83c5bfb2c621,2/1/2011,6,ACTH,adrenocorticotropic hormone,,,
precautions,4799261f-9fac-4b0a-a470-daa709569405,9/10/2009,1,CHO,Chinese Hamster Ovary,,,
precautions,326fa31a-5420-429b-9f7f-170cb38f64bd,7/22/2011,4,CYP3A,cytochrome P450 3A,,,
precautions,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,1c7e1d55-e017-42c7-8ba2-b0ae266a2ba0,8/4/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,b1d149db-ad43-4f3f-aef1-fb0395ba4191,12/24/2008,1,ECT,Electroconvulsive Therapy,,,
precautions,09567287-2cc1-4918-94e2-913634117a3b,3/23/2012,1,NAAED,North American Antiepileptic Drug,,,
precautions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,ECT,electroconvulsive therapy,,,
precautions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,MRHD,maximum recommended human dose,,,
precautions,c478ca8c-5ec7-439a-94a0-90b95eb476b7,10/7/2011,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,SSRIs,selective serotonin re-uptake inhibitors,,,
precautions,dce94664-7e3d-4592-86ac-2a94231e484b,8/16/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,7b39c21b-142f-4775-b459-447d797b5c53,7/16/2012,2,FBG,fasting blood glucose,,,
precautions,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,MRHD,maximum recommended human dose,,,
precautions,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,GFR,glomerular filtration rate,,,
precautions,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,AEDs,antiepilepsy drugs,,,
precautions,6962CABA-EE38-4892-8C90-548E088294B2,2/7/2007,1,BUN,blood urea nitrogen,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,MRHD,maximum recommended human dose,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,CHO,Chinese Hamster  Ovary,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,BUN,blood urea nitrogen,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,NTP,National Toxicology Program,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,CHL,Chinese hamster lung,,,
precautions,cd879bd1-38c0-4f72-904b-cf07f3186342,11/30/2010,1,e.g.,effects of digitalis,,,
precautions,c6b4fe73-ce77-4adf-b787-2bdb2dd74f84,1/23/2009,3,Use,USAGE andDOSAGE AND ADMINISTRATION.,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,OTC,over-the-counter,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,ECT,electroconvulsive therapy,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,MRHD,maximum recommended human dose,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,9bc362d4-489c-4e7f-915a-3076ff8d132a,7/17/2012,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a0ce563a-8a78-4692-bcf5-620b74d84cdd,1/24/2007,1,BUN,blood urea nitrogen,,,
precautions,fde7e9b2-c2d8-47bb-abe1-ec987da951ab,11/24/2006,2,i.e.,interaction,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,PM,PMs - 38% to 105%,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,EM,extensive metabolizers,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,MDD,major depressive disorder,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,PM,poor metabolizers,,,
precautions,e0990ade-320e-4259-8c0e-6d5ef23bc673,4/15/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,PBI,protein-bound iodine,,,
precautions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,TBG,thyroid-binding globulin,,,
precautions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,CBG,corticosteroid binding globulin,,,
precautions,EA3D70E5-DCCD-4302-964B-B5CB1394B514,7/25/2006,1,SHBG,sex hormone-binding globulin,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,ECT,electroconvulsive therapy,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,TCAs,Tricyclic Antidepressants,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,UDS,unscheduled DNA synthesis,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,MRHD,maximum recommended human daily dose,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,ECT,Electroconvulsive Therapy,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,b29fab7c-1282-4bb9-a650-24890501caec,12/1/2009,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,GI,Gastrointestinal,,,
precautions,A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0,3/30/2007,1,INR,International Normalized Ratio,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,PM,PMs - 38% to 105%,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,SIADH,syndrome of inappropriate antidiuretic hormone  secretion,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,SNRIs,Serotonin and  Norepinephrine Reuptake Inhibitors,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,GAD,generalized anxiety disorder,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,ODV,O-desmethylvenlafaxine,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,SSRIs,Selective Serotonin Reuptake  Inhibitors,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,ODV,O-desvenlafaxine,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,EM,extensive metabolizers,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,MDD,major depressive disorder,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,SSRIs,Selective  Serotonin Reuptake Inhibitors,,,
precautions,53b73f2a-d839-41b5-bc9c-aeb3e9dba304,3/4/2012,9,PM,poor metabolizers,,,
precautions,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,CHF,congestive heart failure,,,
precautions,e537ed50-6677-45eb-9e62-af62d3831f19,9/12/2011,2,NTS,nicotine transdermal system,,,
precautions,268fe552-b8f0-45ab-658a-39616c40c9d4,6/5/2012,7,MRHDD,maximum recommended human daily dose,,,
precautions,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,JRA,juvenile rheumatoid arthritis,,,
precautions,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,GI,gastrointestinal,,,
precautions,1a6586f8-6572-4eed-ba24-ecce792d6eb2,8/9/2007,1,CHO,Chinese hamster ovary,,,
precautions,27c971a9-5c54-4085-be89-c85e84317294,5/17/2010,2,MRHDD,maximum recommended human daily dose,,,
precautions,05e29a60-ebf9-470a-b565-40a6f1f6e102,1/28/2011,2,AUCs,a measure of  systemic exposure,,,
precautions,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,60feb082-36f5-4ae4-90be-5f9f0ac8ae14,11/17/2011,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,GAD,generalized anxiety disorder,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,ODV,O-desmethylvenlafaxine,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,ODV,O-desvenlafaxine,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,EM,extensive metabolizers,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,MDD,major depressive disorder,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,49bef388-71ff-43b1-87a8-9fd506a0e63e,9/3/2009,2,PM,poor metabolizers,,,
precautions,c95f0b0d-77ef-e753-be04-2228139df2d3,6/19/2006,1,botanicals,botanical medicines,,,
precautions,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,e.g.,evaluate the specific pathology,,,
precautions,d52d231b-f407-f6a0-466e-0f714244010d,9/18/2009,1,ERG,electroretinogram,,,
precautions,284b5dac-2b8d-46bf-95fe-80ce03fa178a,11/23/2010,4,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,284b5dac-2b8d-46bf-95fe-80ce03fa178a,11/23/2010,4,RIA,radioimmunoassay,,,
precautions,6f25ed16-e5e9-4170-b4b4-3b460887779e,12/16/2011,9,MRHDD,maximum recommended human daily dose,,,
precautions,96C39A66-20B0-4C39-A665-C54A2531F096,1/5/2009,3,MTD,maximally tolerated dose,,,
precautions,85d69d02-c5ef-467e-94aa-903100218795,6/6/2012,1,BUN,blood urea nitrogen,,,
precautions,af884779-915c-4967-b9a0-6de3c1ef3be0,2/15/2011,1,NTP,National Toxicology Program,,,
precautions,38268298-31b6-4756-b8d2-de80a33807e5,3/1/2012,2,CHO,Chinese Hamster Ovary,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,PM,PMs -38% to 105%,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,GAD,generalized anxiety disorder,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,ODV,O-desmethylvenlafaxine,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,EM,extensive metabolizers,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,MDD,major depressive disorder,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,2bb09fc1-1c0a-4586-9af9-5aed8d4322db,9/13/2011,2,PM,poor metabolizers,,,
precautions,43372910-b0a1-4b2d-9d37-7984a6e4cf7f,3/16/2012,2,NAAED,North American Antiepileptic Drug,,,
precautions,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,Mice,Micronucleus Test,,,
precautions,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,CNS,central nervous system,,,
precautions,295265e9-dc9d-4692-8aa6-83ee3c15f7b5,8/25/2010,1,e.g.,exaggerated sunburn reactions,,,
precautions,db1b94a8-6635-4faa-a361-71706ead1ee7,6/30/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,db1b94a8-6635-4faa-a361-71706ead1ee7,6/30/2011,1,I.M.,Intramuscular,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,PM,PMs - 38% to 105%,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,GAD,generalized anxiety disorder,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,ODV,O-desmethylvenlafaxine,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,EM,extensive metabolizers,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,MDD,major depressive disorder,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,09feeadb-d4e6-47dd-8d1e-b03052a9cc5d,11/27/2009,3,PM,poor metabolizers,,,
precautions,f302ddf5-0213-43b3-b6c1-b3edf2bafbcd,6/17/2010,3,MAOI,Monoamine oxidase inhibitors,,,
precautions,4D705C57-FA98-46E0-97F3-38E1B0ADA76B,2/19/2008,1,MRI,Magnetic Resonance Imaging scan,,,
precautions,dafa721e-125a-4a8b-9f4e-2a25c6a667d0,6/19/2012,1,MAO,monoamine  oxidase,,,
precautions,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,LFT,liver function tests,,,
precautions,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,AEDs,Antiepileptic Drugs,,,
precautions,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,NAAED,North American Antiepileptic Drug,,,
precautions,930601ae-c7bb-4ae1-8268-b87eee2bbe22,5/5/2010,1,MRHD,maximum recommended daily human dose,,,
precautions,e58f5696-806d-42ad-9357-a30cb7b3652b,12/19/2011,3394,U.V.,ultraviolet,,,
precautions,615f3d95-197c-4fec-b81f-c26449c93c3b,6/17/2011,9,CNS,central nervous system,,,
precautions,b92f9206-325e-4454-9518-4f7464b23f47,12/15/2011,3,Mice,Micronucleus Test,,,
precautions,b78499dc-4d24-4226-be97-dc618d9da0cf,4/17/2012,2,SC,subcutaneous,,,
precautions,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,CBZ,carbamazepine,,,
precautions,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,SCE,sister chromatid exchange,,,
precautions,cef3e335-5891-412f-89c4-79fcd2f145b7,3/9/2010,3,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,2200ef58-d210-41e6-a535-e8c735507395,3/4/2012,2,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,6052C707-A8A3-43A7-80C2-7AD1AD9391A4,12/18/2006,1,BSA,body surface area,,,
precautions,a96619d8-5c87-4adc-9446-b6d3cb3d04aa,7/23/2009,1002,UDS,unscheduled DNA synthesis,,,
precautions,a96619d8-5c87-4adc-9446-b6d3cb3d04aa,7/23/2009,1002,DSI,DNA synthesis inhibition,,,
precautions,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,d0e098b1-49e2-4aa5-abde-6be16f44b79b,11/3/2011,1,I.M.,Intramuscular,,,
precautions,abff005f-23fc-4d1e-b469-88aa07589a43,6/8/2010,3,MAO,monoamine oxidase,,,
precautions,818a4d9a-c8a2-476c-b70c-0840b6d603a1,8/24/2009,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,71f5c703-94d4-49b0-9c2d-374b9cbcab85,11/17/2010,1,CHO,Chinese Hamster  Ovary,,,
precautions,71f5c703-94d4-49b0-9c2d-374b9cbcab85,11/17/2010,1,NTP,National Toxicology Program,,,
precautions,71f5c703-94d4-49b0-9c2d-374b9cbcab85,11/17/2010,1,e.g.,effects of digitalis,,,
precautions,e31bd38b-2827-4adf-b416-f9064ef61211,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,MRHD,maximum recommended human dose,,,
precautions,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,GFR,glomerular filtration rate,,,
precautions,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,AEDs,antiepilepsy drugs,,,
precautions,b2433b54-da24-45c7-9d48-35f098e15814,3/1/2011,1,BUN,blood urea nitrogen,,,
precautions,b8f4d730-fd8e-4692-aabd-e2b7e63fabe1,11/15/2006,1,CHO,Chinese Hamster Ovary,,,
precautions,b8f4d730-fd8e-4692-aabd-e2b7e63fabe1,11/15/2006,1,eg,effects of digitalis,,,
precautions,b8f4d730-fd8e-4692-aabd-e2b7e63fabe1,11/15/2006,1,NTP,National Toxicology Program,,,
precautions,b8f4d730-fd8e-4692-aabd-e2b7e63fabe1,11/15/2006,1,MRHDD,maximum recommended human daily dose,,,
precautions,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,MRHD,Maximum Recommended Human Dose,,,
precautions,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,c6c048ec-0b99-4fa4-9df7-9926db93749b,4/2/2012,3,MTD,Maximum Tolerated Dose,,,
precautions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,NSAIDs,function.Nonsteroidal Anti-Inflammatory Drugs,,,
precautions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,ACE,Angiotensin Converting Enzyme,,,
precautions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,VMA,vanillylmandelic acid,,,
precautions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,NSAIDs,Nonsteroidal Anti-Inflammatory Drugs,,,
precautions,941E1EC2-1F14-4153-A5EA-CF7669D5EFD1,1/15/2008,1,AST,aspartate aminotransferase,,,
precautions,35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234,7/16/2012,3,CNS,central nervous system,,,
precautions,35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234,7/16/2012,3,Patients,patients,,,
precautions,35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234,7/16/2012,3,NOEL,noobserved-effect level,,,
precautions,b7aba0b2-72d1-4429-bb64-98b92e9d9433,3/1/2010,1,PBI,protein-bound iodine,,,
precautions,b7aba0b2-72d1-4429-bb64-98b92e9d9433,3/1/2010,1,TBG,thyroid-binding globulin,,,
precautions,b7aba0b2-72d1-4429-bb64-98b92e9d9433,3/1/2010,1,SHBG,sex hormone binding globulin,,,
precautions,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,378B3AED-D694-46B8-8629-FF72285ED29A,9/20/2007,3,TCAs,tricyclic antidepressants,,,
precautions,09325220-e4c5-4fac-aefd-ee3e42602198,9/14/2011,5,i.e.,interaction,,,
precautions,0d61ba7b-8aba-4569-8334-5d24bbf99578,10/3/2011,2,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,0d61ba7b-8aba-4569-8334-5d24bbf99578,10/3/2011,2,ie,increased risk of osteoporosis,,,
precautions,7a0bba98-8f39-4020-b2a5-c487278a057a,4/29/2010,1,NSAIDs,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,7a0bba98-8f39-4020-b2a5-c487278a057a,4/29/2010,1,NSAIDs,non-steroidal anti-inflammatory drugs,,,
precautions,7a0bba98-8f39-4020-b2a5-c487278a057a,4/29/2010,1,ECG,electrocardiogram,,,
precautions,7589f8f3-e82a-43b0-868a-cbb991e2183f,12/12/2011,1,Sodium,sodium,,,
precautions,8b682a09-ad34-452d-95a4-58a0a35470f1,12/1/2011,3291,SSRIs,selective  serotonin reuptake inhibitors,,,
precautions,8b682a09-ad34-452d-95a4-58a0a35470f1,12/1/2011,3291,TCAs,tricyclic antidepressants,,,
precautions,36887f75-0a85-4729-9051-9622e946ccda,8/29/2011,5,NTP,National Toxicology Program,,,
precautions,c135323a-33dd-49d5-b55a-33e1ff1b78fd,10/25/2010,2,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,c135323a-33dd-49d5-b55a-33e1ff1b78fd,10/25/2010,2,RIA,radioimmunoassay,,,
precautions,29C78A72-3DDE-493F-B6A2-F286BEC1F09E,2/6/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,9f9b2391-90eb-4773-bb6b-897c49d82ba5,8/7/2009,4,Mice,Micronucleus Test,,,
precautions,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,CNS,central nervous system,,,
precautions,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,Mice, Micronucleus Test,,,
precautions,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,Mice,Assay Micronucleus Test,,,
precautions,6C6B5E68-9CD7-4ABD-AA88-296B96686228,11/28/2008,1,e.g.,exaggerated sunburn reactions,,,
precautions,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,CNS,central nervous system,,,
precautions,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,CC8F105C-C8EE-4C57-86EE-EE6BF917CF78,1/10/2008,5,MRHDD,maximum recommended human daily dose,,,
precautions,a0cfad4b-043e-451e-bfd6-1fe1ac1bd0d6,5/11/2011,5,botanicals,botanical medicines,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,PM,PMs - 38% to 105%,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,SNRIs,Serotonin and  Norepinephrine Reuptake Inhibitors,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,GAD,generalized anxiety disorder,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,SSRIs,Selective Serotonin Reuptake  Inhibitors,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,EM,extensive metabolizers,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,MDD,major depressive disorder,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,SSRIs,Selective  Serotonin Reuptake Inhibitors,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,b4048138-3b43-4952-9c4d-f9278792f2b5,8/9/2011,1,PM,poor metabolizers,,,
precautions,7cf28cc7-ca73-4565-b05a-55629c457804,11/30/2010,114,CBC,complete blood count,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,BPH,benign prostatic hyperplasia,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,HIV,Human Immunodeficiency Virus,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,NAION,non-arteritic anterior ischemic optic neuropathy,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,SBP,systolic blood pressure,,,
precautions,f18a82f7-ce44-4f9c-ae69-d3ad1d375564,11/8/2011,2,CYP,cytochrome P450,,,
precautions,32e2b197-e171-444d-86ca-198d4c84d7a5,11/23/2010,2,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,32e2b197-e171-444d-86ca-198d4c84d7a5,11/23/2010,2,RIA,radioimmunoassay,,,
precautions,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,CBZ,carbamazepine,,,
precautions,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,SCE,sister chromatid exchange,,,
precautions,9fbfe4dc-c4df-4911-a440-099c860cb923,4/5/2010,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,2c5167d7-6227-4d37-8992-bdf10b3616a2,6/23/2010,1,HPA,Hypothalamic-pituitaIy-adrenal,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,ECT,electroconvulsive therapy,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,TCAs,Tricyclic Antidepressants,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,MRHD,maximum  recommended human daily dose,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,UDS,unscheduled DNA synthesis,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,ECT,Electroconvulsive Therapy,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,5caff592-a90f-420d-a6ec-9b2dc914529e,1/20/2010,2,SIADH,syndrome of inappropriate  antidiuretic hormone secretion,,,
precautions,b05bc20e-cd19-ab40-1ad0-84a115d6d69e,3/1/2011,3,WBC,white blood cell count,,,
precautions,b05bc20e-cd19-ab40-1ad0-84a115d6d69e,3/1/2011,3,PKU,phenylketonuria,,,
precautions,b05bc20e-cd19-ab40-1ad0-84a115d6d69e,3/1/2011,3,CBC,complete blood count,,,
precautions,24ce46de-cf8f-401f-8bb6-490b296513c5,12/7/2009,2,PSA,prostate specific antigen,,,
precautions,9B59DC6E-4AE6-4D5A-A313-7732A0CE4380,11/19/2007,3,PSA,Prostate Specific Antigen,,,
precautions,38642D80-AAA6-4196-A033-3977FF35B48A,8/2/2007,1,Pgp,P-glycoprotein,,,
precautions,3F0F6064-CC9F-491C-A940-3F087ABBC774,1/9/2008,1,MAO,monoamine oxidase,,,
precautions,08708dbf-d35c-48ed-9951-faefcba37ed0,9/16/2010,389,MRHD,Maximum Recommended Human Dose,,,
precautions,08708dbf-d35c-48ed-9951-faefcba37ed0,9/16/2010,389,ALC,absolute lymphocyte counts,,,
precautions,FFA8164B-E697-42A4-C8A7-22FB3B26B8AF,4/13/2006,2,e.g.,effects of digitalis,,,
precautions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAO,monoamine oxidase,,,
precautions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAOI,caution.Monoamine oxidase inhibitors,,,
precautions,A53538EB-FE22-4264-BFD7-63036B5D3D6C,12/23/2008,2,MAOI,concomitantly.Monoamine oxidase inhibitors,,,
precautions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,SIADH,syndrome of inappropriate antidiuretic hormone  secretion,,,
precautions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,SNRIs,Serotonin and  Norepinephrine Reuptake Inhibitors,,,
precautions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,GAD,generalized anxiety disorder,,,
precautions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,SSRIs,Selective Serotonin Reuptake  Inhibitors,,,
precautions,e057c25f-dfb3-419b-930b-7f272af400e5,11/23/2010,102,MDD,major depressive disorder,,,
precautions,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,MAO,depression.Monoamine oxidase,,,
precautions,DD62A5EB-DD5A-4329-8696-07ACB555AF10,11/28/2008,1,MAO,of:Monoamine oxidase,,,
precautions,fda09c9d-efee-40dc-8030-065ceacd7a5c,2/22/2010,1,MTD,maximally tolerated dose,,,
precautions,d5e0d06f-ba1e-44d4-aa89-39d6c146dc23,7/14/2011,1,procaine,persons with known drug sensitivities.  Patients allergic to para-aminobenzoic acid derivatives,,,
precautions,d6851c71-0c2f-43f6-883c-a43fe894985d,10/13/2011,6,NIOSH,National Institute for Occupational Safety and Health Administration,,,
precautions,d6851c71-0c2f-43f6-883c-a43fe894985d,10/13/2011,6,MAC,minimum alveolar concentration,,,
precautions,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,NAAED,North American Antiepileptic Drug,,,
precautions,dbd47222-14f1-4588-a009-9b81b55ca60d,12/15/2011,4,SCE,sister chromatid exchange,,,
precautions,7b38ac8a-4540-4eb2-aedd-9aa966d22190,3/27/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,7b38ac8a-4540-4eb2-aedd-9aa966d22190,3/27/2007,1,NTP,National Toxicology Program,,,
precautions,7b38ac8a-4540-4eb2-aedd-9aa966d22190,3/27/2007,1,e.g.,effects of digitalis,,,
precautions,f31d1e8d-d0f3-4bfd-88b0-b2917365b0ca,12/8/2008,1,ANC,absolute neutrophil count,,,
precautions,1dfbf901-c840-4e43-83ac-579ebe565ba3,8/4/2011,1,GFR,[glomerular filtration rate,,,
precautions,5F82E53E-D6DB-432F-AF68-9DE88D1B1720,9/19/2006,1,rec,recombinant,,,
precautions,a5ca8004-9a18-4030-a56c-8938c4823c64,1/12/2010,1,HD,human dose,,,
precautions,238050FD-5221-4B93-BFCD-31793C9088A7,11/15/2007,2,CYP3A,cytochrome P450 3A,,,
precautions,01ab131c-7b06-4982-8cf0-4e60879e0c8c,8/25/2010,1,PBI,protein-bound iodine,,,
precautions,01ab131c-7b06-4982-8cf0-4e60879e0c8c,8/25/2010,1,GGT,gamma glutamyl transpeptidase,,,
precautions,188b8a95-3db7-4a6a-bddf-48b83a0c8e38,8/1/2011,4,cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet,,,
precautions,1b628a38-3557-4fa4-9e08-4c7de40f9d82,8/9/2010,1,MAOI,monoamine oxidase inhibitors,,,
precautions,1b628a38-3557-4fa4-9e08-4c7de40f9d82,8/9/2010,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,SNRIs,serotonin and norepinephrine reuptake  inhibitors,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,MRHD,maximum recommended human dose,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,MRD,maximum recommended dose,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,ECT,Electroconvulsive Therapy,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,e1171b54-c1a3-4220-bc8a-92f49f270183,1/18/2010,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,LFT,liver function tests,,,
precautions,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,AEDs,Antiepileptic Drugs,,,
precautions,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,NAAED,North American Antiepileptic Drug,,,
precautions,6d71e14f-8092-444c-afa1-2b79d69d81e6,12/1/2011,3,MRHD,maximum recommended daily human dose,,,
precautions,8f7cba0f-cfcc-cb98-8657-20bd604165d5,1/1/2009,4,MAO,monoamine oxidase,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,GAD,generalized anxiety disorder,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,EM,extensive metabolizers,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,MDD,major depressive disorder,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,PM,poor metabolizers,,,
precautions,341720f7-f76f-498b-856f-3d207ad63feb,1/30/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,c9f59aa6-ab0b-47ef-bc98-189965936a27,9/16/2010,2,AUC,area under the curve,,,
precautions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,ECT,electroconvulsive therapy,,,
precautions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,MRHD,maximum recommended human dose,,,
precautions,ac788635-7929-48e0-af88-979fe2271501,11/12/2009,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,5B3535D5-B1E2-409F-BF82-DECDE34ABF0C,2/13/2009,1,MCI,Mild Cognitive Impairment,,,
precautions,5B3535D5-B1E2-409F-BF82-DECDE34ABF0C,2/13/2009,1,MCI,mild cognitive impairment,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,ARDS,adult respiratory distress syndrome,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,rT3,reverse T3,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,ALT,values—alanine aminotransferase,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,TdP,torsades de pointes,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,GGT,gamma-glutamyl transferase,,,
precautions,FE8909BF-9106-43D7-B89E-1DC4874CB864,1/30/2009,1,AST,aspartate aminotransferase,,,
precautions,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,MRHD,maximum recommended human dose,,,
precautions,132b0305-07a5-17e9-17c5-a405706567fe,5/1/2008,1,DSST,digit symbol substitution test,,,
precautions,72bcd320-39d6-49db-bc7b-d140d200076a,10/23/2009,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,bb9fbe40-caa8-4402-a54e-3c2c4ee1df3e,8/19/2010,358,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,b8881a81-75d7-43e8-825f-37c352c146dc,12/12/2010,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,b8881a81-75d7-43e8-825f-37c352c146dc,12/12/2010,2,TCAs,tricyclic antidepressants,,,
precautions,265f456a-b7eb-41ba-8eb4-fa417a5191cb,12/7/2011,1,WBC,white blood cell count,,,
precautions,265f456a-b7eb-41ba-8eb4-fa417a5191cb,12/7/2011,1,CBC,complete blood count,,,
precautions,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,ICU,Intensive Care Unit,,,
precautions,e88625f2-ad76-486c-a20e-b8e06ffb6457,6/28/2006,1,MH,malignant hyperthermia,,,
precautions,f4f54d5b-32f7-4765-8702-50a78c9d657e,8/23/2011,1,UDS,unscheduled DNA synthesis,,,
precautions,0c72a828-faa1-431c-a07e-3b4357846805,6/30/2011,1,PKU,phenylketonuria,,,
precautions,F1B1B77A-9F59-4130-9716-08C835935F37,2/6/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,Mice,Micronucleus Test,,,
precautions,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,CNS,central nervous system,,,
precautions,ab62a277-750d-4380-b2bd-f9700eebb128,6/24/2011,2,e.g.,exaggerated sunburn reactions,,,
precautions,13cdccfa-f8fc-4b81-8fa7-1fa5a8da0338,8/17/2009,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,PB,"valign=""top""><td>Phenobarbital",,,
precautions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,MTX,"valign=""top""><td>Methotrexate",,,
precautions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,i.e.,interaction,,,
precautions,6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199,11/9/2006,1,IV,"increase</td></tr> <tr valign=""top""><td>Isoproterenol",,,
precautions,b8066438-9bf2-4417-87ce-f0c0975cf803,7/18/2011,1,GFR,[glomerular filtration rate,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,NSTs,nonstress tests,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,MAO,observation.Monoamine Oxidase,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,TERIS,there is no risk,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,SIDS,sudden infant death syndrome,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,MAO,Monoamine Oxidase,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,SSRI's,selective serotonin reuptake inhibitors,,,
precautions,9bbe219f-3bf1-44f4-a709-cd108c4fa9ef,10/6/2007,1,AUC,area under the concentration-time curve,,,
precautions,508a418e-985f-4208-9324-2230655bb5c2,9/11/2006,3,SCLC,small cell lung cancer,,,
precautions,2cc8803f-51fe-4d66-aab6-9c83096e6cd4,11/5/2010,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,LFT,liver function tests,,,
precautions,894a3724-d375-4ab3-a4d9-f5f3ce9721c5,6/25/2012,14,NAAED,North American Antiepileptic Drug,,,
precautions,8a010871-9422-4bf7-87f7-5850b70a554a,4/2/2012,1,MAO,monoamine  oxidase,,,
precautions,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,Ames test,alone in the following in vitro tests: Salmonella microsome test,,,
precautions,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,507f44a4-7448-487f-8adc-5fca743ee59b,6/1/2011,1,FBG,fasting blood glucose,,,
precautions,39e19789-de4b-4fd1-ab1c-92f59496f496,1/25/2012,2,UDS,unscheduled DNA synthesis,,,
precautions,5664d192-10d8-4766-b0ba-6095d14c927d,6/21/2010,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,5664d192-10d8-4766-b0ba-6095d14c927d,6/21/2010,1,TCAs,tricyclic  antidepressants,,,
precautions,ee10e027-5953-4d10-8c58-5f2412978a49,4/7/2010,1,see,signs of renal insufficiency  or failure,,,
precautions,ee10e027-5953-4d10-8c58-5f2412978a49,4/7/2010,1,see,seek immediate emergency help,,,
precautions,7e593aec-4ef2-445c-b4e9-13dfc99296f2,12/20/2011,3406,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,8F6873A2-E579-FCE7-2296-F49F7673FBA5,12/10/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,f95454ab-33fa-483b-bba3-91d6562765c3,2/14/2012,4,BUN,Blood Urea Nitrogen,,,
precautions,cf2c0eb4-f95a-465c-b7e4-e0b3c06924bb,6/4/2012,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,cf2c0eb4-f95a-465c-b7e4-e0b3c06924bb,6/4/2012,2,CYP,cytochrome P450,,,
precautions,85c0b466-4b32-48ad-a585-60c58ec450e1,4/10/2008,3,e.g.,e.g.:macrolide antibiotics,,,
precautions,665ABE12-209D-4B80-8020-EF9E3F9BDADE,5/28/2009,3,MRDHD,maximum recommended daily human dose,,,
precautions,665ABE12-209D-4B80-8020-EF9E3F9BDADE,5/28/2009,3,MRDHD,maximum recommended daily human oral dose,,,
precautions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,ECT,electroconvulsive therapy,,,
precautions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,SSRI,selective serotonin reuptake inhibitor,,,
precautions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,MRHD,maximum recommended human dose,,,
precautions,56401539-e8a5-4d22-8002-86c28d7d6370,8/20/2009,3,PPHN,pulmonary hypertension of the newborn,,,
precautions,e882d315-5a04-4132-b311-a7750354bb8a,4/23/2012,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,APTT,activated partial thromboplastin time,,,
precautions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,PT,prothrombin time,,,
precautions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,ZE,Zollinger-Ellison,,,
precautions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,GI,Gastrointestinal,,,
precautions,CAF64301-262C-45CA-ACD1-A9D6696C584E,2/6/2006,1,ACE,Angiotensin Converting Enzyme,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,TERIS,Teratogen Information System,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,NSTs,nonstress tests,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,TERIS,there is no risk,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,MAO,Monoamine Oxidase,,,
precautions,5E70E915-B946-4A80-BCC6-3F49BC30F2F5,9/16/2007,1,AUC,area under the concentration-time curve,,,
precautions,682a1210-b26e-426e-8ffe-d25d91bdd608,2/1/2012,8,LNG,levonorgestrel,,,
precautions,682a1210-b26e-426e-8ffe-d25d91bdd608,2/1/2012,8,EE,ethinylestradiol,,,
precautions,A26390E8-EB86-4623-8CDD-45B24B14DF74,3/30/2007,1,APCs,atrial premature contractions,,,
precautions,c8a6c478-1d05-47b2-c98d-99177395b762,4/26/2012,6,MRHD,maximum recommended human dose,,,
precautions,c8a6c478-1d05-47b2-c98d-99177395b762,4/26/2012,6,DSST,digit symbol substitution test,,,
precautions,02FF6501-CCCC-4F7D-9988-856D4E169B0E,4/13/2006,2,PBI,Protein-bound iodine,,,
precautions,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,Patients,Patient Package Insert,,,
precautions,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,PSA,prostate specific antigen,,,
precautions,43CBC779-48D1-48FB-F09E-2D1722B4046D,8/29/2007,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,5b0ba538-4af5-4a8a-8417-7fdc784941f8,12/20/2010,160,CBC,complete blood count,,,
precautions,d667ca75-1a17-43fc-9077-f25ce0908f8d,2/15/2011,1,CYP3A4,cytochrome P450 3A4,,,
precautions,865228be-5f0b-45fa-88a1-ceb89913ec1b,3/31/2008,2,CHO,Chinese Hamster Ovary,,,
precautions,0b386ccc-a2d4-4d18-a2d7-e46ff894c674,6/5/2012,3,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,64217ed0-7b53-4b8b-8e53-2b645640ab22,9/16/2011,2,INR,International Normalized Ratio,,,
precautions,cf3d4110-3ae5-46fd-84f4-127fd2998dbb,8/23/2011,1,Patients,patients,,,
precautions,cf3d4110-3ae5-46fd-84f4-127fd2998dbb,8/23/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,b2cb63c9-f825-4991-9a2c-6260f1bbcc2c,5/23/2012,4,FSH,follicle-stimulating hormone,,,
precautions,b2cb63c9-f825-4991-9a2c-6260f1bbcc2c,5/23/2012,4,RMA,Risk Management Authorization,,,
precautions,b2cb63c9-f825-4991-9a2c-6260f1bbcc2c,5/23/2012,4,LH,luteinizing hormone,,,
precautions,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,CBZ,carbamazepine,,,
precautions,e26005ef-77f0-4393-a2dc-b5fe460cead8,12/4/2008,1,SCE,sister chromatid exchange,,,
precautions,6f41228b-974a-443b-a313-2fbb3d845915,2/16/2010,1,Mice,Micronucleus Test,,,
precautions,abfc6b75-1ed5-41f1-0484-4597488237bc,2/17/2012,10,MRHD,maximum recommended human dose,,,
precautions,abfc6b75-1ed5-41f1-0484-4597488237bc,2/17/2012,10,VMA,vanillylmandelic acid,,,
precautions,3FC06635-1898-4FA2-83B4-E3612577328D,6/19/2008,3,PSA,Prostate Specific Antigen,,,
precautions,5d86f813-e784-4490-a842-bcb78eb0d9a4,8/1/2011,4,NAAED,North American Antiepileptic Drug,,,
precautions,b8d8c29a-414d-4622-bffd-b742725b20f0,4/4/2011,1,WBC,white blood cell count,,,
precautions,b8d8c29a-414d-4622-bffd-b742725b20f0,4/4/2011,1,CBC,complete blood count,,,
precautions,9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a,1/17/2012,1,NAAED,North American Antiepileptic Drug,,,
precautions,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,MRHD,Maximum Recommended Human Dose,,,
precautions,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,fe24cae8-fb13-4f01-aa72-0ea929a432ef,6/10/2011,2,MTD,Maximum Tolerated Dose,,,
precautions,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,GAD,generalized anxiety disorder,,,
precautions,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,MDD,major depressive disorder,,,
precautions,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,f2f03495-12b6-457a-901f-958b9c844bfd,10/27/2009,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,787cda7d-7aa4-4909-8e5c-f2fcf68828e4,6/29/2010,1,SGOT,serum glutamic-oxalacetic transaminase,,,
precautions,787cda7d-7aa4-4909-8e5c-f2fcf68828e4,6/29/2010,1,MAO,monoamine  oxidase,,,
precautions,787cda7d-7aa4-4909-8e5c-f2fcf68828e4,6/29/2010,1,VMA,vanillylmandelic acid,,,
precautions,a8ed14ef-cd4b-3be7-0b5f-b677c72d2e88,7/12/2011,1,PRA,plasma renin activity,,,
precautions,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,PSA,prostate specific antigen,,,
precautions,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,BPH,benign prostatic hyperplasia,,,
precautions,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,FSH,follicle-stimulating hormone,,,
precautions,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,PCPT,Prostate Cancer Prevention Trial,,,
precautions,abd87058-923f-4767-986c-278201c0e688,10/5/2011,1,LH,luteinizing hormone,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,PM,PMs - 38% to 105%,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,EM,extensive metabolizers,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,MDD,major depressive disorder,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,PM,poor metabolizers,,,
precautions,2e8f0889-57ca-498a-8e91-b8a24bbe47fd,5/31/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,3ed014d4-fedd-48b5-a90a-0a799f780079,3/14/2011,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,f1a64637-6143-4543-a785-12e006cba849,5/17/2011,4,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,60979ac0-024e-4dc8-9a84-c9195093c08d,4/19/2012,2,SGOT,serum glutamic oxalacetic transaminase,,,
precautions,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,IM,Intramuscular,,,
precautions,2884c645-fd5f-4aa9-b2dc-854fe9ecd86c,9/28/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,fddc9630-2f9a-4104-888f-3714587d4fe7,1/24/2012,1,CHF,congestive heart failure,,,
precautions,fddc9630-2f9a-4104-888f-3714587d4fe7,1/24/2012,1,MRHD,maximum recommended human dose,,,
precautions,fddc9630-2f9a-4104-888f-3714587d4fe7,1/24/2012,1,NTS,nicotine transdermal system,,,
precautions,fddc9630-2f9a-4104-888f-3714587d4fe7,1/24/2012,1,SR,sustained-release tablets,,,
precautions,e91e3942-2392-4824-bfc5-a839ea89d351,3/6/2012,9,CHO,Chinese Hamster Ovary,,,
precautions,e91e3942-2392-4824-bfc5-a839ea89d351,3/6/2012,9,NTP,National Toxicology Program,,,
precautions,e91e3942-2392-4824-bfc5-a839ea89d351,3/6/2012,9,e.g.,effects of digitalis,,,
precautions,47b09171-bc17-4f32-a08e-6546bd48f78a,6/12/2012,3,HPA,hypothalmic-pituitary-adrenal,,,
precautions,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,MRHD,maximum recommended human dose,,,
precautions,0201a4eb-f127-4e45-92a7-b65a1af65b24,8/20/2008,2,GFR,[glomerular filtration rate,,,
precautions,21f1d859-e73d-4411-b35d-53a281d09177,7/2/2008,1,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,GAD,generalized anxiety disorder,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,ODV,O-desmethylvenlafaxine,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,EM,extensive metabolizers,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,MDD,major depressive disorder,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,185d90ab-1ba4-dd59-0565-e35f0fd39a2d,6/13/2008,1,PM,poor metabolizers,,,
precautions,a6512740-17e0-4f22-a233-4ac084277879,2/27/2012,1,TSH,thyroid stimulating hormone,,,
precautions,c68734cc-d998-4909-922d-8e55cdd780e2,10/19/2011,1,Mice,Micronucleus Test,,,
precautions,b15e5520-0a87-4943-9bbb-ead066456273,2/10/2012,4,i.e.,indicated,,,
precautions,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,G6PD,glucose-6-phosphate dehydrogenase,,,
precautions,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,FBG,fasting blood glucose,,,
precautions,ef7a0709-6d26-4d53-bc31-e8852e443ce4,8/1/2010,10,MRHD,maximum recommended human daily,,,
precautions,8bcdd16b-18f0-4478-8699-85edb1acb17c,4/7/2010,2,NIOSH,National Institute for Occupational Safety and Health Administration,,,
precautions,5ceed28f-2cb1-4eef-b1ce-3cc83b8f49aa,2/3/2010,1,AUC,at doses which produced exposures,,,
precautions,5ceed28f-2cb1-4eef-b1ce-3cc83b8f49aa,2/3/2010,1,CDC,Centers for Disease Control and Prevention,,,
precautions,ef113645-b1a0-4327-86a0-9b066f0dd141,12/4/2009,3,TCAs,tricyclic antidepressants,,,
precautions,ef113645-b1a0-4327-86a0-9b066f0dd141,12/4/2009,3,SSRIs,selective serotonin reuptake  inhibitors,,,
precautions,7c065a08-bd12-4d43-ad9a-13228d99d106,8/13/2007,1,sleep aids,should not combine meperidine hydrochloride tablets with alcohol or other central nervous system depressants,,,
precautions,ac5c3e79-52f7-434e-92ae-24bd32b45edc,2/6/2012,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,709031e4-4c20-4ea7-beff-6c459709a433,1/28/2011,1,PBI,protein-bound iodine,,,
precautions,709031e4-4c20-4ea7-beff-6c459709a433,1/28/2011,1,TBG,thyroid-binding globulin,,,
precautions,709031e4-4c20-4ea7-beff-6c459709a433,1/28/2011,1,e.g.,estrogens,,,
precautions,6d0a12dc-3873-4a46-a927-9e5630b569c0,2/1/2011,2,CHF,congestive heart failure,,,
precautions,6d0a12dc-3873-4a46-a927-9e5630b569c0,2/1/2011,2,MRHD,maximum recommended human dose,,,
precautions,6d0a12dc-3873-4a46-a927-9e5630b569c0,2/1/2011,2,NTS,nicotine transdermal system,,,
precautions,6d0a12dc-3873-4a46-a927-9e5630b569c0,2/1/2011,2,SR®,(SR),,,
precautions,938d167b-bf6d-4c29-8848-fc76aba3cbd0,11/10/2011,2,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,d0a8c5d1-bfc1-4829-bbf4-609e05e6d25c,5/27/2010,1,NSAIDS,Non-Steroidal Anti-Inflammatory DrugsNonsteroidal anti-inflammatory drugs,,,
precautions,d0a8c5d1-bfc1-4829-bbf4-609e05e6d25c,5/27/2010,1,MRHD,maximum recommended human oral daily dose,,,
precautions,e2ca5909-6f4c-4945-b0d8-f7c142dfd26d,8/16/2011,22,WBC,white blood cell count,,,
precautions,e2ca5909-6f4c-4945-b0d8-f7c142dfd26d,8/16/2011,22,PKU,phenylketonuria,,,
precautions,e2ca5909-6f4c-4945-b0d8-f7c142dfd26d,8/16/2011,22,CBC,complete blood count,,,
precautions,53e6b661-39e7-4343-844a-21053b67e8f5,6/25/2012,1,MAO,monoamine  oxidase,,,
precautions,23452a86-8ae2-4165-aca6-056b3d2c6462,7/29/2011,70,Patients,patients,,,
precautions,23452a86-8ae2-4165-aca6-056b3d2c6462,7/29/2011,70,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,CNS,central  nervous system,,,
precautions,cc2e17d0-d781-43d0-a933-2982f757ba5a,11/22/2010,99,e.g.,exaggerated sunburn reactions,,,
precautions,1e2fb42a-5dc9-49c0-8575-116173cd4ccb,3/2/2012,3,Mice,Micronucleus Test,,,
precautions,56bf1b0a-463a-4324-957b-585d4cf352ee,4/14/2011,1,MRHD,Maximum Recommended Human  Dose,,,
precautions,722de2a9-38b3-4518-b262-ba0d1346d0ba,8/23/2011,8,NAAED,North American Antiepileptic Drug,,,
precautions,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,MRDD,maximum recommended daily dose,,,
precautions,ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af,7/18/2012,2,COMT,Catechol-O-methyltransferase,,,
precautions,ba72b914-1252-4370-9b4b-0105186ffb42,5/6/2010,1,CHO,Chinese hamster ovary,,,
precautions,7aa1bd53-b642-41a5-bca5-29af45f25a53,6/21/2012,1,MAO,monoamine  oxidase,,,
precautions,4C52C904-8137-4B10-8A85-D9B96C2D8A00,5/10/2006,1,oxine,oxyquinoline,,,
precautions,c8e51a2a-17c9-473a-aff1-dd776006c0a9,8/8/2011,1,MAO,monoamine oxidase,,,
precautions,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,JRA,juvenile rheumatoid arthritis,,,
precautions,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,GI,gastrointestinal,,,
precautions,de5ea439-a13c-441b-84e0-bc6937abf762,4/18/2011,1,CHO,Chinese hamster ovary,,,
precautions,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,e.g.,evaluate the specific pathology,,,
precautions,cd4d1aeb-debf-458a-83c1-fa098d4d3415,4/29/2010,5,ERG,electroretinogram,,,
precautions,F9752B21-A8BB-40D5-BCAD-6A55802158C5,10/9/2006,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,36a919ce-7a21-40c0-9af5-2299bf2b1f97,12/1/2010,2,botanicals,botanical medicines,,,
precautions,003aee15-e811-4dae-aa8c-4381ae5a17e3,3/5/2012,1,CHF,congestive heart failure,,,
precautions,003aee15-e811-4dae-aa8c-4381ae5a17e3,3/5/2012,1,NTS,nicotine transdermal system,,,
precautions,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,PBI,protein-bound iodine,,,
precautions,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,TBG,thyroid-binding globulin,,,
precautions,56bd0e7f-16fd-4909-af12-ac3acb4f3f56,1/7/2009,2,e.g.,estrogens,,,
precautions,99130b62-7ef7-4ef1-b717-de0798d39aba,9/2/2010,1,AUC,area under the curve,,,
precautions,99130b62-7ef7-4ef1-b717-de0798d39aba,9/2/2010,1,AUC,area under the plasma concentrationtime curve,,,
precautions,46ac55cf-d85e-4c34-bb33-f49e078c4a03,3/14/2012,5,MPA,mycophenolic acid,,,
precautions,3bc802bd-76b4-4f45-8571-a436ec26228e,12/2/2009,1,CML,chronic myeloid leukemia,,,
precautions,9a105eaf-ee77-4016-beeb-d425a5565db2,12/12/2011,2,MRHD,maximum recommended human dose,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,PM,PMs - 38% to 105%,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,GAD,generalized anxiety disorder,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,ODV,O-desmethylvenlafaxine,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,ODV,O-desvenlafaxine,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,EM,extensive metabolizers,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,MDD,major depressive disorder,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,PMs,PMs 4% to 134%,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,a5e32167-9ee0-4fbb-8577-c67fbc794d78,5/31/2012,9,PM,poor metabolizers,,,
precautions,17e47845-daad-434c-a784-6d3875b0d704,7/15/2011,10,CBC,complete blood count,,,
precautions,17e47845-daad-434c-a784-6d3875b0d704,7/15/2011,10,ECG,Electrocardiographic,,,
precautions,3f412c0c-dfc2-4256-b405-dd4aa2b66e43,8/26/2010,1,MRHD,maximum recommended human oral daily dose,,,
precautions,3f412c0c-dfc2-4256-b405-dd4aa2b66e43,8/26/2010,1,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
precautions,a87d78b2-7170-4979-9291-1505bed2f3ca,2/20/2008,1,i.e.,inducers of CYP3A4,,,
precautions,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,MRHD,maximum recommended human dose,,,
precautions,754EE84C-AD16-4B06-BD1C-6791C758F908,5/31/2007,2,GFR,[glomerular filtration rate,,,
precautions,a78a68a4-5425-43c4-81cc-7733b72445b8,12/2/2010,3,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,CF288AD5-D4E7-4B0B-BFD0-41C5327E6984,2/6/2007,1,BUN,Blood Urea Nitrogen,,,
precautions,3537a73d-2411-498a-8e18-a128f8c5eecb,8/28/2010,379,GFR,[glomerular  filtration rate,,,
precautions,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,I.M.,Intramuscular,,,
precautions,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,topical,acidsulindaccisapridemethimazole*tamoxifenclarithromycinmethyldopatetracyclineclofibratemethylphenidatethyroidwarfarin sodium overdosemethylsalicylate ointment,,,
precautions,cb129148-a78e-4712-8391-5a51854f8725,12/6/2011,1,high dose,have been reported.alcohol*warfarin sodium underdosagephenytoin*aminoglutethimidecyclophosphamide*Pravastatin*amobarbitaldicloxacillinPrednisone*atorvastatin*ethchlorvynolprimidoneazathioprineglutethimidePropylthiouracil*butabarbitalgriseofulvinraloxifenebutalbitalhaloperidolranitidine*carbamazepinemeprobamaterifampinchloral hydrate*6-mercaptopurinesecobarbitalchlordiazepoxidemethimazole*spironolactonechlorthalidonemoricizine hydrochloride*sucralfatecholestyramine*nafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,b7f546f3-ed5f-4a7f-b9b1-1f5c3ebef0ea,4/10/2012,2,MAO,monoamine  oxidase,,,
precautions,ae998218-7f49-46cf-9898-0920572b6fd1,9/26/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,704A5E3E-6ADF-4D38-A793-80978AB6E3BB,1/16/2007,1,MAO,Monoamine oxidase,,,
precautions,704A5E3E-6ADF-4D38-A793-80978AB6E3BB,1/16/2007,1,CNS,Central nervous system,,,
precautions,11e8f511-6997-458a-86b2-0416d1354ebb,6/9/2011,2,INR,international normalized ratio,,,
precautions,11e8f511-6997-458a-86b2-0416d1354ebb,6/9/2011,2,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,11e8f511-6997-458a-86b2-0416d1354ebb,6/9/2011,2,ARBs,angiotensin receptor blockers,,,
precautions,11e8f511-6997-458a-86b2-0416d1354ebb,6/9/2011,2,ACE,angiotensin converting enzyme,,,
precautions,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,MRHD,maximum recommended human dose,,,
precautions,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,GFR,glomerular filtration rate,,,
precautions,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,AEDs,antiepilepsy drugs,,,
precautions,31BB7426-63AB-4CCB-9B83-EED9FA912992,5/9/2007,2,BUN,blood urea nitrogen,,,
precautions,790d3557-0b33-4b92-974a-14dc3e95d62b,11/2/2010,12,Pgp,P-glycoprotein,,,
precautions,7b4a3438-57b4-4d88-9843-cc9da529f6f2,8/4/2009,3,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,7b4a3438-57b4-4d88-9843-cc9da529f6f2,8/4/2009,3,TCAs,tricyclic antidepressants,,,
precautions,810fa667-2d9f-4fd1-bdde-aa8ca4390df1,5/11/2006,1,MRHD,maximum recommended human dose,,,
precautions,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,BMD,bone mineral density,,,
precautions,f0b31daa-0792-43d5-af08-8b6a864dc90a,1/4/2010,1,CTC,Common Toxicity Criteria,,,
precautions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,MRHD,maximum recommended human dose,,,
precautions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,GFR,[glomerular filtration rate,,,
precautions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,INR,International Normalized Ratio,,,
precautions,10c0ed21-833a-4267-b388-56d0c1ebada8,7/12/2011,1,AUC,Area Under the Curve,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,NET,norethindrone,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,RHD,recommended human dose,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,NAAED,North American Antiepileptic Drug,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,HCTZ,Hydrochlorothiazide,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,EE,ethinyl estradiol,,,
precautions,50bc013e-b5df-40e0-95e5-2527a62dcda0,2/9/2012,3,CBZ,"valign=""top"">&#160;Carbamazepine",,,
precautions,170ab622-4d2a-4395-831b-2bfffccb0ac1,12/2/2011,4,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,de667f60-0627-4f76-837e-cac8e7490e36,2/23/2012,2,BUN,Blood Urea Nitrogen,,,
precautions,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,LDH,lactate dehydrogenase,,,
precautions,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,ALT,alanine aminotransferase,,,
precautions,fb79c214-e6ff-499a-9e23-a759bef9b7cb,8/13/2010,1,AST,aspartate aminotransferase,,,
precautions,45e1c9d9-b8bc-4df9-acbb-d3a9c31a24b0,5/24/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,06141D73-9A59-4626-C372-390566602B77,11/26/2008,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,445e0341-5f8a-4a59-9cc5-f93177f5bf9c,5/28/2010,1,AUCs,a measure of systemic exposure,,,
precautions,3f2b939c-2206-469b-85a4-b0ee9ba25be8,1/4/2012,3475,MO-TMS,methoxime-trimethylsilyl,,,
precautions,3f2b939c-2206-469b-85a4-b0ee9ba25be8,1/4/2012,3475,GC/MS,Gas  chromatography/mass spectrometry,,,
precautions,3f2b939c-2206-469b-85a4-b0ee9ba25be8,1/4/2012,3475,TLC,thin-layer chromatography,,,
precautions,AD3DA3C3-66B2-09FE-2C85-AAF4367E3732,10/6/2008,3,HD,human dose,,,
precautions,A15D0DF0-3BCA-4FBC-A1D6-34A88C9A9665,3/30/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,ICU,Intensive Care Unit,,,
precautions,ca9e266c-8264-46f4-9df3-8d86a9d8437f,5/11/2006,1,MH,malignant hyperthermia,,,
precautions,86f44ab3-81c4-4d3e-a70e-5985c172af0b,11/3/2011,1,BMD,bone mineral density,,,
precautions,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,CHO,Chinese Hamster Ovary,,,
precautions,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,eg,effects of digitalis,,,
precautions,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,MRHD,maximum recommended human dose,,,
precautions,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,BUN,blood urea nitrogen,,,
precautions,1b0dbf60-9aad-47fa-9ed4-84bbb7ab5d2f,9/29/2008,2,NTP,National Toxicology Program,,,
precautions,4ACDFA96-BD62-4289-8454-276D3886A1A7,12/13/2006,3,AUC,area under the curve,,,
precautions,ad54cca8-db8a-4cd7-aff9-464ccdda6950,9/1/2010,1,Injection,Injectable Emulsion,,,
precautions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,TCAs,Tricyclic Antidepressants,,,
precautions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,TCAs,tricyclic antidepressants,,,
precautions,a93796a3-56fc-4af6-99ba-f76707c32e5d,1/25/2012,4,ECT,Electroconvulsive Therapy,,,
precautions,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,TFMA,trifluoromethylaniline,,,
precautions,b933c448-a7e5-4f38-b5e2-a03615826fa3,12/2/2011,4,INR,International Normalized Ratio,,,
precautions,1beeea2f-a922-43df-aa9e-2231ef404ba4,7/31/2008,1,COX-2,cyclooxgenase-2,,,
precautions,E1A0DA17-D67C-E44F-BD42-33C4009E4CDD,4/2/2009,2,CNS,central nervous system,,,
precautions,cdc77f53-e9f6-486e-896a-069bc7ec47fd,2/22/2011,1,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,c6c48eee-240b-4425-8691-35462523652e,10/27/2009,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,c6c48eee-240b-4425-8691-35462523652e,10/27/2009,1,CYP3A4,cytochrome P450  3A4 isoenzyme system,,,
precautions,c6c48eee-240b-4425-8691-35462523652e,10/27/2009,1,HED,human equivalent dose,,,
precautions,a360d43c-bed8-4f41-ab36-e2aa77dfbff2,8/15/2011,1,i.e.,inducers of CYP3A4,,,
precautions,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,PBI,protein-bound iodine,,,
precautions,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,TBG,thyroid-binding globulin,,,
precautions,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,CBG,corticosteroid binding globulin,,,
precautions,10E1D3EF-808E-47E4-A050-93A5918B1085,1/18/2008,3,SHBG,sex hormone-binding globulin,,,
precautions,6ad2e46c-c76b-4ca3-bfc7-9f903515b1b4,8/10/2010,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,e15a7e9b-8025-49dd-9a6d-bafcccf1959f,2/28/2011,8,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,CNS,central nervous system,,,
precautions,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,EPS,extrapyramidal signs and symptoms,,,
precautions,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,NMS,Neuroleptic Malignant Syndrome,,,
precautions,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,GLP,Good Laboratory Practices,,,
precautions,01417F60-DBF3-4041-BF3C-51E6C9216F06,8/9/2006,1,GLP,Good Laboratory Practice,,,
precautions,68322B78-8B39-4D42-9889-6126CDD7D43A,5/10/2006,1,PSA,Prostate Specific Antigen,,,
precautions,1ecb628e-8bdf-4dbc-b5be-9f40eec183e6,8/31/2009,2,MRHD,maximum recommended human dose,,,
precautions,6414f16f-c3e0-4ca1-ad58-ed081a9c0b09,3/30/2012,10,CHO,Chinese Hamster Ovary,,,
precautions,6414f16f-c3e0-4ca1-ad58-ed081a9c0b09,3/30/2012,10,NTP,National Toxicology Program,,,
precautions,6414f16f-c3e0-4ca1-ad58-ed081a9c0b09,3/30/2012,10,MRHDD,maximum recommended human daily dose,,,
precautions,6414f16f-c3e0-4ca1-ad58-ed081a9c0b09,3/30/2012,10,e.g.,effects of digitalis,,,
precautions,ae8b4a9d-4308-4a3c-8ec9-1e8d9060db68,5/12/2011,1,MROHD,maximum  recommended ocular human dose,,,
precautions,cd0bbdb2-754e-4e66-8f36-985b5819d642,8/13/2009,1,LDL,low-density lipoprotein,,,
precautions,cd0bbdb2-754e-4e66-8f36-985b5819d642,8/13/2009,1,HDL,high-density lipoprotein,,,
precautions,102e6e80-f9ab-4efc-9234-9e3396f3dfb5,12/13/2010,140,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,102e6e80-f9ab-4efc-9234-9e3396f3dfb5,12/13/2010,140,TCAs,tricyclic  antidepressants,,,
precautions,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,I.M.,Intramuscular,,,
precautions,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,topical,acidsulindaccisapridemethimazole*tamoxifenclarithromycinmethyldopatetracyclineclofibratemethylphenidatethyroidwarfarin sodium overdosemethylsalicylate ointment,,,
precautions,96762862-8098-452e-a58a-44bebc475d33,12/2/2011,1,high dose,have been reported.alcohol*warfarin sodium underdosagephenytoin*aminoglutethimidecyclophosphamide*Pravastatin*amobarbitaldicloxacillinPrednisone*atorvastatin*ethchlorvynolprimidoneazathioprineglutethimidePropylthiouracil*butabarbitalgriseofulvinraloxifenebutalbitalhaloperidolranitidine*carbamazepinemeprobamaterifampinchloral hydrate*6-mercaptopurinesecobarbitalchlordiazepoxidemethimazole*spironolactonechlorthalidonemoricizine hydrochloride*sucralfatecholestyramine*nafcillintrazodoneclozapineparaldehydevitamin C,,,
precautions,330e620f-4b7f-4101-91dd-feddb7a823ed,10/16/2009,7,CHO,Chinese Hamster Ovary,,,
precautions,330e620f-4b7f-4101-91dd-feddb7a823ed,10/16/2009,7,MRHD,maximum recommended human dose,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,ECT,Electroconvulsive therapy,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,MRHD,maximum recommended human dose,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,MRD,maximum recommended dose,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,180A07FD-1F6A-4617-B8E0-F938C65BA273,10/10/2008,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,9778AFDE-01AE-49DF-E7AB-D25D89711602,5/10/2006,2,CNS,central nervous system,,,
precautions,9778AFDE-01AE-49DF-E7AB-D25D89711602,5/10/2006,2,e.g.,effects of digitalis,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,OTC,over-the-counter,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,ECT,electroconvulsive therapy,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,MRHD,maximum recommended human dose,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,27CAD186-5F47-49A6-AD75-DF3A38C1C614,1/31/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9720518e-9f70-4811-84ca-69a526d8a904,1/9/2012,1,CHF,congestive heart failure,,,
precautions,9720518e-9f70-4811-84ca-69a526d8a904,1/9/2012,1,MRHD,maximum recommended human dose,,,
precautions,9720518e-9f70-4811-84ca-69a526d8a904,1/9/2012,1,NTS,nicotine transdermal system,,,
precautions,E1E7D3E3-BB89-4BC2-AA63-26F367760FEE,4/1/2008,3,CNS,central nervous system,,,
precautions,1c48aa77-0021-4628-9def-7f9e4c7bbb7a,6/25/2012,1,MAO,monoamine  oxidase,,,
precautions,0fcdbdb5-4b27-4ef8-aa1c-b72d355def41,2/1/2010,1,CHO,Chinese Hamster Ovary,,,
precautions,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,PBI,protein-bound iodine,,,
precautions,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,TBG,thyroid-binding globulin,,,
precautions,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,WHI,Women’s Health Initiative,,,
precautions,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,826f674c-8ef2-400a-bf0b-877320a8cb5d,6/2/2011,1,i.e.,in serum,,,
precautions,6fea0c04-cfbc-4bd2-8a1f-fa3d5ed2a941,4/1/2011,1,TBG,thyroid  binding globulin,,,
precautions,6fea0c04-cfbc-4bd2-8a1f-fa3d5ed2a941,4/1/2011,1,SHBG,Sex hormone-binding globulin,,,
precautions,42097235-FA5F-4052-A558-763116AFD58D,4/5/2007,1,UDS,unscheduled DNA synthesis,,,
precautions,dc35ba25-8746-4ed8-83c1-e6b6a1057863,1/3/2012,5,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,e.g.,evaluate the specific pathology,,,
precautions,a543b4fb-186a-40f4-8c88-861b7db2b3e9,6/23/2011,1,ERG,electroretinogram,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,CHF,congestive heart failure,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,MRHD,maximum recommended human dose,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,NTS,nicotine transdermal system,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,see and,Safety and effectiveness in the pediatric population have not been established,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,see,Seizure Threshold:                            WARNINGS,,,
precautions,1c230d18-4aec-4105-83cc-43e763f1a64a,3/29/2011,1,see,should not be exceeded,,,
precautions,bf588f7e-89de-4b4e-8d33-c1ff2be1b34e,2/8/2012,7,CYP,cytochrome P450,,,
precautions,f2b2bbd5-720b-4871-9785-a60df6e2e00a,2/7/2012,2,CHF,congestive heart failure,,,
precautions,f2b2bbd5-720b-4871-9785-a60df6e2e00a,2/7/2012,2,MRHD,maximum recommended human dose,,,
precautions,f2b2bbd5-720b-4871-9785-a60df6e2e00a,2/7/2012,2,NTS,nicotine transdermal system,,,
precautions,aff713e8-2cb6-4e49-94a2-c55c5491c822,8/4/2009,5,BUN,Blood Urea Nitrogen,,,
precautions,ad07855c-8bec-4c4b-a8d3-cbf0e18a5b42,3/26/2012,1,MAO,monoamine  oxidase,,,
precautions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,NTPR,National Transplantation Pregnancy Registry,,,
precautions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MMF,mycophenolate mofetil,,,
precautions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MPA,mycophenolic acid,,,
precautions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,BSA,body surface area,,,
precautions,9f84ea84-2d8b-4d91-a33f-7dfb5df937dc,7/24/2012,9,MRP-2,multidrug-resistance-associated protein 2,,,
precautions,9963df58-6a18-4f7e-aa98-013635327638,4/5/2012,1,MAO,monoamine  oxidase,,,
precautions,14629e09-a46c-496b-8fe2-1c09ddcd4f71,1/20/2011,1,botanicals,botanical medicines,,,
precautions,cf970688-cd77-b95c-4bd9-c541590e9722,8/1/2011,8,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,cf970688-cd77-b95c-4bd9-c541590e9722,8/1/2011,8,ie,increased risk of osteoporosis,,,
precautions,43ac81cb-1e3f-4d44-86bd-13db2721d060,5/27/2010,2,MRHD,maximum recommended human dose,,,
precautions,9c6e2044-c040-403c-bcd6-99ca1e6bba73,1/19/2012,3,CHF,congestive heart failure,,,
precautions,9c6e2044-c040-403c-bcd6-99ca1e6bba73,1/19/2012,3,MRHD,maximum recommended human dose,,,
precautions,9c6e2044-c040-403c-bcd6-99ca1e6bba73,1/19/2012,3,NTS,nicotine transdermal system,,,
precautions,2D9D9660-EF3A-4ABF-C291-DB8D844FF658,1/15/2008,5,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,2D9D9660-EF3A-4ABF-C291-DB8D844FF658,1/15/2008,5,MRHD,maximum recommended human oral daily dose,,,
precautions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,GAD,generalized anxiety disorder,,,
precautions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,MDD,major depressive disorder,,,
precautions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,2c4cd6a8-b95a-4632-bbb8-c633a8561d43,3/14/2012,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,2f88600e-4b76-43dd-8ded-a454b6ed8a0e,6/12/2012,1,MAO,monoamine  oxidase,,,
precautions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,NET,norethindrone,,,
precautions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,HCTZ,Hydrochlorothiazide,,,
precautions,47fd4c44-56fa-4864-af5d-7b65c7b746d7,2/15/2011,1,EE,ethinyl estradiol,,,
precautions,71fba6d2-209b-45fc-89d4-0bb474ff7f7c,5/14/2012,1,MAO,monoamine  oxidase,,,
precautions,e038fdbc-6d80-4840-afb6-032bf006913f,3/25/2011,2,COX-2,cyclooxgenase-2,,,
precautions,be38b325-3a6f-4569-9ae0-a03feff8535d,10/26/2011,1,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,f622616e-4c11-4149-bf00-5ea5ce97800b,4/9/2007,1,PT,prothrombin time,,,
precautions,A551FAC0-8738-40B3-9B03-602F794A4B66,6/12/2008,1,i.e.,in children and adolescents,,,
precautions,c8b8c294-57b1-4285-b230-fb5ba1cfcfac,2/15/2011,1,Patients,Patient Package Insert,,,
precautions,c62ad12d-a7c1-4846-9dbf-6e11884000bc,12/17/2011,2,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,c62ad12d-a7c1-4846-9dbf-6e11884000bc,12/17/2011,2,RIA,radioimmunoassay,,,
precautions,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,GVHD,graft-versus host disease,,,
precautions,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,HVOD,hepatic veno-occlusive disease,,,
precautions,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,AUC,area under the plasma concentration curve,,,
precautions,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,CVC,central venous catheter,,,
precautions,03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95,5/14/2007,1,i.e.,in a frozen state,,,
precautions,895c7f90-2c53-43c3-ae4d-31d858e11eff,3/16/2007,1,MRHDD,maximum recommended human daily dose,,,
precautions,8634a53f-fba5-4433-87bf-e6cf72acf869,5/19/2011,6,BUN,blood urea nitrogen,,,
precautions,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,TBG,thyroid-binding globulin,,,
precautions,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,SHBG,sex hormone-binding globulin,,,
precautions,03cdbf5b-b572-448f-80e9-b3e812959901,3/14/2012,2,PBI,protein-bound  iodine,,,
precautions,26b5247a-9590-dd1d-7101-e406011d20e3,3/1/1998,1,WBC,white blood cell count,,,
precautions,26b5247a-9590-dd1d-7101-e406011d20e3,3/1/1998,1,PKU,phenylketonuria,,,
precautions,26b5247a-9590-dd1d-7101-e406011d20e3,3/1/1998,1,CBC,complete blood count,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,PM,PMs - 38% to 105%,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,ODV,O-desmethylvenlafaxine,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,EM,extensive metabolizers,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9b5885cc-ef96-4081-8975-9febc6772dc0,2/13/2012,5,PM,poor metabolizers,,,
precautions,14b387ce-d85c-4fa4-9a14-9812d64842a2,5/25/2012,1,MAO,monoamine  oxidase,,,
precautions,187240e9-1eed-45ec-befb-18647d175112,8/4/2011,1,e.g.,effects of digitalis,,,
precautions,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,CHO,Chinese Hamster Ovary,,,
precautions,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,NTP,National Toxicology Program,,,
precautions,25318baf-9c2f-458f-b9ea-f52dabca49af,3/8/2011,5,e.g.,effects of digitalis,,,
precautions,b43d7ece-d41f-4955-944c-416f479c5cc6,11/25/2009,1,GC/MS,gas  chromatography/mass spectrometry,,,
precautions,0e996cf8-6975-452a-a84c-ca1033a629b1,5/28/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,7c6e428b-305f-477e-a758-753d2ea5a060,6/28/2011,1,Mice,Micronucleus Test,,,
precautions,B6D9F638-71C4-4701-8CA0-AC83AFD08266,12/6/2006,1,MAO,monoamine oxidase,,,
precautions,11476433-d06d-4b33-924f-e8066bca7455,12/15/2009,3,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,11476433-d06d-4b33-924f-e8066bca7455,12/15/2009,3,CYP3A4,cytochrome P450 3A4 isoenzyme system,,,
precautions,11476433-d06d-4b33-924f-e8066bca7455,12/15/2009,3,HED,human equivalent dose,,,
precautions,bcbdbb65-3d82-42e8-9564-630748549954,1/4/2012,3477,RIA,radioimmunoassay,,,
precautions,bcbdbb65-3d82-42e8-9564-630748549954,1/4/2012,3477,AIDS,Acquired Immunodeficiency  Syndrome,,,
precautions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,PBI,protein bound iodine,,,
precautions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,GC/MS,gas chromatography/mass  spectrometry,,,
precautions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,ACE,Angiotensin Converting Enzyme,,,
precautions,23a60947-6058-4bf7-a3ee-ae396e55d939,5/23/2011,1,NSAID's,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,84262b69-df29-41d0-9e97-6e1188096aeb,3/9/2010,1,iPTH,intact PTH,,,
precautions,84262b69-df29-41d0-9e97-6e1188096aeb,3/9/2010,1,iPTH,Intact PTH,,,
precautions,780fc63a-6aaf-4b27-a053-c593f3838dd4,6/10/2011,1,NOEL,noobserved-effect level,,,
precautions,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,0e5315bc-c02f-4749-be69-b5b528327d58,11/14/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,59a7cda8-34b4-4c02-b100-91f274918eef,7/8/2009,1,CHF,congestive heart failure,,,
precautions,59a7cda8-34b4-4c02-b100-91f274918eef,7/8/2009,1,MRHD,maximum recommended human dose,,,
precautions,59a7cda8-34b4-4c02-b100-91f274918eef,7/8/2009,1,NTS,nicotine transdermal system,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,GAD,generalized anxiety disorder,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,ODV,O-desmethylvenlafaxine,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,ODV,O-desvenlafaxine,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,EM,extensive metabolizers,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,MDD,major depressive disorder,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,e5a31f69-c237-49b7-83a2-d04eebbc30ce,7/21/2012,9,PM,poor metabolizers,,,
precautions,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,6698bc44-b971-49cc-a5de-11e569493c59,5/31/2007,2,MAOIs,inhibited.Monoamine Oxidase Inhibitors,,,
precautions,f7017eda-e3cb-4e3a-bd2c-d736bc58f197,6/20/2011,1,IFIS,Intraoperative Floppy Iris Syndrome,,,
precautions,B3676136-DA57-415D-9F20-51AD129C50BD,9/24/2007,1,5HIAA,5-hydroxy indoleacetic acid,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,CHF,congestive heart failure,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,MRHD,maximum recommended human dose,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,NTS,nicotine transdermal system,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,see and,Safety and effectiveness in the pediatric population have not been established,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,see,Seizure Threshold:                            WARNINGS,,,
precautions,97330579-8790-c2a8-af59-fe46ce39c58a,7/19/2010,2,see,should not be exceeded,,,
precautions,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,CBZ,carbamazepine,,,
precautions,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,SCE,sister chromatid exchange,,,
precautions,cd83f986-ec38-4e0e-aa03-3db5ad1629c6,2/1/2011,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,PM,PMs -38% to 105%,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,GAD,generalized anxiety disorder,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,ODV,O-desmethylvenlafaxine,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,EM,extensive metabolizers,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,MDD,major depressive disorder,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3,11/29/2011,14,PM,poor metabolizers,,,
precautions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,PBI,protein-bound iodine,,,
precautions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,TBG,thyroid-binding globulin,,,
precautions,92eafd85-0051-44af-ba5c-9194c8deffe2,12/19/2011,1,i.e.,in serum,,,
precautions,b358c1f1-044c-4dd5-a8e8-ef7800315104,5/2/2011,1,CHF,congestive heart failure,,,
precautions,b358c1f1-044c-4dd5-a8e8-ef7800315104,5/2/2011,1,MRHD,maximum recommended human dose,,,
precautions,b358c1f1-044c-4dd5-a8e8-ef7800315104,5/2/2011,1,NTS,nicotine transdermal system,,,
precautions,1a89b390-0cd5-45cb-9e70-20de44652c56,3/26/2012,2,CHO,Chinese Hamster Ovary,,,
precautions,1a89b390-0cd5-45cb-9e70-20de44652c56,3/26/2012,2,MRHD,maximum recommended human dose,,,
precautions,571fe550-399d-4296-835c-37aa1ab9b409,3/7/2012,3,rec,recombinant,,,
precautions,0f8a479f-429c-47ee-80be-c8e47110f34b,10/25/2011,1,WBC,white blood cell count,,,
precautions,0f8a479f-429c-47ee-80be-c8e47110f34b,10/25/2011,1,CBC,complete blood count,,,
precautions,da574350-be6b-49f3-b2ef-64da06af9b9d,2/4/2009,1,ONJ,Osteonecrosis of the jaw,,,
precautions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,PBI,protein-bound iodine,,,
precautions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,e.g.,estrogens,,,
precautions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,TBG,thyroid binding globulin,,,
precautions,FED687F4-1FFA-49EC-92C9-4D09DE17A833,2/17/2009,1,CYP 2C9,cytochrome P450 2C9 enzyme,,,
precautions,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,Pentoxil®,Pentoxifylline Extended-release Tablets,,,
precautions,ff7c9b1c-4192-4d09-a2ab-b80ec14cd424,2/14/2008,2,MRHD,maximum recommended human daily dose,,,
precautions,502fac46-67a6-4c4d-a666-65305d50d7a1,8/29/2011,1,Patients,patients,,,
precautions,502fac46-67a6-4c4d-a666-65305d50d7a1,8/29/2011,1,SUDEP,Sudden Unexplained Death in Epilepsy,,,
precautions,09c6e0a1-85ad-4450-cb99-7a6b7b0d3aff,5/16/2011,10,cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet®,,,
precautions,20e156df-a2b6-4710-b526-0419cd17dd33,4/3/2012,1,CNS,central nervous system,,,
precautions,20e156df-a2b6-4710-b526-0419cd17dd33,4/3/2012,1,Patients,patients,,,
precautions,20e156df-a2b6-4710-b526-0419cd17dd33,4/3/2012,1,NOEL,noobserved-effect level,,,
precautions,57578387-1918-4e56-a564-f14fb22340bf,11/7/2011,4,i.e.,inducers of CYP3A4,,,
precautions,83a005d5-e054-4ff0-afa7-de57811f8de7,4/25/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,83a005d5-e054-4ff0-afa7-de57811f8de7,4/25/2011,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,HCG,human chorionic gonadotropin,,,
precautions,dbdee4c0-86fa-4857-b536-79bf9ebb911a,1/4/2010,2,PT,prothrombin time,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,MRHD,maximum recommended human daily  dose,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,ECT,electroconvulsive therapy,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,TCAs,Tricyclic Antidepressants,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,UDS,unscheduled  DNA synthesis,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,ECT,Electroconvulsive Therapy,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,6c96373f-6744-49d4-aec5-3720bc993fab,12/9/2010,2,SIADH,syndrome of inappropriate antidiureic hormone secretion,,,
precautions,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,PBI,protein-bound iodine,,,
precautions,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,TBG,thyroid-binding globulin,,,
precautions,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,WHI,Women’s Health Initiative,,,
precautions,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,9eb200b0-db96-4a51-87ea-04db862978c8,1/18/2011,2,i.e.,in serum,,,
precautions,AF05203C-16FB-44DE-8F42-802FBAA03578,3/9/2009,3,ALL,acute lymphocytic leukemia,,,
precautions,98f6447f-a46b-4d93-b37c-3dc1a748fe03,6/14/2012,1,MAO,monoamine  oxidase,,,
precautions,fbca2152-0022-47a5-a1ea-58950b45bcbf,5/20/2011,1,CYP,cytochrome P450,,,
precautions,2cb70aa1-f73a-41c8-9a7f-edbcf1a06efd,9/1/2010,1,ie,in children and adolescents,,,
precautions,fa352464-14c8-49e9-b8b7-5a968b1cfa93,2/11/2009,1,cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet,,,
precautions,96D1CD4E-9A27-4504-AC3B-749C0DF7076E,6/25/2008,1,water,water.Prepare an aqueous,,,
precautions,4e6f2764-63a7-4d99-82c6-3b319a246296,8/21/2009,2,HIV,Human Immunodeficiency Virus,,,
precautions,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator,,,
precautions,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,botanicals,botanical medicines,,,
precautions,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,de5e4ed4-e9a5-4784-b512-b40199f17bd8,12/19/2011,2,I.M.,Intramuscular,,,
precautions,d3284649-ed4c-4096-987b-4ac16b8278f2,7/6/2010,1,ACE,angiotensin converting enzyme,,,
precautions,9dca0aba-821e-42fd-8353-d62348c098dc,7/7/2011,1,CHF,congestive heart failure,,,
precautions,9dca0aba-821e-42fd-8353-d62348c098dc,7/7/2011,1,MRHD,maximum recommended human dose,,,
precautions,9dca0aba-821e-42fd-8353-d62348c098dc,7/7/2011,1,NTS,nicotine transdermal system,,,
precautions,31d00e75-4fe0-4aec-9cba-c86cb78762c5,2/3/2012,5,PBI,protein-bound iodine,,,
precautions,31d00e75-4fe0-4aec-9cba-c86cb78762c5,2/3/2012,5,GGT,gamma glutamyl transpeptidase,,,
precautions,AE8F74F0-E600-4452-8557-958B603E2709,12/30/2008,1,MRHD,m*Maximum recommended human dose,,,
precautions,018a7a0d-4b38-4e59-bc37-621ae8786f51,6/30/2011,5,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,34B56F73-BEA4-4265-8B2A-C57520CF8E70,1/23/2008,1,INR,International Normalized Ratio,,,
precautions,143137ca-a13b-45f7-8ed2-adccf3cdfdcf,3/12/2012,2,NSAID's,Nonsteroidal Anti-inflammatory Drugs,,,
precautions,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,Mice,Micronucleus Test,,,
precautions,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,CNS,central nervous system,,,
precautions,702fffd7-b826-4081-83f7-4b6db6770c2c,6/9/2011,2,e.g.,exaggerated sunburn reactions,,,
precautions,965454d1-e7e6-46d1-b82d-7312f45ce84e,3/29/2012,3,MAO,monoamine  oxidase,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,TERIS,Teratogen Information System,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,NSTs,nonstress tests,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,MAO,observation.Monoamine Oxidase,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,TERIS,there is no risk,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,MAO,Monoamine Oxidase,,,
precautions,2c560dba-8b7e-4ba1-a390-30fff6af8aeb,6/6/2007,1,AUC,area under the concentration-time curve,,,
precautions,84718f90-579a-481f-8f39-713e1ed18871,12/20/2010,1,CHF,congestive heart failure,,,
precautions,84718f90-579a-481f-8f39-713e1ed18871,12/20/2010,1,MRHD,maximum recommended human dose,,,
precautions,84718f90-579a-481f-8f39-713e1ed18871,12/20/2010,1,NTS,nicotine transdermal system,,,
precautions,22edd948-d2fe-4df1-b797-1b7d92fc29cf,12/15/2011,8,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,22edd948-d2fe-4df1-b797-1b7d92fc29cf,12/15/2011,8,PPHN,pulmonary hypertension of the newborn,,,
precautions,8ce0eca5-c5a5-444a-b06a-5763be139949,3/30/2011,1,GFR,[glomerular filtration rate,,,
precautions,0d74bb04-8227-4afa-b523-ce1556150e07,6/17/2011,6,MRHD,maximum recommended human oral daily dose,,,
precautions,0d74bb04-8227-4afa-b523-ce1556150e07,6/17/2011,6,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
precautions,04CACB8A-6B1A-42F1-8E24-CAA124C9FD3E,1/9/2007,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,9c4a4784-b063-4c8f-b915-aeb18cb149be,10/23/2009,1,ie,in children and adolescents,,,
precautions,f56be63c-88e4-4b78-b12d-d80e3e8b3893,8/9/2007,1,PT,prothrombin time,,,
precautions,f56be63c-88e4-4b78-b12d-d80e3e8b3893,8/9/2007,1,PTT,partial thromboplastin time,,,
precautions,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,TBG,thyroid-binding globulin,,,
precautions,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,PBI,protein-bound  iodine,,,
precautions,efb195b9-b995-48f3-a4cb-b7e09d56350e,12/10/2010,2,i.e.,in serum,,,
precautions,08ee2a98-627f-4f95-83bd-2cbeb254bf70,1/6/2012,10,Mice,Micronucleus Test,,,
precautions,A918AE8C-6485-42D2-AEBA-3785197C3D7B,4/17/2007,1,i.e.,interaction,,,
precautions,283636b7-0c65-4572-a552-7a7548fb45b4,10/19/2011,1,BUN,blood urea nitrogen,,,
precautions,F388F2D7-DF3A-4AC5-B62B-30846B1A3843,2/17/2009,3,MRHD,maximum recommended human dose,,,
precautions,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,MRHD,Maximum Recommended Human Dose,,,
precautions,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,1da7847b-16e4-4bf1-957f-3894d023b339,7/20/2009,6,MTD,Maximum Tolerated Dose,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,ECT,electroconvulsive therapy,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,TCAs,Tricyclic Antidepressants,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,UDS,unscheduled DNA synthesis,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,MRHD,maximum recommended human daily dose,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,ECT,Electroconvulsive Therapy,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,cf64d0c0-7f1c-443d-93d5-1c41abb4e81d,3/22/2012,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,a1e768fd-c28f-4b49-822d-ccc315b4099c,8/6/2010,8,CHF,congestive heart failure,,,
precautions,a1e768fd-c28f-4b49-822d-ccc315b4099c,8/6/2010,8,MRHD,maximum recommended human dose,,,
precautions,a1e768fd-c28f-4b49-822d-ccc315b4099c,8/6/2010,8,NTS,nicotine transdermal system,,,
precautions,927F1BB9-6C13-4229-A5C8-0BF0B4C3BB35,10/15/2008,4,i.e.,in this respect,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,PM,PMs -38% to 105%,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,GAD,generalized anxiety disorder,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,ODV,O-desmethylvenlafaxine,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,EM,extensive metabolizers,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,MDD,major depressive disorder,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,4fabbef0-1838-4f70-aaf9-9550bd5f6204,10/11/2011,2,PM,poor metabolizers,,,
precautions,6D743386-A8E4-4A3F-AC82-C046896F35AE,8/4/2008,1,CYP 3A,cytochrome P450 3A,,,
precautions,72b10d15-8337-49ab-ad8d-0e990192598e,10/9/2006,1,UDS,unscheduled DNA synthesis,,,
precautions,72b10d15-8337-49ab-ad8d-0e990192598e,10/9/2006,1,SCEs,sister chromatid exchanges,,,
precautions,72b10d15-8337-49ab-ad8d-0e990192598e,10/9/2006,1,RPMC,rat pleural mesothelial cells,,,
precautions,C43C300D-8AEC-4020-984A-42C1A917C08F,4/10/2008,2,p.p.,postpartum,,,
precautions,C43C300D-8AEC-4020-984A-42C1A917C08F,4/10/2008,2,p.c.,post coitum,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,OTC,over-the-counter,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,ECT,electroconvulsive therapy,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SSRI,selective serotonin reuptake inhibitor,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,MRHD,maximum recommended human dose,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,PPHN,pulmonary hypertension of the newborn,,,
precautions,39a85db1-9e59-4ab0-9e18-36757f019faa,6/13/2012,12,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,05964DAE-8B84-467C-AF97-C82706A3CAD2,3/31/2007,1,CBS,cystathionine beta-synthase,,,
precautions,d99b2484-1c4d-4241-b16e-72395f976efb,9/5/2008,1,CAPD,continuous ambulatory peritoneal dialysis,,,
precautions,1e6c2f52-73ff-429b-8f1b-9b5b61ce1ac5,4/26/2011,2,cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in  association with Tagamet®,,,
precautions,351cde63-00fa-404a-92df-cb055e991840,11/23/2011,7,i. e.,indicates a catheter complication,,,
precautions,afde17e7-b95b-4cd5-97eb-e361724014bd,2/15/2012,2,CYP,cytochrome P450,,,
precautions,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,Patients,Patient Package Insert,,,
precautions,35dc1239-62de-41bc-81bd-806af681fa21,4/26/2011,5,i.e.,in vertebrates,,,
precautions,71d6ceef-55c7-4230-a8b8-1ee3cb7cf7f0,4/4/2012,1,MAO,monoamine  oxidase,,,
precautions,1f6059e7-9849-42be-ba17-43e7404a79df,11/14/2011,1,WBC,white blood cell count,,,
precautions,1f6059e7-9849-42be-ba17-43e7404a79df,11/14/2011,1,CBC,complete blood count,,,
precautions,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,Mice,Micronucleus Test,,,
precautions,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,CNS,central nervous system,,,
precautions,1e815845-5336-4b5f-975a-39d79b30cd10,10/19/2009,1,e.g.,exaggerated sunburn reactions,,,
precautions,b8a7573c-e8e0-4b33-ac8c-da9a8fe948c8,10/12/2010,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,Mice,Micronucleus Test,,,
precautions,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,CNS,central nervous system,,,
precautions,d9c8fcd9-bbe2-4ae7-bc44-74abd507d770,5/2/2011,1,e.g.,exaggerated sunburn reactions,,,
precautions,6975d23d-9673-4a28-80ab-d0717d2f1dc5,9/26/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,ad98682f-e421-4cf3-85f5-a042a3708262,3/17/2006,1,MRHD,maximum recommended human dose,,,
precautions,ad98682f-e421-4cf3-85f5-a042a3708262,3/17/2006,1,A®,assay,,,
precautions,ad98682f-e421-4cf3-85f5-a042a3708262,3/17/2006,1,VMA,vanillylmandelic acid,,,
precautions,A000ABB9-92A1-4C84-8932-CD40C476DC00,12/7/2006,1,sc,subcutaneous,,,
precautions,9bfe1903-3313-44b7-a27c-fc0775426f94,9/12/2011,6,CHF,congestive heart failure,,,
precautions,9bfe1903-3313-44b7-a27c-fc0775426f94,9/12/2011,6,MRHD,maximum recommended human dose,,,
precautions,9bfe1903-3313-44b7-a27c-fc0775426f94,9/12/2011,6,NTS,nicotine transdermal system,,,
precautions,7F60424F-B90C-459C-AE53-B732EE3D67B5,11/27/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,625852df-7b39-45c8-ba0a-cbcac798aa47,12/13/2011,4,MRDHD,maximum recommended daily human dose,,,
precautions,3829d74e-b3ab-46df-a08b-f0327b63304e,8/1/2006,1,i.e.,interaction,,,
precautions,5bb0d56c-d58e-4f9f-9848-d241cac5b3db,9/30/2011,2,MAO,monoamine oxidase,,,
precautions,a8b38ef8-67eb-466c-95d4-acb6e4eb0145,12/21/2010,3,NAAED,North American Antiepileptic Drug,,,
precautions,B151E4EB-BB9A-41B9-98A4-2E12BB4E2E5F,5/11/2006,1,MAO,monoamine oxidase,,,
precautions,05562553-0781-4204-b458-8302c6ee27b1,6/26/2011,1,INR,international normalized ratio,,,
precautions,05562553-0781-4204-b458-8302c6ee27b1,6/26/2011,1,NSAIDs,Nonsteroidal anti-inflammatory drugs,,,
precautions,05562553-0781-4204-b458-8302c6ee27b1,6/26/2011,1,ARBs,angiotensin receptor blockers,,,
precautions,05562553-0781-4204-b458-8302c6ee27b1,6/26/2011,1,ACE,angiotensin converting enzyme,,,
precautions,BDD0658E-38FB-4726-9720-09C502138AB0,4/7/2006,1,CHO,Chinese Hamster Ovary,,,
precautions,BDD0658E-38FB-4726-9720-09C502138AB0,4/7/2006,1,NTP,National Toxicology Program,,,
precautions,BDD0658E-38FB-4726-9720-09C502138AB0,4/7/2006,1,e.g.,effects of digitalis,,,
precautions,71359f14-0f8f-4e90-af1d-426e8c21bd61,8/1/2011,12,CHF,congestive heart failure,,,
precautions,71359f14-0f8f-4e90-af1d-426e8c21bd61,8/1/2011,12,NTS,nicotine transdermal system,,,
precautions,7ab194e4-0183-4823-a343-d9f7504662e1,10/31/2011,3,e.g.,effects of digitalis,,,
precautions,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,CBZ,carbamazepine,,,
precautions,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,SCE,sister chromatid exchange,,,
precautions,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,4f569120-9e22-4d0e-a368-d364549f79a0,1/3/2011,1,NAAED,North American Antiepileptic  Drug,,,
precautions,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,PBI,protein-bound iodine,,,
precautions,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,TBG,thyroid-binding globulin,,,
precautions,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,SHBG,sex hormone-binding globulin,,,
precautions,37f3094c-f02d-4a9c-8e30-2c4752bc62ed,6/9/2010,2,CBG,corticosteroid  binding globulin,,,
precautions,27d801ea-b342-4a8a-aeda-301a0175fe84,8/3/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,27d801ea-b342-4a8a-aeda-301a0175fe84,8/3/2007,1,ACE,angiotensin-converting enzyme,,,
precautions,27d801ea-b342-4a8a-aeda-301a0175fe84,8/3/2007,1,MRHD,Maximum Recommended Human Dose,,,
precautions,27d801ea-b342-4a8a-aeda-301a0175fe84,8/3/2007,1,NTP,National Toxicology Program,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,PMs,PMs - 4% to 134%,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,GAD,generalized anxiety disorder,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,ODV,O-desmethylvenlafaxine,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,ODV,O-desvenlafaxine,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,EM,extensive metabolizers,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,MDD,major depressive disorder,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,2c3f8268-ef43-d58c-7da6-dd44f8feb3be,7/13/2010,2,PM,poor metabolizers,,,
precautions,aad4de9c-164c-49b2-930e-03f8026588e1,7/15/2011,1,BUN,blood urea nitrogen,,,
precautions,747d1977-945d-4f51-b493-757c584fee02,11/11/2011,1,CYP 3A,cytochrome P450 3A,,,
precautions,A547CC0A-6AF0-49C7-A5EA-C41684CC36AE,9/30/2008,1,Use,USAGE and DOSAGE AND ADMINISTRATION.,,,
precautions,bcc6273b-3091-4420-8f2f-667fd5fcfb33,9/7/2011,3,MRDHD,maximum recommended daily human dose,,,
precautions,fe91d6c3-5dc3-4486-8b70-7f34955811df,11/29/2011,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,fe8480c4-b176-45ae-b4d6-fa59912fe286,7/22/2010,4,RA,rheumatoid arthritis,,,
precautions,fe8480c4-b176-45ae-b4d6-fa59912fe286,7/22/2010,4,INR,International Normalized Ratio,,,
precautions,13D85420-75E2-46E7-93EB-DCD10675CD03,10/10/2008,1,P.P.I.,Patient Package Insert,,,
precautions,3b0fd893-75f6-44e6-9a8b-ec5c2f0a2828,3/1/2012,7,CYP 3A4,cytochrome P450 3A4,,,
precautions,3b0fd893-75f6-44e6-9a8b-ec5c2f0a2828,3/1/2012,7,BMD,bone mineral density,,,
precautions,3b0fd893-75f6-44e6-9a8b-ec5c2f0a2828,3/1/2012,7,HPA,hypothalamic-pituitary-adrenal,,,
precautions,815270f2-1bb2-4a77-a8ba-3410dc6ae104,7/21/2008,2,CHO,Chinese Hamster Ovary,,,
precautions,bd44ea11-0650-4f9e-8663-b9be5f7bcd8d,4/7/2009,3,MRDHD,maximum recommended daily human dose,,,
precautions,af3eb64f-edfb-470f-924b-ef592b5b88dc,9/1/2011,3,NET,norethindrone,,,
precautions,af3eb64f-edfb-470f-924b-ef592b5b88dc,9/1/2011,3,see,systematically investigated,,,
precautions,af3eb64f-edfb-470f-924b-ef592b5b88dc,9/1/2011,3,RHD,recommended human dose,,,
precautions,af3eb64f-edfb-470f-924b-ef592b5b88dc,9/1/2011,3,HCTZ,Hydrochlorothiazide,,,
precautions,af3eb64f-edfb-470f-924b-ef592b5b88dc,9/1/2011,3,EE,ethinyl estradiol,,,
precautions,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,HO-NEF,hydroxynefazodone,,,
precautions,f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8,10/26/2009,5,CYP3A4,Cytochrome P450 3A4,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,SNRIs,Serotonin and Norepinephrine Reuptake  Inhibitors,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,ODV,O-desmethylvenlafaxine,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,EM,extensive metabolizers,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,MDD,major depressive disorder,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,8d06eb3d-16bd-495a-b58f-90877f3d5188,3/11/2011,1,PM,poor metabolizers,,,
precautions,2f3804f1-ce47-4c1c-a012-b7c0c3088105,3/11/2011,1,CHF,congestive heart failure,,,
precautions,2f3804f1-ce47-4c1c-a012-b7c0c3088105,3/11/2011,1,NTS,nicotine transdermal system,,,
precautions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,MRHD,maximum recommended human dose,,,
precautions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,GFR,[glomerular filtration rate,,,
precautions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,INR,International Normalized Ratio,,,
precautions,3a8a4490-9243-4201-944d-cea27d3d69f5,8/1/2011,6,AUC,Area Under the Curve,,,
precautions,4ab110e4-7b91-42aa-8052-f24cd79293f0,8/30/2011,5,Mice,Micronucleus Test,,,
precautions,4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc,3/30/2011,3,MCI,Mild Cognitive Impairment,,,
precautions,4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc,3/30/2011,3,MCI,mild cognitive impairment,,,
precautions,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,HRT,Estrogen/h                         ormone replacement therapy,,,
precautions,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,FIT,Fracture Intervention Trial,,,
precautions,784c5e89-a431-4233-9787-c98224dbbfb7,7/21/2011,6,NSAIDs,Nonsteroidal                          Anti-inflammatory Dr                         ugs,,,
precautions,ee09b4db-4d28-4748-a471-0f7b8c491f54,5/26/2010,1,MRHD,maximum recommended human oral daily dose,,,
precautions,ee09b4db-4d28-4748-a471-0f7b8c491f54,5/26/2010,1,NSAIDS,Nonsteroidal anti-inflammatory drugs,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,TERIS,Teratogen Information System,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,NSTs,nonstress tests,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,TERIS,there is no risk,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,MAO,Monoamine Oxidase,,,
precautions,8C363F90-C378-48AE-ABBC-AEB25C9BF5CB,9/19/2007,1,AUC,area under the concentration-time curve,,,
precautions,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,CYP,Cytochrome P450,,,
precautions,4BD8FAA3-CB8E-45FB-E280-6DF688DDC3A9,6/16/2006,1,CYP3A,Cytochrome P450 3A,,,
precautions,517fbb02-8793-4647-83c7-25a91be49622,7/8/2010,8,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,PM,PMs -38% to 105%,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,ODV,O?desmethylvenlafaxine,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,GAD,generalized anxiety disorder,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,ODV,O-desmethylvenlafaxine,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,EM,extensive metabolizers,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,MDD,major depressive disorder,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,PM,poor metabolizers,,,
precautions,4c401522-0108-49cb-8a41-fb5ad4dd0fb1,8/24/2011,10,rat,rabbits given doses up to 2.5 times,,,
precautions,a974ef05-1cc3-4cbc-a0b4-36b46ed107c9,9/19/2011,1,Mice,Micronucleus Test,,,
precautions,a00f9c78-ebe9-4afd-b4c4-dceaa7eb27e9,10/15/2009,1,GGT,gamma glutamyl transpeptidase,,,
precautions,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,ACT,activated clotting time,,,
precautions,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,test,the uneventful administration of the initial 1 mL,,,
precautions,8a5982c6-825f-4d05-90f5-1519a7291d15,1/9/2007,1,test,treated with Trasylol® should first receive an initial,,,
precautions,903939b3-a01d-4593-85ca-cfe8d4d48d3e,12/15/2010,2,Pgp,P-glycoprotein,,,
precautions,92ae1de4-6b27-4f03-acb5-7170664f67cb,9/11/2006,1,Plus,prednisolone acetate ophthalmic suspension,,,
precautions,51176835-598d-4da7-8a00-6bd36f52aa82,3/26/2012,2,HPA,Hypothalamic-pituitary-adrenal,,,
precautions,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,CHO,Chinese Hamster ovary,,,
precautions,20682605-557b-4586-9d98-829a63091ddf,1/20/2010,3,HFA BDP,HFA beclomethasone dipropionate,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,PM,PMs -38% to 105%,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,GAD,generalized anxiety disorder,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,ODV,O-desmethylvenlafaxine,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,EM,extensive metabolizers,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,MDD,major depressive disorder,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,b379b413-5d66-4adb-8521-3978f10bbd1d,12/19/2011,4,PM,poor metabolizers,,,
precautions,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,ACE,angiotensin-converting enzyme,,,
precautions,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,FSH,follicle-stimulating hormone,,,
precautions,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad,3/24/2011,2,LH,luteinizing hormone,,,
precautions,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,COX-2,cyclooxygenase-2,,,
precautions,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,ECG,electrocardiographic,,,
precautions,7b958f28-958e-45f9-9cf6-81d4eb753ad4,12/31/2011,6,ACE,angiotensin converting enzyme,,,
precautions,b498d45e-c832-420a-b975-18800a14c029,8/3/2007,1,MAO,recommended.Monoamine oxidase,,,
precautions,ac3dfb81-a4c7-4147-9374-c234153b7c51,12/29/2011,4,i.e.,inducers of CYP3A4,,,
precautions,808E2B04-9E84-440A-B00E-2CBE858041DA,11/27/2007,1,sc,subcutaneous,,,
precautions,2ab4878e-cbe0-46f8-a9fc-e70945a352ed,5/4/2010,1,CHF,congestive heart failure,,,
precautions,2ab4878e-cbe0-46f8-a9fc-e70945a352ed,5/4/2010,1,NTS,nicotine transdermal system,,,
precautions,2ab4878e-cbe0-46f8-a9fc-e70945a352ed,5/4/2010,1,SR,(SR),,,
precautions,2F44755A-2661-475D-83C5-8923101EB7A3,6/13/2007,1,MAO,monoamine oxidase,,,
precautions,2F44755A-2661-475D-83C5-8923101EB7A3,6/13/2007,1,SGOT,serum glutamic-oxaloacetic transaminase,,,
precautions,2F44755A-2661-475D-83C5-8923101EB7A3,6/13/2007,1,VMA,vanillylmandelic acid,,,
precautions,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,MRHD,Maximum Recommended Human Dose,,,
precautions,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,AUCs,a dose resulting in total systemic drug exposure,,,
precautions,40fa9a7d-749a-46c5-931c-4e187f7a00df,12/28/2011,3423,MTD,Maximum Tolerated Dose,,,
precautions,c08f73ff-4f15-449c-9507-c422367f106b,8/10/2009,1,HIV,Human Immunodeficiency Virus,,,
precautions,e31bd548-29ae-419a-831a-80ebb26e042f,10/12/2010,3,CHO,Chinese Hamster Ovary,,,
precautions,e31bd548-29ae-419a-831a-80ebb26e042f,10/12/2010,3,ACTH,adrenocorti­cotropic hormone,,,
precautions,e31bd548-29ae-419a-831a-80ebb26e042f,10/12/2010,3,NTP,National Toxicology Program,,,
precautions,5117D567-2004-C5ED-1391-F8831864696F,11/24/2008,1,UDS,unscheduled DNA synthesis,,,
precautions,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,PBI,protein-bound iodine,,,
precautions,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,TBG,thyroid-binding globulin,,,
precautions,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,WHI,Women’s Health Initiative,,,
precautions,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,WHIMS,Women’s Health Initiative Memory Study,,,
precautions,37275fd0-eb24-40a4-a93f-b818bb98414e,2/13/2012,1,i.e.,in serum,,,
precautions,2a6f411f-fdfa-42b1-ad90-17a288f2a4a2,3/1/2010,3,INR,International Normalized Ratio,,,
precautions,0936a88f-b569-49c4-951b-14e8f6273b53,4/13/2007,1,Maalox®,Maalox administration.Antacid,,,
precautions,06237703-b962-4e9b-9851-fc06070ed1a6,5/10/2011,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,human,heparin is enhanced by concurrent treatment with antithrombin III,,,
precautions,EFCDB321-832B-4554-8049-DBBB33B48334,4/13/2006,1,human,heparin is recommended during treatment with antithrombin III,,,
precautions,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,RA,rheumatoid arthritis,,,
precautions,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,GI,Gastrointestinal,,,
precautions,c8683c04-0e54-4e97-992b-55c2d605793c,11/12/2008,3,INR,International Normalized Ratio,,,
precautions,09abf090-af04-4381-963d-c88b93c82a21,5/8/2012,1,MAO,monoamine  oxidase,,,
precautions,0018861f-1b9b-431b-84ee-9d34aab615c3,6/25/2012,5,FSH,follicle-stimulating hormone,,,
precautions,0018861f-1b9b-431b-84ee-9d34aab615c3,6/25/2012,5,RMA,Risk Management Authorization,,,
precautions,0018861f-1b9b-431b-84ee-9d34aab615c3,6/25/2012,5,LH,luteinizing hormone,,,
precautions,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,JRA,juvenile rheumatoid arthritis,,,
precautions,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,TFMA,4-trifluoromethylaniline,,,
precautions,2DBA6C8E-3C51-4762-AE27-DCD760783F9B,11/5/2008,2,INR,International Normalized Ratio,,,
precautions,fea44910-400c-4688-bedc-bbb1615cd8f5,4/22/2010,1,AIDS,Acquired Immunodeficiency Syndrome,,,
precautions,fea44910-400c-4688-bedc-bbb1615cd8f5,4/22/2010,1,RIA,radioimmunoassay,,,
precautions,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,CNS,central nervous system,,,
precautions,4c41944c-efcb-4a80-b13b-92978ceacf63,1/4/2012,3470,e.g.,exaggerated sunburn reactions,,,
precautions,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,CHF,congestive heart failure,,,
precautions,f0c3cafa-8985-4dac-9be1-a92454a4ef6e,8/8/2011,5,NTS,nicotine transdermal system,,,
precautions,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,CNS,central nervous system,,,
precautions,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,Mice, Micronucleus Test,,,
precautions,B1A6DDA1-8753-4CC5-A5BF-4E0AEE25CEDF,1/17/2008,2,Mice,Assay Micronucleus Test,,,
precautions,ad114052-9af5-c940-1ca2-0f0904c55eb6,6/9/2004,1,Mice,Micronucleus Test,,,
precautions,246f1e96-0a2f-43c8-aa71-8e885b6c350d,10/19/2011,1,Mice,Micronucleus Test,,,
precautions,9f015e60-1aec-4ae7-b28f-42f6c8f50455,7/23/2012,1,i.e.,inducers of CYP3A4,,,
precautions,a0c0811e-9b05-4434-21a3-a25ebb27681f,7/16/2012,1049,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,4022e67f-59ce-44bb-7786-2b82831e2cf0,7/17/2012,814,IHPS,infantile hypertrophic pyloric stenosis,,,
precautions,947D5617-4E91-4507-AC80-977824D2B50B,2/23/2006,1,MAO,monoamine oxidase,,,
precautions,6569dfd1-0164-4241-b508-ccd540d1e858,4/16/2010,2,DST,dexamethasone suppression test,,,
precautions,6569dfd1-0164-4241-b508-ccd540d1e858,4/16/2010,2,PRA,plasma renin activity,,,
precautions,AF0C5240-4A98-4B25-B805-D6D3889BDC62,9/10/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,AF0C5240-4A98-4B25-B805-D6D3889BDC62,9/10/2007,1,NTP,National Toxicology Program,,,
precautions,AF0C5240-4A98-4B25-B805-D6D3889BDC62,9/10/2007,1,MRHDD,maximum recommended human daily dose,,,
precautions,ca09dd2c-02ed-4d26-af3c-aaff4120887e,8/20/2010,2,i.e.,inducers of CYP3 A4,,,
precautions,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,TIMOPTIC,timolol maleate ophthalmic solution,,,
precautions,D4008D19-00A3-4119-49A6-3CD6D7570E3F,2/7/2007,3,mouse,maleate was devoid of mutagenic potential when tested in vivo,,,
precautions,6616D1A2-09A6-429C-8D19-0AC6354980BB,1/22/2007,1,AF,after sotalol hydrochloride tablets,,,
precautions,52ee65a7-ca1f-48fd-8fad-d72ea0dad4de,5/7/2007,1,CHO,Chinese Hamster Ovary,,,
precautions,A274E3EA-BF67-4F81-AAA0-10475B20CD69,10/6/2006,1,UDS,unscheduled DNA synthesis,,,
precautions,14b45f78-0bc0-4e25-831e-d2a0006b2b87,12/13/2010,1,Mice,Micronucleus Test,,,
precautions,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,NSAIDs,non-steroidal anti-inflammatory drugs,,,
precautions,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,NTP,National Toxicology Program,,,
precautions,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,CHO,Chinese  Hamster Ovary,,,
precautions,76678031-5373-498b-b59d-195705e6ac69,4/26/2010,4,e.g.,effects of digitalis,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,ECT,electroconvulsive therapy,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,TCAs,Tricyclic Antidepressants,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,UDS,unscheduled DNA synthesis,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,MRHD,maximum recommended human daily dose,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,ECT,Electroconvulsive Therapy,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,C0FCB440-2C9F-4841-B164-5AB7168D81D9,3/16/2009,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,d0a209f9-0406-4868-89f6-fe864ccc5d7d,8/25/2011,2,CHF,congestive heart failure,,,
precautions,d0a209f9-0406-4868-89f6-fe864ccc5d7d,8/25/2011,2,NTS,nicotine transdermal system,,,
precautions,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,CHF,congestive heart failure,,,
precautions,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,MRHD,maximum recommended human dose,,,
precautions,28fa8921-7546-4681-89ab-9ec32695e701,5/6/2010,2,NTS,nicotine  transdermal system,,,
precautions,aa756b80-11eb-4f67-abb8-8babcee728b2,7/8/2010,4,MPA,mycophenolic acid,,,
precautions,2d8fbab4-d7a7-4f4f-bbcc-56e603f72f73,3/14/2012,2,G6PD,glucose 6-phosphate dehydrogenase,,,
precautions,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,PT,prothrombin time,,,
precautions,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,INR,International Normalized Ratio,,,
precautions,A51DC88F-C298-402E-B204-618609A4721C,10/17/2008,3,e.g.,exaggerated sunburn reactions,,,
precautions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,75bf15c1-ffd8-46d3-8252-60b51e036794,7/25/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,946cd61f-d733-4edf-96b7-f5566c35ae4a,5/21/2010,1,NET,norethindrone,,,
precautions,946cd61f-d733-4edf-96b7-f5566c35ae4a,5/21/2010,1,RHD,recommended human dose,,,
precautions,946cd61f-d733-4edf-96b7-f5566c35ae4a,5/21/2010,1,NAAED,North American Antiepileptic Drug,,,
precautions,946cd61f-d733-4edf-96b7-f5566c35ae4a,5/21/2010,1,HCTZ,Hydrochlorothiazide,,,
precautions,946cd61f-d733-4edf-96b7-f5566c35ae4a,5/21/2010,1,EE,ethinyl estradiol,,,
precautions,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,CNS,central nervous system,,,
precautions,0ecdade5-571e-4082-bbca-106723379f6a,6/8/2011,1,e.g.,exaggerated sunburn reactions,,,
precautions,e3469758-5111-4c30-a7fc-12444e914515,8/31/2010,2,ACE,angiotensin-converting enzyme,,,
precautions,e3469758-5111-4c30-a7fc-12444e914515,8/31/2010,2,FSH,follicle-stimulating hormone,,,
precautions,e3469758-5111-4c30-a7fc-12444e914515,8/31/2010,2,NSAIDs,nonsteroidal anti-inflammatory drugs,,,
precautions,e3469758-5111-4c30-a7fc-12444e914515,8/31/2010,2,LH,luteinizing hormone,,,
precautions,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,Mice,Micronucleus Test,,,
precautions,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,CNS,central nervous system,,,
precautions,29980caf-43b4-4efe-a310-bf52150cc6a6,8/25/2010,1,e.g.,exaggerated sunburn reactions,,,
precautions,E67D21FA-DB5A-4536-FC82-CABFEADB0C6F,2/22/2006,1,PLENDIL,prolongation in the half-life of felodipine.Erythromycin—Co-administration of felodipine,,,
precautions,E67D21FA-DB5A-4536-FC82-CABFEADB0C6F,2/22/2006,1,MRHDD,maximum recommended human daily dose,,,
precautions,a49905cc-dd53-43a2-8113-d8ada3f8cae9,1/4/2011,1,WBC,white blood cell count,,,
precautions,a49905cc-dd53-43a2-8113-d8ada3f8cae9,1/4/2011,1,PKU,phenylketonuria,,,
precautions,a49905cc-dd53-43a2-8113-d8ada3f8cae9,1/4/2011,1,CBC,complete blood count,,,
precautions,c0c15d60-1171-11e1-9be0-0002a5d5c51b,11/23/2011,2,AEDs,antiepileptic drugs,,,
precautions,ce76cbd9-1b1b-4944-28a8-39acfb01eb1d,8/24/2011,3,GGT,gamma glutamyl transpeptidase,,,
precautions,6ed06682-7507-4c11-a782-42e694c21b53,2/21/2012,1,RA,rheumatoid arthritis,,,
precautions,6ed06682-7507-4c11-a782-42e694c21b53,2/21/2012,1,INR,International Normalized Ratio,,,
precautions,a65bf275-09f0-4f1f-983b-fd4e170a550b,3/23/2012,3698,MRD,maximum recommended dose,,,
precautions,a3262279-1f9e-401b-9b02-6da3ef374b46,8/23/2011,1,HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus,,,
precautions,97677ce7-9562-43d0-8b99-8d1f37c1e3c6,7/27/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,97677ce7-9562-43d0-8b99-8d1f37c1e3c6,7/27/2010,1,DSI,DNA synthesis inhibition,,,
precautions,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,Statins,STABILIZED.HMG-CoA Reductase Inhibitors,,,
precautions,65AFA805-603A-43DE-9651-D04E49BD2AA7,8/3/2006,1,MRHD,maximum recommended human dose,,,
precautions,bcb4364f-7884-4aa3-94db-47607a5ce5fc,10/17/2011,2,Mice,Micronucleus Test,,,
precautions,35460df2-18d3-4132-85e6-5289bad4c670,4/26/2011,2,1 mg/kg/min,1000 mcg/kg/min,,,
precautions,35460df2-18d3-4132-85e6-5289bad4c670,4/26/2011,2,10 mg/kg/min,10,000 mcg/kg/min,,
precautions,35460df2-18d3-4132-85e6-5289bad4c670,4/26/2011,2,3 mg/kg/min,3000 mcg/kg/min,,,
precautions,35460df2-18d3-4132-85e6-5289bad4c670,4/26/2011,2,2.5 mg/kg/min,2500 mcg/kg/min,,,
precautions,F103B9F9-E081-419D-A2D8-B86ACDA834DD,6/30/2008,1,MRHDD,maximum recommended human daily dose,,,
precautions,942008d0-dd1a-48cd-8736-80872a04e0e0,3/28/2012,3,APTT,activated partial thromboplastin times,,,
precautions,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,CNS,central  nervous system,,,
precautions,f03f5ae4-e698-417c-b033-b59249768fe2,6/27/2011,1,e.g.,exaggerated sunburn reactions,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,ECT,treatment.Electroconvulsive Therapy,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,MRHD,maximum recommended human dose,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,MRD,maximum recommended dose,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,ECT,Electroconvulsive Therapy,,,
precautions,34efe868-f01a-49c7-ab02-9f659b1689f8,11/27/2007,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,1636fbd8-ac5f-4395-974b-561d0d523aee,10/24/2011,1,BUN,blood urea nitrogen level,,,
precautions,1636fbd8-ac5f-4395-974b-561d0d523aee,10/24/2011,1,e.g,effects of digitalis,,,
precautions,3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1,2/21/2007,1,WPW,Wolff-Parkinson-White syndrome,,,
precautions,8f91e243-7395-4ec9-adf5-37520983daf2,8/18/2006,1,5-HIAA,5?hydroxyindoleacetic acid,,,
precautions,8f91e243-7395-4ec9-adf5-37520983daf2,8/18/2006,1,VMA,vanillylmandelic acid,,,
precautions,4ce6888c-e639-4a0c-8490-2a78bcaa41e9,9/10/2010,1,Mice,Micronucleus Test,,,
precautions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,ECT,electroconvulsive therapy,,,
precautions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,SSRI,selective serotonin reuptake inhibitor,,,
precautions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,MRHD,maximum recommended human dose,,,
precautions,01a172e0-d590-4701-8d88-cf012760e4aa,7/4/2011,2,PPHN,pulmonary hypertension of the newborn,,,
precautions,9d04904f-872b-4e1c-9bc7-e012f42ce584,8/25/2010,1,Mice,Micronucleus Test,,,
precautions,A6CA918F-D031-4601-31A4-1848B580F2F0,8/7/2006,1,MRHD,maximum recommended human dose,,,
precautions,80971965-5c77-4950-b65d-7996b802d2cd,7/8/2010,8,stage 1,study was designed to evaluate the effect of 10 mg vardenafil,,,
precautions,A69EC903-874E-4FEF-9E71-81E608DEB6A7,12/11/2008,1,MAOI,caution.Monoamine Oxidase Inhibitors,,,
precautions,A69EC903-874E-4FEF-9E71-81E608DEB6A7,12/11/2008,1,MAOI,concomitantly.Monoamine Oxidase Inhibitors,,,
precautions,CE61920D-65DF-4423-925D-091E624EA32E,10/14/2008,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,MRHD,maximum recommended human dose,,,
precautions,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,AEDs,antiepilepsy drugs,,,
precautions,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,NAAED,North American Antiepileptic Drug,,,
precautions,3164d438-90bf-420a-9a56-5498b987f91c,7/9/2010,3,BUN,blood urea nitrogen,,,
precautions,59bfb7f9-400c-4bcd-88cc-edde4b1e8189,4/27/2010,1,UDS,unscheduled DNA synthesis,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,ECT,electroconvulsive therapy,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,ECT,citalopram.Electroconvulsive Therapy,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,TCAs,Tricyclic Antidepressants,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,MAOIs,recommended.Monoamine Oxidase Inhibitors,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,UDS,unscheduled DNA synthesis,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,MRHD,maximum recommended human daily dose,,,
precautions,84AFE6C1-378C-4444-9D57-7444D8916ABA,8/2/2007,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,d1697161-ebe8-42b0-83e7-c9de4412546c,2/9/2011,1,MCI,Mild Cognitive Impairment,,,
precautions,d1697161-ebe8-42b0-83e7-c9de4412546c,2/9/2011,1,MCI,mild cognitive impairment,,,
precautions,2e0fa140-85a0-42db-ba15-a068120076b4,6/4/2012,2,HPA,hypothalamic-pituitary-adrenal,,,
precautions,2e0fa140-85a0-42db-ba15-a068120076b4,6/4/2012,2,CYP,cytochrome P450,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,GAD,generalized anxiety disorder,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desmethylvenlafaxine,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,ODV,O-desvenlafaxine,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,EM,extensive metabolizers,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,MDD,major depressive disorder,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,PM,poor metabolizers,,,
precautions,9de97bb7-36e8-4126-bede-d48375da15df,12/21/2010,6,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,NSAIDs,Non-Steroidal Anti-Inflammatory Drugs,,,
precautions,9c5d9912-68d9-4222-937a-ee8d1d8b61d7,11/8/2010,5,BUN,blood urea nitrogen,,,
precautions,3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f,11/3/2011,2,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,61f36cba-e314-4ec9-8c84-5259153049b5,9/2/2009,2,NET,norethindrone,,,
precautions,61f36cba-e314-4ec9-8c84-5259153049b5,9/2/2009,2,RHD,recommended human dose,,,
precautions,61f36cba-e314-4ec9-8c84-5259153049b5,9/2/2009,2,HCTZ,Hydrochlorothiazide,,,
precautions,61f36cba-e314-4ec9-8c84-5259153049b5,9/2/2009,2,EE,ethinyl estradiol,,,
precautions,4256b3c7-23c5-4743-a311-916cee1de1c1,1/25/2012,1,MAOI,monoamine oxidase inhibitors,,,
precautions,e6634d24-08af-44bc-8e76-e759619857fa,2/15/2011,1,CYP3A4,cytochrome P450 3A4,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,OTC,over-the-counter,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,ECT,electroconvulsive therapy,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,MRHD,maximum recommended human dose,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,63643535-0aa4-4cb3-870b-93933e48b9c1,10/25/2007,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
precautions,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,CYP,Cytochrome P450,,,
precautions,f91d9ce0-299e-4d48-a4e7-cb5b87bbae99,7/21/2007,1,CYP3A,Cytochrome P450 3A,,,
precautions,888998CC-C7F7-4F2A-8479-DF60F77BC2A1,1/4/2006,1,Cefizox,ceftizoxime injection,,,
precautions,888998CC-C7F7-4F2A-8479-DF60F77BC2A1,1/4/2006,1,CPK,creatine phosphokinase,,,
precautions,A5359176-9E01-4D51-A48C-1685F4C16BCA,11/20/2008,2,GGT,gamma glutamyl transpeptidase,,,
precautions,a3041c04-0ea8-4d36-81ce-c5091c906316,1/11/2012,4,SGOT,Significant elevations of aminotransferase AST,,,
precautions,BDDE7502-6218-401C-9A4F-DD3BC3A80F72,1/24/2008,1,MAC,minimum alveolar concentration,,,
precautions,3185D299-AB4C-4BF1-86A4-3C126144B245,9/17/2008,1,MAOI,Monoamine Oxidase Inhibitors,,,
precautions,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,ECT,Electroconvulsive therapy,,,
precautions,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,MRHD,maximum recommended human dose,,,
precautions,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,SNRIs,serotonin and  norepinephrine reuptake inhibitors,,,
precautions,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,PPHN,pulmonary hypertension of the newborn,,,
precautions,4b8fcce1-abfc-4631-9975-9d66e178dab6,10/27/2009,1,SIADH,syndrome of inappropriate  antidiuretic hormone secretion,,,
precautions,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,CBZ,carbamazepine,,,
precautions,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,NAAED,North American Antiepileptic Drug,,,
precautions,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,SCE,sister chromatid exchange,,,
precautions,cdce6a8f-02fc-448c-9a81-3d904e49ef97,2/1/2011,1,CBZ-E,carbamazepine-10,11-epoxide,,
precautions,0d8fd775-950a-465d-8d32-4fe40234bc11,9/12/2011,2,e.g.,effects of digitalis,,,
precautions,7CB92CF2-46F2-4379-937C-168D230E43A4,11/14/2008,1,CHO,Chinese Hamster Ovary,,,
precautions,7CB92CF2-46F2-4379-937C-168D230E43A4,11/14/2008,1,NTP,National Toxicology Program,,,
precautions,7CB92CF2-46F2-4379-937C-168D230E43A4,11/14/2008,1,MRHDD,maximum recommended human daily dose,,,
precautions,7CB92CF2-46F2-4379-937C-168D230E43A4,11/14/2008,1,e.g.,effects of digitalis,,,
precautions,1a619a14-0b63-4cba-80e7-474c9a1c90b9,12/28/2011,8,NAAED,North American Antiepileptic Drug,,,
precautions,94b1b057-1784-461e-aa6c-5a482dd589d3,8/13/2010,1,CHO,Chinese Hamster Ovary,,,
precautions,94b1b057-1784-461e-aa6c-5a482dd589d3,8/13/2010,1,ACTH,adrenocorti­cotropic hormone,,,
precautions,94b1b057-1784-461e-aa6c-5a482dd589d3,8/13/2010,1,NTP,National Toxicology Program,,,
precautions,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,LDH,lactate dehydrogenase,,,
precautions,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,ALT,alanine aminotransferase,,,
precautions,A9987047-9C99-45A5-829B-AE8B189CBFD4,2/6/2006,1,AST,aspartate aminotransferase,,,
precautions,0edf333a-776d-45b8-b567-acc863f8599b,8/31/2010,1,HPA,hypothalamic-pituitary-adrenal,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,ECT,electroconvulsive therapy,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,MAOIs,Monoamine Oxidase Inhibitors,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,TCAs,Tricyclic Antidepressants,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,UDS,unscheduled DNA synthesis,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,MRHD,maximum recommended human daily dose,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,ECT,Electroconvulsive Therapy,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,2632b547-2e13-447f-ac85-c774e437d6a8,12/6/2010,9,PPHN,pulmonary hypertension of the newborn,,,
precautions,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,JRA,juvenile rheumatoid arthritis,,,
precautions,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,GI,gastrointestinal,,,
precautions,0F8E31C2-A18C-4004-B995-DF096D06662C,4/17/2007,1,CHO,Chinese hamster ovary,,,
precautions,4d3531fb-82a4-41ab-8c36-eb0aace61f5c,4/2/2012,3,MAOI,monoamine oxidase inhibitors,,,
precautions,37e91a33-f4d6-4617-b107-9fefc4852862,12/1/2009,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,37e91a33-f4d6-4617-b107-9fefc4852862,12/1/2009,1,TCAs,tricyclic  antidepressants,,,
precautions,6f007825-e1c1-49ed-8637-014899945d25,7/12/2011,1,i.e.,in the elderly,,,
precautions,6f007825-e1c1-49ed-8637-014899945d25,7/12/2011,1,CHO,Chinese Hamster Ovary,,,
precautions,6f007825-e1c1-49ed-8637-014899945d25,7/12/2011,1,ACTH,adrenocorti­cotropic hormone,,,
precautions,6f007825-e1c1-49ed-8637-014899945d25,7/12/2011,1,NTP,National Toxicology Program,,,
precautions,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,TERIS,Teratogen Information System,,,
precautions,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,NSTs,nonstress tests,,,
precautions,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,TERIS,there is no  risk,,,
precautions,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,SSRIs,selective serotonin reuptake inhibitors,,,
precautions,ec41ab86-a948-44e4-b21c-c65a22cdf294,11/5/2011,1,AUC,area under the concentration-time curve,,,
precautions,7F56F5C9-32FE-40FE-8151-F7EA9DA1A0C1,7/7/2006,1,MAO,monoamine oxidase,,,
precautions,5be97a06-1a2b-460c-845e-e9ed18016df9,12/13/2011,1,BMD,bone mineral density,,,
precautions,d9303631-4301-4704-b85f-7547e88c68df,5/31/2011,3,CAPD,continuous ambulatory peritoneal dialysis,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,ECT,hydrobromide.Electroconvulsive Therapy,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,Ames test,a mg/mMutagenesis: Citalopram was mutagenic in the in vitro bacterial reverse mutation assay,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,ECT,electroconvulsive therapy,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SSRI,selective serotonin reuptake inhibitor,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,MRHD,maximum recommended human dose,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,TCAs,Tricyclic Antidepressants,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,NSAID,nonsteroidal anti-inflammatory drug,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,MAOIs,recommended.Monoamine Oxidase Inhibitors,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,UDS,unscheduled DNA synthesis,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,MRHD,maximum recommended human daily dose,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SIADH,syndrome of inappropriate antidiuretic hormone secretion,,,
precautions,AEC4204D-8A0C-443A-AAD1-1958DB28C60D,1/24/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
specificPopulations,AE0B595A-36D2-44F3-84F6-7FE9F995F4A1,5/9/2007,1,ie,incidence,,,
specificPopulations,13e802e6-3924-4122-ba3a-1966a164c48a,6/3/2011,3,MRHD,maximum recommended human dose,,,
specificPopulations,e6e25ef9-2671-489e-8eca-58bedb4f59ab,6/15/2012,1,MRHD,maximum recommended human dose for schizophrenia,,,
specificPopulations,8d8cdd21-2403-4284-bdfc-d56d6e8ab117,7/13/2010,1,i.e.,including delayed fetal development,,,
specificPopulations,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1/19/2010,1,BMI,body mass  index,,,
specificPopulations,ea29921d-ae91-4a1b-a8e5-5c00a16be127,8/31/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,e33ac27f-43ae-4912-8e41-626091fc5ad2,1/4/2012,4,EE,erosive esophagitis,,,
specificPopulations,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,MRHD,maximum recommended human dose,,,
specificPopulations,32266029-c710-44dd-943f-7e31d0afa622,6/4/2012,8,DHT,5?-dihydrotestosterone,,,
specificPopulations,22fbf983-a490-42d6-b754-8b303409095c,3/31/2011,5,EE,erosive esophagitis,,,
specificPopulations,a96e22b2-eca3-4438-b959-dc5381085d31,9/3/2011,4,i.e.,including delayed fetal development,,,
specificPopulations,bbe6bcf4-f7d3-4067-93af-218c641059dc,9/14/2011,1,CLr,clearance,,,
specificPopulations,7fccca4e-fb8f-42b8-9555-8f78a5804ed3,4/10/2007,2,MRHD,Maximum Recommended Human Dose,,,
specificPopulations,7fccca4e-fb8f-42b8-9555-8f78a5804ed3,4/10/2007,2,MC,molluscum contagiosum,,,
specificPopulations,c628d376-4b65-4f05-b6fa-eabb1d96a7df,7/30/2009,1,MRHD,maximum recommended daily human dose,,,
specificPopulations,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,RHD,recommended human dose,,,
specificPopulations,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,NAAED,North American Antiepileptic Drug,,,
specificPopulations,32b48ea0-a215-43b8-83b4-a5435a686d68,8/1/2011,8,CDC,Centers for Disease Control and Prevention,,,
specificPopulations,be2a14b5-8dc0-473e-8672-96297e20e199,4/26/2010,3,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,8a7a1fbf-652c-4c2a-8118-815341e8d2c1,4/30/2012,4,EE,erosive esophagitis,,,
specificPopulations,6588514f-84fe-4608-99e6-e3a7ecd338c3,4/18/2011,2,LV,left ventricle,,,
specificPopulations,d8034b31-fa43-480b-91a5-f4ece35d60eb,5/3/2010,4,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,6bc22f65-4aaf-40a5-8f36-8b2419249ff5,6/4/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,c6c7322b-6a89-4d23-90d1-bf9327bd6d91,4/13/2012,10,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,f719162f-cb78-487c-b172-ac10d009e6f5,3/1/2012,1,MRD,maximum recommended dose,,,
specificPopulations,f719162f-cb78-487c-b172-ac10d009e6f5,3/1/2012,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,3c740b43-f396-4998-bc66-6964a21f7161,2/2/2012,3,DLT,dose limiting toxicity,,,
specificPopulations,b03e286a-4d44-489a-89d0-ee563e1f280f,10/27/2009,1,i.e.,impaired renal function,,,
specificPopulations,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,MRD,maximum recommended dose,,,
specificPopulations,bb06af33-8ff7-0b02-0029-d628f62e1382,1/31/2008,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,68c5c707-4539-4ed9-ab12-4ac138c62ff3,1/7/2010,2,EE,erosive esophagitis,,,
specificPopulations,1cf82d42-5ad0-4b86-838e-9230c61cf3d4,3/18/2010,3,RHDID,recommended human daily inhalation dose,,,
specificPopulations,bf170659-a4f3-4ff7-8a0f-b3a0a2d02ff5,7/16/2012,3,EE,erosive esophagitis,,,
specificPopulations,20dc1daf-4732-404d-9904-e046991ce59e,3/5/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,20dc1daf-4732-404d-9904-e046991ce59e,3/5/2011,1,i.e.,incidence,,,
specificPopulations,82d793ee-4039-45fc-ac83-4bd5235f00aa,10/1/2011,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,7d485d38-5d43-4a54-bc63-82734035c66a,10/6/2007,1,LV,left ventricle,,,
specificPopulations,63e54b62-a30d-4a56-9215-75e7a0b0bf02,6/7/2011,2,MRHD,maximum recommended human dose,,,
specificPopulations,473d1684-944c-4a65-aef4-6379f97a0178,6/23/2011,2,LV,left ventricle,,,
specificPopulations,776a1619-c3af-65ff-a5ad-2cd807656205,5/1/2010,8,NST,nonstress test,,,
specificPopulations,776a1619-c3af-65ff-a5ad-2cd807656205,5/1/2010,8,CST,Contraction stress testing,,,
specificPopulations,776a1619-c3af-65ff-a5ad-2cd807656205,5/1/2010,8,BPP,biophysical profiling,,,
specificPopulations,820839ef-e53d-47e8-a3b9-d911ff92e6a9,3/30/2012,15,RHDID,recommended human daily inhalation dose,,,
specificPopulations,a747d8af-0d73-4c4a-b6b1-a254c75194f1,5/31/2011,1,EE,erosive esophagitis,,,
specificPopulations,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,FIT,Fracture Intervention Trial,,,
specificPopulations,815a87c4-e489-4eb9-9a2e-fb7a16642f01,6/4/2012,11,OI,osteogenesis imperfecta,,,
specificPopulations,D4EA84F2-A13F-4335-A184-1E87702BC396,7/13/2007,1,ie,incidence,,,
specificPopulations,ffe52b98-9872-48c1-90fd-8fcd37c3432f,3/29/2012,6,MRHD,maximum recommended human dose for schizophrenia,,,
specificPopulations,0FB7864F-BE1C-4992-A996-556AEF29981F,6/25/2008,2,SDA,single dermal administration,,,
specificPopulations,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,NAAED,North American Antiepileptic Drug,,,
specificPopulations,e77eabc9-9f65-4d4b-8135-0290291e6ee8,5/22/2012,1,AM,and Memory,,,
specificPopulations,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,MRD,maximum recommended dose,,,
specificPopulations,b3230c81-2a58-4033-848b-194dd2439843,12/21/2010,162,PPHN,pulmonary  hypertension of the newborn,,,
specificPopulations,a24e8e53-07b3-49be-87e4-124f7d3aeac1,8/18/2010,1,MRHD,maximum recommended daily human dose,,,
specificPopulations,4211fbea-7a8f-4300-b50e-e1aa58bb7c3f,9/8/2011,1,Mean,mean age 32 years (range 23-59 years,,,
specificPopulations,47ef5501-1408-41fa-b0e5-f078f18129f5,7/30/2009,1,MRHD,maximum recommended daily human dose,,,
specificPopulations,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,MRD,maximum recommended dose,,,
specificPopulations,9e1353d7-83d1-4522-9352-5545db044a50,1/17/2011,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,fa7ddbd9-29e2-4a36-af46-00c96a77ac85,6/20/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,5dd1f9bb-acbf-4deb-9b02-992d52239a6b,6/23/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,7140f8d9-e478-4f69-a4eb-3fd4c9414576,10/30/2009,2,EE,erosive esophagitis,,,
specificPopulations,51c9a29c-a285-40d0-bf3a-7e8c944ee39c,3/7/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,51c9a29c-a285-40d0-bf3a-7e8c944ee39c,3/7/2011,1,i.e.,incidence,,,
specificPopulations,7cc14b86-0833-4c3c-91f3-7963d7052fd5,8/18/2011,11,LV,left ventricle,,,
specificPopulations,5f3a088e-296a-4089-84b3-7ac9311969da,6/3/2008,3,CLr,clearance,,,
specificPopulations,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,NOEL,no-observed-effect level,,,
specificPopulations,a9a4309e-fe43-4a26-a30f-c6577d650336,4/17/2012,8,NAAED,North American Antiepileptic Drug,,,
specificPopulations,d8540843-055c-47fb-9cff-81e64b1d41c3,9/24/2010,1,i.e.,impaired renal function,,,
specificPopulations,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,MRD,maximum recommended dose,,,
specificPopulations,45454555-7402-41cb-a452-e6a76e04f387,3/14/2012,11,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,a9f2f4cb-028c-463f-b400-44b06da90f0c,8/1/2011,1,MRDHD,maximum recommended daily human dose,,,
specificPopulations,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,MRD,maximum recommended dose,,,
specificPopulations,3ccada47-7eb9-285d-5059-06afb4466114,1/31/2008,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,1a5eff69-0c4c-4e20-9e04-05db3ebbd589,6/23/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,4be13bd5-0c39-43c3-9232-b1226ccd4dbc,6/1/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,6/28/2010,2,i.e.,including delayed fetal development,,,
specificPopulations,A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1,5/15/2007,1,ie,incidence,,,
specificPopulations,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,f149569c-05d1-4dba-b35a-4ed6a633f776,8/18/2011,1,DHT,5?-dihydrotestosterone,,,
specificPopulations,6087be15-56c1-4794-b159-ad9082b631b9,7/26/2011,3,HUS,Hemolytic Uremic Syndrome,,,
specificPopulations,cb18564f-663f-4da2-9dd9-700ea9bdd398,12/29/2009,2,HeFH,heterozygous familial hypercholesterolemia,,,
specificPopulations,312e65cb-897f-4c24-b17b-be7e8ce469bb,7/19/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,MRHD,maximum recommended human dose,,,
specificPopulations,de965605-268a-4479-86f7-84de949cf36f,3/27/2009,1,i.e.,incidence,,,
specificPopulations,fc6adb1b-00a2-40d7-ba92-799393fc689d,7/18/2011,1,i.e.,including delayed fetal development,,,
specificPopulations,AC76ACA8-E718-4232-92AB-399166CE9E46,2/18/2009,1,2F-ara-A,2-fluoro-ara-adenine,,,
specificPopulations,e92a97ef-0fe3-40b1-a938-373293a75255,11/29/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,b32d180f-f8d6-4535-a3b6-45045663a96f,9/30/2011,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,NAAED,North American Antiepileptic Drug,,,
specificPopulations,483a42b9-c8f3-4f8b-98be-fcac5ab23c7c,5/18/2012,1,AM,and Memory,,,
specificPopulations,ec559356-75a3-423b-9e8c-3ff88290a98a,1/1/2012,6,D.A.S.,Differential Ability Scale,,,
specificPopulations,fe4734a2-6219-8bf5-9c3a-d392910db4dc,7/1/2011,6,NST,nonstress test,,,
specificPopulations,fe4734a2-6219-8bf5-9c3a-d392910db4dc,7/1/2011,6,CST,Contraction stress testing,,,
specificPopulations,fe4734a2-6219-8bf5-9c3a-d392910db4dc,7/1/2011,6,BPP,biophysical profiling,,,
specificPopulations,A6EB861C-085E-442A-8E71-722587493D5D,9/11/2008,1,LV,left ventricle,,,
specificPopulations,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,MRHD,maximum recommended human dose,,,
specificPopulations,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,NOAEL,no observed adverse effect level,,,
specificPopulations,794aa355-66de-41b8-aedf-f2c40f6bc664,7/12/2012,11,SC,subcutaneous,,,
specificPopulations,3cd2e7f1-cbdb-47f6-b37f-830aaaef2482,3/21/2011,1,Tmax,to maximum plasma concentration,,,
specificPopulations,a3b199d0-4ed4-4392-8db6-3ed9fc48db07,4/26/2010,4,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,MRD,maximum recommended dose,,,
specificPopulations,e07fa54e-f4ee-496d-a7e9-533c85564be1,1/17/2011,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,56e7180d-013d-4605-9444-66f7e857ba2c,10/6/2011,24,EE,erosive esophagitis,,,
specificPopulations,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,NAAED,North American Antiepileptic Drug,,,
specificPopulations,2471ee03-d747-4113-86d0-1aa93c8f3eba,2/9/2012,9,AM,and Memory,,,
specificPopulations,6ed56fa0-4813-4dc9-82c7-6dadf91f586f,5/15/2012,3,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,dd1c68bd-abba-45b3-9c3c-586d77c18853,10/1/2011,14,MRHD,maximum recommended human dose,,,
specificPopulations,9bced3c4-f450-4e21-9baa-ab2efd0ed4bd,10/5/2011,1,Tmax,to maximum plasma concentration,,,
specificPopulations,a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a,1/24/2012,11,SHARP,Study of Heart and Renal Protection,,,
specificPopulations,71d4bca8-0b51-8f0a-ebab-a67c52fff3b7,12/20/1996,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,82174fcc-1b0f-2068-7fc4-db335b43b5e2,2/13/2012,14,EE,erosive esophagitis,,,
specificPopulations,9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171,11/15/2011,3165,GLP,Good Laboratory Practices,,,
specificPopulations,dd674424-b151-d7eb-3acf-b1589347f2f7,1/31/2012,2,RPU,renal pelvis ureter,,,
specificPopulations,27d36fbf-1892-48e1-a9b1-1625607ea516,7/12/2007,1,BSA,body surface area,,,
specificPopulations,27d36fbf-1892-48e1-a9b1-1625607ea516,7/12/2007,1,MTHD,maximum topical human dose,,,
specificPopulations,a23a1cca-bc3e-48c5-abd9-82eddb52e91b,12/28/2010,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,9fd7a181-ab26-4e68-8404-20ce339b0844,9/30/2010,2,DEA,desethylamiodarone,,,
specificPopulations,0818c344-2fc5-4cee-ac06-c9cd7fd07680,8/13/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
specificPopulations,989705dd-929b-4b62-9ef4-e768f0e366cb,8/19/2010,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
specificPopulations,7a6d9491-a4c9-497c-9c17-4037c46f9e6a,12/31/2010,2,AUC,about 2-fold the systemic exposure,,,
specificPopulations,15a80e60-5d8b-4085-ba4c-7616af1ac96b,7/27/2011,5,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,d3f7c414-db83-4a7a-a7aa-745c5606cdba,6/7/2011,1,MRHD,maximum recommended daily human dose,,,
specificPopulations,d61c7acb-a64f-46ee-b125-0c80d3b35585,8/18/2010,1,NOAEL,no-adverse effect levels,,,
specificPopulations,c4582bdf-5eda-438c-98b4-0517500501e8,11/21/2011,10,MRHD,maximum recommended human dose,,,
specificPopulations,0a997a7b-4735-44c9-9b8c-1aa493c70d43,5/26/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,NAAED,North American Antiepileptic Drug,,,
specificPopulations,f65ec19d-b90e-452e-b761-c68b1cf2c892,6/11/2012,8,AM,and Memory,,,
specificPopulations,d2af616e-673a-4fdd-ace8-db2d0f154604,11/24/2011,6,MRHD,maximum recommended human dose,,,
specificPopulations,00332c65-edad-a153-9c78-628931daa732,5/31/2012,4,MRHD,maximum recommended daily human dose,,,
specificPopulations,e2902ed1-cfeb-4815-adc3-129c577917a1,1/15/2012,12,MRHD,maximum recommended human dose,,,
specificPopulations,ccfd9a79-f3fd-4786-b7ba-e4906089d8f7,3/15/2010,1,AUC,about 2-fold the systemic exposure,,,
specificPopulations,28ae35c3-bce3-4a63-a4e4-085ffca92aef,9/30/2010,8,EE,erosive esophagitis,,,
specificPopulations,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHI,Women’s Health  Initiative,,,
specificPopulations,36ec4df9-298d-4b15-9386-7848d217a46c,1/14/2010,2,WHIMS,Women’s Health  Initiative Memory Study,,,
specificPopulations,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
specificPopulations,c3657589-4202-4d67-abb0-15df86eacd39,12/23/2010,169,ESRD,end-stage renal disease,,,
specificPopulations,eb40a594-d58d-4214-b766-9e7a815b2de8,8/8/2011,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,111ad6f9-170d-4a14-a4e2-ff86f60521cd,5/8/2012,4,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,WHIMS,Women's Health Initiative Memory Study,,,
specificPopulations,d8c4a929-c039-4c7d-a3bc-986ae31fc8a6,8/24/2010,1,WHI,Women's Health Initiative,,,
specificPopulations,0b802a9c-332f-4ea8-bb34-75c677264654,5/6/2011,8,LV,left  ventricle,,,
specificPopulations,3e029e9f-0db0-41b7-8552-4728da9bad78,10/15/2010,1,EE,erosive esophagitis,,,
specificPopulations,e12e2850-4980-48de-af58-15e559fb921f,5/30/2012,9,DLT,dose limiting toxicity,,,
specificPopulations,b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3,6/6/2012,1,DEA,desethylamiodarone,,,
specificPopulations,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,MRD,maximum recommended dose,,,
specificPopulations,62c47df4-2c71-437e-b142-bc193f6277f0,3/20/2012,4,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,A0E521C3-7807-464E-922D-CE8F23216828,5/4/2007,1,ie,incidence,,,
specificPopulations,71ba78cb-7e46-43eb-9425-fa130f537f84,5/8/2012,26,EE,erosive esophagitis,,,
specificPopulations,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,NOEL,no-observed-effect level,,,
specificPopulations,e08920c2-04a3-4fb5-acc5-0af3140f82e9,10/21/2011,8,NAAED,North American Antiepileptic Drug,,,
specificPopulations,d19abf04-7723-9a14-e7f3-d992770e211e,11/11/2009,1,EE,erosive esophagitis,,,
specificPopulations,ea2067bd-1622-4d98-8012-2c09405aa88d,8/22/2011,10,MRHD,maximum recommended human dose,,,
specificPopulations,ea2067bd-1622-4d98-8012-2c09405aa88d,8/22/2011,10,i.e.,incidence,,,
specificPopulations,fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343,3/10/2011,6,Tmax,to maximum plasma concentration,,,
specificPopulations,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,fde9c9e4-5275-4aa5-8f56-56037b3db0c7,11/23/2011,1,DHT,5?-dihydrotestosterone,,,
specificPopulations,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,NOEL,no-observed-effect level,,,
specificPopulations,5ce98225-2eb3-4386-bda1-48cb4c132562,8/23/2011,3,NAAED,North American Antiepileptic Drug,,,
specificPopulations,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
specificPopulations,1f0fa7d6-9309-4cf6-b842-3924ec8aebe7,12/6/2011,3320,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
specificPopulations,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,RHD,recommended human dose,,,
specificPopulations,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,NAAED,North American Antiepileptic Drug,,,
specificPopulations,4d78fba4-51af-472c-8b64-5505cb4b91dc,7/8/2011,1,CDC,Centers for Disease Control and Prevention,,,
specificPopulations,7331b2fe-3878-419c-a3ed-453528a86a48,8/5/2011,1,MRDHD,maximum recommended daily human dose,,,
specificPopulations,fd9a64e5-119e-40f8-9a12-fd809f685e1e,11/12/2010,1,MC,molluscum contagiosum,,,
specificPopulations,23ff2d62-b5ff-4837-8b54-439a65609d90,1/12/2010,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,c40c1bb4-25ce-90cb-b8dd-6a4c54cddd4a,2/18/2011,4,AUC,about 2-fold the systemic exposure,,,
specificPopulations,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,NAAED,North American Antiepileptic Drug,,,
specificPopulations,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,CDC,Centers for Disease Control,,,
specificPopulations,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,ACOG,and Gynecologists,,,
specificPopulations,a93b0914-c1ac-4e48-b6b9-1b4e211eb072,12/2/2009,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,1866bcff-0cb2-469c-8952-84179643ae5f,12/1/2011,3289,GLP,Good Laboratory Practices,,,
specificPopulations,c871d3fe-5ca2-410c-976d-9ec4b72c878f,4/24/2012,3,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,7d27c65e-b60b-4f83-a01a-02dc67f61a8b,3/1/2012,25,MRHD,maximum recommended human dose,,,
specificPopulations,a2f317f0-33ee-4298-bb5d-dd631d7bee25,10/15/2010,1,EE,erosive esophagitis,,,
specificPopulations,43934d82-cb79-467e-9092-23756406828b,7/13/2007,1,ie,incidence,,,
specificPopulations,dbe07049-223d-4e54-b1ab-5b57bb9ad8ae,5/16/2011,9,NOEL,no-observed-effect level,,,
specificPopulations,dbe07049-223d-4e54-b1ab-5b57bb9ad8ae,5/16/2011,9,NAAED,North American Antiepileptic Drug,,,
specificPopulations,3277c17e-f953-2b0a-fe0a-4f5d1aeace9d,5/31/2012,3,VZV,varicella-zoster virus,,,
specificPopulations,b367d81d-4eca-4e28-b490-34be4c003561,4/30/2010,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,079fdde2-8b69-42c4-88f5-830ed7d2ba5f,6/7/2011,1,LSAS,Liebowitz Social Anxiety Scale,,,
specificPopulations,079fdde2-8b69-42c4-88f5-830ed7d2ba5f,6/7/2011,1,CGI,Clinical Global Impression,,,
specificPopulations,079fdde2-8b69-42c4-88f5-830ed7d2ba5f,6/7/2011,1,HAM-A,Hamilton Rating Scale for Anxiety,,,
specificPopulations,eeeee9c4-8566-4100-8ca4-3df936a3365d,6/30/2011,1,tmax,to maximum plasma concentration,,,
specificPopulations,dd8d7ec8-79b0-4152-8789-d247c77232ce,7/22/2009,2,BMI,body mass index,,,
specificPopulations,88313e5f-9426-4aac-8909-d56bde6f584f,12/31/2010,8,AUC,about 2-fold the systemic exposure,,,
specificPopulations,2f42fc80-ae39-4301-b140-36e59d71666e,12/10/2010,1,AUC,about 2-fold the systemic exposure,,,
specificPopulations,139f86a4-75c5-4304-894c-8f8b8a396c78,7/27/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,f26ababe-f6f0-443e-8d91-4d2a174675bc,11/29/2011,1,NWS,neonatal withdrawal syndrome,,,
specificPopulations,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,MRD,maximum recommended dose,,,
specificPopulations,b050b0ee-107c-4f82-8031-92ec68baa6a2,4/13/2011,10,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,533260c1-3d9f-4414-a097-068a215876d5,2/10/2012,4,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MRHD,maximum recommended  human dose,,,
specificPopulations,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,MRD,maximum recommended dose,,,
specificPopulations,6bc0214b-b6f9-463d-a689-a93e59512b60,1/18/2010,2,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,32d6371e-ba56-4294-b732-6d43627c5c47,12/19/2011,18,NOAEL,no observable adverse effect level,,,
specificPopulations,f5cfb61e-d971-4a9c-b9ef-4f3368fe02f5,6/12/2012,7,VZV,varicella-zoster virus,,,
specificPopulations,4690d08b-767a-40e2-979d-76f1bc742c32,4/25/2011,3,RHD,recommended human dose,,,
specificPopulations,739dcf8a-ed73-5eb0-899b-7e51cb73c335,10/23/2011,8,MRHD,maximum recommended human dose,,,
specificPopulations,208db529-ae52-462d-8fd2-775b11ce6350,9/18/2008,1,i.e.,incidence,,,
specificPopulations,5f0bdf9d-fa78-45e8-913a-81beff57cf34,2/27/2012,15,MRHD,maximum recommended human dose,,,
specificPopulations,a1f01e8e-97e9-11de-b91d-553856d89593,10/24/2011,10,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,26b65fec-9a5d-4b9b-9b87-c3d328c58cd0,7/30/2009,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,3eb971cf-ab82-49f3-a46c-4d76a8ce599e,9/27/2010,2,GLP,Good Laboratory Practices,,,
specificPopulations,28eefc95-d92e-4555-b6c5-2933860b0610,7/2/2012,1,rats,rabbits at glimepiride doses 50 times,,,
specificPopulations,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,LSAS,Liebowitz Social Anxiety Scale,,,
specificPopulations,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,YGTSS,Yale Global Tic Severity Scale Total Score,,,
specificPopulations,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,PARS,Pediatric Anxiety Rating Scale,,,
specificPopulations,f8f80fca-32b7-4fba-b0ab-e87530bc36b6,3/22/2010,1,Disorder,Disorder: 116 subjects,,,
specificPopulations,b95172dd-ff18-4323-a605-ed5ae58a69ed,10/24/2011,10,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,e812ad55-29ed-49b4-b81b-a789194de228,11/29/2011,1,MRHD,maximum recommended human dose,,,
specificPopulations,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
specificPopulations,81a06b90-50d3-40c1-98ca-0e344c76b2c4,11/25/2009,1,ESRD,end-stage renal disease,,,
specificPopulations,a5c46194-3692-cd26-0d85-6371974ccc44,3/2/2011,5,tmax,to maximum plasma concentration,,,
specificPopulations,5c133dfe-3cb5-426b-ac30-daf814e12c47,1/9/2012,1,tmax,to maximum plasma concentration,,,
specificPopulations,e2015ac5-0441-43fd-b864-a1b1fe944450,9/30/2010,6,MRHD,maximum recommended daily human dose,,,
specificPopulations,8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6,7/7/2012,4,MRHD,maximum recommended human dose for schizophrenia,,,
specificPopulations,398348ed-1b65-4109-9d0f-f9d8a7175d61,4/16/2012,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,c119ed19-5dc6-4c03-b705-2616c65ef041,9/30/2010,1,EE,erosive esophagitis,,,
specificPopulations,188c6fd5-6695-4d8b-af43-61d9c26abfe9,8/29/2011,3,i.e.,including delayed fetal development,,,
specificPopulations,1a123145-2d63-484a-a0a0-061890796137,5/15/2012,1,i.e.,impaired renal function,,,
specificPopulations,40a96527-f89e-4177-9224-5c79167f3e60,7/27/2011,2,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,371ca86d-7ffd-4f20-b6c6-af0a9ff7362f,5/11/2010,1,AUC,about 2-fold the systemic exposure,,,
specificPopulations,29c03bbf-2ab6-4de3-05ca-1e52d7c85a70,6/6/2011,1,EE,erosive esophagitis,,,
specificPopulations,6fabbc1e-4fa9-4830-8740-e6a878c64adf,4/27/2010,2,MRHD,maximum recommended daily human dose,,,
specificPopulations,6686069e-7e43-4963-8a66-961e0b36d84d,4/25/2011,5,LV,left ventricle,,,
specificPopulations,910fae46-5eaf-427f-b137-e4e775b065c7,5/31/2012,3831,RHDID,recommended human daily inhalation dose,,,
specificPopulations,65196e54-fde3-4977-b749-2d7aeed01ad4,3/31/2011,4,EE,erosive esophagitis,,,
specificPopulations,ba60c357-8e61-4a3d-b1dc-25602dbbfc2a,4/3/2012,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,50194d47-2761-4bfd-a35b-9c6a186694a5,3/10/2011,3,Tmax,to maximum plasma concentration,,,
specificPopulations,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,SNRIs,serotonin and norepinephrine reuptake inhibitors,,,
specificPopulations,1BC2A4BF-875D-4670-BBA5-BBCDF05E6B71,5/5/2008,1,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,264a3dc1-596c-43ab-a20c-65c80ab22f2a,1/18/2012,3,LV,left ventricle,,,
specificPopulations,65d1a53c-25cd-4ad0-b5bb-b6e278bd9644,8/19/2010,356,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,6ee54fdc-efe6-4411-a711-8154ceee20b6,1/17/2011,2061,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,34704c52-b71c-4a6d-9335-00cce4ec7302,8/13/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,NOEL,no-observed-effect level,,,
specificPopulations,a278a8ab-4c68-439a-8672-da32175dc1f5,8/22/2011,2,NAAED,North American Antiepileptic Drug,,,
specificPopulations,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,ODV,of venlafaxine and its active metabolite,,,
specificPopulations,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SSRIs,Selective Serotonin Reuptake Inhibitors,,,
specificPopulations,8FBA17DA-573A-425B-B1D7-7DDEEEF3C957,6/3/2008,1,SNRIs,Serotonin and Norepinephrine Reuptake Inhibitors,,,
specificPopulations,8d416349-161d-4232-b6b4-e75214ea4841,1/5/2011,2,AUC,about 2-fold the systemic exposure,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,CAPD,continuous ambulatory peritoneal  dialysis,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,I.V.,intravenous,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,HD,hemodialysis,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,UV,ultraviolet light,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,MED,minimum erythematous dose,,,
specificPopulations,7d74dfa6-0468-43ad-ad7f-dd90d9ae7706,10/25/2009,1,S-warfarin,single dose of  warfarin sodium on the fifth day,,,
specificPopulations,d85c5ab8-a3d8-42a3-ac0b-799ea5a6369e,6/20/2011,1,CAPD,continuous ambulatory peritoneal dialysis,,,
specificPopulations,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,MRD,maximum recommended dose,,,
specificPopulations,0e817af0-85f5-46a5-82a4-e08b1f701e86,5/24/2011,3024,PPHN,pulmonary hypertension of the newborn,,,
specificPopulations,40c43d5a-7523-4ff1-863b-ed0c10a238f7,11/29/2011,2,EE,erosive esophagitis,,,
specificPopulations,18f7f458-9276-4e9d-94b2-99ca8dd4cebf,8/3/2010,3,MRHD,maximum recommended daily human dose,,,
specificPopulations,7e37e999-f225-4d0a-b16d-37ac14ff29da,3/23/2011,2,MRHD,maximum recommended human dose for schizophrenia,,,
specificPopulations,EF56C531-A1CA-B94C-23DE-A0BA617AE2B4,5/29/2007,1,i.e.,incidence,,,
specificPopulations,c7750b68-b3d8-45fa-b134-bf75f6ac510e,1/19/2010,2,MRHD,maximum recommended human dose,,,
specificPopulations,d15c8f36-4dcc-4b28-b03c-4e81b2f9ad2e,1/4/2011,1,EE,erosive esophagitis,,,
specificPopulations,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,MRHD,maximum recommended human dose,,,
specificPopulations,0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314,2/22/2012,7,DHT,5?-dihydrotestosterone,,,
specificPopulations,4f43d057-cba8-4366-86ba-4be361e4c71f,8/22/2011,1,AUC,about 2 fold the systemic exposure,,,
specificPopulations,9832312e-0310-4ab6-8501-afa976fc7eb2,2/29/2012,4,MRHDID,maximum recommended human daily inhalation dose,,,
specificPopulations,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,NAAED,North American Antiepileptic Drug,,,
specificPopulations,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,CDC,Centers for Disease Control,,,
specificPopulations,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,ACOG,and Gynecologists,,,
specificPopulations,da69287c-2f37-4299-b444-914c1ab0054c,7/22/2010,1,MRHD,maximum recommended daily human dose,,,
specificPopulations,427cf924-be17-47dc-8f77-115fa2f3fe17,5/17/2012,10,EE,erosive esophagitis,,,
specificPopulations,22e635cb-98c0-e4f9-6a71-62d7487a0a6c,4/4/2011,7,NWS,neonatal withdrawal syndrome,,,
